,pubmed_id,title,abstract,keywords,journal,publication_date,authors,methods,conclusions,results,copyrights,doi,xml
0,37855285,Sex Differences in Stress Response: Classical Mechanisms and Beyond.,"Neuropsychiatric disorders, which are associated with stress hormone dysregulation, occur at different rates in men and women. Moreover, nowadays, preclinical and clinical evidence demonstrates that sex and gender can lead to differences in stress responses that predispose males and females to different expressions of similar pathologies. In this curated review, we focus on what is known about sex differences in classic mechanisms of stress response, such as glucocorticoid hormones and corticotrophin-releasing factor (CRF), which are components of the hypothalamicpituitary- adrenal (HPA) axis. Then, we present sex differences in neurotransmitter levels, such as serotonin, dopamine, glutamate and GABA, as well as indices of neurodegeneration, such as amyloid β and Tau. Gonadal hormone effects, such as estrogens and testosterone, are also discussed throughout the review. We also review in detail preclinical data investigating sex differences caused by recentlyrecognized regulators of stress and disease, such as the immune system, genetic and epigenetic mechanisms, as well neurosteroids. Finally, we discuss how understanding sex differences in stress responses, as well as in pharmacology, can be leveraged into novel, more efficacious therapeutics for all. Based on the supporting evidence, it is obvious that incorporating sex as a biological variable into preclinical research is imperative for the understanding and treatment of stress-related neuropsychiatric disorders, such as depression, anxiety and Alzheimer's disease.","['HPA axis', 'Stress', 'antidepressants', 'glucocorticoids.', 'immune', 'neurodegeneration', 'sex differences']",Current neuropharmacology,2023-10-19,"[{'lastname': 'Hodes', 'firstname': 'Georgia E', 'initials': 'GE', 'affiliation': 'Virginia Tech, School of Neuroscience, Blacksburg, VA, USA.'}, {'lastname': 'Bangasser', 'firstname': 'Debra', 'initials': 'D', 'affiliation': 'Center for Behavioral Neuroscience, Georgia State University, Atlanta, GA, USA.'}, {'lastname': 'Sotiropoulos', 'firstname': 'Ioannis', 'initials': 'I', 'affiliation': 'Institute of Biosciences & Applications NCSR ""Demokritos"", Athens, Greece.\nLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.'}, {'lastname': 'Kokras', 'firstname': 'Nikolaos', 'initials': 'N', 'affiliation': 'Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.\nFirst Department of Psychiatry, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.'}, {'lastname': 'Dalla', 'firstname': 'Christina', 'initials': 'C', 'affiliation': 'Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1570159X22666231005090134,<Element 'PubmedArticle' at 0x7f05db50cf90>
1,"37852961
28846757
24623176
31139153
9408742
9020850
9811848
31454787
12679432
16630814
28538730
22908268
30085049
24336141
11560301
30928686
17761551
22269187
9727068
12006103
9792624
11668179
12832471
10594926
22074460
16899075
18388310
15176485
15212823
21492414
29725016
25326800
26549211
30530690
10364248
8408049
15059951
9927313
10718932
35236988
9496988
10567497
16720656
20215399
28826672
30941099
33230535
24470773
29985474
24336139
15213206
24745832
9716543
9715373
12730778
15190686
23300939
33339957
33716161
37118426
29632371
34958873
28111074
24022672
29155708",FSH and ApoE4 contribute to Alzheimer's disease-like pathogenesis via C/EBPβ/δ-secretase in female mice.,"Alzheimer's disease (AD) is the most common dementia. It is known that women with one ApoE4 allele display greater risk and earlier onset of AD compared with men. In mice, we previously showed that follicle-stimulating hormone (FSH), a gonadotropin that rises in post-menopausal females, activates its receptor FSHR in the hippocampus, to drive AD-like pathology and cognitive impairment. Here we show in mice that ApoE4 and FSH jointly trigger AD-like pathogenesis by activating C/EBPβ/δ-secretase signaling. ApoE4 and FSH additively activate C/EBPβ/δ-secretase pathway that mediates APP and Tau proteolytic fragmentation, stimulating Aβ and neurofibrillary tangles. Ovariectomy-provoked AD-like pathologies and cognitive defects in female ApoE4-TR mice are ameliorated by anti-FSH antibody treatment. FSH administration facilitates AD-like pathologies in both young male and female ApoE4-TR mice. Furthermore, FSH stimulates AD-like pathologies and cognitive defects in ApoE4-TR mice, but not ApoE3-TR mice. Our findings suggest that in mice, augmented FSH in females with ApoE4 but not ApoE3 genotype increases vulnerability to AD-like process by activating C/EBPβ/δ-secretase signalling.",[],Nature communications,2023-10-19,"[{'lastname': 'Xiong', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, 30322, USA.\nDepartment of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China.'}, {'lastname': 'Kang', 'firstname': 'Seong Su', 'initials': 'SS', 'affiliation': 'Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, 30322, USA.'}, {'lastname': 'Wang', 'firstname': 'Mengmeng', 'initials': 'M', 'affiliation': 'Faculty of Life and Health Sciences, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, 518055, China.'}, {'lastname': 'Wang', 'firstname': 'Zhihao', 'initials': 'Z', 'affiliation': 'Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China.'}, {'lastname': 'Xia', 'firstname': 'Yiyuan', 'initials': 'Y', 'affiliation': 'Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, 30322, USA.'}, {'lastname': 'Liao', 'firstname': 'Jianming', 'initials': 'J', 'affiliation': 'Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, 30322, USA.\nDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China.'}, {'lastname': 'Liu', 'firstname': 'Xia', 'initials': 'X', 'affiliation': 'Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, 30322, USA.'}, {'lastname': 'Yu', 'firstname': 'Shan-Ping', 'initials': 'SP', 'affiliation': 'Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, 30322, USA.'}, {'lastname': 'Zhang', 'firstname': 'Zhaohui', 'initials': 'Z', 'affiliation': 'Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China.'}, {'lastname': 'Ryu', 'firstname': 'Vitaly', 'initials': 'V', 'affiliation': 'Mount Sinai Bone Program, Department of Medicine and Department of Orthopedics, Mount Sinai School of Medicine, New York, NY, 10029, USA.'}, {'lastname': 'Yuen', 'firstname': 'Tony', 'initials': 'T', 'affiliation': 'Mount Sinai Bone Program, Department of Medicine and Department of Orthopedics, Mount Sinai School of Medicine, New York, NY, 10029, USA.'}, {'lastname': 'Zaidi', 'firstname': 'Mone', 'initials': 'M', 'affiliation': 'Mount Sinai Bone Program, Department of Medicine and Department of Orthopedics, Mount Sinai School of Medicine, New York, NY, 10029, USA.'}, {'lastname': 'Ye', 'firstname': 'Keqiang', 'initials': 'K', 'affiliation': 'Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, 30322, USA. kq.ye@siat.ac.cn.\nFaculty of Life and Health Sciences, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, 518055, China. kq.ye@siat.ac.cn.'}]",,,,© 2023. Springer Nature Limited.,10.1038/s41467-023-42282-7,<Element 'PubmedArticle' at 0x7f05dc8b8cc0>
2,37804846,"Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis.","Testosterone replacement therapy is known to improve sexual function in men younger than 40 years with pathological hypogonadism. However, the extent to which testosterone alleviates sexual dysfunction in older men and men with obesity is unclear, despite the fact that testosterone is being increasingly prescribed to these patient populations. We aimed to evaluate whether subgroups of men with low testosterone derive any symptomatic benefit from testosterone treatment.
We did a systematic review and meta-analysis to evaluate characteristics associated with symptomatic benefit of testosterone treatment versus placebo in men aged 18 years and older with a baseline serum total testosterone concentration of less than 12 nmol/L. We searched major electronic databases (MEDLINE, Embase, Science Citation Index, and the Cochrane Central Register of Controlled Trials) and clinical trial registries for reports published in English between Jan 1, 1992, and Aug 27, 2018. Anonymised individual participant data were requested from the investigators of all identified trials. Primary (cardiovascular) outcomes from this analysis have been published previously. In this report, we present the secondary outcomes of sexual function, quality of life, and psychological outcomes at 12 months. We did a one-stage individual participant data meta-analysis with a random-effects linear regression model, and a two-stage meta-analysis integrating individual participant data with aggregated data from studies that did not provide individual participant data. This study is registered with PROSPERO, CRD42018111005.
9871 citations were identified through database searches. After exclusion of duplicates and publications not meeting inclusion criteria, 225 full texts were assessed for inclusion, of which 109 publications reporting 35 primary studies (with a total 5601 participants) were included. Of these, 17 trials provided individual participant data (3431 participants; median age 67 years [IQR 60-72]; 3281 [97%] of 3380 aged ≥40 years) Compared with placebo, testosterone treatment increased 15-item International Index of Erectile Function (IIEF-15) total score (mean difference 5·52 [95% CI 3·95-7·10]; τ
In men aged 40 years or older with baseline serum testosterone of less than 12 nmol/L, short-to-medium-term testosterone treatment could provide clinically meaningful treatment for mild erectile dysfunction, irrespective of patient age, obesity, or degree of low testosterone. However, due to more severe baseline symptoms, the absolute level of sexual function reached during testosterone treatment might be lower in older men and men with obesity.
National Institute for Health and Care Research Health Technology Assessment Programme.",[],The lancet. Healthy longevity,2023-10-08,"[{'lastname': 'Hudson', 'firstname': 'Jemma', 'initials': 'J', 'affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'lastname': 'Cruickshank', 'firstname': 'Moira', 'initials': 'M', 'affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'lastname': 'Quinton', 'firstname': 'Richard', 'initials': 'R', 'affiliation': 'Translational & Clinical Research Institute, University of Newcastle, Newcastle upon Tyne, UK.'}, {'lastname': 'Aucott', 'firstname': 'Lorna', 'initials': 'L', 'affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'lastname': 'Wu', 'firstname': 'Frederick', 'initials': 'F', 'affiliation': 'Division of Diabetes, Endocrinology & Gastroenterology, University of Manchester, Manchester, UK.'}, {'lastname': 'Grossmann', 'firstname': 'Mathis', 'initials': 'M', 'affiliation': 'University of Melbourne Austin Health, Heidelberg, VIC, Australia.'}, {'lastname': 'Bhasin', 'firstname': 'Shalender', 'initials': 'S', 'affiliation': 'Department of Medicine, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Snyder', 'firstname': 'Peter J', 'initials': 'PJ', 'affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Ellenberg', 'firstname': 'Susan S', 'initials': 'SS', 'affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Travison', 'firstname': 'Thomas G', 'initials': 'TG', 'affiliation': 'Division of Gerontology, Boston, MA, USA.'}, {'lastname': 'Brock', 'firstname': 'Gerald B', 'initials': 'GB', 'affiliation': 'Department of Surgery, Western University and Omega Fertility Center, London, ON, Canada.'}, {'lastname': 'Gianatti', 'firstname': 'Emily J', 'initials': 'EJ', 'affiliation': 'Department of Endocrinology, Fiona Stanley Hospital, Murdoch, WA, Australia.'}, {'lastname': 'van der Schouw', 'firstname': 'Yvonne T', 'initials': 'YT', 'affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.'}, {'lastname': 'Emmelot-Vonk', 'firstname': 'Marielle H', 'initials': 'MH', 'affiliation': 'Department of Geriatrics, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.'}, {'lastname': 'Giltay', 'firstname': 'Erik J', 'initials': 'EJ', 'affiliation': 'Department of Psychiatry, Leiden University Medical Centre, Leiden, Netherlands.'}, {'lastname': 'Hackett', 'firstname': 'Geoff', 'initials': 'G', 'affiliation': 'School of Health and Life Sciences, Aston University, Birmingham, UK.'}, {'lastname': 'Ramachandran', 'firstname': 'Sudarshan', 'initials': 'S', 'affiliation': 'Department of Chemical Pathology, University Hospitals Birmingham, Birmingham, UK.'}, {'lastname': 'Svartberg', 'firstname': 'Johan', 'initials': 'J', 'affiliation': 'Division of Internal Medicine, Section of Endocrinology, University Hospital of North Norway, Tromsø, Norway; Tromsø Endocrine Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.'}, {'lastname': 'Hildreth', 'firstname': 'Kerry L', 'initials': 'KL', 'affiliation': 'Division of Geriatric Medicine, University of Colorado School of Medicine, Aurora, CO, USA.'}, {'lastname': 'Antonic', 'firstname': 'Kristina Groti', 'initials': 'KG', 'affiliation': 'Department of Endocrinology, University Medical Centre, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.'}, {'lastname': 'Tenover', 'firstname': 'Joyce Lisa', 'initials': 'JL', 'affiliation': 'Geriatric Medicine, VA Palo Alto Health Care System, Palo Alto, CA, USA; School of Medicine, Stanford University, Stanford, CA, USA.'}, {'lastname': 'Tan', 'firstname': 'Hui Meng', 'initials': 'HM', 'affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Ho Chee Kong', 'firstname': 'Christopher', 'initials': 'C', 'affiliation': ""School of Medicine, Taylor's University, Subang Jaya, Malaysia.""}, {'lastname': 'Tan', 'firstname': 'Wei Shen', 'initials': 'WS', 'affiliation': 'MD Anderson Cancer Center, University of Texas, Houston, TX, USA.'}, {'lastname': 'Marks', 'firstname': 'Leonard S', 'initials': 'LS', 'affiliation': 'David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'lastname': 'Ross', 'firstname': 'Richard J', 'initials': 'RJ', 'affiliation': 'Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.'}, {'lastname': 'Schwartz', 'firstname': 'Robert S', 'initials': 'RS', 'affiliation': 'Division of Geriatric Medicine, University of Colorado School of Medicine, Aurora, CO, USA.'}, {'lastname': 'Manson', 'firstname': 'Paul', 'initials': 'P', 'affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'lastname': 'Roberts', 'firstname': 'Stephen A', 'initials': 'SA', 'affiliation': 'Centre for Biostatistics, University of Manchester, Manchester, UK.'}, {'lastname': 'Skovsager Andersen', 'firstname': 'Marianne', 'initials': 'M', 'affiliation': 'Department of Endocrinology, University of Southern Denmark, Odense, Denmark.'}, {'lastname': 'Velling Magnussen', 'firstname': 'Line', 'initials': 'L', 'affiliation': 'Department of Endocrinology, University of Southern Denmark, Odense, Denmark.'}, {'lastname': 'Aceves-Martins', 'firstname': 'Magaly', 'initials': 'M', 'affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'lastname': 'Gillies', 'firstname': 'Katie', 'initials': 'K', 'affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'lastname': 'Hernández', 'firstname': 'Rodolfo', 'initials': 'R', 'affiliation': 'Health Economics Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'lastname': 'Oliver', 'firstname': 'Nick', 'initials': 'N', 'affiliation': 'Faculty of Medicine, Imperial College London, London, UK.'}, {'lastname': 'Dhillo', 'firstname': 'Waljit S', 'initials': 'WS', 'affiliation': 'Faculty of Medicine, Imperial College London, London, UK.'}, {'lastname': 'Bhattacharya', 'firstname': 'Siladitya', 'initials': 'S', 'affiliation': 'School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.'}, {'lastname': 'Brazzelli', 'firstname': 'Miriam', 'initials': 'M', 'affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, UK.'}, {'lastname': 'Jayasena', 'firstname': 'Channa N', 'initials': 'CN', 'affiliation': 'Faculty of Medicine, Imperial College London, London, UK. Electronic address: c.jayasena@imperial.ac.uk.'}]",,,,Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.,10.1016/S2666-7568(23)00169-1,<Element 'PubmedArticle' at 0x7f05dd46c900>
3,"37587511
27546235
24833586
30471926
26786204
28732515
34107254
33214681
35228310
23273845
28122230
31493147
35260865
30783653
19910308
27508061
16199517
35589920
24994846
21369534
35974106
28602351
30082275
37393197
17969104
28863860
16626397
12670482
25896511
21490621
21642987
17851529
32848093
28970783
36617879
23545502
25666439
34530748
26235985
35177477
30944478
34140954
31959936
25309543
24963278
22198949
18981147
31324751
35487953
28245991
30782788
15833363
34294785
33301878
19689368
34281564
23965734
32379705
27374120
24162652
31018141
28930663
36747024
35181976
11322887
26354916
24019961
35922662
33732142
32589933
28340339
18256700
28928743
28665028
22171895
22036569
24411104
15728241
19503107
20484116
27091843
36257314
33008530
36449413
36624497",Microglial senescence contributes to female-biased neuroinflammation in the aging mouse hippocampus: implications for Alzheimer's disease.,"Microglia, the brain's principal immune cells, have been implicated in the pathogenesis of Alzheimer's disease (AD), a condition shown to affect more females than males. Although sex differences in microglial function and transcriptomic programming have been described across development and in disease models of AD, no studies have comprehensively identified the sex divergences that emerge in the aging mouse hippocampus. Further, existing models of AD generally develop pathology (amyloid plaques and tau tangles) early in life and fail to recapitulate the aged brain environment associated with late-onset AD. Here, we examined and compared transcriptomic and translatomic sex effects in young and old murine hippocampal microglia.
Hippocampal tissue from C57BL6/N and microglial NuTRAP mice of both sexes were collected at young (5-6 month-old [mo]) and old (22-25 mo) ages. Cell sorting and affinity purification techniques were used to isolate the microglial transcriptome and translatome for RNA-sequencing and differential expression analyses. Flow cytometry, qPCR, and imaging approaches were used to confirm the transcriptomic and translatomic findings.
There were marginal sex differences identified in the young hippocampal microglia, with most differentially expressed genes (DEGs) restricted to the sex chromosomes. Both sex chromosomally and autosomally encoded sex differences emerged with aging. These sex DEGs identified at old age were primarily female-biased and enriched in senescent and disease-associated microglial signatures. Normalized gene expression values can be accessed through a searchable web interface ( https://neuroepigenomics.omrf.org/ ). Pathway analyses identified upstream regulators induced to a greater extent in females than in males, including inflammatory mediators IFNG, TNF, and IL1B, as well as AD-risk genes TREM2 and APP.
These data suggest that female microglia adopt disease-associated and senescent phenotypes in the aging mouse hippocampus, even in the absence of disease pathology, to a greater extent than males. This sexually divergent microglial phenotype may explain the difference in susceptibility and disease progression in the case of AD pathology. Future studies will need to explore sex differences in microglial heterogeneity in response to AD pathology and determine how sex-specific regulators (i.e., sex chromosomal or hormonal) elicit these sex effects.","['Alzheimer’s disease', 'Brain aging', 'Disease-associated microglia', 'Hippocampus', 'Microglia', 'Neuroinflammation', 'Senescence', 'Sex divergence', 'Sex effects', 'Transcriptomics']",Journal of neuroinflammation,2023-08-17,"[{'lastname': 'Ocañas', 'firstname': 'Sarah R', 'initials': 'SR', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.\nDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Pham', 'firstname': 'Kevin D', 'initials': 'KD', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Cox', 'firstname': 'Jillian E J', 'initials': 'JEJ', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.\nGraduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Keck', 'firstname': 'Alex W', 'initials': 'AW', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Ko', 'firstname': 'Sunghwan', 'initials': 'S', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.\nGraduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Ampadu', 'firstname': 'Felix A', 'initials': 'FA', 'affiliation': 'Graduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Porter', 'firstname': 'Hunter L', 'initials': 'HL', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Ansere', 'firstname': 'Victor A', 'initials': 'VA', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.\nDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Kulpa', 'firstname': 'Adam', 'initials': 'A', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Kellogg', 'firstname': 'Collyn M', 'initials': 'CM', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.\nDepartment of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'lastname': 'Machalinski', 'firstname': 'Adeline H', 'initials': 'AH', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Thomas', 'firstname': 'Manu A', 'initials': 'MA', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Wright', 'firstname': 'Zsabre', 'initials': 'Z', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Chucair-Elliott', 'firstname': 'Ana J', 'initials': 'AJ', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA.'}, {'lastname': 'Freeman', 'firstname': 'Willard M', 'initials': 'WM', 'affiliation': 'Genes and Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA. bill-freeman@omrf.org.\nDepartment of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. bill-freeman@omrf.org.\nOklahoma City Veterans Affairs Medical Center, Oklahoma City, OK, USA. bill-freeman@omrf.org.'}]",,,"There were marginal sex differences identified in the young hippocampal microglia, with most differentially expressed genes (DEGs) restricted to the sex chromosomes. Both sex chromosomally and autosomally encoded sex differences emerged with aging. These sex DEGs identified at old age were primarily female-biased and enriched in senescent and disease-associated microglial signatures. Normalized gene expression values can be accessed through a searchable web interface ( https://neuroepigenomics.omrf.org/ ). Pathway analyses identified upstream regulators induced to a greater extent in females than in males, including inflammatory mediators IFNG, TNF, and IL1B, as well as AD-risk genes TREM2 and APP.","© 2023. BioMed Central Ltd., part of Springer Nature.",10.1186/s12974-023-02870-2,<Element 'PubmedArticle' at 0x7f05df391f40>
4,"37231172
23414128
29424298
28666209
36829840
31969104
30323144
33347668
32535272
34646644
36901787
35563589
26254982
25792098
34840666
29136946
19481694
27649135
36071869
25490740
33064252
29066163
34803920
28620474
35600880
33615162
32478277
33515559
27591943
21910668
26855490
22687461
15451054
31844967
12641740
33396869
29435096",Therapeutic potential of flavonoids in the management of obesity-induced Alzheimer's disease: an overview of preclinical and clinical studies.,"Obesity is a global epidemic that affects people of all ages, genders, and backgrounds. It can lead to a plethora of disorders, including diabetes mellitus, renal dysfunction, musculoskeletal problems, metabolic syndrome, cardiovascular, and neurodegenerative abnormalities. Obesity has also been linked to neurological diseases such as cognitive decline, dementia, and Alzheimer's disease (AD), caused by oxidative stress, pro-inflammatory cytokines, and the production of reactive oxygen free radicals (ROS). Secretion of insulin hormone is impaired in obese people, leading to hyperglycaemia and increased accumulation of amyloid-β in the brain. Acetylcholine, a key neurotransmitter necessary for forming new neuronal connections in the brain, decreases in AD patients. To alleviate acetylcholine deficiency, researchers have proposed dietary interventions and adjuvant therapies that enhance the production of acetylcholine and assist in the management of AD patients. Such measures include dietary intervention with antioxidant and anti-inflammatory flavonoid-rich diets, which have been found to bind to tau receptors, reduce gliosis, and reduce neuroinflammatory markers in animal models. Furthermore, flavonoids like curcumin, resveratrol, epigallocatechin-3-gallate, morin, delphinidins, quercetin, luteolin, and oleocanthal have shown to cause significant reductions in interleukin-1β, increase BDNF levels, stimulate hippocampal neurogenesis and synapse formation, and ultimately prevent the loss of neurons in the brain. Thus, flavonoid-rich nutraceuticals can be a potential cost-effective therapeutic option for treating obesity-induced AD, but further well-designed, randomized, and placebo-controlled clinical studies are needed to assess their optimal dosages, efficacy, and long-term safety of flavonoids in humans. The main objectives of this review are to underscore the therapeutic potential of different nutraceuticals containing flavonoids that can be added in the daily diet of AD patients to enhance acetylcholine and reduce neuronal inflammation in the brain.","['Animal models of Alzheimer’s disease', 'Curcumin', 'Delphinidins', 'Epigallocatechin-3-gallate', 'Luteolin', 'Morin', 'Neuro-inflammation', 'Nutraceuticals containing flavonoids', 'Obesity-induced Alzheimer’s disease', 'Oleocanthal', 'Oxidative stress', 'Quercetin', 'Resveratrol']",Naunyn-Schmiedeberg's archives of pharmacology,2023-05-26,"[{'lastname': 'Kothawade', 'firstname': 'Sakshi M', 'initials': 'SM', 'affiliation': ""Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai-56, Maharashtra, India.""}, {'lastname': 'Buttar', 'firstname': 'Harpal Singh', 'initials': 'HS', 'affiliation': 'Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.'}, {'lastname': 'Tuli', 'firstname': 'Hardeep Singh', 'initials': 'HS', 'affiliation': 'Department of Biotechnology, Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to Be University), Haryana, Mullana, India.'}, {'lastname': 'Kaur', 'firstname': 'Ginpreet', 'initials': 'G', 'affiliation': ""Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai-56, Maharashtra, India. ginpreet.aneja@gmail.com.""}]",,,,"© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.","10.1007/s00210-023-02529-y
10.1021/cn400024q
10.2174/0929867325666180209132125
10.1016/j.biopha.2017.06.010
10.3390/antiox12020280
10.2174/1570159x18666200122122512
10.4103/1673-5374.230303
10.1002/biof.1703
10.1016/j.arr.2020.101095
10.7759/cureus.17591
10.3390/ijms24054354
10.3390/ijms23095202
10.1016/j.neuint.2015.07.026
10.1016/S1474-4422(15)70016-5
10.3233/bpl-200098
10.1155/2021/4051207
10.1016/j.biopha.2017.11.047
10.1155/2013/162750
10.1016/j.ijpharm.2009.03.021
10.3390/molecules21091243
10.1155/2022/6038996
10.1089/jmf.2014.0053
10.1007/s11064-020-03031-0
10.1016/S1474-4422(17)30084-4
10.3389/fendo.2021.585887
10.1017/jns.2016.41
10.3389/fphar.2022.876614
10.1021/acsptsci.0c00224
10.1021/acsomega.0c01818
10.1016/j.lfs.2021.119129
10.1016/j.colsurfb.2016.08.052
10.1517/14712598.2011.619974
10.1007/s12291-015-0514-0
10.1016/j.jff.2019.05.004
10.1016/j.freeradbiomed.2011.09.010
10.1016/j.freeradbiomed.2004.01.001
10.1007/s00394-019-02105-2
10.1046/j.1471-4159.2003.01652.x
10.3390/ijms21020493
10.1155/2017/1459497",<Element 'PubmedArticle' at 0x7f05de771d60>
5,"36970912
20971753
36315040
21222600
36202819
31810826
31914217
33538206
31119452
16862116
18183624
35039149
21325651
25741868
17726481
27439681
35964197
27311648
28462717
34305575
33486486
24387985
20171924
22818528
26724960
18234697
22366795
20045477
25317628
20479359
17030534
29530724
32772750
34631218
29520145
28916533
33737586
23724906
22647257",Progranulin Gene Mutations in Chinese Patients with Frontotemporal Dementia: A Case Report and Literature Review.,"Progranulin (GRN) mutations in frontotemporal dementia (FTD) have been less frequently reported in China than in Western countries.
This study reports a novel GRN mutation and summarizes the genetic and clinical features of patients with GRN mutations in China.
Comprehensive clinical, genetic, and neuroimaging examinations were conducted on a 58-year-old female patient diagnosed with semantic variant primary progressive aphasia. A literature review was also conducted and clinical and genetic features of patients with GRN mutations in China were summarized.
Neuroimaging revealed marked lateral atrophy and hypometabolism in the left frontal, temporal, and parietal lobes. The patient was negative for pathologic amyloid and tau deposition by positron emission tomography. A novel heterozygous 45-bp deletion (c.1414-14_1444delCCCTTCCCCGCCAGGCTGTGTGCTGCGAGGATCGCCAGCACTGCT) was detected by whole-exome sequencing of the patient's genomic DNA. Nonsense-mediated mRNA decay was presumed to be involved in the degradation of the mutant gene transcript. The mutation was deemed pathogenic according to American College of Medical Genetics and Genomics criteria. The patient had a reduced plasma GRN level. In the literature, there were reports of 13 Chinese patients - mostly female - with GRN mutations; the prevalence was 1.2% -2.6% and patients mostly had early disease onset.
Our findings expand the mutation profile of GRN in China, which can aid the diagnosis and treatment of FTD.","['China', 'Progranulin (GRN)', 'frontotemporal dementia', 'genetics']",Journal of Alzheimer's disease : JAD,2023-03-28,"[{'lastname': 'Chu', 'firstname': 'Min', 'initials': 'M', 'affiliation': 'Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Nan', 'firstname': 'Haitian', 'initials': 'H', 'affiliation': 'Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Jiang', 'firstname': 'Deming', 'initials': 'D', 'affiliation': 'Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Liu', 'firstname': 'Li', 'initials': 'L', 'affiliation': 'Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Huang', 'firstname': 'Anqi', 'initials': 'A', 'affiliation': 'Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Wang', 'firstname': 'Yihao', 'initials': 'Y', 'affiliation': 'Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Wu', 'firstname': 'Liyong', 'initials': 'L', 'affiliation': 'Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.'}]",,"Our findings expand the mutation profile of GRN in China, which can aid the diagnosis and treatment of FTD.","Neuroimaging revealed marked lateral atrophy and hypometabolism in the left frontal, temporal, and parietal lobes. The patient was negative for pathologic amyloid and tau deposition by positron emission tomography. A novel heterozygous 45-bp deletion (c.1414-14_1444delCCCTTCCCCGCCAGGCTGTGTGCTGCGAGGATCGCCAGCACTGCT) was detected by whole-exome sequencing of the patient's genomic DNA. Nonsense-mediated mRNA decay was presumed to be involved in the degradation of the mutant gene transcript. The mutation was deemed pathogenic according to American College of Medical Genetics and Genomics criteria. The patient had a reduced plasma GRN level. In the literature, there were reports of 13 Chinese patients - mostly female - with GRN mutations; the prevalence was 1.2% -2.6% and patients mostly had early disease onset.",,"10.3233/JAD-230052
10.1111/jnp.12297",<Element 'PubmedArticle' at 0x7f05df9c72c0>
6,36967089,Sex difference in biological change and mechanism of Alzheimer's disease: From macro- to micro-landscape.,"Alzheimer's disease (AD) is the most common form of dementia and numerous studies reported a higher prevalence and incidence of AD among women. Although women have longer lifetime, longevity does not wholly explain the higher frequency and lifetime risk in women. It is important to understand sex diﬀerences in AD pathophysiology and pathogenesis, which could provide foundation for future clinical AD research. Here, we reviewed the most recent and relevant literature on sex differences in biological change of AD from macroscopical neuroimaging to microscopical pathologic change (neuronal degeneration, synaptic dysfunction, amyloid-beta and tau accumulation). We also discussed sex differences in cellular mechanisms related to AD (neuroinflammation, mitochondria dysfunction, oxygen stress, apoptosis, autophagy, blood-brain-barrier dysfunction, gut microbiome alteration, bulk and single cell/nucleus omics) and possible causes underlying these differences including sex-chromosome, sex hormone and hypothalamic-pituitary- adrenal (HPA) axis effects.","['Alzheimer’s disease', 'Mechanism', 'Sex-differences']",Ageing research reviews,2023-03-27,"[{'lastname': 'Cui', 'firstname': 'Shi-Shuang', 'initials': 'SS', 'affiliation': 'Department of Neurology & Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Department of Geriatrics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.'}, {'lastname': 'Jiang', 'firstname': 'Qian-Wen', 'initials': 'QW', 'affiliation': 'Department of Neurology & Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Department of Geriatrics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.'}, {'lastname': 'Chen', 'firstname': 'Sheng-Di', 'initials': 'SD', 'affiliation': 'Department of Neurology & Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: chensd@rjh.com.cn.'}]",,,,Copyright © 2023 Elsevier B.V. All rights reserved.,10.1016/j.arr.2023.101918,<Element 'PubmedArticle' at 0x7f05df9b3810>
7,36868496,"Cadmium-promoted thyroid hormones disruption mediates ROS, inflammation, Aβ and Tau proteins production, gliosis, spongiosis and neurodegeneration in rat basal forebrain.","Cadmium (Cd) produces cognition decline following single and repeated treatment, although the complete mechanisms are still unrevealed. Basal forebrain (BF) cholinergic neurons innervate the cortex and hippocampus, regulating cognition. Cd single and repeated exposure induced BF cholinergic neuronal loss, partly through thyroid hormones (THs) disruption, which may cause the cognition decline observed following Cd exposure. However, the mechanisms through which THs disruption mediate this effect remain unknown. To research the possible mechanisms through which Cd-induced THs deficiency may mediate BF neurodegeneration, Wistar male rats were treated with Cd for 1- (1 mg/kg) or 28-days (0.1 mg/kg) with or without triiodothyronine (T3, 40 μg/kg/day). Cd exposure promoted neurodegeneration, spongiosis, gliosis and several mechanisms related to these alterations (increased H","['Aβ and Tau proteins', 'Basal forebrain cholinergic neurons', 'Cadmium', 'Inflammatory cytokines', 'Oxidative stress', 'T3']",Chemico-biological interactions,2023-03-04,"[{'lastname': 'Sola', 'firstname': 'Emma', 'initials': 'E', 'affiliation': 'Department of Pharmacology and Toxicology, Veterinary School, Complutense University of Madrid, 28040, Madrid, Spain.'}, {'lastname': 'Moyano', 'firstname': 'Paula', 'initials': 'P', 'affiliation': 'Department of Pharmacology and Toxicology, Veterinary School, Complutense University of Madrid, 28040, Madrid, Spain. Electronic address: pmoyanocires@ucm.es.'}, {'lastname': 'Flores', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Department of Pharmacology and Toxicology, Veterinary School, Complutense University of Madrid, 28040, Madrid, Spain.'}, {'lastname': 'García', 'firstname': 'José Manuel', 'initials': 'JM', 'affiliation': 'Department of Pharmacology and Toxicology, Veterinary School, Complutense University of Madrid, 28040, Madrid, Spain.'}, {'lastname': 'García', 'firstname': 'Jimena', 'initials': 'J', 'affiliation': 'Department of Pharmacology and Toxicology, Veterinary School, Complutense University of Madrid, 28040, Madrid, Spain.'}, {'lastname': 'Anadon', 'firstname': 'María José', 'initials': 'MJ', 'affiliation': 'Department of Legal Medicine, Psychiatry and Pathology, Medicine School, Complutense University of Madrid, 28041, Madrid, Spain.'}, {'lastname': 'Frejo', 'firstname': 'María Teresa', 'initials': 'MT', 'affiliation': 'Department of Pharmacology and Toxicology, Veterinary School, Complutense University of Madrid, 28040, Madrid, Spain.'}, {'lastname': 'Pelayo', 'firstname': 'Adela', 'initials': 'A', 'affiliation': 'Department of Legal Medicine, Psychiatry and Pathology, Medicine School, Complutense University of Madrid, 28041, Madrid, Spain.'}, {'lastname': 'de la Cabeza Fernandez', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Chemistry in Pharmaceutical Sciences, Pharmacy School, Complutense University of Madrid, 28041, Madrid, Spain.'}, {'lastname': 'Del Pino', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Department of Pharmacology and Toxicology, Veterinary School, Complutense University of Madrid, 28040, Madrid, Spain. Electronic address: jdelpino@pdi.ucm.es.'}]",,,,Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.,10.1016/j.cbi.2023.110428,<Element 'PubmedArticle' at 0x7f05df9ae900>
8,36852497,Characterizing Factors Influencing Baseline Plasma Biomarkers for Sport-Related Concussion in Adolescents.,,"['fluid biomarkers', 'menstrual cycle', 'pediatric', 'sex hormones', 'sport-related concussion']",Journal of neurotrauma,2023-03-01,"[{'lastname': 'Tabor', 'firstname': 'Jason Benjamin', 'initials': 'JB', 'affiliation': ""Sport Injury Prevention Research Center, Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.\nHotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.\nAlberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.""}, {'lastname': 'Penner', 'firstname': 'Linden Chase', 'initials': 'LC', 'affiliation': ""Sport Injury Prevention Research Center, Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.\nHotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.\nAlberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.""}, {'lastname': 'Cooper', 'firstname': 'Jennifer Gradi', 'initials': 'JG', 'affiliation': 'Department of Pathology and Laboratory Medicine, Djavad Mowafaghian Center for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Ghodsi', 'firstname': 'Mohammad', 'initials': 'M', 'affiliation': 'Department of Pathology and Laboratory Medicine, Djavad Mowafaghian Center for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Galarneau', 'firstname': 'Jean-Michel', 'initials': 'JM', 'affiliation': 'Sport Injury Prevention Research Center, Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.'}, {'lastname': 'Fraser', 'firstname': 'Douglas Dale', 'initials': 'DD', 'affiliation': 'Department of Pediatrics and Clinical Neurological Sciences, Western University, London, Ontario, Canada.'}, {'lastname': 'Emery', 'firstname': 'Carolyn Ann', 'initials': 'CA', 'affiliation': ""Sport Injury Prevention Research Center, Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.\nHotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.\nAlberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.\nDepartment of Pediatrics, University of Calgary, Calgary, Alberta, Canada.\nDepartment of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.""}, {'lastname': 'Wellington', 'firstname': 'Cheryl Lea', 'initials': 'CL', 'affiliation': 'Department of Pathology and Laboratory Medicine, Djavad Mowafaghian Center for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Debert', 'firstname': 'Chantel Teresa', 'initials': 'CT', 'affiliation': ""Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.\nAlberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.\nDepartment of Pathology and Laboratory Medicine, Djavad Mowafaghian Center for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.\nDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.""}]",,,,,10.1089/neu.2022.0501,<Element 'PubmedArticle' at 0x7f05df380e00>
9,36809844,The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation.,"An antidiabetic agent sodium glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin has been revealed to bind to catalytic anionic site of acetylcholinesterase (AChE), which is considered to be associated with the cognitive decline in neurodegenerative diseases, such as Alzheimer's disease (AD). The aim of the present study was thus to probe the effect of ertugliflozin on AD. Intracerebroventricular injection of streptozotocin (STZ/i.c.v) (3 mg/kg) was done bilaterally in male Wistar rats at 7-8 weeks of age. Two treatment doses (5 mg/kg and 10 mg/kg) of ertugliflozin were given intragastrically to STZ/i.c.v-induced rats for 20 days daily for behavioral assessment. Biochemical estimations of cholinergic activity, neuronal apoptosis, mitochondrial function and synaptic plasticity were performed. Behavioral results with ertugliflozin treatment revealed attenuation of cognitive deficit. Ertugliflozin also inhibited hippocampal AChE activity, downregulated pro-apoptotic marker expression, as well as mitigated mitochondrial dysfunction and synaptic damage in STZ/i.c.v rats. Importantly, we found that the hyperphosphorylation of tau in the hippocampus of STZ/i.c.v rats was decreased after oral administration of ertugliflozin, which was accompanied by decreased Phospho.IRS-1","[""Alzheimer's disease"", 'Brain insulin signaling', 'Cognitive impairment', 'Ertugliflozin', 'Tau hyperphosphorylation']",Physiology & behavior,2023-02-23,"[{'lastname': 'Pang', 'firstname': 'Bo', 'initials': 'B', 'affiliation': 'NHC Key Laboratory of Hormones and Development, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China; Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University, Tianjin 300134, China.'}, {'lastname': 'Zhang', 'firstname': 'Lu-Lu', 'initials': 'LL', 'affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Li', 'firstname': 'Bin', 'initials': 'B', 'affiliation': 'NHC Key Laboratory of Hormones and Development, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China; Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University, Tianjin 300134, China.'}, {'lastname': 'Sun', 'firstname': 'Feng-Xian', 'initials': 'FX', 'affiliation': 'Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Wang', 'firstname': 'Zhi-Da', 'initials': 'ZD', 'affiliation': 'NHC Key Laboratory of Hormones and Development, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China; Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University, Tianjin 300134, China. Electronic address: zhidawangdr@126.com.'}]",,,,Copyright © 2023 Elsevier Inc. All rights reserved.,10.1016/j.physbeh.2023.114134,<Element 'PubmedArticle' at 0x7f05dba5b310>
10,"36735152
1673054
29850777
24664866
31780819
21852788
33318676
33756057
12130773
8756120
28360418
10319819
26322584
20882069
24493463
26549211
25326800
29725016
9065484
9742219
12860980
18374643
17971664
2213015
20707633
27333827
29630551
27723722
20357768
21442128
30425303
16410745
15542598
34166772
30382187
28345579
26403494
11085925
28826672
30135302
12671646
11520916
31004063
29295929
34343610
34106682
30373880
23197718
16319169
23828492
28546318
26143335
22074460
30530690
31315045
20392958
31349032
10411343
32782380
8062385
8061567
21558366
19721007
32911010
35023303
33863723
25904988
27179961
28533150
29643512
8664441
12115737
34215679
31637998
27776263
32832679
35017199
34260075
32086435
31649329
33958804
20595630
33716161
33339957
34958873
29102564
31139153
29437880
24782009
10468980
9020850
9811848
29440419
28538730
20961245
21159522
35236988
19875111
12730778
12577184
16630814
20171950
30941099
20171951
17003115
20042686
22908268
17192296
24426235
25754247
35289055
30298180
34108509
28855400
31613825
10697060
24042430
15213206
30085049
23836935
27871199
10982164
11560301
9927313
10364248
8408049
15059951
24601954
18045930
32859953
29187895
30559440
33127753",C/EBPβ/AEP Signaling Drives Alzheimer's Disease Pathogenesis.,"Alzheimer's disease (AD) is the most common type of dementia. Almost two-thirds of patients with AD are female. The reason for the higher susceptibility to AD onset in women is unclear. However, hormone changes during the menopausal transition are known to be associated with AD. Most recently, we reported that follicle-stimulating hormone (FSH) promotes AD pathology and enhances cognitive dysfunctions via activating the CCAAT-enhancer-binding protein (C/EBPβ)/asparagine endopeptidase (AEP) pathway. This review summarizes our current understanding of the crucial role of the C/EBPβ/AEP pathway in driving AD pathogenesis by cleaving multiple critical AD players, including APP and Tau, explaining the roles and the mechanisms of FSH in increasing the susceptibility to AD in postmenopausal females. The FSH-C/EBPβ/AEP pathway may serve as a novel therapeutic target for the treatment of AD.","['Alzheimer’s disease', 'Asparagine endopeptidase', 'C/EBPβ', 'Follicle stimulating hormone', 'Pathogenesis']",Neuroscience bulletin,2023-02-04,"[{'lastname': 'Xiong', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.'}, {'lastname': 'Zhang', 'firstname': 'Zhentao', 'initials': 'Z', 'affiliation': 'Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.'}, {'lastname': 'Ye', 'firstname': 'Keqiang', 'initials': 'K', 'affiliation': 'Faculty of Life and Health Sciences, Shenzhen Institute of Advanced Technology (SIAT), Shenzhen, 518034, China. kq.ye@siat.ac.cn.'}]",,,,"© 2023. Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences.","10.1007/s12264-023-01025-w
10.1016/0896-6273(91)90052-2
10.1093/brain/awy132
10.1007/s12264-013-1423-y
10.1038/s41583-019-0240-3
10.1038/nrd3505
10.1038/s41582-020-00435-y
10.1126/science.1072994
10.1074/jbc.271.31.18295
10.1038/nrn.2017.29
10.1016/S0092-8674(00)80748-5
10.1038/nature14864
10.1007/s12264-010-0515-1
10.1001/jamaneurol.2013.5847
10.1038/ncomms9762
10.1038/nm.3700
10.1038/s41467-018-04120-z
10.1074/jbc.272.12.8090
10.1042/bj3350111
10.1074/jbc.M305930200
10.1016/j.molcel.2008.02.017
10.1159/000110576
10.1111/j.1471-4159.1990.tb04948.x
10.3109/00207454.2010.505353
10.1016/j.arr.2016.06.003
10.3233/JAD-170959
10.1038/nm.4199
10.1038/nature08890
10.2119/molmed.2010.00220
10.1038/s41598-018-35130-y
10.1097/01.jnen.0000196133.74087.cb
10.1074/jbc.M409234200
10.1016/j.pneurobio.2021.102113
10.1038/s41380-018-0286-z
10.1038/ncomms14740
10.1016/j.biochi.2015.09.022
10.1042/bj3520327
10.1016/j.molcel.2017.07.018
10.1172/jci.insight.99007
10.1038/nrn1078
10.1146/annurev.neuro.24.1.677
10.1073/pnas.1901348116
10.1073/pnas.1718683115
10.1016/j.neuropharm.2021.108737
10.1021/acschemneuro.1c00181
10.1084/jem.20180539
10.1523/JNEUROSCI.3300-12.2012
10.1091/mbc.e05-10-0963
10.1515/revneuro-2013-0014
10.1126/science.aal3222
10.1016/j.pneurobio.2015.06.003
10.1186/1742-2094-8-156
10.1073/pnas.1815915115
10.1016/j.celrep.2019.06.054
10.1523/JNEUROSCI.6251-09.2010
10.1016/j.nbd.2019.104540
10.1097/00005072-199907000-00007
10.1038/s41380-020-00863-8
10.1016/0092-8674(94)90421-9
10.1242/dev.044529
10.1073/pnas.0901767106
10.1016/j.pneurobio.2020.101905
10.1002/advs.202103396
10.1126/sciadv.abe4499
10.1186/s13195-015-0126-1
10.1016/j.jalz.2016.02.010
10.1016/j.pnpbp.2017.05.007
10.1038/s41586-018-0023-4
10.1006/cyto.1995.0090
10.1002/jcp.10116
10.1126/sciimmunol.abd1287
10.7554/eLife.47013
10.1016/j.neurobiolaging.2016.08.019
10.1126/sciadv.aba0466
10.1136/gutjnl-2021-326269
10.15252/embj.2020106320
10.1038/s41380-020-0687-7
10.1038/s41422-019-0241-9
10.1038/s41593-021-00851-3
10.2353/ajpath.2010.090973
10.1016/j.pneurobio.2021.102032
10.1038/s41380-020-00956-4
10.1016/j.pneurobio.2021.102212
10.1016/j.mce.2017.10.015
10.3389/fendo.2019.00305
10.1530/JME-17-0308
10.1007/978-1-4939-0659-8_7
10.1046/j.1365-2265.1999.00846.x
10.1038/ng0297-201
10.1073/pnas.95.23.13612
10.1073/pnas.1718144115
10.1038/nature22342
10.1056/NEJMoa1001283
10.1016/j.cyto.2010.11.011
10.1038/s41586-022-04463-0
10.1016/j.envres.2009.09.012
10.1007/s00198-002-1329-4
10.1007/s00198-002-1307-x
10.1016/j.cell.2006.01.051
10.1016/j.bbrc.2010.02.112
10.3389/fendo.2019.00136
10.1016/j.bbrc.2010.02.113
10.1073/pnas.0606805103
10.1152/ajpregu.00728.2009
10.1073/pnas.1212806109
10.1210/jc.2006-1393
10.1007/s12291-013-0301-8
10.1111/acel.12331
10.1038/s41598-021-90084-y
10.1212/WNL.0000000000004425
10.1097/GME.0000000000001405
10.1093/epirev/mxt008
10.1001/jama.291.24.2947
10.1210/en.2018-00601
10.1210/jc.2013-1808
10.3109/09513590.2016.1161746
10.1007/s001980070091
10.1016/S0025-6196(11)62109-5
10.1210/endo.140.2.6526
10.1074/jbc.274.25.17987
10.1016/S0021-9258(20)80630-9
10.1210/en.2003-1719
10.1111/jnc.12706
10.1523/JNEUROSCI.2718-07.2007
10.1038/s12276-020-00494-7
10.7150/thno.21216
10.1038/s41422-018-0123-6
10.1073/pnas.2014588117",<Element 'PubmedArticle' at 0x7f05dbd41ea0>
11,36730553,"A systematic review and meta-analysis on overall survival, failure-free survival and safety outcomes in patients with metastatic hormone-sensitive prostate cancer treated with new anti-androgens.","Androgen-deprivation therapy (ADT) combined with new antiandrogens have shown to improve the outcomes of patients with hormone-sensitive metastatic prostate cancer. This systematic review and meta-analysis aim to compare the efficacy and toxicity of these agents in this specific scenario.
Randomized clinical trials (RCT) were identified after systematic searching of databases. A random-effect model was used to determine the pooled hazard ratio (HR) for overall survival (OS) and failure-free survival according to the inverse-variance method. The Mantel-Haenszel method was used to calculate the pooled odds ratio (OR) for treatment-related adverse events (AEs) grade 3 or higher. Heterogeneity was determined using the Tau 2 and I2 statistics.
Seven trials were included in this meta-analysis ( n  = 7544). The addition of ADT plus new-generation anti-androgens, specifically: abiraterone, apalutamide, darolutamide or enzalutamide was associated with improved OS (pooled HR, 0.66; 95% CI, 0.61-0.71; P  < 0.00001) with no significant heterogeneity detected among trials. (Tau 2  = 0; I2  = 0%; P  = 0.88). Failure-free survival was significantly longer in the combination-therapy group than in the control group (pooled HR, 0.43; 95% CI, 0.39-0.47; P  < 0.00001) This effect was consistent among trials (Tau 2  = 0; I2  = 27%; P  = 0.22). The overall OR of AEs grade 3 or higher was significantly increased with the use of the combination therapy (pooled OR, 1.40; 95% CI, 1.13-1.74; P  = 0.002), with significant heterogeneity among trials (Tau 2  = 0.07; I2  = 82%; P  < 0.0001).
The addition of either abiraterone, apalutamide, darolutamide or enzalutamide to ADT improves OS and failure-free survival in hormone-sensitive metastatic prostate cancer, albeit an increase in AEs.",[],Anti-cancer drugs,2023-02-03,"[{'lastname': 'Ramos-Esquivel', 'firstname': 'Allan', 'initials': 'A', 'affiliation': 'Departamento de Oncología Médica, Hospital San Juan de Dios. Caja Costarricense de Seguro Social, Universidad de Costa Rica, San José.'}, {'lastname': 'Garita-Rojas', 'firstname': 'Esteban', 'initials': 'E', 'affiliation': 'Escuela de Medicina. Universidad de Costa Rica, Costa Rica.'}, {'lastname': 'Masis-Marroquín', 'firstname': 'Adriana', 'initials': 'A', 'affiliation': 'Escuela de Medicina. Universidad de Costa Rica, Costa Rica.'}]",,"The addition of either abiraterone, apalutamide, darolutamide or enzalutamide to ADT improves OS and failure-free survival in hormone-sensitive metastatic prostate cancer, albeit an increase in AEs.","Seven trials were included in this meta-analysis ( n  = 7544). The addition of ADT plus new-generation anti-androgens, specifically: abiraterone, apalutamide, darolutamide or enzalutamide was associated with improved OS (pooled HR, 0.66; 95% CI, 0.61-0.71; P  < 0.00001) with no significant heterogeneity detected among trials. (Tau 2  = 0; I2  = 0%; P  = 0.88). Failure-free survival was significantly longer in the combination-therapy group than in the control group (pooled HR, 0.43; 95% CI, 0.39-0.47; P  < 0.00001) This effect was consistent among trials (Tau 2  = 0; I2  = 27%; P  = 0.22). The overall OR of AEs grade 3 or higher was significantly increased with the use of the combination therapy (pooled OR, 1.40; 95% CI, 1.13-1.74; P  = 0.002), with significant heterogeneity among trials (Tau 2  = 0.07; I2  = 82%; P  < 0.0001).","Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.",10.1097/CAD.0000000000001419,<Element 'PubmedArticle' at 0x7f05df9a5860>
12,"36288997
20971753
21810890
21325651
26041104
30508042
29627938
25662776
29172163
31701893
30711674
30711676
30847466
25002573
21986680
18245784
23006986
28738187
28855404
31810826
17572111
26267068
19112065
30128275
11464847
31914218
29064009
11001602
29213551
20479357
1202204
11113214
33452053
20045477
23041626
33247623
34027016
32024404
32219515
28337409
32855285
24695229
33906932
28116236
32417716
25974958
26653846
27986990
29614652
31379483",Longitudinal Brain Atrophy Rates in Presymptomatic Carriers of Genetic Frontotemporal Dementia.,"It is important to identify at what age brain atrophy rates in genetic frontotemporal dementia (FTD) start to accelerate and deviate from normal aging effects to find the optimal starting point for treatment. We investigated longitudinal brain atrophy rates in the presymptomatic stage of genetic FTD using normative brain volumetry software.
Presymptomatic 
Thirty-four 
We provide evidence for longitudinal brain atrophy in the presymptomatic stage of genetic FTD. The affected brain areas and the age after which atrophy rates start to accelerate and diverge from normal aging slopes differed between gene groups. These results highlight the value of normative volumetry software for disease tracking and staging biomarkers in genetic FTD. These techniques could help in identifying the optimal time window for starting treatment and monitoring treatment response.",[],Neurology,2022-10-27,"[{'lastname': 'Poos', 'firstname': 'Jackie M', 'initials': 'JM', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Grandpierre', 'firstname': 'Leonie D M', 'initials': 'LDM', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'van der Ende', 'firstname': 'Emma L', 'initials': 'EL', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Panman', 'firstname': 'Jessica L', 'initials': 'JL', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Papma', 'firstname': 'Janne M', 'initials': 'JM', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Seelaar', 'firstname': 'Harro', 'initials': 'H', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'van den Berg', 'firstname': 'Esther', 'initials': 'E', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': ""van 't Klooster"", 'firstname': 'Ronald', 'initials': 'R', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Bron', 'firstname': 'Esther', 'initials': 'E', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Steketee', 'firstname': 'Rebecca', 'initials': 'R', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Vernooij', 'firstname': 'Meike W', 'initials': 'MW', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Pijnenburg', 'firstname': 'Yolande A L', 'initials': 'YAL', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Rombouts', 'firstname': 'Serge A R B', 'initials': 'SARB', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'van Swieten', 'firstname': 'John', 'initials': 'J', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Jiskoot', 'firstname': 'Lize C', 'initials': 'LC', 'affiliation': 'From the Department of Neurology and Alzheimer Center Erasmus MC (Jackie M. Poos, L.D.M.G., E.L.E., J.L.P., Janne M. Papma, H.S., Esther van den Berg, J.S., L.C.J.), Erasmus MC University Medical Center; Quantib B.V. (R.K.), Rotterdam; Departments of Radiology and Nuclear Medicine (Esther Bron, R.S., M.W.V.) and Epidemiology (M.W.V.), Erasmus MC University Medical Center Rotterdam; Department of Neurology (Y.A.L.P.), Alzheimer Center, Location VU University Medical Center Amsterdam Neuroscience, Amsterdam University Medical Center; Department of Radiology (S.A.R.B.R.), Leiden University Medical Center; Institute of Psychology (S.A.R.B.R.) and Leiden Institute for Brain and Cognition (S.A.R.B.R.), Leiden University, The Netherlands; and Dementia Research Centre (L.C.J.), Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom. l.c.jiskoot@erasmusmc.nl.'}]",,,Thirty-four ,"Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.",10.1212/WNL.0000000000201292,<Element 'PubmedArticle' at 0x7f05dc396450>
13,"36142737
26401763
19903025
26540080
33999717
12895417
30488653
25896362
20558146
21808223
20967592
9670227
15173895
20702575
9356556
15748844
33842910
32949555
34560142
34039953
27424985
33753066
34230948
23804095
31233825
31607916
31156176
23029404
24857980
24837743
35966798
17923159
30770297
29988104
34229088
17659878
21593564
22976078
31622610
34637795
34896160
6106204
35167441
26069008
22315011
20436931
32433245
28633291
10844576
2578498
11738498
25682754
27283378
33808441
35431906
35768852
35033583
19664757
35568928
21297257
35660628
17306982
17368447
26836189
35559229
24144550
22984283
25609597
34308901
28608594",Investigation of Anxiety- and Depressive-like Symptoms in 4- and 8-Month-Old Male Triple Transgenic Mouse Models of Alzheimer's Disease.,"Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia. Approximately 50% of AD patients show anxiety and depressive symptoms, which may contribute to cognitive decline. We aimed to investigate whether the triple-transgenic mouse (3xTg-AD) is a good preclinical model of this co-morbidity. The characteristic histological hallmarks are known to appear around 6-month; thus, 4- and 8-month-old male mice were compared with age-matched controls. A behavioral test battery was used to examine anxiety- (open field (OF), elevated plus maze, light-dark box, novelty suppressed feeding, and social interaction (SI) tests), and depression-like symptoms (forced swim test, tail suspension test, sucrose preference test, splash test, and learned helplessness) as well as the cognitive decline (Morris water maze (MWM) and social discrimination (SD) tests). Acetylcholinesterase histochemistry visualized cholinergic fibers in the cortex. Dexamethasone-test evaluated the glucocorticoid non-suppression. In the MWM, the 3xTg-AD mice found the platform later than controls in the 8-month-old cohort. The SD abilities of the 3xTg-AD mice were missing at both ages. In OF, both age groups of 3xTg-AD mice moved significantly less than the controls. During SI, 8-month-old 3xTg-AD animals spent less time with friendly social behavior than the controls. In the splash test, 3xTg-AD mice groomed themselves significantly less than controls of both ages. Cortical fiber density was lower in 8-month-old 3xTg-AD mice compared to the control. Dexamethasone non-suppression was detectable in the 4-month-old group. All in all, some anxiety- and depressive-like symptoms were present in 3xTg-AD mice. Although this strain was not generally more anxious or depressed, some aspects of comorbidity might be studied in selected tests, which may help to develop new possible treatments.","['3xTg-AD', 'Alzheimer’s disorder', 'anxiety', 'depression', 'mice models']",International journal of molecular sciences,2022-09-24,"[{'lastname': 'Várkonyi', 'firstname': 'Dorottya', 'initials': 'D', 'affiliation': 'Center for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.\nLaboratory of Behavioral and Stress Studies, Institute of Experimental Medicine, 1083 Budapest, Hungary.'}, {'lastname': 'Török', 'firstname': 'Bibiána', 'initials': 'B', 'affiliation': 'Center for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.\nLaboratory of Behavioral and Stress Studies, Institute of Experimental Medicine, 1083 Budapest, Hungary.\nJános Szentágothai Doctoral School of Neurosciences, Semmelweis University, 1085 Budapest, Hungary.'}, {'lastname': 'Sipos', 'firstname': 'Eszter', 'initials': 'E', 'affiliation': 'Laboratory of Behavioral and Stress Studies, Institute of Experimental Medicine, 1083 Budapest, Hungary.'}, {'lastname': 'Fazekas', 'firstname': 'Csilla Lea', 'initials': 'CL', 'affiliation': 'Center for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.\nLaboratory of Behavioral and Stress Studies, Institute of Experimental Medicine, 1083 Budapest, Hungary.\nJános Szentágothai Doctoral School of Neurosciences, Semmelweis University, 1085 Budapest, Hungary.'}, {'lastname': 'Bánrévi', 'firstname': 'Krisztina', 'initials': 'K', 'affiliation': 'Laboratory of Behavioral and Stress Studies, Institute of Experimental Medicine, 1083 Budapest, Hungary.'}, {'lastname': 'Correia', 'firstname': 'Pedro', 'initials': 'P', 'affiliation': 'Center for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.\nLaboratory of Behavioral and Stress Studies, Institute of Experimental Medicine, 1083 Budapest, Hungary.\nJános Szentágothai Doctoral School of Neurosciences, Semmelweis University, 1085 Budapest, Hungary.'}, {'lastname': 'Chaves', 'firstname': 'Tiago', 'initials': 'T', 'affiliation': 'Center for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.\nLaboratory of Behavioral and Stress Studies, Institute of Experimental Medicine, 1083 Budapest, Hungary.\nJános Szentágothai Doctoral School of Neurosciences, Semmelweis University, 1085 Budapest, Hungary.'}, {'lastname': 'Farkas', 'firstname': 'Szidónia', 'initials': 'S', 'affiliation': 'Center for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.'}, {'lastname': 'Szabó', 'firstname': 'Adrienn', 'initials': 'A', 'affiliation': 'Center for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.\nLaboratory of Behavioral and Stress Studies, Institute of Experimental Medicine, 1083 Budapest, Hungary.\nJános Szentágothai Doctoral School of Neurosciences, Semmelweis University, 1085 Budapest, Hungary.'}, {'lastname': 'Martínez-Bellver', 'firstname': 'Sergio', 'initials': 'S', 'affiliation': 'Lendület Laboratory of Systems Neuroscience, Institute of Experimental Medicine, 1083 Budapest, Hungary.\nDepartment of Anatomy and Human Embryology, Faculty of Medicine and Odontology, University of Valencia, 46010 Valencia, Spain.'}, {'lastname': 'Hangya', 'firstname': 'Balázs', 'initials': 'B', 'affiliation': 'Lendület Laboratory of Systems Neuroscience, Institute of Experimental Medicine, 1083 Budapest, Hungary.'}, {'lastname': 'Zelena', 'firstname': 'Dóra', 'initials': 'D', 'affiliation': 'Center for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.\nLaboratory of Behavioral and Stress Studies, Institute of Experimental Medicine, 1083 Budapest, Hungary.'}]",,,,,"10.3390/ijms231810816
10.3233/JAD-148004
10.1586/ern.09.106
10.1016/j.jad.2015.09.069
10.1080/17425255.2021.1931681
10.1016/S0896-6273(03)00434-3
10.1111/acel.12873
10.1016/j.bbr.2015.04.012
10.1016/j.brainres.2010.06.011
10.3791/2920
10.1016/S0193-953X(05)70006-X
10.1210/en.2010-0285
10.1176/ajp.154.11.1497
10.1016/j.neuron.2005.01.040
10.1016/j.ibneur.2020.12.004
10.1016/j.yhbeh.2020.104852
10.1016/j.neuropsychologia.2021.108028
10.1038/s41398-021-01458-9
10.1016/j.brainres.2021.147437
10.1523/JNEUROSCI.1501-13.2013
10.1016/j.neuropharm.2019.107673
10.3389/fphar.2019.01061
10.3233/JAD-190253
10.1371/journal.pone.0046111
10.1016/j.beproc.2014.05.001
10.1016/j.bbr.2014.04.055
10.3389/fnagi.2022.916904
10.1016/j.bbr.2007.08.029
10.1016/j.molmet.2019.01.008
10.1038/s41596-018-0011-z
10.1016/j.mri.2021.06.022
10.1016/j.nbd.2007.06.013
10.3233/JAD-2011-110236
10.3233/JAD-2012-121438
10.1016/j.physbeh.2019.112688
10.1016/j.lfs.2021.120037
10.1016/j.lfs.2021.120223
10.1016/0091-3057(80)90067-2
10.7554/eLife.70271
10.1002/9780470942390.mo110176
10.3791/3769
10.1371/journal.pone.0010404
10.1097/FBP.0000000000000564
10.1093/ijnp/pyx046
10.1046/j.1365-2826.2000.00475.x
10.1177/33.2.2578498
10.1016/S0306-4522(01)00443-2
10.1007/s12021-014-9258-x
10.1016/j.yhbeh.2016.06.001
10.3390/brainsci11040444
10.3389/fnagi.2022.835885
10.1186/s12989-022-00485-8
10.1016/j.neures.2022.01.003
10.1016/j.biopsych.2009.06.015
10.1186/s12974-022-02466-2
10.3233/JAD-2011-101635
10.1016/j.redox.2022.102354
10.1016/j.nbd.2006.12.019
10.1016/j.expneurol.2007.01.037
10.3233/JAD-150975
10.3389/fphar.2022.884170
10.1016/j.bbr.2013.10.017
10.1101/lm.026070.112
10.1093/ijnp/pyu020
10.3233/JAD-210109
10.1002/biof.1369",<Element 'PubmedArticle' at 0x7f05df372e00>
14,"36050455
27692812
28796587
33662287
29949494
29420164
30279582
16046649
17470867
18309951
30191186
32907777
32469184
32905676
23943299
32209449",Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?,"Metastasis-free survival (MFS) is a surrogate for overall survival (OS) in men with non-metastatic castration-resistant prostate cancer (CRPC), but this endpoint may take years to develop in men with non-metastatic castrate-sensitive disease. The study objective was to examine whether progression to CRPC is a potential intermediate endpoint for developing metastatic disease in patients with biochemical recurrence (BCR) after radical prostatectomy (RP).
Men with BCR following RP who had PSA doubling times (PSADT) < 9 months and no metastasis at the time of initiating androgen deprivation therapy (ADT) (n = 210) were included. The primary objective was to assess the correlation between CRPC-free survival (CRPC-FS) and MFS, and the secondary objective was to assess the correlation between time to metastasis and time to CRPC. Kendall's Tau was used to test the correlation for the primary and secondary outcomes.
The median MFS was 104 months (95% CI: 83-114) and median CRPC-FS was 100 months (95% CI: 80-114). Based on the Kaplan-Meier curve, the greatest difference in time to MFS and CRPC-FS was around 70% free survival, which was reached at 61.2 months for MFS and 49.6 months for CRPC-FS. Kendall's Tau for the correlation between CRPC-FS and MFS and between time to CRPC and time to metastasis was 0.867 (95% CI: 0.765-0.968) and 0.764 (95% CI: 0.644-0.884), respectively.
Given the high correlation between CRPC-FS and MFS, after validation, CRPC-FS may serve as a potential intermediate endpoint in trials for men with BCR initiating ADT following local therapy.",[],Prostate cancer and prostatic diseases,2022-09-02,"[{'lastname': 'Klaassen', 'firstname': 'Zachary', 'initials': 'Z', 'affiliation': 'Division of Urology, Department of Surgery, Medical College of Georgia - Augusta University, Augusta, GA, USA. zklaassen19@gmail.com.\nGeorgia Cancer Center, Augusta, GA, USA. zklaassen19@gmail.com.'}, {'lastname': 'Howard', 'firstname': 'Lauren', 'initials': 'L', 'affiliation': 'Veterans Affairs Health Care System, Durham, NC, USA.\nDuke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.'}, {'lastname': 'Wallis', 'firstname': 'Christopher J D', 'initials': 'CJD', 'affiliation': 'Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'lastname': 'Janes', 'firstname': 'Jessica L', 'initials': 'JL', 'affiliation': 'Veterans Affairs Health Care System, Durham, NC, USA.'}, {'lastname': 'De Hoedt', 'firstname': 'Amanda', 'initials': 'A', 'affiliation': 'Veterans Affairs Health Care System, Durham, NC, USA.'}, {'lastname': 'Aronson', 'firstname': 'William J', 'initials': 'WJ', 'affiliation': 'Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.\nDepartment of Urology, UCLA School of Medicine, Los Angeles, CA, USA.'}, {'lastname': 'Polascik', 'firstname': 'Thomas J', 'initials': 'TJ', 'affiliation': 'Veterans Affairs Health Care System, Durham, NC, USA.\nDuke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.'}, {'lastname': 'Amling', 'firstname': 'Christopher J', 'initials': 'CJ', 'affiliation': 'Division of Urology, Oregon Health Sciences University, Portland, OR, USA.'}, {'lastname': 'Kane', 'firstname': 'Christopher J', 'initials': 'CJ', 'affiliation': 'Urology Department, University of California San Diego Health System, San Diego, CA, USA.'}, {'lastname': 'Cooperberg', 'firstname': 'Matthew R', 'initials': 'MR', 'affiliation': 'Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.'}, {'lastname': 'Terris', 'firstname': 'Martha K', 'initials': 'MK', 'affiliation': 'Division of Urology, Department of Surgery, Medical College of Georgia - Augusta University, Augusta, GA, USA.\nGeorgia Cancer Center, Augusta, GA, USA.\nCharlie Norwood Veterans Affairs Medical Center, Augusta, GA, USA.'}, {'lastname': 'Wu', 'firstname': 'Yuan', 'initials': 'Y', 'affiliation': 'Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.'}, {'lastname': 'Freedland', 'firstname': 'Stephen J', 'initials': 'SJ', 'affiliation': 'Veterans Affairs Health Care System, Durham, NC, USA.\nDivision of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}]",,,"The median MFS was 104 months (95% CI: 83-114) and median CRPC-FS was 100 months (95% CI: 80-114). Based on the Kaplan-Meier curve, the greatest difference in time to MFS and CRPC-FS was around 70% free survival, which was reached at 61.2 months for MFS and 49.6 months for CRPC-FS. Kendall's Tau for the correlation between CRPC-FS and MFS and between time to CRPC and time to metastasis was 0.867 (95% CI: 0.765-0.968) and 0.764 (95% CI: 0.644-0.884), respectively.","© 2022. The Author(s), under exclusive licence to Springer Nature Limited.","10.1038/s41391-022-00585-8
10.1016/j.clgc.2016.08.018
10.1200/JCO.2017.73.9987
10.1016/S1470-2045(20)30730-0
10.1056/NEJMoa1800536
10.1056/NEJMoa1715546
10.1038/s41391-018-0095-0
10.1001/jama.294.4.433
10.1200/JCO.2006.08.0572
10.1200/JCO.2007.12.4487
10.1016/j.tjem.2018.08.001
10.1016/0378-3758(80)90023-3
10.1002/bimj.201300162
10.1016/j.eururo.2020.08.011
10.1056/NEJMoa2003892
10.1056/NEJMoa2001342
10.1002/cncr.28270
10.1016/S0140-6736(20)30314-7",<Element 'PubmedArticle' at 0x7f05d9ffdef0>
15,"35737923
28796587
32552276
31977385
29420164
29949494
30763142
29306514
28146658
32960679
2727467
12933525
29512498
31629656
18929505
16979837
19211454
30526194
28097317
22112793
27601545",Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.,"Metastasis-free survival (MFS), but not event-free survival, is a validated surrogate end point for overall survival (OS) in men treated for localized prostate cancer. It remains unknown if this holds true in biochemically recurrent disease after radical prostatectomy. Leveraging NRG/RTOG 9601, we aimed to determine the performance of intermediate clinical end points (ICEs) as surrogate end points for OS in recurrent prostate cancer.
NRG/RTOG 9601 randomly assigned 760 men with recurrence after prostatectomy to salvage radiation therapy with 2 years of placebo versus bicalutamide 150 mg daily. ICEs assessed were biochemical failure (BF) per NRG/RTOG 9601 (prostate-specific antigen nadir + 0.3-0.5 ng/mL or initiation of salvage hormone therapy; [BF1]) and NRG/RTOG 0534 (prostate-specific antigen nadir+2 ng/mL; [BF2]), distant metastasis (DM), and MFS (DM or death). Surrogacy was assessed by the Prentice criteria and a two-stage meta-analytic approach (condition one assessed at the patient level with Kendall's τ and condition two assessed by randomly dividing the entire trial cohort into 10 pseudo trial centers and calculating the average 
BF1, BF2, DM, and MFS satisfied the four Prentice criteria. However, with the two-condition meta-analytic approach, there was strong correlation between MFS and OS (τ = 0.86), moderate correlation between DM and OS (τ = 0.66), and weaker correlation between BF1 (τ = 0.25) or BF2 (τ = 0.40) and OS. Similarly, for condition two, the treatment effect of antiandrogen therapy on MFS and OS were correlated (
MFS is also a strong surrogate for OS in men receiving salvage radiation therapy for recurrence after prostatectomy. Caution should be used when inferring survival benefit from effects on BF in biochemically recurrent prostate cancer. Lack of comorbidity data did not allow us to assess whether BF in men with no/minimal comorbidity could serve as a surrogate for OS.",[],Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2022-06-24,"[{'lastname': 'Jackson', 'firstname': 'William C', 'initials': 'WC', 'affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.'}, {'lastname': 'Tang', 'firstname': 'Ming', 'initials': 'M', 'affiliation': 'University of Michigan, Ann Arbor, MI.'}, {'lastname': 'Schipper', 'firstname': 'Matthew J', 'initials': 'MJ', 'affiliation': 'Department of Biostatistics, University of Michigan, Ann Arbor, MI.'}, {'lastname': 'Sandler', 'firstname': 'Howard M', 'initials': 'HM', 'affiliation': 'Cedars Sinai Medical Center, Los Angeles, CA.'}, {'lastname': 'Zumsteg', 'firstname': 'Zachary S', 'initials': 'ZS', 'affiliation': 'Cedars Sinai Medical Center, Los Angeles, CA.'}, {'lastname': 'Efstathiou', 'firstname': 'Jason A', 'initials': 'JA', 'affiliation': 'Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.'}, {'lastname': 'Shipley', 'firstname': 'William U', 'initials': 'WU', 'affiliation': 'Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.'}, {'lastname': 'Seiferheld', 'firstname': 'Wendy', 'initials': 'W', 'affiliation': 'NRG Oncology SDMC, Philadelphia, PA.'}, {'lastname': 'Lukka', 'firstname': 'Himanshu R', 'initials': 'HR', 'affiliation': 'Hamilton Health Sciences, Hamilton, ON, Canada.'}, {'lastname': 'Bahary', 'firstname': 'Jean-Paul', 'initials': 'JP', 'affiliation': ""Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada.""}, {'lastname': 'Zietman', 'firstname': 'Anthony L', 'initials': 'AL', 'affiliation': 'Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.'}, {'lastname': 'Pisansky', 'firstname': 'Thomas M', 'initials': 'TM', 'affiliation': 'Department of Radiation Oncology, Mayo Clinic, Rochester, MN.'}, {'lastname': 'Zeitzer', 'firstname': 'Kenneth L', 'initials': 'KL', 'affiliation': 'Einstein Medical Center, Philadelphia, PA.'}, {'lastname': 'Hall', 'firstname': 'William A', 'initials': 'WA', 'affiliation': 'Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI.'}, {'lastname': 'Dess', 'firstname': 'Robert T', 'initials': 'RT', 'affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.'}, {'lastname': 'Lovett', 'firstname': 'Richard D', 'initials': 'RD', 'affiliation': 'University of Vermont Medical Center, Burlington, VT.'}, {'lastname': 'Balogh', 'firstname': 'Alexander G', 'initials': 'AG', 'affiliation': 'Tom Baker Cancer Centre, Calgary, AB, Canada.'}, {'lastname': 'Feng', 'firstname': 'Felix Y', 'initials': 'FY', 'affiliation': 'Department of Radiation Oncology, University of California San Francisco, San Francisco, CA.'}, {'lastname': 'Spratt', 'firstname': 'Daniel E', 'initials': 'DE', 'affiliation': 'Department of Radiation Oncology, University Hospitals, Cleveland, OH.\nDepartment of Radiation Oncology, Case Western Reserve University School of Medicine, Cleveland, OH.'}]",,MFS is also a strong surrogate for OS in men receiving salvage radiation therapy for recurrence after prostatectomy. Caution should be used when inferring survival benefit from effects on BF in biochemically recurrent prostate cancer. Lack of comorbidity data did not allow us to assess whether BF in men with no/minimal comorbidity could serve as a surrogate for OS.,"BF1, BF2, DM, and MFS satisfied the four Prentice criteria. However, with the two-condition meta-analytic approach, there was strong correlation between MFS and OS (τ = 0.86), moderate correlation between DM and OS (τ = 0.66), and weaker correlation between BF1 (τ = 0.25) or BF2 (τ = 0.40) and OS. Similarly, for condition two, the treatment effect of antiandrogen therapy on MFS and OS were correlated (",,10.1200/JCO.21.02741,<Element 'PubmedArticle' at 0x7f05da014810>
16,35476966,MicroRNA modulation is a potential molecular mechanism for neuroprotective effects of intranasal insulin administration in amyloid βeta oligomer induced Alzheimer's like rat model.,"Substantial evidence indicates that imbalance in the expression of miR-132-3p, miR-181b-5p, miR-125b-5p, miR-26a-5p, miR-124-3p, miR-146a-5p, miR-29a-3p, and miR-30a-5p in the AD brain are associated with amyloid-beta (Aβ) aggregation, tau pathology, neuroinflammation, and synaptic dysfunction, the major pathological hallmarks of Alzheimer's disease)AD(. Several studies have reported that intranasal insulin administration ameliorates memory in AD patients and animal models. However, the underlying molecular mechanisms are not yet completely elucidated. Therefore, the aim of this study was to determine whether insulin is involved in regulating the expression of AD-related microRNAs. Pursuing this objective, we first investigated the therapeutic effect of intranasal insulin on Aβ oligomer (AβO)-induced memory impairment in male rats using the Morris water maze task. Then, molecular and histological changes in response to AβO and/or insulin time course were assessed in the extracted hippocampi on days 1, 14, and 21 of the study using congo red staining, western blot and quantitative real-time PCR analyses. We observed memory impairment, Aβ aggregation, tau hyper-phosphorylation, neuroinflammation, insulin signaling dys-regulation, and down-regulation of miR-26a, miR-124, miR-29a, miR-181b, miR-125b, miR-132, and miR-146a in the hippocampus of AβO-exposed rats 21 days after AβO injection. Intranasal insulin treatment ameliorated memory impairment and concomitantly increased miR-132, miR-181b, and miR-125b expression, attenuated tau phosphorylation levels, Aβ aggregation, and neuroinflammation, and regulated the insulin signaling as well. In conclusion, our study suggest that the neuroprotective effects of insulin on memory observed in AD-like rats could be partially due to the restoration of miR-132, miR-181b, and miR-125b expression in the brain.","[""Alzheimer's disease"", 'Intranasal insulin treatment', 'Soluble amyloid-beta oligomer', 'microRNA']",Experimental gerontology,2022-04-28,"[{'lastname': 'Bazrgar', 'firstname': 'Maryam', 'initials': 'M', 'affiliation': 'Neuroscience Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran.'}, {'lastname': 'Khodabakhsh', 'firstname': 'Pariya', 'initials': 'P', 'affiliation': 'Department of Pharmacology, Shahid Beheshti University of Medical Science, Tehran, Iran.'}, {'lastname': 'Dargahi', 'firstname': 'Leila', 'initials': 'L', 'affiliation': 'Neurobiology Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran.'}, {'lastname': 'Mohagheghi', 'firstname': 'Fatemeh', 'initials': 'F', 'affiliation': 'Institute of Experimental Hematology, Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany.'}, {'lastname': 'Ahmadiani', 'firstname': 'Abolhassan', 'initials': 'A', 'affiliation': 'Neuroscience Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran. Electronic address: aahmadiani@yahoo.com.'}]",,,,Copyright © 2022 Elsevier Inc. All rights reserved.,10.1016/j.exger.2022.111812,<Element 'PubmedArticle' at 0x7f05dba2f540>
17,"34680117
25549971
33188134
24174584
27239539
22548198
26635640
28467028
22917144
21810890
8710059
30349851
26483753
28719018
29554190
31937580
32878979
32866962
31668596
32699184
14749131
26679858
21521348
27767986
33104518
26365177
29403354
21387376
31477517",Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies.,"Biomarkers to discriminate the main pathologies underlying frontotemporal lobar degeneration (FTLD-Tau, FTLD-TDP) are lacking. Our previous FTLD cerebrospinal fluid (CSF) proteome study revealed that sex hormone-binding globulin (SHBG) was specifically increased in FTLD-Tau patients. Here we investigated the potential of CSF SHBG as a novel biomarker discriminating the main FTLD pathological subtypes. SHBG was measured in CSF samples from patients with FTLD-Tau (","['CSF', 'FTLD-TDP', 'FTLD-Tau', 'biomarkers']",Biomolecules,2021-10-24,"[{'lastname': 'Campo', 'firstname': 'Marta Del', 'initials': 'MD', 'affiliation': 'Neurochemistry Laboratory, Department of Clinical Chemistry, and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.\nDepartamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, 28668 Madrid, Spain.'}, {'lastname': 'Pijnenburg', 'firstname': 'Yolande A L', 'initials': 'YAL', 'affiliation': 'Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location VUmc, 1081 HV Amsterdam, The Netherlands.'}, {'lastname': 'Chen-Plotkin', 'firstname': 'Alice', 'initials': 'A', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.'}, {'lastname': 'Irwin', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.'}, {'lastname': 'Grossman', 'firstname': 'Murray', 'initials': 'M', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.'}, {'lastname': 'Twaalfhoven', 'firstname': 'Harry A M', 'initials': 'HAM', 'affiliation': 'Neurochemistry Laboratory, Department of Clinical Chemistry, and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.'}, {'lastname': 'Hu', 'firstname': 'William T', 'initials': 'WT', 'affiliation': 'Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA.\nRutgers-RWJ Medical School, Institute for Health, Health Care Policy, and Aging Research, Rutgers Biomedical and Health Sciences, New Brunswick, NJ 08901, USA.'}, {'lastname': 'Meeter', 'firstname': 'Lieke H', 'initials': 'LH', 'affiliation': 'Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.'}, {'lastname': 'van Swieten', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.'}, {'lastname': 'Vermunt', 'firstname': 'Lisa', 'initials': 'L', 'affiliation': 'Neurochemistry Laboratory, Department of Clinical Chemistry, and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.\nDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location VUmc, 1081 HV Amsterdam, The Netherlands.'}, {'lastname': 'Martens', 'firstname': 'Frans', 'initials': 'F', 'affiliation': 'Endocrine Laboratory, Amsterdam University Medical Centers, Location AMC, 1105 AZ Amsterdam, The Netherlands.'}, {'lastname': 'Heijboer', 'firstname': 'Annemieke C', 'initials': 'AC', 'affiliation': 'Endocrine Laboratory, Amsterdam University Medical Centers, Location AMC, 1105 AZ Amsterdam, The Netherlands.'}, {'lastname': 'Teunissen', 'firstname': 'Charlotte E', 'initials': 'CE', 'affiliation': 'Neurochemistry Laboratory, Department of Clinical Chemistry, and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.'}]",,,,,"10.3390/biom11101484
10.1007/s00401-014-1380-1
10.1136/jnnp-2020-323520
10.1212/01.wnl.0000436625.63650.27
10.1016/j.dadm.2015.12.004
10.1155/2012/258454
10.3389/fpsyt.2015.00165
10.1002/mds.26987
10.2217/bmm.12.46
10.1093/brain/awr179
10.1212/WNL.47.1.1
10.1002/acn3.629
10.3389/fneur.2015.00202
10.1002/ana.24996
10.1001/jamaneurol.2018.0118
10.1136/jnnp-2019-321954
10.1126/scitranslmed.abb3774
10.1038/s41586-020-2709-7
10.1016/j.jalz.2019.06.4956
10.18632/aging.103497
10.1016/S0197-4580(03)00046-0
10.2174/1567205013666151218145752
10.1111/j.1365-2265.2011.04082.x
10.3233/JAD-160513
10.18632/aging.103813
10.1016/j.cmet.2015.08.016
10.3389/fnmol.2018.00002
10.1002/ana.22244
10.1016/j.jalz.2019.05.013",<Element 'PubmedArticle' at 0x7f05dba4b1d0>
18,"34580742
11092441
26493934
28520755
31616335
33164782
24179466
23163581
29126934
25753028
28782715
28500787
32027960
17321052
17123561
18502412
20142434
7554428
28471062
26631930
26887570
23684085
29089864
28286177
32899468
24290657
20847440
32585289
28507260
19252484
21595115
17548533
23168113
6471907
3228475
28259598
29175423
25820261
28086931
22057275
25058901
28692012
29733897
17051205
19808793
32017944
21799050
24675771
19517227
15313024
18272239
21419797
21848865
30825590
32258255
31907304
19640317
28131230",A cellular approach to understanding and treating Gulf War Illness.,"Gulf War Illness (GWI), a disorder suffered by approximately 200,000 veterans of the first Gulf War, was caused by exposure to low-level organophosphate pesticides and nerve agents in combination with battlefield stress. To elucidate the mechanistic basis of the brain-related symptoms of GWI, human-induced pluripotent stem cells (hiPSCs) derived from veterans with or without GWI were differentiated into forebrain glutamatergic neurons and then exposed to a Gulf War (GW) relevant toxicant regimen consisting of a sarin analog and cortisol, a human stress hormone. Elevated levels of total and phosphorylated tau, reduced microtubule acetylation, altered mitochondrial dynamics/transport, and decreased neuronal activity were observed in neurons exposed to the toxicant regimen. Some of the data are consistent with the possibility that some veterans may have been predisposed to acquire GWI. Wistar rats exposed to a similar toxicant regimen showed a mild learning and memory deficit, as well as cell loss and tau pathology selectively in the CA3 region of the hippocampus. These cellular responses offer a mechanistic explanation for the memory loss suffered by veterans with GWI and provide a cell-based model for screening drugs and developing personalized therapies for these veterans.","['Gulf War Illness', 'Human-induced pluripotent stem cells', 'Memory', 'Microtubule', 'Mitochondria', 'Neuronal activity', 'Tau']",Cellular and molecular life sciences : CMLS,2021-09-29,"[{'lastname': 'Yates', 'firstname': 'Philip L', 'initials': 'PL', 'affiliation': 'Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA, 19129, USA.'}, {'lastname': 'Patil', 'firstname': 'Ankita', 'initials': 'A', 'affiliation': 'Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA, 19129, USA.'}, {'lastname': 'Sun', 'firstname': 'Xiaohuan', 'initials': 'X', 'affiliation': 'Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA, 19129, USA.'}, {'lastname': 'Niceforo', 'firstname': 'Alessia', 'initials': 'A', 'affiliation': 'Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA, 19129, USA.'}, {'lastname': 'Gill', 'firstname': 'Ramnik', 'initials': 'R', 'affiliation': 'Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA, 19129, USA.'}, {'lastname': 'Callahan', 'firstname': 'Patrick', 'initials': 'P', 'affiliation': 'Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, 30912, USA.'}, {'lastname': 'Beck', 'firstname': 'Wayne', 'initials': 'W', 'affiliation': 'Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, 30912, USA.'}, {'lastname': 'Piermarini', 'firstname': 'Emanuela', 'initials': 'E', 'affiliation': 'Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA, 19129, USA.'}, {'lastname': 'Terry', 'firstname': 'Alvin V', 'initials': 'AV', 'affiliation': 'Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, 30912, USA.'}, {'lastname': 'Sullivan', 'firstname': 'Kimberly A', 'initials': 'KA', 'affiliation': 'Department of Environmental Health, Boston University School of Public Health, Boston, MA, 02118, USA.'}, {'lastname': 'Baas', 'firstname': 'Peter W', 'initials': 'PW', 'affiliation': 'Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA, 19129, USA.'}, {'lastname': 'Qiang', 'firstname': 'Liang', 'initials': 'L', 'affiliation': 'Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA, 19129, USA. lq24@drexel.edu.'}]",,,,"© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.",10.1007/s00018-021-03942-3,<Element 'PubmedArticle' at 0x7f05db7b0b80>
19,"34496096
27033237
28515251
30761222
24727820
27143866
11007053
29394124
30254762
27002115
19798094
29720731
30013765
30894516
22552008
25102946
26914976
31097405
26456076
32895455
28642620
32376855
31735560
32444867
32586908
30403938
27557302
32482541
33189178
33129376
29200420
25628469
30413684","Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.","We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse.
OPTIMISMM was a phase 3, multicenter, open-label, randomized study (NCT01734928; N = 559). The primary endpoint was progression-free survival (PFS).
Overall, 226 patients had received one prior line of therapy. PVd significantly prolonged PFS vs Vd in patients aged ≤65 years (median, 22.0 vs 13.1 months; P = .0258) and >65 years (median, 17.6 vs 9.9 months; P = .0369). Median PFS in patients with renal impairment (RI; creatinine clearance <60 mL/min) was 15.1 months with PVd vs 9.5 months with Vd (hazard ratio [HR], 0.67 [95% CI, 0.34-1.34]). In patients without RI, median PFS was 22.0 vs 13.1 months (HR, 0.45 [95% CI, 0.27-0.76]). In patients with high-risk cytogenetics, median PFS was 14.7 vs 9.9 months (HR, 0.39 [95% CI, 0.13-1.17]). PVd significantly improved overall response rate vs Vd in all subgroups. The safety profile of PVd was consistent with previous reports.
These findings confirmed the benefits of PVd at first relapse, including in patients with poor prognostic factors.","['aged', 'chromosome aberrations', 'multiple myeloma', 'pomalidomide', 'renal insufficiency']",European journal of haematology,2021-09-09,"[{'lastname': 'Richardson', 'firstname': 'Paul G', 'initials': 'PG', 'affiliation': 'Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.'}, {'lastname': 'Schjesvold', 'firstname': 'Fredrik', 'initials': 'F', 'affiliation': 'Oslo Myeloma Center at Oslo University Hospital, KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway.'}, {'lastname': 'Weisel', 'firstname': 'Katja', 'initials': 'K', 'affiliation': 'Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'lastname': 'Moreau', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'University Hospital Hôtel-Dieu, Nantes, France.'}, {'lastname': 'Anderson', 'firstname': 'Larry D', 'initials': 'LD', 'affiliation': 'University of Texas Southwestern Medical Center, Dallas, Texas, USA.'}, {'lastname': 'White', 'firstname': 'Darrell', 'initials': 'D', 'affiliation': 'Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.'}, {'lastname': 'Rodriguez-Otero', 'firstname': 'Paula', 'initials': 'P', 'affiliation': 'Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain.'}, {'lastname': 'Sonneveld', 'firstname': 'Pieter', 'initials': 'P', 'affiliation': 'Erasmus MC Cancer Institute, Rotterdam, The Netherlands.'}, {'lastname': 'Engelhardt', 'firstname': 'Monika', 'initials': 'M', 'affiliation': 'Universitätsklinikum Freiburg, Freiburg, Germany.'}, {'lastname': 'Jenner', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': 'Southampton General Hospital, Southampton, UK.'}, {'lastname': 'Corso', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Policlinico San Matteo Universita Di Pavia, Pavia, Italy.'}, {'lastname': 'Dürig', 'firstname': 'Jan', 'initials': 'J', 'affiliation': 'University Hospital Essen, Essen, Germany.'}, {'lastname': 'Pavic', 'firstname': 'Michel', 'initials': 'M', 'affiliation': 'Centre Hospitalier Universitaire De Sherbrooke (CHUS), Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont, Sherbrooke, QC, Canada.'}, {'lastname': 'Salomo', 'firstname': 'Morten', 'initials': 'M', 'affiliation': 'Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.'}, {'lastname': 'Beksac', 'firstname': 'Meral', 'initials': 'M', 'affiliation': 'Ankara University, Ankara, Turkey.'}, {'lastname': 'Oriol', 'firstname': 'Albert', 'initials': 'A', 'affiliation': ""Institut Català d'Oncologia I Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain.""}, {'lastname': 'Lindsay', 'firstname': 'Jindriska', 'initials': 'J', 'affiliation': 'East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK.'}, {'lastname': 'Liberati', 'firstname': 'Anna Marina', 'initials': 'AM', 'affiliation': 'University of Perugia, Perugia, Italy.'}, {'lastname': 'Galli', 'firstname': 'Monica', 'initials': 'M', 'affiliation': 'Ospedale Papa Giovanni XXIII, U.O. di Ematologia, Ispedali Riuniti di Bergamo, Bergamo, Italy.'}, {'lastname': 'Robak', 'firstname': 'Pawel', 'initials': 'P', 'affiliation': 'Medical University of Lodz, Lodz, Poland.'}, {'lastname': 'Larocca', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': 'A.O.U. Citta della Salute e della Scienza di Torino, Torino, Italy.'}, {'lastname': 'Yagci', 'firstname': 'Munci', 'initials': 'M', 'affiliation': 'Gazi University Medical Faculty, Ankara, Turkey.'}, {'lastname': 'Vural', 'firstname': 'Filiz', 'initials': 'F', 'affiliation': 'Ege University, Izmir, Turkey.'}, {'lastname': 'Kanate', 'firstname': 'Abraham S', 'initials': 'AS', 'affiliation': 'West Virginia University, Morgantown, West Virginia, USA.'}, {'lastname': 'Jiang', 'firstname': 'Ruiyun', 'initials': 'R', 'affiliation': 'Bristol Myers Squibb, Princeton, New Jersey, USA.'}, {'lastname': 'Grote', 'firstname': 'Lara', 'initials': 'L', 'affiliation': 'Bristol Myers Squibb, Princeton, New Jersey, USA.'}, {'lastname': 'Peluso', 'firstname': 'Teresa', 'initials': 'T', 'affiliation': 'Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.'}, {'lastname': 'Dimopoulos', 'firstname': 'Meletios', 'initials': 'M', 'affiliation': 'National and Kapodistrian University of Athens, Athens, Greece.'}]",,,"Overall, 226 patients had received one prior line of therapy. PVd significantly prolonged PFS vs Vd in patients aged ≤65 years (median, 22.0 vs 13.1 months; P = .0258) and >65 years (median, 17.6 vs 9.9 months; P = .0369). Median PFS in patients with renal impairment (RI; creatinine clearance <60 mL/min) was 15.1 months with PVd vs 9.5 months with Vd (hazard ratio [HR], 0.67 [95% CI, 0.34-1.34]). In patients without RI, median PFS was 22.0 vs 13.1 months (HR, 0.45 [95% CI, 0.27-0.76]). In patients with high-risk cytogenetics, median PFS was 14.7 vs 9.9 months (HR, 0.39 [95% CI, 0.13-1.17]). PVd significantly improved overall response rate vs Vd in all subgroups. The safety profile of PVd was consistent with previous reports.",© 2021 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.,"10.1111/ejh.13706
10.1182/blood-2014-12-615187",<Element 'PubmedArticle' at 0x7f05db7d2900>
20,"34445147
19686220
21371747
29850777
32778792
1759558
15851853
30532084
23230430
27746722
17997029
33742131
2858057
15778722
28650319
32140092
28821953
30258234
23930978
28559789
33212787
31964406
3789664
32529479
27582691
19559700
30084021
24904307
22312444
21040845
27641495
26306871
15921860
33391505
30315174
33902708
20880504
29311817
30795987
10591291",Somatostatin and Astroglial Involvement in the Human Limbic System in Alzheimer's Disease.,"Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in the elderly. Progressive accumulation of insoluble isoforms of amyloid-β peptide (Aβ) and tau protein are the major neuropathologic hallmarks, and the loss of cholinergic pathways underlies cognitive deficits in patients. Recently, glial involvement has gained interest regarding its effect on preservation and impairment of brain integrity. The limbic system, including temporal lobe regions and the olfactory bulb, is particularly affected in the early stages. In the early 1980s, the reduced expression of the somatostatin neuropeptide was described in AD. However, over the last three decades, research on somatostatin in Alzheimer's disease has been scarce in humans. Therefore, the aim of this study was to stereologically quantify the expression of somatostatin in the human hippocampus and olfactory bulb and analyze its spatial distribution with respect to that of Aβ and au neuropathologic proteins and astroglia. The results indicate that somatostatin-expressing cells are reduced by 50% in the hippocampus but are preserved in the olfactory bulb. Interestingly, the coexpression of somatostatin with the Aβ peptide is very common but not with the tau protein. Finally, the coexpression of somatostatin with astrocytes is rare, although their spatial distribution is very similar. Altogether, we can conclude that somatostatin expression is highly reduced in the human hippocampus, but not the olfactory bulb, and may play a role in Alzheimer's disease pathogenesis.","['Alzheimer’s disease', 'astroglia', 'hippocampus', 'olfactory bulb', 'somatostatin', 'stereology']",International journal of molecular sciences,2021-08-28,"[{'lastname': 'Gonzalez-Rodriguez', 'firstname': 'Melania', 'initials': 'M', 'affiliation': 'Neuroplasticity & Neurodegeneration Laboratory, Ciudad Real Medical School, CRIB, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}, {'lastname': 'Astillero-Lopez', 'firstname': 'Veronica', 'initials': 'V', 'affiliation': 'Neuroplasticity & Neurodegeneration Laboratory, Ciudad Real Medical School, CRIB, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}, {'lastname': 'Villanueva-Anguita', 'firstname': 'Patricia', 'initials': 'P', 'affiliation': 'Neuroplasticity & Neurodegeneration Laboratory, Ciudad Real Medical School, CRIB, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}, {'lastname': 'Paya-Rodriguez', 'firstname': 'M Eugenia', 'initials': 'ME', 'affiliation': 'Neuroplasticity & Neurodegeneration Laboratory, Ciudad Real Medical School, CRIB, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}, {'lastname': 'Flores-Cuadrado', 'firstname': 'Alicia', 'initials': 'A', 'affiliation': 'Neuroplasticity & Neurodegeneration Laboratory, Ciudad Real Medical School, CRIB, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}, {'lastname': 'Villar-Conde', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': 'Neuroplasticity & Neurodegeneration Laboratory, Ciudad Real Medical School, CRIB, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}, {'lastname': 'Ubeda-Banon', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': 'Neuroplasticity & Neurodegeneration Laboratory, Ciudad Real Medical School, CRIB, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}, {'lastname': 'Martinez-Marcos', 'firstname': 'Alino', 'initials': 'A', 'affiliation': 'Neuroplasticity & Neurodegeneration Laboratory, Ciudad Real Medical School, CRIB, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}, {'lastname': 'Saiz-Sanchez', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Neuroplasticity & Neurodegeneration Laboratory, Ciudad Real Medical School, CRIB, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.'}]",,,,,"10.3390/ijms22168434
10.1111/j.1749-6632.2009.04013.x
10.1016/S0140-6736(10)61349-9
10.1093/brain/awy132
10.1038/s41593-020-0687-6
10.1007/BF00308809
10.3233/JAD-2005-7208
10.1038/s41582-018-0097-5
10.3389/fendo.2012.00154
10.3389/fncir.2016.00076
10.1016/j.mce.2007.09.007
10.1038/s12276-021-00580-4
10.1038/314092a0
10.1038/nm1206
10.7554/eLife.28401
10.3389/fnins.2020.00096
10.1007/s00415-017-8593-x
10.1038/s41593-018-0242-x
10.3109/00207454.2013.833510
10.3389/fnins.2017.00254
10.3390/ijms21228651
10.1186/s13024-019-0350-4
10.1002/ana.410200408
10.1007/s40120-020-00199-z
10.3389/fncir.2016.00062
10.1016/j.expneurol.2009.06.010
10.1007/s00441-018-2882-2
10.3389/fnana.2014.00038
10.1371/journal.pone.0031302
10.1016/j.neuron.2010.10.020
10.1016/j.neuron.2016.08.034
10.1016/j.neuroscience.2015.08.033
10.1016/j.mehy.2005.02.045
10.7150/thno.50263
10.1038/s41467-018-06731-y
10.1186/s40478-021-01180-z
10.1016/j.nurt.2010.05.017
10.3389/fnmol.2017.00427
10.1016/S1474-4422(18)30490-3
10.1001/archpsyc.56.12.1135",<Element 'PubmedArticle' at 0x7f05dbd31e00>
21,34435590,Cannabidiol - A phytocannabinoid that widely affects sphingolipid metabolism under conditions of brain insulin resistance.,"Obesity-related insulin resistance (IR) and attenuated brain insulin signaling are significant risk factors for neurodegenerative disorders, e.g., Alzheimer's disease. IR and type 2 diabetes correlate with an increased concentration of sphingolipids, a class of lipids that play an essential structural role in cellular membranes and cell signaling pathways. Cannabidiol (CBD) is a nonpsychoactive constituent of Cannabis sativa plant that interacts with the endocannabinoidome. Despite known positive effects of CBD on improvement in diabetes and its aftermath, e.g., anti-inflammatory and anti-oxidant effects, there are no studies evaluating the effect of phytocannabinoids on the brain insulin resistance and sphingolipid metabolism. Our experiment was carried out on Wistar rats that received a high-fat diet and/or intraperitoneal CBD injections. In our study, we indicated inhibition of de novo synthesis and salvage pathways, which resulted in significant changes in the concentration of sphingolipids, e.g., ceramide and sphingomyelin. Furthermore, we observed reduced brain IR and decreased tau protein phosphorylation what might be protective against neuropathologies development. We believe that our research will concern a new possible therapeutic approach with Cannabis -plant derived compounds and within a few years, cannabinoids would be considered as prominent substances for targeting both metabolic and neurodegenerative pathologies.","['Cannabidiol', 'Endocannabinoid system', 'Insulin resistance', 'Lipid metabolism', 'Sphingolipids']",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2021-08-27,"[{'lastname': 'Charytoniuk', 'firstname': 'Tomasz', 'initials': 'T', 'affiliation': 'Department of Physiology, Medical University of Bialystok, Mickiewicz Str. 2C, 15-222 Bialystok, Poland. Electronic address: tomasz.charytoniuk@umb.edu.pl.'}, {'lastname': 'Sztolsztener', 'firstname': 'Klaudia', 'initials': 'K', 'affiliation': 'Department of Physiology, Medical University of Bialystok, Mickiewicz Str. 2C, 15-222 Bialystok, Poland. Electronic address: klaudia.sztolsztener@umb.edu.pl.'}, {'lastname': 'Harasim-Symbor', 'firstname': 'Ewa', 'initials': 'E', 'affiliation': 'Department of Physiology, Medical University of Bialystok, Mickiewicz Str. 2C, 15-222 Bialystok, Poland. Electronic address: eharasim@umb.edu.pl.'}, {'lastname': 'Berk', 'firstname': 'Klaudia', 'initials': 'K', 'affiliation': 'Department of Physiology, Medical University of Bialystok, Mickiewicz Str. 2C, 15-222 Bialystok, Poland. Electronic address: klaudia.berk@umb.edu.pl.'}, {'lastname': 'Chabowski', 'firstname': 'Adrian', 'initials': 'A', 'affiliation': 'Department of Physiology, Medical University of Bialystok, Mickiewicz Str. 2C, 15-222 Bialystok, Poland. Electronic address: adrian@umb.edu.pl.'}, {'lastname': 'Konstantynowicz-Nowicka', 'firstname': 'Karolina', 'initials': 'K', 'affiliation': 'Department of Physiology, Medical University of Bialystok, Mickiewicz Str. 2C, 15-222 Bialystok, Poland. Electronic address: karolina.konstantynowicz@umb.edu.pl.'}]",,,,Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.,10.1016/j.biopha.2021.112057,<Element 'PubmedArticle' at 0x7f05de789090>
22,"34433056
24617013
32190339
25140125
28355423
24782009
405957
819345
11425840
1403624
19575469
12410709
15386260
16141396
32151259
4942174
19029910
30361544
27566840
27548915
5166472
1614538
24949966
24089208
2144363
18786384
9529006
31827083
26236014
20596023
3805440
12535208
16117741
11337964
26675822
10792581
23493490
27574482
17676034
7926191
16557269
30401431
10783170
12570815
24406016
22567125
27616559
12230501
30107566
30395289
14432658
4200926
26385780
8621768
28287422
15503991
20525243
2133132
2133133
15155004
17015491
29049571
27782186
7472494
25317845
21673307
27716949
11041445
22894052
23939821
25988614
29546369
26468242
8905302
27093585
22271212
962191
21632627
24753944
16388003
17406592
29642423
21732314
31969699
23762466
16982574",Skin exposure to UVB light induces a skin-brain-gonad axis and sexual behavior.,"Ultraviolet (UV) light affects endocrinological and behavioral aspects of sexuality via an unknown mechanism. Here we discover that ultraviolet B (UVB) exposure enhances the levels of sex-steroid hormones and sexual behavior, which are mediated by the skin. In female mice, UVB exposure increases hypothalamus-pituitary-gonadal axis hormone levels, resulting in larger ovaries; extends estrus days; and increases anti-Mullerian hormone (AMH) expression. UVB exposure also enhances the sexual responsiveness and attractiveness of females and male-female interactions. Conditional knockout of p53 specifically in skin keratinocytes abolishes the effects of UVB. Thus, UVB triggers a skin-brain-gonadal axis through skin p53 activation. In humans, solar exposure enhances romantic passion in both genders and aggressiveness in men, as seen in analysis of individual questionaries, and positively correlates with testosterone level. Our findings suggest opportunities for treatment of sex-steroid-related dysfunctions.","['HPG axis', 'UVB', 'behavioral', 'hormones', 'p53', 'questionnaires', 'sexuality', 'skin', 'solar', 'testosterone']",Cell reports,2021-08-26,"[{'lastname': 'Parikh', 'firstname': 'Roma', 'initials': 'R', 'affiliation': 'Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.'}, {'lastname': 'Sorek', 'firstname': 'Eschar', 'initials': 'E', 'affiliation': 'Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.'}, {'lastname': 'Parikh', 'firstname': 'Shivang', 'initials': 'S', 'affiliation': 'Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.'}, {'lastname': 'Michael', 'firstname': 'Keren', 'initials': 'K', 'affiliation': 'Department of Human Services, The Max Stern Yezreel Valley Academic College, Jezreel Valley 1930600, Israel.'}, {'lastname': 'Bikovski', 'firstname': 'Lior', 'initials': 'L', 'affiliation': 'The Myers Neuro-Behavioral Core Facility, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; School of Behavioral Sciences, Netanya Academic College, Netanya 4223587, Israel.'}, {'lastname': 'Tshori', 'firstname': 'Sagi', 'initials': 'S', 'affiliation': 'Research Authority, Kaplan Medical Center, Rehovot, Israel; Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, The Hebrew University, Jerusalem, Israel.'}, {'lastname': 'Shefer', 'firstname': 'Galit', 'initials': 'G', 'affiliation': 'Research Authority, Kaplan Medical Center, Rehovot, Israel.'}, {'lastname': 'Mingelgreen', 'firstname': 'Shira', 'initials': 'S', 'affiliation': 'Research Authority, Kaplan Medical Center, Rehovot, Israel.'}, {'lastname': 'Zornitzki', 'firstname': 'Taiba', 'initials': 'T', 'affiliation': 'Diabetes, Endocrinology and Metabolic Disease Institute, Kaplan Medical Center, Hadassah School of Medicine, Hebrew University in Jerusalem, Rehovot, Israel.'}, {'lastname': 'Knobler', 'firstname': 'Hilla', 'initials': 'H', 'affiliation': 'Diabetes, Endocrinology and Metabolic Disease Institute, Kaplan Medical Center, Hadassah School of Medicine, Hebrew University in Jerusalem, Rehovot, Israel.'}, {'lastname': 'Chodick', 'firstname': 'Gabriel', 'initials': 'G', 'affiliation': 'Maccabitech, Maccabi Healthcare Services, Tel Aviv, Israel; Institute of Endocrinology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.'}, {'lastname': 'Mardamshina', 'firstname': 'Mariya', 'initials': 'M', 'affiliation': 'Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.'}, {'lastname': 'Boonman', 'firstname': 'Arjan', 'initials': 'A', 'affiliation': 'School of Zoology, Faculty of Life Sciences and the Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel.'}, {'lastname': 'Kronfeld-Schor', 'firstname': 'Noga', 'initials': 'N', 'affiliation': 'School of Zoology, Faculty of Life Sciences and the Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel.'}, {'lastname': 'Bar-Joseph', 'firstname': 'Hadas', 'initials': 'H', 'affiliation': 'The TMCR Unit, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.'}, {'lastname': 'Ben-Yosef', 'firstname': 'Dalit', 'initials': 'D', 'affiliation': 'IVF Lab & Wolfe PGD-Stem Cell Lab, Fertility Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Department of Cell Biology and Development, Sackler Faculty of Medicine & Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Amir', 'firstname': 'Hadar', 'initials': 'H', 'affiliation': 'Fertility Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Pavlovsky', 'firstname': 'Mor', 'initials': 'M', 'affiliation': 'Department of Dermatology, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv 6423906, Israel.'}, {'lastname': 'Matz', 'firstname': 'Hagit', 'initials': 'H', 'affiliation': 'Department of Dermatology, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv 6423906, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.'}, {'lastname': 'Ben-Dov', 'firstname': 'Tom', 'initials': 'T', 'affiliation': 'Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; Department of Otolaryngology, Head and Neck surgery, Meir Medical Center, Kfar Saba 4428164, Israel.'}, {'lastname': 'Golan', 'firstname': 'Tamar', 'initials': 'T', 'affiliation': 'Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.'}, {'lastname': 'Nizri', 'firstname': 'Eran', 'initials': 'E', 'affiliation': 'Department of Dermatology, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv 6423906, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.'}, {'lastname': 'Liber', 'firstname': 'Daphna', 'initials': 'D', 'affiliation': 'Faculty of Humanities, Education and Social Sciences, Ono Academic College, Kiryat Ono, Israel.'}, {'lastname': 'Liel', 'firstname': 'Yair', 'initials': 'Y', 'affiliation': 'Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.'}, {'lastname': 'Brenner', 'firstname': 'Ronen', 'initials': 'R', 'affiliation': 'Institute of Pathology, E. Wolfson Medical Center, Holon 58100, Israel.'}, {'lastname': 'Gepner', 'firstname': 'Yftach', 'initials': 'Y', 'affiliation': 'School of Public Health, Sackler Faculty of Medicine and Sylvan Adams Sports Institute, Tel Aviv University, Tel Aviv 69978, Israel.'}, {'lastname': 'Karnieli-Miller', 'firstname': 'Orit', 'initials': 'O', 'affiliation': 'Department of Medical Education, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.'}, {'lastname': 'Hemi', 'firstname': 'Rina', 'initials': 'R', 'affiliation': 'Institute of Endocrinology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.'}, {'lastname': 'Shalgi', 'firstname': 'Ruth', 'initials': 'R', 'affiliation': 'Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.'}, {'lastname': 'Kimchi', 'firstname': 'Tali', 'initials': 'T', 'affiliation': 'Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel.'}, {'lastname': 'Percik', 'firstname': 'Ruth', 'initials': 'R', 'affiliation': 'Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; Institute of Endocrinology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.'}, {'lastname': 'Weller', 'firstname': 'Aron', 'initials': 'A', 'affiliation': 'Department of Psychology and the Gonda Brain Research Center, Bar-Ilan University, Ramat Gan 5290002, Israel.'}, {'lastname': 'Levy', 'firstname': 'Carmit', 'initials': 'C', 'affiliation': 'Department of Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. Electronic address: carmitlevy@post.tau.ac.il.'}]",,,,Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.,10.1016/j.celrep.2021.109579,<Element 'PubmedArticle' at 0x7f05de77dc70>
23,"34420950
29669100
27543171
28735855
25926349
23924004
31378227
28954880
19139294
27755004
26812281
17159101
23314404
20739645
28984587
21911655
28372335
19237574
15750215
26211973
25810947
25190626
30072954
28378260
21277873
22425595
21098287
19188609
11306609
17692997
28538088
26890736
21297276
24899525
23507773
18430999
18765651
30909217
32602137
12433261
25621434
18197741
17879383
22265587
25575135
21999410
29226863
15931653",Alzheimer's Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort.,"Diabetes is a risk factor for Alzheimer's disease and related dementias (ADRD). Epidemiologic evidence shows an association between diabetes medications and ADRD risk; cell and mouse models show diabetes medication association with AD-related neuropathologic change (ADNC).
This hypothesis-generating analysis aimed to describe autopsy-measured ADNC for individuals who used diabetes medications.
Descriptive analysis of ADNC for Adult Changes in Thought (ACT) Study autopsy cohort who used diabetes medications, including sulfonylureas, insulin, and biguanides; total N = 118. ADNC included amyloid plaque distribution (Thal phasing), neurofibrillary tangle (NFT) distribution (Braak stage), and cortical neuritic plaque density (CERAD score). We also examined quantitative measures of ADNC using the means of standardized Histelide measures of cortical PHF-tau and Aβ1-42. Adjusted analyses control for age at death, sex, education, APOE genotype, and diabetes complication severity index.
Adjusted analyses showed no significant association between any drug class and traditional neuropathologic measures compared to nonusers of that class. In adjusted Histelide analyses, any insulin use was associated with lower mean levels of Aβ1-42 (-0.57 (CI: -1.12, -0.02)) compared to nonusers. Five years of sulfonylureas and of biguanides use was associated with lower levels of Aβ1-42 compared to nonusers (-0.15 (CI: -0.28, -0.02), -0.31 (CI: -0.54, -0.07), respectively).
Some evidence exists that diabetes medications are associated with lower levels of Aβ1-42, but not traditional measures of neuropathology. Future studies are needed in larger samples to build understanding of the mechanisms between diabetes, its medications, and ADRD, and to potentially repurpose existing medications for prevention or delay of ADRD.","['Alzheimer’s disease', 'dementia', 'diabetes treatments', 'neuropathology']",Journal of Alzheimer's disease : JAD,2021-08-24,"[{'lastname': 'Barthold', 'firstname': 'Douglas', 'initials': 'D', 'affiliation': 'The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle, WA, USA.\nThe Plein Center for Geriatric Pharmacy Research, Education, and Outreach, School of Pharmacy, University of Washington, Seattle, WA, USA.'}, {'lastname': 'Gibbons', 'firstname': 'Laura E', 'initials': 'LE', 'affiliation': ""General Internal Medicine, Data Management and Statistics Core, Alzheimer's Disease Research Center, University of Washington, Seattle, WA, USA.\nDepartment of Medicine, UW School of Medicine, University of Washington, Seattle, WA, USA.""}, {'lastname': 'Marcum', 'firstname': 'Zachary A', 'initials': 'ZA', 'affiliation': 'The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle, WA, USA.\nThe Plein Center for Geriatric Pharmacy Research, Education, and Outreach, School of Pharmacy, University of Washington, Seattle, WA, USA.'}, {'lastname': 'Gray', 'firstname': 'Shelly L', 'initials': 'SL', 'affiliation': 'The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle, WA, USA.\nThe Plein Center for Geriatric Pharmacy Research, Education, and Outreach, School of Pharmacy, University of Washington, Seattle, WA, USA.'}, {'lastname': 'Dirk Keene', 'firstname': 'C', 'initials': 'C', 'affiliation': 'Laboratory Medicine and Pathology, School of Medicine, University of Washington, Seattle, WA, USA.'}, {'lastname': 'Grabowski', 'firstname': 'Thomas J', 'initials': 'TJ', 'affiliation': ""Departments of Radiology and Neurology, UW School of Medicine, Alzheimer's Disease Research Center, University of Washington, Seattle, WA, USA.""}, {'lastname': 'Postupna', 'firstname': 'Nadia', 'initials': 'N', 'affiliation': 'Laboratory Medicine and Pathology, School of Medicine, University of Washington, Seattle, WA, USA.'}, {'lastname': 'Larson', 'firstname': 'Eric B', 'initials': 'EB', 'affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.\nDepartment of Medicine, UW School of Medicine, University of Washington, Seattle, WA, USA.'}, {'lastname': 'Crane', 'firstname': 'Paul K', 'initials': 'PK', 'affiliation': 'Department of Medicine, UW School of Medicine, University of Washington, Seattle, WA, USA.'}]",,"Some evidence exists that diabetes medications are associated with lower levels of Aβ1-42, but not traditional measures of neuropathology. Future studies are needed in larger samples to build understanding of the mechanisms between diabetes, its medications, and ADRD, and to potentially repurpose existing medications for prevention or delay of ADRD.","Adjusted analyses showed no significant association between any drug class and traditional neuropathologic measures compared to nonusers of that class. In adjusted Histelide analyses, any insulin use was associated with lower mean levels of Aβ1-42 (-0.57 (CI: -1.12, -0.02)) compared to nonusers. Five years of sulfonylureas and of biguanides use was associated with lower levels of Aβ1-42 compared to nonusers (-0.15 (CI: -0.28, -0.02), -0.31 (CI: -0.54, -0.07), respectively).",,10.3233/JAD-210059,<Element 'PubmedArticle' at 0x7f05db71a0e0>
24,"34374777
1759558
18371174
19104448
19321462
22487856
3131773
8811124
18852562
24904272
29758300
14722078
19503072
19282288
21204008
18378771
23041626
28073925
31361008
16862116
21944778
12615641
15365985
16862115
17278999
31864418
25261995
25575133
28070672
20731760
30260505
30135939
2001789
11309366
17353235
32201884
26370502
15255780
31600775
31291241
25619230
22112552
31974314
28640985
9700651
24612177
18208556
19126401
20537899
28473694
26936765
22116524
23407988
24619111
20888804
28903038
29382817
20175216
17024494
27356620
23921974
32019490",Loss of Lysosomal Proteins Progranulin and Prosaposin Associated with Increased Neurofibrillary Tangle Development in Alzheimer Disease.,"Alzheimer disease (AD) is a progressive neurodegenerative disease causing cognitive decline in the aging population. To develop disease-modifying treatments, understanding the mechanisms behind the pathology is important, which should include observations using human brain samples. We reported previously on the association of lysosomal proteins progranulin (PGRN) and prosaposin (PSAP) with amyloid plaques in non-demented aged control and AD brains. In this study, we investigated the possible involvement of PGRN and PSAP in tangle formation using human brain tissue sections of non-demented aged control subjects and AD cases and compared with cases of frontotemporal dementia with granulin (GRN) mutations. The study revealed that decreased amounts of PGRN and PSAP proteins were detected even in immature neurofibrillary tangles, while colocalization was still evident in adjacent neurons in all cases. Results suggest that neuronal loss of PGRN preceded loss of PSAP as tangles developed and matured. The GRN mutation cases exhibited almost complete absence of PGRN in most neurons, while PSAP signal was preserved. Although based on correlative data, we suggest that reduced levels of PGRN and PSAP and their interaction in neurons might predispose to accumulation of p-Tau protein.","['Alzheimer disease', 'Neuropathology', 'Progranulin', 'Prosaposin', 'Tangles']",Journal of neuropathology and experimental neurology,2021-08-11,"[{'lastname': 'Mendsaikhan', 'firstname': 'Anarmaa', 'initials': 'A', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu, Shiga, Japan (AM, IT, DGW).'}, {'lastname': 'Tooyama', 'firstname': 'Ikuo', 'initials': 'I', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu, Shiga, Japan (AM, IT, DGW).'}, {'lastname': 'Serrano', 'firstname': 'Geidy E', 'initials': 'GE', 'affiliation': 'Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona (GES, TGB).'}, {'lastname': 'Beach', 'firstname': 'Thomas G', 'initials': 'TG', 'affiliation': 'Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona (GES, TGB).'}, {'lastname': 'Walker', 'firstname': 'Douglas G', 'initials': 'DG', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu, Shiga, Japan (AM, IT, DGW).\nSchool of Life Sciences and Neurodegenerative Disease Research Center, Arizona State University, Tempe, Arizona (DGW).'}]",,,,"© 2021 American Association of Neuropathologists, Inc. All rights reserved.",10.1093/jnen/nlab056,<Element 'PubmedArticle' at 0x7f05db6ee720>
25,34366339,A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease.,"Alzheimer's disease (AD) is a degenerative disorder, accompanied by progressive cognitive decline, for which there is no cure. Recently, the close correlation between AD and type 2 diabetes mellitus (T2DM) has been noted, and a promising anti-AD strategy is the use of anti-T2DM drugs.
To investigate if the novel glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist DA4-JC shows protective effects in the triple APP/PS1/tau mouse model of AD.
A battery of behavioral tests were followed by in vivo recording of long-term potentiation (LTP) in the hippocampus, quantified synapses using the Golgi method, and biochemical analysis of biomarkers.
DA4-JC improved cognitive impairment in a range of tests and relieved pathological features of APP/PS1/tau mice, enhanced LTP in the hippocampus, increased numbers of synapses and dendritic spines, upregulating levels of post-synaptic density protein 95 (PSD95) and synaptophysin (SYP), normalized volume and numbers of mitochondria and improving the phosphatase and tensin homologue induced putative kinase 1 (PINK1) - Parkin mitophagy signaling pathway, while downregulating amyloid, p-tau, and autophagy marker P62 levels.
DA4-JC is a promising drug for the treatment of AD.","['Alzheimer’s disease', 'cognitive impairment', 'glucagon-like peptide-1', 'glucose-dependent insulinotropic polypeptide', 'type 2 diabetes mellitus']",Journal of Alzheimer's disease : JAD,2021-08-10,"[{'lastname': 'Cai', 'firstname': 'Hong-Yan', 'initials': 'HY', 'affiliation': 'Department of Microbiology and Immunology, Shanxi Medical University, Taiyuan, China.\nKey Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, Taiyuan, China.\nKey Laboratory of Cellular Physiology, Shanxi Province, China.'}, {'lastname': 'Yang', 'firstname': 'Dan', 'initials': 'D', 'affiliation': 'Department of Microbiology and Immunology, Shanxi Medical University, Taiyuan, China.'}, {'lastname': 'Qiao', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Department of Microbiology and Immunology, Shanxi Medical University, Taiyuan, China.'}, {'lastname': 'Yang', 'firstname': 'Jun-Ting', 'initials': 'JT', 'affiliation': 'Department of Physiology, Shanxi Medical University, Taiyuan, China.'}, {'lastname': 'Wang', 'firstname': 'Zhao-Jun', 'initials': 'ZJ', 'affiliation': 'Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, Taiyuan, China.\nKey Laboratory of Cellular Physiology, Shanxi Province, China.\nDepartment of Physiology, Shanxi Medical University, Taiyuan, China.'}, {'lastname': 'Wu', 'firstname': 'Mei-Na', 'initials': 'MN', 'affiliation': 'Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, Taiyuan, China.\nKey Laboratory of Cellular Physiology, Shanxi Province, China.\nDepartment of Physiology, Shanxi Medical University, Taiyuan, China.'}, {'lastname': 'Qi', 'firstname': 'Jin-Shun', 'initials': 'JS', 'affiliation': 'Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, Taiyuan, China.\nKey Laboratory of Cellular Physiology, Shanxi Province, China.\nDepartment of Physiology, Shanxi Medical University, Taiyuan, China.'}, {'lastname': 'Hölscher', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Neuroscience Research Group, Henan University of Chinese Medicine, Zhengzhou, China.'}]",,DA4-JC is a promising drug for the treatment of AD.,"DA4-JC improved cognitive impairment in a range of tests and relieved pathological features of APP/PS1/tau mice, enhanced LTP in the hippocampus, increased numbers of synapses and dendritic spines, upregulating levels of post-synaptic density protein 95 (PSD95) and synaptophysin (SYP), normalized volume and numbers of mitochondria and improving the phosphatase and tensin homologue induced putative kinase 1 (PINK1) - Parkin mitophagy signaling pathway, while downregulating amyloid, p-tau, and autophagy marker P62 levels.",,10.3233/JAD-210256,<Element 'PubmedArticle' at 0x7f05dc5a00e0>
26,34224806,Melatonin protects against methamphetamine-induced Alzheimer's disease-like pathological changes in rat hippocampus.,"Methamphetamine (METH) is a psychostimulant drug of abuse. METH use is associated with cognitive impairments and neurochemical abnormalities comparable to pathological changes observed in Alzheimer's disease (AD). These observations have stimulated the idea that METH abusers might be prone to develop AD-like signs and symptoms. Melatonin, the pineal hormone, is considered as a potential therapeutic intervention against AD. We thus conducted the present study to explore potential protective roles of melatonin against METH-induced deficits in learning and memory as well as in the appearance of AD-like pathological changes in METH-treated male Wistar rats. We found that melatonin ameliorated METH-induced cognitive impairments in those rats. Melatonin prevented METH-induced decrease in dopamine transporter (DAT) expression in rat hippocampus. Melatonin reversed METH-induced activation of β-arrestin2, reduction of phosphorylation of protein kinase B (Akt) and METH-induced excessive activity of glycogen synthase kinase-3β (GSK3β). Importantly, melatonin inhibited METH-induced changes in the expression of β-site APP cleaving enzyme (BACE1), disintegrin and metalloproteinase 10 (ADAM10), and presenilin 1 (PS1), as well as the reduction of amyloid beta (Aβ)42 production. Immunofluorescence double-labeling demonstrated that melatonin not only prevented the METH-induced loss of DAT but also prevented METH-induced Aβ42 overexpression in the dentate gyrus, CA1, and CA3. Furthermore, melatonin also suppressed METH-induced increase in phosphorylated tau. Significantly, melatonin attenuated METH-induced increase in N-methyl-D-aspartate receptor subtype 2 B (NR2B) protein expression and restored METH-induced reduction of Ca","[""Alzheimer's disease"", 'Amyloid beta', 'Learning and memory', 'Melatonin', 'Methamphetamine']",Neurochemistry international,2021-07-06,"[{'lastname': 'Panmak', 'firstname': 'Pattama', 'initials': 'P', 'affiliation': 'Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand. Electronic address: pattama1802@gmail.com.'}, {'lastname': 'Nopparat', 'firstname': 'Chutikorn', 'initials': 'C', 'affiliation': 'Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand. Electronic address: m_chukorn@hotmail.com.'}, {'lastname': 'Permpoonpattana', 'firstname': 'Kannika', 'initials': 'K', 'affiliation': 'National Institute for Child and Family Development, Mahidol University, Nakhon Pathom, Thailand. Electronic address: kannika_pe@hotmail.com.'}, {'lastname': 'Namyen', 'firstname': 'Jatuporn', 'initials': 'J', 'affiliation': 'Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand. Electronic address: jnamyen2@mail.usf.edu.'}, {'lastname': 'Govitrapong', 'firstname': 'Piyarat', 'initials': 'P', 'affiliation': 'Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand; Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand; Chulabhorn Graduate Institute, Chulabhorn Royal Academy, 54 Kamphaeng Phet 6 Road, Lak Si, Bangkok, 10210, Thailand. Electronic address: piyarat.gov@mahidol.ac.th.'}]",,,,Copyright © 2021 Elsevier Ltd. All rights reserved.,10.1016/j.neuint.2021.105121,<Element 'PubmedArticle' at 0x7f05dc5687c0>
27,"34103557
25346723
27567931
21984534
29217283
10746632
19164583
31767182
30149534
26462756
19885299
25088942
15750215
26358886
29710715
28515688
24949886
23249141
26693205
29598932
32562683
24184194
27190643
23721591
28476704
20613859
31137621
15465137
29687202
26635523
6471907
17406317
29175324
26283532
23603201
31199957
24640977
22840238
24529520
23011726
24931035
20225248
21359201
31614121
29165354
29410317
31237881
12006603
31275108
21598254
30542257
29163128
30538427
28402338
12749025
25107586
30355995
30069457
29435980
19144826
16306409
31900863
24983010
23202730
24904272
21525299
26526348
23062825
17906291
21573099
15910549
29080524
28116038
20156420
29755345
33144124
24191238
31931869",Peganum harmala enhanced GLP-1 and restored insulin signaling to alleviate AlCl,"Peganum harmala (P. harmala) is a folk medicinal herb used in the Sinai Peninsula (Egypt) as a remedy for central disorders. The main constituents, harmine and harmaline, have displayed therapeutic efficacy against Alzheimer's disease (AD); however, the P. harmala potential on sensitizing central insulin to combat AD remains to be clarified. An AD-like rat model was induced by aluminum chloride (AlCl",[],Scientific reports,2021-06-10,"[{'lastname': 'Saleh', 'firstname': 'Rofida A', 'initials': 'RA', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}, {'lastname': 'Eissa', 'firstname': 'Tarek F', 'initials': 'TF', 'affiliation': 'Faculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, Egypt.'}, {'lastname': 'Abdallah', 'firstname': 'Dalaal M', 'initials': 'DM', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. dalaal.abdallah@pharma.cu.edu.eg.'}, {'lastname': 'Saad', 'firstname': 'Muhammed A', 'initials': 'MA', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.\nDepartment of Pharmacology and Toxicology, School of Pharmacy, Newgiza University, Cairo, Egypt.'}, {'lastname': 'El-Abhar', 'firstname': 'Hanan S', 'initials': 'HS', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.\nDepartment of Pharmacology, Toxicology & Biochemistry, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt.'}]",,,,,"10.1038/s41598-021-90545-4
10.3389/fendo.2014.00161
10.1016/j.bbadis.2016.08.018
10.1002/emmm.201100177
10.1016/j.neuropharm.2017.12.001
10.1210/endo.141.4.7420
10.1073/pnas.0806720106
10.1016/j.molmet.2019.09.010
10.3390/ijms19092505
10.1038/nrn4019
10.1177/193229680800200619
10.1016/j.euroneuro.2014.06.008
10.3233/JAD-2005-7107
10.1007/s10571-015-0268-5
10.3233/JAD-179923
10.3389/fnagi.2017.00118
10.1016/j.bbadis.2014.06.010
10.1089/ars.2012.5027
10.1155/2015/105828
10.1016/j.dsx.2018.03.002
10.1016/S1474-4422(20)30173-3
10.1016/j.jep.2013.10.041
10.5897/AJB2019.16762
10.1155/2016/7389864
10.1186/1472-6882-13-1
10.1371/journal.pbio.1000412
10.3390/molecules24101992
10.1016/j.neubiorev.2004.06.006
10.1007/s12640-018-9904-4
10.3389/fnmol.2015.00070
10.1016/0165-0270(84)90007-4
10.1038/nprot.2006.116
10.1016/j.bbrc.2017.11.114
10.1016/j.chroma.2015.07.123
10.1016/j.neuropharm.2013.04.008
10.1016/j.neuropharm.2019.107668
10.2217/nmt.13.73
10.1016/j.bmcl.2012.06.101
10.1016/j.jalz.2013.12.007
10.1007/s12017-012-8199-5
10.2337/db14-0287
10.1002/hep.23569
10.1371/journal.pone.0017178
10.1016/j.expneurol.2019.113076
10.3390/ijms18112493
10.1016/j.expneurol.2018.01.013
10.3389/fnins.2019.00629
10.1002/path.2912
10.3389/fnins.2018.00830
10.2147/DDDT.S173970
10.1002/jnr.10611
10.1016/j.neuropharm.2014.07.015
10.3390/ijms19113306
10.21037/atm.2018.04.41
10.1002/path.5056
10.1091/mbc.e08-07-0777
10.1523/JNEUROSCI.1723-05.2005
10.1007/s12035-019-01858-5
10.1172/JCI64516
10.1523/JNEUROSCI.0529-11.2011
10.1016/j.ejphar.2015.10.037
10.1016/j.bmc.2012.09.040
10.1074/jbc.M707358200
10.1371/journal.pone.0019264
10.1111/j.0959-9673.2005.00434.x
10.1016/j.redox.2017.10.014
10.1155/2016/8590578
10.1016/j.brainres.2010.02.024
10.3389/fphar.2018.00346
10.1016/j.arr.2020.101206
10.1016/j.redox.2013.08.006
10.1186/s13195-019-0546-4",<Element 'PubmedArticle' at 0x7f05dc59bbd0>
28,"34035398
19822029
23635781
15459709
15272267
8974629
19399233
27377321
29225787
14676043
24242746
21514250
6610841
25484925
28348546
22925882
11823324
16862116
22355793
29559004
22445064
29715546
17898224
17219193
19164285
18378771
20522652
22732773
27703466
28778989
27292537
30508027
30967444
21048198
23611350
11511720
12660807
19949037
25661086
11385008
20860890
22101365
17525140
32383020
21644037
28592453
18339451
11831556
11309456
24566866
26136723
24174584
25352065
27239528
28719018
19296504
18458217
9452329
11746370
23718879
32928934
10822437
18657254
17469117
17963732
17653732
29460270
29954341
25777512
19773352
16816392
16872484
25886404
16924018
22843257
30771578
21048932
27186717
10634455
32333900
29653606",Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up.,"Various proteins play a decisive role in the pathology of different neurodegenerative diseases. Nonetheless, most of these proteins can only be detected during a neuropathological assessment, although some non-specific biomarkers are routinely tested for in the cerebrospinal fluid (CSF) as a part of the differential diagnosis of dementia. In antemortem CSF samples from 117 patients with different types of neuropathologically confirmed neurodegenerative disease with dementia, we assessed total-tau (t-tau), phosphorylated-tau (181P) (p-tau), amyloid-beta (1-42) (Aβ42), TAR DNA binding protein (TDP)-43, progranulin (PGRN), and neurofilament light (NfL) chain levels, and positivity of protein 14-3-3. We found t-tau levels and the t-tau/p-tau ratios were significantly higher in prion diseases compared to the other neurodegenerative diseases. Statistically significant differences in the t-tau/Aβ42 ratio predominantly corresponded to t-tau levels in prion diseases and Aβ42 levels in AD. TDP-43 levels were significantly lower in prion diseases. Additionally, the TDP-43/Aβ42 ratio was better able to distinguish Alzheimer's disease from other neurodegenerative diseases compared to using Aβ42 alone. In frontotemporal lobar degeneration, PRGN levels were significantly higher in comparison to other neurodegenerative diseases. There is an increasing need for biomarkers suitable for diagnostic workups for neurodegenerative diseases. It appears that adding TDP-43 and PGRN to the testing panel for neurodegenerative diseases could improve the resolution of differential diagnoses.",[],Scientific reports,2021-05-27,"[{'lastname': 'Bruzova', 'firstname': 'Magdalena', 'initials': 'M', 'affiliation': 'Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 14059, Prague 4 - Krc, Czech Republic.'}, {'lastname': 'Rusina', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Department of Neurology, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic.'}, {'lastname': 'Stejskalova', 'firstname': 'Zuzana', 'initials': 'Z', 'affiliation': 'Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 14059, Prague 4 - Krc, Czech Republic.'}, {'lastname': 'Matej', 'firstname': 'Radoslav', 'initials': 'R', 'affiliation': 'Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 14059, Prague 4 - Krc, Czech Republic. radoslav.matej@ftn.cz.\nDepartment of Pathology, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic. radoslav.matej@ftn.cz.\nDepartment of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. radoslav.matej@ftn.cz.'}]",,,,,"10.1038/s41598-021-90366-5
10.1186/alzrt5
10.1172/JCI66029
10.1038/nm1113
10.1038/nm1066
10.1111/j.1750-3639.1995.tb00625.x
10.3390/ijms10030976
10.1111/bpa.12411
10.12688/f1000research.12681.1
10.1001/archneur.60.12.1696
10.1002/ana.24052
10.1016/j.jalz.2011.03.005
10.1212/wnl.34.7.939
10.1186/alzrt274
10.3389/fneur.2017.00089
10.1001/archneurol.2012.1654
10.1192/bjp.180.2.140
10.1038/nature05016
10.1101/cshperspect.a006254
10.1186/s13195-018-0364-0
10.1016/j.brainres.2012.01.016
10.1016/j.neulet.2018.04.053
10.1523/JNEUROSCI.3421-07.2007
10.1007/s00401-006-0189-y
10.1074/jbc.M809462200
10.1083/jcb.200712039
10.2353/ajpath.2010.090915
10.1038/nrneurol.2012.117
10.1159/000447738
10.1084/jem.20160999
10.1016/j.neuron.2016.05.018
10.1001/jamaneurol.2018.3746
10.14735/amcsnn2018185
10.1136/jnnp-2018-320106
10.1212/WNL.0b013e318200d78d
10.3109/09540261.2013.776522
10.1136/jnnp.71.3.401
10.1038/sj.mp.4001220
10.1212/WNL.0b013e3181c47cc2
10.1016/j.cca.2015.01.036
10.1136/jnnp.70.6.744
10.5414/npp29271
10.1007/s00401-011-0910-3
10.1093/brain/awm104
10.1007/s00401-020-02158-2
10.1007/s00401-011-0845-8
10.1212/WNL.0000000000004058
10.1016/j.neurobiolaging.2008.01.013
10.1385/MN:24:1-3:087
10.1136/jnnp.70.5.624
10.1001/jamaneurol.2013.6455
10.3389/fneur.2015.00138
10.14735/amcsnn2019533
10.1212/01.wnl.0000436625.63650.27
10.3109/21678421.2014.971812
10.1016/j.dadm.2015.11.001
10.1002/ana.24996
10.1002/ana.21610
10.1212/01.wnl.0000311445.21321.fc
10.1002/mds.870130116
10.1002/jnr.1242
10.1186/1471-2377-13-54
10.1136/jnnp-2020-323826
10.1212/wnl.54.10.1960
10.1111/j.1365-2990.2008.00963.x
10.1002/ana.21154
10.1016/j.brainres.2007.09.048
10.1007/s00401-007-0261-2
10.1007/s12035-018-0947-6
10.1186/s12883-018-1091-7
10.3233/JAD-150069
10.1093/brain/awp191
10.1093/brain/awl159
10.1186/1471-2377-6-25
10.1186/s12883-015-0300-x
10.1212/01.wnl.0000230159.67128.00
10.1212/WNL.0b013e318263565f
10.1016/j.msard.2019.02.009
10.4061/2010/536538
10.1111/jnc.13669
10.1001/archneur.57.1.100
10.1016/S1474-4422(20)30071-5
10.1016/j.jalz.2018.02.018",<Element 'PubmedArticle' at 0x7f05db4680e0>
29,"33939165
16678907
21256197
21501147
18534982
11586361
24571856
24845457
18096503
22021672
26212325
26779719
19365736
2825898
21418185
23122958
28638858
26109933
22813736
25927213
25378159
24493463
11959919
17270732
16914869
31903881
10604467
25076872
18650918
28975471
28782486
27412492
12061507
11145007
11227497
24729093
24234033
29126071
28733897
24267894
30522932
25492114
12399581
19029917
19635411
26541090
18776886
19575681
21968531
21940435
25131612
22428756
30059673
28213089
23142242
15729296
12522269
29016855
23607970
17517623
20655099
21289177
24263092
22160349
20553765",Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer's Disease.,"Alzheimer's disease (AD) is the most common cause of dementia, which affects more than 5 million individuals in the USA. Unfortunately, no effective therapies are currently available to prevent development of AD or to halt progression of the disease. It has been proposed that monoacylglycerol lipase (MAGL), the key enzyme degrading the endocannabinoid 2-arachidonoylglycerol (2-AG) in the brain, is a therapeutic target for AD based on the studies using the APP transgenic models of AD. While inhibition of 2-AG metabolism mitigates β-amyloid (Aβ) neuropathology, it is still not clear whether inactivation of MAGL alleviates tauopathies as accumulation and deposition of intracellular hyperphosphorylated tau protein are the neuropathological hallmark of AD. Here we show that JZL184, a potent MAGL inhibitor, significantly reduced proinflammatory cytokines, astrogliosis, phosphorylated GSK3β and tau, cleaved caspase-3, and phosphorylated NF-kB while it elevated PPARγ in P301S/PS19 mice, a tau mouse model of AD. Importantly, tau transgenic mice treated with JZL184 displayed improvements in spatial learning and memory retention. In addition, inactivation of MAGL ameliorates deteriorations in expression of synaptic proteins in P301S/PS19 mice. Our results provide further evidence that MAGL is a promising therapeutic target for AD.","['2-Arachidonoylglycerol', 'Alzheimer’s disease', 'Cognition', 'Monoacylglycerol lipase', 'Neuroinflammation', 'Tauopathies']",Molecular neurobiology,2021-05-04,"[{'lastname': 'Hashem', 'firstname': 'Jack', 'initials': 'J', 'affiliation': 'Department of Cellular and Integrative Physiology, School of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.'}, {'lastname': 'Hu', 'firstname': 'Mei', 'initials': 'M', 'affiliation': 'Department of Cellular and Integrative Physiology, School of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.'}, {'lastname': 'Zhang', 'firstname': 'Jian', 'initials': 'J', 'affiliation': 'Department of Cellular and Integrative Physiology, School of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.'}, {'lastname': 'Gao', 'firstname': 'Fei', 'initials': 'F', 'affiliation': 'Department of Cellular and Integrative Physiology, School of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.'}, {'lastname': 'Chen', 'firstname': 'Chu', 'initials': 'C', 'affiliation': 'Department of Cellular and Integrative Physiology, School of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA. chenc7@uthscsa.edu.'}]",,,,"© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s12035-021-02400-2
10.1016/j.plipres.2006.03.003
10.1016/j.neuroscience.2011.01.024
10.1111/j.1476-5381.2011.01444.x
10.1074/jbc.M800524200
10.1038/35097089
10.1177/1073858414524632
10.1016/j.tips.2014.04.006
10.1016/j.chembiol.2007.11.006
10.1126/science.1209200
10.1016/j.celrep.2015.06.075
10.7554/eLife.12345
10.1007/s12035-009-8066-z
10.1111/j.1476-5381.2011.01343.x
10.1016/j.celrep.2012.09.030
10.20517/2347-8659.2016.46
10.4103/1673-5374.156947
10.1016/j.celrep.2012.05.001
10.1186/s12974-015-0305-9
10.1523/jneurosci.1165-14.2014
10.1001/jamaneurol.2013.5847
10.1073/pnas.092136199
10.1016/j.neuron.2007.01.010
10.3233/jad-2006-9s335
10.2174/1568026620666200106125910
10.1038/45159
10.3389/fnmol.2014.00065
10.1038/nature07202
10.1007/s10571-017-0554-5
10.2174/1871527316666170807130011
10.1080/00207454.2016.1212854
10.1177/1073858402008003013
10.1007/s007020070021
10.1023/a:1009625323388
10.1007/s12031-014-0298-3
10.1007/s12031-013-0163-9
10.1016/j.redox.2017.11.001
10.1007/s12035-017-0689-x
10.1016/j.cell.2013.10.042
10.1016/j.ebiom.2018.11.059
10.1038/jcbfm.2014.216
10.1126/science.1074069
10.1038/nchembio.129
10.1016/j.chembiol.2009.05.009
10.1038/srep16257
10.1038/nm.f.1869
10.1146/annurev.physiol.010908.163149
10.1007/s00401-011-0877-0
10.1523/jneurosci.2075-11.2011
10.1002/hipo.22344
10.1111/j.1476-5381.2012.01950.x
10.1016/j.bcp.2018.07.036
10.1016/j.pharmthera.2017.02.033
10.1016/j.lfs.2012.10.025
10.1038/sj.jcbfm.9600047
10.1073/pnas.242720499
10.1093/hmg/ddx284
10.1016/j.biopsych.2013.02.027
10.1073/pnas.0701055104
10.1016/j.cell.2010.06.036
10.1523/jneurosci.2610-10.2011
10.1038/nprot.2013.155
10.1007/s10339-011-0430-z
10.1016/j.bbr.2010.05.034",<Element 'PubmedArticle' at 0x7f05dbd721d0>
30,"33832546
19330340
11150486
29700330
18434355
20133875
22286176
16640647
25920101
12498954
21942864
28739602
10871547
9037507
28395086
29895964
31853635
23781027
19909913
26786552
19282288
11813001
23183883
31414210
28386764
30183251
32440702
29768194
22265587
9130141
31395625
30672825
18849605
23900711
10679279
19242475
22312444
24465703
29536165
31376172
31400306
16237129
22101365
28765400
28159831
11958863
28218419
30355631
11916953
32203399
6801762
29331212
25419243
10885656
25732184
29916037
11531144
30721406
30787106
18620061
12511861
23349488
17146448
11316809
22820466
27039162
30601948
29151170
28808140
29401605
29738880
16467153",Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein.,"Protein misfolding diseases refer to a variety of disorders that develop as a consequence of the misfolding of proteins in various organs. The etiologies of Parkinson's and Alzheimer's disease remain unclear, but it seems that type two diabetes and other prediabetic states could contribute to the appearance of the sporadic forms of these diseases. In addition to amylin deposition, other amyloidogenic proteins implicated in the pathophysiology of neurodegenerative diseases could have important roles in the pathogenesis of this disease. As we have previously demonstrated the presence of α-synuclein deposits in the pancreas of patients with synucleinopathies, as well as tau and Aβ deposits in the pancreatic tissue of Alzheimer's disease patients, we studied the immunoreactivity of amylin, tau and α-synuclein in the pancreas of 138 subjects with neurodegenerative diseases or type two diabetes and assessed whether the pancreatic β-cells of these subjects present cooccurrence of misfolded proteins. Furthermore, we also assessed the pancreatic expression of prion protein (PrP) in these subjects and its interaction, both in the pancreas and brain, with α-synuclein, tau, Aβ and amylin. Our study shows, for the first time, that along with amylin, pancreatic α-synuclein, Aβ, PrP and tau may contribute together to the complex pathophysiology of type two diabetes and in the appearance of insulin resistance in Alzheimer's and Parkinson's disease. Furthermore, we show that the same mixed pathologies that are observed in the brains of patients with neurodegenerative diseases are also present outside the nervous system. Finally, we provide the first histological evidence of an interaction between PrP and Aβ, α-synuclein, amylin or tau in the pancreas and locus coeruleus. These findings will shed more light on the common pathological pathways shared by neurodegenerative diseases and type two diabetes, benefiting the exploration of common therapeutic strategies to prevent or treat these devastating amyloid diseases.","['Alpha-synuclein', 'Alzheimer’s disease', 'Parkinson’s disease', 'PrP', 'Tau', 'Type two diabetes mellitus']",Acta neuropathologica communications,2021-04-10,"[{'lastname': 'Martinez-Valbuena', 'firstname': 'Ivan', 'initials': 'I', 'affiliation': ""Neurosciences Division, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.\nNavarra's Health Research Institute (IDISNA), Pamplona, Spain.\nTanz Center for Neurodegenerative Diseases, University of Toronto, Toronto, Canada.""}, {'lastname': 'Valenti-Azcarate', 'firstname': 'Rafael', 'initials': 'R', 'affiliation': ""Neurosciences Division, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.\nNavarra's Health Research Institute (IDISNA), Pamplona, Spain.\nNeurology Department, Clinica San Miguel, Pamplona, Spain.""}, {'lastname': 'Amat-Villegas', 'firstname': 'Irene', 'initials': 'I', 'affiliation': ""Navarra's Health Research Institute (IDISNA), Pamplona, Spain.\nPathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.""}, {'lastname': 'Marcilla', 'firstname': 'Irene', 'initials': 'I', 'affiliation': ""Neurosciences Division, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.\nNavarra's Health Research Institute (IDISNA), Pamplona, Spain.""}, {'lastname': 'Marti-Andres', 'firstname': 'Gloria', 'initials': 'G', 'affiliation': ""Navarra's Health Research Institute (IDISNA), Pamplona, Spain.\nNeurology Department, Clinica Universidad de Navarra, Avenida de Pio XII 36, 31008, Pamplona, Navarra, Spain.""}, {'lastname': 'Caballero', 'firstname': 'Maria-Cristina', 'initials': 'MC', 'affiliation': ""Navarra's Health Research Institute (IDISNA), Pamplona, Spain.\nPathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.""}, {'lastname': 'Riverol', 'firstname': 'Mario', 'initials': 'M', 'affiliation': ""Navarra's Health Research Institute (IDISNA), Pamplona, Spain.\nNeurology Department, Clinica Universidad de Navarra, Avenida de Pio XII 36, 31008, Pamplona, Navarra, Spain.""}, {'lastname': 'Tuñon', 'firstname': 'María-Teresa', 'initials': 'MT', 'affiliation': 'Pathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.'}, {'lastname': 'Fraser', 'firstname': 'Paul E', 'initials': 'PE', 'affiliation': 'Tanz Center for Neurodegenerative Diseases, University of Toronto, Toronto, Canada.'}, {'lastname': 'Luquin', 'firstname': 'María-Rosario', 'initials': 'MR', 'affiliation': ""Neurosciences Division, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain. rluquin@unav.es.\nNavarra's Health Research Institute (IDISNA), Pamplona, Spain. rluquin@unav.es.\nNeurology Department, Clinica Universidad de Navarra, Avenida de Pio XII 36, 31008, Pamplona, Navarra, Spain. rluquin@unav.es.""}]",,,,,"10.1186/s40478-021-01171-0
10.1007/s00401-009-0523-2
10.1016/S0006-8993(00)03082-1
10.1038/s41598-018-24786-1
10.1677/JOE-07-0516
10.1073/pnas.0911829107
10.1038/nn.3028
10.1111/j.1365-2990.2006.00727.x
10.1007/978-3-319-12679-1_1
10.1016/S0197-4580(02)00065-9
10.1021/ar200189b
10.1042/BCJ20170137
10.1158/1078-0432.CCR-15-0428.Bioactivity
10.1002/1097-0029(20000701)50:1<40::AID-JEMT7>3.0.CO;2-M
10.1016/s0006-8993(96)01262-0
10.1093/jnen/nlx002
10.1038/s41582-018-0013-z
10.1007/s00401-019-02114-9
10.1242/jcs.126086
10.1016/S1474-4422(09)70238-8
10.1038/srep19393
10.1074/jbc.M808759200
10.1038/ncb748
10.1038/nrneurol.2012.242
10.1007/s00401-019-02053-5
10.1007/s00401-017-1707-9
10.1021/acschemneuro.8b00288
10.1007/s00401-020-02163-5
10.1016/J.CELREP.2018.04.040
10.1016/j.jalz.2011.10.007
10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E
10.1136/jclinpath-2019-205952
10.1097/WCO.0000000000000664
10.1159/000161560
10.1007/s00401-013-1157-y
10.1006/bbrc.2000.2152
10.1038/nature07761
10.1371/journal.pone.0031302
10.1371/journal.pone.0085781
10.1007/s00401-018-1832-0
10.1002/ana.25570
10.1016/j.clinbiochem.2019.08.005
10.1212/01.wnl.0000187889.17253.b1
10.1007/s00401-011-0910-3
10.1084/jem.20161134
10.1101/cshperspect.a024315
10.1016/s0306-4522(01)00460-2
10.1002/mds.26909
10.1523/JNEUROSCI.1700-18.2018
10.2337/diabetes.51.4.1256
10.1038/s41582-020-0333-7
10.1126/science.6801762
10.1016/j.biopsych.2017.11.020
10.1186/s13195-014-0082-1
10.1111/J.1750-3639.2000.TB00269.X
10.1093/brain/awv040
10.1007/s00401-018-1872-5
10.1007/s00401-019-01961-w
10.1074/jbc.RA118.006252
10.1016/j.ymeth.2008.06.014
10.1038/nrn1007
10.2337/db12-1045
10.1038/labinvest.3700500
10.1074/jbc.M101318200
10.1038/nn.3178
10.1016/S1474-4422(16)00080-6
10.1093/brain/awy318
10.1007/s00401-017-1790-y
10.1096/fj.201700431R
10.1096/fj.201701352
10.1016/j.semcdb.2018.05.005
10.1073/pnas.0510577103",<Element 'PubmedArticle' at 0x7f05db5f9ea0>
31,33813350,Neuroinflammation modulates the association of PGRN with cerebral amyloid-β burden.,"Progranulin (PGRN) and neuroinflammatory markers increased over the course of Alzheimer's disease (AD). We aimed to determine whether neuroinflammation could modulate the association of PGRN with amyloid pathologies. Baseline cerebrospinal fluid (CSF) PGRN and AD pathologies were measured for 965 participants, among whom 228 had measurements of CSF neuroinflammatory markers. Causal mediation analyses with 10,000 bootstrapped iterations were conducted to explore the mediation effects within the framework of A/T/N biomarker profile. Increased levels of CSF PGRN and inflammatory markers (sTNFR1, sTNFR2, TGF-β1, ICAM1, and VCAM1) were associated with T- or N-positive (TN+) profile, irrespective of the amyloid pathology. In TN+ group, CSF PGRN was associated with increased levels of these inflammatory markers and CSF amyloid-β","['Alzheimer', 'Amyloid', 'Cognition', 'Neuroinflammation', 'Progranulin', 'Tau']",Neurobiology of aging,2021-04-05,"[{'lastname': 'Xu', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. Electronic address: 1037219730@qq.com.'}, {'lastname': 'Tan', 'firstname': 'Chen-Chen', 'initials': 'CC', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Cao', 'firstname': 'Xi-Peng', 'initials': 'XP', 'affiliation': 'Clinical Research Center, Qingdao Municipal Hospital, Qingdao, China.'}, {'lastname': 'Tan', 'firstname': 'Lan', 'initials': 'L', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,Copyright © 2021. Published by Elsevier Inc.,10.1016/j.neurobiolaging.2021.02.016,<Element 'PubmedArticle' at 0x7f05dc8b5540>
32,"33768561
28582862
30368247
30450369
32090272
28025127
31636448
31654430
32043530
30953557
11245811
27916728
22237023
30544500
28944087
25261800
30733760
26374841
25572300
31351089
26201094
28614774
32593740
30190379
30911133
24120943
29882126
27725121
29309801
30617325
30355327
30356412
12859672
15930395
19710325
12886013
10783293
27814296
27167086
30560152
29660685
29946252
20934413
30099679
27432282
28974114
25863528
26193084
28183451
27079240
30716355
17695343
15618360
28733331
32180552
31438646
30569121
30959072
29710702
30810826
27055554
26024756
32069304
30782608
29187642
30350169
29858156
33323410
28346354
31281225
30466091
29098483
28396150
30406177
16709840
30775979
26111885
22245457
30554086
31672472
24334212
31275108
20644946
31507448
24114836
29574076
30692222",Irisin treatment lowers levels of phosphorylated tau in the hippocampus of pre-symptomatic female but not male htau mice.,"Irisin is a hormone cleaved from fibronectin type-III domain-containing protein 5 in response to exercise and may be therapeutic in Alzheimer's disease (AD). Irisin is shown to repair damage caused by midlife cardiometabolic risk factors for AD (i.e., diabetes mellitus; hypertension), prevent neural amyloid beta aggregation and reduce neuroinflammation. However, there are no investigations of irisin's effect on AD-associated tauopathy in the brain. This study begins to address this gap in knowledge.
Transgenic htau mice that selectively develop age-related tauopathy were treated with recombinant irisin (100 µg/kg weekly i.p.) beginning at a pre-symptomatic age (4 months) to determine if irisin could prevent emergence of early neuropathology. One month later, mice were sacrificed to collect brain tissue and serum. Protein levels of ptau (serine 202), inflammatory cytokine tumour necrosis factor alpha (TNFα) and FNDC5 were quantified using capillary-based western blotting (Wes).
Our data show that irisin treatment significantly reduced ptau and TNFα in the hippocampus and serum of female htau mice compared to vehicle-treated controls. Irisin treatment did not alter ptau levels in male htau hippocampus and appeared to enhance both neural and systemic TNFα levels.
This study provides the first evidence that enhancing the endogenous hormone irisin may be therapeutic against emerging neuropathology in a tauopathy-selective AD model. This is important because there are currently no disease-modifying therapeutics available for AD, and few agents in development address the multiple disease targets irisin appears to-making irisin an intriguing therapeutic candidate for further investigation.","[""Alzheimer's disease"", 'anti-inflammatory agents', 'dementia', 'metabolic diseases', 'neurofibrillary tangles', 'physical exertion', 'tauopathies']",Neuropathology and applied neurobiology,2021-03-27,"[{'lastname': 'Bretland', 'firstname': 'Katie A', 'initials': 'KA', 'affiliation': 'Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH, USA.'}, {'lastname': 'Lin', 'firstname': 'Li', 'initials': 'L', 'affiliation': 'Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH, USA.'}, {'lastname': 'Bretland', 'firstname': 'Kimberly M', 'initials': 'KM', 'affiliation': 'Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH, USA.\nKent State University, Kent, OH, USA.'}, {'lastname': 'Smith', 'firstname': 'Matthew A', 'initials': 'MA', 'affiliation': ""Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH, USA.\nAkron Children's Hospital, Rebecca D. Considine Research Institute, Akron, OH, USA.""}, {'lastname': 'Fleming', 'firstname': 'Sheila M', 'initials': 'SM', 'affiliation': 'Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH, USA.'}, {'lastname': 'Dengler-Crish', 'firstname': 'Christine M', 'initials': 'CM', 'affiliation': 'Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH, USA.'}]",,,Our data show that irisin treatment significantly reduced ptau and TNFα in the hippocampus and serum of female htau mice compared to vehicle-treated controls. Irisin treatment did not alter ptau levels in male htau hippocampus and appeared to enhance both neural and systemic TNFα levels.,© 2021 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.,10.1111/nan.12711,<Element 'PubmedArticle' at 0x7f05dc8a1720>
33,33597290,Clinical and Biological Correlates of White Matter Hyperintensities in Patients With Behavioral-Variant Frontotemporal Dementia and Alzheimer Disease.,"To test the hypothesis that white matter hyperintensities (WMH) in behavioral-variant frontotemporal dementia (bvFTD) and Alzheimer disease (AD) are associated with disease variables such as disease severity, cortical atrophy, and cognition, we conducted a cross-sectional brain MRI study with volumetric and voxel-wise analyses.
A total of 129 patients (64 bvFTD, 65 AD) and 66 controls underwent high-resolution brain MRI and clinical and neuropsychological examination. Genetic screening was conducted in 124 cases (54 bvFTD, 44 AD, 26 controls) and postmortem pathology was available in 18 cases (13 bvFTD, 5 AD). WMH were extracted using an automated segmentation algorithm and analyses of total volumes and spatial distribution were conducted. Group differences in total WMH volume and associations with vascular risk and disease severity were examined. Syndrome-specific voxel-wise associations between WMH, cortical atrophy, and performance across different cognitive domains were assessed.
Total WMH volumes were larger in patients with bvFTD than patients with AD and controls. In bvFTD, WMH volumes were associated with disease severity but not vascular risk. Patients with bvFTD and patients with AD showed distinct spatial patterns of WMH that mirrored characteristic patterns of cortical atrophy. Regional WMH load correlated with worse cognitive performance in discrete cognitive domains. WMH-related cognitive impairments were shared between syndromes, with additional associations found in bvFTD.
Increased WMH are common in patients with bvFTD and patients with AD. Our findings suggest that WMH are partly independent of vascular pathology and associated with the neurodegenerative process. WMH occur in processes independent of and related to cortical atrophy. Furthermore, increased WMH in different regions contributes to cognitive deficits.",[],Neurology,2021-02-19,"[{'lastname': 'Huynh', 'firstname': 'Katharine', 'initials': 'K', 'affiliation': 'From the School of Psychology (K.H., O.P., R.L.-R.), Brain and Mind Centre (K.H., O.P., J.K., C.D.-S., G.M.H., J.R.H., R.L.-R.), Central Clinical School (J.K., C.D.-S., G.M.H., J.R.H.), The University of Sydney; and the School of Medical Sciences (J.K., C.D.-S., G.M.H., J.R.H.), University of New South Wales, Sydney, Australia.'}, {'lastname': 'Piguet', 'firstname': 'Olivier', 'initials': 'O', 'affiliation': 'From the School of Psychology (K.H., O.P., R.L.-R.), Brain and Mind Centre (K.H., O.P., J.K., C.D.-S., G.M.H., J.R.H., R.L.-R.), Central Clinical School (J.K., C.D.-S., G.M.H., J.R.H.), The University of Sydney; and the School of Medical Sciences (J.K., C.D.-S., G.M.H., J.R.H.), University of New South Wales, Sydney, Australia.'}, {'lastname': 'Kwok', 'firstname': 'John', 'initials': 'J', 'affiliation': 'From the School of Psychology (K.H., O.P., R.L.-R.), Brain and Mind Centre (K.H., O.P., J.K., C.D.-S., G.M.H., J.R.H., R.L.-R.), Central Clinical School (J.K., C.D.-S., G.M.H., J.R.H.), The University of Sydney; and the School of Medical Sciences (J.K., C.D.-S., G.M.H., J.R.H.), University of New South Wales, Sydney, Australia.'}, {'lastname': 'Dobson-Stone', 'firstname': 'Carol', 'initials': 'C', 'affiliation': 'From the School of Psychology (K.H., O.P., R.L.-R.), Brain and Mind Centre (K.H., O.P., J.K., C.D.-S., G.M.H., J.R.H., R.L.-R.), Central Clinical School (J.K., C.D.-S., G.M.H., J.R.H.), The University of Sydney; and the School of Medical Sciences (J.K., C.D.-S., G.M.H., J.R.H.), University of New South Wales, Sydney, Australia.'}, {'lastname': 'Halliday', 'firstname': 'Glenda M', 'initials': 'GM', 'affiliation': 'From the School of Psychology (K.H., O.P., R.L.-R.), Brain and Mind Centre (K.H., O.P., J.K., C.D.-S., G.M.H., J.R.H., R.L.-R.), Central Clinical School (J.K., C.D.-S., G.M.H., J.R.H.), The University of Sydney; and the School of Medical Sciences (J.K., C.D.-S., G.M.H., J.R.H.), University of New South Wales, Sydney, Australia.'}, {'lastname': 'Hodges', 'firstname': 'John R', 'initials': 'JR', 'affiliation': 'From the School of Psychology (K.H., O.P., R.L.-R.), Brain and Mind Centre (K.H., O.P., J.K., C.D.-S., G.M.H., J.R.H., R.L.-R.), Central Clinical School (J.K., C.D.-S., G.M.H., J.R.H.), The University of Sydney; and the School of Medical Sciences (J.K., C.D.-S., G.M.H., J.R.H.), University of New South Wales, Sydney, Australia.'}, {'lastname': 'Landin-Romero', 'firstname': 'Ramón', 'initials': 'R', 'affiliation': 'From the School of Psychology (K.H., O.P., R.L.-R.), Brain and Mind Centre (K.H., O.P., J.K., C.D.-S., G.M.H., J.R.H., R.L.-R.), Central Clinical School (J.K., C.D.-S., G.M.H., J.R.H.), The University of Sydney; and the School of Medical Sciences (J.K., C.D.-S., G.M.H., J.R.H.), University of New South Wales, Sydney, Australia. ramon.landin-romero@sydney.edu.au.'}]",,"Increased WMH are common in patients with bvFTD and patients with AD. Our findings suggest that WMH are partly independent of vascular pathology and associated with the neurodegenerative process. WMH occur in processes independent of and related to cortical atrophy. Furthermore, increased WMH in different regions contributes to cognitive deficits.","Total WMH volumes were larger in patients with bvFTD than patients with AD and controls. In bvFTD, WMH volumes were associated with disease severity but not vascular risk. Patients with bvFTD and patients with AD showed distinct spatial patterns of WMH that mirrored characteristic patterns of cortical atrophy. Regional WMH load correlated with worse cognitive performance in discrete cognitive domains. WMH-related cognitive impairments were shared between syndromes, with additional associations found in bvFTD.",© 2021 American Academy of Neurology.,10.1212/WNL.0000000000011638,<Element 'PubmedArticle' at 0x7f05dc8f69f0>
34,"33427744
9855500
21810890
21325651
19884572
31119452
27915998
32830218
15851728
17604879
19884571
29562540
27632209
25741868
1431963
17374952
25872513
25495175
19255408
16983677
18234697
21258152
23596077
22366795
20077483
18288693
18438952
23692129
30773994
27280171
26581115
25408367
25853458
19297506
16009765
31350420
16862116
27606344
15615814
10208578
18093153
10775534
14595660
29370822
27439681",The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series.,"Right temporal variant frontotemporal dementia (rtvFTD) has been generally considered as a right sided variant of semantic variant primary progressive aphasia (svPPA), which is a genetically sporadic disorder. Recently, we have shown that rtvFTD has a unique clinical syndrome compared to svPPA and behavioral variant frontotemporal dementia.
We challenge the assumption that rtvFTD is a sporadic, non-familial variant of FTD by identifying potential autosomal dominant inheritance and related genes in rtvFTD.
We collected all subjects with a diagnosis of FTD or primary progressive aphasia who had undergone genetic screening (n = 284) and subsequently who had a genetic variant (n = 48) with a diagnosis of rtvFTD (n = 6) in 2 specialized memory clinics.
Genetic variants in FTD related genes were found in 33% of genetically screened rtvFTD cases; including MAPT (n = 4), GRN (n = 1), and TARDBP (n = 1) genes, whereas only one svPPA case had a genetic variant in our combined cohorts. Additionally, 4 out of 6 rtvFTD subjects had a strong family history for dementia.
Our results demonstrate that rtvFTD, unlike svPPA, is not a pure sporadic, but a heterogeneous potential genetic variant of FTD, and screening for genetic causes for FTD should be performed in patients with rtvFTD.","['Dementia', 'GRN', 'MAPT', 'TARDBP', 'frontotemporal dementia', 'frontotemporal lobar degeneration', 'genetic', 'right temporallobe']",Journal of Alzheimer's disease : JAD,2021-01-12,"[{'lastname': 'Ulugut Erkoyun', 'firstname': 'Hulya', 'initials': 'H', 'affiliation': 'Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'lastname': 'van der Lee', 'firstname': 'Sven J', 'initials': 'SJ', 'affiliation': 'Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'lastname': 'Nijmeijer', 'firstname': 'Bas', 'initials': 'B', 'affiliation': 'Department of Clinical Genetics, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'lastname': 'van Spaendonk', 'firstname': 'Rosalina', 'initials': 'R', 'affiliation': 'Genome diagnostics, Department of Clinical Genetics, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'lastname': 'Nelissen', 'firstname': 'Anne', 'initials': 'A', 'affiliation': 'Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'lastname': 'Scarioni', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'lastname': 'Dijkstra', 'firstname': 'Anke', 'initials': 'A', 'affiliation': 'Alzheimer Center Amsterdam, Department of Pathology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'lastname': 'Samancı', 'firstname': 'Bedia', 'initials': 'B', 'affiliation': 'Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'lastname': 'Gürvit', 'firstname': 'Hakan', 'initials': 'H', 'affiliation': 'Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'lastname': 'Yıldırım', 'firstname': 'Zerrin', 'initials': 'Z', 'affiliation': 'Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.'}, {'lastname': 'Tepgeç', 'firstname': 'Fatih', 'initials': 'F', 'affiliation': 'Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'lastname': 'Bilgic', 'firstname': 'Basar', 'initials': 'B', 'affiliation': 'Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'lastname': 'Barkhof', 'firstname': 'Frederik', 'initials': 'F', 'affiliation': 'Alzheimer Center Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.\nUCL Institutes of Neurology and Healthcare Engineering, University College London, London, United Kingdom.'}, {'lastname': 'Rozemuller', 'firstname': 'Annemieke', 'initials': 'A', 'affiliation': 'Alzheimer Center Amsterdam, Department of Pathology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'lastname': 'van der Flier', 'firstname': 'Wiesje M', 'initials': 'WM', 'affiliation': 'Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.\nAlzheimer Center Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'lastname': 'Scheltens', 'firstname': 'Philip', 'initials': 'P', 'affiliation': 'Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'lastname': 'Cohn-Hokke', 'firstname': 'Petra', 'initials': 'P', 'affiliation': 'Department of Clinical Genetics, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'lastname': 'Pijnenburg', 'firstname': 'Yolande', 'initials': 'Y', 'affiliation': 'Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.'}]",,"Our results demonstrate that rtvFTD, unlike svPPA, is not a pure sporadic, but a heterogeneous potential genetic variant of FTD, and screening for genetic causes for FTD should be performed in patients with rtvFTD.","Genetic variants in FTD related genes were found in 33% of genetically screened rtvFTD cases; including MAPT (n = 4), GRN (n = 1), and TARDBP (n = 1) genes, whereas only one svPPA case had a genetic variant in our combined cohorts. Additionally, 4 out of 6 rtvFTD subjects had a strong family history for dementia.",,10.3233/JAD-201191,<Element 'PubmedArticle' at 0x7f05dc8f16d0>
35,33337055,"Effect of physiological factors, pathologies, and acquired habits on the sweet taste threshold: A systematic review and meta-analysis.","Sweet taste perception is a key factor in the establishment of the food pattern with nonstatic thresholds. Indeed, taste sensitivity can be influenced by physiological factors (age and sex), pathologies (obesity and type 2 diabetes mellitus), and acquired habits (tobacco and alcohol consumption). In order to elucidate how these variables influence the sucrose detection threshold (DT) and recognition threshold (RT), a systematic review and meta-analysis of the relevant literature were performed. After a comprehensive search in the PubMed and Scopus databases, a total of 48 studies were qualitatively considered, and 44 were meta-analyzed. The factors of aging (standard mean difference [SMD]: -0.46; 95% confidence interval (CI), -0.74 to -0.19; I","['chemoperception', 'detection threshold', 'personalized nutrition', 'recognition threshold', 'sucrose']",Comprehensive reviews in food science and food safety,2020-12-19,"[{'lastname': 'Trius-Soler', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Department of Nutrition, Food Sciences and Gastronomy, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.\nINSA-UB, Nutrition and Food Safety Research Institute, University of Barcelona, Santa Coloma de Gramanet, Spain.\nCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.'}, {'lastname': 'Santillán-Alarcón', 'firstname': 'Dimitri A', 'initials': 'DA', 'affiliation': 'Department of Nutrition, Food Sciences and Gastronomy, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.'}, {'lastname': 'Martínez-Huélamo', 'firstname': 'Miriam', 'initials': 'M', 'affiliation': 'Department of Nutrition, Food Sciences and Gastronomy, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.\nINSA-UB, Nutrition and Food Safety Research Institute, University of Barcelona, Santa Coloma de Gramanet, Spain.'}, {'lastname': 'Lamuela-Raventós', 'firstname': 'Rosa M', 'initials': 'RM', 'affiliation': 'Department of Nutrition, Food Sciences and Gastronomy, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.\nINSA-UB, Nutrition and Food Safety Research Institute, University of Barcelona, Santa Coloma de Gramanet, Spain.\nCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.'}, {'lastname': 'Moreno', 'firstname': 'Juan José', 'initials': 'JJ', 'affiliation': 'Department of Nutrition, Food Sciences and Gastronomy, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.\nINSA-UB, Nutrition and Food Safety Research Institute, University of Barcelona, Santa Coloma de Gramanet, Spain.\nCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.'}]",,,,© 2020 The Authors. Comprehensive Reviews in Food Science and Food Safety published by Wiley Periodicals LLC on behalf of Institute of Food Technologists.,10.1111/1541-4337.12643,<Element 'PubmedArticle' at 0x7f05dc47ff40>
36,"33160263
32157747
22272620
22337827
32568367
10579998
24529521
21490323
28034760
23533158
32588967
25130657
11832223
29406582
30804755
27371485
28399252
25342129
31305918
26949733
25563642
25313506
24904272
24315369
19605645
18479783
28105773
28588440
22430529
19210753
23408873
29053786
16412093
14981233
20376313
22476197
31463398
2646917
30400093
25691750
23867200
20501908
17279553
17720802
19406747
15140184",Neuronal insulin signaling and brain structure in nondemented older adults: the Atherosclerosis Risk in Communities Study.,"We used plasma neuronal extracellular vesicles to examine how neuronal insulin signaling proteins relate cross-sectionally to brain structure in nondemented older adults with varying levels of cortical amyloid. Extracellular vesicles enriched for neuronal origin by anti-L1CAM immunoabsorption were isolated from plasma of Atherosclerosis Risk in Communities-Positron Emission Tomography study participants (n = 88; mean age: 77 years [standard deviation: 6]). Neuronal extracellular vesicle levels of phosphorylated insulin signaling cascade proteins were quantified. Brain volume and white matter hyperintensity (WMH) volume were assessed using 3T magnetic resonance imaging. After adjusting for demographic variables and extracellular vesicle marker Alix, higher levels of a neuronal insulin signaling composite measure were associated with lower WMH and greater temporal lobe volume. Secondary analyses found the levels of downstream protein kinases involved in cell survival (p70S6K) and tau phosphorylation/neuroinflammation (GSK-3β) to be most strongly associated with WMH and temporal lobe volume, respectively. Associations between neuronal insulin signaling and lower WMH volume were attenuated in participants with elevated cortical amyloid. These results suggest that enhanced neuronal proximal insulin signaling is associated with preserved brain structure in nondemented older adults.","['Brain', 'Exosome', 'Extracellular vesicle', 'Insulin', 'Magnetic resonance imaging', 'White matter disease']",Neurobiology of aging,2020-11-08,"[{'lastname': 'Walker', 'firstname': 'Keenan A', 'initials': 'KA', 'affiliation': 'Department of Neurology, Johns Hopkins University, Baltimore, MD, USA. Electronic address: Kwalke26@jhmi.edu.'}, {'lastname': 'Chawla', 'firstname': 'Sahil', 'initials': 'S', 'affiliation': 'Laboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, Baltimore, MD, USA.'}, {'lastname': 'Nogueras-Ortiz', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': 'Laboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, Baltimore, MD, USA.'}, {'lastname': 'Coresh', 'firstname': 'Josef', 'initials': 'J', 'affiliation': 'Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.'}, {'lastname': 'Sharrett', 'firstname': 'A Richey', 'initials': 'AR', 'affiliation': 'Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.'}, {'lastname': 'Wong', 'firstname': 'Dean F', 'initials': 'DF', 'affiliation': 'Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MS, USA.'}, {'lastname': 'Jack', 'firstname': 'Clifford R', 'initials': 'CR', 'affiliation': 'Department of Radiology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Spychalla', 'firstname': 'Anthony J', 'initials': 'AJ', 'affiliation': 'Department of Radiology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Gottesman', 'firstname': 'Rebecca F', 'initials': 'RF', 'affiliation': 'Department of Neurology, Johns Hopkins University, Baltimore, MD, USA; Laboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, Baltimore, MD, USA.'}, {'lastname': 'Kapogiannis', 'firstname': 'Dimitrios', 'initials': 'D', 'affiliation': 'Laboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,"10.1016/j.neurobiolaging.2020.09.022
10.1096/fj.202000034R
10.2174/156720512802455386
10.3233/JAD-2012-111880
10.1001/jamaneurol.2020.1840
10.1101/gad.13.22.2905
10.1016/j.jalz.2013.12.004
10.1212/WNL.0b013e3182166e96
10.1016/j.trsl.2016.12.005
10.1002/brb3.124
10.1002/alz.12130
10.1016/j.jalz.2014.06.008
10.1016/S0896-6273(02)00569-X
10.1002/ana.25172
10.3389/fncel.2019.00017
10.1212/WNL.0000000000002914
10.1001/jama.2017.3090
10.1096/fj.14-262048
10.1001/jamaneurol.2019.2462
10.1016/j.dadm.2015.12.002
10.1161/STROKEAHA.114.007847
10.1038/tp.2014.92
10.3389/fnmol.2014.00046
10.1016/j.cmet.2013.11.002
10.1523/JNEUROSCI.1071-09.2009
10.1016/j.neurobiolaging.2008.04.002
10.1002/hbm.23494
10.3389/fnins.2017.00278
10.3233/JAD-2012-112192
10.1111/j.1582-4934.2008.00509.x
10.1212/WNL.0b013e3182840c9f
10.1093/brain/awx256
10.1111/j.1471-4159.2005.03637.x
10.1073/pnas.0308724101
10.1371/journal.pone.0009979
10.1172/JCI59903
10.1016/j.heliyon.2019.e02294
10.3233/JAD-180469
10.1073/pnas.1501441112
10.1016/S1474-4422(13)70124-8
10.2967/jnumed.109.069088
10.1002/jnr.21181
10.1096/fj.06-7703com
10.1074/jbc.M109.011015
10.1111/j.1471-4159.2004.02350.x",<Element 'PubmedArticle' at 0x7f05dc463ea0>
37,"33122395
26595641
31119452
29315334
17270732
15562429
32179883
30847369
21810890
21325651
28064175
18416496
31032387
28912300
31324897
24117616
20920788
20026663
10385576
27540165",In vivo PET imaging of neuroinflammation in familial frontotemporal dementia.,"We report 
Using positron emission tomography (PET), we explored the association of the distribution of activated microglia, as measured by the radioligand [
Patients with familial FTD across all mutation groups showed increased [
This case series suggests that neuroinflammation is part of the pathophysiology of familial FTD, warranting further consideration of immunomodulatory therapies for disease modification and prevention.","['PET', 'frontotemporal dementia', 'genetics']","Journal of neurology, neurosurgery, and psychiatry",2020-10-31,"[{'lastname': 'Malpetti', 'firstname': 'Maura', 'initials': 'M', 'affiliation': 'Department of Clinical Neurosciences, and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, Cambridgeshire, UK.'}, {'lastname': 'Rittman', 'firstname': 'Timothy', 'initials': 'T', 'affiliation': 'Department of Clinical Neurosciences, and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, Cambridgeshire, UK.'}, {'lastname': 'Jones', 'firstname': 'Peter Simon', 'initials': 'PS', 'affiliation': 'Department of Clinical Neurosciences, and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, Cambridgeshire, UK.'}, {'lastname': 'Cope', 'firstname': 'Thomas Edmund', 'initials': 'TE', 'affiliation': 'Department of Clinical Neurosciences, and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, Cambridgeshire, UK.'}, {'lastname': 'Passamonti', 'firstname': 'Luca', 'initials': 'L', 'affiliation': 'Department of Clinical Neurosciences, and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, Cambridgeshire, UK.\nIstituto di Bioimmagini e Fisiologia Molecolare Consiglio Nazionale delle Ricerche, Milan, Italy.'}, {'lastname': 'Bevan-Jones', 'firstname': 'William Richard', 'initials': 'WR', 'affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, Cambridgeshire, UK.'}, {'lastname': 'Patterson', 'firstname': 'Karalyn', 'initials': 'K', 'affiliation': 'Department of Clinical Neurosciences, and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, Cambridgeshire, UK.'}, {'lastname': 'Fryer', 'firstname': 'Tim D', 'initials': 'TD', 'affiliation': 'Department of Clinical Neurosciences, and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, Cambridgeshire, UK.\nWolfson Brain Imaging Centre, University of Cambridge, Cambridge, Cambridgeshire, UK.'}, {'lastname': 'Hong', 'firstname': 'Young T', 'initials': 'YT', 'affiliation': 'Department of Clinical Neurosciences, and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, Cambridgeshire, UK.\nWolfson Brain Imaging Centre, University of Cambridge, Cambridge, Cambridgeshire, UK.'}, {'lastname': 'Aigbirhio', 'firstname': 'Franklin I', 'initials': 'FI', 'affiliation': 'Department of Clinical Neurosciences, and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, Cambridgeshire, UK.\nWolfson Brain Imaging Centre, University of Cambridge, Cambridge, Cambridgeshire, UK.'}, {'lastname': ""O'Brien"", 'firstname': 'John Tiernan', 'initials': 'JT', 'affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, Cambridgeshire, UK.'}, {'lastname': 'Rowe', 'firstname': 'James Benedict', 'initials': 'JB', 'affiliation': 'Department of Clinical Neurosciences, and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, Cambridgeshire, UK James.Rowe@mrc-cbu.cam.ac.uk.\nMedical Research Council Cognition and Brain Sciences Unit, Cambridge, Cambridgeshire, UK.'}]",,,Patients with familial FTD across all mutation groups showed increased [,© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.,"10.1136/jnnp-2020-323698
10.1016/S0140-6736(15)00461-4
10.1007/s00415-019-09363-4
10.1371/journal.pmed.1002487
10.1016/j.neuron.2007.01.010
10.1002/ana.20332
10.1093/brain/awaa033
10.1002/acn3.683
10.1093/brain/awr179
10.1212/WNL.0b013e31821103e6
10.1136/bmjopen-2016-013187
10.1080/02643290701290146
10.1016/j.cobeha.2017.12.015
10.1136/jnnp-2017-316402
10.1038/s41582-019-0231-z
10.1111/nan.12092
10.1016/j.neuron.2010.08.023
10.1084/jem.20091568
10.1006/nimg.1999.0439
10.1126/science.aag2590",<Element 'PubmedArticle' at 0x7f05dcb3c6d0>
38,"33112398
23611351
31918955
25662776
31388560
30508042
28337409
22366795
31784375
23062850
25669145
23332364
29197216
29172163
28855404
30711674
27995069
25683866
21753165
31636026
31810826
31914219
19339253
30456292
29627938
22409939
30698757
31477517
29240561
18829698
31914218
31914217
26190405
12030832
24530839
18501637
16530430
29889573
30596906
24648338
31272932
26631930
26401709
27606344
27703466
18768919
29146050
24445580
22399793
25273996
22742426
19786698","Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants.","Several clinical trials are planned for familial forms of frontotemporal lobar degeneration (f-FTLD). Precise modeling of brain atrophy in f-FTLD could improve the power to detect a treatment effect.
To characterize regions and rates of atrophy in the 3 primary f-FTLD genetic groups (MAPT, GRN, and C9orf72) across all disease stages from asymptomatic to dementia.
This investigation was a case-control study of participants enrolled in the Advancing Research and Treatment for Frontotemporal Lobar Degeneration or Longitudinal Evaluation of Familial Frontotemporal Dementia studies. The study took place at 18 North American academic medical centers between January 2009 and September 2018. Participants with f-FTLD (n = 100) with a known pathogenic variant (MAPT [n = 28], GRN [n = 33], or C9orf72 [n = 39]) were grouped according to disease stage (ie, Clinical Dementia Rating [CDR] plus National Alzheimer's Coordinating Center [NACC] FTLD module). Included were participants with at least 2 structural magnetic resonance images at presymptomatic (CDR + NACC FTLD = 0 [n = 57]), mild or questionable (CDR + NACC FTLD = 0.5 [n = 15]), or symptomatic (CDR + NACC FTLD = ≥1 [n = 28]) disease stages. The control group included family members of known pathogenic variant carriers who did not carry the pathogenic variant (n = 60).
This study fitted bayesian linear mixed-effects models in each voxel of the brain to quantify the rate of atrophy in each of the 3 genes, at each of the 3 disease stages, compared with controls. The study also analyzed rates of clinical decline in each of these groups, as measured by the CDR + NACC FTLD box score.
The sample included 100 participants with f-FTLD with a known pathogenic variant (mean [SD] age, 50.48 [13.78] years; 53 [53%] female) and 60 family members of known pathogenic variant carriers who did not carry the pathogenic variant (mean [SD] age, 47.51 [12.43] years; 36 [60%] female). MAPT and GRN pathogenic variants were associated with increased rates of volume loss compared with controls at all stages of disease. In MAPT pathogenic variant carriers, statistically significant regions of accelerated volume loss compared with controls were identified in temporal regions bilaterally in the presymptomatic stage, with global spread in the symptomatic stage. For example, mean [SD] rates of atrophy in the left temporal were -231 [47] mm3 per year during the presymptomatic stage, -381 [208] mm3 per year during the mild stage, and -1485 [1025] mm3 per year during the symptomatic stage (P < .05). GRN pathogenic variant carriers generally had minimal increases in atrophy rates between the presymptomatic and mild stages, with rapid increases in atrophy rates in the symptomatic stages. For example, in the right frontal lobes, annualized volume loss was -267 [81] mm3 per year in the presymptomatic stage and -182 [90] mm3 per year in the mild stage, but -1169 [555] mm3 per year in the symptomatic stage. Compared with the other groups, C9orf72 expansion carriers showed minimal increases in rate of volume loss with disease progression. For example, the mean (SD) annualized rates of atrophy in the right frontal lobe in C9orf72 expansion carriers was -272 (118) mm3 per year in presymptomatic stages, -310 (189) mm3 per year in mildly symptomatic stages, and -251 (145) mm3 per year in symptomatic stages.
These findings are relevant to clinical trial planning and suggest that the mechanism by which C9orf72 pathogenic variants lead to symptoms may be fundamentally different from the mechanisms associated with other pathogenic variants.",[],JAMA network open,2020-10-29,"[{'lastname': 'Staffaroni', 'firstname': 'Adam M', 'initials': 'AM', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': 'Goh', 'firstname': 'Sheng-Yang M', 'initials': 'SM', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': 'Cobigo', 'firstname': 'Yann', 'initials': 'Y', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': 'Ong', 'firstname': 'Elise', 'initials': 'E', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': 'Lee', 'firstname': 'Suzee E', 'initials': 'SE', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': 'Casaletto', 'firstname': 'Kaitlin B', 'initials': 'KB', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': 'Wolf', 'firstname': 'Amy', 'initials': 'A', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': 'Forsberg', 'firstname': 'Leah K', 'initials': 'LK', 'affiliation': 'Department of Neurology, College of Medicine, Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Ghoshal', 'firstname': 'Nupur', 'initials': 'N', 'affiliation': 'Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri.\nDepartment of Psychiatry, Washington University School of Medicine in St Louis, St Louis, Missouri.'}, {'lastname': 'Graff-Radford', 'firstname': 'Neill R', 'initials': 'NR', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Grossman', 'firstname': 'Murray', 'initials': 'M', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'Heuer', 'firstname': 'Hilary W', 'initials': 'HW', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': 'Hsiung', 'firstname': 'Ging-Yuek R', 'initials': 'GR', 'affiliation': 'Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Kantarci', 'firstname': 'Kejal', 'initials': 'K', 'affiliation': 'Department of Radiology, College of Medicine, Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Knopman', 'firstname': 'David S', 'initials': 'DS', 'affiliation': 'Department of Neurology, College of Medicine, Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Kremers', 'firstname': 'Walter K', 'initials': 'WK', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Mackenzie', 'firstname': 'Ian R', 'initials': 'IR', 'affiliation': 'Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Miller', 'firstname': 'Bruce L', 'initials': 'BL', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': 'Pedraza', 'firstname': 'Otto', 'initials': 'O', 'affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Rascovsky', 'firstname': 'Katya', 'initials': 'K', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'Tartaglia', 'firstname': 'M Carmela', 'initials': 'MC', 'affiliation': 'Division of Neurology, Department of Medicine, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Wszolek', 'firstname': 'Zbigniew K', 'initials': 'ZK', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Kramer', 'firstname': 'Joel H', 'initials': 'JH', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': 'Kornak', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Department of Epidemiology and Biostatistics, Memory and Aging Center, University of California, San Francisco.'}, {'lastname': 'Boeve', 'firstname': 'Bradley F', 'initials': 'BF', 'affiliation': 'Department of Neurology, College of Medicine, Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Boxer', 'firstname': 'Adam L', 'initials': 'AL', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': 'Rosen', 'firstname': 'Howard J', 'initials': 'HJ', 'affiliation': 'Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,"The sample included 100 participants with f-FTLD with a known pathogenic variant (mean [SD] age, 50.48 [13.78] years; 53 [53%] female) and 60 family members of known pathogenic variant carriers who did not carry the pathogenic variant (mean [SD] age, 47.51 [12.43] years; 36 [60%] female). MAPT and GRN pathogenic variants were associated with increased rates of volume loss compared with controls at all stages of disease. In MAPT pathogenic variant carriers, statistically significant regions of accelerated volume loss compared with controls were identified in temporal regions bilaterally in the presymptomatic stage, with global spread in the symptomatic stage. For example, mean [SD] rates of atrophy in the left temporal were -231 [47] mm3 per year during the presymptomatic stage, -381 [208] mm3 per year during the mild stage, and -1485 [1025] mm3 per year during the symptomatic stage (P < .05). GRN pathogenic variant carriers generally had minimal increases in atrophy rates between the presymptomatic and mild stages, with rapid increases in atrophy rates in the symptomatic stages. For example, in the right frontal lobes, annualized volume loss was -267 [81] mm3 per year in the presymptomatic stage and -182 [90] mm3 per year in the mild stage, but -1169 [555] mm3 per year in the symptomatic stage. Compared with the other groups, C9orf72 expansion carriers showed minimal increases in rate of volume loss with disease progression. For example, the mean (SD) annualized rates of atrophy in the right frontal lobe in C9orf72 expansion carriers was -272 (118) mm3 per year in presymptomatic stages, -310 (189) mm3 per year in mildly symptomatic stages, and -251 (145) mm3 per year in symptomatic stages.",,"10.1001/jamanetworkopen.2020.22847
10.3109/09540261.2013.778822
10.1016/j.neurobiolaging.2019.12.004
10.1016/S1474-4422(14)70324-2
10.1016/j.trci.2019.05.010
10.1093/brain/awy288
10.1016/j.nicl.2016.12.006
10.1093/brain/aws001
10.1016/j.jalz.2019.08.196
10.1016/j.jalz.2012.03.003
10.1002/cpt.16
10.1016/S1474-4422(12)70291-0
10.1001/JAMANEUROL.2017.4266
10.1016/j.neurobiolaging.2017.10.008
10.1212/WNL.0000000000004393
10.1016/j.neurobiolaging.2018.12.017
10.1016/j.nicl.2016.10.014
10.1111/ene.12675
10.1212/WNL.0b013e318227047f
10.1016/j.jalz.2019.06.4947
10.1016/S1474-4422(19)30394-1
10.1002/alz.12004
10.1093/brain/awp062
10.1016/j.dadm.2018.07.008
10.1007/s00415-018-8850-7
10.1001/archneurol.2011.3405
10.1093/brain/awy319
10.1016/j.jalz.2019.05.013
10.1097/WAD.0000000000000223
10.1093/brain/awn234
10.1002/alz.12033
10.1002/alz.12011
10.1016/j.neuroimage.2015.06.094
10.1006/nimg.2002.1090
10.1016/j.neuroimage.2014.01.060
10.1016/j.neuroimage.2008.03.061
10.1016/j.neuroimage.2006.01.021
10.1080/14728222.2018.1487951
10.1093/brain/awy314
10.1126/scitranslmed.3007941
10.1016/j.jalz.2019.04.007
10.1038/nrn.2015.1
10.3233/JAD-150270
10.1002/acn3.325
10.1159/000447738
10.1212/01.wnl.0000325058.10218.fc
10.1016/j.neurobiolaging.2017.10.016
10.1001/jamaneurol.2013.6002
10.1136/jnnp-2011-301883
10.1093/brain/awu248
10.3109/17482968.2012.690418
10.1212/WNL.0b013e3181b9c8b9",<Element 'PubmedArticle' at 0x7f05dc3df1d0>
39,33008530,"Sex difference in Alzheimer's disease: An updated, balanced and emerging perspective on differing vulnerabilities.","Sex biology influences Alzheimer's disease (AD). Sex differences exist in the epidemiologic, imaging, biomarker, and pathology studies of this uniquely human condition. The mandate to understand sex differences in major diseases like AD is important for many reasons. First, AD is the most common neurodegenerative condition and a devastating disease-experienced as an insidious and progressive erosion of memory, cognition, and other brain functions. Second, since true sex differences in AD exist, their precise understanding could reveal what protects one sex or makes the other vulnerable-and this knowledge could inform development of new therapeutic approaches to benefit both sexes. Third, AD develops in the aging brain in a milieu of decreased circulating gonadal hormones. Thus, how sex-specific depletion affects the brain along with how replacement of androgens in men and estrogens and progestins in women alters vulnerability to AD are relevant questions, with clinical implications in a future of personalized medicine. This review will highlight advances in sex differences in AD in human populations with a focused perspective on epidemiology, biomarkers, and clinical trials. A thorough and concise overview of sex differences reviewed here indicates varying vulnerabilities in men and women. This review examines several lines of recent and strong evidence that collectively indicate the following: (1) men die faster with AD, (2) more women live with AD, (3) both sexes show similar risk of developing AD until advanced ages when women show increased risk, (4) both sexes show largely similar AD biomarker burden with notable exceptions for higher tau levels in subgroups of women with high amyloid, (5) women show brain reserve and resilience to tau pathology, (6) both sexes are vulnerable to the genetic risk of carrying APOE4, with women showing higher risk, and (7) neither sex has shown clear benefit of hormone replacement for AD or dementia risk in randomized clinical trials to date.","['Aging', ""Alzheimer's disease"", 'Androgen', 'Biomarkers', 'Dementia', 'Estrogen', 'Gender', 'Sex', 'Sex difference', 'Testosterone']",Handbook of clinical neurology,2020-10-04,"[{'lastname': 'Dubal', 'firstname': 'Dena B', 'initials': 'DB', 'affiliation': 'Department of Neurology, Endowed Chair in Aging and Neurodegenerative Disease, University of California San Francisco, San Francisco, CA, United States. Electronic address: Dena.Dubal@ucsf.edu.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/B978-0-444-64123-6.00018-7,<Element 'PubmedArticle' at 0x7f05dc3adb30>
40,"32852718
17999464
17385716
18263584
18720192
20004045
21329555
31754658
16943563
26035622
26434621
29596797
8490014
22531419
15037818
15644984
25712639
9720487
17551515
15659808
16084726
26686249
10627591
28579298
12404531
17569207
26424013
31347728
28060449
31680089
29242522
24589478
15059975
17202663
23159715
22654430
28527218
24036059
20450904
10531052
30942233
29220411
27583652
15590663
26910813
12401334",Inhibitory Effect of Hexahydrocurcumin on Memory Impairment and Amyloidogenesis in Dexamethasone-Treated Mice.,"A high dose of dexamethasone induces neurodegeneration by initiating the inflammatory processes that lead to neural apoptosis. A dexamethasone administration model induces overproduction of amyloid-β (Aβ) and tau protein hyperphosphorylation and shows abnormalities of cholinergic function similar to Alzheimer's disease (AD). This study aimed to investigate the protective effect of hexahydrocurcumin on the brain of dexamethasone-induced mice. The results showed that hexahydrocurcumin and donepezil attenuated the levels of amyloid precursor protein and β-secretase mRNA by reverse transcription polymerase chain reaction, decreased the expression of hyperphosphorylated tau, and improved synaptic function. Moreover, we found that hexahydrocurcumin treatment could decrease interleukin-6 levels by attenuating p65 of nuclear factor kappa-light-chain-enhancer (NF-κB) of activated beta cells. In addition, hexahydrocurcumin also decreased oxidative stress, as demonstrated by the expression of 4-hydroxynonenal and thereby prevented apoptosis. Therefore, our finding suggests that hexahydrocurcumin prevents dexamethasone-induced AD-like pathology and improves memory impairment.","['Alzheimer’s disease', 'Amyloidogenesis', 'Dexamethasone', 'Donepezil', 'Hexahydrocurcumin']",Neurotoxicity research,2020-08-28,"[{'lastname': 'Jearjaroen', 'firstname': 'Pranglada', 'initials': 'P', 'affiliation': 'Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'lastname': 'Pakdeepak', 'firstname': 'Kanet', 'initials': 'K', 'affiliation': 'Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'lastname': 'Tocharus', 'firstname': 'Chainarong', 'initials': 'C', 'affiliation': 'Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'lastname': 'Chaichompoo', 'firstname': 'Waraluck', 'initials': 'W', 'affiliation': 'Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Ramkhamhaeng University, Bangkok, Thailand.'}, {'lastname': 'Suksamrarn', 'firstname': 'Apichart', 'initials': 'A', 'affiliation': 'Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Ramkhamhaeng University, Bangkok, Thailand.'}, {'lastname': 'Tocharus', 'firstname': 'Jiraporn', 'initials': 'J', 'affiliation': 'Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. jtocharus@gmail.com.\nCenter for Research and Development of Natural Products for Health, Chiang Mai University, Chiang Mai, Thailand. jtocharus@gmail.com.'}]",,,,,"10.1007/s12640-020-00269-y
10.1016/j.scient.2012.10.014
10.1021/mp700113r
10.1002/jnr.21252
10.7861/clinmedicine.16-3-247
10.1074/jbc.M706579200
10.1080/14756360802364377
10.1016/j.ejmech.2009.11.035
10.1017/S1461145711000149
10.3233/ADR-190135
10.1016/0006-2952(61)90145-9
10.1523/JNEUROSCI.2797-06.2006
10.1586/14737175.2015.1044981
10.1016/j.bbi.2015.09.019
10.1016/j.abb.2018.03.030
10.1021/bi00069a001
10.3233/JAD-2012-120328
10.1254/jphs.94.325
10.1016/j.pharep.2014.09.004
10.1097/00005072-199808000-00001
10.1038/nrn2168
10.1196/annals.1329.035
10.1016/j.bmc.2005.06.058
10.1016/j.mvr.2015.12.008
10.1523/JNEUROSCI.20-01-00149.2000
10.1016/j.jbior.2017.05.005
10.1002/hup.266
10.1007/978-0-387-46401-5_3
10.1248/bpb.b15-00209
10.1002/med.21622
10.1111/ggi.12971
10.1038/nrneurol.2017.162
10.1016/j.jsbmb.2014.02.011
10.1096/fj.03-1378fje
10.1248/bpb.30.74
10.1016/j.arcmed.2012.11.003
10.3748/wjg.v18.i19.2383
10.3233/JAD-170188
10.1016/j.neuint.2013.08.011
10.1016/j.ejphar.2010.04.041
10.1126/science.286.5440.735
10.1039/c9nr01255a
10.1371/journal.pone.0189211
10.1016/j.jalz.2016.07.150
10.1074/jbc.M404751200
10.1007/s12035-016-9802-9
10.1016/s0306-4522(02)00404-9",<Element 'PubmedArticle' at 0x7f05dc3a8f40>
41,32784004,Sodium orthovanadate improves learning and memory in intracerebroventricular-streptozotocin rat model of Alzheimer's disease through modulation of brain insulin resistance induced tau pathology.,"Sporadic Alzheimer's disease (sAD) is the most common type of dementia and progressive neurodegenerative disease. To establish the sAD model, intracerebroventricular (ICV) streptozotocin (STZ) at a dose of 3 mg/kg was administered bilaterally in rats on a stereotaxic apparatus. Behavioral tests such as Morris water maze (MWM), novel object recognition (NOR) and open field test were performed to evaluate cognitive and locomotor functions. Two treatment doses (5 mg/kg and 10 mg/kg) of sodium orthovanadate (SOV) and rivastigmine (2 mg/kg) were given orally to ICV-STZ induced rats for 21 days. Cortical and hippocampal tissues were dissected. Estimation of oxidative stress, mitochondrial dysfunction as complex I, II, III, IV activity, cholinergic function as acetylcholinesterase activity, ELISA for phosphorylated tau protein and insulin degrading enzyme (IDE), neuroinflammation as NF-κB gene expression and insulin signaling functioning as Q-RT-PCR for IR, IRS-1, PI3K, AKT, GSK-3β gene expression were performed. Behavioral results with SOV and rivastigmine treatment revealed decreased escape latency and increased discrimination index in MWM and NOR respectively. Treatment results with SOV also demonstrated attenuation of oxidative imbalance, improved mitochondrial activity, and reversed IDE and tau pathology. SOV treatment upregulated gene expression of IR, IRS-1, PI3K, and AKT, and downregulated that of GSK-3β. SOV results were compared with standard drug rivastigmine. Conclusively, the memory enhancement by SOV was mediated through oxidative balance, mitochondrial enzyme complex activation, and improved insulin signaling regulation. However, the primary mechanism of SOV remained attenuation of tau pathology by the upregulation of IRS-1/PI3K/AKT/GSK-3β pathway and reversal of insulin resistance in terms of IDE. Hence, in sAD paradigm, SOV contributed to memory improvement evident with the findings of behavioral studies, which can further potentially have clinical significance in AD.","['Alzheimer’s disease', 'ICV-STZ', 'Insulin resistance', 'Mitochondrial dysfunction', 'Oxidative stress', 'Sodium orthovanadate']",Brain research bulletin,2020-08-14,"[{'lastname': 'Akhtar', 'firstname': 'Ansab', 'initials': 'A', 'affiliation': 'Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.'}, {'lastname': 'Bishnoi', 'firstname': 'Mahendra', 'initials': 'M', 'affiliation': 'National Agri-Food Biotechnology Institute (NABI), Sector-81, SAS Nagar, Mohali 140306, Punjab, India.'}, {'lastname': 'Sah', 'firstname': 'Sangeeta Pilkhwal', 'initials': 'SP', 'affiliation': 'Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India. Electronic address: spilkhwal@rediffmail.com.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.brainresbull.2020.08.001,<Element 'PubmedArticle' at 0x7f05db728a40>
42,32759310,Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in ,"Frontotemporal dementia (FTD) is typically associated with changes in behaviour, language and movement. However, recent studies have shown that patients can also develop an abnormal response to pain, either heightened or diminished. We aimed to investigate this symptom in mutation carriers within the Genetic FTD Initiative (GENFI).
Abnormal responsiveness to pain was measured in 462 GENFI participants: 281 mutation carriers and 181 mutation-negative controls. Changes in responsiveness to pain were scored as absent (0), questionable or very mild (0.5), mild (1), moderate (2) or severe (3). Mutation carriers were classified into 
Altered responsiveness to pain was present to a significantly greater extent in symptomatic 
Changes in pain perception are a feature of ","['frontotemporal dementia', 'pain']","Journal of neurology, neurosurgery, and psychiatry",2020-08-08,"[{'lastname': 'Convery', 'firstname': 'Rhian S', 'initials': 'RS', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.'}, {'lastname': 'Bocchetta', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.'}, {'lastname': 'Greaves', 'firstname': 'Caroline V', 'initials': 'CV', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.'}, {'lastname': 'Moore', 'firstname': 'Katrina M', 'initials': 'KM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.'}, {'lastname': 'Cash', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.\nCentre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, UK.'}, {'lastname': 'Van Swieten', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'lastname': 'Moreno', 'firstname': 'Fermin', 'initials': 'F', 'affiliation': 'Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital Gipuzkoa Building, San Sebastian, Spain.'}, {'lastname': 'Sánchez-Valle', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': ""Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.""}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'lastname': 'Laforce', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Clinique Interdisciplinaire de Mémoire (CIME), Département des Sciences Neurologiques du CHU de Québec, Laval University, Quebec, Quebec City, Canada.'}, {'lastname': 'Masellis', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Tartaglia', 'firstname': 'Maria Carmela', 'initials': 'MC', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Graff', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'La Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy.\nCentro Dino Ferrari, University of Milan, Milano, Italy.'}, {'lastname': 'Rowe', 'firstname': 'James B', 'initials': 'JB', 'affiliation': 'Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Finger', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.'}, {'lastname': 'Synofzik', 'firstname': 'Matthis', 'initials': 'M', 'affiliation': 'Hertie-Institute for Clinical Brain Research and Center of Neurology, Department of Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.\nGerman Centre for Neurodegenerative Diseases, Tübingen, Germany.'}, {'lastname': 'Vandenberghe', 'firstname': 'Rik', 'initials': 'R', 'affiliation': 'Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.\nLeuven Brain Institute, KU Leuven, Leuven, Belgium.'}, {'lastname': 'de Mendonca', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Laboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisboa, Portugal.'}, {'lastname': 'Tagliavini', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy.'}, {'lastname': 'Santana', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': 'Faculty of Medicine, University of Coimbra, Coimbra, Portugal.\nCentre of Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal.'}, {'lastname': 'Ducharme', 'firstname': 'Simon', 'initials': 'S', 'affiliation': 'Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.\nMcConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.'}, {'lastname': 'Butler', 'firstname': 'Christopher', 'initials': 'C', 'affiliation': 'Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.'}, {'lastname': 'Gerhard', 'firstname': 'Alex', 'initials': 'A', 'affiliation': 'Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK.\nDepartments of Geriatric Medicine and Nuclear Medicine, University of Duisburg-Essen, Duisburg, Germany.'}, {'lastname': 'Levin', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'German Centre for Neurodegenerative Diseases Site Munich, Munchen, Germany.\nNeurologische Klinik, Ludwig-Maximilians-Universitat Munchen, Munchen, Germany.'}, {'lastname': 'Danek', 'firstname': 'Adrian', 'initials': 'A', 'affiliation': 'Neurologische Klinik, Ludwig-Maximilians-Universitat Munchen, Munchen, Germany.'}, {'lastname': 'Otto', 'firstname': 'Markus', 'initials': 'M', 'affiliation': 'Department of Neurology, University of Ulm, Ulm, Germany.'}, {'lastname': 'Warren', 'firstname': 'Jason D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK j.rohrer@ucl.ac.uk.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,Changes in pain perception are a feature of ,Altered responsiveness to pain was present to a significantly greater extent in symptomatic ,© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.,10.1136/jnnp-2020-323279,<Element 'PubmedArticle' at 0x7f05db72c180>
43,"32738275
28347670
30068637
29053874
17406415
22476196
27552480
30135948
28579870
22966039
23485579
24931033
22921433
19381658
24574966
30542257
24529528
12743238
31157827
7738205
8571133
29653606
30406177
29163145
31564456
26664821
22487856
8895324
21514248
29269073","MA-[D-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, improves episodic memory, and reduces serum levels of tumor necrosis factor-alpha and neurodegeneration in mouse models of Type 1 and Type 2 Diabetes Mellitus.","Extracellular beta-amyloid (Aβ), intra-neuronal hyper-phosphorylated tau protein, and chronic inflammation are neuropathological hallmarks of Alzheimer's Disease (AD). A link between AD, insulin dysfunction, and tumor necrosis factor-alpha (TNF-α) in promoting both tau and Aβ pathologies in vivo has been proposed.
MA-[D-Leu-4]-OB3 was given, with or without insulin, to streptozotocin (STZ)-treated male Swiss Webster mice, and to male diet-induced obese (DIO) mice. Brains were excised, and coronal sections were imaged with fluoro jade-C (FJC), thioflavin-S, or hematoxylin and eosin (H&E). Serum TNF-α and IGF-1 were measured by ELISA. Histopathological changes in the cerebral cortex (CC) and hippocampus (HC) were correlated with changes in glycemic regulation, episodic memory, and serum levels of TNF-α and IGF-1.
In STZ-treated mice, blood glucose and serum TNF-α and IGF-1 were reduced by insulin alone, and normalized when MA-[D-Leu-4]-OB3 was given in combination with insulin. Improvement in episodic memory was inversely correlated with the number of FJC-positive cells in the CC and HC and serum TNF-α and IGF-1. FJC, thioflavin-S and H&E staining indicated no Aβ deposition. Similar results were observed in DIO mice treated with MA-[D-Leu-4]-OB3.
The mechanism by which MA-[D-Leu-4]-OB3 improves episodic memory in mouse models of TIDM and T2DM appears to be related to improved insulin sensitivity and reduced TNF-α-induced neurodegeneration.
MA-[D-Leu-4]-OB3 may have application to human pre-clinical and clinical AD and AD-like dementia by interrupting the cascade of insulin resistance, neuro-inflammation, and neurodegeneration, that characterizes these diseases.","[""Alzheimer's disease"", 'Dementia', 'Episodic memory', 'Insulin resistance', 'Leptin peptides', 'Neurodegeneration']",Biochimica et biophysica acta. General subjects,2020-08-02,"[{'lastname': 'Hirschstein', 'firstname': 'Zall', 'initials': 'Z', 'affiliation': 'Albany Medical College, Albany, NY, USA.'}, {'lastname': 'Vanga', 'firstname': 'Gautam Reddy', 'initials': 'GR', 'affiliation': 'SUNY Upstate Medical University, Syracuse, NY, USA.'}, {'lastname': 'Wang', 'firstname': 'Guirong', 'initials': 'G', 'affiliation': 'SUNY Upstate Medical University, Syracuse, NY, USA.'}, {'lastname': 'Novakovic', 'firstname': 'Zachary M', 'initials': 'ZM', 'affiliation': 'Albany Medical College, Albany, NY, USA.'}, {'lastname': 'Grasso', 'firstname': 'Patricia', 'initials': 'P', 'affiliation': 'Albany Medical College, Albany, NY, USA. Electronic address: grassop@amc.edu.'}]",,,"In STZ-treated mice, blood glucose and serum TNF-α and IGF-1 were reduced by insulin alone, and normalized when MA-[D-Leu-4]-OB3 was given in combination with insulin. Improvement in episodic memory was inversely correlated with the number of FJC-positive cells in the CC and HC and serum TNF-α and IGF-1. FJC, thioflavin-S and H&E staining indicated no Aβ deposition. Similar results were observed in DIO mice treated with MA-[D-Leu-4]-OB3.",Copyright © 2020 Elsevier B.V. All rights reserved.,"10.1016/j.bbagen.2020.129697
10.1016/j.brainres.2017.03.020
10.1007/s10989-019-09929-w
10.1212/WNL.0000000000006075
10.1093/brain/awx243
10.1172/JCI57256
10.1016/j.neurobiolaging.2016.07.009
10.1016/j.ibror.2018.01.003
10.1177/1179573517709278
10.1124/pr.112.005850
10.1172/JCI64595
10.2337/db13-1954
10.1016/j.physbeh.2012.06.019
10.1007/s00401-009-0532-1
10.3389/fncel.2014.00022
10.3389/fnins.2018.00830
10.1016/j.jalz.2013.12.010
10.1212/01.wnl.0000063311.58879.01
10.1001/jamaneurolo.2019.1424
10.1007/s10989-019-09995-0
10.1172/JCI117936
10.1126/science.271.5249.665
10.1016/j.jalz.2018.02.018
10.1016/j.trci.2018.06.014
10.3389/fragi.2017.00365
10.1016/j.cell.2019.09.001
10.1155/2015/515248
10.1097/NEN.0b013e31825018f7
10.1210/2n,137.11.4611
10.1016/j.jalz.2011.03.003
10.1016/j.peptides.2017.12.012",<Element 'PubmedArticle' at 0x7f05dc043d10>
44,32737929,"Insulin deficiency, but not resistance, exaggerates cognitive deficits in transgenic mice expressing human amyloid and tau proteins. Reversal by Exendin-4 treatment.","Epidemiological studies have pointed at diabetes as a risk factor for Alzheimer's disease (AD) and this has been supported by several studies in animal models of both type 1 and type 2 diabetes. However, side-by-side comparison of the two types of diabetes is limited. We investigated the role of insulin deficiency and insulin resistance in the development of memory impairments and the effect of Exendin-4 (Ex4) treatment in a mouse model of AD. Three-4-month-old female wild type (WT) mice and mice overexpressing human tau and amyloid precursor protein (TAPP) were injected with streptozotocin (STZ) or fed a high-fat diet (HFD). A second study was performed in TAPP-STZ mice treated with Ex4, a long-lasting analog of GLP-1. Plasma and brain were collected at study termination for ELISA, Western blot, and immunohistochemistry analysis. Learning and memory deficits were impaired in TAPP transgenic mice compared with WT mice at the end of the study. Deficits were exaggerated by insulin deficiency in TAPP mice but 12 weeks of insulin resistance did not affect memory performances in either WT or TAPP mice. Levels of phosphorylated tau were increased in the brain of WT-STZ and TAPP-STZ mice but not in the brain of WT or TAPP mice on HFD. In the TAPP-STZ mice, treatment with Ex4 initiated after established cognitive deficits ameliorated learning, but not memory, impairments. This was accompanied by the reduction of amyloid β and phosphorylated tau expression. Theses studies support the role of Ex4 in AD, independently from its actions on diabetes.","[""Alzheimer's disease"", 'GLP-1 analog', 'RRID:AB_476730', 'RRID:AB_570891', 'RRID:AB_662807', 'RRID:AB_94944', 'adiponectin', 'diabetes']",Journal of neuroscience research,2020-08-02,"[{'lastname': 'King', 'firstname': 'Matthew R', 'initials': 'MR', 'affiliation': 'Department of Pathology, University of California San Diego, La Jolla, CA, USA.'}, {'lastname': 'Anderson', 'firstname': 'Nicholas J', 'initials': 'NJ', 'affiliation': 'Department of Pathology, University of California San Diego, La Jolla, CA, USA.'}, {'lastname': 'Deciu', 'firstname': 'Mihaela', 'initials': 'M', 'affiliation': 'Department of Pathology, University of California San Diego, La Jolla, CA, USA.'}, {'lastname': 'Guernsey', 'firstname': 'Lucie S', 'initials': 'LS', 'affiliation': 'Department of Pathology, University of California San Diego, La Jolla, CA, USA.'}, {'lastname': 'Cundiff', 'firstname': 'Morgan', 'initials': 'M', 'affiliation': 'Department of Pathology, University of California San Diego, La Jolla, CA, USA.'}, {'lastname': 'Hajizadeh', 'firstname': 'Shohreh', 'initials': 'S', 'affiliation': 'Department of Pathology, University of California San Diego, La Jolla, CA, USA.'}, {'lastname': 'Jolivalt', 'firstname': 'Corinne G', 'initials': 'CG', 'affiliation': 'Department of Pathology, University of California San Diego, La Jolla, CA, USA.'}]",,,,© 2020 Wiley Periodicals LLC.,10.1002/jnr.24706,<Element 'PubmedArticle' at 0x7f05dc029b30>
45,"32724479
31564456
1566067
3088567
17684513
29449700
30128052
29365294
27863809
15148141
20842183
10599761
25088942
28372335
30465895
29223528
30785085
29793329
25871519
27566237
25130400
26724858
28089565
28380381
29657029
30926667
30214638
17996984
28988823
20357365
21926274
23933984
28049395
10811879
7916070
21147038
18332434
22152301
19056987
21376239
25996133
17029594
28130845
22405200
7938003
26698914
17659524
19571222
29292507
29292516
20826658
9245504
29648978
17051205
25766618
30103324
22539584
28938407
30089252
31676432
25924103
25932355
26855936
25121572
26865611
25647291
30312017
31326499
31738978
15240812
30347438
23202295
26795437
29519677
29311680",Modulation of the Astrocyte-Neuron Lactate Shuttle System contributes to Neuroprotective action of Fibroblast Growth Factor 21.,"A viewpoint considering Alzheimer's disease (AD) as ""type 3 diabetes"" emphasizes the pivotal role of dysfunctional brain energy metabolism in AD. The hormone fibroblast growth factor 21 (FGF21) is a crucial regulator in energy metabolism; however, our understanding of the therapeutic potential and mechanisms underlying the effect of FGF21 on neurodegeneration of AD is far from complete. ","[""Alzheimer's disease"", 'Astrocyte', 'FGF21', 'Neuron', 'Neuroprotective']",Theranostics,2020-07-30,"[{'lastname': 'Sun', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, PR China.'}, {'lastname': 'Wang', 'firstname': 'Yue', 'initials': 'Y', 'affiliation': 'Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, PR China.'}, {'lastname': 'Chen', 'firstname': 'Su-Ting', 'initials': 'ST', 'affiliation': 'Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, PR China.'}, {'lastname': 'Chen', 'firstname': 'Ying-Jie', 'initials': 'YJ', 'affiliation': 'Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, PR China.'}, {'lastname': 'Shen', 'firstname': 'Jie', 'initials': 'J', 'affiliation': 'Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, PR China.'}, {'lastname': 'Yao', 'firstname': 'Wen-Bing', 'initials': 'WB', 'affiliation': 'Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, PR China.'}, {'lastname': 'Gao', 'firstname': 'Xiang-Dong', 'initials': 'XD', 'affiliation': 'Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, PR China.'}, {'lastname': 'Chen', 'firstname': 'Song', 'initials': 'S', 'affiliation': 'Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, PR China.'}]",,,,© The author(s).,10.7150/thno.44370,<Element 'PubmedArticle' at 0x7f05dc9cf5e0>
46,"32701063
26921134
28872215
23919770
24398425
21178125
26907614
26044748
24355101
11815627
18263657
25941346
26767952
29516284
31982938
16026957
22288401
29667931
24854124
16914853
12075344
24823497
24493463
16672906
19951717
27974048
20182045
24012919
26448556
28147245
22817481
21685445
25499583
15450169
21091655
27347894
26307455
7311623
24368090
23127917
29362997
27670763",ACE2 activator diminazene aceturate ameliorates Alzheimer's disease-like neuropathology and rescues cognitive impairment in SAMP8 mice.,"Previously, we revealed that brain Ang-(1-7) deficiency was involved in the pathogenesis of sporadic Alzheimer's disease (AD). We speculated that restoration of brain Ang-(1-7) levels might have a therapeutic effect against AD. However, the relatively short duration of biological effect limited the application of Ang-(1-7) in animal experiments. Since Ang-(1-7) is generated by its metabolic enzyme ACE2, we then tested the efficacy of an ACE2 activator diminazene aceturate (DIZE) on AD-like neuropathology and cognitive impairment in senescence-accelerated mouse prone substrain 8 (SAMP8) mice, an animal model of sporadic AD. Eight-month-old SAMP8 mice were injected intraperitoneally with vehicle or DIZE once a day for 30 consecutive days. DIZE markedly elevated brain Ang-(1-7) and MAS1 levels. Meanwhile, DIZE significantly reduced the levels of Aβ","['ACE2', 'Alzheimer’s disease', 'Ang-(1-7)', 'diminazene aceturate']",Aging,2020-07-24,"[{'lastname': 'Duan', 'firstname': 'Rui', 'initials': 'R', 'affiliation': ""School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.""}, {'lastname': 'Xue', 'firstname': 'Xiao', 'initials': 'X', 'affiliation': ""Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China.""}, {'lastname': 'Zhang', 'firstname': 'Qiao-Quan', 'initials': 'QQ', 'affiliation': ""Department of Pathology, Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, People's Republic of China.""}, {'lastname': 'Wang', 'firstname': 'Si-Yu', 'initials': 'SY', 'affiliation': ""Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China.""}, {'lastname': 'Gong', 'firstname': 'Peng-Yu', 'initials': 'PY', 'affiliation': ""Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China.""}, {'lastname': 'E', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': ""Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China.""}, {'lastname': 'Jiang', 'firstname': 'Teng', 'initials': 'T', 'affiliation': ""Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China.""}, {'lastname': 'Zhang', 'firstname': 'Ying-Dong', 'initials': 'YD', 'affiliation': ""School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.\nDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China.""}]",,,,,"10.18632/aging.103544
10.1016/S0140-6736(15)01124-1
10.1111/ene.13439
10.2174/15672050113109990155
10.1016/j.bcp.2013.12.024
10.1152/ajpregu.00222.2010
10.2174/1567202613666160224124739
10.1007/s12035-015-9260-9
10.1016/j.peptides.2013.12.006
10.1097/01.hjh.0000467659.31038.0f
10.1074/jbc.M200581200
10.1113/expphysiol.2007.040311
10.1161/HYPERTENSIONAHA.115.05185
10.1016/j.neuropharm.2015.12.026
10.1007/s12035-018-0966-3
10.1007/s00401-019-02098-6
10.1016/j.exger.2005.05.007
10.2174/138161212799315795
10.18632/aging.101419
10.1016/j.brainres.2014.05.019
10.3233/jad-2006-9s317
10.1038/nature00786
10.1002/jnr.23404
10.1001/jamaneurol.2013.5847
10.1038/sj.ki.5001509
10.1016/j.neuropharm.2009.11.010
10.1186/s13195-016-0221-y
10.3233/JAD-2010-1414
10.1016/j.freeradbiomed.2013.08.183
10.1111/jnc.13386
10.1016/j.neuroscience.2017.01.027
10.1111/j.1476-5381.2012.02105.x
10.1113/expphysiol.2011.058578
10.1016/j.bbi.2014.12.003
10.1016/j.neuron.2004.09.010
10.1111/j.1476-5381.2010.01128.x
10.1002/cphy.c150031
10.1016/j.arr.2015.08.001
10.1016/0047-6374(81)90084-1
10.1016/j.neurobiolaging.2013.11.026
10.1016/j.phrs.2012.10.014
10.1007/s10753-018-0735-5
10.1007/s00401-016-1622-5",<Element 'PubmedArticle' at 0x7f05dc959540>
47,32653415,Suppression of BACE1 and amyloidogenic/RAGE axis by sitagliptin ameliorates PTZ kindling-induced cognitive deficits in rats.,"The debilitating nature of cognitive impairment in epilepsy and the potential of some traditional antiepileptics to further deteriorate cognitive function are areas of growing concern. Glucagon-like peptide-1 (GLP-1) deficiency has been linked to reduced seizure threshold as well as cognitive dysfunction. Here, we tested whether sitagliptin (SITA), by virtue of its neuroprotective properties, could alleviate both epilepsy and associated cognitive dysfunction in a rat model of kindling epilepsy. Chemical kindling was induced by subconvulsive doses of pentylenetetrazol (PTZ) (30 mg/kg; i.p). SITA (50 mg/kg; p.o) was administered 1 h before PTZ injections. SITA conceivably attenuated PTZ hippocampal histological insult, preserved neuronal integrity and amended neurotransmitter perturbations in rat hippocampi paralleled with enhanced hippocampal GLP-1 levels as well as the downstream cAMP content and protein kinase A (PKA) activity. Moreover, SITA improved cognitive functioning of rats in the Morris water maze which was coupled with hampered hippocampal p(Ser","['BDNF', 'DPP-4', 'GLP-1', 'Morris water maze', 'Seizures', 'β-amyloid']",Chemico-biological interactions,2020-07-13,"[{'lastname': 'Safar', 'firstname': 'Marwa M', 'initials': 'MM', 'affiliation': 'Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt; Pharmacology and Biochemistry Department, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt.'}, {'lastname': 'Shahin', 'firstname': 'Nancy N', 'initials': 'NN', 'affiliation': 'Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}, {'lastname': 'Mohamed', 'firstname': 'Ahmed F', 'initials': 'AF', 'affiliation': 'Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Electronic address: ahmed.fathi@pharma.cu.edu.eg.'}, {'lastname': 'Abdelkader', 'firstname': 'Noha F', 'initials': 'NF', 'affiliation': 'Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/j.cbi.2020.109144,<Element 'PubmedArticle' at 0x7f05dc925450>
48,"32647316
18774423
16870212
15363612
18417557
19433474
11130931
1479134
22101980
30193988
10828380
15240184
16540157
19042040
27722926
18502307
15123489
18979198
18428021
11165387
15918910
11140356
19010319
29093334
19239151
18375059
28585544
25749400
28694433
15309576
29988104
15325787
24844704
27757384
22526240
12631430
25444754
28926161
17321089
24370534
15885777
17678633
19150053
26519901
20974046
29552054
29843044
27923588
27680977
26660117
29491217
28469194
22294373
24971521
30707852
23709336
29910467
30136162",Creatine and taurine mixtures alleviate depressive-like behaviour in Drosophila melanogaster and mice via regulating Akt and ERK/BDNF pathways.,"We investigated the antidepressant effect of creatine (CRE) and taurine (TAU) mixtures on behavioural changes and biomarkers in stress-induced depression in Drosophila melanogaster and a mouse model. Following CRE/TAU mixture administration in the Drosophila model, depression-like state induced by vibration, locomotion, climbing activity, and survival rate were measured. The normal stress (NS) group demonstrated decreased movement than the control (CON) group; movements in the CRE/TAU-treated group (particularly 0.15/0.5%) returned to the CON levels. Antidepressant effects of CRE/TAU mixtures were confirmed in a depressive mouse model induced by chronic mild stress. In behavioural assessments, movement and sucrose preference of the CRE/TAU group increased to a similar level as in the positive control group; hippocampal catecholamine and serotonin levels increased significantly. Stress-related hormones (adrenocorticotropic and corticotropin-releasing hormones) and inflammatory factors (IL-1β, IL-6, and TNF-α) increased in the NS group but significantly decreased in the CRE/TAU-treated group. Brain signalling protein expression ratio of phosphorylated protein kinase B (p-Akt)/Akt, phosphorylated extracellular signal-regulated kinase (p-ERK)/ERK, and brain-derived neurotrophic factor (BDNF) significantly increased in the CRE/TAU-treated group. These results indicate that CRE/TAU-induced antidepressant effects are associated with increased behavioural patterns and downregulation of stress hormones and cytokines, mediated through Akt and ERK/BDNF pathways in vertebrate models.",[],Scientific reports,2020-07-11,"[{'lastname': 'Kim', 'firstname': 'Suhyeon', 'initials': 'S', 'affiliation': 'Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul, 02841, Republic of Korea.'}, {'lastname': 'Hong', 'firstname': 'Ki-Bae', 'initials': 'KB', 'affiliation': 'BK21Plus, College of Health Science, Korea University, Seoul, 02841, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Singeun', 'initials': 'S', 'affiliation': 'Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul, 02841, Republic of Korea.'}, {'lastname': 'Suh', 'firstname': 'Hyung Joo', 'initials': 'HJ', 'affiliation': 'Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul, 02841, Republic of Korea. suh1960@korea.ac.k.\nBK21Plus, College of Health Science, Korea University, Seoul, 02841, Republic of Korea. suh1960@korea.ac.k.'}, {'lastname': 'Jo', 'firstname': 'Kyungae', 'initials': 'K', 'affiliation': 'BK21Plus, College of Health Science, Korea University, Seoul, 02841, Republic of Korea. kyungae11@korea.ac.kr.'}]",,,,,"10.1038/s41598-020-68424-1
10.1016/j.genhosppsych.2008.05.001
10.1016/j.jpsychires.2006.05.008
10.1016/j.pnpbp.2004.05.031
10.1136/oem.2007.038430
10.1177/0269881109105498
10.1016/S0924-977X(06)70007-4
10.1016/S0733-8627(05)70151-6
10.1016/0165-0327(92)90099-R
10.1007/s00726-011-1132-7
10.1016/j.pnpbp.2018.08.029
10.1016/S0301-0082(99)00071-4
10.1016/j.lfs.2004.03.010
10.1016/j.pbb.2006.02.007
10.1016/j.tips.2008.10.005
10.1007/s12035-016-0147-1
10.1016/j.brainresbull.2008.02.035
10.1001/archpsyc.61.5.450
10.1007/s11064-008-9865-8
10.1080/07853890801923753
10.1016/S0169-328X(00)00269-2
10.1186/1471-213X-5-9
10.1007/s007260070003
10.1016/j.ejphar.2008.10.049
10.1248/bpb.b17-00321
10.1016/j.neulet.2008.02.070
10.1038/ncomms15738
10.1038/srep08890
10.1038/s41598-017-05051-3
10.1007/s00726-004-0066-8
10.1016/j.eurpsy.2017.01.1972
10.1038/s41596-018-0011-z
10.1016/j.bbr.2004.04.008
10.1016/j.pbb.2014.06.006
10.20463/jenb.2016.09.20.3.4
10.1007/s00726-012-1282-2
10.1016/j.pharmthera.2014.10.002
10.1111/pcn.12604
10.1016/S0924-9338(15)31019-1
10.1016/j.jep.2007.01.025
10.1007/s00213-013-3369-1
10.1016/j.neubiorev.2005.03.023
10.1016/j.biopsych.2007.05.026
10.1016/j.biopsych.2008.11.029
10.1016/j.neuropharm.2015.10.034
10.1016/j.biopha.2018.04.035
10.1016/j.bbr.2016.11.053
10.1186/s12906-016-1356-x
10.1007/s12035-015-9580-9
10.1248/bpb.b17-00763
10.1016/j.pestbp.2012.07.006
10.7783/KJMCS.2014.22.3.196
10.1038/s41598-017-01561-2
10.1002/0471141755.ph0508s49
10.1016/j.jpba.2014.05.039
10.1080/13880209.2018.1557698
10.1007/s12033-013-96723-6
10.1038/s41380-018-0086-5
10.1007/s11064-018-2618-4",<Element 'PubmedArticle' at 0x7f05db519860>
49,"32557841
28697184
26681727
25700985
21683721
31156159
23011726
27810390
28372335
26890744
29865057
12061405
15148141
19743450
17159101
22476197
25107476
31539648
29377010
22369239
28688899
10672251
22245457
18728222
29173281
15750215
21598254
22476196
11377828
22956272
27771511
18479783
26597376
31211691
31551793
32492070
23595620
20427664
25318543
30875674
26812281
27755004","Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function.","To examine associations of molecular markers of brain insulin signaling with Alzheimer disease (AD) and cognition among older persons with or without diabetes.
This clinical-pathologic study was derived from a community-based cohort study, the Religious Orders Study. We studied 150 individuals (mean age at death =87 years, 48% women): 75 with and 75 without diabetes (matched by sex on age at death and education). Using enzyme-linked immunosorbent assay, immunohistochemistry, and ex vivo stimulation of brain tissue with insulin, we assessed insulin signaling in the postmortem middle frontal gyrus cortex. Postmortem data documented AD neuropathology. Clinical evaluations documented cognitive function proximate to death, based on 17 neuropsychological tests. In adjusted regression analyses, we examined associations of brain insulin signaling with diabetes, AD, and level of cognition.
Brain insulin receptor substrate-1 (IRS1) phosphorylation (pS
Brain AKT phosphorylation, a critical node in the signaling of insulin and other growth factors, is associated with AD neuropathology and lower cognitive function. ANN NEUROL 2020;88:513-525.",[],Annals of neurology,2020-06-20,"[{'lastname': 'Arvanitakis', 'firstname': 'Zoe', 'initials': 'Z', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.""}, {'lastname': 'Wang', 'firstname': 'Hoau-Yan', 'initials': 'HY', 'affiliation': 'Department of Molecular, Cellular, and Biomedical Science, City University of New York School of Medicine, New York, New York.\nDepartment of Biology, Neuroscience Program, Graduate School of the City University of New York, New York, New York.'}, {'lastname': 'Capuano', 'firstname': 'Ana W', 'initials': 'AW', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.""}, {'lastname': 'Khan', 'firstname': 'Amber', 'initials': 'A', 'affiliation': 'Department of Molecular, Cellular, and Biomedical Science, City University of New York School of Medicine, New York, New York.\nDepartment of Biology, Neuroscience Program, Graduate School of the City University of New York, New York, New York.'}, {'lastname': 'Taïb', 'firstname': 'Bouchra', 'initials': 'B', 'affiliation': 'Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'lastname': 'Anokye-Danso', 'firstname': 'Frederick', 'initials': 'F', 'affiliation': 'Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'lastname': 'Schneider', 'firstname': 'Julie A', 'initials': 'JA', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.""}, {'lastname': 'Bennett', 'firstname': 'David A', 'initials': 'DA', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.""}, {'lastname': 'Ahima', 'firstname': 'Rexford S', 'initials': 'RS', 'affiliation': 'Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'lastname': 'Arnold', 'firstname': 'Steven E', 'initials': 'SE', 'affiliation': ""Department of Neurology and Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.""}]",,,Brain insulin receptor substrate-1 (IRS1) phosphorylation (pS,© 2020 American Neurological Association.,10.1002/ana.25826,<Element 'PubmedArticle' at 0x7f05db4f1b30>
50,"32520734
9736007
27870425
30928686
18045930
30715078
30947113
28456479
16361959
14561431
24886908
21715678
16894106
25485714
24223109
12413371",Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT).,"Female sex is a major risk factor for late-onset Alzheimer disease (AD), and sex hormones have been implicated as a possible protective factor. Neuroimaging studies that evaluated the effects of sex hormones on brain integrity have primarily emphasized neurodegenerative measures rather than amyloid and tau burden.
We compared cortical amyloid and regional tau positron emission tomography (PET) deposition between cognitively normal males and females. We also compared preclinical AD pathology between females who have and have not used hormone therapy (HT). Finally, we compared the effects of amyloid and tau pathology on cognition, testing for both sex and HT effects.
We analyzed amyloid, tau, and cognition in a cognitively normal cross-sectional cohort of older individuals (n=148) followed at the Knight Alzheimer Disease Research Center. Amyloid and tau PET, medication history, and neuropsychological testing were obtained for each participant.
Within cognitively normal individuals, there was no difference in amyloid burden by sex. Whether or not we controlled for amyloid burden, female participants had significantly higher tau PET levels than males in multiple regions, including the rostral middle frontal and superior and middle temporal regions. HT accounted for a small reduction in tau PET; however, males still had substantially lower tau PET compared with females. Amyloid PET and tau PET burden were negatively associated with cognitive performance, although increasing amyloid PET did not have a deleterious effect on cognitive performance for women with a history of HT.
Regional sex-related differences in tau PET burden may contribute to the disparities in AD prevalence between males and females. The observed decreases tau PET burden in HT users has important implications for clinical practice and trials and deserves future consideration in longitudinal studies.",[],Alzheimer disease and associated disorders,2020-06-11,"[{'lastname': 'Wisch', 'firstname': 'Julie K', 'initials': 'JK', 'affiliation': 'Departments of Neurology.'}, {'lastname': 'Meeker', 'firstname': 'Karin L', 'initials': 'KL', 'affiliation': 'Departments of Neurology.'}, {'lastname': 'Gordon', 'firstname': 'Brian A', 'initials': 'BA', 'affiliation': 'Departments of Neurology.'}, {'lastname': 'Flores', 'firstname': 'Shaney', 'initials': 'S', 'affiliation': 'Departments of Neurology.'}, {'lastname': 'Dincer', 'firstname': 'Aylin', 'initials': 'A', 'affiliation': 'Departments of Neurology.'}, {'lastname': 'Grant', 'firstname': 'Elizabeth A', 'initials': 'EA', 'affiliation': 'Biostatistics.\nKnight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO.'}, {'lastname': 'Benzinger', 'firstname': 'Tammie L', 'initials': 'TL', 'affiliation': 'Radiology, Washington University in St. Louis.\nKnight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO.'}, {'lastname': 'Morris', 'firstname': 'John C', 'initials': 'JC', 'affiliation': 'Departments of Neurology.\nKnight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO.'}, {'lastname': 'Ances', 'firstname': 'Beau M', 'initials': 'BM', 'affiliation': 'Departments of Neurology.\nRadiology, Washington University in St. Louis.\nKnight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO.'}]",,,"Within cognitively normal individuals, there was no difference in amyloid burden by sex. Whether or not we controlled for amyloid burden, female participants had significantly higher tau PET levels than males in multiple regions, including the rostral middle frontal and superior and middle temporal regions. HT accounted for a small reduction in tau PET; however, males still had substantially lower tau PET compared with females. Amyloid PET and tau PET burden were negatively associated with cognitive performance, although increasing amyloid PET did not have a deleterious effect on cognitive performance for women with a history of HT.","Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.","10.1097/WAD.0000000000000393
10.1002/jnr.23827",<Element 'PubmedArticle' at 0x7f05dca15860>
51,32512138,Sex Hormone Depletion Augments Glucocorticoid Induction of Tau Hyperphosphorylation in Male Rat Brain.,"Steroid hormones secreted by the gonads (sex steroids) and adrenal glands (glucocorticoids, GC) are known to influence brain structure and function. While levels of sex steroids wane in late adulthood, corticosteroid levels tend to rise in many individuals due to age-related impairments in their feedback on central mechanisms regulating adrenal function. These fluctuations in sex and adrenal steroid secretion may be relevant to age-related neurodegenerative disorders such as Alzheimer's disease (AD) in which hyperphosphorylation of Tau protein is a key pathological event. We here report that both, long-term GC deprivation (by adrenalectomy) and exogenous GC administration with natural or synthetic glucocorticoid receptor ligands (corticosterone and dexamethasone, respectively) induce Tau hyperphosphorylation in the hippocampus and frontocortical regions at epitopes associated with disruption of cytoskeletal and synaptic function. Interestingly, we observed that the changes in Tau induced by manipulation of the GC milieu of male rats were exacerbated by testosterone depletion (by orchiectomy). While this finding supports previous suggestions of a neuroprotective role of male sex hormones, this is the first study to address interactions between adrenal and sex steroids on Tau hyperphosphorylation and accumulation that are known to endanger neuronal function and plasticity. These results are particularly important for understanding the mechanisms that can precipitate AD because, besides being modulated by age, GC are elevated by stress, a phenomenon now established as a trigger of deficits in neural plasticity and survival, cognitive behaviour and AD-like Tau pathology.","['Tau', 'glucocorticoids', 'hippocampus', 'hyperphosphorylation', 'male gonadal hormones', 'prefrontal cortex']",Neuroscience,2020-06-09,"[{'lastname': 'Monteiro-Fernandes', 'firstname': 'D', 'initials': 'D', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Sousa', 'firstname': 'N', 'initials': 'N', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Almeida', 'firstname': 'O F X', 'initials': 'OFX', 'affiliation': 'Max Plank Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany.'}, {'lastname': 'Sotiropoulos', 'firstname': 'I', 'initials': 'I', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal; Max Plank Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany. Electronic address: ioannis@med.uminho.pt.""}]",,,,Copyright © 2020 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2020.05.049,<Element 'PubmedArticle' at 0x7f05dca01310>
52,"32471175
31293377
26271894
23400560
27453234
29562533
31018141
31396077
28467755
27403169
29353052
30781611
26136647
26890744
19845468
22949105
30417362
26515689
26296668
32256316
29323772
31824296
32116562
31440144
27188415
27073371
27656397
22500228
31417349
30538427
27264956
30074262
28625813
29882416
29753753
29871525
28561773
32004495",The Pluripotency Factor Nanog Protects against Neuronal Amyloid β-Induced Toxicity and Oxidative Stress through Insulin Sensitivity Restoration.,"Amyloid β (Aβ) is a peptide fragment of the amyloid precursor protein that triggers the progression of Alzheimer's Disease (AD). It is believed that Aβ contributes to neurodegeneration in several ways, including mitochondria dysfunction, oxidative stress and brain insulin resistance. Therefore, protecting neurons from Aβ-induced neurotoxicity is an effective strategy for attenuating AD pathogenesis. Recently, applications of stem cell-based therapies have demonstrated the ability to reduce the progression and outcome of neurodegenerative diseases. Particularly, Nanog is recognized as a stem cell-related pluripotency factor that enhances self-renewing capacities and helps reduce the senescent phenotypes of aged neuronal cells. However, whether the upregulation of Nanog can be an effective approach to alleviate Aβ-induced neurotoxicity and senescence is not yet understood. In the present study, we transiently overexpressed Nanog-both in vitro and in vivo-and investigated the protective effects and underlying mechanisms against Aβ. We found that overexpression of Nanog is responsible for attenuating Aβ-triggered neuronal insulin resistance, which restores cell survival through reducing intracellular mitochondrial superoxide accumulation and cellular senescence. In addition, upregulation of Nanog expression appears to increase secretion of neurotrophic factors through activation of the Nrf2 antioxidant defense pathway. Furthermore, improvement of memory and learning were also observed in rat model of Aβ neurotoxicity mediated by upregulation of Nanog in the brain. Taken together, our study suggests a potential role for Nanog in attenuating the neurotoxic effects of Aβ, which in turn, suggests that strategies to enhance Nanog expression may be used as a novel intervention for reducing Aβ neurotoxicity in the AD brain.","['Nanog', 'amyloid β', 'insulin signaling', 'oxidative stress', 'senescence']",Cells,2020-05-31,"[{'lastname': 'Chang', 'firstname': 'Ching-Chi', 'initials': 'CC', 'affiliation': 'Institute of Medicine, Chung Shan Medical University, Taichung 402367, Taiwan.\nDepartment of Psychiatry, Chung Shan Medical University Hospital, Taichung 402367, Taiwan.'}, {'lastname': 'Li', 'firstname': 'Hsin-Hua', 'initials': 'HH', 'affiliation': 'Institute of Medicine, Chung Shan Medical University, Taichung 402367, Taiwan.\nDepartment of Medical Research, Chung Shan Medical University Hospital, Taichung 402367, Taiwan.'}, {'lastname': 'Tsou', 'firstname': 'Sing-Hua', 'initials': 'SH', 'affiliation': 'Institute of Medicine, Chung Shan Medical University, Taichung 402367, Taiwan.'}, {'lastname': 'Hung', 'firstname': 'Hui-Chih', 'initials': 'HC', 'affiliation': 'Department of Life Sciences and Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung 402204, Taiwan.'}, {'lastname': 'Liu', 'firstname': 'Guang-Yaw', 'initials': 'GY', 'affiliation': 'Institute of Medicine, Chung Shan Medical University, Taichung 402367, Taiwan.'}, {'lastname': 'Korolenko', 'firstname': 'Tatiana A', 'initials': 'TA', 'affiliation': 'Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk 630117, Russia.'}, {'lastname': 'Lai', 'firstname': 'Te-Jen', 'initials': 'TJ', 'affiliation': 'Institute of Medicine, Chung Shan Medical University, Taichung 402367, Taiwan.\nDepartment of Psychiatry, Chung Shan Medical University Hospital, Taichung 402367, Taiwan.'}, {'lastname': 'Ho', 'firstname': 'Ying-Jui', 'initials': 'YJ', 'affiliation': 'Department of Psychology, Chung Shan Medical University, Taichung 402367, Taiwan.'}, {'lastname': 'Lin', 'firstname': 'Chih-Li', 'initials': 'CL', 'affiliation': 'Institute of Medicine, Chung Shan Medical University, Taichung 402367, Taiwan.\nDepartment of Medical Research, Chung Shan Medical University Hospital, Taichung 402367, Taiwan.'}]",,,,,"10.3390/cells9061339
10.3389/fnins.2019.00659
10.1016/j.cbi.2015.07.013
10.1001/2013.jamaneurol.405
10.4103/0366-6999.186646
10.3233/JAD-170732
10.1016/j.celrep.2019.03.099
10.3389/fnagi.2019.00185
10.1089/ars.2017.7112
10.1186/s42269-019-0078-x
10.1155/2016/8102478
10.1016/j.neuropharm.2018.01.008
10.3390/ijms20040874
10.3389/fnins.2015.00204
10.3233/JAD-150741
10.1089/scd.2009.0276
10.1002/stem.1223
10.1002/jcp.27659
10.1016/j.expneurol.2015.10.009
10.1016/j.bbr.2015.08.011
10.3389/fncel.2020.00019
10.1111/febs.14379
10.3389/fnagi.2019.00311
10.3389/fncel.2020.00016
10.3389/fncel.2019.00363
10.1111/ejn.13278
10.4103/1673-5374.177724
10.1016/j.molmet.2016.06.011
10.1155/2012/384017
10.3389/fnins.2019.00788
10.2147/dddt.S173970
10.1038/srep27358
10.1002/jcb.27202
10.1016/j.bcp.2017.06.116
10.1177/0963689718779777
10.1016/j.neubiorev.2018.05.011
10.1177/0963689718774030
10.3390/ijms18061168
10.1016/j.stemcr.2019.12.013",<Element 'PubmedArticle' at 0x7f05dc9ec0e0>
53,"32385548
24444786
16024764
27615390
19818384
9566385
27659056
11914555
9369525
7488136
11390632
12963085
27225768
26959139
16872778
26891883
26740397
12888622
11255424
11391701
16914862
11896151
26048476
12824266
9191758
27014598
19807907
28708069
28577965
14745052
8518206
21555069
23316132
24481323
2172709
8885820
15930385
17055174
27870425
10098861
19427328
11531607
23841874
27458370
15232619
15383512
11796520
24802975
15308615
16837159
12706234
8709781
9427355
22415565
27196727
20457142","Estrogen Protects Optic Nerve Head Astrocytes Against Oxidative Stress by Preventing Caspase-3 Activation, Tau Dephosphorylation at Ser","Glaucoma is a neurodegenerative disorder that leads to the slow degeneration of retinal ganglion cells, and results in damage to the optic nerve and concomitant vision loss. As in other disorders affecting the viability of central nervous system neurons, neurons affected by glaucoma do not have the ability to regenerate after injury. Recent studies indicate a critical role for optic nerve head astrocytes (ONHAs) in this process of retinal ganglion cell degeneration. Cleavage of tau, a microtubule stabilizing protein and constituent of neurofibrillary tangles (NFT), plays a major part in the mechanisms that lead to toxicity in CNS neurons and astrocytes. Here, we tested the hypothesis that estrogen, a pleiotropic neuro- and cytoprotectant with high efficacy in the CNS, prevents tau cleavage, and hence, protects ONHAs against cell damage caused by oxidative stress. Our results indicate that estrogen prevents caspase-3 mediated tau cleavage, and thereby decreases the levels of the resulting form of proteolytically cleaved tau protein, which leads to a decrease in NFT formation, which requires proteolytically cleaved tau protein. Overall, our data propose that by stopping the reduction of estrogen levels involved with aging the sensitivity of the optic nerve to glaucomatous damage might be reduced. Furthermore, our data suggest that therapeutic use of estrogen may be beneficial in slowing or preventing the onset or severity of neurodegenerative diseases such as glaucoma and potentially also other degenerative diseases of the CNS through direct control of posttranslational modifications of tau protein.","['17β-estradiol', 'Brain', 'Central nervous system', 'Eye', 'Glaucoma', 'Neurofibrillary tangles', 'Phosphorylation', 'Retina', 'Tau cleavage']",Cellular and molecular neurobiology,2020-05-10,"[{'lastname': 'Means', 'firstname': 'John C', 'initials': 'JC', 'affiliation': 'Department of Ophthalmology, School of Medicine, Vision Research Center, University of Missouri - Kansas City, 2411 Holmes St., Kansas City, MO, 64108, USA.'}, {'lastname': 'Lopez', 'firstname': 'Adam A', 'initials': 'AA', 'affiliation': 'Department of Ophthalmology, School of Medicine, Vision Research Center, University of Missouri - Kansas City, 2411 Holmes St., Kansas City, MO, 64108, USA.'}, {'lastname': 'Koulen', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Department of Ophthalmology, School of Medicine, Vision Research Center, University of Missouri - Kansas City, 2411 Holmes St., Kansas City, MO, 64108, USA. koulenp@umkc.edu.\nDepartment of Biomedical Sciences, School of Medicine, University of Missouri - Kansas City, 2411 Holmes St., Kansas City, MO, USA. koulenp@umkc.edu.'}]",,,,,"10.1007/s10571-020-00859-6
10.1016/j.mce.2014.01.009
10.1196/annals.1347.016
10.1016/j.brainresbull.2016.08.018
10.1016/j.bbagen.2009.10.002
10.1016/j.pneurobio.2016.09.001
10.1159/000047976
10.1006/bbrc.1995.2647
10.1101/lm.39601
10.1016/S0197-0186(03)00101-3
10.1523/JNEUROSCI.3986-15.2016
10.3109/08820538.2015.1114845
10.1016/j.exger.2006.06.032
10.1016/j.pneurobio.2015.12.008
10.1016/j.brainres.2015.12.044
10.1073/pnas.1630428100
10.1001/jama.285.11.1475
10.1002/jnr.1098
10.1523/JNEUROSCI.22-06-02115.2002
10.1016/j.exer.2015.05.023
10.1167/iovs.02-1204
10.5498/wjp.v6.i1.54
10.1186/1471-2202-10-126
10.3390/ijms18071521
10.1016/j.ejphar.2017.05.059
10.1016/j.neuron.2011.04.009
10.3389/fncel.2012.00060
10.1001/jamaophthalmol.2013.7618
10.1016/0076-6879(90)86126-G
10.1523/JNEUROSCI.1125-05.2005
10.1016/j.neuroscience.2007.09.012
10.1002/jnr.23827
10.1046/j.1471-4159.1999.721552.x
10.1016/j.yfrne.2009.04.015
10.1034/j.1600-0412.2001.080008679.x
10.1021/mp400313u
10.3389/fnagi.2016.00160
10.1172/JCI20640
10.1001/jama.292.12.1431-b
10.1210/endo.143.2.8615
10.1111/1471-0528
10.1210/en.2004-0973
10.1016/j.exger.2006.05.013
10.1016/S0006-8993(03)02349-7
10.1016/S0140-6736(96)03356-9
10.1097/gme.0b013e3182443137
10.1210/er.2016-1007
10.1016/j.brainres.2010.04.074",<Element 'PubmedArticle' at 0x7f05db5c29f0>
54,"32344399
27144467
27306735
26041104
27114033
23041626
23543794
20026663
15509534
21212632
24117616
26979938
27412785
27844039
26989253
28409281
30252044
29315334
27899424
26021560
29957385
30112957
28093491
26791154
29305438
29665116
27716675
29679378
12615642
28445885
19513731
12472885
24990881
28281838
29246232
8132768
26881065
30111356
21810890
21325651
27845782
9748235
24820015
28592456
30297518
30349851
30291183
26783546
30224549
27239539
28337476
29142138
30215603
28989002
29331073
24295388
27634542
25563799
21035623
25254036
26383836
26270969
29126445
26698298
26827642
25024322
29328927
26836182
29580670
27832767
26754172
27423963
26941262
27974666
21567187
22323746
26485083
19433893
11455181
9389582
11578776
12505619
29867449
26624524
21645364
25435337
23239020
24619111
28404863
9382473
25775479
29396296
28319420
22890100
30311914
28599675","Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.","Chronic glial dysfunction may contribute to the pathogenesis of frontotemporal dementia (FTD). Cerebrospinal fluid (CSF) levels of glia-derived proteins YKL-40 and chitotriosidase are increased in Alzheimer's disease (AD) but have not been explored in detail across the spectrum of FTD.
We investigated whether CSF YKL-40 and chitotriosidase levels differed between FTD patients and controls, across different clinical and genetic subtypes of FTD, and between individuals with a clinical FTD syndrome due to AD versus non-AD (frontotemporal lobar degeneration, FTLD) pathology (based on CSF neurodegenerative biomarkers). Eighteen healthy controls and 64 people with FTD (behavioural variant FTD, n = 20; primary progressive aphasia [PPA], n = 44: nfvPPA, n = 16, svPPA, n = 11, lvPPA, n = 14, PPA-NOS, n = 3) were included. 10/64 had familial FTD, with mutations in GRN(n = 3), MAPT(n = 4), or C9orf72 (n = 3). 15/64 had neurodegenerative biomarkers consistent with AD pathology. Levels were measured by immunoassay and compared using multiple linear regressions. We also examined relationships of YKL-40 and chitotriosidase with CSF total tau (T-tau), phosphorylated tau 181 (P-tau) and β-amyloid 1-42 (Aβ42), with each other, and with age and disease du-ration.
CSF YKL-40 and chitotriosidase levels were higher in FTD, particularly lvPPA (both) and nfvPPA (YKL-40), compared with controls. GRN mutation carriers had higher levels of both proteins than controls and C9orf72 expansion carriers, and YKL-40 was higher in MAPT mutation carriers than controls. Individuals with underlying AD pathology had higher YKL-40 and chitotriosidase levels than both controls and those with likely FTLD pathology. CSF YKL-40 and chitotriosidase levels were variably associated with levels of T-tau, P-tau and Aβ42, and with each other, depending on clinical syndrome and underlying pathology. CSF YKL-40 but not chitotriosidase was associated with age, but not disease duration.
CSF YKL-40 and chitotriosidase levels are increased in individuals with clinical FTD syndromes, particularly due to AD pathology. In a preliminary analysis of genetic groups, levels of both proteins are found to be highly elevated in FTD due to GRN mutations, while YKL-40 is increased in individuals with MAPT mutations. As glia-derived protein levels generally correlate with T-tau and P-tau levels, they may reflect the glial response to neurodegeneration in FTLD.","['Astrocytes', 'Biomarkers', 'CHI3L1', 'Cerebrospinal fluid', 'Chitotriosidase', 'Frontotemporal dementia', 'Microglia', 'Neuroinflammation', 'Progranulin', 'YKL-40']",Dementia and geriatric cognitive disorders,2020-04-29,"[{'lastname': 'Woollacott', 'firstname': 'Ione O C', 'initials': 'IOC', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Nicholas', 'firstname': 'Jennifer M', 'initials': 'JM', 'affiliation': 'Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'lastname': 'Heller', 'firstname': 'Carolin', 'initials': 'C', 'affiliation': 'UK Dementia Research Institute, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Foiani', 'firstname': 'Martha S', 'initials': 'MS', 'affiliation': 'UK Dementia Research Institute, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Moore', 'firstname': 'Katrina M', 'initials': 'KM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Russell', 'firstname': 'Lucy L', 'initials': 'LL', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Paterson', 'firstname': 'Ross W', 'initials': 'RW', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Keshavan', 'firstname': 'Ashvini', 'initials': 'A', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Schott', 'firstname': 'Jonathan M', 'initials': 'JM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Warren', 'firstname': 'Jason D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Heslegrave', 'firstname': 'Amanda', 'initials': 'A', 'affiliation': 'UK Dementia Research Institute, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': 'UK Dementia Research Institute, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.\nDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom, j.rohrer@ucl.ac.uk.'}]",,"CSF YKL-40 and chitotriosidase levels are increased in individuals with clinical FTD syndromes, particularly due to AD pathology. In a preliminary analysis of genetic groups, levels of both proteins are found to be highly elevated in FTD due to GRN mutations, while YKL-40 is increased in individuals with MAPT mutations. As glia-derived protein levels generally correlate with T-tau and P-tau levels, they may reflect the glial response to neurodegeneration in FTLD.","CSF YKL-40 and chitotriosidase levels were higher in FTD, particularly lvPPA (both) and nfvPPA (YKL-40), compared with controls. GRN mutation carriers had higher levels of both proteins than controls and C9orf72 expansion carriers, and YKL-40 was higher in MAPT mutation carriers than controls. Individuals with underlying AD pathology had higher YKL-40 and chitotriosidase levels than both controls and those with likely FTLD pathology. CSF YKL-40 and chitotriosidase levels were variably associated with levels of T-tau, P-tau and Aβ42, and with each other, depending on clinical syndrome and underlying pathology. CSF YKL-40 but not chitotriosidase was associated with age, but not disease duration.","© 2020 The Author(s) Published by S. Karger AG, Basel.","10.1159/000506282
10.1111/jnc.13588
10.1212/NXI.0000000000000301
10.1212/WNL.0b013e31821103e6
10.1186/s13024-017-0226-4
10.1186/s13024-016-0071-x
10.1007/s12017-011-8147-9
10.1126/scitranslmed.aah5642",<Element 'PubmedArticle' at 0x7f05db657e50>
55,32335219,Serum tau levels are increased in patients with hyperthyroidism.,"Hyperthyroidism may cause cognitive decline and increases the risk of Alzheimer's disease (AD), the major form of dementia; however, the underlying mechanism of this relationship is unclear. AD is associated with increased serum levels of tau. In this study, we investigated the relationship between serum thyroid hormones (THs) and tau. Fifty participants diagnosed with hyperthyroidism and fifty euthyroid counterparts were included and received clinical examinations. Serum concentrations of thyroid-stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3) and tau protein were assessed. The total tau protein level was significantly higher in hyperthyroidism participants than in their euthyroid counterparts. The level of circulating total tau had a significant positive association with the serum concentrations of FT3 and FT4. Total tau level was increased in the low TSH group and the serum THs decreased with the increase of age. These findings reveal that peripheral THs are associated with the serum concentration of tau, which may be involved in the pathogenesis of AD, suggesting a potential therapeutic target of AD via hyperthyroidism therapy.","['Alzheimer’s disease', 'Hyperthyroidism', 'Tau', 'Thyroid hormone']",Neuroscience letters,2020-04-27,"[{'lastname': 'Li', 'firstname': 'Lun-Xi', 'initials': 'LX', 'affiliation': 'Department of Neurology, Army Medical University Daping Hospital, China.'}, {'lastname': 'Yang', 'firstname': 'Tong', 'initials': 'T', 'affiliation': 'Department of Neurology, Army Medical University Daping Hospital, China.'}, {'lastname': 'Guo', 'firstname': 'Lu', 'initials': 'L', 'affiliation': 'Department of Neurology, Army Medical University Daping Hospital, China.'}, {'lastname': 'Wang', 'firstname': 'Da-Yan', 'initials': 'DY', 'affiliation': 'Department of Neurology, the Seventh Affiliated Hospital, Sun Yat-sen University, China.'}, {'lastname': 'Tang', 'firstname': 'Chun-Hua', 'initials': 'CH', 'affiliation': 'Department of Neurology, Army Medical University Daping Hospital, China.'}, {'lastname': 'Li', 'firstname': 'Qiong', 'initials': 'Q', 'affiliation': 'Department of Neurology, Army Medical University Daping Hospital, China.'}, {'lastname': 'Yang', 'firstname': 'Hai-Mei', 'initials': 'HM', 'affiliation': 'Department of Neurology, Army Medical University Daping Hospital, China.'}, {'lastname': 'Zhu', 'firstname': 'Jie', 'initials': 'J', 'affiliation': 'Department of Neurology, Army Medical University Daping Hospital, China. Electronic address: dpapof@hotmail.com.'}, {'lastname': 'Zhang', 'firstname': 'Li-Li', 'initials': 'LL', 'affiliation': 'Department of Neurology, Army Medical University Daping Hospital, China.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/j.neulet.2020.135003,<Element 'PubmedArticle' at 0x7f05dc6e01d0>
56,32278051,Prenatal bisphenol A exposure contributes to Tau pathology: Potential roles of CDK5/GSK3β/PP2A axis in BPA-induced neurotoxicity.,"Bisphenol A (BPA) is a well-known endocrine disruptor used to manufacture polycarbonate plastics and epoxy resins. BPA exposure especially occupational perinatal exposure to has been linked to numerous adverse effects for the offspring. Available data have shown that perinatal exposure to BPA contributes to neurodegenerative pathological changes; however, the potential mechanisms remain unclear. This study attempted to investigate the long-term consequences of perinatal exposure to BPA on the offspring mouse brain. The pregnant mice were given either a vehicle control or BPA (2, 10, 100 μg/kg/d) from day 6 of gestation until weaning (P6-PND21, foetal and neonatal exposure). At 3, 6 and 9 months of age, the neurotoxic effects in the offspring in each group were investigated. We found that the spine density but not the dendritic branches in the hippocampus were noticeably reduced at 6 and 9 months of age. Meanwhile, p-Tau, the characteristic protein for tauopathy, was dramatically increased in both the hippocampus and cortex at 3-9 months of age. Mechanically, the balance of kinase and protein phosphatase, which plays critical roles in p-Tau regulation, was disturbed. It indicated that GSK3β and CDK5, two critical kinases, were activated in most of the BPA perinatal exposure group, while protein phosphatase 2A (PP2A), one of the important phosphatases, regulated p-Tau expression through its demethylation, methylation and phosphorylation. Taken together, the present study may be translatable to the human occupational BPA exposure due to a similar exposure level. BPA perinatal exposure causes long-term adverse effects on the mouse brain and may be a risk factor for tauopathies, and the CDK5/GSK3β/PP2A axis might be a promising therapeutic target for BPA-induced neurodegenerative pathological changes.","['Bisphenol A', 'CDK5/GSK3β/PP2A/p-Tau axis', 'In vivo study', 'Perinatal exposure', 'Tauopathy']",Toxicology,2020-04-12,"[{'lastname': 'Xue', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, 818 Tianyuan East Road, Nanjing, Jiangsu, 211166, China.'}, {'lastname': 'Zhang', 'firstname': 'Li', 'initials': 'L', 'affiliation': ""Department of Anesthesiology, Children's Hospital of Nanjing Medical University, China.""}, {'lastname': 'Xie', 'firstname': 'Xuexue', 'initials': 'X', 'affiliation': 'Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, 818 Tianyuan East Road, Nanjing, Jiangsu, 211166, China.'}, {'lastname': 'Gao', 'firstname': 'Yue', 'initials': 'Y', 'affiliation': 'Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, 818 Tianyuan East Road, Nanjing, Jiangsu, 211166, China.'}, {'lastname': 'Jiang', 'firstname': 'Lei', 'initials': 'L', 'affiliation': 'Department of Emergency Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu, 210029, China.'}, {'lastname': 'Wang', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, 818 Tianyuan East Road, Nanjing, Jiangsu, 211166, China; China International Cooperation Center for Environment and Human Health, Nanjing Medical University, 818 Tianyuan East Road, Nanjing, Jiangsu, 211166, China.'}, {'lastname': 'Wang', 'firstname': 'Yu', 'initials': 'Y', 'affiliation': 'Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, 818 Tianyuan East Road, Nanjing, Jiangsu, 211166, China.'}, {'lastname': 'Gao', 'firstname': 'Rong', 'initials': 'R', 'affiliation': 'Department of Hygienic Analysis and Detection, Key Laboratory of Modern Toxicology, Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China.'}, {'lastname': 'Yu', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Department of Hygienic Analysis and Detection, Key Laboratory of Modern Toxicology, Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China.'}, {'lastname': 'Xiao', 'firstname': 'Hang', 'initials': 'H', 'affiliation': 'Key Lab of Modern Toxicology (NJMU), Ministry of Education, Department of Toxicology, School of Public Health, Nanjing Medical University, 818 Tianyuan East Road, Nanjing, Jiangsu, 211166, China. Electronic address: hxiao@njmu.edu.cn.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/j.tox.2020.152442,<Element 'PubmedArticle' at 0x7f05dc6c5130>
57,"32241177
18762245
21986894
15930395
12859672
11164808
23635041
15802185
15605990
14528911
12160938
12787059
12354300
12354300
23211594
30347620
21548781
21895520
16784548
17420316
27924013
22065591
25992526
10783293
26157646
29311903
12810767
21388376
2794319
11822882
25712633
7895820
8159737
9427614
10547924
24217171
15473992
22285252
20216546
28068405
18648646
26667418
23208308
1833351
22900595
29927671
24243523
29993324
29376093
27265785
26360375
30618712
27251042
26054886
23334597
21358359
17518533
20101720
19710325
1683421
8163989
21223993
15198121
21699958
23458973
29215295
30484371
31183671
25943889
17522440
19777328
16634065
19288120
16378731
21726674
26126631
15174014
17618986
15094077
16129700
12214102
10588580
28371386","Unbiased Proteomic Approach Identifies Pathobiological Profiles in the Brains of Preclinical Models of Repetitive Mild Traumatic Brain Injury, Tauopathy, and Amyloidosis.","No concerted investigation has been conducted to explore overlapping and distinct pathobiological mechanisms between repetitive mild traumatic brain injury (r-mTBI) and tau/amyloid proteinopathies considering the long history of association between TBI and Alzheimer’s disease. We address this problem by using unbiased proteomic approaches to generate detailed time-dependent brain molecular profiles of response to repetitive mTBI in C57BL/6 mice and in mouse models of amyloidosis (with amyloid precursor protein KM670/671NL (Swedish) and Presenilin 1 M146L mutations [PSAPP]) and tauopathy (hTau). Brain tissues from animals were collected at different timepoints after injuries (24 hr–12 months post-injury) and at different ages for tau or amyloid transgenic models (3, 9, and 15 months old), encompassing the pre-, peri-, and post-“onset” of cognitive and pathological phenotypes. We identified 30 hippocampal and 47 cortical proteins that were significantly modulated over time in the r-mTBI compared with sham mice. These proteins identified TBI-dependent modulation of phosphatidylinositol-3-kinase/AKT signaling, protein kinase A signaling, and PPARα/RXRα activation in the hippocampus and protein kinase A signaling, gonadotropin-releasing hormone signaling, and B cell receptor signaling in the cortex. Previously published neuropathological studies of our mTBI model showed a lack of amyloid and tau pathology. In PSAPP mice, we identified 19 proteins significantly changing in the cortex and only 7 proteins in hTau mice versus wild-type littermates. When we explored the overlap between our r-mTBI model and the PSAPP/hTau models, a fairly small coincidental change was observed involving only eight significantly regulated proteins. This work suggests a very distinct TBI neurodegeneration and also that other factors are needed to drive pathologies such as amyloidosis and tauopathy postinjury.","['TBI', 'amyloidosis', 'molecular pathobiology', 'neurodegeneration', 'proteomics', 'tauopathy']",ASN neuro,2020-04-04,"[{'lastname': 'Ojo', 'firstname': 'Joseph O', 'initials': 'JO', 'affiliation': ""Experimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, Florida, United States.\nJames A. Haley Veterans' Hospital, Tampa, Florida, United States.\nSchool of Life, Health and Chemical Sciences, The Open University, Milton Keynes, United Kingdom.""}, {'lastname': 'Crynen', 'firstname': 'Gogce', 'initials': 'G', 'affiliation': 'Experimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, Florida, United States.\nSchool of Life, Health and Chemical Sciences, The Open University, Milton Keynes, United Kingdom.'}, {'lastname': 'Algamal', 'firstname': 'Moustafa', 'initials': 'M', 'affiliation': 'Experimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, Florida, United States.\nSchool of Life, Health and Chemical Sciences, The Open University, Milton Keynes, United Kingdom.'}, {'lastname': 'Vallabhaneni', 'firstname': 'Prashanti', 'initials': 'P', 'affiliation': 'Experimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, Florida, United States.'}, {'lastname': 'Leary', 'firstname': 'Paige', 'initials': 'P', 'affiliation': 'Experimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, Florida, United States.'}, {'lastname': 'Mouzon', 'firstname': 'Benoit', 'initials': 'B', 'affiliation': ""Experimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, Florida, United States.\nJames A. Haley Veterans' Hospital, Tampa, Florida, United States.\nSchool of Life, Health and Chemical Sciences, The Open University, Milton Keynes, United Kingdom.""}, {'lastname': 'Reed', 'firstname': 'Jon M', 'initials': 'JM', 'affiliation': 'Experimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, Florida, United States.\nBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, United States.'}, {'lastname': 'Mullan', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Experimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, Florida, United States.\nSchool of Life, Health and Chemical Sciences, The Open University, Milton Keynes, United Kingdom.'}, {'lastname': 'Crawford', 'firstname': 'Fiona', 'initials': 'F', 'affiliation': ""Experimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, Florida, United States.\nJames A. Haley Veterans' Hospital, Tampa, Florida, United States.\nSchool of Life, Health and Chemical Sciences, The Open University, Milton Keynes, United Kingdom.""}]",,,,,"10.1177/1759091420914768
10.1016/j.freeradbiomed.2008.08.012
10.1007/s12017-011-8160-z
10.1001/archneur.64.4.541
10.1001/jamaneurol.2013.4847
10.1016/j.expneurol.2004.06.011
10.1371/journal.pone.0169650
10.1371/journal.pone.0002750
10.1007/s00401-015-1515-z
10.1089/neu.2018.5720
10.3389/fnagi.2018.00405
10.1093/jnen/nlw035
10.1089/neu.2006.0229
10.1002/msj.20157
10.1016/0140-6736(91)92724-G
10.1136/jnnp.57.4.419
10.1016/j.neuroscience.2011.01.005
10.1016/j.neulet.2011.06.009
10.1038/nrneurol.2013.29
10.1007/s00401-015-1435-y
10.1007/s10863-009-9241-7
10.1002/jnr.20876
10.1016/j.nbd.2005.10.004
10.1016/j.jprot.2011.06.015
10.1007/s00204-015-1556-z
10.1002/ana.20101
10.1016/S0079-6123(06)61021-2
10.1016/j.ejphar.2004.02.048
10.1096/fj.05-4263fje",<Element 'PubmedArticle' at 0x7f05dc6c1860>
58,"32215583
30743264
16192588
26119559
27528718
28146658
27480153
27614333
30920593
22147380
27737437
22422832
27160475
1594819
23415868
22282466
20354011
2503724
30238901
28716370
31629656
16983113
15647578
27598804
23845839
31051281
31279067
17428247
31375469",Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.,"In men with recurrent prostate cancer, addition of long-term antiandrogen therapy to salvage radiotherapy (SRT) was associated with overall survival (OS) in the NRG/RTOG 9601 study. However, hormone therapy has associated morbidity, and there are no validated predictive biomarkers to identify which patients derive most benefit from treatment.
To examine the role of pre-SRT prostate-specific antigen (PSA) levels to personalize hormone therapy use with SRT.
Men were randomized to SRT plus high-dose nonsteroidal antiandrogen (bicalutamide, 150 mg/d) or placebo for 2 years.
In this secondary analysis of the multicenter RTOG 9601 double-blind, placebo-controlled randomized clinical trial conducted from 1998 to 2003 by a multinational cooperative group, men with a positive surgical margin or pathologic T3 disease after radical prostatectomy with pre-SRT PSA of 0.2 to 4.0 ng/mL were included. Analysis was performed between March 4, 2019, and December 20, 2019.
The primary outcome was overall survival (OS). Secondary end points included distant metastasis (DM), other-cause mortality (OCM), and grades 3 to 5 cardiac and neurologic toxic effects. Subgroup analyses were performed using the protocol-specified PSA stratification variable (1.5 ng/mL) and additional PSA cut points, including test for interaction. Competing risk analyses were performed for DM and other-cause mortality (OCM).
Overall, 760 men with PSA elevation after radical prostatectomy for prostate cancer were included. The median (range) age of particpants was 65 (40-83) years. Antiandrogen assignment was associated with an OS benefit in the PSA stratum greater than 1.5 ng/mL (n = 118) with a 25% 12-year absolute benefit (hazard ratio [HR], 0.45; 95% CI, 0.25-0.81), but not in the PSA of 1.5 ng/mL or less stratum (n = 642) (1% 12-year absolute difference; HR, 0.87; 95% CI, 0.66-1.16). In a subanalysis of men with PSA of 0.61 to 1.5 (n = 253), there was an OS benefit associated with antiandrogen assignment (HR, 0.61; 95% CI, 0.39-0.94). In those receiving early SRT (PSA ≤0.6 ng/mL, n = 389), there was no improvement in OS (HR, 1.16; 95% CI, 0.79-1.70), an increased OCM hazard (subdistribution HR, 1.94; 95% CI, 1.17-3.20; P = .01), and an increased odds of late grades 3 to 5 cardiac and neurologic toxic effects (odds ratio, 3.57; 95% CI, 1.09-15.97; P = .05).
These results suggest that pre-SRT PSA level may be a prognostic biomarker for outcomes of antiandrogen treatment with SRT. In patients receiving late SRT (PSA >0.6 ng/mL, hormone therapy was associated with improved outcomes. In men receiving early SRT (PSA ≤0.6 ng/mL), long-term antiandrogen treatment was not associated with improved OS. Future randomized clinical trials are needed to determine hormonal therapy benefit in this population.
ClinicalTrials.gov Identifier: NCT00002874.",[],JAMA oncology,2020-03-28,"[{'lastname': 'Dess', 'firstname': 'Robert T', 'initials': 'RT', 'affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor.'}, {'lastname': 'Sun', 'firstname': 'Yilun', 'initials': 'Y', 'affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor.\nDepartment of Biostatistics, University of Michigan, Ann Arbor.'}, {'lastname': 'Jackson', 'firstname': 'William C', 'initials': 'WC', 'affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor.'}, {'lastname': 'Jairath', 'firstname': 'Neil K', 'initials': 'NK', 'affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor.'}, {'lastname': 'Kishan', 'firstname': 'Amar U', 'initials': 'AU', 'affiliation': 'Department of Radiation Oncology, University of California, Los Angeles.'}, {'lastname': 'Wallington', 'firstname': 'David G', 'initials': 'DG', 'affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor.'}, {'lastname': 'Mahal', 'firstname': 'Brandon A', 'initials': 'BA', 'affiliation': 'Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'lastname': 'Stish', 'firstname': 'Bradley J', 'initials': 'BJ', 'affiliation': 'Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Zumsteg', 'firstname': 'Zachery S', 'initials': 'ZS', 'affiliation': 'Department of Radiation Oncology, Cedars-Sinai Medical Center, West Hollywood, California.'}, {'lastname': 'Den', 'firstname': 'Robert B', 'initials': 'RB', 'affiliation': 'Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.'}, {'lastname': 'Hall', 'firstname': 'William A', 'initials': 'WA', 'affiliation': 'Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee.'}, {'lastname': 'Gharzai', 'firstname': 'Laila A', 'initials': 'LA', 'affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor.'}, {'lastname': 'Jaworski', 'firstname': 'Elizabeth M', 'initials': 'EM', 'affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor.'}, {'lastname': 'Reichert', 'firstname': 'Zachary R', 'initials': 'ZR', 'affiliation': 'Department of Medicine, University of Michigan, Ann Arbor.'}, {'lastname': 'Morgan', 'firstname': 'Todd M', 'initials': 'TM', 'affiliation': 'Department of Urology, University of Michigan, Ann Arbor.'}, {'lastname': 'Mehra', 'firstname': 'Rohit', 'initials': 'R', 'affiliation': 'Department of Pathology, University of Michigan, Ann Arbor.'}, {'lastname': 'Schaeffer', 'firstname': 'Edward M', 'initials': 'EM', 'affiliation': 'Department of Urology, Northwestern University, Chicago, Illinois.'}, {'lastname': 'Sartor', 'firstname': 'Oliver', 'initials': 'O', 'affiliation': 'Department of Medicine, Tulane Cancer Center, New Orleans, Louisiana.'}, {'lastname': 'Nguyen', 'firstname': 'Paul L', 'initials': 'PL', 'affiliation': 'Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'lastname': 'Lee', 'firstname': 'William Robert', 'initials': 'WR', 'affiliation': 'Department of Radiation Oncology, Duke Health, Durham, North Carolina.'}, {'lastname': 'Rosenthal', 'firstname': 'Seth A', 'initials': 'SA', 'affiliation': 'Department of Radiation Oncology, Sutter Medical Group, Sacramento, California.'}, {'lastname': 'Michalski', 'firstname': 'Jeff M', 'initials': 'JM', 'affiliation': 'Department of Radiation Oncology, Washington University School of Medicine in St Louis, St Louis, Missouri.'}, {'lastname': 'Schipper', 'firstname': 'Matthew J', 'initials': 'MJ', 'affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor.\nDepartment of Biostatistics, University of Michigan, Ann Arbor.'}, {'lastname': 'Dignam', 'firstname': 'James J', 'initials': 'JJ', 'affiliation': 'Department of Public Health Sciences, University of Chicago, Chicago, Illinois.'}, {'lastname': 'Pisansky', 'firstname': 'Thomas M', 'initials': 'TM', 'affiliation': 'Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Zietman', 'firstname': 'Anthony L', 'initials': 'AL', 'affiliation': 'Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'lastname': 'Sandler', 'firstname': 'Howard M', 'initials': 'HM', 'affiliation': 'Department of Radiation Oncology, Cedars-Sinai Medical Center, West Hollywood, California.'}, {'lastname': 'Efstathiou', 'firstname': 'Jason A', 'initials': 'JA', 'affiliation': 'Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'lastname': 'Feng', 'firstname': 'Felix Y', 'initials': 'FY', 'affiliation': 'Department of Radiation Oncology, University of California, San Francisco.\nDepartment of Urology, University of California, San Francisco.\nDepartment of Medicine, University of California, San Francisco.'}, {'lastname': 'Shipley', 'firstname': 'William U', 'initials': 'WU', 'affiliation': 'Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'lastname': 'Spratt', 'firstname': 'Daniel E', 'initials': 'DE', 'affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor.'}]",,,"Overall, 760 men with PSA elevation after radical prostatectomy for prostate cancer were included. The median (range) age of particpants was 65 (40-83) years. Antiandrogen assignment was associated with an OS benefit in the PSA stratum greater than 1.5 ng/mL (n = 118) with a 25% 12-year absolute benefit (hazard ratio [HR], 0.45; 95% CI, 0.25-0.81), but not in the PSA of 1.5 ng/mL or less stratum (n = 642) (1% 12-year absolute difference; HR, 0.87; 95% CI, 0.66-1.16). In a subanalysis of men with PSA of 0.61 to 1.5 (n = 253), there was an OS benefit associated with antiandrogen assignment (HR, 0.61; 95% CI, 0.39-0.94). In those receiving early SRT (PSA ≤0.6 ng/mL, n = 389), there was no improvement in OS (HR, 1.16; 95% CI, 0.79-1.70), an increased OCM hazard (subdistribution HR, 1.94; 95% CI, 1.17-3.20; P = .01), and an increased odds of late grades 3 to 5 cardiac and neurologic toxic effects (odds ratio, 3.57; 95% CI, 1.09-15.97; P = .05).",,"10.1001/jamaoncol.2020.0109
10.1001/jama.2018.19941
10.1200/JCO.2005.01.867
10.1016/j.eururo.2015.06.020
10.1200/JCO.2016.67.9647
10.1056/NEJMoa1607529
10.1200/JCO.2016.68.3425
10.1016/j.juro.2016.08.106
10.1001/jamaoncol.2019.0096
10.1001/jama.2011.1745
10.1001/jamaoncol.2016.3662
10.1136/bmj.e1553
10.1016/S1470-2045(16)00111-X
10.1016/j.ijrobp.2018.08.052
10.1080/01621459.1958.10501452
10.1080/01621459.1999.10474144
10.1002/sim.4780110611
10.1016/j.jclinepi.2012.09.017
10.1158/1078-0432.CCR-11-2097
10.1136/bmj.c117
10.1056/NEJM198908173210702
10.1016/j.ijrobp.2018.06.037
10.1016/j.eururo.2017.06.027
10.1016/S1470-2045(19)30486-3
10.1200/JCO.2006.06.2497
10.1056/NEJMoa041943
10.1016/j.ijrobp.2016.06.2445
10.1016/j.ijrobp.2013.05.029
10.1016/j.prro.2019.04.008
10.1016/j.prro.2019.06.006
10.1111/j.1464-410X.2007.06844.x
10.1016/S1470-2045(19)30415-2",<Element 'PubmedArticle' at 0x7f05dcbccb30>
59,"32059611
14522854
14522862
14522861
14522863
29887137
22607808
27364252
30588682
16855204
11071481
26268531
16924018
15465434
19159063
17646628
9450766
30294658
27735933
19506221
10994001
10987652
25947081
28056460
30136097
29391125
29126445
26718584
27870938
25823511
30755683
22407223
17472986
21628843
15361416
10833616
12131950
22065911
21970675
26940479
31541342
23216655
26108478
16476821
29934424
21471469
19773352
31206160
27929120
28816001
26270969
26783546
28205010
29887145
30309804
29368621
26836182",Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease.,"Human prion diseases are classified into sporadic, genetic, and acquired forms. Within this last group, iatrogenic Creutzfeldt-Jakob disease (iCJD) is caused by human-to-human transmission through surgical and medical procedures. After reaching an incidence peak in the 1990s, it is believed that the iCJD historical period is probably coming to an end, thanks to lessons learnt from past infection sources that promoted new prion prevention and decontamination protocols. At this point, we sought to characterise the biomarker profile of iCJD and compare it to that of sporadic CJD (sCJD) for determining the value of available diagnostic tools in promptly recognising iCJD cases. To that end, we collected 23 iCJD samples from seven national CJD surveillance centres and analysed the electroencephalogram and neuroimaging data together with a panel of seven CSF biomarkers: 14-3-3, total tau, phosphorylated/total tau ratio, alpha-synuclein, neurofilament light, YKL-40, and real-time quaking induced conversion of prion protein. Using the cut-off values established for sCJD, we found the sensitivities of these biomarkers for iCJD to be similar to those described for sCJD. Given the limited relevant information on this issue to date, the present study validates the use of current sCJD biomarkers for the diagnosis of future iCJD cases.","['Iatrogenic Creutzfeldt-Jakob disease', 'RT-QuIC', 'biomarker', 'cerebrospinal fluid', 'corneal transplant', 'dura matter graft', 'electroencephalogram', 'growth hormone', 'magnetic resonance imaging']",Biomolecules,2020-02-16,"[{'lastname': 'Llorens', 'firstname': 'Franc', 'initials': 'F', 'affiliation': ""Department of Neurology, National Reference Center for CJD Surveillance, University Medical Centre Göttingen, 37075 Göttingen, Germany.\nNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.\nBellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.""}, {'lastname': 'Villar-Piqué', 'firstname': 'Anna', 'initials': 'A', 'affiliation': ""Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.\nBellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.""}, {'lastname': 'Hermann', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Department of Neurology, National Reference Center for CJD Surveillance, University Medical Centre Göttingen, 37075 Göttingen, Germany.'}, {'lastname': 'Schmitz', 'firstname': 'Matthias', 'initials': 'M', 'affiliation': 'Department of Neurology, National Reference Center for CJD Surveillance, University Medical Centre Göttingen, 37075 Göttingen, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE), Göttingen 37075, Germany.'}, {'lastname': 'Calero', 'firstname': 'Olga', 'initials': 'O', 'affiliation': 'Chronic Disease Programme (UFIEC)-CROSADIS, Instituto de Salud Carlos III, 28029 Madrid, Spain.\nNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain.'}, {'lastname': 'Stehmann', 'firstname': 'Christiane', 'initials': 'C', 'affiliation': 'Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute, The University of Melbourne, Melbourne 3010, Australia.'}, {'lastname': 'Sarros', 'firstname': 'Shannon', 'initials': 'S', 'affiliation': 'Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute, The University of Melbourne, Melbourne 3010, Australia.'}, {'lastname': 'Moda', 'firstname': 'Fabio', 'initials': 'F', 'affiliation': 'Fondazione IRCCS Istituto Neurologico Carlo Besta, Unit of Neurology 5 and Neuropathology, 20133 Milan, Italy.'}, {'lastname': 'Ferrer', 'firstname': 'Isidre', 'initials': 'I', 'affiliation': ""Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.\nBellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Llobregat, Spain.\nDepartment of Pathology and Experimental Therapeutics, University of Barcelona, L'Hospitalet de Llobregat, 08907 Llobregat, Spain.""}, {'lastname': 'Poleggi', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'Department of Neuroscience, Istituto Superiore di Sanità, 00161 Rome, Italy.'}, {'lastname': 'Pocchiari', 'firstname': 'Maurizio', 'initials': 'M', 'affiliation': 'Department of Neuroscience, Istituto Superiore di Sanità, 00161 Rome, Italy.'}, {'lastname': 'Catania', 'firstname': 'Marcella', 'initials': 'M', 'affiliation': 'Fondazione IRCCS Istituto Neurologico Carlo Besta, Unit of Neurology 5 and Neuropathology, 20133 Milan, Italy.'}, {'lastname': 'Klotz', 'firstname': 'Sigrid', 'initials': 'S', 'affiliation': 'Institute of Neurology, Medical University of Vienna, Vienna 1097, Austria.'}, {'lastname': ""O'Regan"", 'firstname': 'Carl', 'initials': 'C', 'affiliation': 'Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland.'}, {'lastname': 'Brett', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': 'Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland.'}, {'lastname': 'Heffernan', 'firstname': 'Josephine', 'initials': 'J', 'affiliation': 'Department of Neuropathology, Beaumont Hospital, Dublin 9, Ireland.'}, {'lastname': 'Ladogana', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'Department of Neuroscience, Istituto Superiore di Sanità, 00161 Rome, Italy.'}, {'lastname': 'Collins', 'firstname': 'Steven J', 'initials': 'SJ', 'affiliation': 'Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute, The University of Melbourne, Melbourne 3010, Australia.\nDepartment of Medicine (RMH), The University of Melbourne, Melbourne 3050, Australia.'}, {'lastname': 'Calero', 'firstname': 'Miguel', 'initials': 'M', 'affiliation': 'Chronic Disease Programme (UFIEC)-CROSADIS, Instituto de Salud Carlos III, 28029 Madrid, Spain.\nNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain.'}, {'lastname': 'Kovacs', 'firstname': 'Gabor G', 'initials': 'GG', 'affiliation': 'Institute of Neurology, Medical University of Vienna, Vienna 1097, Austria.\nDepartment of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto On, M5T 0S8, Canada.\nLaboratory Medicine Program, University Health Network, Toronto ON, M5G 2C4, Canada.'}, {'lastname': 'Zerr', 'firstname': 'Inga', 'initials': 'I', 'affiliation': 'Department of Neurology, National Reference Center for CJD Surveillance, University Medical Centre Göttingen, 37075 Göttingen, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE), Göttingen 37075, Germany.'}]",,,,,"10.3390/biom10020290
10.1093/bmb/66.1.121
10.1093/bmb/66.1.241
10.1093/bmb/66.1.213
10.1093/bmb/66.1.255
10.3201/eid1806.120116
10.3171/2016.5.FOCUS15126
10.1111/bpa.12696
10.14252/foodsafetyfscj.2016021
10.1212/01.wnl.0000231528.65069.3f
10.1212/WNL.55.8.1075
10.1093/brain/awv235
10.1212/01.wnl.0000230159.67128.00
10.1016/j.clinph.2004.05.032
10.1007/s00415-009-0026-z
10.1212/01.wnl.0000266624.63387.4a
10.1002/ana.410430109
10.1016/j.dadm.2018.06.005
10.1038/nprot.2016.120
10.1212/WNL.0b013e3181a96e5d
10.1212/WNL.55.6.811
10.1007/s004399900124
10.1007/s12035-015-9167-5
10.1159/000454802
10.1007/s12035-018-1313-4
10.1016/j.jalz.2017.12.008
10.1186/s13024-017-0226-4
10.1016/j.jalz.2015.10.009
10.1016/j.jalz.2016.09.013
10.1007/s12035-015-9133-2
10.1038/s41598-019-38520-y
10.1097/WAD.0b013e31824d578a
10.1093/brain/awm063
10.2188/jea.JE20100085
10.1093/brain/awh249
10.1054/jocn.1999.0193
10.1590/S0004-282X2002000300022
10.3346/jkms.2011.26.11.1515
10.1186/1471-2377-11-120
10.1016/j.neuroscience.2016.02.057
10.1007/s00415-019-09537-0
10.1186/1471-2377-12-153
10.1186/s40478-015-0214-2
10.1001/archneur.63.2.288
10.1212/WNL.0000000000005860
10.1212/WNL.0b013e31821a4439
10.1093/brain/awp191
10.1001/jamaneurol.2019.1534
10.1038/srep38737
10.1111/ene.13389
10.1371/journal.pone.0135458
10.1002/acn3.266
10.1007/s00401-017-1683-0
10.1016/j.jocn.2018.09.031
10.1186/s13195-017-0331-1
10.3233/JAD-150897",<Element 'PubmedArticle' at 0x7f05dcba4a90>
60,31958095,Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal Fluid.,"The present study explores the associations of soluble TREM2, an important regulator of microglial activity linked to Alzheimer's disease (AD), with other known inflammatory proteins in cerebrospinal fluid (CSF). We studied 303 participants, including 89 controls, 135 mild cognitive impairment, and 79 AD dementia patients. Using established CSF biomarkers, subjects were classified according to the National Institute on Aging-Alzheimer's Association research framework, which groups markers into those of amyloid-β deposition (A), tau pathology (T), and neurodegeneration (N). TNFR1, TNFR2, TGF-β1, TGFβ2, IL-9, TNF-α, ICAM1, and VCAM1 showed significant concentration differences between the ATN groups, with higher concentrations in more advanced disease categories. sTREM2 was positively associated with the pro-inflammatory proteins TNF-α, TNFR1, TNFR2, ICAM1, VCAM1, and IP-10 and negatively with IL-21; also, positive associations with the anti-inflammatory proteins TGFβ1, IL-10, and IL-9 were found. Pathway enrichment analysis highlighted the involvement of sTREM2 in key functional clusters including immunoglobulin and cytokine production and cellular response to lipopolysaccharides, cytokines, and steroid hormones. Our work provides further evidence in support of TREM2 as amarker of neuroinflammatory response in AD.","['Alzheimer’s disease', 'biomarker', 'functional annotation', 'interactions \nnetwork', 'neurodegeneration', 'neuroinflammation']",Journal of Alzheimer's disease : JAD,2020-01-21,"[{'lastname': 'Rauchmann', 'firstname': 'Boris-Stephan', 'initials': 'BS', 'affiliation': 'Department of Radiology, University Hospital, LMU Munich, Germany.\nDepartment of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Germany.'}, {'lastname': 'Sadlon', 'firstname': 'Angélique', 'initials': 'A', 'affiliation': 'Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, UK.'}, {'lastname': 'Perneczky', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Germany.\nAgeing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, UK.\nGerman Center for Neurodegenerative Diseases (DZNE) Munich, Germany.\nMunich Cluster for Systems Neurology (SyNergy), Munich, Germany.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,,10.3233/JAD-191120,<Element 'PubmedArticle' at 0x7f05dcb72f90>
61,31931042,Estrogen protects neuroblastoma cell from amyloid-β 42 (Aβ42)-induced apoptosis via TXNIP/TRX axis and AMPK signaling.,"Alzheimer's disease (AD), a massive challenge to global health, is featured with the extracellular plaques made up of amyloid-β 42 (Aβ42) and the intracellular neurofibrillary pathology composed of the microtubule-associated protein tau. Women seem to have a higher vulnerability to AD. In the present study, we identified Thioredoxin-interacting protein (TXNIP) as a specifically highly-expressed gene in the hippocampus in female AD patients by bioinformatics analysis. Consistently, in the hippocampus in female AD mice, apoptosis and TXNIP expression were enhanced while TRX expression was suppressed. In Aβ42-stimulated SH-SY5Y cells, the administration of estradiol significantly rescued Aβ42-suppressed cell viability and protein level of TRX while inhibited Aβ42-induced increases in ROS production, cell apoptosis, ΔΨm, and the protein levels of PERK, IREα, and TXNIP, further confirming the potential role of estrogen in AD progression and the involvement of TXNIP/TRX axis. Furthermore, the protective effects of estradiol against Aβ42-induced in vitro neurotoxicity on SH-SY5Y cells could be significantly reversed by AMPK inhibitor, Compound C, indicating that estradiol could improve Aβ42-induced AD via TXNIP/TRX and AMPK signaling. In summary, we demonstrated the cellular function of estradiol on Aβ42-induced in vitro neurotoxicity on SH-SY5Y cells and a novel mechanism of TXNIP/TRX axis involved in estradiol function via AMPK signaling.","['AMPK signaling', ""Alzheimer's disease (AD)"", 'Amyloid-β 42 (Aβ42)', 'Estradiol', 'Neurotoxicity', 'Thioredoxin-interacting protein (TXNIP)']",Neurochemistry international,2020-01-14,"[{'lastname': 'Pan', 'firstname': 'Qiong', 'initials': 'Q', 'affiliation': 'Department of Obstetrics and Gynecology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.'}, {'lastname': 'Guo', 'firstname': 'Ke', 'initials': 'K', 'affiliation': 'Department of Neurology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.'}, {'lastname': 'Xue', 'firstname': 'Min', 'initials': 'M', 'affiliation': 'Department of Obstetrics and Gynecology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.'}, {'lastname': 'Tu', 'firstname': 'Qiuyun', 'initials': 'Q', 'affiliation': 'Department of Geriatric, The Third Xiangya Hospital of Central South University, Changsha, 410013, China. Electronic address: xy_tuqiuyun@sina.com.'}]",,,,Copyright © 2020 Elsevier Ltd. All rights reserved.,10.1016/j.neuint.2020.104685,<Element 'PubmedArticle' at 0x7f05dc1df450>
62,"31924211
26151266
20180026
22895668
24477973
21525445
25187369
23991045
25791290
31497854
26378978
31067395
30882238
31535829
25616707
27208375
30071860
27884680
30359575
29197997
21030723
31456369
31535828
31535828
28102030
30757937
31125563
30935417
31429767
29142025
28667906
30732594
30999996
30444646
30710997
27752710
26316524
19509029
30519189
19318235
19789379
26142467
25351341
29038209
23747642",Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.,"Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 inhibitors (SGLT2I) are recently developed diabetic drugs that primarily work on the kidney. Clinical data describing the cardiovascular benefits of SGLT2Is highlight the potential therapeutic benefit of these drugs in the prevention of cardiovascular events and heart failure. However, the underlying mechanism of protection remains unclear. We investigated the effect of Dapagliflozin-SGLT2I, on diabetic cardiomyopathy in a mouse model of DM2.
Cardiomyopathy was induced in diabetic mice (db/db) by subcutaneous infusion of angiotensin II (ATII) for 30 days using an osmotic pump. Dapagliflozin (1.5 mg/kg/day) was administered concomitantly in drinking water. Male homozygous, 12-14 weeks old WT or db/db mice (n = 4-8/group), were used for the experiments. Isolated cardiomyocytes were exposed to glucose (17.5-33 mM) and treated with Dapagliflozin in vitro. Intracellular calcium transients were measured using a fluorescent indicator indo-1.
Angiotensin II infusion induced cardiomyopathy in db/db mice, manifested by cardiac hypertrophy, myocardial fibrosis and inflammation (TNFα, TLR4). Dapagliflozin decreased blood glucose (874 ± 111 to 556 ± 57 mg/dl, p < 0.05). In addition it attenuated fibrosis and inflammation and increased the left ventricular fractional shortening in ATII treated db/db mice. In isolated cardiomyocytes Dapagliflozin decreased intracellular calcium transients, inflammation and ROS production. Finally, voltage-dependent L-type calcium channel (CACNA1C), the sodium-calcium exchanger (NCX) and the sodium-hydrogen exchanger 1 (NHE) membrane transporters expression was reduced following Dapagliflozin treatment.
Dapagliflozin was cardioprotective in ATII-stressed diabetic mice. It reduced oxygen radicals, as well the activity of membrane channels related to calcium transport. The cardioprotective effect manifested by decreased fibrosis, reduced inflammation and improved systolic function. The clinical implication of our results suggest a novel pharmacologic approach for the treatment of diabetic cardiomyopathy through modulation of ion homeostasis.","['Calcium transport fibrosis', 'Cardiomyocytes', 'Cardiomyopathy', 'Dapagliflozin', 'Diabetes mellitus type 2', 'Inflammation', 'ROS']",Cardiovascular diabetology,2020-01-12,"[{'lastname': 'Arow', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.\nLeviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Waldman', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.\nLeviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Yadin', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.\nLeviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Nudelman', 'firstname': 'V', 'initials': 'V', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Shainberg', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Bar Ilan University, Ramat Gan, Israel.'}, {'lastname': 'Abraham', 'firstname': 'N G', 'initials': 'NG', 'affiliation': 'Pharmacology Department, New York Medical College, Valhalla, NY, 10595, USA.'}, {'lastname': 'Freimark', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Leviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Kornowski', 'firstname': 'R', 'initials': 'R', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Aravot', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Hochhauser', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. hochhaus@post.tau.ac.il.'}, {'lastname': 'Arad', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Leviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. michael.arad@sheba.health.gov.il.'}]",,"Dapagliflozin was cardioprotective in ATII-stressed diabetic mice. It reduced oxygen radicals, as well the activity of membrane channels related to calcium transport. The cardioprotective effect manifested by decreased fibrosis, reduced inflammation and improved systolic function. The clinical implication of our results suggest a novel pharmacologic approach for the treatment of diabetic cardiomyopathy through modulation of ion homeostasis.","Angiotensin II infusion induced cardiomyopathy in db/db mice, manifested by cardiac hypertrophy, myocardial fibrosis and inflammation (TNFα, TLR4). Dapagliflozin decreased blood glucose (874 ± 111 to 556 ± 57 mg/dl, p < 0.05). In addition it attenuated fibrosis and inflammation and increased the left ventricular fractional shortening in ATII treated db/db mice. In isolated cardiomyocytes Dapagliflozin decreased intracellular calcium transients, inflammation and ROS production. Finally, voltage-dependent L-type calcium channel (CACNA1C), the sodium-calcium exchanger (NCX) and the sodium-hydrogen exchanger 1 (NHE) membrane transporters expression was reduced following Dapagliflozin treatment.",,"10.1186/s12933-019-0980-4
10.1001/jama.2015.7008
10.1007/s11154-010-9131-7
10.1161/ATVBAHA.111.241984
10.1007/s00125-014-3171-6
10.2337/dc11-s208
10.2337/db13-1896
10.1371/journal.pone.0072080
10.1016/S2213-8587(15)00044-3
10.1093/eurheartj/ehz486
10.1056/NEJMoa1504720
10.1161/CIRCULATIONAHA.119.040130
10.1056/NEJMoa1911303
10.1177/1479164114561992
10.2337/dc16-0041
10.1186/s12933-018-0754-4
10.1016/j.yexcr.2016.11.016
10.1016/j.yexcr.2018.10.003
10.1007/s00125-017-4509-7
10.1161/CIRCRESAHA.110.223545
10.4070/kcj.2019.0180
10.1056/NEJMe1912180
10.1056/NEJMe1912180
10.1002/phar.1903
10.1080/00325481.2019.1581971
10.1016/j.lfs.2019.05.051
10.1186/s12933-019-0849-6
10.1186/s12933-019-0914-1
10.1530/JOE-17-0457
10.1016/j.redox.2017.06.009
10.1186/s12933-019-0820-6
10.1016/j.jacc.2019.01.056
10.1139/cjpp-2018-0466
10.1186/s12933-019-0816-2
10.1007/s00125-016-4134-x
10.1161/JAHA.115.002183
10.1093/cvr/cvp190
10.3389/fphys.2018.01575
10.1016/j.yjmcc.2008.12.022
10.1152/physrev.00040.2008
10.1093/eurheartj/ehv305
10.1007/s11010-014-2262-5
10.1161/CIRCULATIONAHA.117.030418
10.1016/j.jacc.2013.05.019",<Element 'PubmedArticle' at 0x7f05dc1ca5e0>
63,31914623,Glucocorticoid receptors signaling impairment potentiates amyloid-β oligomers-induced pathology in an acute model of Alzheimer's disease.,"Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis occurs early in Alzheimer's disease (AD), associated with elevated circulating glucocorticoids (GC) and glucocorticoid receptors (GR) signaling impairment. However, the precise role of GR in the pathophysiology of AD remains unclear. Using an acute model of AD induced by the intracerebroventricular injection of amyloid-β oligomers (oAβ), we analyzed cellular and behavioral hallmarks of AD, GR signaling pathways, processing of amyloid precursor protein, and enzymes involved in Tau phosphorylation. We focused on the prefrontal cortex (PFC), particularly rich in GR, early altered in AD and involved in HPA axis control and cognitive functions. We found that oAβ impaired cognitive and emotional behaviors, increased plasma GC levels, synaptic deficits, apoptosis and neuroinflammatory processes. Moreover, oAβ potentiated the amyloidogenic pathway and enzymes involved both in Tau hyperphosphorylation and GR activation. Treatment with a selective GR modulator (sGRm) normalized plasma GC levels and all behavioral and biochemical parameters analyzed. GR seems to occupy a central position in the pathophysiology of AD. Deregulation of the HPA axis and a feed-forward effect on PFC GR sensitivity could participate in the etiology of AD, in perturbing Aβ and Tau homeostasis. These results also reinforce the therapeutic potential of sGRm in AD.","['Cdk5', 'GSK‐3β', 'PDK1', 'ROCK', 'selective GR modulator']",FASEB journal : official publication of the Federation of American Societies for Experimental Biology,2020-01-10,"[{'lastname': 'Canet', 'firstname': 'Geoffrey', 'initials': 'G', 'affiliation': ""Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, INSERM U1198, Team Environmental Impact in Alzheimer's Disease and Related Disorders (EiAlz), Montpellier, France.\nUniversity of Montpellier, Montpellier, France.\nEPHE, Paris, France.""}, {'lastname': 'Pineau', 'firstname': 'Fanny', 'initials': 'F', 'affiliation': ""Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, INSERM U1198, Team Environmental Impact in Alzheimer's Disease and Related Disorders (EiAlz), Montpellier, France.\nUniversity of Montpellier, Montpellier, France.\nEPHE, Paris, France.""}, {'lastname': 'Zussy', 'firstname': 'Charleine', 'initials': 'C', 'affiliation': ""Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, INSERM U1198, Team Environmental Impact in Alzheimer's Disease and Related Disorders (EiAlz), Montpellier, France.\nUniversity of Montpellier, Montpellier, France.\nEPHE, Paris, France.""}, {'lastname': 'Hernandez', 'firstname': 'Célia', 'initials': 'C', 'affiliation': ""Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, INSERM U1198, Team Environmental Impact in Alzheimer's Disease and Related Disorders (EiAlz), Montpellier, France.\nUniversity of Montpellier, Montpellier, France.\nEPHE, Paris, France.""}, {'lastname': 'Hunt', 'firstname': 'Hazel', 'initials': 'H', 'affiliation': 'Corcept Therapeutics, Menlo Park, CA, USA.'}, {'lastname': 'Chevallier', 'firstname': 'Nathalie', 'initials': 'N', 'affiliation': ""Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, INSERM U1198, Team Environmental Impact in Alzheimer's Disease and Related Disorders (EiAlz), Montpellier, France.\nUniversity of Montpellier, Montpellier, France.\nEPHE, Paris, France.""}, {'lastname': 'Perrier', 'firstname': 'Véronique', 'initials': 'V', 'affiliation': ""Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, INSERM U1198, Team Environmental Impact in Alzheimer's Disease and Related Disorders (EiAlz), Montpellier, France.\nUniversity of Montpellier, Montpellier, France.\nEPHE, Paris, France.""}, {'lastname': 'Torrent', 'firstname': 'Joan', 'initials': 'J', 'affiliation': ""Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, INSERM U1198, Team Environmental Impact in Alzheimer's Disease and Related Disorders (EiAlz), Montpellier, France.\nUniversity of Montpellier, Montpellier, France.\nEPHE, Paris, France.""}, {'lastname': 'Belanoff', 'firstname': 'Joseph K', 'initials': 'JK', 'affiliation': 'Corcept Therapeutics, Menlo Park, CA, USA.'}, {'lastname': 'Meijer', 'firstname': 'Onno C', 'initials': 'OC', 'affiliation': 'Einthoven Laboratory, Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'lastname': 'Desrumaux', 'firstname': 'Catherine', 'initials': 'C', 'affiliation': ""Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, INSERM U1198, Team Environmental Impact in Alzheimer's Disease and Related Disorders (EiAlz), Montpellier, France.\nUniversity of Montpellier, Montpellier, France.\nEPHE, Paris, France.""}, {'lastname': 'Givalois', 'firstname': 'Laurent', 'initials': 'L', 'affiliation': ""Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, INSERM U1198, Team Environmental Impact in Alzheimer's Disease and Related Disorders (EiAlz), Montpellier, France.\nUniversity of Montpellier, Montpellier, France.\nEPHE, Paris, France.""}]",,,,© 2019 Federation of American Societies for Experimental Biology.,10.1096/fj.201900723RRR,<Element 'PubmedArticle' at 0x7f05dcafcb30>
64,"31914226
19884572
21944778
22399793
11402146
16862116
16862115
25803835
19350673
21222599
21810890
29053860
19924424
20045477
27132501
28264768
20526405
17405767
8232972
21575870
21282594
26008815
23421625
29253099",Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort.,"Behavioral variant frontotemporal dementia (bvFTD) may present sporadically or due to an autosomal dominant mutation. Characterization of both forms will improve understanding of the generalizability of assessments and treatments.
A total of 135 sporadic (s-bvFTD; mean age 63.3 years; 34% female) and 99 familial (f-bvFTD; mean age 59.9; 48% female) bvFTD participants were identified. f-bvFTD cases included 43 with known or presumed chromosome 9 open reading frame 72 (C9orf72) gene expansions, 28 with known or presumed microtubule-associated protein tau (MAPT) mutations, 14 with known progranulin (GRN) mutations, and 14 with a strong family history of FTD but no identified mutation.
Participants with f-bvFTD were younger and had earlier age at onset. s-bvFTD had higher total Neuropsychiatric Inventory Questionnaire (NPI-Q) scores due to more frequent endorsement of depression and irritability.
f-bvFTD and s-bvFTD cases are clinically similar, suggesting the generalizability of novel biomarkers, therapies, and clinical tools developed in either form to the other.","['C9orf72', 'GRN', 'MAPT', 'bvFTD', 'clinical trials', 'frontotemporal dementia', 'genetics']",Alzheimer's & dementia : the journal of the Alzheimer's Association,2020-01-09,"[{'lastname': 'Heuer', 'firstname': 'Hilary W', 'initials': 'HW', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Wang', 'firstname': 'P', 'initials': 'P', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Rascovsky', 'firstname': 'K', 'initials': 'K', 'affiliation': 'University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'lastname': 'Wolf', 'firstname': 'A', 'initials': 'A', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Appleby', 'firstname': 'B', 'initials': 'B', 'affiliation': 'Case Western Reserve University, Cleveland, Ohio.'}, {'lastname': 'Bove', 'firstname': 'J', 'initials': 'J', 'affiliation': 'University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'lastname': 'Bordelon', 'firstname': 'Y', 'initials': 'Y', 'affiliation': 'University of California, Los Angeles, Los Angeles, California.'}, {'lastname': 'Brannelly', 'firstname': 'P', 'initials': 'P', 'affiliation': 'Tau Consortium, Rainwater Charitable Foundation, Fort Worth, Texas.'}, {'lastname': 'Brushaber', 'firstname': 'D E', 'initials': 'DE', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Caso', 'firstname': 'C', 'initials': 'C', 'affiliation': 'U Washington, Seattle, Washington.'}, {'lastname': 'Coppola', 'firstname': 'G', 'initials': 'G', 'affiliation': 'University of California, Los Angeles, Los Angeles, California.'}, {'lastname': 'Dickerson', 'firstname': 'B', 'initials': 'B', 'affiliation': 'Harvard University/MGH, Boston, Massachusetts.'}, {'lastname': 'Dickinson', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Association for Frontotemporal Degeneration, Radnor, Pennsylvania.'}, {'lastname': 'Domoto-Reilly', 'firstname': 'K', 'initials': 'K', 'affiliation': 'U Washington, Seattle, Washington.'}, {'lastname': 'Faber', 'firstname': 'K', 'initials': 'K', 'affiliation': ""National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, Indiana.""}, {'lastname': 'Ferrall', 'firstname': 'J', 'initials': 'J', 'affiliation': 'University of North Carolina, Chapel Hill, North Carolina.'}, {'lastname': 'Fields', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Fishman', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Johns Hopkins University, Baltimore, Maryland.'}, {'lastname': 'Fong', 'firstname': 'J', 'initials': 'J', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Foroud', 'firstname': 'T', 'initials': 'T', 'affiliation': ""National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, Indiana.""}, {'lastname': 'Forsberg', 'firstname': 'L K', 'initials': 'LK', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Gearhart', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Ghazanfari', 'firstname': 'B', 'initials': 'B', 'affiliation': 'University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Ghoshal', 'firstname': 'N', 'initials': 'N', 'affiliation': 'Washington University, St. Louis, Missouri.'}, {'lastname': 'Goldman', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Columbia University, New York, New York.'}, {'lastname': 'Graff-Radford', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Graff-Radford', 'firstname': 'N', 'initials': 'N', 'affiliation': 'Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Grant', 'firstname': 'I', 'initials': 'I', 'affiliation': 'Northwestern University, Chicago, Illinois.'}, {'lastname': 'Grossman', 'firstname': 'M', 'initials': 'M', 'affiliation': 'University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'lastname': 'Haley', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Hsiung', 'firstname': 'G-Y', 'initials': 'GY', 'affiliation': 'University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Huey', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Columbia University, New York, New York.'}, {'lastname': 'Irwin', 'firstname': 'D', 'initials': 'D', 'affiliation': 'University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'lastname': 'Jones', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Kantarci', 'firstname': 'K', 'initials': 'K', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Karydas', 'firstname': 'A', 'initials': 'A', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Kaufer', 'firstname': 'D', 'initials': 'D', 'affiliation': 'University of North Carolina, Chapel Hill, North Carolina.'}, {'lastname': 'Kerwin', 'firstname': 'D', 'initials': 'D', 'affiliation': 'The University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas.'}, {'lastname': 'Knopman', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Kornak', 'firstname': 'J', 'initials': 'J', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Kramer', 'firstname': 'J H', 'initials': 'JH', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Kraft', 'firstname': 'R', 'initials': 'R', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Kremers', 'firstname': 'W K', 'initials': 'WK', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Kukull', 'firstname': 'W', 'initials': 'W', 'affiliation': 'National Alzheimer Coordinating Center (NACC), University of Washington, Seattle, Washington.'}, {'lastname': 'Litvan', 'firstname': 'I', 'initials': 'I', 'affiliation': 'University of California, San Diego, San Diego, California.'}, {'lastname': 'Ljubenkov', 'firstname': 'P', 'initials': 'P', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Mackenzie', 'firstname': 'I R', 'initials': 'IR', 'affiliation': 'University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Maldonado', 'firstname': 'M', 'initials': 'M', 'affiliation': 'University of California, Los Angeles, Los Angeles, California.'}, {'lastname': 'Manoochehri', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Columbia University, New York, New York.'}, {'lastname': 'McGinnis', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Harvard University/MGH, Boston, Massachusetts.'}, {'lastname': 'McKinley', 'firstname': 'E', 'initials': 'E', 'affiliation': 'University of Alabama at Birmingham, Birmingham, Alabama.'}, {'lastname': 'Mendez', 'firstname': 'M F', 'initials': 'MF', 'affiliation': 'University of California, Los Angeles, Los Angeles, California.'}, {'lastname': 'Miller', 'firstname': 'B L', 'initials': 'BL', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Onyike', 'firstname': 'C', 'initials': 'C', 'affiliation': 'Johns Hopkins University, Baltimore, Maryland.'}, {'lastname': 'Pantelyat', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Johns Hopkins University, Baltimore, Maryland.'}, {'lastname': 'Pearlman', 'firstname': 'R', 'initials': 'R', 'affiliation': 'Bluefield Project, San Francisco, California.'}, {'lastname': 'Petrucelli', 'firstname': 'L', 'initials': 'L', 'affiliation': 'Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Potter', 'firstname': 'M', 'initials': 'M', 'affiliation': ""National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, Indiana.""}, {'lastname': 'Rademakers', 'firstname': 'R', 'initials': 'R', 'affiliation': 'Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Ramos', 'firstname': 'E M', 'initials': 'EM', 'affiliation': 'University of California, Los Angeles, Los Angeles, California.'}, {'lastname': 'Rankin', 'firstname': 'K P', 'initials': 'KP', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Roberson', 'firstname': 'E D', 'initials': 'ED', 'affiliation': 'University of Alabama at Birmingham, Birmingham, Alabama.'}, {'lastname': 'Rogalski', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Northwestern University, Chicago, Illinois.'}, {'lastname': 'Sengdy', 'firstname': 'P', 'initials': 'P', 'affiliation': 'University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Shaw', 'firstname': 'L', 'initials': 'L', 'affiliation': 'University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'lastname': 'Syrjanen', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Tartaglia', 'firstname': 'M C', 'initials': 'MC', 'affiliation': 'University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Tatton', 'firstname': 'N', 'initials': 'N', 'affiliation': 'Association for Frontotemporal Degeneration, Radnor, Pennsylvania.'}, {'lastname': 'Taylor', 'firstname': 'J', 'initials': 'J', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Toga', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Laboratory of Neuroimaging (LONI), USC, Los Angeles, California.'}, {'lastname': 'Trojanowski', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Case Western Reserve University, Cleveland, Ohio.'}, {'lastname': 'Weintraub', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Northwestern University, Chicago, Illinois.'}, {'lastname': 'Wong', 'firstname': 'B', 'initials': 'B', 'affiliation': 'Harvard University/MGH, Boston, Massachusetts.'}, {'lastname': 'Wszolek', 'firstname': 'Z', 'initials': 'Z', 'affiliation': 'Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Boeve', 'firstname': 'B F', 'initials': 'BF', 'affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Rosen', 'firstname': 'H J', 'initials': 'HJ', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': 'Boxer', 'firstname': 'A L', 'initials': 'AL', 'affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,Participants with f-bvFTD were younger and had earlier age at onset. s-bvFTD had higher total Neuropsychiatric Inventory Questionnaire (NPI-Q) scores due to more frequent endorsement of depression and irritability.,© 2020 the Alzheimer's Association.,10.1002/alz.12046,<Element 'PubmedArticle' at 0x7f05dcb020e0>
65,"31864418
31375134
29296624
30040716
27582220
29744576
10858277
2268320
21645364
23041626
18378771
22781549
23830905
28073925
16862116
17458552
28479389
30448285
25261995
23516300
28070672
20667979
28379303
29378861
24804730
28837568
22890097
26682689
30482868
19776335
26124111
19557827
24684749
29044416
30260505
25130661
30135939
27356620
28640985
26370502
28541286
25461957
30858094
25619230
16237129
10560657
22112552
19399512
2341813
30076830
25448602
28638323
31340569
22930834
30361629
21886844
26599299
26381815
3977910
28828399
17071926
27114033
30180904
17291356
25575133
21092856
21698296
29690919
21178100
28453791
27903606
25478031
21497117",Characterization of lysosomal proteins Progranulin and Prosaposin and their interactions in Alzheimer's disease and aged brains: increased levels correlate with neuropathology.,"Progranulin (PGRN) is a protein encoded by the GRN gene with multiple identified functions including as a neurotrophic factor, tumorigenic growth factor, anti-inflammatory cytokine and regulator of lysosomal function. A single mutation in the human GRN gene resulting in reduced PGRN expression causes types of frontotemporal lobar degeneration resulting in frontotemporal dementia. Prosaposin (PSAP) is also a multifunctional neuroprotective secreted protein and regulator of lysosomal function. Interactions of PGRN and PSAP affect their functional properties. Their roles in Alzheimer's disease (AD), the leading cause of dementia, have not been defined. In this report, we examined in detail the cellular expression of PGRN in middle temporal gyrus samples of a series of human brain cases (n = 45) staged for increasing plaque pathology. Immunohistochemistry showed PGRN expression in cortical neurons, microglia, cerebral vessels and amyloid beta (Aβ) plaques, while PSAP expression was mainly detected in neurons and Aβ plaques, and to a limited extent in astrocytes. We showed that there were increased levels of PGRN protein in AD cases and corresponding increased levels of PSAP. Levels of PGRN and PSAP protein positively correlated with amyloid beta (Aβ), with PGRN levels correlating with phosphorylated tau (serine 205) levels in these samples. Although PGRN colocalized with lysosomal-associated membrane protein-1 in neurons, most PGRN associated with Aβ plaques did not. Aβ plaques with PGRN and PSAP deposits were identified in the low plaque non-demented cases suggesting this was an early event in plaque formation. We did not observe PGRN-positive neurofibrillary tangles. Co-immunoprecipitation studies of PGRN from brain samples identified only PSAP associated with PGRN, not sortilin or other known PGRN-binding proteins, under conditions used. Most PGRN associated with Aβ plaques were immunoreactive for PSAP showing a high degree of colocalization of these proteins that did not change between disease groups. As PGRN supplementation has been considered as a therapeutic approach for AD, the possible involvement of PGRN and PSAP interactions in AD pathology needs to be further considered.","['Aggregation', 'Alzheimer’s disease', 'Amyloid', 'Growth factors', 'Interactions', 'Neuropathology', 'Progranulin', 'Prosaposin', 'Tangles']",Acta neuropathologica communications,2019-12-23,"[{'lastname': 'Mendsaikhan', 'firstname': 'Anarmaa', 'initials': 'A', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Seta, Otsu, Otsu, 520-2192, Japan.'}, {'lastname': 'Tooyama', 'firstname': 'Ikuo', 'initials': 'I', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Seta, Otsu, Otsu, 520-2192, Japan.'}, {'lastname': 'Bellier', 'firstname': 'Jean-Pierre', 'initials': 'JP', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Seta, Otsu, Otsu, 520-2192, Japan.'}, {'lastname': 'Serrano', 'firstname': 'Geidy E', 'initials': 'GE', 'affiliation': 'Civin Neuropathology Laboratory, Banner Sun Health Research Institute, Sun City, AZ, USA.'}, {'lastname': 'Sue', 'firstname': 'Lucia I', 'initials': 'LI', 'affiliation': 'Civin Neuropathology Laboratory, Banner Sun Health Research Institute, Sun City, AZ, USA.'}, {'lastname': 'Lue', 'firstname': 'Lih-Fen', 'initials': 'LF', 'affiliation': 'Civin Neuropathology Laboratory, Banner Sun Health Research Institute, Sun City, AZ, USA.\nSchool of Life Sciences and Neurodegenerative Disease Research Center, Biodesign Institute, Arizona State University, Tempe, AZ, USA.'}, {'lastname': 'Beach', 'firstname': 'Thomas G', 'initials': 'TG', 'affiliation': 'Civin Neuropathology Laboratory, Banner Sun Health Research Institute, Sun City, AZ, USA.'}, {'lastname': 'Walker', 'firstname': 'Douglas G', 'initials': 'DG', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Seta, Otsu, Otsu, 520-2192, Japan. walker@belle.shiga-med.ac.jp.\nSchool of Life Sciences and Neurodegenerative Disease Research Center, Biodesign Institute, Arizona State University, Tempe, AZ, USA. walker@belle.shiga-med.ac.jp.'}]",,,,,"10.1186/s40478-019-0862-8
10.1186/s13024-019-0333-5
10.1002/acn3.469
10.3233/JAD-180145
10.1038/nature19323
10.1007/s00401-018-1861-8
10.1177/002215540004800713
10.1016/S0006-291X(05)80908-8
10.1186/1742-2094-8-65
10.1172/JCI63113
10.1083/jcb.200712039
10.1186/1750-1326-7-33
10.1016/j.neuroscience.2013.06.049
10.1093/hmg/ddx011
10.1038/nature05016
10.1007/s00401-007-0223-8
10.1016/j.exger.2017.05.003
10.1016/j.nbd.2018.11.011
10.1038/nm.3672
10.1523/JNEUROSCI.6103-11.2013
10.1007/s00401-017-1668-z
10.1096/fj.10-161471
10.1093/brain/awx060
10.1126/scitranslmed.aah5642
10.1523/JNEUROSCI.3081-17.2018
10.1371/journal.pone.0097032
10.1371/journal.pone.0182896
10.3233/JAD-2012-120946
10.3233/JAD-150746
10.15252/emmm.201809712
10.1177/1533317509346209
10.1073/pnas.1510329112
10.1002/path.2580
10.1186/alzrt247
10.1093/jnen/nlx085
10.1002/glia.23480
10.1016/j.brainres.2014.08.022
10.1016/j.ibror.2017.07.001
10.1038/ncomms11992
10.1111/jnc.14110
10.1083/jcb.201502029
10.1038/ncomms15277
10.1371/journal.pone.0110534
10.1016/j.cca.2019.03.243
10.1111/neup.12189
10.1212/01.wnl.0000187889.17253.b1
10.1097/00005072-199911000-00004
10.3233/JAD-2011-111340
10.1007/s00401-009-0538-8
10.1016/j.expneurol.2018.07.016
10.1016/j.neurobiolaging.2014.09.023
10.3390/cells8070766
10.1038/nmeth.2089
10.1038/s41598-018-33592-8
10.1371/journal.pone.0023939
10.3233/JPD-150670
10.1038/srep14211
10.1016/0006-291x(85)90311-0
10.1523/ENEURO.0100-17.2017
10.1093/brain/awl271
10.1016/j.cell.2016.04.001
10.1186/s13024-018-0281-5
10.1186/1742-2094-4-7
10.1097/NEN.0000000000000158
10.1016/j.neuron.2010.09.034
10.1371/journal.pone.0021023
10.1186/s13195-018-0370-2
10.1212/WNL.0b013e31820a0e3b
10.1093/hmg/ddx162
10.1083/jcb.201603079
10.1186/s13195-014-0070-5
10.1016/j.immuni.2011.01.018",<Element 'PubmedArticle' at 0x7f05dbf4b180>
66,31833155,Melatonin and its metabolite N(1)-acetyl-N(1)-formyl-5-methoxykynuramine improve learning and memory impairment related to Alzheimer's disease in rats.,"The aim of this study was to investigate the effect of melatonin (MT) and its metabolite N(1)-acetyl-N(2)-formyl-5-methoxykynuramine (AFMK) on Alzheimer-like learning and memory impairment in rats intracerebroventricularly injected with streptozotocin (STZ). The results showed that the escape latency of the STZ group was longer than that of the control (CON), MT, and AFMK groups. Increased levels of hyperphosphorylated tau, neurofilament proteins, and malondialdehyde and decreased superoxide dismutase levels were observed in the brains of the rats from the STZ group compared with the brains of the rats from the CON, MT, AFMK high and low group. These results suggest that exogenous MT and AFMK can improve memory impairment and downregulate AD-like hyperphosphorylation induced by STZ, most likely through their antioxidation function. Meanwhile, we found that an equal dose of AFMK had a stronger effect than that of MT. Our results indicate that MT and its metabolite AFMK represent novel treatment strategies for Alzheimer's disease.","['AFMK', ""Alzheimer's disease"", 'antioxidation', 'melatonin', 'memory']",Journal of biochemical and molecular toxicology,2019-12-14,"[{'lastname': 'Rong', 'firstname': 'Kai', 'initials': 'K', 'affiliation': 'Nephrology Department, Second Hospital of Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Zheng', 'firstname': 'Hong', 'initials': 'H', 'affiliation': 'Nursing School, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Yang', 'firstname': 'Ruibo', 'initials': 'R', 'affiliation': 'Nursing School, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Liu', 'firstname': 'Xiaoli', 'initials': 'X', 'affiliation': ""Pathology Department, Xingtai People's Hospital, Xingtai, Hebei, China.""}, {'lastname': 'Li', 'firstname': 'Liya', 'initials': 'L', 'affiliation': 'Nursing School, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Chen', 'firstname': 'Ning', 'initials': 'N', 'affiliation': 'Pathophysiology Department, Basic Medical College, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Zhao', 'firstname': 'Gang', 'initials': 'G', 'affiliation': 'Department of Pathology, Tianjin Cancer Hospital, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Gong', 'firstname': 'Chengxin', 'initials': 'C', 'affiliation': 'Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York.'}, {'lastname': 'Deng', 'firstname': 'Yanqiu', 'initials': 'Y', 'affiliation': 'Pathophysiology Department, Basic Medical College, Tianjin Medical University, Tianjin, China.'}]",,,,"© 2019 Wiley Periodicals, Inc.",10.1002/jbt.22430,<Element 'PubmedArticle' at 0x7f05db58bc70>
67,31830829,Collaborative Regulation of LRG1 by TGF-β1 and PPAR-β/δ Modulates Chronic Pressure Overload-Induced Cardiac Fibrosis.,"Despite its established significance in fibrotic cardiac remodeling, clinical benefits of global inhibition of TGF (transforming growth factor)-β1 signaling remain controversial. LRG1 (leucine-rich-α2 glycoprotein 1) is known to regulate endothelial TGFβ signaling. This study evaluated the role of LRG1 in cardiac fibrosis and its transcriptional regulatory network in cardiac fibroblasts.
Pressure overload-induced heart failure was established by transverse aortic constriction. Western blot, quantitative reverse transcription polymerase chain reaction, immunofluorescence, and immunohistochemistry were used to evaluate the expression level and pattern of interested targets or pathology during fibrotic cardiac remodeling. Cardiac function was assessed by pressure-volume loop analysis.
LRG1 expression was significantly suppressed in left ventricle of mice with transverse aortic constriction-induced fibrotic cardiac remodeling (mean difference, -0.00085 [95% CI, -0.0013 to -0.00043]; 
Our results established a highly complex molecular network involving LRG1, TGFβ1, PPARβ/δ, and SMRT in regulating cardiac fibroblast activation and cardiac fibrosis. Targeting LRG1 or PPARβ/δ represents a promising strategy to control pathological cardiac remodeling in response to chronic pressure overload.","['animals', 'humans', 'leucine', 'mice', 'stroke volume']",Circulation. Heart failure,2019-12-14,"[{'lastname': 'Liu', 'firstname': 'Chenghao', 'initials': 'C', 'affiliation': 'Lee Kong Chian School of Medicine (C.L., S.T.L., M.H.Y.T., M.S.Y.T., M.D.K., N.S.T., W.W., M.A.F., W.S., X.W.), Nanyang Technological University Singapore.'}, {'lastname': 'Lim', 'firstname': 'Seok Ting', 'initials': 'ST', 'affiliation': 'Lee Kong Chian School of Medicine (C.L., S.T.L., M.H.Y.T., M.S.Y.T., M.D.K., N.S.T., W.W., M.A.F., W.S., X.W.), Nanyang Technological University Singapore.'}, {'lastname': 'Teo', 'firstname': 'Melissa Hui Yen', 'initials': 'MHY', 'affiliation': 'Lee Kong Chian School of Medicine (C.L., S.T.L., M.H.Y.T., M.S.Y.T., M.D.K., N.S.T., W.W., M.A.F., W.S., X.W.), Nanyang Technological University Singapore.'}, {'lastname': 'Tan', 'firstname': 'Michelle Si Ying', 'initials': 'MSY', 'affiliation': 'Lee Kong Chian School of Medicine (C.L., S.T.L., M.H.Y.T., M.S.Y.T., M.D.K., N.S.T., W.W., M.A.F., W.S., X.W.), Nanyang Technological University Singapore.'}, {'lastname': 'Kulkarni', 'firstname': 'Madhura Dattatraya', 'initials': 'MD', 'affiliation': 'Lee Kong Chian School of Medicine (C.L., S.T.L., M.H.Y.T., M.S.Y.T., M.D.K., N.S.T., W.W., M.A.F., W.S., X.W.), Nanyang Technological University Singapore.'}, {'lastname': 'Qiu', 'firstname': 'Beiying', 'initials': 'B', 'affiliation': 'Institute of Molecular and Cell Biology, Proteos, Agency for Science, Technology and Research, Singapore (B.Q., N.S.T., W.H., X.W.).'}, {'lastname': 'Li', 'firstname': 'Amy', 'initials': 'A', 'affiliation': 'Anatomy and Histology, School of Medical Sciences, Bosch Institute, University of Sydney, Australia (A.L., S.L., C.G.d.R.).'}, {'lastname': 'Lal', 'firstname': 'Sean', 'initials': 'S', 'affiliation': 'Anatomy and Histology, School of Medical Sciences, Bosch Institute, University of Sydney, Australia (A.L., S.L., C.G.d.R.).'}, {'lastname': 'Dos Remedios', 'firstname': 'Cristobal G', 'initials': 'CG', 'affiliation': 'Anatomy and Histology, School of Medical Sciences, Bosch Institute, University of Sydney, Australia (A.L., S.L., C.G.d.R.).'}, {'lastname': 'Tan', 'firstname': 'Nguan Soon', 'initials': 'NS', 'affiliation': ""Lee Kong Chian School of Medicine (C.L., S.T.L., M.H.Y.T., M.S.Y.T., M.D.K., N.S.T., W.W., M.A.F., W.S., X.W.), Nanyang Technological University Singapore.\nSchool of Biological Sciences (N.S.T.), Nanyang Technological University Singapore.\nInstitute of Molecular and Cell Biology, Proteos, Agency for Science, Technology and Research, Singapore (B.Q., N.S.T., W.H., X.W.).\nKK Research Centre, KK Women's and Children Hospital, Singapore (N.S.T.).""}, {'lastname': 'Wahli', 'firstname': 'Walter', 'initials': 'W', 'affiliation': 'Lee Kong Chian School of Medicine (C.L., S.T.L., M.H.Y.T., M.S.Y.T., M.D.K., N.S.T., W.W., M.A.F., W.S., X.W.), Nanyang Technological University Singapore.\nINRA ToxAlim, UMR1331, Chemin de Tournefeuille, Toulouse, France (W.W.).\nCentre for Integrative Genomics, University of Lausanne, Le Genopode, Switzerland (W.W.).'}, {'lastname': 'Ferenczi', 'firstname': 'Michael Alan', 'initials': 'MA', 'affiliation': 'Lee Kong Chian School of Medicine (C.L., S.T.L., M.H.Y.T., M.S.Y.T., M.D.K., N.S.T., W.W., M.A.F., W.S., X.W.), Nanyang Technological University Singapore.'}, {'lastname': 'Song', 'firstname': 'Weihua', 'initials': 'W', 'affiliation': 'Lee Kong Chian School of Medicine (C.L., S.T.L., M.H.Y.T., M.S.Y.T., M.D.K., N.S.T., W.W., M.A.F., W.S., X.W.), Nanyang Technological University Singapore.\nNational Heart Centre Singapore (W.S.).'}, {'lastname': 'Hong', 'firstname': 'Wanjin', 'initials': 'W', 'affiliation': 'Institute of Molecular and Cell Biology, Proteos, Agency for Science, Technology and Research, Singapore (B.Q., N.S.T., W.H., X.W.).'}, {'lastname': 'Wang', 'firstname': 'Xiaomeng', 'initials': 'X', 'affiliation': 'Lee Kong Chian School of Medicine (C.L., S.T.L., M.H.Y.T., M.S.Y.T., M.D.K., N.S.T., W.W., M.A.F., W.S., X.W.), Nanyang Technological University Singapore.\nInstitute of Molecular and Cell Biology, Proteos, Agency for Science, Technology and Research, Singapore (B.Q., N.S.T., W.H., X.W.).\nInstitute of Ophthalmology, University College London, United Kingdom (X.W.).\nSingapore Eye Research Institute, The Academia, Singapore (X.W.).'}]",,,"LRG1 expression was significantly suppressed in left ventricle of mice with transverse aortic constriction-induced fibrotic cardiac remodeling (mean difference, -0.00085 [95% CI, -0.0013 to -0.00043]; ",,10.1161/CIRCHEARTFAILURE.119.005962,<Element 'PubmedArticle' at 0x7f05db57eae0>
68,31799531,Diet control to achieve euglycaemia induces tau hyperphosphorylation via AMPK activation in the hippocampus of diabetic rats.,"Alzheimer's disease (AD) is a chronic neurodegenerative disease, and typical pathologic findings include abnormally hyperphosphorylated tau aggregation and neurofibrillary tangles. Insulin resistance and hyperglycaemia have been proposed as risk factors for AD development. As the maintenance of optimal blood glucose level is an important indicator of diabetes mellitus (DM) treatment, diet control is essential. AMPK is a crucial sensor of cellular bioenergetics for controlling anabolic and catabolic metabolism. Since AMPK is a direct regulator of tau phosphorylation, we hypothesized that strict diet control to achieve euglycaemia affects tau protein phosphorylation through increased AMPK activity in the hippocampus of DM rats. To test this hypothesis, we generated insulin-deficient DM rats by subtotal pancreatectomy and the animals were categorized into the diet-restriction (R) group and ad libitum (AL) feeding group. We found that tau phosphorylation was significantly higher in the R group than that in the sham-control (C) or AL group. AMPK activity in the R group was significantly higher than that in the C or AL group, as expected. Furthermore, the R group showed more critical tau pathology in the hippocampus than the other groups. These results suggest that diet control to achieve euglycaemia in an insulin-deficient DM condition may be harmful because of the greater possibility of AD development through increased tau phosphorylation by AMPK activation in the hippocampus.",[],Food & function,2019-12-05,"[{'lastname': 'Sung', 'firstname': 'Dong Jun', 'initials': 'DJ', 'affiliation': 'Division of Sport and Health Studies, College of Biomedical and Health Science, Konkuk University, Chungju, 27478, Republic of Korea.'}, {'lastname': 'Noh', 'firstname': 'Yun-Hee', 'initials': 'YH', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Jun-Ho', 'initials': 'JH', 'affiliation': None}, {'lastname': 'Jin', 'firstname': 'Mingli', 'initials': 'M', 'affiliation': None}, {'lastname': 'Kim', 'firstname': 'Jin-Seoung', 'initials': 'JS', 'affiliation': None}, {'lastname': 'Han', 'firstname': 'Sang-Don', 'initials': 'SD', 'affiliation': None}]",,,,,10.1039/c9fo00709a,<Element 'PubmedArticle' at 0x7f05db563e00>
69,"31784375
29478591
27306957
20369906
22732773
29240561
11001602
1891530
7183759
12815652
8232972
21575870
17405767
28413716
26260856
30698757
16530430
20656036
31872042
25002573
25662776
28621768
22366795
31272932",Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration.,"The Advancing Research and Treatment in Frontotemporal Lobar Degeneration and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects longitudinal studies were designed to describe the natural history of familial-frontotemporal lobar degeneration due to autosomal dominant mutations.
We examined cognitive performance, behavioral ratings, and brain volumes from the first time point in 320 MAPT, GRN, and C9orf72 family members, including 102 non-mutation carriers, 103 asymptomatic carriers, 43 mildly/questionably symptomatic carriers, and 72 carriers with dementia.
Asymptomatic carriers showed similar scores on all clinical measures compared with noncarriers but reduced frontal and temporal volumes. Those with mild/questionable impairment showed decreased verbal recall, fluency, and Trail Making Test performance and impaired mood and self-monitoring. Dementia was associated with impairment in all measures. All MAPT carriers with dementia showed temporal atrophy, but otherwise, there was no single cognitive test or brain region that was abnormal in all subjects.
Imaging changes appear to precede clinical changes in familial-frontotemporal lobar degeneration, but specific early clinical and imaging changes vary across individuals.","['C9ORF72', 'Familial', 'Frontotemporal lobar degeneration', 'GRN', 'Genetic', 'MAPT']",Alzheimer's & dementia : the journal of the Alzheimer's Association,2019-12-01,"[{'lastname': 'Olney', 'firstname': 'Nicholas T', 'initials': 'NT', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Ong', 'firstname': 'Elise', 'initials': 'E', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Goh', 'firstname': 'Sheng-Yang M', 'initials': 'SM', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Bajorek', 'firstname': 'Lynn', 'initials': 'L', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Dever', 'firstname': 'Reilly', 'initials': 'R', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Staffaroni', 'firstname': 'Adam M', 'initials': 'AM', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Cobigo', 'firstname': 'Yann', 'initials': 'Y', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Bock', 'firstname': 'Meredith', 'initials': 'M', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Chiang', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Ljubenkov', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Kornak', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Heuer', 'firstname': 'Hilary W', 'initials': 'HW', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Wang', 'firstname': 'Ping', 'initials': 'P', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Rascovsky', 'firstname': 'Katya', 'initials': 'K', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Wolf', 'firstname': 'Amelia', 'initials': 'A', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Appleby', 'firstname': 'Brian', 'initials': 'B', 'affiliation': 'Department of Neurology, Case Western Reserve University, Cleveland, OH, USA.'}, {'lastname': 'Bove', 'firstname': 'Jessica', 'initials': 'J', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Bordelon', 'firstname': 'Yvette', 'initials': 'Y', 'affiliation': 'Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'lastname': 'Brannelly', 'firstname': 'Patrick', 'initials': 'P', 'affiliation': 'Tau Consortium, Rainwater Charitable Foundation, Fort Worth, TX, USA.'}, {'lastname': 'Brushaber', 'firstname': 'Danielle', 'initials': 'D', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Caso', 'firstname': 'Christine', 'initials': 'C', 'affiliation': 'Department of Neurology, University of Washington, Seattle, WA, USA.'}, {'lastname': 'Coppola', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'lastname': 'Dickerson', 'firstname': 'Bradford C', 'initials': 'BC', 'affiliation': 'Department of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Dickinson', 'firstname': 'Susan', 'initials': 'S', 'affiliation': 'Association for Frontotemporal Degeneration, Radnor, PA, USA.'}, {'lastname': 'Domoto-Reilly', 'firstname': 'Kimiko', 'initials': 'K', 'affiliation': 'Department of Neurology, University of Washington, Seattle, WA, USA.'}, {'lastname': 'Faber', 'firstname': 'Kelly', 'initials': 'K', 'affiliation': ""National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, IN, USA.""}, {'lastname': 'Ferrall', 'firstname': 'Jessica', 'initials': 'J', 'affiliation': 'Department of Neurology, University of North Carolina, Chapel Hill, NC, USA.'}, {'lastname': 'Fields', 'firstname': 'Julie', 'initials': 'J', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Fishman', 'firstname': 'Ann', 'initials': 'A', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.'}, {'lastname': 'Fong', 'firstname': 'Jamie', 'initials': 'J', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Foroud', 'firstname': 'Tatiana', 'initials': 'T', 'affiliation': ""National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, IN, USA.""}, {'lastname': 'Forsberg', 'firstname': 'Leah K', 'initials': 'LK', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Gearhart', 'firstname': 'Debra J', 'initials': 'DJ', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Ghazanfari', 'firstname': 'Behnaz', 'initials': 'B', 'affiliation': 'Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Ghoshal', 'firstname': 'Nupur', 'initials': 'N', 'affiliation': 'Department of Psychiatry, Washington University, St. Louis, MO, USA.\nDepartment of Neurology, Washington University, St. Louis, MO, USA.'}, {'lastname': 'Goldman', 'firstname': 'Jill', 'initials': 'J', 'affiliation': ""Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.\nDepartment of Neurology, Columbia University, New York, NY, USA.""}, {'lastname': 'Graff-Radford', 'firstname': 'Jonathan', 'initials': 'J', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Graff-Radford', 'firstname': 'Neill R', 'initials': 'NR', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'Grant', 'firstname': 'Ian', 'initials': 'I', 'affiliation': 'Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'lastname': 'Grossman', 'firstname': 'Murray', 'initials': 'M', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Haley', 'firstname': 'Dana', 'initials': 'D', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'Hsiung', 'firstname': 'Gingyuek', 'initials': 'G', 'affiliation': 'Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Huey', 'firstname': 'Edward D', 'initials': 'ED', 'affiliation': ""Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.\nDepartment of Neurology, Columbia University, New York, NY, USA.""}, {'lastname': 'Irwin', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Jones', 'firstname': 'David T', 'initials': 'DT', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Kantarci', 'firstname': 'Kejal', 'initials': 'K', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Karydas', 'firstname': 'Anna M', 'initials': 'AM', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Kaufer', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Department of Neurology, University of North Carolina, Chapel Hill, NC, USA.'}, {'lastname': 'Kerwin', 'firstname': 'Diana', 'initials': 'D', 'affiliation': ""Department of Neurology and Neurotherapeutics, Center for Alzheimer's and Neurodegenerative Diseases, The University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, USA.\nDepartment of Internal Medicine, The University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, USA.""}, {'lastname': 'Knopman', 'firstname': 'David S', 'initials': 'DS', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Kramer', 'firstname': 'Joel H', 'initials': 'JH', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Kraft', 'firstname': 'Ruth', 'initials': 'R', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Kremers', 'firstname': 'Walter', 'initials': 'W', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Kukull', 'firstname': 'Walter', 'initials': 'W', 'affiliation': 'National Alzheimer Coordinating Center (NACC), University of Washington, Seattle, WA, USA.'}, {'lastname': 'Lapid', 'firstname': 'Maria I', 'initials': 'MI', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Litvan', 'firstname': 'Irene', 'initials': 'I', 'affiliation': 'Department of Neurosciences, Parkinson and Other Movement Disorders Center, University of California, San Diego, San Diego, CA, USA.'}, {'lastname': 'Mackenzie', 'firstname': 'Ian R', 'initials': 'IR', 'affiliation': 'Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.'}, {'lastname': 'Maldonado', 'firstname': 'Miranda', 'initials': 'M', 'affiliation': 'Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'lastname': 'Manoochehri', 'firstname': 'Masood', 'initials': 'M', 'affiliation': ""Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.\nDepartment of Neurology, Columbia University, New York, NY, USA.""}, {'lastname': 'McGinnis', 'firstname': 'Scott M', 'initials': 'SM', 'affiliation': 'Department of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'McKinley', 'firstname': 'Emily C', 'initials': 'EC', 'affiliation': ""Department of Neurology, Alzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL, USA.""}, {'lastname': 'Mendez', 'firstname': 'Mario F', 'initials': 'MF', 'affiliation': 'Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'lastname': 'Miller', 'firstname': 'Bruce L', 'initials': 'BL', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Onyike', 'firstname': 'Chiadi', 'initials': 'C', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.'}, {'lastname': 'Pantelyat', 'firstname': 'Alex', 'initials': 'A', 'affiliation': 'Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.'}, {'lastname': 'Pearlman', 'firstname': 'Rodney', 'initials': 'R', 'affiliation': 'The Bluefield Project, San Francisco, CA, USA.'}, {'lastname': 'Petrucelli', 'firstname': 'Len', 'initials': 'L', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'Potter', 'firstname': 'Madeleine', 'initials': 'M', 'affiliation': ""National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, IN, USA.""}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'Ramos', 'firstname': 'Eliana M', 'initials': 'EM', 'affiliation': 'Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'lastname': 'Rankin', 'firstname': 'Katherine P', 'initials': 'KP', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Roberson', 'firstname': 'Erik D', 'initials': 'ED', 'affiliation': ""Department of Neurology, Alzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL, USA.""}, {'lastname': 'Rogalski', 'firstname': 'Emily', 'initials': 'E', 'affiliation': 'Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'lastname': 'Sengdy', 'firstname': 'Pheth', 'initials': 'P', 'affiliation': 'Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Shaw', 'firstname': 'Leslie M', 'initials': 'LM', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Syrjanen', 'firstname': 'Jeremy', 'initials': 'J', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Tartaglia', 'firstname': 'M Carmela', 'initials': 'MC', 'affiliation': 'Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.\nTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Tatton', 'firstname': 'Nadine', 'initials': 'N', 'affiliation': 'Association for Frontotemporal Degeneration, Radnor, PA, USA.'}, {'lastname': 'Taylor', 'firstname': 'Joanne', 'initials': 'J', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Toga', 'firstname': 'Arthur', 'initials': 'A', 'affiliation': 'Laboratory of Neuroimaging (LONI), University of Southern California, Los Angeles, CA, USA.'}, {'lastname': 'Trojanowski', 'firstname': 'John Q', 'initials': 'JQ', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Weintraub', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': 'Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'lastname': 'Wong', 'firstname': 'Bonnie', 'initials': 'B', 'affiliation': 'Department of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Wszolek', 'firstname': 'Zbigniew', 'initials': 'Z', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'Boxer', 'firstname': 'Adam L', 'initials': 'AL', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Boeve', 'firstname': 'Brad F', 'initials': 'BF', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Rosen', 'firstname': 'Howard J', 'initials': 'HJ', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,"Asymptomatic carriers showed similar scores on all clinical measures compared with noncarriers but reduced frontal and temporal volumes. Those with mild/questionable impairment showed decreased verbal recall, fluency, and Trail Making Test performance and impaired mood and self-monitoring. Dementia was associated with impairment in all measures. All MAPT carriers with dementia showed temporal atrophy, but otherwise, there was no single cognitive test or brain region that was abnormal in all subjects.","© 2019 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.","10.1016/j.jalz.2019.08.196
10.1016/j.dadm.2019.08.003.
10.1016/j.jalz.2019.04.007",<Element 'PubmedArticle' at 0x7f05db817e00>
70,31743983,Predictability of the effects of epidural injection in lumbar spinal stenosis by assessment of lumbar MRI scans.,"Numerous classification systems have been proposed to interpret lumbar MRI scans. The clinical impact of the measured parameters remains unclear. To evaluate the clinical significance of imaging results in patients with multisegmental degenerative pathologies, treating specialists can perform image-guided local injections to target defined areas such as the epidural space.
The aim of this retrospective study was to evaluate the correlation between lumbar spinal stenosis measurements obtained by MRI and improvement obtained through local epidural injection.
In this retrospective study various measurement and classification systems for lumbar spinal stenosis were applied to MRI scans of 100 patients with this pathological condition. The reported effect of epidural bupivacaine/triamcinolone injections at the site was recorded in these patients and a comparative analysis performed.
MRI features assessed in this study did not show any relevant correlation with reported pain relief after epidural injection in patients with chronic lumbar stenosis, with the exception of posterior disc height with a weak Kendall's tau of -0.187 (p= 0.009).
Although MRI is crucial for evaluating lumbar spinal stenosis, it cannot replace but is rather complementary to a good patient history and clinical examination or the results of local diagnostic injections.","['Lumbar spinal stenosis', 'MRI', 'Schizas’ spinal stenosis classification', 'Sipola’s neuroforaminal cross-sectional area', 'epidural injection', 'neuroforaminal stenosis']",Journal of back and musculoskeletal rehabilitation,2019-11-21,"[{'lastname': 'Hofmann', 'firstname': 'Ulf Krister', 'initials': 'UK', 'affiliation': 'Department of Orthopaedic Surgery, University Hospital of Tübingen, D-72076 Tübingen, Germany.'}, {'lastname': 'Keller', 'firstname': 'Ramona Luise', 'initials': 'RL', 'affiliation': 'Department of Orthopaedic Surgery, University Hospital of Tübingen, D-72076 Tübingen, Germany.\nFaculty of Medicine, Julius-Maximilians University of Würzburg, D-97080 Würzburg, Germany.'}, {'lastname': 'von Bernstorff', 'firstname': 'Maximilian', 'initials': 'M', 'affiliation': 'Department of Orthopaedic Surgery, University Hospital of Tübingen, D-72076 Tübingen, Germany.\nFaculty of Medicine, Eberhard-Karls University of Tübingen, D-72076 Tübingen, Germany.'}, {'lastname': 'Walter', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Department of Orthopaedic Surgery, University Hospital of Tübingen, D-72076 Tübingen, Germany.'}, {'lastname': 'Mittag', 'firstname': 'Falk', 'initials': 'F', 'affiliation': 'Department of Orthopaedic Surgery, University Hospital of Tübingen, D-72076 Tübingen, Germany.'}]",,,"MRI features assessed in this study did not show any relevant correlation with reported pain relief after epidural injection in patients with chronic lumbar stenosis, with the exception of posterior disc height with a weak Kendall's tau of -0.187 (p= 0.009).",,10.3233/BMR-181249,<Element 'PubmedArticle' at 0x7f05db7edae0>
71,"31700010
1093271
16595463
12172519
9585380
12521376
17704191
18071301
10594169
12900610
28777474
21678472
26566937
19425099
23545229
20502692
29887828
18481028
9972437
3806205
12732240
21120456
28514188
15908955
16772520
28752643
2270775
27936149
28429354
26636276
31441378
17243171
8825235
27900261
24523504
17459586",Bone Anabolic Response in the Calvaria Following Mild Traumatic Brain Injury is Mediated by the Cannabinoid-1 Receptor.,"Brain trauma was clinically associated with increased osteogenesis in the appendicular skeleton. We showed previously in C57BL/6J mice that mild traumatic brain injury (mTBI) transiently induced bone formation in the femur via the cannabinoid-1 (CB1) receptor. Here, we subjected ICR mice to mTBI and examined the bone response in the skull using microCT. We also measured mast cell degranulation (MCD)72 h post-injury. Finally, we measured brain and calvarial endocannabinoids levels post-mTBI. mTBI led to decreased bone porosity on the contralateral (untouched) side. This effect was apparent both in young and mature mice. Administration of rimonabant (CB1 inverse agonist) completely abrogated the effect of mTBI on calvarial porosity and significantly reduced MCD, compared with vehicle-treated controls. We also found that mTBI resulted in elevated levels of anandamide, but not 2-arachidonoylglycerol, in the contralateral calvarial bone, whereas brain levels remained unchanged. In C57BL/6J CB1 knockout mice, mTBI did not reduce porosity but in general the porosity was significantly lower than in WT controls. Our findings suggest that mTBI induces a strain-specific CB1-dependent bone anabolic response in the skull, probably mediated by anandamide, but seemingly unrelated to inflammation. The endocannabinoid system is therefore a plausible target in management of bone response following head trauma.",[],Scientific reports,2019-11-09,"[{'lastname': 'Eger', 'firstname': 'Michal', 'initials': 'M', 'affiliation': 'Department of Anatomy & Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Bader', 'firstname': 'Miaad', 'initials': 'M', 'affiliation': 'Department of Anatomy & Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Bree', 'firstname': 'Dara', 'initials': 'D', 'affiliation': 'Departments of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, MA, USA.'}, {'lastname': 'Hadar', 'firstname': 'Rivka', 'initials': 'R', 'affiliation': 'Obesity and Metabolism Laboratory, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, 9112001, Israel.'}, {'lastname': 'Nemirovski', 'firstname': 'Alina', 'initials': 'A', 'affiliation': 'Obesity and Metabolism Laboratory, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, 9112001, Israel.'}, {'lastname': 'Tam', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': 'Obesity and Metabolism Laboratory, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, 9112001, Israel.'}, {'lastname': 'Levy', 'firstname': 'Dan', 'initials': 'D', 'affiliation': 'Departments of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, MA, USA.'}, {'lastname': 'Pick', 'firstname': 'Chaim G', 'initials': 'CG', 'affiliation': 'Department of Anatomy & Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.\nSagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, 69978, Israel.\nThe Dr. Miriam and Sheldon G. Adelson Chair and Center for the Biology of Addictive Diseases, Tel-Aviv University, Tel-Aviv, 69978, Israel.'}, {'lastname': 'Gabet', 'firstname': 'Yankel', 'initials': 'Y', 'affiliation': 'Department of Anatomy & Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. yankel@tauex.tau.ac.il.\nSagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, 69978, Israel. yankel@tauex.tau.ac.il.'}]",,,,,"10.1038/s41598-019-51720-w
10.1097/00002060-200209000-00006
10.1007/BF03350319
10.1096/fj.06-7957com
10.1038/sj.bjp.0707593
10.1007/s002239900737
10.1097/01.PRS.0000070728.56716.51
10.1002/jbmr.3234
10.1002/jcb.23225
10.1177/0333102415617412
10.1002/cne.22049
10.1016/j.bone.2013.03.013
10.1371/journal.pone.0010692
10.3389/fneur.2018.00372
10.1007/112_0505
10.1080/026990599121827
10.3171/jns.1987.66.2.0234
10.1016/S0306-4522(03)00048-4
10.1007/s00213-010-2098-y
10.1089/neu.2016.4909
10.1038/nm1255
10.1124/mol.106.026435
10.1111/acel.12638
10.1002/jbmr.5650051104
10.1371/journal.pone.0167964
10.1002/jnr.21160
10.1007/BF02509542
10.1016/j.molmet.2016.10.004
10.4049/jimmunol.1301794
10.1016/j.pain.2007.03.012",<Element 'PubmedArticle' at 0x7f05db6875e0>
72,"31677609
18284372
18073185
25170153
14694190
11459806
12958311
17919783
20382181
24484697
20388076
9023877
16572394
23628345
23434911
18727047
9881851
29044447
11550742
2967880
8831298
25485772
23773059
2638633
7333338
6115326
17923630
21331174
11891823
15118105
25959522
23573795
21411205
23488281
22820676
10887978
20925068
21463042
20153425
25712639
27001133
26635213
11274343
27188934
28960209
20946954
19446073
19446080
9208405
12493707
3549275
10529900
23157556
834244
2080192
15678158
2644044
9872937
10965881
8125934
15219700
6147898
18054400
23481590
16487665
17917157
19042092
15727517
15860479
16771043
10064172
16387720
15582112
11282357
7582815
7557918
8891311
8943785
2253030
9409701
15753424
14644069
11971659
20552051
23023216
24250491
19252678
19900488
19067676
9768651
10588579
11739250
10854906
18649493
17851537
19063914
18771935
20399839
23253178
16855455
20540592
17054283
17018237
24363726
12471243
19818674
23524293
23985307
20027184
28473255
22964758
26687711
17089919
20493887
15555642
17207788
22306745
22209852
15622518
19895879
23197040
8051084
20431074
21035454
16635641
21733754
21389984
17565007
12397090
11153812
19552485
20540694
16254221
14762097
15207847
9576922
1943460
16698938
11467851
17541419
16914869
10873588
17218018
17553691
27103044
21978545
7737456
7592622
10506528
23905995
16707559
21820043
10558990
11598293
15829628
10411321
10407026
12244210
12086646
12764111
10707967
10985282
15263086
15466214
14584725
18222446
12971891
16361258
5576164
7891098
17303658
15585562
15189137
10931172
14580317
12831855
11880503
19837873
12130773
14622134
11099831
10655508
17595254
15383512
18855662
12700769
14690523
27863808
22710914
17078951
12000125",The Implication of Androgens in the Presence of Protein Kinase C to Repair Alzheimer’s Disease-Induced Cognitive Dysfunction.,"Aging, as a major risk factor of memory deficiency, affects neural signaling pathways in hippocampus. In particular, age-dependent androgens deficiency causes cognitive impairments. Several enzymes like protein kinase C (PKC) are involved in memory deficiency. Indeed, PKC regulatory process mediates α-secretase activation to cleave APP in β-amyloid cascade and tau proteins phosphorylation mechanism. Androgens and cortisol regulate PKC signaling pathways, affecting the modulation of receptor for activated C kinase 1. Mitogen-activated protein kinase/ERK signaling pathway depends on CREB activity in hippocampal neurons and is involved in regulatory processes via PKC and androgens. Therefore, testosterone and PKC contribute in the neuronal apoptosis. The present review summarizes the current status of androgens, PKC, and their influence on cognitive learning. Inconsistencies in experimental investigations related to this fundamental correlation are also discussed, with emphasis on the mentioned contributors as the probable potent candidates for learning and memory improvement.","['Androgens', 'Cognition', 'Hippocampus', 'Protein kinase C', 'Spatial memory']",Iranian biomedical journal,2019-11-05,"[{'lastname': 'Amiri', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran.'}, {'lastname': 'Azadmanesh', 'firstname': 'Kayhan', 'initials': 'K', 'affiliation': 'Department of Virology, Pasteur Institute of Iran, Tehran, Iran.'}, {'lastname': 'Dehghan Shasaltaneh', 'firstname': 'Marzieh', 'initials': 'M', 'affiliation': 'Department of Biology, Faculty of Science, University of Zanjan, Zanjan, Iran.'}, {'lastname': 'Mayahi', 'firstname': 'Vafa', 'initials': 'V', 'affiliation': 'Department of Microbiology, Islamic Azad University, Karaj, Iran.'}, {'lastname': 'Naghdi', 'firstname': 'Nasser', 'initials': 'N', 'affiliation': 'Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran.'}]",,,,,10.29252/ibj.24.2.64,<Element 'PubmedArticle' at 0x7f05db67fc70>
73,31669775,Silibinin ameliorates STZ-induced impairment of memory and learning by up- regulating insulin signaling pathway and attenuating apoptosis.,"Alzheimer's disease (AD) is a neurodegenerative disease, mainly characterized by cognitive dysfunction and memory impairment. Due to its pathological similarities to type 2 diabetes mellitus (T2DM), such as β-amyloid deposition, oxidative stress, inflammation, disordered glucose metabolism, impaired signaling pathways of insulin and insulin-like growth factor-1 (IGF-1), we speculate that AD is another form of brain diabetes. Clarifying the relationship between T2DM and AD is important for us to better understand the exact pathological mechanisms of AD. Silibinin, a polyphenolic flavonoid extracted from the seeds of Silybum marianum, exerts hepatoprotective, anti- diabetic and neuroprotective effects. Streptozotocin (STZ), which is used to disrupt the insulin signal transduction pathway, could well mimic the sporadic AD models by intracerebroventricular (ICV) injection. Therefore, we selected ICV injection of STZ (ICV-STZ) to investigate the neuroprotective effects of silibinin in rats and to make a foundation for further exploring the relationship between AD and T2DM. ICV-STZ obviously caused memory damage, sharply reduced the number of nissl bodies and destroyed morphological structure of hippocampal neuronal cells, while silibinin attenuated the damages. Moreover, silibinin significantly decreased STZ-induced tau hyperphosphorylation (ser404) in hippocampus and cerebral cortex, markedly inhibited apoptosis of neurons induced by STZ, and up-regulated insulin signal transduction pathway. Silibinin exerts neuroprotective effect in STZ-treated rats, indicating the potential of silibinin for the treatment of AD patients with T2DM in future.","[""Alzheimer's disease"", 'Insulin signaling pathway', 'Silibinin', 'Streptozotocin']",Physiology & behavior,2019-11-02,"[{'lastname': 'Liu', 'firstname': 'Panwen', 'initials': 'P', 'affiliation': 'China-Japan Research Institute of Medical and Pharmaceutical Sciences, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China.'}, {'lastname': 'Cui', 'firstname': 'Lingyu', 'initials': 'L', 'affiliation': 'China-Japan Research Institute of Medical and Pharmaceutical Sciences, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China.'}, {'lastname': 'Liu', 'firstname': 'Bo', 'initials': 'B', 'affiliation': 'China-Japan Research Institute of Medical and Pharmaceutical Sciences, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China.'}, {'lastname': 'Liu', 'firstname': 'Weiwei', 'initials': 'W', 'affiliation': 'China-Japan Research Institute of Medical and Pharmaceutical Sciences, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China.'}, {'lastname': 'Hayashi', 'firstname': 'Toshihiko', 'initials': 'T', 'affiliation': 'China-Japan Research Institute of Medical and Pharmaceutical Sciences, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China; Department of Chemistry and Life Science, School of Advanced Engineering Kogakuin University, 2665-1, Nakanomachi Hachioji, Tokyo, 192-0015, Japan.'}, {'lastname': 'Mizuno', 'firstname': 'Kazunori', 'initials': 'K', 'affiliation': 'Nippi Research Institute of Biomatrix, Toride, Ibaraki 302-0017, Japan.'}, {'lastname': 'Hattori', 'firstname': 'Shunji', 'initials': 'S', 'affiliation': 'Nippi Research Institute of Biomatrix, Toride, Ibaraki 302-0017, Japan.'}, {'lastname': 'Ushiki-Kaku', 'firstname': 'Yuko', 'initials': 'Y', 'affiliation': 'Nippi Research Institute of Biomatrix, Toride, Ibaraki 302-0017, Japan.'}, {'lastname': 'Onodera', 'firstname': 'Satoshi', 'initials': 'S', 'affiliation': 'Medical Research Institute of Curing Mibyo, 1-6-28, Narusedai, Machida, Tokyo, 194-0042, Japan.'}, {'lastname': 'Ikejima', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': 'China-Japan Research Institute of Medical and Pharmaceutical Sciences, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Shenyang 110016, China. Electronic address: ikejimat@vip.sina.com.'}]",,,,Copyright © 2019 Elsevier Inc. All rights reserved.,10.1016/j.physbeh.2019.112689,<Element 'PubmedArticle' at 0x7f05db4a63b0>
74,31612291,"Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.","We report the results of a retrospective analysis of the fulvestrant and palbociclib combination within a temporary authorization of use (TAU) program in 77 heavily pretreated patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer.
All patients who received the fulvestrant and palbociclib combination within this TAU program were included. Toxicities were graded using the CTCAE v5 scale.
The majority of patients (62.3%) were previously treated with the mTOR inhibitor everolimus. The median number of previous treatments for their metastatic disease was 4. With a median follow-up of 14 months, the median progression-free survival (PFS) was 7.6 months. The median PFS significantly (p < 0.0001) decreased with the number of previous treatment lines in the metastatic setting. The median PFS was 5.5 months in patients who had previously progressed on everolimus compared to 9.3 months in the everolimus non-pretreated subgroup. No significant difference in median PFS was detected in patients according to age. The median overall survival rate was not reached. The clinical benefit rate was 64%, including 4% of complete responses, 26% partial responses, and 34% stable diseases for the entire cohort.
The fulvestrant and palbociclib combination exerts an appreciable effect on metastatic heavily pretreated patients with a tolerable toxicity profile.","['Advanced breast cancer', 'CDK 4/6 inhibitors', 'Endocrine therapy', 'Fulvestrant', 'Palbociclib']",Breast cancer research and treatment,2019-10-16,"[{'lastname': 'Herrscher', 'firstname': 'Hugo', 'initials': 'H', 'affiliation': ""Department of Medical Oncology, Centre Paul Strauss, 3, rue de la Porte de l'Hôpital, BP 30042, 67065, Strasbourg, Cedex, France.""}, {'lastname': 'Velten', 'firstname': 'Michel', 'initials': 'M', 'affiliation': 'Department of Epidemiology, Centre Paul Strauss, Strasbourg, France.'}, {'lastname': 'Leblanc', 'firstname': 'Julie', 'initials': 'J', 'affiliation': ""Department of Medical Oncology, Centre Paul Strauss, 3, rue de la Porte de l'Hôpital, BP 30042, 67065, Strasbourg, Cedex, France.""}, {'lastname': 'Kalish-Weindling', 'firstname': 'Michal', 'initials': 'M', 'affiliation': ""Department of Medical Oncology, Centre Paul Strauss, 3, rue de la Porte de l'Hôpital, BP 30042, 67065, Strasbourg, Cedex, France.""}, {'lastname': 'Fischbach', 'firstname': 'Cathie', 'initials': 'C', 'affiliation': ""Department of Medical Oncology, Centre Paul Strauss, 3, rue de la Porte de l'Hôpital, BP 30042, 67065, Strasbourg, Cedex, France.""}, {'lastname': 'Exinger', 'firstname': 'Delphine', 'initials': 'D', 'affiliation': 'Pharmacy, Centre Paul Strauss, Strasbourg, France.'}, {'lastname': 'Pivot', 'firstname': 'Xavier', 'initials': 'X', 'affiliation': ""Department of Medical Oncology, Centre Paul Strauss, 3, rue de la Porte de l'Hôpital, BP 30042, 67065, Strasbourg, Cedex, France.""}, {'lastname': 'Petit', 'firstname': 'Thierry', 'initials': 'T', 'affiliation': ""Department of Medical Oncology, Centre Paul Strauss, 3, rue de la Porte de l'Hôpital, BP 30042, 67065, Strasbourg, Cedex, France. tpetit@strasbourg.unicancer.fr.""}]",,,"The majority of patients (62.3%) were previously treated with the mTOR inhibitor everolimus. The median number of previous treatments for their metastatic disease was 4. With a median follow-up of 14 months, the median progression-free survival (PFS) was 7.6 months. The median PFS significantly (p < 0.0001) decreased with the number of previous treatment lines in the metastatic setting. The median PFS was 5.5 months in patients who had previously progressed on everolimus compared to 9.3 months in the everolimus non-pretreated subgroup. No significant difference in median PFS was detected in patients according to age. The median overall survival rate was not reached. The clinical benefit rate was 64%, including 4% of complete responses, 26% partial responses, and 34% stable diseases for the entire cohort.",,10.1007/s10549-019-05439-x,<Element 'PubmedArticle' at 0x7f05dc870360>
75,31594235,Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease.,"Observations in autopsied brain tissue indicate that overactivation of the classical renin-angiotensin system (cRAS) and underactivity within regulatory RAS pathways (rRAS) are associated with pathology in Alzheimer's disease (AD). The primary aim of this study was to investigate whether cerebrospinal fluid (CSF) markers of RAS are altered in AD in relation to established CSF markers of disease pathology (lower Aβ42 and elevated tau) and CSF markers of capillary dysfunction. We studied 40 controls and 40 AD cases grouped according to a biomarker profile (i.e., AD cases t-tau>400 pg/mL, pTau >60 pg/mL, and Aβ42 <550 pg/mL). Angiotensin-II converting enyme-1 (ACE1) and ACE2 enzyme activity was measured using fluorogenic peptide substrates; sPDGFRβ and albumin level by sandwich ELISA; and angiotensin-I (Ang-I), Ang-II, and Ang-(1-7) by direct ELISA. CSF Aβ42, total, and phosphorylated tau levels were previously measured by INNOTEST sandwich ELISA. CSF ACE1 activity was significantly elevated in AD (p = 0.008) and positively correlated with ACE2 in AD (r = 0.420, p = 0.007). CSF ACE1 weakly correlated with t-tau (r = 0.294, p = 0.066) and p-tau (r = 0.329, p = 0.038) but not with Aβ42 in the controls but not in AD. ACE1 correlated positively with sPDGFRβ (r = 0.426, p = 0.007), a marker of pericyte injury, and ACE2 correlated positively with albumin (r = 0.422, p = 0.008), a marker of blood-brain barrier integrity. CSF Ang-I, Ang-II, and Ang-(1-7) levels were unchanged in AD. This cross-sectional CSF study indicates RAS dysfunction in relation to capillary damage in AD.","['Alzheimer’s disease', 'angiotensin-(1-7)', 'angiotensin-II', 'angiotensin-II \nconverting enyme-1 (ACE1)', 'angiotensin-II converting enyme-2 (ACE2)', 'cerebrospinal fluid', 'renin-angiotensin system']",Journal of Alzheimer's disease : JAD,2019-10-09,"[{'lastname': 'Kehoe', 'firstname': 'Patrick G', 'initials': 'PG', 'affiliation': 'Dementia Research Group, Clinical Neuroscience, Southmead Hospital, University of Bristol, Bristol, UK.'}, {'lastname': 'Al Mulhim', 'firstname': 'Noura', 'initials': 'N', 'affiliation': 'Dementia Research Group, Clinical Neuroscience, Southmead Hospital, University of Bristol, Bristol, UK.'}, {'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.\nDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.\nUK Dementia Research Institute at UCL, London, UK.'}, {'lastname': 'Blennow', 'firstname': 'Kaj', 'initials': 'K', 'affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.\nClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.'}, {'lastname': 'Miners', 'firstname': 'James S', 'initials': 'JS', 'affiliation': 'Dementia Research Group, Clinical Neuroscience, Southmead Hospital, University of Bristol, Bristol, UK.'}]",,,,,10.3233/JAD-190721,<Element 'PubmedArticle' at 0x7f05dc883540>
76,"31578297
22732773
27306957
25662776
21839829
22502999
17988893
18669512
22430496
20637289
22366795
20045477
29228211
19470967
23006986
25683866
27995069
17659998
27463684
27080517
15615814
29172163",Ventricular volume expansion in presymptomatic genetic frontotemporal dementia.,"To characterize the time course of ventricular volume expansion in genetic frontotemporal dementia (FTD) and identify the onset time and rates of ventricular expansion in presymptomatic FTD mutation carriers.
Participants included patients with a mutation in 
A total of 123 participants met the inclusion criteria and were included in the analysis (18 symptomatic carriers, 46 presymptomatic mutation carriers, and 56 noncarriers). Ventricular volume differences were observed 4 years prior to symptom disease onset for presymptomatic carriers compared to noncarriers. Annualized rates of ventricular volume expansion were greater in presymptomatic carriers relative to noncarriers. Importantly, time-intensive manually edited and fully automated ventricular volume resulted in similar findings.
Ventricular volume differences are detectable in presymptomatic genetic FTD. Concordance of results from time-intensive manual editing and fully automatic segmentation approaches support its value as a measure of disease onset and progression in future studies in both presymptomatic and symptomatic genetic FTD.",[],Neurology,2019-10-04,"[{'lastname': 'Tavares', 'firstname': 'Tamara P', 'initials': 'TP', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Mitchell', 'firstname': 'Derek G V', 'initials': 'DGV', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Coleman', 'firstname': 'Kristy', 'initials': 'K', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Shoesmith', 'firstname': 'Christen', 'initials': 'C', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Bartha', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Cash', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Moore', 'firstname': 'Katrina M', 'initials': 'KM', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'van Swieten', 'firstname': 'John', 'initials': 'J', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Tartaglia', 'firstname': 'Maria Carmela', 'initials': 'MC', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Rowe', 'firstname': 'James', 'initials': 'J', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Graff', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Tagliavini', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Frisoni', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Cappa', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Laforce', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'de Mendonça', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Sorbi', 'firstname': 'Sandro', 'initials': 'S', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Wallstrom', 'firstname': 'Garrick', 'initials': 'G', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Masellis', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.'}, {'lastname': 'Finger', 'firstname': 'Elizabeth C', 'initials': 'EC', 'affiliation': 'From the Graduate Program in Neuroscience and Brain and Mind Institute (T.P.T., D.G.V.M., E.C.F.) and Departments of Clinical Neurological Sciences (C.S., E.C.F.) and Medical Biophysics (R.B.), Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario; Parkwood Institute (K.C., E.C.F.), Lawson Health Research Institute, London, Canada; Dementia Research Centre, Department of Neurodegenerative Disease (D.M.C., K.M.M., J.D.R.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (D.M.C.), University College London, UK; Department of Neurology (J.v.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Neurology Unit, Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Pathophysiology and Transplantation (D.G.), ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Italy; Toronto Western Hospital (M.C.T.), Tanz Centre for Research in Neurodegenerative Disease, Canada; Department of Clinical Neurosciences (J.R.), University of Cambridge, UK; Department NVS (C.G.), Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Sweden; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta (F.T.), Milan; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli (G.F., S.C.), Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging (G.F.), University Hospitals and University of Geneva, Switzerland; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques (R.L.), CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and the IRCCS Foundazione Don Carlo Gnocchi (S.S.), Florence, Italy; Statistics & Data Corporation (G.W.), Tempe, AZ; and LC Campbell Cognitive Neurology Research Unit (M.M.), Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada. elizabeth.finger@lhsc.on.ca.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,"A total of 123 participants met the inclusion criteria and were included in the analysis (18 symptomatic carriers, 46 presymptomatic mutation carriers, and 56 noncarriers). Ventricular volume differences were observed 4 years prior to symptom disease onset for presymptomatic carriers compared to noncarriers. Annualized rates of ventricular volume expansion were greater in presymptomatic carriers relative to noncarriers. Importantly, time-intensive manually edited and fully automated ventricular volume resulted in similar findings.","Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.",10.1212/WNL.0000000000008386,<Element 'PubmedArticle' at 0x7f05dc87f950>
77,"31537715
26854827
28990425
29213965
24081456
21416021
22815225
26990251
17615171
21810890
21514250
19015862
22490326
22526019
19901167
26022924
28130640
29554190
25549971
23117491
19917988
27543771
25556536
29172163
22366795
26501846
25683866
29264395
23338682
29724592
18771956
18192287
30565360
25795648
25388784
25239657",Genetic predictors of survival in behavioral variant frontotemporal degeneration.,"To determine autosomal dominant genetic predictors of survival in individuals with behavioral variant frontotemporal degeneration (bvFTD).
A retrospective chart review of 174 cases with a clinical phenotype of bvFTD but no associated elementary neurologic features was performed, with diagnosis either autopsy-confirmed (n = 57) or supported by CSF evidence of non-Alzheimer pathology (n = 117). Genetic analysis of the 3 most common genes with pathogenic autosomal dominant mutations associated with frontotemporal degeneration was performed in all patients, which identified cases with 
Across all patients with bvFTD, the presence of a disease-associated pathogenic mutation was associated with shortened survival (hazard ratio [HR] 2.164, 95% confidence interval [CI] 1.391, 3.368). In separate models, a 
Our findings suggest that autosomal dominantly inherited mutations, modulated by age at symptom onset, associate with shorter survival among patients with bvFTD. We suggest that clinical trials and clinical management should consider mutation status and age at onset when evaluating disease progression.",[],Neurology,2019-09-21,"[{'lastname': 'Caswell', 'firstname': 'Carrie', 'initials': 'C', 'affiliation': 'From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'McMillan', 'firstname': 'Corey T', 'initials': 'CT', 'affiliation': 'From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'Xie', 'firstname': 'Sharon X', 'initials': 'SX', 'affiliation': 'From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'Van Deerlin', 'firstname': 'Vivianna M', 'initials': 'VM', 'affiliation': 'From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'Suh', 'firstname': 'EunRan', 'initials': 'E', 'affiliation': 'From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'Lee', 'firstname': 'Edward B', 'initials': 'EB', 'affiliation': 'From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'Trojanowski', 'firstname': 'John Q', 'initials': 'JQ', 'affiliation': 'From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'Lee', 'firstname': 'Virginia M-Y', 'initials': 'VM', 'affiliation': 'From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'Irwin', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'Grossman', 'firstname': 'Murray', 'initials': 'M', 'affiliation': 'From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'lastname': 'Massimo', 'firstname': 'Lauren M', 'initials': 'LM', 'affiliation': 'From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia. lmassimo@upenn.edu.'}]",,,"Across all patients with bvFTD, the presence of a disease-associated pathogenic mutation was associated with shortened survival (hazard ratio [HR] 2.164, 95% confidence interval [CI] 1.391, 3.368). In separate models, a ",© 2019 American Academy of Neurology.,10.1212/WNL.0000000000008387,<Element 'PubmedArticle' at 0x7f05dc75ccc0>
78,"31535628
28324103
23775354
29683196
20173018
29562364
21697255
23248766
25462195
14675485
10637462
27716209
19747904
10523012
16503925
20299083
17212806
20649934
3678498
7470804
12519849
12175406
7558385
3100455
3997660
29264488
16304204
3371482
6434579
3106102
24115523
16225533
12350491
19351657
29282765
9532468
2516757
29235139
24407187
16582411
6811834
20531281
24215138
17270639
27049351
20816687
20346001
20554979",Testicular volume and clinical correlates of hypothalamic-pituitary-testicular function: A cross-sectional study in obese men.,"The aim of this study was to determine whether testicular volume is correlated with clinical and biochemical markers of hypothalamic-pituitary-testicular (HPT) axis function. This was a cross-sectional substudy of a larger randomized controlled trial including obese men, body mass index (BMI) ≥30 kg m","['hypothalamic– pituitary– gonadal axis', 'testicular volume', 'testosterone']",Asian journal of andrology,2019-09-20,"[{'lastname': 'Tang Fui', 'firstname': 'Mark Ng', 'initials': 'MN', 'affiliation': 'Department of Medicine Austin Health, University of Melbourne, Melbourne, Victoria 3084, Australia.\nDepartment of Endocrinology, Austin Health, Melbourne, Victoria 3084, Australia.'}, {'lastname': 'Hoermann', 'firstname': 'Rudolf', 'initials': 'R', 'affiliation': 'Department of Medicine Austin Health, University of Melbourne, Melbourne, Victoria 3084, Australia.'}, {'lastname': 'Wittert', 'firstname': 'Gary', 'initials': 'G', 'affiliation': 'School of Medicine, University of Adelaide, Adelaide, South Australia 5005, Australia.'}, {'lastname': 'Grossmann', 'firstname': 'Mathis', 'initials': 'M', 'affiliation': 'Department of Medicine Austin Health, University of Melbourne, Melbourne, Victoria 3084, Australia.\nDepartment of Endocrinology, Austin Health, Melbourne, Victoria 3084, Australia.'}]",,,,,10.4103/aja.aja_96_19,<Element 'PubmedArticle' at 0x7f05dc7387c0>
79,"31481130
20139996
9005861
19381658
26354483
29450646
27016065
24362441
25080588
25073522
22288403
16362635
21802530
21411860
30271916
20970891
8980017
10671318
25131002
1542387
9255387
19564059
27435172
17029828
16877359
14587009
26716699
26618512
23717620
9639030
24834052
17761438
11525331
11906227
19247483
1793176
21170538
23609018
26782335
26302353
20354534
18270514
17623852
22992647
23332364
27318146
8994041
19231987
17245412
21645391
29253129
23050084
29459625
30003517
12391400",Encephalopathy induced by Alzheimer brain inoculation in a non-human primate.,"Alzheimer's disease is characterized by cognitive alterations, cerebral atrophy and neuropathological lesions including neuronal loss, accumulation of misfolded and aggregated β-amyloid peptides (Aβ) and tau proteins. Iatrogenic induction of Aβ is suspected in patients exposed to pituitary-derived hormones, dural grafts, or surgical instruments, presumably contaminated with Aβ. Induction of Aβ and tau lesions has been demonstrated in transgenic mice after contamination with Alzheimer's disease brain homogenates, with very limited functional consequences. Unlike rodents, primates naturally express Aβ or tau under normal conditions and attempts to transmit Alzheimer pathology to primates have been made for decades. However, none of earlier studies performed any detailed functional assessments. For the first time we demonstrate long term memory and learning impairments in a non-human primate (Microcebus murinus) following intracerebral injections with Alzheimer human brain extracts. Animals inoculated with Alzheimer brain homogenates displayed progressive cognitive impairments (clinical tests assessing cognitive and motor functions), modifications of neuronal activity (detected by electroencephalography), widespread and progressive cerebral atrophy (in vivo MRI assessing cerebral volume loss using automated voxel-based analysis), neuronal loss in the hippocampus and entorhinal cortex (post mortem stereology). They displayed parenchymal and vascular Aβ depositions and tau lesions for some of them, in regions close to the inoculation sites. Although these lesions were sparse, they were never detected in control animals. Tau-positive animals had the lowest performances in a memory task and displayed the greatest neuronal loss. Our study is timely and important as it is the first one to highlight neuronal and clinical dysfunction following inoculation of Alzheimer's disease brain homogenates in a primate. Clinical signs in a chronic disease such as Alzheimer take a long time to be detectable. Documentation of clinical deterioration and/or dysfunction following intracerebral inoculations with Alzheimer human brain extracts could lead to important new insights about Alzheimer initiation processes.","['Alzheimer’s disease', 'Cerebral atrophy', 'Cognitive impairment', 'Microcebus murinus', 'Mouse', 'Neurodegenerative disease', 'Neuronal function', 'Prion', 'Tau pathology', 'β-Amyloid pathology']",Acta neuropathologica communications,2019-09-05,"[{'lastname': 'Gary', 'firstname': 'Charlotte', 'initials': 'C', 'affiliation': ""Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.\nCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.""}, {'lastname': 'Lam', 'firstname': 'Suzanne', 'initials': 'S', 'affiliation': ""Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.\nCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.""}, {'lastname': 'Hérard', 'firstname': 'Anne-Sophie', 'initials': 'AS', 'affiliation': ""Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.\nCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.""}, {'lastname': 'Koch', 'firstname': 'James E', 'initials': 'JE', 'affiliation': ""Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.\nCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.\nUniversity of Wisconsin Oshkosh, 800 Algoma Boulevard, Oshkosh, WI, 54901, USA.""}, {'lastname': 'Petit', 'firstname': 'Fanny', 'initials': 'F', 'affiliation': ""Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.\nCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.""}, {'lastname': 'Gipchtein', 'firstname': 'Pauline', 'initials': 'P', 'affiliation': ""Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.\nCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.""}, {'lastname': 'Sawiak', 'firstname': 'Stephen J', 'initials': 'SJ', 'affiliation': ""Wolfson Brain Imaging Centre, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.\nBehavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.""}, {'lastname': 'Caillierez', 'firstname': 'Raphaëlle', 'initials': 'R', 'affiliation': ""LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Université de Lille, Inserm, CHU-Lille, UMR-S1172, Alzheimer & Tauopathies, Rue Polonovski, 59045, Lille, France.""}, {'lastname': 'Eddarkaoui', 'firstname': 'Sabiha', 'initials': 'S', 'affiliation': ""LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Université de Lille, Inserm, CHU-Lille, UMR-S1172, Alzheimer & Tauopathies, Rue Polonovski, 59045, Lille, France.""}, {'lastname': 'Colin', 'firstname': 'Morvane', 'initials': 'M', 'affiliation': ""LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Université de Lille, Inserm, CHU-Lille, UMR-S1172, Alzheimer & Tauopathies, Rue Polonovski, 59045, Lille, France.""}, {'lastname': 'Aujard', 'firstname': 'Fabienne', 'initials': 'F', 'affiliation': 'UMR7179 CNRS-MNHN, MECADEV (Adaptive Mechanisms and Evolution), 1 Avenue du Petit Château, 91800, Brunoy, France.'}, {'lastname': 'Deslys', 'firstname': 'Jean-Philippe', 'initials': 'JP', 'affiliation': ""Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, SEPIA, Université Paris-Saclay, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.""}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': 'Brouillet', 'firstname': 'Emmanuel', 'initials': 'E', 'affiliation': ""Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.\nCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.""}, {'lastname': 'Buée', 'firstname': 'Luc', 'initials': 'L', 'affiliation': ""LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Université de Lille, Inserm, CHU-Lille, UMR-S1172, Alzheimer & Tauopathies, Rue Polonovski, 59045, Lille, France.""}, {'lastname': 'Comoy', 'firstname': 'Emmanuel E', 'initials': 'EE', 'affiliation': ""Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, SEPIA, Université Paris-Saclay, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.""}, {'lastname': 'Pifferi', 'firstname': 'Fabien', 'initials': 'F', 'affiliation': 'UMR7179 CNRS-MNHN, MECADEV (Adaptive Mechanisms and Evolution), 1 Avenue du Petit Château, 91800, Brunoy, France.'}, {'lastname': 'Picq', 'firstname': 'Jean-Luc', 'initials': 'JL', 'affiliation': ""Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.\nCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France.\nLaboratoire de Psychopathologie et de Neuropsychologie, EA, 2027, Université Paris 8, St-Denis, France.""}, {'lastname': 'Dhenain', 'firstname': 'Marc', 'initials': 'M', 'affiliation': ""Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France. marc.dhenain@cea.fr.\nCommissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, 18 Route du Panorama, F-92265, Fontenay-aux-Roses, France. marc.dhenain@cea.fr.""}]",,,,,"10.1186/s40478-019-0771-x
10.1038/nrneurol.2009.215
10.1002/ana.410410106
10.1007/s00401-009-0532-1
10.1038/nature15369
10.1007/s00401-018-1822-2
10.1007/s00401-016-1565-x
10.1007/s00401-013-1231-5
10.1523/JNEUROSCI.1608-14.2014
10.1007/s00401-014-1324-9
10.2174/138161212799315885
10.1007/s00702-005-0385-2
10.1016/j.arr.2011.07.001
10.1111/jzo.12230
10.1093/ilar.52.1.78
10.1038/s42003-018-0024-8
10.1016/j.neurobiolaging.2010.09.009
10.1006/nbdi.1996.0017
10.1006/nbdi.1999.0270
10.1016/j.neurobiolaging.2014.07.017
10.1016/0197-4580(92)90016-Q
10.1007/s004010050684
10.1016/j.neurobiolaging.2009.05.018
10.1186/s40478-016-0345-0
10.1016/j.nbd.2006.08.017
10.2353/ajpath.2006.060002
10.1002/mrm.10612
10.1371/journal.pone.0146238
10.1371/journal.pone.0143719
10.1371/journal.pone.0064493
10.1016/S0361-9230(97)00458-9
10.3389/fnagi.2014.00082
10.1016/j.neuroimage.2007.07.007
10.1006/nimg.2001.0786
10.1006/nimg.2001.1037
10.1371/journal.pone.0004637
10.1002/ar.1092310411
10.1007/s00401-010-0789-4
10.1038/mt.2013.66
10.1038/nrneurol.2015.251
10.1001/jamaneurol.2015.1721
10.1038/nrn2822
10.1038/nrn2335
10.1002/hipo.20333
10.1038/nrn3338
10.1016/S1474-4422(12)70291-0
10.1016/j.neurobiolaging.2016.04.019
10.1126/science.275.5298.402
10.1146/annurev.biochem.78.082907.145410
10.1038/nrm2101
10.1186/1750-1326-6-39
10.1093/brain/awx342
10.1038/srep00700
10.1007/s12035-018-1209-3
10.1093/ilar.43.4.244",<Element 'PubmedArticle' at 0x7f05db6d63b0>
80,"31448566
22732773
25549971
25853864
16862115
16862116
21944778
21944779
24800652
16950801
22890575
23596077
22366793
17579875
21644037
26374446
24366528
23746459
26989253
28828399
9855500
21325651
23359374
24011653
25805643
19383787
19816201
23053135
30029693
23147507
19513731
28916533
22366790
22366791
22300876
27435172
18245784
18234697
18192287
25186741
27114033
25261995
24117616
15266782
26001591
30112957
7583681",Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations.,"To identify clinicopathological differences between frontotemporal lobar degeneration (FTLD) due to mutations in progranulin (FTLD-GRN) and chromosome 9 open reading frame 72 (FTLD-C9ORF72).
We performed quantitative neuropathologic comparison of 17 FTLD-C9ORF72 and 15 FTLD-GRN with a focus on microglia. For clinical comparisons, only cases with high quality medical documentation and concurring diagnoses by at least two neurologists were included (14 FTLD-GRN and 13 FTLD-C9ORF72). Neuropathological analyses were limited to TDP-43 Type A to assure consistent assessment between the groups, acknowledging that Type A is a minority of C9ORF72 patients. Furthermore, only cases with sufficient tissue from all regions were studied (11 FTLD-GRN and 11 FTLD-C9ORF72). FTLD cases were also compared to age- and sex-matched normal controls. Immunohistochemistry was performed for pTDP-43, IBA-1, CD68, and GFAP. Morphological characterization of microglia was performed in sections of cortex blinded to clinical and genetic information.
FTLD-GRN patients had frequent asymmetric clinical features, including aphasia and apraxia, as well as more asymmetric cortical atrophy. Neuropathologically, FTLD-C9ORF72 had greater hippocampal tau pathology and more TDP-43 neuronal cytoplasmic inclusions. FTLD-GRN had more neocortical microvacuolation, as well as more IBA-1-positive ameboid microglia in superficial cortical layers and in subcortical white matter. FTLD-GRN also had more microglia with nuclear condensation, possibly indicating apoptosis. Microglial morphology with CD68 immunohistochemistry in FTLD-GRN and FTLD-C9ORF72 differed from controls.
Our findings underscore differences in microglial response in FTLD-C9ORF72 and FTLD-GRN as shown by significant differences in ameboid microglia in gray and white matter. These results suggest the differential contribution of microglial dysfunction in FTLD-GRN and FTLD-C9ORF72 and suggest that clinical, neuroimaging and pathologic differences could in part be related to differences in microglia response.",[],Annals of clinical and translational neurology,2019-08-27,"[{'lastname': 'Sakae', 'firstname': 'Nobutaka', 'initials': 'N', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Roemer', 'firstname': 'Shanu F', 'initials': 'SF', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Bieniek', 'firstname': 'Kevin F', 'initials': 'KF', 'affiliation': 'Department of Pathology & Laboratory Medicine, University of Texas Health Science Center, San Antonio, Texas.'}, {'lastname': 'Murray', 'firstname': 'Melissa E', 'initials': 'ME', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Baker', 'firstname': 'Matthew C', 'initials': 'MC', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Kasanuki', 'firstname': 'Koji', 'initials': 'K', 'affiliation': 'Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.'}, {'lastname': 'Graff-Radford', 'firstname': 'Neill R', 'initials': 'NR', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Petrucelli', 'firstname': 'Leonard', 'initials': 'L', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Van Blitterswijk', 'firstname': 'Marka', 'initials': 'M', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Dickson', 'firstname': 'Dennis W', 'initials': 'DW', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}]",,,"FTLD-GRN patients had frequent asymmetric clinical features, including aphasia and apraxia, as well as more asymmetric cortical atrophy. Neuropathologically, FTLD-C9ORF72 had greater hippocampal tau pathology and more TDP-43 neuronal cytoplasmic inclusions. FTLD-GRN had more neocortical microvacuolation, as well as more IBA-1-positive ameboid microglia in superficial cortical layers and in subcortical white matter. FTLD-GRN also had more microglia with nuclear condensation, possibly indicating apoptosis. Microglial morphology with CD68 immunohistochemistry in FTLD-GRN and FTLD-C9ORF72 differed from controls.","© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.","10.1002/acn3.50875
10.1523/ENEURO.0100-17.2017",<Element 'PubmedArticle' at 0x7f05db91c3b0>
81,"31396860
20107219
19503072
28140402
25107476
28652303
14981233
23421912
22102449
12438433
23529219
28252521
26450683
27190028
16931765
29476642
28148553
26949217
27138913
23643691
25100603
24908665
23218930
22585904
23089927
23250356
25305153
24995127
20705776
27717815
25987958
20004218
15681835
28229243
20385908
24574966
26895791
30665005
21538175
28688899
21889406
15486293
29360258
20668182
17270732
27256292
27743026
26076170
19513731
25598354
26847266","Knock-in of Mutated hTAU Causes Insulin Resistance, Inflammation and Proteostasis Disturbance in a Mouse Model of Frontotemporal Dementia.","Diabetes and obesity have been implicated as risk factors for dementia. However, metabolic mechanisms and associated signalling pathways have not been investigated in detail in frontotemporal dementia. We therefore here characterised physiological, behavioural and molecular phenotypes of 3- and 8-month-old male tau knock-in (PLB2","['Diabetes', 'ER stress', 'Glucose', 'Insulin', 'Knock-in', 'Proteinopathy', 'Transgenic', 'UPR']",Molecular neurobiology,2019-08-10,"[{'lastname': 'Hull', 'firstname': 'Claire', 'initials': 'C', 'affiliation': 'Institute of Medical Sciences School of Medicine, Medical Sciences & Nutrition Foresterhill, University of Aberdeen, Aberdeen, Scotland, AB25 2ZD, UK.'}, {'lastname': 'Dekeryte', 'firstname': 'Ruta', 'initials': 'R', 'affiliation': 'Institute of Medical Sciences School of Medicine, Medical Sciences & Nutrition Foresterhill, University of Aberdeen, Aberdeen, Scotland, AB25 2ZD, UK.'}, {'lastname': 'Koss', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Institute of Medical Sciences School of Medicine, Medical Sciences & Nutrition Foresterhill, University of Aberdeen, Aberdeen, Scotland, AB25 2ZD, UK.'}, {'lastname': 'Crouch', 'firstname': 'Barry', 'initials': 'B', 'affiliation': 'Institute of Medical Sciences School of Medicine, Medical Sciences & Nutrition Foresterhill, University of Aberdeen, Aberdeen, Scotland, AB25 2ZD, UK.'}, {'lastname': 'Buchanan', 'firstname': 'Heather', 'initials': 'H', 'affiliation': 'Institute of Medical Sciences School of Medicine, Medical Sciences & Nutrition Foresterhill, University of Aberdeen, Aberdeen, Scotland, AB25 2ZD, UK.'}, {'lastname': 'Delibegovic', 'firstname': 'Mirela', 'initials': 'M', 'affiliation': 'Institute of Medical Sciences School of Medicine, Medical Sciences & Nutrition Foresterhill, University of Aberdeen, Aberdeen, Scotland, AB25 2ZD, UK.'}, {'lastname': 'Platt', 'firstname': 'Bettina', 'initials': 'B', 'affiliation': 'Institute of Medical Sciences School of Medicine, Medical Sciences & Nutrition Foresterhill, University of Aberdeen, Aberdeen, Scotland, AB25 2ZD, UK. b.platt@abdn.ac.uk.'}]",,,,,"10.1007/s12035-019-01722-6
10.1056/NEJMra0909142
10.1038/ncb1901
10.1038/tp.2016.296
10.1007/s00401-014-1328-5
10.1084/jem.20161731
10.1073/pnas.0308724101
10.1111/cns.12064
10.1002/path.3969
10.1172/JCI0216784
10.1007/s00281-013-0369-5
10.1097/FBP.0000000000000299
10.1007/s00401-015-1487-z
10.1093/brain/aww101
10.1126/science.1128294
10.1111/febs.14422
10.15252/emmm.201606664
10.1016/j.nbd.2016.03.002
10.1007/s00125-016-3960-1
10.1016/j.bbr.2013.04.041
10.1523/JNEUROSCI.0433-14.2014
10.1093/hmg/ddu285
10.1016/j.ceca.2012.11.004
10.3945/an.112.002113
10.1097/JES.0b013e3182798a95
10.2337/db12-0866
10.1212/WNL.0000000000000993
10.1186/2047-9158-3-13
10.2337/db10-1032
10.1016/j.bbr.2016.10.005
10.4239/wjd.v6.i4.613
10.1016/j.bbr.2009.12.002
10.1016/S0002-9440(10)62274-2
10.1007/s00415-017-8405-3
10.1055/s-0029-1237430.Imprinting
10.3389/fncel.2014.00022
10.2337/db15-1428
10.1016/j.nbd.2019.01.008
10.1007/s00125-011-2160-2
10.1016/j.neurobiolaging.2017.06.003
10.1016/j.molmed.2011.07.010
10.1126/science.1103160
10.1111/febs.14389
10.1523/JNEUROSCI.0834-10.2010
10.1016/j.neuron.2007.01.010
10.1186/s12974-016-0601-z
10.1007/s00401-016-1630-5
10.1001/jamaneurol.2015.0979
10.1007/s00401-009-0556-6
10.1007/s12035-014-9070-5
10.1002/glia.22966",<Element 'PubmedArticle' at 0x7f05db8f89a0>
82,31394203,Glucocorticoid receptors modulate dendritic spine plasticity and microglia activity in an animal model of Alzheimer's disease.,"Chronic exposure to high circulating levels of glucocorticoids (GCs) may be a key risk factor for Alzheimer's Disease (AD) development and progression. In addition, hyper-activation of glucocorticoid receptors (GRs) induces brain alterations comparable to those produced by AD. In transgenic mouse models of AD, GCs increase the production of the most important and typical hallmarks of this dementia such as: Aβ40, Aβ42 and tau protein (both the total tau and its hyperphosphorylated isoforms). Moreover, GCs in brain are pivotal regulators of dendritic spine turnover and microglia activity, two phenomena strongly altered in AD. Although it is well-established that GCs primes the neuroinflammatory response in the brain to some stimuli, it is unknown whether or how GRs modulates dendritic spine plasticity and microglia activity in AD. In this study, we evaluated, using combined Golgi Cox and immunofluorescence techniques, the role of GR agonists and antagonists on dendritic spine plasticity and microglia activation in hippocampus of 3xTg-AD mice. We found that dexamethasone, an agonist of GRs, was able to significantly reduce dendritic spine density and induced proliferation and activation of microglia in CA1 region of hippocampus of 3xTg-AD mice at 6 and 10 months of age. On the contrary, the treatment with mifepristone, an antagonist of GRs, strongly enhanced dendritic spine density, decreased microglia density and improved the behavioural performance of 3xTg-AD mice. Additionally, primary microglial cells in vitro were directly activated by dexamethasone. Together, these data demonstrate that stress exacerbates AD and promotes a rapid progression of the pathology acting on both neurons and glial cells, supporting an important pro-inflammatory role of GC within CNS in AD. Consequently, these results further strengthen the need to test clinical interventions that correct GCs dysregulation as promising therapeutic strategy to delay the onset and slow down the progression of AD.","[""Alzheimer's disease"", 'Dendritic spines', 'Glucocorticoid receptor', 'Glucocorticoids', 'Hippocampus', 'Microglia']",Neurobiology of disease,2019-08-09,"[{'lastname': 'Pedrazzoli', 'firstname': 'Matteo', 'initials': 'M', 'affiliation': 'University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Verona, Italy.'}, {'lastname': 'Losurdo', 'firstname': 'Morris', 'initials': 'M', 'affiliation': 'University of Milano-Bicocca, School of Medicine and Surgery, Milan, Italy.'}, {'lastname': 'Paolone', 'firstname': 'Giovanna', 'initials': 'G', 'affiliation': 'University of Verona, Department of Diagnostics and Public Health, Verona, Italy.'}, {'lastname': 'Medelin', 'firstname': 'Manuela', 'initials': 'M', 'affiliation': 'University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Verona, Italy.'}, {'lastname': 'Jaupaj', 'firstname': 'Lejdi', 'initials': 'L', 'affiliation': 'University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Verona, Italy.'}, {'lastname': 'Cisterna', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Verona, Italy.'}, {'lastname': 'Slanzi', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'University of Verona, Department of Medicine, Verona, Italy.'}, {'lastname': 'Malatesta', 'firstname': 'Manuela', 'initials': 'M', 'affiliation': 'University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Verona, Italy.'}, {'lastname': 'Coco', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': 'University of Milano-Bicocca, School of Medicine and Surgery, Milan, Italy.'}, {'lastname': 'Buffelli', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Verona, Italy. Electronic address: mario.buffelli@univr.it.'}]",,,,Copyright © 2019 Elsevier Inc. All rights reserved.,10.1016/j.nbd.2019.104568,<Element 'PubmedArticle' at 0x7f05dc28b400>
83,31376172,Amylin as a potential link between type 2 diabetes and alzheimer disease.,"Alzheimer disease (AD) is the leading cause of dementia, and although its etiology remains unclear, it seems that type 2 diabetes mellitus (T2DM) and other prediabetic states of insulin resistance could contribute to the appearance of sporadic AD. As such, we have assessed whether tau and β-amyloid (Aβ) deposits might be present in pancreatic tissue of subjects with AD, and whether amylin, an amyloidogenic protein deposited in the pancreas of T2DM patients, might accumulate in the brain of AD patients.
We studied pancreatic and brain tissue from 48 individuals with no neuropathological alterations and from 87 subjects diagnosed with AD. We examined Aβ and tau accumulation in the pancreas as well as that of amylin in the brain. Moreover, we performed proximity ligation assays to ascertain whether tau and/or Aβ interact with amylin in either the pancreas or brain of these subjects.
Cytoplasmic tau and Aβ protein deposits were detected in pancreatic β cells of subjects with AD as well as in subjects with a normal neuropathological examination but with a history of T2DM and in a small cohort of control subjects without T2DM. Furthermore, we found amylin deposits in the brain of these subjects, providing histological evidence that amylin can interact with Aβ and tau in both the pancreas and hippocampus.
The presence of both tau and Aβ inclusions in pancreatic β cells, and of amylin deposits in the brain, provides new evidence of a potential overlap in the mechanisms underlying the pathogenesis of T2DM and AD. ANN NEUROL 2019;86:539-551.",[],Annals of neurology,2019-08-04,"[{'lastname': 'Martinez-Valbuena', 'firstname': 'Ivan', 'initials': 'I', 'affiliation': 'Neurology Department, Clínica Universidad de Navarra, Pamplona, Spain.\nRegenerative Therapy Laboratory, Neurosciences Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.\nNavarra Health Research Institute, Pamplona, Spain.'}, {'lastname': 'Valenti-Azcarate', 'firstname': 'Rafael', 'initials': 'R', 'affiliation': 'Neurology Department, Clínica Universidad de Navarra, Pamplona, Spain.\nRegenerative Therapy Laboratory, Neurosciences Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.\nNavarra Health Research Institute, Pamplona, Spain.'}, {'lastname': 'Amat-Villegas', 'firstname': 'Irene', 'initials': 'I', 'affiliation': 'Navarra Health Research Institute, Pamplona, Spain.\nPathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.'}, {'lastname': 'Riverol', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Neurology Department, Clínica Universidad de Navarra, Pamplona, Spain.\nNavarra Health Research Institute, Pamplona, Spain.'}, {'lastname': 'Marcilla', 'firstname': 'Irene', 'initials': 'I', 'affiliation': 'Regenerative Therapy Laboratory, Neurosciences Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.\nNavarra Health Research Institute, Pamplona, Spain.'}, {'lastname': 'de Andrea', 'firstname': 'Carlos E', 'initials': 'CE', 'affiliation': 'Pathology Department, University of Navarra Clinic, Pamplona, Spain.'}, {'lastname': 'Sánchez-Arias', 'firstname': 'Juan Antonio', 'initials': 'JA', 'affiliation': 'Navarra Health Research Institute, Pamplona, Spain.\nSmall Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.'}, {'lastname': 'Del Mar Carmona-Abellan', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Neurology Department, Clínica Universidad de Navarra, Pamplona, Spain.\nRegenerative Therapy Laboratory, Neurosciences Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.\nNavarra Health Research Institute, Pamplona, Spain.'}, {'lastname': 'Marti', 'firstname': 'Gloria', 'initials': 'G', 'affiliation': 'Neurology Department, Clínica Universidad de Navarra, Pamplona, Spain.\nNavarra Health Research Institute, Pamplona, Spain.'}, {'lastname': 'Erro', 'firstname': 'Maria-Elena', 'initials': 'ME', 'affiliation': 'Navarra Health Research Institute, Pamplona, Spain.\nNeurology Department, Navarra Hospital Complex, Pamplona, Spain.'}, {'lastname': 'Martínez-Vila', 'firstname': 'Eduardo', 'initials': 'E', 'affiliation': 'Neurology Department, Clínica Universidad de Navarra, Pamplona, Spain.\nNavarra Health Research Institute, Pamplona, Spain.'}, {'lastname': 'Tuñon', 'firstname': 'Maria-Teresa', 'initials': 'MT', 'affiliation': 'Navarra Health Research Institute, Pamplona, Spain.\nPathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.'}, {'lastname': 'Luquin', 'firstname': 'Maria-Rosario', 'initials': 'MR', 'affiliation': 'Neurology Department, Clínica Universidad de Navarra, Pamplona, Spain.\nRegenerative Therapy Laboratory, Neurosciences Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.\nNavarra Health Research Institute, Pamplona, Spain.'}]",,,"Cytoplasmic tau and Aβ protein deposits were detected in pancreatic β cells of subjects with AD as well as in subjects with a normal neuropathological examination but with a history of T2DM and in a small cohort of control subjects without T2DM. Furthermore, we found amylin deposits in the brain of these subjects, providing histological evidence that amylin can interact with Aβ and tau in both the pancreas and hippocampus.",© 2019 American Neurological Association.,10.1002/ana.25570,<Element 'PubmedArticle' at 0x7f05dc27e7c0>
84,"31364823
24028961
27397854
27885006
28239743
24136970
30679382
27931262
28576566
29195051
22896675
30561329
29479071
28826498
25204284
27234656
25589747
25471560
26526066
16237719
24512957
24470695
29773907
30535688
28412142
24263092
30192999
19246392
29880854
28123668
29632177
28679595
22120156
21148344
25947369
28043900
28539349
28109896
24367384
29549603
19855404
28722711
27549340
30876981
26255702
19779148
21281561
30347264
18495879
17121991
21329555
19660138
22365952
17074507
21257712
8987746
18951529
28551776
19393298
29405337
28755467",Aquaporin 4 deletion exacerbates brain impairments in a mouse model of chronic sleep disruption.,"As a normal physiological process, sleep has recently been shown to facilitate clearance of macromolecular metabolic wastes from the brain via the glymphatic system. The aim of the present study was to investigate pathophysiological roles of astroglial aquaporin 4 (AQP4), a functional regulator of glymphatic clearance, in a mouse model of chronic sleep disruption (SD).
Adult AQP4 null mice and wild-type (WT) mice were given 7 days of SD using the improved rotating rod method, and then received behavioral, neuropathological, and neurochemical analyses.
Aquaporin 4 deletion resulted in an impairment of glymphatic transport and accumulation of β-amyloid and Tau proteins in the brain following SD. AQP4 null SD mice exhibited severe activation of microglia, neuroinflammation, and synaptic protein loss in the hippocampus, as well as decreased working memory, compared with WT-SD mice.
These results demonstrate that AQP4-mediated glymphatic clearance ameliorates brain impairments caused by abnormal accumulation of metabolic wastes following chronic SD, thus serving as a potential target for sleep-related disorders.","['aquaporin-4', 'behavioral test', 'glymphatic system', 'hippocampus', 'sleep disruption']",CNS neuroscience & therapeutics,2019-08-01,"[{'lastname': 'Zhang', 'firstname': 'Rui', 'initials': 'R', 'affiliation': 'Department of Neurology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.\nJiangsu Province, Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing, China.'}, {'lastname': 'Liu', 'firstname': 'Yun', 'initials': 'Y', 'affiliation': 'Department of Neurology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.\nJiangsu Province, Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing, China.'}, {'lastname': 'Chen', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Jiangsu Province, Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing, China.\nBrain Institute, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, China.'}, {'lastname': 'Li', 'firstname': 'Qian', 'initials': 'Q', 'affiliation': 'Jiangsu Province, Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing, China.\nBrain Institute, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, China.'}, {'lastname': 'Marshall', 'firstname': 'Charles', 'initials': 'C', 'affiliation': 'Department of Rehabilitation Sciences, University of Kentucky Center of Excellence in Rural Health, Hazard, KY, USA.'}, {'lastname': 'Wu', 'firstname': 'Ting', 'initials': 'T', 'affiliation': 'Department of Neurology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.\nJiangsu Province, Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing, China.'}, {'lastname': 'Hu', 'firstname': 'Gang', 'initials': 'G', 'affiliation': 'Jiangsu Province, Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing, China.'}, {'lastname': 'Xiao', 'firstname': 'Ming', 'initials': 'M', 'affiliation': 'Jiangsu Province, Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing, China.\nBrain Institute, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing, China.'}]",,"These results demonstrate that AQP4-mediated glymphatic clearance ameliorates brain impairments caused by abnormal accumulation of metabolic wastes following chronic SD, thus serving as a potential target for sleep-related disorders.","Aquaporin 4 deletion resulted in an impairment of glymphatic transport and accumulation of β-amyloid and Tau proteins in the brain following SD. AQP4 null SD mice exhibited severe activation of microglia, neuroinflammation, and synaptic protein loss in the hippocampus, as well as decreased working memory, compared with WT-SD mice.",© 2019 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.,10.1111/cns.13194,<Element 'PubmedArticle' at 0x7f05dc265310>
85,"31272932
28084326
27306957
22784036
20083042
22892055
28703214
26902171
23411394
27037234
16157905
27144467
17439980
24928124
15025718
28855404
25662776
24753999
23611351
25683866
23139856
21930184
29240561
18829698
29584904
9617910
17761438
23386806
9305341
29282337
16530430
19201945
21471273
30094168
26260856",Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration.,"Some models of therapy for neurodegenerative diseases envision starting treatment before symptoms develop. Demonstrating that such treatments are effective requires accurate knowledge of when symptoms would have started without treatment. Familial frontotemporal lobar degeneration offers a unique opportunity to develop predictors of symptom onset.
We created dementia risk scores in 268 familial frontotemporal lobar degeneration family members by entering covariate-adjusted standardized estimates of brain atrophy into a logistic regression to classify asymptomatic versus demented participants. The score's predictive value was tested in a separate group who were followed up longitudinally (stable vs. converted to dementia) using Cox proportional regressions with dementia risk score as the predictor.
Cross-validated logistic regression achieved good separation of asymptomatic versus demented (accuracy = 90%, SE = 0.06). Atrophy scores predicted conversion from asymptomatic or mildly/questionably symptomatic to dementia (HR = 1.51, 95% CI: [1.16,1.98]).
Individualized quantification of baseline brain atrophy is a promising predictor of progression in asymptomatic familial frontotemporal lobar degeneration mutation carriers.","['Frontotemporal dementia', 'Genetics', 'Magnetic resonance imaging (MRI)', 'TDP-43', 'Tau']",Alzheimer's & dementia : the journal of the Alzheimer's Association,2019-07-06,"[{'lastname': 'Staffaroni', 'firstname': 'Adam M', 'initials': 'AM', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Cobigo', 'firstname': 'Yann', 'initials': 'Y', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Goh', 'firstname': 'Sheng-Yang M', 'initials': 'SM', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Kornak', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco CA, USA Department of Neurology, Memory and Aging Center.'}, {'lastname': 'Bajorek', 'firstname': 'Lynn', 'initials': 'L', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Chiang', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Appleby', 'firstname': 'Brian', 'initials': 'B', 'affiliation': 'Department of Neurology, Case Western Reserve University, Cleveland, OH, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Bove', 'firstname': 'Jessica', 'initials': 'J', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Department of Epidemiology and Biostatistics.'}, {'lastname': 'Bordelon', 'firstname': 'Yvette', 'initials': 'Y', 'affiliation': 'Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA Case Western Reserve University, Cleveland, OH, USA.'}, {'lastname': 'Brannelly', 'firstname': 'Patrick', 'initials': 'P', 'affiliation': 'Tau Consortium, Rainwater Charitable Foundation, Fort Worth, TX, USA Department of Neurology.'}, {'lastname': 'Brushaber', 'firstname': 'Danielle', 'initials': 'D', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Caso', 'firstname': 'Christina', 'initials': 'C', 'affiliation': 'Department of Neurology, University of Washington, Seattle, WA, USA Perelman School of Medicine, Department of Neurology.'}, {'lastname': 'Coppola', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA Case Western Reserve University, Cleveland, OH, USA.\nDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA University of California, Los Angeles, Los Angeles, CA, USA.'}, {'lastname': 'Dever', 'firstname': 'Reilly', 'initials': 'R', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Dheel', 'firstname': 'Christina', 'initials': 'C', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA Department of Neurology.'}, {'lastname': 'Dickerson', 'firstname': 'Bradford C', 'initials': 'BC', 'affiliation': 'Department of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Tau Consortium, Rainwater Charitable Foundation, Fort Worth, TX, USA.'}, {'lastname': 'Dickinson', 'firstname': 'Susan', 'initials': 'S', 'affiliation': 'Association for Frontotemporal Degeneration, Radnor, PA, USA Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Dominguez', 'firstname': 'Sophia', 'initials': 'S', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Department of Epidemiology and Biostatistics.'}, {'lastname': 'Domoto-Reilly', 'firstname': 'Kimiko', 'initials': 'K', 'affiliation': 'Department of Neurology, University of Washington, Seattle, WA, USA Perelman School of Medicine, Department of Neurology.'}, {'lastname': 'Faber', 'firstname': 'Kelly', 'initials': 'K', 'affiliation': ""National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA.""}, {'lastname': 'Ferrall', 'firstname': 'Jessica', 'initials': 'J', 'affiliation': 'Department of Neurology, University of North Carolina, Chapel Hill, NC, USA University of Washington, Seattle, WA, USA.'}, {'lastname': 'Fields', 'firstname': 'Julie A', 'initials': 'JA', 'affiliation': 'Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Fishman', 'firstname': 'Ann', 'initials': 'A', 'affiliation': 'Department of Psychiatry, School of Medicine, Johns Hopkins University, Baltimore, MD, USA School of Medicine, Department of Psychiatry.'}, {'lastname': 'Fong', 'firstname': 'Jamie', 'initials': 'J', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Foroud', 'firstname': 'Tatiana', 'initials': 'T', 'affiliation': ""National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA.""}, {'lastname': 'Forsberg', 'firstname': 'Leah K', 'initials': 'LK', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA Department of Neurology.'}, {'lastname': 'Gavrilova', 'firstname': 'Ralitza', 'initials': 'R', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA Department of Neurology.'}, {'lastname': 'Gearhart', 'firstname': 'Debra', 'initials': 'D', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA Department of Neurology.'}, {'lastname': 'Ghazanfari', 'firstname': 'Behnaz', 'initials': 'B', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada University of California, Los Angeles, Los Angeles, CA, USA.\nDivision of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Ghoshal', 'firstname': 'Nupur', 'initials': 'N', 'affiliation': 'Departments of Neurology and Psychiatry, Washington University School of Medicine, Washington University, St. Louis, MO, USA Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Goldman', 'firstname': 'Jill', 'initials': 'J', 'affiliation': ""Department of Neurology, Columbia University, New York, NY, USA Department of Neurology.\nTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA Department of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.""}, {'lastname': 'Graff-Radford', 'firstname': 'Jonathan', 'initials': 'J', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA Department of Neurology.'}, {'lastname': 'Graff-Radford', 'firstname': 'Neill', 'initials': 'N', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA Association for Frontotemporal Degeneration, Radnor, PA, USA.'}, {'lastname': 'Grant', 'firstname': 'Ian', 'initials': 'I', 'affiliation': ""Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA.""}, {'lastname': 'Grossman', 'firstname': 'Murray', 'initials': 'M', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Department of Epidemiology and Biostatistics.'}, {'lastname': 'Haley', 'firstname': 'Dana', 'initials': 'D', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA Association for Frontotemporal Degeneration, Radnor, PA, USA.'}, {'lastname': 'Heuer', 'firstname': 'Hilary W', 'initials': 'HW', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Hsiung', 'firstname': 'Ging-Yuek', 'initials': 'GY', 'affiliation': 'Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada University of North Carolina, Chapel Hill, NC, USA.'}, {'lastname': 'Huey', 'firstname': 'Edward D', 'initials': 'ED', 'affiliation': ""Department of Neurology, Columbia University, New York, NY, USA Department of Neurology.\nTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA Department of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.""}, {'lastname': 'Irwin', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Department of Epidemiology and Biostatistics.'}, {'lastname': 'Jones', 'firstname': 'David T', 'initials': 'DT', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA Department of Neurology.'}, {'lastname': 'Jones', 'firstname': 'Lynne', 'initials': 'L', 'affiliation': 'Department of Radiology, Washington University School of Medicine, Washington University, St. Louis, MO, USA Johns Hopkins University, Baltimore, MD, USA.'}, {'lastname': 'Kantarci', 'firstname': 'Kejal', 'initials': 'K', 'affiliation': 'Department of Radiology, Mayo Clinic, Rochester, MN, USA Department of Radiology.'}, {'lastname': 'Karydas', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Kaufer', 'firstname': 'Daniel I', 'initials': 'DI', 'affiliation': 'Department of Neurology, University of North Carolina, Chapel Hill, NC, USA University of Washington, Seattle, WA, USA.'}, {'lastname': 'Kerwin', 'firstname': 'Diana R', 'initials': 'DR', 'affiliation': ""Department of Neurology and Neurotherapeutics, Center for Alzheimer's and Neurodegenerative Diseases, The University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, USA Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto.\nDepartment of Internal Medicine, The University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, USA Division of Neurology, Department of Medicine, University of Toronto.""}, {'lastname': 'Knopman', 'firstname': 'David S', 'initials': 'DS', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA Department of Neurology.'}, {'lastname': 'Kraft', 'firstname': 'Ruth', 'initials': 'R', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA Department of Neurology.'}, {'lastname': 'Kramer', 'firstname': 'Joel H', 'initials': 'JH', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Kremers', 'firstname': 'Walter K', 'initials': 'WK', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Kukull', 'firstname': 'Walter A', 'initials': 'WA', 'affiliation': 'National Alzheimer Coordinating Center (NACC), University of Washington, Seattle, WA, USA Washington University, St. Louis, MO, USA.'}, {'lastname': 'Litvan', 'firstname': 'Irene', 'initials': 'I', 'affiliation': 'Department of Neurosciences, Parkinson and Other Movement Disorders Center, University of California, San Diego, San Diego, CA, USA Department of Neurosciences, Parkinson and Other Movement Disorders Center.'}, {'lastname': 'Ljubenkov', 'firstname': 'Peter A', 'initials': 'PA', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Lucente', 'firstname': 'Diane', 'initials': 'D', 'affiliation': 'Department of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Tau Consortium, Rainwater Charitable Foundation, Fort Worth, TX, USA.'}, {'lastname': 'Lungu', 'firstname': 'Codrin', 'initials': 'C', 'affiliation': 'National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, USA Columbia University, New York, NY, USA.'}, {'lastname': 'Mackenzie', 'firstname': 'Ian R', 'initials': 'IR', 'affiliation': 'Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Maldonado', 'firstname': 'Miranda', 'initials': 'M', 'affiliation': 'Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA Case Western Reserve University, Cleveland, OH, USA.'}, {'lastname': 'Manoochehri', 'firstname': 'Masood', 'initials': 'M', 'affiliation': 'Department of Neurology, Columbia University, New York, NY, USA Department of Neurology.'}, {'lastname': 'McGinnis', 'firstname': 'Scott M', 'initials': 'SM', 'affiliation': 'Department of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Tau Consortium, Rainwater Charitable Foundation, Fort Worth, TX, USA.'}, {'lastname': 'McKinley', 'firstname': 'Emily', 'initials': 'E', 'affiliation': ""Department of Neurology, Alzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL, USA Columbia University, New York, NY, USA.""}, {'lastname': 'Mendez', 'firstname': 'Mario F', 'initials': 'MF', 'affiliation': 'Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA Case Western Reserve University, Cleveland, OH, USA.\nDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA University of California, Los Angeles, Los Angeles, CA, USA.'}, {'lastname': 'Miller', 'firstname': 'Bruce L', 'initials': 'BL', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Multani', 'firstname': 'Namita', 'initials': 'N', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada University of California, Los Angeles, Los Angeles, CA, USA.\nDivision of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Onyike', 'firstname': 'Chiadi', 'initials': 'C', 'affiliation': 'Department of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University, Baltimore, MD, USA Department of Geriatric Psychiatry and Neuropsychiatry.'}, {'lastname': 'Padmanabhan', 'firstname': 'Jaya', 'initials': 'J', 'affiliation': 'Department of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Tau Consortium, Rainwater Charitable Foundation, Fort Worth, TX, USA.'}, {'lastname': 'Pantelyat', 'firstname': 'Alex', 'initials': 'A', 'affiliation': 'Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'Pearlman', 'firstname': 'Rodney', 'initials': 'R', 'affiliation': 'Bluefield Project, San Francisco, CA, USA Bluefield Project, San Francisco, CA, USA.'}, {'lastname': 'Petrucelli', 'firstname': 'Len', 'initials': 'L', 'affiliation': 'Department of Neurosciences, Mayo Clinic, Jacksonville, FL, USA Northwestern University, Chicago, IL, USA.'}, {'lastname': 'Potter', 'firstname': 'Madeline', 'initials': 'M', 'affiliation': ""National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA.""}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Department of Neurosciences, Mayo Clinic, Jacksonville, FL, USA Northwestern University, Chicago, IL, USA.'}, {'lastname': 'Ramos', 'firstname': 'Eliana Marisa', 'initials': 'EM', 'affiliation': 'Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA University of California, Los Angeles, Los Angeles, CA, USA.'}, {'lastname': 'Rankin', 'firstname': 'Katherine P', 'initials': 'KP', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Rascovsky', 'firstname': 'Katya', 'initials': 'K', 'affiliation': 'Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Department of Epidemiology and Biostatistics.'}, {'lastname': 'Roberson', 'firstname': 'Erik D', 'initials': 'ED', 'affiliation': ""Department of Neurology, Alzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL, USA Columbia University, New York, NY, USA.""}, {'lastname': 'Rogalski', 'firstname': 'Emily', 'initials': 'E', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA Feinberg School of Medicine, Department of Psychiatry and Behavioral Sciences.'}, {'lastname': 'Sengdy', 'firstname': 'Pheth', 'initials': 'P', 'affiliation': 'Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada University of North Carolina, Chapel Hill, NC, USA.'}, {'lastname': 'Shaw', 'firstname': 'Leslie M', 'initials': 'LM', 'affiliation': 'Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Syrjanen', 'firstname': 'Jeremy', 'initials': 'J', 'affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Tartaglia', 'firstname': 'M Carmela', 'initials': 'MC', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada University of California, Los Angeles, Los Angeles, CA, USA.\nDivision of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Tatton', 'firstname': 'Nadine', 'initials': 'N', 'affiliation': 'Association for Frontotemporal Degeneration, Radnor, PA, USA Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Taylor', 'firstname': 'Joanne', 'initials': 'J', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Toga', 'firstname': 'Arthur', 'initials': 'A', 'affiliation': 'Departments of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences, Radiology and Engineering, Laboratory of Neuroimaging (LONI), USC, Los Angeles, CA, USA Laboratory of Neuroimaging (LONI), Departments of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences, Radiology and Engineering.'}, {'lastname': 'Trojanowski', 'firstname': 'John Q', 'initials': 'JQ', 'affiliation': 'Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Weintraub', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': ""Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA.""}, {'lastname': 'Wang', 'firstname': 'Ping', 'initials': 'P', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Wong', 'firstname': 'Bonnie', 'initials': 'B', 'affiliation': 'Department of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Tau Consortium, Rainwater Charitable Foundation, Fort Worth, TX, USA.'}, {'lastname': 'Wszolek', 'firstname': 'Zbigniew', 'initials': 'Z', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA Association for Frontotemporal Degeneration, Radnor, PA, USA.'}, {'lastname': 'Boxer', 'firstname': 'Adam L', 'initials': 'AL', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': 'Boeve', 'firstname': 'Brad F', 'initials': 'BF', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA Department of Neurology.'}, {'lastname': 'Rosen', 'firstname': 'Howard J', 'initials': 'HJ', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco CA, USA University of California, San Francisco, San Francisco CA, USA.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,"Cross-validated logistic regression achieved good separation of asymptomatic versus demented (accuracy = 90%, SE = 0.06). Atrophy scores predicted conversion from asymptomatic or mildly/questionably symptomatic to dementia (HR = 1.51, 95% CI: [1.16,1.98]).","© 2019 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.",10.1016/j.jalz.2019.04.007,<Element 'PubmedArticle' at 0x7f05dc6379f0>
86,31256135,Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease.,"Alzheimer's disease (AD) is a multifactorial condition in which, along with amyloid-β (Aβ) and tau-related pathology, the synergistic activity of co-morbidity factors promote the onset and progression of the disease. Epidemiological evidence indicates that glucose intolerance, deficits in insulin secretion, or type-2 diabetes mellitus (T2DM) participate in increasing cognitive impairment or dementia risk. Insulin plays a pivotal role in the process as the hormone critically regulates brain functioning. GLP-1, the glucagon-like peptide 1, facilitates insulin signaling, regulates glucose homeostasis, and modulates synaptic plasticity. Exenatide is a synthetic GLP-1 analog employed in T2DM. However, exenatide has also been shown to affect the signaling of the brain-derived neurotrophic factor (BDNF), synaptic plasticity, and cognitive performances in animal models. In this study, we tested whether exenatide exerts neuroprotection in a preclinical AD model set to mimic the clinical complexity of the human disease. We investigated the effects of exenatide treatment in 3xTg-AD mice challenged with a high-fat diet (HFD). Endpoints of the study were variations in systemic metabolism, insulin and neurotrophic signaling, neuroinflammation, Aβ and tau pathology, and cognitive performances. Results of the study indicate that exenatide reverts the adverse changes of BDNF signaling and the neuroinflammation status of 3xTg-AD mice undergoing HFD without affecting systemic metabolism or promoting changes in cognitive performances.","['Aging', 'BDNF', 'T2DM', 'dementia', 'diabetes', 'exendin-4', 'insulin', 'insulin resistance', 'neurotrophic factors']",Journal of Alzheimer's disease : JAD,2019-07-01,"[{'lastname': 'Bomba', 'firstname': 'Manuela', 'initials': 'M', 'affiliation': ""Center of Excellence on Aging and Translational Medicine - CeSI-MeT, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartment of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Italy.""}, {'lastname': 'Granzotto', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': ""Center of Excellence on Aging and Translational Medicine - CeSI-MeT, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartment of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Italy.""}, {'lastname': 'Castelli', 'firstname': 'Vanessa', 'initials': 'V', 'affiliation': ""Department of Life, Health and Environmental Sciences, University of L'Aquila, Italy.""}, {'lastname': 'Onofrj', 'firstname': 'Marco', 'initials': 'M', 'affiliation': ""Center of Excellence on Aging and Translational Medicine - CeSI-MeT, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartment of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Italy.""}, {'lastname': 'Lattanzio', 'firstname': 'Rossano', 'initials': 'R', 'affiliation': ""Center of Excellence on Aging and Translational Medicine - CeSI-MeT, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartment of Medical, Oral, and Biotechnological Sciences, University G. d'Annunzio of Chieti-Pescara, Italy.""}, {'lastname': 'Cimini', 'firstname': 'Annamaria', 'initials': 'A', 'affiliation': ""Department of Life, Health and Environmental Sciences, University of L'Aquila, Italy.\nSbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, Temple University, Philadelphia, PA, USA.\nNational Institute for Nuclear Physics (INFN), Gran Sasso National Laboratory (LNGS), Assergi, Italy.""}, {'lastname': 'Sensi', 'firstname': 'Stefano L', 'initials': 'SL', 'affiliation': ""Center of Excellence on Aging and Translational Medicine - CeSI-MeT, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartment of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartments of Neurology and Pharmacology, Institute for Mind Impairments and Neurological Disorders - iMIND, University of California - Irvine, Irvine, CA, USA.""}]",,,,,10.3233/JAD-190237,<Element 'PubmedArticle' at 0x7f05dc23a310>
87,31182509,Education modulates brain maintenance in presymptomatic frontotemporal dementia.,"Cognitively engaging lifestyles have been associated with reduced risk of conversion to dementia. Multiple mechanisms have been advocated, including increased brain volumes (ie, brain reserve) and reduced disease progression (ie, brain maintenance). In cross-sectional studies of presymptomatic frontotemporal dementia (FTD), higher education has been related to increased grey matter volume. Here, we examine the effect of education on grey matter loss over time.
Two-hundred twenty-nine subjects at-risk of carrying a pathogenic mutation leading to FTD underwent longitudinal cognitive assessment and T1-weighted MRI at baseline and at 1 year follow-up. The first principal component score of the graph-Laplacian Principal Component Analysis on 112 grey matter region-of-interest volumes was used to summarise the grey matter volume (GMV). The effects of education on cognitive performances and GMV at baseline and on the change between 1 year follow-up and baseline (slope) were tested by Structural Equation Modelling.
Highly educated at-risk subjects had better cognition and higher grey matter volume at baseline; moreover, higher educational attainment was associated with slower loss of grey matter over time in mutation carriers.
This longitudinal study demonstrates that even in presence of ongoing pathological processes, education may facilitate both brain reserve and brain maintenance in the presymptomatic phase of genetic FTD.","['brain maintenance', 'brain reserve', 'frontotemporal dementia (FTD)', 'graph theory', 'magnetic resonance imaging (MRI)']","Journal of neurology, neurosurgery, and psychiatry",2019-06-12,"[{'lastname': 'Gazzina', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': 'Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'lastname': 'Grassi', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Department of Brain and Behavioral Science, Medical and Genomic Statistics Unit, University of Pavia, Pavia, Italy.'}, {'lastname': 'Premi', 'firstname': 'Enrico', 'initials': 'E', 'affiliation': 'Stroke Unit, Neurology Unit, Spedali Civili Hospital, Brescia, Italy.'}, {'lastname': 'Cosseddu', 'firstname': 'Maura', 'initials': 'M', 'affiliation': 'Neurology Unit, Spedali Civili Hospital, Brescia, Italy.'}, {'lastname': 'Alberici', 'firstname': 'Antonella', 'initials': 'A', 'affiliation': 'Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'lastname': 'Archetti', 'firstname': 'Silvana', 'initials': 'S', 'affiliation': 'Biotechnology Laboratory, Department of Diagnostics, Spedali Civili Hospital, Brescia, Italy.'}, {'lastname': 'Gasparotti', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': 'Neuroradiology Unit, University of Brescia, Brescia, Italy.'}, {'lastname': 'Van Swieten', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': ""Centro Dino Ferrari, University of Milan, Milan, Italy.\nNeurodegenerative Diseases Unit, Fondazione IRCSS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.""}, {'lastname': 'Sanchez-Valle', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': ""Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain.""}, {'lastname': 'Laforce', 'firstname': 'Robert Jr', 'initials': 'RJ', 'affiliation': 'Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec, Quebec, Canada.'}, {'lastname': 'Moreno', 'firstname': 'Fermin', 'initials': 'F', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain.'}, {'lastname': 'Synofzik', 'firstname': 'Matthis', 'initials': 'M', 'affiliation': 'Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research & Center of Neurology, University of Tübingen, Tübingen, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.'}, {'lastname': 'Graff', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogenetics, Stockholm, Sweden.'}, {'lastname': 'Masellis', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, Ontario, Canada.'}, {'lastname': 'Tartaglia', 'firstname': 'Maria Carmela', 'initials': 'MC', 'affiliation': 'Toronto Western Hospital, Tanz Centre for Research in Neurodegenerative Disease, Toronto, Ontario, Canada.'}, {'lastname': 'Rowe', 'firstname': 'James B', 'initials': 'JB', 'affiliation': 'Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.'}, {'lastname': 'Vandenberghe', 'firstname': 'Rik', 'initials': 'R', 'affiliation': 'Department of Neurosciences, Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.'}, {'lastname': 'Finger', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.'}, {'lastname': 'Tagliavini', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy.'}, {'lastname': 'de Mendonça', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Faculty of Medicine, University of Lisbon, Lisbon, Portugal.'}, {'lastname': 'Santana', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': 'Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.'}, {'lastname': 'Butler', 'firstname': 'Christopher R', 'initials': 'CR', 'affiliation': 'Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom.'}, {'lastname': 'Ducharme', 'firstname': 'Simon', 'initials': 'S', 'affiliation': 'Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.\nMcConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.'}, {'lastname': 'Gerhard', 'firstname': 'Alex', 'initials': 'A', 'affiliation': 'Institute of Brain, Behaviour and Mental Health, The University of Manchester, Withington, Manchester, United Kingdom.'}, {'lastname': 'Danek', 'firstname': 'Adrian', 'initials': 'A', 'affiliation': 'Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.'}, {'lastname': 'Levin', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.'}, {'lastname': 'Otto', 'firstname': 'Markus', 'initials': 'M', 'affiliation': 'Department of Neurology, University Hospital Ulm, Ulm, Germany.'}, {'lastname': 'Frisoni', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.\nMemory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland.'}, {'lastname': 'Sorbi', 'firstname': 'Sandro', 'initials': 'S', 'affiliation': 'Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.\nIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) ""Don Gnocchi"", Florence, Italy.'}, {'lastname': 'Padovani', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, UCL Institute of Neurology, London, United Kingdom.'}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy bborroni@inwind.it.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,"Highly educated at-risk subjects had better cognition and higher grey matter volume at baseline; moreover, higher educational attainment was associated with slower loss of grey matter over time in mutation carriers.",© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.,10.1136/jnnp-2019-320439,<Element 'PubmedArticle' at 0x7f05dc231270>
88,"31160730
23906002
22703631
25346723
29377010
22329651
29562518
12810767
21715616
26091850
19416677
20413847
23874297
29467605
1789684
24853936
26786552
28696204
19188609
17942819
20709114
26136647
29180222
26462756
22476197
24332562
27626493
21610428
26833850
22776913
11377828
17720802
18590543
23847533
24384568
29973864
21710619
23617241
26912237
27383587
17692997
27432942
24101698
20176121
29118388
26774027
26973101
28522250
18782350
21047142
30120733
29560412",Chronic synaptic insulin resistance after traumatic brain injury abolishes insulin protection from amyloid beta and tau oligomer-induced synaptic dysfunction.,"Traumatic brain injury (TBI) is a risk factor for Alzheimer's disease (AD), although the mechanisms contributing to this increased risk are unknown. Insulin resistance is an additional risk factor for AD whereby decreased insulin signaling increases synaptic sensitivity to amyloid beta (Aβ) and tau. Considering this, we used rats that underwent a lateral fluid percussion injury at acute and chronic time-points to investigate whether decreased insulin responsiveness in TBI animals is playing a role in synaptic vulnerability to AD pathology. We detected acute and chronic decreases in insulin responsiveness in isolated hippocampal synaptosomes after TBI. In addition to assessing both Aβ and tau binding on synaptosomes, we performed electrophysiology to assess the dysfunctional impact of Aβ and tau oligomers as well as the protective effect of insulin. While we saw no difference in binding or degree of LTP inhibition by either Aβ or tau oligomers between sham and TBI animals, we found that insulin treatment was able to block oligomer-induced LTP inhibition in sham but not in TBI animals. Since insulin treatment has been discussed as a therapy for AD, this gives valuable insight into therapeutic implications of treating AD patients based on one's history of associated risk factors.",[],Scientific reports,2019-06-05,"[{'lastname': 'Franklin', 'firstname': 'Whitney', 'initials': 'W', 'affiliation': 'Mitchell Center for Neurodegenerative Diseases, Department of Neurology, University of Texas Medical Branch, Galveston, Texas, 77555, USA.\nDepartment of Neuroscience, Cell Biology & Anatomy, University of Texas Medical Branch, Galveston, Texas, 77555, USA.'}, {'lastname': 'Krishnan', 'firstname': 'Balaji', 'initials': 'B', 'affiliation': 'Mitchell Center for Neurodegenerative Diseases, Department of Neurology, University of Texas Medical Branch, Galveston, Texas, 77555, USA.'}, {'lastname': 'Taglialatela', 'firstname': 'Giulio', 'initials': 'G', 'affiliation': 'Mitchell Center for Neurodegenerative Diseases, Department of Neurology, University of Texas Medical Branch, Galveston, Texas, 77555, USA. gtaglial@utmb.edu.'}]",,,,,"10.1038/s41598-019-44635-z
10.2174/15672050113109990142
10.1038/nrneurol.2017.185
10.3233/JAD-179911
10.1136/jnnp.74.7.857
10.1523/JNEUROSCI.0858-11.2011
10.1016/j.expneurol.2015.06.015
10.1016/j.expneurol.2009.01.011
10.3233/JAD-2010-100504
10.3389/fnins.2018.00037
10.1002/ana.410300410
10.1016/j.neuron.2014.05.004
10.1073/pnas.0809158106
10.1212/01.WNL.0000265401.62434.36
10.1016/j.bbr.2010.08.002
10.3389/fnins.2015.00204
10.1016/j.neuropharm.2017.11.037
10.1038/nrn4019
10.1172/JCI59903
10.1016/j.mehy.2013.11.028
10.1097/TA.0b013e3182146d66
10.1111/ejn.13194
10.1001/archneurol.2011.3747
10.1016/S0303-7207(01)00455-5
10.1096/fj.06-7703com
10.1186/1742-2094-5-28
10.3389/fnagi.2013.00029
10.3389/fnins.2018.00417
10.1002/ana.22455
10.1186/1471-2164-14-282
10.1186/s12864-016-2412-0
10.1523/JNEUROSCI.3212-15.2016
10.1016/j.neurobiolaging.2007.06.014
10.1084/jem.20160493
10.2337/dc13-1672
10.1016/j.nlm.2010.02.002
10.1016/j.jneumeth.2016.01.006
10.1016/j.neurobiolaging.2015.12.021
10.1016/j.expneurol.2017.05.005
10.1111/j.1474-9726.2008.00434.x
10.1021/bi1016233
10.1007/s12035-018-1248-9
10.1016/j.trci.2018.01.002",<Element 'PubmedArticle' at 0x7f05db83b810>
89,"31127154
27540165
21345167
25689443
25792098
21035623
28599675
26180139
28592456
27725108
30291183
30033062
23150934
23150908
26941262
26754172
26754641
27974666
29053785
21691802
16862116
16862115
18768919
19158106
18565828
24680777
25766679
20071342
17576580
21562886
24820015
29653606
29849029
26682689
26270969
26783546
29126445
29558979
23847144
27239539
24878508
28450268
28189343
29621548
26365049
28527215
19023204
29889064
28592453
15324367
28453473
29665124
21514249
21514250
24990881
28463681",Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.,"The role of innate immunity in dementia with Lewy bodies (DLB) has been little studied. We investigated the levels in cerebrospinal fluid (CSF) of glial proteins YKL-40, soluble TREM2 (sTREM2) and progranulin in DLB and their relationship with Alzheimer's disease (AD) biomarkers. We included patients with DLB (n = 37), prodromal DLB (prodDLB, n = 23), AD dementia (n = 50), prodromal AD (prodAD, n = 53), and cognitively normal subjects (CN, n = 44). We measured levels of YKL-40, sTREM2, progranulin, Aβ",[],Scientific reports,2019-05-28,"[{'lastname': 'Morenas-Rodríguez', 'firstname': 'Estrella', 'initials': 'E', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Alcolea', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Suárez-Calvet', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.'}, {'lastname': 'Muñoz-Llahuna', 'firstname': 'Laia', 'initials': 'L', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Vilaplana', 'firstname': 'Eduard', 'initials': 'E', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Sala', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Subirana', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Querol-Vilaseca', 'firstname': 'Marta', 'initials': 'M', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Carmona-Iragui', 'firstname': 'María', 'initials': 'M', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Illán-Gala', 'firstname': 'Ignacio', 'initials': 'I', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Ribosa-Nogué', 'firstname': 'Roser', 'initials': 'R', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Blesa', 'firstname': 'Rafael', 'initials': 'R', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Haass', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.\nGerman Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.\nMunich Cluster for Systems Neurology (SyNergy), Munich, Germany.'}, {'lastname': 'Fortea', 'firstname': 'Juan', 'initials': 'J', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain.""}, {'lastname': 'Lleó', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': ""Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. alleo@santpau.es.\nInstitut d'Investigacions Biomediques Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain. alleo@santpau.es.\nCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Instituto de Salud Carlos III, Barcelona, Spain. alleo@santpau.es.""}]",,,,,"10.1038/s41598-019-44173-8
10.1126/science.aag2590
10.2174/156720511795256080
10.1038/ni.3102
10.1016/S1474-4422(15)70016-5
10.1016/j.biopsych.2010.08.025
10.1186/s12974-017-0893-7
10.1212/WNL.0000000000001859
10.1212/WNL.0000000000004088
10.1016/j.jneuroim.2016.08.004
10.1212/WNL.0000000000006383
10.1016/S1474-4422(18)30232-1
10.1056/NEJMoa1211851
10.1056/NEJMoa1211103
10.15252/emmm.201506123
10.1007/s00401-016-1533-5
10.1126/scitranslmed.aag1767
10.1093/brain/awx198
10.1007/s12031-011-9569-4
10.1038/nature05016
10.1038/nature05017
10.1212/01.wnl.0000325058.10218.fc
10.1093/brain/awn352
10.1212/01.wnl.0000319688.89790.7a
10.1016/j.gene.2014.03.041
10.1016/j.nbd.2015.03.003
10.1074/jbc.M109.081125
10.1007/s00401-007-0244-3
10.1007/s00401-011-0833-z
10.3233/JAD-140240
10.1016/j.jalz.2018.02.018
10.3233/JAD-150746
10.1371/journal.pone.0135458
10.1002/acn3.266
10.1002/mds.25589
10.1016/j.nbd.2014.05.020
10.1016/j.mcn.2017.04.009
10.1016/j.neurobiolaging.2017.01.010
10.1016/j.bbrc.2018.03.226
10.1007/s12035-015-9416-7
10.3233/JAD-170073
10.1159/000173710
10.3233/JAD-180167
10.1212/WNL.0000000000004058
10.1111/j.1365-2796.2004.01380.x
10.3233/JAD-161089
10.1002/ana.25239
10.1016/j.jalz.2011.03.008
10.1016/j.jalz.2011.03.005
10.1126/scitranslmed.3009093
10.1016/j.jalz.2017.03.007",<Element 'PubmedArticle' at 0x7f05db9963b0>
90,"31126115
25712639
1759558
12130773
21170538
9641683
17478722
1549228
25728442
27229721
26136647
21277873
24574966
22560217
12474021
23250356
16627931
19712582
24931035
15655721
25071725
21312223
20128800
20337586
24529520
23011726
23973293
27699599
26746341
22245388
29195509
17270732
22843705
26898123
25580570
25986579
25740520",The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.,"Vascular risk factors, such as type 2 diabetes mellitus (T2DM), are associated with the increased risk of Alzheimer's disease. One of the common T2DM medications, dipeptidyl peptidase (DPP)-4 inhibitors, have a minimum risk for hypoglycemia and have recently been suggested to ameliorate β-amyloid pathology. However, conflicting results have been reported regarding the effects of DPP-4 inhibition on cognitive function and tau pathology. Thus, we investigated whether inhibiting DPP-4 affects tau pathology and cognition in a mouse model of tauopathy with hyperglycemia. Male mice overexpressing the P301S mutant human microtubule-associated protein tau gene (PS19) were fed either a low or high-fat diet. PS19 mice were then administered either linagliptin, a DPP-4 inhibitor, or vehicle, from 6 weeks to 8 months of age. Linagliptin-treated mice exhibited higher levels of glucagon-like peptide-1 and decreased fasting blood glucose, compared with the vehicle-treated mice at 8 months. Linagliptin treatment significantly restored spatial reference memory and increased cerebral blood flow without affecting phosphorylation levels of tau or endothelial nitric oxide synthase (eNOS) in the brain. Linagliptin may ameliorate HFD-induced cognitive worsening in tauopathy, at least partially, by increasing cerebral perfusion via the eNOS-independent pathway.","['cerebral blood flow', 'dipeptidyl peptidase-4 inhibitors', 'high-fat diet', 'spatial reference memory', 'tau']",International journal of molecular sciences,2019-05-28,"[{'lastname': 'Nakaoku', 'firstname': 'Yuriko', 'initials': 'Y', 'affiliation': 'Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan. yurikon@kuhp.kyoto-u.ac.jp.\nDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita 565-8565, Japan. yurikon@kuhp.kyoto-u.ac.jp.'}, {'lastname': 'Saito', 'firstname': 'Satoshi', 'initials': 'S', 'affiliation': 'Department of Neurology, National Cerebral and Cardiovascular Center, Suita 565-8565, Japan. saitosa@ncvc.go.jp.\nResearch Fellow of Japan Society for the Promotion of Science, Tokyo 102-0083, Japan. saitosa@ncvc.go.jp.'}, {'lastname': 'Yamamoto', 'firstname': 'Yumi', 'initials': 'Y', 'affiliation': 'Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Suita 565-8565, Japan. yumi.yamamoto@ncvc.go.jp.'}, {'lastname': 'Maki', 'firstname': 'Takakuni', 'initials': 'T', 'affiliation': 'Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan. harutoma@kuhp.kyoto-u.ac.jp.'}, {'lastname': 'Takahashi', 'firstname': 'Ryosuke', 'initials': 'R', 'affiliation': 'Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan. ryosuket@kuhp.kyoto-u.ac.jp.'}, {'lastname': 'Ihara', 'firstname': 'Masafumi', 'initials': 'M', 'affiliation': 'Department of Neurology, National Cerebral and Cardiovascular Center, Suita 565-8565, Japan. ihara@ncvc.go.jp.'}]",,,,,"10.3390/ijms20102539
10.1016/j.pharep.2014.09.004
10.1007/BF00308809
10.1126/science.1072994
10.1007/s00401-010-0789-4
10.1038/31508
10.1126/science.1141736
10.1212/WNL.42.3.631
10.1016/S1474-4422(14)70249-2
10.2174/1381612822666160527160236
10.3389/fnins.2015.00204
10.1016/j.neuropharm.2011.01.033
10.3389/fncel.2014.00022
10.1016/j.cmet.2012.01.013
10.2337/db12-0866
10.3233/JAD-2006-9102
10.5483/BMBRep.2009.42.8.475
10.2337/db14-0287
10.1055/s-2004-826178
10.3389/fendo.2014.00110
10.1002/jnr.22565
10.1111/j.1476-5381.2009.00486.x
10.2174/157488910791213130
10.1016/j.jalz.2013.12.007
10.1007/s12017-012-8199-5
10.1016/j.neuropharm.2013.08.005
10.1007/s12035-016-0125-7
10.1016/j.brainres.2015.12.052
10.1016/j.nbd.2011.12.043
10.1186/s12933-017-0639-y
10.1016/j.neuron.2007.01.010
10.1093/cvr/cvs246
10.1016/j.lfs.2016.02.067
10.1111/dom.12432
10.1186/s12933-015-0218-z
10.1523/JNEUROSCI.3970-14.2015",<Element 'PubmedArticle' at 0x7f05db9648b0>
91,"31081340
23348013
11031087
8114936
27713036
23627751
26894890
26595641
24915640
26462756
16244482
12226541
19251056
24819789
15665417
19128208
24418058
29018822
29562518
11170733
10527802
27037234
19273747
22936011
22337830
25088942
27988872
19777393
24380887
27802237
15750214
15196466
10812969
22500228
28716886
10670781
19744960
20176597
23519767
17448147
23299523
18546284
7852995
8215046
23999914
11520916
18656473
15695781
15728305
27701410
18612850
16033782
17034818
25323961
21863317
16179614
9546296
17442827
24361004
19018247
11578774
10672236
26888921
19828530
18780965
28374141
28767196
24046442
23400497
8898237
21207049
14602830
21810890
22368970
16340083
23142262
27676333
10383122
7666203
29867188
23848536
27617773
25354497
15750215
24640977
22476197
21881402
22970712
19276553
17985145
23920254
21605064
15758069
25708826
26869919
27054030",Altered Brain Expression of Insulin and Insulin-Like Growth Factors in Frontotemporal Lobar Degeneration: Another Degenerative Disease Linked to Dysregulation of Insulin Metabolic Pathways.,"Frontotemporal lobar degeneration (FTLD) is the third most common dementing neurodegenerative disease with nearly 80% having no known etiology.
Growing evidence that neurodegeneration can be linked to dysregulated metabolism prompted us to measure a panel of trophic factors, receptors, and molecules that modulate brain metabolic function in FTLD.
Postmortem frontal (Brodmann's area [BA]8/9 and BA24) and temporal (BA38) lobe homogenates were used to measure immunoreactivity to Tau, phosphorylated tau (pTau), ubiquitin, 4-hydroxynonenal (HNE), transforming growth factor-beta 1 (TGF-β1) and its receptor (TGF-β1R), brain-derived neurotrophic factor (BDNF), nerve growth factor, neurotrophin-3, neurotrophin-4, tropomyosin receptor kinase, and insulin and insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-2 (IGF-2) and their receptors by direct-binding enzyme-linked immunosorbent assay.
FTLD brains had significantly elevated pTau, ubiquitin, TGF-β1, and HNE immunoreactivity relative to control. In addition, BDNF and neurotrophin-4 were respectively reduced in BA8/9 and BA38, while neurotrophin-3 and nerve growth factor were upregulated in BA38, and tropomyosin receptor kinase was elevated in BA24. Lastly, insulin and insulin receptor expressions were elevated in the frontal lobe, IGF-1 was increased in BA24, IGF-1R was upregulated in all three brain regions, and IGF-2 receptor was reduced in BA24 and BA38.
Aberrantly increased levels of pTau, ubiquitin, HNE, and TGF-β1, marking neurodegeneration, oxidative stress, and neuroinflammation, overlap with altered expression of insulin/IGF signaling ligand and receptors in frontal and temporal lobe regions targeted by FTLD. Dysregulation of insulin-IGF signaling networks could account for brain hypometabolism and several characteristic neuropathologic features that characterize FTLD but overlap with Alzheimer's disease, Parkinson's disease, and Dementia with Lewy Body Disease.","['neurodegenerative diseases', 'neurodevelopmental disorders', 'neuropathology']",ASN neuro,2019-05-14,"[{'lastname': 'Liou', 'firstname': 'Connie J', 'initials': 'CJ', 'affiliation': '1 Warren Alpert Medical School of Brown University, Providence, RI, USA.'}, {'lastname': 'Tong', 'firstname': 'Ming', 'initials': 'M', 'affiliation': '1 Warren Alpert Medical School of Brown University, Providence, RI, USA.\n2 Division of Neuropathology, Departments of Pathology, Medicine, Neurology, and Neurosurgery, Rhode Island Hospital, Providence, RI, USA.\n3 Department of Pathology and Laboratory Medicine, the Providence VA Medical Center, Providence, RI, USA.'}, {'lastname': 'Vonsattel', 'firstname': 'Jean P', 'initials': 'JP', 'affiliation': '4 New York Brain Bank, Taub Institute, Columbia University, New York, NY, USA.'}, {'lastname': 'de la Monte', 'firstname': 'Suzanne M', 'initials': 'SM', 'affiliation': '1 Warren Alpert Medical School of Brown University, Providence, RI, USA.\n2 Division of Neuropathology, Departments of Pathology, Medicine, Neurology, and Neurosurgery, Rhode Island Hospital, Providence, RI, USA.\n3 Department of Pathology and Laboratory Medicine, the Providence VA Medical Center, Providence, RI, USA.'}]",,,"FTLD brains had significantly elevated pTau, ubiquitin, TGF-β1, and HNE immunoreactivity relative to control. In addition, BDNF and neurotrophin-4 were respectively reduced in BA8/9 and BA38, while neurotrophin-3 and nerve growth factor were upregulated in BA38, and tropomyosin receptor kinase was elevated in BA24. Lastly, insulin and insulin receptor expressions were elevated in the frontal lobe, IGF-1 was increased in BA24, IGF-1R was upregulated in all three brain regions, and IGF-2 receptor was reduced in BA24 and BA38.",,10.1177/1759091419839515,<Element 'PubmedArticle' at 0x7f05db9c5270>
92,"31078468
19553647
24304873
18334672
21370418
15576413
28035022
28890157
12091180
1991946
25693770
20377575
23953334
29167278
29146535
24002505
27102402
25605853
26265699
25814529
23633361
29530893
16921038
26858334
24190124
27269941
23960182
23024097",The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study.,"Treatment for childhood acute lymphoblastic leukemia has evolved over the past five decades, with moderation of traditional chemotherapy and radiotherapy and the introduction of targeted immune-based and cellular-based therapies. The affect of these changes on late health outcomes has not been assessed. Using data from the The St Jude Lifetime (SJLIFE) Cohort, we aimed to characterise the magnitude of morbidity and patterns of late health outcomes among survivors of childhood acute lymphoblastic leukaemia treated over time.
The St Jude Lifetime (SJLIFE) Cohort is a retrospective cohort study with prospective follow-up and ongoing data accrual designed to facilitate longitudinal, clinically-based assessment of health outcomes among survivors of paediatric malignancies. 980 survivors included in this analysis were diagnosed with paediatric acute lymphoblastic leukaemia at St Jude Children's Research Hospital (SJCRH) between Aug 28, 1963, and July 19, 2003, were aged 18 years old and older at enrolment, had a minimum follow-up of 10 years after diagnosis, and completed an initial on-campus SJLIFE assessment as of data cutoff (June 30, 2015). 272 community control participants, matched to survivors on 5-year age blocks in each sex, were recruited for comparison. Cumulative chemotherapy and radiation dose exposures and major medical events during and after therapy were retrieved from the medical records of the survivors. History or physical examination, laboratory analysis, physical fitness, and neurocognitive testing were done. Health conditions were graded according to a modified version of the Common Terminology Criteria for Adverse Events. Neurocognitive domains of attention (Trial Making Test Part A and Conner's Continuous Performance Test-II) and executive function (Trail Making Test Part B, Controlled Oral Word Association Test, and Wechsler Adult Intelligence Scale-III Digit Span Test Backward) were measured and age-adjusted Z scores were calculated. Mean cumulative count was used to calculate the age-standardised cumulative burden of health conditions over time. This cohort study is registered at ClinicalTrials.gov, number NCT00760656.
980 survivors of acute lymphoblastic leukaemia (50% women, median age at diagnosis 5 years [IQR 3·1-9·1 years], and median time from diagnosis of 30·0 years [22·7-36·3]) had a median age of 35·8 years (29·4-42·9) at assessment compared with 35·1 years (28·7-42·6) for 272 controls. Survivors had significantly more growth hormone deficiency, hypogonadism, and neuropathy than controls. By age 30 years, survivors of acute lymphoblastic leukaemia had, on average, 5·4 (95% CI 5·1-5·8) grade 1-4 health conditions, including 3·2 (2·9-3·4) grade 2-4 health conditions, compared with 2·0 (CI 1·7-2·2) grade 1-4 and 1·2 (1·03-1·4) grade 2-4 health conditions among controls. The cumulative burden of grade 2-4 health conditions involved multiple organ systems for survivors treated on protocols between 1962-91, but after elimination of cranial radiotherapy for children with acute lymphoblastic leukaemia, conditions now predominately include musculoskeletal and endocrine disorders for survivors on protocols between 1991-2007.
Although changes in paediatric acute lymphoblastic leukaemia treatment protocols have improved overall survival, the burden of late morbidity remains high for these patients. We show that the pattern of late toxic effects has markedly changed over time, with survivors having a reduction in health conditions that are immediately life-threatening, however, maintaining health status and quality of life for survivors of paediatric acute lymphoblastic leukaemia requires continued medical surveillance, counselling, and lifestyle modifications.
US National Cancer Institute and the American Lebanese Syrian Associated Charities.",[],The Lancet. Haematology,2019-05-13,"[{'lastname': 'Mulrooney', 'firstname': 'Daniel A', 'initials': 'DA', 'affiliation': ""Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Departments of Pediatrics and Medicine, University of Tennessee Health Science Center, College of Medicine, Memphis, TN, USA. Electronic address: daniel.mulrooney@stjude.org.""}, {'lastname': 'Hyun', 'firstname': 'Geehong', 'initials': 'G', 'affiliation': ""Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Ness', 'firstname': 'Kirsten K', 'initials': 'KK', 'affiliation': ""Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Bhakta', 'firstname': 'Nickhill', 'initials': 'N', 'affiliation': ""Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Pui', 'firstname': 'Ching-Hon', 'initials': 'CH', 'affiliation': ""Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Ehrhardt', 'firstname': 'Matthew J', 'initials': 'MJ', 'affiliation': ""Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Krull', 'firstname': 'Kevin R', 'initials': 'KR', 'affiliation': ""Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Psychology, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Crom', 'firstname': 'Deborah B', 'initials': 'DB', 'affiliation': ""Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Chemaitilly', 'firstname': 'Wassim', 'initials': 'W', 'affiliation': ""Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Srivastava', 'firstname': 'Deokumar K', 'initials': 'DK', 'affiliation': ""Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Relling', 'firstname': 'Mary V', 'initials': 'MV', 'affiliation': ""Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Jeha', 'firstname': 'Sima', 'initials': 'S', 'affiliation': ""Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Green', 'firstname': 'Daniel M', 'initials': 'DM', 'affiliation': ""Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Yasui', 'firstname': 'Yutaka', 'initials': 'Y', 'affiliation': ""Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Robison', 'firstname': 'Leslie L', 'initials': 'LL', 'affiliation': ""Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'lastname': 'Hudson', 'firstname': 'Melissa M', 'initials': 'MM', 'affiliation': ""Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Departments of Pediatrics and Medicine, University of Tennessee Health Science Center, College of Medicine, Memphis, TN, USA.""}]",,,,Copyright © 2019 Elsevier Ltd. All rights reserved.,10.1016/S2352-3026(19)30050-X,<Element 'PubmedArticle' at 0x7f05dbe95b80>
93,31019099,Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration.,"To investigate the prevalence of clinically relevant multiple system atrophy (MSA) and Lewy body disease (LBD) pathologies in a large frontotemporal lobar degeneration (FTLD) cohort to determine if concomitant pathologies underlie the heterogeneity of clinical features.
All prospectively followed FTLD-tau and FTLD-TDP cases held by the Sydney Brain Bank (n = 126) were screened for coexisting MSA and LBD (Braak ≥ stage IV) pathology. Relevant clinical (including family history) and genetic associations were determined.
MSA pathology was not identified in this series. Of the FTLD cohort, 9 cases had coexisting LBD ≥ Braak stage IV and were associated with different FTLD subtypes including Pick disease (n = 2), corticobasal degeneration (n = 2), progressive supranuclear palsy (n = 2), and TDP type A (n = 3). All FTLD-TDP cases with coexisting LBD had mutations in 
Coexisting LBD in FTLD comprises a small proportion of cases but has implications for clinical and neuropathologic diagnoses and the identification of biomarkers.",[],Neurology,2019-04-26,"[{'lastname': 'Forrest', 'firstname': 'Shelley L', 'initials': 'SL', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Crockford', 'firstname': 'Daniel R', 'initials': 'DR', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Sizemova', 'firstname': 'Anastasia', 'initials': 'A', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'McCann', 'firstname': 'Heather', 'initials': 'H', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Shepherd', 'firstname': 'Claire E', 'initials': 'CE', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'McGeachie', 'firstname': 'Andrew B', 'initials': 'AB', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Affleck', 'firstname': 'Andrew J', 'initials': 'AJ', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Carew-Jones', 'firstname': 'Francine', 'initials': 'F', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Bartley', 'firstname': 'Lauren', 'initials': 'L', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Kwok', 'firstname': 'John B', 'initials': 'JB', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Kim', 'firstname': 'Woojin Scott', 'initials': 'WS', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Jary', 'firstname': 'Eve', 'initials': 'E', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Tan', 'firstname': 'Rachel H', 'initials': 'RH', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'McGinley', 'firstname': 'Ciara V', 'initials': 'CV', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Piguet', 'firstname': 'Olivier', 'initials': 'O', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Hodges', 'firstname': 'John R', 'initials': 'JR', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Kril', 'firstname': 'Jillian J', 'initials': 'JJ', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia.'}, {'lastname': 'Halliday', 'firstname': 'Glenda M', 'initials': 'GM', 'affiliation': 'From the Discipline of Pathology (S.L.F., D.R.C., A.S., C.V.M., J.J.K.), Central Clinical School (J.B.K., W.S.K., E.J., R.H.T., J.R.H., G.M.H.), Faculty of Medicine and Health, Brain and Mind Centre (J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), and School of Psychology (O.P.), The University of Sydney; Neuroscience Research Australia (H.M., C.E.S., A.B.M., A.J.A., F.C.-J., L.B., J.B.K., W.S.K., E.J., R.H.T., O.P., J.R.H., G.M.H.), Sydney; School of Medical Sciences (C.E.S., A.J.A., F.C.-J., J.B.K., W.S.K., R.H.T., G.M.H.), University of New South Wales; and ARC Centre of Excellence in Cognition and its Disorders (O.P., J.R.H.), Sydney, Australia. glenda.halliday@sydney.edu.au.'}]",,Coexisting LBD in FTLD comprises a small proportion of cases but has implications for clinical and neuropathologic diagnoses and the identification of biomarkers.,"MSA pathology was not identified in this series. Of the FTLD cohort, 9 cases had coexisting LBD ≥ Braak stage IV and were associated with different FTLD subtypes including Pick disease (n = 2), corticobasal degeneration (n = 2), progressive supranuclear palsy (n = 2), and TDP type A (n = 3). All FTLD-TDP cases with coexisting LBD had mutations in ",© 2019 American Academy of Neurology.,10.1212/WNL.0000000000007530,<Element 'PubmedArticle' at 0x7f05dbe6e360>
94,30964766,Association of cerebrospinal fluid zinc-α2-glycoprotein and tau protein with temporal lobe epilepsy and related white matter impairment.,"This study aimed to identify the change of cerebrospinal fluid (CSF) zinc-α2-glycoprotein (ZAG), tau protein and phosphorylated tau 181 (P-Tau 181), and analyze their association with white matter impairment (WMI) in patients with temporal lobe epilepsy (TLE). Levels of ZAG, tau, and P-Tau 181 in CSF were measured by enzyme-linked immunosorbent assay. WMI was scored based on Scheltens and Ylikoski scales. ZAG and total tau (T-Tau) were decreased in CSF of patients with TLE than controls (P<0.05 and 0.01, respectively), but P-Tau 181 showed no statistical difference. P-Tau 181/T-Tau ratio was increased in CSF of patients with TLE than controls (P<0.01). Patients with TLE have severer WMIs than controls (P<0.01). Linear by linear association analysis showed a correlation between WMI and TLE (P<0.01), Spearman's correlation analysis showed a correlation between T-Tau, P-Tau 181/T-Tau ratio and scores of WMIs (P<0.01). Receiver operating curves indicated apparent diagnostic value of T-Tau and P-Tau 181/T-Tau ratio in differentiating patients with TLE from controls (area under curve=1 and 0.936, respectively). ZAG also showed a lower but favorable diagnostic value (area under curve=0.771). ZAG, T-Tau, and P-Tau 181/T-Tau ratio in CSF may be potential biomarkers of WMI of TLE if further researched, and these findings may also be involved in potential mechanism of brain damage in TLE.",[],Neuroreport,2019-04-10,"[{'lastname': 'Mo', 'firstname': 'Lijuan', 'initials': 'L', 'affiliation': None}, {'lastname': 'Ding', 'firstname': 'Xueying', 'initials': 'X', 'affiliation': None}, {'lastname': 'Tan', 'firstname': 'Changhong', 'initials': 'C', 'affiliation': None}, {'lastname': 'Liu', 'firstname': 'Xi', 'initials': 'X', 'affiliation': None}, {'lastname': 'Wei', 'firstname': 'Xin', 'initials': 'X', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Hui', 'initials': 'H', 'affiliation': None}, {'lastname': 'Zhou', 'firstname': 'Wen', 'initials': 'W', 'affiliation': None}, {'lastname': 'Chen', 'firstname': 'Lifen', 'initials': 'L', 'affiliation': None}]",,,,,10.1097/WNR.0000000000001252,<Element 'PubmedArticle' at 0x7f05dbe63b80>
95,30775979,Impaired Glucose Tolerance and Reduced Plasma Insulin Precede Decreased AKT Phosphorylation and GLUT3 Translocation in the Hippocampus of Old 3xTg-AD Mice.,"Several studies have demonstrated that mouse models of Alzheimer's disease (AD) can exhibit impaired peripheral glucose tolerance. Further, in the APP/PS1 mouse model, this is observed prior to the appearance of AD-related neuropathology (e.g., amyloid-β plaques; Aβ) or cognitive impairment. In the current study, we examined whether impaired glucose tolerance also preceded AD-like changes in the triple transgenic model of AD (3xTg-AD). Glucose tolerance testing (GTT), insulin ELISAs, and insulin tolerance testing (ITT) were performed at ages prior to (1-3 months and 6-8 months old) and post-pathology (16-18 months old). Additionally, we examined for altered insulin signaling in the hippocampus. Western blots were used to evaluate the two-primary insulin signaling pathways: PI3K/AKT and MAPK/ERK. Since the PI3K/AKT pathway affects several downstream targets associated with metabolism (e.g., GSK3, glucose transporters), western blots were used to examine possible alterations in the expression, translocation, or activation of these targets. We found that 3xTg-AD mice display impaired glucose tolerance as early as 1 month of age, concomitant with a decrease in plasma insulin levels well prior to the detection of plaques (∼14 months old), aggregates of hyperphosphorylated tau (∼18 months old), and cognitive decline (≥18 months old). These alterations in peripheral metabolism were seen at all time points examined. In comparison, PI3K/AKT, but not MAPK/ERK, signaling was altered in the hippocampus only in 18-20-month-old 3xTg-AD mice, a time point at which there was a reduction in GLUT3 translocation to the plasma membrane. Taken together, our results provide further evidence that disruptions in energy metabolism may represent a foundational step in the development of AD.","['3xTg-AD', 'AKT', 'Alzheimer’s disease', 'GLUT', 'diabetes', 'glucose', 'hippocampus', 'insulin', 'metabolism']",Journal of Alzheimer's disease : JAD,2019-02-19,"[{'lastname': 'Griffith', 'firstname': 'Chelsea M', 'initials': 'CM', 'affiliation': 'Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA.\nCenter for Integrated Research in Cognitive and Neural Sciences, Southern Illinois University, Carbondale, IL, USA.'}, {'lastname': 'Macklin', 'firstname': 'Lauren N', 'initials': 'LN', 'affiliation': 'Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA.\nCenter for Integrated Research in Cognitive and Neural Sciences, Southern Illinois University, Carbondale, IL, USA.'}, {'lastname': 'Cai', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Department of Anatomy and Neurobiology, Central South University Xiangya School of Medicine, Changsha, Hunan, China.\nKey Laboratory of Hunan Province in Neurodegenerative Disorders, Changsha, Hunan, China.'}, {'lastname': 'Sharp', 'firstname': 'Andrew A', 'initials': 'AA', 'affiliation': 'Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA.\nDepartment of Anatomy, Southern Illinois University School of Medicine, Carbondale, IL, USA.\nCenter for Integrated Research in Cognitive and Neural Sciences, Southern Illinois University, Carbondale, IL, USA.'}, {'lastname': 'Yan', 'firstname': 'Xiao-Xin', 'initials': 'XX', 'affiliation': 'Department of Anatomy and Neurobiology, Central South University Xiangya School of Medicine, Changsha, Hunan, China.\nKey Laboratory of Hunan Province in Neurodegenerative Disorders, Changsha, Hunan, China.'}, {'lastname': 'Reagan', 'firstname': 'Lawrence P', 'initials': 'LP', 'affiliation': 'Department of Pharmacology, Physiology & Neuroscience, University of South Carolina, Columbia, SC, USA.\nWJB Dorn Veterans Affairs Medical Center, Columbia, SC, USA.'}, {'lastname': 'Strader', 'firstname': 'April D', 'initials': 'AD', 'affiliation': 'Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA.\nCenter for Integrated Research in Cognitive and Neural Sciences, Southern Illinois University, Carbondale, IL, USA.'}, {'lastname': 'Rose', 'firstname': 'Gregory M', 'initials': 'GM', 'affiliation': 'Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA.\nDepartment of Anatomy, Southern Illinois University School of Medicine, Carbondale, IL, USA.\nCenter for Integrated Research in Cognitive and Neural Sciences, Southern Illinois University, Carbondale, IL, USA.'}, {'lastname': 'Patrylo', 'firstname': 'Peter R', 'initials': 'PR', 'affiliation': 'Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA.\nDepartment of Anatomy, Southern Illinois University School of Medicine, Carbondale, IL, USA.\nCenter for Integrated Research in Cognitive and Neural Sciences, Southern Illinois University, Carbondale, IL, USA.'}]",,,,,10.3233/JAD-180707,<Element 'PubmedArticle' at 0x7f05dc192220>
96,30773255,Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β.,"Dulaglutide, a novel long-acting glucagon-like peptide 1 (GLP-1) receptor agonist, is an incretin mimetic approved for type 2 diabetes mellitus (T2DM) treatment. Alzheimer's disease (AD) is called type 3 diabetes. The aim of this study is to explore the effects of dulaglutide on the learning and memory impairment in AD mice induced by injection of streptozocin (STZ) via intracerebroventricularly (i.c.v.). 32 male C57/BL6 mice were randomly divided into four groups: control group (CON); AD model group (STZ); dulaglutide treated (Dul); dulaglutide and exendin(9-39) (Ex). Western blotting was used to detect the levels of phosphorylated tau, neurofilament (NFs) proteins and phosphorylated PI3K/AKT/GSK3β signaling pathway. Morris water maze (MWM) test was used to assess the spatial learning and memory ability. The results displayed that the hyperphosphorylation of tau and NFs were increased in the STZ and Ex groups compared to the control and Dul groups. Dulaglutide also significantly shortened the escape latency and increased the number of hidden platform crossings in MWM test. The effects of dulaglutide on decreasing the hyperphosphorylation of tau and NFs proteins through improving the PI3K/AKT/GSK3β signaling pathway may be related to its protective effects on impairment of AD-like learning and memory.","[""Alzheimer's disease"", 'Dulaglutide', 'Insulin signaling', 'NFs', 'STZ mice', 'Tau']",Biochemical and biophysical research communications,2019-02-19,"[{'lastname': 'Zhou', 'firstname': 'Mei', 'initials': 'M', 'affiliation': 'Pathophysiology Department, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Chen', 'firstname': 'Shuyi', 'initials': 'S', 'affiliation': 'Pathophysiology Department, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Peng', 'firstname': 'Peng', 'initials': 'P', 'affiliation': 'Pathophysiology Department, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Gu', 'firstname': 'Zhongya', 'initials': 'Z', 'affiliation': 'Pathophysiology Department, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Yu', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Pathophysiology Department, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Zhao', 'firstname': 'Gang', 'initials': 'G', 'affiliation': 'Department of Pathology, Tianjin Tumor Hospital, Tianjin, China.'}, {'lastname': 'Deng', 'firstname': 'Yanqiu', 'initials': 'Y', 'affiliation': 'Pathophysiology Department, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. Electronic address: 1766464240@qq.com.'}]",,,,Copyright © 2019 Elsevier Inc. All rights reserved.,10.1016/j.bbrc.2019.01.103,<Element 'PubmedArticle' at 0x7f05dc18c5e0>
97,"30739077
23056194
17229088
30270329
8307060
16186530
22782295
10548280
79141
21038965
6199464
22644789
15933391
27603322
284371
20451870
30278372
9740363
8905166
18160529
8872869
1674117
2597886
18455838
6268760
7961057
6246582
10436075
21311900
25676562
7706619
24993476
8831298
26214150
23069842
6300358","Cholecystokinin and Alzheimer's disease: a biomarker of metabolic function, neural integrity, and cognitive performance.","Cholecystokinin (CCK) is a satiety hormone that is highly expressed in brain regions like the hippocampus. CCK is integral for maintaining or enhancing memory and thus may be a useful marker of cognitive and neural integrity in participants with normal cognition, mild cognitive impairment, and Alzheimer's disease (AD). Cerebrospinal fluid (CSF) CCK levels were examined in 287 subjects from the Alzheimer's Disease Neuroimaging Initiative. Linear or voxelwise regression was used to examine associations between CCK, regional gray matter, CSF AD biomarkers, and cognitive outcomes. Briefly, higher CCK was related to a decreased likelihood of having mild cognitive impairment or AD, better global and memory scores, and more gray matter volume primarily spanning posterior cingulate cortex, parahippocampal gyrus, and medial prefrontal cortex. CSF CCK was also strongly related to higher CSF total tau (R","[""Alzheimer's disease"", 'Biomarkers', 'Cholecystokinin', 'Cognition', 'MRI', 'Neuropathology']",Neurobiology of aging,2019-02-11,"[{'lastname': 'Plagman', 'firstname': 'Alexandra', 'initials': 'A', 'affiliation': 'Department of Food Science and Human Nutrition, Iowa State University, Ames, IA, USA.'}, {'lastname': 'Hoscheidt', 'firstname': 'Siobhan', 'initials': 'S', 'affiliation': 'Department of Internal Medicine-Gerontology and Geriatic Medicine, Wake Forest School of Medicine, Salem, NC, USA.'}, {'lastname': 'McLimans', 'firstname': 'Kelsey E', 'initials': 'KE', 'affiliation': 'Department of Food Science and Human Nutrition, Iowa State University, Ames, IA, USA.'}, {'lastname': 'Klinedinst', 'firstname': 'Brandon', 'initials': 'B', 'affiliation': 'Neuroscience Graduate Program, Iowa State University, Ames, IA, USA.'}, {'lastname': 'Pappas', 'firstname': 'Colleen', 'initials': 'C', 'affiliation': 'Department of Food Science and Human Nutrition, Iowa State University, Ames, IA, USA.'}, {'lastname': 'Anantharam', 'firstname': 'Vellareddy', 'initials': 'V', 'affiliation': 'Department of Biomedical Sciences, Iowa State University, Ames, IA, USA.'}, {'lastname': 'Kanthasamy', 'firstname': 'Anumantha', 'initials': 'A', 'affiliation': 'Department of Biomedical Sciences, Iowa State University, Ames, IA, USA.'}, {'lastname': 'Willette', 'firstname': 'Auriel A', 'initials': 'AA', 'affiliation': 'Department of Food Science and Human Nutrition, Iowa State University, Ames, IA, USA; Neuroscience Graduate Program, Iowa State University, Ames, IA, USA; Department of Biomedical Sciences, Iowa State University, Ames, IA, USA; Department of Psychology, Iowa State University, Ames, IA, USA; Department of Neurology, University of Iowa, Iowa City, IA, USA. Electronic address: awillett@iastate.edu.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,Copyright © 2019 Elsevier Inc. All rights reserved.,"10.1016/j.neurobiolaging.2019.01.002
10.1371/journal.pone.0045179
10.1111/j.1460-9568.2006.05243.x
10.1248/bpb.b18-00359
10.1159/000116984
10.1212/01.wnl.0000176061.33817.90
10.1007/s11682-012-9186-z
10.1037/a0020176
10.1007/s11682-012-9176-1
10.1159/000442615
10.1016/j.jalz.2010.03.003
10.1016/j.nicl.2018.09.013
10.1016/S0028-3932(98)00017-7
10.1152/ajpregu.00682.2007
10.1007/BF01273363
10.1192/bjp.154.6.801
10.1007/s00401-011-0808-0
10.1002/prca.201400178
10.1016/j.neuroscience.2014.06.048
10.1001/jamaneurol.2015.0613
10.2337/dc12-0922",<Element 'PubmedArticle' at 0x7f05dc17acc0>
98,30711674,Gray and white matter changes in presymptomatic genetic frontotemporal dementia: a longitudinal MRI study.,"In genetic frontotemporal dementia, cross-sectional studies have identified profiles of presymptomatic neuroanatomical loss for C9orf72 repeat expansion, MAPT, and GRN mutations. In this study, we characterize longitudinal gray matter (GM) and white matter (WM) brain changes in presymptomatic frontotemporal dementia. We included healthy carriers of C9orf72 repeat expansion (n = 12), MAPT (n = 15), GRN (n = 33) mutations, and related noncarriers (n = 53), that underwent magnetic resonance imaging at baseline and 2-year follow-up. We analyzed cross-sectional baseline, follow-up, and longitudinal GM and WM changes using voxel-based morphometry and cortical thickness analysis in SPM and tract-based spatial statistics in FSL. Compared with noncarriers, C9orf72 repeat expansion carriers showed lower GM volume in the cerebellum and insula, and WM differences in the anterior thalamic radiation, at baseline and follow-up. MAPT mutation carriers showed emerging GM temporal lobe changes and longitudinal WM degeneration of the uncinate fasciculus. GRN mutation carriers did not show presymptomatic neurodegeneration. This study shows distinct presymptomatic cross-sectional and longitudinal patterns of GM and WM changes across C9orf72 repeat expansion, MAPT, and GRN mutation carriers compared with noncarriers.","['Diffusion tensor imaging', 'Frontotemporal dementia', 'Frontotemporal lobar degeneration', 'Hereditary dementia', 'Magnetic resonance imaging', 'Preclinical disease']",Neurobiology of aging,2019-02-04,"[{'lastname': 'Panman', 'firstname': 'Jessica L', 'initials': 'JL', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'lastname': 'Jiskoot', 'firstname': 'Lize C', 'initials': 'LC', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'lastname': 'Bouts', 'firstname': 'Mark J R J', 'initials': 'MJRJ', 'affiliation': 'Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands.'}, {'lastname': 'Meeter', 'firstname': 'Lieke H H', 'initials': 'LHH', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.'}, {'lastname': 'van der Ende', 'firstname': 'Emma L', 'initials': 'EL', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'lastname': 'Poos', 'firstname': 'Jackie M', 'initials': 'JM', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'lastname': 'Feis', 'firstname': 'Rogier A', 'initials': 'RA', 'affiliation': 'Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands.'}, {'lastname': 'Kievit', 'firstname': 'Anneke J A', 'initials': 'AJA', 'affiliation': 'Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands.'}, {'lastname': 'van Minkelen', 'firstname': 'Rick', 'initials': 'R', 'affiliation': 'Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands.'}, {'lastname': 'Dopper', 'firstname': 'Elise G P', 'initials': 'EGP', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Department of Neurology, VU medical Center, Amsterdam, the Netherlands.'}, {'lastname': 'Rombouts', 'firstname': 'Serge A R B', 'initials': 'SARB', 'affiliation': 'Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands.'}, {'lastname': 'van Swieten', 'firstname': 'John C', 'initials': 'JC', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Clinical Genetics, VU Medical Center, Amsterdam, the Netherlands.'}, {'lastname': 'Papma', 'firstname': 'Janne M', 'initials': 'JM', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: j.papma@erasmusmc.nl.'}]",,,,Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2018.12.017,<Element 'PubmedArticle' at 0x7f05dc518db0>
99,"30632006
6375662
3088567
9052708
29120844
17537547
21860088
19264913
23157378
12750016
9044391
16884700
19573562
12925848
21152969
11812750
12829647
22115895
18466898
23973293
10600787
17406317
27065817
9699908
29667002
29377010
12475787
7897397
15374226
12660262
16963146
22869320
18460333
24529520
22476197
22815492
22476196
25183970
17360897
28337257
11309494
11224536
16039562
8043280
14557249",Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting.,"Hyperhomocysteinemia (Hhcy) is an independent risk factor for Alzheimer's disease (AD), and insulin-resistance is commonly seen in patients with Hhcy. Liraglutide (Lir), a glucagon-like peptide that increases the secretion and sensitivity of insulin, has a neurotrophic or neuroprotective effect. However, it is not known whether Lir ameliorates the AD-like pathology and memory deficit induced by Hhcy. By vena caudalis injection of homocysteine to produce the Hhcy model in rats, we found here that simultaneous administration of Lir for 2 weeks ameliorated the Hhcy-induced memory deficit, along with increased density of dendritic spines and up-regulation of synaptic proteins. Lir also attenuated the Hhcy-induced tau hyperphosphorylation and Aβ overproduction, and the molecular mechanisms involved the restoration of protein phosphatase-2A activity and inhibition of β- and γ-secretases. Phosphorylated insulin receptor substrate-1 also decreased after treatment with Lir. Our data reveal that Lir improves the Hhcy-induced AD-like spatial memory deficit and the mechanisms involve the modulation of insulin-resistance and the pathways generating abnormal tau and Aβ.","['Glucagon-like peptide-1 receptor', 'Hyperhomocysteinemia', 'Liraglutide', 'Tau', 'β-Amyloid']",Neuroscience bulletin,2019-01-12,"[{'lastname': 'Zhang', 'firstname': 'Yao', 'initials': 'Y', 'affiliation': 'Endocrinology Department of Liyuan Hospital and Key Laboratory of the Ministry of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430077, China.'}, {'lastname': 'Xie', 'firstname': 'Jia-Zhao', 'initials': 'JZ', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of the Ministry of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'lastname': 'Xu', 'firstname': 'Xiang-Yang', 'initials': 'XY', 'affiliation': 'Radiology Department, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430077, China.'}, {'lastname': 'Hu', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'Endocrinology Department, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430077, China.'}, {'lastname': 'Xu', 'firstname': 'Teng', 'initials': 'T', 'affiliation': 'Endocrinology Department, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430077, China.'}, {'lastname': 'Jin', 'firstname': 'Si', 'initials': 'S', 'affiliation': 'Endocrinology Department, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430077, China.'}, {'lastname': 'Yang', 'firstname': 'Shao-Juan', 'initials': 'SJ', 'affiliation': 'Endocrinology Department, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430077, China.'}, {'lastname': 'Wang', 'firstname': 'Jian-Zhi', 'initials': 'JZ', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of the Ministry of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. wangjz@mail.hust.edu.cn.'}]",,,,,"10.1007/s12264-018-00336-7
10.1016/S0006-291X(84)80190-4
10.1073/pnas.83.13.4913
10.1001/jama.1997.03540340027028
10.1016/j.psychres.2017.08.063
10.1016/j.neurobiolaging.2007.04.015
10.3233/JAD-2011-110770
10.2353/ajpath.2009.081036
10.1111/jnc.12094
10.1016/S0169-328X(03)00125-6
10.1016/S0306-4522(96)00434-4
10.1016/j.brainres.2006.06.090
10.1016/j.bbr.2009.06.035
10.1038/nm919
10.1007/s10571-010-9632-7
10.2337/diabetes.51.2.424
10.2337/diabetes.52.7.1786
10.1016/j.ejphar.2011.11.005
10.1016/j.ejphar.2008.03.025
10.1016/j.neuropharm.2013.08.005
10.1038/nprot.2006.116
10.3389/fnana.2016.00038
10.1016/S0021-9150(98)00067-7
10.1007/s12264-018-0226-6
10.1038/nrneurol.2017.185
10.2337/diabetes.51.2007.S434
10.1016/0167-4943(95)00646-3
10.1093/humrep/deg190
10.1016/j.diabres.2006.07.026
10.1007/s00125-012-2644-8
10.1016/j.cmet.2008.04.005
10.1016/j.jalz.2013.12.007
10.1172/JCI59903
10.1523/JNEUROSCI.0354-12.2012
10.1172/JCI57256
10.1155/2014/312452
10.1523/JNEUROSCI.3316-06.2007
10.1073/pnas.081612998
10.1038/85064
10.1016/j.neuron.2005.06.030
10.1016/0896-6273(94)90458-8
10.1083/jcb.200301115",<Element 'PubmedArticle' at 0x7f05dc4fb4f0>
100,"30546139
26354483
27830781
26988744
24005412
11071481
16798390
14504321
28334869
21519520
14533778
2111584
1303239
27025652
27411637
27629649
27629648
27411638
26268531
507895
24852598
24728269
20966215
26812492
27016065
27314593
28349199
29209767
29450646
21555601
9057170",Transmission of amyloid-β protein pathology from cadaveric pituitary growth hormone.,We previously reported,[],Nature,2018-12-14,"[{'lastname': 'Purro', 'firstname': 'Silvia A', 'initials': 'SA', 'affiliation': 'MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK.'}, {'lastname': 'Farrow', 'firstname': 'Mark A', 'initials': 'MA', 'affiliation': 'MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK.'}, {'lastname': 'Linehan', 'firstname': 'Jacqueline', 'initials': 'J', 'affiliation': 'MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK.'}, {'lastname': 'Nazari', 'firstname': 'Tamsin', 'initials': 'T', 'affiliation': 'MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK.'}, {'lastname': 'Thomas', 'firstname': 'David X', 'initials': 'DX', 'affiliation': 'MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK.'}, {'lastname': 'Chen', 'firstname': 'Zhicheng', 'initials': 'Z', 'affiliation': ""Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'lastname': 'Mengel', 'firstname': 'David', 'initials': 'D', 'affiliation': ""Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'lastname': 'Saito', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': 'Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako, Japan.'}, {'lastname': 'Saido', 'firstname': 'Takaomi', 'initials': 'T', 'affiliation': 'Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako, Japan.'}, {'lastname': 'Rudge', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK.'}, {'lastname': 'Brandner', 'firstname': 'Sebastian', 'initials': 'S', 'affiliation': 'MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK.\nDivision of Neuropathology, National Hospital for Neurology and Neurosurgery, London, UK.'}, {'lastname': 'Walsh', 'firstname': 'Dominic M', 'initials': 'DM', 'affiliation': ""MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK.\nLaboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'lastname': 'Collinge', 'firstname': 'John', 'initials': 'J', 'affiliation': 'MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK. jc@prion.ucl.ac.uk.'}]",,,,,10.1038/s41586-018-0790-y,<Element 'PubmedArticle' at 0x7f05dc4e5720>
101,30545478,Presence of tau astrogliopathy in frontotemporal dementia caused by a novel Grn nonsense (Trp2*) mutation.,"Frontotemporal lobar degeneration caused by GRN mutations is mainly associated with a TDP-43 type A proteinopathy. We present a family with autosomal dominant frontotemporal lobar degeneration caused by a novel GRN nonsense mutation (c.5G>A: p.Trp2*) in which the proband's brain also showed prominent glial tauopathy consistent with an aging-related tau astrogliopathy. Astrocytic tauopathy, 4R(+) and 3R(-) immunoreactive, was characterized by thorn-shaped astrocytes present in subpial, subependymal, and perivascular areas, and in gray matter; plus granular or fuzzy tau immunoreactivity in astrocytic processes in gray matter, either solitary or clustered in different regions. Some neurofibrillary tangles and pretangles, both 3R and 4R(+), were present in the medial temporal lobe but did not exhibit the characteristic distribution of Alzheimer's type pathology. This 4R-tau aging-related tau astrogliopathy is likely a co-occurring pathology, although an interaction between progranulin and tau proteins within the neurodegenerative process should not be ruled out.","['ARTAG', 'Astrogliopathy', 'GRN mutations', 'Neuropathology', 'Tauopathy']",Neurobiology of aging,2018-12-14,"[{'lastname': 'Gómez-Tortosa', 'firstname': 'Estrella', 'initials': 'E', 'affiliation': 'Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain. Electronic address: egomezt@fjd.es.'}, {'lastname': 'Baradaran-Heravi', 'firstname': 'Yalda', 'initials': 'Y', 'affiliation': 'Neurodegenerative Brain Diseases group, Center for Molecular Neurology, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.'}, {'lastname': 'González Alvarez', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'Brain Tissue Bank, Fundación CIEN, Instituto de Salud Carlos III, Madrid, Spain.'}, {'lastname': 'Sainz', 'firstname': 'María José', 'initials': 'MJ', 'affiliation': 'Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain.'}, {'lastname': 'Prieto-Jurczynska', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': 'Department of Neurology, Hospital Infanta Elena, Madrid, Spain.'}, {'lastname': 'Guerrero-López', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS-FJD) and CIBERER Madrid, Spain.'}, {'lastname': 'Agüero Rabes', 'firstname': 'Pablo', 'initials': 'P', 'affiliation': 'Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain.'}, {'lastname': 'Van Broeckhoven', 'firstname': 'Christine', 'initials': 'C', 'affiliation': 'Neurodegenerative Brain Diseases group, Center for Molecular Neurology, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.'}, {'lastname': 'van der Zee', 'firstname': 'Julie', 'initials': 'J', 'affiliation': 'Neurodegenerative Brain Diseases group, Center for Molecular Neurology, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.'}, {'lastname': 'Rábano Gutiérrez', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': 'Brain Tissue Bank, Fundación CIEN, Instituto de Salud Carlos III, Madrid, Spain.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2018.11.010,<Element 'PubmedArticle' at 0x7f05dca8eef0>
102,"30508042
21646331
19759202
21988828
22784036
13688369
24194552
18593276
26329689
26401709
29172163
29353234
24672743
19020205
15004322
24445580
25138488
25002573
27625986
11113214
28975068
1202204
24595028
21325651
14761903
18166605
27620011
21785117
15654025
27358337
29627938
30250860
11001602
22399793
28738187
18829698
25050433
29453244
23312804
24510641
22592372
28621768
27606344
26594624
25377694
26143154
28562080
28087578
21147039
21810890
16087904
25662776
20045477
23611351
24928124
25632156
18268196
19376066
22109837
27357347
23664844
19323967
18771956
23920254
19762452
19255408
22366795
25683866
15405679
22976075
21760989",Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia.,"Developing and validating sensitive biomarkers for the presymptomatic stage of familial frontotemporal dementia is an important step in early diagnosis and for the design of future therapeutic trials. In the longitudinal Frontotemporal Dementia Risk Cohort, presymptomatic mutation carriers and non-carriers from families with familial frontotemporal dementia due to microtubule-associated protein tau (MAPT) and progranulin (GRN) mutations underwent a clinical assessment and multimodal MRI at baseline, 2-, and 4-year follow-up. Of the cohort of 73 participants, eight mutation carriers (three GRN, five MAPT) developed clinical features of frontotemporal dementia ('converters'). Longitudinal whole-brain measures of white matter integrity (fractional anisotropy) and grey matter volume in these converters (n = 8) were compared with healthy mutation carriers ('non-converters'; n = 35) and non-carriers (n = 30) from the same families. We also assessed the prognostic performance of decline within white matter and grey matter regions of interest by means of receiver operating characteristic analyses followed by stepwise logistic regression. Longitudinal whole-brain analyses demonstrated lower fractional anisotropy values in extensive white matter regions (genu corpus callosum, forceps minor, uncinate fasciculus, and superior longitudinal fasciculus) and smaller grey matter volumes (prefrontal, temporal, cingulate, and insular cortex) over time in converters, present from 2 years before symptom onset. White matter integrity loss of the right uncinate fasciculus and genu corpus callosum provided significant classifiers between converters, non-converters, and non-carriers. Converters' within-individual disease trajectories showed a relatively gradual onset of clinical features in MAPT, whereas GRN mutations had more rapid changes around symptom onset. MAPT converters showed more decline in the uncinate fasciculus than GRN converters, and more decline in the genu corpus callosum in GRN than MAPT converters. Our study confirms the presence of spreading predominant frontotemporal pathology towards symptom onset and highlights the value of multimodal MRI as a prognostic biomarker in familial frontotemporal dementia.",[],Brain : a journal of neurology,2018-12-07,"[{'lastname': 'Jiskoot', 'firstname': 'Lize C', 'initials': 'LC', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.\nDepartment of Radiology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'lastname': 'Panman', 'firstname': 'Jessica L', 'initials': 'JL', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.\nDepartment of Radiology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'lastname': 'Meeter', 'firstname': 'Lieke H', 'initials': 'LH', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'lastname': 'Dopper', 'firstname': 'Elise G P', 'initials': 'EGP', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.\nDepartment of Radiology, Leiden University Medical Center, Leiden, The Netherlands.\nDepartment of Neurology, VU Medical Center, Amsterdam, The Netherlands.'}, {'lastname': 'Donker Kaat', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.\nDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.'}, {'lastname': 'Franzen', 'firstname': 'Sanne', 'initials': 'S', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'lastname': 'van der Ende', 'firstname': 'Emma L', 'initials': 'EL', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'lastname': 'van Minkelen', 'firstname': 'Rick', 'initials': 'R', 'affiliation': 'Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'lastname': 'Rombouts', 'firstname': 'Serge A R B', 'initials': 'SARB', 'affiliation': 'Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.\nInstitute of Psychology, Leiden University, Leiden, The Netherlands.\nLeiden Institute for Brain and Cognition, Leiden University, Leiden, The Netherlands.'}, {'lastname': 'Papma', 'firstname': 'Janne M', 'initials': 'JM', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'lastname': 'van Swieten', 'firstname': 'John C', 'initials': 'JC', 'affiliation': 'Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.'}]",,,,,"10.1093/brain/awy288
10.1007/s00415-018-8850-7",<Element 'PubmedArticle' at 0x7f05dca7c7c0>
103,30509034,Human chorionic gonadotropin decreases the phosphorylated tau protein level in streptozotocin-Alzheimeric male rats' hippocampus.,"The pharmacological suppression of luteinising hormone or human chorionic gonadotropin (hCG) can reduce Aβ plaques in the brains of rats and mice, but the effects of hCG on the phosphorylated tau protein level in the hippocampus have not been studied. Therefore, we investigated the effects of hCG on the phosphorylated tau protein level and its effect on hCG receptor-immunoreactive neuron density in the hippocampus of Alzheimer's disease (AD) model rats (streptozotocin [STZ] injected intracerebroventricularly).
The rats were administered hCG (50, 100, and 200 IU/200 µl saline, intraperitoneally) or vehicle once/day for three days after injection of STZ. The passive avoidance memory test was performed 6 hours after the last hCG injection. The phosphorylated tau protein level in the hippocampus was measured by ELISA, and hCG receptor-immunoreactive neurons were shown by immunohistochemical technique in areas of hippocampus.
Treatment with hCG attenuated memory deficiencies and reduced the level of phosphorylated tau protein in the hippocampus. hCG also improved the density of hCG receptor-immunoreactive neurons. The high dose of hCG hormone (200 IU/200 µl saline) seemed to have a significant effect on passive avoidance memory, phosphorylated tau protein concentration, and accumulation of hCG receptor-immunoreactive neurons in Alzheimeric rats' hippocampus.
In conclusion, hCG can provide protection against memory deficits induced by STZ and it can inhibit accumulation of tau hyperphosphorylation in the hippocampus. Furthermore, hCG can increase the hCG receptor-ir neurons number in the rats hippocampus after ICV injection of STZ.","[' hCG receptor', ' hippocampus', ' passive avoidance memory', ' phosphorylated tau protein', ' streptozotocin', 'hCG']",Folia neuropathologica,2018-12-05,"[{'lastname': 'Bahlakeh', 'firstname': 'Gozal', 'initials': 'G', 'affiliation': None}, {'lastname': 'Jahanshahi', 'firstname': 'Mehrdad', 'initials': 'M', 'affiliation': None}, {'lastname': 'Saeidi', 'firstname': 'Mohsen', 'initials': 'M', 'affiliation': None}]",,,"Treatment with hCG attenuated memory deficiencies and reduced the level of phosphorylated tau protein in the hippocampus. hCG also improved the density of hCG receptor-immunoreactive neurons. The high dose of hCG hormone (200 IU/200 µl saline) seemed to have a significant effect on passive avoidance memory, phosphorylated tau protein concentration, and accumulation of hCG receptor-immunoreactive neurons in Alzheimeric rats' hippocampus.",,10.5114/fn.2018.76619,<Element 'PubmedArticle' at 0x7f05dcc37b30>
104,30428311,Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.,"Obesity and type 2 diabetes mellitus (T2DM) are important risk factors for Alzheimer's disease (AD). Drugs originally developed for T2DM treatment, e.g., analog of glucagon-like peptide 1 liraglutide, have shown neuroprotective effects in mouse models of AD. We previously examined the neuroprotective properties of palm","['APP/PS1 mice', ""Alzheimer's disease"", 'Neuroinflammation', 'Palm(11)-PrRP31', 'Tau phosphorylation', 'β-amyloid plaques']",Neuropharmacology,2018-11-15,"[{'lastname': 'Holubová', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic.'}, {'lastname': 'Hrubá', 'firstname': 'Lucie', 'initials': 'L', 'affiliation': 'Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic.'}, {'lastname': 'Popelová', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic.'}, {'lastname': 'Bencze', 'firstname': 'Michal', 'initials': 'M', 'affiliation': 'Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic; Institute of Physiology of the Czech Academy of Sciences, 142 20, Prague 4, Czech Republic.'}, {'lastname': 'Pražienková', 'firstname': 'Veronika', 'initials': 'V', 'affiliation': 'Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic.'}, {'lastname': 'Gengler', 'firstname': 'Simon', 'initials': 'S', 'affiliation': 'Biomedical and Life Science, Faculty of Health and Medicine, Lancaster University, Bailrigg, Lancaster, LA1 4YW, United Kingdom.'}, {'lastname': 'Kratochvílová', 'firstname': 'Helena', 'initials': 'H', 'affiliation': 'Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21, Prague 4, Czech Republic; Department of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague and General University Hospital, 128 08, Prague 2, Czech Republic.'}, {'lastname': 'Haluzík', 'firstname': 'Martin', 'initials': 'M', 'affiliation': 'Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21, Prague 4, Czech Republic; Department of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague and General University Hospital, 128 08, Prague 2, Czech Republic.'}, {'lastname': 'Železná', 'firstname': 'Blanka', 'initials': 'B', 'affiliation': 'Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic.'}, {'lastname': 'Kuneš', 'firstname': 'Jaroslav', 'initials': 'J', 'affiliation': 'Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic; Institute of Physiology of the Czech Academy of Sciences, 142 20, Prague 4, Czech Republic.'}, {'lastname': 'Hölscher', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Biomedical and Life Science, Faculty of Health and Medicine, Lancaster University, Bailrigg, Lancaster, LA1 4YW, United Kingdom.'}, {'lastname': 'Maletínská', 'firstname': 'Lenka', 'initials': 'L', 'affiliation': 'Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 166 10, Prague 6, Czech Republic. Electronic address: maletin@uochb.cas.cz.'}]",,,,Copyright © 2018 Elsevier Ltd. All rights reserved.,10.1016/j.neuropharm.2018.11.002,<Element 'PubmedArticle' at 0x7f05dcc41900>
105,30408479,Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy.,"Recent studies indicate that glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonists exhibit neurotrophic and neuroprotective effects. The aim of this study was to explore whether the GLP-1R agonist exendin-4 can alter surgery-induced behavioral deficits and exert neuroprotective effects via the activation of the hippocampal GLP-1/GLP-1R pathway. 120 male Sprague-Dawley rats (aged 18-20 months old) were randomly divided into four groups: control group, exendin-4 group, surgery group, and surgery + exendin-4 group. The animals received either exendin-4 (5 µg/kg/day) or saline intra-peritoneally for 14 days, and then were subjected to partial hepatectomy 24 h after the last injection. Behavioral changes were evaluated with Morris Water Maze and Open field testing on postoperative days 7 and 14. The levels of IL-1β, NF-κB, Iba-1, Synaptophysin, GLP-1/GLP-1R, GSK-3β, p-GSK-3β (Ser9), p-Tau (Ser396), and p-Tau (Ser202/199) in the hippocampus were measured at the same time point. Surgical trauma induced an exacerbated spatial learning and memory impairment, increased the levels of depressive performance, and enhanced hippocampal NF-κB and IL-1β expression in the aged rats on postoperative day 7. A corresponding decline in GLP-1R was also found following surgical challenge on postoperative day 7. Exendin-4 treatment partly reversed surgery-induced postoperative behavioral impairment, downregulated the levels of NF-κB and IL-1β, ameliorated tau hyperphosphorylation and enhanced the activity of p-GSK-3β (Ser9). Together, the downregulation of GLP-1R exacerbated surgery-induced behavior deficits. Exendin-4 treatment attenuated these effects by inhibiting neuroinflammation and tau hyperphosphorylation. These findings suggest that pretreatment with exendin-4 is a potential adjuvant for preventing surgery-induced behavioral deficits.","['Ageing', 'Cytokines', 'GLP-1/GLP-1R', 'Hippocampus', 'Neuroinflammation', 'Postoperative cognitive dysfunction (POCD)']",Brain research,2018-11-09,"[{'lastname': 'Zhou', 'firstname': 'Yongjian', 'initials': 'Y', 'affiliation': 'Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.'}, {'lastname': 'Li', 'firstname': 'Zhe', 'initials': 'Z', 'affiliation': 'Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.'}, {'lastname': 'Cao', 'firstname': 'Xuezhao', 'initials': 'X', 'affiliation': 'Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address: xuezhaocao2011@hotmail.com.'}, {'lastname': 'Ma', 'firstname': 'Hong', 'initials': 'H', 'affiliation': 'Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.'}, {'lastname': 'White', 'firstname': 'Paul F', 'initials': 'PF', 'affiliation': 'Department of Anesthesiology, Cedars Sinai Medical Center, Los Angeles, CA, USA. Electronic address: Paul.White@cshs.org.'}, {'lastname': 'Xu', 'firstname': 'Xiaohan', 'initials': 'X', 'affiliation': 'Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.'}, {'lastname': 'Jiang', 'firstname': 'Yanhua', 'initials': 'Y', 'affiliation': 'Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.'}, {'lastname': 'Sun', 'firstname': 'Xijia', 'initials': 'X', 'affiliation': 'Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.'}, {'lastname': 'Cui', 'firstname': 'Yong', 'initials': 'Y', 'affiliation': 'Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.'}]",,,,Copyright © 2018. Published by Elsevier B.V.,10.1016/j.brainres.2018.11.007,<Element 'PubmedArticle' at 0x7f05dcc554a0>
106,30381076,Intranasal Insulin Prevents Anesthesia-induced Cognitive Impairments in Aged Mice.,"Preclinical and clinical evidence suggests that elderly individuals are at increased risk of cognitive decline after general anesthesia. General anesthesia is also believed to be a risk factor for Postoperative Cognitive Dysfunction (POCD) and Alzheimer's Disease (AD). Intranasal administration of insulin, which delivers the drug directly into the brain, improves memory and cognition in both animal studies and small clinical trials. However, how insulin treatment improves cognitive function is poorly understood.
Aged mice were pretreated with intranasal insulin or saline before anesthesia. Propofol was added intraperitoneally to the mice from 7th day of insulin/saline treatment, and general anesthesia was induced and maintained for 2 hours/day for 5 consecutive days. Mice were evaluated at 26th day when the mice were continued on insulin or saline administration for another 15 days.
We found that intranasal insulin treatment prevented anesthesia-induced cognitive impairments, as measured by novel object recognition test and contextual-dependent fear conditioning test. Insulin treatment also increased the expression level of Post-synaptic Density Protein 95 (PSD95), as well as upregulated Microtubule-associated Protein-2 (MAP-2) in the dentate gyrus of the hippocampus. Furthermore, we found that insulin treatment restored insulin signaling disturbed by anesthesia via activating PI3K/PDK1/AKT pathway, and attenuated anesthesia-induced hyperphosphorylation of tau at multiple AD-associated sites. We found the attenuation of tau hyperphosphorylation occurred by increasing the level of GSK3β phosphorylated at Ser9, which leads to inactivation of GSK-3β.
Intranasal insulin administration might be a promising therapy to prevent anesthesiainduced cognitive deficit in elderly individuals.","['Postoperative cognitive dysfunction (POCD)', 'cognitive impairments', 'insulin', 'memory deficit', 'propofol', 'tau hyperphosphorylation.']",Current Alzheimer research,2018-11-02,"[{'lastname': 'Li', 'firstname': 'Xing', 'initials': 'X', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'lastname': 'Run', 'firstname': 'Xiaoqin', 'initials': 'X', 'affiliation': 'Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'lastname': 'Wei', 'firstname': 'Zhen', 'initials': 'Z', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'lastname': 'Zeng', 'firstname': 'Kuan', 'initials': 'K', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'lastname': 'Liang', 'firstname': 'Zhihou', 'initials': 'Z', 'affiliation': 'Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'lastname': 'Huang', 'firstname': 'Fang', 'initials': 'F', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'lastname': 'Ke', 'firstname': 'Dan', 'initials': 'D', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'lastname': 'Wang', 'firstname': 'Qun', 'initials': 'Q', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'lastname': 'Wang', 'firstname': 'Jian-Zhi', 'initials': 'JZ', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.\nCo-innovation Center of Neuroregeneration, Nantong University, Nantong, JS 226001, China.'}, {'lastname': 'Liu', 'firstname': 'Rong', 'initials': 'R', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.'}, {'lastname': 'Zhang', 'firstname': 'Bin', 'initials': 'B', 'affiliation': 'Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.'}, {'lastname': 'Wang', 'firstname': 'Xiaochuan', 'initials': 'X', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.\nCo-innovation Center of Neuroregeneration, Nantong University, Nantong, JS 226001, China.'}]",,Intranasal insulin administration might be a promising therapy to prevent anesthesiainduced cognitive deficit in elderly individuals.,"We found that intranasal insulin treatment prevented anesthesia-induced cognitive impairments, as measured by novel object recognition test and contextual-dependent fear conditioning test. Insulin treatment also increased the expression level of Post-synaptic Density Protein 95 (PSD95), as well as upregulated Microtubule-associated Protein-2 (MAP-2) in the dentate gyrus of the hippocampus. Furthermore, we found that insulin treatment restored insulin signaling disturbed by anesthesia via activating PI3K/PDK1/AKT pathway, and attenuated anesthesia-induced hyperphosphorylation of tau at multiple AD-associated sites. We found the attenuation of tau hyperphosphorylation occurred by increasing the level of GSK3β phosphorylated at Ser9, which leads to inactivation of GSK-3β.","Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1567205015666181031145045,<Element 'PubmedArticle' at 0x7f05dc7e7360>
107,30324586,Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.,"The PARP inhibitor olaparib is efficacious as monotherapy and has potential application in combination with endocrine therapy for the treatment of breast cancer. This phase I study assessed the safety and pharmacokinetic (PK) profiles of olaparib combined with tamoxifen, anastrozole or letrozole in patients with advanced solid tumours.
During part A, PK profiles were assessed in three consecutive treatment periods: (1) olaparib (tablet) 300 mg bid, days 1-5 followed by a 4-day washout; (2) cohort 1, tamoxifen 60 mg loading dose qd days 10-13, 20 mg qd days 14-26; cohort 2, anastrozole 1 mg qd days 10-19; cohort 3, letrozole 2.5 mg qd days 10-38; (3) as for period 2, with concomitant olaparib 300 mg bid for 5 days. Patients could then enter part B and receive olaparib monotherapy (300 mg bid continuously). Safety was assessed in parts A and B until 12 months after the last patient entered part B.
Seventy-nine patients (20.3% with breast cancer) received treatment in part A; 72 completed part A and 69 entered part B. Anastrozole and letrozole had no effect on the PK profile of olaparib and vice versa. Co-administration with tamoxifen produced a modest decrease in exposure to olaparib [geometric least-squares mean (GLSmean) C
The combination of olaparib and either anastrozole, letrozole or tamoxifen was generally well tolerated, with no clinically relevant PK interactions identified.
AstraZeneca.
NCT02093351.","['Anastrozole', 'Antihormonal therapy', 'Endocrine therapy', 'Letrozole', 'Lynparza', 'Olaparib', 'PARP inhibitor', 'Pharmacokinetics', 'Safety', 'Tamoxifen']",Advances in therapy,2018-10-17,"[{'lastname': 'Plummer', 'firstname': 'Ruth', 'initials': 'R', 'affiliation': 'Northern Centre for Cancer Care, Newcastle University, Newcastle upon Tyne, UK. ruth.plummer@ncl.ac.uk.'}, {'lastname': 'Verheul', 'firstname': 'Henk M', 'initials': 'HM', 'affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.'}, {'lastname': 'De Vos', 'firstname': 'Filip Y F L', 'initials': 'FYFL', 'affiliation': 'University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.'}, {'lastname': 'Leunen', 'firstname': 'Karin', 'initials': 'K', 'affiliation': 'Universitair Ziekenhuis Leuven, Leuven, Belgium.'}, {'lastname': 'Molife', 'firstname': 'L Rhoda', 'initials': 'LR', 'affiliation': 'The Royal Marsden and Institute of Cancer Research, Sutton, UK.'}, {'lastname': 'Rolfo', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Universitair Ziekenhuis Antwerpen, Antwerp, Belgium.'}, {'lastname': 'Grundtvig-Sørensen', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Herlev Hospital, University of Copenhagen, Herlev, Denmark.'}, {'lastname': 'De Grève', 'firstname': 'Jacques', 'initials': 'J', 'affiliation': 'Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Brussels, Belgium.'}, {'lastname': 'Rottey', 'firstname': 'Sylvie', 'initials': 'S', 'affiliation': 'Universitair Ziekenhuis Gent, Ghent, Belgium.'}, {'lastname': 'Jerusalem', 'firstname': 'Guy', 'initials': 'G', 'affiliation': 'CHU Sart-Tilman Liege, Liege University, Liege, Belgium.'}, {'lastname': 'Italiano', 'firstname': 'Antoine', 'initials': 'A', 'affiliation': 'Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre Bordeaux, Bordeaux, France.'}, {'lastname': 'Spicer', 'firstname': 'James', 'initials': 'J', 'affiliation': ""King's College London, Guy's Hospital, London, UK.""}, {'lastname': 'Dirix', 'firstname': 'Luc', 'initials': 'L', 'affiliation': 'Campus Sint-Augustinus, GZA Ziekenhuizen, Antwerp, Belgium.'}, {'lastname': 'Goessl', 'firstname': 'Carsten', 'initials': 'C', 'affiliation': 'AstraZeneca, Gaithersburg, MD, USA.'}, {'lastname': 'Birkett', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': 'AstraZeneca, Macclesfield, UK.'}, {'lastname': 'Spencer', 'firstname': 'Stuart', 'initials': 'S', 'affiliation': 'AstraZeneca, Macclesfield, UK.'}, {'lastname': 'Learoyd', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'AstraZeneca, Cambridge, UK.'}, {'lastname': 'Bailey', 'firstname': 'Christopher', 'initials': 'C', 'affiliation': 'AstraZeneca, Cambridge, UK.'}, {'lastname': 'Dean', 'firstname': 'Emma', 'initials': 'E', 'affiliation': 'The Christie NHS Foundation Trust, University of Manchester, Manchester, UK.'}]",,,Seventy-nine patients (20.3% with breast cancer) received treatment in part A; 72 completed part A and 69 entered part B. Anastrozole and letrozole had no effect on the PK profile of olaparib and vice versa. Co-administration with tamoxifen produced a modest decrease in exposure to olaparib [geometric least-squares mean (GLSmean) C,,10.1007/s12325-018-0804-z,<Element 'PubmedArticle' at 0x7f05dc7f72c0>
108,"30223827
26111096
18043678
20934926
11738103
26950049
11967923
18008354
26332308
25709784
27938518
16252094
20124393
12447914
23933994
21691752
19429265
20804629
9280130
9212818
36810
4831804
942051
11328886
24332378
25542992
26003521
22783848
25837702
19883798
23853633
27838343
24063297
25201602
26938720
15253891
19398656
21804631
19260847
19110071
18298010
16793327
18846107
18554864
20509324
16107271
27087316
20832445
26757429
25957528
19234314
25276168
25539540
21476075
29216642
28959654
27034737
26148612
25323734
25789226",Ameliorative effect of taurine-chloramine in azathioprine-induced testicular damage; a deeper insight into the mechanism of protection.,"The male reproductive system is a sensitive and intricate process that can be distressed following exposure to various toxicants. Therapeutic drugs, especially chemotherapeutics, can also adversely affect male fertility by instigating hormonal changes leading to testicular cells injury. Azathioprine (AZA) is an effective anticancer drug, but some cases of testicular toxicity have been reported. The aim of this work was to investigate the protective effects of taurine chloramine (TAU-Cl), a reported antioxidant and antiinflammtory peptide, against AZA-induced testicular dysfunction in male rats and ascertain the contributing mechanisms.
Forty male rats were allocated into four equal groups; (i) normal control rats, (ii) TAU-Cl group (100 mg/kg b.w/day for 10 weeks, (iii) AZA group (5 mg/day for 4 weeks); (iv) TAU-Cl/AZA group.
AZA caused increased DNA damage in the testes, and alterations in sex hormones and sperm quality, including sperm count, viability, and motility. Moreover, testicular tissue from the AZA-treated group had increased levels of oxidative stress indicator, MDA, and decreased activity of the antioxidant enzymes as superoxide dismutase (SOD), reduced glutathione (GSH) and catalase (CAT) levels. These deleterious events were accompanied by upregulated levels of the pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-α), and protein expression of iNOS and NFκB-p65, interleukin-1beta (IL-1β), and proapoptotic marker; caspase-9, together with decreased Bcl-2, NrF2 and hemeoxygenase (HO-1) expression. In contrast, TAU-Cl pretreatment significantly abrogated these toxic effects which were confirmed histologically.
Pretreatment with TAU-Cl exerts a protective effect against AZA-induced male reproductive testicular atrophy. This finding could open new avenues for the use of TAU-Cl as a complementary approach to chemotherapy supportive care.","['Azathioprine', 'Bcl-2, Caspase-9', 'DNA fragmentation', 'IL-1β', 'Taurine-chloramine', 'Testicular atrophy']",BMC complementary and alternative medicine,2018-09-19,"[{'lastname': 'Schaalan', 'firstname': 'Mona F', 'initials': 'MF', 'affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Misr International University, Km 28, Cairo-Ismailia road, PO Box 1, Heliopolis, Cairo, Egypt. Mona.schaalan@miuegypt.edu.eg.'}, {'lastname': 'Ramadan', 'firstname': 'Basma K', 'initials': 'BK', 'affiliation': 'Department of Physiology, Faculty of Medicine for Girls (Cairo), Al-Azhar University, Cairo, Egypt.'}, {'lastname': 'H Abd Elwahab', 'firstname': 'Azza', 'initials': 'A', 'affiliation': 'Department of Physiology, Faculty of Medicine for Girls (Cairo), Al-Azhar University, Cairo, Egypt.'}]",,Pretreatment with TAU-Cl exerts a protective effect against AZA-induced male reproductive testicular atrophy. This finding could open new avenues for the use of TAU-Cl as a complementary approach to chemotherapy supportive care.,"AZA caused increased DNA damage in the testes, and alterations in sex hormones and sperm quality, including sperm count, viability, and motility. Moreover, testicular tissue from the AZA-treated group had increased levels of oxidative stress indicator, MDA, and decreased activity of the antioxidant enzymes as superoxide dismutase (SOD), reduced glutathione (GSH) and catalase (CAT) levels. These deleterious events were accompanied by upregulated levels of the pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-α), and protein expression of iNOS and NFκB-p65, interleukin-1beta (IL-1β), and proapoptotic marker; caspase-9, together with decreased Bcl-2, NrF2 and hemeoxygenase (HO-1) expression. In contrast, TAU-Cl pretreatment significantly abrogated these toxic effects which were confirmed histologically.",,"10.1186/s12906-018-2272-z
10.2460/ajvr.76.7.649
10.1038/ncpgasthep1000
10.1016/j.dld.2010.09.001
10.1016/S0168-8278(01)00196-9
10.1002/tera.10043
10.1002/em.20352
10.1097/MIB.0000000000000570
10.3949/ccjm.83a.15050
10.1007/s00418-005-0095-8
10.1093/humrep/dep475
10.1002/1521-4184(200212)335:9<411::AID-ARDP411>3.0.CO;2-D
10.1007/s00726-013-1545-6
10.1007/s00726-011-0962-7
10.1016/j.toxlet.2009.03.001
10.1186/1423-0127-17-S1-S9
10.1177/019262339702500415
10.3168/jds.S0022-0302(61)89916-5
10.1177/002215549704500702
10.1016/0003-2697(79)90738-3
10.1159/000136485
10.1016/0003-2697(76)90527-3
10.1093/nar/29.9.e45
10.1016/j.fertnstert.2013.10.048
10.1016/j.taap.2014.12.007
10.1016/j.freeradbiomed.2015.05.020
10.1111/j.1442-200X.2012.03695.x
10.1093/molehr/gav014
10.1016/j.intimp.2009.10.013
10.1016/j.fct.2016.11.008
10.3109/10799893.2013.839999
10.3892/mmr.2014.2544
10.1371/journal.pone.0149353
10.1152/ajpcell.00042.2004
10.1161/HYPERTENSIONAHA.109.129924
10.1016/S1642-431X(12)60047-3
10.1111/j.1439-0272.2008.00897.x
10.1016/j.mrgentox.2008.11.011
10.3844/ajavsp.2011.153.159
10.1016/j.mrgentox.2006.04.019
10.1038/cdd.2008.150
10.1016/j.reprotox.2008.04.009
10.1016/j.mrfmmm.2004.09.018
10.5897/AJCPATH14.012
10.1002/tox.22274
10.1016/j.fct.2010.09.004
10.1111/andr.12154
10.1007/s00726-015-1995-0
10.2164/jandrol.108.006270
10.3906/sag-1308-20
10.1007/s00726-011-0904-4
10.1159/000485762
10.1016/j.toxrep.2017.06.002
10.4103/0973-1482.151933
10.1007/s00726-014-1840-x",<Element 'PubmedArticle' at 0x7f05dc80d180>
109,30165141,"E-selectin-targeted copolymer reduces atherosclerotic lesions, adverse cardiac remodeling, and dysfunction.","Endothelial activation with up-regulation of E-selectin adhesion molecules mediates leukocyte rolling along the vascular wall and controls inflammation in many diseases including atherosclerosis and heart failure. Therefore, we aimed to test the hypothesis that inhibition of E-selectin-mediated interactions by a new E-selectin-targeted copolymer could inhibit the progression of atherosclerosis. To target E-selectin on activated endothelium, we developed a new N-(2-hydroxypropyl)methacrylamide (HPMA)-based E-selectin binding copolymer with or without dexamethasone (Dex) (designated P-(Esbp)-Dex and P-Esbp, respectively). To determine the effect of P-(Esbp)-Dex and P-Esbp on atherosclerosis, we allocated ApoE ","['Adhesion molecules', 'Atherosclerosis', 'E-selectin', 'Inflammation', 'Nano-medicine']",Journal of controlled release : official journal of the Controlled Release Society,2018-08-31,"[{'lastname': 'Tsoref', 'firstname': 'Olga', 'initials': 'O', 'affiliation': 'Tamman Cardiovascular Research Institute, Sheba Medical Center, Ramat Gan, Israel; Neufeld Cardiac Research Institute, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'lastname': 'Tyomkin', 'firstname': 'Dalia', 'initials': 'D', 'affiliation': 'Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.'}, {'lastname': 'Amit', 'firstname': 'Uri', 'initials': 'U', 'affiliation': 'Tamman Cardiovascular Research Institute, Sheba Medical Center, Ramat Gan, Israel; Neufeld Cardiac Research Institute, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'lastname': 'Landa', 'firstname': 'Natalie', 'initials': 'N', 'affiliation': 'Tamman Cardiovascular Research Institute, Sheba Medical Center, Ramat Gan, Israel; Neufeld Cardiac Research Institute, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'lastname': 'Cohen-Rosenboim', 'firstname': 'Osnat', 'initials': 'O', 'affiliation': 'Tamman Cardiovascular Research Institute, Sheba Medical Center, Ramat Gan, Israel; Neufeld Cardiac Research Institute, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'lastname': 'Kain', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Tamman Cardiovascular Research Institute, Sheba Medical Center, Ramat Gan, Israel; Neufeld Cardiac Research Institute, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'lastname': 'Golan', 'firstname': 'Moran', 'initials': 'M', 'affiliation': 'Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.'}, {'lastname': 'Naftali-Shani', 'firstname': 'Nili', 'initials': 'N', 'affiliation': 'Tamman Cardiovascular Research Institute, Sheba Medical Center, Ramat Gan, Israel; Neufeld Cardiac Research Institute, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'lastname': 'David', 'firstname': 'Ayelet', 'initials': 'A', 'affiliation': 'Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel. Electronic address: ayeletda@bgu.ac.il.'}, {'lastname': 'Leor', 'firstname': 'Jonathan', 'initials': 'J', 'affiliation': 'Tamman Cardiovascular Research Institute, Sheba Medical Center, Ramat Gan, Israel; Neufeld Cardiac Research Institute, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: leorj@post.tau.ac.il.'}]",,,,Copyright © 2018. Published by Elsevier B.V.,10.1016/j.jconrel.2018.08.029,<Element 'PubmedArticle' at 0x7f05dc774ef0>
110,"30131669
24623176
26432245
8065934
15985573
15213207
23545426
22248573
14624021
25964245
15582279
12325053
11449190
19744108
12668243
26154489
26139635
28968746
14745052
8232972
26644522
27737437
18666210
8030628
14745075
16785599
17701901
25174004
28241356
15383512
19428144
2324335
12809076
23089633
15045695
26194308
14573323
11982672",Genetic Variation in the Androgen Receptor and Measures of Plasma Testosterone Levels Suggest Androgen Dysfunction in Alzheimer's Disease.,"Alzheimer's disease (AD) prevalence varies by sex, suggesting that sex chromosomes, sex hormones and/or their signaling could potentially modulate AD risk and progression. Low testosterone levels are reported in men with AD. Further, variation in the androgen receptor (AR) gene has been associated with AD risk and cognitive impairment. We assessed measures of plasma testosterone levels as a biomarker of AD in male participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Baseline testosterone levels were significantly different between clinical diagnosis groups [cognitively normal controls, mild cognitive impairment (MCI), or AD], with the lowest testosterone levels in men with AD. Lower baseline testosterone levels were associated with higher baseline clinical severity. Change in testosterone levels between baseline and 1-year follow-up varied by diagnosis; MCI had the greatest decreases in testosterone levels between baseline and 1-year follow-up. Despite differences by clinical diagnosis, there was no association between plasma testosterone and CSF biomarkers of AD pathology. We also tested single nucleotide polymorphisms (SNPs) in ","['Alzheimer’s disease', 'androgen receptor', 'biomarker', 'steroid', 'testosterone']",Frontiers in neuroscience,2018-08-23,"[{'lastname': 'Carr', 'firstname': 'Jessie S', 'initials': 'JS', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States.'}, {'lastname': 'Bonham', 'firstname': 'Luke W', 'initials': 'LW', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States.\nDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States.\nSchool of Medicine, Johns Hopkins University, Baltimore, MD, United States.'}, {'lastname': 'Morgans', 'firstname': 'Alicia K', 'initials': 'AK', 'affiliation': 'Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States.'}, {'lastname': 'Ryan', 'firstname': 'Charles J', 'initials': 'CJ', 'affiliation': 'Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, United States.'}, {'lastname': 'Yokoyama', 'firstname': 'Jennifer S', 'initials': 'JS', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States.'}, {'lastname': 'Geier', 'firstname': 'Ethan G', 'initials': 'EG', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,,"10.3389/fnins.2018.00529
10.1002/ana.24135
10.1038/nature15393
10.1093/nar/22.15.3181
10.1212/01.WNL.0000165995.98986.F1
10.1001/jama.291.24.2959
10.1016/j.neurobiolaging.2013.02.017
10.1016/j.neuroimage.2012.01.021
10.3233/JAD-2003-5401
10.1200/JCO.2014.60.1963
10.1016/j.exger.2004.06.019
10.1002/gps.714
10.1111/j.1365-2265.2009.03692.x
10.1016/S0304-3940(03)00069-7
10.1007/s12035-015-9315-y
10.1093/bioinformatics/btv402
10.1093/bioinformatics/btx561
10.1212/WNL.62.2.188
10.1212/WNL.43.11.2412-a
10.1200/JCO.2015.63.6266
10.1001/jamaoncol.2016.3662
10.1002/cncr.23658
10.1093/oxfordjournals.aje.a117244
10.1212/01.WNL.0000094199.60829.F5
10.1385/ENDO:29:2:233
10.1086/519795
10.1038/nn.3801
10.1001/jama.2016.21044
10.1001/jama.292.12.1431-b
10.1016/j.neurobiolaging.2009.04.008
10.1002/cne.902940107
10.1080/tam.6.1.13.17
10.1038/mp.2012.147
10.1016/j.metabol.2003.11.020
10.1016/j.jalz.2015.05.007
10.1016/S0006-3223(03)00115-X
10.1046/j.1532-5415.2002.50166.x",<Element 'PubmedArticle' at 0x7f05dc784a90>
111,30081082,"Neuroprotective effect of treadmill exercise against blunted brain insulin signaling, NADPH oxidase, and Tau hyperphosphorylation in rats fed a high-fat diet.","Obesity induces oxidative stress by causing hyperglycemia and insulin resistance, while contributing to cognitive and memory decline by inducing insulin resistance in the brain and hyperphosphorylation of Tau proteins. We aimed to investigate the effects of treadmill exercise in improving these obesity-induced pathological phenomena. Sprague-Dawley rats aged 20 weeks were fed a high-fat diet (HFD) for 20 weeks to induce obesity. The rats were subsequently subjected to treadmill exercise (progressively increasing load intensity) for 8 weeks. The rats were divided into three groups: normal diet-control (n = 15), HFD-control (n = 15), and HFD-treadmill exercise (n = 15). We performed water maze and passive avoidance tests and assessed weight, area under the curve, homeostatic model assessment of insulin resistance, and abdominal visceral fat/body weight. Western blot was used to examine protein expression related to brain insulin signaling, tau hyperphosphorylation, and NADPH oxidase, and immunohistochemistry was performed to examine the immunoreactivity of p-Tau (Ser 202/Thr 205) and p22-phox. Treadmill exercise effectively rescued brain insulin signaling, hyperphosphorylation and aggregation of Tau protein, and NADPH oxidase activation in the high fat diet group. Furthermore, it improved insulin resistance inhibitors, decreased abdominal fat mass, inhibited weight gain, and rescued learning and memory. Obesity-induced insulin resistance contributes to cognitive decline, such as reduced learning and memory, but physical activity, such as treadmill exercise, was found to have a positive effect on brain function by improving thesepathological phenomena. Therefore, we suggest that treadmill exercise must be considered in the prevention and treatment of metabolic and neurodegenerative diseases.","['Alzheimer’s disease', 'Brain insulin signaling', 'NADPH oxidase', 'Tau hyperphosphorylation', 'Type 2 diabetes mellitus']",Brain research bulletin,2018-08-07,"[{'lastname': 'Jeong', 'firstname': 'Jae-Hoon', 'initials': 'JH', 'affiliation': 'Department of Physical Education, Hanyang University, 222, Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea.'}, {'lastname': 'Koo', 'firstname': 'Jung-Hoon', 'initials': 'JH', 'affiliation': 'Exercise Biochemistry Laboratory, Korea National Sport University, 1239, Yangjae-daero, Songpa-gu, Seoul 05541, Republic of Korea.'}, {'lastname': 'Cho', 'firstname': 'Joon-Yong', 'initials': 'JY', 'affiliation': 'Exercise Biochemistry Laboratory, Korea National Sport University, 1239, Yangjae-daero, Songpa-gu, Seoul 05541, Republic of Korea.'}, {'lastname': 'Kang', 'firstname': 'Eun-Bum', 'initials': 'EB', 'affiliation': 'Division of Sports Science, College of Health and Medical Science, Daejeon University, 62 Daehak-ro, Dong-gu, Daejeon 34520, Republic of Korea. Electronic address: kbume23@gmail.com.'}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,10.1016/j.brainresbull.2018.08.001,<Element 'PubmedArticle' at 0x7f05dc523db0>
112,"30073505
10536278
11074263
11248117
11278740
12895417
14643377
15020250
15870194
15964100
16092951
16120771
16493415
1656157
16936707
17639074
17942819
18040829
18430999
18439434
18463290
18486110
18549783
18569016
19188609
19217170
19458242
19887566
20178983
20571484
20837517
20934413
21241799
21266573
21483094
21532579
21683721
21741995
21772323
21911655
22035587
22119441
22202101
22275369
22476196
22476197
22584576
22776971
22869320
22936005
23046860
23135822
23485579
24095978
24568842
24735980
24910612
25232124
25576061
25609597
25645581
25889938
26136647
26366437
26401706
26462756
26606243
26698666
26879001
27166089
27190008
27222390
27426863
27432942
27457264
27626216
28034760
28259806
28400135
28402338
28539885
28635330
29257872
29377010
29382825
29981845
3544219",Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease.,"Impairment of biliverdin reductase-A (BVR-A) is an early event leading to brain insulin resistance in AD. Intranasal insulin (INI) administration is under evaluation as a strategy to alleviate brain insulin resistance; however, the molecular mechanisms underlying INI beneficial effects are still unclear. We show that INI improves insulin signaling activation in the hippocampus and cortex of adult and aged 3×Tg-AD mice by ameliorating BVR-A activation. These changes were associated with a reduction of nitrosative stress, Tau phosphorylation, and Aβ oligomers in brain, along with improved cognitive functions. The role of BVR-A was strengthened by showing that cells lacking BVR-A: (i) develop insulin resistance if treated with insulin and (ii) can be recovered from insulin resistance only if treated with a BVR-A-mimetic peptide. These novel findings shed light on the mechanisms underlying INI treatment effects and suggest BVR-A as potential therapeutic target to prevent brain insulin resistance in AD.","['Alzheimer disease', 'Biliverdin reductase-A', 'Insulin resistance', 'Intranasal', 'Neuroprotection']",Molecular neurobiology,2018-08-04,"[{'lastname': 'Barone', 'firstname': 'Eugenio', 'initials': 'E', 'affiliation': 'Department of Biochemical Sciences ""A. Rossi-Fanelli"", Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy.\nInstituto de Ciencias Biomédicas, Facultad de Salud, Universidad Autónoma de Chile, Avenida Pedro de Valdivia 425, Providencia, Santiago, Chile.'}, {'lastname': 'Tramutola', 'firstname': 'Antonella', 'initials': 'A', 'affiliation': 'Department of Biochemical Sciences ""A. Rossi-Fanelli"", Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Triani', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': 'Department of Biochemical Sciences ""A. Rossi-Fanelli"", Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Calcagnini', 'firstname': 'Silvio', 'initials': 'S', 'affiliation': 'Department of Physiology and Pharmacology ""V. Erspamer"", Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Di Domenico', 'firstname': 'Fabio', 'initials': 'F', 'affiliation': 'Department of Biochemical Sciences ""A. Rossi-Fanelli"", Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Ripoli', 'firstname': 'Cristian', 'initials': 'C', 'affiliation': 'Institute of Human Physiology, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.\nFondazione Policlinico Universitario A. Gemelli IRCCS, 00168, Rome, Italy.'}, {'lastname': 'Gaetani', 'firstname': 'Silvana', 'initials': 'S', 'affiliation': 'Department of Physiology and Pharmacology ""V. Erspamer"", Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Grassi', 'firstname': 'Claudio', 'initials': 'C', 'affiliation': 'Institute of Human Physiology, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.\nFondazione Policlinico Universitario A. Gemelli IRCCS, 00168, Rome, Italy.'}, {'lastname': 'Butterfield', 'firstname': 'D Allan', 'initials': 'DA', 'affiliation': 'Department of Chemistry, Markey Cancer Center, and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40506-0055, USA.'}, {'lastname': 'Cassano', 'firstname': 'Tommaso', 'initials': 'T', 'affiliation': 'Department of Clinical and Experimental Medicine, University of Foggia, Via L. Pinto, 71122, Foggia, Italy. tommaso.cassano@unifg.it.'}, {'lastname': 'Perluigi', 'firstname': 'Marzia', 'initials': 'M', 'affiliation': 'Department of Biochemical Sciences ""A. Rossi-Fanelli"", Sapienza University of Rome, Piazzale A. Moro 5, 00185, Rome, Italy. marzia.perluigi@uniroma1.it.'}]",,,,,10.1007/s12035-018-1231-5,<Element 'PubmedArticle' at 0x7f05dc52f900>
113,"30071860
20609967
24416343
16487830
16231753
22453289
19782765
23011912
21388274
9495860
9622149
14699000
8348686
20863707
22474255
18602635
16412867
21840335
22932268
18040027
15236764
10693811
11095969
12939617
14706864
15254550
17112576
18990685
27633970
27884680
20175764
26673217
23537701
19426696
27448767
19879981
22444502
22895668
18323402
27153943
28887535
24356600
26297672
8238377
15276467
9719054
10841519
17011502
18582964
23577024
10839530
27519769
19687505
21635224
16936699
21293009
25562138
26112889
28870631
28883902
28770830
19262508
15744310
20068143
23698802
26956801
27224420
25853493
24658657
22445099",Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α'.,"Metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (DM2) are all linked to diabetic cardiomyopathy that lead to heart failure. Cardiomyopathy is initially characterized by cardiomyocyte hypertrophy, followed by mitochondrial dysfunction and fibrosis, both of which are aggravated by angiotensin. Caloric restriction (CR) is cardioprotective in animal models of heart disease through its catabolic activity and activation of the expression of adaptive genes. We hypothesized that in the diabetic heart; this effect involves antioxidant defenses and is mediated by SIRT1 and the transcriptional coactivator PGC-1α (Peroxisome proliferator-activated receptor-γ coactivator).
Obese Leptin resistant (db/db) mice characterized by DM2 were treated with angiotensin II (AT) for 4 weeks to enhance the development of cardiomyopathy. Mice were concomitantly either on a CR diet or fed ad libitum. Cardiomyocytes were exposed to high levels of glucose and were treated with EX-527 (SIRT1 inhibitor). Cardiac structure and function, gene and protein expression and oxidative stress parameters were analyzed.
AT treated db/db mice developed cardiomyopathy manifested by elevated levels of serum glucose, cholesterol and cardiac hypertrophy. Leukocyte infiltration, fibrosis and an increase in an inflammatory marker (TNFα) and natriuretic peptides (ANP, BNP) gene expression were also observed. Oxidative stress was manifested by low SOD and PGC-1α levels and an increase in ROS and MDA. DM2 resulted in ERK1/2 activation. CR attenuated all these deleterious perturbations and prevented the development of cardiomyopathy. ERK1/2 phosphorylation was reduced in CR mice (p = 0.008). Concomitantly CR prevented the reduction in SIRT activity and PGC-1α (p < 0.04). Inhibition of SIRT1 activity in cardiomyocytes led to a marked reduction in both SIRT1 and PGC-1α. ROS levels were significantly (p < 0.03) increased by glucose and SIRT1 inhibition.
In the current study we present evidence of the cardioprotective effects of CR operating through SIRT1 and PGC-1 α, thereby decreasing oxidative stress, fibrosis and inflammation. Our results suggest that increasing SIRT1 and PGC-1α levels offer new therapeutic approaches for the protection of the diabetic heart.","['Caloric restriction', 'Cardiomyopathy', 'Diabetes mellitus', 'PGC-1α', 'SIRT1']",Cardiovascular diabetology,2018-08-04,"[{'lastname': 'Waldman', 'firstname': 'Maayan', 'initials': 'M', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.\nLeviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Cohen', 'firstname': 'Keren', 'initials': 'K', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.\nLeviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Yadin', 'firstname': 'Dor', 'initials': 'D', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.\nLeviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Nudelman', 'firstname': 'Vadim', 'initials': 'V', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Gorfil', 'firstname': 'Dan', 'initials': 'D', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Laniado-Schwartzman', 'firstname': 'Michal', 'initials': 'M', 'affiliation': 'Department of Pharmacology, New York Medical College, Valhalla, NY, 10595, USA.'}, {'lastname': 'Kornwoski', 'firstname': 'Ran', 'initials': 'R', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Aravot', 'firstname': 'Dan', 'initials': 'D', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Abraham', 'firstname': 'Nader G', 'initials': 'NG', 'affiliation': 'Department of Pharmacology, New York Medical College, Valhalla, NY, 10595, USA.'}, {'lastname': 'Arad', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Leviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Hochhauser', 'firstname': 'Edith', 'initials': 'E', 'affiliation': 'Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. hochhaus@post.tau.ac.il.\nFelsenstein Research Center, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Jabotinsky St, 49100, Petach Tikva, Israel. hochhaus@post.tau.ac.il.'}]",,"In the current study we present evidence of the cardioprotective effects of CR operating through SIRT1 and PGC-1 α, thereby decreasing oxidative stress, fibrosis and inflammation. Our results suggest that increasing SIRT1 and PGC-1α levels offer new therapeutic approaches for the protection of the diabetic heart.","AT treated db/db mice developed cardiomyopathy manifested by elevated levels of serum glucose, cholesterol and cardiac hypertrophy. Leukocyte infiltration, fibrosis and an increase in an inflammatory marker (TNFα) and natriuretic peptides (ANP, BNP) gene expression were also observed. Oxidative stress was manifested by low SOD and PGC-1α levels and an increase in ROS and MDA. DM2 resulted in ERK1/2 activation. CR attenuated all these deleterious perturbations and prevented the development of cardiomyopathy. ERK1/2 phosphorylation was reduced in CR mice (p = 0.008). Concomitantly CR prevented the reduction in SIRT activity and PGC-1α (p < 0.04). Inhibition of SIRT1 activity in cardiomyocytes led to a marked reduction in both SIRT1 and PGC-1α. ROS levels were significantly (p < 0.03) increased by glucose and SIRT1 inhibition.",,"10.1186/s12933-018-0754-4
10.1016/S0140-6736(10)60484-9
10.1371/journal.pone.0085078
10.1016/j.jacc.2005.09.050
10.1291/hypres.28.483
10.1007/s10741-012-9313-3
10.1016/j.bbalip.2009.09.014
10.1002/path.4113
10.1667/RR1950.1
10.1161/01.HYP.31.6.1324
10.1161/01.HYP.0000111831.50834.93
10.1161/01.RES.73.3.413
10.1016/j.tibs.2010.07.003
10.1016/j.atherosclerosis.2008.05.036
10.1016/j.jacc.2005.08.069
10.1016/j.mam.2011.07.001
10.1038/nature11432
10.1161/CIRCULATIONAHA.107.725697
10.1016/j.exger.2004.03.024
10.1038/35001622
10.1006/bbrc.2000.3854
10.1038/nature01960
10.1016/S0014-5793(03)01444-3
10.1038/nature02789
10.1016/j.cell.2006.11.013
10.1074/jbc.M805301200
10.1016/j.tips.2016.08.001
10.1016/j.yexcr.2016.11.016
10.1371/journal.pone.0144593
10.1016/j.bcp.2013.03.014
10.1016/j.bcp.2009.02.010
10.1016/j.yexcr.2016.07.020
10.1016/j.bbapap.2009.10.022
10.1016/j.jnutbio.2011.11.002
10.1161/ATVBAHA.111.241984
10.1124/pr.107.07104
10.1186/s12933-016-0383-8
10.1038/s41467-017-00664-8
10.2337/dc13-1423
10.1016/j.pharmthera.2015.08.003
10.1152/ajprenal.1993.265.4.F477
10.1016/j.cardiores.2004.04.030
10.1161/01.HYP.32.2.273
10.1172/JCI7818
10.1016/j.cmet.2006.09.005
10.1016/j.ijcard.2008.03.080
10.1038/35013000
10.1186/s12933-016-0430-5
10.1194/jlr.R001115
10.1042/BJ20101484
10.1038/nrm1983
10.1161/CIRCRESAHA.110.224287
10.1016/j.copbio.2014.12.007
10.1093/eurheartj/ehv290
10.1016/j.atherosclerosis.2017.08.027
10.1038/aps.2017.50
10.1038/nature07813
10.1038/nature03354
10.2337/db09-1187
10.1038/hr.2013.48
10.1186/s12933-016-0361-1
10.1089/scd.2016.0072
10.1371/journal.pone.0125176
10.1371/journal.pone.0092246
10.1016/j.cjca.2012.01.013",<Element 'PubmedArticle' at 0x7f05dc5555e0>
114,30060819,Quantitative fluorescence in situ hybridization for investigation of telomere length dynamics in the pituitary gland using samples from 128 autopsied patients.,"In order to investigate the population dynamics of telomere status, we measured the telomere lengths of glandular cells in the adenohypophysis (AH) and pituicytes, a type of glial cell, in the neurohypophysis (NH) of 128 autopsied humans (65 men, 63 women, 0 and 102 years) using our original quantitative fluorescence in situ hybridization (Q-FISH) method. Telomeres in the AH shortened with aging in both men and women, but those of pituicytes did not. Pituicyte telomeres were significantly longer in women than in men. The data suggest that telomeres shorten with age in the AH, whereas those in pituicytes maintain a constant length throughout life. Comparison of pituicyte telomere lengths among 5 generations, <18, 18-69, 70-79, 80-89, and >90 years, revealed a tendency for telomeres to be longer in individuals in their 80 s and 90 s than in those in their 70 s. These findings lend support to the widely held notion that humans with longer telomeres may have a longer life span, and shed light on the biology of pituitary gland in terms of telomere length dynamics, as well contributing to the development of bioengineered hormone-producing cell replacement strategies and regenerative therapies.","['Adenohypophysis', 'Neurohypophysis', 'Q-FISH', 'Telomere']",Tissue & cell,2018-08-01,"[{'lastname': 'Hiraishi', 'firstname': 'Naoki', 'initials': 'N', 'affiliation': 'Clinical Laboratory Department, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya-ku, Tokyo 150-8935, Japan; Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan.'}, {'lastname': 'Terai', 'firstname': 'Masanori', 'initials': 'M', 'affiliation': 'Department of Judotherapy, Faculty of Health Sciences, Tokyo Ariake University of Medical and Health Sciences, Tokyo 135-0063, Japan; Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan. Electronic address: terai@tau.ac.jp.'}, {'lastname': 'Fujiwara', 'firstname': 'Mutsunori', 'initials': 'M', 'affiliation': 'Clinical Laboratory Department, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya-ku, Tokyo 150-8935, Japan; Department of Pathology, Nissan Tamagawa Hospital, 4-8-1 Seta, Setagaya-ku, Tokyo 158-0095, Japan.'}, {'lastname': 'Aida', 'firstname': 'Junko', 'initials': 'J', 'affiliation': 'Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan; Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo 173-0015, Japan.'}, {'lastname': 'Izumiyama-Shimomura', 'firstname': 'Naotaka', 'initials': 'N', 'affiliation': 'Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan.'}, {'lastname': 'Ishikawa', 'firstname': 'Naoshi', 'initials': 'N', 'affiliation': 'Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan.'}, {'lastname': 'Tomita', 'firstname': 'Ken-Ichiro', 'initials': 'KI', 'affiliation': 'Department of Pathology, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya-ku, Tokyo 150-8935, Japan; Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan.'}, {'lastname': 'Matsuda', 'firstname': 'Yoko', 'initials': 'Y', 'affiliation': 'Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan; Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo 173-0015, Japan.'}, {'lastname': 'Arai', 'firstname': 'Tomio', 'initials': 'T', 'affiliation': 'Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan; Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo 173-0015, Japan.'}, {'lastname': 'Takubo', 'firstname': 'Kaiyo', 'initials': 'K', 'affiliation': 'Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan.'}, {'lastname': 'Ishiwata', 'firstname': 'Toshiyuki', 'initials': 'T', 'affiliation': 'Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan; Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo 173-0015, Japan. Electronic address: tishiwat@tmig.or.jp.'}]",,,,Copyright © 2018 Elsevier Ltd. All rights reserved.,10.1016/j.tice.2018.05.008,<Element 'PubmedArticle' at 0x7f05dc44a680>
115,"30010122
20971753
19884572
21986680
21382304
21810890
25486967
25958088
26473392
24898651
18245784
28238272
25662776
29172163
21693094
9153155
17761438
18848632
25255942
20479357
20832997
25743635
17329432
19096369
23825317
23810119
17786822
20559786
25342578
22300873
24521566
27182487
22366795
22080494
27473935
16055780
25113955
20175186
23495075
28458140
16399806
16648344
12053130
25804311
29427365
22366791
26977398
28116236
26096665
28059789
29439333",Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort.,"The overlap between frontotemporal dementia (FTD) and primary psychiatric disorders has been brought to light by reports of prominent neuropsychiatric symptoms (NPS) in FTD-related genetic mutations, particularly among C9orf72 and GRN carriers. It has been recently demonstrated that early neuroanatomical changes in genetic FTD may be different across the major disease-causing mutations.
We aimed to identify whether NPS could be driven by distinct structural correlates.
One hundred and sixty-seven mutation carriers (75 GRN, 60 C9orf72, and 32 MAPT) were included from the Genetic FTD Initiative (GENFI) study, a large international cohort of genetic FTD. Neuropsychiatric symptoms including delusions, hallucinations (visual, auditory, and tactile), depression, and anxiety were investigated using a structured interview. Voxel-based morphometry was performed to identify neuroanatomical correlates of NPS.
Psychotic symptoms correlated mainly with grey matter (GM) atrophy in the anterior insula, left thalamus, cerebellum, and cortical regions including frontal, parietal, and occipital lobes in GRN mutations carriers. GM atrophy in posterior structures of the default-mode network was associated with anxiety in the GRN group. Delusions in C9orf72 expansion carriers were mainly associated with left frontal cortical atrophy. Cerebellar atrophy was found to be correlated only with anxiety in C9orf72 carriers. NPS in the MAPT group were mainly associated with volume loss in the temporal lobe.
Neuroanatomical correlates of NPS appear to be distinct across the main forms of genetic FTD. Overall, our findings support overlapping brain structural changes between FTD and primary psychiatric disorders.","['Frontotemporal dementia', 'genetics', 'magnetic resonance imaging', 'neuropsychiatry']",Journal of Alzheimer's disease : JAD,2018-07-17,"[{'lastname': 'Sellami', 'firstname': 'Leila', 'initials': 'L', 'affiliation': 'Clinique Interdisciplinaire de Mémoire(CIME), Université Laval, QC, Canada.'}, {'lastname': 'Bocchetta', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Masellis', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Cognitive Neurology Research Unit, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences ResearchProgram, Sunnybrook Research Institute; Department of Medicine, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Cash', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.\nCentre for Medical Image Computing, UCL, UK.'}, {'lastname': 'Dick', 'firstname': 'Katrina M', 'initials': 'KM', 'affiliation': 'Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'van Swieten', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Erasmus Medical Center, Rotterdam, Netherlands.'}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'University of Brescia, Brescia, Italy.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Department of Pathophysiologyand Transplantation, ""Dino Ferrari"" Center, University of Milan, Fondazione Cá Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Tartaglia', 'firstname': 'Maria Carmela', 'initials': 'MC', 'affiliation': 'TanzCentre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Rowe', 'firstname': 'James B', 'initials': 'JB', 'affiliation': 'University of Cambridge, Cambridge, UK.'}, {'lastname': 'Graff', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Karolinska Institutet, Stockholm, Sweden; Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Sweden.\nDepartment of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden.'}, {'lastname': 'Tagliavini', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'Istituto Neurologico Carlo Besta, Milan, Italy.'}, {'lastname': 'Frisoni', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'IRCCS San Giovanni di Dio Fatebenefratelli Brescia, Italy.'}, {'lastname': 'Finger', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'Clinique Interdisciplinaire de Mémoire (CIME), Université Laval, QC, Canada.'}, {'lastname': 'de Mendonça', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Faculdade de Medicina, Universidade de Lisboa, Portugal.'}, {'lastname': 'Sorbi', 'firstname': 'Sandro', 'initials': 'S', 'affiliation': 'Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.\nIRCCS Don Carlo Gnocchi, Florence, Italy.'}, {'lastname': 'Warren', 'firstname': 'Jason D', 'initials': 'JD', 'affiliation': 'Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Laforce', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Clinique Interdisciplinaire de Mémoire(CIME), Université Laval, QC, Canada.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,"Neuroanatomical correlates of NPS appear to be distinct across the main forms of genetic FTD. Overall, our findings support overlapping brain structural changes between FTD and primary psychiatric disorders.","Psychotic symptoms correlated mainly with grey matter (GM) atrophy in the anterior insula, left thalamus, cerebellum, and cortical regions including frontal, parietal, and occipital lobes in GRN mutations carriers. GM atrophy in posterior structures of the default-mode network was associated with anxiety in the GRN group. Delusions in C9orf72 expansion carriers were mainly associated with left frontal cortical atrophy. Cerebellar atrophy was found to be correlated only with anxiety in C9orf72 carriers. NPS in the MAPT group were mainly associated with volume loss in the temporal lobe.",,10.3233/JAD-180053,<Element 'PubmedArticle' at 0x7f05dc457950>
116,29961074,Testicular Function and Bone in Young Men with Severe Childhood-Onset Obesity.,"Previous studies suggest increased risk for hypoandrogenism and fractures in men with obesity. We aimed to describe the effects of severe childhood-onset obesity on the cross talk between metabolic state, testes, and skeleton at late puberty.
A cohort of adolescent and young adult males with severe childhood-onset obesity (n = 21, mean age 18.5 years) and an age-matched control group were assessed for testicular hormones and X-ray absorptiometry-derived bone mass.
Current median body mass indexes for the obese and control subjects were 37.4 and 22.9. Severe early-onset obesity manifested with lower free testosterone (median [interquartile range] 244 [194-332] vs. 403 [293-463] pmol/L, p = 0.002). Lower insulin-like 3 (1.02 [0.82-1.23] vs. 1.22 [1.01-1.46] ng/mL, p = 0.045) and lower ratio of testosterone to luteinizing hormone (2.81 [1.96-3.98] vs. 4.10 [3.03-5.83] nmol/IU, p = 0.008) suggested disrupted Leydig cell function. The degree of current obesity inversely correlated with free testosterone (τ = -0.516, p = 0.003), which in turn correlated positively with bone area at all measurement sites in males with childhood-onset obesity.
Severe childhood-onset obesity is associated with impaired Leydig cell function in young men and lower free testosterone may contribute to impaired skeletal characteristics.","['Boys', 'Metabolism', 'Puberty', 'Sex hormones', 'Testosterone']",Hormone research in paediatrics,2018-07-02,"[{'lastname': 'Laakso', 'firstname': 'Saila', 'initials': 'S', 'affiliation': ""Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.""}, {'lastname': 'Viljakainen', 'firstname': 'Heli', 'initials': 'H', 'affiliation': ""Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.\nFolkhälsan Research Center, Biomedicum, Helsinki, Finland.""}, {'lastname': 'Lipsanen-Nyman', 'firstname': 'Marita', 'initials': 'M', 'affiliation': ""Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.""}, {'lastname': 'Turpeinen', 'firstname': 'Ursula', 'initials': 'U', 'affiliation': 'HUSlab, Helsinki University Hospital, Helsinki, Finland.'}, {'lastname': 'Ivaska', 'firstname': 'Kaisa K', 'initials': 'KK', 'affiliation': 'Department of Cell Biology and Anatomy, University of Turku, Turku, Finland.'}, {'lastname': 'Anand-Ivell', 'firstname': 'Ravinder', 'initials': 'R', 'affiliation': 'School of Biosciences, University of Nottingham, Nottingham, United Kingdom.'}, {'lastname': 'Ivell', 'firstname': 'Richard', 'initials': 'R', 'affiliation': 'School of Biosciences, University of Nottingham, Nottingham, United Kingdom.'}, {'lastname': 'Mäkitie', 'firstname': 'Outi', 'initials': 'O', 'affiliation': ""Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.\nFolkhälsan Research Center, Biomedicum, Helsinki, Finland.\nDepartment of Molecular Medicine and Surgery and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.\nDepartment of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.""}]",,,"Current median body mass indexes for the obese and control subjects were 37.4 and 22.9. Severe early-onset obesity manifested with lower free testosterone (median [interquartile range] 244 [194-332] vs. 403 [293-463] pmol/L, p = 0.002). Lower insulin-like 3 (1.02 [0.82-1.23] vs. 1.22 [1.01-1.46] ng/mL, p = 0.045) and lower ratio of testosterone to luteinizing hormone (2.81 [1.96-3.98] vs. 4.10 [3.03-5.83] nmol/IU, p = 0.008) suggested disrupted Leydig cell function. The degree of current obesity inversely correlated with free testosterone (τ = -0.516, p = 0.003), which in turn correlated positively with bone area at all measurement sites in males with childhood-onset obesity.","© 2018 S. Karger AG, Basel.",10.1159/000489818,<Element 'PubmedArticle' at 0x7f05dc345220>
117,"29945658
15148141
20837822
26136647
15288712
3345066
21911655
28634787
24401693
11306609
20961662
18196237
26831110
14747300
23183882
28852028
9854307
3159021
18479783
29078805
8933010
26237226
11916953
16823473
26928090
28596451
28825056
26909319
24416243
15750215
27303627
28721257
22476197
25008180
26214150
15477535
28957663
10395573",iPSC-derived familial Alzheimer's PSEN2 ,"Type 2 diabetes (T2D) is a recognized risk factor for the development of cognitive impairment (CI) and/or dementia, although the exact nature of the molecular pathology of T2D-associated CI remains obscure. One link between T2D and CI might involve decreased insulin signaling in brain and/or neurons in either animal or postmortem human brains as has been reported as a feature of Alzheimer's disease (AD). Here we asked if neuronal insulin resistance is a cell autonomous phenomenon in a familial form of AD.
We have applied a newly developed protocol for deriving human basal forebrain cholinergic neurons (BFCN) from skin fibroblasts via induced pluripotent stem cell (iPSC) technology. We generated wildtype and familial AD mutant PSEN2 
We report herein that wildtype, PSEN2 
Our studies indicate that the familial AD mutation PSEN2 ",[],Molecular neurodegeneration,2018-06-28,"[{'lastname': 'Moreno', 'firstname': 'Cesar L', 'initials': 'CL', 'affiliation': ""Department of Neurology, NFL Neurological Care Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.\nDepartment of Psychiatry, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, 5 E 98th St, New York, NY, 10029, USA.""}, {'lastname': 'Della Guardia', 'firstname': 'Lucio', 'initials': 'L', 'affiliation': 'Department of Medicine, Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.'}, {'lastname': 'Shnyder', 'firstname': 'Valeria', 'initials': 'V', 'affiliation': 'Department of Medicine, Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.'}, {'lastname': 'Ortiz-Virumbrales', 'firstname': 'Maitane', 'initials': 'M', 'affiliation': 'Department of Neurology, NFL Neurological Care Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.'}, {'lastname': 'Kruglikov', 'firstname': 'Ilya', 'initials': 'I', 'affiliation': 'New York Stem Cell Foundation Laboratories, New York, NY, 10032, USA.'}, {'lastname': 'Zhang', 'firstname': 'Bin', 'initials': 'B', 'affiliation': 'Icahn Institute and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.'}, {'lastname': 'Schadt', 'firstname': 'Eric E', 'initials': 'EE', 'affiliation': 'Icahn Institute and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.'}, {'lastname': 'Tanzi', 'firstname': 'Rudolph E', 'initials': 'RE', 'affiliation': 'Genetics and Aging Unit, Harvard Medical School, Massachusetts General Hospital, 114 16th Street, Charlestown, MA, 02129, USA.'}, {'lastname': 'Noggle', 'firstname': 'Scott', 'initials': 'S', 'affiliation': 'New York Stem Cell Foundation Laboratories, New York, NY, 10032, USA. snoggle@nyscf.orgu.'}, {'lastname': 'Buettner', 'firstname': 'Christoph', 'initials': 'C', 'affiliation': 'Department of Medicine, Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. Christoph.buettner@mssm.edu.'}, {'lastname': 'Gandy', 'firstname': 'Sam', 'initials': 'S', 'affiliation': ""Department of Neurology, NFL Neurological Care Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. Samuel.gandy@mssm.edu.\nDepartment of Psychiatry, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, 5 E 98th St, New York, NY, 10029, USA. Samuel.gandy@mssm.edu.""}]",,,"We report herein that wildtype, PSEN2 ",,"10.1186/s13024-018-0265-5
10.1001/archneurol.2010.225
10.3389/fnins.2015.00204
10.1016/j.psyneuen.2004.04.003
10.1002/ana.410230106
10.1001/archneurol.2011.233
10.1007/s11011-017-0050-0
10.1186/1750-1326-9-3
10.1016/j.neurobiolaging.2010.08.015
10.1007/s00259-007-0699-4
10.1073/pnas.1525665113
10.2337/diabetes.53.2.474
10.1038/nrneurol.2012.236
10.1038/s41598-017-09577-4
10.1016/S0962-8924(98)01368-3
10.1073/pnas.82.12.4245
10.1016/j.neurobiolaging.2008.04.002
10.1186/s40478-017-0475-z
10.1007/s001250050588
10.1038/nmeth.3507
10.2337/diabetes.51.4.1256
10.1172/JCI29063
10.1161/STROKEAHA.116.016563
10.1016/j.molmet.2015.11.006
10.1371/journal.pone.0084547
10.3233/JAD-2005-7107
10.1038/npjamd.2015.8
10.1172/JCI59903
10.2337/db14-0375
10.1001/jamaneurol.2015.0613
10.1212/01.WNL.0000140291.86406.D1
10.1016/j.neuron.2017.09.003
10.1016/S0959-4388(99)80045-2",<Element 'PubmedArticle' at 0x7f05dc34fc20>
118,29907977,Melatonin induces mechanisms of brain resilience against neurodegeneration.,"Melatonin is an endogenous pleiotropic molecule which orchestrates regulatory functions and protective capacity against age-related ailments. The increase in circulating levels of melatonin through dietary supplements intensifies its health benefits. Investigations in animal models have shown that melatonin protects against Alzheimer's disease (AD)-like pathology, although clinical studies have not been conclusive. We hypothesized that melatonin induces changes in the brain that prevent or attenuate AD by increasing resilience. Therefore, we treated healthy nontransgenic (NoTg) and AD transgenic (3xTg-AD) 6-month-old mice with a daily dose of 10 mg/kg of melatonin until 12 months of age. As expected, melatonin reversed cognitive impairment and dementia-associated behaviors of anxiety and apathy and reduced amyloid and tau burden in 3xTg-AD mice. Remarkably, melatonin induced cognitive enhancement and higher wellness level-related behavior in NoTg mice. At the mechanism level, NF-κB and proinflammatory cytokine expressions were decreased in both NoTg and 3xTg-AD mice. The SIRT1 pathway of longevity and neuroprotection was also activated in both mouse strains after melatonin dosing. Furthermore, we explored new mechanisms and pathways not previously associated with melatonin treatment such as the ubiquitin-proteasome proteolytic system and the recently proposed neuroprotective Gas6/TAM pathway. The upregulation of proteasome activity and the modulation of Gas6 and its receptors by melatonin were similarly displayed by both NoTg and 3xTg-AD mice. Therefore, these results confirm the potential of melatonin treatment against AD pathology, by way of opening new pathways in its mechanisms of action, and demonstrating that melatonin induces cognitive enhancement and brain resilience against neurodegenerative processes.","['Gas6', 'SIRT1', 'inflammation', 'melatonin', 'neuroprotection', 'proteasome', 'resilience']",Journal of pineal research,2018-06-17,"[{'lastname': 'Corpas', 'firstname': 'Rubén', 'initials': 'R', 'affiliation': ""Institut d'Investigacions Biomèdiques de Barcelona (IIBB), CSIC and IDIBAPS, Barcelona, Spain.\nCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.""}, {'lastname': 'Griñán-Ferré', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Faculty of Pharmacy and Food Sciences, Institut de Neurociències, Universitat de Barcelona and CIBERNED, Barcelona, Spain.'}, {'lastname': 'Palomera-Ávalos', 'firstname': 'Verónica', 'initials': 'V', 'affiliation': 'Faculty of Pharmacy and Food Sciences, Institut de Neurociències, Universitat de Barcelona and CIBERNED, Barcelona, Spain.'}, {'lastname': 'Porquet', 'firstname': 'David', 'initials': 'D', 'affiliation': ""Institut d'Investigacions Biomèdiques de Barcelona (IIBB), CSIC and IDIBAPS, Barcelona, Spain.""}, {'lastname': 'García de Frutos', 'firstname': 'Pablo', 'initials': 'P', 'affiliation': ""Institut d'Investigacions Biomèdiques de Barcelona (IIBB), CSIC and IDIBAPS, Barcelona, Spain.""}, {'lastname': 'Franciscato Cozzolino', 'firstname': 'Silvia M', 'initials': 'SM', 'affiliation': 'Department of Food and Experimental Nutrition, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.'}, {'lastname': 'Rodríguez-Farré', 'firstname': 'Eduard', 'initials': 'E', 'affiliation': ""Institut d'Investigacions Biomèdiques de Barcelona (IIBB), CSIC and IDIBAPS, Barcelona, Spain.\nCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.""}, {'lastname': 'Pallàs', 'firstname': 'Mercè', 'initials': 'M', 'affiliation': 'Faculty of Pharmacy and Food Sciences, Institut de Neurociències, Universitat de Barcelona and CIBERNED, Barcelona, Spain.'}, {'lastname': 'Sanfeliu', 'firstname': 'Coral', 'initials': 'C', 'affiliation': ""Institut d'Investigacions Biomèdiques de Barcelona (IIBB), CSIC and IDIBAPS, Barcelona, Spain.\nCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.""}, {'lastname': 'Cardoso', 'firstname': 'Bárbara R', 'initials': 'BR', 'affiliation': 'Institute for Physical Activity and Nutrition Research (IPAN), School of Exercise and Nutrition Sciences, Deakin\xa0University, Geelong, Vic., Australia.\nThe Florey Institute of Neuroscience and Mental Health, Melbourne, Vic., Australia.'}]",,,,© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.,10.1111/jpi.12515,<Element 'PubmedArticle' at 0x7f05dc2f34f0>
119,"29796989
10403175
10560925
10844026
11145972
11224546
11603044
11844744
11994750
12191816
12440572
12798262
12832561
12915350
1379612
14976517
15046861
15184598
15325781
15483087
15505375
15745981
15757863
15928247
16004982
16150911
16549764
16725120
17050710
17199430
17381359
17543038
18391188
18585460
18680156
19263040
19276542
19419557
19547756
19584178
20021390
20403092
20458138
20886273
20970492
22070634
22324892
22674261
22870949
23159010
23389809
24106641
24205791
24216002
24484699
24744751
24910631
24978200
25582288
25623236
25896972
26089777
26175217
26747302
26770096
27051079
27258653
27501182
28390960
28855267
7923378
8344193
8641203
8894063
9013778
9275045
9387861
9832432","Thyroid Hormone Supplementation Restores Spatial Memory, Hippocampal Markers of Neuroinflammation, Plasticity-Related Signaling Molecules, and β-Amyloid Peptide Load in Hypothyroid Rats.","Hypothyroidism is a condition that becomes more prevalent with age. Patients with untreated hypothyroidism have consistently reported symptoms of severe cognitive impairments. In patients suffering hypothyroidism, thyroid hormone supplementation offers the prospect to alleviate the cognitive consequences of hypothyroidism; however, the therapeutic value of TH supplementation remains at present uncertain and the link between cellular modifications associated with hypothyroidism and neurodegeneration remains to be elucidated. In the present study, we therefore evaluated the molecular and behavioral consequences of T3 hormone replacement in an animal model of hypothyroidism. We have previously reported that the antithyroid molecule propylthiouracil (PTU) given in the drinking water favors cerebral atrophy, brain neuroinflammation, Aβ production, Tau hyperphosphorylation, and altered plasticity-related cell-signaling pathways in the hippocampus in association with hippocampal-dependent spatial memory deficits. In the present study, our aim was to explore, in this model, the effect of hippocampal T3 signaling normalization on various molecular mechanisms involved in learning and memory that goes awry under conditions of hypothyroidism and to evaluate its potential for recovery of hippocampal-dependent memory deficits. We report that T3 supplementation can alleviate hippocampal-dependent memory impairments displayed by hypothyroid rats and normalize key markers of thyroid status in the hippocampus, of neuroinflammation, Aβ production, and of cell-signaling pathways known to be involved in synaptic plasticity and memory function. Together, these findings suggest that normalization of hippocampal T3 signaling is sufficient to reverse molecular and cognitive dysfunctions associated with hypothyroidism.","['Amyloid peptide', 'Hippocampus', 'Hypothyroidism', 'Inflammation', 'Memory', 'Signaling pathways']",Molecular neurobiology,2018-05-26,"[{'lastname': 'Chaalal', 'firstname': 'Amina', 'initials': 'A', 'affiliation': 'Neuroscience Paris-Saclay Institute (Neuro-PSI), UMR 9197, CNRS, University Paris-Sud, University Paris-Saclay, F-91405, Orsay, France.'}, {'lastname': 'Poirier', 'firstname': 'Roseline', 'initials': 'R', 'affiliation': 'Neuroscience Paris-Saclay Institute (Neuro-PSI), UMR 9197, CNRS, University Paris-Sud, University Paris-Saclay, F-91405, Orsay, France.'}, {'lastname': 'Blum', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Institut National de la Santé et de la Recherche Medicale (INSERM), CHU-Lille, UMR-S 1172, Alzheimer and Tauopathies, LabEx DISTALZ, University Lille, F-59000, Lille, France.'}, {'lastname': 'Laroche', 'firstname': 'Serge', 'initials': 'S', 'affiliation': 'Neuroscience Paris-Saclay Institute (Neuro-PSI), UMR 9197, CNRS, University Paris-Sud, University Paris-Saclay, F-91405, Orsay, France.'}, {'lastname': 'Enderlin', 'firstname': 'Valérie', 'initials': 'V', 'affiliation': 'Neuroscience Paris-Saclay Institute (Neuro-PSI), UMR 9197, CNRS, University Paris-Sud, University Paris-Saclay, F-91405, Orsay, France. valerie.enderlin@u-psud.fr.'}]",,,,,10.1007/s12035-018-1111-z,<Element 'PubmedArticle' at 0x7f05dc302bd0>
120,"29793546
21986680
19884572
25662776
21325651
21810890
20045477
17088691
17353379
22366795
29172163
21625137
25872513
26936938
24445580
17101833
17374952
1431963
21805370
17583985
17761438
22366791
22502999
28536518",Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales.,"In patients with frontotemporal dementia, it has been shown that brain atrophy occurs earliest in the anterior cingulate, insula and frontal lobes. We used visual rating scales to investigate whether identifying atrophy in these areas may be helpful in distinguishing symptomatic patients carrying different causal mutations in the microtubule-associated protein tau (MAPT), progranulin (GRN) and chromosome 9 open reading frame (C9ORF72) genes. We also analysed asymptomatic carriers to see whether it was possible to visually identify brain atrophy before the appearance of symptoms.
Magnetic resonance imaging of 343 subjects (63 symptomatic mutation carriers, 132 presymptomatic mutation carriers and 148 control subjects) from the Genetic Frontotemporal Dementia Initiative study were analysed by two trained raters using a protocol of six visual rating scales that identified atrophy in key regions of the brain (orbitofrontal, anterior cingulate, frontoinsula, anterior and medial temporal lobes and posterior cortical areas).
Intra- and interrater agreement were greater than 0.73 for all the scales. Voxel-based morphometric analysis demonstrated a strong correlation between the visual rating scale scores and grey matter atrophy in the same region for each of the scales. Typical patterns of atrophy were identified: symmetric anterior and medial temporal lobe involvement for MAPT, asymmetric frontal and parietal loss for GRN, and a more widespread pattern for C9ORF72. Presymptomatic MAPT carriers showed greater atrophy in the medial temporal region than control subjects, but the visual rating scales could not identify presymptomatic atrophy in GRN or C9ORF72 carriers.
These simple-to-use and reproducible scales may be useful tools in the clinical setting for the discrimination of different mutations of frontotemporal dementia, and they may even help to identify atrophy prior to onset in those with MAPT mutations.","['Frontotemporal dementia', 'Genetics', 'MRI', 'Visual rating']",Alzheimer's research & therapy,2018-05-26,"[{'lastname': 'Fumagalli', 'firstname': 'Giorgio G', 'initials': 'GG', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Milan, Italy. giorgiofumagalli@hotmail.com.\nFondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy. giorgiofumagalli@hotmail.com.\nDepartment of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy. giorgiofumagalli@hotmail.com.'}, {'lastname': 'Basilico', 'firstname': 'Paola', 'initials': 'P', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Milan, Italy.\nFondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Arighi', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Milan, Italy.\nFondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Bocchetta', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Dick', 'firstname': 'Katrina M', 'initials': 'KM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Cash', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Harding', 'firstname': 'Sophie', 'initials': 'S', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Mercurio', 'firstname': 'Matteo', 'initials': 'M', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Milan, Italy.\nFondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Fenoglio', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Milan, Italy.\nFondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Pietroboni', 'firstname': 'Anna M', 'initials': 'AM', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Milan, Italy.\nFondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Ghezzi', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Milan, Italy.\nFondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'van Swieten', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'University of Brescia, Brescia, Italy.'}, {'lastname': 'de Mendonça', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.'}, {'lastname': 'Masellis', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Cognitive Neurology Research Unit, Sunnybrook Health Sciences Centre, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Tartaglia', 'firstname': 'Maria C', 'initials': 'MC', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Rowe', 'firstname': 'James B', 'initials': 'JB', 'affiliation': 'University of Cambridge, Cambridge, UK.'}, {'lastname': 'Graff', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.\nDepartment of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden.'}, {'lastname': 'Tagliavini', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'Istituto Neurologico Carlo Besta, Milan, Italy.'}, {'lastname': 'Frisoni', 'firstname': 'Giovanni B', 'initials': 'GB', 'affiliation': 'IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}, {'lastname': 'Laforce', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Université Laval, Quebec, QC, Canada.'}, {'lastname': 'Finger', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'University of Western Ontario, London, ON, Canada.'}, {'lastname': 'Sorbi', 'firstname': 'Sandro', 'initials': 'S', 'affiliation': 'Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.\nIRCCS Don Gnocchi, Florence, Italy.'}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Milan, Italy.\nFondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Milan, Italy.\nFondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,"Intra- and interrater agreement were greater than 0.73 for all the scales. Voxel-based morphometric analysis demonstrated a strong correlation between the visual rating scale scores and grey matter atrophy in the same region for each of the scales. Typical patterns of atrophy were identified: symmetric anterior and medial temporal lobe involvement for MAPT, asymmetric frontal and parietal loss for GRN, and a more widespread pattern for C9ORF72. Presymptomatic MAPT carriers showed greater atrophy in the medial temporal region than control subjects, but the visual rating scales could not identify presymptomatic atrophy in GRN or C9ORF72 carriers.",,"10.1186/s13195-018-0376-9
10.1097/WCO.0b013e32834cd442
10.1212/WNL.0b013e3181bf997a
10.1016/S1474-4422(14)70324-2
10.1212/WNL.0b013e31821103e6
10.1093/brain/awr179
10.1016/j.neuroimage.2009.12.088
10.1097/01.rmr.0000245457.98029.e1
10.1001/archneur.64.3.371
10.1093/brain/aws001
10.1016/j.neurobiolaging.2017.10.008
10.1159/000328415
10.1136/jnnp-2014-310090
10.1093/brain/aww005
10.1001/jamaneurol.2013.6002
10.1001/archneur.63.11.1627
10.1159/000100973
10.1136/jnnp.55.10.967
10.1007/s00330-011-2205-4
10.1162/jocn.2007.19.7.1081
10.1016/j.neuroimage.2007.07.007
10.1093/brain/awr361
10.1016/j.neurobiolaging.2012.03.009
10.3389/fnagi.2017.00117",<Element 'PubmedArticle' at 0x7f05dc0e24a0>
121,29738850,Intermittent streptozotocin administration induces behavioral and pathological features relevant to Alzheimer's disease and vascular dementia.,"Diabetes mellitus (DM) is a major risk factor for Alzheimer's disease and vascular dementia. Few animal models exist that focus on the metabolic contributions to dementia onset and progression. Thus, there is strong scientific rationale to explore the effects of streptozotocin (STZ), a diabetogenic compound, on vascular and inflammatory changes within the brain.
The present study was designed to evaluate the effect of staggered, low-dose administration of STZ on behavioral and cognitive deficits, neuroinflammation, tau pathology, and histopathological alterations related to dementia.
Staggered administration (Days 1, 2, 3, 14, 15) of streptozotocin (40 mg/kg/mL) induced a diabetic-like state in mice, resulting in sustained hyperglycemia. STZ-treated animals displayed memory deficits in the novel object recognition task as well as increased tau phosphorylation and increased neuroinflammation. Additionally, STZ led to altered insulin signaling, exhibited by decreased plasma insulin and decreased levels of insulin degrading enzyme and pAKT within the hippocampus.
STZ-treated animals exhibit cognitive deficits and histopathological changes seen in dementia. This model of dementia warrants continued investigation to better understand the role that DM plays in dementia-related alterations.","[""Alzheimer's disease"", 'Diabetes mellitus', 'Insulin', 'Neuroinflammation', 'Streptozotocin', 'Streptozotocin (PubChem CID: 5300)', 'Vascular dementia']",Neuropharmacology,2018-05-09,"[{'lastname': 'Murtishaw', 'firstname': 'Andrew S', 'initials': 'AS', 'affiliation': 'Neurobiology of Disease and Behavior Laboratory, Department of Psychology, University of Nevada, Las Vegas, Las Vegas, NV, USA.'}, {'lastname': 'Heaney', 'firstname': 'Chelcie F', 'initials': 'CF', 'affiliation': 'Neurobiology of Disease and Behavior Laboratory, Department of Psychology, University of Nevada, Las Vegas, Las Vegas, NV, USA.'}, {'lastname': 'Bolton', 'firstname': 'Monica M', 'initials': 'MM', 'affiliation': 'Neurobiology of Disease and Behavior Laboratory, Department of Psychology, University of Nevada, Las Vegas, Las Vegas, NV, USA.'}, {'lastname': 'Belmonte', 'firstname': 'Krystal Courtney D', 'initials': 'KCD', 'affiliation': 'Neurobiology of Disease and Behavior Laboratory, Department of Psychology, University of Nevada, Las Vegas, Las Vegas, NV, USA.'}, {'lastname': 'Langhardt', 'firstname': 'Michael A', 'initials': 'MA', 'affiliation': 'Neurobiology of Disease and Behavior Laboratory, Department of Psychology, University of Nevada, Las Vegas, Las Vegas, NV, USA.'}, {'lastname': 'Kinney', 'firstname': 'Jefferson W', 'initials': 'JW', 'affiliation': 'Neurobiology of Disease and Behavior Laboratory, Department of Psychology, University of Nevada, Las Vegas, Las Vegas, NV, USA. Electronic address: Jefferson.Kinney@unlv.edu.'}]",,,"Staggered administration (Days 1, 2, 3, 14, 15) of streptozotocin (40 mg/kg/mL) induced a diabetic-like state in mice, resulting in sustained hyperglycemia. STZ-treated animals displayed memory deficits in the novel object recognition task as well as increased tau phosphorylation and increased neuroinflammation. Additionally, STZ led to altered insulin signaling, exhibited by decreased plasma insulin and decreased levels of insulin degrading enzyme and pAKT within the hippocampus.",Copyright © 2018 Elsevier Ltd. All rights reserved.,10.1016/j.neuropharm.2018.04.021,<Element 'PubmedArticle' at 0x7f05dc10e770>
122,29712510,Modulation of brain insulin signaling in Alzheimer's disease: New insight on the protective role of green coffee bean extract.,,"['Fructose', 'Insulin resistance', 'Neurofilament', 'Pioglitazone', 'Tau hyperphosphorylation']",Nutritional neuroscience,2018-05-02,"[{'lastname': 'Mohamed', 'firstname': 'Hoda E', 'initials': 'HE', 'affiliation': 'Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.'}, {'lastname': 'Asker', 'firstname': 'Mervat E', 'initials': 'ME', 'affiliation': 'Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.'}, {'lastname': 'Younis', 'firstname': 'Nahla N', 'initials': 'NN', 'affiliation': 'Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.'}, {'lastname': 'Shaheen', 'firstname': 'Mohamed A', 'initials': 'MA', 'affiliation': 'Department of Histology and Cell Biology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}, {'lastname': 'Eissa', 'firstname': 'Rana G', 'initials': 'RG', 'affiliation': 'Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.'}]",,,,,10.1080/1028415X.2018.1468535,<Element 'PubmedArticle' at 0x7f05dc11e090>
123,"29671277
15365985
22334720
1530909
19184068
11959919
12606950
28866832
29187812
15068247
19644039
28386764
14502651
20858652
26923268
25495175
28100023
26528178
18325988
12057909
24849348
8800092
19924424
21644037
24433963",Reduced Adrenomedullin Parallels Microtubule Dismantlement in Frontotemporal Lobar Degeneration.,"Tau is a microtubule-associated protein highly expressed in neurons with a chief role in microtubule dynamics and axonal maintenance. Adrenomedullin gene (ADM) codifies for various peptides that exert broad range of actions in the body. Previous works in our groups have shown that increased ADM products are positively correlated to microtubule disruption and tau pathology in Alzheimer's disease brains. In the present study, we explore the involvement of ADM in the neuropathology of frontotemporal lobar degeneration that presents with primary tauopathy (FTLD-tau). Proteins from frontal cortices of FTLD-tau patients and age- and sex-matched non-demented controls were analyzed with antibodies against different microtubule components, including adrenomedullin, and synaptic markers. Tau pathology in frontal cortex from FTLD patients was confirmed. Levels of total βIII-tubulin as well as acetylated and detyrosinated tubulins, two markers of stabilized and aged microtubules, were significantly reduced and directly correlated with PSD95 and proBDNF in FTLD-tau patients when compared to non-demented controls. In contrast, no change in actin cytoskeleton was found. Interestingly, changes in microtubule elements, indicators of disturbed axonal preservation, were accompanied by decreased levels of free adrenomedullin, although no association was found. Altogether, reduced levels of adrenomedullin might not be directly linked to the microtubule pathology of FTLD-tau, but based on previous works, it is suggested that downregulation of ADM might be an adaptive attempt of neurons to mitigate microtubule disruption.","['Adrenomedullin', 'Frontotemporal', 'Tauopathy', 'Tubulin']",Molecular neurobiology,2018-04-20,"[{'lastname': 'Ferrero', 'firstname': 'Hilda', 'initials': 'H', 'affiliation': 'Department of Pharmacology and Toxicology, University of Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.'}, {'lastname': 'Larrayoz', 'firstname': 'Ignacio M', 'initials': 'IM', 'affiliation': 'Biomarkers and Molecular Signaling, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain.'}, {'lastname': 'Solas', 'firstname': 'Maite', 'initials': 'M', 'affiliation': 'Department of Pharmacology and Toxicology, University of Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.'}, {'lastname': 'Martínez', 'firstname': 'Alfredo', 'initials': 'A', 'affiliation': 'Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain.'}, {'lastname': 'Ramírez', 'firstname': 'María J', 'initials': 'MJ', 'affiliation': 'Department of Pharmacology and Toxicology, University of Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.'}, {'lastname': 'Gil-Bea', 'firstname': 'Francisco J', 'initials': 'FJ', 'affiliation': 'Neurosciences Area, Biodonostia Health Research Institute, Donostia University Hospital, San Sebastian, Spain. francisco.gilbea@biodonostia.org.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Health Institute Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain. francisco.gilbea@biodonostia.org.'}]",,,,,10.1007/s12035-018-1079-8,<Element 'PubmedArticle' at 0x7f05dc0a7b80>
124,29656013,Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity.,"Chronic stress, a causal factor for depression, can also cause cognitive impairments and tau pathology. However, whether and how the selective serotonin reuptake inhibitor antidepressant escitalopram ameliorates these effects are still unclear. In the present study, rats were subjected to chronic mild unpredictable stress for 8 weeks. Following the initial 4 weeks, the stressed animals were separated into susceptible (depressive) and unsusceptible (resistant) groups based on behavioral tests. Then, escitalopram (10 mg/kg i.p.) was administered for 28 days. Pathophysiological changes were assessed by performing behavioral and biochemical analyses. The results showed that both depressive and resistant rats displayed spatial memory deficits and an accumulation of tau in the hippocampus. Increased levels of corticosterone and insulin and a decreased level of glucocorticoid receptor were found in both depressive and resistant rats. We also found that activity-dependent phosphorylated insulin receptor substrate and glycogen synthase kinase-3β (Ser9 site) were significantly decreased in both depressive and resistant rats. However, other important kinases, such as cyclin-dependent kinase 5 and mitogen-activated protein kinase kinase-1/2, did not change in our study. Furthermore, we found that the mRNA expression of tau was increased in depressive and resistant rats. No significant change in LC3B expression was found. Interestingly, almost all the pathological changes in depressive and resistant rats previously mentioned could be reversed by escitalopram. Our results suggested that escitalopram ameliorates cognitive impairments and selectively attenuates phosphorylated tau accumulation in stressed rats through the regulation of hypothalamic-pituitary-adrenal axis activity and the insulin receptor substrate/glycogen synthase kinase-3β signaling pathway.","[""Alzheimer's disease"", 'Chronic stress', 'Escitalopram', 'Tau']",Neurobiology of aging,2018-04-16,"[{'lastname': 'Wu', 'firstname': 'Chao', 'initials': 'C', 'affiliation': 'Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, Nanjing, China.'}, {'lastname': 'Gong', 'firstname': 'Wei-Gang', 'initials': 'WG', 'affiliation': 'Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, Nanjing, China.'}, {'lastname': 'Wang', 'firstname': 'Yan-Juan', 'initials': 'YJ', 'affiliation': 'Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, Nanjing, China.'}, {'lastname': 'Sun', 'firstname': 'Jun-Jun', 'initials': 'JJ', 'affiliation': 'Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, Nanjing, China.'}, {'lastname': 'Zhou', 'firstname': 'Hong', 'initials': 'H', 'affiliation': 'Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, Nanjing, China.'}, {'lastname': 'Zhang', 'firstname': 'Zhi-Jun', 'initials': 'ZJ', 'affiliation': 'Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, Nanjing, China.'}, {'lastname': 'Ren', 'firstname': 'Qing-Guo', 'initials': 'QG', 'affiliation': 'Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, Nanjing, China. Electronic address: renqingguo1976@163.com.'}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2018.03.011,<Element 'PubmedArticle' at 0x7f05dc0b93b0>
125,"29611103
22886150
24529521
7897397
22329651
10393845
28049395
22476197
18470479
28469281
18930564
28688899
27631195
24155879
12111436
10818091
5776547
18479783
25050342
17406317
23485579
12467491
21471435
28470423
15331422
15750215
22956272
18088381
21356829
28174113
22929442
21745636
1371102
25580119
16340083
21371747
16182371
26464760
27022020
23238038
28089765
19777393
17428800
11557751
21629439
28059794
19815707
10574963
12427828
14980532
22528106
20798880
27518562
27065817
22886014
29055815
18794889
25744568
25414013
19885299
15501490
21045163
12084635
364489
22273754
22910909",Evidence for Compromised Insulin Signaling and Neuronal Vulnerability in Experimental Model of Sporadic Alzheimer's Disease.,"Evidence from animal studies categorizes sporadic Alzheimer's disease (sAD) as a metabolic syndrome with accompanying cognitive deficits. Given that glial cells act as ""silent partners"" to neurons by providing trophic support and defense, the present study investigated the role of glia in sAD pathology. A streptozotocin (STZ)-induced glial-neuronal co-culture model of sAD was used to study the metabolic status of the two cell types. Real time RT-PCR and Western blotting results indicated that amyloid precursor protein (APP) and β-secretase (BACE1) were highly expressed in co-cultured neurons than in monocultures. Increased amyloidogenesis was accompanied by decreased expression of mediators in insulin signaling pathway that included insulin receptor (IR), insulin receptor substrate 2 (IRS2), insulin-like growth factor 2 (IGF2), insulin-like growth factor 1 receptor (IGF1R), total-glycogen synthase kinase 3β (t-GSK3β), and phosphorylated-GSK3β","['Alzheimer’s disease', 'Amyloid precursor protein', 'Beta amyloid', 'Dendritic spines', 'Diabetes', 'Memory', 'Neurofibriallary tangles']",Molecular neurobiology,2018-04-04,"[{'lastname': 'Gupta', 'firstname': 'Smriti', 'initials': 'S', 'affiliation': 'Department of Biochemistry, Basic Medical Science Block II, Sector 25, Panjab University, Chandigarh, 160014, India.'}, {'lastname': 'Yadav', 'firstname': 'Kamalendra', 'initials': 'K', 'affiliation': 'National Agri-Food Biotechnology Institute, Sector 81, S.A.S. Nagar, Mohali, Punjab, 140306, India.'}, {'lastname': 'Mantri', 'firstname': 'Shrikant S', 'initials': 'SS', 'affiliation': 'National Agri-Food Biotechnology Institute, Sector 81, S.A.S. Nagar, Mohali, Punjab, 140306, India.'}, {'lastname': 'Singhal', 'firstname': 'Nitin K', 'initials': 'NK', 'affiliation': 'National Agri-Food Biotechnology Institute, Sector 81, S.A.S. Nagar, Mohali, Punjab, 140306, India.'}, {'lastname': 'Ganesh', 'firstname': 'Subramaniam', 'initials': 'S', 'affiliation': 'Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, 208016, India.'}, {'lastname': 'Sandhir', 'firstname': 'Rajat', 'initials': 'R', 'affiliation': 'Department of Biochemistry, Basic Medical Science Block II, Sector 25, Panjab University, Chandigarh, 160014, India. sandhir@pu.ac.in.'}]",,,,,10.1007/s12035-018-0985-0,<Element 'PubmedArticle' at 0x7f05dc0c7b80>
126,"29594021
25220842
26224061
7523723
27626136
22808955
25066872
7932824
11279618
12216104
1512834
23434102
9828589
17368710
7388802
1707989
15371827
22801674
25569441
19293796
19733959
19562736
22652152
22841674
23292082
22236224
12474142
20736950
17565157
23569316
20215531
23149842
24556621
27433846
18264097
18708398
21769933
18199855
23535732
28783718
26510020
28843286
25465337
26058959
28400167
26028995
29129398
19767753
20840664
24327678
27151655",Men with a susceptibility to prostate cancer and the role of genetic based screening.,"Prostate cancer is the second most common malignancy affecting men worldwide, and the commonest affecting men of African descent. Significant diagnostic and therapeutic advances have been made in the past decade. Improvements in the accuracy of prostate cancer diagnosis include the uptake of multi-parametric MRI and a shift towards targeted biopsy. We also now have more life-prolonging systemic and hormonal therapies for men with advanced disease at our disposal than ever before. However, the development of robust screening tools and targeted screening programs has not followed at the same pace. Evidence to support population-based screening remains unclear, with the use of PSA as a screening test limiting our ability to discriminate between clinically significant and insignificant disease. Prostate cancer has a large heritable component. Given that most men without risk factors have a low lifetime risk of developing lethal prostate cancer, much work is being done to further our knowledge of how we can best screen men in higher risk categories, such as those with a family history (FH) of the disease or those of African ancestry. These men have been reported to carry upwards of a two-fold increased risk of developing the disease at an earlier age, with evidence suggesting poorer survival outcomes. In men with a FH of prostate cancer, this is felt to be due to rare, high-penetrance mutations and the presence of multiple, common low penetrance alleles, with men carrying specific germline mutations in the BRCA and other DNA repair genes at particularly high risk. To date, large scale genome-wide association studies (GWAS) have led to the discovery of approximately 170 single nucleotide polymorphisms (SNPs) associated with prostate cancer risk, allowing over 30% of prostate cancer risk to be explained. Genomic tests, utilising somatic (prostate biopsy) tissue can also predict the risk of unfavourable pathology, biochemical recurrence and the likelihood of metastatic disease using gene expression. Targeted screening studies are currently under way in men with DNA repair mutations, men with a FH and those of Afro-Caribbean ethnicity which will greater inform our understanding of disease incidence and behaviour in these men, treatment outcomes and developing the most appropriate screening regime for such men. Incorporating a patient's genetic mutation status into risk algorithms allows us an opportunity to develop targeted screening programs for men in whom early cancer detection and treatment will positively influence survival, and in the process offer male family members of affected men the chance to be counselled and screened accordingly.","['Prostate cancer', 'genetic screening', 'single nucleotide polymorphisms (SNPs)']",Translational andrology and urology,2018-03-30,"[{'lastname': 'Eeles', 'firstname': 'Rosalind', 'initials': 'R', 'affiliation': 'Division of Genetics & Epidemiology, Institute of Cancer Research, Sutton, London, UK.'}, {'lastname': 'Ni Raghallaigh', 'firstname': 'Holly', 'initials': 'H', 'affiliation': 'Division of Genetics & Epidemiology, Institute of Cancer Research, Sutton, London, UK.'}]",,,,,"10.21037/tau.2017.12.30
10.1002/ijc.29210
10.1186/s12916-015-0405-5
10.1016/S0022-5347(17)32379-0
10.1056/NEJMoa1606220
10.1056/NEJMoa1113162
10.1016/j.juro.2014.07.085
10.1093/jnci/86.21.1600
10.1002/1097-0215(200102)9999:9999<::AID-IJC1147>3.0.CO;2-C
10.1002/cncr.10819
10.1016/S0022-5347(17)36733-2
10.1016/j.urology.2012.10.074
10.1016/j.eururo.2007.02.047
10.1016/S0022-5347(17)38491-4
10.1097/01.ju.0000139993.51181.5d
10.7326/0003-4819-157-2-201207170-00459
10.1038/gim.2014.192
10.1038/sj.bjc.6604973
10.1016/j.eururo.2009.08.025
10.1002/pros.21002
10.1016/j.eururo.2012.05.006
10.1016/j.eururo.2012.07.027
10.1158/1055-9965.EPI-12-1000-T
10.1056/NEJMoa1110000
10.1086/345310
10.1038/sj.bjc.6605822
10.1093/jnci/djm005
10.1200/JCO.2012.43.1882
10.1158/1078-0432.CCR-09-2871
10.1038/bjc.2012.486
10.1038/bjc.2014.30
10.1056/NEJMoa1603144
10.1038/ng.90
10.1158/1055-9965.EPI-08-0317
10.1056/NEJMoa075819
10.1038/nature23306
10.1056/NEJMoa1506859
10.1016/j.cell.2015.06.053
10.1016/j.eururo.2014.11.030
10.1016/j.eururo.2015.05.042
10.1016/j.eururo.2017.03.036
10.1016/j.eururo.2017.10.036
10.1038/ng.450
10.1111/j.1464-410X.2010.09648.x
10.1158/2159-8290.CD-NB2013-159
10.1634/theoncologist.2015-0336",<Element 'PubmedArticle' at 0x7f05dbfa8180>
127,"29584904
28401333
24574501
27911311
28488154
17579875
21607722
20361198
21644037
27915998
21614463
11310619
14561797
21810890
27009575
25653292
23800361
25943890
25803835
22101365
20644199
20601685
21944778
19743450
24659241
27209644
21863317
17591968
28133816
20512649
21569259
22522938
28076711",Combined Pathologies in FTLD-TDP Types A and C.,"This study investigated the presence of combined pathologies in a large cohort of autopsies that show a primary pathologic diagnosis of phosphorylated 43-kDa TAR DNA-binding protein (FTLD-TDP), the majority of which portrayed clinical phenotypes consistent with primary progressive aphasia or behavioral variant frontotemporal dementia (bvFTD). Thirty-eight cases with FTLD-TDP (30 type-A and 8 type-C) were identified to determine characteristic differences between cases with and without combined pathologies. Findings indicated that combined pathologies co-occur with FTLD-TDP type-A at a high frequency (50%)-greater than when compared to FTLD-TDP type-C cases (12.5%). Those with FTLD-TDP type-A and combined pathologies showed significantly longer lifespans (p < 0.05), and longer disease durations (p < 0.05), than those with only FTLD-TDP type-A. Cases with FTLD-TDP type-A and known genetic mutations tended not to show combined pathology. Those with the GRN mutation and FTLD-TDP type-A showed a significantly younger age of onset (p < 0.05) and younger age at death (p < 0.01) compared to noncarriers. In 1 bvFTD case, we highlight the rare presence of ""triple"" FTLD-TDP type-A, FTLD-tau, and Alzheimer pathology. The ante- and post-mortem features associated with combined pathologies in FTLD-related disorders are of useful consideration in the stratification of patients to drug trials, and in the development of therapeutic targets for FTLD.",[],Journal of neuropathology and experimental neurology,2018-03-28,"[{'lastname': 'Gefen', 'firstname': 'Tamar', 'initials': 'T', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.\nDepartment of Psychiatry and Behavioral Sciences, University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Ahmadian', 'firstname': 'Saman S', 'initials': 'SS', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.""}, {'lastname': 'Mao', 'firstname': 'Qinwen', 'initials': 'Q', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.\nDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Kim', 'firstname': 'Garam', 'initials': 'G', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.""}, {'lastname': 'Seckin', 'firstname': 'Mustafa', 'initials': 'M', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.""}, {'lastname': 'Bonakdarpour', 'firstname': 'Borna', 'initials': 'B', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.""}, {'lastname': 'Ramos', 'firstname': 'Eliana Marisa', 'initials': 'EM', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.\nDepartment of Psychiatry and Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California.""}, {'lastname': 'Coppola', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'Department of Psychiatry and Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California.'}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Rogalski', 'firstname': 'Emily', 'initials': 'E', 'affiliation': None}, {'lastname': 'Rademaker', 'firstname': 'Alfred', 'initials': 'A', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.\nDepartment of Preventive Medicine, University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Weintraub', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.\nDepartment of Psychiatry and Behavioral Sciences, University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Mesulam', 'firstname': 'M-Marsel', 'initials': 'MM', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.\nDepartment of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Geula', 'firstname': 'Changiz', 'initials': 'C', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.\nDepartment of Cellular and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Bigio', 'firstname': 'Eileen H', 'initials': 'EH', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center.\nDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}]",,,,,10.1093/jnen/nly018,<Element 'PubmedArticle' at 0x7f05dbfc73b0>
128,29551659,"DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease.","Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which there is no cure. The early primary symptom of AD is the decline of memory ability, which gradually develops into complete dementia. Type 2 diabetes mellitus (T2DM) is an important risk factor of AD; and mimetics of the incretin hormone GLP-1 developed to treat diabetes are being tested as a novel therapeutic strategy for AD. In the present study, we reported for the first time the neuroprotective effects of a novel GLP-1/GIP dual agonist DA5-CH that activates the incretin hormone GLP-1 and GIP receptors in the APP/PS1 transgenic AD mouse model. We found that: (1) DA5-CH administration effectively improved working-memory and long-term spatial memory of 9-month-old AD mice in Y-maze and Morris water maze tests; (2) DA5-CH also reduced hippocampal amyloid senile plaques and phosphorylated tau protein levels; (3) DA5-CH basically reversed the deficits in hippocampal late-phase long-term potentiation; (4) DA5-CH up-regulated the levels of p-PI3K and p-AKT growth factor kinases and prevented excessive activation of p-GSK3β in the hippocampus of APP/PS1 mice. Therefore, the neuroprotection of DA5-CH in alleviating cognitive impairments and pathological damages might be associated with the improvement of hippocampal synaptic plasticity and activation of the PI3K/AKT signaling pathway. We propose that DA5-CH may be beneficial for the treatment of AD patients, especially those with T2DM or hyperglycemia.","['APP/PS1 AD mice', 'Amyloid-β protein', 'GLP-1/GIP dual agonist', 'L-LTP', 'Long term memory', 'PI3K/AKT/GSK3β', 'Phosphorylated tau protein', 'Working memory']",European journal of pharmacology,2018-03-20,"[{'lastname': 'Cao', 'firstname': 'Yue', 'initials': 'Y', 'affiliation': 'Department of Neurobiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Hölscher', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Biomedical and Life Science, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK.'}, {'lastname': 'Hu', 'firstname': 'Meng-Ming', 'initials': 'MM', 'affiliation': 'Department of Neurobiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Wang', 'firstname': 'Ting', 'initials': 'T', 'affiliation': 'Department of Neurobiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Zhao', 'firstname': 'Fang', 'initials': 'F', 'affiliation': 'Department of Neurobiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Bai', 'firstname': 'Yu', 'initials': 'Y', 'affiliation': 'Department of Neurobiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Zhang', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'Department of Neurobiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Wu', 'firstname': 'Mei-Na', 'initials': 'MN', 'affiliation': 'Department of Neurobiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Qi', 'firstname': 'Jin-Shun', 'initials': 'JS', 'affiliation': 'Department of Neurobiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China. Electronic address: jinshunqi2009@163.com.'}]",,,,Copyright © 2018 Elsevier B.V. All rights reserved.,10.1016/j.ejphar.2018.03.024,<Element 'PubmedArticle' at 0x7f05dbfe0ef0>
129,"29505099
9990854
24623176
16877355
15993515
21508957
22201929
1759558
21255744
11238065
22927427
11279122
24211352
21113149
17659878
29169609
23982319
23639788
23126652
15213207
9343467
21079415
24211851
26035291
11099831
10655508
26041910
21948247
27327541
27312772
18486110
22913619
23217709
20046096
20087369
10513583
12507964
11741394
28692878
10987824
26451386
12944500
24470773
8427562
7706247
27866325
11689174
27870425
19427328
18304749
23939249
9724804
14622134
22282647
17182789
15383512
9556608
19931595
27692800
22972991
23507120
28802038
14678749
21186265
18346198
28890695
27143423",Higher levels of kallikrein-8 in female brain may increase the risk for Alzheimer's disease.,"Women seem to have a higher vulnerability to Alzheimer's disease (AD), but the underlying mechanisms of this sex dichotomy are not well understood. Here, we first determined the influence of sex on various aspects of Alzheimer's pathology in transgenic CRND8 mice. We demonstrate that beta-amyloid (Aβ) plaque burden starts to be more severe around P180 (moderate disease stage) in female transgenics when compared to males and that aging aggravates this sex-specific difference. Furthermore, we show that female transgenics suffer from higher levels of neurovascular dysfunction around P180, resulting in impaired Aβ peptide clearance across the blood-brain-barrier at P360. Female transgenics show also higher levels of diffuse microgliosis and inflammation, but the density of microglial cells surrounding Aβ plaques is less in females. In line with this finding, testosterone compared to estradiol was able to improve microglial viability and Aβ clearance in vitro. The spatial memory of transgenics was in general poorer than in wildtypes and at P360 worse in females irrespective of their genotype. This difference was accompanied by a slightly diminished dendritic complexity in females. While all the above-named sex-differences emerged after the onset of Aβ pathology, kallikrein-8 (KLK8) protease levels were, as an exception, higher in female than in male brains very early when virtually no plaques were detectable. In a second step, we quantified cerebral KLK8 levels in AD patients and healthy controls, and could ascertain, similar to mice, higher KLK8 levels not only in AD-affected but also in healthy brains of women. Accordingly, we could demonstrate that estradiol but not testosterone induces KLK8 synthesis in neuronal and microglial cells. In conclusion, multiple features of AD are more pronounced in females. Here, we show for the first time that this sex-specific difference may be meditated by estrogen-induced KLK8 overproduction long before AD pathology emerges.","[""Alzheimer's disease"", 'Aβ metabolism', 'kallikrein-8', 'microglial phagocytosis', 'neuroinflammation', 'neuroplasticity', 'neuropsin', 'neurovascular dysfunction', 'sex hormones', 'sex-specific differences', 'tau pathology and autophagy']","Brain pathology (Zurich, Switzerland)",2018-03-06,"[{'lastname': 'Keyvani', 'firstname': 'Kathy', 'initials': 'K', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Münster', 'firstname': 'Yvonne', 'initials': 'Y', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Kurapati', 'firstname': 'Nirup K', 'initials': 'NK', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Rubach', 'firstname': 'Sebastian', 'initials': 'S', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Schönborn', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Kocakavuk', 'firstname': 'Emre', 'initials': 'E', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Karout', 'firstname': 'Mohamed', 'initials': 'M', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Hammesfahr', 'firstname': 'Pia', 'initials': 'P', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Wang', 'firstname': 'Ya-Chao', 'initials': 'YC', 'affiliation': 'Department of Neurology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Hermann', 'firstname': 'Dirk M', 'initials': 'DM', 'affiliation': 'Department of Neurology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Teuber-Hanselmann', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Herring', 'firstname': 'Arne', 'initials': 'A', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}]",,,,© 2018 International Society of Neuropathology.,"10.1111/bpa.12599
10.1038/nprot.2007.390",<Element 'PubmedArticle' at 0x7f05dbeb0900>
130,"29492847
21108071
23939185
23209186
21760736
24085619
22220562
19060908
19151107
21143982
18588978
15259345
16875352
24380887
17113010
27500468
10818091
28353042
28425939
25463011
24691544
9778314
25197811
15078544
26282832
24529521
27185156
25988134
8765217
22355328
2497634
28455700
28208663
21402242
1675950
15298006
22473784
24529528
22400114
20639132
21131360
26504474
23354480
27302647
23813704
10722675
17248908
22998574
2233308
3036004
26549253
28555043
942051
22345552
20504892
23112876
9605485
26236094
23999505
28420091
23857055
22982228
19254570
25947912",High-Fructose Consumption Impairs the Redox System and Protein Quality Control in the Brain of Syrian Hamsters: Therapeutic Effects of Melatonin.,"Although numerous studies have demonstrated the harmful effect of excessive fructose consumption at the systemic level, there is little information on its effects in the central nervous system. The purpose of the present work was to study the cellular alterations related to oxidative stress and protein quality control systems induced by a high-fructose diet in the brain of Syrian hamsters and their possible attenuation by exogenous melatonin. High-fructose intake induced type II diabetes together with oxidative damage, led to alterations of the unfolded protein response by activating the eIF2α branch, and impaired the macroautophagic machinery in the brain, favoring the accumulation of aggregates labeled for selective degradation and neurodegeneration markers such as β-amyloid (1-42), tau-p-S199, and tau-p-S404. Melatonin attenuated the manifestation of type II diabetes and reduced oxidative stress, deactivated eIF2α, and decreased tau-p-S404 levels in the brain of animals fed a high-fructose diet.","['Autophagy', 'Brain', 'ER stress', 'High-fructose', 'Melatonin', 'Neurodegeneration']",Molecular neurobiology,2018-03-02,"[{'lastname': 'Bermejo-Millo', 'firstname': 'Juan Carlos', 'initials': 'JC', 'affiliation': 'Department of Morphology and Cell Biology, Faculty of Medicine, University of Oviedo, 33006, Oviedo, Spain.\nInstituto de Investigacion Sanitaria del Principado de Asturias (IISPA), 33011, Oviedo, Spain.'}, {'lastname': 'Guimarães', 'firstname': 'Marcela Rodrigues Moreira', 'initials': 'MRM', 'affiliation': 'Department of Morphology and Cell Biology, Faculty of Medicine, University of Oviedo, 33006, Oviedo, Spain.'}, {'lastname': 'de Luxán-Delgado', 'firstname': 'Beatriz', 'initials': 'B', 'affiliation': 'Department of Morphology and Cell Biology, Faculty of Medicine, University of Oviedo, 33006, Oviedo, Spain.'}, {'lastname': 'Potes', 'firstname': 'Yaiza', 'initials': 'Y', 'affiliation': 'Department of Morphology and Cell Biology, Faculty of Medicine, University of Oviedo, 33006, Oviedo, Spain.\nInstituto de Investigacion Sanitaria del Principado de Asturias (IISPA), 33011, Oviedo, Spain.'}, {'lastname': 'Pérez-Martínez', 'firstname': 'Zulema', 'initials': 'Z', 'affiliation': 'Department of Morphology and Cell Biology, Faculty of Medicine, University of Oviedo, 33006, Oviedo, Spain.\nInstituto de Investigacion Sanitaria del Principado de Asturias (IISPA), 33011, Oviedo, Spain.\nService of Microbiology, University Central Hospital of Asturias, 33011, Oviedo, Spain.'}, {'lastname': 'Díaz-Luis', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Department of Morphology and Cell Biology, Faculty of Medicine, University of Oviedo, 33006, Oviedo, Spain.\nInstituto de Investigacion Sanitaria del Principado de Asturias (IISPA), 33011, Oviedo, Spain.'}, {'lastname': 'Caballero', 'firstname': 'Beatriz', 'initials': 'B', 'affiliation': 'Department of Morphology and Cell Biology, Faculty of Medicine, University of Oviedo, 33006, Oviedo, Spain.\nInstituto de Investigacion Sanitaria del Principado de Asturias (IISPA), 33011, Oviedo, Spain.'}, {'lastname': 'Solano', 'firstname': 'Juan José', 'initials': 'JJ', 'affiliation': 'Instituto de Investigacion Sanitaria del Principado de Asturias (IISPA), 33011, Oviedo, Spain.'}, {'lastname': 'Vega-Naredo', 'firstname': 'Ignacio', 'initials': 'I', 'affiliation': 'Department of Morphology and Cell Biology, Faculty of Medicine, University of Oviedo, 33006, Oviedo, Spain. naredo@gmail.com.\nInstituto de Investigacion Sanitaria del Principado de Asturias (IISPA), 33011, Oviedo, Spain. naredo@gmail.com.'}, {'lastname': 'Coto-Montes', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Department of Morphology and Cell Biology, Faculty of Medicine, University of Oviedo, 33006, Oviedo, Spain.\nInstituto de Investigacion Sanitaria del Principado de Asturias (IISPA), 33011, Oviedo, Spain.'}]",,,,,10.1007/s12035-018-0967-2,<Element 'PubmedArticle' at 0x7f05dbe210e0>
131,"29480193
22908189
22078173
21062019
24041970
24608097
24992214
9663454
17614161
24239383
24614496
28503657
23183359
18561511
23567418
15592144
17804958
6610841
10190820
21514249
27648916
11872257
12873852
15268655
26377465
16857565
18537770
8764620
11910111
11160418
12805660
11730979
28341160
1311847
21872257
27693183
25468144
7782901
12917896
24898653
25120481
28363773",Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease.,"Studies suggest that a single injection of pramlintide, an amylin analog, induces changes in Alzheimer's disease (AD) biomarkers in the blood of AD mouse models and AD patients. The aim of this study was to examine whether a pramlintide challenge combined with a phosphatidylcholine (PC) profile diagnoses of AD and mild cognitive impairment (MCI) better than PC alone. Non-diabetic subjects with cognitive status were administered a single subcutaneous injection of 60 mcg of pramlintide under fasting condition. A total of 71 PCs, amyloid-β peptide (Aβ), and total tau (t-tau) in plasma at different time points were measured and treated as individual variables. A single injection of pramlintide altered the levels of 7 PCs in the blood, while a pramlintide injection plus food modulated the levels of 10 PCs in the blood (p < 0.05). The levels of 2 PCs in MCI and 12 PCs in AD in the pramlintide challenge were significantly lower than the ones in controls. We found that while some PCs were associated with only Aβ levels, other PCs were associated with both Aβ and t-tau levels. A receiver operating characteristic analysis of the PCs was combined with the Aβ and t-tau data to produce an area under the curve predictive value of 0.9799 between MCI subjects and controls, 0.9794 between AD subjects and controls, and 0.9490 between AD and MCI subjects. A combination of AD biomarkers and a group of PCs post a pramlintide challenge may provide a valuable diagnostic and prognostic test for AD and MCI.","['Alzheimer’s disease', 'amylin', 'mild cognitive impairment', 'phosphatidylcholine', 'pramlintide']",Journal of Alzheimer's disease : JAD,2018-02-27,"[{'lastname': 'Tao', 'firstname': 'Qiushan', 'initials': 'Q', 'affiliation': 'Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.'}, {'lastname': 'Zhu', 'firstname': 'Haihao', 'initials': 'H', 'affiliation': 'Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.'}, {'lastname': 'Chen', 'firstname': 'Xi', 'initials': 'X', 'affiliation': 'Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.'}, {'lastname': 'Stern', 'firstname': 'Robert A', 'initials': 'RA', 'affiliation': ""Neurology, Boston University School of Medicine, Boston, MA, USA.\nNeurosurgery, Boston University School of Medicine, Boston, MA, USA.\nAlzheimer's Disease Center, Boston University School of Medicine, Boston, MA, USA.""}, {'lastname': 'Kowall', 'firstname': 'Neil', 'initials': 'N', 'affiliation': ""Neurology, Boston University School of Medicine, Boston, MA, USA.\nAlzheimer's Disease Center, Boston University School of Medicine, Boston, MA, USA.""}, {'lastname': 'Au', 'firstname': 'Rhoda', 'initials': 'R', 'affiliation': 'Neurology, Boston University School of Medicine, Boston, MA, USA.\nDepartments of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA, USA.'}, {'lastname': 'Blusztajn', 'firstname': 'Jan Krzysztof', 'initials': 'JK', 'affiliation': 'Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA.'}, {'lastname': 'Qiu', 'firstname': 'Wei Qiao', 'initials': 'WQ', 'affiliation': ""Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.\nAlzheimer's Disease Center, Boston University School of Medicine, Boston, MA, USA.\nDepartments of Psychiatry, Boston University School of Medicine, Boston, MA, USA.""}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,,10.3233/JAD-170948,<Element 'PubmedArticle' at 0x7f05dbe3ef90>
132,29473979,A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease.,"Type 2 diabetes mellitus (T2DM) is an important risk factor for Alzheimer's disease (AD). Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have been identified to be effective in T2DM treatment and neuroprotection. In this study, we further explored the effects of a novel unimolecular GLP-1/GIP/Gcg triagonist on the cognitive behavior and cerebral pathology in the 7-month-old triple transgenic mouse model of AD (3xTg-AD), and investigated its possible electrophysiological and molecular mechanisms. After chronic administration of the GLP-1/GIP/Gcg triagonist (10 nmol/kg bodyweight, once daily, i.p.) for 30 days, open field, Y maze and Morris water maze tests were performed, followed by in vivo electrophysiological recording, immunofluorescence and Western blotting experiments. We found that the chronic treatment with the triagonist could improve long-term spatial memory of 3xTg-AD mice in Morris water maze, as well as the working memory in Y maze task. The triagonist also alleviated the suppression of long-term potentiation (LTP) in the CA1 region of hippocampus. In addition, the triagonist significantly reduced hippocampal pathological damages, including amyloid-β (Aβ) and phosphorylated tau aggregates, and upregulated the expression levels of ","['3xTg-AD mice', 'GLP-1/GIP/Gcg triagonist', 'amyloid-β (Aβ) protein', 'learning and memory', 'long-term potentiation', 'p-CAMKII', 'p-CREB', 'p-GSK3β', 'phosphorylated tau protein']",Hippocampus,2018-02-24,"[{'lastname': 'Li', 'firstname': 'Tian', 'initials': 'T', 'affiliation': 'Department of Neurobiology and National Key Discipline of Physiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Jiao', 'firstname': 'Juan-Juan', 'initials': 'JJ', 'affiliation': 'Department of Neurobiology and National Key Discipline of Physiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Hölscher', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Division of Biomed and Life Sciences, Faculty of Health and Medicine Lancaster University, Lancaster, LA1 4YQ, United Kingdom.'}, {'lastname': 'Wu', 'firstname': 'Mei-Na', 'initials': 'MN', 'affiliation': 'Department of Neurobiology and National Key Discipline of Physiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Zhang', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'Department of Neurobiology and National Key Discipline of Physiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Tong', 'firstname': 'Jia-Qing', 'initials': 'JQ', 'affiliation': 'Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.'}, {'lastname': 'Dong', 'firstname': 'Xue-Fan', 'initials': 'XF', 'affiliation': 'Department of Neurobiology and National Key Discipline of Physiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Qu', 'firstname': 'Xue-Song', 'initials': 'XS', 'affiliation': 'Department of Neurobiology and National Key Discipline of Physiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Cao', 'firstname': 'Yue', 'initials': 'Y', 'affiliation': 'Department of Neurobiology and National Key Discipline of Physiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Cai', 'firstname': 'Hong-Yan', 'initials': 'HY', 'affiliation': 'Department of Immunology and Microbiology, Shanxi Medical University, Taiyuan, Shanxi, 030001, PR China.'}, {'lastname': 'Su', 'firstname': 'Qiang', 'initials': 'Q', 'affiliation': 'Department of Neurology, First Hospital, Shanxi Medical University, Taiyuan, Shanxi, 030001, PR China.'}, {'lastname': 'Qi', 'firstname': 'Jin-Shun', 'initials': 'JS', 'affiliation': 'Department of Neurobiology and National Key Discipline of Physiology, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}]",,,,"© 2018 Wiley Periodicals, Inc.",10.1002/hipo.22837,<Element 'PubmedArticle' at 0x7f05dbe60b80>
133,"29435980
8933010
19885299
21284695
23485579
22476196
18479783
19188609
22476197
17692997
25035815
22622544
22710630
21911655
24070815
27899872
23332584
12925848
25035078
24296712
26500843
15686481
19573562
12949521
22938097
18466898
20035739
24315369
21525299
20308787
23973293
27131827
25869785
12749025
23948890
28382596
28337257
27721184
28781108
28777758
27132792
12832099
26974159
12925731
18568035
17720802
27693185
25297091
9600986
23739959
21115476
22235132
17403556
17627483
23183490
25617315
19156775
15707899
23011726
12183643
17308309
9525985
9651552
22583753
17214602
18523239
21775615
18549783
26216852
27222392
26462756
26955646
25380238
2360787
8434881
1789684
20042680
18525123
26696824
21550980
23050084
28382304
22867711
26786552
19555648
27025652
28035937
26829469
27582220
20140000
12244210
18272254
17908236
11771749
26519433
27480489
28400135
27033548
28607171
28283575
24853936
3572454
14643375
9862637
10460236
20230616
25374101
23719722
18430999
25576060
16936707
28302722
25008180
24918340
26851597
18508100
21525469
27252647",The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.,"Alzheimer's disease (AD) is a devastating neurological disorder that still lacks an effective treatment, and this has stimulated an intense pursuit of disease-modifying therapeutics. Given the increasingly recognized link between AD and defective brain insulin signaling, we investigated the actions of liraglutide, a glucagon-like peptide-1 (GLP-1) analog marketed for treatment of type 2 diabetes, in experimental models of AD. Insulin receptor pathology is an important feature of AD brains that impairs the neuroprotective actions of central insulin signaling. Here, we show that liraglutide prevented the loss of brain insulin receptors and synapses, and reversed memory impairment induced by AD-linked amyloid-β oligomers (AβOs) in mice. Using hippocampal neuronal cultures, we determined that the mechanism of neuroprotection by liraglutide involves activation of the PKA signaling pathway. Infusion of AβOs into the lateral cerebral ventricle of non-human primates (NHPs) led to marked loss of insulin receptors and synapses in brain regions related to memory. Systemic treatment of NHPs with liraglutide provided partial protection, decreasing AD-related insulin receptor, synaptic, and tau pathology in specific brain regions. Synapse damage and elimination are amongst the earliest known pathological changes and the best correlates of memory impairment in AD. The results illuminate mechanisms of neuroprotection by liraglutide, and indicate that GLP-1 receptor activation may be harnessed to protect brain insulin receptors and synapses in AD. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.","[""Alzheimer's disease"", 'GLP-1', 'PKA signaling', 'diabetes', 'insulin receptors', 'liraglutide', 'neurodegeneration', 'non-human primates', 'synapse damage', 'tau pathology']",The Journal of pathology,2018-02-13,"[{'lastname': 'Batista', 'firstname': 'Andre F', 'initials': 'AF', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'lastname': 'Forny-Germano', 'firstname': 'Leticia', 'initials': 'L', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'lastname': 'Clarke', 'firstname': 'Julia R', 'initials': 'JR', 'affiliation': 'School of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'lastname': 'Lyra E Silva', 'firstname': 'Natalia M', 'initials': 'NM', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'lastname': 'Brito-Moreira', 'firstname': 'Jordano', 'initials': 'J', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'lastname': 'Boehnke', 'firstname': 'Susan E', 'initials': 'SE', 'affiliation': ""Centre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.""}, {'lastname': 'Winterborn', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': ""Animal Care Service, Queen's University, Kingston, Ontario, Canada.""}, {'lastname': 'Coe', 'firstname': 'Brian C', 'initials': 'BC', 'affiliation': ""Centre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.""}, {'lastname': 'Lablans', 'firstname': 'Ann', 'initials': 'A', 'affiliation': ""Centre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.""}, {'lastname': 'Vital', 'firstname': 'Juliana F', 'initials': 'JF', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'lastname': 'Marques', 'firstname': 'Suelen A', 'initials': 'SA', 'affiliation': 'Departament of Neurobiology, Fluminense Federal University, Niteroi, Brazil.'}, {'lastname': 'Martinez', 'firstname': 'Ana Mb', 'initials': 'AM', 'affiliation': 'Department of Pathology, Faculty of Medicine, Hospital Universitário Clementino Fraga Filho, UFRJ, Rio de Janeiro, Brazil.'}, {'lastname': 'Gralle', 'firstname': 'Matthias', 'initials': 'M', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'lastname': 'Holscher', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Division of Biomed and Life Sciences, Faculty of Health and Medicine Lancaster University, Lancaster, UK.'}, {'lastname': 'Klein', 'firstname': 'William L', 'initials': 'WL', 'affiliation': 'Department of Neurobiology, Northwestern University, Evanston, Illinois, USA.'}, {'lastname': 'Houzel', 'firstname': 'Jean-Christophe', 'initials': 'JC', 'affiliation': 'Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'lastname': 'Ferreira', 'firstname': 'Sergio T', 'initials': 'ST', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.\nInstitute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'lastname': 'Munoz', 'firstname': 'Douglas P', 'initials': 'DP', 'affiliation': ""Centre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.""}, {'lastname': 'De Felice', 'firstname': 'Fernanda G', 'initials': 'FG', 'affiliation': ""Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.\nCentre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.""}]",,,,© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.,10.1002/path.5056,<Element 'PubmedArticle' at 0x7f05dbc34400>
134,29401605,Tau ablation in mice leads to pancreatic β cell dysfunction and glucose intolerance.,"The microtubule-associated protein tau is highly expressed in pancreatic islets. Abnormally phosphorylated tau aggregates assemble into neurofibrillary tangles linked to Alzheimer's disease pathology and has also been found in islets of patients with type 2 diabetes. However, the significance of tau in islet function remains relatively unexplored. Therefore, we investigated the role of tau on β cell function and glucose homeostasis using tau knockout (tauKO) mice. TauKO mice were hyperglycemic and glucose intolerant at an early age. Islet insulin content was reduced and proinsulin levels were significantly elevated in tauKO mice, resulting in impaired glucose-stimulated insulin secretion. Loss of tau also resulted in increased epididymal fat mass and leptin levels, reduced glucose production, and insulin resistance at later ages, leading to complete onset of diabetes. Transgenic expression of human tau in islets was unable to rescue those defects in glucose regulation, indicating structural and/or functional differences between mouse and human tau. Cumulatively, these results suggest an important role for tau in the proper maintenance of pancreatic β cell function and glucose homeostasis.-Wijesekara, N., Gonçalves, R. A., Ahrens, R., De Felice, F. G., Fraser, P. E. Tau ablation in mice leads to pancreatic β cell dysfunction and glucose intolerance.","['Alzheimer’s disease', 'MAPT', 'insulin', 'islets']",FASEB journal : official publication of the Federation of American Societies for Experimental Biology,2018-02-07,"[{'lastname': 'Wijesekara', 'firstname': 'Nadeeja', 'initials': 'N', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Gonçalves', 'firstname': 'Rafaella Araujo', 'initials': 'RA', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.\nInstitute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'lastname': 'Ahrens', 'firstname': 'Rosemary', 'initials': 'R', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'De Felice', 'firstname': 'Fernanda G', 'initials': 'FG', 'affiliation': ""Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.\nDepartment of Biomedical and Molecular Sciences, Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada; and.""}, {'lastname': 'Fraser', 'firstname': 'Paul E', 'initials': 'PE', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.\nDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.'}]",,,,,10.1096/fj.201701352,<Element 'PubmedArticle' at 0x7f05db93a7c0>
135,29391240,Atorvastatin and insulin equally mitigate brain pathology in diabetic rats.,"Although insulin and atorvastatin have been shown to exert glycemic control and could improve brain function, the effects of atorvastatin or insulin as well as the combination of atorvastatin plus insulin on brain pathology in diabetes mellitus type 1 (T1DM) are unclear. Therefore, this study investigated the effect of atorvastatin, insulin or combined drugs on brain pathology in streptozotocin-induced diabetic rats. Thirty-six male rats were divided into two groups, a control group (n = 12) and a diabetic or experimental group (n = 24). Diabetic rats were further divided into four groups (n = 6/group) and the groups received either a vehicle (normal saline), atorvastatin (10 mg/kg/day), insulin (4 U/day) or a combination of the drugs for 4 weeks. The control group rats were divided into two groups (n = 6/group) to receive either just the vehicle or atorvastatin for 4 weeks. We found that streptozotocin-induced diabetic rats developed hyperglycemia, showing evidence of increased brain oxidative stress, impaired brain mitochondrial function, increased brain apoptosis, increased tau protein expression, increased phosphorylation of tau protein expression and amyloid beta levels, and decreased dendritic spine density. Although atorvastatin and insulin therapies led to an equal reduction in plasma glucose level in these diabetic rats, the combined drug therapy showed the greatest efficacy in decreasing plasma glucose level. Interestingly, atorvastatin, insulin and the combined drugs equally mitigated brain pathology. Our findings indicate that the combined drug therapy showed the greatest efficacy in improving metabolic parameters. However, atorvastatin, insulin and the combined drug therapy shared a similar efficacy in preventing brain damage in T1DM rats.","['Amyloid beta', 'Atorvastatin', 'Brain apoptosis', 'Brain mitochondrial function', 'Diabetes mellitus type 1', 'Insulin']",Toxicology and applied pharmacology,2018-02-03,"[{'lastname': 'Pratchayasakul', 'firstname': 'Wasana', 'initials': 'W', 'affiliation': 'Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Thongnak', 'firstname': 'La-Ongdao', 'initials': 'LO', 'affiliation': 'Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Chattipakorn', 'firstname': 'Kenneth', 'initials': 'K', 'affiliation': 'Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Lungaphin', 'firstname': 'Anusorn', 'initials': 'A', 'affiliation': 'Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Pongchaidecha', 'firstname': 'Anchalee', 'initials': 'A', 'affiliation': 'Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Satjaritanun', 'firstname': 'Pattarapong', 'initials': 'P', 'affiliation': 'Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Jaiwongkam', 'firstname': 'Thidarat', 'initials': 'T', 'affiliation': 'Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Kerdphoo', 'firstname': 'Sasiwan', 'initials': 'S', 'affiliation': 'Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Chattipakorn', 'firstname': 'Siriporn C', 'initials': 'SC', 'affiliation': 'Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Chiang Mai 50200, Thailand. Electronic address: siriporn.c@cmu.ac.th.'}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,10.1016/j.taap.2018.01.021,<Element 'PubmedArticle' at 0x7f05db9464a0>
136,"29382817
12973694
8496151
8471244
18378771
21813674
23041626
27114033
16862115
16862116
16950801
16983685
17071927
22277331
17436289
24252647
17023659
17084815
18309045
20653509
22579281
26526393
20667979
20026663
22733568
22062772
20522652
21933710
24728269
21644037
27435172
25231903
25568918
24596417
27165780
11923480
26101221
25770685
22251793
27546785
22710920
18287029
20823850
20130576
21976697
20655099
21172610
20691893
24853936
24344647
11163132
146092
7718249
8202528
1739121
8356085
11146125
12641730
17241267
17562708
20962218
21731734
18546284
21062285
23424178
24105464
26769969
27138926
12527478
22701746
11084030
17980494
25567680
10227296
20613859
25070536
17533153
15130806
20134419
20439996",Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology.,"Mutations in the progranulin (PGRN) gene cause a tau pathology-negative and TDP43 pathology-positive form of frontotemporal lobar degeneration (FTLD-TDP). We generated a knock-in mouse harboring the R504X mutation (PGRN-KI). Phosphoproteomic analysis of this model revealed activation of signaling pathways connecting PKC and MAPK to tau prior to TDP43 aggregation and cognitive impairments, and identified PKCα as the kinase responsible for the early-stage tau phosphorylation at Ser203. Disinhibition of Gas6 binding to Tyro3 due to PGRN reduction results in activation of PKCα via PLCγ, inducing tau phosphorylation at Ser203, mislocalization of tau to dendritic spines, and spine loss. Administration of a PKC inhibitor, B-Raf inhibitor, or knockdown of molecules in the Gas6-Tyro3-tau axis rescues spine loss and cognitive impairment of PGRN-KI mice. Collectively, these results suggest that targeting of early-stage and aggregation-independent tau signaling represents a promising therapeutic strategy for this disease.",[],Nature communications,2018-02-01,"[{'lastname': 'Fujita', 'firstname': 'Kyota', 'initials': 'K', 'affiliation': 'Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.'}, {'lastname': 'Chen', 'firstname': 'Xigui', 'initials': 'X', 'affiliation': 'Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.'}, {'lastname': 'Homma', 'firstname': 'Hidenori', 'initials': 'H', 'affiliation': 'Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.'}, {'lastname': 'Tagawa', 'firstname': 'Kazuhiko', 'initials': 'K', 'affiliation': 'Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.'}, {'lastname': 'Amano', 'firstname': 'Mutsuki', 'initials': 'M', 'affiliation': 'Department of Cell Pharmacology, Graduate School of Medicine, Nagoya University, 65, Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.'}, {'lastname': 'Saito', 'firstname': 'Ayumu', 'initials': 'A', 'affiliation': 'Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.'}, {'lastname': 'Imoto', 'firstname': 'Seiya', 'initials': 'S', 'affiliation': 'Health Intelligence Center, Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.'}, {'lastname': 'Akatsu', 'firstname': 'Hiroyasu', 'initials': 'H', 'affiliation': 'Department of Medicine for Aging in Place and Community-Based Medical Education, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, 467-8601, Japan.'}, {'lastname': 'Hashizume', 'firstname': 'Yoshio', 'initials': 'Y', 'affiliation': 'Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.'}, {'lastname': 'Kaibuchi', 'firstname': 'Kozo', 'initials': 'K', 'affiliation': 'Department of Cell Pharmacology, Graduate School of Medicine, Nagoya University, 65, Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.'}, {'lastname': 'Miyano', 'firstname': 'Satoru', 'initials': 'S', 'affiliation': 'Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.'}, {'lastname': 'Okazawa', 'firstname': 'Hitoshi', 'initials': 'H', 'affiliation': 'Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan. okazawa-tky@umin.ac.jp.'}]",,,,,"10.1038/s41467-018-02821-z
10.1002/mrd.1080340302
10.1083/jcb.200712039
10.1523/JNEUROSCI.6244-10.2011
10.1172/JCI63113
10.1016/j.cell.2016.04.001
10.1038/nature05017
10.1038/nature05016
10.1093/hmg/ddl241
10.1002/ana.20963
10.1093/brain/awl289
10.1186/alzrt102
10.1002/humu.20520
10.1186/2051-5960-1-16
10.1126/science.1134108
10.1016/j.bbrc.2006.10.093
10.1126/science.1154584
10.1586/epr.10.36
10.1016/j.cell.2012.04.017
10.1016/j.neuron.2015.10.030
10.1096/fj.10-161471
10.1084/jem.20091568
10.1016/j.nbd.2011.10.016
10.2353/ajpath.2010.090915
10.1016/j.nbd.2011.08.029
10.1038/nn.3697
10.1007/s00401-011-0845-8
10.1186/s40478-016-0345-0
10.1093/hmg/ddu475
10.1038/nrc3847
10.1182/blood-2013-09-528752
10.1126/scisignal.aaf6209
10.1083/jcb.201412008
10.1016/j.bbapap.2015.03.001
10.1247/csf.11044
10.1016/j.tips.2016.07.003
10.1073/pnas.0711741105
10.1038/nature09454
10.1038/nature08833
10.1091/mbc.E11-01-0072
10.1016/j.cell.2010.06.036
10.1016/j.neuron.2010.11.030
10.1016/j.cell.2010.07.032
10.1016/j.neuron.2014.05.004
10.1186/2051-5960-1-82
10.1016/S0955-0674(00)00172-1
10.1016/0022-2836(77)90214-5
10.1016/0896-6273(95)90232-5
10.1073/pnas.91.12.5562
10.1073/pnas.90.16.7789
10.1016/S0169-328X(00)00245-X
10.1046/j.1471-4159.2003.01645.x
10.1111/j.1460-9568.2006.05226.x
10.1074/jbc.M703269200
10.1523/JNEUROSCI.3637-10.2010
10.1371/journal.pone.0021405
10.1002/ana.21425
10.1111/j.1471-4159.2010.07098.x
10.1002/ana.23870
10.1093/hmg/ddt498
10.1074/jbc.M115.695379
10.1186/s13024-016-0102-7
10.1016/S0028-3908(02)00333-7
10.1371/journal.pone.0039035
10.1074/jbc.M007393200
10.1016/j.neuroscience.2007.09.047
10.4049/jimmunol.1401933
10.1038/19554
10.1371/journal.pbio.1000412
10.1038/mp.2014.69
10.1074/mcp.T600050-MCP200
10.1038/nprot.2009.222
10.1083/jcb.200905138",<Element 'PubmedArticle' at 0x7f05db952d60>
137,"29310723
21816775
15760286
17994521
27364252
7566337
22002422
22607808
8093899
16923954
26108478
19503072
25688081
20508117
1675319
16816392
25348064
4591849
29209767
20966215
27411637
20133839
26812492
19822779
8419831
8006664
27658420
9705125
22101366
27314593
11320182
1566067
24452628
23380910
15994784
26354483
2446004
24685293
25609817
26669818
20089646
27016065
27377321
16764717
26873446
16990547
21968933
10443888
16484658
20473510
20940625
28349199
27812793
26268531
10850703
22229116
18638852
26878132
11895043
18369648
20535486
12084879
26226132
17645242
1763890
25840008
24982139
21997298
26352792
20194495",Iatrogenic Creutzfeldt-Jakob disease with Amyloid-β pathology: an international study.,"The presence of pathology related to the deposition of amyloid-β (Aβ) has been recently reported in iatrogenic Creutzfeldt-Jakob disease (iCJD) acquired from inoculation of growth hormone (GH) extracted from human cadaveric pituitary gland or use of cadaveric dura mater (DM) grafts.To investigate this phenomenon further, a cohort of 27 iCJD cases - 21 with adequate number of histopathological sections - originating from Australia, France, Italy, and the Unites States, were examined by immunohistochemistry, amyloid staining, and Western blot analysis of the scrapie prion protein (PrP","['Amyloid-β', 'Cerebral amyloid angiopathy', 'Pathology', 'Thioflavin S', 'iCJD']",Acta neuropathologica communications,2018-01-10,"[{'lastname': 'Cali', 'firstname': 'Ignazio', 'initials': 'I', 'affiliation': 'Departments of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA. ixc20@case.edu.\nDepartment of Pathology, 4th floor, room 402C, Case Western Reserve University, 2085 Adelbert Road, Cleveland, OH, 44106, USA. ixc20@case.edu.'}, {'lastname': 'Cohen', 'firstname': 'Mark L', 'initials': 'ML', 'affiliation': 'Departments of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.\nNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.'}, {'lastname': 'Haik', 'firstname': 'Stephane', 'initials': 'S', 'affiliation': 'Inserm U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris VI UMR S 1127, Institut du Cerveau et de la Moelle épinière, Paris, France.\nAP-HP, Cellule Nationale de Référence des maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.\nAP-HP, Laboratoire de Neuropathologie R Escourolle, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Parchi', 'firstname': 'Piero', 'initials': 'P', 'affiliation': 'Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.\nIRCCS, Institute of Neurological Sciences, Bologna, Italy.'}, {'lastname': 'Giaccone', 'firstname': 'Giorgio', 'initials': 'G', 'affiliation': 'Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy.'}, {'lastname': 'Collins', 'firstname': 'Steven J', 'initials': 'SJ', 'affiliation': 'Australian National Creutzfeldt-Jakob Disease Registry, Department of Medicine, and The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, 3010, Australia.'}, {'lastname': 'Kofskey', 'firstname': 'Diane', 'initials': 'D', 'affiliation': 'Departments of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.\nNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.'}, {'lastname': 'Wang', 'firstname': 'Han', 'initials': 'H', 'affiliation': 'Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USA.'}, {'lastname': 'McLean', 'firstname': 'Catriona A', 'initials': 'CA', 'affiliation': 'Department of Anatomical Pathology, Alfred Health, Melbourne, 3181, Australia.\nVictorian Brain Bank, the Florey institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, 3010, Australia.'}, {'lastname': 'Brandel', 'firstname': 'Jean-Philippe', 'initials': 'JP', 'affiliation': 'Inserm U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris VI UMR S 1127, Institut du Cerveau et de la Moelle épinière, Paris, France.\nAP-HP, Cellule Nationale de Référence des maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Privat', 'firstname': 'Nicolas', 'initials': 'N', 'affiliation': 'Inserm U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris VI UMR S 1127, Institut du Cerveau et de la Moelle épinière, Paris, France.'}, {'lastname': 'Sazdovitch', 'firstname': 'Véronique', 'initials': 'V', 'affiliation': 'Inserm U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris VI UMR S 1127, Institut du Cerveau et de la Moelle épinière, Paris, France.\nAP-HP, Laboratoire de Neuropathologie R Escourolle, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Duyckaerts', 'firstname': 'Charles', 'initials': 'C', 'affiliation': 'Inserm U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris VI UMR S 1127, Institut du Cerveau et de la Moelle épinière, Paris, France.\nAP-HP, Laboratoire de Neuropathologie R Escourolle, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Kitamoto', 'firstname': 'Tetsuyuki', 'initials': 'T', 'affiliation': 'Department of Neurological Science, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'lastname': 'Belay', 'firstname': 'Ermias D', 'initials': 'ED', 'affiliation': 'Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.'}, {'lastname': 'Maddox', 'firstname': 'Ryan A', 'initials': 'RA', 'affiliation': 'Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.'}, {'lastname': 'Tagliavini', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy.'}, {'lastname': 'Pocchiari', 'firstname': 'Maurizio', 'initials': 'M', 'affiliation': 'Department of Neurosciences, Istituto Superiore di Sanità, Rome, Italy.'}, {'lastname': 'Leschek', 'firstname': 'Ellen', 'initials': 'E', 'affiliation': 'National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.'}, {'lastname': 'Appleby', 'firstname': 'Brian S', 'initials': 'BS', 'affiliation': 'Departments of Neurology, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.\nDepartments of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.\nNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.'}, {'lastname': 'Safar', 'firstname': 'Jiri G', 'initials': 'JG', 'affiliation': 'Departments of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.\nDepartments of Neurology, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.\nNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA.'}, {'lastname': 'Schonberger', 'firstname': 'Lawrence B', 'initials': 'LB', 'affiliation': 'Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.'}, {'lastname': 'Gambetti', 'firstname': 'Pierluigi', 'initials': 'P', 'affiliation': 'Departments of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA. pxg13@case.edu.\nDepartment of Pathology, 4th floor, room 419, Case Western Reserve University, 2085 Adelbert Road, Cleveland, OH, 44106, USA. pxg13@case.edu.'}]",,,,,"10.1186/s40478-017-0503-z
10.1210/jc.2011-1357
10.1146/annurev.publhealth.26.021304.144536
10.1086/523862
10.3171/2016.5.FOCUS15126
10.1016/0197-4580(95)00021-6
10.1097/NEN.0b013e318232a379
10.3201/eid1806.120116
10.1097/00005072-199301000-00008
10.1093/brain/awl224
10.1186/s40478-015-0214-2
10.1038/ncb1901
10.1093/brain/awv006
10.1016/0140-6736(91)93128-V
10.1093/brain/awl159
10.1007/s00401-014-1349-0
10.1126/science.1194516
10.1038/nature18602
10.1073/pnas.0904532106
10.1001/archneurol.2009.224
10.1056/NEJM199302043280520
10.1136/jnnp.57.6.757
10.1093/brain/aww230
10.1007/s004010050870
10.1007/s00401-011-0912-1
10.1007/s00401-016-1588-3
10.1212/WNL.56.8.1080
10.1126/science.1566067
10.1007/s00401-014-1243-9
10.1001/jamaneurol.2013.1933
10.1128/JVI.79.14.8904-8908.2005
10.1038/nature15369
10.1186/2051-5960-2-32
10.1128/JVI.03183-14
10.1111/neup.12270
10.1128/JVI.02387-09
10.1007/s00401-016-1565-x
10.1111/bpa.12411
10.1186/1746-6148-2-19
10.1016/j.ajpath.2015.11.013
10.1126/science.1131864
10.1038/mp.2011.120
10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W
10.1136/jnnp.2005.070805
10.1007/s00401-010-0691-0
10.1097/NEN.0b013e3181fab558
10.1007/s00401-016-1638-x
10.1093/brain/awv235
10.1038/35014735
10.1101/cshperspect.a006189
10.1038/labinvest.2016.27
10.1093/jnen/61.3.282
10.1007/s00401-008-0366-2
10.1007/s00401-010-0707-9
10.1212/WNL.58.12.1791
10.1097/NEN.0000000000000228
10.1111/j.1440-1789.2007.00755.x
10.1002/ana.410300503
10.1146/annurev-neuro-071714-033828
10.1073/pnas.1408900111
10.1038/embor.2011.192
10.1038/nn.4117
10.1074/jbc.M109.088831",<Element 'PubmedArticle' at 0x7f05db8cb130>
138,29246974,Pancreatic Pericytes Support β-Cell Function in a Tcf7l2-Dependent Manner.,Polymorphism in ,[],Diabetes,2017-12-17,"[{'lastname': 'Sakhneny', 'firstname': 'Lina', 'initials': 'L', 'affiliation': 'Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Rachi', 'firstname': 'Eleonor', 'initials': 'E', 'affiliation': 'Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Epshtein', 'firstname': 'Alona', 'initials': 'A', 'affiliation': 'Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Guez', 'firstname': 'Helen C', 'initials': 'HC', 'affiliation': 'Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Wald-Altman', 'firstname': 'Shane', 'initials': 'S', 'affiliation': 'Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences and the Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Lisnyansky', 'firstname': 'Michal', 'initials': 'M', 'affiliation': 'Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Khalifa-Malka', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Hazan', 'firstname': 'Adina', 'initials': 'A', 'affiliation': 'Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.'}, {'lastname': 'Baer', 'firstname': 'Daria', 'initials': 'D', 'affiliation': 'Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Priel', 'firstname': 'Avi', 'initials': 'A', 'affiliation': 'Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.'}, {'lastname': 'Weil', 'firstname': 'Miguel', 'initials': 'M', 'affiliation': 'Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences and the Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Landsman', 'firstname': 'Limor', 'initials': 'L', 'affiliation': 'Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel limorl@post.tau.ac.il.'}]",,,,© 2017 by the American Diabetes Association.,10.2337/db17-0697,<Element 'PubmedArticle' at 0x7f05db88c270>
139,29174383,Intracerebroventricular streptozotocin impairs adult neurogenesis and cognitive functions via regulating neuroinflammation and insulin signaling in adult rats.,"Neurogenesis is a complex process involved in memory formation and is known to be altered in Alzheimer's disease (AD). Neuroinflammation and insulin signaling dysfunction, key players during intracerebroventricular Streptozotocin (ICV-STZ) induced dementia variedly affects neurogenesis. The aim of this work was to study the variation in neurogenic process associated with AD in ICV STZ induced dementia. Adult male Sprague Dawley rats weighing 180-200 g were given two different doses of ICV STZ (3 mg/kg on Day 1 and 3, & 1 mg/kg on Day 1) in two different experimental setup. Memory functions were assessed by Morris Water Maze. Immunofluorescence and western blotting was done to study the variation in neurogenesis, amyloid and tau pathology, neuroinflammation and insulin signaling. ICV STZ 6 mg/kg (3 mg/kg twice on Day 1 and 3 of 21 days study) caused impairment in learning and memory and severe atrophy of the neurogenic areas. Modified dose of ICV STZ (1 mg/kg once on Day 1) caused a significant decline in neurogenesis in subventricular zone (SVZ) and dentate gyrus (DG) as indicated by decrease in the number of (5-Bromo-2'-deoxyuridine) BrdU","[""Alzheimer's disease"", 'Dementia', 'ICV streptozotocin', 'Insulin signaling', 'Neurogenesis', 'Neuroinflammation']",Neurochemistry international,2017-11-28,"[{'lastname': 'Mishra', 'firstname': 'Sandeep Kumar', 'initials': 'SK', 'affiliation': 'Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Innovative Research (AcSIR), India.'}, {'lastname': 'Singh', 'firstname': 'Sonu', 'initials': 'S', 'affiliation': 'Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow, India.'}, {'lastname': 'Shukla', 'firstname': 'Shubha', 'initials': 'S', 'affiliation': 'Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Innovative Research (AcSIR), India.'}, {'lastname': 'Shukla', 'firstname': 'Rakesh', 'initials': 'R', 'affiliation': 'Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Innovative Research (AcSIR), India. Electronic address: rakeshshuklacdri@gmail.com.'}]",,,,Copyright © 2017 Elsevier Ltd. All rights reserved.,10.1016/j.neuint.2017.11.012,<Element 'PubmedArticle' at 0x7f05db89d220>
140,"29172163
15955494
21216294
26977398
26401709
23164495
20858974
18245784
23085935
28337409
22366791
25255942
23041626
19884572
25662776
20045477
19376066
17329432
19255408
22366795
20026663
20410145",Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study.,"Frontotemporal dementia (FTD) is a highly heritable condition with multiple genetic causes. In this study, similarities and differences of gray matter (GM) atrophy patterns were assessed among 3 common forms of genetic FTD (mutations in C9orf72, GRN, and MAPT). Participants from the Genetic FTD Initiative (GENFI) cohort with a suitable volumetric T1 magnetic resonance imaging scan were included (319): 144 nonmutation carriers, 128 presymptomatic mutation carriers, and 47 clinically affected mutation carriers. Cross-sectional differences in GM volume between noncarriers and carriers were analyzed using voxel-based morphometry. In the affected carriers, each genetic mutation group exhibited unique areas of atrophy but also a shared network involving the insula, orbitofrontal lobe, and anterior cingulate. Presymptomatic GM atrophy was observed particularly in the thalamus and cerebellum in the C9orf72 group, the anterior and medial temporal lobes in MAPT, and the posterior frontal and parietal lobes as well as striatum in GRN. Across all presymptomatic carriers, there were significant decreases in the anterior insula. These results suggest that although there are important differences in atrophy patterns for each group (which can be seen presymptomatically), there are also similarities (a fronto-insula-anterior cingulate network) that help explain the clinical commonalities of the disease.","['Atrophy', 'Frontotemporal dementia', 'Magnetic resonance imaging', 'Preclinical dementia', 'Voxel-based morphometry']",Neurobiology of aging,2017-11-25,"[{'lastname': 'Cash', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; Centre for Medical Image Computing, University College London, London, UK.'}, {'lastname': 'Bocchetta', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.'}, {'lastname': 'Thomas', 'firstname': 'David L', 'initials': 'DL', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; Centre for Medical Image Computing, University College London, London, UK.'}, {'lastname': 'Dick', 'firstname': 'Katrina M', 'initials': 'KM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.'}, {'lastname': 'van Swieten', 'firstname': 'John C', 'initials': 'JC', 'affiliation': 'Erasmus Medical Center, Rotterdam, the Netherlands.'}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Masellis', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Cognitive Neurology Research Unit, Sunnybrook Health Sciences Centre, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Tartaglia', 'firstname': 'Maria Carmela', 'initials': 'MC', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Rowe', 'firstname': 'James B', 'initials': 'JB', 'affiliation': 'Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Graff', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden; Department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden.'}, {'lastname': 'Tagliavini', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'Istituto Neurologico Carlo Besta, Milan, Italy.'}, {'lastname': 'Frisoni', 'firstname': 'Giovanni B', 'initials': 'GB', 'affiliation': 'IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}, {'lastname': 'Laforce', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Université Laval, Quebec, Canada.'}, {'lastname': 'Finger', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'University of Western Ontario, Ontario, Canada.'}, {'lastname': 'de Mendonça', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.'}, {'lastname': 'Sorbi', 'firstname': 'Sandro', 'initials': 'S', 'affiliation': 'Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy; IRCCS Don Gnocchi, Firenze, Italy.'}, {'lastname': 'Rossor', 'firstname': 'Martin N', 'initials': 'MN', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.'}, {'lastname': 'Ourselin', 'firstname': 'Sebastien', 'initials': 'S', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; Centre for Medical Image Computing, University College London, London, UK.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK. Electronic address: j.rohrer@ucl.ac.uk.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2017.10.008,<Element 'PubmedArticle' at 0x7f05db52c680>
141,"29154275
17132977
22205300
24070815
24652456
15750215
18401020
9366728
25812851
26276262
27079723
21115952
15477536
22820012
16951936
1852315
10461029
1790263
9443474
12460139
20847404
23473966
25374101
23507773
18230654
15964100
18430999
25551191
4056765
15892905
1202204
15094077
26462756
2081237
19433663
18395614
25646706
18803648
19439965
10515194
27221635
21897007
25346723
28140402
25450107
24574966
12606509
15504987
12663695
20719831
17942819
8770017
26996255",Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.,"Abnormal insulin signaling in the brain has been linked to Alzheimer's disease (AD).
To evaluate whether cerebrospinal fluid (CSF) insulin levels are associated with cognitive performance and CSF amyloid-β and Tau. Additionally, we explore whether any such association differs by sex or APOE ɛ4 genotype.
From 258 individuals participating in the Parelsnoer Institute Neurodegenerative Diseases, a nationwide multicenter memory clinic population, we selected 138 individuals (mean age 66±9 years, 65.2% male) diagnosed with subjective cognitive impairment (n = 45), amnestic mild cognitive impairment (n = 44), or AD (n = 49), who completed a neuropsychological assessment, including tests of global cognition and memory performance, and who underwent lumbar puncture. We measured CSF levels of insulin, amyloid-β1-42, total (t-)Tau, and phosphorylated (p-)Tau.
CSF insulin levels did not differ between the diagnostic groups (p = 0.136). Across the whole study population, CSF insulin was unrelated to cognitive performance and CSF biomarkers of AD, after adjustment for age, sex, body mass index, diabetes status, and clinic site (all p≥0.131). Importantly, however, we observed effect modification by sex and APOE ɛ4 genotype. Specifically, among women, higher insulin levels in the CSF were associated with worse global cognition (standardized regression coefficient -0.483; p = 0.008) and higher p-Tau levels (0.353; p = 0.040). Among non-carriers of the APOE ɛ4 allele, higher CSF insulin was associated with higher t-Tau (0.287; p = 0.008) and p-Tau (0.246; p = 0.029).
Our findings provide further evidence for a relationship between brain insulin signaling and AD pathology. It also highlights the need to consider sex and APOE ɛ4 genotype when assessing the role of insulin.","['Alzheimer’s disease', 'cerebrospinal fluid', 'cognition', 'epidemiology', 'insulin']",Journal of Alzheimer's disease : JAD,2017-11-21,"[{'lastname': 'Geijselaers', 'firstname': 'Stefan L C', 'initials': 'SLC', 'affiliation': 'Departments of Neurology and Geriatrics Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, the Netherlands.\nDepartment of Internal Medicine and Cardiovascular Research Institute, Maastricht University Medical Centre +, Maastricht, the Netherlands.'}, {'lastname': 'Aalten', 'firstname': 'Pauline', 'initials': 'P', 'affiliation': 'Alzheimer Centre Limburg, School for Mental Health and Neuroscience (MHeNS), Maastricht University Medical Centre +, Maastricht, the Netherlands.'}, {'lastname': 'Ramakers', 'firstname': 'Inez H G B', 'initials': 'IHGB', 'affiliation': 'Alzheimer Centre Limburg, School for Mental Health and Neuroscience (MHeNS), Maastricht University Medical Centre +, Maastricht, the Netherlands.'}, {'lastname': 'De Deyn', 'firstname': 'Peter Paul', 'initials': 'PP', 'affiliation': 'Department of Neurology and Alzheimer Research Centre, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.'}, {'lastname': 'Heijboer', 'firstname': 'Annemieke C', 'initials': 'AC', 'affiliation': 'Department of Clinical Chemistry, Endocrine Laboratory, VU University Medical Centre, Amsterdam, the Netherlands.'}, {'lastname': 'Koek', 'firstname': 'Huiberdina L', 'initials': 'HL', 'affiliation': 'Departments of Neurology and Geriatrics Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, the Netherlands.'}, {'lastname': 'OldeRikkert', 'firstname': 'Marcel G M', 'initials': 'MGM', 'affiliation': 'Radboudumc Alzheimer Centre, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands.'}, {'lastname': 'Papma', 'firstname': 'Janne M', 'initials': 'JM', 'affiliation': 'Departments of Neurology and Radiology, Erasmus University Medical Centre, Rotterdam, the Netherlands.'}, {'lastname': 'Reesink', 'firstname': 'Fransje E', 'initials': 'FE', 'affiliation': 'Department of Neurology and Alzheimer Research Centre, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.'}, {'lastname': 'Smits', 'firstname': 'Lieke L', 'initials': 'LL', 'affiliation': 'Alzheimer Centre Amsterdam, VU University Medical Centre, Amsterdam, the Netherlands.'}, {'lastname': 'Stehouwer', 'firstname': 'Coen D A', 'initials': 'CDA', 'affiliation': 'Department of Internal Medicine and Cardiovascular Research Institute, Maastricht University Medical Centre +, Maastricht, the Netherlands.'}, {'lastname': 'Teunissen', 'firstname': 'Charlotte E', 'initials': 'CE', 'affiliation': 'Department of Clinical Chemistry, Neurochemistry Laboratory and Biobank, VU University Medical Centre, Amsterdam, the Netherlands.'}, {'lastname': 'Verhey', 'firstname': 'Frans R J', 'initials': 'FRJ', 'affiliation': 'Alzheimer Centre Limburg, School for Mental Health and Neuroscience (MHeNS), Maastricht University Medical Centre +, Maastricht, the Netherlands.'}, {'lastname': 'van der Flier', 'firstname': 'Wiesje M', 'initials': 'WM', 'affiliation': 'Alzheimer Centre Amsterdam, VU University Medical Centre, Amsterdam, the Netherlands.'}, {'lastname': 'Biessels', 'firstname': 'Geert Jan', 'initials': 'GJ', 'affiliation': 'Department of Internal Medicine and Cardiovascular Research Institute, Maastricht University Medical Centre +, Maastricht, the Netherlands.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,Our findings provide further evidence for a relationship between brain insulin signaling and AD pathology. It also highlights the need to consider sex and APOE ɛ4 genotype when assessing the role of insulin.,"CSF insulin levels did not differ between the diagnostic groups (p = 0.136). Across the whole study population, CSF insulin was unrelated to cognitive performance and CSF biomarkers of AD, after adjustment for age, sex, body mass index, diabetes status, and clinic site (all p≥0.131). Importantly, however, we observed effect modification by sex and APOE ɛ4 genotype. Specifically, among women, higher insulin levels in the CSF were associated with worse global cognition (standardized regression coefficient -0.483; p = 0.008) and higher p-Tau levels (0.353; p = 0.040). Among non-carriers of the APOE ɛ4 allele, higher CSF insulin was associated with higher t-Tau (0.287; p = 0.008) and p-Tau (0.246; p = 0.029).",,10.3233/JAD-170522,<Element 'PubmedArticle' at 0x7f05db54fa90>
142,29132997,Thyroid hormone improves insulin signaling and reduces the activation of neurodegenerative pathway in the hippocampus of diabetic adult male rats.,"Diabetes mellitus (DM) and impairments of glucose metabolism and insulin resistance in the brain have been suggested as a likely etiology of Alzheimer's disease (AD). Studies have shown that thyroid hormones (THs) improve insulin sensitivity in DM rats and act as mediators of the plasticity of the nervous system altering behavior and cognitive function. Based on these findings, this study aimed to evaluate the effects of diabetes and triiodothyronine (T3) treatment upon proteins associated with DM and AD in the central nervous system.
Euglycemic and Diabetic (alloxan-induced) male Wistar rats were daily treated with T3 (1.5μg/100g body weight) or vehicle (saline) for a 4-week period and subdivided into the following groups: euglycemic treated with saline (Control=C); diabetic treated with saline (Diabetic=D); euglycemic treated with T3 (T3); diabetic treated with T3 (DT3). The expression of insulin signaling, neurodegenerative and neuron survival markers was evaluated in the hippocampus by immunoblotting, ELISA, and RT-PCR.
T3 treatment decreased glycemia, restored the insulin signaling and reduced the activation of glycogen synthase kinase 3 (GSK3) and tau proteins content in the hippocampus of diabetic rats.
The present data provide evidence that T3 treatment of diabetic rats is able to improve insulin sensitivity and reduce the activation of the neurodegenerative pathway in the brain, which might provide neuroprotection in this experimental model.","['Diabetes', 'GSK3', 'Hippocampus', 'Insulin signaling', 'Neurodegeneration', 'Tau protein', 'Triiodothyronine']",Life sciences,2017-11-15,"[{'lastname': 'Prieto-Almeida', 'firstname': 'Fernanda', 'initials': 'F', 'affiliation': 'Departamento de Fisiologia e Biofísica, Instituto de Ciências Biomédicas, Universidade de São Paulo, 05508-000 São Paulo, SP, Brazil.'}, {'lastname': 'Panveloski-Costa', 'firstname': 'Ana Carolina', 'initials': 'AC', 'affiliation': 'Departamento de Fisiologia e Biofísica, Instituto de Ciências Biomédicas, Universidade de São Paulo, 05508-000 São Paulo, SP, Brazil.'}, {'lastname': 'Crunfli', 'firstname': 'Fernanda', 'initials': 'F', 'affiliation': 'Departamento de Fisiologia e Biofísica, Instituto de Ciências Biomédicas, Universidade de São Paulo, 05508-000 São Paulo, SP, Brazil.'}, {'lastname': 'da Silva Teixeira', 'firstname': 'Silvania', 'initials': 'S', 'affiliation': 'Departamento de Fisiologia e Biofísica, Instituto de Ciências Biomédicas, Universidade de São Paulo, 05508-000 São Paulo, SP, Brazil.'}, {'lastname': 'Nunes', 'firstname': 'Maria Tereza', 'initials': 'MT', 'affiliation': 'Departamento de Fisiologia e Biofísica, Instituto de Ciências Biomédicas, Universidade de São Paulo, 05508-000 São Paulo, SP, Brazil. Electronic address: mtnunes@icb.usp.br.'}, {'lastname': 'Torrão', 'firstname': 'Andréa da Silva', 'initials': 'ADS', 'affiliation': 'Departamento de Fisiologia e Biofísica, Instituto de Ciências Biomédicas, Universidade de São Paulo, 05508-000 São Paulo, SP, Brazil. Electronic address: andrea@icb.usp.br.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.lfs.2017.11.013,<Element 'PubmedArticle' at 0x7f05d9fb5810>
143,29066367,Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.,"Physiopathological mechanisms of Alzheimer's disease (AD) are still matter of debate. Especially the role of amyloid β and tau pathology in the development of the disease are still matter of debate. Changes in tau and amyloid β peptide concentration in cerebrospinal fluid (CSF) and hypometabolic patterns at fluorine-18 fluorodeoxyglucose (
We examined 131 newly diagnosed AD patients according to the NINCDS-ADRDA criteria and 20 healthy controls. The mean (±SD) age of the patients was 70 (±7) years; 57 were male and 74 were female. All patients and controls underwent a complete clinical investigation, including medical history, neurological examination, mini-mental state examination (MMSE), a complete blood screening (including routine exams, thyroid hormones and a complete neuropsychological evaluation). Structural MRI was performed not earlier than 1 month before the 
t-Tau, p-Tau and Aβ(1-42) in CSF resulted 774 ± 345 pg/ml, 98 ± 64 pg/ml and 348.8 ± 111 pg/ml respectively. SPM analysis showed a significant negative correlation between CSF t-Tau and 
t-Tau deposition in brain is related to temporal, parietal and frontal hypometabolism in AD.","['Alzheimer', 'Brain imaging', 'CSF', 'PET', 'Tau']",Brain research,2017-10-27,"[{'lastname': 'Chiaravalloti', 'firstname': 'Agostino', 'initials': 'A', 'affiliation': 'Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy; IRCCS Neuromed, Pozzilli, Italy. Electronic address: agostino.chiaravalloti@uniroma2.it.'}, {'lastname': 'Barbagallo', 'firstname': 'Gaetano', 'initials': 'G', 'affiliation': 'Institute of Neurology, University Magna Graecia of Catanzaro, Italy.'}, {'lastname': 'Ricci', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Italy.'}, {'lastname': 'Martorana', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Department of Neurosciences, University Tor Vergata, Rome, Italy; IRCCS Santa Lucia, Rome, Italy.'}, {'lastname': 'Ursini', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': 'Department of Health Sciences, University Magna Graecia, Catanzaro, Italy.'}, {'lastname': 'Sannino', 'firstname': 'Pasqualina', 'initials': 'P', 'affiliation': 'IRCCS Neuromed, Pozzilli, Italy.'}, {'lastname': 'Karalis', 'firstname': 'Georgios', 'initials': 'G', 'affiliation': 'Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.'}, {'lastname': 'Schillaci', 'firstname': 'Orazio', 'initials': 'O', 'affiliation': 'Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy; IRCCS Neuromed, Pozzilli, Italy.'}]",,,"t-Tau, p-Tau and Aβ(1-42) in CSF resulted 774 ± 345 pg/ml, 98 ± 64 pg/ml and 348.8 ± 111 pg/ml respectively. SPM analysis showed a significant negative correlation between CSF t-Tau and ",Copyright © 2017 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2017.10.016,<Element 'PubmedArticle' at 0x7f05d9fc5310>
144,29027854,Long-term outcomes of tissue-based ACTH-antibody assay-guided transsphenoidal resection of pituitary adenomas in Cushing disease.,"OBJECTIVE Cushing disease is caused by a pituitary micro- or macroadenoma that hypersecretes adrenocorticotropic hormone (ACTH), resulting in hypercortisolemia. For decades, transsphenoidal resection (TSR) has been an efficacious treatment but with certain limitations, namely precise tumor localization and complete excision. The authors evaluated the novel use of a double-antibody sandwich assay for the real-time quantitation of ACTH in resected pituitary specimens with the goals of augmenting pathological diagnosis and ultimately improving long-term patient outcome. METHODS This study involved a retrospective review of records and an analysis of assay values, pathology slides, and MRI studies of patients with Cushing disease who had undergone TSR in the period from 2009 to 2014 and had at least 1 year of follow-up in coordination with an endocrinologist. In the operating room, biopsy specimens from the patients had been analyzed for tissue ACTH concentration. Additional samples were simultaneously sent for frozen-section pathological analysis. The ACTH assay performance was compared against pathology assessments of surgical tumor samples using receiver operating characteristic (ROC) analysis and against pre- and postoperative MRI studies. RESULTS Fourteen patients underwent TSR with guidance by ACTH-antibody assay and pathological assessment of 127 biopsy samples and were followed up for an average of 3 years. The ACTH threshold for discriminating adenomatous from normal tissue was 290,000 pg/mg of tissue, based on jointly maximized sensitivity (95.0%) and specificity (71.3%). Lateralization discordance between preoperative MRI studies and surgical visualization was noted in 3 patients, confirming the impression that MRI alone may not achieve optimal localization. A majority of the patients (85.7%) attained long-term disease remission based on urinary free cortisol levels, plasma cortisol levels, and long-term corticosteroid therapy. Comparisons of patient-months of remission and treatment failure showed that the remission rate in the study sample statistically exceeds the rate in historical controls (71.9%; p = 0.0007, Fisher's exact test). Long-term unexpected hormonal deficiencies were statistically similar between study patients (29%) and those in a meta-analysis (25%; p = 0.7596, Fisher's exact test). CONCLUSIONS These preliminary findings reflect the promising potential of tissue-based ACTH-antibody-guided assay for improving the cure rates of Cushing disease patients undergoing TSR. Further studies with larger sample sizes, further refinements of assay interpretation, and longer-term follow-ups are needed.","['ACTH', 'ACTH = adrenocorticotropic hormone', 'AP = anteroposterior', 'BIPSS = bilateral inferior petrosal sinus sampling', 'CC = craniocaudal', 'Cushing disease', 'NPV = negative predictive value', 'POMC = pro-opiomelanocortin', 'PPV = positive predictive value', 'ROC = receiver operating characteristic', 'STIR = short tau inversion recovery', 'TR = transverse', 'TSR = transsphenoidal resection', 'UFC = urinary free cortisol', 'YNHH = Yale New Haven Hospital', 'pituitary adenoma', 'pituitary surgery', 'transsphenoidal resection']",Journal of neurosurgery,2017-10-14,"[{'lastname': 'Erfe', 'firstname': 'J Mark', 'initials': 'JM', 'affiliation': '1Yale School of Medicine, New Haven, Connecticut.'}, {'lastname': 'Perry', 'firstname': 'Avital', 'initials': 'A', 'affiliation': '2Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'McClaskey', 'firstname': 'John', 'initials': 'J', 'affiliation': '3Department of Pathology, Mount Sinai Hospital, New York, New York; and.'}, {'lastname': 'Inzucchi', 'firstname': 'Silvio E', 'initials': 'SE', 'affiliation': 'Sections of4Endocrinology.'}, {'lastname': 'James', 'firstname': 'Whitney Sheen', 'initials': 'WS', 'affiliation': '5Division of Neurosurgery, University of Arizona, Tucson, Arizona.'}, {'lastname': 'Eid', 'firstname': 'Tore', 'initials': 'T', 'affiliation': '6Laboratory Medicine, and.'}, {'lastname': 'Bronen', 'firstname': 'Richard A', 'initials': 'RA', 'affiliation': '7Radiology and Biomedical Imaging.'}, {'lastname': 'Mahajan', 'firstname': 'Amit', 'initials': 'A', 'affiliation': '7Radiology and Biomedical Imaging.'}, {'lastname': 'Huttner', 'firstname': 'Anita', 'initials': 'A', 'affiliation': 'Departments of8Pathology and.'}, {'lastname': 'Santos', 'firstname': 'Florecita', 'initials': 'F', 'affiliation': '6Laboratory Medicine, and.'}, {'lastname': 'Spencer', 'firstname': 'Dennis', 'initials': 'D', 'affiliation': '9Neurological Surgery.'}]",,,,,10.3171/2017.3.JNS162245,<Element 'PubmedArticle' at 0x7f05d9fd5c70>
145,"29021478
23045170
9643314
20112401
1975174
16651050
21200183
12740683
12429545
26797367
4392011
6124033
1352825
8101570
2868655
11729667
11327266
12740683
24120178",Rhabdomyolysis in a Patient with Polyarteritis Nodosa.,"Polyarteritis nodosa (PAN) is a medium vessel vasculitis affecting systemic organs. Muscle involvement of PAN usually lacks elevation of creatinine kinase (CK). We herein report a case of PAN with rhabdomyolysis. A 71-year-old man was hospitalized because of muscle weakness of the lower limbs that persisted for 1 month. On a physical examination, rapidly progressive lower proximal muscle weakness and bilateral drop foot were observed. His blood test showed an elevation in the C-reactive protein (19.5 mg/dL) and CK (13,435 IU/L) levels and negativity for anti-neutrophilic cytoplasmic antibody. Computed tomographic angiography showed stenosis of the left renal artery. Electromyogram indicated mono-neuritis multiplex pattern, and enhanced magnetic resonance imaging demonstrated discretely granular hyperintensities on T2 and slow tau inversion recovery in his femoral muscles. A femoral muscle-biopsy specimen showed fibrinoid necrosis of medium-sized vessels and disruption of the elastic lamina of the vessel wall in fascia. Furthermore, muscle necrosis was localized depending on the arterial distribution, suggesting ischemic changes in the muscles. Given these findings, he was diagnosed with PAN with rhabdomyolysis and treated with methyl-prednisolone pulse therapy followed by oral prednisolone at 50 mg/day. He was additionally treated with monthly intravenous cyclophosphamide at 500 mg. Sustained remission has been obtained for two months since the treatment. Although rhabdomyolysis rarely manifests with PAN, it should be included in a differential diagnosis of febrile patients presenting with acute myalgia and weakness with CK elevation.","['muscle involvement', 'polyarteritis nodosa', 'rhabdomyolysis']","Internal medicine (Tokyo, Japan)",2017-10-13,"[{'lastname': 'Iida', 'firstname': 'Harunobu', 'initials': 'H', 'affiliation': 'Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.'}, {'lastname': 'Hanaoka', 'firstname': 'Hironari', 'initials': 'H', 'affiliation': 'Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.'}, {'lastname': 'Asari', 'firstname': 'Yusa', 'initials': 'Y', 'affiliation': 'Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.'}, {'lastname': 'Ishimori', 'firstname': 'Kana', 'initials': 'K', 'affiliation': 'Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.'}, {'lastname': 'Kiyokawa', 'firstname': 'Tomofumi', 'initials': 'T', 'affiliation': 'Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.'}, {'lastname': 'Takakuwa', 'firstname': 'Yukiko', 'initials': 'Y', 'affiliation': 'Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.'}, {'lastname': 'Yamasaki', 'firstname': 'Yoshioki', 'initials': 'Y', 'affiliation': 'Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.'}, {'lastname': 'Yamada', 'firstname': 'Hidehiro', 'initials': 'H', 'affiliation': 'Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.'}, {'lastname': 'Okazaki', 'firstname': 'Takahiro', 'initials': 'T', 'affiliation': 'Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.'}, {'lastname': 'Doi', 'firstname': 'Masatomo', 'initials': 'M', 'affiliation': 'Division of Pathology, St. Marianna University School of Medicine, Japan.'}, {'lastname': 'Ozaki', 'firstname': 'Shoichi', 'initials': 'S', 'affiliation': 'Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.'}]",,,,,10.2169/internalmedicine.8913-17,<Element 'PubmedArticle' at 0x7f05d9f63ae0>
146,28994117,Melatonin ameliorates Aβ,"The objective of this study was to evaluate whether melatonin could ameliorate cognitive function in Aβ
Series behaviour tests were performed to demonstrate the amelioration of cognitive function of the Alzheimer's disease (AD) mice induced by Aβ
Melatonin significantly ameliorated the cognitive function and mitochondrial damage in AD mice, reduced the expression levels of GSK-3β, caspase-3, Aβ
From the overall results, we concluded that melatonin alleviated the mitochondrial damage effectively and decreased the expressions of the p-tau and some key proteins of apoptosis, leading to the improvement of cognitive function of the mice induced by Aβ","[""Alzheimer's disease"", 'Aβ1-42', 'apoptosis', 'melatonin', 'mitochondrial damage']",The Journal of pharmacy and pharmacology,2017-10-11,"[{'lastname': 'Gong', 'firstname': 'Yu-Hang', 'initials': 'YH', 'affiliation': 'Department of Pharmacology, China Pharmaceutical University, Nanjing, China.'}, {'lastname': 'Hua', 'firstname': 'Nan', 'initials': 'N', 'affiliation': 'Department of Pharmacology, China Pharmaceutical University, Nanjing, China.'}, {'lastname': 'Zang', 'firstname': 'Xuan', 'initials': 'X', 'affiliation': 'Department of Pharmacology, China Pharmaceutical University, Nanjing, China.'}, {'lastname': 'Huang', 'firstname': 'Tao', 'initials': 'T', 'affiliation': 'Department of Pharmacology, China Pharmaceutical University, Nanjing, China.'}, {'lastname': 'He', 'firstname': 'Ling', 'initials': 'L', 'affiliation': 'Department of Pharmacology, China Pharmaceutical University, Nanjing, China.'}]",,"From the overall results, we concluded that melatonin alleviated the mitochondrial damage effectively and decreased the expressions of the p-tau and some key proteins of apoptosis, leading to the improvement of cognitive function of the mice induced by Aβ",,© 2017 Royal Pharmaceutical Society.,10.1111/jphp.12830,<Element 'PubmedArticle' at 0x7f05d9f764a0>
147,28988132,Ferulic acid attenuates diabetes-induced cognitive impairment in rats via regulation of PTP1B and insulin signaling pathway.,"Cognitive impairment has been recognized as a typical characteristic of neurodegenerative disease in diabetes mellitus (DM) and this cognitive dysfunction may be a risk factor for Alzheimer's disease (AD). Ferulic acid, a phenolic compound commonly found in a range of plants, has emerged various properties including anti-inflammatory and neuroprotective effects. In the present study, the protective activities and relevant mechanisms of ferulic acid were evaluated in diabetic rats with cognitive deficits, which were induced by a high-glucose-fat (HGF) diet and low dose of streptozotocin (STZ). It was observed that ferulic acid significantly increased body weight and decreased blood glucose levels. Meanwhile, ferulic acid could markedly ameliorate spatial memory of diabetic rats in Morris water maze (MWM) and decrease AD-like pathologic changes (Aβ deposition and Tau phosphorylation) in the hippocampus, which might be correlated with the inhibition of inflammatory cytokines release and reduction of protein tyrosine phosphatase 1B (PTP1B) expression. Moreover, the levels of brain insulin signal molecules p-IRS, p-Akt and p-GSK3β were also investigated. We found that ferulic acid administration restored the alterations in insulin signaling. In conclusion, ferulic acid exhibited beneficial effects on diabetes-induced cognition lesions, which was involved in the regulation of PTP1B and insulin signaling pathway. We suppose that PTP1B inhibition may represent a promising approach to correct abnormal signaling linked to diabetes-induced cognitive impairment.","['Cognitive dysfunction', 'Diabetes', 'Ferulic acid', 'Insulin signaling', 'PTP1B']",Physiology & behavior,2017-10-11,"[{'lastname': 'Wang', 'firstname': 'Hao', 'initials': 'H', 'affiliation': 'Department of Pharmacology of Chinese Materia Medica, China Pharmaceeutical University, 639, Longmian Road, Nanjing 211198, China.'}, {'lastname': 'Sun', 'firstname': 'Xiaoxu', 'initials': 'X', 'affiliation': 'Department of Pharmacology of Chinese Materia Medica, China Pharmaceeutical University, 639, Longmian Road, Nanjing 211198, China.'}, {'lastname': 'Zhang', 'firstname': 'Ning', 'initials': 'N', 'affiliation': 'Department of Pharmacology of Chinese Materia Medica, China Pharmaceeutical University, 639, Longmian Road, Nanjing 211198, China.'}, {'lastname': 'Ji', 'firstname': 'Zhouye', 'initials': 'Z', 'affiliation': 'Department of Pharmacology of Chinese Materia Medica, China Pharmaceeutical University, 639, Longmian Road, Nanjing 211198, China.'}, {'lastname': 'Ma', 'firstname': 'Zhanqiang', 'initials': 'Z', 'affiliation': 'Department of Pharmacology of Chinese Materia Medica, China Pharmaceeutical University, 639, Longmian Road, Nanjing 211198, China.'}, {'lastname': 'Fu', 'firstname': 'Qiang', 'initials': 'Q', 'affiliation': 'Department of Pharmacology of Chinese Materia Medica, China Pharmaceeutical University, 639, Longmian Road, Nanjing 211198, China.'}, {'lastname': 'Qu', 'firstname': 'Rong', 'initials': 'R', 'affiliation': 'Department of Pharmacology of Traditional Chinese Medical Formulae, Nanjing University of Traditional Chinese Medicine, 138, Xianlin Road, Nanjing 210029, China.'}, {'lastname': 'Ma', 'firstname': 'Shiping', 'initials': 'S', 'affiliation': 'Department of Pharmacology of Chinese Materia Medica, China Pharmaceeutical University, 639, Longmian Road, Nanjing 211198, China. Electronic address: spma@cpu.edu.cn.'}]",,,,Copyright © 2017. Published by Elsevier Inc.,10.1016/j.physbeh.2017.10.001,<Element 'PubmedArticle' at 0x7f05d9f83b80>
148,"28916533
23611343
11708987
27490513
26925510
15217349
22325331
22922503
27172148
22819134
12876142
20061630
23941283
26617288
19622511
8163988
9855500
11310619
14991811
21810890
7807156
11464847
18090417
21325651
21222600
26061376
17938369
23881933
24126629
19399866
21944778
24166615
23463871
26979938
22406228
21382304
19721334
17179653
16862116
21691802
17953663
15365985
18079297",Sex differences in the prevalence of genetic mutations in FTD and ALS: A meta-analysis.,"To conduct a meta-analysis that investigates sex differences in the prevalence of mutations in the 3 most common genes that cause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)-chromosome 9 open reading frame 72 (
MEDLINE, EMBASE, and PsycINFO databases were searched (inception to June 30, 2016). Studies of patients with FTD or ALS that reported the number of men and women with and without mutations of interest were selected. Female to male pooled risk ratios (RR) and 95% confidence intervals (CI) for each mutation were calculated using random-effects models.
Thirty-two articles reporting 12,784 patients with ALS (including 1,244 
Higher female prevalence of ",[],Neurology,2017-09-17,"[{'lastname': 'Curtis', 'firstname': 'Ashley F', 'initials': 'AF', 'affiliation': 'From the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute (A.F.C., M.M., K.Z., M.C.T.), Primary Care Research Unit (A.F.C., K.Z., B.A., G.M., M.C.T.), and Cognitive & Movement Disorders Clinic (M.M.), Sunnybrook Health Sciences Center, Toronto; Division of Neurology (G.-Y.R.H.) and Department of Pathology and Laboratory Medicine (I.M.), University of British Columbia, Vancouver; Departments of Family and Community Medicine (R.M., M.C.T.) and Medicine (E.R.) and Tanz Centre for Research in Neurodegenerative Diseases (E.R.), University of Toronto; and Department of Neuropathology (I.M.), Vancouver General Hospital, Canada.'}, {'lastname': 'Masellis', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'From the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute (A.F.C., M.M., K.Z., M.C.T.), Primary Care Research Unit (A.F.C., K.Z., B.A., G.M., M.C.T.), and Cognitive & Movement Disorders Clinic (M.M.), Sunnybrook Health Sciences Center, Toronto; Division of Neurology (G.-Y.R.H.) and Department of Pathology and Laboratory Medicine (I.M.), University of British Columbia, Vancouver; Departments of Family and Community Medicine (R.M., M.C.T.) and Medicine (E.R.) and Tanz Centre for Research in Neurodegenerative Diseases (E.R.), University of Toronto; and Department of Neuropathology (I.M.), Vancouver General Hospital, Canada.'}, {'lastname': 'Hsiung', 'firstname': 'Ging-Yuek Robin', 'initials': 'GR', 'affiliation': 'From the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute (A.F.C., M.M., K.Z., M.C.T.), Primary Care Research Unit (A.F.C., K.Z., B.A., G.M., M.C.T.), and Cognitive & Movement Disorders Clinic (M.M.), Sunnybrook Health Sciences Center, Toronto; Division of Neurology (G.-Y.R.H.) and Department of Pathology and Laboratory Medicine (I.M.), University of British Columbia, Vancouver; Departments of Family and Community Medicine (R.M., M.C.T.) and Medicine (E.R.) and Tanz Centre for Research in Neurodegenerative Diseases (E.R.), University of Toronto; and Department of Neuropathology (I.M.), Vancouver General Hospital, Canada.'}, {'lastname': 'Moineddin', 'firstname': 'Rahim', 'initials': 'R', 'affiliation': 'From the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute (A.F.C., M.M., K.Z., M.C.T.), Primary Care Research Unit (A.F.C., K.Z., B.A., G.M., M.C.T.), and Cognitive & Movement Disorders Clinic (M.M.), Sunnybrook Health Sciences Center, Toronto; Division of Neurology (G.-Y.R.H.) and Department of Pathology and Laboratory Medicine (I.M.), University of British Columbia, Vancouver; Departments of Family and Community Medicine (R.M., M.C.T.) and Medicine (E.R.) and Tanz Centre for Research in Neurodegenerative Diseases (E.R.), University of Toronto; and Department of Neuropathology (I.M.), Vancouver General Hospital, Canada.'}, {'lastname': 'Zhang', 'firstname': 'Kathy', 'initials': 'K', 'affiliation': 'From the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute (A.F.C., M.M., K.Z., M.C.T.), Primary Care Research Unit (A.F.C., K.Z., B.A., G.M., M.C.T.), and Cognitive & Movement Disorders Clinic (M.M.), Sunnybrook Health Sciences Center, Toronto; Division of Neurology (G.-Y.R.H.) and Department of Pathology and Laboratory Medicine (I.M.), University of British Columbia, Vancouver; Departments of Family and Community Medicine (R.M., M.C.T.) and Medicine (E.R.) and Tanz Centre for Research in Neurodegenerative Diseases (E.R.), University of Toronto; and Department of Neuropathology (I.M.), Vancouver General Hospital, Canada.'}, {'lastname': 'Au', 'firstname': 'Bonnie', 'initials': 'B', 'affiliation': 'From the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute (A.F.C., M.M., K.Z., M.C.T.), Primary Care Research Unit (A.F.C., K.Z., B.A., G.M., M.C.T.), and Cognitive & Movement Disorders Clinic (M.M.), Sunnybrook Health Sciences Center, Toronto; Division of Neurology (G.-Y.R.H.) and Department of Pathology and Laboratory Medicine (I.M.), University of British Columbia, Vancouver; Departments of Family and Community Medicine (R.M., M.C.T.) and Medicine (E.R.) and Tanz Centre for Research in Neurodegenerative Diseases (E.R.), University of Toronto; and Department of Neuropathology (I.M.), Vancouver General Hospital, Canada.'}, {'lastname': 'Millett', 'firstname': 'Geneva', 'initials': 'G', 'affiliation': 'From the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute (A.F.C., M.M., K.Z., M.C.T.), Primary Care Research Unit (A.F.C., K.Z., B.A., G.M., M.C.T.), and Cognitive & Movement Disorders Clinic (M.M.), Sunnybrook Health Sciences Center, Toronto; Division of Neurology (G.-Y.R.H.) and Department of Pathology and Laboratory Medicine (I.M.), University of British Columbia, Vancouver; Departments of Family and Community Medicine (R.M., M.C.T.) and Medicine (E.R.) and Tanz Centre for Research in Neurodegenerative Diseases (E.R.), University of Toronto; and Department of Neuropathology (I.M.), Vancouver General Hospital, Canada.'}, {'lastname': 'Mackenzie', 'firstname': 'Ian', 'initials': 'I', 'affiliation': 'From the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute (A.F.C., M.M., K.Z., M.C.T.), Primary Care Research Unit (A.F.C., K.Z., B.A., G.M., M.C.T.), and Cognitive & Movement Disorders Clinic (M.M.), Sunnybrook Health Sciences Center, Toronto; Division of Neurology (G.-Y.R.H.) and Department of Pathology and Laboratory Medicine (I.M.), University of British Columbia, Vancouver; Departments of Family and Community Medicine (R.M., M.C.T.) and Medicine (E.R.) and Tanz Centre for Research in Neurodegenerative Diseases (E.R.), University of Toronto; and Department of Neuropathology (I.M.), Vancouver General Hospital, Canada.'}, {'lastname': 'Rogaeva', 'firstname': 'Ekaterina', 'initials': 'E', 'affiliation': 'From the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute (A.F.C., M.M., K.Z., M.C.T.), Primary Care Research Unit (A.F.C., K.Z., B.A., G.M., M.C.T.), and Cognitive & Movement Disorders Clinic (M.M.), Sunnybrook Health Sciences Center, Toronto; Division of Neurology (G.-Y.R.H.) and Department of Pathology and Laboratory Medicine (I.M.), University of British Columbia, Vancouver; Departments of Family and Community Medicine (R.M., M.C.T.) and Medicine (E.R.) and Tanz Centre for Research in Neurodegenerative Diseases (E.R.), University of Toronto; and Department of Neuropathology (I.M.), Vancouver General Hospital, Canada.'}, {'lastname': 'Tierney', 'firstname': 'Mary C', 'initials': 'MC', 'affiliation': 'From the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute (A.F.C., M.M., K.Z., M.C.T.), Primary Care Research Unit (A.F.C., K.Z., B.A., G.M., M.C.T.), and Cognitive & Movement Disorders Clinic (M.M.), Sunnybrook Health Sciences Center, Toronto; Division of Neurology (G.-Y.R.H.) and Department of Pathology and Laboratory Medicine (I.M.), University of British Columbia, Vancouver; Departments of Family and Community Medicine (R.M., M.C.T.) and Medicine (E.R.) and Tanz Centre for Research in Neurodegenerative Diseases (E.R.), University of Toronto; and Department of Neuropathology (I.M.), Vancouver General Hospital, Canada. mary.tierney@sunnybrook.ca.'}]",,,"Thirty-two articles reporting 12,784 patients with ALS (including 1,244 ",© 2017 American Academy of Neurology.,10.1212/WNL.0000000000004494,<Element 'PubmedArticle' at 0x7f05d9f94f90>
149,28867578,Streptozotocin-induced hippocampal astrogliosis and insulin signaling malfunction as experimental scales for subclinical sporadic Alzheimer model.,"Insulin signaling malfunction has recently been suggested as a preliminary event involved in the etiology of Sporadic Alzheimer's disease (SAD). In order to develop insulin resistance-related SAD model, rats were treated with streptozotocin, intracerebroventricularly (icv-STZ). Nevertheless, given the lack of knowledge regarding sub-clinical stages of SAD, the current challenging issue is establishing a practical pre-clinical SAD model. Despite some proposed mechanisms, such as insulin malfunction, neuroinflammation, and gliosis, icv-STZ mechanism of action is not fully understood yet and Streptozotocin-induced rat model of Alzheimer has still major shortcomings.
Using three STZ doses (0.5, 1, and 3mg/kg) and three testing time (short-term, medium-term and long-term), we sought the best dose of STZ in order to mimic the characteristic feature of sAD in rats. So, we conducted a series of fifteen-week follow-up cognitive and non-cognitive studies. Besides, IR, tau and ChAT mRNA levels were measured, along with histological analysis of astrocyte, dark neuron numbers, and pyramidal layer thickness, in order to compare the effects of different doses of icv-STZ.
STZ 3mg/kg caused cognitive and insulin signaling disturbance from the very first testing-time. STZ1-injected animals, however, showed an augmented hippocampal astrocyte numbers in a short time; they, also, were diagnosed with disturbed insulin signaling in medium-term post icv-STZ-injection. Moreover, behavioral, molecular and histological impairments induced by 0.5mg/kg icv-STZ were slowly progressing in comparison to high doses of STZ.
STZ1 and 0.5mg/kg-treated animals are, respectively, suggested as a suitable experimental model of MCI, and sub-clinical stage.","[""Alzheimer's disease"", 'Insulin resistance', 'Non-transgenic sAD model', 'Pre-clinical stages', 'Rodent', 'Streptozotocin', 'Streptozotocin (PubChem CID: 29327)']",Life sciences,2017-09-05,"[{'lastname': 'Rostami', 'firstname': 'Farzaneh', 'initials': 'F', 'affiliation': 'Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.'}, {'lastname': 'Javan', 'firstname': 'Mohammad', 'initials': 'M', 'affiliation': 'Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.'}, {'lastname': 'Moghimi', 'firstname': 'Ali', 'initials': 'A', 'affiliation': 'Rayan Center for Neuroscience and Behavior, Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.'}, {'lastname': 'Haddad-Mashadrizeh', 'firstname': 'Aliakbar', 'initials': 'A', 'affiliation': 'Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran; Cell and Molecular Research group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.'}, {'lastname': 'Fereidoni', 'firstname': 'Masoud', 'initials': 'M', 'affiliation': 'Rayan Center for Neuroscience and Behavior, Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. Electronic address: fereidoni@um.ac.ir.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.lfs.2017.08.025,<Element 'PubmedArticle' at 0x7f05d9f35590>
150,28859337,Amygdala TDP-43 Pathology in Frontotemporal Lobar Degeneration and Motor Neuron Disease.,"TDP-43-positive inclusions are present in the amygdala in frontotemporal lobar degeneration (FTLD) and motor neuron disease (MND) including amyotrophic lateral sclerosis. Behavioral abnormalities, one of the chief symptoms of FTLD, could be, at least partly, related to amygdala pathology. We examined TDP-43 inclusions in the amygdala of patients with sporadic FTLD/MND (sFTLD/MND), FTLD/MND with mutation of the C9ORF72 (FTLD/MND-C9) and FTLD with mutation of the progranulin (FTLD-GRN). TDP-43 inclusions were common in each one of these subtypes, which can otherwise be distinguished on topographical and genetic grounds. Conventional and immunological stainings were performed and we quantified the numerical density of inclusions on a regional basis. TDP-43 inclusions in amygdala could be seen in 10 out of 26 sFTLD/MND cases, 5 out of 9 FTLD/MND-C9 cases, and all 4 FTLD-GRN cases. Their numerical density was lower in FTLD/MND-C9 than in sFTLD/MND and FTLD-GRN. TDP-43 inclusions were more numerous in the ventral region of the basolateral nucleus group in all subtypes. This contrast was apparent in sporadic and C9-mutated FTLD/MND, while it was less evident in FTLD-GRN. Such differences in subregional involvement of amygdala may be related to the region-specific neuronal connections that are differentially affected in FTLD/MND and FTLD-GRN.","['Amygdala', 'Amyotrophic lateral sclerosis', 'C9ORF72', 'Frontotemporal lobar degeneration', 'Motor neuron disease', 'Progranulin', 'TDP-43']",Journal of neuropathology and experimental neurology,2017-09-02,"[{'lastname': 'Takeda', 'firstname': 'Takahiro', 'initials': 'T', 'affiliation': ""Service de Neuropathologie, Laboratoire Raymond Escourolle, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Hôpital de la Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U1127, CNRS UMR 7225, Sorbonne Universités, Université Pierre et Marie Curie, Univ Paris 06, UPMC-P6 UMR S 1127, Hôpital de la Pitié-Salpêtrière, Paris, France; Département de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Centre de Référence des Démences Rares, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan; and Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.""}, {'lastname': 'Seilhean', 'firstname': 'Danielle', 'initials': 'D', 'affiliation': ""Service de Neuropathologie, Laboratoire Raymond Escourolle, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Hôpital de la Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U1127, CNRS UMR 7225, Sorbonne Universités, Université Pierre et Marie Curie, Univ Paris 06, UPMC-P6 UMR S 1127, Hôpital de la Pitié-Salpêtrière, Paris, France; Département de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Centre de Référence des Démences Rares, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan; and Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.""}, {'lastname': 'Le Ber', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': ""Service de Neuropathologie, Laboratoire Raymond Escourolle, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Hôpital de la Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U1127, CNRS UMR 7225, Sorbonne Universités, Université Pierre et Marie Curie, Univ Paris 06, UPMC-P6 UMR S 1127, Hôpital de la Pitié-Salpêtrière, Paris, France; Département de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Centre de Référence des Démences Rares, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan; and Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.""}, {'lastname': 'Millecamps', 'firstname': 'Stéphanie', 'initials': 'S', 'affiliation': ""Service de Neuropathologie, Laboratoire Raymond Escourolle, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Hôpital de la Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U1127, CNRS UMR 7225, Sorbonne Universités, Université Pierre et Marie Curie, Univ Paris 06, UPMC-P6 UMR S 1127, Hôpital de la Pitié-Salpêtrière, Paris, France; Département de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Centre de Référence des Démences Rares, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan; and Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.""}, {'lastname': 'Sazdovitch', 'firstname': 'Véronique', 'initials': 'V', 'affiliation': ""Service de Neuropathologie, Laboratoire Raymond Escourolle, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Hôpital de la Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U1127, CNRS UMR 7225, Sorbonne Universités, Université Pierre et Marie Curie, Univ Paris 06, UPMC-P6 UMR S 1127, Hôpital de la Pitié-Salpêtrière, Paris, France; Département de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Centre de Référence des Démences Rares, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan; and Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.""}, {'lastname': 'Kitagawa', 'firstname': 'Kazuo', 'initials': 'K', 'affiliation': ""Service de Neuropathologie, Laboratoire Raymond Escourolle, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Hôpital de la Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U1127, CNRS UMR 7225, Sorbonne Universités, Université Pierre et Marie Curie, Univ Paris 06, UPMC-P6 UMR S 1127, Hôpital de la Pitié-Salpêtrière, Paris, France; Département de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Centre de Référence des Démences Rares, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan; and Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.""}, {'lastname': 'Uchihara', 'firstname': 'Toshiki', 'initials': 'T', 'affiliation': ""Service de Neuropathologie, Laboratoire Raymond Escourolle, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Hôpital de la Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U1127, CNRS UMR 7225, Sorbonne Universités, Université Pierre et Marie Curie, Univ Paris 06, UPMC-P6 UMR S 1127, Hôpital de la Pitié-Salpêtrière, Paris, France; Département de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Centre de Référence des Démences Rares, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan; and Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.""}, {'lastname': 'Duyckaerts', 'firstname': 'Charles', 'initials': 'C', 'affiliation': ""Service de Neuropathologie, Laboratoire Raymond Escourolle, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Hôpital de la Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U1127, CNRS UMR 7225, Sorbonne Universités, Université Pierre et Marie Curie, Univ Paris 06, UPMC-P6 UMR S 1127, Hôpital de la Pitié-Salpêtrière, Paris, France; Département de Neurologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Centre de Référence des Démences Rares, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France; Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan; and Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.""}]",,,,"© 2017 American Association of Neuropathologists, Inc. All rights reserved.",10.1093/jnen/nlx063,<Element 'PubmedArticle' at 0x7f05d9f42d60>
151,"28832656
26994258
26999245
20420489
26890783
20837822
16340083
22425595
26629991
26211973
23603201
26967226
24669284
21262264
23603201
21497160
21808223
6345750
36810
13967893
14761864
2054253
11282018
2573290
7916070
9127971
12931206
23546742
24552807
25744568
26888066
26721223
26738855
27316747
26796432
26931809
27366660
26455387
27179961
26831258
21907815
25586103
18448809
27123241
20966918
16631207
26268336
26119401
21568789
15189333
15195085
10378882",Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.,"Age-related dementia is one of the most devastating disorders affecting the elderly. Recently, emerging data suggest that impaired insulin signaling is the major contributor in the development of Alzheimer's dementia (AD), which is the most common type of senile dementia. In the present study, we investigated the potential therapeutic effects of metformin (Met) and saxagliptin (Saxa), as insulin sensitizing agents, in a rat model of brain aging and AD using D-galactose (D-gal, 150 mg/kg/day, s.c. for 90 successive days). Six groups of adult male Wistar rats were used: normal, D-gal, Met (500 mg/kg/day, p.o), and Saxa (1 mg/kg/day, p.o) control groups, as well as D-gal/Met and D-gal/Sax treated groups. Impaired learning and memory function was observed in rats treated with D-gal using Morris water maze test. Biochemical and histopathological findings also revealed some characteristic changes of AD in the brain that include the increased content of acetylcholine, glutamate, and phosphorelated tau, as well as deposition of amyloid plaques and neurofibrillary tangles. Induction of insulin resistance in experimentally aged rats was evidenced by increased blood glycated hemoglobin, brain contents of insulin and receptors for advanced glycated end-products, as well as decreased brain insulin receptor level. Elevation of oxidative stress markers and TNF-α brain content was also demonstrated. Met and Saxa, with a preference to Met, restored the normal memory and learning functions in rats, improved D-gal-induced state of insulin resistance, oxidative stress and inflammation, and ameliorated the AD biochemical and histopathological alterations in brain tissues. Our findings suggest that D-gal model of aging results in a diminishing of learning and memory function by producing a state of impaired insulin signaling that causes a cascade of deleterious events like oxidative stress, inflammation, and tau hyper-phosphorylation. Reversing of these harmful effects by the use of insulin-sensitizing drugs like Met and Saxa suggests their involvement in alleviation insulin resistance as the underlying pathology of AD and hence their potential use as anti-dementia drugs.",[],PloS one,2017-08-24,"[{'lastname': 'Kenawy', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Pharmacology Department, Medical division, National Research Centre, Giza, Egypt.'}, {'lastname': 'Hegazy', 'firstname': 'Rehab', 'initials': 'R', 'affiliation': 'Pharmacology Department, Medical division, National Research Centre, Giza, Egypt.'}, {'lastname': 'Hassan', 'firstname': 'Azza', 'initials': 'A', 'affiliation': 'Pathology Department, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.'}, {'lastname': 'El-Shenawy', 'firstname': 'Siham', 'initials': 'S', 'affiliation': 'Pharmacology Department, Medical division, National Research Centre, Giza, Egypt.'}, {'lastname': 'Gomaa', 'firstname': 'Nawal', 'initials': 'N', 'affiliation': 'Pharmacology Department, Medical division, National Research Centre, Giza, Egypt.'}, {'lastname': 'Zaki', 'firstname': 'Hala', 'initials': 'H', 'affiliation': 'Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}, {'lastname': 'Attia', 'firstname': 'Amina', 'initials': 'A', 'affiliation': 'Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}]",,,,,"10.1371/journal.pone.0183565
10.1093/geront/gnw035
10.1007/s12603-015-0585-x
10.1586/ern.10.27
10.3233/JAD-151089
10.1001/archneurol.2010.225
10.1016/j.pbb.2012.03.002
10.1371/journal.pone.0143814
10.1016/j.neuropharm.2015.07.023
10.1016/j.neuropharm.2013.04.008
10.3233/JAD-151200
10.1155/2014/320513
10.1016/j.ejphar.2011.03.052
10.3791/2920
10.1152/ajpregu.00361.2003
10.1038/sj.mp.4001379
10.1007/s12035-013-8445-3
10.4161/cc.28255
10.1007/s12035-015-9132-3
10.1007/s11883-016-0568-3
10.1016/j.jep.2015.12.020
10.1007/s12035-015-9604-510.1007
10.1016/j.brainresbull.2016.06.005
10.1016/j.jdiacomp.2015.12.017
10.1101/cshperspect.a025932
10.1016/j.krcp.2016.02.004
10.1016/j.vph.2015.10.002
10.1016/j.jalz.2016.02.010
10.1016/j.nlm.2011.08.005
10.1517/13543784.2015.1001490
10.1196/annals.1433.026
10.3892/br.2016.630
10.1038/mp.2010.17
10.1016/j.jns.2005.08.017
10.3109/01677063.2015.1067203
10.1515/RNS.2011.029
10.1111/j.1471-4159.2004.02422.x
10.1038/nm1058",<Element 'PubmedArticle' at 0x7f05d9f564f0>
152,28808140,Amyloid-β and islet amyloid pathologies link Alzheimer's disease and type 2 diabetes in a transgenic model.,"Alzheimer's disease (AD) and type 2 diabetes (T2D) present a significant risk to each other. AD and T2D are characterized by deposition of cerebral amyloid-β (Aβ) and pancreatic human islet amyloid polypeptide (hIAPP), respectively. We investigated the role of amyloidogenic proteins in the interplay between these diseases. A novel double transgenic mouse model combining T2D and AD was generated and characterized. AD-related amyloid transgenic mice coexpressing hIAPP displayed peripheral insulin resistance, hyperglycemia, and glucose intolerance. Aβ and IAPP amyloid co-deposition increased tau phosphorylation, and a reduction in pancreatic β-cell mass was detected in islets. Increased brain Aβ deposition and tau phosphorylation and reduced insulin levels and signaling were accompanied by extensive synaptic loss and decreased neuronal counts. Aβ immunization rescued the peripheral insulin resistance and hyperglycemia, suggesting a role for Aβ in T2D pathogenesis for individuals predisposed to AD. These findings demonstrate that Aβ and IAPP are key factors in the overlapping pathologies of AD and T2D.-Wijesekara, N., Ahrens, R., Sabale, M., Wu, L., Ha, K., Verdile, G., Fraser, P. E. Amyloid-β and islet amyloid pathologies link Alzheimer's disease and type 2 diabetes in a transgenic model.","['hyperglycemia', 'insulin resistance', 'neurodegeneration', 'tau', 'β cells']",FASEB journal : official publication of the Federation of American Societies for Experimental Biology,2017-08-16,"[{'lastname': 'Wijesekara', 'firstname': 'Nadeeja', 'initials': 'N', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada; nadeeja.wijesekara@utoronto.ca.'}, {'lastname': 'Ahrens', 'firstname': 'Rosemary', 'initials': 'R', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Sabale', 'firstname': 'Miheer', 'initials': 'M', 'affiliation': 'School of Biomedical Sciences, Curtin Health and Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.'}, {'lastname': 'Wu', 'firstname': 'Ling', 'initials': 'L', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Ha', 'firstname': 'Kathy', 'initials': 'K', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Verdile', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': 'School of Biomedical Sciences, Curtin Health and Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.'}, {'lastname': 'Fraser', 'firstname': 'Paul E', 'initials': 'PE', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.\nDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.'}]",,,,© FASEB.,10.1096/fj.201700431R,<Element 'PubmedArticle' at 0x7f05d9e7e9f0>
153,"28768549
18809630
18463375
26004196
8585997
24398403
21862611
19519395
26842601
25265045
27244820
25187090
12937785
21123564
23146033
19458242
22414803
23790682
24586614
26156287
26708068
27177549
17472706
26254770
24664798
26566144
26479041
28462474
21257329
25028522
21883804
26151680
24529523
24101698
19015157
22241286
15140924
26794272
24462248
25200291
22410672
28259806
19819959
24918775
23085934
25403388
14982935
22457786
20176722
24765237",Intranasal insulin reverts central pathology and cognitive impairment in diabetic mother offspring.,"Adverse effects in diabetic mothers offspring (DMO) are a major concern of increasing incidence. Among these, chronic central complications in DMO remain poorly understood, and in extreme cases, diabetes can essentially function as a gestational brain insult. Nevertheless, therapeutic alternatives for DMO are limited.
Therefore, we have analyzed the central long-term complications in the offspring from CD1 diabetic mothers treated with streptozotozin, as well as the possible reversion of these alterations by insulin administration to neonates. Brain atrophy, neuronal morphology, tau phosphorylation, proliferation and neurogenesis were assessed in the short term (P7) and in the early adulthood (10 weeks) and cognitive function was also analyzed in the long-term.
Central complications in DMO were still detected in the adulthood, including cortical and hippocampal thinning due to synaptic loss and neuronal simplification, increased tau hyperphosphorylation, and diminished cell proliferation and neurogenesis. Additionally, maternal diabetes increased the long-term susceptibility to spontaneous central bleeding, inflammation and cognition impairment in the offspring. On the other hand, intracerebroventricular insulin administration to neonates significantly reduced observed alterations. Moreover, non-invasive intranasal insulin reversed central atrophy and tau hyperphosphorylation, and rescued central proliferation and neurogenesis. Vascular damage, inflammation and cognitive alterations were also comparable to their counterparts born to nondiabetic mice, supporting the utility of this pathway to access the central nervous system.
Our data underlie the long-term effects of central complications in DMO. Moreover, observed improvement after insulin treatment opens the door to therapeutic alternatives for children who are exposed to poorly controlled gestational diabetes, and who may benefit from more individualized treatments.","['Diabetes', 'Haemorrhage', 'Inflammation', 'Insulin', 'Offspring', 'Tau']",Molecular neurodegeneration,2017-08-05,"[{'lastname': 'Ramos-Rodriguez', 'firstname': 'Juan Jose', 'initials': 'JJ', 'affiliation': 'Division of Physiology, School of Medicine Universidad de Cadiz, Plaza Fragela sn, 4 piso 410, Cadiz, Spain.\nInstituto de Investigación Biomédica e Innovación en Ciencias Biomédicas de la Provincia de Cádiz (INiBICA), Cadiz, Spain.'}, {'lastname': 'Sanchez-Sotano', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Division of Physiology, School of Medicine Universidad de Cadiz, Plaza Fragela sn, 4 piso 410, Cadiz, Spain.\nInstituto de Investigación Biomédica e Innovación en Ciencias Biomédicas de la Provincia de Cádiz (INiBICA), Cadiz, Spain.\nDivision of Neonatology, Hospital Universitario Puerta del Mar, Cadiz, Spain.'}, {'lastname': 'Doblas-Marquez', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': 'Division of Physiology, School of Medicine Universidad de Cadiz, Plaza Fragela sn, 4 piso 410, Cadiz, Spain.\nInstituto de Investigación Biomédica e Innovación en Ciencias Biomédicas de la Provincia de Cádiz (INiBICA), Cadiz, Spain.'}, {'lastname': 'Infante-Garcia', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Division of Physiology, School of Medicine Universidad de Cadiz, Plaza Fragela sn, 4 piso 410, Cadiz, Spain.\nInstituto de Investigación Biomédica e Innovación en Ciencias Biomédicas de la Provincia de Cádiz (INiBICA), Cadiz, Spain.'}, {'lastname': 'Lubian-Lopez', 'firstname': 'Simon', 'initials': 'S', 'affiliation': 'Division of Pediatrics, Hospital Universitario Puerta del Mar, Cadiz, Spain.'}, {'lastname': 'Garcia-Alloza', 'firstname': 'Monica', 'initials': 'M', 'affiliation': 'Division of Physiology, School of Medicine Universidad de Cadiz, Plaza Fragela sn, 4 piso 410, Cadiz, Spain. monica.garcia@uca.es.\nInstituto de Investigación Biomédica e Innovación en Ciencias Biomédicas de la Provincia de Cádiz (INiBICA), Cadiz, Spain. monica.garcia@uca.es.'}]",,,"Central complications in DMO were still detected in the adulthood, including cortical and hippocampal thinning due to synaptic loss and neuronal simplification, increased tau hyperphosphorylation, and diminished cell proliferation and neurogenesis. Additionally, maternal diabetes increased the long-term susceptibility to spontaneous central bleeding, inflammation and cognition impairment in the offspring. On the other hand, intracerebroventricular insulin administration to neonates significantly reduced observed alterations. Moreover, non-invasive intranasal insulin reversed central atrophy and tau hyperphosphorylation, and rescued central proliferation and neurogenesis. Vascular damage, inflammation and cognitive alterations were also comparable to their counterparts born to nondiabetic mice, supporting the utility of this pathway to access the central nervous system.",,"10.1186/s13024-017-0198-4
10.2337/dc08-1038
10.1056/NEJMoa0707943
10.1016/j.bpobgyn.2015.04.009
10.2337/diacare.18.5.611
10.1152/ajpendo.00308.2013
10.1210/en.2011-1279
10.2174/092986709788453069
10.1007/s11011-016-9802-5
10.1080/21622965.2013.874951
10.1111/jnc.12939
10.1590/S0100-879X2003000900008
10.1523/JNEUROSCI.3202-10.2010
10.1111/j.2042-7158.2012.01555.x
10.1523/JNEUROSCI.1350-09.2009
10.1152/ajpendo.00500.2011
10.1016/j.psyneuen.2013.05.010
10.1371/journal.pone.0089229
10.1007/s12035-015-9311-2
10.1016/j.psyneuen.2015.12.001
10.1111/j.1471-4159.2007.04613.x
10.1016/j.psyneuen.2015.07.606
10.1007/s11892-014-0489-x
10.1371/journal.pone.0142583
10.3109/10799893.2015.1086884
10.1016/j.diabet.2010.10.008
10.2337/db14-0477
10.1111/j.1463-1326.2011.01490.x
10.1016/j.neuroscience.2015.06.063
10.1016/j.jalz.2013.12.006
10.2337/dc13-1672
10.1093/brain/awn288
10.1007/s00429-011-0377-y
10.1016/j.neuroscience.2016.01.025
10.1016/j.cell.2014.01.008
10.1111/dom.12337
10.1007/s10571-012-9820-8
10.1016/j.physbeh.2017.02.044
10.1210/en.2009-0695
10.1371/journal.pone.0099226
10.1136/jnnp-2012-303365
10.1007/s10517-014-2681-z
10.1074/jbc.M311768200
10.1371/journal.pone.0033722
10.1210/en.2009-1019
10.4239/wjd.v5.i6.739",<Element 'PubmedArticle' at 0x7f05d9e8e040>
154,"28768311
26374296
28512159
25552356
10948081
26908404
1850668
27081022
25637629
10993857
12034658
1828192
23130141
23130126
24657693
26683218
23756336
22851543
25411195
16275882
27150688
27482002
25104786
20427700
23324403
23599309
26362631
21375743
24124732
19043405
27974408",Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome.,"Among myriad changes occurring during the evolution of heart failure with preserved ejection fraction (HFpEF), cardiomyocyte-extracellular matrix interactions from excess collagen may affect microvascular, mechanical, and electrical function.
To investigate whether myocardial fibrosis (MF) is similarly prevalent both in those with HFpEF and those at risk for HFpEF, similarly associating with disease severity and outcomes.
Observational cohort study from June 1, 2010, to September 17, 2015, with follow-up until December 14, 2015, at a cardiovascular magnetic resonance (CMR) center serving an integrated health system. Consecutive patients with preserved systolic function referred for CMR were eligible. Cardiovascular magnetic resonance was used to exclude patients with cardiac amyloidosis (n = 19).
Myocardial fibrosis quantified by extracellular volume (ECV) CMR measures.
Baseline BNP; subsequent hospitalization for heart failure or death.
Of 1174 patients identified (537 [46%] female; median [interquartile range {IQR}] age, 56 [44-66] years), 250 were ""at risk"" for HFpEF given elevated brain-type natriuretic peptide (BNP) level; 160 had HFpEF by documented clinical diagnosis, and 745 did not have HFpEF. Patients either at risk for HFpEF or with HFpEF demonstrated similarly higher prevalence/extent of MF and worse prognosis compared with patients with no HFpEF. Among those at risk for HFpEF or with HFpEF, the actual diagnosis of HFpEF was not associated with significant differences in MF (median ECV, 28.2%; IQR, 26.2%-30.7% vs 28.3%; IQR, 25.5%-31.4%; P = .60) or prognosis (log-rank 0.8; P = .38). Over a median of 1.9 years, 61 patients at risk for HFpEF or with HFpEF experienced adverse events (19 hospitalization for heart failure, 48 deaths, 6 with both). In those with HFpEF, ECV was associated with baseline log BNP (disease severity surrogate) in multivariable linear regression models, and was associated with outcomes in multivariable Cox regression models (eg, hazard ratio 1.75 per 5% increase in ECV, 95% CI, 1.25-2.45; P = .001 in stepwise model) whether grouped with patients at risk for HFpEF or not.
Among myriad changes occurring during the apparent evolution of HFpEF where elevated BNP is prevalent, MF was similarly prevalent in those with or at risk for HFpEF. Conceivably, MF might precede clinical HFpEF diagnosis. Regardless, MF was associated with disease severity (ie, BNP) and outcomes. Whether cells and secretomes mediating MF represent therapeutic targets in HFpEF warrants further evaluation.",[],JAMA cardiology,2017-08-03,"[{'lastname': 'Schelbert', 'firstname': 'Erik B', 'initials': 'EB', 'affiliation': 'Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.\nUPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, Pittsburgh, Pennsylvania.\nClinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Fridman', 'firstname': 'Yaron', 'initials': 'Y', 'affiliation': 'Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.\nUPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, Pittsburgh, Pennsylvania.'}, {'lastname': 'Wong', 'firstname': 'Timothy C', 'initials': 'TC', 'affiliation': 'Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.\nUPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, Pittsburgh, Pennsylvania.\nClinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Abu Daya', 'firstname': 'Hussein', 'initials': 'H', 'affiliation': 'Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.\nUPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, Pittsburgh, Pennsylvania.'}, {'lastname': 'Piehler', 'firstname': 'Kayla M', 'initials': 'KM', 'affiliation': 'Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.\nUPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, Pittsburgh, Pennsylvania.\nClinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Kadakkal', 'firstname': 'Ajay', 'initials': 'A', 'affiliation': 'Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.\nUPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, Pittsburgh, Pennsylvania.'}, {'lastname': 'Miller', 'firstname': 'Christopher A', 'initials': 'CA', 'affiliation': 'Centre for Imaging Sciences and Biomedical Imaging Institute, University of Manchester, Manchester, England.'}, {'lastname': 'Ugander', 'firstname': 'Martin', 'initials': 'M', 'affiliation': 'Department of Clinical Physiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.'}, {'lastname': 'Maanja', 'firstname': 'Maren', 'initials': 'M', 'affiliation': 'Department of Clinical Physiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.'}, {'lastname': 'Kellman', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'National Heart, Lung, and Blood Institute, Bethesda, Maryland.'}, {'lastname': 'Shah', 'firstname': 'Dipan J', 'initials': 'DJ', 'affiliation': 'Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas.'}, {'lastname': 'Abebe', 'firstname': 'Kaleab Z', 'initials': 'KZ', 'affiliation': 'Center for Clinical Trials and Data Coordination, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.'}, {'lastname': 'Simon', 'firstname': 'Marc A', 'initials': 'MA', 'affiliation': 'Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.\nClinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'lastname': 'Quarta', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'Department of Cardiology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.'}, {'lastname': 'Senni', 'firstname': 'Michele', 'initials': 'M', 'affiliation': 'Department of Cardiology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.'}, {'lastname': 'Butler', 'firstname': 'Javed', 'initials': 'J', 'affiliation': 'Cardiology Division, Stony Brook University, Stony Brook, New York.'}, {'lastname': 'Diez', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Program of Cardiovascular Diseases, Center for Applied Medical Research, Department of Cardiology and Cardiac Surgery, University Clinic, University of Navarra, Pamplona, Spain.\nCIBERCV, Carlos III Institute of Health, Madrid, Spain.'}, {'lastname': 'Redfield', 'firstname': 'Margaret M', 'initials': 'MM', 'affiliation': 'Department of Medicine, Mayo Clinic, Rochester, Minnesota.'}, {'lastname': 'Gheorghiade', 'firstname': 'Mihai', 'initials': 'M', 'affiliation': 'Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois.'}]",,,"Of 1174 patients identified (537 [46%] female; median [interquartile range {IQR}] age, 56 [44-66] years), 250 were ""at risk"" for HFpEF given elevated brain-type natriuretic peptide (BNP) level; 160 had HFpEF by documented clinical diagnosis, and 745 did not have HFpEF. Patients either at risk for HFpEF or with HFpEF demonstrated similarly higher prevalence/extent of MF and worse prognosis compared with patients with no HFpEF. Among those at risk for HFpEF or with HFpEF, the actual diagnosis of HFpEF was not associated with significant differences in MF (median ECV, 28.2%; IQR, 26.2%-30.7% vs 28.3%; IQR, 25.5%-31.4%; P = .60) or prognosis (log-rank 0.8; P = .38). Over a median of 1.9 years, 61 patients at risk for HFpEF or with HFpEF experienced adverse events (19 hospitalization for heart failure, 48 deaths, 6 with both). In those with HFpEF, ECV was associated with baseline log BNP (disease severity surrogate) in multivariable linear regression models, and was associated with outcomes in multivariable Cox regression models (eg, hazard ratio 1.75 per 5% increase in ECV, 95% CI, 1.25-2.45; P = .001 in stepwise model) whether grouped with patients at risk for HFpEF or not.",,10.1001/jamacardio.2017.2511,<Element 'PubmedArticle' at 0x7f05d9e32040>
155,"28740088
12438432
11072264
16103997
9786247
17210801
1438654
19415145
26519440
26329688
17043339
25029415
3937167
3136487
3118642
3651705
11115806
11155096
16869339
15184598
24101811
11079505
24819789
22173840
19550060
10071097
15351384
24388825
23505435
1202204
16987634
17406322
15178173
22605785
25646706
24952892
20042432
10458940
20408222
12880848
12414259
25610765
6501442
18491089
8894063
15622018
20975518
25453043
15073255
20451872
23360840
20021390
7361631
25380804
10452218
2544414
19942154
25792098
23134495
27631200","Functional correlates of TSH, fT3 and fT4 in Alzheimer disease: a F-18 FDG PET/CT study.","The present study was aimed to investigate the relationships between thyroid stimulating hormone (TSH), freeT3 (fT3) and freeT4 (fT4) and brain glucose consumption as detectable by means of 2-deoxy-2-(F-18) fluoro-D-glucose (F-18 FDG) Positron Emission Tomography/Computed Tomography (PET/CT) in a selected population with Alzheimer disease (AD). We evaluated 87 subjects (37 males and 50 females, mean age 70 (±6) years old) with AD. All of them were subjected to TSH, fT3 and fT4 assay and to cerebrospinal fluid amyloid (Aβ1-42) and tau [phosphorylated-tau (p-tau) and total-tau (t-tau)] assay prior PET/CT examination. Values for TSH, fT3 and fT4 were in the normal range. The relationships were evaluated by means of statistical parametric mapping (SPM8) using age, sex, MMSE, scholarship and CSF values of amyloid and tau as covariates. We found a significant positive correlation between TSH values and cortical glucose consumption in a wide portion of the anterior cingulate cortex bilaterally (BA32) and left frontal lobe (BA25) (p FWE-corr <0.001; p FDRcorr <0.000; cluster extent 66950). No significant relationships were found between cortical F-18 FDG uptake and T3 and T4 serum levels. The results of our study suggest that a cortical dysfunction in anterior cingulate and frontal lobes may affect serum values of TSH in AD patients.",[],Scientific reports,2017-07-26,"[{'lastname': 'Chiaravalloti', 'firstname': 'Agostino', 'initials': 'A', 'affiliation': 'Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy. agostino.chiaravalloti@uniroma2.it.\nIRCCS Neuromed, Pozzilli (IS), Italy. agostino.chiaravalloti@uniroma2.it.'}, {'lastname': 'Ursini', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': 'Department of Health Sciences, University Magna Graecia, Catanzaro, Italy.'}, {'lastname': 'Fiorentini', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.'}, {'lastname': 'Barbagallo', 'firstname': 'Gaetano', 'initials': 'G', 'affiliation': 'Institute of Neurology, University Magna Graecia, Catanzaro, Italy.'}, {'lastname': 'Martorana', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Department of Neurosciences, University Tor Vergata, Rome, Italy.\nIRCCS Santa Lucia, Rome, Italy.'}, {'lastname': 'Koch', 'firstname': 'Giacomo', 'initials': 'G', 'affiliation': 'Department of Neurosciences, University Tor Vergata, Rome, Italy.\nIRCCS Santa Lucia, Rome, Italy.'}, {'lastname': 'Tavolozza', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.'}, {'lastname': 'Schillaci', 'firstname': 'Orazio', 'initials': 'O', 'affiliation': 'Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.\nIRCCS Neuromed, Pozzilli (IS), Italy.'}]",,,,,"10.1038/s41598-017-06138-7
10.1172/JCI0216783
10.1016/S0733-8619(05)70229-2
10.1002/jemt.20190
10.1097/00005072-199810000-00009
10.1001/archneur.64.3.noc60123
10.1016/0306-4530(92)90041-5
10.3233/JAD-150561
10.1016/j.neurobiolaging.2015.08.002
10.7326/0003-4819-145-8-200610170-00006
10.1210/jc.2013-4454
10.1016/0165-1781(85)90118-0
10.1016/0306-4530(88)90022-4
10.1111/j.1600-0447.1987.tb02879.x
10.1192/bjp.150.5.674
10.1046/j.1365-2265.2000.01146.x
10.1177/1533317506289282
10.1212/01.WNL.0000128134.84230.9F
10.4103/0972-2327.116916
10.1148/rg.343135065
10.2967/jnumed.111.096578
10.4103/0022-3859.52846
10.1136/jnnp.66.2.184
10.1016/j.clinph.2004.04.022
10.1371/journal.pone.0057596
10.1016/0022-3956(75)90026-6
10.1016/j.acn.2006.06.010
10.1038/nprot.2006.115
10.1016/j.neuropsychologia.2004.02.001
10.1177/1073191112446655
10.1097/MNM.0000000000000314
10.1007/s12021-014-9235-4
10.1093/scan/nsp053
10.1006/nimg.1999.0459
10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4
10.1016/S1053-8119(03)00169-1
10.1006/nimg.2002.1259
10.1016/j.nicl.2014.11.007
10.1038/jcbfm.1984.73
10.1007/s00259-008-0808-z
10.1016/0006-3223(95)00489-0
10.1097/WAD.0b013e3181f9aff2
10.2967/jnumed.114.143347
10.1016/j.jalz.2010.03.006
10.2310/JIM.0b013e318280aafb
10.2174/1874609810801030175
10.1093/ageing/9.1.1
10.1177/1533317514556876
10.1210/endo-125-1-575
10.1016/j.beem.2009.08.003
10.1016/S1474-4422(15)70016-5
10.1111/j.1528-1167.2012.03702.x",<Element 'PubmedArticle' at 0x7f05d9e4c6d0>
156,"28733814
15681797
21111714
23673233
17105433
18234183
22563252
9482271
20871769
18086530
25505579
24736197
18667359
24938777
23241453
24084576
24505383
18042001
26171115
6066618
18189165
22107832
11309494
25471398
22191013
24819880
23348042
18393806
26349970
22152059
26939918
4436300
22200590
17035515
24466326
20392807
25974329
19877497
21901320
24389340
22002808
19890493
974099
20530246
17433250
24669288
21722314
24646911
18311520
13650640
28164770
27547756
23721591
23080310
26132096
25946560
14643852
20079433
22096544
18255190
9826439
8525173
15837579
11967539
20487207
16511588
17149751
22050745
27023569
14907713
27773727
25189792
28084618
24398425
26649298
27814578
23112420
19159013
27870425
1491124
22189166
26317805
25231482
11296263
14715130
19427328
13726518
20452460
15757637",Neuroprotective effect of ipriflavone against scopolamine-induced memory impairment in rats.,"Alzheimer's disease is an age-related neurodegenerative disorder characterized clinically by a progressive loss of memory and cognitive functions resulting in severe dementia. Ipriflavone (IPRI) is a non-hormonal, semi-synthetic isoflavone, clinically used in some countries for the treatment and prevention of postmenopausal osteoporosis. Moreover, ipriflavone is a non-peptidomimetic small molecule AChE inhibitor with an improved bioavailability after systemic administration, due to its efficient blood-brain barrier permeability in comparison with peptidomimetic inhibitors.
The present study aimed to evaluate the possible enhancing effects of IPRI on memory impairments caused by scopolamine administration.
Male rats were administered IPRI (50 mg/kg, oral) 2 h before scopolamine injection (2 mg/kg, intraperitoneally injected) daily for 4 weeks. Effects of IPRI on acetylcholinesterase activity, amyloid-β precursor processing, and neuroplasticity in the rats' hippocampus were investigated.
Daily administration of IPRI reverted memory impairment caused by scopolamine as measured by the reduction of the escape latency. IPRI significantly alleviated the oxidative stress and restored the mRNA expression of both cAMP-response element-binding protein and brain-derived neurotrophic factor in the hippocampus. Furthermore, it significantly increased the expression of ADAM10 and ADAM17 (two putative α-secretase enzymes) and phosphorylated extracellular signal-regulated kinase 1/2 (pERK1/2) that associated with decreased expression of β-secretase (BACE) in the hippocampus. Finally, both the amyloid-β (Aβ) and Tau pathologies were reduced.
IPRI showed promising neuroprotective effects against scopolamine-induced memory dysfunction in rats. These findings contributed to the stimulation of α-secretase enzymes, the activation of MAPK/ERK1/2, and the alleviation of oxidative stress.","['Acetylcholinesterase', 'Alzheimer’s disease', 'Amyloid-β', 'MAPK/ERK1/2 pathway', 'Neuroprotection']",Psychopharmacology,2017-07-25,"[{'lastname': 'Hafez', 'firstname': 'Hani S', 'initials': 'HS', 'affiliation': 'Zoology Department, Faculty of Science, Suez University, Suez, Egypt.'}, {'lastname': 'Ghareeb', 'firstname': 'Doaa A', 'initials': 'DA', 'affiliation': 'Biochemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt.\nMedical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute, City for Scientific Research and Technology Applications, Alexandria, Egypt.'}, {'lastname': 'Saleh', 'firstname': 'Samar R', 'initials': 'SR', 'affiliation': 'Biochemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt. ssaleh84@yahoo.com.'}, {'lastname': 'Abady', 'firstname': 'Mariam M', 'initials': 'MM', 'affiliation': 'Department of Nutrition and Food Science, National Research Center, Dokki, Cairo, 12622, Egypt.'}, {'lastname': 'El Demellawy', 'firstname': 'Maha A', 'initials': 'MA', 'affiliation': 'Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute, City for Scientific Research and Technology Applications, Alexandria, Egypt.'}, {'lastname': 'Hussien', 'firstname': 'Hend', 'initials': 'H', 'affiliation': 'Pharmacology and Toxicology Department, Faculty of Pharmacy and Drug Manufacturing, Pharos University, Alexandria, Egypt.'}, {'lastname': 'Abdel-Monem', 'firstname': 'Nihad', 'initials': 'N', 'affiliation': 'Biochemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt.'}]",,,"Daily administration of IPRI reverted memory impairment caused by scopolamine as measured by the reduction of the escape latency. IPRI significantly alleviated the oxidative stress and restored the mRNA expression of both cAMP-response element-binding protein and brain-derived neurotrophic factor in the hippocampus. Furthermore, it significantly increased the expression of ADAM10 and ADAM17 (two putative α-secretase enzymes) and phosphorylated extracellular signal-regulated kinase 1/2 (pERK1/2) that associated with decreased expression of β-secretase (BACE) in the hippocampus. Finally, both the amyloid-β (Aβ) and Tau pathologies were reduced.",,10.1007/s00213-017-4690-x,<Element 'PubmedArticle' at 0x7f05d9df9900>
157,"28666471
18291657
17084815
26869068
15094196
20584894
19765185
17219193
24950788
28431575
22405725
18174314
27500866
15371533
21325651
9641683
28027391
7556077
20948999
21644037
12003487
10455157
24252525
23381195
27461252
9855500
17023659
15384226
9852755
11912108
3129338
21810890
28554960
16222525
16239184
21840888
15965196
18088371
17451601
11958862",Heterogeneous ribonuclear protein E2 (hnRNP E2) is associated with TDP-43-immunoreactive neurites in Semantic Dementia but not with other TDP-43 pathological subtypes of Frontotemporal Lobar Degeneration.,"Frontotemporal Lobar Degeneration (FTLD) encompasses certain related neurodegenerative disorders which alter personality and cognition. Heterogeneous ribonuclear proteins (hnRNPs) maintain RNA metabolism and changes in their function may underpin the pathogenesis of FTLD. Immunostaining for hnRNP E2 was performed on sections of frontal and temporal cortex with hippocampus from 80 patients with FTLD, stratified by pathology into FTLD-tau and FTLD-TDP type A, B and C subtypes, and by genetics into patients with C9orf72 expansions, MAPT or GRN mutations, or those with no known mutation, and on 10 healthy controls. Semi-quantitative analysis assessed hnRNP staining in frontal and temporal cortex, and in dentate gyrus (DG) of hippocampus, in the different pathology and genetic groups. We find that hnRNP E2 immunostaining detects the TDP-43 positive dystrophic neurites (DN) within frontal and temporal cortex, and the neuronal cytoplasmic inclusions (NCI) seen in DG granule cells, characteristic of patients with Semantic Dementia (SD) and type C TDP-43 pathology, but did not detect TDP-43 or tau inclusions in any of the other pathological or genetic variants of FTLD. Double immunofluorescence for hnRNP E2 and TDP-43 showed most TDP-43 immunopositive DN to contain hnRNP E2. Present findings indicate an association between TDP-43 and hnRNP E2 which might underlie the pathogenetic mechanism of this form of FTLD.",[],Acta neuropathologica communications,2017-07-02,"[{'lastname': 'Davidson', 'firstname': 'Yvonne S', 'initials': 'YS', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, M6 8HD, Salford, UK.'}, {'lastname': 'Robinson', 'firstname': 'Andrew C', 'initials': 'AC', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, M6 8HD, Salford, UK.'}, {'lastname': 'Flood', 'firstname': 'Louis', 'initials': 'L', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, M6 8HD, Salford, UK.'}, {'lastname': 'Rollinson', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, A V Hill Building, Manchester, M13 9PT, UK.'}, {'lastname': 'Benson', 'firstname': 'Bridget C', 'initials': 'BC', 'affiliation': 'Institute of Neurology, Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, University College London, 1 Wakefield St, London, WC1N 1PJ, UK.'}, {'lastname': 'Asi', 'firstname': 'Yasmine T', 'initials': 'YT', 'affiliation': 'Institute of Neurology, Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, University College London, 1 Wakefield St, London, WC1N 1PJ, UK.'}, {'lastname': 'Richardson', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'Cerebral Function Unit, Greater Manchester Neurosciences Centre, Salford Royal Hospital, Stott Lane, M6 8HD, Salford, UK.'}, {'lastname': 'Jones', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': 'Cerebral Function Unit, Greater Manchester Neurosciences Centre, Salford Royal Hospital, Stott Lane, M6 8HD, Salford, UK.'}, {'lastname': 'Snowden', 'firstname': 'Julie S', 'initials': 'JS', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, M6 8HD, Salford, UK.\nCerebral Function Unit, Greater Manchester Neurosciences Centre, Salford Royal Hospital, Stott Lane, M6 8HD, Salford, UK.'}, {'lastname': 'Pickering-Brown', 'firstname': 'Stuart', 'initials': 'S', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, A V Hill Building, Manchester, M13 9PT, UK.'}, {'lastname': 'Lashley', 'firstname': 'Tammaryn', 'initials': 'T', 'affiliation': 'Institute of Neurology, Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, University College London, 1 Wakefield St, London, WC1N 1PJ, UK.'}, {'lastname': 'Mann', 'firstname': 'David M A', 'initials': 'DMA', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, M6 8HD, Salford, UK. david.mann@manchester.ac.uk.'}]",,,,,"10.1186/s40478-017-0454-4
10.1016/j.tibs.2007.12.003
10.1016/j.bbrc.2006.10.093
10.1038/srep20877
10.1016/j.gene.2004.02.005
10.1261/rna.2254110
10.1111/j.1471-4159.2009.06383.x
10.1007/s00401-006-0189-y
10.1186/2051-5960-2-70
10.1186/s40478-017-0437-5
10.1016/j.brainres.2012.02.032
10.1261/rna.780708
10.1016/j.neurobiolaging.2016.07.004
10.1091/mbc.E04-08-0715
10.1212/WNL.0b013e31821103e6
10.1038/31508
10.1002/1873-3468.12544
10.1371/journal.pone.0013250
10.1007/s00401-011-0845-8
10.1017/S1355838202024627
10.1074/jbc.274.35.24849
10.1186/2051-5960-1-68
10.1007/s00401-013-1088-7
10.15252/embr.201541724
10.1212/WNL.51.6.1546
10.1126/science.1134108
10.1016/j.biolcel.2004.03.010
10.1093/brain/awf069
10.1101/gad.2.2.215
10.1093/brain/awr179
10.1007/s00401-005-1079-4
10.1016/S1474-4422(05)70223-4
10.1093/brain/awr355
10.1136/jnnp.2003.033779
10.1111/j.1471-4159.2007.05190.x
10.1186/1742-4690-4-28
10.1016/S0306-4522(01)00522-X",<Element 'PubmedArticle' at 0x7f05d9e1d310>
158,"28652303
25443285
27615390
26742856
22476196
22002422
16979194
11000114
23082852
25617315
22869320
27106561
22291999
1572948
9443474
23485579
26494219
25088942
18202255
20116045
20081858
9263190
22430016
20561791
17585961
26216852
10674422
15741232
8202139
26365177
8529629
20655099
14747300
24005412
24298146
26780512
28053030
25393002
22286308
21598254
26906354
19605645
24849348
20061514
26824039
4065091
22908189
8315179
18479783
21555069
23332171
8626671
27717815
28229243
8550375
12021765
23245767
18382657
22961084
22848683
24699409
7825486
17942819
18467332
20081857
18466052
27432942
27852778
21131359
20231468
22476197
22723018
16127446
11135642
0
16092951
8636218
24672431
26631930
116135
25107476
17720802",Tau deletion promotes brain insulin resistance.,"The molecular pathways underlying tau pathology-induced synaptic/cognitive deficits and neurodegeneration are poorly understood. One prevalent hypothesis is that hyperphosphorylation, misfolding, and fibrillization of tau impair synaptic plasticity and cause degeneration. However, tau pathology may also result in the loss of specific physiological tau functions, which are largely unknown but could contribute to neuronal dysfunction. In the present study, we uncovered a novel function of tau in its ability to regulate brain insulin signaling. We found that tau deletion leads to an impaired hippocampal response to insulin, caused by altered IRS-1 and PTEN (phosphatase and tensin homologue on chromosome 10) activities. Our data also demonstrate that tau knockout mice exhibit an impaired hypothalamic anorexigenic effect of insulin that is associated with energy metabolism alterations. Consistently, we found that tau haplotypes are associated with glycemic traits in humans. The present data have far-reaching clinical implications and raise the hypothesis that pathophysiological tau loss-of-function favors brain insulin resistance, which is instrumental for cognitive and metabolic impairments in Alzheimer's disease patients.",[],The Journal of experimental medicine,2017-06-28,"[{'lastname': 'Marciniak', 'firstname': 'Elodie', 'initials': 'E', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}, {'lastname': 'Leboucher', 'firstname': 'Antoine', 'initials': 'A', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}, {'lastname': 'Caron', 'firstname': 'Emilie', 'initials': 'E', 'affiliation': 'Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.'}, {'lastname': 'Ahmed', 'firstname': 'Tariq', 'initials': 'T', 'affiliation': 'Laboratory of Biological Psychology, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium.\nNeurological Disorders Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha, Qatar.'}, {'lastname': 'Tailleux', 'firstname': 'Anne', 'initials': 'A', 'affiliation': 'Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011EGID, Lille, France.'}, {'lastname': 'Dumont', 'firstname': 'Julie', 'initials': 'J', 'affiliation': ""LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.\nUniversité de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1167 RID-AGE Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, Lille, France.""}, {'lastname': 'Issad', 'firstname': 'Tarik', 'initials': 'T', 'affiliation': 'INSERM U1016, CNRS UMR8104, Université Paris Descartes Sorbonne Paris Cité, Institut Cochin, Paris, France.'}, {'lastname': 'Gerhardt', 'firstname': 'Ellen', 'initials': 'E', 'affiliation': 'Department of Experimental Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Goettingen, Goettingen, Germany.'}, {'lastname': 'Pagesy', 'firstname': 'Patrick', 'initials': 'P', 'affiliation': 'INSERM U1016, CNRS UMR8104, Université Paris Descartes Sorbonne Paris Cité, Institut Cochin, Paris, France.'}, {'lastname': 'Vileno', 'firstname': 'Margaux', 'initials': 'M', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}, {'lastname': 'Bournonville', 'firstname': 'Clément', 'initials': 'C', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}, {'lastname': 'Hamdane', 'firstname': 'Malika', 'initials': 'M', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}, {'lastname': 'Bantubungi', 'firstname': 'Kadiombo', 'initials': 'K', 'affiliation': 'Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011EGID, Lille, France.'}, {'lastname': 'Lancel', 'firstname': 'Steve', 'initials': 'S', 'affiliation': 'Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011EGID, Lille, France.'}, {'lastname': 'Demeyer', 'firstname': 'Dominique', 'initials': 'D', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}, {'lastname': 'Eddarkaoui', 'firstname': 'Sabiha', 'initials': 'S', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}, {'lastname': 'Vallez', 'firstname': 'Emmanuelle', 'initials': 'E', 'affiliation': 'Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011EGID, Lille, France.'}, {'lastname': 'Vieau', 'firstname': 'Didier', 'initials': 'D', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}, {'lastname': 'Humez', 'firstname': 'Sandrine', 'initials': 'S', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}, {'lastname': 'Faivre', 'firstname': 'Emilie', 'initials': 'E', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}, {'lastname': 'Grenier-Boley', 'firstname': 'Benjamin', 'initials': 'B', 'affiliation': ""LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.\nUniversité de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1167 RID-AGE Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, Lille, France.""}, {'lastname': 'Outeiro', 'firstname': 'Tiago F', 'initials': 'TF', 'affiliation': 'Department of Experimental Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Goettingen, Goettingen, Germany.'}, {'lastname': 'Staels', 'firstname': 'Bart', 'initials': 'B', 'affiliation': 'Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011EGID, Lille, France.'}, {'lastname': 'Amouyel', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': ""LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.\nUniversité de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1167 RID-AGE Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, Lille, France.""}, {'lastname': 'Balschun', 'firstname': 'Detlef', 'initials': 'D', 'affiliation': 'Laboratory of Biological Psychology, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium.'}, {'lastname': 'Buee', 'firstname': 'Luc', 'initials': 'L', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}, {'lastname': 'Blum', 'firstname': 'David', 'initials': 'D', 'affiliation': ""Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France david.blum@inserm.fr.\nLabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.""}]",,,,© 2017 Marciniak et al.,"10.1084/jem.20161731
10.1016/j.neurobiolaging.2014.09.015
10.1016/j.brainresbull.2016.08.018
10.1021/acs.jproteome.5b01001
10.1172/JCI57256
10.1097/NEN.0b013e318232a379
10.1016/j.physbeh.2006.08.008
10.1126/science.289.5487.2122
10.1111/acel.12018
10.15252/emmm.201404183
10.1007/s00125-012-2644-8
10.1002/oby.21476
10.1371/journal.pone.0030616
10.1080/01688639208402827
10.1212/WNL.50.1.164
10.1172/JCI64595
10.2337/dbi15-0011
10.1016/j.euroneuro.2014.06.008
10.1126/science.1152993
10.1016/j.ajhg.2010.01.007
10.1038/ng.520
10.1016/S0197-4580(97)80306-5
10.1038/nrn3209
10.1016/j.tibs.2010.05.007
10.1016/j.physbeh.2007.05.043
10.2337/db15-0596
10.1016/S0197-4580(99)00063-9
10.1242/jcs.01724
10.1038/369488a0
10.1016/j.cmet.2015.08.016
10.1111/j.1432-1033.1995.108_c.x
10.1016/j.cell.2010.06.036
10.2337/diabetes.53.2.474
10.1038/nature12481
10.1098/rstb.2013.0144
10.1038/nn.4225
10.1523/JNEUROSCI.2305-16.2016
10.1371/journal.pgen.1004741
10.1038/nm.2613
10.1002/path.2912
10.2174/156720501303160217111434
10.1523/JNEUROSCI.1071-09.2009
10.1523/JNEUROSCI.3439-13.2014
10.1677/JOE-09-0341
10.1155/2016/1964634
10.1101/cshperspect.a006239
10.1111/j.1532-5415.1993.tb07458.x
10.1016/j.neurobiolaging.2008.04.002
10.1016/j.neuron.2011.04.009
10.1016/j.neurobiolaging.2012.12.003
10.1074/jbc.271.19.11222
10.1016/j.bbr.2016.10.005
10.1007/s00415-017-8405-3
10.1007/BF02388454
10.1038/nn0602-861
10.1016/j.tem.2012.11.002
10.1371/journal.pone.0001867
10.2337/db12-0187
10.1371/journal.pone.0041992
10.1371/journal.pgen.1004235
10.1093/ageing/23.5.396
10.1212/01.WNL.0000265401.62434.36
10.1074/jbc.M709715200
10.1038/ng.521
10.1586/14789450.5.2.207
10.1084/jem.20160493
10.1523/JNEUROSCI.2119-16.2016
10.1074/jbc.M110.199976
10.1073/pnas.1000645107
10.1172/JCI59903
10.1093/hmg/dds238
10.1038/nn0905-1136
10.1038/82868
10.1016/j.jalz.2013.05.573
10.1111/j.1471-4159.2005.03269.x
10.1083/jcb.132.3.413
10.3389/fncel.2014.00084
10.1038/nrn.2015.1
10.1038/282503a0
10.1007/s00401-014-1328-5
10.1096/fj.06-7703com",<Element 'PubmedArticle' at 0x7f05d9dc4270>
159,"28594853
17950702
19858458
17826340
18771956
21482928
26444794
22556362
23518664
24319659
27594585
21810890
21325651
12833363
1202204
3249766
15891946
11254454
15700229
11404350
12053178
25440984
17458552
21644037
22101365
22595371
23692670
21176711
24861427
23053135
27435172
22550220
22892647
23053136
24286341
24703252
24027057",The unexpected co-occurrence of GRN and MAPT p.A152T in Basque families: Clinical and pathological characteristics.,"The co-occurrence of the c.709-1G>A GRN mutation and the p.A152T MAPT variant has been identified in 18 Basque families affected by frontotemporal dementia (FTD). We aimed to investigate the influence of the p.A152T MAPT variant on the clinical and neuropathological features of these Basque GRN families.
We compared clinical characteristics of 14 patients who carried the c.709-1G>A GRN mutation (GRN+/A152T-) with 21 patients who carried both the c.709-1G>A GRN mutation and the p.A152T MAPT variant (GRN+/A152T+). Neuropsychological data (n = 17) and plasma progranulin levels (n = 23) were compared between groups, and 7 subjects underwent neuropathological studies. We genotyped six short tandem repeat markers in the two largest families. By the analysis of linkage disequilibrium decay in the haplotype block we estimated the time when the first ancestor to carry both genetic variants emerged. GRN+/A152T+ and GRN+/A152T- patients shared similar clinical and neuropsychological features and plasma progranulin levels. All were diagnosed with an FTD disorder, including behavioral variant FTD or non fluent / agrammatic variant primary progressive aphasia, and shared a similar pattern of neuropsychological deficits, predominantly in executive function, memory, and language. All seven participants with available brain autopsies (6 GRN+/A152T+, 1 GRN+/A152T-) showed frontotemporal lobar degeneration with TDP-43 inclusions (type A classification), which is characteristic of GRN carriers. Additionally, all seven showed mild to moderate tau inclusion burden: five cases lacked β-amyloid pathology and two cases had Alzheimer's pathology. The co-occurrence of both genes within one individual is recent, with the birth of the first GRN+/A152T+ individual estimated to be within the last 50 generations (95% probability).
In our sample, the p.A152T MAPT variant does not appear to show a discernible influence on the clinical phenotype of GRN carriers. Whether p.A152T confers a greater than expected propensity for tau pathology in these GRN carriers remains an open question.",[],PloS one,2017-06-09,"[{'lastname': 'Moreno', 'firstname': 'Fermin', 'initials': 'F', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Indakoetxea', 'firstname': 'Begoña', 'initials': 'B', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Barandiaran', 'firstname': 'Myriam', 'initials': 'M', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Caballero', 'firstname': 'María Cristina', 'initials': 'MC', 'affiliation': 'Department of Pathology, Hospital Universitario Donostia, San Sebastián, Spain.\nBrain Bank Hospital Universitario Donostia, from the Basque Biobank for Research (OEHUN), San Sebastian, Spain.'}, {'lastname': 'Gorostidi', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Calafell', 'firstname': 'Francesc', 'initials': 'F', 'affiliation': 'Institute of Evolutionary Biology (CSIC-UPF), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.'}, {'lastname': 'Gabilondo', 'firstname': 'Alazne', 'initials': 'A', 'affiliation': 'Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.\nDepartment of Neurology, Hospital de Bidasoa, Irun, Spain.'}, {'lastname': 'Tainta', 'firstname': 'Mikel', 'initials': 'M', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Zulaica', 'firstname': 'Miren', 'initials': 'M', 'affiliation': 'Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Martí Massó', 'firstname': 'José F', 'initials': 'JF', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.\nDepartment of Neurosciences, Universidad del País Vasco UPV-EHU, San Sebastian, Spain.'}, {'lastname': 'López de Munain', 'firstname': 'Adolfo', 'initials': 'A', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.\nDepartment of Neurosciences, Universidad del País Vasco UPV-EHU, San Sebastian, Spain.'}, {'lastname': 'Sánchez-Juan', 'firstname': 'Pascual', 'initials': 'P', 'affiliation': ""Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla' (IDIVAL), Santander, Spain.""}, {'lastname': 'Lee', 'firstname': 'Suzee E', 'initials': 'SE', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, United States of America.'}]",,,,,"10.1371/journal.pone.0178093
10.1016/j.biopsych.2007.08.015
10.1212/WNL.0b013e3181bd82a7
10.1016/S1474-4422(07)70221-1
10.1016/S1474-4422(08)70194-7
10.1001/archneurol.2011.53
10.1093/hmg/dds161
10.1097/WAD.0b013e31828cc357
10.1016/j.stemcr.2013.08.001
10.1016/j.stemcr.2016.08.001
10.1093/brain/awr179
10.1212/WNL.0b013e31821103e6
10.1086/319501
10.1086/428594
10.1038/ng917
10.1111/ahg.12088
10.1007/s00401-007-0223-8
10.1007/s00401-011-0845-8
10.1007/s00401-011-0910-3
10.1016/j.parkreldis.2013.04.023
10.1111/nan.12155
10.1007/s00401-012-1048-7
10.1186/s40478-016-0345-0
10.1136/jnnp-2012-302219
10.1097/WAD.0b013e318266fae5
10.1007/s00401-012-1050-0
10.1016/j.jns.2014.03.030
10.1212/WNL.0b013e3182a8250c",<Element 'PubmedArticle' at 0x7f05d9d84450>
160,"28582864
26979082
16906426
12498954
16237129
17023659
19330340
12084879
26810071
18849605
26649319
25224501
27181391
27917876
22847497
27648178
27660698
26967215
24440525
28044060
18346114
15933386
26333802
19184666
11895043
12502659
2198187
27895533
27423001
26812281
27021820
27815632
21326809
17195931
23967244
20639693
21051541
24240737
18950899
23794448
28106068
26249371
27893041
27600683
17101823
11916953
17159101
9371913
10794849
20739645
19139294
26233574
22265587
22101365",Transactive DNA Binding Protein 43 Rather Than Other Misfolded Proteins in the Brain is Associated with Islet Amyloid Polypeptide in Pancreas in Aged Subjects with Diabetes Mellitus.,"A link between diabetes mellitus (DM) related islet amyloid polypeptide (IAPP) and Alzheimer's disease (AD) related amyloid-β (Aβ) has been suggested in epidemiological and clinical studies. In 2017, proof for existing interaction between type 2 DM and AD on a molecular level was provided based on research carried out in experimental animal models. We assessed aging-related neurodegenerative lesions, i.e., misfolded proteins, associated with dementia such as hyperphosphorylated τ (HPτ), Aβ, α-synuclein (αS), and phosphorylated transactive DNA binding protein 43 (pTDP43) seen in the brain and IAPP seen in the pancreas in subjects with and without DM applying immunohistochemical techniques. HPτ in the brain and IAPP in the pancreas were observed in most subjects. The prevalence and the extent of all misfolded proteins increased with age but this increase was not influenced by DM. Interestingly the extent of misfolded proteins in the brain was higher in non-diabetics when compared with diabetics in demented. A significant correlation was observed between HPτ, Aβ, αS, and pTDP43, whereas IAPP showed no association with HPτ, Aβ, and αS. In subjects with DM, the extent of pTDP43 in brain correlated with the extent of IAPP in pancreas. Thus, there is no evidence of a link between AD-related pathology and DM in humans, whereas an association was found between pTDP43 and IAPP in DM. TDP43 is ubiquitously expressed in all organs but whether TDP43 is phosphorylated in other organs in DM or whether the phosphorylation of TDP43 is influenced by glucose metabolism is yet unknown.","['amyloid-β', 'diabetes mellitus', 'hyperphosphorylated τ', 'islet amyloid polypeptide', 'phosphorylated transactive DNA binding protein 43', 'α-synuclein']",Journal of Alzheimer's disease : JAD,2017-06-07,"[{'lastname': 'Leino', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Department of Pathology, Uppsala University Hospital, Sweden.\nDepartment of Immunology, Genetics and Pathology, Uppsala University, Sweden.'}, {'lastname': 'Popova', 'firstname': 'Svetlana N', 'initials': 'SN', 'affiliation': 'Department of Pathology, Uppsala University Hospital, Sweden.\nDepartment of Immunology, Genetics and Pathology, Uppsala University, Sweden.'}, {'lastname': 'Alafuzoff', 'firstname': 'Irina', 'initials': 'I', 'affiliation': 'Department of Pathology, Uppsala University Hospital, Sweden.\nDepartment of Immunology, Genetics and Pathology, Uppsala University, Sweden.'}]",,,,,"10.3233/JAD-170192
10.1038/mp.2016.230",<Element 'PubmedArticle' at 0x7f05d9d2aae0>
161,"28529873
21645364
25879909
25317628
20575080
24252608
24336722
18471801
26041104
22116036
23041626
23543794
26827655
21258152
21986680
25662776
25510382
25850086
21393509
23741441
11513020
26104658
18471801
17357725
20026663
17088690",White matter hyperintensities are seen only in ,Genetic frontotemporal dementia is most commonly caused by mutations in the progranulin ,"['CI, Confidence interval', 'FTD, Frontotemporal dementia', 'IQR, Inter Quartile Range', 'PS, Presymptomatic', 'S, Symptomatic', 'TIV, Total Intracranial volume', 'WMH, White matter hyperintensity']",NeuroImage. Clinical,2017-05-23,"[{'lastname': 'Sudre', 'firstname': 'Carole H', 'initials': 'CH', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; Centre for Medical Image Computing, University College London, UK.'}, {'lastname': 'Bocchetta', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Cash', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; Centre for Medical Image Computing, University College London, UK.'}, {'lastname': 'Thomas', 'firstname': 'David L', 'initials': 'DL', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; Centre for Medical Image Computing, University College London, UK.'}, {'lastname': 'Woollacott', 'firstname': 'Ione', 'initials': 'I', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Dick', 'firstname': 'Katrina M', 'initials': 'KM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'van Swieten', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Erasmus Medical Center, Rotterdam, Netherlands.'}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'University of Brescia, Italy.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Dept. of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Masellis', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Cognitive Neurology Research Unit, Sunnybrook Health Sciences Centre, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute; Department of Medicine, University of Toronto, Canada.'}, {'lastname': 'Tartaglia', 'firstname': 'Maria Carmela', 'initials': 'MC', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Canada.'}, {'lastname': 'Rowe', 'firstname': 'James B', 'initials': 'JB', 'affiliation': 'University of Cambridge, UK.'}, {'lastname': 'Graff', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Karolinska Institutet, Stockholm, Sweden; Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Sweden; Department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden.'}, {'lastname': 'Tagliavini', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'Istituto Neurologico Carlo Besta, Milan, Italy.'}, {'lastname': 'Frisoni', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'IRCCS San Giovanni di Dio Fatebenefratelli Brescia, Italy.'}, {'lastname': 'Laforce', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Université Laval, Quebec, Canada.'}, {'lastname': 'Finger', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'University of Western Ontario, Ontario, Canada.'}, {'lastname': 'de Mendonça', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Faculdade de Medicina, Universidade de Lisboa, Portugal.'}, {'lastname': 'Sorbi', 'firstname': 'Sandro', 'initials': 'S', 'affiliation': 'Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy; IRCCS Don Gnocchi, Firenze, Italy.'}, {'lastname': 'Ourselin', 'firstname': 'Sébastien', 'initials': 'S', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; Centre for Medical Image Computing, University College London, UK.'}, {'lastname': 'Cardoso', 'firstname': 'M Jorge', 'initials': 'MJ', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; Centre for Medical Image Computing, University College London, UK.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK. Electronic address: j.rohrer@ucl.ac.uk.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,,10.1016/j.nicl.2017.04.015,<Element 'PubmedArticle' at 0x7f05d9d4ba90>
162,"28473694
20026663
12524533
12526812
12889069
18378771
12973694
21224065
16862116
16862115
16950801
16983685
17923627
18245784
17949857
17826340
19288468
19158106
19683260
18752597
20142525
19625741
21212639
17030534
17917583
17157414
23609919
17439980
25575133
20703815
25619230
1759558
21644037
10483782
17071926
17591968
17278999
22699850
25022663
12000724
28073925",Accumulation of multiple neurodegenerative disease-related proteins in familial frontotemporal lobar degeneration associated with granulin mutation.,"In 2006, mutations in the granulin gene were identified in patients with familial Frontotemporal Lobar Degeneration. Granulin transcript haploinsufficiency has been proposed as a disease mechanism that leads to the loss of functional progranulin protein. Granulin mutations were initially found in tau-negative patients, though recent findings indicate that these mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease and corticobasal degeneration. Moreover, a reduction in progranulin in tau transgenic mice is associated with increasing tau accumulation. To investigate the influence of a decline in progranulin protein on other forms of neurodegenerative-related protein accumulation, human granulin mutation cases were investigated by histochemical and biochemical analyses. Results showed a neuronal and glial tau accumulation in granulin mutation cases. Tau staining revealed neuronal pretangle forms and glial tau in both astrocytes and oligodendrocytes. Furthermore, phosphorylated α-synuclein-positive structures were also found in oligodendrocytes and the neuropil. Immunoblot analysis of fresh frozen brain tissues revealed that tau was present in the sarkosyl-insoluble fraction, and composed of three- and four-repeat tau isoforms, resembling Alzheimer's disease. Our data suggest that progranulin reduction might be the cause of multiple proteinopathies due to the accelerating accumulation of abnormal proteins including TDP-43 proteinopathy, tauopathy and α-synucleinopathy.",[],Scientific reports,2017-05-06,"[{'lastname': 'Hosokawa', 'firstname': 'Masato', 'initials': 'M', 'affiliation': 'Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan. hosokawa-ms@igakuken.or.jp.'}, {'lastname': 'Kondo', 'firstname': 'Hiromi', 'initials': 'H', 'affiliation': 'Histology Center, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.'}, {'lastname': 'Serrano', 'firstname': 'Geidy E', 'initials': 'GE', 'affiliation': 'Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ, 85351, USA.'}, {'lastname': 'Beach', 'firstname': 'Thomas G', 'initials': 'TG', 'affiliation': 'Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ, 85351, USA.'}, {'lastname': 'Robinson', 'firstname': 'Andrew C', 'initials': 'AC', 'affiliation': 'Faculty of Biology, Medicine and Health, School of Biological Sciences, Division of Neuroscience & Experimental Psychology, University of Manchester, Clinical Sciences Building, Salford Royal Hospital, Stott Lane, Salford, M6 8HD, UK.'}, {'lastname': 'Mann', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'Faculty of Biology, Medicine and Health, School of Biological Sciences, Division of Neuroscience & Experimental Psychology, University of Manchester, Clinical Sciences Building, Salford Royal Hospital, Stott Lane, Salford, M6 8HD, UK.'}, {'lastname': 'Akiyama', 'firstname': 'Haruhiko', 'initials': 'H', 'affiliation': 'Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.'}, {'lastname': 'Hasegawa', 'firstname': 'Masato', 'initials': 'M', 'affiliation': 'Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.'}, {'lastname': 'Arai', 'firstname': 'Tetsuaki', 'initials': 'T', 'affiliation': 'Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.\nDepartment of Neuropsychiatry, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki, 305-8576, Japan.'}]",,,,,"10.1038/s41598-017-01587-6
10.1084/jem.20091568
10.1038/nm816
10.1016/S0092-8674(02)01141-8
10.1002/dvdy.10341
10.1083/jcb.200712039
10.1016/j.ajpath.2010.11.002
10.1038/nature05016
10.1038/nature05017
10.1093/hmg/ddl241
10.1002/ana.20963
10.1001/archneur.64.10.1436
10.1093/brain/awn012
10.1016/j.neurobiolaging.2007.08.022
10.1016/S1474-4422(07)70221-1
10.1002/ana.21621
10.1093/brain/awn352
10.1016/j.jns.2009.07.011
10.1111/j.1468-1331.2008.02266.x
10.1001/archneurol.2010.113
10.3233/JAD-2009-1170
10.1159/000322538
10.1093/brain/awl276
10.1097/nen.0b013e3181567873
10.1016/j.neurobiolaging.2006.10.028
10.1001/2013.jamaneurol.393
10.1093/brain/awm069
10.1097/NEN.0000000000000158
10.1007/s10561-010-9210-8
10.1111/neup.12189
10.1007/BF00308809
10.1007/s00401-011-0845-8
10.1007/s004010051077
10.1093/brain/awl271
10.2353/ajpath.2007.070182
10.1097/nen.0b013e31803020cf
10.1186/s40478-014-0078-x
10.1016/S0002-9440(10)61119-4
10.1093/hmg/ddx011",<Element 'PubmedArticle' at 0x7f05d9cf58b0>
163,"28467789
8624132
16361024
16932542
26462756
27521218
24489845
17192484
15750215
14981233
20837822
12808450
20231468
24949886
26095350
26961231
27179961
24931033
21044348
27406855
19828790
19184068
18675468
24833600
24827147
15295589
20212036
1663746
25888781
18596919
23872402
12151012
25812852
15249195
17465978
24080896
10830966
26603284
24899720
19295602
19881535
17760871
27626660
10811821
21106831
27340665
20061018
18191198
11074263
24998414
22961084
24574966
24879856
27087442
11148253
20573181
20634587
23541064
20858652
17308309
20950339
22035109
25442114
25815110
8197133
7893666
21440603
20638753
23850509
26586913
11375353
11245811
12415294
26957303
22717236
26293690",Chronic diabetic states worsen Alzheimer neuropathology and cognitive deficits accompanying disruption of calcium signaling in leptin-deficient APP/PS1 mice.,"The coincidences between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are so compelling that it is attractive to speculate that diabetic conditions might aggravate AD pathologies by calcium dysfunction, although the understanding of the molecular mechanisms involved remains elusive. The present work was undertaken to investigate whether calcium dyshomeostasis is associated with the exacerbated Alzheimer-like cognitive dysfunction observed in diabetic conditions in APP/PS1-ob/ob mice, which were generated by crossing ob/ob mice with APP/PS1 mice. We confirmed that the diabetic condition can aggravate not only Aβ deposition but also tau phosphorylation, synaptic loss, neuronal death, and inflammation, exacerbating cognitive impairment in AD mice. More importantly, we found that the diabetic condition dramatically elevated calcium levels in APP/PS1 mice, thereby stimulating the phosphorylation of the calcium-dependent kinases. Our findings suggest that controlling over-elevation of intracellular calcium may provide novel insights for approaching AD in diabetic patients and delaying AD progression.","['Alzheimer’s disease', 'calcium', 'diabetes mellitus', 'tau', 'β-amyloid']",Oncotarget,2017-05-04,"[{'lastname': 'Zhang', 'firstname': 'Shuai', 'initials': 'S', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang, China.'}, {'lastname': 'Chai', 'firstname': 'Rui', 'initials': 'R', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang, China.'}, {'lastname': 'Yang', 'firstname': 'Ying-Ying', 'initials': 'YY', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang, China.'}, {'lastname': 'Guo', 'firstname': 'Shi-Qi', 'initials': 'SQ', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang, China.'}, {'lastname': 'Wang', 'firstname': 'Shan', 'initials': 'S', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang, China.'}, {'lastname': 'Guo', 'firstname': 'Tian', 'initials': 'T', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang, China.'}, {'lastname': 'Xu', 'firstname': 'Shuang-Feng', 'initials': 'SF', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang, China.'}, {'lastname': 'Zhang', 'firstname': 'Yan-Hui', 'initials': 'YH', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang, China.'}, {'lastname': 'Wang', 'firstname': 'Zhan-You', 'initials': 'ZY', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang, China.'}, {'lastname': 'Guo', 'firstname': 'Chuang', 'initials': 'C', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang, China.'}]",,,,,10.18632/oncotarget.17116,<Element 'PubmedArticle' at 0x7f05d9d1b040>
164,"28431575
17084815
26869068
21847626
7807156
23827524
20584894
25943887
24866055
24950788
22497712
27500866
21325651
19099192
23455423
24119545
16901787
27768896
27768897
11886857
21644037
24252525
23381195
27461252
9855500
17415574
17023659
22546510
3129338
21810890
24612671
16222525
16239184
21840888
15965196",Heterogeneous ribonuclear protein A3 (hnRNP A3) is present in dipeptide repeat protein containing inclusions in Frontotemporal Lobar Degeneration and Motor Neurone disease associated with expansions in C9orf72 gene.,"Frontotemporal Lobar Degeneration (FTLD) encompasses certain related neurodegenerative disorders which alter behaviour, personality and language. Heterogeneous ribonuclear proteins (hnRNPs) maintain RNA metabolism and changes in their function may underpin the pathogenesis of FTLD. Immunostaining for hnRNP A1, A2/B1 and A3 was performed on sections of temporal cortex with hippocampus from 61 patients with FTLD, stratified by pathological hallmarks into FTLD-tau and FTLD-TDP type A, B and C subtypes, and by genetics into patients with C9orf72 expansions, MAPT or GRN mutations, or those without known mutation. Four patients with Motor Neurone Disease (MND) with C9orf72 expansions and 10 healthy controls were also studied. Semi-quantitative analysis assessed hnRNP staining intensity in dentate gyrus (DG) and CA4 region of hippocampus, and temporal cortex (Tcx) in the different pathological and genetic groups.Immunostaining for hnRNP A1, A2/B1 and A3 revealed no consistent changes in pattern or amount of physiological staining across any of the pathological or genetic groups. No immunostaining of any inclusions resembling TDP-43 immunoreactive neuronal cytoplasmic inclusions or dystrophic neurites, was seen in either Tcx or DG of the hippocampus in any of the FTLD cases investigated for hnRNP A1, A2/B1 and A3. However, immunostaining for hnRNP A3 showed that inclusion bodies, resembling those TDP-43 negative, p62-immunopositive structures containing dipeptide repeat proteins (DPR) were variably observed in hippocampus and cerebellum. The proportion of cases showing hnRNP A3-immunoreactive DPR, and the number of hnRNP A3-positive inclusions within cases, was significantly greater in DG than in cells of CA4 region and cerebellum, but the latter was significantly less in all three regions compared to that detected by p62 immunostaining.","['C9orf72 gene', 'Dipeptide repeat proteins', 'Frontotemporal Lobar Degeneration', 'Heterogeneous ribonuclear proteins', 'Motor neuron disease']",Acta neuropathologica communications,2017-04-23,"[{'lastname': 'Davidson', 'firstname': 'Yvonne S', 'initials': 'YS', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, Salford, M6 8HD, UK.'}, {'lastname': 'Flood', 'firstname': 'Louis', 'initials': 'L', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, Salford, M6 8HD, UK.'}, {'lastname': 'Robinson', 'firstname': 'Andrew C', 'initials': 'AC', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, Salford, M6 8HD, UK.'}, {'lastname': 'Nihei', 'firstname': 'Yoshihiro', 'initials': 'Y', 'affiliation': 'Biomedical Centre (BMC), Biochemistry, Ludwig-Maximilians Universitat Munchen, Munich, Germany.'}, {'lastname': 'Mori', 'firstname': 'Kohji', 'initials': 'K', 'affiliation': 'Biomedical Centre (BMC), Biochemistry, Ludwig-Maximilians Universitat Munchen, Munich, Germany.\nDepartment of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan.'}, {'lastname': 'Rollinson', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, A V Hill Building, Manchester, M13 9PT, UK.'}, {'lastname': 'Richardson', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'Cerebral Function Unit, Greater Manchester Neurosciences Centre, Salford Royal Hospital, Stott Lane, Salford, M6 8HD, UK.'}, {'lastname': 'Benson', 'firstname': 'Bridget C', 'initials': 'BC', 'affiliation': 'Department of Molecular Neuroscience, University College London, Institute of Neurology, Queen Square Brain Bank for Neurological Disorders, 1 Wakefield St, London, WC1N 1PJ, UK.'}, {'lastname': 'Jones', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': 'Cerebral Function Unit, Greater Manchester Neurosciences Centre, Salford Royal Hospital, Stott Lane, Salford, M6 8HD, UK.'}, {'lastname': 'Snowden', 'firstname': 'Julie S', 'initials': 'JS', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, Salford, M6 8HD, UK.\nCerebral Function Unit, Greater Manchester Neurosciences Centre, Salford Royal Hospital, Stott Lane, Salford, M6 8HD, UK.'}, {'lastname': 'Pickering-Brown', 'firstname': 'Stuart', 'initials': 'S', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, A V Hill Building, Manchester, M13 9PT, UK.'}, {'lastname': 'Haass', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Biomedical Centre (BMC), Biochemistry, Ludwig-Maximilians Universitat Munchen, Munich, Germany.\nGerman Centre for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.\nMunich Cluster for Systems Neurology (SyNergy), Munich, Germany.'}, {'lastname': 'Lashley', 'firstname': 'Tammaryn', 'initials': 'T', 'affiliation': 'Department of Molecular Neuroscience, University College London, Institute of Neurology, Queen Square Brain Bank for Neurological Disorders, 1 Wakefield St, London, WC1N 1PJ, UK.'}, {'lastname': 'Mann', 'firstname': 'David M A', 'initials': 'DMA', 'affiliation': 'Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, Salford, M6 8HD, UK. david.mann@manchester.ac.uk.'}]",,,,,"10.1186/s40478-017-0437-5
10.1016/j.bbrc.2006.10.093
10.1038/srep20877
10.1007/s00401-011-0863-6
10.1016/0022-510X(94)90191-0
10.1016/j.neurobiolaging.2013.05.025
10.1261/rna.2254110
10.1007/s00401-015-1429-9
10.1093/brain/awu120
10.1186/2051-5960-2-70
10.1111/j.1365-2990.2012.01274.x
10.1016/j.neurobiolaging.2016.07.004
10.1212/WNL.0b013e31821103e6
10.1007/s00018-008-8532-1
10.1038/nature11922
10.1016/j.neurobiolaging.2013.09.016
10.1016/j.cell.2006.05.049
10.1016/j.cell.2016.10.002
10.1016/j.cell.2016.10.003
10.1074/jbc.M200050200
10.1007/s00401-011-0845-8
10.1186/2051-5960-1-68
10.1007/s00401-013-1088-7
10.15252/embr.201541724
10.1212/WNL.51.6.1546
10.1007/s00401-007-0221-x
10.1126/science.1134108
10.1016/j.abb.2012.04.012
10.1101/gad.2.2.215
10.1093/brain/awr179
10.1016/j.neurobiolaging.2014.01.152
10.1007/s00401-005-1079-4
10.1016/S1474-4422(05)70223-4
10.1093/brain/awr355
10.1136/jnnp.2003.033779",<Element 'PubmedArticle' at 0x7f05d9cc4a90>
165,28400135,Insulin deficiency results in reversible protein kinase A activation and tau phosphorylation.,"Alzheimer's disease (AD) is a highly prevalent multifactorial disease for which Diabetes Mellitus (DM) is a risk factor. Abnormal phosphorylation and aggregation of tau is a key hallmark of AD. In animal models, DM induces or exacerbates the phosphorylation of tau, suggesting that DM may influence the risk at AD by directly facilitating tau pathology. Previously we reported that tau phosphorylation induced in response to metabolic stress is reversible. Since identification and understanding of early players in tau pathology is pivotal for therapeutic intervention, we here investigated the mechanism underlying tau phosphorylation in the diabetic brain and its potential for reversibility. To model DM we used streptozotocin-treatment to induce insulin deficiency in rats. Insulin depletion leads to increased tau phosphorylation in the brain and we investigated the activation status of known tau kinases and phosphatases in this model. We identified protein kinase A (PKA) as a tau kinase activated by DM in the brain. The potential relevance of this signaling pathway to AD pathogenesis is indicated by the increased level of active PKA in temporal cortex of early stage AD patients. Our data indicate that activation of PKA and tau phosphorylation are associated with insulin deficiency per se, rather than the downstream energy deprivation. In vitro studies confirm that insulin deficiency results in PKA activation and tau phosphorylation. Strikingly, both active PKA and induced tau phosphorylation are reversed upon insulin treatment in the steptozotocin animal model. Our data identify insulin deficiency as a direct trigger that induces the activity of the tau kinase PKA and results in tau phosphorylation. The reversibility upon insulin treatment underscores the potential of insulin as an early disease-modifying intervention in AD and other tauopathies.","[""Alzheimer's disease"", 'Diabetes mellitus', 'Insulin deficiency', 'Phosphorylated tau', 'Protein kinase A']",Neurobiology of disease,2017-04-13,"[{'lastname': 'van der Harg', 'firstname': 'Judith M', 'initials': 'JM', 'affiliation': 'Dept. of Genome Analysis, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Dept. of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience VU University, Amsterdam, The Netherlands. Electronic address: judithvdharg@hotmail.com.'}, {'lastname': 'Eggels', 'firstname': 'Leslie', 'initials': 'L', 'affiliation': 'Dept. Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: l.eggels@amc.uva.nl.'}, {'lastname': 'Bangel', 'firstname': 'Fabian N', 'initials': 'FN', 'affiliation': 'Dept. of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience VU University, Amsterdam, The Netherlands; Dept. of Clinical Genetics and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: fabian.bangel@gmail.com.'}, {'lastname': 'Ruigrok', 'firstname': 'Silvie R', 'initials': 'SR', 'affiliation': 'Dept. of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience VU University, Amsterdam, The Netherlands. Electronic address: silvieruigrok@gmail.com.'}, {'lastname': 'Zwart', 'firstname': 'Rob', 'initials': 'R', 'affiliation': 'Dept. of Genome Analysis, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: r.zwart@amc.uva.nl.'}, {'lastname': 'Hoozemans', 'firstname': 'Jeroen J M', 'initials': 'JJM', 'affiliation': 'Dept. of Pathology, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: JJM.Hoozemans@vumc.nl.'}, {'lastname': 'la Fleur', 'firstname': 'Susanne E', 'initials': 'SE', 'affiliation': 'Dept. Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: s.e.lafleur@amc.uva.nl.'}, {'lastname': 'Scheper', 'firstname': 'Wiep', 'initials': 'W', 'affiliation': 'Dept. of Genome Analysis, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Dept. of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience VU University, Amsterdam, The Netherlands; Dept. of Clinical Genetics and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: w.scheper@vumc.nl.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.nbd.2017.04.005,<Element 'PubmedArticle' at 0x7f05d9c67e50>
166,28387670,Angiotensin-III is Increased in Alzheimer's Disease in Association with Amyloid-β and Tau Pathology.,"Hyperactivity of the renin-angiotensin system (RAS) is associated with the pathogenesis of Alzheimer's disease (AD) believed to be mediated by angiotensin-II (Ang-II) activation of the angiotensin type 1 receptor (AT1R). We previously showed that angiotensin-converting enzyme-1 (ACE-1) activity, the rate-limiting enzyme in the production of Ang-II, is increased in human postmortem brain tissue in AD. Angiotensin-III (Ang-III) activates the AT1R and angiotensin type-2 receptor (AT2R), but its potential role in the pathophysiology of AD remains unexplored. We measured Ang-II and Ang-III levels by ELISA, and the levels and activities of aminopeptidase-A (AP-A) and aminopeptidase-N (AP-N) (responsible for the production and metabolism of Ang-III, respectively) in human postmortem brain tissue in the mid-frontal cortex (Brodmann area 9) in a cohort of AD (n = 90) and age-matched non-demented controls (n = 59), for which we had previous measurements of ACE-1 activity, Aβ level, and tau pathology (also in the mid-frontal cortex). We found that both Ang-II and Ang-III levels were significantly higher in AD compared to age-matched controls and that Ang-III, rather than Ang-II, was strongly associated with Aβ load and tau load. Levels of AP-A were significantly reduced in AD but AP-A enzyme activity was unchanged whereas AP-N activity was reduced in AD but AP-N protein level was unchanged. Together, these data indicate that the APA/Ang-III/APN/Ang-IV/AT4R pathway is dysregulated and that elevated Ang-III could contribute to the pathogenesis of AD.","['Alzheimer’s disease', 'aminopeptidase-A', 'aminopeptidase-P', 'angiotensin-II', 'angiotensin-III', 'renin-angiotensin system']",Journal of Alzheimer's disease : JAD,2017-04-08,"[{'lastname': 'Kehoe', 'firstname': 'Patrick Gavin', 'initials': 'PG', 'affiliation': None}, {'lastname': 'Hibbs', 'firstname': 'Elliott', 'initials': 'E', 'affiliation': None}, {'lastname': 'Palmer', 'firstname': 'Laura E', 'initials': 'LE', 'affiliation': None}, {'lastname': 'Miners', 'firstname': 'J Scott', 'initials': 'JS', 'affiliation': None}]",,,,,10.3233/JAD-161265,<Element 'PubmedArticle' at 0x7f05d9c78130>
167,"28382978
15148141
21913970
24931033
24443714
22820012
24881967
15750215
15288712
16936707
15964100
21911655
26298663
25744568
24918340
24910612
19458242
23150171
23996345
17448147
24142524
26635213
18448228
16262633
10191253
1325671
11754997
17262990
10403017
12399581
26268336
22476197
22205300
26401706
26879001
21533606
16412093
18077675
17241267
27076423
25792098
20552234
12612547
22315714
25663025
20107219
17123555
16627931
23554921
24069173
27457264
19930651
10588583
10588584
19777393
25088942
19815707
22337827
15262337","Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer's rat model.","Recent evidence reveals that aberrant brain insulin signaling plays an important role in the pathology of Alzheimer's disease (AD). Intranasal insulin administration has been reported to improve memory and attention in healthy participants and in AD patients. However, the underlying molecular mechanisms are poorly understood. Here, we treated intracerebroventricular streptozotocin-injected (ICV-STZ) rats, a commonly used animal model of sporadic AD, with daily intranasal delivery of insulin (2 U/day) for 6 consecutive weeks and then studied their cognitive function with the Morris water maze test and biochemical changes via Western blotting. We observed cognitive deficits, tau hyperphosphorylation, and neuroinflammation in the brains of ICV-STZ rats. Intranasal insulin treatment for 6 weeks significantly improved cognitive function, attenuated the level of tau hyperphosphorylation, ameliorated microglial activation, and enhanced neurogenesis in ICV-STZ rats. Additionally, our results indicate that intranasal delivery of insulin probably attenuates tau hyperphosphorylation through the down-regulation of ERK1/2 and CaMKII in the brains of ICV-STZ rats. Our findings demonstrate a beneficial effect of intranasal insulin and provide the mechanistic basis for treating AD patients with intranasal insulin.",[],Scientific reports,2017-04-07,"[{'lastname': 'Guo', 'firstname': 'Zhangyu', 'initials': 'Z', 'affiliation': 'Department of Neurology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China.'}, {'lastname': 'Chen', 'firstname': 'Yanxing', 'initials': 'Y', 'affiliation': 'Department of Neurology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China.'}, {'lastname': 'Mao', 'firstname': 'Yan-Fang', 'initials': 'YF', 'affiliation': 'Department of Neurology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China.'}, {'lastname': 'Zheng', 'firstname': 'Tingting', 'initials': 'T', 'affiliation': 'Department of Neurology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China.'}, {'lastname': 'Jiang', 'firstname': 'Yasi', 'initials': 'Y', 'affiliation': 'Department of Neurology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China.'}, {'lastname': 'Yan', 'firstname': 'Yaping', 'initials': 'Y', 'affiliation': 'Department of Neurology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China.'}, {'lastname': 'Yin', 'firstname': 'Xinzhen', 'initials': 'X', 'affiliation': 'Department of Neurology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China.'}, {'lastname': 'Zhang', 'firstname': 'Baorong', 'initials': 'B', 'affiliation': 'Department of Neurology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China.'}]",,,,,10.1038/srep45971,<Element 'PubmedArticle' at 0x7f05d9c81630>
168,"28382596
24652456
26131323
18627032
18328008
26746341
26139609
19815707
26793112
15750215
27373531
26888634
18077675
26903798
27421117
18407262
12916818
27721184
25690731
27131827
23948890
22115895
15823755
22951438
17406317
24008687
23158895
22476196
19056984
17760871
25553822
24529526
24112036
27252647
26344875
20969897
21525299
12895417
21915226
18406062",Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice.,"The purpose of this study was to explore how liraglutide affects AD-like pathology and cognitive function in APP/PS1/Tau triple transgenic (3 × Tg) Alzheimer disease (AD) model mice. Male 3 × Tg mice and C57BL/6 J mice were treated for 8 weeks with liraglutide (300 μg/kg/day, subcutaneous injection) or saline. Levels of phosphorylated tau, neurofilaments (NFs), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) in brain tissues were assessed with western blots. Fluoro-Jade-B labeling were applied to detect pathological changes. The Morris water maze (MWM) was used to assess the spatial learning and memory. Liraglutide decreased levels of hyperphosphorylated tau and NFs in 3 × Tg liraglutide-treated (Tg + LIR) mice, increased ERK phosphorylation, and decreased JNK phosphorylation. Liraglutide also decreased the number of degenerative neurons in the hippocampus and cortex of Tg + LIR mice, and shortened their escape latencies and increased their hidden platform crossings in the MWM task. Liraglutide did not significantly affect the animals' body weight (BW) or fasting blood glucose. Liraglutide can reduce hyperphosphorylation of tau and NFs and reduce neuronal degeneration, apparently through alterations in JNK and ERK signaling, which may be related to its positive effects on AD-like learning and memory impairment.","['3\u2009×\u2009Tg mice', 'Alzheimer disease', 'ERK', 'JNK', 'Liraglutide', 'Tau']",Neurochemical research,2017-04-07,"[{'lastname': 'Chen', 'firstname': 'Shuyi', 'initials': 'S', 'affiliation': 'Pathophysiology Department, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Sun', 'firstname': 'Jie', 'initials': 'J', 'affiliation': 'Pathophysiology Department, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Zhao', 'firstname': 'Gang', 'initials': 'G', 'affiliation': 'Department of Pathology, Tianjin Cancer Hospital, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Guo', 'firstname': 'Ai', 'initials': 'A', 'affiliation': 'Pathophysiology Department, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Chen', 'firstname': 'Yanlin', 'initials': 'Y', 'affiliation': 'Pathophysiology Department, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Fu', 'firstname': 'Rongxia', 'initials': 'R', 'affiliation': 'Food science and Biological Engineering Department, Tianjin Agriculture University, Tianjin, China.'}, {'lastname': 'Deng', 'firstname': 'Yanqiu', 'initials': 'Y', 'affiliation': 'Pathophysiology Department, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. 1766464240@qq.com.\n, No. 22, Qi Xiang Tai Road, He Ping District, Tianjin, China. 1766464240@qq.com.'}]",,,,,10.1007/s11064-017-2250-8,<Element 'PubmedArticle' at 0x7f05d9c26c70>
169,"28372335
27739227
11306609
17692997
19188609
25107476
9443474
25492117
11992114
25869922
21911655
23507773
15306834
15642078
18030331
18259084
6610841
26206202
27558973
17942819
6496779
8919494
19156543
10860804
25834730
24548642
20424816
17881328
22718756
25659889
16936707",Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.,"Long acting insulin detemir administered intranasally for three weeks enhanced memory for adults with Alzheimer's disease dementia (AD) or amnestic mild cognitive impairment (MCI). The investigation of longer-term administration is necessary to determine whether benefits persist, whether they are similar to benefits provided by regular insulin, and whether either form of insulin therapy affects AD biomarkers.
The present study aimed to determine whether four months of treatment with intranasal insulin detemir or regular insulin improves cognition, daily functioning, and AD biomarkers for adults with MCI or AD.
This randomized, double-blind, placebo-controlled trial included an intent-to-treat sample consisting of 36 adults diagnosed with MCI or mild to moderate AD. Participants received placebo (n = 12), 40 IU of insulin detemir (n = 12), or 40 IU of regular insulin (n = 12) daily for four months, administered with a nasal delivery device. A cognitive battery was administered at baseline and after two and four months of treatment. MRI was administered for all participants and lumbar puncture for a subset (n = 20) at baseline and four months. The primary outcome was change from baseline to four months on a memory composite (sum of Z scores for delayed list and story recall). Secondary outcomes included: global cognition (Alzheimer's Disease Assessment Scale-Cognition), daily functioning (Dementia Severity Rating Scale), MRI volume changes in AD-related regions of interest, and cerebrospinal fluid AD markers.
The regular insulin treated group had better memory after two and four months compared with placebo (p < 0.03). No significant effects were observed for the detemir-assigned group compared with the placebo group, or for daily functioning for either group. Regular insulin treatment was associated with preserved volume on MRI. Regular insulin treatment was also associated with reduction in the tau-P181/Aβ42 ratio.
Future research is warranted to examine the mechanistic basis of treatment differences, and to further assess the efficacy and safety of intranasal insulin.","['Alzheimer’s disease', 'clinical trial', 'insulin', 'intranasal', 'magnetic resonance imaging', 'memory']",Journal of Alzheimer's disease : JAD,2017-04-05,"[{'lastname': 'Craft', 'firstname': 'Suzanne', 'initials': 'S', 'affiliation': 'Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'lastname': 'Claxton', 'firstname': 'Amy', 'initials': 'A', 'affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'lastname': 'Baker', 'firstname': 'Laura D', 'initials': 'LD', 'affiliation': 'Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'lastname': 'Hanson', 'firstname': 'Angela J', 'initials': 'AJ', 'affiliation': 'Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.'}, {'lastname': 'Cholerton', 'firstname': 'Brenna', 'initials': 'B', 'affiliation': 'Department of Pathology, Stanford University, Stanford, CA, USA.'}, {'lastname': 'Trittschuh', 'firstname': 'Emily H', 'initials': 'EH', 'affiliation': 'Department of Psychiatry & Behavioral Science, University of Washington School of Medicine, Seattle, WA, USA.\nGeriatric Research, Education, & Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.'}, {'lastname': 'Dahl', 'firstname': 'Deborah', 'initials': 'D', 'affiliation': 'Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'lastname': 'Caulder', 'firstname': 'Erin', 'initials': 'E', 'affiliation': 'Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'lastname': 'Neth', 'firstname': 'Bryan', 'initials': 'B', 'affiliation': 'Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'lastname': 'Montine', 'firstname': 'Thomas J', 'initials': 'TJ', 'affiliation': 'Department of Pathology, Stanford University, Stanford, CA, USA.'}, {'lastname': 'Jung', 'firstname': 'Youngkyoo', 'initials': 'Y', 'affiliation': 'Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.\nDepartment of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'lastname': 'Maldjian', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': 'Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'lastname': 'Whitlow', 'firstname': 'Christopher', 'initials': 'C', 'affiliation': 'Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.\nDepartment of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'lastname': 'Friedman', 'firstname': 'Seth', 'initials': 'S', 'affiliation': ""Seattle Children's Hospital, Seattle, WA, USA.""}]",,"Future research is warranted to examine the mechanistic basis of treatment differences, and to further assess the efficacy and safety of intranasal insulin.","The regular insulin treated group had better memory after two and four months compared with placebo (p < 0.03). No significant effects were observed for the detemir-assigned group compared with the placebo group, or for daily functioning for either group. Regular insulin treatment was associated with preserved volume on MRI. Regular insulin treatment was also associated with reduction in the tau-P181/Aβ42 ratio.",,10.3233/JAD-161256,<Element 'PubmedArticle' at 0x7f05d9c407c0>
170,"28349199
23128226
23990795
20157306
23587616
1759558
16906426
22002422
22607808
8093899
27368068
20966215
26715565
27411637
26812492
23651976
2863752
14602879
26250687
27314593
21166938
22082318
22265587
7810298
23380910
26354483
24005412
28003435
3137002
26669818
3897861
27649940
27016065
11389157
19261174
24754000
16462753
22908189
26667418
2011243
1349451
19718500
22744790
10443888
18551298
16507908
17325383
26413742
2862420
6801762
24274755
27812793
15305981
26268531
25195061
24857020
26844828
7108410
14504321
12084879
24612177
20858967
11476832
6277903",Amyloid-β accumulation in the CNS in human growth hormone recipients in the UK.,"Human-to-human transmission of Creutzfeldt-Jakob disease (CJD) has occurred through medical procedures resulting in iatrogenic CJD (iCJD). One of the commonest causes of iCJD was the use of human pituitary-derived growth hormone (hGH) to treat primary or secondary growth hormone deficiency. As part of a comprehensive tissue-based analysis of the largest cohort yet collected (35 cases) of UK hGH-iCJD cases, we describe the clinicopathological phenotype of hGH-iCJD in the UK. In the 33/35 hGH-iCJD cases with sufficient paraffin-embedded tissue for full pathological examination, we report the accumulation of the amyloid beta (Aβ) protein associated with Alzheimer's disease (AD) in the brains and cerebral blood vessels in 18/33 hGH-iCJD patients and for the first time in 5/12 hGH recipients who died from causes other than CJD. Aβ accumulation was markedly less prevalent in age-matched patients who died from sporadic CJD and variant CJD. These results are consistent with the hypothesis that Aβ, which can accumulate in the pituitary gland, was present in the inoculated hGH preparations and had a seeding effect in the brains of around 50% of all hGH recipients, producing an AD-like neuropathology and cerebral amyloid angiopathy (CAA), regardless of whether CJD neuropathology had occurred. These findings indicate that Aβ seeding can occur independently and in the absence of the abnormal prion protein in the human brain. Our findings provide further evidence for the prion-like seeding properties of Aβ and give insights into the possibility of iatrogenic transmission of AD and CAA.","['Amyloid β', 'Cerebral amyloid angiopathy', 'Human growth hormone', 'Iatrogenic Creutzfeldt–Jakob disease', 'Neuropathology', 'Prion protein']",Acta neuropathologica,2017-03-30,"[{'lastname': 'Ritchie', 'firstname': 'Diane L', 'initials': 'DL', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK. diane.ritchie@ed.ac.uk.'}, {'lastname': 'Adlard', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.'}, {'lastname': 'Peden', 'firstname': 'Alexander H', 'initials': 'AH', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.'}, {'lastname': 'Lowrie', 'firstname': 'Suzanne', 'initials': 'S', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.'}, {'lastname': 'Le Grice', 'firstname': 'Margaret', 'initials': 'M', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.'}, {'lastname': 'Burns', 'firstname': 'Kimberley', 'initials': 'K', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.'}, {'lastname': 'Jackson', 'firstname': 'Rosemary J', 'initials': 'RJ', 'affiliation': 'Centre for Cognitive and Neural Systems, University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.'}, {'lastname': 'Yull', 'firstname': 'Helen', 'initials': 'H', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.'}, {'lastname': 'Keogh', 'firstname': 'Michael J', 'initials': 'MJ', 'affiliation': 'Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.'}, {'lastname': 'Wei', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0XY, UK.'}, {'lastname': 'Chinnery', 'firstname': 'Patrick F', 'initials': 'PF', 'affiliation': 'MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0XY, UK.'}, {'lastname': 'Head', 'firstname': 'Mark W', 'initials': 'MW', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.'}, {'lastname': 'Ironside', 'firstname': 'James W', 'initials': 'JW', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.'}]",,,,,"10.1007/s00401-017-1703-0
10.1038/nature11632
10.1371/journal.pgen.1003685
10.1038/nrneurol.2010.4
10.1016/j.tracli.2013.02.029
10.1007/BF00308809
10.1007/s00401-006-0127-z
10.1097/NEN.0b013e318232a379
10.3201/eid1806.120116
10.1097/00005072-199301000-00008
10.7326/M15-2421
10.1126/science.1194516
10.1007/s00401-015-1516-y
10.1038/nature18602
10.1016/j.brainres.2013.04.052
10.1056/NEJM198509193131207
10.1056/NEJMoa030351
10.1126/science.1255555
10.1007/s00401-016-1588-3
10.1111/j.1440-1827.2010.02610.x
10.1111/j.1440-1789.2011.01273.x
10.1016/j.jalz.2011.10.007
10.1007/BF00293403
10.1001/jamaneurol.2013.1933
10.1038/nature15369
10.1038/nature12481
10.1101/gr.210609.116
10.1111/neup.12270
10.1056/NEJM198509193131206
10.1080/19336896.2016.1228507
10.1007/s00401-016-1565-x
10.1136/jmg.38.6.353
10.1186/gb-2009-10-3-r25
10.1038/nrmicro1346
10.1007/s00401-015-1515-z
10.1212/WNL.41.4.479
10.1007/BF00713522
10.1007/s00401-009-0585-1
10.1007/s00401-012-1002-8
10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W
10.1007/s00401-008-0394-y
10.2353/ajpath.2006.050788
10.1099/vir.0.81913-0
10.1097/WNN.0000000000000071
10.1016/S0140-6736(85)90292-2
10.1126/science.6801762
10.1146/annurev-genet-110711-155524
10.1007/s00401-016-1638-x
10.1111/j.1365-2990.2003.00544.x
10.1093/brain/awv235
10.1007/s00401-014-1340-9
10.1016/j.neuron.2014.04.047
10.1016/j.neuron.2016.01.026
10.1677/joe.0.0940203
10.1212/01.WNL.0000084000.27403.15
10.1212/WNL.58.12.1791
10.1111/neup.12108
10.3233/JAD-2010-100843
10.1016/S0140-6736(01)05403-4",<Element 'PubmedArticle' at 0x7f05d9c5de50>
171,28342971,A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model.,"Alzheimer's disease (AD) is a progressive neurodegenerative disorder, accompanied by memory loss and cognitive impairments, and there is no effective treatment for it at present. Since type 2 diabetes (T2DM) has been identified as a risk factor for AD, the incretins glucagon-like peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP), promising antidiabetic agents for the treatment of type 2 diabetes, have been tested in models of neurodegenerative disease including AD and achieved good results. Here we show for the first time the potential neuroprotective effect of a novel dual GLP-1/GIP receptor agonist (DA-JC4) in the icv. streptozotocin (STZ)-induced AD rat model. Treatment with DA-JC4 (10nmol/kg ip.) once-daily for 14days after STZ intracerebroventricular (ICV) administration significantly prevented spatial learning deficits in a Y- maze test and Morris water maze tests, and decreased phosphorylated tau levels in the rat cerebral cortex and hippocampus. DA-JC4 also alleviated the chronic inflammation response in the brain (GFAP-positive astrocytes, IBA1-positive microglia). Apoptosis was reduced as shown in the reduced ratio of pro-apoptotic BAX to anti- apoptotic Bcl-2 levels. Importantly, insulin signaling was re-sensitized as evidenced by a reduction of phospho-IRS1","['Alzheimer’s disease', 'Apoptosis', 'Incretin', 'Inflammation', 'Insulin signaling', 'Tau phosphorylation', 'Type 2 diabetes mellitus']",Behavioural brain research,2017-03-28,"[{'lastname': 'Shi', 'firstname': 'Lijuan', 'initials': 'L', 'affiliation': 'Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, PR China.'}, {'lastname': 'Zhang', 'firstname': 'Zhihua', 'initials': 'Z', 'affiliation': 'Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, PR China.'}, {'lastname': 'Li', 'firstname': 'Lin', 'initials': 'L', 'affiliation': 'Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, PR China. Electronic address: linlilin999@163.com.'}, {'lastname': 'Hölscher', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Biomedical and Life Science, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK; Neurology Department, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, PR China.'}]",,,,Copyright © 2017 Elsevier B.V. All rights reserved.,10.1016/j.bbr.2017.03.032,<Element 'PubmedArticle' at 0x7f05d9c177c0>
172,"28225806
22674539
3088567
3084478
1549228
9005861
26681727
22389813
25479064
21598254
18479783
22936005
9349813
24951385
10725386
26686003
26403087
19285736
23340038
25411593
2039598
25849380
22664955
3899825
24652456
21047779
22718609
16519507
21985169
26431291
25030513
23023032
19798065
15358238
25888600
15611784
23179202
21840335
12130773
26007212
20450234
22329651
25755673
26459162
27918554
24405299",Capsaicin reduces Alzheimer-associated tau changes in the hippocampus of type 2 diabetes rats.,"Type 2 diabetes (T2D) is a high-risk factor for Alzheimer's disease (AD) due to impaired insulin signaling pathway in brain. Capsaicin is a specific transient receptor potential vanilloid 1 (TRPV1) agonist which was proved to ameliorate insulin resistance. In this study, we investigated whether dietary capsaicin could reduce the risk of AD in T2D. T2D rats were fed with capsaicin-containing high fat (HF) diet for 10 consecutive days (T2D+CAP). Pair-fed T2D rats (T2D+PF) fed with the HF-diet of average dose of T2D+CAP group were included to control for the effects of reduced food intake and body weight. Capsaicin-containing standard chow was also introduced to non-diabetic rats (NC+CAP). Blood glucose and insulin were monitored. The phosphorylation level of tau at individual sites, the activities of phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) and glycogen synthase kinase-3β (GSK-3β) were analyzed by Western blots. The results revealed that the levels of phosphorylated tau protein at sites Ser199, Ser202 and Ser396 in hippocampus of T2D+CAP group were decreased significantly, but these phospho-sites in T2D+PF group didn't show such improvements compared with T2D group. There were almost no changes in non-diabetic rats on capsaicin diet (NC+CAP) compared with the non-diabetic rats with normal chow (NC). Increased activity of PI3K/AKT and decreased activity of GSK-3β were detected in hippocampus of T2D+CAP group compared with T2D group, and these changes did not show in T2D+PF group either. These results demonstrated that dietary capsaicin appears to prevent the hyperphosphorylation of AD-associated tau protein by increasing the activity of PI3K/AKT and inhibiting GSK-3β in hippocampus of T2D rats, which supported that dietary capsaicin might have a potential use for the prevention of AD in T2D.",[],PloS one,2017-02-23,"[{'lastname': 'Xu', 'firstname': 'Weijie', 'initials': 'W', 'affiliation': 'Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'lastname': 'Liu', 'firstname': 'Juanhong', 'initials': 'J', 'affiliation': 'Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'lastname': 'Ma', 'firstname': 'Delin', 'initials': 'D', 'affiliation': 'Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'lastname': 'Yuan', 'firstname': 'Gang', 'initials': 'G', 'affiliation': 'Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'lastname': 'Lu', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'lastname': 'Yang', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}]",,,,,"10.1371/journal.pone.0172477
10.1002/gps.3829
10.1002/ana.410410106
10.2337/dc15-1588
10.5402/2011/306905
10.1097/JIM.0000000000000129
10.1002/path.2912
10.1016/j.neurobiolaging.2008.04.002
10.3233/JAD-2012-121294
10.1038/39807
10.1124/pr.113.008268
10.1073/pnas.060496197
10.1007/s00281-015-0529-x
10.1016/j.tins.2008.12.006
10.3233/JAD-121837
10.1111/jdi.12235
10.1080/10408399109527536
10.1186/s12933-015-0183-6
10.2337/db11-1503
10.1007/s12264-013-1408-x
10.1074/jbc.M110.170704
10.1021/bi051634r
10.2165/11595870-000000000-00000
10.1111/1753-0407.12345
10.1016/S1474-4422(14)70136-X
10.1124/pr.112.006163
10.1016/j.bbrc.2004.06.149
10.1096/fj.14-268300
10.1007/s00394-012-0463-9
10.1016/j.mam.2011.07.001
10.1126/science.1072994
10.1038/nn.4017
10.2165/11536110-000000000-00000
10.2174/156720512799015037
10.1111/pcmr.12430
10.1042/BJ20131176",<Element 'PubmedArticle' at 0x7f05d9ba8450>
173,"28205591
25352419
23400634
22886562
17296232
26097723
10506509
24605807
12168556
21040844
22133276
22314218
18698331
20731763
26122962
25446575
24846612
24508637
20965156
17379265
16310963
18677155
26891883
26627258
25423896
24815952
22079780
9347981
24904307
15917746
26161867
24431989
9185530
1613547
24267647
26756439
24622829
24382885
22516877
26562682
25512503
18284372
25980457
25673833
18297067
25926772
23276632
24594140
20479872
20114038
19123057
26607074
8282823
10359841
23536494
18976694
23483801
20619320
20062809
25532911
25505884
21808025
20830300
6471907
26538645
24595328
21867737",Protective Effect of 17β-Estradiol Upon Hippocampal Spine Density and Cognitive Function in an Animal Model of Vascular Dementia.,"The current study examined whether the steroid hormone, 17β-estradiol (E2) can exert long-lasting beneficial effects upon axonal health, synaptic plasticity, dementia-related amyloid-beta (Aβ) protein expression, and hippocampal-dependent cognitive function in an animal model of chronic cerebral hypoperfusion and vascular dementia (VaD). Chronic cerebral hypoperfusion and VaD was induced by bilateral common carotid artery occlusion (BCCAO) in adult male Sprague Dawley rats. Low dose E2 administered for the first 3-months after BCCAO exerted long-lasting beneficial effects, including significant neuroprotection of hippocampal CA1 neurons and preservation of hippocampal-dependent cognitive function when examined at 6-months after BCCAO. E2 treatment also prevented BCCAO-induced damage to hippocampal myelin sheaths and oligodendrocytes, enhanced expression of the synaptic proteins synaptophysin and PSD95 in the hippocampus, and prevented BCCAO-induced loss of total and mushroom dendritic spines in the hippocampal CA1 region. Furthermore, E2-treatment also reduced BCCAO induction of dementia-related proteins expression such as p-tau (PHF1), total ubiquitin, and Aβ1-42, when examined at 6 m after BCCAO. Taken as a whole, the results suggest that low-dose E2 replacement might be a potentially promising therapeutic modality to attenuate or block negative neurological consequences of chronic cerebral hypoperfusion and VaD.",[],Scientific reports,2017-02-17,"[{'lastname': 'Zhu', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': 'Neurobiology Institute of Medical Research Center, International Science &Technology Cooperation Base of Geriatric Medicine, North China University of Science and Technology, Tangshan 063000, China.'}, {'lastname': 'Zhang', 'firstname': 'Quanguang', 'initials': 'Q', 'affiliation': 'Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta 30912, USA.'}, {'lastname': 'Zhang', 'firstname': 'Wenli', 'initials': 'W', 'affiliation': 'Neurobiology Institute of Medical Research Center, International Science &Technology Cooperation Base of Geriatric Medicine, North China University of Science and Technology, Tangshan 063000, China.'}, {'lastname': 'Li', 'firstname': 'Ning', 'initials': 'N', 'affiliation': 'Neurobiology Institute of Medical Research Center, International Science &Technology Cooperation Base of Geriatric Medicine, North China University of Science and Technology, Tangshan 063000, China.'}, {'lastname': 'Dai', 'firstname': 'Yongxin', 'initials': 'Y', 'affiliation': 'Neurobiology Institute of Medical Research Center, International Science &Technology Cooperation Base of Geriatric Medicine, North China University of Science and Technology, Tangshan 063000, China.'}, {'lastname': 'Tu', 'firstname': 'Jingyi', 'initials': 'J', 'affiliation': 'Neurobiology Institute of Medical Research Center, International Science &Technology Cooperation Base of Geriatric Medicine, North China University of Science and Technology, Tangshan 063000, China.'}, {'lastname': 'Yang', 'firstname': 'Fang', 'initials': 'F', 'affiliation': 'Neurobiology Institute of Medical Research Center, International Science &Technology Cooperation Base of Geriatric Medicine, North China University of Science and Technology, Tangshan 063000, China.'}, {'lastname': 'Brann', 'firstname': 'Darrell W', 'initials': 'DW', 'affiliation': 'Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta 30912, USA.'}, {'lastname': 'Wang', 'firstname': 'Ruimin', 'initials': 'R', 'affiliation': 'Neurobiology Institute of Medical Research Center, International Science &Technology Cooperation Base of Geriatric Medicine, North China University of Science and Technology, Tangshan 063000, China.'}]",,,,,"10.1038/srep42660
10.1007/s10571-014-0127-9
10.1007/s12640-013-9379-2
10.1007/s11064-012-0854-6
10.1016/j.brainresrev.2007.01.003
10.12703/P7-50
10.1006/exnr.1999.7183
10.1111/joim.12178
10.1016/j.neuron.2010.09.043
10.1016/j.neurobiolaging.2011.10.033
10.1016/j.ejphar.2012.01.025
10.1038/jcbfm.2008.91
10.1111/j.1471-4159.2010.06958.x
10.5603/FHC.a2015.0012
10.1016/j.neuropharm.2014.10.019
10.1016/j.neuroscience.2014.05.003
10.1016/j.mce.2013.12.019
10.1016/j.brainres.2010.10.031
10.1016/j.steroids.2007.02.003
10.1097/GRF.0b013e318180ba10
10.1016/j.pneurobio.2015.12.008
10.1073/pnas.1516729112
10.1038/nrn3856
10.1016/j.jsbmb.2014.05.001
10.1016/j.yfrne.2011.10.001
10.3171/jns.1997.87.5.0724
10.3389/fnana.2014.00038
10.1038/sj.jcbfm.9600153
10.1371/journal.pone.0132637
10.3389/fncel.2013.00284
10.1016/j.neuron.2013.10.008
10.1016/j.bbr.2015.12.047
10.1152/physrev.00012.2013
10.1016/j.bandc.2012.03.002
10.1016/j.neubiorev.2015.09.020
10.1073/pnas.1421285111
10.1146/annurev.neuro.31.060407.125646
10.1002/hipo.22475
10.1523/JNEUROSCI.1298-14.2015
10.1038/nn2057
10.3389/fncel.2015.00137
10.1016/j.steroids.2012.12.005
10.1016/j.mce.2014.01.024
10.1371/journal.pone.0009851
10.1016/j.brainres.2010.01.046
10.1007/s11064-008-9899-y
10.1155/2016/3816256
10.1172/JCI116985
10.1002/hipo.22126
10.1016/j.neuroscience.2008.10.003
10.1007/s12975-012-0211-8
10.1016/j.neuroscience.2010.06.076
10.1371/journal.pone.0008642
10.1038/srep07564
10.3389/fnagi.2014.00322
10.1073/pnas.1104391108
10.1371/journal.pone.0012606
10.1523/JNEUROSCI.1304-15.2015
10.1093/alcalc/agu009
10.1016/j.neuint.2011.08.008",<Element 'PubmedArticle' at 0x7f05d9bc6d10>
174,"28189700
17485268
27079753
17195931
17469117
25988319
25188341
24270205
24270205
21891865
22859297
23342160
20197700
20197700
19625741
22505994
22820512
26782335
19822868
23089745
22890097
26194312
18087705
12117357
24094581
22101365
26682689
24446231
24899141
8078890
19021630
24770881
21596774
23864344
26597697
17023659
24743097
21346515
20042704
18192287
18723524
22855871
21311900
8929997
25239657
22420316
24080705
15857407
22950047",CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN.,"Hippocampal sclerosis of aging (HS-Aging) is a common cause of dementia in older adults. We tested the variability in cerebrospinal fluid (CSF) proteins associated with previously identified HS-Aging risk single nucleotide polymorphisms (SNPs).
Alzheimer's Disease Neuroimaging Initiative cohort (ADNI; n=237) data, combining both multiplexed proteomics CSF and genotype data, were used to assess the association between CSF analytes and risk SNPs in four genes (SNPs): GRN (rs5848), TMEM106B (rs1990622), ABCC9 (rs704180), and KCNMB2 (rs9637454). For controls, non-HS-Aging SNPs in APOE (rs429358/rs7412) and MAPT (rs8070723) were also analyzed against Aβ1-42 and total tau CSF analytes.
The GRN risk SNP (rs5848) status correlated with variation in CSF proteins, with the risk allele (T) associated with increased levels of AXL Receptor Tyrosine Kinase (AXL), TNF-Related Apoptosis-Inducing Ligand Receptor 3 (TRAIL-R3), Vascular Cell Adhesion Molecule-1 (VCAM-1) and clusterin (CLU) (all p<0.05 after Bonferroni correction). The TRAIL-R3 correlation was significant in meta-analysis with an additional dataset (p=5.05×10","['Biomarkers', 'Clusterin', 'Granulin', 'Neuroinflammation', 'Progranulin', 'Proteomics']",Experimental gerontology,2017-02-13,"[{'lastname': 'Fardo', 'firstname': 'David W', 'initials': 'DW', 'affiliation': 'Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA; Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY, USA. Electronic address: david.fardo@uky.edu.'}, {'lastname': 'Katsumata', 'firstname': 'Yuriko', 'initials': 'Y', 'affiliation': 'Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA; Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY, USA.'}, {'lastname': 'Kauwe', 'firstname': 'John S K', 'initials': 'JSK', 'affiliation': 'Department of Biology, BYU, Provo, UT, USA.'}, {'lastname': 'Deming', 'firstname': 'Yuetiva', 'initials': 'Y', 'affiliation': 'Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.'}, {'lastname': 'Harari', 'firstname': 'Oscar', 'initials': 'O', 'affiliation': 'Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.'}, {'lastname': 'Cruchaga', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': 'Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': 'Nelson', 'firstname': 'Peter T', 'initials': 'PT', 'affiliation': 'Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA; Department of Pathology, College of Medicine, University of Kentucky, Lexington, KY, USA.'}]",,,"The GRN risk SNP (rs5848) status correlated with variation in CSF proteins, with the risk allele (T) associated with increased levels of AXL Receptor Tyrosine Kinase (AXL), TNF-Related Apoptosis-Inducing Ligand Receptor 3 (TRAIL-R3), Vascular Cell Adhesion Molecule-1 (VCAM-1) and clusterin (CLU) (all p<0.05 after Bonferroni correction). The TRAIL-R3 correlation was significant in meta-analysis with an additional dataset (p=5.05×10",Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.exger.2017.01.025,<Element 'PubmedArticle' at 0x7f05d9b78ea0>
175,28178614,Geraniol alleviates diabetic cardiac complications: Effect on cardiac ischemia and oxidative stress.,"The present study was planned to assess the possible protective effect of geraniol on cardiovascular complications in an animal model with diabetes. Diabetes was induced in rats by a single streptozotocin injection. In the treated group, geraniol (150mgkg","['Cardioprotective', 'Cardiovascular complications', 'Diabetes', 'Electrocardiogram', 'Geraniol', 'Heart', 'Hemodynamics']",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2017-02-09,"[{'lastname': 'El-Bassossy', 'firstname': 'Hany M', 'initials': 'HM', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmacology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.'}, {'lastname': 'Ghaleb', 'firstname': 'Hanna', 'initials': 'H', 'affiliation': 'Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Saudi Arabia.'}, {'lastname': 'Elberry', 'firstname': 'Ahmed A', 'initials': 'AA', 'affiliation': 'Department of Pharmacology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt. Electronic address: berry_ahmed@yahoo.com.'}, {'lastname': 'Balamash', 'firstname': 'Khadijah S', 'initials': 'KS', 'affiliation': 'Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Saudi Arabia.'}, {'lastname': 'Ghareib', 'firstname': 'Salah A', 'initials': 'SA', 'affiliation': 'Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Saudi Arabia; Department of Pharmacology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.'}, {'lastname': 'Azhar', 'firstname': 'Ahmad', 'initials': 'A', 'affiliation': 'Department of Pediatric Cardiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.'}, {'lastname': 'Banjar', 'firstname': 'Zainy', 'initials': 'Z', 'affiliation': 'Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.'}]",,,,Copyright © 2017 Elsevier Masson SAS. All rights reserved.,10.1016/j.biopha.2017.01.131,<Element 'PubmedArticle' at 0x7f05d9b24540>
176,28147245,Angiotensin-(1-7) administration attenuates Alzheimer's disease-like neuropathology in rats with streptozotocin-induced diabetes via Mas receptor activation.,"Diabetes mellitus (DM) is associated with cognitive deficits and an increased risk of Alzheimer's disease (AD). Recently, a newly identified heptapeptide of the renin-angiotensin system (RAS), angiotensin-(1-7) [Ang-(1-7)], was found to protect against brain damage. This study investigated the effects of Ang-(1-7) on diabetes-induced cognitive deficits. Sprague-Dawley rats were randomly divided into four groups. Diabetes was induced via single i.p. streptozotocin (STZ) injections. Ten weeks after diabetes induction, rats in each group received an intracerebral-ventricular (ICV) infusion of either vehicle, Ang-(1-7) alone, or Ang-(1-7)+A779 daily for two weeks. At the end of the study, Morris water maze (MWM) tests were performed to test cognitive functions before the rats were euthanized. Ang-(1-7) treatment significantly reduced escape latencies in diabetic rats in acquisition trials and markedly enhanced platform area crossing frequency and time spent in the target quadrant in probe trials (3.0±0.39 vs. 1.0±0.33, 39.39±1.11% vs. 25.62±3.07%, respectively, P<0.01). Ang-(1-7) treatment ameliorated damage to the ultrastructure of hippocampal synapses, reduced the expression of hippocampal phospho-tau at Ser396 (P<0.01), Ser404 (P<0.01) and Ser202/Thr205 (P<0.05), and decreased amyloid-β oligomer and both soluble and insoluble β-amyloid peptide 1-42 (Aβ 1-42) and Aβ 1-40 levels (P<0.01). These protective effects were significantly reversed by the co-administration of A779. These findings show that Ang-(1-7) is a promising therapeutic target for diabetes-induced cognitive impairment. The neuroprotective effects of Ang-(1-7) were mainly through Mas receptor (MasR) activation.","['Alzheimer’s disease', 'amyloid-β', 'angiotensin-(1–7)', 'diabetes mellitus', 'tau']",Neuroscience,2017-02-02,"[{'lastname': 'Chen', 'firstname': 'Jin-Liang', 'initials': 'JL', 'affiliation': 'Department of Geriatrics, the First Affiliated Hospital of Chongqing Medical University, Friendship Road 1, Yuan Jiagang, 400016 Chongqing, China.'}, {'lastname': 'Zhang', 'firstname': 'Dong-Ling', 'initials': 'DL', 'affiliation': 'Department of Geriatrics, the First Affiliated Hospital of Chongqing Medical University, Friendship Road 1, Yuan Jiagang, 400016 Chongqing, China.'}, {'lastname': 'Sun', 'firstname': 'Yue', 'initials': 'Y', 'affiliation': 'Department of Geriatrics, the First Affiliated Hospital of Chongqing Medical University, Friendship Road 1, Yuan Jiagang, 400016 Chongqing, China.'}, {'lastname': 'Zhao', 'firstname': 'Yu-Xing', 'initials': 'YX', 'affiliation': 'Department of Geriatrics, the First Affiliated Hospital of Chongqing Medical University, Friendship Road 1, Yuan Jiagang, 400016 Chongqing, China.'}, {'lastname': 'Zhao', 'firstname': 'Ke-Xiang', 'initials': 'KX', 'affiliation': 'Department of Geriatrics, the First Affiliated Hospital of Chongqing Medical University, Friendship Road 1, Yuan Jiagang, 400016 Chongqing, China.'}, {'lastname': 'Pu', 'firstname': 'Die', 'initials': 'D', 'affiliation': 'Department of Geriatrics, the First Affiliated Hospital of Chongqing Medical University, Friendship Road 1, Yuan Jiagang, 400016 Chongqing, China.'}, {'lastname': 'Xiao', 'firstname': 'Qian', 'initials': 'Q', 'affiliation': 'Department of Geriatrics, the First Affiliated Hospital of Chongqing Medical University, Friendship Road 1, Yuan Jiagang, 400016 Chongqing, China. Electronic address: xiaoqian1956@126.com.'}]",,,,Copyright © 2017 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2017.01.027,<Element 'PubmedArticle' at 0x7f05d9b31d10>
177,28093241,New isatin derivative inhibits neurodegeneration by restoring insulin signaling in brain.,"Diabetes is associated with neurodegeneration. Glycation ensues in diabetes and glycated proteins cause insulin resistance in brain resulting in amyloid plaques and NFTs. Also glycation enhances gliosis by promoting neuroinflammation. Currently there is no therapy available to target neurodegenration in brain therefore, development of new therapy that offers neuroprotection is critical. The objective of this study was to evaluate mechanistic effect of isatin derivative URM-II-81, an anti-glycation agent for improvement of insulin action in brain and inhibition of neurodegenration. Methylglyoxal induced stress was inhibited by treatment with URM-II-81. Also, Ser473 and Ser9 phosphorylation of Akt and GSK-3β respectively were restored by URM-II-81. Effect of URM-II-81 on axonal integrity was studied by differentiating Neuro2A using retinoic acid. URM-II-81 restored axonal length in MGO treated cells. Its effects were also studied in high fat and low dose streptozotocin induced diabetic mice where it reduced RBG levels and inhibited glycative stress by reducing HbA1c. URM-II-81 treatment also showed inhibition of gliosis in hippocampus. Histological analysis showed reduced NFTs in CA3 hippocampal region and restoration of insulin signaling in hippocampii of diabetic mice. Our findings suggest that URM-II-81 can be developed as a new therapeutic agent for treatment of neurodegenration.","['Gliosis', 'Neurodegenration', 'Neurofibrillary tangles', 'Schiff base', 'Tau']",Journal of chemical neuroanatomy,2017-01-18,"[{'lastname': 'Aftab', 'firstname': 'Meha Fatima', 'initials': 'MF', 'affiliation': 'Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270 Pakistan.'}, {'lastname': 'Afridi', 'firstname': 'Shabbir Khan', 'initials': 'SK', 'affiliation': 'Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270 Pakistan.'}, {'lastname': 'Mughal', 'firstname': 'Uzma Rasool', 'initials': 'UR', 'affiliation': 'H.E.J Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270 Pakistan.'}, {'lastname': 'Karim', 'firstname': 'Aneela', 'initials': 'A', 'affiliation': 'H.E.J Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270 Pakistan.'}, {'lastname': 'Haleem', 'firstname': 'Darakhshan Jabeen', 'initials': 'DJ', 'affiliation': 'Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270 Pakistan.'}, {'lastname': 'Kabir', 'firstname': 'Nurul', 'initials': 'N', 'affiliation': 'University of Malaya, Institute of Biological Sciences, Kuala Lumpur 50603, Malaysia.'}, {'lastname': 'Khan', 'firstname': 'Khalid M', 'initials': 'KM', 'affiliation': 'H.E.J Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270 Pakistan.'}, {'lastname': 'Hafizur', 'firstname': 'Rahman M', 'initials': 'RM', 'affiliation': 'Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270 Pakistan.'}, {'lastname': 'Waraich', 'firstname': 'Rizwana S', 'initials': 'RS', 'affiliation': 'Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270 Pakistan. Electronic address: rizwanas.waraich@gmail.com.'}]",,,,Copyright © 2017 Elsevier B.V. All rights reserved.,10.1016/j.jchemneu.2017.01.001,<Element 'PubmedArticle' at 0x7f05d9b3f900>
178,"27893415
19282026
24319572
19539211
25987657
22863728
20371463
18832652
22286196
25377785
22383800
25585275
26687425
17934526
23527487
27476448
15477419
10606983
16508993
16865225
18596636
24039869
18978736
16449522
19443659
24060373
21558065
8442093
7809932
19968561
25679762
20208538
23924003
14515272
16546701
25049357
16840729
20119647
11445697
15878974
12931120
27403536
20388871
21383686
21979939
18941203
10931803",Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.,"Acute Graft-versus-Host Disease (GvHD) remains a major complication of allogeneic haematopoietic stem cell transplantation, with a significant proportion of patients failing to respond to first-line systemic corticosteroids. Reliable biomarkers predicting disease severity and response to treatment are warranted to improve its management. Thus, we sought to determine whether pentraxin 3 (PTX3), an acute-phase protein produced locally at the site of inflammation, could represent a novel acute GvHD biomarker. Using a murine model of the disease, we found increased PTX3 plasma levels after irradiation and at GvHD onset. Similarly, plasma PTX3 was enhanced in 115 pediatric patients on day of transplantation, likely due to conditioning, and at GvHD onset in patients experiencing clinical symptoms of the disease. PTX3 was also found increased in skin and colon biopsies from patients with active disease. Furthermore, PTX3 plasma levels at GvHD onset were predictive of disease outcome since they resulted significantly higher in both severe and therapy-unresponsive patients. Multiple injections of rhPTX3 in the murine model of GvHD did not influence the disease course. Taken together, our results indicate that PTX3 constitutes a biomarker of GvHD severity and therapy response useful to tailor treatment intensity according to early risk-stratification of GvHD patients.","['Immune response', 'Immunity', 'Immunology and Microbiology Section', 'acute graft-versus-host disease', 'biomarkers', 'hematology', 'pediatric haematopoietic stem cell transplantation', 'pentraxin 3 (PTX3)']",Oncotarget,2016-11-29,"[{'lastname': 'Dander', 'firstname': 'Erica', 'initials': 'E', 'affiliation': '""M. Tettamanti"" Research Center, Pediatric Department, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': 'De Lorenzo', 'firstname': 'Paola', 'initials': 'P', 'affiliation': 'Center of Biostatistics for Clinical Epidemiology, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': 'Bottazzi', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Humanitas Clinical and Research Center, Rozzano, Italy.'}, {'lastname': 'Quarello', 'firstname': 'Paola', 'initials': 'P', 'affiliation': ""Pediatric Onco-Haematology, City of Science and Health of Turin, Regina Margherita Children's Hospital, Torino, Italy.""}, {'lastname': 'Vinci', 'firstname': 'Paola', 'initials': 'P', 'affiliation': '""M. Tettamanti"" Research Center, Pediatric Department, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': 'Balduzzi', 'firstname': 'Adriana', 'initials': 'A', 'affiliation': 'Clinica Pediatrica Ospedale S. Gerardo, Fondazione MBBM, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': 'Masciocchi', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': 'Clinica Pediatrica Ospedale S. Gerardo, Fondazione MBBM, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': 'Bonanomi', 'firstname': 'Sonia', 'initials': 'S', 'affiliation': 'Clinica Pediatrica Ospedale S. Gerardo, Fondazione MBBM, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': 'Cappuzzello', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': '""M. Tettamanti"" Research Center, Pediatric Department, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': 'Prunotto', 'firstname': 'Giulia', 'initials': 'G', 'affiliation': 'Clinica Pediatrica Ospedale S. Gerardo, Fondazione MBBM, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': 'Pavan', 'firstname': 'Fabio', 'initials': 'F', 'affiliation': 'Clinica Pediatrica Ospedale S. Gerardo, Fondazione MBBM, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': 'Pasqualini', 'firstname': 'Fabio', 'initials': 'F', 'affiliation': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Humanitas Clinical and Research Center, Rozzano, Italy.'}, {'lastname': 'Sironi', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Humanitas Clinical and Research Center, Rozzano, Italy.'}, {'lastname': 'Cuccovillo', 'firstname': 'Ivan', 'initials': 'I', 'affiliation': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Humanitas Clinical and Research Center, Rozzano, Italy.'}, {'lastname': 'Leone', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Humanitas Clinical and Research Center, Rozzano, Italy.'}, {'lastname': 'Salvatori', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'Sigma-tau S.p.A., Department of R&D, Biotechnology, San Gerardo Hospital, Monza, Italy.'}, {'lastname': 'Parma', 'firstname': 'Matteo', 'initials': 'M', 'affiliation': 'Haematology Division and BMT Unit, San Gerardo Hospital, Monza, Italy.'}, {'lastname': 'Terruzzi', 'firstname': 'Elisabetta', 'initials': 'E', 'affiliation': 'Haematology Division and BMT Unit, San Gerardo Hospital, Monza, Italy.'}, {'lastname': 'Pagni', 'firstname': 'Fabio', 'initials': 'F', 'affiliation': 'Department of Surgery and Interdisciplinary Medicine, University Milano-Bicocca, Section of Pathology, San Gerardo Hospital, Monza, Italy.'}, {'lastname': 'Locatelli', 'firstname': 'Franco', 'initials': 'F', 'affiliation': 'Department of Pediatric Haematology-Oncology, IRCCS, Bambino Gesù Children Hospital, Roma-Department of Pediatric Science, University of Pavia, Pavia, Italy.'}, {'lastname': 'Mantovani', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Humanitas Clinical and Research Center, Rozzano, Italy.\nHumanitas University, Rozzano, Italy.'}, {'lastname': 'Fagioli', 'firstname': 'Franca', 'initials': 'F', 'affiliation': ""Pediatric Onco-Haematology, City of Science and Health of Turin, Regina Margherita Children's Hospital, Torino, Italy.""}, {'lastname': 'Biondi', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': '""M. Tettamanti"" Research Center, Pediatric Department, University of Milano-Bicocca, Monza, Italy.\nClinica Pediatrica Ospedale S. Gerardo, Fondazione MBBM, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': 'Garlanda', 'firstname': 'Cecilia', 'initials': 'C', 'affiliation': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Humanitas Clinical and Research Center, Rozzano, Italy.'}, {'lastname': 'Valsecchi', 'firstname': 'Maria Grazia', 'initials': 'MG', 'affiliation': 'Center of Biostatistics for Clinical Epidemiology, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': 'Rovelli', 'firstname': 'Attilio', 'initials': 'A', 'affiliation': 'Clinica Pediatrica Ospedale S. Gerardo, Fondazione MBBM, University of Milano-Bicocca, Monza, Italy.'}, {'lastname': ""D'Amico"", 'firstname': 'Giovanna', 'initials': 'G', 'affiliation': '""M. Tettamanti"" Research Center, Pediatric Department, University of Milano-Bicocca, Monza, Italy.'}]",,,,,"10.18632/oncotarget.13488
10.1016/S0140-6736(09)60237-3
10.1177/2040620713489842
10.1016/j.bbmt.2008.03.012
10.1182/blood-2015-03-636753
10.1038/bmt.2012.143
10.1126/scitranslmed.3000406
10.1182/blood-2008-07-167098
10.1182/blood-2011-10-387357
10.1182/blood-2014-06-584789
10.1182/blood-2012-01-403063
10.1016/j.bbmt.2015.01.001
10.1016/S2352-3026(14)00035-0
10.1038/sj.bmt.1705885
10.1111/nyas.12043
10.1016/j.semcdb.2016.07.026
10.1161/01.CIR.0000145167.30987.2E
10.1046/j.1365-2249.2000.01110.x
10.1002/art.21669
10.3892/ijmm.18.3.415
10.1097/CCM.0b013e3181809aaf
10.1371/journal.pone.0073119
10.1038/bmt.2008.294
10.1182/blood-2005-12-4851
10.1182/blood-2009-03-212290
10.1186/1479-5876-11-223
10.1242/dmm.006668
10.1016/j.bbmt.2012.11.076
10.1146/annurev-immunol-030409-101305
10.1016/j.cell.2015.01.004
10.1038/ni.1854
10.1056/NEJMoa1213299
10.1002/eji.200324390
10.1016/j.intimp.2005.08.027
10.4049/jimmunol.1400814
10.1182/blood-2006-03-009266
10.1007/s00134-010-1752-5
10.1097/00003246-200107000-00017
10.1182/blood-2004-11-4557
10.1016/S1083-8791(03)00162-9
10.1016/j.exphem.2016.07.002
10.1182/blood-2009-12-258442
10.1038/bmt.2011.41
10.1182/blood-2011-08-375006
10.4049/jimmunol.181.9.6132
10.1161/01.CIR.102.6.636",<Element 'PubmedArticle' at 0x7f05d9b4cf90>
179,"27884212
19796831
21297982
22982863
17973905
19956428
20370487
21593435
24807206
19635982
17965777
20627092
21709373
9802273
20068258
12742805
21929736
9916793
17192785
14872014
12668609
16033878
17998437
10969042
10924499
15141377
16946085
16176966
12075344
20424953
19014390
21178125
23997755
18310257
21685445
22817481
19136547
24823497
23562443
26044748
22101365
21139807
20175777
8710076
12787320
17502555
19240967
12960780
1674030
7654074
21777652
22535332
18385968
26793405
18263657
11815627
16055515
10967201
12829792
15950155
22067210
19923158
24440367
24814023
23800077
19124678
16810285
20375118
18497476
24599018
21952934
20093667
22025374
18258853
7706234",Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-β and tau pathology.,"Hyperactivity of the classical axis of the renin-angiotensin system (RAS), mediated by angiotensin II (Ang II) activation of the angiotensin II type 1 receptor (AT1R), is implicated in the pathogenesis of Alzheimer's disease (AD). Angiotensin-converting enzyme-2 (ACE-2) degrades Ang II to angiotensin 1-7 (Ang ﻿﻿(1-7)) and counter-regulates the classical axis of RAS. We have investigated the expression and distribution of ACE-2 in post-mortem human brain tissue in relation to AD pathology and classical RAS axis activity.
We measured ACE-2 activity by fluorogenic peptide substrate assay in mid-frontal cortex (Brodmann area 9) in a cohort of AD (n = 90) and age-matched non-demented controls (n = 59) for which we have previous data on ACE-1 activity, amyloid β (Aβ) level and tau pathology, as well as known ACE1 (rs1799752) indel polymorphism, apolipoprotein E (APOE) genotype, and cerebral amyloid angiopathy severity scores.
ACE-2 activity was significantly reduced in AD compared with age-matched controls (P < 0.0001) and correlated inversely with levels of Aβ (r = -0.267, P < 0.001) and phosphorylated tau (p-tau) pathology (r = -0.327, P < 0.01). ACE-2 was reduced in individuals possessing an APOE ε4 allele (P < 0.05) and was associated with ACE1 indel polymorphism (P < 0.05), with lower ACE-2 activity in individuals homozygous for the ACE1 insertion AD risk allele. ACE-2 activity correlated inversely with ACE-1 activity (r = -0.453, P < 0.0001), and the ratio of ACE-1 to ACE-2 was significantly elevated in AD (P < 0.0001). Finally, we show that the ratio of Ang II to Ang (1-7) (a proxy measure of ACE-2 activity indicating  conversion of Ang II to Ang (1-7)) is reduced in AD.
Together, our findings indicate that ACE-2 activity is reduced in AD and is an important regulator of the central classical ACE-1/Ang II/AT1R axis of RAS, and also that dysregulation of this pathway likely plays a significant role in the pathogenesis of AD.","['Alzheimer’s disease', 'Angiotensin II', 'Angiotensin-converting enzyme-1', 'Angiotensin-converting enzyme-2', 'Renin-angiotensin system']",Alzheimer's research & therapy,2016-11-26,"[{'lastname': 'Kehoe', 'firstname': 'Patrick Gavin', 'initials': 'PG', 'affiliation': 'Dementia Research Group, University of Bristol, Level 1, Learning and Research, Southmead Hospital, Bristol, BS10 5NB, UK. Patrick.Kehoe@bristol.ac.uk.'}, {'lastname': 'Wong', 'firstname': 'Steffenny', 'initials': 'S', 'affiliation': 'Dementia Research Group, University of Bristol, Level 1, Learning and Research, Southmead Hospital, Bristol, BS10 5NB, UK.'}, {'lastname': 'Al Mulhim', 'firstname': 'Noura', 'initials': 'N', 'affiliation': 'Dementia Research Group, University of Bristol, Level 1, Learning and Research, Southmead Hospital, Bristol, BS10 5NB, UK.'}, {'lastname': 'Palmer', 'firstname': 'Laura Elyse', 'initials': 'LE', 'affiliation': 'Dementia Research Group, University of Bristol, Level 1, Learning and Research, Southmead Hospital, Bristol, BS10 5NB, UK.'}, {'lastname': 'Miners', 'firstname': 'J Scott', 'initials': 'JS', 'affiliation': 'Dementia Research Group, University of Bristol, Level 1, Learning and Research, Southmead Hospital, Bristol, BS10 5NB, UK. Scot.Miners@bristol.ac.uk.'}]",,,"ACE-2 activity was significantly reduced in AD compared with age-matched controls (P < 0.0001) and correlated inversely with levels of Aβ (r = -0.267, P < 0.001) and phosphorylated tau (p-tau) pathology (r = -0.327, P < 0.01). ACE-2 was reduced in individuals possessing an APOE ε4 allele (P < 0.05) and was associated with ACE1 indel polymorphism (P < 0.05), with lower ACE-2 activity in individuals homozygous for the ACE1 insertion AD risk allele. ACE-2 activity correlated inversely with ACE-1 activity (r = -0.453, P < 0.0001), and the ratio of ACE-1 to ACE-2 was significantly elevated in AD (P < 0.0001). Finally, we show that the ratio of Ang II to Ang (1-7) (a proxy measure of ACE-2 activity indicating  conversion of Ang II to Ang (1-7)) is reduced in AD.",,"10.1186/s13195-016-0217-7
10.1016/j.tins.2009.07.006
10.1371/journal.pone.0016037
10.1016/j.febslet.2012.09.004
10.1111/j.1365-2990.2007.00885.x
10.1089/rej.2009.0944
10.1096/fj.11-182873
10.1016/j.nbd.2014.04.018
10.1161/HYPERTENSIONAHA.109.136879
10.1172/JCI31547
10.1016/j.brainres.2010.07.006
10.1016/S0140-6736(98)03086-4
10.1136/bmj.b5465
10.1001/archinte.163.9.1069
10.1111/j.1447-0594.2011.00746.x
10.1038/5009
10.1038/ng1934
10.1212/01.WNL.0000106823.72493.FF
10.1093/hmg/ddg094
10.1093/aje/kwi202
10.1001/archneurol.2007.3
10.1161/01.RES.87.5.e1
10.1074/jbc.M002615200
10.1002/path.1570
10.1152/ajpregu.00292.2006
10.1152/ajpcell.00409.2004
10.1038/nature00786
10.1007/s11906-010-0105-7
10.1111/j.1471-4159.2008.05723.x
10.1152/ajpregu.00222.2010
10.2174/1570159X11311020007
10.1113/expphysiol.2008.042002
10.1113/expphysiol.2011.058578
10.1111/j.1476-5381.2012.02105.x
10.1177/1352458508097923
10.1002/jnr.23404
10.1016/j.ajpath.2013.01.053
10.1007/s12035-015-9260-9
10.1007/s00401-011-0910-3
10.1111/j.1750-3639.2010.00374.x
10.1212/WNL.47.1.190
10.1046/j.1365-2990.2003.00457.x
10.1212/01.wnl.0000261920.03297.64
10.1007/s00415-009-5000-2
10.1097/00001756-200308060-00027
10.1016/0140-6736(91)92823-K
10.1002/ana.410380219
10.1016/j.pneurobio.2011.07.001
10.1007/s00424-012-1102-2
10.1007/s00109-008-0331-5
10.1113/expphysiol.2007.040311
10.1074/jbc.M200581200
10.1152/ajpheart.00618.2005
10.1016/S0167-0115(00)00138-5
10.1073/pnas.1432869100
10.1016/j.mcn.2005.03.012
10.1016/j.nlm.2011.10.003
10.1113/expphysiol.2009.047407
10.1016/j.neuropharm.2014.01.004
10.1016/j.neuroscience.2014.04.060
10.1517/13543784.2013.812631
10.1161/HYPERTENSIONAHA.108.123844
10.1038/sj.ki.5000321
10.1152/ajprenal.zh2-6109-corr.2010
10.1291/hypres.31.553
10.1038/hr.2014.49
10.1093/cvr/cvr242
10.1152/japplphysiol.00840.2009
10.1161/HYPERTENSIONAHA.111.176636
10.1161/CIRCRESAHA.107.169110
10.1074/jbc.270.13.7013",<Element 'PubmedArticle' at 0x7f05d9afd040>
180,"27884163
22476197
24652456
15326238
25230227
26214150
23485579
23155049
12761548
22829447
21945540
22476196
24259244
23790682
26216852
26248591
24918340
24417942
17391153
25242063
26993044
24764191
24417941
22778410
21718299
17242917
22039048
25331877
23640763
24164711
22405025
23300647
25902149
24625795
23055000
20727007
23576130
16541076
11160388
24529528
17244624
16823476
12068289
24931033
22213409
22718609
11424194
24445162
11755003
27093924
24582565
21357416
16155579
7738205
17258715
22459600
23137804
17287464
22704931
19066529
20728226
20359773",Chronic adiponectin deficiency leads to Alzheimer's disease-like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice.,"Insulin resistance is the major pathogenesis underlying type 2 diabetes mellitus (T2DM) and these patients have doubled risk of Alzheimer's disease (AD). Increasing evidence suggests that insulin resistance plays an important role in AD pathogenesis, possibly due to abnormal GSK3β activation, causing intra- and extracellular amyloid-beta (Aβ) accumulation. Adiponectin (APN) is an adipokine with insulin-sensitizing and anti-inflammatory effects. Reduced circulatory APN level is associated with insulin resistance and T2DM. The role of APN in AD has not been elucidated. In this study, we aim to examine if adiponectin deficiency would lead to cerebral insulin resistance, cognitive decline and Alzheimer's-like pathology in mice.
To study the role of adiponectin in cognitive functions, we employed adiponectin-knockout (APN-KO) mice and demonstrated chronic APN deficiency in their CNS. Behavioral tests were performed to study the cognitions of male APN-KO mice. Brains and tissue lysates were collected to study the pathophysiological and molecular changes in the brain of APN-KO mice. SH-SY5Y neuroblastoma cell line was used to study the molecular mechanism upon APN and insulin treatment.
Aged APN-deficient mice displayed spatial memory and learning impairments, fear-conditioned memory deficit as well as anxiety. These mice also developed AD pathologies including increased cerebral Aβ
Our results indicated that chronic APN deficiency inactivated AMPK causing insulin desensitization and elicited AD-like pathogenesis in aged mice which also developed significant cognitive impairments and psychiatric symptoms.","['AMPK', 'Adiponectin', 'Alzheimer’s disease', 'Aβ', 'Cognitive impairments', 'Insulin resistance']",Molecular neurodegeneration,2016-11-26,"[{'lastname': 'Ng', 'firstname': 'Roy Chun-Laam', 'initials': 'RC', 'affiliation': 'Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.\nNeuroimmunology and Neuroinflammation Research Laboratory, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.'}, {'lastname': 'Cheng', 'firstname': 'On-Yin', 'initials': 'OY', 'affiliation': 'Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.\nNeuroimmunology and Neuroinflammation Research Laboratory, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.'}, {'lastname': 'Jian', 'firstname': 'Min', 'initials': 'M', 'affiliation': 'Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.'}, {'lastname': 'Kwan', 'firstname': 'Jason Shing-Cheong', 'initials': 'JS', 'affiliation': 'Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.\nNeuroimmunology and Neuroinflammation Research Laboratory, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.'}, {'lastname': 'Ho', 'firstname': 'Philip Wing-Lok', 'initials': 'PW', 'affiliation': 'Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.\nResearch Center of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.'}, {'lastname': 'Cheng', 'firstname': 'Kenneth King-Yip', 'initials': 'KK', 'affiliation': 'Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.\nResearch Center of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.'}, {'lastname': 'Yeung', 'firstname': 'Patrick Ka Kit', 'initials': 'PK', 'affiliation': 'School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.'}, {'lastname': 'Zhou', 'firstname': 'Lena Lei', 'initials': 'LL', 'affiliation': 'School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.'}, {'lastname': 'Hoo', 'firstname': 'Ruby Lai-Chong', 'initials': 'RL', 'affiliation': 'Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.\nResearch Center of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.'}, {'lastname': 'Chung', 'firstname': 'Sookja Kim', 'initials': 'SK', 'affiliation': ""Research Center of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.\nHong Kong University Alzheimer's Disease Research Network, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.\nSchool of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.""}, {'lastname': 'Xu', 'firstname': 'Aimin', 'initials': 'A', 'affiliation': 'Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.\nResearch Center of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.'}, {'lastname': 'Lam', 'firstname': 'Karen Siu-Ling', 'initials': 'KS', 'affiliation': ""Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China. ksllam@hku.hk.\nResearch Center of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China. ksllam@hku.hk.\nHong Kong University Alzheimer's Disease Research Network, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China. ksllam@hku.hk.\nLKS Faculty of Medicine, The University of Hong Kong, Hong Kong, HKSAR, 8/F Department of Medicine, 21 Sassoon Road, Pofulam, China. ksllam@hku.hk.""}, {'lastname': 'Chan', 'firstname': 'Koon Ho', 'initials': 'KH', 'affiliation': ""Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China. koonho@hkucc.hku.hk.\nResearch Center of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China. koonho@hkucc.hku.hk.\nHong Kong University Alzheimer's Disease Research Network, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China. koonho@hkucc.hku.hk.\nNeuroimmunology and Neuroinflammation Research Laboratory, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China. koonho@hkucc.hku.hk.\nLKS Faculty of Medicine, The University of Hong Kong, Hong Kong, HKSAR, 8/F Department of Medicine, 21 Sassoon Road, Pofulam, China. koonho@hkucc.hku.hk.""}]",,Our results indicated that chronic APN deficiency inactivated AMPK causing insulin desensitization and elicited AD-like pathogenesis in aged mice which also developed significant cognitive impairments and psychiatric symptoms.,"Aged APN-deficient mice displayed spatial memory and learning impairments, fear-conditioned memory deficit as well as anxiety. These mice also developed AD pathologies including increased cerebral Aβ",,"10.1186/s13024-016-0136-x
10.1007/s12264-013-1408-x
10.1212/01.WNL.0000134666.64593.BA
10.2174/1871527313666140917114537
10.1074/jbc.M112.409250
10.1038/nature01640
10.2337/db11-1735
10.1016/j.nbd.2011.09.002
10.1172/JCI57256
10.1016/j.psyneuen.2013.05.010
10.1016/j.expneurol.2014.06.004
10.1016/j.beem.2013.09.003
10.1111/j.1463-1326.2006.00610.x
10.1016/j.ymgme.2014.09.003
10.1242/dmm.015750
10.1016/j.beem.2013.06.006
10.1073/pnas.1202835109
10.1111/j.1476-5381.2011.01560.x
10.1007/s00125-006-0577-9
10.1074/jbc.M111.310052
10.1002/eji.201242836
10.1111/cns.12198
10.1016/j.metabol.2012.01.016
10.1371/journal.pone.0125186
10.1007/s12017-012-8201-2
10.1111/j.1468-1331.2010.03194.x
10.1093/brain/awt062
10.1016/j.jalz.2013.12.010
10.1074/jbc.M700098200
10.1172/JCI29126
10.1038/nm724
10.2337/db13-1954
10.1515/rns.2011.061
10.1002/glia.1072
10.1016/j.bcp.2014.01.008
10.1016/S0197-4580(01)00311-6
10.1038/srep24493
10.1016/j.bbrc.2014.02.077
10.1074/jbc.M110.204644
10.1038/nm1295
10.1172/JCI117936
10.1053/j.gastro.2006.11.026
10.1016/j.neurobiolaging.2012.02.016
10.1016/j.pscychresns.2012.09.010
10.1016/j.bbrc.2012.06.017
10.1016/j.jneuroim.2010.07.016
10.1016/j.neurobiolaging.2010.02.014",<Element 'PubmedArticle' at 0x7f05d9ab7220>
181,"27853086
880559
11003793
3293742
10544855
8734704
15335189
1986753
7699673
8232395
8983369
15546587
18280048
22220695
18342576
338934
304900
10728451
18664991
21816012
9013843
12209048
21073838
7316842
12353138
5462242
7247766
19609922
8230031
18534849
7158450
7028234
17278954
8480146
9071493
6383191
19590880
7580245
19363438
378177
8252323
9270685
12422007
15696437
10587565
24859416
7554571
17993438
16344354
16033136
8290436
9782537",Recurrent Bilateral Focal Myositis.,"This report describes a rare case of recurrent bilateral focal myositis and its successful treatment via methotrexate. A 38-year-old man presented myalgia of the right gastrocnemius in May 2005. Magnetic resonance imaging showed very high signal intensity in the right gastrocnemius on short-tau inversion recovery images. A muscle biopsy revealed inflammatory CD4+ cell-dominant myogenic change. Focal myositis was diagnosed. The first steroid treatment was effective. Tapering of prednisolone, however, repeatedly induced myositis relapse, which progressed to multiple muscle lesions of both lower limbs. Initiation of methotrexate finally allowed successful tapering of prednisolone, with no relapse in the past 4 years.",[],"Internal medicine (Tokyo, Japan)",2016-11-18,"[{'lastname': 'Nagafuchi', 'firstname': 'Hiroko', 'initials': 'H', 'affiliation': 'Division of Rheumatology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.'}, {'lastname': 'Nakano', 'firstname': 'Hiromasa', 'initials': 'H', 'affiliation': None}, {'lastname': 'Ooka', 'firstname': 'Seido', 'initials': 'S', 'affiliation': None}, {'lastname': 'Takakuwa', 'firstname': 'Yukiko', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Yamada', 'firstname': 'Hidehiro', 'initials': 'H', 'affiliation': None}, {'lastname': 'Tadokoro', 'firstname': 'Mamoru', 'initials': 'M', 'affiliation': None}, {'lastname': 'Shimojo', 'firstname': 'Sadatomo', 'initials': 'S', 'affiliation': None}, {'lastname': 'Ozaki', 'firstname': 'Shoichi', 'initials': 'S', 'affiliation': None}]",,,,,10.2169/internalmedicine.55.7172,<Element 'PubmedArticle' at 0x7f05d9a65f40>
182,"27802237
19363256
22329651
22201977
19777393
22476197
26836193
26836193
27525190
20508742
20414208
12867511
12840602
9720971
16627931
22577490
12464347
12614280
8237464
14991459
3492011
2774485
25071440
18266959
25418885
2505201
12226541
8821049
7897397
12084635
8740985
17430239
16340083
15750215
16988486
10963684
10407014
11344093",Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease.,"Alzheimer's disease (AD) is associated with progressive impairments in brain insulin, insulin-like growth factor (IGF), and insulin receptor substrate (IRS) signaling through Akt pathways that regulate neuronal growth, survival, metabolism, and plasticity. The intracerebral streptozotocin (i.c. STZ) model replicates the full range of abnormalities in sporadic AD. T3D-959, an orally active PPAR-delta/gamma agonist remediates neurocognitive deficits and AD neuropathology in the i.c. STZ model.
This study characterizes the effects of T3D-959 on AD biomarkers, insulin/IGF/IRS signaling through Akt pathways, and neuroinflammation in an i.c. STZ model.
Long Evans rats were treated with i.c. STZ or saline, followed by daily oral doses of T3D-959 (1 mg/kg) or saline initiated 1 day (T3D-959-E) or 7 days (T3D-959-L) later through Experimental Day 28. Protein and phospho-protein expression and pro-inflammatory cytokine activation were measured in temporal lobe homogenates by duplex or multiplex bead-based ELISAs.
i.c. STZ treatments caused neurodegeneration with increased pTau, AβPP, Aβ42, ubiquitin, and SNAP-25, and reduced levels of synaptophysin, IGF-1 receptor (R), IRS-1, Akt, p70S6K, mTOR, and S9-GSK-3β. i.c. STZ also broadly increased neuroinflammation. T3D-959 abrogated or reduced most of the AD neuropathological and biomarker abnormalities, increased/normalized IGF-1R, IRS-1, Akt, p70S6K, and S9-GSK-3β, and decreased expression of multiple pro-inflammatory cytokines. T3D-959-E or -L effectively restored insulin/IGF signaling, whereas T3D-959-L more broadly resolved neuroinflammation.
AD remediating effects of T3D-959 are potentially due to enhanced expression of key insulin/IGF signaling proteins and inhibition of GSK-3β and neuroinflammation. These effects lead to reduced neurodegeneration, cognitive impairment, and AD biomarker levels in the brain.","['Alzheimer’s disease', 'PPAR delta', 'T3D-959', 'cytokines', 'insulin resistance', 'neurodegeneration', 'rat model']",Journal of Alzheimer's disease : JAD,2016-11-02,"[{'lastname': 'de la Monte', 'firstname': 'Suzanne M', 'initials': 'SM', 'affiliation': 'Liver Research Center, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA.\nDivision of Gastroenterology, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA.\nDivision of Neuropathology, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA.\nDepartment of Medicine, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA.\nDepartment of Pathology, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA.\nDepartment of Neurology, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA.\nDepartment of Neurosurgery, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA.'}, {'lastname': 'Tong', 'firstname': 'Ming', 'initials': 'M', 'affiliation': 'Liver Research Center, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA.\nDivision of Gastroenterology, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA.\nDepartment of Medicine, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA.'}, {'lastname': 'Schiano', 'firstname': 'Irio', 'initials': 'I', 'affiliation': 'Quinnipiac University, Biomedical Sciences Department in Hamden, CT, USA.'}, {'lastname': 'Didsbury', 'firstname': 'John', 'initials': 'J', 'affiliation': 'T3D Therapeutics, Inc., Research Triangle Park, NC, USA.'}]",,"AD remediating effects of T3D-959 are potentially due to enhanced expression of key insulin/IGF signaling proteins and inhibition of GSK-3β and neuroinflammation. These effects lead to reduced neurodegeneration, cognitive impairment, and AD biomarker levels in the brain.","i.c. STZ treatments caused neurodegeneration with increased pTau, AβPP, Aβ42, ubiquitin, and SNAP-25, and reduced levels of synaptophysin, IGF-1 receptor (R), IRS-1, Akt, p70S6K, mTOR, and S9-GSK-3β. i.c. STZ also broadly increased neuroinflammation. T3D-959 abrogated or reduced most of the AD neuropathological and biomarker abnormalities, increased/normalized IGF-1R, IRS-1, Akt, p70S6K, and S9-GSK-3β, and decreased expression of multiple pro-inflammatory cytokines. T3D-959-E or -L effectively restored insulin/IGF signaling, whereas T3D-959-L more broadly resolved neuroinflammation.",,10.3233/JAD-160656,<Element 'PubmedArticle' at 0x7f05d9a7f630>
183,"27802235
26921134
26149638
19457065
24071439
26903809
19808793
23159640
15607982
16055061
20552046
18218341
14643375
16873959
16943564
11312286
10858595
16210396
16551656
15115763
25608860
8773140
22824543
18992327
12587008
16223549
20606436
21167850
16231030
18835864
19273752
22543853
19506566
19801534
15863436
18367704
21536637
23212584
19662657
24686304
24662056
22542746
24998196
24895269
21093599
23820496
24205258
24630364
22197104
25008180
12895417
12944518
16192276
23212379
26823471
24336722
20651247
19730425
26819773
26823968
24746486
17659878
18486110
18698410
20359775
22864021
23601757
24898649
26401703
20176121
20974195
18651634
24070815
25227250
10574963
26462756
24643136
12765956
23271319
11424235
22634281
22108721
24064496
25120476
9364575
19893002
19705573
24631967
23486084
17959383
24074868
22717037
24663492
21646527
21873260
22367970
19605646
18599615
18188455
22543089
22109891
24949983
22427376
22393443
23900018
16289476
23584198
24022672
20679202
23703152",Mitochondrial Abnormalities and Synaptic Loss Underlie Memory Deficits Seen in Mouse Models of Obesity and Alzheimer's Disease.,"Obesity is associated with impaired memory in humans, and obesity induced by high-fat diets leads to cognitive deficits in rodents and in mouse models of Alzheimer's disease (AD). However, it remains unclear how high-fat diets contribute to memory impairment. Therefore, we tested the effect of a high-fat diet on memory in male and female control non-transgenic (Non-Tg) and triple-transgenic AD (3xTgAD) mice and determined if a high-fat diet caused similar ultrastructural abnormalities to those observed in AD. Behavior was assessed in mice on control or high-fat diet at 4, 8, or 14 months of age and ultrastructural analysis at 8 months of age. A high-fat diet increased body weight, fat weight, and insulin levels with some differences in these metabolic responses observed between Non-Tg and 3xTgAD mice. In both sexes, high-fat feeding caused memory impairments in Non-Tg mice and accelerated memory deficits in 3xTgAD mice. In 3xTgAD mice, changes in hippocampal mitochondrial morphology were observed in capillaries and brain neuropil that were accompanied by a reduction in synapse number. A high-fat diet also caused mitochondria abnormalities and a reduction in synapse number in Non-Tg mice, but did not exacerbate the changes seen in 3xTgAD mice. Our data demonstrate that a high-fat diet affected memory in Non-Tg mice and produced similar impairments in mitochondrial morphology and synapse number comparable to those seen in AD mice, suggesting that the detrimental effects of a high-fat diet on memory might be due to changes in mitochondrial morphology leading to a reduction in synaptic number.","['3xTgAD', 'Alzheimer’s disease', 'Non-Tg', 'high-fat diet', 'memory', 'mitochondria', 'obesity', 'synapses']",Journal of Alzheimer's disease : JAD,2016-11-02,"[{'lastname': 'Martins', 'firstname': 'Isaura V A', 'initials': 'IV', 'affiliation': None}, {'lastname': 'Rivers-Auty', 'firstname': 'Jack', 'initials': 'J', 'affiliation': None}, {'lastname': 'Allan', 'firstname': 'Stuart M', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Lawrence', 'firstname': 'Catherine B', 'initials': 'CB', 'affiliation': None}]",,,,,"10.3233/JAD-160640
10.1177/0271678X16629976",<Element 'PubmedArticle' at 0x7f05d9a9ed10>
184,27793638,Tau hyperphosphorylation in the brain of ob/ob mice is due to hypothermia: Importance of thermoregulation in linking diabetes and Alzheimer's disease.,"Over the last few decades, there has been a significant increase in epidemiological studies suggesting that type 2 diabetes (T2DM) is linked to a higher risk of Alzheimer's disease (AD). However, how T2DM affects AD pathology, such as tau hyperphosphorylation, is not well understood. In this study, we investigated the impact of T2DM on tau phosphorylation in ob/ob mice, a spontaneous genetic model of T2DM. Tau phosphorylation at the AT8 epitope was slightly elevated in 4-week-old ob/ob mice while 26-week-old ob/ob mice exhibited tau hyperphosphorylation at multiple tau phospho-epitopes (Tau1, CP13, AT8, AT180, PHF1). We then examined the mechanism of tau hyperphosphorylation and demonstrated that it is mostly due to hypothermia, as ob/ob mice were hypothermic and normothermia restored tau phosphorylation to control levels. As caffeine has been shown to be beneficial for diabetes, obesity and tau phosphorylation, we, therefore, used it as therapeutic treatment. Unexpectedly, chronic caffeine intake exacerbated tau hyperphosphorylation by promoting deeper hypothermia. Our data indicate that tau hyperphosphorylation is predominately due to hypothermia consequent to impaired thermoregulation in ob/ob mice. This study establishes a novel link between diabetes and AD, and reinforces the importance of recording body temperature to better assess the relationship between diabetes and AD.","[""Alzheimer's disease"", 'Caffeine', 'Diabetes mellitus', 'Hypothermia', 'Kinase', 'Leptin', 'Phosphatase', 'Tau hyperphosphorylation, hippocampus', 'Temperature', 'Thermoregulation', 'ob/ob mice']",Neurobiology of disease,2016-10-30,"[{'lastname': 'Gratuze', 'firstname': 'Maud', 'initials': 'M', 'affiliation': ""Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'El Khoury', 'firstname': 'Noura B', 'initials': 'NB', 'affiliation': ""Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Turgeon', 'firstname': 'Andréanne', 'initials': 'A', 'affiliation': ""Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Julien', 'firstname': 'Carl', 'initials': 'C', 'affiliation': ""Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Marcouiller', 'firstname': 'François', 'initials': 'F', 'affiliation': ""Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Morin', 'firstname': 'Françoise', 'initials': 'F', 'affiliation': ""Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Whittington', 'firstname': 'Robert A', 'initials': 'RA', 'affiliation': 'Columbia University Medical Center, Department of Anesthesiology, New York, NY, USA.'}, {'lastname': 'Marette', 'firstname': 'André', 'initials': 'A', 'affiliation': ""Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, QC, Canada.""}, {'lastname': 'Calon', 'firstname': 'Frédéric', 'initials': 'F', 'affiliation': ""Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada; Université Laval, Faculté de Pharmacie, Québec, QC, Canada.""}, {'lastname': 'Planel', 'firstname': 'Emmanuel', 'initials': 'E', 'affiliation': ""Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada. Electronic address: emmanuel@planel.org.""}]",,,,Copyright © 2016 Elsevier Inc. All rights reserved.,10.1016/j.nbd.2016.10.004,<Element 'PubmedArticle' at 0x7f05d9a5dae0>
185,"27752081
11859685
8279933
9736007
11445258
16974109
6267699
9137116
6334362
2171685
20548297
16123744
22508464
17305471
15845844
23849813
1597149
22045495
19241008
21949786
19829701
21976528
11837744
22500016
11055423
22710920
22449939
18688088
21876254
22449939
18688088
21876254
19022346
14663028
9464214
11036168
17151169
17430248
22451915
19794442
8318230
21098983
10599770
11445258
11033346
17551018
24862368
11278841
25964433
23202293",Corticotropin-releasing factor overexpression gives rise to sex differences in Alzheimer's disease-related signaling.,"Several neuropsychiatric and neurodegenerative disorders share stress as a risk factor and are more prevalent in women than in men. Corticotropin-releasing factor (CRF) orchestrates the stress response, and excessive CRF is thought to contribute to the pathophysiology of these diseases. We previously found that the CRF",[],Molecular psychiatry,2016-10-19,"[{'lastname': 'Bangasser', 'firstname': 'D A', 'initials': 'DA', 'affiliation': ""Department of Anesthesiology and Critical Care, The Children's Hospital of Philadelphia, Abramson Research Center, Philadelphia, PA, USA.\nDepartment of Psychology and Neuroscience Program, Temple University, Philadelphia, PA, USA.""}, {'lastname': 'Dong', 'firstname': 'H', 'initials': 'H', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'lastname': 'Carroll', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Department of Pathology and Laboratory Medicine, The University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Plona', 'firstname': 'Z', 'initials': 'Z', 'affiliation': ""Department of Anesthesiology and Critical Care, The Children's Hospital of Philadelphia, Abramson Research Center, Philadelphia, PA, USA.""}, {'lastname': 'Ding', 'firstname': 'H', 'initials': 'H', 'affiliation': ""Proteomics Core, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}, {'lastname': 'Rodriguez', 'firstname': 'L', 'initials': 'L', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'lastname': 'McKennan', 'firstname': 'C', 'initials': 'C', 'affiliation': ""Proteomics Core, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}, {'lastname': 'Csernansky', 'firstname': 'J G', 'initials': 'JG', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'lastname': 'Seeholzer', 'firstname': 'S H', 'initials': 'SH', 'affiliation': ""Proteomics Core, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}, {'lastname': 'Valentino', 'firstname': 'R J', 'initials': 'RJ', 'affiliation': ""Department of Anesthesiology and Critical Care, The Children's Hospital of Philadelphia, Abramson Research Center, Philadelphia, PA, USA.""}]",,,,,10.1038/mp.2016.185,<Element 'PubmedArticle' at 0x7f05d99eec70>
186,"27730513
15911792
21695767
17720802
25451899
11837744
20206415
20417581
12469361
26425886
21068429
22554955
9324061
17075721
22572745
19464758
23803348
12765956
21218508
20478442
17090425
18515273
10368772
17919193
18348871
7491495
14990773
9708813
20798963
27061677
16807785
12193536
24220636
22198872
25419621
17130475
21913970
25182811
23999914
17901235
11750861
23638783
16580076
24072478
24833464
23716494
15755688
9201960
24470773
18445128
11772901
1734291
10993815
7595582
20807511
12753303
17116223
20467821
23103091
17175109
23491264
22438574
17615392
9267986
18486110
17440111
10647003
20739649
23994581
24237065
23314404
15111519
21977022
25258546
20798334
25998101
10580437
21974744
23438839
21185655
18332097
15537830
9685228
24931033
11599307
12699330
26727124
11193809
12650718
17187935
22443187
21538657
21447386
23853041
23271317
26202354
11125843
15668425
12414126
20934413
16179343
20421697
23939539
21795660
14595538
8732681
16344155
21215781
20061333
23388174
17414060
25071725
17408764
22369239
22517552
16365303
22393359
16216005
23419687
16187836
68686
17686551
27159875
17124377
21500874
14993490
19508596
22451324
20053478
15944465
19284598
8182132
12510204
19667196
18774188
23314196
18380531
12700177
17662459
24643136
19199871
23905488
20226793
22500228
15277393
11978641
17010478
21262392
17695343
17573819
15850667
17127355
12415260
20875808
20200346
20118458
12475375",Middle-Aged Diabetic Females and Males Present Distinct Susceptibility to Alzheimer Disease-like Pathology.,"Type 2 diabetes (T2D) is a highly concerning public health problem of the twenty-first century. Currently, it is estimated that T2D affects 422 million people worldwide with a rapidly increasing prevalence. During the past two decades, T2D has been widely shown to have a major impact in the brain. This, together with the cognitive decline and increased risk for dementia upon T2D, may arise from the complex interaction between normal brain aging and central insulin signaling dysfunction. Among the several features shared between T2D and some neurodegenerative disorders (e.g., Alzheimer disease (AD)), the impairment of insulin signaling may be a key link. However, these may also involve changes in sex hormones' function and metabolism, ultimately contributing to the different susceptibilities between females and males to some pathologies. For example, female sex has been pointed as a risk factor for AD, particularly after menopause. However, less is known on the underlying molecular mechanisms or even if these changes start during middle-age (perimenopause). From the above, we hypothesized that sex differentially affects hormone-mediated intracellular signaling pathways in T2D brain, ultimately modulating the risk for neurodegenerative conditions. We aimed to evaluate sex-associated alterations in estrogen/insulin-like growth factor-1 (IGF-1)/insulin-related signaling, oxidative stress markers, and AD-like hallmarks in middle-aged control and T2D rat brain cortices. We used brain cortices homogenates obtained from middle-aged (8-month-old) control Wistar and non-obese, spontaneously T2D Goto-Kakizaki (GK) male and female rats. Peripheral characterization of the animal models was done by standard biochemical analyses of blood, plasma, or serum. Steroid sex hormones, oxidative stress markers, and AD-like hallmarks were given by specific ELISA kits and colorimetric techniques, whereas the levels of intracellular signaling proteins were determined by Western blotting. Albeit the high levels of plasma estradiol and progesterone observed in middle-aged control females suggested that they were still under their reproductive phase, some gonadal dysfunction might be already occurring in T2D ones, hence, anticipating their menopause. Moreover, the higher blood and lower brain cholesterol levels in female rats suggested that its dysfunctional uptake into the brain cortex may also hamper peripheral estrogen uptake and/or its local brain steroidogenic metabolism. Despite the massive drop in IGF-1 levels in females' brains, particularly upon T2D, they might have developed some compensatory mechanisms towards the maintenance of estrogen, IGF-1, and insulin receptors function and of the subsequent Akt- and ERK1/2-mediated signaling. These may ultimately delay the deleterious AD-like brain changes (including oxidative damage to lipids and DNA, amyloidogenic processing of amyloid precursor protein and increased tau protein phosphorylation) associated with T2D and/or age (reproductive senescence) in female rats. By demonstrating that differential sex steroid hormone profiles/action may play a pivotal role in brain over T2D progression, the present study reinforces the need to establish sex-specific preventive and/or therapeutic approaches and an appropriate time window for the efficient treatment against T2D and AD.","['Alzheimer disease-like hallmarks', 'Insulin', 'Sex', 'Sex steroids', 'Type 2 diabetes']",Molecular neurobiology,2016-10-13,"[{'lastname': 'Candeias', 'firstname': 'E', 'initials': 'E', 'affiliation': 'CNC- Center for Neuroscience and Cell Biology, Rua Larga, Faculty of Medicine (Pólo 1, 1st Floor), University of Coimbra, 3004-517, Coimbra, Portugal.\nInstitute for Interdisciplinary Research (IIIUC), University of Coimbra, Casa Costa Alemão - Pólo II, Rua D. Francisco de Lemos, 3030-789, Coimbra, Portugal.'}, {'lastname': 'Duarte', 'firstname': 'A I', 'initials': 'AI', 'affiliation': 'CNC- Center for Neuroscience and Cell Biology, Rua Larga, Faculty of Medicine (Pólo 1, 1st Floor), University of Coimbra, 3004-517, Coimbra, Portugal. anaimduarte@gmail.com.\nInstitute for Interdisciplinary Research (IIIUC), University of Coimbra, Casa Costa Alemão - Pólo II, Rua D. Francisco de Lemos, 3030-789, Coimbra, Portugal. anaimduarte@gmail.com.'}, {'lastname': 'Sebastião', 'firstname': 'I', 'initials': 'I', 'affiliation': 'CNC- Center for Neuroscience and Cell Biology, Rua Larga, Faculty of Medicine (Pólo 1, 1st Floor), University of Coimbra, 3004-517, Coimbra, Portugal.'}, {'lastname': 'Fernandes', 'firstname': 'M A', 'initials': 'MA', 'affiliation': 'Life Sciences Department, University of Coimbra, Largo Marquês de Pombal, 3004-517, Coimbra, Portugal.\nInstituto do Mar, Life Sciences Department, University of Coimbra, 3004-517, Coimbra, Portugal.'}, {'lastname': 'Plácido', 'firstname': 'A I', 'initials': 'AI', 'affiliation': 'CNC- Center for Neuroscience and Cell Biology, Rua Larga, Faculty of Medicine (Pólo 1, 1st Floor), University of Coimbra, 3004-517, Coimbra, Portugal.\nFaculty of Medicine, University of Coimbra, 3004-504, Coimbra, Portugal.'}, {'lastname': 'Carvalho', 'firstname': 'C', 'initials': 'C', 'affiliation': 'CNC- Center for Neuroscience and Cell Biology, Rua Larga, Faculty of Medicine (Pólo 1, 1st Floor), University of Coimbra, 3004-517, Coimbra, Portugal.\nInstitute for Interdisciplinary Research (IIIUC), University of Coimbra, Casa Costa Alemão - Pólo II, Rua D. Francisco de Lemos, 3030-789, Coimbra, Portugal.'}, {'lastname': 'Correia', 'firstname': 'S', 'initials': 'S', 'affiliation': 'CNC- Center for Neuroscience and Cell Biology, Rua Larga, Faculty of Medicine (Pólo 1, 1st Floor), University of Coimbra, 3004-517, Coimbra, Portugal.\nInstitute for Interdisciplinary Research (IIIUC), University of Coimbra, Casa Costa Alemão - Pólo II, Rua D. Francisco de Lemos, 3030-789, Coimbra, Portugal.'}, {'lastname': 'Santos', 'firstname': 'R X', 'initials': 'RX', 'affiliation': 'CNC- Center for Neuroscience and Cell Biology, Rua Larga, Faculty of Medicine (Pólo 1, 1st Floor), University of Coimbra, 3004-517, Coimbra, Portugal.\nLife Sciences Department, University of Coimbra, Largo Marquês de Pombal, 3004-517, Coimbra, Portugal.'}, {'lastname': 'Seiça', 'firstname': 'R', 'initials': 'R', 'affiliation': 'Institute of Physiology, Faculty of Medicine, University of Coimbra, 3004-504, Coimbra, Portugal.'}, {'lastname': 'Santos', 'firstname': 'M S', 'initials': 'MS', 'affiliation': 'CNC- Center for Neuroscience and Cell Biology, Rua Larga, Faculty of Medicine (Pólo 1, 1st Floor), University of Coimbra, 3004-517, Coimbra, Portugal.\nInstituto do Mar, Life Sciences Department, University of Coimbra, 3004-517, Coimbra, Portugal.'}, {'lastname': 'Oliveira', 'firstname': 'C R', 'initials': 'CR', 'affiliation': 'CNC- Center for Neuroscience and Cell Biology, Rua Larga, Faculty of Medicine (Pólo 1, 1st Floor), University of Coimbra, 3004-517, Coimbra, Portugal.\nInstitute of Biochemistry, Faculty of Medicine, University of Coimbra, 3004-504, Coimbra, Portugal.'}, {'lastname': 'Moreira', 'firstname': 'P I', 'initials': 'PI', 'affiliation': 'CNC- Center for Neuroscience and Cell Biology, Rua Larga, Faculty of Medicine (Pólo 1, 1st Floor), University of Coimbra, 3004-517, Coimbra, Portugal. pimoreira@fmed.uc.pt.\nInstitute of Physiology, Faculty of Medicine, University of Coimbra, 3004-504, Coimbra, Portugal. pimoreira@fmed.uc.pt.'}]",,,,,10.1007/s12035-016-0155-1,<Element 'PubmedArticle' at 0x7f05d9a0f8b0>
187,27657817,NO,Air pollution has been evidenced as a risk factor for neurodegenerative tauopathies. NO,"['Hyperinsulinemia', 'Insulin resistance', 'Nitrogen dioxide', 'Synaptic protein loss', 'tau hyperphosphorylation']",Chemosphere,2016-09-23,"[{'lastname': 'Yan', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'College of Environment and Resources, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, PR China.'}, {'lastname': 'Ku', 'firstname': 'Tingting', 'initials': 'T', 'affiliation': 'College of Environment and Resources, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, PR China.'}, {'lastname': 'Yue', 'firstname': 'Huifeng', 'initials': 'H', 'affiliation': 'College of Environment and Resources, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, PR China.'}, {'lastname': 'Li', 'firstname': 'Guangke', 'initials': 'G', 'affiliation': 'College of Environment and Resources, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, PR China.'}, {'lastname': 'Sang', 'firstname': 'Nan', 'initials': 'N', 'affiliation': 'College of Environment and Resources, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, PR China. Electronic address: sangnan@sxu.edu.cn.'}]",,,,Copyright © 2016 Elsevier Ltd. All rights reserved.,10.1016/j.chemosphere.2016.09.063,<Element 'PubmedArticle' at 0x7f05d99c57c0>
188,27567882,Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alzheimer's Disease Stage in APP/PS1 Mice.,"Alzheimer's disease (AD) is currently an incurable aging-related neurodegenerative disorder. Recent studies give support to the hypotheses that AD should be considered as a metabolic disease. The present study aimed to explore the relationship between hippocampal neuropathological amyloid-β (Aβ) plaque formation and obesity at an early presymptomatic disease stage (3 months of age). For this purpose, we used APPswe/PS1dE9 (APP/PS1) transgenic mice, fed with a high-fat diet (HFD) in order to investigate the potential molecular mechanisms involved in both disorders. The results showed that the hippocampus from APP/PS1 mice fed with a HFD had an early significant decrease in Aβ signaling pathway specifically in the insulin degrading enzyme protein levels, an enzyme involved in (Aβ) metabolism, and α-secretase. These changes were accompanied by a significant increase in the occurrence of plaques in the hippocampus of these mice. Furthermore, APP/PS1 mice showed a significant hippocampal decrease in PGC-1α levels, a cofactor involved in mitochondrial biogenesis. However, HFD does not provoke changes in neither insulin receptors gene expression nor enzymes involved in the signaling pathway. Moreover, there are no changes in any enzymes (kinases) involved in tau phosphorylation, such as CDK5, and neither in brain oxidative stress production. These results suggest that early changes in brains of APP/PS1 mice fed with a HFD are mediated by an increase in Aβ1 ‒ 42, which induces a decrease in PKA levels and alterations in the p-CREB/ NMDA2B /PGC1-α pathway, favoring early AD neuropathology in mice.","['APPSwe/PS1dE9', 'Alzheimer’s disease', 'hippocampus', 'insulin receptor', 'mitochondria', 'tau']",Journal of Alzheimer's disease : JAD,2016-08-29,"[{'lastname': 'Ettcheto', 'firstname': 'Miren', 'initials': 'M', 'affiliation': 'Unitat de Farmacologia i Farmacognòsia, Institut de Neurociencias, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain.\nBiomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.'}, {'lastname': 'Petrov', 'firstname': 'Dmitry', 'initials': 'D', 'affiliation': 'Unitat de Farmacologia i Farmacognòsia, Institut de Neurociencias, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain.\nBiomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.'}, {'lastname': 'Pedrós', 'firstname': 'Ignacio', 'initials': 'I', 'affiliation': 'Unitats de Bioquímica i Farmacologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus (Tarragona), Spain.\nBiomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.'}, {'lastname': 'Alva', 'firstname': 'Norma', 'initials': 'N', 'affiliation': 'Department of Physiology and Immunology, Faculty of Biology, University of Barcelona, Barcelona, Spain.'}, {'lastname': 'Carbonell', 'firstname': 'Teresa', 'initials': 'T', 'affiliation': 'Department of Physiology and Immunology, Faculty of Biology, University of Barcelona, Barcelona, Spain.'}, {'lastname': 'Beas-Zarate', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': 'Laboratorio de Neurobiología Celular y Molecular, División de Neurociencias, CIBO, IMSS, México.\nLaboratorio de Regeneración y Desarrollo Neural, Instituto de Neurobiología, Departamento de Biología Celular y Molecular, CUCBA, México.'}, {'lastname': 'Pallas', 'firstname': 'Merce', 'initials': 'M', 'affiliation': 'Unitat de Farmacologia i Farmacognòsia, Institut de Neurociencias, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain.\nBiomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.'}, {'lastname': 'Auladell', 'firstname': 'Carme', 'initials': 'C', 'affiliation': 'Departament de Biologia Cellular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.'}, {'lastname': 'Folch', 'firstname': 'Jaume', 'initials': 'J', 'affiliation': 'Unitats de Bioquímica i Farmacologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus (Tarragona), Spain.\nBiomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.'}, {'lastname': 'Camins', 'firstname': 'Antoni', 'initials': 'A', 'affiliation': 'Unitat de Farmacologia i Farmacognòsia, Institut de Neurociencias, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain.\nBiomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.'}]",,,,,10.3233/JAD-160150,<Element 'PubmedArticle' at 0x7f05d99d59f0>
189,27484105,Exaggerated phosphorylation of brain tau protein in CRH KO mice exposed to repeated immobilization stress.,"Neuroendocrine and behavioral stress responses are orchestrated by corticotropin-releasing hormone (CRH) and norepinephrine (NE) synthesizing neurons. Recent findings indicate that stress may promote development of neurofibrillary pathology in Alzheimer's disease. Therefore, we investigated relationships among stress, tau protein phosphorylation, and brain NE using wild-type (WT) and CRH-knockout (CRH KO) mice. We assessed expression of phosphorylated tau (p-tau) at the PHF-1 epitope and NE concentrations in the locus coeruleus (LC), A1/C1 and A2/C2 catecholaminergic cell groups, hippocampus, amygdala, nucleus basalis magnocellularis, and frontal cortex of unstressed, singly stressed or repeatedly stressed mice. Moreover, gene expression and protein levels of tyrosine hydroxylase (TH) and CRH receptor mRNA were determined in the LC. Plasma corticosterone levels were also measured. Exposure to a single stress increases tau phosphorylation throughout the brain in WT mice when compared to singly stressed CRH KO animals. In contrast, repeatedly stressed CRH KO mice showed exaggerated tau phosphorylation relative to WT controls. We also observed differences in extent of tau phosphorylation between investigated structures, e.g. the LC and hippocampus. Moreover, CRH deficiency leads to different responses to stress in gene expression of TH, NE concentrations, CRH receptor mRNA, and plasma corticosterone levels. Our data indicate that CRH effects on tau phosphorylation are dependent on whether stress is single or repeated, and differs between brain regions. Our findings indicate that CRH attenuates mechanisms responsible for development of stress-induced tau neuropathology, particularly in conditions of chronic stress. However, the involvement of central catecholaminergic neurons in these mechanisms remains unclear and is in need of further investigation.","[""Alzheimer's disease"", 'cornu amonis', 'corticosterone', 'locus coeruleus', 'norepinephrine', 'nucleus basalis magnocellularis']","Stress (Amsterdam, Netherlands)",2016-08-04,"[{'lastname': 'Kvetnansky', 'firstname': 'Richard', 'initials': 'R', 'affiliation': 'a Institute of Experimental Endocrinology, Biomedical Research Center , Slovak Academy of Sciences , Bratislava , Slovakia ;'}, {'lastname': 'Novak', 'firstname': 'Petr', 'initials': 'P', 'affiliation': 'b Institute of Neuroimmunology , Slovak Academy of Sciences , Bratislava , Slovakia ;'}, {'lastname': 'Vargovic', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'a Institute of Experimental Endocrinology, Biomedical Research Center , Slovak Academy of Sciences , Bratislava , Slovakia ;'}, {'lastname': 'Lejavova', 'firstname': 'Katarina', 'initials': 'K', 'affiliation': 'a Institute of Experimental Endocrinology, Biomedical Research Center , Slovak Academy of Sciences , Bratislava , Slovakia ;\nc Faculty of Medicine, Institute of Physiology , Comenius University in Bratislava, Bratislava , Slovakia ;'}, {'lastname': 'Horvathova', 'firstname': 'Lubica', 'initials': 'L', 'affiliation': 'a Institute of Experimental Endocrinology, Biomedical Research Center , Slovak Academy of Sciences , Bratislava , Slovakia ;'}, {'lastname': 'Ondicova', 'firstname': 'Katarina', 'initials': 'K', 'affiliation': 'a Institute of Experimental Endocrinology, Biomedical Research Center , Slovak Academy of Sciences , Bratislava , Slovakia ;\nc Faculty of Medicine, Institute of Physiology , Comenius University in Bratislava, Bratislava , Slovakia ;'}, {'lastname': 'Manz', 'firstname': 'George', 'initials': 'G', 'affiliation': 'd LDN, Labor Diagnostika Nord , Nordhorn , Germany.'}, {'lastname': 'Filipcik', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'b Institute of Neuroimmunology , Slovak Academy of Sciences , Bratislava , Slovakia ;'}, {'lastname': 'Novak', 'firstname': 'Michal', 'initials': 'M', 'affiliation': 'b Institute of Neuroimmunology , Slovak Academy of Sciences , Bratislava , Slovakia ;'}, {'lastname': 'Mravec', 'firstname': 'Boris', 'initials': 'B', 'affiliation': 'a Institute of Experimental Endocrinology, Biomedical Research Center , Slovak Academy of Sciences , Bratislava , Slovakia ;\nc Faculty of Medicine, Institute of Physiology , Comenius University in Bratislava, Bratislava , Slovakia ;'}]",,,,,10.1080/10253890.2016.1183119,<Element 'PubmedArticle' at 0x7f05d99689f0>
190,"27435172
20369906
24421286
21325651
21840887
9855500
18703462
9641683
16862116
16862115
21944778
21944779
15034582
16041373
17579875
22732773
17023659
17084815
19674978
20490813
19844732
11220736
12677447
19015862
16900341
24747743
11846609
27036121
10967355
20400460
20234357
22127299
24507191
11517247
26903860
22509148
26362250
25574843
22323604
24971751
24800652
22859297
20737593
22781549
21813674
23063362
22608501
26109656
3930508
1421571
1057175
18202255
20655099
22833681
21131359
24672431
8202139
25124182
22286308
22787440
24913895
24298146
27114033
27079722
14522144
19782411
16495941
20012068
24059854
23340677
11590131
25974414
2509637
12408865
22709448
8247129
12231625
23361961
24718614
26161668",Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation.,"Reduction of Tau protein expression was described in 2003 by Zhukareva et al. in a variant of frontotemporal lobar degeneration (FTLD) referred to as diagnosis of dementia lacking distinctive histopathology, then re-classified as FTLD with ubiquitin inclusions. However, the analysis of Tau expression in FTLD has not been reconsidered since then. Knowledge of the molecular basis of protein aggregates and genes that are mutated in the FTLD spectrum would enable to determine whether the ""Tau-less"" is a separate pathological entity or if it belongs to an existing subclass of FTLD. To address this question, we have analyzed Tau expression in the frontal brain areas from control, Alzheimer's disease and FTLD cases, including FTLD- Tau (MAPT), FTLD-TDP (sporadic, FTLD-TDP-GRN, FTLD-TDP-C9ORF72) and sporadic FTLD-FUS, using western blot and 2D-DIGE (Two-Dimensional fluorescence Difference Gel Electrophoresis) approaches. Surprisingly, we found that most of the FTLD-TDP-GRN brains are characterized by a huge reduction of Tau protein expression without any decrease in Tau mRNA levels. Interestingly, only cases affected by point mutations, rather than cases with total deletion of one GRN allele, seem to be affected by this reduction of Tau protein expression. Moreover, proteomic analysis highlighted correlations between reduced Tau protein level, synaptic impairment and massive reactive astrogliosis in these FTLD-GRN cases. Consistent with a recent study, our data also bring new insights regarding the role of progranulin in neurodegeneration by suggesting its involvement in lysosome and synaptic regulation. Together, our results demonstrate a strong association between progranulin deficiency and reduction of Tau protein expression that could lead to severe neuronal and glial dysfunctions. Our study also indicates that this FTLD-TDP-GRN subgroup could be part as a distinct entity of FTLD classification.","['Astrogliosis', 'Frontotemporal lobar degeneration', 'Progranulin', 'Synaptic impairment', 'Tau protein']",Acta neuropathologica communications,2016-07-21,"[{'lastname': 'Papegaey', 'firstname': 'Anthony', 'initials': 'A', 'affiliation': 'University of Lille, Inserm, CHU-Lille, F-59000, Lille, France.'}, {'lastname': 'Eddarkaoui', 'firstname': 'Sabiha', 'initials': 'S', 'affiliation': 'University of Lille, Inserm, CHU-Lille, F-59000, Lille, France.'}, {'lastname': 'Deramecourt', 'firstname': 'Vincent', 'initials': 'V', 'affiliation': 'University of Lille, Inserm, CHU-Lille, F-59000, Lille, France.'}, {'lastname': 'Fernandez-Gomez', 'firstname': 'Francisco-Jose', 'initials': 'FJ', 'affiliation': 'University of Lille, Inserm, CHU-Lille, F-59000, Lille, France.'}, {'lastname': 'Pantano', 'firstname': 'Pierre', 'initials': 'P', 'affiliation': 'University of Lille, Inserm, CHU-Lille, F-59000, Lille, France.'}, {'lastname': 'Obriot', 'firstname': 'Hélène', 'initials': 'H', 'affiliation': 'University of Lille, Inserm, CHU-Lille, F-59000, Lille, France.'}, {'lastname': 'Machala', 'firstname': 'Camille', 'initials': 'C', 'affiliation': 'University of Lille, Inserm, CHU-Lille, F-59000, Lille, France.'}, {'lastname': 'Anquetil', 'firstname': 'Vincent', 'initials': 'V', 'affiliation': 'Sorbonne Universités, UPMC Univ Paris 06, Hôpital Pitié-Salpêtrière, Paris, France.\nINSERM UMRS_1127, Hôpital Pitié-Salpêtrière, Paris, France.\nCNRS UMR_7225, Hôpital Pitié-Salpêtrière, Paris, France.\nAP-HP, Hôpital Pitié-Salpêtrière, Paris, France.\nICM, Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Camuzat', 'firstname': 'Agnès', 'initials': 'A', 'affiliation': 'Sorbonne Universités, UPMC Univ Paris 06, Hôpital Pitié-Salpêtrière, Paris, France.\nINSERM UMRS_1127, Hôpital Pitié-Salpêtrière, Paris, France.\nCNRS UMR_7225, Hôpital Pitié-Salpêtrière, Paris, France.\nAP-HP, Hôpital Pitié-Salpêtrière, Paris, France.\nICM, Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Brice', 'firstname': 'Alexis', 'initials': 'A', 'affiliation': 'Sorbonne Universités, UPMC Univ Paris 06, Hôpital Pitié-Salpêtrière, Paris, France.\nINSERM UMRS_1127, Hôpital Pitié-Salpêtrière, Paris, France.\nCNRS UMR_7225, Hôpital Pitié-Salpêtrière, Paris, France.\nAP-HP, Hôpital Pitié-Salpêtrière, Paris, France.\nICM, Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Maurage', 'firstname': 'Claude-Alain', 'initials': 'CA', 'affiliation': 'University of Lille, Inserm, CHU-Lille, F-59000, Lille, France.'}, {'lastname': 'Le Ber', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'Sorbonne Universités, UPMC Univ Paris 06, Hôpital Pitié-Salpêtrière, Paris, France.\nINSERM UMRS_1127, Hôpital Pitié-Salpêtrière, Paris, France.\nCNRS UMR_7225, Hôpital Pitié-Salpêtrière, Paris, France.\nAP-HP, Hôpital Pitié-Salpêtrière, Paris, France.\nICM, Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Duyckaerts', 'firstname': 'Charles', 'initials': 'C', 'affiliation': 'Sorbonne Universités, UPMC Univ Paris 06, Hôpital Pitié-Salpêtrière, Paris, France.\nINSERM UMRS_1127, Hôpital Pitié-Salpêtrière, Paris, France.\nCNRS UMR_7225, Hôpital Pitié-Salpêtrière, Paris, France.\nAP-HP, Hôpital Pitié-Salpêtrière, Paris, France.\nICM, Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Buée', 'firstname': 'Luc', 'initials': 'L', 'affiliation': 'University of Lille, Inserm, CHU-Lille, F-59000, Lille, France.'}, {'lastname': 'Sergeant', 'firstname': 'Nicolas', 'initials': 'N', 'affiliation': 'University of Lille, Inserm, CHU-Lille, F-59000, Lille, France.'}, {'lastname': 'Buée-Scherrer', 'firstname': 'Valérie', 'initials': 'V', 'affiliation': 'University of Lille, Inserm, CHU-Lille, F-59000, Lille, France. valerie.buee-scherrer@inserm.fr.\nUniversité Artois, Faculté Jean Perrin, F-62307, Lens, France. valerie.buee-scherrer@inserm.fr.\nInserm UMRS1172 - Alzheimer & Tauopathies, Faculty of Medecine-Research Pole, University of Lille, Place de Verdun, F-59045, Lille cedex, France. valerie.buee-scherrer@inserm.fr.'}]",,,,,"10.1186/s40478-016-0345-0
10.2165/11533100-000000000-00000
10.1136/jnnp-2013-306948
10.1212/WNL.0b013e31821103e6
10.1093/brain/awr195
10.1212/WNL.51.6.1546
10.1212/01.wnl.0000319702.37497.72
10.1038/31508
10.1038/nature05016
10.1038/nature05017
10.1016/j.neuron.2011.09.011
10.1016/j.neuron.2011.09.010
10.1038/ng1332
10.1038/ng1609
10.1007/s00401-007-0237-2
10.1126/science.1134108
10.1016/j.bbrc.2006.10.093
10.1093/brain/awp214
10.1007/s00401-010-0698-6
10.1007/s00401-009-0593-1
10.1002/1531-8249(20010201)49:2<165::AID-ANA36>3.0.CO;2-3
10.1007/s00401-008-0460-5
10.1007/s00401-006-0123-3
10.1006/meth.2001.1262
10.1186/s40478-016-0301-z
10.1016/S0165-0173(00)00019-9
10.1093/hmg/ddq137
10.1038/nrneurol.2010.18
10.1016/j.neuron.2013.12.018
10.3389/fnagi.2016.00017
10.3389/fnins.2012.00048
10.1093/hmg/ddv377
10.1172/JCI78421
10.1073/pnas.1112427109
10.1371/journal.pone.0100760
10.1016/j.tins.2014.04.003
10.1074/jbc.R112.399170
10.1002/cne.22430
10.1186/1750-1326-7-33
10.1523/JNEUROSCI.6244-10.2011
10.1016/j.celrep.2012.09.007
10.1016/j.ajhg.2012.04.021
10.1523/JNEUROSCI.4808-14.2015
10.1083/jcb.101.4.1371
10.1091/mbc.3.10.1141
10.1073/pnas.72.5.1858
10.1126/science.1152993
10.1016/j.cell.2010.06.036
10.1074/jbc.M112.401240
10.1074/jbc.M110.199976
10.3389/fncel.2014.00084
10.1038/369488a0
10.1186/1750-1326-9-29
10.1038/nm.2613
10.3389/fnins.2012.00104
10.1016/j.neurobiolaging.2014.05.005
10.1016/j.cell.2016.04.001
10.3233/JAD-160076
10.1016/j.tins.2003.08.008
10.1016/j.tins.2009.08.002
10.1038/nrn1870
10.1007/s00401-009-0619-8
10.1042/AN20130017
10.1038/jcbfm.2012.212
10.1093/hmg/10.19.2143
10.1038/srep09659
10.1016/0022-510X(89)90131-7
10.1016/S0092-8674(02)01012-7
10.1111/j.1755-5949.2012.00357.x
10.1038/366347a0
10.1101/gad.223302
10.1002/glia.22453",<Element 'PubmedArticle' at 0x7f05d9975900>
191,27418439,A novel role for the immunophilin FKBP52 in motor coordination.,"FKBP52 is a ubiquitously distributed immunophilin that has been associated with wide-ranging functions in cell signalling as well as hormonal and stress responses. Amongst other pathways, it acts via complex-formation with corticosteroid receptors and has consequently been associated with stress- and age- related neurodegenerative disorders including Alzheimer's and Parkinson's diseases. Reduced levels of FKBP52 have been linked to tau dysfunction and amyloid beta toxicity in AD. However, FKBP52's role in cognition and neurodegenerative disorder-like phenotypes remain to be elucidated. The present study aimed therefore at investigating the cognitive and behavioural effects of reduced FKBP52 levels of genetically modified mice during ageing. Female and male FKBP52(+/+), FKBP52(+/-) and FKBP52(-/-) mice were compared at two-, ten-, twelve-, fifteen- and eighteen-months-of-age in a series of behavioural tests covering specie-specific behaviour, motor activity and coordination, fear-, spatial and recognition memory as well as curiosity and emotionality. Whilst cognitively unimpaired, FKBP52(+/-) mice performed worse on an accelerating rotating rod than FKBP52(+/+) littermates across all age-groups suggesting that FKBP52 is involved in processes controlling motor coordination. This deficit did not exacerbate with age but did worsen with repeated testing; pointing towards a role for FKBP52 in learning of tasks requiring motor coordination abilities. This study contributes to the knowledge base of FKBP52's implication in neurodegenerative diseases by demonstrating that FKBP52 by itself does not directly affect cognition and may therefore rather play an indirect, modulatory role in the functional pathology of AD, whereas it directly affects motor coordination, an early sign of neurodegenerative damages to the brain.","['Behaviour', 'Cognition', 'FKBP52', 'Motor coordination', 'Rotarod']",Behavioural brain research,2016-07-16,"[{'lastname': 'Young', 'firstname': 'Matthew J', 'initials': 'MJ', 'affiliation': ""University of Nottingham Medical School, School of Life Sciences, Neuroscience group, Queen's Medical Centre, Nottingham NG7 2UH United Kingdom.""}, {'lastname': 'Geiszler', 'firstname': 'Philippine C', 'initials': 'PC', 'affiliation': ""University of Nottingham Medical School, School of Life Sciences, Neuroscience group, Queen's Medical Centre, Nottingham NG7 2UH United Kingdom.""}, {'lastname': 'Pardon', 'firstname': 'Marie-Christine', 'initials': 'MC', 'affiliation': ""University of Nottingham Medical School, School of Life Sciences, Neuroscience group, Queen's Medical Centre, Nottingham NG7 2UH United Kingdom. Electronic address: marie.pardon@nottingham.ac.uk.""}]",,,,Copyright © 2016 Elsevier B.V. All rights reserved.,10.1016/j.bbr.2016.07.015,<Element 'PubmedArticle' at 0x7f05d9938130>
192,"27143353
11834007
21947934
15710776
21593863
19221231
18579813
24355923
24913570
10841519
20088827
16601194
22503226
25904646
23220275
20101093
24583853
8784109
23316287
24175067
14553839
11349006
25480301
10583712
25368028
19589439
14676238
21903061
16287739
12379578
14608525
2174912
24201113
16806260
12573277
15519020
23177972
25231636
18391168
21119198
15596561
16641931
17224478
17433959
17823281
16534030
18955677
12607654
17868877
10403851
21263005
19608970
25286359
25405392
21798417",Local Application of Leptin Antagonist Attenuates Angiotensin II-Induced Ascending Aortic Aneurysm and Cardiac Remodeling.,"Ascending thoracic aortic aneurysm (ATAA) is driven by angiotensin II (AngII) and contributes to the development of left ventricular (LV) remodeling through aortoventricular coupling. We previously showed that locally available leptin augments AngII-induced abdominal aortic aneurysms in apolipoprotein E-deficient mice. We hypothesized that locally synthesized leptin mediates AngII-induced ATAA.
Following demonstration of leptin synthesis in samples of human ATAA associated with different etiologies, we modeled in situ leptin expression in apolipoprotein E-deficient mice by applying exogenous leptin on the surface of the ascending aorta. This treatment resulted in local aortic stiffening and dilation, LV hypertrophy, and thickening of aortic/mitral valve leaflets. Similar results were obtained in an AngII-infusion ATAA mouse model. To test the dependence of AngII-induced aortic and LV remodeling on leptin activity, a leptin antagonist was applied to the ascending aorta in AngII-infused mice. Locally applied single low-dose leptin antagonist moderated AngII-induced ascending aortic dilation and protected mice from ATAA rupture. Furthermore, LV hypertrophy was attenuated and thickening of aortic valve leaflets was moderated. Last, analysis of human aortic valve stenosis leaflets revealed de novo leptin synthesis, whereas exogenous leptin stimulated proliferation and promoted mineralization of human valve interstitial cells in culture.
AngII-induced ATAA is mediated by locally synthesized leptin. Aortoventricular hemodynamic coupling drives LV hypertrophy and promotes early aortic valve lesions, possibly mediated by valvular in situ leptin synthesis. Clinical implementation of local leptin antagonist therapy may attenuate AngII-induced ATAA and moderate related LV hypertrophy and pre-aortic valve stenosis lesions.
URL: https://www.clinicaltrials.gov/. Unique identifier: NCT00449306.","['angiotensin II', 'aortic aneurysm', 'aortic valve stenosis', 'left ventricular hypertrophy', 'leptin', 'leptin antagonist', 'vascular remodeling']",Journal of the American Heart Association,2016-05-05,"[{'lastname': 'Ben-Zvi', 'firstname': 'Danny', 'initials': 'D', 'affiliation': 'Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA.'}, {'lastname': 'Savion', 'firstname': 'Naphtali', 'initials': 'N', 'affiliation': 'Goldschleger Eye Research Institute, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Kolodgie', 'firstname': 'Frank', 'initials': 'F', 'affiliation': 'CVPath Institute, Gaithersburg, MD.'}, {'lastname': 'Simon', 'firstname': 'Amos', 'initials': 'A', 'affiliation': 'Cancer Research Laboratory, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Fisch', 'firstname': 'Sudeshna', 'initials': 'S', 'affiliation': ""Cardiovascular Physiology Core, Brigham and Women's Hospital, Boston, MA.""}, {'lastname': 'Schäfer', 'firstname': 'Katrin', 'initials': 'K', 'affiliation': 'Medical Clinic 2, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.'}, {'lastname': 'Bachner-Hinenzon', 'firstname': 'Noa', 'initials': 'N', 'affiliation': 'Analyze IT Research Institute, Tuval, Israel.'}, {'lastname': 'Cao', 'firstname': 'Xin', 'initials': 'X', 'affiliation': ""Cardiovascular Physiology Core, Brigham and Women's Hospital, Boston, MA.""}, {'lastname': 'Gertler', 'firstname': 'Arieh', 'initials': 'A', 'affiliation': 'Faculty of Agriculture, Food and Environment, Hebrew University, Rehovot, Israel.'}, {'lastname': 'Solomon', 'firstname': 'Gili', 'initials': 'G', 'affiliation': 'Faculty of Agriculture, Food and Environment, Hebrew University, Rehovot, Israel.'}, {'lastname': 'Kachel', 'firstname': 'Erez', 'initials': 'E', 'affiliation': 'Department of Cardiac Surgery, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Raanani', 'firstname': 'Ehud', 'initials': 'E', 'affiliation': 'Department of Cardiac Surgery, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Lavee', 'firstname': 'Jacob', 'initials': 'J', 'affiliation': 'Department of Cardiac Surgery, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Kotev Emeth', 'firstname': 'Shlomo', 'initials': 'S', 'affiliation': 'Goldschleger Eye Research Institute, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Virmani', 'firstname': 'Renu', 'initials': 'R', 'affiliation': 'CVPath Institute, Gaithersburg, MD.'}, {'lastname': 'Schoen', 'firstname': 'Frederick J', 'initials': 'FJ', 'affiliation': ""Department of Pathology, Brigham and Women's Hospital, Harvard-MIT Division of Health Sciences and Technology, and Harvard Medical School, Boston, MA.""}, {'lastname': 'Schneiderman', 'firstname': 'Jacob', 'initials': 'J', 'affiliation': ""The Gottesdiener Vascular Biology Laboratory, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Department of Vascular Surgery, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Vascular Surgery Research Laboratory, Department of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA jschneid@post.tau.ac.il.""}]",,,,"© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.","10.1161/JAHA.116.003474
10.1161/JAHA.112.001727",<Element 'PubmedArticle' at 0x7f05d99427c0>
193,27131827,Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model.,"Type 2 diabetes mellitus is a risk factor for Alzheimer's disease (AD). The glucagon-like peptide-1 analog liraglutide, a novel long-lasting incretin hormone, has been used to treat type 2 diabetes mellitus. In addition, liraglutide has been shown to be neurotrophic and neuroprotective. Here, we investigated the effects of liraglutide on amyloid β protein (Aβ)-induced AD in mice and explored its mechanism of action. The results showed that subcutaneous administration of liraglutide (25nmol/day), once daily for 8 weeks, prevented memory impairments in the Y Maze and Morris Water Maze following Aβ1-42 intracerebroventricular injection, and alleviated the ultra-structural changes of pyramidal neurons and chemical synapses in the hippocampal CA1 region. Furthermore, liraglutide reduced Aβ1-42-induced tau phosphorylation via the protein kinase B and glycogen synthase kinase-3β pathways. Thus liraglutide may alleviate cognitive impairment in AD by at least decreasing the phosphorylation of tau.","['Alzheimer disease', 'Amyloid beta protein', 'GLP-1', 'GSK-3β', 'Tau protein']",European journal of pharmacology,2016-05-02,"[{'lastname': 'Qi', 'firstname': 'Liqin', 'initials': 'L', 'affiliation': ""Department of Endocrinology, Union Hospital, Fujian Institute of Endocrinology, The Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.""}, {'lastname': 'Ke', 'firstname': 'Linfang', 'initials': 'L', 'affiliation': ""Department of Endocrinology, Union Hospital, Fujian Institute of Endocrinology, The Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.""}, {'lastname': 'Liu', 'firstname': 'Xiaohong', 'initials': 'X', 'affiliation': ""Department of Endocrinology, Union Hospital, Fujian Institute of Endocrinology, The Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.""}, {'lastname': 'Liao', 'firstname': 'Lianming', 'initials': 'L', 'affiliation': ""Department of Endocrinology, Union Hospital, Fujian Institute of Endocrinology, The Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.""}, {'lastname': 'Ke', 'firstname': 'Sujie', 'initials': 'S', 'affiliation': ""Department of Endocrinology, Union Hospital, Fujian Institute of Endocrinology, The Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.""}, {'lastname': 'Liu', 'firstname': 'Xiaoying', 'initials': 'X', 'affiliation': ""Department of Endocrinology, Union Hospital, Fujian Institute of Endocrinology, The Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.""}, {'lastname': 'Wang', 'firstname': 'Yanping', 'initials': 'Y', 'affiliation': ""Department of Endocrinology, Union Hospital, Fujian Institute of Endocrinology, The Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.""}, {'lastname': 'Lin', 'firstname': 'Xiaowei', 'initials': 'X', 'affiliation': ""Department of Endocrinology, Union Hospital, Fujian Institute of Endocrinology, The Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.""}, {'lastname': 'Zhou', 'firstname': 'Yu', 'initials': 'Y', 'affiliation': ""Department of Endocrinology, Union Hospital, Fujian Institute of Endocrinology, The Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.""}, {'lastname': 'Wu', 'firstname': 'Lijuan', 'initials': 'L', 'affiliation': ""Department of Endocrinology, Union Hospital, Fujian Institute of Endocrinology, The Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.""}, {'lastname': 'Chen', 'firstname': 'Zhou', 'initials': 'Z', 'affiliation': ""Department of Pharmacology, College of Pharmacy, Fujian Medical University, Fuzhou, Fujian, People's Republic of China. Electronic address: kellandchen1007@hotmail.com.""}, {'lastname': 'Liu', 'firstname': 'Libin', 'initials': 'L', 'affiliation': ""Department of Endocrinology, Union Hospital, Fujian Institute of Endocrinology, The Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China. Electronic address: libin_liu1@yeah.net.""}]",,,,Copyright © 2016 Elsevier B.V. All rights reserved.,10.1016/j.ejphar.2016.04.052,<Element 'PubmedArticle' at 0x7f05d98e9c20>
194,"27082848
19884572
16344531
23254636
22123177
19158106
20798611
22818528
18234697
21325651
21810890
14595482
3344216
17698705
11255441
25179257
21644037
18703462
21944778
23338682
23463024
23317568
24387985
25355519
22322200
18464284
21482928
16950801
17030534
18245784
24022032
17826340
17949857
22819134
23396349
24771538
12473774
14568818
22581678
19766248",GRN and MAPT Mutations in 2 Frontotemporal Dementia Research Centers in Brazil.,"Mutations in GRN (progranulin) and MAPT (microtubule-associated protein tau) are among the most frequent causes of monogenic frontotemporal dementia (FTD), but data on the frequency of these mutations in regions such as Latin America are still lacking.
We aimed to investigate the frequencies of GRN and MAPT mutations in FTD cohorts from 2 Brazilian dementia research centers, the University of Sao Paulo and the Federal University of Minas Gerais medical schools.
We included 76 probands diagnosed with behavioral-variant FTD (n=55), semantic-variant Primary Progressive Aphasia (PPA) (n=11), or nonfluent-variant PPA (n=10). Twenty-five percent of the cohort had at least 1 relative affected with FTD.
Mutations in GRN were identified in 7 probands, and in MAPT, in 2 probands. We identified 3 novel GRN mutations (p.Q130X, p.317Afs*12, and p.K259Afs*23) in patients diagnosed with nonfluent-variant PPA or behavioral-variant FTD. Plasma progranulin levels were measured and a cutoff value of 70 ng/mL was found, with 100% sensitivity and specificity to detect null GRN mutations.
The frequency of GRN mutations was 9.6% and that of MAPT mutations was 7.1%. Among familial cases of FTD, the frequency of GRN mutations was 31.5% and that of MAPT mutations was 10.5%.",[],Alzheimer disease and associated disorders,2016-04-16,"[{'lastname': 'Takada', 'firstname': 'Leonel T', 'initials': 'LT', 'affiliation': '*Cognitive and Behavioral Neurology Unit, Department of Neurology, Hospital das Clinicas, University of Sao Paulo (USP) Medical School ‡Department of Neurology, Neuroregeneration Center (LIM 45) ∥Department of Pathology §Discipline of Pathophysiology, University of Sao Paulo Medical School, Sao Paulo †Cognitive and Behavioral Neurology Unit, Department of Internal Medicine, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil ¶Department of Neurology, University of California, San Francisco, CA.'}, {'lastname': 'Bahia', 'firstname': 'Valeria S', 'initials': 'VS', 'affiliation': None}, {'lastname': 'Guimarães', 'firstname': 'Henrique C', 'initials': 'HC', 'affiliation': None}, {'lastname': 'Costa', 'firstname': 'Thais V M M', 'initials': 'TV', 'affiliation': None}, {'lastname': 'Vale', 'firstname': 'Thiago C', 'initials': 'TC', 'affiliation': None}, {'lastname': 'Rodriguez', 'firstname': 'Roberta D', 'initials': 'RD', 'affiliation': None}, {'lastname': 'Porto', 'firstname': 'Fabio H G', 'initials': 'FH', 'affiliation': None}, {'lastname': 'Machado', 'firstname': 'João C B', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Beato', 'firstname': 'Rogério G', 'initials': 'RG', 'affiliation': None}, {'lastname': 'Cesar', 'firstname': 'Karolina G', 'initials': 'KG', 'affiliation': None}, {'lastname': 'Smid', 'firstname': 'Jerusa', 'initials': 'J', 'affiliation': None}, {'lastname': 'Nascimento', 'firstname': 'Camila F', 'initials': 'CF', 'affiliation': None}, {'lastname': 'Grinberg', 'firstname': 'Lea T', 'initials': 'LT', 'affiliation': None}, {'lastname': 'Brucki', 'firstname': 'Sonia M D', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Maximino', 'firstname': 'Jessica R', 'initials': 'JR', 'affiliation': None}, {'lastname': 'Camargos', 'firstname': 'Sarah T', 'initials': 'ST', 'affiliation': None}, {'lastname': 'Chadi', 'firstname': 'Gerson', 'initials': 'G', 'affiliation': None}, {'lastname': 'Caramelli', 'firstname': 'Paulo', 'initials': 'P', 'affiliation': None}, {'lastname': 'Nitrini', 'firstname': 'Ricardo', 'initials': 'R', 'affiliation': None}]",,,"Mutations in GRN were identified in 7 probands, and in MAPT, in 2 probands. We identified 3 novel GRN mutations (p.Q130X, p.317Afs*12, and p.K259Afs*23) in patients diagnosed with nonfluent-variant PPA or behavioral-variant FTD. Plasma progranulin levels were measured and a cutoff value of 70 ng/mL was found, with 100% sensitivity and specificity to detect null GRN mutations.",,10.1097/WAD.0000000000000153,<Element 'PubmedArticle' at 0x7f05d98fb6d0>
195,27079710,"Possible Involvement of Adiponectin, the Anti-Diabetes Molecule, in the Pathogenesis of Alzheimer's Disease.","Adiponectin (APN) is protective in animal models of neurodegenerative diseases, but the role of APN in human brain has not been established. Using an enzyme-linked immunosorbent assay, we found that APN was significantly decreased in cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD), compared to those in patients with mild cognitive impairment (MCI) and in normal controls (NC), despite elevation of APN in serum of patients with MCI and AD compared to that in NC. The discrepancy of CSF APN from serum APN in AD may suggest some critical actions of APN in the pathogenesis of AD. Indeed, it was histologically observed that APN was co-localized with tau in neurofibrillary tangles and immunoblot analysis showed that the functional trimers of APN were significantly decreased in AD compared to those in NC. Collectively, a loss of function of APN may be involved in the pathogenesis of AD.","['Adiponectin', 'Alzheimer’s disease', 'cerebrospinal fluid', 'neurofibrillary tangles', 'sequestration', 'serum', 'tau']",Journal of Alzheimer's disease : JAD,2016-04-16,"[{'lastname': 'Waragai', 'firstname': 'Masaaki', 'initials': 'M', 'affiliation': 'Department of Neurology, Higashi Matsudo Municipal Hospital, Matsudo-shi, Chiba, Japan.\nTokyo Metropolitan Institute of Medical Sciences, Setagaya-ku, Tokyo, Japan.'}, {'lastname': 'Adame', 'firstname': 'Anthony', 'initials': 'A', 'affiliation': 'Department of Neurosciences, University of California, San Diego, CA, USA.'}, {'lastname': 'Trinh', 'firstname': 'Ivy', 'initials': 'I', 'affiliation': 'Department of Neurosciences, University of California, San Diego, CA, USA.'}, {'lastname': 'Sekiyama', 'firstname': 'Kazunari', 'initials': 'K', 'affiliation': 'Tokyo Metropolitan Institute of Medical Sciences, Setagaya-ku, Tokyo, Japan.'}, {'lastname': 'Takamatsu', 'firstname': 'Yoshiki', 'initials': 'Y', 'affiliation': 'Tokyo Metropolitan Institute of Medical Sciences, Setagaya-ku, Tokyo, Japan.'}, {'lastname': 'Une', 'firstname': 'Kaori', 'initials': 'K', 'affiliation': 'Department of Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.'}, {'lastname': 'Masliah', 'firstname': 'Eliezer', 'initials': 'E', 'affiliation': 'Department of Neurosciences, University of California, San Diego, CA, USA.'}, {'lastname': 'Hashimoto', 'firstname': 'Makoto', 'initials': 'M', 'affiliation': 'Tokyo Metropolitan Institute of Medical Sciences, Setagaya-ku, Tokyo, Japan.'}]",,,,,10.3233/JAD-151116,<Element 'PubmedArticle' at 0x7f05d99171d0>
196,27061773,Increased insulin-like growth factor-1 levels in cerebrospinal fluid of advanced subacute sclerosing panencephalitis patients.,"Subacute sclerosing panencephalitis (SSPE) is a progressive, lethal disease. Brain histopathology in certain SSPE patients shows, neurofibrillary tangles composed of abnormally phosphorylated, microtubule-associated protein tau (PHF-tau). Because the, phosphorylation of tau is inhibited by insulin and insulin-like growth factor-1 (IGF-1), we investigated cerebrospinal fluid (CSF) insulin and IGF-1 levels in SSPE patients.
In this study CSF IGF-1 and insulin levels of 45 SSPE and 25 age-matched control patients were investigated. CSF IGF-1 levels were significantly higher in SSPE patients at stage 4, compared to other stages (p 0.05). CSF insulin and IGF-1 levels were both positively correlated with serum measles IgG.
The correlation between CSF insulin and IGF-1 levels and serum measles virus IgG titer may be the result of, insulin activating IGF-1 receptors, and consequently, IGF-1 stimulating, plasma cells and enhancing IgG production. Increased IGF-1 may also, inhibit the phosphorylation of tau. Further studies examining the, correlation between IGF-1, insulin, tau, and PHF-tau levels in the same, patients may clarify any possible pathogenetic relation between these, pathways.","['Insulin', 'Insulin-like growth factor-1', 'Neurofibrillary tangles', 'Subacute sclerosing panencephalitis']",European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society,2016-04-12,"[{'lastname': 'Yılmaz', 'firstname': 'Deniz', 'initials': 'D', 'affiliation': 'Kecioren Education Hospital, Ankara, Turkey. Electronic address: dayilmaz2002@yahoo.com.'}, {'lastname': 'Yüksel', 'firstname': 'Deniz', 'initials': 'D', 'affiliation': ""Dr Sami Ulus Children's Hospital, Ankara, Turkey. Electronic address: drdeniz_yuksel@yahoo.com.tr.""}, {'lastname': 'Gökkurt', 'firstname': 'Didem', 'initials': 'D', 'affiliation': 'Polatli State Hospital, Ankara, Turkey. Electronic address: didemakgun@gmail.com.'}, {'lastname': 'Oguz', 'firstname': 'Hava', 'initials': 'H', 'affiliation': 'Hacettepe University, Faculty of Medicine, Pediatric Endocrinology, Ankara, Turkey. Electronic address: hava.oguz@hacettepe.edu.tr.'}, {'lastname': 'Anlar', 'firstname': 'Banu', 'initials': 'B', 'affiliation': 'Hacettepe University, Faculty of Medicine, Pediatric Neurology Department, Ankara, Turkey. Electronic address: banlar@hacettepe.edu.tr.'}]",,,,Copyright © 2016 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.,10.1016/j.ejpn.2016.03.007,<Element 'PubmedArticle' at 0x7f05d991fc70>
197,"26977398
25538606
12808459
26338813
22975160
18063391
25879909
23335884
19457380
20965257
24521566
19340289
23117491
22366791
12803969
25255942
10719151
25134682
21986680
20045477
25662776
1953406
9617910
18835452
19555291
22366795",Patterns of regional cerebellar atrophy in genetic frontotemporal dementia.,"Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder with a strong genetic component. The cerebellum has not traditionally been felt to be involved in FTD but recent research has suggested a potential role.
We investigated the volumetry of the cerebellum and its subregions in a cohort of 44 patients with genetic FTD (20 MAPT, 7 GRN, and 17 C9orf72 mutation carriers) compared with 18 cognitively normal controls. All groups were matched for age and gender. On volumetric T1-weighted magnetic resonance brain images we used an atlas propagation and label fusion strategy of the Diedrichsen cerebellar atlas to automatically extract subregions including the cerebellar lobules, the vermis and the deep nuclei.
The global cerebellar volume was significantly smaller in C9orf72 carriers (mean (SD): 99989 (8939) mm(3)) compared with controls (108136 (7407) mm(3)). However, no significant differences were seen in the MAPT and GRN carriers compared with controls (104191 (6491) mm(3) and 107883 (6205) mm(3) respectively). Investigating the individual subregions, C9orf72 carriers had a significantly lower volume than controls in lobule VIIa-Crus I (15% smaller, p < 0.0005), whilst MAPT mutation carriers had a significantly lower vermal volume (10% smaller, p = 0.001) than controls. All cerebellar subregion volumes were preserved in GRN carriers compared with controls.
There appears to be a differential pattern of cerebellar atrophy in the major genetic forms of FTD, being relatively spared in GRN, localized to the lobule VIIa-Crus I in the superior-posterior region of the cerebellum in C9orf72, the area connected via the thalamus to the prefrontal cortex and involved in cognitive function, and localized to the vermis in MAPT, the 'limbic cerebellum' involved in emotional processing.","['C9orf72', 'Cerebellum', 'Genetic frontotemporal dementia']",NeuroImage. Clinical,2016-03-16,"[{'lastname': 'Bocchetta', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Cardoso', 'firstname': 'M Jorge', 'initials': 'MJ', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; Translational Imaging Group, Centre for Medical Image Computing (CMIC), University College London, UK.'}, {'lastname': 'Cash', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; Translational Imaging Group, Centre for Medical Image Computing (CMIC), University College London, UK.'}, {'lastname': 'Ourselin', 'firstname': 'Sebastien', 'initials': 'S', 'affiliation': 'Translational Imaging Group, Centre for Medical Image Computing (CMIC), University College London, UK.'}, {'lastname': 'Warren', 'firstname': 'Jason D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK. Electronic address: j.rohrer@ucl.ac.uk.'}]",,"There appears to be a differential pattern of cerebellar atrophy in the major genetic forms of FTD, being relatively spared in GRN, localized to the lobule VIIa-Crus I in the superior-posterior region of the cerebellum in C9orf72, the area connected via the thalamus to the prefrontal cortex and involved in cognitive function, and localized to the vermis in MAPT, the 'limbic cerebellum' involved in emotional processing.","The global cerebellar volume was significantly smaller in C9orf72 carriers (mean (SD): 99989 (8939) mm(3)) compared with controls (108136 (7407) mm(3)). However, no significant differences were seen in the MAPT and GRN carriers compared with controls (104191 (6491) mm(3) and 107883 (6205) mm(3) respectively). Investigating the individual subregions, C9orf72 carriers had a significantly lower volume than controls in lobule VIIa-Crus I (15% smaller, p < 0.0005), whilst MAPT mutation carriers had a significantly lower vermal volume (10% smaller, p = 0.001) than controls. All cerebellar subregion volumes were preserved in GRN carriers compared with controls.",,10.1016/j.nicl.2016.02.008,<Element 'PubmedArticle' at 0x7f05d98abe50>
198,26907614,Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer's Disease.,"Brain angiotensin-(1-7) (Ang-(1-7)) concentration has been shown to be reduced and inversely correlated with tau pathology in a mouse model of Alzheimer's disease (AD). In this study, to determine whether the concentration of Ang-(1-7) and the activity of its converting enzyme angiotensin-converting enzyme 2 were altered in plasma under AD context, the plasma samples from 110 AD patients and 128 age- and gender-matched controls were screened. In AD patients, the plasma concentration of Ang-(1-7) was significantly reduced (15.63±4.35pg/mL vs. 19.58±3.22pg/mL, P<0.001) and positively correlated with cognitive functions (R=0.66, P<0.001). Meanwhile, receiver-operating characteristic analysis showed that the Ang-(1-7) concentration in plasma could distinguish AD patients from controls with the sensitivity and specificity of 69.1% and 74.2%, respectively, when the optimal cut-off value (18.2 pg/mL) was chosen. These findings indicate that plasma Ang-(1-7) may represent a potential biomarker for AD diagnosis, and further suggest an involvement of this heptapeptide in the pathogenesis of this disease.",[],Current neurovascular research,2016-02-26,"[{'lastname': 'Jiang', 'firstname': 'Teng', 'initials': 'T', 'affiliation': 'Department of Neurology, Nanjing First Hospital, Nanjing Medical University, No.68, Changle Road, Nanjing, China. jt870918@163.com.'}, {'lastname': 'Tan', 'firstname': 'Lan', 'initials': 'L', 'affiliation': None}, {'lastname': 'Gao', 'firstname': 'Qing', 'initials': 'Q', 'affiliation': None}, {'lastname': 'Lu', 'firstname': 'Huan', 'initials': 'H', 'affiliation': None}, {'lastname': 'Zhu', 'firstname': 'Xi-Chen', 'initials': 'XC', 'affiliation': None}, {'lastname': 'Zhou', 'firstname': 'Jun-Shan', 'initials': 'JS', 'affiliation': None}, {'lastname': 'Zhang', 'firstname': 'Ying-Dong', 'initials': 'YD', 'affiliation': None}]",,,,,10.2174/1567202613666160224124739,<Element 'PubmedArticle' at 0x7f05d98c7860>
199,26890764,Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.,"The endogenous cannabinoid system represents a promising therapeutic target to modify neurodegenerative pathways linked to Alzheimer's disease (AD). The aim of the present study was to evaluate the specific contribution of CB2 receptor to the progression of AD-like pathology and its role in the positive effect of a cannabis-based medicine (1:1 combination of Δ9-tetrahidrocannabinol and cannabidiol) previously demonstrated to be beneficial in the AβPP/PS1 transgenic model of the disease. A new mouse strain was generated by crossing AβPP/PS1 transgenic mice with CB2 knockout mice. Results show that lack of CB2 exacerbates cortical Aβ deposition and increases the levels of soluble Aβ40. However, CB2 receptor deficiency does not affect the viability of AβPP/PS1 mice, does not accelerate their memory impairment, does not modify tau hyperphosphorylation in dystrophic neurites associated to Aβ plaques, and does not attenuate the positive cognitive effect induced by the cannabis-based medicine in these animals. These findings suggest a minor role for the CB2 receptor in the therapeutic effect of the cannabis-based medicine in AβPP/PS1 mice, but also constitute evidence of a link between CB2 receptor and Aβ processing.","['Alzheimer’s disease', 'AβPP/PS1 mice', 'amyloid', 'cannabinoid receptor 2', 'cognitive impairment', 'tau', 'therapy', 'Δ9-tetrahidrocannabinol and cannabidiol']",Journal of Alzheimer's disease : JAD,2016-02-19,"[{'lastname': 'Aso', 'firstname': 'Ester', 'initials': 'E', 'affiliation': ""Institut de Neuropatologia, Servei d'Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.\nCIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto Carlos III, Spain.""}, {'lastname': 'Andrés-Benito', 'firstname': 'Pol', 'initials': 'P', 'affiliation': ""Institut de Neuropatologia, Servei d'Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.\nCIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto Carlos III, Spain.""}, {'lastname': 'Carmona', 'firstname': 'Margarita', 'initials': 'M', 'affiliation': ""Institut de Neuropatologia, Servei d'Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.\nCIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto Carlos III, Spain.""}, {'lastname': 'Maldonado', 'firstname': 'Rafael', 'initials': 'R', 'affiliation': 'Laboratori de Neurofarmacologia, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.'}, {'lastname': 'Ferrer', 'firstname': 'Isidre', 'initials': 'I', 'affiliation': ""Institut de Neuropatologia, Servei d'Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.\nCIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto Carlos III, Spain.""}]",,,,,10.3233/JAD-150913,<Element 'PubmedArticle' at 0x7f05d98d4770>
200,26883687,Time-course changes in muscle protein degradation in heat-stressed chickens: Possible involvement of corticosterone and mitochondrial reactive oxygen species generation in induction of the ubiquitin-proteasome system.,"Heat stress (HS) induces muscle protein degradation as well as production of mitochondrial reactive oxygen species (ROS). In the present study, to improve our understanding of how protein degradation is induced by HS treatment in birds, a time course analysis of changes in the circulating levels of glucocorticoid and N(τ)-methylhistidine, muscle proteolysis-related gene expression, and mitochondrial ROS generation, was conducted. At 25 days of age, chickens were exposed to HS conditions (33 °C) for 0, 0.5, 1 or 3 days. While no alteration in plasma N(τ)-methylhistidine concentration relative to that of the control group was observed in the 0.5 day HS group, the concentration was significantly higher in the 3-d HS treatment group. Plasma corticosterone concentrations increased in response to 0.5-d HS treatment, but subsequently returned to near-normal values. HS treatment for 0.5 days did not change the levels of μ-calpain, cathepsin B, or proteasome C2 subunit mRNA, but increased the levels of mRNA encoding atrogin-1 (P<0.05) and its transcription factor, forkhead box O3 (P=0.09). Under these hyperthermic conditions, mitochondrial superoxide production was significantly increased than that of thermoneutral control. Here, we show that HS-induced muscle protein degradation may be due to the activation of ubiquitination by atrogin-1, and that this process may involve mitochondrial ROS production as well as corticosterone secretion.","['Atrogin-1', 'FoxO', 'N(τ)-methylhistidine', 'Oxidative stress', 'Superoxide']",General and comparative endocrinology,2016-02-18,"[{'lastname': 'Furukawa', 'firstname': 'Kyohei', 'initials': 'K', 'affiliation': 'Animal Nutrition, Life Sciences, Graduate School of Agricultural Science, Tohoku University, 1-1 Tsutsumidori-Amamiyamachi, Aoba-ku, Miyagi, Sendai 981-8555, Japan.'}, {'lastname': 'Kikusato', 'firstname': 'Motoi', 'initials': 'M', 'affiliation': 'Animal Nutrition, Life Sciences, Graduate School of Agricultural Science, Tohoku University, 1-1 Tsutsumidori-Amamiyamachi, Aoba-ku, Miyagi, Sendai 981-8555, Japan. Electronic address: kmotoi@bios.tohoku.ac.jp.'}, {'lastname': 'Kamizono', 'firstname': 'Tomomi', 'initials': 'T', 'affiliation': 'Animal Nutrition, Life Sciences, Graduate School of Agricultural Science, Tohoku University, 1-1 Tsutsumidori-Amamiyamachi, Aoba-ku, Miyagi, Sendai 981-8555, Japan.'}, {'lastname': 'Toyomizu', 'firstname': 'Masaaki', 'initials': 'M', 'affiliation': 'Animal Nutrition, Life Sciences, Graduate School of Agricultural Science, Tohoku University, 1-1 Tsutsumidori-Amamiyamachi, Aoba-ku, Miyagi, Sendai 981-8555, Japan.'}]",,,,Copyright © 2016 Elsevier Inc. All rights reserved.,10.1016/j.ygcen.2016.02.007,<Element 'PubmedArticle' at 0x7f05d98646d0>
201,"26836182
10858586
12921904
12509851
16307829
12933918
23824488
19884614
16960575
20303880
15681802
7635444
16081203
8782901
11160388
25024322
22890100
21035623
25254036
21029241
25865441
8863508
9566405
9930748
12542908
11561025
10227624
12023417
12377381
16056141
16005548
17456872
18243252
18050329
20157252
19584447
20713315
21987546
23100402
17599699
12489094
22701578
20051356
24852682
24094581
19260027
8080390
6610841
21514250
25155658
24936424
22119648
24199958
20114082
21352927
15193596
10524599
21514248
9225377
8757628
22303443
21182970
21196063
10806312
26147946
9700652
17296833
23142525
14643379
15823755
11831556
11137759
23539189
24936411
23877934
23332364
23137948
25978969
16212664
21729288",Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.,"The immune response in Alzheimer's disease (AD) involves activation of microglia which may remove amyloid-β (Aβ). However, overproduction of inflammatory compounds may exacerbate neural damage in AD. AD pathology accumulates years before diagnosis, yet the extent to which neuroinflammation is involved in the earliest disease stages is unknown.
To determine whether neuroinflammation exacerbates neural damage in preclinical AD.
We utilized cerebrospinal fluid (CSF) and magnetic resonance imaging collected in 192 asymptomatic late-middle-aged adults (mean age = 60.98 years). Neuroinflammatory markers chitinase-3-like protein 1 (YKL-40) and monocyte chemoattractant protein-1 (MCP-1) in CSF were utilized as markers of neuroinflammation. Neural cell damage was assessed using CSF neurofilament light chain protein (NFL), CSF total tau (T-Tau), and neural microstructure assessed with diffusion tensor imaging (DTI). With regard to AD pathology, CSF Aβ42 and tau phosphorylated at threonine 181 (P-Tau181) were used as markers of amyloid and tau pathology, respectively. We hypothesized that higher YKL-40 and MCP-1 in the presence of AD pathology would be associated with higher NFL, T-Tau, and altered microstructure on DTI.
Neuroinflammation was associated with markers of neural damage. Higher CSF YKL-40 was associated with both higher CSF NFL and T-Tau. Inflammation interacted with AD pathology, such that greater MCP-1 and lower Aβ42 was associated with altered microstructure in bilateral frontal and right temporal lobe and that greater MCP-1 and greater P-Tau181 was associated with altered microstructure in precuneus.
Inflammation may play a role in neural damage in preclinical AD.","['Alzheimer’s disease', 'cerebrospinal fluid proteins', 'diffusion tensor imaging', 'inflammation']",Journal of Alzheimer's disease : JAD,2016-02-03,"[{'lastname': 'Melah', 'firstname': 'Kelsey E', 'initials': 'KE', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.""}, {'lastname': 'Lu', 'firstname': 'Sharon Yuan-Fu', 'initials': 'SY', 'affiliation': 'Waisman Laboratory for Brain Imaging and Behavior, Madison, WI, USA.'}, {'lastname': 'Hoscheidt', 'firstname': 'Siobhan M', 'initials': 'SM', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.""}, {'lastname': 'Alexander', 'firstname': 'Andrew L', 'initials': 'AL', 'affiliation': 'Waisman Laboratory for Brain Imaging and Behavior, Madison, WI, USA.'}, {'lastname': 'Adluru', 'firstname': 'Nagesh', 'initials': 'N', 'affiliation': 'Waisman Laboratory for Brain Imaging and Behavior, Madison, WI, USA.'}, {'lastname': 'Destiche', 'firstname': 'Daniel J', 'initials': 'DJ', 'affiliation': 'Waisman Laboratory for Brain Imaging and Behavior, Madison, WI, USA.'}, {'lastname': 'Carlsson', 'firstname': 'Cynthia M', 'initials': 'CM', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.""}, {'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': 'Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.\nUCL Institute of Neurology, Queen Square, London, UK.'}, {'lastname': 'Blennow', 'firstname': 'Kaj', 'initials': 'K', 'affiliation': 'Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.'}, {'lastname': 'Okonkwo', 'firstname': 'Ozioma C', 'initials': 'OC', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.\nWisconsin Alzheimer's Institute, School of Medicine and Public Health, Madison, WI, USA.""}, {'lastname': 'Gleason', 'firstname': 'Carey E', 'initials': 'CE', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.\nGeriatric Research Education and Clinical Center, Wm. S. Middleton Memorial Veterans Hospital, Madison, WI, USA.""}, {'lastname': 'Dowling', 'firstname': 'N Maritza', 'initials': 'NM', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.\nDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.""}, {'lastname': 'Bratzke', 'firstname': 'Lisa C', 'initials': 'LC', 'affiliation': 'School of Nursing, Wisconsin School of Medicine and Public Health, Madison, WI, USA.'}, {'lastname': 'Rowley', 'firstname': 'Howard A', 'initials': 'HA', 'affiliation': 'Department of Neuroradiology, School of Medicine and Public Health, Madison, WI, USA.'}, {'lastname': 'Sager', 'firstname': 'Mark A', 'initials': 'MA', 'affiliation': ""Wisconsin Alzheimer's Institute, School of Medicine and Public Health, Madison, WI, USA.""}, {'lastname': 'Asthana', 'firstname': 'Sanjay', 'initials': 'S', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.\nGeriatric Research Education and Clinical Center, Wm. S. Middleton Memorial Veterans Hospital, Madison, WI, USA.""}, {'lastname': 'Johnson', 'firstname': 'Sterling C', 'initials': 'SC', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.\nWisconsin Alzheimer's Institute, School of Medicine and Public Health, Madison, WI, USA.\nGeriatric Research Education and Clinical Center, Wm. S. Middleton Memorial Veterans Hospital, Madison, WI, USA.""}, {'lastname': 'Bendlin', 'firstname': 'Barbara B', 'initials': 'BB', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.\nWisconsin Alzheimer's Institute, School of Medicine and Public Health, Madison, WI, USA.""}]",,Inflammation may play a role in neural damage in preclinical AD.,"Neuroinflammation was associated with markers of neural damage. Higher CSF YKL-40 was associated with both higher CSF NFL and T-Tau. Inflammation interacted with AD pathology, such that greater MCP-1 and lower Aβ42 was associated with altered microstructure in bilateral frontal and right temporal lobe and that greater MCP-1 and greater P-Tau181 was associated with altered microstructure in precuneus.",,10.3233/JAD-150897,<Element 'PubmedArticle' at 0x7f05d9873cc0>
202,26836157,Effect of Continuous Propofol Infusion in Rat on Tau Phosphorylation with or without Temperature Control.,"Several studies suggest a relationship between anesthesia-induced tau hyperphosphorylation and the development of postoperative cognitive dysfunction. This study further characterized the effects of continuous propofol infusion on tau protein phosphorylation in rats, with or without temperature control. Propofol was administered intravenously to 8-10-week-old male Sprague-Dawley rats and infused to the loss of the righting reflex for 2 h continuously. Proteins from cortex and hippocampus were examined by western blot and immunohistochemistry. Rectal temperature was significantly decreased during propofol infusion. Propofol with hypothermia significantly increased phosphorylation of tau at AT8, AT180, Thr205, and Ser199 in cortex and hippocampus except Ser396. With temperature maintenance, propofol still induced significant elevation of AT8, Thr205, and Ser199 in cortex and hippocampus; however, increase of AT180 and Ser396 was only found in hippocampus and cortex, respectively. Differential effects of propofol with or without hypothermia on multiple tau related kinases, such as Akt/GSK3β, MAPK pathways, or phosphatase (PP2A), were demonstrated in region-specific manner. These findings indicated that propofol increased tau phosphorylation under both normothermic and hypothermic conditions, and temperature control could partially attenuate the hyperphosphorylation of tau. Further studies are warranted to determine the long-term impact of propofol on the tau pathology and cognitive functions.","['Hypothermia', 'propofol', 'protein kinases', 'tau phosphorylation']",Journal of Alzheimer's disease : JAD,2016-02-03,"[{'lastname': 'Huang', 'firstname': 'Chunxia', 'initials': 'C', 'affiliation': 'Department of Anaesthesiology, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.\nLaboratory of Neurodegenerative Diseases, School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.'}, {'lastname': 'Ng', 'firstname': 'Olivia Tsz-Wa', 'initials': 'OT', 'affiliation': 'Laboratory of Neurodegenerative Diseases, School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.\nState Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong SAR, China.'}, {'lastname': 'Ho', 'firstname': 'Yuen-Shan', 'initials': 'YS', 'affiliation': 'School of Nursing, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, China.'}, {'lastname': 'Irwin', 'firstname': 'Michael Garnet', 'initials': 'MG', 'affiliation': 'Department of Anaesthesiology, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.\nResearch Centre of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.'}, {'lastname': 'Chang', 'firstname': 'Raymond Chuen-Chung', 'initials': 'RC', 'affiliation': 'Laboratory of Neurodegenerative Diseases, School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.\nResearch Centre of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.\nState Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong SAR, China.'}, {'lastname': 'Wong', 'firstname': 'Gordon Tin-Chun', 'initials': 'GT', 'affiliation': 'Department of Anaesthesiology, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.\nResearch Centre of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.'}]",,,,,10.3233/JAD-150645,<Element 'PubmedArticle' at 0x7f05d9828ea0>
203,26778730,Spontaneous convexity subarachnoid haemorrhage: Clinical series of 3 patients with associated cerebral amyloid angiopathy.,"Convexity subarachnoid haemorrhage (cSAH) is a rare type of spontaneous, non-traumatic, and nonaneurysmal SAH characterised by blood collections in one or more cortical sulci in the convexity of the brain; the aetiology varies. We report a clinical case series of 3 patients with cSAH associated with probable cerebral amyloid angiopathy (CAA) who presented with focal sensory seizures and responded well to corticosteroid treatment.
Case 1 was a 67-year-old man reporting right-sided paroxysmal sensory episodes with Jacksonian progression, cheiro-oral symptoms, and motor dysphasia. Case 2 was a 79-year-old man reporting left-sided paroxysmal episodes with cheiro-oral signs and dysarthria. Case 3 was a 71-year-old woman also reporting recurrent left cheiro-oral signs and dysarthria. None of the patients had headache or clinical dementia. Aneurysms were ruled out using MR angiography.
Brain CT scan detected an isolated hyperintensity in a sulcus of the frontal convexity; brain gradient echo T2-weighted MRI sequences showed meningeal haemosiderosis and microbleeds. However, no atrophy was identified in medial temporal lobes including the hippocampal formation. All patients had low levels of beta-amyloid in CSF, low values on the Hulstaert index and high levels of phosphorylated tau protein. Patients were initially treated with prednisone and levetiracetam, but symptoms recurred in 2 patients after prednisone was discontinued.
We present a series of 3 patients with cSAH associated with CAA, characterised by a stereotypical syndrome responding well to corticoid treatment; there were no cases of headache or clinical dementia.","['Apolipoprotein E', 'Apolipoproteína E', 'Beta-amyloid peptide', 'Cheiro-oral symptoms', 'Hemorragia subaracnoidea', 'Hemosiderosis meníngea', 'Meningeal haemosiderosis', 'Microbleeds', 'Microsangrados', 'Péptido beta-amiloide', 'Subarachnoid haemorrhage', 'Síntomas queiroorales']","Neurologia (Barcelona, Spain)",2016-01-19,"[{'lastname': 'García Estévez', 'firstname': 'D A', 'initials': 'DA', 'affiliation': 'Unidad de Neurología, Hospital Comarcal de Monforte de Lemos, Monforte de Lemos, Lugo, España. Electronic address: daniel.apolinar.garcia.estevez@sergas.es.'}, {'lastname': 'García-Dorrego', 'firstname': 'R M', 'initials': 'RM', 'affiliation': 'Servicio de Radiología, Hospital Comarcal de Monforte de Lemos, Monforte de Lemos, Lugo, España.'}, {'lastname': 'Nieto-Baltar', 'firstname': 'B', 'initials': 'B', 'affiliation': 'Servicio de Radiología, Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, España.'}, {'lastname': 'Marey-Garrido', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Servicio de Radiología, Hospital Comarcal de Monforte de Lemos, Monforte de Lemos, Lugo, España.'}, {'lastname': 'Hierro-Torner', 'firstname': 'T', 'initials': 'T', 'affiliation': 'Servicio de Radiología, Hospital Comarcal de Monforte de Lemos, Monforte de Lemos, Lugo, España.'}]",,,"Brain CT scan detected an isolated hyperintensity in a sulcus of the frontal convexity; brain gradient echo T2-weighted MRI sequences showed meningeal haemosiderosis and microbleeds. However, no atrophy was identified in medial temporal lobes including the hippocampal formation. All patients had low levels of beta-amyloid in CSF, low values on the Hulstaert index and high levels of phosphorylated tau protein. Patients were initially treated with prednisone and levetiracetam, but symptoms recurred in 2 patients after prednisone was discontinued.","Copyright © 2015 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved.",10.1016/j.nrl.2015.11.004,<Element 'PubmedArticle' at 0x7f05d98382c0>
204,26777665,Hypothermia mediates age-dependent increase of tau phosphorylation in db/db mice.,"Accumulating evidence from epidemiological studies suggest that type 2 diabetes is linked to an increased risk of Alzheimer's disease (AD). However, the consequences of type 2 diabetes on AD pathologies, such as tau hyperphosphorylation, are not well understood. Here, we evaluated the impact of type 2 diabetes on tau phosphorylation in db/db diabetic mice aged 4 and 26weeks. We found increased tau phosphorylation at the CP13 epitope correlating with a deregulation of c-Jun. N-terminal kinase (JNK) and Protein Phosphatase 2A (PP2A) in 4-week-old db/db mice. 26-week-old db/db mice displayed tau hyperphosphorylation at multiple epitopes (CP13, AT8, PHF-1), but no obvious change in kinases or phosphatases, no cleavage of tau, and no deregulation of central insulin signaling pathways. In contrast to younger animals, 26-week-old db/db mice were hypothermic and restoration of normothermia rescued phosphorylation at most epitopes. Our results suggest that, at early stages of type 2 diabetes, changes in tau phosphorylation may be due to deregulation of JNK and PP2A, while at later stages hyperphosphorylation is mostly a consequence of hypothermia. These results provide a novel link between diabetes and tau pathology, and underlie the importance of recording body temperature to better understand the relationship between diabetes and AD.","[""Alzheimer's disease"", 'Diabetes mellitus', 'Hippocampus', 'Hypothermia', 'Kinase', 'Phosphatase', 'Tau hyperphosphorylation', 'Temperature', 'Thermoregulation', 'db/db mice']",Neurobiology of disease,2016-01-19,"[{'lastname': 'El Khoury', 'firstname': 'Noura B', 'initials': 'NB', 'affiliation': ""Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Gratuze', 'firstname': 'Maud', 'initials': 'M', 'affiliation': ""Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Petry', 'firstname': 'Franck', 'initials': 'F', 'affiliation': ""Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Papon', 'firstname': 'Marie-Amélie', 'initials': 'MA', 'affiliation': ""Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Julien', 'firstname': 'Carl', 'initials': 'C', 'affiliation': ""Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Marcouiller', 'firstname': 'François', 'initials': 'F', 'affiliation': ""Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Morin', 'firstname': 'Françoise', 'initials': 'F', 'affiliation': ""Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Nicholls', 'firstname': 'Samantha B', 'initials': 'SB', 'affiliation': ""MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Alzheimer's Disease Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.""}, {'lastname': 'Calon', 'firstname': 'Frédéric', 'initials': 'F', 'affiliation': ""Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada; Université Laval, Faculté de Pharmacie, Québec, Canada.""}, {'lastname': 'Hébert', 'firstname': 'Sébastien S', 'initials': 'SS', 'affiliation': ""Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada.""}, {'lastname': 'Marette', 'firstname': 'André', 'initials': 'A', 'affiliation': ""Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, QC, Canada.""}, {'lastname': 'Planel', 'firstname': 'Emmanuel', 'initials': 'E', 'affiliation': ""Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada. Electronic address: emmanuel@planel.org.""}]",,,,Copyright © 2016 Elsevier Inc. All rights reserved.,10.1016/j.nbd.2016.01.005,<Element 'PubmedArticle' at 0x7f05d9846ae0>
205,"26701291
22533436
17151290
12234175
11837744
20837822
10799542
23132321
11085989
10729790
7624778
23798682
16413228
24614172
22704263
16249434
8584938
9442812
8532024
18614690
16690869
9380271
16266773
24858405
11742217
19367261
10482243
16293343
24529528
9247005
11563964
16306348
23152597
11013246
20308782
18801339
17993459
9873206
7624777
16942441
23029293
18024215
12726816
15615638
21281635
19936237
19819959
17955025
14695347
14695347
21123564
20472896
2424016
11904757
23050084
22211890
10938436
17108166
10932182
12150780
20009056
12507904
19471248
20558294
16406150
20042680
20042680
20157255
16236384
2734001
12503980
7822317
11708988
12697721
24916066
23274884
11677594
17472708
16914228
8923837
18769731
21335656
18077675
23619198
9629852
19358976
12623993
21163346
18335524
10890871
14988302
10617129
16873679
21366474
11734601
15542619
9535108
10775532
10229302
16522636
20643941
10194465
15203246
1057175
16958643
16300445
2424015
18952836
15326238
17600230
12101402
18414476","Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease.","Obesity and type 2 diabetes mellitus (T2DM) convey an increased risk for developing dementia. The microtubule-associated protein tau is implicated in neurodegenerative disease by undergoing hyperphosphorylation and aggregation, leading to cytotoxicity and neurodegeneration. Enzymes involved in the regulation of tau phosphorylation, such as GSK3β, are tightly associated with pathways found to be dysregulated in T2DM. We have shown previously that leptin-resistant mice, which develop obesity and a diabetic phenotype, display elevated levels of tau phosphorylation. Here we show cells cultured with leptin, an adipokine shown to have neuroprotective effects, reduces tau phosphorylation. To explore how this mechanism works in vivo we transduced an existing diabetic mouse line (Lepr(db/db)) with a tau mutant (tau(P301L)) via adeno-associated virus (AAV). The resulting phenotype included a striking increase in tau phosphorylation and the number of neurofibrillary tangles (NFTs) found within the hippocampus. We conclude that leptin resistance-induced obesity and diabetes accelerates the development of tau pathology. This model of metabolic dysfunction and tauopathy provides a new system in which to explore the mechanisms underlying the ways in which leptin resistance and diabetes influence development of tau pathology, and may ultimately be related to the development of NFTs.","['Alzheimer’s disease', 'diabetes', 'leptin', 'obesity', 'tau']",Neuroscience,2015-12-25,"[{'lastname': 'Platt', 'firstname': 'T L', 'initials': 'TL', 'affiliation': 'Department of Molecular and Cellular Biochemistry, University of Kentucky, United States.'}, {'lastname': 'Beckett', 'firstname': 'T L', 'initials': 'TL', 'affiliation': 'Sanders Brown Center on Aging, University of Kentucky, United States.'}, {'lastname': 'Kohler', 'firstname': 'K', 'initials': 'K', 'affiliation': 'Sanders Brown Center on Aging, University of Kentucky, United States.'}, {'lastname': 'Niedowicz', 'firstname': 'D M', 'initials': 'DM', 'affiliation': 'Department of Molecular and Cellular Biochemistry, University of Kentucky, United States; Sanders Brown Center on Aging, University of Kentucky, United States.'}, {'lastname': 'Murphy', 'firstname': 'M P', 'initials': 'MP', 'affiliation': 'Department of Molecular and Cellular Biochemistry, University of Kentucky, United States; Sanders Brown Center on Aging, University of Kentucky, United States. Electronic address: mpmurp3@email.uky.edu.'}]",,,,Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2015.12.011,<Element 'PubmedArticle' at 0x7f05d98594a0>
206,26577520,"Aging as a Precipitating Factor in Chronic Restraint Stress-Induced Tau Aggregation Pathology, and the Protective Effects of Rosmarinic Acid.","Stress is an important risk factor of Alzheimer's disease (AD). It has been evidenced that stress could induce tau phosphorylation and increase tau insolubility in brain; however, little is known about the interactional effect of stress with aging on tauopathy. Therefore, we explored the effects of aging on stress-induced tauopathy and the potential mechanism in mouse model of chronic restraint stress (CRS). Here we found that in general, the level of phosphorylated tau (P-tau) was higher in brain of middle-aged mice than that in adult mice under physiological conditions. CRS-induced tau phosphorylation and its insolubility were more prominent in middle-aged mice. The increase of AT8-labeled insoluble P-tau was dramatic in middle-aged mice, which was highly ubiquitinated but did not form PHF structures. The levels of chaperones were relatively lower in middle-aged mice brain; CRS further reduced the expression, especially for HDJ2/HSP40. CRS also suppressed the expression of Pin1, the peptidylprolyl cis/trans isomerase, in middle-aged mice but not in adult mice. Downregulation of HSP40 or Pin1 caused an increase of transfected extraneous tau in 293 cells. Rosmarinic acid (RA) could effectively suppress the elevation of P-tau and insoluble P-tau formation induced by CRS, and reversed the abnormal changes of chaperones and Pin1 particularly in middle-aged mice. Taken together, our findings provided evidence that aging could be a promoting factor in stress-induced tauopathy, which was relevant with malregulation of chaperones and Pin1, and RA might be a promising beneficial agent for stress-induced tauopathy.","['Aging', 'chaperones', 'chronic restraint stress', 'insolubility', 'rosmarinic acid', 'tau phosphorylation']",Journal of Alzheimer's disease : JAD,2015-11-19,"[{'lastname': 'Shan', 'firstname': 'Ye', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Dan-Dan', 'initials': 'DD', 'affiliation': None}, {'lastname': 'Xu', 'firstname': 'Yu-Xia', 'initials': 'YX', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Chu', 'initials': 'C', 'affiliation': None}, {'lastname': 'Cao', 'firstname': 'Lan', 'initials': 'L', 'affiliation': None}, {'lastname': 'Liu', 'firstname': 'Yun-Sheng', 'initials': 'YS', 'affiliation': None}, {'lastname': 'Zhu', 'firstname': 'Cui-Qing', 'initials': 'CQ', 'affiliation': None}]",,,,,10.3233/JAD-150486,<Element 'PubmedArticle' at 0x7f05d9811e50>
207,26473392,"Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations.","Our objective was to compare the clinical and pathological characteristics of frontotemporal dementia patients with MAPT, GRN and C9orf72 gene mutations. We carried out a cross-sectional comparative study of 74 gene-positive patients (15 MAPT, 17 GRN and 42 C9orf72). Thirty had post mortem pathological data permitting clinico-pathological correlation. MAPT patients were younger than other groups, and showed more frequent behavioural disinhibition, repetitive and stereotyped behaviours, semantic impairment and temporal predominance of atrophy. GRN patients were older at death and more likely to present with non-fluent aphasia. C9orf72 patients alone showed a co-occurrence of ALS. They showed more psychotic symptoms and irrational behaviour, yet were more often reported clinically as socially appropriate and warm. They showed less dietary change than other groups. C9orf72 patients with and without ALS differed only in frequency of psychosis. Greater clinical overlap was observed between GRN and C9orf72 compared to MAPT cases. MAPT cases had tau and GRN and C9orf72, with one exception, TDP-43 pathology. Non-fluent aphasia was linked to TDP subtype A in both GRN and C9orf72 cases and ALS with subtype B. In conclusion, the findings reinforce clinical heterogeneity in FTD and strengthen evidence that genotype influences clinical presentation. Clinical features may inform targeted genetic testing.","['Frontotemporal dementia', 'behaviour', 'clinical phenotype', 'gene mutation', 'neuropathology']",Amyotrophic lateral sclerosis & frontotemporal degeneration,2015-10-17,"[{'lastname': 'Snowden', 'firstname': 'Julie S', 'initials': 'JS', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Adams', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Harris', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Thompson', 'firstname': 'Jennifer C', 'initials': 'JC', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Rollinson', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'b Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Richardson', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Jones', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Neary', 'firstname': 'David', 'initials': 'D', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.'}, {'lastname': 'Mann', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'b Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Pickering-Brown', 'firstname': 'Stuart', 'initials': 'S', 'affiliation': 'b Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}]",,,,,10.3109/21678421.2015.1074700,<Element 'PubmedArticle' at 0x7f05d97a2630>
208,26402111,Adipose Tissue Distribution in Patients with Alzheimer's Disease: A Whole Body MRI Case-Control Study.,"Total and central adiposity have been associated with increased risk of Alzheimer's disease (AD). Visceral and subcutaneous adipose tissues have different metabolic characteristics and could therefore be differentially associated with AD.
To compare regional fat distribution determined by magnetic resonance imaging (MRI) in AD patients and healthy controls and investigate associations with stage of the disease and chemical markers. The investigation was performed in a prospective case-control study.
We examined thirty patients with mild to moderate AD by whole-body MRI (1.5 T) and clinical questionnaires in comparison to thirty cognitively healthy age- and gender-matched study participants. Volumes of total, subcutaneous, and visceral body fat tissue were determined by an unbiased automatic analysis algorithm. Levels of leptin, ghrelin, and adiponectin were determined in serum, amyloid-β (Aβ)(1-42) and tau protein levels in cerebrospinal fluid (CSF).
Male AD patients displayed significantly more total fat tissue than male controls. This difference was not observed in women. We observed a trend toward higher volume of visceral fat tissue in all patients (p = 0.13). Severity of disease was not associated with fat distribution in our study. Increased leptin levels correlated with lower CSF Aβ(1-42) in female, but not in male, AD patients.
Fat volume is increased in male, but not in female AD patients. Negative correlation of leptin levels and CSF Aβ(1-42) in females might be one co-factor for the increased AD risk of females. Further studies are required to confirm this gender difference in fat volume during AD and evaluate its pathophysiological importance.","['Leptin', 'magnetic resonance imaging', 'subcutaneous fat', 'visceral fat']",Journal of Alzheimer's disease : JAD,2015-09-25,"[{'lastname': 'Diehl-Wiesenecker', 'firstname': 'Eva', 'initials': 'E', 'affiliation': 'Department of Neurology, Ulm University, Ulm, Germany.'}, {'lastname': 'von Armin', 'firstname': 'Christine A F', 'initials': 'CA', 'affiliation': 'Department of Neurology, Ulm University, Ulm, Germany.'}, {'lastname': 'Dupuis', 'firstname': 'Luc', 'initials': 'L', 'affiliation': 'Department of Neurology, Ulm University, Ulm, Germany.\nInserm U1118, Mécanismes centraux et périphériques de la neurodegenerescence, Strasbourg, France.\nUniversité de Strasbourg, Faculté de Médecine, UMR_S1118, Strasbourg, France.'}, {'lastname': 'Müller', 'firstname': 'Hans-Peter', 'initials': 'HP', 'affiliation': 'Department of Neurology, Ulm University, Ulm, Germany.'}, {'lastname': 'Ludolph', 'firstname': 'Albert C', 'initials': 'AC', 'affiliation': 'Department of Neurology, Ulm University, Ulm, Germany.'}, {'lastname': 'Kassubek', 'firstname': 'Jan', 'initials': 'J', 'affiliation': 'Department of Neurology, Ulm University, Ulm, Germany.'}]",,,"Male AD patients displayed significantly more total fat tissue than male controls. This difference was not observed in women. We observed a trend toward higher volume of visceral fat tissue in all patients (p = 0.13). Severity of disease was not associated with fat distribution in our study. Increased leptin levels correlated with lower CSF Aβ(1-42) in female, but not in male, AD patients.",,10.3233/JAD-150426,<Element 'PubmedArticle' at 0x7f05d97b0ea0>
209,"26373814
18602817
20238402
23532958
12464347
15014175
18478238
21915069
18717656
18299999
17431646
20132926
17645580
18992344
15592467
17017859
9151015
11410727
12088287
15750214
19542621
21063035
24370929
16988486
18616667
18505416
19777393
19393862
20034403
20693650
20814553
8989772
21723318
9005851
22162230
7747600
17923369
24924665
20888407
25169748
24096296
10799086
18717815
22178884
16054982
21682752
18845238
7997056
19941067
19374888
17375135
8664810
22285544
12614280
24202912
21445263
16627931
23363978
3390968
22577490
24699333
21428986
21303840
24275321
17673211
1469101
8307999
23016132
23550918
12670480
3657748
23862076
22997409
22706383
3180100
16340083
18381539
14992787
17559547
7533231
18760715
25106033
21790669
17127134
10991772
16909201
10817843
15750215
24795209
23516262
19276553
20387270
20302640
20444641
8118807
16724068
14556645
19156697
21310443
12700235
22699086
17187424
23151138
21720761
1471772",Differential Contributions of Alcohol and the Nicotine-Derived Nitrosamine Ketone (NNK) to Insulin and Insulin-Like Growth Factor Resistance in the Adolescent Rat Brain.,"Since epidemiologic studies suggest that tobacco smoke toxins, e.g. the nicotine-derived nitrosamine ketone (NNK) tobacco-specific nitrosamine, can be a co-factor in alcohol-related brain disease (ARBD), we examined the independent and additive effects of alcohol and NNK exposures on spatial learning/memory, and brain insulin/IGF signaling, neuronal function and oxidative stress.
Adolescent Long Evans rats were fed liquid diets containing 0 or 26% caloric ethanol for 8 weeks. During weeks 3-8, rats were treated with i.p. NNK (2 mg/kg, 3×/week) or saline. In weeks 7-8, ethanol groups were binge-administered ethanol (2 g/kg; 3×/week). In week 8, at 12 weeks of age, rats were subjected to Morris Water Maze tests. Temporal lobes were used to assess molecular indices of insulin/IGF resistance, oxidative stress and neuronal function.
Ethanol and NNK impaired spatial learning, and NNK ± ethanol impaired memory. Linear trend analysis demonstrated worsening performance from control to ethanol, to NNK, and then ethanol + NNK. Ethanol ± NNK, caused brain atrophy, inhibited insulin signaling through the insulin receptor and Akt, activated GSK-3β, increased protein carbonyl and 3-nitrotyrosine, and reduced acetylcholinesterase. NNK increased NTyr. Ethanol + NNK had synergistic stimulatory effects on 8-iso-PGF-2α, inhibitory effects on p-p70S6K, tau and p-tau and trend effects on insulin-like growth factor type 1 (IGF-1) receptor expression and phosphorylation.
Ethanol, NNK and combined ethanol + NNK exposures that begin in adolescence impair spatial learning and memory in young adults. The ethanol and/or NNK exposures differentially impair insulin/IGF signaling through neuronal growth, survival and plasticity pathways, increase cellular injury and oxidative stress and reduce expression of critical proteins needed for neuronal function.",[],"Alcohol and alcoholism (Oxford, Oxfordshire)",2015-09-17,"[{'lastname': 'Tong', 'firstname': 'Ming', 'initials': 'M', 'affiliation': 'Department of Medicine, Division of Gastroenterology, and the Liver Research Center, Rhode Island Hospital, Providence, RI, USA Warren Alpert Medical School of Brown University, Providence, RI, USA.'}, {'lastname': 'Yu', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Departments of Pathology and Neurology, and the Division of Neuropathology, Rhode Island Hospital, Providence, RI, USA.'}, {'lastname': 'Deochand', 'firstname': 'Chetram', 'initials': 'C', 'affiliation': 'Biotechnology Graduate Program, Brown University, Providence, RI, USA.'}, {'lastname': 'de la Monte', 'firstname': 'Suzanne M', 'initials': 'SM', 'affiliation': 'Department of Medicine, Division of Gastroenterology, and the Liver Research Center, Rhode Island Hospital, Providence, RI, USA Warren Alpert Medical School of Brown University, Providence, RI, USA Departments of Pathology and Neurology, and the Division of Neuropathology, Rhode Island Hospital, Providence, RI, USA suzanne_delamonte_md@brown.edu.'}]",,,"Ethanol and NNK impaired spatial learning, and NNK ± ethanol impaired memory. Linear trend analysis demonstrated worsening performance from control to ethanol, to NNK, and then ethanol + NNK. Ethanol ± NNK, caused brain atrophy, inhibited insulin signaling through the insulin receptor and Akt, activated GSK-3β, increased protein carbonyl and 3-nitrotyrosine, and reduced acetylcholinesterase. NNK increased NTyr. Ethanol + NNK had synergistic stimulatory effects on 8-iso-PGF-2α, inhibitory effects on p-p70S6K, tau and p-tau and trend effects on insulin-like growth factor type 1 (IGF-1) receptor expression and phosphorylation.",© The Author 2015. Medical Council on Alcohol and Oxford University Press. All rights reserved.,"10.1093/alcalc/agv101
10.1155/2010/312790",<Element 'PubmedArticle' at 0x7f05d97c0220>
210,"26342213
14990799
18180061
12970163
24447627
22738025
23762877
17258092
17720993
19942859
10499166
12529934
18367740
7755719
8652652
11416224
24043794
18729805
20606117
12782192
20388649
21536015
21666107
14651473
11087261
22493448
22456184
11337096
16825287
11226328
22179539
21160056
15314686
21623793
21056617
21416543
8703220
7565810
23024374
10221670
10098881
22487381
21535395
23753877
15319360
16386238
20942811
18268160
19508385
18372911",The Modulation of Cardiac Contractile Function by the Pharmacological and Toxicological Effects of Urocortin2.,"Urocortin2 (Ucn2) has been revealed to enhance cardiac function in heart failure. However, the pharmacological and toxicological effects of Ucn2 on cardiomyocytes are incompletely understood. In this study, we investigated the possible mechanisms of Ucn2 on mediating the contractility of cardiomyocytes. Mechanical properties and intracellular Ca(2+) properties were measured in isolated cardiomyocytes from different treatment groups. The stress signaling was evaluated using Western blot. The results demonstrated that Ucn2 induced maximal velocity of shortening (+dL/dt), peak height, peak shortening (PS) amplitude, maximal velocity of relengthening (-dL/dt), accompanied by a significant rise in intracellular Ca(2+) level and a fall of the mean time constant of Ca(2+) transient decay (Tau) in WT cardiomyocytes. However, these effects were abolished by preincubation of type 2 CRF receptors (CRFR2) antagonist anti-sauvagine 30 (a-SVG-30). We also found that Ucn2 treatment activated the AMPK pathway in isolated cardiomyocytes via CRFR2. Furthermore, Ucn2 induced protein kinase A (PKA) and phospholamban (PLN) phosphorylation. Pretreatment of PKA inhibitor H89 reduced the inotropic and lusitropic effects of Ucn2 as well as decreased the intracellular Ca(2+) load and slowed down the Ca(2+) transient decay. We also showed that preincubation of Compound C, an inhibitor of AMPK, inhibited the phosphorylation of PKA and the intracellular Ca(2+) level in cardiomyocytes without affecting the contractile function and the Tau of cardiomyocytes. Taken together, it suggests that Ucn2 facilitate the contractility of cardiomyocytes via activating both AMPK and PKA.","['AMPK', 'PKA', 'Ucn2', 'cardiac toxicology', 'contractile function']",Toxicological sciences : an official journal of the Society of Toxicology,2015-09-06,"[{'lastname': 'Chen', 'firstname': 'Si', 'initials': 'S', 'affiliation': 'State University of New York at Buffalo, Buffalo, New York 14214.'}, {'lastname': 'Wang', 'firstname': 'Zhenhua', 'initials': 'Z', 'affiliation': '*College of Life Sciences, Yantai University, Yantai, Shandong 264005.'}, {'lastname': 'Xu', 'firstname': 'Bo', 'initials': 'B', 'affiliation': '*College of Life Sciences, Yantai University, Yantai, Shandong 264005, Key Laboratory of Pharmacology and Molecular Drug Evaluation, School of Pharmacy, Yantai University, Yantai, Shandong 264005.'}, {'lastname': 'Mi', 'firstname': 'Xiangquan', 'initials': 'X', 'affiliation': 'School of Life Sciences, Lanzhou University, Lanzhou, Gansu 730000.'}, {'lastname': 'Sun', 'firstname': 'Wanqing', 'initials': 'W', 'affiliation': 'Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi 39216, and The First Affiliated Hospital, Jilin University, Changchun, Jilin 130000.'}, {'lastname': 'Quan', 'firstname': 'Nanhu', 'initials': 'N', 'affiliation': 'Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi 39216, and The First Affiliated Hospital, Jilin University, Changchun, Jilin 130000.'}, {'lastname': 'Wang', 'firstname': 'Lin', 'initials': 'L', 'affiliation': 'Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi 39216, and The First Affiliated Hospital, Jilin University, Changchun, Jilin 130000.'}, {'lastname': 'Chen', 'firstname': 'Xingchi', 'initials': 'X', 'affiliation': 'Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi 39216, and.'}, {'lastname': 'Liu', 'firstname': 'Quan', 'initials': 'Q', 'affiliation': 'The First Affiliated Hospital, Jilin University, Changchun, Jilin 130000.'}, {'lastname': 'Zheng', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': 'The First Affiliated Hospital, Jilin University, Changchun, Jilin 130000.'}, {'lastname': 'Leng', 'firstname': 'Jiyan', 'initials': 'J', 'affiliation': 'The First Affiliated Hospital, Jilin University, Changchun, Jilin 130000.'}, {'lastname': 'Li', 'firstname': 'Ji', 'initials': 'J', 'affiliation': 'Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi 39216, and jli3@umc.edu.'}]",,,,"© The Author 2015. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.",10.1093/toxsci/kfv202,<Element 'PubmedArticle' at 0x7f05d977acc0>
211,"26328538
24065130
25159665
22833681
11141497
17912249
8356085
25125464
14690523
17478722
23715095
17082516
18691381
14627651
24298146
16943563
23840493
9735171
19933758
21555069
22867711
18198423
21388709
23000140
20826658
15891777
24713000
20655099
24760868
16120780
21613497
10725221
23772223
12927759
18007595
24653715
18573532
21172610",Tau Mislocation in Glucocorticoid-Triggered Hippocampal Pathology.,"The exposure to high glucocorticoids (GC) triggers neuronal atrophy and cognitive deficits, but the exact cellular mechanisms underlying the GC-associated dendritic remodeling and spine loss are still poorly understood. Previous studies have implicated sustained GC elevations in neurodegenerative mechanisms through GC-evoked hyperphosphorylation of the cytoskeletal protein Tau while Tau mislocation has recently been proposed as relevant in Alzheimer's disease (AD) pathology. In light of the dual cytoplasmic and synaptic role of Tau, this study monitored the impact of prolonged GC treatment on Tau intracellular localization and its phosphorylation status in different cellular compartments. We demonstrate, both by biochemical and ultrastructural analysis, that GC administration led to cytosolic and dendritic Tau accumulation in rat hippocampus, and triggered Tau hyperphosphorylation in epitopes related to its malfunction (Ser396/404) and cytoskeletal pathology (e.g., Thr231 and Ser262). In addition, we show, for the first time, that chronic GC administration also increased Tau levels in synaptic compartment; however, at the synapse, there was an increase in phosphorylation of Ser396/404, but a decrease of Thr231. These GC-triggered Tau changes were paralleled by reduced levels of synaptic scaffolding proteins such as PSD-95 and Shank proteins as well as reduced dendritic branching and spine loss. These in vivo findings add to our limited knowledge about the underlying mechanisms of GC-evoked synaptic atrophy and neuronal disconnection implicating Tau missorting in mechanism(s) of synaptic damage, beyond AD pathology.","['Glucocorticoids', 'Hippocampus', 'Neurodegeneration', 'Synaptic atrophy', 'Tau']",Molecular neurobiology,2015-09-04,"[{'lastname': 'Pinheiro', 'firstname': 'Sara', 'initials': 'S', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus Gualtar, 4710-057, Braga, Portugal.\nICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Silva', 'firstname': 'Joana', 'initials': 'J', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus Gualtar, 4710-057, Braga, Portugal.\nICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Mota', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus Gualtar, 4710-057, Braga, Portugal.\nICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Vaz-Silva', 'firstname': 'João', 'initials': 'J', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus Gualtar, 4710-057, Braga, Portugal.\nICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Veloso', 'firstname': 'Ana', 'initials': 'A', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus Gualtar, 4710-057, Braga, Portugal.\nICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Pinto', 'firstname': 'Vítor', 'initials': 'V', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus Gualtar, 4710-057, Braga, Portugal.\nICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Sousa', 'firstname': 'Nuno', 'initials': 'N', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus Gualtar, 4710-057, Braga, Portugal.\nICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Cerqueira', 'firstname': 'João', 'initials': 'J', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus Gualtar, 4710-057, Braga, Portugal.\nICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Sotiropoulos', 'firstname': 'Ioannis', 'initials': 'I', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus Gualtar, 4710-057, Braga, Portugal. ioannis@ecsaude.uminho.pt.\nICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal. ioannis@ecsaude.uminho.pt.""}]",,,,,10.1007/s12035-015-9356-2,<Element 'PubmedArticle' at 0x7f05d97a07c0>
212,"26297517
10463726
23450014
1555357
18350345
10569492
8519124
3155745
9364947
20224959
15476219
23243507
21742723
8444940
8113255
11595370
10204945
11709458
8465804
23313282",MRI-detected bone marrow changes within 3 weeks after initiation of high-dose corticosteroid therapy: a possible change preceding the subsequent appearance of low-intensity band in femoral head osteonecrosis.,"Osteonecrosis of the femoral head is considered to occur early during the course of corticosteroid treatment. However, it remains unclear exactly how early it can develop after initiation of corticosteroid treatment. We report a case of osteonecrosis of the femoral head in which abnormal findings were observed on short-tau inversion recovery (STIR) sequence image performed 2 weeks and 4 days after initiation of high-dose corticosteroid therapy. A 45-year-old man with hemophagocytic syndrome was started on prednisolone, with a maximum dose of 40 mg/day. On day 13 after initiation of this corticosteroid therapy, he transiently experienced left hip pain with no apparent cause. STIR sequence image 5 days after the onset of pain revealed high-intensity bone marrow lesions at the femoral neck of both hips. At 3 months after initiation of corticosteroid therapy, T1-weighted magnetic resonance imaging revealed concave-shaped low-intensity bands, which corresponded to the preceding high-intensity lesions on both hips. Because of the subsequent progression to collapse of the left femoral head, he underwent prosthetic replacement surgery. The high-intensity lesions on STIR sequence image indicate the possibility that osteonecrosis can occur within 3 weeks after initiation of high-dose corticosteroid therapy.","['Corticosteroid treatment', 'Hemophagocytic syndrome', 'Osteonecrosis of the femoral head', 'Short-tau inversion recovery (STIR) sequence image']",Rheumatology international,2015-08-25,"[{'lastname': 'Kubo', 'firstname': 'Yusuke', 'initials': 'Y', 'affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.'}, {'lastname': 'Yamamoto', 'firstname': 'Takuaki', 'initials': 'T', 'affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. yamataku@ortho.med.kyushu-u.ac.jp.'}, {'lastname': 'Motomura', 'firstname': 'Goro', 'initials': 'G', 'affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.'}, {'lastname': 'Tsukamoto', 'firstname': 'Nobuaki', 'initials': 'N', 'affiliation': 'Department of Orthopaedic Surgery, Saga Prefectural Medical Center Koseikan, 400 Kase-Town, Saga City, 840-8571, Japan.'}, {'lastname': 'Karasuyama', 'firstname': 'Kazuyuki', 'initials': 'K', 'affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.'}, {'lastname': 'Sonoda', 'firstname': 'Kazuhiko', 'initials': 'K', 'affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.'}, {'lastname': 'Hatanaka', 'firstname': 'Hiroyuki', 'initials': 'H', 'affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.'}, {'lastname': 'Utsunomiya', 'firstname': 'Takeshi', 'initials': 'T', 'affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.'}, {'lastname': 'Iwamoto', 'firstname': 'Yukihide', 'initials': 'Y', 'affiliation': 'Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.'}]",,,,,10.1007/s00296-015-3346-6,<Element 'PubmedArticle' at 0x7f05d9737720>
213,26188171,Central acylated ghrelin improves memory function and hippocampal AMPK activation and partly reverses the impairment of energy and glucose metabolism in rats infused with β-amyloid.,"Ghrelin is a gastric hormone released during the fasting state that targets the hypothalamus where it induces hunger; however, emerging evidence suggests it may also affect memory function. We examined the effect of central acylated-ghrelin and DES-acetylated ghrelin (native ghrelin) on memory function and glucose metabolism in an experimentally induced Alzheimer's disease (AD) rat model. AD rats were divided into 3 groups and Non-AD rats were used as a normal-control group. Each rat in the AD groups had intracerebroventricular (ICV) infusion of β-amyloid (25-35; 16.8nmol/day) into the lateral ventricle for 3 days, and then the pumps were changed to infuse either acylated-ghrelin (0.2nmol/h; AD-G), DES-acylated ghrelin (0.2nmol/h; AD-DES-G), or saline (control; AD-C) for 3 weeks. The Non-AD group had ICV infusion of β-amyloid (35-25) which does not deposit in the hippocampus. During the next 3 weeks memory function, food intake, body weight gain, body fat composition, and glucose metabolism were measured. AD-C exhibited greater β-amyloid deposition compared to Non-AD-C, and AD-G suppressed the increased β-amyloid deposition and potentiated the phosphorylation AMPK. In addition, AD-G increased the phosphorylation GSK and decreased the phosphorylation of Tau in comparison to AD-C and AD-DES-G. Cognitive function, measured by passive avoidance and water maze tests, was much lower in AD-C than Non-AD-C whereas AD-G but not AD-DES-G prevented the decrease (p<0.021). Body weight gain was lower in AD-C group than Non-AD-C group without changing epididymal fat mass. AD-G reversed the decrease in body weight which was due to increased energy intake and decreased energy expenditure. The AD-G group exhibited a decrease in the second part of serum glucose levels during an oral glucose tolerance test (OGTT) compared to the AD-C and AD-DES-G group (p<0.009). However, area under the curve of insulin during the first part of OGTT was higher in AD-DES-G than other groups, whereas during the second part it was suppressed in AD-G as much as Non-AD. In conclusion, central acylated ghrelin in rats prevented the deterioration of memory function, and energy and glucose metabolisms were partially improved, possibly due to less β-amyloid accumulation. This research suggests that interventions such as intermittent fasting to facilitate sustained elevations of acyl-ghrelin should be investigated for cognitive and metabolic benefits, especially in person with early symptoms of memory impairment.","['Cognitive function', 'Energy', 'Ghrelin', 'Glucose', 'Tau']",Peptides,2015-07-19,"[{'lastname': 'Kang', 'firstname': 'Suna', 'initials': 'S', 'affiliation': 'Food & Nutrition, Obesity/Diabetes Center, Hoseo University, Asan, Republic of Korea.'}, {'lastname': 'Moon', 'firstname': 'Na Rang', 'initials': 'NR', 'affiliation': 'Food & Nutrition, Obesity/Diabetes Center, Hoseo University, Asan, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Da Sol', 'initials': 'DS', 'affiliation': 'Food & Nutrition, Obesity/Diabetes Center, Hoseo University, Asan, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Sung Hoon', 'initials': 'SH', 'affiliation': ""Division of Endocrinology & Metabolism, Cheil General Hospital & Women's Healthcare Center, Dankook University College of Medicine, Seoul, Republic of Korea.""}, {'lastname': 'Park', 'firstname': 'Sunmin', 'initials': 'S', 'affiliation': 'Food & Nutrition, Obesity/Diabetes Center, Hoseo University, Asan, Republic of Korea. Electronic address: smpark@hoseo.edu.'}]",,,,Copyright © 2015 Elsevier Inc. All rights reserved.,10.1016/j.peptides.2015.07.005,<Element 'PubmedArticle' at 0x7f05d974a4a0>
214,26180139,Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.,"To investigate CSF markers involved in amyloid precursor protein processing, neuronal damage, and neuroinflammation in the preclinical stages of Alzheimer disease (AD) and participants with suspected non-Alzheimer pathology (SNAP).
We collected CSF from 266 cognitively normal volunteers participating in a cross-sectional multicenter study (the SIGNAL study) to investigate markers involved in amyloid precursor protein processing (Aβ42, sAPPβ, β-secretase activity), neuronal damage (total-tau [t-tau], phospho-tau [p-tau]), and neuroinflammation (YKL-40). We analyzed the relationship among biomarkers, clinical variables, and the APOE genotype, and compared biomarker levels across the preclinical stages of the National Institute on Aging-Alzheimer's Association classification: stage 0, 1, 2, 3, and SNAP.
The median age in the whole cohort was 58.8 years (range 39.8-81.6). Participants in stages 2-3 and SNAP had higher levels of YKL-40 than those in stages 0 and 1. Participants with SNAP had higher levels of sAPPβ than participants in stage 0 and 1. No differences were found between stages 0, 1, and 2-3 in sAPPβ and β-secretase activity in CSF. Age correlated with t-tau, p-tau, and YKL-40. It also correlated with Aβ42, but only in APOE ε4 carriers. Aβ42 correlated positively with t-tau, sAPPβ, and YKL-40 in participants with normal Aβ42.
Our findings suggest that inflammation in the CNS increases in normal aging and is intimately related to markers of neurodegeneration in the preclinical stages of AD and SNAP. sAPPβ and β-secretase activity are not useful diagnostic or staging markers in preclinical AD.",[],Neurology,2015-07-17,"[{'lastname': 'Alcolea', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Martínez-Lage', 'firstname': 'Pablo', 'initials': 'P', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Sánchez-Juan', 'firstname': 'Pascual', 'initials': 'P', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Olazarán', 'firstname': 'Javier', 'initials': 'J', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Antúnez', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Izagirre', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Ecay-Torres', 'firstname': 'Mirian', 'initials': 'M', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Estanga', 'firstname': 'Ainara', 'initials': 'A', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Clerigué', 'firstname': 'Montserrat', 'initials': 'M', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Guisasola', 'firstname': 'Maria Concepción', 'initials': 'MC', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Sánchez Ruiz', 'firstname': 'Domingo', 'initials': 'D', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Marín Muñoz', 'firstname': 'Juan', 'initials': 'J', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Calero', 'firstname': 'Miguel', 'initials': 'M', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Blesa', 'firstname': 'Rafael', 'initials': 'R', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Clarimón', 'firstname': 'Jordi', 'initials': 'J', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Carmona-Iragui', 'firstname': 'María', 'initials': 'M', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Morenas-Rodríguez', 'firstname': 'Estrella', 'initials': 'E', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Rodríguez-Rodríguez', 'firstname': 'Eloy', 'initials': 'E', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Vázquez Higuera', 'firstname': 'José Luis', 'initials': 'JL', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Fortea', 'firstname': 'Juan', 'initials': 'J', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain.""}, {'lastname': 'Lleó', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': ""From the Department of Neurology (D.A., R.B., J.C., M.C.-I., E.M.-R., J.F., A.L.), Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona; Fundación CITA-Alzhéimer Fundazioa (P.M.-L., A.I., M.E.-T., A.E., M.C.), San Sebastián; Servicio de Neurología (P.S.-J., E.R.-R., J.L.V.H.), Hospital Universitario Marqués de Valdecilla, Santander; Servicio de Neurología (J.O., D.S.R.) and Unidad de Medicina Experimental (M.C.G.), Hospital General Gregorio Marañón, Madrid; Unidad de Demencias (C.A., J.M.M.), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia; Instituto de Salud Carlos III (M.C.), CIBERNED, Madrid; Fundación CIEN (J.O., M.C.), Fundación Reina Sofía, Madrid; and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED (The SIGNAL Study), Spain. alleo@santpau.es.""}]",,,"The median age in the whole cohort was 58.8 years (range 39.8-81.6). Participants in stages 2-3 and SNAP had higher levels of YKL-40 than those in stages 0 and 1. Participants with SNAP had higher levels of sAPPβ than participants in stage 0 and 1. No differences were found between stages 0, 1, and 2-3 in sAPPβ and β-secretase activity in CSF. Age correlated with t-tau, p-tau, and YKL-40. It also correlated with Aβ42, but only in APOE ε4 carriers. Aβ42 correlated positively with t-tau, sAPPβ, and YKL-40 in participants with normal Aβ42.",© 2015 American Academy of Neurology.,10.1212/WNL.0000000000001859,<Element 'PubmedArticle' at 0x7f05d9755360>
215,"26178392
5749269
4142117
52727
4136630
3052787
9866376
7776556
8297810",Relapse of prostate cancer from the viewpoint of total gland volume kinetics theory.,"In many cases of prostate cancer, changes of prostate volume were measured very frequently after castration by means of transrectal ultrasound. For short-term observations, a factor called as ""reduction time (tau [τ]),"" which means the time required for the volume of ""effective portion"" (volume responded to castration) to be reduced to one-tenth of its original value, correlated very well with patients' prognosis. For long-term observations for relapse, changes of prostate volume could be divided clearly into two types, namely, ""metastatic progressive type"" with metastasis without volume increase and ""local progressive type"" with remarkable volume increase without metastasis. ""τ"" in the ""local progressive type"" was far shorter than that in the ""metastatic progressive type."" Much longer survival was obtained when the patient belonged to the ""local progressive type,"" than to the ""metastatic progressive type."" Thus, ""τ"" was the most important and the most reliable factor to predict the prognosis. Based upon these observations, a schematic analysis of prostate cancer relapse was shown.",[],Asian journal of andrology,2015-07-17,"[{'lastname': 'Watanabe', 'firstname': 'Hiroki', 'initials': 'H', 'affiliation': 'Director, Watanabe Memorial Choumei Research Laboratory, Shiga; Honorary Professor, Kyoto Prefectural University of Medicine and Meiji University of Integrated Medicine, Kyoto, Japan.'}]",,,,,10.4103/1008-682X.153543,<Element 'PubmedArticle' at 0x7f05d96f3720>
216,26159189,Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer's Disease.,"Alzheimer's disease (AD) is an aging-related multi-factorial disorder to which metabolic factors contribute at what has canonically been considered a centrally mediated process. Although the exact underlying mechanisms are still unknown, obesity is recognized as a risk factor for AD and the condition of insulin resistance seems to be the link between the two pathologies. Using mice with high fat diet (HFD) obesity we dissected the molecular mechanisms shared by the two disorders. Brains of HFD fed mice showed elevated levels of APP and Aβ40/Aβ42 together with BACE, GSK3β and Tau proteins involved in APP processing and Aβ accumulation. Immunofluorescence, Thioflavin T staining experiments, confirmed increased Aβ generation, deposition in insoluble fraction and plaques formation in both the hippocampus and the cerebral cortex of HFD mice. Presence of Aβ40/Aβ42 in the insoluble fraction was also shown by ELISA assay. Brain insulin resistance was demonstrated by reduced presence of insulin receptor (IRs) and defects in Akt-Foxo3a insulin signaling. We found reduced levels of phospho-Akt and increased levels of Foxo3a in the nuclei of neurons where proapototic genes were activated. Dysregulation of different genes related to insulin resistance, especially those involved in inflammation and adipocytokines synthesis were analyzed by Profiler PCR array. Further, HFD induced oxidative stress, mitochondrial dysfunction and dynamics as demonstrated by expression of biomarkers involved in these processes. Here, we provide evidence that obesity and AD markers besides insulin resistance are associated with inflammation, adipokine dyshomeostasis, oxidative stress and mitochondrial dysfunction, all mechanisms leading to neurodegeneration.",[],Current Alzheimer research,2015-07-15,"[{'lastname': 'Nuzzo', 'firstname': 'Domenico', 'initials': 'D', 'affiliation': None}, {'lastname': 'Picone', 'firstname': 'Pasquale', 'initials': 'P', 'affiliation': None}, {'lastname': 'Baldassano', 'firstname': 'Sara', 'initials': 'S', 'affiliation': None}, {'lastname': 'Caruana', 'firstname': 'Luca', 'initials': 'L', 'affiliation': None}, {'lastname': 'Messina', 'firstname': 'Elisa', 'initials': 'E', 'affiliation': None}, {'lastname': 'Marino Gammazza', 'firstname': 'Antonella', 'initials': 'A', 'affiliation': None}, {'lastname': 'Cappello', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': None}, {'lastname': 'Mulè', 'firstname': 'Flavia', 'initials': 'F', 'affiliation': None}, {'lastname': 'Di Carlo', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Institute of Biomedicine and Molecular Immunology CNR, via Ugo La Malfa 153, 90146 Palermo, Italy. marta.dicarlo@ibim.cnr.it.'}]",,,,,10.2174/1567205012666150710115506,<Element 'PubmedArticle' at 0x7f05d96fe270>
217,"26147946
24598707
24605808
8699259
9330992
9862640
11816784
11559310
16401735
22784036
24598588
23477989
25079804
21987546
23800368
20798852
21035623
21823155
22357717
23800322
25254036
8232972
9520006
12891668
16372280
17254013
17374949
22652762
16488378
17210801
17698783
16894106
24223109
22162065
11832223
16530430
25485714
19679070
21715678
8346443
25580592
20008664
20049742
19273758
23812320
21514248",Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.,"Individuals in the presymptomatic stage of Alzheimer disease (AD) are increasingly being targeted for AD secondary prevention trials. How early during the normal life span underlying AD pathologies begin to develop, their patterns of change over time, and their relationship with future cognitive decline remain to be determined.
To characterize the within-person trajectories of cerebrospinal fluid (CSF) biomarkers of AD over time and their association with changes in brain amyloid deposition and cognitive decline in cognitively normal middle-aged individuals.
As part of a cohort study, cognitively normal (Clinical Dementia Rating [CDR] of 0) middle-aged research volunteers (n = 169) enrolled in the Adult Children Study at Washington University, St Louis, Missouri, had undergone serial CSF collection and longitudinal clinical assessment (mean, 6 years; range, 0.91-11.3 years) at 3-year intervals at the time of analysis, between January 2003 and November 2013. A subset (n = 74) had also undergone longitudinal amyloid positron emission tomographic imaging with Pittsburgh compound B (PiB) in the same period. Serial CSF samples were analyzed for β-amyloid 40 (Aβ40), Aβ42, total tau, tau phosphorylated at threonine 181 (P-tau181), visinin-like protein 1 (VILIP-1), and chitinase-3-like protein 1 (YKL-40). Within-person measures were plotted according to age and AD risk defined by APOE genotype (ε4 carriers vs noncarriers). Linear mixed models were used to compare estimated biomarker slopes among middle-age bins at baseline (early, 45-54 years; mid, 55-64 years; late, 65-74 years) and between risk groups. Within-person changes in CSF biomarkers were also compared with changes in cortical PiB binding and progression to a CDR higher than 0 at follow-up.
Changes in Aβ40, Aβ42, total tau, P-tau181, VILIP-1, and YKL-40 and, in a subset of participants, changes in cortical PiB binding.
While there were no consistent longitudinal patterns in Aβ40 (P = .001-.97), longitudinal reductions in Aβ42 were observed in some individuals as early as early middle age (P ≤ .05) and low Aβ42 levels were associated with the development of cortical PiB-positive amyloid plaques (area under receiver operating characteristic curve = 0.9352; 95% CI, 0.8895-0.9808), especially in mid middle age (P < .001). Markers of neuronal injury (total tau, P-tau181, and VILIP-1) dramatically increased in some individuals in mid and late middle age (P ≤ .02), whereas the neuroinflammation marker YKL-40 increased consistently throughout middle age (P ≤ .003). These patterns were more apparent in at-risk ε4 carriers (Aβ42 in an allele dose-dependent manner) and appeared to be associated with future cognitive deficits as determined by CDR.
Longitudinal CSF biomarker patterns consistent with AD are first detectable during early middle age and are associated with later amyloid positivity and cognitive decline. Such measures may be useful for targeting middle-aged, asymptomatic individuals for therapeutic trials designed to prevent cognitive decline.",[],JAMA neurology,2015-07-07,"[{'lastname': 'Sutphen', 'firstname': 'Courtney L', 'initials': 'CL', 'affiliation': ""Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.""}, {'lastname': 'Jasielec', 'firstname': 'Mateusz S', 'initials': 'MS', 'affiliation': ""Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri4Division of Biostatistics, Washington University, St Louis, Missouri.""}, {'lastname': 'Shah', 'firstname': 'Aarti R', 'initials': 'AR', 'affiliation': ""Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.""}, {'lastname': 'Macy', 'firstname': 'Elizabeth M', 'initials': 'EM', 'affiliation': 'Department of Pathology and Immunology, Washington University, St Louis, Missouri.'}, {'lastname': 'Xiong', 'firstname': 'Chengjie', 'initials': 'C', 'affiliation': ""Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri4Division of Biostatistics, Washington University, St Louis, Missouri.""}, {'lastname': 'Vlassenko', 'firstname': 'Andrei G', 'initials': 'AG', 'affiliation': ""Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri6Department of Radiology, Washington University, St Louis, Missouri.""}, {'lastname': 'Benzinger', 'firstname': 'Tammie L S', 'initials': 'TL', 'affiliation': ""Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri6Department of Radiology, Washington University, St Louis, Missouri.""}, {'lastname': 'Stoops', 'firstname': 'Erik E J', 'initials': 'EE', 'affiliation': 'ADx NeuroSciences, Ghent, Belgium.'}, {'lastname': 'Vanderstichele', 'firstname': 'Hugo M J', 'initials': 'HM', 'affiliation': 'ADx NeuroSciences, Ghent, Belgium.'}, {'lastname': 'Brix', 'firstname': 'Britta', 'initials': 'B', 'affiliation': 'EUROIMMUN, Lübeck, Germany.'}, {'lastname': 'Darby', 'firstname': 'Heather D', 'initials': 'HD', 'affiliation': 'Fujirebio US, Malvern, Pennsylvania.'}, {'lastname': 'Vandijck', 'firstname': 'Manu L J', 'initials': 'ML', 'affiliation': 'Fujirebio Europe, Ghent, Belgium.'}, {'lastname': 'Ladenson', 'firstname': 'Jack H', 'initials': 'JH', 'affiliation': 'Department of Pathology and Immunology, Washington University, St Louis, Missouri.'}, {'lastname': 'Morris', 'firstname': 'John C', 'initials': 'JC', 'affiliation': ""Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.""}, {'lastname': 'Holtzman', 'firstname': 'David M', 'initials': 'DM', 'affiliation': ""Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.""}, {'lastname': 'Fagan', 'firstname': 'Anne M', 'initials': 'AM', 'affiliation': ""Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri2Department of Neurology, Washington University, St Louis, Missouri3Hope Center for Neurodegenerative Disorders, Washington University, St Louis, Missouri.""}]",,,"While there were no consistent longitudinal patterns in Aβ40 (P = .001-.97), longitudinal reductions in Aβ42 were observed in some individuals as early as early middle age (P ≤ .05) and low Aβ42 levels were associated with the development of cortical PiB-positive amyloid plaques (area under receiver operating characteristic curve = 0.9352; 95% CI, 0.8895-0.9808), especially in mid middle age (P < .001). Markers of neuronal injury (total tau, P-tau181, and VILIP-1) dramatically increased in some individuals in mid and late middle age (P ≤ .02), whereas the neuroinflammation marker YKL-40 increased consistently throughout middle age (P ≤ .003). These patterns were more apparent in at-risk ε4 carriers (Aβ42 in an allele dose-dependent manner) and appeared to be associated with future cognitive deficits as determined by CDR.",,"10.1001/jamaneurol.2015.1285
10.4061/2010/986310
10.1007/BF02288586",<Element 'PubmedArticle' at 0x7f05d970cc20>
218,26133737,Taurine supplementation preserves hypothalamic leptin action in normal and protein-restricted mice fed on a high-fat diet.,"Malnutrition programs the neuroendocrine axis by disruption of food-intake control, leading to obesity. Taurine (Tau) is neuroprotective and improves anorexigenic actions in the hypothalamus. We evaluated the hypothalamic gene-expression profile and food-intake control in protein-restricted mice submitted to a high-fat diet (HFD) and Tau supplementation. Mice were fed on a control (14 % protein-C) or a protein-restricted diet (6 % protein-R) for 6 weeks. Thereafter, mice received, or not, HFD for 8 weeks (CH and RH) with or without 5 % Tau supplementation (CHT and RHT). Protein restriction led to higher food intake, but calories were matched to controls. Excessive calorie intake occurred in HFD mice and this was prevented by Tau supplementation only in the CH group. Additionally, RH and CH mice developed hypothalamic leptin resistance, which was prevented by Tau. Global alterations in the expressions of genes involved in hypothalamic metabolism, cellular defense, apoptosis and endoplasmic reticulum stress pathways were induced by dietary manipulations and Tau treatment. The orexigenic peptides NPY and AgRP were increased by protein restriction and lowered by the HFD. The anorexigenic peptide Pomc was increased by HFD, and this was prevented by Tau only in CH mice. Thus, food intake was disrupted by dietary protein restriction and obesity. HFD-induced alterations were not enhanced by previous protein deficiency, but the some beneficial effects of Tau supplementation upon food intake were blunted by protein restriction. Tau effects upon feeding behavior control are complex and involve interactions with a vast gene network, preventing hypothalamic leptin resistance.","['Food intake', 'High-fat diet', 'Hypothalamus', 'Neuropeptides', 'Protein restriction', 'Taurine supplementation']",Amino acids,2015-07-03,"[{'lastname': 'Camargo', 'firstname': 'Rafael L', 'initials': 'RL', 'affiliation': 'Departamento de Biologia Funcional e Estrutural, Instituto de Biologia, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, CEP 13083-970, Brazil. rlcamargo.bio@gmail.com.'}, {'lastname': 'Batista', 'firstname': 'Thiago M', 'initials': 'TM', 'affiliation': 'Departamento de Biologia Funcional e Estrutural, Instituto de Biologia, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, CEP 13083-970, Brazil.'}, {'lastname': 'Ribeiro', 'firstname': 'Rosane A', 'initials': 'RA', 'affiliation': 'Universidade Federal do Rio de Janeiro (UFRJ), Macaé, RJ, Brazil.'}, {'lastname': 'Branco', 'firstname': 'Renato C S', 'initials': 'RC', 'affiliation': 'Departamento de Biologia Funcional e Estrutural, Instituto de Biologia, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, CEP 13083-970, Brazil.'}, {'lastname': 'Da Silva', 'firstname': 'Priscilla M R', 'initials': 'PM', 'affiliation': 'Departamento de Biologia Funcional e Estrutural, Instituto de Biologia, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, CEP 13083-970, Brazil.'}, {'lastname': 'Izumi', 'firstname': 'Clarice', 'initials': 'C', 'affiliation': 'Centro de Química de Proteínas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.'}, {'lastname': 'Araujo', 'firstname': 'Thiago R', 'initials': 'TR', 'affiliation': 'Universidade Federal do Rio de Janeiro (UFRJ), Macaé, RJ, Brazil.'}, {'lastname': 'Greene', 'firstname': 'Lewis J', 'initials': 'LJ', 'affiliation': 'Centro de Química de Proteínas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.'}, {'lastname': 'Boschero', 'firstname': 'Antonio C', 'initials': 'AC', 'affiliation': 'Departamento de Biologia Funcional e Estrutural, Instituto de Biologia, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, CEP 13083-970, Brazil.'}, {'lastname': 'Carneiro', 'firstname': 'Everardo M', 'initials': 'EM', 'affiliation': 'Departamento de Biologia Funcional e Estrutural, Instituto de Biologia, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, CEP 13083-970, Brazil. emc@unicamp.br.'}]",,,,,10.1007/s00726-015-2035-9,<Element 'PubmedArticle' at 0x7f05d96b5b30>
219,26120052,Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes.,"To assess the effect of testosterone treatment on cardiac biomarkers in men with type 2 diabetes (T2D).
Randomized double-blind, parallel, placebo-controlled trial.
Men aged 35-70 years with T2D and a total testosterone level ≤12·0 nmol/l (346 ng/dl) at high risk of cardiovascular events, median 10-year United Kingdom Prospective Diabetes Study (UKPDS) coronary heart disease (CHD) risk 21% (IQR 16%, 27%). Eighty-eight participants were randomly assigned to 40 weeks of intramuscular testosterone undecanoate (n = 45) or matching placebo (n = 43).
N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT).
Testosterone treatment reduced NT-proBNP (mean adjusted difference (MAD) in change over 40 weeks across the testosterone and placebo groups, -17·9 ng/l [95% CI -32·4, -3·5], P = 0·047), but did not change hs-cTnT (MAD, 0·41 ng/l (95% CI -0·56, 1·39), P = 0·62). Six men, three in each group experienced an adverse cardiac event, displaying already higher baseline NT-proBNP (P < 0·01) and hs-cTnT levels (P = 0·01). At baseline, 10-year UKPDS CHD risk was associated positively with NT-proBNP (τ = 0·21, P = 0·004) and hs-cTnT (τ = 0·23, P = 0·003) and inversely with testosterone (total testosterone τ = -0·18, P = 0·02, calculated free testosterone τ = -0·19, P = 0·01), but there was no significant association between testosterone and cardiac biomarkers (P > 0·05).
In this trial of men with T2D and high cardiovascular risk, testosterone treatment reduced NT-proBNP and did not change hs-cTnT. Further studies should determine whether men with increased cardiac biomarkers prior to testosterone therapy are at higher risk of testosterone treatment-associated adverse cardiac events.",[],Clinical endocrinology,2015-06-30,"[{'lastname': 'Gianatti', 'firstname': 'Emily J', 'initials': 'EJ', 'affiliation': 'Department of Medicine Austin Health, Austin Health, University of Melbourne, Heidelberg, Vic., Australia.\nEndocrine Unit, Austin Health, University of Melbourne, Heidelberg, Vic., Australia.'}, {'lastname': 'Hoermann', 'firstname': 'Rudolf', 'initials': 'R', 'affiliation': 'Department of Medicine Austin Health, Austin Health, University of Melbourne, Heidelberg, Vic., Australia.'}, {'lastname': 'Lam', 'firstname': 'Que', 'initials': 'Q', 'affiliation': 'Department of Biochemistry, Austin Health, University of Melbourne, Heidelberg, Vic., Australia.'}, {'lastname': 'Dupuis', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'Department of Medicine Austin Health, Austin Health, University of Melbourne, Heidelberg, Vic., Australia.\nEndocrine Unit, Austin Health, University of Melbourne, Heidelberg, Vic., Australia.'}, {'lastname': 'Zajac', 'firstname': 'Jeffrey D', 'initials': 'JD', 'affiliation': 'Department of Medicine Austin Health, Austin Health, University of Melbourne, Heidelberg, Vic., Australia.\nEndocrine Unit, Austin Health, University of Melbourne, Heidelberg, Vic., Australia.'}, {'lastname': 'Grossmann', 'firstname': 'Mathis', 'initials': 'M', 'affiliation': 'Department of Medicine Austin Health, Austin Health, University of Melbourne, Heidelberg, Vic., Australia.\nEndocrine Unit, Austin Health, University of Melbourne, Heidelberg, Vic., Australia.'}]",,,,© 2015 John Wiley & Sons Ltd.,10.1111/cen.12842,<Element 'PubmedArticle' at 0x7f05d96c0e50>
220,"26077803
24155300
19455173
20413859
23312564
20028732
16221841
23273603
2113539
21976528
17912249
20043285
8254363
17507558
18337421
20615973
22411227
10822158
17151169
22045482
7700534
15464754
11683906
18571864
22045495
10529444
22222439
16307829
16943563
10348656
16198445
19570680
20881118
19120092
16467370
19339973
17551018
12042880
23839597
15751228
19948164
19401723
22386641
24589888
17615391
12895417
20870017
12000121
17567816
22451915
22791026
17487207
18431482
21855175
21771612
15803159
18691381
21613497
11036168
17286590
12122087
10092043
17562829
15572107
23955525",Short-term modern life-like stress exacerbates Aβ-pathology and synapse loss in 3xTg-AD mice.,"Alzheimer's disease (AD) is a progressive neurological disorder that impairs memory and other cognitive functions in the elderly. The social and financial impacts of AD are overwhelming and are escalating exponentially as a result of population aging. Therefore, identifying AD-related risk factors and the development of more efficacious therapeutic approaches are critical to cure this neurological disorder. Current epidemiological evidence indicates that life experiences, including chronic stress, are a risk for AD. However, it is unknown if short-term stress, lasting for hours, influences the onset or progression of AD. Here, we determined the effect of short-term, multi-modal 'modern life-like' stress on AD pathogenesis and synaptic plasticity in mice bearing three AD mutations (the 3xTg-AD mouse model). We found that combined emotional and physical stress lasting 5 h severely impaired memory in wild-type mice and tended to impact it in already low-performing 3xTg-AD mice. This stress reduced the number of synapse-bearing dendritic spines in 3xTg-AD mice and increased Aβ levels by augmenting AβPP processing. Thus, short-term stress simulating modern-life conditions may exacerbate cognitive deficits in preclinical AD by accelerating amyloid pathology and reducing synapse numbers. Epidemiological evidence indicates that life experiences, including chronic stress, are a risk for Alzheimer disease (AD). However, it is unknown if short stress in the range of hours influences the onset or progression of AD. Here, we determined the effect of short, multi-modal 'modern-lifelike'stress on AD pathogenesis and synaptic plasticity in mice bearing three AD mutations (the 3xTg-AD mouse model). We found that combined emotional and physical stress lasting 5 h severely impaired memory in wild-type mice and tended to impact it in already low-performing 3xTg-AD mice. This stress reduced the number of synapse-bearing dendritic spines in 3xTg-AD mice and increased Aβ levels by augmenting AβPP processing. Thus, short stress simulating modern-life conditions may exacerbate cognitive deficits in preclinical AD by accelerating amyloid pathology and reducing synapse numbers.","[""Alzheimer's disease"", 'amyloid', 'dementia', 'dendritic spines', 'hippocampus', 'stress']",Journal of neurochemistry,2015-06-17,"[{'lastname': 'Baglietto-Vargas', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Chen', 'firstname': 'Yuncai', 'initials': 'Y', 'affiliation': 'Department of Pediatrics, University of California, Irvine, California, USA.'}, {'lastname': 'Suh', 'firstname': 'Dongjin', 'initials': 'D', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Ager', 'firstname': 'Rahasson R', 'initials': 'RR', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Rodriguez-Ortiz', 'firstname': 'Carlos J', 'initials': 'CJ', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Medeiros', 'firstname': 'Rodrigo', 'initials': 'R', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Myczek', 'firstname': 'Kristoffer', 'initials': 'K', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Green', 'firstname': 'Kim N', 'initials': 'KN', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Baram', 'firstname': 'Tallie Z', 'initials': 'TZ', 'affiliation': 'Department of Pediatrics, University of California, Irvine, California, USA.\nDepartment of Anatomy/Neurobiology, University of California, Irvine, California, USA.'}, {'lastname': 'LaFerla', 'firstname': 'Frank M', 'initials': 'FM', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}]",,,,© 2015 International Society for Neurochemistry.,10.1111/jnc.13195,<Element 'PubmedArticle' at 0x7f05d96d3b80>
221,"26077691
19570680
17466428
11275014
9065522
21948247
15554887
23951061
24113652
19012747
23937971
7608248
22487856
22750275
11972430
19469026
24625695
21098983
22313790
16974109
16980541
21976528
22795785
23312564
16554481
16943563
22531419
23357209
11005874
21427641
17553985
17367828
20180948
18423592
23634895
18243386
17151169
11246145
12110446
23901130
8417586
21280074
22738723
22426398
21149712
16085319",Maternal dexamethasone exposure ameliorates cognition and tau pathology in the offspring of triple transgenic AD mice.,"Dysregulation of stress hormones, such as glucocorticoids, in adult life increases the risk to develop Alzheimer's disease (AD). However, the effect of prenatal glucocorticoids exposure on AD development in the offspring remains unknown. We studied how gestational dexamethasone exposure influences the AD-like phenotype in the offspring of triple transgenic AD mice (3 × Tg). To this end, female mice received dexamethasone or vehicle during the entire pregnancy time in the drinking water. Offspring from vehicle-treated 3 × Tg (controls) were compared with offspring from dexamethasone-treated 3 × Tg later in life for their memory, learning ability and brain pathology. Compared with controls, offspring from dexamethasone-treated mothers displayed improvement in their memory as assessed by fear conditioning test, both in the cue and recall phases. The same animals had a significant reduction in the insoluble fraction of tau, which was associated with an increase in autophagy. In addition, they showed an activation of the transcription factor cellular response element-binding protein and an increase in brain-derived neurotrophic factor and c-FOS protein levels, key regulators of synaptic plasticity and memory. We conclude that dexamethasone exposure during pregnancy provides long-lasting protection against the onset and development of the AD-like phenotype by improving cognition and tau pathology.",[],Molecular psychiatry,2015-06-17,"[{'lastname': 'Di Meco', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Department of Pharmacology and Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA.'}, {'lastname': 'Joshi', 'firstname': 'Y B', 'initials': 'YB', 'affiliation': 'Department of Pharmacology and Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA.'}, {'lastname': 'Lauretti', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Department of Pharmacology and Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA.'}, {'lastname': 'Praticò', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Department of Pharmacology and Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA.'}]",,,,,10.1038/mp.2015.78,<Element 'PubmedArticle' at 0x7f05d96824f0>
222,"26044748
22669013
22817481
18079436
24854124
24823497
24090950
24298267
21178125
23911756
23997755
25560760
20649560
24602800
23948883
21777652
24799613
24127429
23127917
23667480
19956428
16171847
15950155
24284365
19782074
24824997
17973905
22535332
22142563
24611741
24194717
22711212
24807206
21297982
22067210
22339213
23919770
21091655
24368090
20068258
21593435
22982863
24809692
23499735
20649561",Angiotensin-(1-7) is Reduced and Inversely Correlates with Tau Hyperphosphorylation in Animal Models of Alzheimer's Disease.,"As a recently identified bioactive peptide of brain renin-angiotensin system (RAS), angiotensin-(1-7) [Ang-(1-7)] along with its metabolic enzyme angiotensin-converting enzyme (ACE) 2 and its receptor Mas forms ACE2/Ang-(1-7)/Mas axis. Accumulating evidence suggests an essential role of ACE2/Ang-(1-7)/Mas axis in maintaining normal cognitive functions in both animals and human subjects, and dysregulation of this axis contributed to the pathogenesis of several neurodegenerative diseases such as hypertension-induced neurodegeneration and vascular dementia. To date, whether this axis was associated with the etiology and progression of Alzheimer's disease (AD), the most prevalent neurodegenerative disease in the elderly, remains unclear. In the current study, by using senescence-accelerated mouse prone 8 (SAMP8) mice, an animal model of sporadic AD, we showed for the first time that the level of Ang-(1-7) in the brain was significantly reduced during disease progression. More importantly, an inverse correlation was found between Ang-(1-7) level and tau hyperphosphorylation, a pathological hallmark of AD, in cerebral cortex and hippocampus of SAMP8 mice. Meanwhile, this has been further confirmed in P301S mice, an animal model of pure tauopathy. All these findings suggested that Ang-(1-7), the main effector of brain ACE2/Ang-(1-7)/Mas axis, might be implicated in the etiology and progression of AD, possibly via modulation of tau hyperphosphorylation.","['Alzheimer’s disease', 'Angiotensin-(1-7)', 'Hyperphosphorylation', 'P301S mice', 'SAMP8', 'Tau']",Molecular neurobiology,2015-06-06,"[{'lastname': 'Jiang', 'firstname': 'Teng', 'initials': 'T', 'affiliation': ""Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China.""}, {'lastname': 'Zhang', 'firstname': 'Ying-Dong', 'initials': 'YD', 'affiliation': ""Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China.""}, {'lastname': 'Zhou', 'firstname': 'Jun-Shan', 'initials': 'JS', 'affiliation': ""Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China.""}, {'lastname': 'Zhu', 'firstname': 'Xi-Chen', 'initials': 'XC', 'affiliation': ""Department of Neurology, Qingdao Municipal Hospital, Nanjing Medical University, Nanjing, People's Republic of China.""}, {'lastname': 'Tian', 'firstname': 'You-Yong', 'initials': 'YY', 'affiliation': ""Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China.""}, {'lastname': 'Zhao', 'firstname': 'Hong-Dong', 'initials': 'HD', 'affiliation': ""Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China.""}, {'lastname': 'Lu', 'firstname': 'Huan', 'initials': 'H', 'affiliation': ""Department of Neurology, Qingdao Municipal Hospital, Nanjing Medical University, Nanjing, People's Republic of China.""}, {'lastname': 'Gao', 'firstname': 'Qing', 'initials': 'Q', 'affiliation': ""Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China.""}, {'lastname': 'Tan', 'firstname': 'Lan', 'initials': 'L', 'affiliation': ""Department of Neurology, Qingdao Municipal Hospital, Nanjing Medical University, Nanjing, People's Republic of China. dr.tanlan@163.com.""}, {'lastname': 'Yu', 'firstname': 'Jin-Tai', 'initials': 'JT', 'affiliation': ""Department of Neurology, Qingdao Municipal Hospital, Nanjing Medical University, Nanjing, People's Republic of China. yu-jintai@163.com.\nMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA. yu-jintai@163.com.""}]",,,,,10.1007/s12035-015-9260-9,<Element 'PubmedArticle' at 0x7f05d9697f40>
223,"26010513
24969117
24380887
21916834
24931034
23249141
18855585
12004130
22638775
23703152
22910909
21450370
24333407
17098089
23855508
22913735
20337586
23999914
24008687
22938097
18223196
22761701
16524383
23603201
24264040
24561226
23863634
22836009
20068143
23314404
15750215
22500228
21312223
24529520
24931033
24265619
24949886
25128166
24949659
24199159
24667360
24117480
19562682
11931352
23209191",DPP-4 Inhibitor Linagliptin Attenuates Aβ-induced Cytotoxicity through Activation of AMPK in Neuronal Cells.,"It is now clear that insulin signaling has important roles in regulation of neuronal functions in the brain. Dysregulation of brain insulin signaling has been linked to neurodegenerative disease, particularly Alzheimer's disease (AD). In this regard, there is evidence that improvement of neuronal insulin signaling has neuroprotective activity against amyloid β (Aβ)-induced neurotoxicity for patients with AD. Linagliptin is an inhibitor of dipeptidylpeptidase-4 (DPP-4), which improves impaired insulin secretion and insulin downstream signaling in the in peripheral tissues. However, whether the protective effects of linagliptin involved in Aβ-mediated neurotoxicity have not yet been investigated.
In the present study, we evaluated the mechanisms by which linagliptin protects against Aβ-induced impaired insulin signaling and cytotoxicity in cultured SK-N-MC human neuronal cells.
Our results showed that Aβ impairs insulin signaling and causes cell death. However, linagliptin significantly protected against Aβ-induced cytotoxicity, and prevented the activation of glycogen synthase kinase 3β (GSK3β) and tau hyperphosphorylation by restoring insulin downstream signaling. Furthermore, linagliptin alleviated Aβ-induced mitochondrial dysfunction and intracellular ROS generation, which may be due to the activation of 5' AMP-activated protein kinase (AMPK)-Sirt1 signaling. This upregulation of Sirt1 expression was also observed in diabetic patients with AD coadministration of linagliptin.
Taken together, our findings suggest linagliptin can restore the impaired insulin signaling caused by Aβ in neuronal cells, suggesting DPP-4 inhibitors may have therapeutic potential for reducing Aβ-induced impairment of insulin signaling and neurotoxicity in AD pathogenesis.","['AMP-activated protein kinase', ""Alzheimer's disease"", 'Amyloid-β', 'Linagliptin', 'Sirtuin 1']",CNS neuroscience & therapeutics,2015-05-27,"[{'lastname': 'Kornelius', 'firstname': 'Edy', 'initials': 'E', 'affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.\nInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.'}, {'lastname': 'Lin', 'firstname': 'Chih-Li', 'initials': 'CL', 'affiliation': 'Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.\nDepartment of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.'}, {'lastname': 'Chang', 'firstname': 'Hsiu-Han', 'initials': 'HH', 'affiliation': 'Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.'}, {'lastname': 'Li', 'firstname': 'Hsin-Hua', 'initials': 'HH', 'affiliation': 'Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.'}, {'lastname': 'Huang', 'firstname': 'Wen-Nung', 'initials': 'WN', 'affiliation': 'Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.'}, {'lastname': 'Yang', 'firstname': 'Yi-Sun', 'initials': 'YS', 'affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.\nInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.'}, {'lastname': 'Lu', 'firstname': 'Ying-Li', 'initials': 'YL', 'affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.\nInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.'}, {'lastname': 'Peng', 'firstname': 'Chiung-Huei', 'initials': 'CH', 'affiliation': 'Division of Basic Medical Science, Hungkuang University, Taichung, Taiwan.'}, {'lastname': 'Huang', 'firstname': 'Chien-Ning', 'initials': 'CN', 'affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.\nInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.'}]",,,"Our results showed that Aβ impairs insulin signaling and causes cell death. However, linagliptin significantly protected against Aβ-induced cytotoxicity, and prevented the activation of glycogen synthase kinase 3β (GSK3β) and tau hyperphosphorylation by restoring insulin downstream signaling. Furthermore, linagliptin alleviated Aβ-induced mitochondrial dysfunction and intracellular ROS generation, which may be due to the activation of 5' AMP-activated protein kinase (AMPK)-Sirt1 signaling. This upregulation of Sirt1 expression was also observed in diabetic patients with AD coadministration of linagliptin.",© 2015 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.,10.1111/cns.12404,<Element 'PubmedArticle' at 0x7f05d962eb80>
224,25987199,Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.,"Our previous study has proved that glucagon-like peptide-1 (GLP-1), which is developed to treat type 2 diabetes, has a significant effect on neuroprotection against advanced glycation end product (AGE)-induced neuronal insult in vitro models of diabetes-related Alzheimer's disease (AD). However, the molecular mechanisms remain to be elucidated and it is not clear whether GLP-1 receptor mediates the down-regulation effects on AGE-induced AD-like changes in vivo. This study aims to explore the effect and mechanisms of GLP-1 receptor agonists (GLP-1RA) against the AGE-dependent signaling pathway both in vitro and in vivo. In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs. Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly. Collectively, our results suggest that GLP-1RA protects neurons against AGE-induced tau hyperphosphorylation via regulating GSK-3β and PGC-1α two cooperative signaling pathways.","['Mitochondrial biogenesis', 'advanced glycation end products', 'glucagon-like peptide-1', 'reactive oxygen species', 'tau pathology']",Neuroscience,2015-05-20,"[{'lastname': 'An', 'firstname': 'F-M', 'initials': 'FM', 'affiliation': 'State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China.'}, {'lastname': 'Chen', 'firstname': 'S', 'initials': 'S', 'affiliation': 'State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China.'}, {'lastname': 'Xu', 'firstname': 'Z', 'initials': 'Z', 'affiliation': 'State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China.'}, {'lastname': 'Yin', 'firstname': 'L', 'initials': 'L', 'affiliation': 'State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China.'}, {'lastname': 'Wang', 'firstname': 'Y', 'initials': 'Y', 'affiliation': 'State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China.'}, {'lastname': 'Liu', 'firstname': 'A-R', 'initials': 'AR', 'affiliation': 'Medical School, Southeast University, Nanjing 210009, PR China.'}, {'lastname': 'Yao', 'firstname': 'W-B', 'initials': 'WB', 'affiliation': 'State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China. Electronic address: wbyao@cpu.edu.cn.'}, {'lastname': 'Gao', 'firstname': 'X-D', 'initials': 'XD', 'affiliation': 'State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China. Electronic address: xdgao@cpu.edu.cn.'}]",,,,Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2015.05.023,<Element 'PubmedArticle' at 0x7f05d9658400>
225,"25884302
23958310
18182665
20888992
7608911
16287438
21612468
18309951
23643785
24382803
23576708
21487065
25018037
23816964
24999168
24458472
24881730
22894553
24200698
22771826
24491307
25242048",Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.,"COU-AA-301 trial has proved that abiraterone acetate (AA), a selective inhibitor of androgen biosynthesis, improved overall survival (OS) of patients with metastatic castration resistant prostate cancer (mCRPC) after a first line of docetaxel. Based on this result, a Temporary Authorization for Use (TAU) was performed between December 2010 and July 2011 to provide patients with mCRPC the opportunity to receive AA before its commercialization. The aim of this study was to evaluate safety and efficacy of AA treatment in this TAU.
Between December 2010 and July 2011, we conducted an ambispective, multicentric cohort study and investigated data from 20 centres participating to the AA TAU for patients presenting mCRPC and already treated by a first line of chemotherapy (CT). Statistical analyses of the data were performed using the Stata software v13 to identify predictive and prognostic factors.
Among the 408 patients, 306 were eligible with a follow-up at 3 years. Median OS was 37.1 months from beginning of CT and 14.6 months from AA introduction. 211 patients (69%) received ≥ 3 months of AA and 95 patients (31%) were treated less than 3 months. In the multivariate analyses, duration of AA was significantly correlated with PSA decrease at 3 months. Additionally, shorter time under AA treatment, presence of multiple sites of metastasis and previous hormonal treatment duration were three independent factors associated with poorer OS. At the time of analysis ten patients were still under treatment for more than 3 years.
Biochemical response monitored by PSA changes at 3 months is a strong predictive factor for AA treatment duration. Some high responders' patients could beneficiate from AA for more than 3 years.",[],BMC cancer,2015-04-18,"[{'lastname': 'Houédé', 'firstname': 'Nadine', 'initials': 'N', 'affiliation': 'Department of Medical Oncology, Nîmes University Hospital, Nîmes, France. nadine.houede@chu-nimes.fr.\nINSERM U1194, Montpellier, France. nadine.houede@chu-nimes.fr.'}, {'lastname': 'Beuzeboc', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'Department of Medical Oncology, Curie Institute, Paris, France. philippe.beuzeboc@curie.net.'}, {'lastname': 'Gourgou', 'firstname': 'Sophie', 'initials': 'S', 'affiliation': 'Biostatistics Unit, ICM - Montpellier Cancer Institute, Montpellier, France. sophie.gourgou@icm.unicancer.fr.'}, {'lastname': 'Tosi', 'firstname': 'Diego', 'initials': 'D', 'affiliation': 'Department of Medical Oncology, ICM - Montpellier Cancer Institute, Montpellier, France. diego.tosi@icm.unicancer.fr.'}, {'lastname': 'Moise', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Department of Medical Oncology, François Baclesse Cancer Centre, Caen, France. l.moise@baclesse.fr.'}, {'lastname': 'Gravis', 'firstname': 'Gwenaëlle', 'initials': 'G', 'affiliation': 'Department of Medical Oncology, Paoli Calmette Institute, Marseille, France. gravisg@ipc.unicancer.fr.'}, {'lastname': 'Delva', 'firstname': 'Remy', 'initials': 'R', 'affiliation': 'Department of Medical Oncology, Paul Papin Cancer Centre, Angers, France. r.delva@unimedia.fr.'}, {'lastname': 'Fléchon', 'firstname': 'Aude', 'initials': 'A', 'affiliation': 'Department of Medical Oncology, Leon Bérard Cancer Centre, Lyon, France. aude.flechon@lyon.unicancer.fr.'}, {'lastname': 'Latorzeff', 'firstname': 'Igor', 'initials': 'I', 'affiliation': 'Clinique Pasteur, Toulouse, France. i.latorzeff@clinique-pasteur.com.'}, {'lastname': 'Ferrero', 'firstname': 'Jean-Marc', 'initials': 'JM', 'affiliation': 'Department of Medical Oncology, Antoine Lacassagne Cancer Centre, Nice, France. jean-marc.ferrero@nice.unicancer.fr.'}, {'lastname': 'Oudard', 'firstname': 'Stéphane', 'initials': 'S', 'affiliation': 'Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France. stephane.oudard@egp.aphp.fr.'}, {'lastname': 'Tartas', 'firstname': 'Sophie', 'initials': 'S', 'affiliation': 'Department of Medical Oncology, Lyon University Hospital, Lyon, France. sophie.tartas@chu-lyon.fr.'}, {'lastname': 'Laguerre', 'firstname': 'Brigitte', 'initials': 'B', 'affiliation': 'Department of Medical Oncology, Eugène Marquis Cancer Centre, Rennes, France. b.laguerre@rennes.unicancer.fr.'}, {'lastname': 'Topart', 'firstname': 'Delphine', 'initials': 'D', 'affiliation': 'Department of Medical Oncology, Montpellier University Hospital, Montpellier, France. d-topart@chu-montpellier.fr.'}, {'lastname': 'Roubaud', 'firstname': 'Guilhem', 'initials': 'G', 'affiliation': 'Department of Medical Oncology, Bergonié Cancer Institute, Bordeaux, France. g.roubaud@bordeaux.unicancer.fr.'}, {'lastname': 'Agherbi', 'firstname': 'Hanane', 'initials': 'H', 'affiliation': 'INSERM U1194, Montpellier, France. hanane.agherbi@inserm.fr.'}, {'lastname': 'Rebillard', 'firstname': 'Xavier', 'initials': 'X', 'affiliation': 'Department of Urology, Clinique Beausoleil, Montpellier, France. xavier.rebillard@wanadoo.fr.'}, {'lastname': 'Azria', 'firstname': 'David', 'initials': 'D', 'affiliation': 'INSERM U1194, Montpellier, France. david.azria@montpellier.unicancer.fr.\nDepartment of Radiation Oncology, ICM - Montpellier Cancer Institute, Montpellier, France. david.azria@montpellier.unicancer.fr.'}]",,,"Among the 408 patients, 306 were eligible with a follow-up at 3 years. Median OS was 37.1 months from beginning of CT and 14.6 months from AA introduction. 211 patients (69%) received ≥ 3 months of AA and 95 patients (31%) were treated less than 3 months. In the multivariate analyses, duration of AA was significantly correlated with PSA decrease at 3 months. Additionally, shorter time under AA treatment, presence of multiple sites of metastasis and previous hormonal treatment duration were three independent factors associated with poorer OS. At the time of analysis ten patients were still under treatment for more than 3 years.",,"10.1186/s12885-015-1257-2
10.1016/j.ctrv.2013.06.008
10.1200/JCO.2007.12.4008
10.1016/S0140-6736(10)61389-X
10.1021/jm00013a022
10.1111/j.1464-410X.2005.05821.x
10.1056/NEJMoa1014618
10.1200/JCO.2007.12.4487
10.1016/j.steroids.2013.04.012
10.1002/cncr.28518
10.1093/annonc/mdt136
10.1158/1078-0432.CCR-10-1959
10.1200/JCO.2012.45.4595
10.1016/j.clgc.2014.06.010
10.1093/annonc/mdt581
10.1056/NEJMoa1405095
10.1056/NEJMoa1207506
10.1016/j.ejca.2013.09.026
10.1093/annonc/mds119
10.1016/j.eururo.2014.01.018
10.1016/S1470-2045(14)70417-6",<Element 'PubmedArticle' at 0x7f05d95e8ea0>
226,25865441,Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease.,"Cerebrospinal fluid YKL-40 has been described as a marker of glial inflammation. We aimed to study the relationship between YKL-40 and brain structure and its interactions with core Alzheimer's disease (AD) biomarkers. We measured cortical thickness (CTh) and cerebrospinal fluid biomarkers (amyloid-β 1-42 [Aβ42], total tau, p-tau, and YKL-40) of 80 cognitively normal controls and 27 patients with amnestic mild cognitive impairment. Subjects were classified as Aβ42+ (<550 pg/mL) or Aβ42- (>550 pg/mL). CTh difference maps were derived from the interaction and correlation analyses in the whole sample and within clinical groups. There was a strong correlation between YKL-40 and markers of neurodegeneration (total tau and p-tau). In the whole sample, we found a negative correlation between YKL-40 and CTh in AD vulnerable areas in Aβ42+ subjects but not in Aβ42 participants. Our results suggest that YKL-40 could track the inflammatory processes associated to tau-related neurodegeneration in the presence of the AD pathophysiological process.","['CSF biomarkers', 'Cortical thickness', 'Neuroinflammation', ""Preclinical Alzheimer's disease"", 'Structural MRI', 'YKL-40']",Neurobiology of aging,2015-04-14,"[{'lastname': 'Alcolea', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Vilaplana', 'firstname': 'Eduard', 'initials': 'E', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Pegueroles', 'firstname': 'Jordi', 'initials': 'J', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Montal', 'firstname': 'Victor', 'initials': 'V', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Sánchez-Juan', 'firstname': 'Pascual', 'initials': 'P', 'affiliation': 'Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; Department of Neurology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain.'}, {'lastname': 'González-Suárez', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; Department of Neurology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain.'}, {'lastname': 'Pozueta', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; Department of Neurology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain.'}, {'lastname': 'Rodríguez-Rodríguez', 'firstname': 'Eloy', 'initials': 'E', 'affiliation': 'Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; Department of Neurology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain.'}, {'lastname': 'Bartrés-Faz', 'firstname': 'David', 'initials': 'D', 'affiliation': ""Department of Psychiatry and Clinical Psychobiology, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.""}, {'lastname': 'Vidal-Piñeiro', 'firstname': 'Dídac', 'initials': 'D', 'affiliation': ""Department of Psychiatry and Clinical Psychobiology, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.""}, {'lastname': 'González-Ortiz', 'firstname': 'Sofía', 'initials': 'S', 'affiliation': 'Department of Radiology, Hospital del Mar, Barcelona, Spain.'}, {'lastname': 'Medrano', 'firstname': 'Santiago', 'initials': 'S', 'affiliation': 'Department of Radiology, Hospital del Mar, Barcelona, Spain.'}, {'lastname': 'Carmona-Iragui', 'firstname': 'María', 'initials': 'M', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Sánchez-Saudinós', 'firstname': 'MaBelén', 'initials': 'M', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Sala', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Anton-Aguirre', 'firstname': 'Sofía', 'initials': 'S', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Sampedro', 'firstname': 'Frederic', 'initials': 'F', 'affiliation': 'Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.'}, {'lastname': 'Morenas-Rodríguez', 'firstname': 'Estrella', 'initials': 'E', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Clarimón', 'firstname': 'Jordi', 'initials': 'J', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Blesa', 'firstname': 'Rafael', 'initials': 'R', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Lleó', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.""}, {'lastname': 'Fortea', 'firstname': 'Juan', 'initials': 'J', 'affiliation': ""Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau-Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. Electronic address: jfortea@santpau.cat.""}]",,,,Copyright © 2015 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2015.03.001,<Element 'PubmedArticle' at 0x7f05d9605630>
227,25837922,Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.,"Sitagliptin, a dipeptidyl peptidase IV (DPP-Ⅳ) inhibitor, has a biological role in improving the serum levels of glucagon-like peptide 1 (GLP-1). Hence, we sought to determine the effect of sitagliptin on myocardial inflammation, collagen metabolism, lipid content and myocardial apoptosis in diabetic rats.
The type 2 diabetic rat model was induced by low-dose streptozotocin and a high-fat diet. Characteristics of diabetic rats were evaluated by electrocardiography, echocardiography and blood analysis. Cardiac inflammation, fibrosis, cardiomyocyte density, lipid accumulation, and receptor-interacting protein kinase 3 (RIP3) level, related to apoptosis, were detected by histopathologic analysis, RT-PCR and western blot analysis to evaluate the effects of sitagliptin on myocardial remodeling of the left ventricle.
Diabetic rats showed myocardial hypertrophy or apoptosis, inflammation, lipid accumulation, myocardial fibrosis, elevated collagen content, RIP3 overexpression, and left-ventricular dysfunction. Sitagliptin could reverse the overexpression of RIP3 and alleviate cellular apoptosis in myocardial tissues. It could significantly improve left-ventricular systolic pressure and +dp/dt max, reduce the E/E' ratio, left ventricular end diastolic pressure, -dp/dt max and Tau in diabetic rats.
Sitagliptin might have a myocardial protective effect by inhibiting apoptosis, inflammation, lipid accumulation and myocardial fibrosis in diabetic rats, for a potential role in improving left-ventricular function in diabetes.","['Cardiac function', 'Diabetes mellitus', 'Myocardial remodeling', 'Sitagliptin']",Journal of pharmacological sciences,2015-04-04,"[{'lastname': 'Liu', 'firstname': 'Yu-Sheng', 'initials': 'YS', 'affiliation': 'Department of Cardiology, The Qilu Hospital of Shandong University, Jinan, Shandong, 250033, PR China; Department of Cardiology, The Second Hospital of Shandong University, Jinan, Shandong, 250033, PR China. Electronic address: lyssyl188@sina.com.'}, {'lastname': 'Huang', 'firstname': 'Zhi-Wei', 'initials': 'ZW', 'affiliation': 'Department of Cardiology, The Qilu Hospital of Shandong University, Jinan, Shandong, 250033, PR China. Electronic address: huangzhiwei88@tom.com.'}, {'lastname': 'Wang', 'firstname': 'Lin', 'initials': 'L', 'affiliation': 'Department of Cardiology, The Qilu Hospital of Shandong University, Jinan, Shandong, 250033, PR China. Electronic address: wanglin2004@yahoo.com.cn.'}, {'lastname': 'Liu', 'firstname': 'Xin-Xin', 'initials': 'XX', 'affiliation': 'Department of Cardiology, The Qilu Hospital of Shandong University, Jinan, Shandong, 250033, PR China. Electronic address: liuxx@tom.com.'}, {'lastname': 'Wang', 'firstname': 'Yong-Mei', 'initials': 'YM', 'affiliation': 'Department of Cardiology, The Second Hospital of Shandong University, Jinan, Shandong, 250033, PR China. Electronic address: xinzang2012@126.com.'}, {'lastname': 'Zhang', 'firstname': 'Yun', 'initials': 'Y', 'affiliation': 'Department of Cardiology, The Qilu Hospital of Shandong University, Jinan, Shandong, 250033, PR China. Electronic address: daixh@vip.sina.com.'}, {'lastname': 'Zhang', 'firstname': 'Mei', 'initials': 'M', 'affiliation': 'Department of Cardiology, The Qilu Hospital of Shandong University, Jinan, Shandong, 250033, PR China. Electronic address: daixh@vip.sina.com.'}]",,,"Diabetic rats showed myocardial hypertrophy or apoptosis, inflammation, lipid accumulation, myocardial fibrosis, elevated collagen content, RIP3 overexpression, and left-ventricular dysfunction. Sitagliptin could reverse the overexpression of RIP3 and alleviate cellular apoptosis in myocardial tissues. It could significantly improve left-ventricular systolic pressure and +dp/dt max, reduce the E/E' ratio, left ventricular end diastolic pressure, -dp/dt max and Tau in diabetic rats.",Copyright © 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.,10.1016/j.jphs.2014.12.007,<Element 'PubmedArticle' at 0x7f05d96199f0>
228,25771251,Beyond the HPA-axis: The role of the gonadal steroid hormone receptors in modulating stress-related responses in an animal model of PTSD.,"The hypothalamic-pituitary-adrenal (HPA) axis, which plays a major role in the response to stress, and the hypothalamic-pituitary-gonadal (HPG) axis are closely linked with the ability to inhibit the other. Testosterone, a product of the HPG, has many beneficial effects beyond its functions as a sex hormone including anti-anxiety properties. In this study we examined the effect of stress exposure on gonadal hormones, and their efficacy in modulating anxiety-like response in an animal model of PTSD. Male rats were exposed to predator scent stress, followed by analysis of brain expression of androgen receptor (AR) receptor and estrogen receptor α (ERα). The behavioral effects of immediate treatment with testosterone, testosterone receptor antagonist (flutamide) or vehicle were evaluated using the elevated plus-maze, acoustic startle response and trauma-cue response. Levels of circulating corticosterone and testosterone were also measured after treatment. The behavioral effects of delayed testosterone treatment were explored in the same manner. We report that animals whose behavior was extremely disrupted (EBR) selectively displayed significant down-regulation of AR and ERα in the hippocampus. Immediate treatment with flutamide or delayed treatment with testosterone significantly increased prevalence rates of minimal behavioral response (MBR) and decreased prevalence of EBR with favorable behavioral results. Testosterone levels were higher in control un-exposed animals, while corticosterone was higher in control exposed animals. This study suggests that gonadal steroid hormones are involved in the neurobiological response to predator scent stress and thus warrant further study as a potential therapeutic avenue for the treatment of anxiety-related disorders.","['Androgen receptor', 'Estrogen receptor α', 'HPA-axis', 'HPG-axis', 'Post-traumatic stress disorder', 'Testosterone']",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,2015-03-17,"[{'lastname': 'Fenchel', 'firstname': 'Daphna', 'initials': 'D', 'affiliation': 'Beer-Yaakov Mental Health Center, Ministry of Health, Sackler Faculty of Medicine, Tel Aviv University, Beer-Yaakov, Israel.'}, {'lastname': 'Levkovitz', 'firstname': 'Yechiel', 'initials': 'Y', 'affiliation': 'Beer-Yaakov Mental Health Center, Ministry of Health, Sackler Faculty of Medicine, Tel Aviv University, Beer-Yaakov, Israel. Electronic address: yeheal@post.tau.ac.il.'}, {'lastname': 'Vainer', 'firstname': 'Ella', 'initials': 'E', 'affiliation': 'Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.'}, {'lastname': 'Kaplan', 'firstname': 'Zeev', 'initials': 'Z', 'affiliation': 'Beer-Sheva Mental Health Center, Ministry of Health, Anxiety and Stress Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.'}, {'lastname': 'Zohar', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': 'Division of Psychiatry, The Chaim Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Ramat-Gan, Israel.'}, {'lastname': 'Cohen', 'firstname': 'Hagit', 'initials': 'H', 'affiliation': 'Beer-Sheva Mental Health Center, Ministry of Health, Anxiety and Stress Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.'}]",,,,Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved.,10.1016/j.euroneuro.2015.02.004,<Element 'PubmedArticle' at 0x7f05d95a5f40>
229,"25765123
22382356
23803320
16613895
25113789
23927914
9641683
16862116
21944778
14561797
21325651
22699846
24598709
22366795
20139998
22732773
24449064
17210807
19940270
16344531",Dominant frontotemporal dementia mutations in 140 cases of primary progressive aphasia and speech apraxia.,"Mutations in three genes [chromosome 9 open-reading-frame 72 (C9ORF72); microtubule-associated protein tau (MAPT) and progranulin (GRN)] account for the vast majority of familial, and a proportion of sporadic, frontotemporal dementia (FTD) cases. Progressive apraxia of speech (PAOS) is a type of FTD characterized by speech production deficits without a known cause.
We therefore assessed for genetic mutations in C9ORF72, MAPT and GRN in 40 prospectively recruited PAOS patients. For comparison, we also assessed these mutations in 100 patients with primary progressive aphasia (PPA), including logopenic PPA (n = 54), nonfluent/agrammatic PPA (n = 17), semantic PPA (n = 16), and unclassifiable PPA (n = 13).
The mean age at onset of PAOS patients was 66.7 years (± 9.3); 50% were women. Ten patients (25%) had ≥1 first-degree relative with a neurodegenerative disease. No mutations were found in any PAOS patient. In comparison, 36% of the PPA patients had a family history and 5 (5%) had a genetic mutation detected: MAPT (n = 0), GRN (n = 3) and C9ORF72 (n = 2).
Although limited by an overrepresentation of logopenic PPA, which frequently predicts Alzheimer's disease pathology, this study suggests that mutations in the three genes most commonly associated with FTD are not associated with PAOS and are not commonly associated with PPA.",[],Dementia and geriatric cognitive disorders,2015-03-15,"[{'lastname': 'Flanagan', 'firstname': 'Eoin P', 'initials': 'EP', 'affiliation': 'Division of Behavioral Neurology, Mayo Clinic, Rochester, Minn., USA.'}, {'lastname': 'Baker', 'firstname': 'Matthew C', 'initials': 'MC', 'affiliation': None}, {'lastname': 'Perkerson', 'firstname': 'Ralph B', 'initials': 'RB', 'affiliation': None}, {'lastname': 'Duffy', 'firstname': 'Joseph R', 'initials': 'JR', 'affiliation': None}, {'lastname': 'Strand', 'firstname': 'Edythe A', 'initials': 'EA', 'affiliation': None}, {'lastname': 'Whitwell', 'firstname': 'Jennifer L', 'initials': 'JL', 'affiliation': None}, {'lastname': 'Machulda', 'firstname': 'Mary M', 'initials': 'MM', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': None}, {'lastname': 'Josephs', 'firstname': 'Keith A', 'initials': 'KA', 'affiliation': None}]",,,"The mean age at onset of PAOS patients was 66.7 years (± 9.3); 50% were women. Ten patients (25%) had ≥1 first-degree relative with a neurodegenerative disease. No mutations were found in any PAOS patient. In comparison, 36% of the PPA patients had a family history and 5 (5%) had a genetic mutation detected: MAPT (n = 0), GRN (n = 3) and C9ORF72 (n = 2).",,10.1159/000375299,<Element 'PubmedArticle' at 0x7f05d95b43b0>
230,"25683866
9641683
16862116
16862115
21944778
21944779
18090429
22366791
20045477
22875087
19255408
22366795
21753165
16950801
9855500
16606762
21325651
6610841
18263627
15325354
9368118
12815635
17659998
24706010
11771995
19786698",Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images.,"The aim of our study was to determine the utility of longitudinal magnetic resonance imaging (MRI) measurements as potential biomarkers in the main genetic variants of frontotemporal dementia (FTD), including microtubule-associated protein tau (MAPT) and progranulin (GRN) mutations and C9ORF72 repeat expansions, as well as sporadic FTD.
In this longitudinal study, 58 subjects were identified who had at least two MRI and MAPT mutations (n = 21), GRN mutations (n = 11), C9ORF72 repeat expansions (n = 11) or sporadic FTD (n = 15). A total of 198 serial MRI measurements were analyzed. Rates of whole brain atrophy were calculated using the boundary shift integral. Regional rates of atrophy were calculated using tensor-based morphometry. Sample size estimates were calculated.
Progressive brain atrophy was observed in all groups, with fastest rates of whole brain atrophy in GRN, followed by sporadic FTD, C9ORF72 and MAPT. All variants showed greatest rates in the frontal and temporal lobes, with parietal lobes also strikingly affected in GRN. Regional rates of atrophy across all lobes were greater in GRN compared to the other groups. C9ORF72 showed greater rates of atrophy in the left cerebellum and right occipital lobe than MAPT, and sporadic FTD showed greater rates in the anterior cingulate than C9ORF72 and MAPT. Sample size estimates were lowest using temporal lobe rates in GRN, ventricular rates in MAPT and C9ORF72, and whole brain rates in sporadic FTD.
These data support the utility of using rates of atrophy as outcome measures in future drug trials in FTD and show that different imaging biomarkers may offer advantages in the different variants of FTD.","['MRI', 'frontotemporal dementia', 'genetics', 'longitudinal', 'tensor-based morphometry']",European journal of neurology,2015-02-17,"[{'lastname': 'Whitwell', 'firstname': 'J L', 'initials': 'JL', 'affiliation': 'Department of Radiology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Boeve', 'firstname': 'B F', 'initials': 'BF', 'affiliation': None}, {'lastname': 'Weigand', 'firstname': 'S D', 'initials': 'SD', 'affiliation': None}, {'lastname': 'Senjem', 'firstname': 'M L', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Gunter', 'firstname': 'J L', 'initials': 'JL', 'affiliation': None}, {'lastname': 'Baker', 'firstname': 'M C', 'initials': 'MC', 'affiliation': None}, {'lastname': 'DeJesus-Hernandez', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Knopman', 'firstname': 'D S', 'initials': 'DS', 'affiliation': None}, {'lastname': 'Wszolek', 'firstname': 'Z K', 'initials': 'ZK', 'affiliation': None}, {'lastname': 'Petersen', 'firstname': 'R C', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Jack', 'firstname': 'C R', 'initials': 'CR', 'affiliation': None}, {'lastname': 'Josephs', 'firstname': 'K A', 'initials': 'KA', 'affiliation': None}]",,These data support the utility of using rates of atrophy as outcome measures in future drug trials in FTD and show that different imaging biomarkers may offer advantages in the different variants of FTD.,"Progressive brain atrophy was observed in all groups, with fastest rates of whole brain atrophy in GRN, followed by sporadic FTD, C9ORF72 and MAPT. All variants showed greatest rates in the frontal and temporal lobes, with parietal lobes also strikingly affected in GRN. Regional rates of atrophy across all lobes were greater in GRN compared to the other groups. C9ORF72 showed greater rates of atrophy in the left cerebellum and right occipital lobe than MAPT, and sporadic FTD showed greater rates in the anterior cingulate than C9ORF72 and MAPT. Sample size estimates were lowest using temporal lobe rates in GRN, ventricular rates in MAPT and C9ORF72, and whole brain rates in sporadic FTD.",© 2015 EAN.,10.1111/ene.12675,<Element 'PubmedArticle' at 0x7f05d95c6b80>
231,25676386,Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: new aspects on Alzheimer's disease.,"Alzheimer's disease and other age-related neurodegenerative disorders are associated with deterioration of the noradrenergic locus coeruleus (LC), a probable trigger for mood and memory dysfunction. LC noradrenergic neurons exhibit particularly high levels of somatostatin binding sites. This is noteworthy since cortical and hypothalamic somatostatin content is reduced in neurodegenerative pathologies. Yet a possible role of a somatostatin signal deficit in the maintenance of noradrenergic projections remains unknown. Here, we deployed tissue microarrays, immunohistochemistry, quantitative morphometry and mRNA profiling in a cohort of Alzheimer's and age-matched control brains in combination with genetic models of somatostatin receptor deficiency to establish causality between defunct somatostatin signalling and noradrenergic neurodegeneration. In Alzheimer's disease, we found significantly reduced somatostatin protein expression in the temporal cortex, with aberrant clustering and bulging of tyrosine hydroxylase-immunoreactive afferents. As such, somatostatin receptor 2 (SSTR2) mRNA was highly expressed in the human LC, with its levels significantly decreasing from Braak stages III/IV and onwards, i.e., a process preceding advanced Alzheimer's pathology. The loss of SSTR2 transcripts in the LC neurons appeared selective, since tyrosine hydroxylase, dopamine β-hydroxylase, galanin or galanin receptor 3 mRNAs remained unchanged. We modeled these pathogenic changes in Sstr2(-/-) mice and, unlike in Sstr1(-/-) or Sstr4(-/-) genotypes, they showed selective, global and progressive degeneration of their central noradrenergic projections. However, neuronal perikarya in the LC were found intact until late adulthood (<8 months) in Sstr2(-/-) mice. In contrast, the noradrenergic neurons in the superior cervical ganglion lacked SSTR2 and, as expected, the sympathetic innervation of the head region did not show any signs of degeneration. Our results indicate that SSTR2-mediated signaling is integral to the maintenance of central noradrenergic projections at the system level, and that early loss of somatostatin receptor 2 function may be associated with the selective vulnerability of the noradrenergic system in Alzheimer's disease.",[],Acta neuropathologica,2015-02-14,"[{'lastname': 'Ádori', 'firstname': 'Csaba', 'initials': 'C', 'affiliation': 'Department of Neuroscience, Retzius Laboratory, Karolinska Institutet, Retzius väg 8, 17177, Stockholm, Sweden, adorics@gmail.com.'}, {'lastname': 'Glück', 'firstname': 'Laura', 'initials': 'L', 'affiliation': None}, {'lastname': 'Barde', 'firstname': 'Swapnali', 'initials': 'S', 'affiliation': None}, {'lastname': 'Yoshitake', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': None}, {'lastname': 'Kovacs', 'firstname': 'Gabor G', 'initials': 'GG', 'affiliation': None}, {'lastname': 'Mulder', 'firstname': 'Jan', 'initials': 'J', 'affiliation': None}, {'lastname': 'Maglóczky', 'firstname': 'Zsófia', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Havas', 'firstname': 'László', 'initials': 'L', 'affiliation': None}, {'lastname': 'Bölcskei', 'firstname': 'Kata', 'initials': 'K', 'affiliation': None}, {'lastname': 'Mitsios', 'firstname': 'Nicholas', 'initials': 'N', 'affiliation': None}, {'lastname': 'Uhlén', 'firstname': 'Mathias', 'initials': 'M', 'affiliation': None}, {'lastname': 'Szolcsányi', 'firstname': 'János', 'initials': 'J', 'affiliation': None}, {'lastname': 'Kehr', 'firstname': 'Jan', 'initials': 'J', 'affiliation': None}, {'lastname': 'Rönnbäck', 'firstname': 'Annica', 'initials': 'A', 'affiliation': None}, {'lastname': 'Schwartz', 'firstname': 'Thue', 'initials': 'T', 'affiliation': None}, {'lastname': 'Rehfeld', 'firstname': 'Jens F', 'initials': 'JF', 'affiliation': None}, {'lastname': 'Harkany', 'firstname': 'Tibor', 'initials': 'T', 'affiliation': None}, {'lastname': 'Palkovits', 'firstname': 'Miklós', 'initials': 'M', 'affiliation': None}, {'lastname': 'Schulz', 'firstname': 'Stefan', 'initials': 'S', 'affiliation': None}, {'lastname': 'Hökfelt', 'firstname': 'Tomas', 'initials': 'T', 'affiliation': None}]",,,,,10.1007/s00401-015-1394-3,<Element 'PubmedArticle' at 0x7f05d95dfea0>
232,25624414,Anorexigenic lipopeptides ameliorate central insulin signaling and attenuate tau phosphorylation in hippocampi of mice with monosodium glutamate-induced obesity.,"Numerous epidemiological and experimental studies have demonstrated that patients who suffer from metabolic disorders, such as type 2 diabetes mellitus (T2DM) or obesity, have higher risks of cognitive dysfunction and of Alzheimer's disease (AD). Impaired insulin signaling in the brain could contribute to the formation of neurofibrillary tangles, which contain an abnormally hyperphosphorylated tau protein. This study aimed to determine whether potential tau hyperphosphorylation could be detected in an obesity-induced pre-diabetes state and whether anorexigenic agents could affect this state. We demonstrated that 6-month-old mice with monosodium glutamate (MSG) obesity, which represent a model of obesity-induced pre-diabetes, had increased tau phosphorylation at Ser396 and Thr231 in the hippocampus compared with the controls, as determined by western blots. Two weeks of subcutaneous treatment with a lipidized analog of prolactin-releasing peptide (palm-PrRP31) or with the T2DM drug liraglutide, which both had a central anorexigenic effect, resulted in increased phosphorylation of the insulin cascade kinases PDK1 (Ser241), Akt (Thr308), and GSK-3β (Ser9). Furthermore, these drugs attenuated phosphorylation at Ser396, Thr231, and Thr212 of tau and of the primary tau kinases in the hippocampi of 6-month-old MSG-obese mice. We identified tau hyperphosphorylation in the obesity-induced pre-diabetes state in MSG-obese mice and demonstrated the beneficial effects of palm-PrRP31 and liraglutide, both of known central anorexigenic effects, on hippocampal insulin signaling and on tau phosphorylation.","[""Alzheimer's disease"", 'insulin signaling', 'liraglutide', 'monosodium glutamate-obese mice', 'obesity', 'pre-diabetes', 'prolactin-releasing peptide', 'tau phosphorylation']",Journal of Alzheimer's disease : JAD,2015-01-28,"[{'lastname': 'Špolcová', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic INSERM UMR837, Lille, France, Jean Pierre Aubert Research Centre, Faculté de Médecine-Pòle Recherche, Institut de Médecine Prédictive et de Recherche Thérapeutique, Université Droit et Santé de Lille, CHU-Lille, Lille, France.'}, {'lastname': 'Mikulášková', 'firstname': 'Barbora', 'initials': 'B', 'affiliation': 'Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.'}, {'lastname': 'Holubová', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.'}, {'lastname': 'Nagelová', 'firstname': 'Veronika', 'initials': 'V', 'affiliation': 'Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.'}, {'lastname': 'Pirnik', 'firstname': 'Zdenko', 'initials': 'Z', 'affiliation': 'Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic Laboratory of Functional Neuromorphology, Institute of Experimental Endocrinology, SAS, Bratislava, Slovak Republic Department of Human and Clinical Pharmacology, University of Veterinary Medicine, Košice, Slovak Republic.'}, {'lastname': 'Zemenová', 'firstname': 'Jana', 'initials': 'J', 'affiliation': 'Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic Institute of Chemical Technology, Department of Analytical Chemistry, Prague, Czech Republic.'}, {'lastname': 'Haluzík', 'firstname': 'Martin', 'initials': 'M', 'affiliation': 'Third Department of Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.'}, {'lastname': 'Železná', 'firstname': 'Blanka', 'initials': 'B', 'affiliation': 'Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.'}, {'lastname': 'Galas', 'firstname': 'Marie-Christine', 'initials': 'MC', 'affiliation': 'INSERM UMR837, Lille, France, Jean Pierre Aubert Research Centre, Faculté de Médecine-Pòle Recherche, Institut de Médecine Prédictive et de Recherche Thérapeutique, Université Droit et Santé de Lille, CHU-Lille, Lille, France.'}, {'lastname': 'Maletínská', 'firstname': 'Lenka', 'initials': 'L', 'affiliation': 'Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.'}]",,,,,10.3233/JAD-143150,<Element 'PubmedArticle' at 0x7f05d9574950>
233,25592136,Investigating degeneration of the retina in young and aged tau P301L mice.,"Tau is a microtubule-binding protein facilitating the stability of the cytoskeleton. It is important for neurons as several neurodegenerative diseases involve hyperphosphorylation and aggregation of tau. It is known that mutated tau P301L results in aggregation of tau proteins, leading to neuronal loss in the brain. The aim of this study was to investigate the effect of tau mutation on the retina using a transgenic tau P301L mouse model.
Morphometric analysis was utilized to quantify the neurodegenerative changes, including the thickness of the inner nuclear layer (INL), and the density and size of retinal ganglion cells (RGCs). Sections of retina tissue stained by hematoxylin and eosin (H&E) and immunohistochemistry were analyzed. Comparisons were made between the tau P301L mice and control mice, as well as between different age groups.
A significant decrease in the thickness of the INL in tau P301L mice was found when compared with that of control mice. The effect was more pronounced in the peripheral area, and the effect increased with age. Regarding density of RGCs, tau P301L mice showed a similar age-related decline as in control mice. Furthermore, the RGCs from tau P301L mice increased in size with age, and the RGCs from control mice decreased in size with age.
Tau may be an age-independent factor of accelerated neurodegeneration, with effects differing by types of neurons and regions of the retina.","['Aging', 'Neurodegeneration', 'Retina', 'Retinal ganglion cells', 'Tau']",Life sciences,2015-01-17,"[{'lastname': 'Ho', 'firstname': 'Wing Lau', 'initials': 'WL', 'affiliation': 'Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'lastname': 'Leung', 'firstname': 'Yen', 'initials': 'Y', 'affiliation': 'Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'lastname': 'Cheng', 'firstname': 'Sally Shuk Yee', 'initials': 'SS', 'affiliation': 'Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'lastname': 'Lok', 'firstname': 'Carmen Ka Ming', 'initials': 'CK', 'affiliation': 'Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'lastname': 'Ho', 'firstname': 'Yuen-Shan', 'initials': 'YS', 'affiliation': 'Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China; School of Nursing, Faculty of Health and Social Sciences, Hong Kong Polytechnic University, Hunghom, Kowloon, Hong Kong, China.'}, {'lastname': 'Baum', 'firstname': 'Larry', 'initials': 'L', 'affiliation': 'School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China.'}, {'lastname': 'Yang', 'firstname': 'Xifei', 'initials': 'X', 'affiliation': 'Shenzhen Center of Disease Control and Prevention, Shenzhen, China.'}, {'lastname': 'Chiu', 'firstname': 'Kin', 'initials': 'K', 'affiliation': 'Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China. Electronic address: ckirischiu@gmail.com.'}, {'lastname': 'Chang', 'firstname': 'Raymond Chuen-Chung', 'initials': 'RC', 'affiliation': 'Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Research Centre of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pokfulam, Hong Kong, China. Electronic address: rccchang@hku.hk.'}]",,,,Copyright © 2015 Elsevier Inc. All rights reserved.,10.1016/j.lfs.2014.12.019,<Element 'PubmedArticle' at 0x7f05d9582b30>
234,25500362,Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids.,"Ipilimumab is an anti-CTLA-4 antibody which has recently been approved in Europe as a monotherapy in the treatment of metastatic melanoma. We report a single-center study among patients treated within a Temporary Authorization for Use (TAU) protocol. We also performed a review of the literature involving expanded access program studies with a focus on factors associated with overall survival (OS).
This retrospective, observational study included patients between June 2010 and July 2011 with a diagnosis of non-resectable stage III or IV melanoma with at least one previous line of chemotherapy. Treatment consisted of four courses of ipilimumab at a dose of 3mg/kg every three weeks.
45 patients were included, among whom 23 (51%) had brain metastases. 33 (71%) of the patients completed the induction phase. The best overall response rate (BORR) was 13% and median overall survival (OS) was 8 months (95%CI: 7 to 12). OS was not different between patients with brain metastases at baseline and those without (p = 0.10), regardless of BRAF V600E status (p = 0.61). OS was poorer in patients who were being treated with corticoids at baseline (p<0.001) or with LDH at baseline > 500 UI/ml (p = 0.008).
A subset of patients most likely to benefit from ipilimumab should be defined. In our series we found a negative association of baseline corticosteroids with OS. Unlike high LDH levels, BRAF V600 E status and brain metastases should not be barriers to the initiation of treatment.","['baseline corticosteroids', 'ipilimumab', 'melanoma']",European journal of dermatology : EJD,2014-12-17,"[{'lastname': 'Chasset', 'firstname': 'François', 'initials': 'F', 'affiliation': 'APHP Department of Dermatology Hôpital Saint-Louis, 1, avenue Claude-Vellefaux. 75010 Paris, France; Université Paris 7-Diderot, INSERM U976.'}, {'lastname': 'Pages', 'firstname': 'Cécile', 'initials': 'C', 'affiliation': 'APHP Department of Dermatology Hôpital Saint-Louis, 1, avenue Claude-Vellefaux. 75010 Paris, France; Université Paris 7-Diderot, INSERM U976.'}, {'lastname': 'Biard', 'firstname': 'Lucie', 'initials': 'L', 'affiliation': 'APHP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRA Team, CRESS UMR 1153, INSERM, Paris Diderot University.'}, {'lastname': 'Roux', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': 'APHP Department of Dermatology Hôpital Saint-Louis, 1, avenue Claude-Vellefaux. 75010 Paris, France; Université Paris 7-Diderot, INSERM U976.'}, {'lastname': 'Sidina', 'firstname': 'Irina', 'initials': 'I', 'affiliation': 'APHP Department of Dermatology Hôpital Saint-Louis, 1, avenue Claude-Vellefaux. 75010 Paris, France; Université Paris 7-Diderot, INSERM U976.'}, {'lastname': 'Madelaine', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'APHP Department of Pharmacy Hôpital Saint-Louis\xa0; Université Paris 7-Diderot, Paris, France.'}, {'lastname': 'Basset-Seguin', 'firstname': 'Nicole', 'initials': 'N', 'affiliation': 'APHP Department of Dermatology Hôpital Saint-Louis, 1, avenue Claude-Vellefaux. 75010 Paris, France; Université Paris 7-Diderot, INSERM U976.'}, {'lastname': 'Viguier', 'firstname': 'Manuelle', 'initials': 'M', 'affiliation': 'APHP Department of Dermatology Hôpital Saint-Louis, 1, avenue Claude-Vellefaux. 75010 Paris, France; Université Paris 7-Diderot, INSERM U976.'}, {'lastname': 'Madjlessi-EzrA', 'firstname': 'Nika', 'initials': 'N', 'affiliation': 'APHP Department of Dermatology Hôpital Saint-Louis, 1, avenue Claude-Vellefaux. 75010 Paris, France; Université Paris 7-Diderot, INSERM U976.'}, {'lastname': 'Schneider', 'firstname': 'Pierre', 'initials': 'P', 'affiliation': 'APHP Department of Dermatology Hôpital Saint-Louis, 1, avenue Claude-Vellefaux. 75010 Paris, France; Université Paris 7-Diderot, INSERM U976.'}, {'lastname': 'Bagot', 'firstname': 'Martine', 'initials': 'M', 'affiliation': 'APHP Department of Dermatology Hôpital Saint-Louis, 1, avenue Claude-Vellefaux. 75010 Paris, France; Université Paris 7-Diderot, INSERM U976.'}, {'lastname': 'Resche-Rigon', 'firstname': 'Matthieu', 'initials': 'M', 'affiliation': 'APHP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRA Team, CRESS UMR 1153, INSERM, Paris Diderot University.'}, {'lastname': 'Lebbe', 'firstname': 'Céleste', 'initials': 'C', 'affiliation': 'APHP Department of Dermatology Hôpital Saint-Louis, 1, avenue Claude-Vellefaux. 75010 Paris, France; Université Paris 7-Diderot, INSERM U976.'}]",,"A subset of patients most likely to benefit from ipilimumab should be defined. In our series we found a negative association of baseline corticosteroids with OS. Unlike high LDH levels, BRAF V600 E status and brain metastases should not be barriers to the initiation of treatment.","45 patients were included, among whom 23 (51%) had brain metastases. 33 (71%) of the patients completed the induction phase. The best overall response rate (BORR) was 13% and median overall survival (OS) was 8 months (95%CI: 7 to 12). OS was not different between patients with brain metastases at baseline and those without (p = 0.10), regardless of BRAF V600E status (p = 0.61). OS was poorer in patients who were being treated with corticoids at baseline (p<0.001) or with LDH at baseline > 500 UI/ml (p = 0.008).",,10.1684/ejd.2014.2471,<Element 'PubmedArticle' at 0x7f05d958fb30>
235,25479064,"Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes.","Impaired insulin signaling pathway in the brain in type 2 diabetes (T2D) is a risk factor for Alzheimer disease (AD). Glucagon-like peptide-1 (GLP-1) and its receptor agonist are widely used for treatment of T2D. Here we studied whether the effects of exendin-4 (EX-4), a long-lasting GLP-1 receptor agonist, could reduce the risk of AD in T2D.
Type 2 diabetes rats were injected with EX-4 for 28 consecutive days. Blood glucose and insulin levels, as well as GLP-1 and insulin in cerebrospinal fluid, were determined during the experiment. The phosphorylation level of tau at individual phosphorylation sites, the activities of phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT), and glycogen synthase kinase-3β (GSK-3β) were analyzed with Western blots.
The levels of phosphorylated tau protein at site Ser199/202 and Thr217 level in the hippocampus of T2D rats were found to be raised notably and evidently decreased after EX-4 intervention. In addition, brain insulin signaling pathway was ameliorated after EX-4 treatment, and this result was reflected by a decreased activity of PI3K/AKT and an increased activity of GSK-3β in the hippocampus of T2D rats as well as a rise in PI3K/AKT activity and a decline in GSK-3β activity after 4 weeks intervention of EX-4.
These results demonstrate that multiple days with EX-4 appears to prevent the hyperphosphorylation of AD-associated tau protein due to increased insulin signaling pathway in the brain. These findings support the potential use of GLP-1 for the prevention and treatment of AD in individuals with T2D.",[],Journal of investigative medicine : the official publication of the American Federation for Clinical Research,2014-12-06,"[{'lastname': 'Xu', 'firstname': 'Weijie', 'initials': 'W', 'affiliation': 'From the Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.'}, {'lastname': 'Yang', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Yuan', 'firstname': 'Gang', 'initials': 'G', 'affiliation': None}, {'lastname': 'Zhu', 'firstname': 'Wenjun', 'initials': 'W', 'affiliation': None}, {'lastname': 'Ma', 'firstname': 'Delin', 'initials': 'D', 'affiliation': None}, {'lastname': 'Hu', 'firstname': 'Shuhong', 'initials': 'S', 'affiliation': None}]",,,"The levels of phosphorylated tau protein at site Ser199/202 and Thr217 level in the hippocampus of T2D rats were found to be raised notably and evidently decreased after EX-4 intervention. In addition, brain insulin signaling pathway was ameliorated after EX-4 treatment, and this result was reflected by a decreased activity of PI3K/AKT and an increased activity of GSK-3β in the hippocampus of T2D rats as well as a rise in PI3K/AKT activity and a decline in GSK-3β activity after 4 weeks intervention of EX-4.",,10.1097/JIM.0000000000000129,<Element 'PubmedArticle' at 0x7f05d959e5e0>
236,"25448468
11952043
2765444
12059873
7835442
12457917
22040641
15896938
3340276
10782363
24573324
8130995
20181974
18299459
18480610
11454505
11450728
8977792
9075609
16889639
1493371
18230831
6389860
2519530
2732742
11876739
7951498
8413459
581653
582090
6136647
3415198",Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy.,"To quantitatively evaluate the efficacy of methylprednisolone pulse therapy for extraocular muscle inflammation in thyroid-associated ophthalmopathy (TAO) using the short-tau inversion-recovery (STIR) technique of magnetic resonance imaging (MRI).
The signal intensities of the superior rectus (SR), inferior rectus (IR), lateral rectus (LR), medial rectus (MR), and superior oblique (SO) muscles were measured using the STIR images from 34 eyes of 17 patients with TAO before and after methylprednisolone pulse therapy and 19 eyes of 19 controls. The signal intensity ratio (SIR) of the signal intensity in muscles to that in brain white matter was calculated.
The mean SIRs of the controls were 1.08 ± 0.26 in the SR, 1.32 ± 0.29 in the IR, 1.34 ± 0.19 in the LR, 1.47 ± 0.25 in the MR, and 1.28 ± 0.22 in the SO muscles. SIRs exceeding 2.0 were out of the normal range. The SIRs of the patients with TAO before treatment were 2.19 ± 0.64, 2.44 ± 0.58, 1.96 ± 0.43, 2.24 ± 0.47, and 1.91 ± 0.42, respectively, which was significantly (P < 0.001) higher than those of the controls; after treatment, the mean SIRs were 1.82 ± 0.57, 1.81 ± 0.49, 1.64 ± 0.35, 1.88 ± 0.43, and 1.54 ± 0.33, respectively, significantly (P < 0.001) lower in all muscles than those before treatment. However, the SIRs of some muscles remained over 2.0. Moreover, all cases that had deterioration of TAO had one or more muscles with a SIR exceeding 2.5 after treatment.
Extraocular muscle inflammation in TAO improved with treatment. However, inflammation in some muscles persisted after treatment, and a high SIR in the muscle after treatment suggested the risk of deterioration of TAO.",[],Japanese journal of ophthalmology,2014-12-03,"[{'lastname': 'Higashiyama', 'firstname': 'Tomoaki', 'initials': 'T', 'affiliation': 'Department of Ophthalmology, Shiga University of Medical Science, Seta, Tsukinowa-cho, Otsu, Shiga, 520-2192, Japan, higashi@belle.shiga-med.ac.jp.'}, {'lastname': 'Nishida', 'firstname': 'Yasuhiro', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Morino', 'firstname': 'Katsutaro', 'initials': 'K', 'affiliation': None}, {'lastname': 'Ugi', 'firstname': 'Satoshi', 'initials': 'S', 'affiliation': None}, {'lastname': 'Nishio', 'firstname': 'Yoshihiko', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Maegawa', 'firstname': 'Hiroshi', 'initials': 'H', 'affiliation': None}, {'lastname': 'Ohji', 'firstname': 'Masahito', 'initials': 'M', 'affiliation': None}]",,"Extraocular muscle inflammation in TAO improved with treatment. However, inflammation in some muscles persisted after treatment, and a high SIR in the muscle after treatment suggested the risk of deterioration of TAO.","The mean SIRs of the controls were 1.08 ± 0.26 in the SR, 1.32 ± 0.29 in the IR, 1.34 ± 0.19 in the LR, 1.47 ± 0.25 in the MR, and 1.28 ± 0.22 in the SO muscles. SIRs exceeding 2.0 were out of the normal range. The SIRs of the patients with TAO before treatment were 2.19 ± 0.64, 2.44 ± 0.58, 1.96 ± 0.43, 2.24 ± 0.47, and 1.91 ± 0.42, respectively, which was significantly (P < 0.001) higher than those of the controls; after treatment, the mean SIRs were 1.82 ± 0.57, 1.81 ± 0.49, 1.64 ± 0.35, 1.88 ± 0.43, and 1.54 ± 0.33, respectively, significantly (P < 0.001) lower in all muscles than those before treatment. However, the SIRs of some muscles remained over 2.0. Moreover, all cases that had deterioration of TAO had one or more muscles with a SIR exceeding 2.5 after treatment.",,10.1007/s10384-014-0365-x,<Element 'PubmedArticle' at 0x7f05d952be50>
237,25374108,Dexmedetomidine directly increases tau phosphorylation.,"Exposure to anesthetic agents has been linked to abnormal tau protein phosphorylation, an antecedent to the development of neurofibrillary tangles. This study evaluates the direct and indirect effects of dexmedetomidine. Primary culture of cortical neurons established from Sprague-Dawley (SD) rat embryos were exposed to dexmedetomidine for 1 or 6 hours, and the degree of tau phosphorylation at the AT8, AT180, and S396 sites was assessed by western blot analysis. To assess and compare their relative in vivo effects, the same agent was administered intravenously to 8 to 10 week old male SD rats and titrated to the loss of the righting reflex for 2 hours. After 1 hour of recovery, the rats were sacrificed and samples taken from the cortex and hippocampus were subjected to western blot and immunohistochemical analysis. The in vitro studies reviewed significant hyperphosphorylation only at the S396 site, and these changes have largely disappeared at 6 hours. With temperature maintenance, dexmedetomidine induced significant changes in hyperphosphorylation at the AT8 site in the cortex and hippocampus and at the AT180 in the hippocampus. The direct effect of anesthetic agents on fully differentiated cortical neurons is epitope-specific and short-lived. The in vivo effects are comparatively more complicated and depend not only on the phosphorylation site but the regions of the brain examined. These findings suggest that dexmedetomidine increases tau phosphorylation both in vitro and in vivo under normothermic conditions, and further studies are warranted to determine the long-term impact of this anesthetic on the tau pathology and even cognitive function.","['Anesthetics', 'dexmedetomidine', 'hypothermia', 'protein kinases', 'tau phosphorylation']",Journal of Alzheimer's disease : JAD,2014-11-07,"[{'lastname': 'Huang', 'firstname': 'Chunxia', 'initials': 'C', 'affiliation': 'Department of Anaesthesiology, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.'}, {'lastname': 'Ho', 'firstname': 'Yuen-Shan', 'initials': 'YS', 'affiliation': 'Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China School of Nursing, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, China.'}, {'lastname': 'Ng', 'firstname': 'Olivia Tsz-Wa', 'initials': 'OT', 'affiliation': 'Department of Anaesthesiology, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.'}, {'lastname': 'Irwin', 'firstname': 'Michael G', 'initials': 'MG', 'affiliation': 'Department of Anaesthesiology, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China Research Centre of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.'}, {'lastname': 'Chang', 'firstname': 'Raymond Chuen-Chung', 'initials': 'RC', 'affiliation': 'Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China Research Centre of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong SAR, China.'}, {'lastname': 'Wong', 'firstname': 'Gordon Tin-Chun', 'initials': 'GT', 'affiliation': 'Department of Anaesthesiology, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China Research Centre of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.'}]",,,,,10.3233/JAD-142238,<Element 'PubmedArticle' at 0x7f05d9543180>
238,"25368968
20101737
18358930
17032921
17611565
10506707
18846563
16502413
20466853
14551133
22730540
20345338
7049375
2434214
4725366
2578094
284840
8350624
21281233
17264295
8558211
10506705
12531809
8708730
2056971
8649318
11222362
9593262","Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.","Newer approaches are needed for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). Asparaginase-based regimens are active in the treatment of pediatric ALL and may be important in salvage therapy for adult patients. We conducted a pilot trial combining methotrexate, vincristine, PEGylated-asparaginase, and dexamethasone (MOpAD) in adults with relapsed or refractory ALL. We added tyrosine kinase inhibitors in patients with Philadelphia chromosome positive (Ph+) ALL and rituximab in patients with CD20 positive B-cell ALL. Among 37 patients treated (median age 42 years; median 2 prior therapies), the complete remission (CR) rate was 28% and an overall response rate (ORR) was 39%. The median CR duration was 4.3 months. Patients with Ph+ ALL had CR and ORR of 50% and 67%, respectively and the CR and ORR in patients with T-cell leukemia were 45% and 56%, respectively. The median survival in patients with CR/CRp was 10.4 versus 3.4 months in nonresponders (P = 0.02). The most common grade 3 or 4 nonhematologic toxicities were elevations in bilirubin and transaminases, nausea, peripheral neuropathy, and hyperglycemia, which were managed with supportive care, dose adjustments, and interruptions.",[],American journal of hematology,2014-11-05,"[{'lastname': 'Kadia', 'firstname': 'Tapan M', 'initials': 'TM', 'affiliation': 'Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas.'}, {'lastname': 'Kantarjian', 'firstname': 'Hagop M', 'initials': 'HM', 'affiliation': None}, {'lastname': 'Thomas', 'firstname': 'Deborah A', 'initials': 'DA', 'affiliation': None}, {'lastname': ""O'Brien"", 'firstname': 'Susan', 'initials': 'S', 'affiliation': None}, {'lastname': 'Estrov', 'firstname': 'Zeev', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Ravandi', 'firstname': 'Farhad', 'initials': 'F', 'affiliation': None}, {'lastname': 'Jabbour', 'firstname': 'Elias', 'initials': 'E', 'affiliation': None}, {'lastname': 'Pemmaraju', 'firstname': 'Naveen', 'initials': 'N', 'affiliation': None}, {'lastname': 'Daver', 'firstname': 'Naval', 'initials': 'N', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Xuemei', 'initials': 'X', 'affiliation': None}, {'lastname': 'Jain', 'firstname': 'Preetesh', 'initials': 'P', 'affiliation': None}, {'lastname': 'Pierce', 'firstname': 'Sherry', 'initials': 'S', 'affiliation': None}, {'lastname': 'Brandt', 'firstname': 'Mark', 'initials': 'M', 'affiliation': None}, {'lastname': 'Garcia-Manero', 'firstname': 'Guillermo', 'initials': 'G', 'affiliation': None}, {'lastname': 'Cortes', 'firstname': 'Jorge', 'initials': 'J', 'affiliation': None}, {'lastname': 'Borthakur', 'firstname': 'Gautam', 'initials': 'G', 'affiliation': None}]",,,,"© 2014 Wiley Periodicals, Inc.",10.1002/ajh.23886,<Element 'PubmedArticle' at 0x7f05d954f400>
239,"25257559
19815707
19387104
21598254
9235959
14981233
8250835
8524413
16914869
19819959
22425595
18627032
22893404
18820002
12397027
17940659
17687114
19732809
10567721
1284442
8870824
18088381
9565682
23798682
20679343
11943712
18801339
21623793
10902785",Deficient hippocampal insulin signaling and augmented Tau phosphorylation is related to obesity- and age-induced peripheral insulin resistance: a study in Zucker rats.,"Insulin signaling and Tau protein phosphorylation in the hippocampi of young and old obese Zucker fa/fa rats and their lean controls were assessed to determine whether obesity-induced peripheral insulin resistance and aging are risk factors for central insulin resistance and whether central insulin resistance is related to the pathologic phosphorylation of the Tau protein.
Aging and obesity significantly attenuated the phosphorylation of the insulin cascade kinases Akt (protein kinase B, PKB) and GSK-3β (glycogen synthase kinase 3β) in the hippocampi of the fa/fa rats. Furthermore, the hyperphosphorylation of Tau Ser396 alone and both Tau Ser396 and Thr231 was significantly augmented by aging and obesity, respectively, in the hippocampi of these rats.
Both age-induced and obesity-induced peripheral insulin resistance are associated with central insulin resistance that is linked to hyperTau phosphorylation. Peripheral hyperinsulinemia, rather than hyperglycemia, appears to promote central insulin resistance and the Tau pathology in fa/fa rats.",[],BMC neuroscience,2014-09-27,"[{'lastname': 'Špolcová', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': None}, {'lastname': 'Mikulášková', 'firstname': 'Barbora', 'initials': 'B', 'affiliation': None}, {'lastname': 'Kršková', 'firstname': 'Katarína', 'initials': 'K', 'affiliation': None}, {'lastname': 'Gajdošechová', 'firstname': 'Lucia', 'initials': 'L', 'affiliation': None}, {'lastname': 'Zórad', 'firstname': 'Štefan', 'initials': 'Š', 'affiliation': None}, {'lastname': 'Olszanecki', 'firstname': 'Rafał', 'initials': 'R', 'affiliation': None}, {'lastname': 'Suski', 'firstname': 'Maciej', 'initials': 'M', 'affiliation': None}, {'lastname': 'Bujak-Giżycka', 'firstname': 'Beata', 'initials': 'B', 'affiliation': None}, {'lastname': 'Železná', 'firstname': 'Blanka', 'initials': 'B', 'affiliation': None}, {'lastname': 'Maletínská', 'firstname': 'Lenka', 'initials': 'L', 'affiliation': 'Institute of Organic Chemistry and Biochemistry, Prague, 166 10, Czech Republic. maletin@uochb.cas.cz.'}]",,,"Aging and obesity significantly attenuated the phosphorylation of the insulin cascade kinases Akt (protein kinase B, PKB) and GSK-3β (glycogen synthase kinase 3β) in the hippocampi of the fa/fa rats. Furthermore, the hyperphosphorylation of Tau Ser396 alone and both Tau Ser396 and Thr231 was significantly augmented by aging and obesity, respectively, in the hippocampi of these rats.",,"10.1186/1471-2202-15-111
10.2353/ajpath.2009.090157
10.1002/path.2912
10.1074/jbc.272.31.19547
10.1073/pnas.0308724101
10.1038/378785a0
10.1210/en.2009-0695
10.1016/j.pbb.2012.03.002
10.1002/jnr.21787
10.1113/expphysiol.2008.044529
10.1039/b704905f
10.1096/fj.07-8309com
10.1016/j.bbagen.2009.08.008
10.1016/S0014-5793(99)01480-5
10.1016/0304-3940(92)90839-Y
10.1007/s004010050513
10.1111/j.1471-4159.2007.05194.x
10.1016/S0304-4165(97)00139-6
10.1074/jbc.M113.463984
10.1074/jbc.M110.149419
10.1016/S0002-9440(10)62554-0
10.1016/j.bbrc.2008.09.026
10.1111/j.1471-4159.2011.07331.x
10.1210/jcem.85.7.6661",<Element 'PubmedArticle' at 0x7f05d94e9a40>
240,"25210802
20107219
20934914
16876668
11754997
16960575
16081203
19748514
23063604
22163051
20382448
15465922
16796380
9006968
16434061
8769879
9685157
12944505
22845893
24066256
16997973
22405189
23394526
20096327
21255263
20694024
22339481
21076683
21303299
16472958
22162727
23954849
19584454
18067990
21288189
20955418
21629736
19917131
15453089
11224535
18393796
16449801
22843498
11005793
8247344
12767722
23160851
18494933
19457090
23798682
8167029
23961278
15934851
22834835
11114266
10927795
15229249
11571036
15755686
20832251
23271318
23473707
17403556
15461672
19997057
11724968
24265678",Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease.,"Given the complex heterogeneity of pathological changes occurring in Alzheimer's disease (AD), any therapeutic effort absolutely requires a multi-targeted approach, because attempts addressing only a single event may result ineffective. Palmitoylethanolamide (PEA), a naturally occurring lipid amide between palmitic acid and ethanolamine, seems to be a compound able to fulfill the criteria of a multi-factorial therapeutic approach. Here, we describe the anti-inflammatory and neuroprotective activities of systemic administration of PEA in adult male rats given intrahippocampal injection of beta amyloid 1-42 (Aβ 1-42). Moreover, to investigate the molecular mechanisms responsible for the effects induced by PEA, we co-administered PEA with the GW6471, an antagonist of peroxisome proliferator-activated receptor-α (PPAR-α). We found that Aβ 1-42 infusion results in severe changes of biochemical markers related to reactive gliosis, amyloidogenesis, and tau protein hyperphosphorylation. Interestingly, PEA was able to restore the Aβ 1-42-induced alterations through PPAR-α involvement. In addition, results from the Morris water maze task highlighted a mild cognitive deficit during the reversal learning phase of the behavioral study. Similarly to the biochemical data, also mnestic deficits were reduced by PEA treatment. These data disclose novel findings about the therapeutic potential of PEA, and suggest novel strategies that hopefully could have the potential not just to alleviate the symptoms but also to modify disease progression.",[],Cell death & disease,2014-09-12,"[{'lastname': 'Scuderi', 'firstname': 'C', 'initials': 'C', 'affiliation': ""Department of Physiology and Pharmacology 'Vittorio Erspamer'-SAPIENZA University of Rome, P.le A. Moro, Rome 5-00185, Italy.""}, {'lastname': 'Stecca', 'firstname': 'C', 'initials': 'C', 'affiliation': ""Department of Physiology and Pharmacology 'Vittorio Erspamer'-SAPIENZA University of Rome, P.le A. Moro, Rome 5-00185, Italy.""}, {'lastname': 'Valenza', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Laboratory of the Biology of Addictive Diseases-The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.'}, {'lastname': 'Ratano', 'firstname': 'P', 'initials': 'P', 'affiliation': ""Department of Physiology and Pharmacology 'Vittorio Erspamer'-SAPIENZA University of Rome, P.le A. Moro, Rome 5-00185, Italy.""}, {'lastname': 'Bronzuoli', 'firstname': 'M R', 'initials': 'MR', 'affiliation': ""Department of Physiology and Pharmacology 'Vittorio Erspamer'-SAPIENZA University of Rome, P.le A. Moro, Rome 5-00185, Italy.""}, {'lastname': 'Bartoli', 'firstname': 'S', 'initials': 'S', 'affiliation': ""Department of Physiology and Pharmacology 'Vittorio Erspamer'-SAPIENZA University of Rome, P.le A. Moro, Rome 5-00185, Italy.""}, {'lastname': 'Steardo', 'firstname': 'L', 'initials': 'L', 'affiliation': 'Department of Psychiatry-University of Naples SUN, Largo Madonna delle Grazie, Naples 1-80138, Italy.'}, {'lastname': 'Pompili', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Department of Anatomy, Histology, Forensic Medicine and Orthopedics-SAPIENZA University of Rome, Via A. Borelli 50, Rome 00161, Italy.'}, {'lastname': 'Fumagalli', 'firstname': 'L', 'initials': 'L', 'affiliation': 'Department of Anatomy, Histology, Forensic Medicine and Orthopedics-SAPIENZA University of Rome, Via A. Borelli 50, Rome 00161, Italy.'}, {'lastname': 'Campolongo', 'firstname': 'P', 'initials': 'P', 'affiliation': ""Department of Physiology and Pharmacology 'Vittorio Erspamer'-SAPIENZA University of Rome, P.le A. Moro, Rome 5-00185, Italy.""}, {'lastname': 'Steardo', 'firstname': 'L', 'initials': 'L', 'affiliation': ""Department of Physiology and Pharmacology 'Vittorio Erspamer'-SAPIENZA University of Rome, P.le A. Moro, Rome 5-00185, Italy.""}]",,,,,10.1038/cddis.2014.376,<Element 'PubmedArticle' at 0x7f05d9506630>
241,"25175602
21487420
22166456
16773621
1900728
1484530
7778678
9797005
23867865
22261560
16540122
16157754
24121548
19690093
24005336
23359374
21773886
20140439
16691120
11305868
22166431
14534923
21810889
21246604
23787135
4798818
18307268
17917583
17914064
22650353","A familial form of parkinsonism, dementia, and motor neuron disease: a longitudinal study.","To describe the clinical, positron emission tomography (PET), pathological, and genetic findings of a large kindred with progressive neurodegenerative phenotypes in which the proband had autopsy-confirmed corticobasal degeneration (CBD).
Five family members, including the proband, were examined neurologically. Clinical information from the other family members was collected by questionnaires. Three individuals underwent PET with (11)C-dihydrotetrabenazine and (18)F-fludeoxyglucose. The proband was examined post-mortem. Genetic studies were performed.
The pedigree contains 64 individuals, including 8 affected patients. The inheritance is likely autosomal dominant with reduced penetrance. The proband developed progressive speech and language difficulties at the age of 64 years. Upon examination at the age of 68 years, she showed non-fluent aphasia, word-finding difficulties, circumlocution, frontal release signs, and right-sided bradykinesia, rigidity, and pyramidal signs. She died 5 years after disease onset. The neuropathology was consistent with CBD, including many cortical and subcortical astrocytic plaques. Other family members had progressive neurodegenerative phenotypes - two were diagnosed with parkinsonism and behavioral problems, two with parkinsonism alone, one with amyotrophic lateral sclerosis alone, one with dementia, and one with progressive gait and speech problems. PET on three potentially affected individuals showed no significant pathology. Genetic sequencing of DNA from the proband excluded mutations in known neurodegenerative-related genes including MAPT, PGRN, LRRK2, and C9ORF72.
Families with such complex phenotypes rarely occur. They are usually associated with MAPT mutations; however, in this family, MAPT mutations have been excluded, implicating another causative gene or genes. Further genetic studies on this family may eventually disclose the etiology.","['Cognitive disorders', 'Corticobasal degeneration', 'Dementia', 'Genetics', 'PET', ""Parkinson's disease/Parkinsonism""]",Parkinsonism & related disorders,2014-09-02,"[{'lastname': 'Fujioka', 'firstname': 'Shinsuke', 'initials': 'S', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'Boeve', 'firstname': 'Bradley F', 'initials': 'BF', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Parisi', 'firstname': 'Joseph E', 'initials': 'JE', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Tacik', 'firstname': 'Pawel', 'initials': 'P', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'Aoki', 'firstname': 'Naoya', 'initials': 'N', 'affiliation': 'Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA.'}, {'lastname': 'Strongosky', 'firstname': 'Audrey J', 'initials': 'AJ', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'Baker', 'firstname': 'Matt', 'initials': 'M', 'affiliation': 'Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA.'}, {'lastname': 'Sanchez-Contreras', 'firstname': 'Monica', 'initials': 'M', 'affiliation': 'Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA.'}, {'lastname': 'Ross', 'firstname': 'Owen A', 'initials': 'OA', 'affiliation': 'Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA.'}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA.'}, {'lastname': 'Sossi', 'firstname': 'Vesna', 'initials': 'V', 'affiliation': 'Department of Physics and Astronomy, University of British Colombia, BC, Canada.'}, {'lastname': 'Dickson', 'firstname': 'Dennis W', 'initials': 'DW', 'affiliation': 'Department of Neuropathology, Mayo Clinic Florida, Jacksonville, FL, USA.'}, {'lastname': 'Stoessl', 'firstname': 'A Jon', 'initials': 'AJ', 'affiliation': ""Pacific Parkinson's Research Centre, Division of Neurology, University of British Colombia & Vancouver Coastal Health, BC, Canada.""}, {'lastname': 'Wszolek', 'firstname': 'Zbigniew K', 'initials': 'ZK', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA. Electronic address: wszolek.zbigniew@mayo.edu.'}]",,,"The pedigree contains 64 individuals, including 8 affected patients. The inheritance is likely autosomal dominant with reduced penetrance. The proband developed progressive speech and language difficulties at the age of 64 years. Upon examination at the age of 68 years, she showed non-fluent aphasia, word-finding difficulties, circumlocution, frontal release signs, and right-sided bradykinesia, rigidity, and pyramidal signs. She died 5 years after disease onset. The neuropathology was consistent with CBD, including many cortical and subcortical astrocytic plaques. Other family members had progressive neurodegenerative phenotypes - two were diagnosed with parkinsonism and behavioral problems, two with parkinsonism alone, one with amyotrophic lateral sclerosis alone, one with dementia, and one with progressive gait and speech problems. PET on three potentially affected individuals showed no significant pathology. Genetic sequencing of DNA from the proband excluded mutations in known neurodegenerative-related genes including MAPT, PGRN, LRRK2, and C9ORF72.",Copyright © 2014 Elsevier Ltd. All rights reserved.,10.1016/j.parkreldis.2014.07.014,<Element 'PubmedArticle' at 0x7f05d94acd60>
242,"25113804
23863050
24002508
24080993
23957945
22386623
21612468
20888992
18309951
22995653
23966222
23957948
22771826
24200698
24074764
23550669
15470213
23928659
22894553",Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.,"To report the outcome and course of disease in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel followed by abiraterone acetate in a single center.
In this retrospective observational study, we reviewed the course of disease of all applicable patients with mCRPC treated with docetaxel followed by abiraterone at our center. We analyzed progression-free survival (PFS) of docetaxel and abiraterone treatments. We further searched for predictive factors for the duration of treatment response.
Median PFS between initiation of androgen deprivation therapy and the diagnosis of mCRPC was 32 months. Median PFS on docetaxel treatment was 9 months. Median PFS on abiraterone treatment was 11 months. Patients with higher Gleason scores (GS) (8-10) at initial diagnosis had a significantly longer median PFS on docetaxel as compared to patients with GS 6-7, p = 0.01. We demonstrate a significant correlation between the PFS on docetaxel and PFS on abiraterone in the post-docetaxel setting (Kendall tau r = 0.32, p = 0.019) as well as a significant negative correlation between the PSA nadir under abiraterone treatment and the time to progression under abiraterone (Kendall tau r = -0.43, p = 0.007).
High Gleason score appears to be predictive of duration of response to docetaxel. Interestingly, progression-free survival with abiraterone appears to be correlated with the duration of response with docetaxel, whereas PSA decline and low nadir appear to be predictive of response to abiraterone.",[],World journal of urology,2014-08-13,"[{'lastname': 'Höfner', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Department of Urology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Im Neuenheimer Feld 110, Heidelberg, Germany, kontakt@thomashoefner.de.'}, {'lastname': 'Vallet', 'firstname': 'Sonia', 'initials': 'S', 'affiliation': None}, {'lastname': 'Hadaschik', 'firstname': 'Boris A', 'initials': 'BA', 'affiliation': None}, {'lastname': 'Pahernik', 'firstname': 'Sascha', 'initials': 'S', 'affiliation': None}, {'lastname': 'Duensing', 'firstname': 'Stefan', 'initials': 'S', 'affiliation': None}, {'lastname': 'Hohenfellner', 'firstname': 'Markus', 'initials': 'M', 'affiliation': None}, {'lastname': 'Jäger', 'firstname': 'Dirk', 'initials': 'D', 'affiliation': None}, {'lastname': 'Grüllich', 'firstname': 'Carsten', 'initials': 'C', 'affiliation': None}]",,,"Median PFS between initiation of androgen deprivation therapy and the diagnosis of mCRPC was 32 months. Median PFS on docetaxel treatment was 9 months. Median PFS on abiraterone treatment was 11 months. Patients with higher Gleason scores (GS) (8-10) at initial diagnosis had a significantly longer median PFS on docetaxel as compared to patients with GS 6-7, p = 0.01. We demonstrate a significant correlation between the PFS on docetaxel and PFS on abiraterone in the post-docetaxel setting (Kendall tau r = 0.32, p = 0.019) as well as a significant negative correlation between the PSA nadir under abiraterone treatment and the time to progression under abiraterone (Kendall tau r = -0.43, p = 0.007).",,10.1007/s00345-014-1375-5,<Element 'PubmedArticle' at 0x7f05d94cba90>
243,25024321,A mutation in the 5'-UTR of GRN gene associated with frontotemporal lobar degeneration: phenotypic variability and possible pathogenetic mechanisms.,"Frontotemporal lobar degeneration (FTLD) is a very heterogeneous disorder. It is genetically linked to three major genes: microtubule-associated protein tau (MAPT), progranulin (GRN), and C9ORF72. In particular, mutations in GRN account for 5-10% of all cases and give rise to a wide spectrum of clinical phenotypes, ranging from behavioral frontotemporal dementia (bvFTD) to primary progressive aphasia, including progressive non-fluent aphasia (PNFA) and semantic dementia, and corticobasal syndrome (CBS). We studied a family affected by FTLD whose members showed three different phenotypes: bvFTD, PNFA, and CBS. We performed plasma progranulin measurement before any genetic analyses and, due to the low level detected, we sequenced GRN and found the new mutation EX0-5' splice site A > G in the 5'-UTR region, where no pathogenic mutations had been previously demonstrated. Genetic analyses of MAPT and C9ORF72 were normal. GRN mRNA expression showed about 50% reduction caused by this mutation, and similar results were found for progranulin level. Testing of nonsense mediated RNA decay gave negative results, suggesting a different mechanism of mRNA degradation. In summary, the EX0-5' splice site A > G mutation widens the GRN regions affected by null mutations, including the 5'-UTR, and confirms once more the large phenotypic variability linked to GRN mutations.","['Frontotemporal lobar degeneration', 'GRN', 'haploinsufficiency', 'mutation', 'phenotype', 'progranulin']",Journal of Alzheimer's disease : JAD,2014-07-16,"[{'lastname': 'Puoti', 'firstname': 'Gianfranco', 'initials': 'G', 'affiliation': 'Division of Neurology, Department of Clinical and Experimental Medicine, Second University of Naples, Italy.'}, {'lastname': 'Lerza', 'firstname': 'Maria Cristina', 'initials': 'MC', 'affiliation': 'Division of Neurology, Department of Clinical and Experimental Medicine, Second University of Naples, Italy.'}, {'lastname': 'Ferretti', 'firstname': 'Maria Giulia', 'initials': 'MG', 'affiliation': 'Division of Neurology V - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.'}, {'lastname': 'Bugiani', 'firstname': 'Orso', 'initials': 'O', 'affiliation': 'Division of Neurology V - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.'}, {'lastname': 'Tagliavini', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'Division of Neurology V - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.'}, {'lastname': 'Rossi', 'firstname': 'Giacomina', 'initials': 'G', 'affiliation': 'Division of Neurology V - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.'}]",,,,,10.3233/JAD-140717,<Element 'PubmedArticle' at 0x7f05d94660e0>
244,25002573,Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia.,"We aimed to investigate whether cognitive deficits and structural and functional connectivity changes can be detected before symptom onset in a large cohort of carriers of MAPT (microtubule-associated protein tau) or GRN (progranulin) mutations.
In this case-control study, 75 healthy individuals (aged 20-70 years) with 50% risk of frontotemporal dementia (FTD) underwent DNA screening, neuropsychological assessment, structural MRI, and fMRI. We used voxel-based morphometry and tract-based spatial statistics for voxel-wise analyses of gray matter volume and diffusion tensor imaging measures. Using resting-state fMRI scans, we assessed whole-brain functional connectivity to frontoinsular, anterior midcingulate, and posterior cingulate cortices.
Carriers (n = 39) and noncarriers (n = 36) had similar neuropsychological performance, except for lower Letter Digit Substitution Test scores in carriers. Worse performance on Stroop III, Rivermead Behavioral Memory Test, and Happé Cartoons correlated with higher age in carriers, but not controls. Reduced fractional anisotropy in the right uncinate fasciculus was found in carriers compared with controls. Reductions in functional connectivity between anterior midcingulate cortex and frontoinsula and several other brain regions were found in carriers compared with controls and correlated with higher age in carriers, but not controls. We found no significant differences or age correlations in posterior cingulate cortex connectivity. No differences in regional gray matter volume were found, except for a small cluster of higher volume in the precentral gyrus in carriers.
This study demonstrates that alterations in structural and functional connectivity develop before the first symptoms of FTD arise. These findings suggest that diffusion tensor imaging and resting-state fMRI may have the potential to become sensitive biomarkers for early FTD in future clinical trials.",[],Neurology,2014-07-09,"[{'lastname': 'Dopper', 'firstname': 'Elise G P', 'initials': 'EG', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'Rombouts', 'firstname': 'Serge A R B', 'initials': 'SA', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'Jiskoot', 'firstname': 'Lize C', 'initials': 'LC', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'den Heijer', 'firstname': 'Tom', 'initials': 'T', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'de Graaf', 'firstname': 'J Roos A', 'initials': 'JR', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'de Koning', 'firstname': 'Inge', 'initials': 'I', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'Hammerschlag', 'firstname': 'Anke R', 'initials': 'AR', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'Seelaar', 'firstname': 'Harro', 'initials': 'H', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'Seeley', 'firstname': 'William W', 'initials': 'WW', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'Veer', 'firstname': 'Ilya M', 'initials': 'IM', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'van Buchem', 'firstname': 'Mark A', 'initials': 'MA', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'Rizzu', 'firstname': 'Patrizia', 'initials': 'P', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco.'}, {'lastname': 'van Swieten', 'firstname': 'John C', 'initials': 'JC', 'affiliation': 'From the Departments of Neurology (E.G.P.D., L.C.J., T.d.H., H.S., J.C.v.S.), Epidemiology (T.d.H.), and Neuropsychology (J.R.A.d.G., I.d.K.), Erasmus Medical Center, Rotterdam; Department of Radiology (E.G.P.D., S.A.R.B.R., I.M.V., M.A.v.B.), Leiden University Medical Center; Departments of Neurology (E.G.P.D.) and Clinical Genetics (A.R.H., P.R., J.C.v.S.), VU Medical Center, Amsterdam; Leiden Institute for Brain and Cognition (S.A.R.B.R., I.M.V., M.A.v.B.) and Institute of Psychology (S.A.R.B.R., I.M.V.), Leiden University; Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands; and Department of Neurology (W.W.S.) and Memory and Aging Center (W.W.S.), University of California, San Francisco. j.c.vanswieten@erasmusmc.nl.'}]",,,"Carriers (n = 39) and noncarriers (n = 36) had similar neuropsychological performance, except for lower Letter Digit Substitution Test scores in carriers. Worse performance on Stroop III, Rivermead Behavioral Memory Test, and Happé Cartoons correlated with higher age in carriers, but not controls. Reduced fractional anisotropy in the right uncinate fasciculus was found in carriers compared with controls. Reductions in functional connectivity between anterior midcingulate cortex and frontoinsula and several other brain regions were found in carriers compared with controls and correlated with higher age in carriers, but not controls. We found no significant differences or age correlations in posterior cingulate cortex connectivity. No differences in regional gray matter volume were found, except for a small cluster of higher volume in the precentral gyrus in carriers.",© 2014 American Academy of Neurology.,10.1212/WNL.0000000000000583,<Element 'PubmedArticle' at 0x7f05d94724a0>
245,"24986188
9817534
8780061
20082242
23683163
24256407
24292503
14636486
22612755
16420395
15530171
12767502
22096630
11176941
9588727
6126730
11254764
12957406
15957504
16629417
15620855
12076997
9389582
11456302
8228996
9352454
15896809
11207383
10463853
15494405
15083285
10828654
16764350
7635444
2822856
11390274
7093711
8776798",Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients.,"Multiple sclerosis (MS) is the most common inflammatory disease of the central nervous system in young adults. Over time, the disease progresses and, with accumulating disability, symptoms such as spasticity may occur. Although several treatment options are available, some patients may not respond to first-line therapeutics. However, some of these patients may benefit from intrathecally administered triamcinolone-acetonide (TCA), a derivative of glucocorticosteroids (GCS). GCS may have neurotoxic effects, and cell apoptosis may occur. The aim of this study was to investigate the effects of TCA on biomarkers in the cerebrospinal fluid (CSF) suggestive of neurodegeneration.
In order to assess neurotoxic effects of TCA, neurofilament heavy-chain (NfH)(SMI35), tau protein, and S-100B protein levels were determined before and during treatment with TCA in 54 patients with primary progressive MS, as well as relapsing MS (relapsing-remitting and secondary progressive MS).
NfH(SMI35) levels in the CSF of patients treated with TCA intrathecally did not increase significantly during the treatment cycle (p = 0.068). After application of TCA, tau protein levels were increased significantly at day 4 (p = 0.03) and at day 8 (p ≤ 0.001). S-100B protein levels decreased significantly (p ≤ 0.05) during treatment with TCA.
NfH(SMI35) levels did not change significantly; however, tau protein levels did increase significantly within the reference range. Taking these findings together, the long-term effects of TCA on NfH(SMI35) and tau protein levels need to be investigated further to understand whether levels of both biomarkers will change over repeated TCA applications. Interestingly, S-100B protein levels decreased significantly during the first applications, which may have represented reduced astrocytic activity during TCA treatment.",[],Molecular diagnosis & therapy,2014-07-06,"[{'lastname': 'Rommer', 'firstname': 'P S', 'initials': 'PS', 'affiliation': 'Department of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany, paulus.rommer@meduniwien.ac.at.'}, {'lastname': 'Kamin', 'firstname': 'F', 'initials': 'F', 'affiliation': None}, {'lastname': 'Petzold', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Tumani', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Abu-Mugheisib', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Koehler', 'firstname': 'W', 'initials': 'W', 'affiliation': None}, {'lastname': 'Hoffmann', 'firstname': 'F', 'initials': 'F', 'affiliation': None}, {'lastname': 'Winkelmann', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Benecke', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Zettl', 'firstname': 'U K', 'initials': 'UK', 'affiliation': None}]",,"NfH(SMI35) levels did not change significantly; however, tau protein levels did increase significantly within the reference range. Taking these findings together, the long-term effects of TCA on NfH(SMI35) and tau protein levels need to be investigated further to understand whether levels of both biomarkers will change over repeated TCA applications. Interestingly, S-100B protein levels decreased significantly during the first applications, which may have represented reduced astrocytic activity during TCA treatment.","NfH(SMI35) levels in the CSF of patients treated with TCA intrathecally did not increase significantly during the treatment cycle (p = 0.068). After application of TCA, tau protein levels were increased significantly at day 4 (p = 0.03) and at day 8 (p ≤ 0.001). S-100B protein levels decreased significantly (p ≤ 0.05) during treatment with TCA.",,"10.1007/s40291-014-0114-3
10.1055/s-2008-1040881
10.1212/WNL.46.4.907
10.1007/s12325-009-0082-x
10.1111/ane.12202
10.2174/138161212802502251
10.1111/j.1468-1331.2006.01145.x
10.1186/1471-2377-4-18
10.1016/S0022-510X(03)00060-1
10.1002/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M
10.1016/S0140-6736(82)90833-9
10.1136/jnnp.70.4.433
10.1016/S0022-1759(03)00189-3
10.1191/1352458505ms1159oa
10.1191/135248506ms1263oa
10.1016/S1474-4422(04)00964-0
10.1093/brain/awf165
10.1016/S0304-3940(97)00701-5
10.1002/ana.1032
10.1111/j.1471-4159.1993.tb09823.x
10.1007/s004150050145
10.1016/j.jns.2005.03.015
10.1016/S0304-3940(01)01556-7
10.1016/S0920-1211(99)00026-1
10.1074/jbc.M409954200
10.1007/s00415-004-0336-0
10.1159/000008181
10.1191/1352458506ms1288sr
10.1016/0046-8177(95)90001-2
10.1111/j.1471-4159.1987.tb01027.x
10.1016/S1357-2725(01)00046-2
10.1016/0006-8993(82)90648-5
10.1016/0039-128X(96)00041-4",<Element 'PubmedArticle' at 0x7f05d94811d0>
246,24861427,No interaction between tau and TDP-43 pathologies in either frontotemporal lobar degeneration or motor neurone disease.,"Frontotemporal lobar degeneration (FTLD) is classified mainly into FTLD-tau and FTLD-TDP according to the protein present within inclusion bodies. While such a classification implies only a single type of protein should be present, recent studies have demonstrated dual tau and TDP-43 proteinopathy can occur, particularly in inherited FTLD.
We therefore investigated 33 patients with FTLD-tau (including 9 with MAPT mutation) for TDP-43 pathological changes, and 45 patients with FTLD-TDP (including 12 with hexanucleotide expansion in C9ORF72 and 12 with GRN mutation), and 23 patients with motor neurone disease (3 with hexanucleotide expansion in C9ORF72), for tauopathy.
TDP-43 pathological changes, of the kind seen in many elderly individuals with Alzheimer's disease, were seen in only two FTLD-tau cases--a 70-year-old male with exon 10 + 13 mutation in MAPT, and a 73-year-old female with corticobasal degeneration. Such changes were considered to be secondary and probably reflective of advanced age. Conversely, there was generally only scant tau pathology, usually only within hippocampus and/or entorhinal cortex, in most patients with FTLD-TDP or MND. The extent of tau pathology in FTLD-TDP and MND, as with amyloid β protein, may relate to increased age and possession of Apolipoprotein ε4 allele.
We find no predilection or predisposition towards an accompanying TDP-43 pathology in patients with FTLD-tau, irrespective of presence or absence of MAPT mutation, or that genetic changes associated with FTLD-TDP predispose towards excessive tauopathy. Where the two processes coexist, this is limited and probably causatively independent of each other.","['C9ORF72', 'TDP-43', 'progranulin gene', 'tau', 'tau gene']",Neuropathology and applied neurobiology,2014-05-28,"[{'lastname': 'Robinson', 'firstname': 'Andrew C', 'initials': 'AC', 'affiliation': 'Clinical and Cognitive Sciences Research Group, Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Salford Royal Hospital, Salford.'}, {'lastname': 'Thompson', 'firstname': 'Jennifer C', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Weedon', 'firstname': 'Lindsey', 'initials': 'L', 'affiliation': None}, {'lastname': 'Rollinson', 'firstname': 'Sara', 'initials': 'S', 'affiliation': None}, {'lastname': 'Pickering-Brown', 'firstname': 'Stuart', 'initials': 'S', 'affiliation': None}, {'lastname': 'Snowden', 'firstname': 'Julie S', 'initials': 'JS', 'affiliation': None}, {'lastname': 'Davidson', 'firstname': 'Yvonne S', 'initials': 'YS', 'affiliation': None}, {'lastname': 'Mann', 'firstname': 'David M A', 'initials': 'DM', 'affiliation': None}]",,"We find no predilection or predisposition towards an accompanying TDP-43 pathology in patients with FTLD-tau, irrespective of presence or absence of MAPT mutation, or that genetic changes associated with FTLD-TDP predispose towards excessive tauopathy. Where the two processes coexist, this is limited and probably causatively independent of each other.","TDP-43 pathological changes, of the kind seen in many elderly individuals with Alzheimer's disease, were seen in only two FTLD-tau cases--a 70-year-old male with exon 10 + 13 mutation in MAPT, and a 73-year-old female with corticobasal degeneration. Such changes were considered to be secondary and probably reflective of advanced age. Conversely, there was generally only scant tau pathology, usually only within hippocampus and/or entorhinal cortex, in most patients with FTLD-TDP or MND. The extent of tau pathology in FTLD-TDP and MND, as with amyloid β protein, may relate to increased age and possession of Apolipoprotein ε4 allele.",© 2014 British Neuropathological Society.,10.1111/nan.12155,<Element 'PubmedArticle' at 0x7f05d9421c70>
247,24842481,Immunologic and psychologic parameters associated with geographic tongue.,"Several conditions have been associated with geographic tongue (GT). However, there is no consensus on the etiology of GT. The purpose of this study was to investigate whether immunologic and psychologic parameters are associated with diagnosis of GT.
A case-control study was performed on 170 participants (85 with GT, 85 controls). Unstimulated whole saliva was collected, and tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) concentrations were measured. Anxiety level was measured using psychologic and physiologic testing instruments. An independent t test and a Pearson correlation analysis were performed with SPSS (α = .05).
There was a significant difference between the 2 groups regarding the salivary concentrations of TNF-α (P = .008) and IL-6 (P = .001). The concentration of salivary cortisol and state and trait anxiety levels in the GT group were significantly higher than those in the control group (P = .001).
Immunologic and psychologic parameters appear associated with GT and may constitute risk factors of this condition.",[],"Oral surgery, oral medicine, oral pathology and oral radiology",2014-05-21,"[{'lastname': 'Alikhani', 'firstname': 'Milad', 'initials': 'M', 'affiliation': 'Postgraduate student, Department of Oral and Maxillofacial Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'lastname': 'Khalighinejad', 'firstname': 'Navid', 'initials': 'N', 'affiliation': 'Researcher, Torabinejad Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'lastname': 'Ghalaiani', 'firstname': 'Parichehr', 'initials': 'P', 'affiliation': 'Associate Professor, Department of Oral and Maxillofacial Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'lastname': 'Khaleghi', 'firstname': 'Mehrdad Akhavan', 'initials': 'MA', 'affiliation': 'Researcher, Torabinejad Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'lastname': 'Askari', 'firstname': 'Elham', 'initials': 'E', 'affiliation': 'Doctorate student, Psychology Department, Allameh University, Tehran, Iran.'}, {'lastname': 'Gorsky', 'firstname': 'Meir', 'initials': 'M', 'affiliation': 'Professor Emeritus, Department of Oral Pathology and Oral Medicine, Faculty of Medicine, School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: gorskym@post.tau.ac.il.'}]",,,There was a significant difference between the 2 groups regarding the salivary concentrations of TNF-α (P = .008) and IL-6 (P = .001). The concentration of salivary cortisol and state and trait anxiety levels in the GT group were significantly higher than those in the control group (P = .001).,Copyright © 2014 Elsevier Inc. All rights reserved.,10.1016/j.oooo.2014.03.007,<Element 'PubmedArticle' at 0x7f05d9431220>
248,24748561,"Interneurons, tau and amyloid-β in the piriform cortex in Alzheimer's disease.","Impaired olfaction has been described as an early symptom of Alzheimer's disease. Neuroanatomical changes underlying this deficit in the olfactory system are largely unknown. Interestingly, neuropathology begins in the transentorhinal cortex and extends to the neighboring limbic system and basal telencephalic structures that mediate olfactory processing, including the anterior olfactory nucleus and olfactory bulb. The human piriform cortex has been described as a crucial area in odor quality coding; disruption of this region mediates early olfactory deficits in Alzheimer's disease. Most neuropathological investigations have focused on the entorhinal cortex and hippocampus, whereas the piriform cortex has largely been neglected. This work aims to characterize the expression of the neuropathological amyloid-β peptide, tau protein and interneuron population markers (calretinin, parvalbumin and somatostatin) in the piriform cortex of ten Alzheimer-diagnosed (80.4 ± 8.3 years old) and five control (69.6 ± 11.1) cases. Here, we examined the distribution of different interneuronal markers as well as co-localization of interneurons and pathological markers. Results indicated preferential vulnerability of somatostatin- (p = 0.0001 < α = 0.05) and calretinin-positive (p = 0.013 < α = 0.05) cells that colocalized with amyloid-β peptide, while the prevalence of parvalbumin-positive cells was increased (p = 0.045 < α = 0.05) in the Alzheimer's cases. These data may help to reveal the neural basis of olfactory deficits linked to Alzheimer's disease as well as to characterize neuronal populations preferentially vulnerable to neuropathology in regions critically involved in early stages of the disease.",[],Brain structure & function,2014-04-22,"[{'lastname': 'Saiz-Sanchez', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Laboratorio de Neuroplasticidad y Neurodegeneración, Facultad de Medicina de Ciudad Real, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, Avda. de Moledores s/n, 13071, Ciudad Real, Spain.'}, {'lastname': 'De la Rosa-Prieto', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': None}, {'lastname': 'Ubeda-Banon', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': None}, {'lastname': 'Martinez-Marcos', 'firstname': 'Alino', 'initials': 'A', 'affiliation': None}]",,,,,10.1007/s00429-014-0771-3,<Element 'PubmedArticle' at 0x7f05d943aae0>
249,"24722782
9330981
21952260
15285801
15197750
16981823
18198416
19276557
22720070
14657172
22763024
15728830
22248049
23515018
22795792
22397366
1782548
21777559
12629164
17270732
20846376
16192374
22727277
10822068
17965741
17401376
17556587
19805493
10818140
15212840
11160418
20080969
15638406
11238027
16343349
10415140
17556361
9610679
9610678
15864274
9630473
23171029
17656099
18997302
16343349
15294141
17056594",CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.,"The endocannabinoid CB2 receptor system has been implicated in the neuropathology of Alzheimer's disease (AD). In order to investigate the impact of the CB2 receptor system on AD pathology, a colony of mice with a deleted CB2 receptor gene, CNR2, was established on a transgenic human mutant APP background for pathological comparison with CB2 receptor-sufficient transgenic mice. J20 APP (PDGFB-APPSwInd) mice were bred over two generations with CNR2(-/-) (Cnr2(tm1Dgen)/J) mice to produce a colony of J20 CNR2(+/+) and J20 CNR2(-/-) mice. Seventeen J20 CNR2(+/+) mice (12 females, 5 males) and 16 J20 CNR2(-/-) mice (11 females, 5 males) were killed at 12 months, and their brains were interrogated for AD-related pathology with both biochemistry and immunocytochemistry (ICC). In addition to amyloid-dependent endpoints such as soluble Aβ production and plaque deposition quantified with 6E10 staining, the effect of CB2 receptor deletion on total soluble mouse tau production was assayed by using a recently developed high-sensitivity assay. Results revealed that soluble Aβ42 and plaque deposition were significantly increased in J20 CNR2(-/-) mice relative to CNR2(+/+) mice. Microgliosis, quantified with ionized calcium-binding adapter molecule 1 (Iba-1) staining, did not differ between groups, whereas plaque associated microglia was more abundant in J20 CNR2(-/-) mice. Total tau was significantly suppressed in J20 CNR2(-/-) mice relative to J20 CNR2(+/+) mice. The results confirm the constitutive role of the CB2 receptor system both in reducing amyloid plaque pathology in AD and also support tehpotential of cannabinoid therapies targeting CB2 to reduce Aβ; however, the results suggest that interventions may have a divergent effect on tau pathology.",[],"Molecular medicine (Cambridge, Mass.)",2014-04-12,"[{'lastname': 'Koppel', 'firstname': 'Jeremy', 'initials': 'J', 'affiliation': 'Litwin-Zucker Research Center, Feinstein Institute for Medical Research, North-Shore Long Island Jewish Health System, Manhasset, New York, United States of America.'}, {'lastname': 'Vingtdeux', 'firstname': 'Valerie', 'initials': 'V', 'affiliation': 'Litwin-Zucker Research Center, Feinstein Institute for Medical Research, North-Shore Long Island Jewish Health System, Manhasset, New York, United States of America.'}, {'lastname': 'Marambaud', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'Litwin-Zucker Research Center, Feinstein Institute for Medical Research, North-Shore Long Island Jewish Health System, Manhasset, New York, United States of America.'}, {'lastname': ""d'Abramo"", 'firstname': 'Cristina', 'initials': 'C', 'affiliation': 'Litwin-Zucker Research Center, Feinstein Institute for Medical Research, North-Shore Long Island Jewish Health System, Manhasset, New York, United States of America.'}, {'lastname': 'Jimenez', 'firstname': 'Heidy', 'initials': 'H', 'affiliation': 'Litwin-Zucker Research Center, Feinstein Institute for Medical Research, North-Shore Long Island Jewish Health System, Manhasset, New York, United States of America.'}, {'lastname': 'Stauber', 'firstname': 'Mark', 'initials': 'M', 'affiliation': 'Yeshiva University, New York, New York, United States of America.'}, {'lastname': 'Friedman', 'firstname': 'Rachel', 'initials': 'R', 'affiliation': 'Queens College, New York, New York, United States of America.'}, {'lastname': 'Davies', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Litwin-Zucker Research Center, Feinstein Institute for Medical Research, North-Shore Long Island Jewish Health System, Manhasset, New York, United States of America.'}]",,,,,10.2119/molmed.2013.00140.revised,<Element 'PubmedArticle' at 0x7f05d9445130>
250,24675496,Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.,"The aims of this study were to investigate the correlation between topoisomerase II alpha (TOP2A), microtubule-associated protein-tau (MAP-tau) and other prognostic factors in breast cancer and to evaluate the predictive value of TOP2A and MAP-tau in breast cancer patients who received anthracycline and taxane-containing adjuvant chemotherapy.
Seventy patients with axillary lymph node positive breast cancer who underwent curative surgery between January 2000 and December 2005 were evaluated retrospectively. The levels of protein expression of TOP2A and MAP-tau were assessed using immunohistochemistry.
Among the 70 patients, 43 (61.4%) showed TOP2A overexpression and 30 (42.9%) showed MAP-tau positivity. TOP2A overexpression was associated with p53 positivity and high histological grade. MAP-tau positivity was associated with a lower positive lymph node ratio, lower proliferative activity, and hormone receptor positivity. Based on the TOP2A and MAP-tau expression, there was no significant difference in disease-free survival in the breast cancer patients who received anthracycline and taxane-containing adjuvant chemotherapy.
We conclude that immunohistochemical analysis of TOP2A and MAP-tau protein expression may not predict the benefits of adjuvant anthracycline and taxane chemotherapy in axillary node positive breast cancer.",[],Tumori,2014-03-29,"[{'lastname': 'Won', 'firstname': 'Hye Sung', 'initials': 'HS', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Kyoung Eun', 'initials': 'KE', 'affiliation': None}, {'lastname': 'Sung', 'firstname': 'Sun Hee', 'initials': 'SH', 'affiliation': None}, {'lastname': 'Choi', 'firstname': 'Moon Young', 'initials': 'MY', 'affiliation': None}, {'lastname': 'Jo', 'firstname': 'Jung Youn', 'initials': 'JY', 'affiliation': None}, {'lastname': 'Nam', 'firstname': 'Eun Mi', 'initials': 'EM', 'affiliation': None}, {'lastname': 'Mun', 'firstname': 'Yeung-Chul', 'initials': 'YC', 'affiliation': None}, {'lastname': 'Seong', 'firstname': 'Chu-Myong', 'initials': 'CM', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Soon Nam', 'initials': 'SN', 'affiliation': None}]",,,"Among the 70 patients, 43 (61.4%) showed TOP2A overexpression and 30 (42.9%) showed MAP-tau positivity. TOP2A overexpression was associated with p53 positivity and high histological grade. MAP-tau positivity was associated with a lower positive lymph node ratio, lower proliferative activity, and hormone receptor positivity. Based on the TOP2A and MAP-tau expression, there was no significant difference in disease-free survival in the breast cancer patients who received anthracycline and taxane-containing adjuvant chemotherapy.",,10.1700/1430.15820,<Element 'PubmedArticle' at 0x7f05d9579860>
251,"24667917
1936601
11723062
1345335
11092432
18464753
17429039
16216938
15863436
17430231
12860573
12088740
18651634
24309633
17116226
22593080
18560126
12453890
9262404
22638775
10574963
11248117
16092951
20230616
18461448
18077675
23703152
15166226
22043356
18618016
24076449
23831150
17334649
16234245
23372648
8835879
21356305
23831150
22108721",Short-term high-fat-and-fructose feeding produces insulin signaling alterations accompanied by neurite and synaptic reduction and astroglial activation in the rat hippocampus.,"Chronic consumption of high-fat-and-fructose diets (HFFD) is associated with the development of insulin resistance (InsRes) and obesity. Systemic insulin resistance resulting from long-term HFFD feeding has detrimental consequences on cognitive performance, neurogenesis, and long-term potentiation establishment, accompanied by neuronal alterations in the hippocampus. However, diet-induced hippocampal InsRes has not been reported. Therefore, we investigated whether short-term HFFD feeding produced hippocampal insulin signaling alterations associated with neuronal changes in the hippocampus. Rats were fed with a control diet or an HFFD consisting of 10% lard supplemented chow and 20% high-fructose syrup in the drinking water. Our results show that 7 days of HFFD feeding induce obesity and InsRes, associated with the following alterations in the hippocampus: (1) a decreased insulin signaling; (2) a decreased hippocampal weight; (3) a reduction in dendritic arborization in CA1 and microtubule-associated protein 2 (MAP-2) levels; (4) a decreased dendritic spine number in CA1 and synaptophysin content, along with an increase in tau phosphorylation; and finally, (5) an increase in reactive astrocyte associated with microglial changes. To our knowledge, this is the first report addressing hippocampal insulin signaling, as well as morphologic, structural, and functional modifications due to short-term HFFD feeding in the rat.",[],Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,2014-03-29,"[{'lastname': 'Calvo-Ochoa', 'firstname': 'Erika', 'initials': 'E', 'affiliation': 'Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México DF, México.'}, {'lastname': 'Hernández-Ortega', 'firstname': 'Karina', 'initials': 'K', 'affiliation': 'Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México DF, México.'}, {'lastname': 'Ferrera', 'firstname': 'Patricia', 'initials': 'P', 'affiliation': 'Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México DF, México.'}, {'lastname': 'Morimoto', 'firstname': 'Sumiko', 'initials': 'S', 'affiliation': 'Departamento de Biología de la Reproducción, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México DF, México.'}, {'lastname': 'Arias', 'firstname': 'Clorinda', 'initials': 'C', 'affiliation': 'Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México DF, México.'}]",,,,,10.1038/jcbfm.2014.48,<Element 'PubmedArticle' at 0x7f05d983d6d0>
252,24667360,Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease.,"Alzheimer's disease (AD), the most common form of dementia, is characterized by the loss of normal functions of brain cells and neuronal death, ultimately leading to memory loss. Recent accumulating evidences have demonstrated the therapeutic potential of anti-diabetic agents, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, for the treatment of Alzheimer's disease (AD), providing opportunities to explore and test the DPP-4 inhibitors for treating this fatal disease. Prior studies determining the efficacy of Pterocarpus marsupium (PM, Fabaceae) and Eugenia jambolana (EJ, Myrtaceae) extracts for ameliorating type 2 diabetes have demonstrated the DPP-4 inhibitory properties indicating the possibility of using of these extracts even for the treating AD. Therefore, in the present study, the neuroprotective roles of PM and EJ for ameliorating the streptozotocin (STZ) induced AD have been tested in rat model. Experimentally, PM and EJ extracts, at a dose range of 200 and 400mg/kg, were administered orally to STZ induced AD Wistar rats and cognitive evaluation tests were performed using radial arm maze and hole-board apparatus. Following 30 days of treatment with the extracts, a dose- and time-dependent attenuation of AD pathology, as evidenced by decreasing amyloid beta 42, total tau, phosphorylated tau and neuro-inflammation with an increase in glucagon-like peptide-1 (GLP-1) levels was observed. Therefore, PM and EJ extracts contain cognitive enhancers as well as neuroprotective agents against STZ induced AD.","['Amyloid load', 'Eugenia jambolana', 'Glucagon-like peptide-1', 'Neuro-inflammation', 'Pterocarpus marsupium', 'Tau phosphorylation']",Behavioural brain research,2014-03-29,"[{'lastname': 'Kosaraju', 'firstname': 'Jayasankar', 'initials': 'J', 'affiliation': 'Department of Pharmacognosy, JSS College of Pharmacy, Udhagamandalam, Tamilnadu 643001, India. Electronic address: jayasankar87@hotmail.com.'}, {'lastname': 'Madhunapantula', 'firstname': 'Subbarao V', 'initials': 'SV', 'affiliation': 'Department of Biochemistry, JSS Medical College, Sri Shivarathresshwara Nagar, Mysore 570015, India.'}, {'lastname': 'Chinni', 'firstname': 'Santhivardhan', 'initials': 'S', 'affiliation': 'Department of Pharmacology, JSS College of Pharmacy, Udhagamandalam, Tamilnadu 643001, India.'}, {'lastname': 'Khatwal', 'firstname': 'Rizwan Basha', 'initials': 'RB', 'affiliation': 'Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, Udhagamandalam, Tamilnadu 643001, India.'}, {'lastname': 'Dubala', 'firstname': 'Anil', 'initials': 'A', 'affiliation': 'Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, Udhagamandalam, Tamilnadu 643001, India.'}, {'lastname': 'Muthureddy Nataraj', 'firstname': 'Satish Kumar', 'initials': 'SK', 'affiliation': 'Department of Pharmacology, JSS College of Pharmacy, Udhagamandalam, Tamilnadu 643001, India.'}, {'lastname': 'Basavan', 'firstname': 'Duraiswamy', 'initials': 'D', 'affiliation': 'Department of Pharmacognosy, JSS College of Pharmacy, Udhagamandalam, Tamilnadu 643001, India.'}]",,,,Copyright © 2014 Elsevier B.V. All rights reserved.,10.1016/j.bbr.2014.03.026,<Element 'PubmedArticle' at 0x7f05d9f49270>
253,"24566994
12534856
23022395
15177915
22330611
23770428
6232394
22124434
19679745
16517946
21763763
15718168
17070838
15998712
21244954
11913616
1661757
15364606
19478206
9564874
8087942
19966062
19181960
14608525
7869240
9704680
15695247
1123533
7481207
2009615
17714085
11473056
16103265
9279776
9622149
10775573
22198170
23417603
16859699
10994762
18548147
16132238
21856918
15265849
23027453
12742294
1593465
18287217
15526242",Ageing-related cardiomyocyte functional decline is sex and angiotensin II dependent.,"Clinically, heart failure is an age-dependent pathological phenomenon and displays sex-specific characteristics. The renin-angiotensin system mediates cardiac pathology in heart failure. This study investigated the sexually dimorphic functional effects of ageing combined with angiotensin II (AngII) on cardiac muscle cell function, twitch and Ca(2+)-handling characteristics of isolated cardiomyocytes from young (~13 weeks) and aged (~87 weeks) adult wild type (WT) and AngII-transgenic (TG) mice. We hypothesised that AngII-induced contractile impairment would be exacerbated in aged female cardiomyocytes and linked to Ca(2+)-handling disturbances. AngII-induced cardiomyocyte hypertrophy was evident in young adult mice of both sexes and accentuated by age (aged adult ~21-23 % increases in cell length relative to WT). In female AngII-TG mice, ageing was associated with suppressed cardiomyocyte contractility (% shortening, maximum rate of shortening, maximum rate of relaxation). This was associated with delayed cytosolic Ca(2+) removal during twitch relaxation (Tau ~20 % increase relative to young adult female WT), and myofilament responsiveness to Ca(2+) was maintained. In contrast, aged AngII-TG male cardiomyocytes exhibited peak shortening equivalent to young TG; yet, myofilament Ca(2+) responsiveness was profoundly reduced with ageing. Increased pro-arrhythmogenic spontaneous activity was evident with age and cardiac AngII overexpression in male mice (42-55 % of myocytes) but relatively suppressed in female aged transgenic mice. Female myocytes with elevated AngII appear more susceptible to an age-related contractile deficit, whereas male AngII-TG myocytes preserve contractile function with age but exhibit desensitisation of myofilaments to Ca(2+) and a heightened vulnerability to arrhythmic activity. These findings support the contention that sex-specific therapies are required for the treatment of age-progressive heart failure.",[],"Age (Dordrecht, Netherlands)",2014-02-26,"[{'lastname': 'Mellor', 'firstname': 'Kimberley M', 'initials': 'KM', 'affiliation': 'Department of Physiology, University of Melbourne, Melbourne, VIC, Australia, k.mellor@auckland.ac.nz.'}, {'lastname': 'Curl', 'firstname': 'Claire L', 'initials': 'CL', 'affiliation': None}, {'lastname': 'Chandramouli', 'firstname': 'Chanchal', 'initials': 'C', 'affiliation': None}, {'lastname': 'Pedrazzini', 'firstname': 'Thierry', 'initials': 'T', 'affiliation': None}, {'lastname': 'Wendt', 'firstname': 'Igor R', 'initials': 'IR', 'affiliation': None}, {'lastname': 'Delbridge', 'firstname': 'Lea M D', 'initials': 'LM', 'affiliation': None}]",,,,,"10.1007/s11357-014-9630-7
10.1034/j.1601-5215.2002.51020.x
10.1016/j.regpep.2004.04.004
10.1038/nrcardio.2012.10
10.1016/S0022-2828(84)80587-8
10.1161/HYPERTENSIONAHA.111.178715
10.1152/japplphysiol.00407.2009
10.1152/ajpheart.00660.2005
10.1016/j.toxlet.2011.07.001
10.1016/j.ejheart.2004.10.017
10.1016/j.yjmcc.2006.09.019
10.1161/01.HYP.0000173069.53699.d9
10.1016/1050-1738(93)90039-9
10.1097/00004872-199111000-00005
10.1016/j.cardiores.2004.07.018
10.1161/CIRCRESAHA.108.189779
10.1161/01.CIR.90.3.1328
10.1152/ajpheart.00214.2009
10.1152/ajpheart.01151.2008
10.3317/jraas.2003.030
10.1053/hj.1998.v136.90226
10.1113/jphysiol.2004.078782
10.1093/geronj/30.2.157
10.1002/sim.4780141604
10.1161/01.RES.68.4.905
10.1111/j.1440-1681.2007.04675.x
10.2337/diabetes.50.8.1918
10.1161/01.HYP.0000178600.88820.b2
10.1016/S1056-8719(97)00020-8
10.1161/01.HYP.31.6.1324
10.1161/01.HYP.35.4.985
10.1152/ajpheart.00797.2011
10.1007/s00424-013-1233-0
10.1016/j.yjmcc.2006.06.004
10.1097/00004872-200018090-00017
10.1016/S0828-282X(08)70624-X
10.1007/s00059-005-2718-1
10.1152/ajpheart.01092.2010
10.1001/jama.292.3.344
10.1016/S0735-1097(03)00262-6
10.1152/ajpregu.00864.2007
10.3317/jraas.2004.024",<Element 'PubmedArticle' at 0x7f05dca8a900>
254,"24559032
57438
1970008
10442557
23208308
20102526
20720505
7969952
8710059
14107684
23432126
15788542
17712855
8558176
22595371
18276036
16204452
12060695
22445326
12084879
16906426
22101365
22488922
23966253
22035690
23217738
4729191
18373478
9214529
10946737
11071494
20129626
16718702
8710069
20669292
19702573
20584946
10072441
11425937
19458322
21685912
23635960
22261560
16157754
20864052
17023659
18520774
20512649
18401022
17469117
22101322
11484824
1285493
1759560
1580329
9386782",Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer.,"We report the case of a 75-year-old ex-professional boxer who developed diplopia and eye movement abnormalities in his 60's followed by memory impairment, low mood and recurrent falls. Examination shortly before death revealed hypomimia, dysarthria, vertical supranuclear gaze palsy and impaired postural reflexes. Pathological examination demonstrated 4-repeat tau neuronal and glial lesions, including tufted astrocytes, consistent with a diagnosis of progressive supranuclear palsy. In addition, neurofibrillary tangles composed of mixed 3-repeat and 4-repeat tau and astrocytic tangles in a distribution highly suggestive of chronic traumatic encephalopathy were observed together with limbic TDP-43 pathology. Possible mechanisms for the co-occurrence of these two tau pathologies are discussed.",[],Acta neuropathologica communications,2014-02-25,"[{'lastname': 'Ling', 'firstname': 'Helen', 'initials': 'H', 'affiliation': None}, {'lastname': 'Kara', 'firstname': 'Eleanna', 'initials': 'E', 'affiliation': None}, {'lastname': 'Revesz', 'firstname': 'Tamas', 'initials': 'T', 'affiliation': None}, {'lastname': 'Lees', 'firstname': 'Andrew J', 'initials': 'AJ', 'affiliation': None}, {'lastname': 'Plant', 'firstname': 'Gordon T', 'initials': 'GT', 'affiliation': None}, {'lastname': 'Martino', 'firstname': 'Davide', 'initials': 'D', 'affiliation': None}, {'lastname': 'Houlden', 'firstname': 'Henry', 'initials': 'H', 'affiliation': None}, {'lastname': 'Hardy', 'firstname': 'John', 'initials': 'J', 'affiliation': None}, {'lastname': 'Holton', 'firstname': 'Janice L', 'initials': 'JL', 'affiliation': 'Reta Lila Weston Institute of Neurological Studies, Queen Square Brain Bank for Neurological Disorders, UCL Institute of Neurology, University College London, London, UK. Janice.holton@ucl.ac.uk.'}]",,,,,"10.1186/2051-5960-2-24
10.1001/jama.1928.02700150029009
10.1007/s004010051066
10.1093/brain/aws307
10.1111/j.1440-1789.2009.01085.x
10.1097/NEN.0b013e3181ee7d85
10.1212/WNL.44.11.2015
10.1212/WNL.47.1.1
10.1001/archneur.1964.00460160003001
10.1111/nan.12037
10.1093/brain/awh488
10.1002/mds.21698
10.1097/00005072-199601000-00010
10.1016/j.neurobiolaging.2007.12.017
10.1093/nar/gni155
10.1093/nar/gnf056
10.1212/WNL.58.12.1791
10.1007/s00401-006-0127-z
10.1007/s00401-011-0910-3
10.1002/mds.24968
10.1212/WNL.0b013e3182a55f7f
10.1016/j.pmrj.2011.08.008
10.1016/j.neuron.2012.11.021
10.1017/S0033291700049588
10.1089/neu.2007.0489
10.1001/jama.1997.03550020068040
10.1055/s-2000-9826
10.1212/WNL.55.8.1158
10.1016/j.jns.2010.01.011
10.1002/ana.20882
10.1212/WNL.47.1.148
10.1002/mds.23210
10.2174/187152709789541998
10.1093/brain/awq123
10.1093/hmg/8.4.711
10.1212/WNL.56.12.1702
10.1212/WNL.0b013e3181a92bcc
10.1038/ng.859
10.1212/WNL.0b013e318294b2eb
10.1159/000334731
10.1001/archneur.62.9.1453
10.1016/S1474-4422(10)70195-2
10.1126/science.1134108
10.1097/NEN.0b013e31817713b5
10.1007/s00401-010-0702-1
10.1002/ana.21154
10.1007/s00401-011-0909-9
10.1007/BF00304630
10.1007/BF00308813
10.1007/s004010050737",<Element 'PubmedArticle' at 0x7f05da018590>
255,"24349472
18174459
16246463
22476197
12812866
21277873
16340083
15750214
16627931
19885299
18651634
14633804
11506060
17296187
17316549
18500972
19433898
19969552
19937569
20513336
20515642
21550075
14709014
21875098
17207279
20554184
16582031
9075239
21305046
10380075
12678878
22205300
22245457
22301128
19293236
22820146
20524222
19734396
20854384
22749176
17592939
8873290
19374947
18651634
7816869
17574275
16793938
11438364
11445137
20421697
18430999
10713291
12468892
22664636
17659525
20814415
16269321
17478722
22536172
18640458
23499750
21597043
19523444
21316350
20851586","Cinnamon counteracts the negative effects of a high fat/high fructose diet on behavior, brain insulin signaling and Alzheimer-associated changes.","Insulin resistance leads to memory impairment. Cinnamon (CN) improves peripheral insulin resistance but its effects in the brain are not known. Changes in behavior, insulin signaling and Alzheimer-associated mRNA expression in the brain were measured in male Wistar rats fed a high fat/high fructose (HF/HFr) diet to induce insulin resistance, with or without CN, for 12 weeks. There was a decrease in insulin sensitivity associated with the HF/HFr diet that was reversed by CN. The CN fed rats were more active in a Y maze test than rats fed the control and HF/HFr diets. The HF/HFr diet fed rats showed greater anxiety in an elevated plus maze test that was lessened by feeding CN. The HF/HFr diet also led to a down regulation of the mRNA coding for GLUT1 and GLUT3 that was reversed by CN in the hippocampus and cortex. There were increases in Insr, Irs1 and Irs2 mRNA in the hippocampus and cortex due to the HF/HFr diet that were not reversed by CN. Increased peripheral insulin sensitivity was also associated with increased glycogen synthase in both hippocampus and cortex in the control and HF/HFr diet animals fed CN. The HF/HFr diet induced increases in mRNA associated with Alzheimers including PTEN, Tau and amyloid precursor protein (App) were also alleviated by CN. In conclusion, these data suggest that the negative effects of a HF/HFr diet on behavior, brain insulin signaling and Alzheimer-associated changes were alleviated by CN suggesting that neuroprotective effects of CN are associated with improved whole body insulin sensitivity and related changes in the brain.",[],PloS one,2013-12-19,"[{'lastname': 'Anderson', 'firstname': 'Richard A', 'initials': 'RA', 'affiliation': 'Diet, Genomics, and Immunology Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, United States Department of Agriculture, Beltsville, Maryland, United States of America.'}, {'lastname': 'Qin', 'firstname': 'Bolin', 'initials': 'B', 'affiliation': 'Diet, Genomics, and Immunology Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, United States Department of Agriculture, Beltsville, Maryland, United States of America ; Integrity Nutraceuticals International, Spring Hill, Tennessee, United States of America.'}, {'lastname': 'Canini', 'firstname': 'Frederic', 'initials': 'F', 'affiliation': 'Army Institute for Research in Biology, Grenoble, France ; Ecole du Val de Grâce, 1 place Laveran, Paris, France.'}, {'lastname': 'Poulet', 'firstname': 'Laurent', 'initials': 'L', 'affiliation': 'Army Institute for Research in Biology, Grenoble, France ; National Institute for Health, Joseph Fourier University, Grenoble, France.'}, {'lastname': 'Roussel', 'firstname': 'Anne Marie', 'initials': 'AM', 'affiliation': 'National Institute for Health, Joseph Fourier University, Grenoble, France.'}]",,,,,"10.1371/journal.pone.0083243
10.1161/ATVBAHA.107.151092
10.1016/j.neurobiolaging.2005.09.018
10.1172/JCI59903
10.1016/S0306-4530(02)00087-2
10.1016/j.neuropharm.2011.01.033
10.1002/hipo.20470
10.2337/diacare.26.12.3215
10.1080/07315724.2001.10719053
10.1016/j.fertnstert.2006.11.082
10.1016/j.abb.2006.12.034
10.1055/s-0029-1242746
10.1016/j.abb.2010.05.032
10.1016/j.metabol.2011.03.016
10.1021/jf034916b
10.1021/np1007944
10.1186/1476-9255-4-1
10.1016/j.phymed.2010.03.023
10.1080/07315724.2006.10719525
10.1006/nlme.1997.3746
10.1371/journal.pone.0016564
10.1002/(SICI)1097-4695(19990615)39:4
10.2174/1381612033455323
10.1007/s12035-011-8229-6
10.1016/j.tem.2011.12.004
10.2337/dc11-2075
10.1016/j.bbr.2012.07.017
10.1080/13803390903224928
10.3122/jabfm.2009.05.080093
10.1111/j.1464-5491.2010.03079.x
10.1016/j.nutres.2012.05.003
10.1037/0735-7044.121.3.483
10.1016/S0031-9384(96)00135-7
10.1016/j.nbd.2009.04.002
10.1002/hipo.20470
10.1016/0091-3057(94)90472-3
10.1016/j.lfs.2007.05.001
10.1152/ajpregu.00234.2006
10.1016/S0031-9384(01)00493-0
10.1016/S0149-7634(01)00016-1
10.1016/S0031-9384(99)00220-6
10.1007/s11064-012-0805-2
10.1002/glia.20557
10.1038/oby.2010.183
10.1016/j.brainresrev.2005.03.002
10.1126/science.1141736
10.1016/S0140-6736(08)61075-2
10.1016/j.fct.2013.02.049
10.1101/lm.2111311
10.1016/j.bbrc.2009.06.032
10.1016/j.brainres.2011.02.014
10.1016/j.phymed.2010.08.008",<Element 'PubmedArticle' at 0x7f05d935e0e0>
256,"24337945
12904469
15888536
20466736
16627931
11396955
12634421
20308787
16340083
12788204
11901170
17982898
21289177
18625459
10786709
9809441
19705549
12006603
9829797
19727895
16515786
22898296
21262392
15030205
20222152
15750215
14747300
19329286
10783157
18072811
12761548
19358976
15450169
11932745
20655900
17065836
14586007
14977212
22279939
10599761
19815707
19353221
17406865
19026743
19383491
12084635
21901364
20725514",Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats.,"Recent evidence indicates that severe abnormalities in brain glucose/energy metabolism and insulin signaling have been documented to take a pivotal role in early sporadic Alzheimer's disease pathology. It has been reported that naringenin (NAR), derived from citrus aurantium, exhibits antioxidant potential and protects the brain against neurodegeneration. The current study was designed to further investigate the protective effect of the NAR on neurodegeneration in a rat model of AD induced by an intracerebroventricular (ICV) injection of streptozotocin (STZ), and to determine whether this neuroprotective effect was associated with brain insulin signaling. Rats were injected bilaterally with ICV-STZ (3 mg/kg), while sham rats received the same volume of vehicle and then supplemented with NAR (25, 50 mg, 100 mg/kg, respectively) for 3 weeks. The ICV-STZ injected rats did not have elevated blood glucose levels. 21 days following ICV-STZ injection, rats treated with NAR had better learning and memory performance in the Morris water maze test compared with rats treated with saline. We demonstrated that NAR increased the mRNA expression of INS and INSR in cerebral cortex and hippocampus. In addition, NAR reversed ICV-STZ induced Tau hyper-phosphorylation in both hippocampus and cerebral cortex through downregulation of glycogen synthase kinase-3β (GSK-3β) activity, a key kinase in the insulin signaling. Brain levels of Abeta, which were elevated in ICV-STZ rats, were significantly reduced in NAR-treated rats via upregulation of insulin degrading enzyme. These effects were mediated by increased insulin and insulin receptors expression in the brain, suggesting that insulin sensitizer agents might have therapeutic efficacy in early AD.",[],Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,2013-12-18,"[{'lastname': 'Yang', 'firstname': 'Wenqing', 'initials': 'W', 'affiliation': 'Department of Physiology, Research Center of Neuroscience, Chongqing Medical University, Chongqing, 400016, China.'}, {'lastname': 'Ma', 'firstname': 'Jing', 'initials': 'J', 'affiliation': None}, {'lastname': 'Liu', 'firstname': 'Zheng', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Lu', 'firstname': 'Yongliang', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Hu', 'firstname': 'Bin', 'initials': 'B', 'affiliation': None}, {'lastname': 'Yu', 'firstname': 'Huarong', 'initials': 'H', 'affiliation': None}]",,,,,10.1007/s10072-013-1594-3,<Element 'PubmedArticle' at 0x7f05d93057c0>
257,"24333572
22504092
22796551
9059887
9428780
10074922
21277367
11402277
18359186
17512275
18398660
20124103
14533877
6580499
9146774
17091332
15664788
12742657
10416272
11124582
21559428
2120421
10080858
2477332
11104557
6951051
12734098
9531281
19765644
6711312
22890132
23153554
22504092
11948495
19952959
15664784
3871818
6863925
8597957
21475023
10525171
8557827
23164528
17023059
8378099
1588052
2466943
18951972
1329524
8013385
22659252
16139959
8623006
19242372
18037507
6184617
9806750
17192566
2176460
9038153
8980388
1333965
23178744
6871844
16598674
19351748
22753587
22186256",In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins.,"Most in vitro and ex-vivo studies indicate a profound suppression of NK cell cytotoxicity (NKCC) by glucocorticoids; while catecholamines and prostaglandins were reported both to suppress and to enhance NKCC. However, methodological considerations hinder our ability to deduce from these findings to the impact of endogenous release of these factors on in vivo levels of NKCC and their implications to NK-dependent resistance to pathologies in living humans or animals. Here we used an in vivo approach that sensitively and specifically reflects NKCC in living F344 rats, based on lung clearance of NK-sensitive tumor cells (MADB106), and based on comparing effects between NK-intact and NK-depleted rats. To study the role of corticosterone, epinephrine, and prostaglandins, we administered these factors to rats, or antagonized their endogenous release following different stress paradigms or surgery. The results indicated that endogenous or exogenous elevated corticosterone levels can suppress in vivo NKCC levels, but only under some conditions, and mostly secondarily to the NK-suppressing impact of epinephrine. Specifically, corticosterone-induced NKCC suppression occurred (i) only under prolonged, but not short exposure to stress, and mainly in males; (ii) was smaller than the prominent impact of epinephrine; (iii) was mostly ascribed to corticosterone-induced potentiation of the effects of epinephrine or/and prostaglandins; and (iv) was completely abolished through antagonizing epinephrine or/and prostaglandins. Overall, these findings markedly limit the significance of stress/surgery-induced corticosterone release in the in vivo suppression of NKCC, and highlight the blockade of epinephrine or/and prostaglandins as effective and clinically feasible approaches to overcome such immuno-suppressive effects.","['Catecholamines', 'Glucocorticoids', 'In vivo', 'NK cell cytotoxicity', 'Prostaglandins']","Brain, behavior, and immunity",2013-12-18,"[{'lastname': 'Rosenne', 'firstname': 'Ella', 'initials': 'E', 'affiliation': 'Neuroimmunology Research Unit, Department of Psychology, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Sorski', 'firstname': 'Liat', 'initials': 'L', 'affiliation': 'Neuroimmunology Research Unit, Department of Psychology, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Shaashua', 'firstname': 'Lee', 'initials': 'L', 'affiliation': 'Neuroimmunology Research Unit, Department of Psychology, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Neeman', 'firstname': 'Elad', 'initials': 'E', 'affiliation': 'Neuroimmunology Research Unit, Department of Psychology, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Matzner', 'firstname': 'Pini', 'initials': 'P', 'affiliation': 'Neuroimmunology Research Unit, Department of Psychology, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Levi', 'firstname': 'Ben', 'initials': 'B', 'affiliation': 'Neuroimmunology Research Unit, Department of Psychology, Tel Aviv University, Tel Aviv, Israel.'}, {'lastname': 'Ben-Eliyahu', 'firstname': 'Shamgar', 'initials': 'S', 'affiliation': 'Neuroimmunology Research Unit, Department of Psychology, Tel Aviv University, Tel Aviv, Israel. Electronic address: shamgar@post.tau.ac.il.'}]",,,,Copyright © 2013 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2013.12.007,<Element 'PubmedArticle' at 0x7f05d931f090>
258,24298897,Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.,"To investigate the association of radiographic progression defined by Prostate Cancer Working Group (PCWG)-2 guidelines and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).
Two trials that used PCWG-2 guidelines to define progression were analysed: a randomized phase II trial (n = 221) comparing first-line docetaxel-prednisone plus AT-101 or placebo, and a phase III trial (n = 873) comparing prednisone plus sunitinib or placebo after docetaxel-based chemotherapy. Cox proportional hazards regression models were used to estimate the association of radiographic progression with OS. Landmark analyses compared progressing patients with those who had not progressed. Sub-analyses compared patients removed from trial for progression vs other reasons.
An increased risk of death was seen for radiographic progression at landmark times from 6 to 12 months with docetaxel-based therapy (hazard ratio [HR] >1.7 at all time-points). An increased risk of death was also seen with post-docetaxel prednisone alone or with sunitinib for progression at landmark times from 2 to 8 months (HR >2.7 at all time-points). Kendall's τ was 0.50 (P < 0.001) in the setting of docetaxel-based therapy and 0.34 (P < 0.001) in the post-docetaxel setting for association between radiographic progression and death amongst patients with both events. Removal from study due to radiographic progression was associated with a significantly lower OS compared with removal for other reasons in both trials. Limitations of a retrospective analysis apply and there was no central radiology review.
Radiographic progression by PCWG-2 criteria was significantly associated with OS in patients with mCRPC receiving first-line docetaxel-based chemotherapy or post-docetaxel therapy. With external validation as a surrogate endpoint in trials showing survival benefits, the use of radiographic progression-free survival may expedite drug development in mCRPC, which has been hampered by the lack of intermediate endpoints.","['Prostate Cancer Working Group (PCWG)-2', 'castration-resistant prostate cancer', 'metastatic', 'overall survival (OS)', 'radiographic progression']",BJU international,2013-12-05,"[{'lastname': 'Sonpavde', 'firstname': 'Guru', 'initials': 'G', 'affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Alabama, Birmingham (UAB) Comprehensive Cancer Center, Birmingham, AL, USA.'}, {'lastname': 'Pond', 'firstname': 'Gregory R', 'initials': 'GR', 'affiliation': 'Department of Biostatistics, McMaster University, Hamilton, ON, Canada.'}, {'lastname': 'Armstrong', 'firstname': 'Andrew J', 'initials': 'AJ', 'affiliation': 'Department of Medicine, Division of Hematology-Oncology, Duke Prostate Center, Durham, NC, USA.'}, {'lastname': 'Galsky', 'firstname': 'Matthew D', 'initials': 'MD', 'affiliation': 'Department of Medicine, Division of Hematology-Oncology, Mt Sinai Tisch Cancer Institute, New York, NY, USA.'}, {'lastname': 'Leopold', 'firstname': 'Lance', 'initials': 'L', 'affiliation': 'Ascenta Therapeutics, Malvern, PA, USA.'}, {'lastname': 'Wood', 'firstname': 'Brian A', 'initials': 'BA', 'affiliation': 'Ascenta Therapeutics, Malvern, PA, USA.'}, {'lastname': 'Wang', 'firstname': 'Shaw-Ling', 'initials': 'SL', 'affiliation': 'Pfizer Inc., Madison, NJ, USA.\nICON Clinical Research Inc., San Diego, CA, USA.'}, {'lastname': 'Paolini', 'firstname': 'Jolanda', 'initials': 'J', 'affiliation': 'Pfizer Inc., Madison, NJ, USA.'}, {'lastname': 'Chen', 'firstname': 'Isan', 'initials': 'I', 'affiliation': 'Pfizer Inc., Madison, NJ, USA.\nSeragon Pharmaceuticals, San Diego, CA, USA.'}, {'lastname': 'Chow-Maneval', 'firstname': 'Edna', 'initials': 'E', 'affiliation': 'Pfizer Inc., Madison, NJ, USA.\nSeragon Pharmaceuticals, San Diego, CA, USA.'}, {'lastname': 'Mooney', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Alabama, Birmingham (UAB) Comprehensive Cancer Center, Birmingham, AL, USA.'}, {'lastname': 'Lechuga', 'firstname': 'Mariajose', 'initials': 'M', 'affiliation': 'Pfizer Inc., Madison, NJ, USA.'}, {'lastname': 'Smith', 'firstname': 'Matthew R', 'initials': 'MR', 'affiliation': 'Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital and the Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Michaelson', 'firstname': 'M Dror', 'initials': 'MD', 'affiliation': 'Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital and the Harvard Medical School, Boston, MA, USA.'}]",,,An increased risk of death was seen for radiographic progression at landmark times from 6 to 12 months with docetaxel-based therapy (hazard ratio [HR] >1.7 at all time-points). An increased risk of death was also seen with post-docetaxel prednisone alone or with sunitinib for progression at landmark times from 2 to 8 months (HR >2.7 at all time-points). Kendall's τ was 0.50 (P < 0.001) in the setting of docetaxel-based therapy and 0.34 (P < 0.001) in the post-docetaxel setting for association between radiographic progression and death amongst patients with both events. Removal from study due to radiographic progression was associated with a significantly lower OS compared with removal for other reasons in both trials. Limitations of a retrospective analysis apply and there was no central radiology review.,© 2013 The Authors. BJU International © 2013 BJU International.,10.1111/bju.12589,<Element 'PubmedArticle' at 0x7f05d92c5900>
259,"24244639
22611136
22142519
18166598
20570377
12034159
22740508
20177398
15860516
18294490
20395261
22985248
16055882
12091180
15477419
12377932
19168510
22309369
20005086
21700606
23018914
2864891
21920889
11179105
12392035
18057097
17356059
19291375
11377293
11514694
8651123
8837575
21418620","Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: an observational study.","Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) may coexist in elderly patients with a history of smoking. Low-grade systemic inflammation induced by smoking may represent the link between these 2 conditions. In this study, we investigated left ventricular dysfunction in patients primarily diagnosed with COPD, and nonreversible airflow limitation in patients primarily diagnosed with CHF. The levels of circulating high-sensitive C-reactive protein (Hs-CRP), pentraxin 3 (PTX3), interleukin-1β (IL-1 β), and soluble type II receptor of IL-1 (sIL-1RII) were also measured as markers of systemic inflammation in these 2 cohorts. Patients aged ≥ 50 years and with ≥ 10 pack years of cigarette smoking who presented with a diagnosis of stable COPD (n=70) or stable CHF (n=124) were recruited. All patients underwent echocardiography, N-terminal pro-hormone of brain natriuretic peptide measurements, and post-bronchodilator spirometry. Plasma levels of Hs-CRP, PTX3, IL-1 β, and sIL-1RII were determined by using a sandwich enzyme-linked immuno-sorbent assay in all patients and in 24 healthy smokers (control subjects). Although we were unable to find a single COPD patient with left ventricular dysfunction, we found nonreversible airflow limitation in 34% of patients with CHF. On the other hand, COPD patients had higher plasma levels of Hs-CRP, IL1 β, and sIL-1RII compared with CHF patients and control subjects (p < 0.05). None of the inflammatory biomarkers was different between CHF patients and control subjects. In conclusion, although the COPD patients had no evidence of CHF, up to one third of patients with CHF had airflow limitation, suggesting that routine spirometry is warranted in patients with CHF, whereas echocardiography is not required in well characterized patients with COPD. Only smokers with COPD seem to have evidence of systemic inflammation.",[],PloS one,2013-11-19,"[{'lastname': 'Beghé', 'firstname': 'Bianca', 'initials': 'B', 'affiliation': 'Department of Medical and Surgical Sciences, University of Modena & Reggio Emilia, Modena, Italy.'}, {'lastname': 'Verduri', 'firstname': 'Alessia', 'initials': 'A', 'affiliation': None}, {'lastname': 'Bottazzi', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': None}, {'lastname': 'Stendardo', 'firstname': 'Mariarita', 'initials': 'M', 'affiliation': None}, {'lastname': 'Fucili', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': None}, {'lastname': 'Balduzzi', 'firstname': 'Sara', 'initials': 'S', 'affiliation': None}, {'lastname': 'Leuzzi', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': None}, {'lastname': 'Papi', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': None}, {'lastname': 'Mantovani', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': None}, {'lastname': 'Fabbri', 'firstname': 'Leonardo M', 'initials': 'LM', 'affiliation': None}, {'lastname': 'Ceconi', 'firstname': 'Claudio', 'initials': 'C', 'affiliation': None}, {'lastname': 'Boschetto', 'firstname': 'Piera', 'initials': 'P', 'affiliation': None}]",,,,,"10.1371/journal.pone.0080166
10.1093/eurheartj/ehs104
10.1111/j.1440-1843.2011.02118.x
10.1183/09031936.00114307
10.1016/j.ijcard.2010.04.082
10.1016/S1388-9842(02)00021-1
10.1093/eurjhf/hfs092
10.1038/nrrheum.2010.4
10.1093/eurheartj/ehi291
10.1016/j.ahj.2007.10.040
10.1093/eurjhf/hfq050
10.1111/j.1440-1843.2012.02264.x
10.1183/09031936.05.00034805
10.1164/ajrccm.166.1.at
10.1161/01.CIR.0000145167.30987.2E
10.1093/eurjhf/hfn013
10.1186/1465-9921-13-13
10.1016/j.rmed.2009.11.013
10.1183/09031936.00044411
10.1183/09031936.00222511
10.1183/09031936.00138110
10.1164/ajrccm.163.2.2003122
10.1136/thx.2007.086751
10.1136/thx.2006.064428
10.1007/s10875-009-9286-8
10.1016/S1471-4906(01)01941-X
10.1136/thorax.56.9.721
10.1016/S0002-9149(97)89206-5
10.1016/S0735-1097(96)00268-9
10.1186/1479-5876-9-28",<Element 'PubmedArticle' at 0x7f05d92d4db0>
260,"24174584
16718704
16401843
21048198
20232070
22855864
17023659
21944779
16950801
16862116
9392579
17721707
20139998
6610841
9855500
23538862
21400565
17213280
19296504
19474568
18458217
21810890
23622690
22801723
22855860
16831961
20157014
23062850
22347799
22784036
21971471
23139856",Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP.,"To validate the ability of candidate CSF biomarkers to distinguish between the 2 main forms of frontotemporal lobar degeneration (FTLD), FTLD with TAR DNA-binding protein 43 (TDP-43) inclusions (FTLD-TDP) and FTLD with Tau inclusions (FTLD-Tau).
Antemortem CSF samples were collected from 30 patients with FTLD in a single-center validation cohort, and CSF levels of 5 putative FTLD-TDP biomarkers as well as levels of total Tau (t-Tau) and Tau phosphorylated at threonine 181 (p-Tau181) were measured using independent assays. Biomarkers most associated with FTLD-TDP were then tested in a separate 2-center validation cohort composed of subjects with FTLD-TDP, FTLD-Tau, Alzheimer disease (AD), and cognitively normal subjects. The sensitivity and specificity of FTLD-TDP biomarkers were determined.
In the first validation cohort, FTLD-TDP cases had decreased levels of p-Tau181 and interleukin-23, and increased Fas. Reduced ratio of p-Tau181 to t-Tau (p/t-Tau) was the strongest predictor of FTLD-TDP pathology. Analysis in the second validation cohort showed CSF p/t-Tau ratio <0.37 to distinguish FTLD-TDP from FTLD-Tau, AD, and healthy seniors with 82% sensitivity and 82% specificity.
A reduced CSF p/t-Tau ratio represents a reproducible, validated biomarker for FTLD-TDP with performance approaching well-established CSF AD biomarkers. Introducing this biomarker into research and the clinical arena can significantly increase the power of clinical trials targeting abnormal accumulations of TDP-43 or Tau, and select the appropriate patients for target-specific therapies.
This study provides Class II evidence that the CSF p/t-Tau ratio distinguishes FTLD-TDP from FTLD-Tau.",[],Neurology,2013-11-01,"[{'lastname': 'Hu', 'firstname': 'William T', 'initials': 'WT', 'affiliation': ""From the Department of Neurology (W.T.H., K.W., J.G., J.J.L., C.H., M.S., A.I.L.), Center for Neurodegenerative Diseases Research (W.T.H., K.W., J.G., J.J.L., C.H., A.I.L.), Alzheimer's Disease Research Center (W.T.H., J.G., J.J.L., C.H., A.I.L.), Emory University School of Medicine, Atlanta, GA; and Departments of Neurology (M.G.) and Laboratory Medicine and Pathology (V.V.D., J.Q.T.), University of Pennsylvania, Philadelphia.""}, {'lastname': 'Watts', 'firstname': 'Kelly', 'initials': 'K', 'affiliation': None}, {'lastname': 'Grossman', 'firstname': 'Murray', 'initials': 'M', 'affiliation': None}, {'lastname': 'Glass', 'firstname': 'Jonathan', 'initials': 'J', 'affiliation': None}, {'lastname': 'Lah', 'firstname': 'James J', 'initials': 'JJ', 'affiliation': None}, {'lastname': 'Hales', 'firstname': 'Chadwick', 'initials': 'C', 'affiliation': None}, {'lastname': 'Shelnutt', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': None}, {'lastname': 'Van Deerlin', 'firstname': 'Vivianna', 'initials': 'V', 'affiliation': None}, {'lastname': 'Trojanowski', 'firstname': 'John Q', 'initials': 'JQ', 'affiliation': None}, {'lastname': 'Levey', 'firstname': 'Allan I', 'initials': 'AI', 'affiliation': None}]",,"A reduced CSF p/t-Tau ratio represents a reproducible, validated biomarker for FTLD-TDP with performance approaching well-established CSF AD biomarkers. Introducing this biomarker into research and the clinical arena can significantly increase the power of clinical trials targeting abnormal accumulations of TDP-43 or Tau, and select the appropriate patients for target-specific therapies.","In the first validation cohort, FTLD-TDP cases had decreased levels of p-Tau181 and interleukin-23, and increased Fas. Reduced ratio of p-Tau181 to t-Tau (p/t-Tau) was the strongest predictor of FTLD-TDP pathology. Analysis in the second validation cohort showed CSF p/t-Tau ratio <0.37 to distinguish FTLD-TDP from FTLD-Tau, AD, and healthy seniors with 82% sensitivity and 82% specificity.",,10.1212/01.wnl.0000436625.63650.27,<Element 'PubmedArticle' at 0x7f05d9272e50>
261,24117480,Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.,"Adults who develop type 2 diabetes (T2D) at later stages are at a higher risk of developing Alzheimer's disease (AD). Pharmacological agents such as dipeptidyl peptidase-4 (DPP-4) inhibitors that increase the levels of glucagon-like peptide-1 (GLP-1) and ameliorate T2D have also become promising candidates as disease-modifying agents in the treatment of AD. The present study investigates the efficacy of vildagliptin, a DPP-4 inhibitor in a streptozotocin (STZ)-induced rat model of AD.
Three months following the induction of AD by intracerebral injection of STZ, animals were orally administered with vildagliptin (2.5, 5 and 10 mg/kg) for 30 days. Dose-dependent and time-course effects of vildagliptin on memory retention were investigated during the course of treatment. Following treatment, the animals were sacrificed, and brain tissues were used to evaluate the effects of vildagliptin on hippocampal and cortical GLP-1 levels, amyloid beta (Aβ) burden, tau phosphorylation and inflammatory markers.
The results reveal a time-dependent improvement in memory retention and a dose-dependent attenuation of Aβ, tau phosphorylation and inflammatory markers and increased GLP-1 levels.
These robust therapeutic effects of vildagliptin demonstrate a unique mechanism for Aβ and tau clearance and reverse the cognitive deficits and pathology observed in AD.","['amyloid beta', 'dipeptidyl peptidase-4', 'glucagon-like peptide-1', 'tau', 'type 2 diabetes']",The Journal of pharmacy and pharmacology,2013-10-15,"[{'lastname': 'Kosaraju', 'firstname': 'Jayasankar', 'initials': 'J', 'affiliation': 'Department of Pharmacognosy, JSS College of Pharmacy, Udhagamandalam, Tamilnadu, India.'}, {'lastname': 'Murthy', 'firstname': 'Vishakantha', 'initials': 'V', 'affiliation': None}, {'lastname': 'Khatwal', 'firstname': 'Rizwan Basha', 'initials': 'RB', 'affiliation': None}, {'lastname': 'Dubala', 'firstname': 'Anil', 'initials': 'A', 'affiliation': None}, {'lastname': 'Chinni', 'firstname': 'Santhivardhan', 'initials': 'S', 'affiliation': None}, {'lastname': 'Muthureddy Nataraj', 'firstname': 'Satish Kumar', 'initials': 'SK', 'affiliation': None}, {'lastname': 'Basavan', 'firstname': 'Duraiswamy', 'initials': 'D', 'affiliation': None}]",,,,© 2013 Royal Pharmaceutical Society.,10.1111/jphp.12148,<Element 'PubmedArticle' at 0x7f05d928def0>
262,"24081596
1565123
10540038
14981746
15885300
18206215
22153989
23728114
12740683
11426033",Unilateral calf hypertrophy and focal myositis induced by S1 radiculopathy: dramatic response to steroid treatment.,Unilateral enlargement of the calf in a 57-year-old man with S1 radiculopathy is described in this case report. Short tau inversion recovery-weighted imaging provided evidence of selective hypertrophy and a high signal intensity of the gastrocnemius and soleus. Histopathological analysis of the gastrocnemius revealed an endomysial inflammatory infiltrate and marked denervation lesions. Marked signs of denervation are suggestive of focal myositis secondary to neurogenic damage. The patient was treated with an oral corticosteroid (30 mg/day) and the calf hypertrophy was dramatically reduced within 5 weeks. Our case indicates that steroid therapy should be tried because it may be a potentially treatable disease.,[],BMJ case reports,2013-10-02,"[{'lastname': 'Hemmi', 'firstname': 'Shoji', 'initials': 'S', 'affiliation': 'Kawasaki Medical School, Kurashiki, Okayama, Japan.'}, {'lastname': 'Shirakawa', 'firstname': 'Shunichi', 'initials': 'S', 'affiliation': None}, {'lastname': 'Kurokawa', 'firstname': 'Katsumi', 'initials': 'K', 'affiliation': None}, {'lastname': 'Sunada', 'firstname': 'Yoshihide', 'initials': 'Y', 'affiliation': None}]",,,,,10.1136/bcr-2013-200870,<Element 'PubmedArticle' at 0x7f05d929dae0>
263,"24081456
21944779
21944778
16344531
11708987
19884572
23338682
16862116
16862115
9641683
9629852
18703462
16041373
19655382
19609911
20124201
15034582
11094121
12053127
10404983
9633692
18234697
17436289
22406228
23117491
21810890
21325651
8710059
19462523
15604628
7837392
14757853
15335440
16950801
20142524
14500612
22426854
22366791
20139998
15786453",Development and validation of pedigree classification criteria for frontotemporal lobar degeneration.,"A significant portion of frontotemporal lobar degeneration (FTLD) is due to inherited gene mutations, and we are unaware of a large sequential series that includes a recently discovered inherited cause of FTLD. There is also great need to develop clinical tools and approaches that will assist clinicians in the identification and counseling of patients with FTLD and their families regarding the likelihood of an identifiable genetic cause.
To ascertain the frequency of inherited FTLD and develop validated pedigree classification criteria for FTLD that provide a standardized means to evaluate pedigree information and insight into the likelihood of mutation-positive genetic test results for C9orf72, MAPT, and GRN.
Information about pedigrees and DNA was collected from 306 serially assessed patients with a clinical diagnosis of FTLD. This information included gene test results for C9orf72, MAPT, and GRN. Pedigree classification criteria were developed based on a literature review of FTLD genetics and pedigree tools and then refined by reviewing mutation-positive and -negative pedigrees to determine differentiating characteristics.
Academic medical center.
Patients with FTLD.
Familial risk.
The rate of C9orf72, MAPT, or GRN mutation-positive FTLD in this series was 15.4%. Categories designating the risk level for hereditary cause were termed high, medium, low, apparent sporadic, and unknown significance. Thirty-nine pedigrees (12.7%) met criteria for high, 31 (10.1%) for medium, 46 (15.0%) for low, 91 (29.7%) for apparent sporadic, and 99 (32.4%) for unknown significance. The mutation-detection rates were as follows: high, 64.1%; medium, 29%; low, 10.9%; apparent sporadic, 1.1%; and unknown significance, 7.1%. Mutation-detection rates differed significantly between the high and other categories.
Mutation rates are high in FTLD spectrum disorders, and the proposed criteria provide a validated standard for the classification of FTLD pedigrees. The combination of pedigree criteria and mutation-detection rates has important implications for genetic counseling and testing in clinical settings.",[],JAMA neurology,2013-10-02,"[{'lastname': 'Wood', 'firstname': 'Elisabeth M', 'initials': 'EM', 'affiliation': 'Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.'}, {'lastname': 'Falcone', 'firstname': 'Dana', 'initials': 'D', 'affiliation': None}, {'lastname': 'Suh', 'firstname': 'Eunran', 'initials': 'E', 'affiliation': None}, {'lastname': 'Irwin', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': None}, {'lastname': 'Chen-Plotkin', 'firstname': 'Alice S', 'initials': 'AS', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Edward B', 'initials': 'EB', 'affiliation': None}, {'lastname': 'Xie', 'firstname': 'Sharon X', 'initials': 'SX', 'affiliation': None}, {'lastname': 'Van Deerlin', 'firstname': 'Vivianna M', 'initials': 'VM', 'affiliation': None}, {'lastname': 'Grossman', 'firstname': 'Murray', 'initials': 'M', 'affiliation': None}]",,,"The rate of C9orf72, MAPT, or GRN mutation-positive FTLD in this series was 15.4%. Categories designating the risk level for hereditary cause were termed high, medium, low, apparent sporadic, and unknown significance. Thirty-nine pedigrees (12.7%) met criteria for high, 31 (10.1%) for medium, 46 (15.0%) for low, 91 (29.7%) for apparent sporadic, and 99 (32.4%) for unknown significance. The mutation-detection rates were as follows: high, 64.1%; medium, 29%; low, 10.9%; apparent sporadic, 1.1%; and unknown significance, 7.1%. Mutation-detection rates differed significantly between the high and other categories.",,10.1001/jamaneurol.2013.3956,<Element 'PubmedArticle' at 0x7f05d9229590>
264,"24027057
21944778
21944779
22732773
22645277
23160421
23053136
22892647
19383787
23415312
21644037
17071926
22101323
23393093
23434116
23273600
23413259
22985429
22964910
22637429
22305801
23329412
23248642
22890575
22459598
23053135
23338682
23254636
22366795
22366793
22300876
22406228
22445326
16950801
22815225",C9ORF72 repeat expansions in cases with previously identified pathogenic mutations.,"To identify potential genetic modifiers contributing to the phenotypic variability that is detected in patients with repeat expansions in chromosome 9 open reading frame 72 (C9ORF72), we investigated the frequency of these expansions in a cohort of 334 subjects previously found to carry mutations in genes known to be associated with a spectrum of neurodegenerative diseases.
A 2-step protocol, with a fluorescent PCR and a repeat-primed PCR, was used to determine the presence of hexanucleotide expansions in C9ORF72. For one double mutant, we performed Southern blots to assess expansion sizes, and immunohistochemistry to characterize neuropathology.
We detected C9ORF72 repeat expansions in 4 of 334 subjects (1.2% [or 1.8% of 217 families]). All these subjects had behavioral phenotypes and also harbored well-known pathogenic mutations in either progranulin (GRN: p.C466LfsX46, p.R493X, p.C31LfsX35) or microtubule-associated protein tau (MAPT: p.P301L). Southern blotting of one double mutant with a p.C466LfsX46 GRN mutation demonstrated a long repeat expansion in brain (>3,000 repeats), and immunohistochemistry showed mixed neuropathology with characteristics of both C9ORF72 expansions and GRN mutations.
Our findings indicate that co-occurrence of 2 evidently pathogenic mutations could contribute to the pleiotropy that is detected in patients with C9ORF72 repeat expansions. These findings suggest that patients with known mutations should not be excluded from further studies, and that genetic counselors should be aware of this phenomenon when advising patients and their family members.",[],Neurology,2013-09-13,"[{'lastname': 'van Blitterswijk', 'firstname': 'Marka', 'initials': 'M', 'affiliation': ""From the Departments of Neuroscience (M.v.B., M.C.B., M.D.-H., M.E.M., N.J.R., P.E.B., T.R., B.M., P.E.A.A., K.F.B., L.P., D.W.D., R.R.) and Neurology (Z.K.W., K.B.B., N.R.G.-R.), Mayo Clinic, Jacksonville, FL; Proteomics Unit and NeuroBioGen Lab-Memory Clinic (R.G., L.B., G.B.), IRCCS Istituto Centro San Giovanni di Dio-Fatebenefratelli, Brescia, Italy; Department of Clinical Neurological Sciences (E.F., M.J.S.), Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Canada; Division of Neurology (G.-Y.R.H.), and Department of Pathology and Laboratory Medicine (I.R.M.), University of British Columbia, Vancouver, Canada; Department of Neurology (B.J.K., D.S.K., R.C.P., B.F.B.), Mayo Clinic, Rochester, MN; Department of Pathology and Alzheimer's Disease Center (K.J.H., C.L.W.), University of Texas Southwestern Medical Center, Dallas; Department of Neurology (A.K., B.L.M.), University of California, San Francisco; Center for Neurodegenerative Disease Research (E.M.W., V.M.V.D.), Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia; Department of Neurology (G.C., D.H.G.), The David Geffen School of Medicine at University of California, Los Angeles; Cognitive Neurology & Alzheimer Disease Center (E.H.B., M.M.), Northwestern University Feinberg School of Medicine, Chicago, IL; Department of Neurology (C.L.), Drexel University College of Medicine, Philadelphia, PA; Molecular Brain Research Group (M.J.S.), Robarts Research Institute, London, Canada; Banner Sun Health Research Institute (T.G.B.), Sun City, AZ; Cognitive Neuroscience Section (E.D.H.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Departments of Psychiatry and Neurology (E.D.H.), Columbia University, New York; and Department of Neurology (T.B.), University of Washington School of Medicine, Seattle.""}, {'lastname': 'Baker', 'firstname': 'Matthew C', 'initials': 'MC', 'affiliation': None}, {'lastname': 'DeJesus-Hernandez', 'firstname': 'Mariely', 'initials': 'M', 'affiliation': None}, {'lastname': 'Ghidoni', 'firstname': 'Roberta', 'initials': 'R', 'affiliation': None}, {'lastname': 'Benussi', 'firstname': 'Luisa', 'initials': 'L', 'affiliation': None}, {'lastname': 'Finger', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': None}, {'lastname': 'Hsiung', 'firstname': 'Ging-Yuek R', 'initials': 'GY', 'affiliation': None}, {'lastname': 'Kelley', 'firstname': 'Brendan J', 'initials': 'BJ', 'affiliation': None}, {'lastname': 'Murray', 'firstname': 'Melissa E', 'initials': 'ME', 'affiliation': None}, {'lastname': 'Rutherford', 'firstname': 'Nicola J', 'initials': 'NJ', 'affiliation': None}, {'lastname': 'Brown', 'firstname': 'Patricia E', 'initials': 'PE', 'affiliation': None}, {'lastname': 'Ravenscroft', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': None}, {'lastname': 'Mullen', 'firstname': 'Bianca', 'initials': 'B', 'affiliation': None}, {'lastname': 'Ash', 'firstname': 'Peter E A', 'initials': 'PE', 'affiliation': None}, {'lastname': 'Bieniek', 'firstname': 'Kevin F', 'initials': 'KF', 'affiliation': None}, {'lastname': 'Hatanpaa', 'firstname': 'Kimmo J', 'initials': 'KJ', 'affiliation': None}, {'lastname': 'Karydas', 'firstname': 'Anna', 'initials': 'A', 'affiliation': None}, {'lastname': 'Wood', 'firstname': 'Elisabeth McCarty', 'initials': 'EM', 'affiliation': None}, {'lastname': 'Coppola', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': None}, {'lastname': 'Bigio', 'firstname': 'Eileen H', 'initials': 'EH', 'affiliation': None}, {'lastname': 'Lippa', 'firstname': 'Carol', 'initials': 'C', 'affiliation': None}, {'lastname': 'Strong', 'firstname': 'Michael J', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Beach', 'firstname': 'Thomas G', 'initials': 'TG', 'affiliation': None}, {'lastname': 'Knopman', 'firstname': 'David S', 'initials': 'DS', 'affiliation': None}, {'lastname': 'Huey', 'firstname': 'Edward D', 'initials': 'ED', 'affiliation': None}, {'lastname': 'Mesulam', 'firstname': 'Marsel', 'initials': 'M', 'affiliation': None}, {'lastname': 'Bird', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': None}, {'lastname': 'White', 'firstname': 'Charles L', 'initials': 'CL', 'affiliation': None}, {'lastname': 'Kertesz', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': None}, {'lastname': 'Geschwind', 'firstname': 'Dan H', 'initials': 'DH', 'affiliation': None}, {'lastname': 'Van Deerlin', 'firstname': 'Vivianna M', 'initials': 'VM', 'affiliation': None}, {'lastname': 'Petersen', 'firstname': 'Ronald C', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Binetti', 'firstname': 'Giuliano', 'initials': 'G', 'affiliation': None}, {'lastname': 'Miller', 'firstname': 'Bruce L', 'initials': 'BL', 'affiliation': None}, {'lastname': 'Petrucelli', 'firstname': 'Leonard', 'initials': 'L', 'affiliation': None}, {'lastname': 'Wszolek', 'firstname': 'Zbigniew K', 'initials': 'ZK', 'affiliation': None}, {'lastname': 'Boylan', 'firstname': 'Kevin B', 'initials': 'KB', 'affiliation': None}, {'lastname': 'Graff-Radford', 'firstname': 'Neill R', 'initials': 'NR', 'affiliation': None}, {'lastname': 'Mackenzie', 'firstname': 'Ian R', 'initials': 'IR', 'affiliation': None}, {'lastname': 'Boeve', 'firstname': 'Bradley F', 'initials': 'BF', 'affiliation': None}, {'lastname': 'Dickson', 'firstname': 'Dennis W', 'initials': 'DW', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': None}]",,,"We detected C9ORF72 repeat expansions in 4 of 334 subjects (1.2% [or 1.8% of 217 families]). All these subjects had behavioral phenotypes and also harbored well-known pathogenic mutations in either progranulin (GRN: p.C466LfsX46, p.R493X, p.C31LfsX35) or microtubule-associated protein tau (MAPT: p.P301L). Southern blotting of one double mutant with a p.C466LfsX46 GRN mutation demonstrated a long repeat expansion in brain (>3,000 repeats), and immunohistochemistry showed mixed neuropathology with characteristics of both C9ORF72 expansions and GRN mutations.",,10.1212/WNL.0b013e3182a8250c,<Element 'PubmedArticle' at 0x7f05d9246ef0>
265,"23895348
8801538
22784036
9394684
7936061
7566337
18688087
20831921
18813209
22078238
17430246
9619505
18430992
15576490
11052823
20666730
18367451
19429119
19166821
18801339
14709788
17076761
10814526
18358569
14698759
22211890
17070506
16998902
20009056
8665687
17039473
19491239
18336525
10579368
19724019
9755363
21335656
10190820
11173891
10684907
12482897
19387109
22555794
10334302
22105948
11214857",Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance.,"Leptin signaling has received considerable attention in the Alzheimer disease (AD) field. Within the past decade, the peptide hormone has been demonstrated to attenuate tau hyperphosphorylation in neuronal cells and to be modulated by amyloid-β. Moreover, a role in neuroprotection and neurogenesis within the hippocampus has been shown in animal models. To further characterize the association between leptin signaling and vulnerable regions in AD, we assessed the profile of leptin and the leptin receptor in AD and control patients. We analyzed leptin levels in CSF, and the concentration and localization of leptin and leptin receptor in the hippocampus. Significant elevations in leptin levels in both CSF and hippocampal tissue of AD patients, compared with age-matched control cases, indicate a physiological up-regulation of leptin in AD. However, the level of leptin receptor mRNA decreased in AD brain and the leptin receptor protein was localized to neurofibrillary tangles, suggesting a severe discontinuity in the leptin signaling pathway. Collectively, our results suggest that leptin resistance in the hippocampus may play a role in the characteristic changes associated with the disease. These findings are the first to demonstrate such dysregulated leptin-signaling circuitry and provide novel insights into the possible role of aberrant leptin signaling in AD. In this study, increased leptin was found in CSF and hippocampus in Alzheimer disease indicating its physiological up-regulation, yet leptin receptor mRNA was decreased and leptin receptor protein was localized to neurofibrillary tangles, suggesting a discontinuity in the leptin signaling pathway. The lack of leptin signaling within degenerating neurons may represent a novel neuronal leptin resistance in Alzheimer disease.","['Alzheimer disease', 'leptin', 'leptin receptor', 'neurofibrillary tangles', 'tau']",Journal of neurochemistry,2013-07-31,"[{'lastname': 'Bonda', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.'}, {'lastname': 'Stone', 'firstname': 'Jeremy G', 'initials': 'JG', 'affiliation': None}, {'lastname': 'Torres', 'firstname': 'Sandy L', 'initials': 'SL', 'affiliation': None}, {'lastname': 'Siedlak', 'firstname': 'Sandra L', 'initials': 'SL', 'affiliation': None}, {'lastname': 'Perry', 'firstname': 'George', 'initials': 'G', 'affiliation': None}, {'lastname': 'Kryscio', 'firstname': 'Richard', 'initials': 'R', 'affiliation': None}, {'lastname': 'Jicha', 'firstname': 'Gregory', 'initials': 'G', 'affiliation': None}, {'lastname': 'Casadesus', 'firstname': 'Gemma', 'initials': 'G', 'affiliation': None}, {'lastname': 'Smith', 'firstname': 'Mark A', 'initials': 'MA', 'affiliation': None}, {'lastname': 'Zhu', 'firstname': 'Xiongwei', 'initials': 'X', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Hyoung-Gon', 'initials': 'HG', 'affiliation': None}]",,,,© 2013 International Society for Neurochemistry.,10.1111/jnc.12380,<Element 'PubmedArticle' at 0x7f05d91f0a40>
266,"23856323
17803017
2914155
21869460
10586975
17912249
18607201
16944667
21225347
17151169
3953862
18761360
9231952
15283960
18571864
19742409
12773581
16943563
16014798
21907245
9739118
16467370
19779148
15659808
15033418
21875679
10483925
15000414
17135354
12895417
20713712
16423541
17713353
17919293
11257240
21855175
15059975
19070401
10716540
17983292
11036168
12683469
16177036
8871772
2365965
11329390
17406317","Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical Aβ and pTau in a mouse model of Alzheimer's disease.","Age-associated dysregulation of sleep can be worsened by Alzheimer's disease (AD). AD and sleep restriction both impair cognition, yet it is unknown if mild chronic sleep restriction modifies the proteopathic processes involved in AD. The goal of this work was to test the hypothesis that sleep restriction worsens memory impairments, and amyloid β-peptide (Aβ) and pTau accumulations in the brain in a mouse model of AD, with a focus on a role for circulating glucocorticoids (GC). Male 3xTgAD mice were subjected to sleep restriction (SR) for 6h/day for 6 weeks using the modified multiple platform technique, and behavioral (Morris water maze, fear conditioning, open field) and biochemical (immunoblot) outcomes were compared to mice undergoing daily cage transfers (large cage control; LCC) as well as control mice that remained in their home cage (control; CTL). At one week, both LCC and SR mice displayed significant elevations in plasma corticosterone compared to CTL (p<0.002). By four weeks, SR mice displayed a two-fold increase in circulating corticosterone levels compared to CTL. Behavioral data indicated deficits in contextual and cued memory in SR mice that were not present for LCC or CTL (p<0.04). Both Aβ and pTau levels increased in the cortex of SR mice compared to CTL and LCC; however these changes were not noted in the hippocampus. Significant positive correlations between cortical Aβ and pTau levels and circulating corticosterone indicate a potential role for GCs in mediating behavioral and biochemical changes observed after sleep restriction in a mouse model of AD.","['AD', 'Alzheimer′s disease', 'Amyloid', 'Aβ', 'CTL', 'Fear conditioning', 'GC', 'Glucocorticoids', 'LCC', 'MMP', 'MWM', 'Morris water maze', 'SR', 'Sleep restriction', 'amyloid beta', 'control', 'glucocorticoid', 'large cage control', 'modified multiple platform', 'pTau', 'phosphorylated tau', 'sleep restriction']",Brain research,2013-07-17,"[{'lastname': 'Rothman', 'firstname': 'Sarah M', 'initials': 'SM', 'affiliation': 'Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, National Institutes of Health, 251 Bayview Blvd. Baltimore, MD 21224, USA.'}, {'lastname': 'Herdener', 'firstname': 'Nathan', 'initials': 'N', 'affiliation': None}, {'lastname': 'Frankola', 'firstname': 'Kathryn A', 'initials': 'KA', 'affiliation': None}, {'lastname': 'Mughal', 'firstname': 'Mohamed R', 'initials': 'MR', 'affiliation': None}, {'lastname': 'Mattson', 'firstname': 'Mark P', 'initials': 'MP', 'affiliation': None}]",,,,Published by Elsevier B.V.,10.1016/j.brainres.2013.07.010,<Element 'PubmedArticle' at 0x7f05d9210040>
267,23812288,"HPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matter.","The hypothalamus-pituitary-adrenal (HPA) axis is activated in most, but not all multiple sclerosis (MS) patients and is implicated in disease progression and comorbid mood disorders. In this post-mortem study, we investigated how HPA axis activity in MS is related to disease severity, neurodegeneration, depression, lesion pathology and gene expression in normal-appearing white matter (NAWM). In 42 MS patients, HPA axis activity was determined by measuring cortisol in cerebrospinal fluid (CSF) and counting hypothalamic corticotropin-releasing hormone (CRH)-expressing neurons. Degree of neurodegeneration was based on levels of glutamate, tau and neurofilament in CSF. Duration of MS and time to EDSS 6 served as indicators of disease severity. Glutamate levels correlated with numbers of CRH-expressing neurons, most prominently in primary progressive MS patients, suggesting that neurodegeneration is a strong determinant of HPA axis activity. High cortisol levels were associated with slower disease progression, especially in females with secondary progressive MS. Patients with low cortisol levels had greater numbers of active lesions and tended towards having less remyelinated plaques than patients with high cortisol levels. Interestingly, NAWM of patients with high cortisol levels displayed elevated expression of glucocorticoid-responsive genes, such as CD163, and decreased expression of pro-inflammatory genes, such as tumor necrosis factor-α. Thus, HPA axis hyperactivity in MS coincides with low inflammation and/or high neurodegeneration, and may impact on lesion pathology and molecular mechanisms in NAWM and thereby be of great importance for suppression of disease activity.",[],Acta neuropathologica,2013-07-03,"[{'lastname': 'Melief', 'firstname': 'Jeroen', 'initials': 'J', 'affiliation': 'Department of Neuroimmunology, Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA, Amsterdam, The Netherlands. j.melief@nin.knaw.nl'}, {'lastname': 'de Wit', 'firstname': 'Stella J', 'initials': 'SJ', 'affiliation': None}, {'lastname': 'van Eden', 'firstname': 'Corbert G', 'initials': 'CG', 'affiliation': None}, {'lastname': 'Teunissen', 'firstname': 'Charlotte', 'initials': 'C', 'affiliation': None}, {'lastname': 'Hamann', 'firstname': 'Jörg', 'initials': 'J', 'affiliation': None}, {'lastname': 'Uitdehaag', 'firstname': 'Bernard M', 'initials': 'BM', 'affiliation': None}, {'lastname': 'Swaab', 'firstname': 'Dick', 'initials': 'D', 'affiliation': None}, {'lastname': 'Huitinga', 'firstname': 'Inge', 'initials': 'I', 'affiliation': None}]",,,,,10.1007/s00401-013-1140-7,<Element 'PubmedArticle' at 0x7f05d91b2d60>
268,"23804503
12574618
16524713
15178768
15010446
14742838
21686173
15681386
14698276
469859
1741934
3365252
1913653
7544384
9143236
18608174
23050969
18483478
16249451
15795423
8742364
7533735
19106310
12125354
3666283
18029483
1764469
21547361
10900012
18564175
21196250
14715917
20448535
17473055
20374957
16369774
22560213
22429824
15509890
14988435
9689151
11949882
11015490
17476214
19574505
23553707",Oral administration of interferon tau enhances oxidation of energy substrates and reduces adiposity in Zucker diabetic fatty rats.,"Male Zucker diabetic fatty (ZDF) rats were used to study effects of oral administration of interferon tau (IFNT) in reducing obesity. Eighteen ZDF rats (28 days of age) were assigned randomly to receive 0, 4, or 8 μg IFNT/kg body weight (BW) per day (n = 6/group) for 8 weeks. Water consumption was measured every two days. Food intake and BW were recorded weekly. Energy expenditure in 4-, 6-, 8-, and 10-week-old rats was determined using indirect calorimetry. Starting at 7 weeks of age, urinary glucose, and ketone bodies were tested daily. Rates of glucose and oleate oxidation in liver, brown adipose tissue, and abdominal adipose tissue, as well as leucine catabolism in skeletal muscle, and lipolysis in white and brown adipose tissues were greater for rats treated with 8 μg IFNT/kg BW/day in comparison with control rats. Treatment with 8 μg IFNT/kg BW/day increased heat production, reduced BW gain and adiposity, ameliorated fatty liver syndrome, delayed the onset of diabetes, and decreased concentrations of glucose, free fatty acids, triacylglycerol, cholesterol, and branched-chain amino acids in plasma, compared with control rats. Oral administration of 8 µg IFNT/kg BW/day ameliorated oxidative stress in skeletal muscle, liver, and adipose tissue, as indicated by decreased ratios of oxidized glutathione to reduced glutathione and increased concentrations of tetrahydrobiopterin. These results indicate that IFNT stimulates oxidation of energy substrates and reduces obesity in ZDF rats and may have broad important implications for preventing and treating obesity-related diseases in mammals.","['diabetes', 'energy expenditure', 'interferon tau', 'obesity', 'tissue oxidation']","BioFactors (Oxford, England)",2013-06-28,"[{'lastname': 'Tekwe', 'firstname': 'Carmen D', 'initials': 'CD', 'affiliation': 'Department of Animal Science, Texas A&M University, College Station, TX, USA; Department of Statistics, Texas A&M University, College Station, TX, USA; Faculty of Nutrition, Texas A&M University, College Station, TX, USA.'}, {'lastname': 'Lei', 'firstname': 'Jian', 'initials': 'J', 'affiliation': None}, {'lastname': 'Yao', 'firstname': 'Kang', 'initials': 'K', 'affiliation': None}, {'lastname': 'Rezaei', 'firstname': 'Reza', 'initials': 'R', 'affiliation': None}, {'lastname': 'Li', 'firstname': 'Xilong', 'initials': 'X', 'affiliation': None}, {'lastname': 'Dahanayaka', 'firstname': 'Sudath', 'initials': 'S', 'affiliation': None}, {'lastname': 'Carroll', 'firstname': 'Raymond J', 'initials': 'RJ', 'affiliation': None}, {'lastname': 'Meininger', 'firstname': 'Cynthia J', 'initials': 'CJ', 'affiliation': None}, {'lastname': 'Bazer', 'firstname': 'Fuller W', 'initials': 'FW', 'affiliation': None}, {'lastname': 'Wu', 'firstname': 'Guoyao', 'initials': 'G', 'affiliation': None}]",,,,"© 2013 International Union of Biochemistry and Molecular Biology, Inc.","10.1002/biof.1113
10.1002/biof.1099",<Element 'PubmedArticle' at 0x7f05d91c1860>
269,"23798570
18090421
17015226
20645878
21840887
20410196
19013502
19322681
20545634
12586554
16723044
21325651
22578468
22674539
15349867
22289667
21487420
19556136
21031579
19924424
20479357
21810890
12058088
16244655
21837549
22890575
22732134
23383382
18309045
21497181
22608070
19833869",Endogenous progesterone levels and frontotemporal dementia: modulation of TDP-43 and Tau levels in vitro and treatment of the A315T TARDBP mouse model.,"Frontotemporal dementia (FTD) is associated with motor neurone disease (FTD-MND), corticobasal syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). Together, this group of disorders constitutes a major cause of young-onset dementia. One of the three clinical variants of FTD is progressive nonfluent aphasia (PNFA), which is focused on in this study. The steroid hormone progesterone (PROG) is known to have an important role as a neurosteroid with potent neuroprotective and promyelination properties. In a case-control study of serum samples (39 FTD, 91 controls), low serum PROG was associated with FTD overall. In subgroup analysis, low PROG levels were significantly associated with FTD-MND and CBS, but not with PSPS or PNFA. PROG levels of >195 pg/ml were significantly correlated with lower disease severity (frontotemporal dementia rating scale) for individuals with CBS. In the human neuroblastoma SK-N-MC cell line, exogenous PROG (9300-93,000 pg/ml) had a significant effect on overall Tau and nuclear TDP-43 levels, reducing total Tau levels by ∼1.5-fold and increasing nuclear TDP-43 by 1.7- to 2.0-fold. Finally, elevation of plasma PROG to a mean concentration of 5870 pg/ml in an Ala315Thr (A315T) TARDBP transgenic mouse model significantly reduced the rate of loss of locomotor control in PROG-treated, compared with placebo, mice. The PROG treatment did not significantly increase survival of the mice, which might be due to the limitation of the transgenic mouse to accurately model TDP-43-mediated neurodegeneration. Together, our clinical, cellular and animal data provide strong evidence that PROG could be a valid therapy for specific related disorders of FTD.",[],Disease models & mechanisms,2013-06-27,"[{'lastname': 'Dang', 'firstname': 'Theresa N T', 'initials': 'TN', 'affiliation': 'Department of Pathology, The University of Melbourne, Victoria 3010, Australia.'}, {'lastname': 'Dobson-Stone', 'firstname': 'Carol', 'initials': 'C', 'affiliation': None}, {'lastname': 'Glaros', 'firstname': 'Elias N', 'initials': 'EN', 'affiliation': None}, {'lastname': 'Kim', 'firstname': 'Woojin S', 'initials': 'WS', 'affiliation': None}, {'lastname': 'Hallupp', 'firstname': 'Marianne', 'initials': 'M', 'affiliation': None}, {'lastname': 'Bartley', 'firstname': 'Lauren', 'initials': 'L', 'affiliation': None}, {'lastname': 'Piguet', 'firstname': 'Olivier', 'initials': 'O', 'affiliation': None}, {'lastname': 'Hodges', 'firstname': 'John R', 'initials': 'JR', 'affiliation': None}, {'lastname': 'Halliday', 'firstname': 'Glenda M', 'initials': 'GM', 'affiliation': None}, {'lastname': 'Double', 'firstname': 'Kay L', 'initials': 'KL', 'affiliation': None}, {'lastname': 'Schofield', 'firstname': 'Peter R', 'initials': 'PR', 'affiliation': None}, {'lastname': 'Crouch', 'firstname': 'Peter J', 'initials': 'PJ', 'affiliation': None}, {'lastname': 'Kwok', 'firstname': 'John B J', 'initials': 'JB', 'affiliation': None}]",,,,,10.1242/dmm.011460,<Element 'PubmedArticle' at 0x7f05d9161450>
270,"23640454
8800646
22476197
11005876
12946706
12420363
2819907
19041902
12882908
1313498
9114067
19279000
19444259
3033647
19617854
15974903
12925848
15270203
22344583
16672274
15748844
16908998
16125228
12895417
16534527
2310495
20308787
17125767
9883847
22393443
17708691
19667196
12515900
20951130
22476196
20005285
23254291
21368864
21423579
21368863
12871671
22944173
16178023
19682525
17659525
2990038
14600437
12668764
9778565
18971930
21376239
21541279
22948140
8865078
6018717
942051
18538643",Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.,"Recent studies have shown that type 2 diabetes mellitus (T2DM) is a risk factor for cognitive dysfunction or dementia. Insulin resistance is often associated with T2DM and can induce defective insulin signaling in the central nervous system as well as increase the risk of cognitive impairment in the elderly. Glucagone like peptide-1 (GLP-1) is an incretin hormone and, like GLP-1 analogs, stimulates insulin secretion and has been employed in the treatment of T2DM. GLP-1 and GLP-1 analogs also enhance synaptic plasticity and counteract cognitive deficits in mouse models of neuronal dysfunction and/or degeneration. In this study, we investigated the potential neuroprotective effects of long-term treatment with exenatide, a GLP-1 analog, in two animal models of neuronal dysfunction: the PS1-KI and 3xTg-AD mice. We found that exenatide promoted beneficial effects on short- and long-term memory performances in PS1-KI but not in 3xTg-AD animals. In PS1-KI mice, the drug increased brain lactate dehydrogenase activity leading to a net increase in lactate levels, while no effects were observed on mitochondrial respiration. On the contrary, exenatide had no effects on brain metabolism of 3xTg-AD mice. In summary, our data indicate that exenatide improves cognition in PS1-KI mice, an effect likely driven by increasing the brain anaerobic glycolysis rate.",[],Cell death & disease,2013-05-04,"[{'lastname': 'Bomba', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Molecular Neurology Unit, Center of Excellence on Aging (CeSI), University Gd Annunzio Chieti-Pescara, Chieti, Italy.'}, {'lastname': 'Ciavardelli', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Silvestri', 'firstname': 'E', 'initials': 'E', 'affiliation': None}, {'lastname': 'Canzoniero', 'firstname': 'L M T', 'initials': 'LM', 'affiliation': None}, {'lastname': 'Lattanzio', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Chiappini', 'firstname': 'P', 'initials': 'P', 'affiliation': None}, {'lastname': 'Piantelli', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Di Ilio', 'firstname': 'C', 'initials': 'C', 'affiliation': None}, {'lastname': 'Consoli', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Sensi', 'firstname': 'S L', 'initials': 'SL', 'affiliation': None}]",,,,,10.1038/cddis.2013.139,<Element 'PubmedArticle' at 0x7f05d917c9a0>
271,23613616,Maternal taurine supplementation in rats partially prevents the adverse effects of early-life protein deprivation on β-cell function and insulin sensitivity.,"Dietary protein restriction during pregnancy and lactation in rats impairs β-cell function and mass in neonates and leads to glucose intolerance in adult offspring. Maternal taurine (Tau) supplementation during pregnancy in rats restores β-cell function and mass in neonates, but its long-term effects are unclear. The prevention of postnatal catch-up growth has been suggested to improve glucose tolerance in adult offspring of low-protein (LP)-fed mothers. The objective of this study was to examine the relative contribution of β-cell dysfunction and insulin resistance to impaired glucose tolerance in 130-day-old rat offspring of LP-fed mothers and the effects of maternal Tau supplementation on β-cell function and insulin resistance in these offspring. Pregnant rats were fed i) control, ii) LP, and iii) LP+Tau diets during gestation and lactation. Offspring were given a control diet following weaning. A fourth group consisting of offspring of LP-fed mothers, maintained on a LP diet following weaning, was also studied (LP-all life). Insulin sensitivity in the offspring of LP-fed mothers was reduced in females but not in males. In both genders, LP exposure decreased β-cell function. Tau supplementation improved insulin sensitivity in females and β-cell function in males. The LP-all life diet improved β-cell function in males. We conclude that i) maternal Tau supplementation has persistent effects on improving glucose metabolism (β-cell function and insulin sensitivity) in adult rat offspring of LP-fed mothers and ii) increasing the amount of protein in the diet of offspring adapted to a LP diet after weaning may impair glucose metabolism (β-cell function) in a gender-specific manner.",[],"Reproduction (Cambridge, England)",2013-04-25,"[{'lastname': 'Tang', 'firstname': 'Christine', 'initials': 'C', 'affiliation': 'Department of Physiology, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Marchand', 'firstname': 'Kelly', 'initials': 'K', 'affiliation': None}, {'lastname': 'Lam', 'firstname': 'Loretta', 'initials': 'L', 'affiliation': None}, {'lastname': 'Lux-Lantos', 'firstname': 'Victoria', 'initials': 'V', 'affiliation': None}, {'lastname': 'Thyssen', 'firstname': 'Sandra M', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Guo', 'firstname': 'June', 'initials': 'J', 'affiliation': None}, {'lastname': 'Giacca', 'firstname': 'Adria', 'initials': 'A', 'affiliation': None}, {'lastname': 'Arany', 'firstname': 'Edith', 'initials': 'E', 'affiliation': None}]",,,,,10.1530/REP-12-0388,<Element 'PubmedArticle' at 0x7f05d9123130>
272,"23609919
1202204
10860804
17761438
9330978
1759558
21644037
18412267
18245784
17826340
17278999
18565828
19625741
21212639
19016491
17620546
16950801
20186853
21892758
21645364
20026663
21393509
17536046
12383924
11513911
18701698
19738171
17255335
18974297
17724122
20971085
18759972
18401022
18520774
21070634",Progranulin mutations as risk factors for Alzheimer disease.,"Mutations in the progranulin gene are known to cause diverse clinical syndromes, all attributed to frontotemporal lobar degeneration. We describe 2 patients with progranulin gene mutations and evidence of Alzheimer disease (AD) pathology. We also conducted a literature review.
This study focused on case reports of 2 unrelated patients with progranulin mutations at the University of California, San Francisco, Memory and Aging Center. One patient presented at age 65 years with a clinical syndrome suggestive of AD and showed evidence of amyloid aggregation on positron emission tomography. Another patient presented at age 54 years with logopenic progressive aphasia and, at autopsy, showed both frontotemporal lobar degeneration with TDP-43 inclusions and AD.
In addition to autosomal-dominant frontotemporal lobar degeneration, mutations in the progranulin gene may be a risk factor for AD clinical phenotypes and neuropathology.",[],JAMA neurology,2013-04-24,"[{'lastname': 'Perry', 'firstname': 'David C', 'initials': 'DC', 'affiliation': 'Department of Neurology, University of California, San Francisco, CA 94158, USA. dperry@memory.ucsf.edu'}, {'lastname': 'Lehmann', 'firstname': 'Manja', 'initials': 'M', 'affiliation': None}, {'lastname': 'Yokoyama', 'firstname': 'Jennifer S', 'initials': 'JS', 'affiliation': None}, {'lastname': 'Karydas', 'firstname': 'Anna', 'initials': 'A', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Jason Jiyong', 'initials': 'JJ', 'affiliation': None}, {'lastname': 'Coppola', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': None}, {'lastname': 'Grinberg', 'firstname': 'Lea T', 'initials': 'LT', 'affiliation': None}, {'lastname': 'Geschwind', 'firstname': 'Dan', 'initials': 'D', 'affiliation': None}, {'lastname': 'Seeley', 'firstname': 'William W', 'initials': 'WW', 'affiliation': None}, {'lastname': 'Miller', 'firstname': 'Bruce L', 'initials': 'BL', 'affiliation': None}, {'lastname': 'Rosen', 'firstname': 'Howard', 'initials': 'H', 'affiliation': None}, {'lastname': 'Rabinovici', 'firstname': 'Gil', 'initials': 'G', 'affiliation': None}]",,,,,10.1001/2013.jamaneurol.393,<Element 'PubmedArticle' at 0x7f05d912e1d0>
273,23603201,Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease.,"Type 2 diabetes (T2D) is one of the major risk factors associated with Alzheimer's disease (AD). Recent studies have found similarities in molecular mechanisms that underlie the respective degenerative developments in the two diseases. Pharmacological agents, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase the level of glucagon-like peptide-1 (GLP-1) and ameliorate T2D, have become valuable candidates as disease modifying agents in the treatment of AD. In addition, endogenous GLP-1 levels decrease amyloid beta (Aβ) peptide and tau phosphorylation in AD. The present study examines the efficacy of Saxagliptin, a DPP-4 inhibitor in a streptozotocin (STZ) induced rat model of AD. Three months following induction of AD by intracerebral administration of streptozotocin, animals were orally administered Saxagliptin (0.25, 0.5 and 1 mg/kg) for 60 days. The effect of the DPP-4 inhibitor on hippocampal GLP-1 levels, Aβ burden, tau phosphorylation, inflammatory markers and memory retention were evaluated. The results reveal an attenuation of Aβ, tau phosphorylation and inflammatory markers and an improvement in hippocampal GLP-1 and memory retention following treatment. This remarkable therapeutic effect of Saxagliptin mediated through DPP-4 inhibition demonstrates a unique mechanism for Aβ and tau clearance by increasing GLP-1 levels and reverses the behavioural deficits and pathology observed in AD.",[],Neuropharmacology,2013-04-23,"[{'lastname': 'Kosaraju', 'firstname': 'Jayasankar', 'initials': 'J', 'affiliation': 'Department of Pharmacognosy, JSS College of Pharmacy, Udhagamandalam, Tamilnadu 643001, India. jayasankar87@hotmail.com'}, {'lastname': 'Gali', 'firstname': 'Chaitanya Chakravarthi', 'initials': 'CC', 'affiliation': None}, {'lastname': 'Khatwal', 'firstname': 'Rizwan Basha', 'initials': 'RB', 'affiliation': None}, {'lastname': 'Dubala', 'firstname': 'Anil', 'initials': 'A', 'affiliation': None}, {'lastname': 'Chinni', 'firstname': 'Santhivardhan', 'initials': 'S', 'affiliation': None}, {'lastname': 'Holsinger', 'firstname': 'R M Damian', 'initials': 'RM', 'affiliation': None}, {'lastname': 'Madhunapantula', 'firstname': 'V Subba Rao', 'initials': 'VS', 'affiliation': None}, {'lastname': 'Muthureddy Nataraj', 'firstname': 'Satish Kumar', 'initials': 'SK', 'affiliation': None}, {'lastname': 'Basavan', 'firstname': 'Duraiswamy', 'initials': 'D', 'affiliation': None}]",,,,Copyright © 2013 Elsevier Ltd. All rights reserved.,10.1016/j.neuropharm.2013.04.008,<Element 'PubmedArticle' at 0x7f05d914b040>
274,23478312,Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy.,"Cannabinoids are neuroprotective in models of neurodegenerative dementias. Their effects are mostly mediated through CB1 and CB2 receptor-dependent modulation of excitotoxicity, inflammation, oxidative stress, and other processes. We tested the effects of Sativex®, a mixture of Δ9-tetrahydrocannabinol and cannabidiol, acting on both CB1 and CB2 receptors, in parkin-null, human tau overexpressing (PK-/-/TauVLW) mice, a model of complex frontotemporal dementia, parkinsonism, and lower motor neuron disease. The animals received Sativex®, 4.63 mg/kg, ip, daily, for one month, at six months of age, at the onset of the clinical symptoms. We evaluated the effects of Sativex® on behavior, dopamine neurotransmission, glial activation, redox state, mitochondrial activity, and deposition of abnormal proteins. PK-/-/TauVLW mice developed the neurological deficits, but those treated with Sativex® showed less abnormal behaviors related to stress, less auto and hetero-aggression, and less stereotypy. Sativex® significantly reduced the intraneuronal, MAO-related free radicals produced during dopamine metabolism in the limbic system. Sativex® also decreased gliosis in cortex and hippocampus, increased the ratio reduced/oxidized glutathione in the limbic system, reduced the levels of iNOS, and increased those of complex IV in the cerebral cortex. With regard to tau and amyloid pathology, Sativex® reduced the deposition of both in the hippocampus and cerebral cortex of PK-/-/TauVLW mice and increased autophagy. Sativex®, even after a short administration in animals with present behavioral and pathological abnormalities, improves the phenotype, the oxidative stress, and the deposition of proteins in PK-/-/TauVLW mice, a model of complex neurodegenerative disorders.",[],Journal of Alzheimer's disease : JAD,2013-03-13,"[{'lastname': 'Casarejos', 'firstname': 'Maria J', 'initials': 'MJ', 'affiliation': 'Department of Neurobiology, Ramon y Cajal University Hospital, Ctra. de Colmenar Km. 9, Madrid, Spain.'}, {'lastname': 'Perucho', 'firstname': 'Juan', 'initials': 'J', 'affiliation': None}, {'lastname': 'Gomez', 'firstname': 'Ana', 'initials': 'A', 'affiliation': None}, {'lastname': 'Muñoz', 'firstname': 'Maria P', 'initials': 'MP', 'affiliation': None}, {'lastname': 'Fernandez-Estevez', 'firstname': 'Marian', 'initials': 'M', 'affiliation': None}, {'lastname': 'Sagredo', 'firstname': 'Onintza', 'initials': 'O', 'affiliation': None}, {'lastname': 'Fernandez Ruiz', 'firstname': 'Javier', 'initials': 'J', 'affiliation': None}, {'lastname': 'Guzman', 'firstname': 'Manuel', 'initials': 'M', 'affiliation': None}, {'lastname': 'de Yebenes', 'firstname': 'Justo Garcia', 'initials': 'JG', 'affiliation': None}, {'lastname': 'Mena', 'firstname': 'Maria A', 'initials': 'MA', 'affiliation': None}]",,,,,10.3233/JAD-130050,<Element 'PubmedArticle' at 0x7f05d9157ef0>
275,23402899,Disease-modified glycogen synthase kinase-3β intervention by melatonin arrests the pathology and memory deficits in an Alzheimer's animal model.,"The current therapies for Alzheimer's disease (AD) are merely palliative that cannot arrest the pathologic progression of the disease. Therefore, it is critical to develop treatments that can target the disease-modifying molecule(s). In the present study, we found that treatment of tg2576 mice with melatonin from 4-8 months of age did not improve the pathology or behavioral performance of the mice. However, remarkable attenuation of tau and β-amyloid pathologies with memory improvement were observed when melatonin was supplied from the age of 8-12 months or 4-12 months of the mice; more importantly, the improvements were still significant when the mice survived to old age. We also found that the disease stage-specific alteration of glycogen synthase kinase-3β (GSK-3β) but not protein phosphatase-2A, was correlated with the alterations of the pathology and behavior, and the timely targeting of GSK-3β was critical for the efficacy of melatonin. Our finding suggests that melatonin treatment only at proper timing could arrest AD by targeting the activated GSK-3β, which provides primary evidence for the importance and strategy in developing disease-modifying interventions of AD.",[],Neurobiology of aging,2013-02-14,"[{'lastname': 'Peng', 'firstname': 'Cai-Xia', 'initials': 'CX', 'affiliation': 'Pathophysiology Department, Key Laboratory of Education Ministry for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,\xa0P.R. China.'}, {'lastname': 'Hu', 'firstname': 'Juan', 'initials': 'J', 'affiliation': None}, {'lastname': 'Liu', 'firstname': 'Dan', 'initials': 'D', 'affiliation': None}, {'lastname': 'Hong', 'firstname': 'Xiao-Ping', 'initials': 'XP', 'affiliation': None}, {'lastname': 'Wu', 'firstname': 'Yuan-Yuan', 'initials': 'YY', 'affiliation': None}, {'lastname': 'Zhu', 'firstname': 'Ling-Qiang', 'initials': 'LQ', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Jian-Zhi', 'initials': 'JZ', 'affiliation': None}]",,,,Copyright © 2013 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2012.12.010,<Element 'PubmedArticle' at 0x7f05d90e5310>
276,23392948,Comparative evaluation of taurine and thiotaurine as protectants against diabetes-induced nephropathy in a rat model.,"Taking into account the proven effectiveness of antioxidants in preventing experimentally induced diabetes in laboratory animals, this study was carried out with the specific purpose of comparing the effectiveness of two known antioxidants, the β-aminosulfonate taurine (TAU) and β-aminothiosulfonate thiotaurine (TTAU), in preventing biochemical, functional and histological alterations indicative of -diabetic nephropathy. In the study, streptozotocin (60 mg/kg, orally) was used to induce type 2 diabetes mellitus in Sprague-Dawley rats. Starting on day 15 and continuing up to day 56, the rats received a daily single 2.4 mmol/kg oral dose of a sulfur-containing compound (TAU or TTAU) or 4 U/kg subcutaneous dose of isophane insulin (INS). Rats not receiving any treatment served as controls. After obtaining a 24 h urine sample, the animals were sacrificed by decapitation on day 57, and their blood and kidneys immediately collected. Diabetic rats exhibited marked hyperglycemia, hypoinsulinemia, hypoproteinemia, hyponatremia, hyperkalemia, azotemia, hypercreatinemia, increased plasma TGF β(1), lipid peroxidation, plasma and kidney nitrite, and urine output; decreased glutathione redox status in plasma and kidney, decreased urine Na(+) and K(+), proteinuria and hypocreatinuria. Without exceptions, all the treatment compounds were found to markedly and variously attenuate these changes. Confirmation of protection by INS, TAU and TTAU was provided by the results of histological examination of kidney sections and which showed a more normal appearance than sections from diabetic animals. In most instances protection by TTAU was about equal to that by INS but greater than that by TAU.",[],Advances in experimental medicine and biology,2013-02-09,"[{'lastname': 'Pandya', 'firstname': 'Kashyap G', 'initials': 'KG', 'affiliation': ""Department of Pharmaceutical Sciences, St. John's University, Jamaica, New York, NY 11439, USA.""}, {'lastname': 'Budhram', 'firstname': 'Roshil', 'initials': 'R', 'affiliation': None}, {'lastname': 'Clark', 'firstname': 'George', 'initials': 'G', 'affiliation': None}, {'lastname': 'Lau-Cam', 'firstname': 'Cesar A', 'initials': 'CA', 'affiliation': None}]",,,,,10.1007/978-1-4614-6130-2_29,<Element 'PubmedArticle' at 0x7f05d90eff40>
277,23392947,The effects of taurine and thiotaurine on oxidative stress in the aorta and heart of diabetic rats.,"This study has compared the actions of the sulfur-containing compounds taurine (TAU) and thiotaurine (TTAU) with those of insulin (INS) on the oxidative stress that develops in the aorta and heart as a result of diabetes. Diabetes was induced in male Sprague-Dawley rats with streptozotocin (60 mg/kg, i.p.). Starting on day 15, and continuing for the next 41 days, the diabetic rats received each day 2 mL of physiological saline or 2.4 mmol/kg/2 mL of TAU (or TTAU) p.o. or 4 U/kg of isophane INS s.c. Normal rats served as controls. The rats were sacrificed on day 57 to collect blood, heart and thoracic aorta samples. Untreated diabetic rats exhibited a lower body weight gain (by 34%), higher than normal plasma glucose (by ∼4-fold), cholesterol (by 66%) and triglycerides (by 188%) levels, and lower INS levels (by 76%). Also there was a marked increase in catalase activity (≥90%); and clear decreases in nitrite (≥40%), glutathione redox status (≥67%), and glutathione peroxidase (≥66%) and superoxide dismutase (≥51%) activities in both the aorta and heart. With only a few isolated instances (plasma lipids), TTAU was either markedly more effective (plasma glucose, plasma INS, aorta and heart glutathione, aorta redox status, and antioxidant enzymes) or marginally more effective (heart redox status) than TAU in attenuating the alterations brought about by diabetes. These results suggest that replacing the sulfonic acid group of TAU by thiosulfonic acid can lead to a greater potency against diabetes-related biochemical changes in the plasma, heart and aorta. However, except for effects on plasma lipids, these sulfur-containing compounds were less effective than INS in counteracting diabetes-related changes.",[],Advances in experimental medicine and biology,2013-02-09,"[{'lastname': 'Mathew', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': ""Department of Pharmaceutical Sciences, St. John's University, Jamaica, New York, NY 11439, USA.""}, {'lastname': 'Barletta', 'firstname': 'Michael A', 'initials': 'MA', 'affiliation': None}, {'lastname': 'Lau-Cam', 'firstname': 'Cesar A', 'initials': 'CA', 'affiliation': None}]",,,,,10.1007/978-1-4614-6130-2_28,<Element 'PubmedArticle' at 0x7f05d90fbdb0>
278,23392946,Protection by taurine and thiotaurine against biochemical and cellular alterations induced by diabetes in a rat model.,"In this study, the actions of taurine (TAU), a sulfonate, and thiotaurine (TTAU), a thiosulfonate, on diabetes-mediated biochemical alterations in red blood cells (RBCs) and plasma and on the RBC membrane, morphology and spectrin distribution were examined in rats. Diabetes was induced in male Sprague-Dawley rats with streptozotocin (60 mg/kg i.p.) and allowed to progress for 14 days. From days to 56, the rats received a daily, 2.4 mmol/kg, oral dose of TAU or TTAU, 2 mL oral dose of physiological saline or 4 U/kg subcutaneous dose of isophane insulin (INS). Naive rats served as the control group. The rats were sacrificed on day 57 and their blood was collected to measure HbA(1c), to isolate intact RBCs, and to obtain plasma. A 6-weeks treatment with INS effectively lowered the elevations in plasma glucose, cholesterol, triglycerides, and plasma and RBC malondialdehyde and glutathione disulfide while effectively counteracting the decreases in plasma INS, plasma and RBC glutathione redox status, and plasma and RBC activities of antioxidant enzymes caused by diabetes. Also, INS returned the echynocytic appearance and peripheral location of spectrin seen in RBCs from diabetic rats to the normal discocytic shape and uniform distribution. TAU and TTAU were as effective as INS in inhibiting malondialdehyde formation, changes in redox status and oxidative stress in both the plasma and RBC, but were much less effective in controlling hyperglycemia and hypoinsulinemia. Furthermore TTAU was more effective than INS or TAU in lowering the increase in cholesterol to phospholipids ratio in the RBC membrane and, unlike TAU, it was able to normalize the RBC morphology and spectrin distribution.",[],Advances in experimental medicine and biology,2013-02-09,"[{'lastname': 'Budhram', 'firstname': 'Roshil', 'initials': 'R', 'affiliation': ""Department of Pharmaceutical Sciences, St. John's University, Jamaica, New York, NY, USA.""}, {'lastname': 'Pandya', 'firstname': 'Kashyap G', 'initials': 'KG', 'affiliation': None}, {'lastname': 'Lau-Cam', 'firstname': 'Cesar A', 'initials': 'CA', 'affiliation': None}]",,,,,10.1007/978-1-4614-6130-2_27,<Element 'PubmedArticle' at 0x7f05d910d090>
279,"23380910
20966215
22508839
23161999
19503072
10804202
21968933
22711819
19892735
21982369
21454603
21624403
21566660
22101366
20064386
22566400
22723400
22646635
6801762
16703338
23280834
3929089
16855204
22607808
12210791
2210615
20437581
3474545
17325383
11357156
14522863
14007012
12714745
1899488
15069388
22002422
20083042
21825215
21514248
8179297
8217779
8086126
18391963
18391962
18391961
19006193
19786018",Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone.,"Growing evidence of cell-to-cell transmission of neurodegenerative disease (ND)-associated proteins (NDAPs) (ie, tau, Aβ, and α-synuclein) suggests possible similarities to the infectious prion protein (PrPsc) in spongiform encephalopathies. There are limited data on the potential human-to-human transmission of NDAPs associated with Alzheimer disease (AD) and other non-PrPsc ND.
To examine evidence for human-to-human transmission of AD, Parkinson disease (PD), and related NDAPs in cadaveric human growth hormone (c-hGH) recipients.
We conducted a detailed immunohistochemical analysis of pathological NDAPs other than PrPsc in human pituitary glands. We also searched for ND in recipients of pituitary-derived c-hGH by reviewing the National Hormone and Pituitary Program (NHPP) cohort database and medical literature.
University-based academic center and agencies of the US Department of Health and Human Services.
Thirty-four routine autopsy subjects (10 non-ND controls and 24 patients with ND) and a US cohort of c-hGH recipients in the NHPP.
Detectable NDAPs in human pituitary sections and death certificate reports of non-PrPsc ND in the NHPP database.
We found mild amounts of pathological tau, Aβ, and α-synuclein deposits in the adeno/neurohypophysis of patients with ND and control patients. No cases of AD or PD were identified, and 3 deaths attributed to amyotrophic lateral sclerosis (ALS) were found among US NHPP c-hGH recipients, including 2 of the 796 decedents in the originally confirmed NHPP c-hGH cohort database.
Despite the likely frequent exposure of c-hGH recipients to NDAPs, and their markedly elevated risk of PrPsc-related disease, this population of NHPP c-hGH recipients does not appear to be at increased risk of AD or PD. We discovered 3 ALS cases of unclear significance among US c-hGH recipients despite the absence of pathological deposits of ALS-associated proteins (TDP-43, FUS, and ubiquilin) in human pituitary glands. In this unique in vivo model of human-to-human transmission, we found no evidence to support concerns that NDAPs underlying AD and PD transmit disease in humans despite evidence of their cell-to-cell transmission in model systems of these disorders. Further monitoring is required to confirm these conclusions.",[],JAMA neurology,2013-02-06,"[{'lastname': 'Irwin', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Center for Neurodegenerative Disease Research and Institute on Aging, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.'}, {'lastname': 'Abrams', 'firstname': 'Joseph Y', 'initials': 'JY', 'affiliation': None}, {'lastname': 'Schonberger', 'firstname': 'Lawrence B', 'initials': 'LB', 'affiliation': None}, {'lastname': 'Leschek', 'firstname': 'Ellen Werber', 'initials': 'EW', 'affiliation': None}, {'lastname': 'Mills', 'firstname': 'James L', 'initials': 'JL', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Virginia M-Y', 'initials': 'VM', 'affiliation': None}, {'lastname': 'Trojanowski', 'firstname': 'John Q', 'initials': 'JQ', 'affiliation': None}]",,,"We found mild amounts of pathological tau, Aβ, and α-synuclein deposits in the adeno/neurohypophysis of patients with ND and control patients. No cases of AD or PD were identified, and 3 deaths attributed to amyotrophic lateral sclerosis (ALS) were found among US NHPP c-hGH recipients, including 2 of the 796 decedents in the originally confirmed NHPP c-hGH cohort database.",,10.1001/jamaneurol.2013.1933,<Element 'PubmedArticle' at 0x7f05d911b4a0>
280,"23362919
22132081
8900272
15853618
10751445
12415260
20410196
20005808
10875265
11292860
18843793
20395504
18759009
17328672
7624036
21325617
18831990
17306982
17719253
19228785
7758431
15734678
7476312
11336996
16192374
21516129
16125823
12610293
12164721
16899414
19304940
16011467
19699265
14643377
20098959
15748777
17478722
17182789
18000817
20561541
21544578
10647962
18316725
22476197
8156941
18198415
15650008
16157452
17499883
7561610
8811719
22053982","Protein restriction cycles reduce IGF-1 and phosphorylated Tau, and improve behavioral performance in an Alzheimer's disease mouse model.","In laboratory animals, calorie restriction (CR) protects against aging, oxidative stress, and neurodegenerative pathologies. Reduced levels of growth hormone and IGF-1, which mediate some of the protective effects of CR, can also extend longevity and/or protect against age-related diseases in rodents and humans. However, severely restricted diets are difficult to maintain and are associated with chronically low weight and other major side effects. Here we show that 4 months of periodic protein restriction cycles (PRCs) with supplementation of nonessential amino acids in mice already displaying significant cognitive impairment and Alzheimer's disease (AD)-like pathology reduced circulating IGF-1 levels by 30-70% and caused an 8-fold increase in IGFBP-1. Whereas PRCs did not affect the levels of β amyloid (Aβ), they decreased tau phosphorylation in the hippocampus and alleviated the age-dependent impairment in cognitive performance. These results indicate that periodic protein restriction cycles without CR can promote changes in circulating growth factors and tau phosphorylation associated with protection against age-related neuropathologies.",[],Aging cell,2013-02-01,"[{'lastname': 'Parrella', 'firstname': 'Edoardo', 'initials': 'E', 'affiliation': 'Longevity Institute, Davis School of Gerontology, and Department of Biological Sciences, University of Southern California, Los Angeles, CA 90089-0191, USA.'}, {'lastname': 'Maxim', 'firstname': 'Tom', 'initials': 'T', 'affiliation': None}, {'lastname': 'Maialetti', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': None}, {'lastname': 'Zhang', 'firstname': 'Lu', 'initials': 'L', 'affiliation': None}, {'lastname': 'Wan', 'firstname': 'Junxiang', 'initials': 'J', 'affiliation': None}, {'lastname': 'Wei', 'firstname': 'Min', 'initials': 'M', 'affiliation': None}, {'lastname': 'Cohen', 'firstname': 'Pinchas', 'initials': 'P', 'affiliation': None}, {'lastname': 'Fontana', 'firstname': 'Luigi', 'initials': 'L', 'affiliation': None}, {'lastname': 'Longo', 'firstname': 'Valter D', 'initials': 'VD', 'affiliation': None}]",,,,© 2013 The Authors Aging Cell © 2013 Blackwell Publishing Ltd/Anatomical Society of Great Britain and Ireland.,10.1111/acel.12049,<Element 'PubmedArticle' at 0x7f05d90b9ef0>
281,"23312564
17151169
16198445
11036168
16943563
17912249
16467370
15751228
10908610
18691381
2998738
22388814
12895417
21922193
21811679
20518810
3228475
15748844
21704011
17659878
20042680
20413859
9769155
15922554
14643377
12559833
21149712
11035007
14598310
10097139
15146243
10531052
11683988
17567816
15517432
1336152
20553310
12765608
10830966
21976528
16125145
12000027
11744092
20943927
21471376
12011303
21416488
15241189
15096691
17988898
18045930
21803451
20231471
21918687
19168709
3560943",Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.,"Increased circulating glucocorticoids are features of both aging and Alzheimer's disease (AD), and increased glucocorticoids accelerate the accumulation of AD pathologies. Here, we analyzed the effects of the glucocorticoid receptor antagonist mifepristone (RU486) in the 3xTg-AD mouse model at an age where hippocampal damage leads to high circulating corticosterone levels.
The effects of mifepristone were investigated in 3xTg-AD mice using a combination of biochemical, histological, and behavior analyses.
Mifepristone treatment rescues the pathologically induced cognitive impairments and markedly reduces amyloid beta (Aβ)-load and levels, as well as tau pathologies. Analysis of amyloid precursor protein (APP) processing revealed concomitant decreases in both APP C-terminal fragments C99 and C83 and the appearance of a larger 17-kDa C-terminal fragment. Hence, mifepristone induces a novel C-terminal cleavage of APP that prevents it being cleaved by α- or β-secretase, thereby precluding Aβ generation in the central nervous system; this cleavage and the production of the 17-kDa APP fragment was generated by a calcium-dependent cysteine protease. In addition, mifepristone treatment also reduced the phosphorylation and accumulation of tau, concomitant with reductions in p25. Notably, deficits in cyclic-AMP response element-binding protein signaling were restored with the treatment.
These preclinical results point to a potential therapeutic role for mifepristone as an effective treatment for AD and further highlight the impact the glucocorticoid system has as a regulator of Aβ generation.","['3xTg-AD', ""Alzheimer's disease"", 'Amyloid beta', 'glucocorticoids', 'mifepristone', 'tau']",Biological psychiatry,2013-01-15,"[{'lastname': 'Baglietto-Vargas', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Department of Neurobiology and Behavior, University of California, Irvine, USA.'}, {'lastname': 'Medeiros', 'firstname': 'Rodrigo', 'initials': 'R', 'affiliation': None}, {'lastname': 'Martinez-Coria', 'firstname': 'Hilda', 'initials': 'H', 'affiliation': None}, {'lastname': 'LaFerla', 'firstname': 'Frank M', 'initials': 'FM', 'affiliation': None}, {'lastname': 'Green', 'firstname': 'Kim N', 'initials': 'KN', 'affiliation': None}]",,,"Mifepristone treatment rescues the pathologically induced cognitive impairments and markedly reduces amyloid beta (Aβ)-load and levels, as well as tau pathologies. Analysis of amyloid precursor protein (APP) processing revealed concomitant decreases in both APP C-terminal fragments C99 and C83 and the appearance of a larger 17-kDa C-terminal fragment. Hence, mifepristone induces a novel C-terminal cleavage of APP that prevents it being cleaved by α- or β-secretase, thereby precluding Aβ generation in the central nervous system; this cleavage and the production of the 17-kDa APP fragment was generated by a calcium-dependent cysteine protease. In addition, mifepristone treatment also reduced the phosphorylation and accumulation of tau, concomitant with reductions in p25. Notably, deficits in cyclic-AMP response element-binding protein signaling were restored with the treatment.",Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.,10.1016/j.biopsych.2012.12.003,<Element 'PubmedArticle' at 0x7f05d90daa90>
282,"23301030
15295589
11274343
17245412
16354549
9427614
15608634
15834427
9600986
17505973
17286590
6375662
10850703
12214065
17477976
11457586
12391608
8463843
7798921
2218531
21703413
11150591
11403592
18585459
18621989
9030890
8822355
8883881
17057756
12478619
19052542
11166290
17223274
19889791
12832007
15205309
15519243
7557541
12736326
15231696
16457953
16328175
14984798
16246051
15979880
3670729
3263583
2549464
16042131
17036175
15172746
18673008
18067990
16876668
19330877
10844576
17541643
15829187
8103203
7901339
18282566
17912249
8780008
3953862
2560104
14634622
12097332
11919205
19473994
9024796
17254009
17086548
18846424
18420184
1759558
22752387
22278629
12084879
16456666
9705127
1653521
19263040
9461057
16877359
20394726
10516307
20201807","Alzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-β peptide injection in rats.","Alzheimer's disease (AD) is a neurodegenerative pathology associated with aging characterized by the presence of senile plaques and neurofibrillary tangles that finally result in synaptic and neuronal loss. The major component of senile plaques is an amyloid-β protein (Aβ). Recently, we characterized the effects of a single intracerebroventricular (icv) injection of Aβ fragment (25-35) oligomers (oAβ(25-35)) for up to 3 weeks in rats and established a clear parallel with numerous relevant signs of AD. To clarify the long-term effects of oAβ(25-35) and its potential role in the pathogenesis of AD, we determined its physiological, behavioral, biochemical and morphological impacts 6 weeks after injection in rats. oAβ(25-35) was still present in the brain after 6 weeks. oAβ(25-35) injection did not affect general activity and temperature rhythms after 6 weeks, but decreased body weight, induced short- and long-term memory impairments, increased corticosterone plasma levels, brain oxidative (lipid peroxidation), mitochondrial (caspase-9 levels) and reticulum stress (caspase-12 levels), astroglial and microglial activation. It provoked cholinergic neuron loss and decreased brain-derived neurotrophic factor levels. It induced cell loss in the hippocampic CA subdivisions and decreased hippocampic neurogenesis. Moreover, oAβ(25-35) injection resulted in increased APP expression, Aβ(1-42) generation, and increased Tau phosphorylation. In conclusion, this in vivo study evidenced that the soluble oligomeric forms of short fragments of Aβ, endogenously identified in AD patient brains, not only provoked long-lasting pathological alterations comparable to the human disease, but may also directly contribute to the progressive increase in amyloid load and Tau pathology, involved in the AD physiopathology.",[],PloS one,2013-01-10,"[{'lastname': 'Zussy', 'firstname': 'Charleine', 'initials': 'C', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia Laboratory, Inserm U710, Montpellier, France.'}, {'lastname': 'Brureau', 'firstname': 'Anthony', 'initials': 'A', 'affiliation': None}, {'lastname': 'Keller', 'firstname': 'Emeline', 'initials': 'E', 'affiliation': None}, {'lastname': 'Marchal', 'firstname': 'Stéphane', 'initials': 'S', 'affiliation': None}, {'lastname': 'Blayo', 'firstname': 'Claire', 'initials': 'C', 'affiliation': None}, {'lastname': 'Delair', 'firstname': 'Brice', 'initials': 'B', 'affiliation': None}, {'lastname': 'Ixart', 'firstname': 'Guy', 'initials': 'G', 'affiliation': None}, {'lastname': 'Maurice', 'firstname': 'Tangui', 'initials': 'T', 'affiliation': None}, {'lastname': 'Givalois', 'firstname': 'Laurent', 'initials': 'L', 'affiliation': None}]",,,,,10.1371/journal.pone.0053117,<Element 'PubmedArticle' at 0x7f05d907f900>
283,"23202804
19801821
8784142
11255033
22307058
11546910
20226770
11826099
19096367
21288204
18781985
2643202
17406427
12829867
20709152
20064557
16282546
20832403
20667450
17020783
20552017
19274095
16943255
20150984
15056463
15378065
8795628
19226510
15135175
15992372
22693678
20157251
12427829
20036240
22737633
16954222
22434066","WIN55,212-2 protects oligodendrocyte precursor cells in stroke penumbra following permanent focal cerebral ischemia in rats.","To explore whether the synthetic cannabinoid receptor agonist WIN55,212-2 could protect oligodendrocyte precursor cells (OPCs) in stroke penumbra, thereby providing neuroprotection following permanent focal cerebral ischemia in rats.
Adult male SD rats were subjected to permanent middle cerebral artery occlusion (p-MCAO). The animals were administered WIN55,212-2 at 2 h, and sacrificed at 24 h after the ischemic insult. The infarct volumes and brain swelling were assessed. The expression of cannabinoid receptor type 1 (CB1) in the stroke penumbra was examined using Western blot assay. The pathological changes and proliferation of neural glial antigen 2-positive OPCs (NG2(+) cells) in the stroke penumbra were studied using immunohistochemistry staining.
p-MCAO significantly increased the expression of CB1 within the stroke penumbra with the highest level appearing at 2 h following the ischemic insult. Administration of WIN55,212-2 (9 mg/kg, iv) significantly attenuated the brain swelling, and reduced the infarct volume as well as the number of tau-immunoreactive NG2(+) cells (tau-1(+)/NG2(+) cells) in the stroke penumbra. Moreover, WIN55,212-2 significantly promoted the proliferation of NG2(+) cells in the stroke penumbra and in the ipsilateral subventricular zone at 24 h following the ischemic insult. Administration of the selective CB1 antagonist rimonabant (1 mg/kg, iv) partially blocked the effects caused by WIN55,212-2.
Tau-1 is expressed in NG2(+) cells following permanent focal cerebral ischemic injury. Treatment with WIN55,212-2 reduces the number of tau-1(+)/NG2(+) cells and promotes NG2(+) cell proliferation in the stroke penumbra, which are mediated partially via CB1 and may contribute to its neuroprotective effects.",[],Acta pharmacologica Sinica,2012-12-04,"[{'lastname': 'Sun', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Neurobiology Laboratory, Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing, China.'}, {'lastname': 'Fang', 'firstname': 'Yin-quan', 'initials': 'YQ', 'affiliation': None}, {'lastname': 'Ren', 'firstname': 'Hong', 'initials': 'H', 'affiliation': None}, {'lastname': 'Chen', 'firstname': 'Tao', 'initials': 'T', 'affiliation': None}, {'lastname': 'Guo', 'firstname': 'Jing-jing', 'initials': 'JJ', 'affiliation': None}, {'lastname': 'Yan', 'firstname': 'Jun', 'initials': 'J', 'affiliation': None}, {'lastname': 'Song', 'firstname': 'Shu', 'initials': 'S', 'affiliation': None}, {'lastname': 'Zhang', 'firstname': 'Lu-yong', 'initials': 'LY', 'affiliation': None}, {'lastname': 'Liao', 'firstname': 'Hong', 'initials': 'H', 'affiliation': None}]",,"Tau-1 is expressed in NG2(+) cells following permanent focal cerebral ischemic injury. Treatment with WIN55,212-2 reduces the number of tau-1(+)/NG2(+) cells and promotes NG2(+) cell proliferation in the stroke penumbra, which are mediated partially via CB1 and may contribute to its neuroprotective effects.","p-MCAO significantly increased the expression of CB1 within the stroke penumbra with the highest level appearing at 2 h following the ischemic insult. Administration of WIN55,212-2 (9 mg/kg, iv) significantly attenuated the brain swelling, and reduced the infarct volume as well as the number of tau-immunoreactive NG2(+) cells (tau-1(+)/NG2(+) cells) in the stroke penumbra. Moreover, WIN55,212-2 significantly promoted the proliferation of NG2(+) cells in the stroke penumbra and in the ipsilateral subventricular zone at 24 h following the ischemic insult. Administration of the selective CB1 antagonist rimonabant (1 mg/kg, iv) partially blocked the effects caused by WIN55,212-2.",,"10.1038/aps.2012.141
10.1155/2012/493670",<Element 'PubmedArticle' at 0x7f05d902d360>
284,23194475,"Propranolol reduces cognitive deficits, amyloid β levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration.","Chronic exposure to glucocorticoids might result not only in insulin resistance or cognitive deficits, but it is also considered as a risk factor for pathologies such as Alzheimer's disease. Propranolol is a β-adrenergic antagonist commonly used in the treatment of hypertension or acute anxiety. The effects of propranolol (5 mg/kg) have been tested in a model of chronic corticosterone administration (100 μg/ml, 4 wk) in drinking water. Corticosterone administration led to cognitive impairment in the novel object recognition test that was reversed by propranolol. Increased levels of Aβ in the hippocampus of corticosterone-treated mice were counteracted by propranolol treatment, purportedly through an increased IDE expression. Chronic corticosterone treatment induced responses characteristic of insulin resistance, as increased peripheral insulin levels, decreased activation of the insulin receptor (pIR) and decreased associated intracellular pathways (pAkt). These effects might be related to a decreased c-Jun N terminal kinase 1 expression. Again, propranolol was able to counteract all corticosterone-induced effects. One of the main kinases involved in tau phosphorylation, glycogen synthase kinase 3β (GSK3β), which is inactivated by phosphorylation by pAkt, was found to be decreased after corticosterone and increased after propranolol treatment. Concomitant changes in pTau expression were found. Overall, these data further strengthen the potential of propranolol as a therapeutic agent for pathologies associated with the interaction glucocorticoids-insulin resistance and the development of relevant cellular processes for Alzheimer's disease.",[],The international journal of neuropsychopharmacology,2012-12-01,"[{'lastname': 'Dobarro', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Dpto Farmacologia, Universidad de Navarra, Pamplona, Spain.'}, {'lastname': 'Orejana', 'firstname': 'Lourdes', 'initials': 'L', 'affiliation': None}, {'lastname': 'Aguirre', 'firstname': 'Norberto', 'initials': 'N', 'affiliation': None}, {'lastname': 'Ramírez', 'firstname': 'Maria J', 'initials': 'MJ', 'affiliation': None}]",,,,,10.1017/S1461145712001393,<Element 'PubmedArticle' at 0x7f05d9048180>
285,23063057,Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer.,"To analyze the correlation between circulating tumor cell (CTC) levels and clinicopathologic parameters (prostate-specific antigen level, Gleason score, and TNM stage) in patients with metastatic hormone-sensitive prostate cancer (PCa) and to establish its prognostic value in overall survival (OS) and progression-free survival (PFS).
A prospective, 3-arm study was performed that included 30 patients with localized PCa; 30 patients with metastatic PCa, and 30 healthy volunteers. A single 7.5-mL peripheral blood sample was taken. The CTCs were isolated using an immunomagnetic method based on the CellSearch system. Kendall's tau and Spearman's rho coefficients of correlation were used. The multivariate Cox regression model addressed OS and PFS.
The median follow-up was 42.9 months (interquartile range 27.14-49.5). A significant positive correlation was demonstrated between the CTC level and all tumor burden markers (prostate-specific antigen and T, N, and M stage; P <.001), except for Gleason score (tau = 0.16). A cutoff of ≥ 4 CTCs/7.5 mL was chosen to distinguish patients with a poor prognosis. These patients had a significantly shorter median OS and PFS (24 vs 45 months and 7 vs 44 months, respectively; P <.001). As the CTC level increased, the OS and PFS decreased. The risk of mortality and progression for the patients with ≥ 4 CTCs was 4.1 (P = .029) and 8.5 (P <.001) times greater. Multivariate analyses indicated that a CTC of ≥4 was an independent prognostic factor for PFS (hazard ratio 5.9, P <.005).
The CTC count in peripheral blood could provide a method of staging PCa correctly and be of value when assessing the prognosis of metastatic hormone-sensitive PCa.",[],Urology,2012-10-16,"[{'lastname': 'Resel Folkersma', 'firstname': 'Luis', 'initials': 'L', 'affiliation': 'Department of Urology, Hospital Clínico San Carlos, Madrid, Spain. lresel@gmail.com'}, {'lastname': 'San José Manso', 'firstname': 'Luis', 'initials': 'L', 'affiliation': None}, {'lastname': 'Galante Romo', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': None}, {'lastname': 'Moreno Sierra', 'firstname': 'Jesüs', 'initials': 'J', 'affiliation': None}, {'lastname': 'Olivier Gómez', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': None}]",,The CTC count in peripheral blood could provide a method of staging PCa correctly and be of value when assessing the prognosis of metastatic hormone-sensitive PCa.,"The median follow-up was 42.9 months (interquartile range 27.14-49.5). A significant positive correlation was demonstrated between the CTC level and all tumor burden markers (prostate-specific antigen and T, N, and M stage; P <.001), except for Gleason score (tau = 0.16). A cutoff of ≥ 4 CTCs/7.5 mL was chosen to distinguish patients with a poor prognosis. These patients had a significantly shorter median OS and PFS (24 vs 45 months and 7 vs 44 months, respectively; P <.001). As the CTC level increased, the OS and PFS decreased. The risk of mortality and progression for the patients with ≥ 4 CTCs was 4.1 (P = .029) and 8.5 (P <.001) times greater. Multivariate analyses indicated that a CTC of ≥4 was an independent prognostic factor for PFS (hazard ratio 5.9, P <.005).",Copyright © 2012 Elsevier Inc. All rights reserved.,10.1016/j.urology.2012.09.001,<Element 'PubmedArticle' at 0x7f05d9051900>
286,"23053135
22101323
17469117
19139911
15953362
17334266
22366793
1759558
22426854
17579875
11483959
21944778
21857683
1311804
2165197
16783167
16950801
17226741
16945923
22344582
18592255
9329452
18273624
19455346
15477512
18401022
17949857
2864910
11447312
12060347
9633693
12370467
12682312
17021754
21644037
11076969
22366791
22083254
21802369
19674978
16807408
17826340
21944779
16116120
18802454
22300876
21852239
12084879
11770901
22181065
16825955
18520774
21342021
15034582",Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion.,"An expanded GGGGCC hexanucleotide repeat in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal lobar degeneration associated with TDP-43 pathology (FTLD-TDP). In addition to TDP-43-positive neuronal and glial inclusions, C9ORF72-linked FTLD-TDP has characteristic TDP-43-negative neuronal cytoplasmic and intranuclear inclusions as well as dystrophic neurites in the hippocampus and cerebellum. These lesions are immunopositive for ubiquitin and ubiquitin-binding proteins, such as sequestosome-1/p62 and ubiquilin-2. Studies examining the frequency of the C9ORF72 mutation in clinically probable Alzheimer's disease (AD) have found a small proportion of AD cases with the mutation. This prompted us to systematically explore the frequency of Alzheimer-type pathology in a series of 17 FTLD-TDP cases with mutations in C9ORF72 (FTLD-C9ORF72). We identified four cases with sufficient Alzheimer-type pathology to meet criteria for intermediate-to-high-likelihood AD. We compared AD pathology in the 17 FTLD-C9ORF72 to 13 cases of FTLD-TDP linked to mutations in the gene for progranulin (FTLD-GRN) and 36 cases of sporadic FTLD (sFTLD). FTLD-C9ORF72 cases had higher Braak neurofibrillary tangle stage than FTLD-GRN. Increased tau pathology in FTLD-C9ORF72 was assessed with thioflavin-S fluorescent microscopy-based neurofibrillary tangle counts and with image analysis of tau burden in temporal cortex and hippocampus. FTLD-C9ORF72 had significantly more neurofibrillary tangles and higher tau burden compared with FTLD-GRN. The differences were most marked in limbic regions. On the other hand, sFTLD and FTLD-C9ORF72 had a similar burden of tau pathology. These results suggest FTLD-C9ORF72 has increased propensity for tau pathology compared to FTLD-GRN, but not sFTLD. The accumulation of tau as well as lesions immunoreactive for ubiquitin and ubiquitin-binding proteins (p62 and ubiquilin-2) suggests that mutations in C9ORF72 may involve disrupted protein degradation that favors accumulation of multiple different proteins.",[],Acta neuropathologica,2012-10-12,"[{'lastname': 'Bieniek', 'firstname': 'Kevin F', 'initials': 'KF', 'affiliation': 'Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.'}, {'lastname': 'Murray', 'firstname': 'Melissa E', 'initials': 'ME', 'affiliation': None}, {'lastname': 'Rutherford', 'firstname': 'Nicola J', 'initials': 'NJ', 'affiliation': None}, {'lastname': 'Castanedes-Casey', 'firstname': 'Monica', 'initials': 'M', 'affiliation': None}, {'lastname': 'DeJesus-Hernandez', 'firstname': 'Mariely', 'initials': 'M', 'affiliation': None}, {'lastname': 'Liesinger', 'firstname': 'Amanda M', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Baker', 'firstname': 'Matthew C', 'initials': 'MC', 'affiliation': None}, {'lastname': 'Boylan', 'firstname': 'Kevin B', 'initials': 'KB', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': None}, {'lastname': 'Dickson', 'firstname': 'Dennis W', 'initials': 'DW', 'affiliation': None}]",,,,,10.1007/s00401-012-1048-7,<Element 'PubmedArticle' at 0x7f05d905aa90>
287,"23016131
21321947
10906002
19824582
7826275
11784353
19168210
19198152
12838517
18440777
15561484
1185039
4912963
5699730
5111801
14278632
591201
6054512
3594257
18646107
16926172
9872352
11511711
11425941
16969158
17645580
19742171
18616667
18505416
15750214
18299999
18687773
16388110
1370250
9699879
7943669
11173973
11141048
10679786
8989772
8864287
10728202
17299765
21426453
21063035
19398227
20814553
15203069
1251239
18054075
16909201
16279987
6254354
17559547
8406680
1725670
9235959",Experimental alcohol-related peripheral neuropathy: role of insulin/IGF resistance.,"The mechanisms of alcohol-related peripheral neuropathy (ALPN) are poorly understood. We hypothesize that, like alcohol-related liver and brain degeneration, ALPN may be mediated by combined effects of insulin/IGF resistance and oxidative stress. Adult male Long Evans rats were chronically pair-fed with diets containing 0% or 37% ethanol (caloric), and subjected to nerve conduction studies. Chronic ethanol feeding slowed nerve conduction in the tibial (p = 0.0021) motor nerve, and not plantar sensory nerve, but it did not affect amplitude. Histological studies of the sciatic nerve revealed reduced nerve fiber diameters with increased regenerative sprouts, and denervation myopathy in ethanol-fed rats. qRT-PCR analysis demonstrated reduced mRNA levels of insulin, IGF-1, and IGF-2 polypeptides, IGF-1 receptor, and IRS2, and ELISAs revealed reduced immunoreactivity for insulin and IGF-1 receptors, IRS-1, IRS-4, myelin-associated glycoprotein, and tau in sciatic nerves of ethanol-fed rats (all p < 0.05 or better). The findings suggest that ALPN is characterized by (1) slowed conduction velocity with demyelination, and a small component of axonal degeneration; (2) impaired trophic factor signaling due to insulin and IGF resistance; and (3) degeneration of myelin and axonal cytoskeletal proteins. Therefore, ALPN is likely mediated by molecular and signal transduction abnormalities similar to those identified in alcoholic liver and brain degeneration.","['alcoholic peripheral neuropathy', 'demyelination', 'experimental animal model', 'gene expression', 'insulin resistance', 'nerve conduction', 'nutritional deficiency']",Nutrients,2012-09-28,"[{'lastname': 'Nguyen', 'firstname': 'Van Anh', 'initials': 'VA', 'affiliation': 'Department of Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI 02903, USA. va.nguyen87@gmail.com'}, {'lastname': 'Le', 'firstname': 'Tran', 'initials': 'T', 'affiliation': None}, {'lastname': 'Tong', 'firstname': 'Ming', 'initials': 'M', 'affiliation': None}, {'lastname': 'Mellion', 'firstname': 'Michelle', 'initials': 'M', 'affiliation': None}, {'lastname': 'Gilchrist', 'firstname': 'James', 'initials': 'J', 'affiliation': None}, {'lastname': 'de la Monte', 'firstname': 'Suzanne M', 'initials': 'SM', 'affiliation': None}]",,,,,"10.3390/nu4081042
10.3928/01477447-20090818-19
10.1001/archneur.1995.00540250049012
10.1046/j.1468-1331.2001.00303.x
10.5692/clinicalneurol.48.1026
10.1002/ana.10550
10.1016/j.nut.2008.02.022
10.1016/j.nut.2004.08.002
10.1016/0014-4800(71)90098-0
10.1016/0006-8993(87)90150-8
10.1002/14651858.CD004573.pub3
10.1136/jnnp.71.3.357
10.1212/WNL.56.12.1727
10.1097/01.wco.0000245371.89941.eb
10.1111/j.1530-0277.2007.00450.x
10.1111/j.1530-0277.2008.00731.x
10.1111/j.1440-1746.2008.05339.x
10.1007/s12031-008-9041-2
10.1210/en.2008-0920
10.1385/MN:33:1:051
10.1097/00000441-199201000-00009
10.1016/S0960-0760(97)00191-X
10.1111/j.1530-0277.1994.tb00924.x
10.1111/j.1530-0277.2000.tb01993.x
10.1007/BF02740625
10.1111/j.1750-3639.1996.tb00858.x
10.1016/S1090-3798(97)80039-6
10.1002/glia.20496
10.1111/j.1872-034X.2011.00775.x
10.1016/j.jhep.2009.01.021
10.1155/2010/312790
10.1016/j.clinph.2004.02.007
10.1097/00007611-197602000-00015
10.1016/j.placenta.2007.10.002
10.1007/s00018-006-6208-2
10.1111/j.1085-9489.2005.00050.x
10.1111/j.1530-0277.2007.00436.x
10.1002/glia.440080403
10.1159/000112192
10.1074/jbc.272.31.19547",<Element 'PubmedArticle' at 0x7f05d9001090>
288,"23008023
18278731
15514916
14633779
21081568
20390263
18799279
20576660
3420260
22146869
16423955
17442995
16423956
20582497
21512065
21148812
9658431
19329269
10986059
18528962
9251731
9917747
19553647
16407512
11408503
8050228
14677098
10429715",Widespread osteonecrosis in children with leukemia revealed by whole-body MRI.,"Confirmation of early long-bone epiphyseal osteonecrosis in pediatric patients with leukemia allows for medical and surgical intervention before articular surface collapse. MRI detects early osteonecrosis, but multiple focused MR images are required to capture all lesions.
We determined whether whole-body MRI (WB-MRI) could (1) assist in diagnosing long-bone epiphyseal and other osteonecroses, (2) characterize articular surface involvement, and (3) detect preferential sites for osteonecrosis.
We retrospectively reviewed prospectively collected data on all 11 pediatric patients newly diagnosed with leukemia who had musculoskeletal pain develop that persisted 4 weeks or more during leukemia treatment. All were screened for osteonecrosis by WB-MRI, which consisted of a one-time scan of the entire body. Osteonecrosis was defined as circumscribed lesions with a distinct rim of low signal intensity in the normally high-intensity marrow on T1-weighted images and high signal intensity in the normally low-intensity marrow on short-tau inversion recovery images.
WB-MRI confirmed osteonecrosis in nine of 11 patients. All patients had multisite lesions; eight had long-bone epiphyseal lesions, which comprised 66 of 129 (51%) of all lesions. Osteonecrosis involving greater than 50% of the epiphyseal surface was present in 57% of distal femoral and proximal tibial lesions. All humeral and femoral head lesions involved more than 1/3 of the medial surface volume but were asymptomatic. No articular collapse was present. All osteonecrotic lesions were more common in the lower extremities.
WB-MRI confirmed early epiphyseal osteonecrosis, with quantification of articular surface involvement. Lower limbs were preferentially affected, but asymptomatic humeral head osteonecrosis was present in five of nine patients.
Level IV, diagnostic study. See Instructions for Authors for a complete description of levels of evidence.",[],Clinical orthopaedics and related research,2012-09-26,"[{'lastname': 'Miettunen', 'firstname': 'Paivi Maria', 'initials': 'PM', 'affiliation': ""Division of Pediatric Rheumatology, Department of Pediatrics, Alberta Children's Hospital and University of Calgary, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada. paivi.miettunen@albertahealthservices.ca""}, {'lastname': 'Lafay-Cousin', 'firstname': 'Lucie', 'initials': 'L', 'affiliation': None}, {'lastname': 'Guilcher', 'firstname': 'Gregory M T', 'initials': 'GM', 'affiliation': None}, {'lastname': 'Nettel-Aguirre', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': None}, {'lastname': 'Moorjani', 'firstname': 'Vijay', 'initials': 'V', 'affiliation': None}]",,,"WB-MRI confirmed osteonecrosis in nine of 11 patients. All patients had multisite lesions; eight had long-bone epiphyseal lesions, which comprised 66 of 129 (51%) of all lesions. Osteonecrosis involving greater than 50% of the epiphyseal surface was present in 57% of distal femoral and proximal tibial lesions. All humeral and femoral head lesions involved more than 1/3 of the medial surface volume but were asymptomatic. No articular collapse was present. All osteonecrotic lesions were more common in the lower extremities.",,"10.1007/s11999-012-2579-x
10.1055/s-2008-1027185
10.1002/pbc.20244
10.1182/asheducation-2003.1.102
10.1259/bjr/34972239
10.1007/s00247-010-1636-4
10.1016/j.ejrad.2008.05.018
10.1136/adc.2009.172528
10.1007/s00256-011-1333-x
10.2214/AJR.04.1598
10.1200/JCO.2006.07.9947
10.2214/AJR.04.1597
10.1007/s11999-010-1358-9
10.2214/AJR.10.6073
10.3109/08880019809014014
10.1016/j.ejrad.2009.02.012
10.1002/(SICI)1096-911X(199710)29:4<260::AID-MPO5>3.0.CO;2-K
10.1002/(SICI)1096-911X(199901)32:1<11::AID-MPO4>3.0.CO;2-F
10.1056/NEJMoa0900386
10.1056/NEJMra052603
10.1097/00003086-199408000-00023
10.1055/s-2003-45495",<Element 'PubmedArticle' at 0x7f05d8fa82c0>
289,22982863,Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains.,"Growing evidence suggests that Alzheimer disease (AD) origins in vascular lesions. As the crucial mediator of vascular pathology, angiotensin II-induced significant amyloid production in our laboratory, although amyloid neurotoxicity depended on phosphorylated tau (p-tau) in recent studies. In the present study, p-tau levels were significantly elevated by central angiotensin II via glycogen synthase kinase 3β (GSK 3β) and other tau kinases. Moreover, angiotensin II-induced cognitive impairment and tau phosphorylation was attenuated by losartan and a GSK 3β inhibitor. These findings implicate Ang II as a crucial mediator of AD pathology and a link between cardiovascular events and AD.",[],FEBS letters,2012-09-18,"[{'lastname': 'Tian', 'firstname': 'Minjie', 'initials': 'M', 'affiliation': 'Department of Neurology, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, PR China.'}, {'lastname': 'Zhu', 'firstname': 'Donglin', 'initials': 'D', 'affiliation': None}, {'lastname': 'Xie', 'firstname': 'Wei', 'initials': 'W', 'affiliation': None}, {'lastname': 'Shi', 'firstname': 'Jingping', 'initials': 'J', 'affiliation': None}]",,,,Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.,10.1016/j.febslet.2012.09.004,<Element 'PubmedArticle' at 0x7f05d8fc0b30>
290,"22889357
1759558
12084879
19427328
15721829
15306238
12697714
16365303
18045930
20410196
14622134
20807511
20505099
21945538
12895417
14643377
16504943
19524671
20798886
17182789
21206751
17342777
20144714
20937383
14519499
9528939
16267229
9225742
15351520
10348656
22654806
21933867
17949721
21623961
20144613
11413547
15101093
716781
15477372
19458064
17592029
22384388
4943189
4855864
15621042
11449190
10094414
9766760
14745052
11325319
18346198
11805297
11389183
11796757
19457436
10077336
14993062
16426763
22138012
15522833
2269895
16034187",Sex steroid levels and AD-like pathology in 3xTgAD mice.,"Decreases in testosterone and 17β-oestradiol (E(2)) are associated with an increased risk for Alzheimer's disease (AD), which has been attributed to an increase in β-amyloid and tau pathological lesions. Although recent studies have used transgenic animal models to test the effects of sex steroid manipulations on AD-like pathology, almost none have systematically characterised the associations between AD lesions and sex steroid levels in the blood or brain in any mutant model. The present study evaluated age-related changes in testosterone and E(2) concentrations, as well as androgen receptor (AR) and oestrogen receptor (ER) α and β expression, in brain regions displaying AD pathology in intact male and female 3xTgAD and nontransgenic (ntg) mice. We report for the first time that circulating and brain testosterone levels significantly increase in male 3xTgAD mice with age, but without changes in AR-immunoreactive (IR) cell number in the hippocampal CA1 or medial amygdala. The age-related increase in hippocampal testosterone levels correlated positively with increases in the conformational tau isoform, Alz50. These data suggest that the over-expression of human tau up-regulate the hypothalamic-pituitary-gonadal axis in these mice. Although circulating and brain E(2) levels remained stable with age in both male and female 3xTgAD and ntg mice, ER-IR cell number in the hippocampus and medial amygdala decreased with age in female transgenic mice. Furthermore, E(2) levels were significantly higher in the hippocampus than in serum, suggesting local production of E(2). Although triple transgenic mice mimic AD-like pathology, they do not fully replicate changes in human sex steroid levels, and may not be the best model for studying the effects of sex steroids on AD lesions.",[],Journal of neuroendocrinology,2012-08-15,"[{'lastname': 'Overk', 'firstname': 'Cassia R', 'initials': 'CR', 'affiliation': 'Department of Neurological Sciences, Rush University Medical Center, Chicago, IL USA 60612.'}, {'lastname': 'Perez', 'firstname': 'Sylvia E', 'initials': 'SE', 'affiliation': 'Department of Neurological Sciences, Rush University Medical Center, Chicago, IL USA 60612.'}, {'lastname': 'Ma', 'firstname': 'Chunqi', 'initials': 'C', 'affiliation': 'Department of Psychology, Department of Zoology, and Graduate Program in Neuroscience, University of British Columbia, Vancouver, BC Canada V6T 1Z4.'}, {'lastname': 'Taves', 'firstname': 'Matthew D', 'initials': 'MD', 'affiliation': 'Department of Psychology, Department of Zoology, and Graduate Program in Neuroscience, University of British Columbia, Vancouver, BC Canada V6T 1Z4.'}, {'lastname': 'Soma', 'firstname': 'Kiran K', 'initials': 'KK', 'affiliation': 'Department of Psychology, Department of Zoology, and Graduate Program in Neuroscience, University of British Columbia, Vancouver, BC Canada V6T 1Z4.'}, {'lastname': 'Mufson', 'firstname': 'Elliott J', 'initials': 'EJ', 'affiliation': 'Department of Neurological Sciences, Rush University Medical Center, Chicago, IL USA 60612.'}]",,,,© 2012 British Society for Neuroendocrinology.,10.1111/j.1365-2826.2012.02374.x,<Element 'PubmedArticle' at 0x7f05d8fd0180>
291,22831649,Elevation of tau protein levels in the cerebrospinal fluid of children with West syndrome.,"West syndrome is an epileptic encephalopathy with a poor developmental outcome. Tau protein levels in the cerebrospinal fluid (CSF) are reported to be markers of axonal damage and neurodegeneration. This study aimed to investigate axonal damage and the effects of adrenocorticotropic hormone (ACTH) therapy on axons in West syndrome, as measured by tau protein levels in CSF.
Tau protein levels in CSF before and after ACTH therapy were determined by an enzyme-linked immunosorbent assay in 26 children with West syndrome. Of these 26 children, 18 were symptomatic, and 8 had a cryptogenic form of West syndrome. A group of 41 unaffected children was included in the study as a control group.
The levels of tau protein in CSF were significantly higher in children with West syndrome than in the control group, and these levels remained high after ACTH therapy. ACTH therapy was effective for 20 of the 26 children with West syndrome, and their CSF tau protein levels were significantly higher after ACTH therapy than before therapy.
Our results suggest that axonal damage occurs in West syndrome, as judged by tau protein levels in CSF.",[],Epilepsy research,2012-07-27,"[{'lastname': 'Inoue', 'firstname': 'Hirofumi', 'initials': 'H', 'affiliation': 'Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan. m003um@yamaguchi-u.ac.jp'}, {'lastname': 'Matsushige', 'firstname': 'Takeshi', 'initials': 'T', 'affiliation': None}, {'lastname': 'Hasegawa', 'firstname': 'Shunji', 'initials': 'S', 'affiliation': None}, {'lastname': 'Abe', 'firstname': 'Arisa', 'initials': 'A', 'affiliation': None}, {'lastname': 'Iida', 'firstname': 'Yasunori', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Inoue', 'firstname': 'Teruaki', 'initials': 'T', 'affiliation': None}, {'lastname': 'Ichiyama', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': None}]",,"Our results suggest that axonal damage occurs in West syndrome, as judged by tau protein levels in CSF.","The levels of tau protein in CSF were significantly higher in children with West syndrome than in the control group, and these levels remained high after ACTH therapy. ACTH therapy was effective for 20 of the 26 children with West syndrome, and their CSF tau protein levels were significantly higher after ACTH therapy than before therapy.",Copyright © 2012 Elsevier B.V. All rights reserved.,10.1016/j.eplepsyres.2012.07.002,<Element 'PubmedArticle' at 0x7f05d8f729a0>
292,22800987,The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload.,"Activation of the vitamin D-vitamin D receptor (VDR) axis has been shown to reduce blood pressure and left ventricular (LV) hypertrophy. Besides cardiac hypertrophy, cardiac fibrosis is a key element of adverse cardiac remodeling. We hypothesized that activation of the VDR by paricalcitol would prevent fibrosis and LV diastolic dysfunction in an established murine model of cardiac remodeling.
Mice were subjected to transverse aortic constriction (TAC) to induce cardiac hypertrophy. Mice were treated with paricalcitol, losartan, or a combination of both for a period of four consecutive weeks.
The fixed aortic constriction caused similar increase in blood pressure, both in untreated and paricalcitol- or losartan-treated mice. TAC significantly increased LV weight compared to sham operated animals (10.2±0.7 vs. 6.9±0.3 mg/mm, p<0.05). Administration of either paricalcitol (10.5±0.7), losartan (10.8±0.4), or a combination of both (9.2±0.6) did not reduce LV weight. Fibrosis was significantly increased in mice undergoing TAC (5.9±1.0 vs. sham 2.4±0.8%, p<0.05). Treatment with losartan and paricalcitol reduced fibrosis (paricalcitol 1.6±0.3% and losartan 2.9±0.6%, both p<0.05 vs. TAC). This reduction in fibrosis in paricalcitol treated mice was associated with improved indices of LV contraction and relaxation, e.g. dPdtmax and dPdtmin and lower LV end diastolic pressure, and relaxation constant Tau. Also, treatment with paricalcitol and losartan reduced mRNA expression of ANP, fibronectin, collagen III and TIMP-1.
Treatment with the selective VDR activator paricalcitol reduces myocardial fibrosis and preserves diastolic LV function due to pressure overload in a mouse model. This is associated with a reduced percentage of fibrosis and a decreased expression of ANP and several other tissue markers.",[],The Journal of steroid biochemistry and molecular biology,2012-07-18,"[{'lastname': 'Meems', 'firstname': 'Laura M G', 'initials': 'LM', 'affiliation': 'Department of Cardiology, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, Postal code AB43, 9700 RB Groningen, The Netherlands.'}, {'lastname': 'Cannon', 'firstname': 'Megan V', 'initials': 'MV', 'affiliation': None}, {'lastname': 'Mahmud', 'firstname': 'Hasan', 'initials': 'H', 'affiliation': None}, {'lastname': 'Voors', 'firstname': 'Adriaan A', 'initials': 'AA', 'affiliation': None}, {'lastname': 'van Gilst', 'firstname': 'Wiek H', 'initials': 'WH', 'affiliation': None}, {'lastname': 'Silljé', 'firstname': 'Herman H W', 'initials': 'HH', 'affiliation': None}, {'lastname': 'Ruifrok', 'firstname': 'Willem P T', 'initials': 'WP', 'affiliation': None}, {'lastname': 'de Boer', 'firstname': 'Rudolf A', 'initials': 'RA', 'affiliation': None}]",,,"The fixed aortic constriction caused similar increase in blood pressure, both in untreated and paricalcitol- or losartan-treated mice. TAC significantly increased LV weight compared to sham operated animals (10.2±0.7 vs. 6.9±0.3 mg/mm, p<0.05). Administration of either paricalcitol (10.5±0.7), losartan (10.8±0.4), or a combination of both (9.2±0.6) did not reduce LV weight. Fibrosis was significantly increased in mice undergoing TAC (5.9±1.0 vs. sham 2.4±0.8%, p<0.05). Treatment with losartan and paricalcitol reduced fibrosis (paricalcitol 1.6±0.3% and losartan 2.9±0.6%, both p<0.05 vs. TAC). This reduction in fibrosis in paricalcitol treated mice was associated with improved indices of LV contraction and relaxation, e.g. dPdtmax and dPdtmin and lower LV end diastolic pressure, and relaxation constant Tau. Also, treatment with paricalcitol and losartan reduced mRNA expression of ANP, fibronectin, collagen III and TIMP-1.",Copyright © 2012 Elsevier Ltd. All rights reserved.,10.1016/j.jsbmb.2012.06.004,<Element 'PubmedArticle' at 0x7f05d8f7f130>
293,"22796872
16360788
19703213
20182021
12793519
15590663
19656855
16177050
21305046
18562609
17442823
21324907
15788759
16765602
21383850
15339646
21103342
22045486
21524430
12895417
19476738
17030655
10790869
16942758
20677372
18358666
8592548
7916431
14688411
17123871
11425920
20847408
7777133
16882019
7088155
17005052
15748844
18486110
17112576
19442751
20074654
18045930
20934413
20846376",Broad-based nutritional supplementation in 3xTg mice corrects mitochondrial function and indicates sex-specificity in response to Alzheimer's disease intervention.,"Nutrition has been highlighted as a potential factor in Alzheimer's disease (AD) risk and decline and has been investigated as a therapeutic target. Broad-based combination diet therapies have the potential to simultaneously effect numerous protective and corrective processes, both directly (e.g., neuroprotection) and indirectly (e.g., improved vascular health). Here we administered either normal mouse chow with a broad-based nutritional supplement or mouse chow alone to aged male and female 3xTg mice and wildtype (WT) controls. After approximately 4 months of feeding, mice were given a battery of cognitive tasks and then injected with a radiolabeled glucose analog. Brains were assessed for differences in regional glucose uptake and mitochondrial cytochrome oxidase activity, AD pathology, and inflammatory markers. Supplementation induced behavioral changes in the 3xTg, but not WT, mice, and the mode of these changes was influenced by sex. Subsequent analyses indicated that differential response to supplementation by male and female 3xTg mice highlighted brain regional strategies for the preservation of function. Several regions involved have been shown to mediate responses to steroid hormones, indicating a mechanism for sex-based vulnerability. Thus, these findings may have broad implications for the human response to future therapeutics.",[],Journal of Alzheimer's disease : JAD,2012-07-17,"[{'lastname': 'Wolf', 'firstname': 'Andrew B', 'initials': 'AB', 'affiliation': ""Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.""}, {'lastname': 'Braden', 'firstname': 'B Blair', 'initials': 'BB', 'affiliation': None}, {'lastname': 'Bimonte-Nelson', 'firstname': 'Heather', 'initials': 'H', 'affiliation': None}, {'lastname': 'Kusne', 'firstname': 'Yael', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Young', 'firstname': 'Nicole', 'initials': 'N', 'affiliation': None}, {'lastname': 'Engler-Chiurazzi', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': None}, {'lastname': 'Garcia', 'firstname': 'Alexandra N', 'initials': 'AN', 'affiliation': None}, {'lastname': 'Walker', 'firstname': 'Douglas G', 'initials': 'DG', 'affiliation': None}, {'lastname': 'Moses', 'firstname': 'Guna S D', 'initials': 'GS', 'affiliation': None}, {'lastname': 'Tran', 'firstname': 'Hung', 'initials': 'H', 'affiliation': None}, {'lastname': 'LaFerla', 'firstname': 'Frank', 'initials': 'F', 'affiliation': None}, {'lastname': 'Lue', 'firstname': 'LihFen', 'initials': 'L', 'affiliation': None}, {'lastname': 'Emerson Lombardo', 'firstname': 'Nancy', 'initials': 'N', 'affiliation': None}, {'lastname': 'Valla', 'firstname': 'Jon', 'initials': 'J', 'affiliation': None}]",,,,,10.3233/JAD-2012-120478,<Element 'PubmedArticle' at 0x7f05d8f897c0>
294,22575708,Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques.,"Despite having a similar large extent of atherosclerotic coronary affliction, some patients suffer of recurrent cardiac events, whereas others remain asymptomatic.
We hypothesized the existence of a systemic ""signature"" that could distinguish ""vulnerable"" patients with preexisting coronary atherosclerosis from those having similar risk factors and atheromatous burden, but no history of clinically evident plaque rupture/erosion.
Twenty three patients who had at least two prior myocardial infarctions (""vulnerable group"") were matched in respect to their background and coronary atherosclerosis extent with twenty one patients without a history of previous myocardial infarction who underwent routine coronary angiography before valvular surgery. We studied a panel of cytokines, antibodies and hormones including IL-6, IL-10, IL-12, antibodies to β2 glycoprotein I (β2GPI), antibodies to oxidized-LDL, adiponectin and resistin, along with levels of circulating EPCs and Tregs.
A significantly higher level of Treg cells was present in the control (73.4%±4) than in the ""vulnerable patient"" group (62.2%±10.7), p<0.001. IL-10 level was also significantly higher in the control than in the vulnerable patients (2.6±1.2 pg/ml versus 0.9±0.1 pg/ml respectively, p=0.03). There was no significant difference in the circulating levels of the other cytokines, hormones or EPCs between the two groups.
Regulatory T cells and serum IL-10 may discriminate ""vulnerable"" versus stable patients and may have a protective role against plaque rupture in patients with coronary atherosclerosis.",[],Atherosclerosis,2012-05-12,"[{'lastname': 'George', 'firstname': 'Jacob', 'initials': 'J', 'affiliation': 'Heart Institute, Kaplan Medical Center, Rehovot, Affiliated to the Hebrew University and Hadassah Medical School, Jerusalem, Israel. jacobg@post.tau.ac.il'}, {'lastname': 'Schwartzenberg', 'firstname': 'Shmuel', 'initials': 'S', 'affiliation': None}, {'lastname': 'Medvedovsky', 'firstname': 'Diego', 'initials': 'D', 'affiliation': None}, {'lastname': 'Jonas', 'firstname': 'Michael', 'initials': 'M', 'affiliation': None}, {'lastname': 'Charach', 'firstname': 'Gideon', 'initials': 'G', 'affiliation': None}, {'lastname': 'Afek', 'firstname': 'Arnon', 'initials': 'A', 'affiliation': None}, {'lastname': 'Shamiss', 'firstname': 'Ari', 'initials': 'A', 'affiliation': None}]",,"Regulatory T cells and serum IL-10 may discriminate ""vulnerable"" versus stable patients and may have a protective role against plaque rupture in patients with coronary atherosclerosis.","A significantly higher level of Treg cells was present in the control (73.4%±4) than in the ""vulnerable patient"" group (62.2%±10.7), p<0.001. IL-10 level was also significantly higher in the control than in the vulnerable patients (2.6±1.2 pg/ml versus 0.9±0.1 pg/ml respectively, p=0.03). There was no significant difference in the circulating levels of the other cytokines, hormones or EPCs between the two groups.",Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.atherosclerosis.2012.03.016,<Element 'PubmedArticle' at 0x7f05d8f322c0>
295,"22539844
20061018
20004110
9128149
19945522
17545985
8377226
15961189
19954954
15852400
9928452
7832454
13345836
220260
12122214
14739060
2720061
18987186
15345489
9763459
15657641
3367161
6135779
16987039
19799853
22027063
7847664
8572312
11342263
2334850
3760866
21942371
18021291
20194732
10782128
9596412
19298790
10066249
12895417
14643377
17335078
18438923
12704814
19374891
18423383
20520725
10931172
16125228
16156741
9603784
16687509
19667196
18020963",A reversible early oxidized redox state that precedes macromolecular ROS damage in aging nontransgenic and 3xTg-AD mouse neurons.,"The brain depends on redox electrons from nicotinamide adenine dinucleotide (reduced form; NADH) to produce ATP and oxyradicals (reactive oxygen species [ROS]). Because ROS damage and mitochondrial dysregulation are prominent in aging and Alzheimer's disease (AD) and their relationship to the redox state is unclear, we wanted to know whether an oxidative redox shift precedes these markers and leads to macromolecular damage in a mouse model of AD. We used the 3xTg-AD mouse model, which displays cognitive deficits beginning at 4 months. Hippocampal/cortical neurons were isolated across the age span and cultured in common nutrients to control for possible hormonal and vascular differences. We found an increase of NAD(P)H levels and redox state in nontransgenic (non-Tg) neurons until middle age, followed by a decline in old age. The 3xTg-AD neurons maintained much lower resting NAD(P)H and redox states after 4 months, but the NADH regenerating capacity continuously declined with age beginning at 2 months. These redox characteristics were partially reversible with nicotinamide, a biosynthetic precursor of NAD+. Nicotinamide also protected against glutamate excitotoxicity. Compared with non-Tg neurons, 3xTg-AD neurons had more mitochondria/neuron and lower glutathione (GSH) levels that preceded age-related increases in ROS levels. These GSH deficits were again reversible with nicotinamide in 3xTg-AD neurons. Surprisingly, low macromolecular ROS damage was only elevated after 4 months in the 3xTg-AD neurons if antioxidants were removed. The present data suggest that a more oxidized redox state and a lower antioxidant GSH defense can be dissociated from neuronal ROS damage, changes that precede the onset of cognitive deficits in the 3xTg-AD model.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,2012-04-28,"[{'lastname': 'Ghosh', 'firstname': 'Debolina', 'initials': 'D', 'affiliation': 'Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, Illinois 62794-9626, USA.'}, {'lastname': 'LeVault', 'firstname': 'Kelsey R', 'initials': 'KR', 'affiliation': None}, {'lastname': 'Barnett', 'firstname': 'Aaron J', 'initials': 'AJ', 'affiliation': None}, {'lastname': 'Brewer', 'firstname': 'Gregory J', 'initials': 'GJ', 'affiliation': None}]",,,,,10.1523/JNEUROSCI.6192-11.2012,<Element 'PubmedArticle' at 0x7f05d8f40680>
296,"22527887
20410233
14764775
11980628
16940446
22383336
21732759
15817922
16003295
22364824
21673137
22282526
17977644
12588807
11145235
19820006
21870170
18957506
6623350
22124940
22713526
22397653
8522631
16311419
21993190","Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.","A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects. Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences. Thirty-three subjects were randomized. The most frequently reported drug-related adverse events were injection-site reactions (n = 18), diarrhea (n = 14) and nausea (n = 10), which were mostly mild or moderate in intensity. Pasireotide 600 μg sc was associated with pre- and post-prandial elevations in glucose levels relative to placebo; however, this effect was less pronounced on day 14 compared with day 1. PK steady state appeared to be achieved after 3 days of dosing and PK exposures had a moderate accumulation of 20-40 % across doses. Pasireotide demonstrated fast absorption (T(max,ss): 0.25-0.5 h), low clearance (CL/F(ss): 8.10-9.03 L/h), long effective half-life (T(½,eff): ~12 h, on average between 9.7 and 13.1 h for 50, 200, and 600 μg sc qd), and large volume of distribution (V(z)/F(ss): 251-1,091 L) at steady state. Dose proportionality was confirmed for C(max,ss); other PK parameters (C(max), AUC(0-24 h) and AUC(tau)) were approximately dose proportional. Growth hormone inhibition was observed with pasireotide 200 and 600 μg sc qd. Gallbladder volume increased post-prandially with pasireotide 200 and 600 μg sc qd, which appeared to correlate with reduced levels of cholecystokinin at these doses. Pasireotide was generally well tolerated up to the tested dose of 600 μg qd, with a linear and time-independent PK profile after sc qd dosing in healthy subjects.",[],Endocrine,2012-04-25,"[{'lastname': 'Beglinger', 'firstname': 'Christoph', 'initials': 'C', 'affiliation': 'Division of Gastroenterology, University Hospital Basel, Basel, Switzerland. beglingerc@uhbs.ch'}, {'lastname': 'Hu', 'firstname': 'Ke', 'initials': 'K', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Bouillaud', 'firstname': 'Emmanuel', 'initials': 'E', 'affiliation': None}, {'lastname': 'Darstein', 'firstname': 'Christelle', 'initials': 'C', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Yanfeng', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Mohideen', 'firstname': 'Pharis', 'initials': 'P', 'affiliation': None}]",,,,,10.1007/s12020-012-9668-1,<Element 'PubmedArticle' at 0x7f05d8ee5090>
297,22493071,Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade.,"To investigate whether heart rate reduction via I(f)-channel blockade and β-receptor blockade prevents left ventricular (LV) dysfunction, we studied ivabradine and metoprolol in angiotensin II-induced heart failure. Cardiac dysfunction in C57BL/6J mice was induced by implantation of osmotic pumps for continuous subcutaneous dosing of angiotensin II (1.8 mg/kg per day SC) over a period of 3 weeks. Ivabradine (10 mg/kg per day) and metoprolol (90 mg/kg per day), which resulted in similar heart rate reduction, or placebo treatments were simultaneously started with infusion of angiotensin II. After 3 weeks, LV function was estimated by conductance catheter technique, cardiac remodeling assessed by estimation of cardiac hypertrophy, fibrosis, and inflammatory stress response by immunohistochemistry or PCR, respectively. Compared with controls, angiotensin II infusion resulted in hypertension in impaired systolic (LV contractility, stroke volume, end systolic elastance, afterload, index of arterial-ventricular coupling, and cardiac output; P<0.05) and diastolic (LV relaxation, LV end diastolic pressure, τ, and stiffness constant β; P<0.05) LV function. This was associated with a significant increase in cardiac hypertrophy and fibrosis. Increased cardiac stress was also indicated by an increase in cardiac inflammation and apoptosis. Both ivabradine and metoprolol led to a similar reduction in heart rate. Metoprolol also reduced systolic blood pressure. Ivabradine led to a significant improvement in systolic and diastolic LV function (P<0.05). This was associated with less cardiac hypertrophy, fibrosis, inflammation, and cardiac apoptosis (P<0.05). Metoprolol treatment did not prevent the reduction in cardiac function and adverse remodeling, despite a reduction of the inflammatory stress response. Behind heart rate reduction, additional beneficial cardiac effects contribute to heart failure prevention with I(f)-channel inhibition.",[],"Hypertension (Dallas, Tex. : 1979)",2012-04-12,"[{'lastname': 'Becher', 'firstname': 'Peter Moritz', 'initials': 'PM', 'affiliation': 'Department of Cardiology and Pneumology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.'}, {'lastname': 'Lindner', 'firstname': 'Diana', 'initials': 'D', 'affiliation': None}, {'lastname': 'Miteva', 'firstname': 'Kapka', 'initials': 'K', 'affiliation': None}, {'lastname': 'Savvatis', 'firstname': 'Konstantinos', 'initials': 'K', 'affiliation': None}, {'lastname': 'Zietsch', 'firstname': 'Christin', 'initials': 'C', 'affiliation': None}, {'lastname': 'Schmack', 'firstname': 'Bastian', 'initials': 'B', 'affiliation': None}, {'lastname': 'Van Linthout', 'firstname': 'Sophie', 'initials': 'S', 'affiliation': None}, {'lastname': 'Westermann', 'firstname': 'Dirk', 'initials': 'D', 'affiliation': None}, {'lastname': 'Schultheiss', 'firstname': 'Heinz-Peter', 'initials': 'HP', 'affiliation': None}, {'lastname': 'Tschöpe', 'firstname': 'Carsten', 'initials': 'C', 'affiliation': None}]",,,,,10.1161/HYPERTENSIONAHA.111.183913,<Element 'PubmedArticle' at 0x7f05d8ef7310>
298,"22425595
15122244
18782901
15735218
19237574
19940606
17130475
19373446
10604838
8714271
20026079
16127210
12413946
7706234
21277873
18670165
3139677
15709112
14747300
15537830
18627032
18926603
15522998
21098287
19819959
12093242
11832527
9526970
12150780
17456849
10973319
8687413
11248668
18363935
19738399
16914228
10599761
17376970
18077675
11441005
14633764
17233641
10737616
20393934
11274343
12399581
11711878
9051402
18651634
19293705
8896801
15126696
11055423
22117616
20655383
19026743
19650667","Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice.","Diabetes increases the risk of Alzheimer's disease (AD). The pathological hallmarks for AD brains are extracellular amyloid plaques formed by β-amyloid peptide (Aβ) and intracellular neurofibrillary tangles consisting of hyperphosphorylated tau protein. This study was designed to determine AD-like brain changes in mice modeling for type 2 diabetes. The effects of metformin on these changes also were studied. Seven-week old male db/db mice received intraperitoneal injection of 200 mg kg⁻¹ d⁻¹ metformin for 18 weeks. They were subjected to Barnes maze at an age of 21 weeks and fear conditioning at an age of 24 weeks to assess their cognitive functions. Hippocampus was harvested after these tests for biochemical evaluation. The db/db mice had more tau phosphorylated at S396 and total tau in their hippocampi than their non-diabetic control db+mice. Activated/phosphorylated c-jun N-terminal kinase (JNK), a tau kinase, was increased in the db/db mouse hippocampus. Metformin attenuated the increase of total tau, phospho-tau and activated JNK. The db/db mice had increased Aβ levels. Metformin attenuated the reduction of synaptophysin, a synaptic protein, in the db/db mouse hippocampus. Metformin did not attenuate the impairments of spatial learning and memory as well as long-term hyperglycemia in the db/db mice. Our results suggest that the db/db mice have multiple AD-like brain changes including impaired cognitive functions, increased phospho-tau and Aβ as well as decreased synaptic proteins. Activation of JNK may contribute to the increased phospho-tau in the db/db mice. Metformin attenuates AD-like biochemical changes in the brain of these mice.",[],"Pharmacology, biochemistry, and behavior",2012-03-20,"[{'lastname': 'Li', 'firstname': 'Jiejie', 'initials': 'J', 'affiliation': 'Department of Anesthesiology, University of Virginia, Charlottesville, VA 22908, USA.'}, {'lastname': 'Deng', 'firstname': 'Jiao', 'initials': 'J', 'affiliation': None}, {'lastname': 'Sheng', 'firstname': 'Wenli', 'initials': 'W', 'affiliation': None}, {'lastname': 'Zuo', 'firstname': 'Zhiyi', 'initials': 'Z', 'affiliation': None}]",,,,Copyright © 2012 Elsevier Inc. All rights reserved.,10.1016/j.pbb.2012.03.002,<Element 'PubmedArticle' at 0x7f05d8f03cc0>
299,22418865,Taurine supplementation prevents morpho-physiological alterations in high-fat diet mice pancreatic β-cells.,"Taurine (Tau) is involved in beta (β)-cell function and insulin action regulation. Here, we verified the possible preventive effect of Tau in high-fat diet (HFD)-induced obesity and glucose intolerance and in the disruption of pancreatic β-cell morpho-physiology. Weaning Swiss mice were distributed into four groups: mice fed on HFD diet (36 % of saturated fat, HFD group); HTAU, mice fed on HFD diet and supplemented with 5 % Tau; control (CTL); and CTAU. After 19 weeks of diet and Tau treatments, glucose tolerance, insulin sensitivity and islet morpho-physiology were evaluated. HFD mice presented higher body weight and fat depots, and were hyperglycemic, hyperinsulinemic, glucose intolerant and insulin resistant. Their pancreatic islets secreted high levels of insulin in the presence of increasing glucose concentrations and 30 mM K(+). Tau supplementation improved glucose tolerance and insulin sensitivity with a higher ratio of Akt phosphorylated (pAkt) related to Akt total protein content (pAkt/Akt) following insulin administration in the liver without altering body weight and fat deposition in HTAU mice. Isolated islets from HTAU mice released insulin similarly to CTL islets. HFD intake induced islet hypertrophy, increased β-cell/islet area and islet and β-cell mass content in the pancreas. Tau prevented islet and β-cell/islet area, and islet and β-cell mass alterations induced by HFD. The total insulin content in HFD islets was higher than that of CTL islets, and was not altered in HTAU islets. In conclusion, for the first time, we showed that Tau enhances liver Akt activation and prevents β-cell compensatory morpho-functional adaptations induced by HFD.",[],Amino acids,2012-03-16,"[{'lastname': 'Ribeiro', 'firstname': 'Rosane Aparecida', 'initials': 'RA', 'affiliation': 'Departamento de Biologia Celular e Estrutural, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil. rosaneribeirobio@yahoo.com.br'}, {'lastname': 'Santos-Silva', 'firstname': 'Junia Carolina', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Vettorazzi', 'firstname': 'Jean Francisco', 'initials': 'JF', 'affiliation': None}, {'lastname': 'Cotrim', 'firstname': 'Beatriz Borghi', 'initials': 'BB', 'affiliation': None}, {'lastname': 'Mobiolli', 'firstname': 'Daniela D M', 'initials': 'DD', 'affiliation': None}, {'lastname': 'Boschero', 'firstname': 'Antonio Carlos', 'initials': 'AC', 'affiliation': None}, {'lastname': 'Carneiro', 'firstname': 'Everardo Magalhães', 'initials': 'EM', 'affiliation': None}]",,,,,10.1007/s00726-012-1263-5,<Element 'PubmedArticle' at 0x7f05d8eac4f0>
300,"22366795
22101323
17196872
10860804
15955494
16862116
18234697
12833363
15615814
20562461
16009889
19020205
16862115
21944778
20808728
16950801
18322394
9641683
11971081
15728305
18668533
21614463
16300968
17949857
18245784
17021754
21644037
19015862
16503405
17030534
6610841
17210807
7114808
2011243
20452812
22083254
9855500
21072532
18192287
21944779
11089577
21172843
20045477
21753175
15907317
9617910
17003069
18065436
17917583
8163988
11771995
10514099
21912680
17353379
19786698
19255408
21172844
16401855
16157747
19762452
11293691","Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics.","A major recent discovery was the identification of an expansion of a non-coding GGGGCC hexanucleotide repeat in the C9ORF72 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Mutations in two other genes are known to account for familial frontotemporal dementia: microtubule-associated protein tau and progranulin. Although imaging features have been previously reported in subjects with mutations in tau and progranulin, no imaging features have been published in C9ORF72. Furthermore, it remains unknown whether there are differences in atrophy patterns across these mutations, and whether regional differences could help differentiate C9ORF72 from the other two mutations at the single-subject level. We aimed to determine the regional pattern of brain atrophy associated with the C9ORF72 gene mutation, and to determine which regions best differentiate C9ORF72 from subjects with mutations in tau and progranulin, and from sporadic frontotemporal dementia. A total of 76 subjects, including 56 with a clinical diagnosis of behavioural variant frontotemporal dementia and a mutation in one of these genes (19 with C9ORF72 mutations, 25 with tau mutations and 12 with progranulin mutations) and 20 sporadic subjects with behavioural variant frontotemporal dementia (including 50% with amyotrophic lateral sclerosis), with magnetic resonance imaging were included in this study. Voxel-based morphometry was used to assess and compare patterns of grey matter atrophy. Atlas-based parcellation was performed utilizing the automated anatomical labelling atlas and Statistical Parametric Mapping software to compute volumes of 37 regions of interest. Hemispheric asymmetry was calculated. Penalized multinomial logistic regression was utilized to create a prediction model to discriminate among groups using regional volumes and asymmetry score. Principal component analysis assessed for variance within groups. C9ORF72 was associated with symmetric atrophy predominantly involving dorsolateral, medial and orbitofrontal lobes, with additional loss in anterior temporal lobes, parietal lobes, occipital lobes and cerebellum. In contrast, striking anteromedial temporal atrophy was associated with tau mutations and temporoparietal atrophy was associated with progranulin mutations. The sporadic group was associated with frontal and anterior temporal atrophy. A conservative penalized multinomial logistic regression model identified 14 variables that could accurately classify subjects, including frontal, temporal, parietal, occipital and cerebellum volume. The principal component analysis revealed similar degrees of heterogeneity within all disease groups. Patterns of atrophy therefore differed across subjects with C9ORF72, tau and progranulin mutations and sporadic frontotemporal dementia. Our analysis suggested that imaging has the potential to be useful to help differentiate C9ORF72 from these other groups at the single-subject level.",[],Brain : a journal of neurology,2012-03-01,"[{'lastname': 'Whitwell', 'firstname': 'Jennifer L', 'initials': 'JL', 'affiliation': 'Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. whitwell.jennifer@mayo.edu'}, {'lastname': 'Weigand', 'firstname': 'Stephen D', 'initials': 'SD', 'affiliation': None}, {'lastname': 'Boeve', 'firstname': 'Bradley F', 'initials': 'BF', 'affiliation': None}, {'lastname': 'Senjem', 'firstname': 'Matthew L', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Gunter', 'firstname': 'Jeffrey L', 'initials': 'JL', 'affiliation': None}, {'lastname': 'DeJesus-Hernandez', 'firstname': 'Mariely', 'initials': 'M', 'affiliation': None}, {'lastname': 'Rutherford', 'firstname': 'Nicola J', 'initials': 'NJ', 'affiliation': None}, {'lastname': 'Baker', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': None}, {'lastname': 'Knopman', 'firstname': 'David S', 'initials': 'DS', 'affiliation': None}, {'lastname': 'Wszolek', 'firstname': 'Zbigniew K', 'initials': 'ZK', 'affiliation': None}, {'lastname': 'Parisi', 'firstname': 'Joseph E', 'initials': 'JE', 'affiliation': None}, {'lastname': 'Dickson', 'firstname': 'Dennis W', 'initials': 'DW', 'affiliation': None}, {'lastname': 'Petersen', 'firstname': 'Ronald C', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': None}, {'lastname': 'Jack', 'firstname': 'Clifford R', 'initials': 'CR', 'affiliation': None}, {'lastname': 'Josephs', 'firstname': 'Keith A', 'initials': 'KA', 'affiliation': None}]",,,,,10.1093/brain/aws001,<Element 'PubmedArticle' at 0x7f05d8eb9360>
301,"22366793
22101323
15955494
16862116
20562461
1759558
11464847
21840887
21208036
16862115
21944778
1202204
14597319
20457961
21325651
1603339
9641683
9408798
19455346
16606762
16930776
18372902
19251627
19433740
20625088
12194385
12370467
15178949
9777473
9892057
18755042
21644037
17021754
1891084
2011243
21925771
16421333
22083254
9855500
21072532
21387376
21810890
21944779
18259084
21559874
8446170
11805245
18309045
9524887
19336463
11771995
17296840
16495328
19251628
21195775
15034582
16908994
16157747
17659193
19762452
20433413",Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72.,"Numerous kindreds with familial frontotemporal dementia and/or amyotrophic lateral sclerosis have been linked to chromosome 9, and an expansion of the GGGGCC hexanucleotide repeat in the non-coding region of chromosome 9 open reading frame 72 has recently been identified as the pathogenic mechanism. We describe the key characteristics in the probands and their affected relatives who have been evaluated at Mayo Clinic Rochester or Mayo Clinic Florida in whom the hexanucleotide repeat expansion were found. Forty-three probands and 10 of their affected relatives with DNA available (total 53 subjects) were shown to carry the hexanucleotide repeat expansion. Thirty-six (84%) of the 43 probands had a familial disorder, whereas seven (16%) appeared to be sporadic. Among examined subjects from the 43 families (n = 63), the age of onset ranged from 33 to 72 years (median 52 years) and survival ranged from 1 to 17 years, with the age of onset <40 years in six (10%) and >60 in 19 (30%). Clinical diagnoses among examined subjects included behavioural variant frontotemporal dementia with or without parkinsonism (n = 30), amyotrophic lateral sclerosis (n = 18), frontotemporal dementia/amyotrophic lateral sclerosis with or without parkinsonism (n = 12), and other various syndromes (n = 3). Parkinsonism was present in 35% of examined subjects, all of whom had behavioural variant frontotemporal dementia or frontotemporal dementia/amyotrophic lateral sclerosis as the dominant clinical phenotype. No subject with a diagnosis of primary progressive aphasia was identified with this mutation. Incomplete penetrance was suggested in two kindreds, and the youngest generation had significantly earlier age of onset (>10 years) compared with the next oldest generation in 11 kindreds. Neuropsychological testing showed a profile of slowed processing speed, complex attention/executive dysfunction, and impairment in rapid word retrieval. Neuroimaging studies showed bilateral frontal abnormalities most consistently, with more variable degrees of parietal with or without temporal changes; no case had strikingly focal or asymmetric findings. Neuropathological examination of 14 patients revealed a range of transactive response DNA binding protein molecular weight 43 pathology (10 type A and four type B), as well as ubiquitin-positive cerebellar granular neuron inclusions in all but one case. Motor neuron degeneration was detected in nine patients, including five patients without ante-mortem signs of motor neuron disease. While variability exists, most cases with this mutation have a characteristic spectrum of demographic, clinical, neuropsychological, neuroimaging and especially neuropathological findings.",[],Brain : a journal of neurology,2012-03-01,"[{'lastname': 'Boeve', 'firstname': 'Bradley F', 'initials': 'BF', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA. bboeve@mayo.edu'}, {'lastname': 'Boylan', 'firstname': 'Kevin B', 'initials': 'KB', 'affiliation': None}, {'lastname': 'Graff-Radford', 'firstname': 'Neill R', 'initials': 'NR', 'affiliation': None}, {'lastname': 'DeJesus-Hernandez', 'firstname': 'Mariely', 'initials': 'M', 'affiliation': None}, {'lastname': 'Knopman', 'firstname': 'David S', 'initials': 'DS', 'affiliation': None}, {'lastname': 'Pedraza', 'firstname': 'Otto', 'initials': 'O', 'affiliation': None}, {'lastname': 'Vemuri', 'firstname': 'Prashanthi', 'initials': 'P', 'affiliation': None}, {'lastname': 'Jones', 'firstname': 'David', 'initials': 'D', 'affiliation': None}, {'lastname': 'Lowe', 'firstname': 'Val', 'initials': 'V', 'affiliation': None}, {'lastname': 'Murray', 'firstname': 'Melissa E', 'initials': 'ME', 'affiliation': None}, {'lastname': 'Dickson', 'firstname': 'Dennis W', 'initials': 'DW', 'affiliation': None}, {'lastname': 'Josephs', 'firstname': 'Keith A', 'initials': 'KA', 'affiliation': None}, {'lastname': 'Rush', 'firstname': 'Beth K', 'initials': 'BK', 'affiliation': None}, {'lastname': 'Machulda', 'firstname': 'Mary M', 'initials': 'MM', 'affiliation': None}, {'lastname': 'Fields', 'firstname': 'Julie A', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Ferman', 'firstname': 'Tanis J', 'initials': 'TJ', 'affiliation': None}, {'lastname': 'Baker', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': None}, {'lastname': 'Rutherford', 'firstname': 'Nicola J', 'initials': 'NJ', 'affiliation': None}, {'lastname': 'Adamson', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': None}, {'lastname': 'Wszolek', 'firstname': 'Zbigniew K', 'initials': 'ZK', 'affiliation': None}, {'lastname': 'Adeli', 'firstname': 'Anahita', 'initials': 'A', 'affiliation': None}, {'lastname': 'Savica', 'firstname': 'Rodolfo', 'initials': 'R', 'affiliation': None}, {'lastname': 'Boot', 'firstname': 'Brendon', 'initials': 'B', 'affiliation': None}, {'lastname': 'Kuntz', 'firstname': 'Karen M', 'initials': 'KM', 'affiliation': None}, {'lastname': 'Gavrilova', 'firstname': 'Ralitza', 'initials': 'R', 'affiliation': None}, {'lastname': 'Reeves', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': None}, {'lastname': 'Whitwell', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': None}, {'lastname': 'Kantarci', 'firstname': 'Kejal', 'initials': 'K', 'affiliation': None}, {'lastname': 'Jack', 'firstname': 'Clifford R', 'initials': 'CR', 'affiliation': None}, {'lastname': 'Parisi', 'firstname': 'Joseph E', 'initials': 'JE', 'affiliation': None}, {'lastname': 'Lucas', 'firstname': 'John A', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Petersen', 'firstname': 'Ronald C', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': None}]",,,,,10.1093/brain/aws004,<Element 'PubmedArticle' at 0x7f05d8e62770>
302,"22366267
12144738
15775020
3525490
14529811
24923970
12766938
11242031
6805001
16167089
9858740
11144344
10725928
21219937
17210805
6125971
21329752
9050113
12385793
9491940
10580307
2705984
24897196
10390720
9193740
12883917
11250003
15766212
14523435
3378680
4934556
4084624
12526035
24923973
6049627
22526692",Some stereotypic behaviors in rhesus macaques (Macaca mulatta) are correlated with both perseveration and the ability to cope with acute stressors.,"The most prevalent sub-group of abnormal repetitive behaviors among captive animals is that of stereotypies. Previous studies have demonstrated some resemblance between stereotypy in captive animals and in humans, including the involvement of neurological malfunctions that lead to the expression of stereotypies. This malfunction can be evaluated through the use of neuropsychological tasks that assess perseveration as implying a failure of the basal ganglia (BG) to operate properly. Other studies, in contrast, have suggested that stereotypies are the product of neurologically intact individuals reacting to the abnormal nature of their surroundings, and are possibly characterized by an adaptive feature that enables the subject to cope with such adversity. Employing neuropsychological tests and also measuring the levels of fecal corticoids in captive rhesus macaques, we tested the hypothesis that stereotypies are related both to brain pathology and to a coping mechanism with stress, resembling accounts by autistic individuals exhibiting basal ganglia malfunction, and who report a sense of relief when performing stereotypies. Self-directed and fine-motor stereotypies exhibited by the monkeys were positively correlated with perseveration, suggesting BG malfunction; while self-directed stereotypies were also negatively correlated with an increase in fecal corticoids following a stress challenge, suggesting a related coping mechanism. We therefore suggest that not all repetitive, unvarying, and apparently functionless behaviors should be regarded as one homogeneous group of stereotypic behaviors; and that, reflecting reports from autistic individuals, self-directed stereotypies in captive rhesus monkeys are related both to brain pathology, and to an adaptive mechanism that allows those that express them to better cope with acute stressors.",[],Behavioural brain research,2012-03-01,"[{'lastname': 'Pomerantz', 'firstname': 'Ori', 'initials': 'O', 'affiliation': 'Department of Zoology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel. oripomer@post.tau.ac.il'}, {'lastname': 'Paukner', 'firstname': 'Annika', 'initials': 'A', 'affiliation': None}, {'lastname': 'Terkel', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': None}]",,,,Copyright © 2012 Elsevier B.V. All rights reserved.,10.1016/j.bbr.2012.02.019,<Element 'PubmedArticle' at 0x7f05d8e91ea0>
303,22329650,The potential use of hormone-based therapeutics for the treatment of Alzheimer's disease.,"In both men and women, age-related loss of sex steroid hormones has been linked to an increased risk for Alzheimer's disease (AD). The primary female hormone estrogen, and the primary male hormone testosterone have numerous protective effects in the brain relevant to the prevention of AD such as the promotion of neuron viability, reduction of β- amyloid accumulation and alleviation of tau hyperphosphorylation. Therefore it has been hypothesized that the precipitous loss of these hormones either through menopause or normal aging, can increase susceptibility to AD pathogenesis. This review will discuss the basic science research and epidemiological evidence largely supporting this hypothesis, as well as the estrogen-based hormone therapy clinical findings that have recently shed doubt on this theory. The complications associated with estrogen-based hormone therapy such as the inclusion of a progestogen, hormone responsiveness with age, and natural vs. synthetic hormones will be discussed. Further, we will outline the cancer risks facing both estrogen and testosterone-based hormone therapy. Most importantly, this review will discuss the present and future strategies to translate the neuroprotective properties of sex steroid hormones into safe and efficacious treatments for AD. One of the most promising translational tools thus far may be the development of selective estrogen and androgen receptor modulators. However, additional research is needed to optimize these and other translational tools towards the successful use of hormone therapies in both men and women to delay, prevent, and or treat AD.",[],Current Alzheimer research,2012-02-15,"[{'lastname': 'Carroll', 'firstname': 'Jenna C', 'initials': 'JC', 'affiliation': 'Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. jennac@mail.med.upenn.edu'}, {'lastname': 'Rosario', 'firstname': 'Emily R', 'initials': 'ER', 'affiliation': None}]",,,,,10.2174/156720512799015109,<Element 'PubmedArticle' at 0x7f05d8e29e00>
304,22300876,The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions.,"There is increasing evidence that frontotemporal dementia and amyotrophic lateral sclerosis are part of a disease continuum. Recently, a hexanucleotide repeat expansion in C9orf72 was identified as a major cause of both sporadic and familial frontotemporal dementia and amyotrophic lateral sclerosis. The aim of this study was to investigate clinical and neuropathological characteristics of hexanucleotide repeat expansions in C9orf72 in a large cohort of Dutch patients with frontotemporal dementia. Repeat expansions were successfully determined in a cohort of 353 patients with sporadic or familial frontotemporal dementia with or without amyotrophic lateral sclerosis, and 522 neurologically normal controls. Immunohistochemistry was performed in a series of 10 brains from patients carrying expanded repeats using a panel of antibodies. In addition, the presence of RNA containing GGGGCC repeats in paraffin-embedded sections of post-mortem brain tissue was investigated using fluorescence in situ hybridization with a locked nucleic acid probe targeting the GGGGCC repeat. Hexanucleotide repeat expansions in C9orf72 were found in 37 patients with familial (28.7%) and five with sporadic frontotemporal dementia (2.2%). The mean age at onset was 56.9 ± 8.3 years (range 39-76), and disease duration 7.6 ± 4.6 years (range 1-22). The clinical phenotype of these patients varied between the behavioural variant of frontotemporal dementia (n = 34) and primary progressive aphasia (n = 8), with concomitant amyotrophic lateral sclerosis in seven patients. Predominant temporal atrophy on neuroimaging was present in 13 of 32 patients. Pathological examination of the 10 brains from patients carrying expanded repeats revealed frontotemporal lobar degeneration with neuronal transactive response DNA binding protein-positive inclusions of variable type, size and morphology in all brains. Fluorescence in situ hybridization analysis of brain material from patients with the repeat expansion, a microtubule-associated protein tau or a progranulin mutation, and controls did not show RNA-positive inclusions specific for brains with the GGGGCC repeat expansion. The hexanucleotide repeat expansion in C9orf72 is an important cause of frontotemporal dementia with and without amyotrophic lateral sclerosis, and is sometimes associated with primary progressive aphasia. Neuropathological hallmarks include neuronal and glial inclusions, and dystrophic neurites containing transactive response DNA binding protein. Future studies are needed to explain the wide variation in clinical presentation.",[],Brain : a journal of neurology,2012-02-04,"[{'lastname': 'Simón-Sánchez', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Department of Clinical Genetics, VU University Medical Centre, 1007 MB Amsterdam, The Netherlands.'}, {'lastname': 'Dopper', 'firstname': 'Elise G P', 'initials': 'EG', 'affiliation': None}, {'lastname': 'Cohn-Hokke', 'firstname': 'Petra E', 'initials': 'PE', 'affiliation': None}, {'lastname': 'Hukema', 'firstname': 'Renate K', 'initials': 'RK', 'affiliation': None}, {'lastname': 'Nicolaou', 'firstname': 'Nayia', 'initials': 'N', 'affiliation': None}, {'lastname': 'Seelaar', 'firstname': 'Harro', 'initials': 'H', 'affiliation': None}, {'lastname': 'de Graaf', 'firstname': 'J Roos A', 'initials': 'JR', 'affiliation': None}, {'lastname': 'de Koning', 'firstname': 'Inge', 'initials': 'I', 'affiliation': None}, {'lastname': 'van Schoor', 'firstname': 'Natasja M', 'initials': 'NM', 'affiliation': None}, {'lastname': 'Deeg', 'firstname': 'Dorly J H', 'initials': 'DJ', 'affiliation': None}, {'lastname': 'Smits', 'firstname': 'Marion', 'initials': 'M', 'affiliation': None}, {'lastname': 'Raaphorst', 'firstname': 'Joost', 'initials': 'J', 'affiliation': None}, {'lastname': 'van den Berg', 'firstname': 'Leonard H', 'initials': 'LH', 'affiliation': None}, {'lastname': 'Schelhaas', 'firstname': 'Helenius J', 'initials': 'HJ', 'affiliation': None}, {'lastname': 'De Die-Smulders', 'firstname': 'Christine E M', 'initials': 'CE', 'affiliation': None}, {'lastname': 'Majoor-Krakauer', 'firstname': 'Danielle', 'initials': 'D', 'affiliation': None}, {'lastname': 'Rozemuller', 'firstname': 'Annemieke J M', 'initials': 'AJ', 'affiliation': None}, {'lastname': 'Willemsen', 'firstname': 'Rob', 'initials': 'R', 'affiliation': None}, {'lastname': 'Pijnenburg', 'firstname': 'Yolande A L', 'initials': 'YA', 'affiliation': None}, {'lastname': 'Heutink', 'firstname': 'Peter', 'initials': 'P', 'affiliation': None}, {'lastname': 'van Swieten', 'firstname': 'John C', 'initials': 'JC', 'affiliation': None}]",,,,,10.1093/brain/awr353,<Element 'PubmedArticle' at 0x7f05d8e329a0>
305,22281444,Differences in brain cholesterol metabolism and insulin in two subgroups of patients with different CSF biomarkers but similar white matter lesions suggest different pathogenic mechanisms.,"Investigate possible associations of white matter hyperintensities (WMHs) with the metabolism of cholesterol and insulin in two subgroups of patients with memory complaints and different CSF Aβ42 and CSF tau levels. 59 patients from the memory clinic at Karolinska Hospital were included. Degree of WMHs was rated using the ARWMC scale and the following biomarkers were measured in CSF and plasma: insulin, cholesterol, lanosterol, lathosterol, and oxidized cholesterol metabolites. The WMHs in CSF control-like group correlated with increased brain cholesterol synthesis and reduced efflux of oxysterols and insulin in CSF. In the CSF AD-like group, the WMHs correlated with increased peripheral cholesterol metabolism. Despite having similar appearance on FLAIR images, the pathogenic mechanisms of WMHS are likely to be different in the two groups investigated.",[],Neuroscience letters,2012-01-28,"[{'lastname': 'Besga', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Department of Psychiatry, Hospital Universitario de Álava, Vitoria, Spain. ariadna.besgabasterra@osakidetza.net'}, {'lastname': 'Cedazo-Minguez', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Kåreholt', 'firstname': 'I', 'initials': 'I', 'affiliation': None}, {'lastname': 'Solomon', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Björkhem', 'firstname': 'I', 'initials': 'I', 'affiliation': None}, {'lastname': 'Winblad', 'firstname': 'B', 'initials': 'B', 'affiliation': None}, {'lastname': 'Leoni', 'firstname': 'V', 'initials': 'V', 'affiliation': None}, {'lastname': 'Hooshmand', 'firstname': 'B', 'initials': 'B', 'affiliation': None}, {'lastname': 'Spulber', 'firstname': 'G', 'initials': 'G', 'affiliation': None}, {'lastname': 'Gonzalez-Pinto', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Kivipelto', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Wahlund', 'firstname': 'L O', 'initials': 'LO', 'affiliation': None}]",,,,Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.neulet.2012.01.017,<Element 'PubmedArticle' at 0x7f05d8e40e50>
306,22245388,Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures.,"Increasing evidence supports an association between Alzheimer's disease (AD) and diabetes. In this context, anti-diabetic agents such as rosiglitazone and glucagon-like peptide (GLP)-1 have been reported to reduce pathologies associated with AD, including tau hyperphosphorylation, suggesting that such agents might be used to treat AD. One such anti-diabetic agent is sitagliptin, which acts through inhibition of dipeptidyl peptidase (DPP)-IV to increase GLP-1 levels. Given this action, sitagliptin would be predicted to reduce AD pathology. Accordingly, we investigated whether sitagliptin is effective in attenuating AD pathologies, focusing on tau phosphorylation in the OLETF type 2 diabetic rat model. Unexpectedly, we found that sitagliptin was not effective against pathological tau phosphorylation in the hippocampus of OLETF type 2 diabetes rats, and instead aggravated it. This paradoxically increased tau phosphorylation was attributed to activation of the tau kinase, GSK3β (glycogen synthase kinase 3β). Sitagliptin also increased ser-616 phosphorylation of the insulin receptor substrate (IRS)-1, suggesting increased insulin resistance in the brain. These phenomena were recapitulated in primary rat cortical neurons treated with sitagliptin, further confirming sitagliptin's effects on AD-related pathologies in neurons. These results highlight the need for caution in considering the use of sitagliptin in AD therapy.",[],Neurobiology of disease,2012-01-17,"[{'lastname': 'Kim', 'firstname': 'Dong-Hou', 'initials': 'DH', 'affiliation': 'Department of Anatomy and Cell Biology, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'lastname': 'Huh', 'firstname': 'Jae-Wan', 'initials': 'JW', 'affiliation': None}, {'lastname': 'Jang', 'firstname': 'Mi', 'initials': 'M', 'affiliation': None}, {'lastname': 'Suh', 'firstname': 'Jung-Hyun', 'initials': 'JH', 'affiliation': None}, {'lastname': 'Kim', 'firstname': 'Tae-Wan', 'initials': 'TW', 'affiliation': None}, {'lastname': 'Park', 'firstname': 'Jeong-Su', 'initials': 'JS', 'affiliation': None}, {'lastname': 'Yoon', 'firstname': 'Seung-Yong', 'initials': 'SY', 'affiliation': None}]",,,,Copyright Â© 2012 Elsevier Inc. All rights reserved.,10.1016/j.nbd.2011.12.043,<Element 'PubmedArticle' at 0x7f05d8e4fa40>
307,22208821,Effects of estrogen and progesterone on cerebrovascular responses to euoxic hypercapnia in women.,"To determine the cerebral blood flow response to step changes in end-tidal Pco(2) in premenopausal women (n = 10; mean age±standard deviation 27.0±6.4 years) during the follicular (FP), mid-cycle (MC) and luteal (LP) phases of the menstrual cycle.
Transcranial Doppler ultrasound was used to measure beat-by-beat averaged peak blood flow velocity (V(p)) in the middle cerebral artery in response to 20 min of euoxic hypercapnia (end-tidal PO(2) = 88 Torr; end-tidal PCO(2) = 7.0 Torr above resting values). The V(p) responses to euoxic hypercapnia were fitted to a simple mathematical model that included gain terms for the on (G(on)) and off (G(off)) responses, time constants for the on (τ(on)) and off (τ(off)) responses, baseline terms and a time delay (T(d)).
Serum progesterone levels were significantly greater for LP compared to FP and MC (40.6±13.2 vs. 32.6±1.4 nmol/l (p < 0.001) and 8.8±3.8 nmol/l (p < 0.001), respectively). Serum estrogen concentrations were significantly lower in FP compared to MC and LP (150.9±51.2 vs. 506.5±220.5 pmol/l (p = 0.002) and 589.1±222.8 pmol/l (p < 0.001), respectively). Arterial PCO(2) was significantly greater in MC compared to LP (35.0±2.1 and 32.6±1.4 Torr, respectively; p = 0.02). There was a significant increase in G(off) during LP compared with FP and MC (3.38±0.68 vs. 2.79±0.82 cm s(-1) Torr(-1) (p = 0.021) and 2.74±0.90 (p = 0.018) cm s(-1) Torr2(1), respectively). Progesterone and the estrogen/progesterone ratio contributed to the observed differences in G(off).
There is an increase in G(off) during LP that is explained, at least in part, by increases in serum progesterone and estrogen and a decrease in arterial PCO(2).",[],Climacteric : the journal of the International Menopause Society,2012-01-03,"[{'lastname': 'Debert', 'firstname': 'C T', 'initials': 'CT', 'affiliation': 'Department of Physical Medicine and Rehabilitation, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.'}, {'lastname': 'Ide', 'firstname': 'K', 'initials': 'K', 'affiliation': None}, {'lastname': 'Poulin', 'firstname': 'M J', 'initials': 'MJ', 'affiliation': None}]",,"There is an increase in G(off) during LP that is explained, at least in part, by increases in serum progesterone and estrogen and a decrease in arterial PCO(2).","Serum progesterone levels were significantly greater for LP compared to FP and MC (40.6±13.2 vs. 32.6±1.4 nmol/l (p < 0.001) and 8.8±3.8 nmol/l (p < 0.001), respectively). Serum estrogen concentrations were significantly lower in FP compared to MC and LP (150.9±51.2 vs. 506.5±220.5 pmol/l (p = 0.002) and 589.1±222.8 pmol/l (p < 0.001), respectively). Arterial PCO(2) was significantly greater in MC compared to LP (35.0±2.1 and 32.6±1.4 Torr, respectively; p = 0.02). There was a significant increase in G(off) during LP compared with FP and MC (3.38±0.68 vs. 2.79±0.82 cm s(-1) Torr(-1) (p = 0.021) and 2.74±0.90 (p = 0.018) cm s(-1) Torr2(1), respectively). Progesterone and the estrogen/progesterone ratio contributed to the observed differences in G(off).",,10.3109/13697137.2011.631231,<Element 'PubmedArticle' at 0x7f05d8e5da90>
308,22177720,Melatonin plus physical exercise are highly neuroprotective in the 3xTg-AD mouse.,"Alzheimer's disease (AD) is a devastating age-related neurodegenerative disease with no specific treatment at present. Several healthy lifestyle options and over-the-counter drugs that it has been suggested delay the onset of the disease are in an experimental phase, but it is unclear whether they will have any therapeutic value against AD. We assayed physical exercise and melatonin in 3xTg-AD male mice aged from 6 to 12 months, therefore from moderate to advanced phases of AD pathology. Analysis of behavior and brain tissue at termination showed differential patterns of neuroprotection for the 2 treatments. Both treatments decreased soluble amyloid β oligomers, whereas only melatonin decreased hyperphosphorylated tau. Melatonin was effective against the immunosenescence that 3xTg-AD mice present. Voluntary physical exercise protected against behavioral and psychological symptoms of dementia such as anxiety, a lack of exploration, and emotionality. Both treatments protected against cognitive impairment, brain oxidative stress, and a decrease in mitochondrial DNA (mtDNA). Interestingly, only the combined treatment of physical exercise plus melatonin was effective against the decrease of mitochondrial complexes. Therefore, melatonin plus physical exercise may exert complementary, additive, or even synergistic effects against a range of disturbances present in AD.",[],Neurobiology of aging,2011-12-20,"[{'lastname': 'García-Mesa', 'firstname': 'Yoelvis', 'initials': 'Y', 'affiliation': 'Institute of Biomedical Research of Barcelona (IIBB), CSIC, IDIBAPS, Barcelona, Spain.'}, {'lastname': 'Giménez-Llort', 'firstname': 'Lydia', 'initials': 'L', 'affiliation': None}, {'lastname': 'López', 'firstname': 'Luis C', 'initials': 'LC', 'affiliation': None}, {'lastname': 'Venegas', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': None}, {'lastname': 'Cristòfol', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': None}, {'lastname': 'Escames', 'firstname': 'Germain', 'initials': 'G', 'affiliation': None}, {'lastname': 'Acuña-Castroviejo', 'firstname': 'Darío', 'initials': 'D', 'affiliation': None}, {'lastname': 'Sanfeliu', 'firstname': 'Coral', 'initials': 'C', 'affiliation': None}]",,,,Copyright © 2012 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2011.11.016,<Element 'PubmedArticle' at 0x7f05d8de74a0>
309,22005651,Genetic association between ghrelin polymorphisms and Alzheimer's disease in a Japanese population.,"Ghrelin has been reported to enter the hippocampus and to bind to the neurons of the hippocampal formation. This peptide also affects neuronal glucose uptake and decreases tau hyperphosphorylation. There is increasing evidence suggesting an association between ghrelin and Alzheimer's disease (AD) pathology. The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) of the ghrelin gene are associated with AD.
The SNPs were genotyped using TaqMan technology and were analyzed using a case-control study design. Our case-control dataset consisted of 182 AD patients and 143 age-matched controls.
Hardy-Weinberg equilibrium and linkage disequilibrium analyses suggest that the region in and around the gene is highly polymorphic. One SNP, rs4684677 (Leu90Gln), showed a marginal association with age of AD onset. We did not detect any association between the other SNPs of the ghrelin gene and AD.
There have been few genetic studies on the relationship between circulating ghrelin and functional SNPs. Further multifactorial studies are needed to clarify the relationship between ghrelin and AD.",[],Dementia and geriatric cognitive disorders,2011-10-19,"[{'lastname': 'Shibata', 'firstname': 'Nobuto', 'initials': 'N', 'affiliation': 'Department of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan. nshibata @ juntendo.ac.jp'}, {'lastname': 'Ohnuma', 'firstname': 'Tohru', 'initials': 'T', 'affiliation': None}, {'lastname': 'Kuerban', 'firstname': 'Bolati', 'initials': 'B', 'affiliation': None}, {'lastname': 'Komatsu', 'firstname': 'Miwa', 'initials': 'M', 'affiliation': None}, {'lastname': 'Arai', 'firstname': 'Heii', 'initials': 'H', 'affiliation': None}]",,There have been few genetic studies on the relationship between circulating ghrelin and functional SNPs. Further multifactorial studies are needed to clarify the relationship between ghrelin and AD.,"Hardy-Weinberg equilibrium and linkage disequilibrium analyses suggest that the region in and around the gene is highly polymorphic. One SNP, rs4684677 (Leu90Gln), showed a marginal association with age of AD onset. We did not detect any association between the other SNPs of the ghrelin gene and AD.","Copyright © 2011 S. Karger AG, Basel.",10.1159/000333075,<Element 'PubmedArticle' at 0x7f05d8defbd0>
310,"21976528
12752792
12904458
20420491
21098983
1734291
14744257
17524488
16046283
12933679
10674423
17950926
20943926
21163349
18407425
16688123
11238065
18276750
18045930
20410196
17151169
11683906
20134206
21059265
19571591
19584430
8515288
12941376
18363841
16005567
20495459
15534039
11920153
16943563
18801622
19906236
9023876
19071150
16484629
15049707
18272149
21114967
20802182
16467370
21110971
17551018
12042880
7659281
17430248
18593777
12480937
19012747
8637878
11224535
8637635
10202533
12392796
10413774
11596127
16924259
8769877
19022298
11442356
11784785
20541663
11441005
17904651
21157033
20182027
17567816
19943124
11445258
3998818
10737051
21269457
17194565
8083742
20881321
1597149
15996533
18155095
1393587
17234600
1793176
16974109
10567721
20513368
17270732
21418733","Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy.","Because overactivation of the hypothalamic-pituitary-adrenal (HPA) axis occurs in Alzheimer's disease (AD), dysregulation of stress neuromediators may play a mechanistic role in the pathophysiology of AD. However, the effects of stress on tau phosphorylation are poorly understood, and the relationship between corticosterone and corticotropin-releasing factor (CRF) on both β-amyloid (Aβ) and tau pathology remain unclear. Therefore, we first established a model of chronic stress, which exacerbates Aβ accumulation in Tg2576 mice and then extended this stress paradigm to a tau transgenic mouse model with the P301S mutation (PS19) that displays tau hyperphosphorylation, insoluble tau inclusions and neurodegeneration. We show for the first time that both Tg2576 and PS19 mice demonstrate a heightened HPA stress profile in the unstressed state. In Tg2576 mice, 1 month of restraint/isolation (RI) stress increased Aβ levels, suppressed microglial activation, and worsened spatial and fear memory compared with nonstressed mice. In PS19 mice, RI stress promoted tau hyperphosphorylation, insoluble tau aggregation, neurodegeneration, and fear-memory impairments. These effects were not mimicked by chronic corticosterone administration but were prevented by pre-stress administration of a CRF receptor type 1 (CRF(1)) antagonist. The role for a CRF(1)-dependent mechanism was further supported by the finding that mice overexpressing CRF had increased hyperphosphorylated tau compared with wild-type littermates. Together, these results implicate HPA dysregulation in AD neuropathogenesis and suggest that prolonged stress may increase Aβ and tau hyperphosphorylation. These studies also implicate CRF in AD pathophysiology and suggest that pharmacological manipulation of this neuropeptide may be a potential therapeutic strategy for AD.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,2011-10-07,"[{'lastname': 'Carroll', 'firstname': 'Jenna C', 'initials': 'JC', 'affiliation': 'Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, School of Medicine and Institute on Aging, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.'}, {'lastname': 'Iba', 'firstname': 'Michiyo', 'initials': 'M', 'affiliation': None}, {'lastname': 'Bangasser', 'firstname': 'Debra A', 'initials': 'DA', 'affiliation': None}, {'lastname': 'Valentino', 'firstname': 'Rita J', 'initials': 'RJ', 'affiliation': None}, {'lastname': 'James', 'firstname': 'Michael J', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Brunden', 'firstname': 'Kurt R', 'initials': 'KR', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Virginia M-Y', 'initials': 'VM', 'affiliation': None}, {'lastname': 'Trojanowski', 'firstname': 'John Q', 'initials': 'JQ', 'affiliation': None}]",,,,,"10.1523/JNEUROSCI.3836-11.2011
10.1016/j.expneurol.2010.11.014",<Element 'PubmedArticle' at 0x7f05d8dfb090>
311,"21945538
10599770
7918112
17898668
4341276
16906426
1759558
18045930
20410196
15742545
9736007
2329377
18458809
4688315
10348656
8557847
11449190
18473974
10908890
15582747
11476589
18768369
19217534
10363709
16336225
11311591
9225742
19909788
5539894
12895417
20798886
21163304
19524671
19181629
16267229
19427328
7949201
20807511
17182789
8131123
9388019
2269895
1613547
8245220
8876466
20629047
16365303",Effects of aromatase inhibition versus gonadectomy on hippocampal complex amyloid pathology in triple transgenic mice.,"Alzheimer's disease (AD) is the most common form of dementia among the elderly with women exhibiting a higher risk than men for the disease. Due to these gender differences, there is great interest in the role that estrogens play in cognitive impairment and the onset of the classic amyloid and tau lesions in AD. Human and rodent studies indicate a strong association between low brain aromatase, sex hormone levels, and beta amyloid deposition. Therefore, the effects of depleting both circulating and brain estrogen levels, through gonadectomy and/or treatment with the aromatase inhibitor, anastrozole, upon hippocampal AD-like pathology in male and female 3xTgAD mice were evaluated. Liquid chromatography-mass spectrometry revealed anastrozole serum levels of 10.19 ng/mL and for the first time brain levels were detected at 4.7 pg/mL. Densitometric analysis of the hippocampus revealed that anastrozole significantly increased Aβ- but not APP/Aβ-immunoreactivity in intact 3xTgAD females compared to controls (p<0.001). Moreover, anastrozole significantly increased the number of Aβ- compared to APP/Aβ-positive hippocampal CA1 neurons in intact and gonadectomized female mice. Concurrently, anastrozole significantly reduced the APP/Aβ plaque load in 9 month old female 3xTgAD mice. These data suggest that anastrozole treatment differentially affects select amyloid species which in turn may play a role in the extraneuronal to intraneuronal deposition of this peptide.",[],Neurobiology of disease,2011-09-29,"[{'lastname': 'Overk', 'firstname': 'Cassia R', 'initials': 'CR', 'affiliation': 'Department of Neurological Sciences, Rush University Medical Center Chicago, IL 60612, USA.'}, {'lastname': 'Lu', 'firstname': 'Pei-Yi', 'initials': 'PY', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Yue-Ting', 'initials': 'YT', 'affiliation': None}, {'lastname': 'Choi', 'firstname': 'Jaewoo', 'initials': 'J', 'affiliation': None}, {'lastname': 'Shaw', 'firstname': 'James W', 'initials': 'JW', 'affiliation': None}, {'lastname': 'Thatcher', 'firstname': 'Gregory R', 'initials': 'GR', 'affiliation': None}, {'lastname': 'Mufson', 'firstname': 'Elliott J', 'initials': 'EJ', 'affiliation': None}]",,,,Copyright © 2011 Elsevier Inc. All rights reserved.,10.1016/j.nbd.2011.08.035,<Element 'PubmedArticle' at 0x7f05d8dab090>
312,"21901364
8507199
18776992
19237574
17130475
16877004
20444434
19728172
11074263
19617854
15094078
20648061
19234767
12629557
20030463
16627931
19164583
18984744
6471907
20054635
19711182
17242403
10599761
11861804
12749025
19836029
19358976
18093848
20107219
16446752
19923038
7926307
21115952
20231468
9421374
20655383",Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4.,"Growing evidence suggests that type 2 diabetes mellitus (DM) is associated with age-dependent Alzheimer's disease (AD), the latter of which has even been considered as type 3 diabetes. Several physiopathological features including hyperglycemia, oxidative stress, and dysfunctional insulin signaling relate DM to AD. In this study, high glucose-, oxidative stress-induced neuronal injury and intracerebroventricular-streptozotocin (ICV-STZ) animals as the possible models for diabetes-related AD were employed to investigate the effects of exendin-4 (Ex-4), a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, on diabetes-associated Alzheimer-like changes as well as the molecular mechanisms involved. Our study demonstrated that GLP-1/Ex-4 could exert a protective effect against reduced viability of PC12 cells caused by high glucose and that this protective effect was mediated via the PI3-kinase pathway. In addition, GLP-1/Ex-4 ameliorated oxidative stress-induced injury in PC12 cells. In rat models, bilateral ICV-STZ administration was used to produce impaired insulin signaling in the brain. Fourteen days following ICV-STZ injection, rats treated with twice-daily Ex-4 had better learning and memory performance in the Morris water maze test compared with rats treated with saline. Additionally, histopathological evaluation confirmed the protective effects of Ex-4 treatment on hippocampal neurons against degeneration. Furthermore, we demonstrated that Ex-4 reversed ICV-STZ-induced tau hyperphosphorylation through downregulation of GSK-3β activity, a key kinase in both DM and AD. Our findings suggests that Ex-4 can protect neurons from diabetes-associated glucose metabolic dysregulation insults in vitro and from ICV-STZ insult in vivo, and that Ex-4 may prove of therapeutic value in the treatment of AD especially DM-related AD.",[],"Age (Dordrecht, Netherlands)",2011-09-09,"[{'lastname': 'Chen', 'firstname': 'Song', 'initials': 'S', 'affiliation': 'State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, China.'}, {'lastname': 'Liu', 'firstname': 'Ai-ran', 'initials': 'AR', 'affiliation': None}, {'lastname': 'An', 'firstname': 'Feng-mao', 'initials': 'FM', 'affiliation': None}, {'lastname': 'Yao', 'firstname': 'Wen-bing', 'initials': 'WB', 'affiliation': None}, {'lastname': 'Gao', 'firstname': 'Xiang-dong', 'initials': 'XD', 'affiliation': None}]",,,,,"10.1007/s11357-011-9303-8
10.1006/bbrc.1993.1557
10.1073/pnas.0807991106
10.2337/db06-0485
10.1016/j.phrs.2006.06.009
10.1016/j.arr.2010.04.007
10.1007/s12010-009-8725-6
10.1016/S0166-2236(00)01656-8
10.1097/WNR.0b013e32832fbf14
10.1016/j.ejphar.2004.02.049
10.1038/nrn2870
10.1007/s11357-008-9078-8
10.1038/sj.ijo.0802206
10.1073/pnas.0806720106
10.2337/db08-0799
10.1016/0165-0270(84)90007-4
10.1007/s10571-009-9484-1
10.1007/s10571-009-9441-z
10.1074/jbc.M609637200
10.1212/WNL.53.9.1937
10.1124/jpet.300.3.958
10.1002/jnr.10611
10.1016/j.jns.2009.09.022
10.1016/j.biopsych.2009.02.013
10.1056/NEJMra0909142
10.2337/diabetes.43.11.1326
10.1212/WNL.0b013e3181ffe4f6
10.1073/pnas.1000645107
10.2337/diabetes.47.1.50
10.1016/j.foodchem.2007.03.031
10.1016/j.foodchem.2007.05.068
10.1016/j.nbd.2010.07.005",<Element 'PubmedArticle' at 0x7f05d8dc8bd0>
313,"21885799
16517245
16935112
20170794
19936192
8945927
16014610
18652937
18242538
17762660
21421827
16932768
19318933
19858411
2142618
7611486
19524591
2910541
17853871
19016989
21444064
21558448
12365169
20044278
17174323
1351488
17268230
7053293
17306712
8246553
19858419
12676546
20362456
12829179
2401072
17822384
1951734",Temporal pattern of left ventricular structural and functional remodeling following reversal of volume overload heart failure.,"Current surgical management of volume overload-induced heart failure (HF) leads to variable recovery of left ventricular (LV) function despite a return of LV geometry. The mechanisms that prevent restoration of function are unknown but may be related to the timing of intervention and the degree of LV contractile impairment. This study determined whether reduction of aortocaval fistula (ACF)-induced LV volume overload during the compensatory stage of HF results in beneficial LV structural remodeling and restoration of pump function. Rats were subjected to ACF for 4 wk; a subset then received a load-reversal procedure by closing the shunt using a custom-made stent graft approach. Echocardiography or in vivo pressure-volume analysis was used to assess LV morphology and function in sham rats; rats subjected to 4-, 8-, or 15-wk ACF; and rats subjected to 4-wk ACF followed by 4- or 11-wk reversal. Structural and functional changes were correlated to LV collagen content, extracellular matrix (ECM) proteins, and hypertrophic markers. ACF-induced volume overload led to progressive LV chamber dilation and contractile dysfunction. Rats subjected to short-term reversal (4-wk ACF + 4-wk reversal) exhibited improved chamber dimensions (LV diastolic dimension) and LV compliance that were associated with ECM remodeling and normalization of atrial and brain natriuretic peptides. Load-independent parameters indicated LV systolic (preload recruitable stroke work, Ees) and diastolic dysfunction (tau, arterial elastance). These changes were associated with an altered α/β-myosin heavy chain ratio. However, these changes were normalized to sham levels in long-term reversal rats (4-wk ACF + 11-wk reversal). Acute hemodynamic changes following ACF reversal improve LV geometry, but LV dysfunction persists. Gradual restoration of function was related to normalization of eccentric hypertrophy, LV wall stress, and ECM remodeling. These results suggest that mild to moderate LV systolic dysfunction may be an important indicator of the ability of the myocardium to remodel following the reversal of hemodynamic overload.",[],"Journal of applied physiology (Bethesda, Md. : 1985)",2011-09-03,"[{'lastname': 'Hutchinson', 'firstname': 'Kirk R', 'initials': 'KR', 'affiliation': ""Center for Cardiovascular and Pulmonary Research, Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.""}, {'lastname': 'Guggilam', 'firstname': 'Anuradha', 'initials': 'A', 'affiliation': None}, {'lastname': 'Cismowski', 'firstname': 'Mary J', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Galantowicz', 'firstname': 'Maarten L', 'initials': 'ML', 'affiliation': None}, {'lastname': 'West', 'firstname': 'Thomas A', 'initials': 'TA', 'affiliation': None}, {'lastname': 'Stewart', 'firstname': 'James A', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Zhang', 'firstname': 'Xiaojin', 'initials': 'X', 'affiliation': None}, {'lastname': 'Lord', 'firstname': 'Kevin C', 'initials': 'KC', 'affiliation': None}, {'lastname': 'Lucchesi', 'firstname': 'Pamela A', 'initials': 'PA', 'affiliation': None}]",,,,,10.1152/japplphysiol.00691.2011,<Element 'PubmedArticle' at 0x7f05d8d69310>
314,"21855175
17420070
19235231
19482049
10051210
20132928
15618887
6685230
19387667
17912249
17360899
17636405
17151169
16276115
3953862
10481183
18761360
15283960
18571864
8515288
19664757
11743957
16943563
9843882
12925369
2795152
2070776
16467370
17551018
21147038
19530223
9287082
14575731
15751228
15659808
715460
19012747
18402983
20818789
19230009
15295589
18162444
21594669
11063969
12000027
15000414
18391224
16616814
16257404
20839293
3012985
17347454
4342885
17467182
19221421
12895417
18222612
10691302
16515786
20829621
11257240
21477639
2998738
17923777
11713467
19943124
15860617
18178006
9824681
10938581
20307586
19187707
9363796
8964797
18691381
18849021
8083742
20558146
18278039
19280661
11278679
15212843
11036168
8675562
17618986
9226345
11750898
1393587
6393179
19554673
16974109
17244848
21427641
19049887",3xTgAD mice exhibit altered behavior and elevated Aβ after chronic mild social stress.,"Chronic stress may be a risk factor for developing Alzheimer's disease (AD), but most studies of the effects of stress in models of AD utilize acute adverse stressors of questionable clinical relevance. The goal of this work was to determine how chronic psychosocial stress affects behavioral and pathological outcomes in an animal model of AD, and to elucidate underlying mechanisms. A triple-transgenic mouse model of AD (3xTgAD mice) and nontransgenic control mice were used to test for an affect of chronic mild social stress on blood glucose, plasma glucocorticoids, plasma insulin, anxiety, and hippocampal amyloid β-particle (Aβ), phosphorylated tau (ptau), and brain-derived neurotrophic factor (BDNF) levels. Despite the fact that both control and 3xTgAD mice experienced rises in corticosterone during episodes of mild social stress, at the end of the 6-week stress period 3xTgAD mice displayed increased anxiety, elevated levels of Aβ oligomers and intraneuronal Aβ, and decreased brain-derived neurotrophic factor levels, whereas control mice did not. Findings suggest 3xTgAD mice are more vulnerable than control mice to chronic psychosocial stress, and that such chronic stress exacerbates Aβ accumulation and impairs neurotrophic signaling.",[],Neurobiology of aging,2011-08-23,"[{'lastname': 'Rothman', 'firstname': 'Sarah M', 'initials': 'SM', 'affiliation': 'Laboratory of Neurosciences, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.'}, {'lastname': 'Herdener', 'firstname': 'Nathan', 'initials': 'N', 'affiliation': None}, {'lastname': 'Camandola', 'firstname': 'Simonetta', 'initials': 'S', 'affiliation': None}, {'lastname': 'Texel', 'firstname': 'Sarah J', 'initials': 'SJ', 'affiliation': None}, {'lastname': 'Mughal', 'firstname': 'Mohamed R', 'initials': 'MR', 'affiliation': None}, {'lastname': 'Cong', 'firstname': 'Wei-Na', 'initials': 'WN', 'affiliation': None}, {'lastname': 'Martin', 'firstname': 'Bronwen', 'initials': 'B', 'affiliation': None}, {'lastname': 'Mattson', 'firstname': 'Mark P', 'initials': 'MP', 'affiliation': None}]",,,,Published by Elsevier Inc.,10.1016/j.neurobiolaging.2011.07.005,<Element 'PubmedArticle' at 0x7f05d8d857c0>
315,21824572,MRI findings and steroid therapy for neuralgic amyotrophy in children.,"Neuralgic amyotrophy is not uncommon in adults but is relatively rare in children. We recently encountered 2 cases of neuralgic amyotrophy in children. Patient 1 was a 7-year-old girl who developed a right leg paralysis after an epileptic seizure. Lumbar plexus T(2)-weighted magnetic resonance imaging (MRI) revealed a hyperintense and thickened portion extending from the root to the knee region of the right sciatic nerve, and T(1)-weighted conventional spin echo with gadolinium administration revealed enhancement. Patient 2 was a 4-year-old boy who experienced a sudden onset of severe right arm pain and paralysis. T(2)-weighted MRI with a short tau inversion recovery revealed a slightly thickened and high intensity region at the right C(6)-C(8) level. After high-dose methylprednisolone pulse therapy was performed in each case, patient 1 experienced complete recovery, whereas patient 2 experienced only amelioration of pain. A diagnosis of neuralgic amyotrophy in children was facilitated by an MRI study (T(2) weighed with short tau inversion recovery and T(1) weighted with gadolinium enhancement), and early steroid therapy might have improved the condition of these children.",[],Pediatric neurology,2011-08-10,"[{'lastname': 'Yamada', 'firstname': 'Keitaro', 'initials': 'K', 'affiliation': 'Department of Pediatric Neurology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan. keitaro_ymd1976@yahoo.co.jp'}, {'lastname': 'Mano', 'firstname': 'Toshiyuki', 'initials': 'T', 'affiliation': None}, {'lastname': 'Toribe', 'firstname': 'Yasuhisa', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Yanagihara', 'firstname': 'Keiko', 'initials': 'K', 'affiliation': None}, {'lastname': 'Suzuki', 'firstname': 'Yasuhiro', 'initials': 'Y', 'affiliation': None}]",,,,Copyright © 2011 Elsevier Inc. All rights reserved.,10.1016/j.pediatrneurol.2011.05.011,<Element 'PubmedArticle' at 0x7f05d8d39630>
316,21778189,Effect of high-dose glucocorticosteroid treatment for infantile spasms on quantitative bone parameters later in life.,"This study evaluated possible long-term effects of prolonged high-dose glucocorticosteroid administration in infancy. Thirty patients (16 male, 14 female; age 4.8-33 years) who had completed treatment with adrenocorticotropic hormone (ACTH) followed by glucocorticoids for infantile spasms at a tertiary pediatric hospital at least 2 years previously were invited to undergo quantitative bone ultrasound. The mean speed of soundZ score was -1.085 ± 1.079 for the radius and -0.22 ± 1.19 for the tibia on the nondominant side (P = .0022). The difference from the reference mean (0) was statistically significant for the radius (P < .001). There were no significant differences in radial or tibial mean speed of soundZ scores by age (prepubertal versus pubertal/postpubertal). In conclusion, a high percentage of patients treated with glucocorticoids for infantile spasms have a low radial speed of soundZ score later in life. Long-term follow-up can help to prevent and treat impairments in bone density, especially in non-weight-bearing organs.",[],Journal of child neurology,2011-07-23,"[{'lastname': 'Eidlitz-Markus', 'firstname': 'Tal', 'initials': 'T', 'affiliation': ""Department of Pediatrics E/Ambulatory Day Care Center, Schneider Children's Medical Center of Israel, Petach Tikva, Israel. eidlitz@post.tau.ac.il""}, {'lastname': 'Kivity', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': None}, {'lastname': 'Goldberg-Stern', 'firstname': 'Hadassa', 'initials': 'H', 'affiliation': None}, {'lastname': 'Haimi-Cohen', 'firstname': 'Yishai', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Zeharia', 'firstname': 'Avraham', 'initials': 'A', 'affiliation': None}]",,,,,10.1177/0883073811413583,<Element 'PubmedArticle' at 0x7f05d8d43cc0>
317,"21762376
14747300
15477536
9870136
18195144
18401020
19280172
20739645
19084083
20739649
18346114
10684867
12900169
17430239
15102436
12761548
15033922
19487308
20231468
14645205
10727441
5333500
12711363
19605645
17279354
18926603
16288750
17942819
10570203
4589719
2963191
21270887
12196559
15342738",Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice.,"According to epidemiological studies, type-2 diabetes increases the risk of Alzheimer's disease. Here, we induced hyperglycaemia in mice overexpressing mutant amyloid precursor protein and presenilin-1 (APdE9) either by cross-breeding them with pancreatic insulin-like growth factor 2 (IGF-2) overexpressing mice or by feeding them with high-fat diet. Glucose and insulin tolerance tests revealed significant hyperglycaemia in mice overexpressing IGF-2, which was exacerbated by high-fat diet. However, sustained hyperinsulinaemia and insulin resistance were observed only in mice co-expressing IGF-2 and APdE9 without correlation to insulin levels in brain. In behavioural tests in aged mice, APdE9 was associated with poor spatial learning and the combination of IGF-2 and high-fat diet further impaired learning. Neither high-fat diet nor IGF-2 increased β-amyloid burden in the brain. In male mice, IGF-2 increased β-amyloid 42/40 ratio, which correlated with poor spatial learning. In contrast, inhibitory phosphorylation of glycogen synthase kinase 3β, which correlated with good spatial learning, was increased in APdE9 and IGF-2 female mice on standard diet, but not on high-fat diet. Interestingly, high-fat diet altered τ isoform expression and increased phosphorylation of τ at Ser202 site in female mice regardless of genotype. These findings provide evidence for new regulatory mechanisms that link type-2 diabetes and Alzheimer pathology.",[],Journal of cellular and molecular medicine,2011-07-19,"[{'lastname': 'Hiltunen', 'firstname': 'Mikko', 'initials': 'M', 'affiliation': 'Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland. mikko.hiltunen@uef.fi'}, {'lastname': 'Khandelwal', 'firstname': 'Vinoth K M', 'initials': 'VK', 'affiliation': None}, {'lastname': 'Yaluri', 'firstname': 'Nagendra', 'initials': 'N', 'affiliation': None}, {'lastname': 'Tiilikainen', 'firstname': 'Tea', 'initials': 'T', 'affiliation': None}, {'lastname': 'Tusa', 'firstname': 'Maija', 'initials': 'M', 'affiliation': None}, {'lastname': 'Koivisto', 'firstname': 'Henna', 'initials': 'H', 'affiliation': None}, {'lastname': 'Krzisch', 'firstname': 'Marine', 'initials': 'M', 'affiliation': None}, {'lastname': 'Vepsäläinen', 'firstname': 'Saila', 'initials': 'S', 'affiliation': None}, {'lastname': 'Mäkinen', 'firstname': 'Petra', 'initials': 'P', 'affiliation': None}, {'lastname': 'Kemppainen', 'firstname': 'Susanna', 'initials': 'S', 'affiliation': None}, {'lastname': 'Miettinen', 'firstname': 'Pasi', 'initials': 'P', 'affiliation': None}, {'lastname': 'Haapasalo', 'firstname': 'Annakaisa', 'initials': 'A', 'affiliation': None}, {'lastname': 'Soininen', 'firstname': 'Hilkka', 'initials': 'H', 'affiliation': None}, {'lastname': 'Laakso', 'firstname': 'Markku', 'initials': 'M', 'affiliation': None}, {'lastname': 'Tanila', 'firstname': 'Heikki', 'initials': 'H', 'affiliation': None}]",,,,© 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.,10.1111/j.1582-4934.2011.01384.x,<Element 'PubmedArticle' at 0x7f05d8d4ce50>
318,"21753165
11723259
17347250
18192287
17949857
19255408
12815635
10984517
20045477
21252111
19786698",Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN.,"To use multiple serial MRI to assess rates and trajectories of brain and hippocampal atrophy in subjects with frontotemporal dementia (FTD) with progranulin (GRN) or microtubule-associated protein tau (MAPT) gene mutations.
In this case-control study, we identified 8 subjects with mutations in GRN and 12 subjects with mutations in MAPT who had at least 2 serial MRIs. Serial MRIs were registered to baseline MRI for each subject using 9 df registration and rate of whole brain atrophy was calculated using the boundary-shift integral. Hippocampal volume was measured using Freesurfer. Mixed effects linear regression models were used to model volume change over time in both groups after adjusting for head size, age at baseline, and disease duration at baseline.
The annual rate of whole brain atrophy in the MAPT subjects was 2.4% per year (95% confidence interval [CI] 1.9-2.8). The GRN subjects showed a higher rate of whole brain atrophy at 3.5% per year (95% CI 2.8-4.2; p = 0.01). Rates of hippocampal atrophy were not different across the groups (MAPT = 7.8% [95% CI 3.9-12], GRN = 6.5% [95% CI 1.7-11], p = 0.66). Rates of whole brain atrophy in GRN, and hippocampal atrophy in MAPT, were associated with age, with older subjects showing slower rates of atrophy (p = 0.01 and p < 0.001).
Subjects with FTD with GRN mutations have a faster rate of whole brain atrophy than subjects with FTD with MAPT mutations, with similar rates of hippocampal atrophy. Rates of atrophy in both groups were associated with age. These findings are important for future treatment trials in FTD that use rates of atrophy as an outcome measure.",[],Neurology,2011-07-15,"[{'lastname': 'Whitwell', 'firstname': 'J L', 'initials': 'JL', 'affiliation': 'Department of Radiology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. Whitwell.jennifer@mayo.edu'}, {'lastname': 'Weigand', 'firstname': 'S D', 'initials': 'SD', 'affiliation': None}, {'lastname': 'Gunter', 'firstname': 'J L', 'initials': 'JL', 'affiliation': None}, {'lastname': 'Boeve', 'firstname': 'B F', 'initials': 'BF', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Baker', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Knopman', 'firstname': 'D S', 'initials': 'DS', 'affiliation': None}, {'lastname': 'Wszolek', 'firstname': 'Z K', 'initials': 'ZK', 'affiliation': None}, {'lastname': 'Petersen', 'firstname': 'R C', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Jack', 'firstname': 'C R', 'initials': 'CR', 'affiliation': None}, {'lastname': 'Josephs', 'firstname': 'K A', 'initials': 'KA', 'affiliation': None}]",,,"The annual rate of whole brain atrophy in the MAPT subjects was 2.4% per year (95% confidence interval [CI] 1.9-2.8). The GRN subjects showed a higher rate of whole brain atrophy at 3.5% per year (95% CI 2.8-4.2; p = 0.01). Rates of hippocampal atrophy were not different across the groups (MAPT = 7.8% [95% CI 3.9-12], GRN = 6.5% [95% CI 1.7-11], p = 0.66). Rates of whole brain atrophy in GRN, and hippocampal atrophy in MAPT, were associated with age, with older subjects showing slower rates of atrophy (p = 0.01 and p < 0.001).",,10.1212/WNL.0b013e318227047f,<Element 'PubmedArticle' at 0x7f05d8ce96d0>
319,21752397,Characterization of multiple sclerosis traits: nuclear receptors (NR) impaired apoptosis pathway and the role of 1-α 25-dihydroxyvitamin D3.,"Low expression of NR4A gene family members (NR4A1, NR4A3) and 1-alpha, 25-dihydroxyvitamin D(3) receptor (VDR) genes was demonstrated in peripheral blood mononuclear cells (PBMC) of subjects evaluated during the pre-disease state of multiple sclerosis (MS-to-be, MS2b), in patients with clinically isolated syndrome (CIS) during the very early presentation of neurological symptomatology and in relapsing-remitting MS (RRMS) patients. Both NR4A1 and NR4A3 are known to be involved in T-cell receptor-induced apoptosis and are regulated by VDR. We further evaluated the precise implications of apoptosis signaling regulators in relation to MS pathogenesis at the cellular level by studying the effects of 1-alpha, 25-dihydroxyvitamin D(3) (Vit D(3)) upon NR4A1 expression. We demonstrated that the low apoptotic level in MS patients was repaired by Vit D(3) mainly through NR4A1 and to a lesser extent thorough BCL2-associated X protein (BAX). These findings prove a role for Vit D(3) as a possible therapeutic intervention in MS patients aimed to activate the repressed apoptosis and enhance better control of the disease.",[],Journal of the neurological sciences,2011-07-15,"[{'lastname': 'Achiron', 'firstname': 'Anat', 'initials': 'A', 'affiliation': 'Multiple Sclerosis Center, Sheba Medical Center, and Sackler School of Medicine Tel-Aviv University, Israel. achiron@post.tau.ac.il'}, {'lastname': 'Feldman', 'firstname': 'Anna', 'initials': 'A', 'affiliation': None}, {'lastname': 'Gurevich', 'firstname': 'Michael', 'initials': 'M', 'affiliation': None}]",,,,Copyright © 2011 Elsevier B.V. All rights reserved.,10.1016/j.jns.2011.06.038,<Element 'PubmedArticle' at 0x7f05d8cfad60>
320,"21747829
19733720
10959073
18421270
17200703
18227398
17513701
15780434
19881250
15671918
18200801
18343241
19916988
19707255
163776
15662227
12524016
9219356
18427132
12039708
19856809
17761767
19726805
20969435
20921292
18931022
19026584
15353407
19894030",Assessment of glucagon-like peptide-1 analogue and renin inhibitor on the binding and regulation of GLP-1 receptor in type 1 diabetic rat hearts.,"This study focuses on the effects of long-term renin-angiotensin system suppression and/or incretin mimetic therapies on the regulation and binding affinity of GLP-1 to its receptor in the coronary endothelium (CE) and cardiomyocytes (CMs) of type 1 diabetic male Sprague-Dawley rats. The groups assessed are normal (N), streptozotocin-induced diabetic (D), Insulin treated (DI), Exendin-4 treated (DE), Aliskiren treated (DA), cotreated with Insulin and Aliskiren (DIA) and cotreated with exendin-4 and Aliskiren (DEA). Heart perfusion with (125)I-GLP-1 was performed to estimate GLP-1 binding affinity (τ = 1/k-n) to its receptor in the heart. Western Blotting was assessed to determine the expression variation of GLP-1 receptor in the heart. Plasma GLP-1 levels were measured using Enzyme-Linked Immunosorbent Assay (ELISA). Diabetes decreased the τ value on CE and increased it on CMs compared to normal. The combination of Exendin-4 with Aliskiren showed a normalizing effect on the binding affinity of GLP-1 at the coronary endothelium, while at the cardiomyocyte level Exendin-4 treatment alone was the most effective.",[],Experimental diabetes research,2011-07-13,"[{'lastname': 'Artinian', 'firstname': 'Shushan B', 'initials': 'SB', 'affiliation': 'Department of Physiology, Faculty of Medicine, American University of Beirut, Beirut 11-236, Lebanon.'}, {'lastname': 'Al Lafi', 'firstname': 'Sawsan M', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Boutary', 'firstname': 'Suzan S', 'initials': 'SS', 'affiliation': None}, {'lastname': 'Bitar', 'firstname': 'Khalil M', 'initials': 'KM', 'affiliation': None}, {'lastname': 'Zwainy', 'firstname': 'Nadine S', 'initials': 'NS', 'affiliation': None}, {'lastname': 'Bikhazi', 'firstname': 'Anwar B', 'initials': 'AB', 'affiliation': None}]",,,,,10.1155/2011/489708,<Element 'PubmedArticle' at 0x7f05d8d0a090>
321,"21722209
1549228
10742108
11756502
14744257
11086171
20920788
1759558
16730956
11584304
11683906
18202255
15283960
8835720
9416669
1530909
2484340
9005861
10681533
9023876
9641683
17551018
19698778
16192374
18318434
20846376
12629164
14713290
10604467
20962218
15014115
17376970
11441005
9629852
10378870
19494154
19584431
17567816
9688995
15645263
16081879
7712198
11978814
8782521
10737051
12097512
20152116
3374833
9655498
9636220
11901170
14526225
17117478
8793108
17947696
16974109
15358438
14663028
17562829
19292978
12811798","Lipopolysaccharide-induced tau phosphorylation and kinase activity--modulation, but not mediation, by corticotropin-releasing factor receptors.","Clinical studies suggest that exposure to stress can increase risk for Alzheimer's disease (AD). Although the precise links between stress and vulnerability to develop AD remain uncertain, recent animal work suggests that stress may promote susceptibility to AD pathology by activating tau kinases and inducing tau phosphorylation (tau-P). Our previous findings indicate the differential involvement of corticotropin-releasing factor receptor (CRFR) types 1 and 2 in regulating tau-P in the hippocampus induced by acute restraint, an emotional stressor. To assess the generality of CRFR involvement in stress-induced tau-P and tau kinase activity, the present study extends our investigation to a well-characterized physiological stressor, i.e. immune challenge induced by bacterial lipopolysaccharide (LPS). Acute systemic administration of LPS (100 μg/kg) robustly increased hippocampal (but not isocortical or cerebellar) tau-P, peaking at 40-120 min postinjection and abating thereafter. Assessments of the genotype dependence of this effect yielded results that were distinct from the restraint model. Treatment with LPS increased phosphorylation in wild-type, single and double CRFR knockouts with only subtle variation, which included a reliable exaggeration of tau-P responses in CRFR1-deficient mice. Parallel analyses implicated glycogen synthase kinase-3 and cyclin-dependent kinase-5 as likely cellular mediators of LPS-induced tau-P. Conversely, our data suggest that temperature-dependent fluctuations in tau protein phosphatase 2A (PP2A) may not play a role in this context. Thus, neither the strict CRFR1 dependence of restraint-induced tau-P nor the exaggeration of these responses in CRFR2 null mice generalize to the LPS model. CRFR mediation of stress-induced hippocampal tau-P may be limited to emotional stressors.",[],The European journal of neuroscience,2011-07-05,"[{'lastname': 'Roe', 'firstname': 'Allyson D', 'initials': 'AD', 'affiliation': 'Department of Neurosciences, University of California, San Diego School of Medicine, La Jolla, CA, USA.'}, {'lastname': 'Staup', 'firstname': 'Michael A', 'initials': 'MA', 'affiliation': None}, {'lastname': 'Serrats', 'firstname': 'Jordi', 'initials': 'J', 'affiliation': None}, {'lastname': 'Sawchenko', 'firstname': 'Paul E', 'initials': 'PE', 'affiliation': None}, {'lastname': 'Rissman', 'firstname': 'Robert A', 'initials': 'RA', 'affiliation': None}]",,,,© 2011 The Authors. European Journal of Neuroscience © 2011 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.,10.1111/j.1460-9568.2011.07764.x,<Element 'PubmedArticle' at 0x7f05d8d209f0>
322,21705954,Perfusion computed tomography findings of autoimmune pancreatitis.,"The aim of this study was to clarify the pancreatic blood perfusion in patients with autoimmune pancreatitis (AIP) and the changes after steroid treatment.
Perfusion computed tomography was performed in 11 patients with AIP and 12 control subjects. Pancreatic volumetric blood flow (F(V)), volume of distribution (V(D)), and blood transit time τ were determined from a single-compartment kinetic model. Nine patients with AIP were reexamined by perfusion computed tomography after corticosteroid administration.
The pancreatic F(V) values of the 11 patients with AIP (82.7/min) were significantly lower than those of control subjects (163.5/min, P = 0.0006). On the other hand, the pancreatic V(D) and τ values were not significantly different between AIP and normal. After steroid treatment, the F(V) values of 9 reexamined patients with AIP (76.2/min) were significantly elevated (109.8/min, P = 0.0391). However, the changes of the values after the treatment differed in degree among individuals. The values of 4 patients were dramatically elevated to greater than 100/min, whereas those of 4 other patients did not improve well. The value of the remaining patient whose initial F(V) value was normal (168.09/min) did not change after the treatment.
Pancreatic volumetric perfusion was attenuated in AIP patients. The perfusion was improved after the steroid treatment.",[],Pancreas,2011-06-28,"[{'lastname': 'Hirota', 'firstname': 'Morihisa', 'initials': 'M', 'affiliation': 'Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai City, Miyagi, Japan. morihirota@med.tohoku.ac.jp'}, {'lastname': 'Tsuda', 'firstname': 'Masashi', 'initials': 'M', 'affiliation': None}, {'lastname': 'Tsuji', 'firstname': 'Yoshihisa', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Kanno', 'firstname': 'Atsushi', 'initials': 'A', 'affiliation': None}, {'lastname': 'Kikuta', 'firstname': 'Kazuhiro', 'initials': 'K', 'affiliation': None}, {'lastname': 'Kume', 'firstname': 'Kiyoshi', 'initials': 'K', 'affiliation': None}, {'lastname': 'Hamada', 'firstname': 'Shin', 'initials': 'S', 'affiliation': None}, {'lastname': 'Unno', 'firstname': 'Jun', 'initials': 'J', 'affiliation': None}, {'lastname': 'Ito', 'firstname': 'Hiromichi', 'initials': 'H', 'affiliation': None}, {'lastname': 'Ariga', 'firstname': 'Hiroyuki', 'initials': 'H', 'affiliation': None}, {'lastname': 'Chiba', 'firstname': 'Tsutomu', 'initials': 'T', 'affiliation': None}, {'lastname': 'Masamune', 'firstname': 'Atsushi', 'initials': 'A', 'affiliation': None}, {'lastname': 'Satoh', 'firstname': 'Kennichi', 'initials': 'K', 'affiliation': None}, {'lastname': 'Shimosegawa', 'firstname': 'Tooru', 'initials': 'T', 'affiliation': None}]",,,"The pancreatic F(V) values of the 11 patients with AIP (82.7/min) were significantly lower than those of control subjects (163.5/min, P = 0.0006). On the other hand, the pancreatic V(D) and τ values were not significantly different between AIP and normal. After steroid treatment, the F(V) values of 9 reexamined patients with AIP (76.2/min) were significantly elevated (109.8/min, P = 0.0391). However, the changes of the values after the treatment differed in degree among individuals. The values of 4 patients were dramatically elevated to greater than 100/min, whereas those of 4 other patients did not improve well. The value of the remaining patient whose initial F(V) value was normal (168.09/min) did not change after the treatment.",,10.1097/MPA.0b013e31821fcc4f,<Element 'PubmedArticle' at 0x7f05d8cc58b0>
323,"21613497
11381127
16735465
11837744
17409229
7718249
12025941
17912249
17229084
17360899
20097254
17151169
16125145
18071141
16461860
19837693
16943563
3088567
12756137
15883264
9190286
9263193
20231476
21172610
20655099
16467370
17551018
8835879
18007595
20921222
19321462
17430248
12927759
19401723
16406150
17541419
9629527
1674004
16651510
11959919
17567816
17478722
10090741
18177670
9735171
21289177
18573532
18691381
10799757
8083742
15810904
18458206
9809590
1789684
19307538
7876258
17241267
9386855
14663028
17562829",Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits.,"Stressful life experiences are likely etiological factors in sporadic forms of Alzheimer's disease (AD). Many AD patients hypersecrete glucocorticoids (GCs), and their GC levels correlate with the rate of cognitive impairment and extent of neuronal atrophy. Severity of cognitive deficits in AD correlates strongly with levels of hyperphosphorylated forms of the cytoskeletal protein TAU, an essential mediator of the actions of amyloid β (Aβ), another molecule with a key pathogenic role in AD. Our objective was to investigate the sequential interrelationships between these various pathogenic elements, in particular with respect to the mechanisms through which stress might precipitate cognitive decline. We thus examined whether stress, through the mediation of GCs, influences TAU hyperphosphorylation, a critical and early event in the cascade of processes leading to AD pathology. Results from healthy, wild-type, middle-aged rats show that chronic stress and GC induce abnormal hyperphosphorylation of TAU in the hippocampus and prefrontal cortex (PFC), with contemporaneous impairments of hippocampus- and PFC-dependent behaviors. Exogenous GC potentiated the ability of centrally infused Aβ to induce hyperphosphorylation of TAU epitopes associated with AD and cytoplasmic accumulation of TAU, while previous exposure to stress aggravated the biochemical and behavioral effects of GC in Aβ-infused animals. Thus, lifetime stress/GC exposure may have a cumulative impact on the onset and progress of AD pathology, with TAU hyperphosphorylation serving to transduce the negative effects of stress and GC on cognition.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,2011-05-27,"[{'lastname': 'Sotiropoulos', 'firstname': 'Ioannis', 'initials': 'I', 'affiliation': 'Max Planck Institute of Psychiatry, 80804 Munich, Germany.'}, {'lastname': 'Catania', 'firstname': 'Caterina', 'initials': 'C', 'affiliation': None}, {'lastname': 'Pinto', 'firstname': 'Lucilia G', 'initials': 'LG', 'affiliation': None}, {'lastname': 'Silva', 'firstname': 'Rui', 'initials': 'R', 'affiliation': None}, {'lastname': 'Pollerberg', 'firstname': 'G Elizabeth', 'initials': 'GE', 'affiliation': None}, {'lastname': 'Takashima', 'firstname': 'Akihiko', 'initials': 'A', 'affiliation': None}, {'lastname': 'Sousa', 'firstname': 'Nuno', 'initials': 'N', 'affiliation': None}, {'lastname': 'Almeida', 'firstname': 'Osborne F X', 'initials': 'OF', 'affiliation': None}]",,,,,10.1523/JNEUROSCI.0730-11.2011,<Element 'PubmedArticle' at 0x7f05d8cd26d0>
324,21558644,A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia.,"A number of mutations in microtubule associated protein tau gene (MAPT), causing frontotemporal lobar degeneration (FTLD) with tau pathology, are located in the four-repeated microtubule (MT) binding domains and affect the ability of tau to bind MTs. Here, we describe a novel variant lying in the second MT domain, found in a female patient diagnosed clinically with progressive nonfluent aphasia (PNFA), with a positive family history for dementia. At 65 years, she started developing progressive language deficits, characterized by expression difficulties and word coordination impairment. She came to our attention at 67 years. Her MMSE score was 22/30. A Brain CT scan showed mild diffuse cortical atrophy, ventricles' asymmetry (left > right), and very mild signs of chronic vasculopathy. Cerebrospinal fluid analysis showed normal amyloid-β₄₂, tau, and P-tau levels. She was diagnosed with PNFA according to current diagnostic criteria. A novel exon 10 MAPT variant was identified (g.123798G > A), which leads to an amino acidic change (p.Gly304Ser) in the second MT microtubule binding domain. In silico analysis predicted that this variant is damaging on protein structure and function. Additional 168 FTLD patients and 503 controls screened (1342 chromosomes) did not carry the variant, suggesting that it is a mutation rather than a polymorphism. The amino acid change likely compromises the ability of tau to properly regulate the dynamic behavior of microtubules.",[],Journal of Alzheimer's disease : JAD,2011-05-12,"[{'lastname': 'Villa', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': 'Department of Neurological Sciences, University of Milan, IRCCS Fondazione Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Ghezzi', 'firstname': 'Laura', 'initials': 'L', 'affiliation': None}, {'lastname': 'Pietroboni', 'firstname': 'Anna M', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Fenoglio', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': None}, {'lastname': 'Cortini', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': None}, {'lastname': 'Serpente', 'firstname': 'Maria', 'initials': 'M', 'affiliation': None}, {'lastname': 'Cantoni', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': None}, {'lastname': 'Ridolfi', 'firstname': 'Elisa', 'initials': 'E', 'affiliation': None}, {'lastname': 'Marcone', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': None}, {'lastname': 'Benussi', 'firstname': 'Luisa', 'initials': 'L', 'affiliation': None}, {'lastname': 'Ghidoni', 'firstname': 'Roberta', 'initials': 'R', 'affiliation': None}, {'lastname': 'Jacini', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': None}, {'lastname': 'Arighi', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': None}, {'lastname': 'Fumagalli', 'firstname': 'Giorgio G', 'initials': 'GG', 'affiliation': None}, {'lastname': 'Mandelli', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': None}, {'lastname': 'Binetti', 'firstname': 'Giuliano', 'initials': 'G', 'affiliation': None}, {'lastname': 'Cappa', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': None}, {'lastname': 'Bresolin', 'firstname': 'Nereo', 'initials': 'N', 'affiliation': None}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': None}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': None}]",,,,,10.3233/JAD-2011-102124,<Element 'PubmedArticle' at 0x7f05d8c74270>
325,21535936,Dexamethasone potentiated Aβ-induced learning and memory impairment in rats.,"To determine whether dexamethasone (DEX) could potentiate amyloid beta-protein (Abeta)-induced learning and memory impairment in rats, and, if so, what the underlying mechanism is.
Morris water maze was used to investigate whether DEX could potentiate Abeta-induced learning and memory impairment in rats, and the histopathologic changes in CA1 field of hippocampus were examined under a light microscope. Immunohistochemistry was used to observe the change of the phosphorylated tau at Thr-231 in the CA1 field of hippocampus. The effects of DEX on the levels of phospho-tau and p25 induced by Abeta were analyzed by Western blot.
The results showed that DEX could potentiate Abeta-induced learning and memory impairment and pathological damage in CA1 field of hippocampus in Sprague Dawley (SD) rats, and could enhance the increased levels of phosphorylated tau induced by Abeta(25-35) in the neuronal cell bodies in CA1 field of hippocampus of SD rats and in the protein extracts from hippocampus. Pretreatment of hippocampal neurons with DEX could up-regulate the increased levels of phosphorylated tau and p25 protein induced by Abeta(25-35) in vitro.
These results suggest that DEX could potentiate Abeta-induced learning and memory impairment and pathological damage in CA1 field of hippocampus in SD rats, which might be related to DEX up-regulating the levels of phosphorylated tau and p25 protein induced by Abeta(25-35). Since Abeta and glucocorticoids increase with aging, DEX potentiating Abeta-induced learning and memory impairment may be one of the etiology of Alzheimer's disease.",[],Neurological research,2011-05-04,"[{'lastname': 'Yao', 'firstname': 'Yu-You', 'initials': 'YY', 'affiliation': 'Department of Laboratory Medcine, Anhui Medical University, Hefei, China.'}, {'lastname': 'Wu', 'firstname': 'Qing-Si', 'initials': 'QS', 'affiliation': None}, {'lastname': 'Li', 'firstname': 'Wei-Zu', 'initials': 'WZ', 'affiliation': None}, {'lastname': 'Li', 'firstname': 'Wei-Ping', 'initials': 'WP', 'affiliation': None}]",,,"The results showed that DEX could potentiate Abeta-induced learning and memory impairment and pathological damage in CA1 field of hippocampus in Sprague Dawley (SD) rats, and could enhance the increased levels of phosphorylated tau induced by Abeta(25-35) in the neuronal cell bodies in CA1 field of hippocampus of SD rats and in the protein extracts from hippocampus. Pretreatment of hippocampal neurons with DEX could up-regulate the increased levels of phosphorylated tau and p25 protein induced by Abeta(25-35) in vitro.",,10.1179/016164110X12816242542698,<Element 'PubmedArticle' at 0x7f05d8c7e8b0>
326,21533831,Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload.,"Chronic pressure-overload and diabetes mellitus are two frequent disorders affecting the heart. We aimed to characterize myocardial structural and functional changes induced by both conditions. Pressure-overload was established in Wistar-han male rats by supra-renal aortic banding. Six-weeks later, diabetes was induced by streptozotocin (65 mg/kg,ip), resulting in four groups: SHAM, banding (BA), diabetic (DM) and diabetic-banding (DB). Six-weeks later, pressure-volume loops were obtained and left ventricular samples were collected to evaluate alterations in insulin signalling pathways, extracellular matrix as well as myofilament function and phosphorylation. Pressure-overload increased cardiomyocyte diameter (BA 22.0 ± 0.4 μm, SHAM 18.2 ± 0.3 μm) and myofilament maximal force (BA 25.7 ± 3.6 kN/m(2), SHAM 18.6 ± 1.4 kN/m(2)), Ca(2+) sensitivity (BA 5.56 ± 0.02, SHAM 5.50 ± 0.02) as well as MyBP-C, Akt and Erk phosphorylation, while decreasing rate of force redevelopment (K (tr); BA 14.9 ± 1.1 s(-1), SHAM 25.2 ± 1.5 s(-1)). At the extracellular matrix level, fibrosis (BA 10.8 ± 0.9%, SHAM 5.3 ± 0.6%), pro-MMP-2 and MMP-9 activities increased and, in vivo, relaxation was impaired (τ; BA 14.0 ± 0.9 ms, SHAM 12.9 ± 0.4 ms). Diabetes increased cardiomyocyte diameter, fibrosis (DM 21.4 ± 0.4 μm, 13.9 ± 1.8%, DB 20.6 ± 0.4 μm, 13.8 ± 0.8%, respectively), myofilament Ca(2+)sensitivity (DM 5.57 ± 0.02, DB 5.57 ± 0.01), advanced glycation end-product deposition (DM 4.9 ± 0.6 score/mm(2), DB 5.1 ± 0.4 score/mm(2), SHAM 2.1 ± 0.3 score/mm(2)), and apoptosis, while decreasing K (tr) (DM 13.5 ± 1.9 s(-1), DB 15.2 ± 1.4 s(-1)), Akt phosphorylation and MMP-9/TIMP-1 and MMP-1/TIMP-1 ratios. Diabetic hearts were stiffer (higher end-diastolic-pressure: DM 7.0 ± 1.2 mmHg, DB 6.7 ± 0.7 mmHg, SHAM 5.3 ± 0.4 mmHg, steeper end-diastolic-pressure-volume relation: DM 0.59 ± 0.18, DB 0.83 ± 0.17, SHAM 0.41 ± 0.10), and hypo-contractile (decreased end-systolic-pressure-volume-relation). DB animals presented further pulmonary congestion (Lungs/body-weight: DB 5.23 ± 0.21 g/kg, SHAM 3.80 ± 0.14 g/kg) as this group combined overload-induced relaxation abnormalities and diabetes-induced stiffness. Diabetes mellitus and pressure overload led to distinct diastolic dysfunction phenotypes: while diabetes promoted myocardial stiffening, pressure overload impaired relaxation. The association of these damages accelerates the progression of diastolic heart failure progression in diabetic-banded animals.",[],Basic research in cardiology,2011-05-03,"[{'lastname': 'Falcão-Pires', 'firstname': 'Inês', 'initials': 'I', 'affiliation': 'Department of Physiology and Cardiothoracic Surgery, Cardiovascular R&D Unit, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.'}, {'lastname': 'Palladini', 'firstname': 'Giuseppina', 'initials': 'G', 'affiliation': None}, {'lastname': 'Gonçalves', 'firstname': 'Nádia', 'initials': 'N', 'affiliation': None}, {'lastname': 'van der Velden', 'firstname': 'Jolanda', 'initials': 'J', 'affiliation': None}, {'lastname': 'Moreira-Gonçalves', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': None}, {'lastname': 'Miranda-Silva', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': None}, {'lastname': 'Salinaro', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': None}, {'lastname': 'Paulus', 'firstname': 'Walter J', 'initials': 'WJ', 'affiliation': None}, {'lastname': 'Niessen', 'firstname': 'Hans W M', 'initials': 'HW', 'affiliation': None}, {'lastname': 'Perlini', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': None}, {'lastname': 'Leite-Moreira', 'firstname': 'Adelino F', 'initials': 'AF', 'affiliation': None}]",,,,,10.1007/s00395-011-0184-x,<Element 'PubmedArticle' at 0x7f05d8c8aea0>
327,"21459826
12498988
16271419
14657172
16221768
18781980
14610053
18096503
20929960
942051
18802001
21256197
8900284
12136125
20147530
18041776
2484340
19240035
20967887
16129564
14622230
17267577
3092131
17145504
14645205
17584991
12670422
19126760
16723519
16540577
20962221
15078543
18096504
12813001
17435795
18667150
19957260
15537891
15837565
21034788
19029917
18354002
21035522
20657592
12909083
14522360
20149873
19295151
15456244
20079333
18068305
12895417
19805493
3510221
20107219
15728830
19057621
20181604
19547699
7139323
20729846
1786532
21255263
16630051
18227059
19038212
16025111
20159446
17409230
15949819
16732431
11932745
15450169
12598628
7898667
19322169
17988243
8714863
16672646",Molecular reorganization of endocannabinoid signalling in Alzheimer's disease.,"Retrograde messengers adjust the precise timing of neurotransmitter release from the presynapse, thus modulating synaptic efficacy and neuronal activity. 2-Arachidonoyl glycerol, an endocannabinoid, is one such messenger produced in the postsynapse that inhibits neurotransmitter release upon activating presynaptic CB(1) cannabinoid receptors. Cognitive decline in Alzheimer's disease is due to synaptic failure in hippocampal neuronal networks. We hypothesized that errant retrograde 2-arachidonoyl glycerol signalling impairs synaptic neurotransmission in Alzheimer's disease. Comparative protein profiling and quantitative morphometry showed that overall CB(1) cannabinoid receptor protein levels in the hippocampi of patients with Alzheimer's disease remain unchanged relative to age-matched controls, and CB(1) cannabinoid receptor-positive presynapses engulf amyloid-β-containing senile plaques. Hippocampal protein concentrations for the sn-1-diacylglycerol lipase α and β isoforms, synthesizing 2-arachidonoyl glycerol, significantly increased in definite Alzheimer's (Braak stage VI), with ectopic sn-1-diacylglycerol lipase β expression found in microglia accumulating near senile plaques and apposing CB(1) cannabinoid receptor-positive presynapses. We found that microglia, expressing two 2-arachidonoyl glycerol-degrading enzymes, serine hydrolase α/β-hydrolase domain-containing 6 and monoacylglycerol lipase, begin to surround senile plaques in probable Alzheimer's disease (Braak stage III). However, Alzheimer's pathology differentially impacts serine hydrolase α/β-hydrolase domain-containing 6 and monoacylglycerol lipase in hippocampal neurons: serine hydrolase α/β-hydrolase domain-containing 6 expression ceases in neurofibrillary tangle-bearing pyramidal cells. In contrast, pyramidal cells containing hyperphosphorylated tau retain monoacylglycerol lipase expression, although at levels significantly lower than in neurons lacking neurofibrillary pathology. Here, monoacylglycerol lipase accumulates in CB(1) cannabinoid receptor-positive presynapses. Subcellular fractionation revealed impaired monoacylglycerol lipase recruitment to biological membranes in post-mortem Alzheimer's tissues, suggesting that disease progression slows the termination of 2-arachidonoyl glycerol signalling. We have experimentally confirmed that altered 2-arachidonoyl glycerol signalling could contribute to synapse silencing in Alzheimer's disease by demonstrating significantly prolonged depolarization-induced suppression of inhibition when superfusing mouse hippocampi with amyloid-β. We propose that the temporal dynamics and cellular specificity of molecular rearrangements impairing 2-arachidonoyl glycerol availability and actions may differ from those of anandamide. Thus, enhanced endocannabinoid signalling, particularly around senile plaques, can exacerbate synaptic failure in Alzheimer's disease.",[],Brain : a journal of neurology,2011-04-05,"[{'lastname': 'Mulder', 'firstname': 'Jan', 'initials': 'J', 'affiliation': 'European Neuroscience Institute at Aberdeen, School of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK.'}, {'lastname': 'Zilberter', 'firstname': 'Misha', 'initials': 'M', 'affiliation': None}, {'lastname': 'Pasquaré', 'firstname': 'Susana J', 'initials': 'SJ', 'affiliation': None}, {'lastname': 'Alpár', 'firstname': 'Alán', 'initials': 'A', 'affiliation': None}, {'lastname': 'Schulte', 'firstname': 'Gunnar', 'initials': 'G', 'affiliation': None}, {'lastname': 'Ferreira', 'firstname': 'Samira G', 'initials': 'SG', 'affiliation': None}, {'lastname': 'Köfalvi', 'firstname': 'Attila', 'initials': 'A', 'affiliation': None}, {'lastname': 'Martín-Moreno', 'firstname': 'Ana M', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Keimpema', 'firstname': 'Erik', 'initials': 'E', 'affiliation': None}, {'lastname': 'Tanila', 'firstname': 'Heikki', 'initials': 'H', 'affiliation': None}, {'lastname': 'Watanabe', 'firstname': 'Masahiko', 'initials': 'M', 'affiliation': None}, {'lastname': 'Mackie', 'firstname': 'Ken', 'initials': 'K', 'affiliation': None}, {'lastname': 'Hortobágyi', 'firstname': 'Tibor', 'initials': 'T', 'affiliation': None}, {'lastname': 'de Ceballos', 'firstname': 'Maria L', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Harkany', 'firstname': 'Tibor', 'initials': 'T', 'affiliation': None}]",,,,,10.1093/brain/awr046,<Element 'PubmedArticle' at 0x7f05d8c96e50>
328,21287411,Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters.,"Istaroxime is a new luso-inotropic compound. It exerts inotropic action by reducing Na+/K+-ATPase activity, and simultaneously it stimulates sarcoplasmic reticulum Ca(2+)-ATPase function, thus also inducing lusitropic action. The aim of present study is to assess the effect of chronic istaroxime treatment on cardiac function and heart rate variability in Bio TO.2 Syrian hamster model of progressive heart failure.
Bio TO.2 hamsters were daily treated, from 12 to 28 weeks of age, with 30 mg/kg/day oral istaroxime. Age-matched Bio TO.2 and Bio F1B hamsters were treated with vehicle and used as diseased and healthy controls. At the end of treatment, hearts function and autonomic cardiac control were evaluated.
Hearts from vehicle-treated Bio TO.2 when compared with hearts from Bio F1B showed higher heart/body weight ratio, and lower left ventricular systolic pressure (LVSP), positive and negative derivative of LV pressure (dP/dT), coronary flow rate (CFR). Hearts from istaroxime-treated when compared with those of vehicle-treated hamsters, showed the reduction of heart/body weight ratio, and the increase of LVSP, of both positive and negative dP/dT, and of CFR. Autonomic cardiac control, evaluated by HRV analysis, indicated in vehicle-treated Bio TO.2 hamsters, when compared to healthy, a shift towards increased sympathetic and decreased parasympathetic activities. Istaroxime-treatment preserved parasympathetic activity.
Chronic istaroxime improves cardiac function and heart rate variability in Bio TO.2 Syrian hamster model of progressive heart failure.",[],Cardiovascular drugs and therapy,2011-02-03,"[{'lastname': 'Lo Giudice', 'firstname': 'Pietro', 'initials': 'P', 'affiliation': 'Research and Development, Pharmacology Department, Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina km 30.400, 00040, Pomezia, Rome, Italy. pietro.logiudice@sigma-tau.it'}, {'lastname': 'Mattera', 'firstname': 'Giovan Giuseppe', 'initials': 'GG', 'affiliation': None}, {'lastname': 'Gagnol', 'firstname': 'Jean-Pierre', 'initials': 'JP', 'affiliation': None}, {'lastname': 'Borsini', 'firstname': 'Franco', 'initials': 'F', 'affiliation': None}]",,,"Hearts from vehicle-treated Bio TO.2 when compared with hearts from Bio F1B showed higher heart/body weight ratio, and lower left ventricular systolic pressure (LVSP), positive and negative derivative of LV pressure (dP/dT), coronary flow rate (CFR). Hearts from istaroxime-treated when compared with those of vehicle-treated hamsters, showed the reduction of heart/body weight ratio, and the increase of LVSP, of both positive and negative dP/dT, and of CFR. Autonomic cardiac control, evaluated by HRV analysis, indicated in vehicle-treated Bio TO.2 hamsters, when compared to healthy, a shift towards increased sympathetic and decreased parasympathetic activities. Istaroxime-treatment preserved parasympathetic activity.",,10.1007/s10557-011-6283-y,<Element 'PubmedArticle' at 0x7f05d8c47b30>
329,21258152,Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred.,"The Asp22fs(g.63_64insC) mutation in progranulin gene (GRN) has been so far reported in one patient who developed frontotemporal dementia (FTD) at the age of 65. Here, we describe the clinical heterogeneity associated with the GRN Asp22fs mutation in a large Italian family. Clinical and instrumental workup of two symptomatic carriers in two generations has been carried out, together with genetic analysis of probands and of nine asymptomatic family members. The first proband was a 47-year old male clinically diagnosed with FTD. Family history was positive and suggestive of an autosomal dominant pattern of inheritance. Evaluation of plasma GRN levels was consistent with the presence of a mutation in its encoding gene, that was demonstrated by sequencing [Asp22fs(g.63_64insC)]. Brain MRI showed multiple T2 and FLAIR hyperintense areas in the frontal lobe white matter and right hemisphere cortical atrophy. The second proband was his 79 year old uncle, presenting with mild cognitive impairment. Brain MRI showed small T2 hyperintense lesions and widespread cortical atrophy. Cerebrospinal fluid amyloid-β, tau, and phosphotau protein levels were in both cases in the range of normality. Additional nine asymptomatic family members were studied. This family's description expands the spectrum of clinical presentations of frontotemporal lobar degeneration caused by GRN mutations, suggesting that the diagnosis could be missed in some individuals with an atypical presentation, and points up the importance of GRN plasma level evaluation.",[],Journal of Alzheimer's disease : JAD,2011-01-25,"[{'lastname': 'Pietroboni', 'firstname': 'Anna M', 'initials': 'AM', 'affiliation': 'Department of Neurological Sciences, University of Milan, IRCCS Fondazione Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Fumagalli', 'firstname': 'Giorgio G', 'initials': 'GG', 'affiliation': None}, {'lastname': 'Ghezzi', 'firstname': 'Laura', 'initials': 'L', 'affiliation': None}, {'lastname': 'Fenoglio', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': None}, {'lastname': 'Cortini', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': None}, {'lastname': 'Serpente', 'firstname': 'Maria', 'initials': 'M', 'affiliation': None}, {'lastname': 'Cantoni', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': None}, {'lastname': 'Rotondo', 'firstname': 'Emanuela', 'initials': 'E', 'affiliation': None}, {'lastname': 'Corti', 'firstname': 'Priscilla', 'initials': 'P', 'affiliation': None}, {'lastname': 'Carecchio', 'firstname': 'Miryam', 'initials': 'M', 'affiliation': None}, {'lastname': 'Bassi', 'firstname': 'Mariateresa', 'initials': 'M', 'affiliation': None}, {'lastname': 'Bresolin', 'firstname': 'Nereo', 'initials': 'N', 'affiliation': None}, {'lastname': 'Galbiati', 'firstname': 'Domenico', 'initials': 'D', 'affiliation': None}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': None}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': None}]",,,,,10.3233/JAD-2011-101704,<Element 'PubmedArticle' at 0x7f05d8c57270>
330,"21257748
14744442
17167471
17167474
20148674
19326096
12637977
19251040
17130640
10819232
7864111
16002529
18781083
19144836
19822168
16025253
11927363
18469022
18267346
14576981
7028561
8703019
16916951
15105990
17353295
12502499
6074000
11739446
19996183
7621989
17459524
16638016
8486775
20369226
2006144
2886385
2210063
12612139
7568143
16081518
19903739
16377570
9048644
20421300
20179270
17209127
15591151
18854155",Inflammation of the hypothalamus leads to defective pancreatic islet function.,"Type 2 diabetes mellitus results from the complex association of insulin resistance and pancreatic β-cell failure. Obesity is the main risk factor for type 2 diabetes mellitus, and recent studies have shown that, in diet-induced obesity, the hypothalamus becomes inflamed and dysfunctional, resulting in the loss of the perfect coupling between caloric intake and energy expenditure. Because pancreatic β-cell function is, in part, under the control of the autonomic nervous system, we evaluated the role of hypothalamic inflammation in pancreatic islet function. In diet-induced obesity, the earliest markers of hypothalamic inflammation are present at 8 weeks after the beginning of the high fat diet; similarly, the loss of the first phase of insulin secretion is detected at the same time point and is restored following sympathectomy. Intracerebroventricular injection of a low dose of tumor necrosis factor α leads to a dysfunctional increase in insulin secretion and activates the expression of a number of markers of apoptosis in pancreatic islets. In addition, the injection of stearic acid intracerebroventricularly, which leads to hypothalamic inflammation through the activation of tau-like receptor-4 and endoplasmic reticulum stress, produces an impairment of insulin secretion, accompanied by increased expression of markers of apoptosis. The defective insulin secretion, in this case, is partially dependent on sympathetic signal-induced peroxisome proliferator receptor-γ coactivator Δα and uncoupling protein-2 expression and is restored after sympathectomy or following PGC1α expression inhibition by an antisense oligonucleotide. Thus, the autonomic signals generated in concert with hypothalamic inflammation can impair pancreatic islet function, a phenomenon that may explain the early link between obesity and defective insulin secretion.",[],The Journal of biological chemistry,2011-01-25,"[{'lastname': 'Calegari', 'firstname': 'Vivian C', 'initials': 'VC', 'affiliation': 'Laboratory of Cell Signaling, of Campinas, 13084-970 Sao Paulo, Brazil.'}, {'lastname': 'Torsoni', 'firstname': 'Adriana S', 'initials': 'AS', 'affiliation': None}, {'lastname': 'Vanzela', 'firstname': 'Emerielle C', 'initials': 'EC', 'affiliation': None}, {'lastname': 'Araújo', 'firstname': 'Eliana P', 'initials': 'EP', 'affiliation': None}, {'lastname': 'Morari', 'firstname': 'Joseane', 'initials': 'J', 'affiliation': None}, {'lastname': 'Zoppi', 'firstname': 'Claudio C', 'initials': 'CC', 'affiliation': None}, {'lastname': 'Sbragia', 'firstname': 'Lourenço', 'initials': 'L', 'affiliation': None}, {'lastname': 'Boschero', 'firstname': 'Antonio C', 'initials': 'AC', 'affiliation': None}, {'lastname': 'Velloso', 'firstname': 'Lício A', 'initials': 'LA', 'affiliation': None}]",,,,,10.1074/jbc.M110.173021,<Element 'PubmedArticle' at 0x7f05d8be33b0>
331,"21257720
8520495
20169425
17379101
20840586
14695190
16149080
18027090
15533755
17339423
17339837
16366604
19917571
14978514
2955820
17408406
19176992
17890944
19228727
7657522
12173939
15647251
11001907
17347152
6601984
18228298
9763577
18812315
17536013
17557930
21029368
12181051
20097882
10037022
16797965
1602136
8427968
17975015
19344388
15471951
16452201
15638855
9446640
11830493
14500349
12091355
9623978
11049995
19255147
19596856
19965677","SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.","Heparanase promotes myeloma growth, dissemination, and angiogenesis through modulation of the tumor microenvironment, thus highlighting the potential of therapeutically targeting this enzyme. SST0001, a nonanticoagulant heparin with antiheparanase activity, was examined for its inhibition of myeloma tumor growth in vivo and for its mechanism of action.
The ability of SST0001 to inhibit growth of myeloma tumors was assessed using multiple animal models and a diverse panel of human and murine myeloma cell lines. To investigate the mechanism of action of SST0001, pharmacodynamic markers of angiogenesis, heparanase activity, and pathways downstream of heparanase were monitored. The potential use of SST0001 as part of a combination therapy was also evaluated in vivo.
SST0001 effectively inhibited myeloma growth in vivo, even when confronted with an aggressively growing tumor within human bone. In addition, SST0001 treatment causes changes within tumors consistent with the compound's ability to inhibit heparanase, including downregulation of HGF, VEGF, and MMP-9 expression and suppressed angiogenesis. SST0001 also diminishes heparanase-induced shedding of syndecan-1, a heparan sulfate proteoglycan known to be a potent promoter of myeloma growth. SST0001 inhibited the heparanase-mediated degradation of syndecan-1 heparan sulfate chains, thus confirming the antiheparanase activity of this compound. In combination with dexamethasone, SST0001 blocked tumor growth in vivo presumably through dual targeting of the tumor and its microenvironment.
These results provide mechanistic insight into the antitumor action of SST0001 and validate its use as a novel therapeutic tool for treating multiple myeloma.",[],Clinical cancer research : an official journal of the American Association for Cancer Research,2011-01-25,"[{'lastname': 'Ritchie', 'firstname': 'Joseph P', 'initials': 'JP', 'affiliation': 'Department of Pathology, Center for Metabolic Bone Disease, and Comprehensive Cancer Center, University of Alabama at Birmingham, Alabama 35294, USA.'}, {'lastname': 'Ramani', 'firstname': 'Vishnu C', 'initials': 'VC', 'affiliation': None}, {'lastname': 'Ren', 'firstname': 'Yongsheng', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Naggi', 'firstname': 'Annamaria', 'initials': 'A', 'affiliation': None}, {'lastname': 'Torri', 'firstname': 'Giangiacomo', 'initials': 'G', 'affiliation': None}, {'lastname': 'Casu', 'firstname': 'Benito', 'initials': 'B', 'affiliation': None}, {'lastname': 'Penco', 'firstname': 'Sergio', 'initials': 'S', 'affiliation': None}, {'lastname': 'Pisano', 'firstname': 'Claudio', 'initials': 'C', 'affiliation': None}, {'lastname': 'Carminati', 'firstname': 'Paolo', 'initials': 'P', 'affiliation': None}, {'lastname': 'Tortoreto', 'firstname': 'Monica', 'initials': 'M', 'affiliation': None}, {'lastname': 'Zunino', 'firstname': 'Franco', 'initials': 'F', 'affiliation': None}, {'lastname': 'Vlodavsky', 'firstname': 'Israel', 'initials': 'I', 'affiliation': None}, {'lastname': 'Sanderson', 'firstname': 'Ralph D', 'initials': 'RD', 'affiliation': None}, {'lastname': 'Yang', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': None}]",,,"SST0001 effectively inhibited myeloma growth in vivo, even when confronted with an aggressively growing tumor within human bone. In addition, SST0001 treatment causes changes within tumors consistent with the compound's ability to inhibit heparanase, including downregulation of HGF, VEGF, and MMP-9 expression and suppressed angiogenesis. SST0001 also diminishes heparanase-induced shedding of syndecan-1, a heparan sulfate proteoglycan known to be a potent promoter of myeloma growth. SST0001 inhibited the heparanase-mediated degradation of syndecan-1 heparan sulfate chains, thus confirming the antiheparanase activity of this compound. In combination with dexamethasone, SST0001 blocked tumor growth in vivo presumably through dual targeting of the tumor and its microenvironment.",©2011 AACR.,10.1158/1078-0432.CCR-10-2476,<Element 'PubmedArticle' at 0x7f05d8c02090>
332,"21252111
15955494
17350290
3337672
20360166
12794387
9678739
17101833
18816511
9061124
1202204
19917988
16950801
20177120
7104545
9641683
18302232
18263627
18668533
15477512
19884571
16300968
11001602
19470967
18829698
17071924
9777473
9447441
9855500
19255708
18192287
12084880
16087904
12058088
15592131
2081237
18268196
9617910
11181853
8163988
11771995
19786698
19255408
17988893
19299900
19762452",Predicting functional decline in behavioural variant frontotemporal dementia.,"Behavioural variant frontotemporal dementia is characterized by a change in comportment. It is associated with considerable functional decline over the course of the illness albeit with sometimes dramatic variability among patients. It is unknown whether any baseline features, or combination of features, could predict rate of functional decline in behavioural variant frontotemporal dementia. The aim of this study was to investigate the effects of different baseline clinical, neuropsychological, neuropsychiatric, genetic and anatomic predictors on the rate of functional decline as measured by the Clinical Dementia Rating Sum of Boxes scale. We identified 86 subjects with behavioural variant frontotemporal dementia that had multiple serial Clinical Dementia Rating Sum of Boxes assessments (mean 4, range 2-18). Atlas-based parcellation was used to generate volumes for specific regions of interest at baseline. Volumes were utilized to classify subjects into different anatomical subtypes using the advanced statistical technique of cluster analysis and were assessed as predictor variables. Composite scores were generated for the neuropsychological domains of executive, language, memory and visuospatial function. Behaviours from the brief questionnaire form of the Neuropsychiatric Inventory were assessed. Linear mixed-effects regression modelling was used to determine which baseline features predict rate of future functional decline. Rates of functional decline differed across the anatomical subtypes of behavioural variant frontotemporal dementia, with faster rates observed in the frontal dominant and frontotemporal subtypes. In addition, subjects with poorer performance on neuropsychological tests of executive, language and visuospatial function, less disinhibition, agitation/aggression and night-time behaviours at presentation, and smaller medial, lateral and orbital frontal lobe volumes showed faster rates of decline. In many instances, the effect of the predictor variables observed across all subjects was also preserved within anatomical subtypes. Furthermore, some of the predictor variables improved our prediction of rate of functional decline after anatomical subtype was taken into account. In particular, age at onset was a highly significant predictor but only after adjusting for subtype. We also found that although some predictor variables, for example gender, Mini-Mental State Examination score, and apathy/indifference, did not affect the rate of functional decline; these variables were associated with the actual Clinical Dementia Rating Sum of Boxes score estimated for any given time-point. These findings suggest that in behavioural variant frontotemporal dementia, rate of functional decline is driven by the combination of anatomical pattern of atrophy, age at onset, and neuropsychiatric characteristics of the subject at baseline.",[],Brain : a journal of neurology,2011-01-22,"[{'lastname': 'Josephs', 'firstname': 'Keith A', 'initials': 'KA', 'affiliation': 'Department of Neurology (Behavioural Neurology), Mayo Clinic, Rochester, Minnesota 55905, USA. josephs.keith@mayo.edu'}, {'lastname': 'Whitwell', 'firstname': 'Jennifer L', 'initials': 'JL', 'affiliation': None}, {'lastname': 'Weigand', 'firstname': 'Stephen D', 'initials': 'SD', 'affiliation': None}, {'lastname': 'Senjem', 'firstname': 'Matthew L', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Boeve', 'firstname': 'Bradley F', 'initials': 'BF', 'affiliation': None}, {'lastname': 'Knopman', 'firstname': 'David S', 'initials': 'DS', 'affiliation': None}, {'lastname': 'Smith', 'firstname': 'Glenn E', 'initials': 'GE', 'affiliation': None}, {'lastname': 'Ivnik', 'firstname': 'Robert J', 'initials': 'RJ', 'affiliation': None}, {'lastname': 'Jack', 'firstname': 'Clifford R', 'initials': 'CR', 'affiliation': None}, {'lastname': 'Petersen', 'firstname': 'Ronald C', 'initials': 'RC', 'affiliation': None}]",,,,,10.1093/brain/awq348,<Element 'PubmedArticle' at 0x7f05d8ba5450>
333,21175533,Chronic traumatic encephalopathy in a professional American wrestler.,"We present in this case report the tissue substrates and forensic evidence for chronic traumatic encephalopathy (CTE) in a professional American wrestler with Apolipoprotein E (apoE) genotyping. Professional wrestling is a contact-sport, with an integral risk for players to sustain repeated concussions over their careers. This case provides the first autopsy evidence of neuropathological abnormalities that accompany CTE in professional American wrestlers. A complete autopsy was performed on a 40-year-old Caucasian male, after he died unexpectedly by suicidal hanging after he had killed his wife and son. The brain showed no atrophy and no recent or remote contusions or necrosis. There was a mild to moderate neocortical neuronal dropout without any amyloid plaques. There were diffuse, sparse to frequent tau-immunoreactive Neurofibrillary Tangles and Neuropil Threads in the neocortex, subcortical ganglia, and brainstem nuclei including the substantia nigra consistent with CTE. The apoE genotype was determined to be E3/E3. Other autopsy findings included cardiomegaly, left ventricular hypertrophy, and bilateral atrioventricular dilatation; toxicologic analyses showed alprazolam and hydrocodone in the blood, and evidence of exogenous testosterone in the urine. Longitudinal studies of professional contact-sport athletes are needed to identify the differentiating characteristics of athletes who develop CTE and devise strategies for intervention.",[],Journal of forensic nursing,2010-12-24,"[{'lastname': 'Omalu', 'firstname': 'Bennet I', 'initials': 'BI', 'affiliation': 'San Joaquin General Hospital, French Camp, California, USA. bennetomalu@comcast.net'}, {'lastname': 'Fitzsimmons', 'firstname': 'Robert P', 'initials': 'RP', 'affiliation': None}, {'lastname': 'Hammers', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': None}, {'lastname': 'Bailes', 'firstname': 'Julian', 'initials': 'J', 'affiliation': None}]",,,,© 2010 International Association of Forensic Nurses.,10.1111/j.1939-3938.2010.01078.x,<Element 'PubmedArticle' at 0x7f05d8bc4b30>
334,"21048198
11708987
17579875
19015862
16401843
17998443
18420483
19299900
17347655
19296504
19273758
18506455
19001167
20232070
20652578
17616482
9855500
9521272
19125255
12722160
19901167
19434074
18989684
18987350
19236470
17903209
16481598
17116217
16815630
18798831
19647470
10888928
7902099
19810097
18164424
16718704
15349867",Novel CSF biomarkers for frontotemporal lobar degenerations.,"To identify antemortem CSF diagnostic biomarkers that can potentially distinguish between the 2 main causes of frontotemporal lobar degeneration (FTLD), i.e., FTLD with TDP-43 pathology (FTLD-TDP) and FTLD with tau pathology (FTLD-tau).
CSF samples were collected antemortem from 23 patients with FTLD with known pathology to form a autopsy cohort as part of a comparative biomarker study that additionally included 33 living cognitively normal subjects and 66 patients with autopsy-confirmed Alzheimer disease (AD). CSF samples were also collected from 80 living patients clinically diagnosed with frontotemporal dementia (FTD). Levels of 151 novel analytes were measured via a targeted multiplex panel enriched in neuropeptides, cytokines, and growth factors, along with levels of CSF biomarkers for AD.
CSF levels of multiple analytes differed between FTLD-TDP and FTLD-tau, including Fas, neuropeptides (agouti-related peptide and adrenocorticotropic hormone), and chemokines (IL-23, IL-17). Classification by random forest analysis achieved high sensitivity for FTLD-TDP (86%) with modest specificity (78%) in the autopsy cohort. When the classification algorithm was applied to a living FTD cohort, semantic dementia was the phenotype with the highest predicted proportion of FTLD-TDP. When living patients with behavioral variant FTD were examined in detail, those predicted to have FTLD-TDP demonstrated neuropsychological differences vs those predicted to have FTLD-tau in a pattern consistent with previously reported trends in autopsy-confirmed cases.
Clinical cases with FTLD-TDP and FTLD-tau pathology can be potentially identified antemortem by assaying levels of specific analytes that are well-known and readily measurable in CSF.",[],Neurology,2010-11-05,"[{'lastname': 'Hu', 'firstname': 'W T', 'initials': 'WT', 'affiliation': 'Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA. trojanow@mail.med.upenn.edu'}, {'lastname': 'Chen-Plotkin', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Grossman', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Arnold', 'firstname': 'S E', 'initials': 'SE', 'affiliation': None}, {'lastname': 'Clark', 'firstname': 'C M', 'initials': 'CM', 'affiliation': None}, {'lastname': 'Shaw', 'firstname': 'L M', 'initials': 'LM', 'affiliation': None}, {'lastname': 'McCluskey', 'firstname': 'L', 'initials': 'L', 'affiliation': None}, {'lastname': 'Elman', 'firstname': 'L', 'initials': 'L', 'affiliation': None}, {'lastname': 'Hurtig', 'firstname': 'H I', 'initials': 'HI', 'affiliation': None}, {'lastname': 'Siderowf', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'V M-Y', 'initials': 'VM', 'affiliation': None}, {'lastname': 'Soares', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Trojanowski', 'firstname': 'J Q', 'initials': 'JQ', 'affiliation': None}]",,,"CSF levels of multiple analytes differed between FTLD-TDP and FTLD-tau, including Fas, neuropeptides (agouti-related peptide and adrenocorticotropic hormone), and chemokines (IL-23, IL-17). Classification by random forest analysis achieved high sensitivity for FTLD-TDP (86%) with modest specificity (78%) in the autopsy cohort. When the classification algorithm was applied to a living FTD cohort, semantic dementia was the phenotype with the highest predicted proportion of FTLD-TDP. When living patients with behavioral variant FTD were examined in detail, those predicted to have FTLD-TDP demonstrated neuropsychological differences vs those predicted to have FTLD-tau in a pattern consistent with previously reported trends in autopsy-confirmed cases.",,10.1212/WNL.0b013e318200d78d,<Element 'PubmedArticle' at 0x7f05d8bcdae0>
335,"21035623
3054625
11816784
9862640
19010417
19829371
18631949
20083042
8245017
17005052
17087877
19792974
20237129
6610841
8191290
16894109
14991808
16372280
16894106
17210801
9855500
8710059
21136637
16199891
17698783
16488378
19433664
19543540
18280741
18556781
11986266
12759259
20540736
10369305
18057559
20049742
12165466
10858586
17222916
16234240
18802121
11467840
12071845
15015934
16704970
10388530
12799184
19414556
20186853
10072051
12709467",YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.,"Disease-modifying therapies for Alzheimer's disease (AD) would be most effective during the preclinical stage (pathology present, cognition intact) before significant neuronal loss occurs. Therefore, biomarkers that detect AD pathology in its early stages and predict dementia onset and progression will be invaluable for patient care and efficient clinical trial design.
AD-associated changes in cerebrospinal fluid (CSF) were measured using two-dimensional difference gel electrophoresis and liquid chromatography tandem mass spectrometry. Subsequently, CSF YKL-40 was measured by enzyme-linked immunosorbent assay in the discovery cohort (n = 47), validation cohort (n = 292) with paired plasma samples (n = 237), frontotemporal lobar degeneration (n=9) [corrected], and progressive supranuclear palsy (PSP; n = 6). Immunohistochemistry was performed to identify source(s) of YKL-40 in human AD brain.
Discovery and validation cohorts, showed higher mean CSF YKL-40 in very mild and mild AD-type dementia (Clinical Dementia Rating [CDR] 0.5 and 1) versus control subjects (CDR 0) and PSP subjects. Importantly, CSF YKL-40/Aβ42 ratio predicted risk of developing cognitive impairment (CDR 0 to CDR > 0 conversion), as well as the best CSF biomarkers identified to date, tau/Aβ42 and p-tau 181/Aβ42. Mean plasma YKL-40 was higher in CDR 0.5 and 1 versus CDR 0, and correlated with CSF levels. YKL-40 immunoreactivity labeled astrocytes near a subset of amyloid plaques, implicating YKL-40 in the neuroinflammatory response to Aβ deposition.
These data demonstrate that YKL-40, a putative indicator of neuroinflammation, is elevated in AD and, together with Aβ42, has potential prognostic utility as a biomarker for preclinical AD.",[],Biological psychiatry,2010-11-03,"[{'lastname': 'Craig-Schapiro', 'firstname': 'Rebecca', 'initials': 'R', 'affiliation': 'Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.'}, {'lastname': 'Perrin', 'firstname': 'Richard J', 'initials': 'RJ', 'affiliation': None}, {'lastname': 'Roe', 'firstname': 'Catherine M', 'initials': 'CM', 'affiliation': None}, {'lastname': 'Xiong', 'firstname': 'Chengjie', 'initials': 'C', 'affiliation': None}, {'lastname': 'Carter', 'firstname': 'Deborah', 'initials': 'D', 'affiliation': None}, {'lastname': 'Cairns', 'firstname': 'Nigel J', 'initials': 'NJ', 'affiliation': None}, {'lastname': 'Mintun', 'firstname': 'Mark A', 'initials': 'MA', 'affiliation': None}, {'lastname': 'Peskind', 'firstname': 'Elaine R', 'initials': 'ER', 'affiliation': None}, {'lastname': 'Li', 'firstname': 'Ge', 'initials': 'G', 'affiliation': None}, {'lastname': 'Galasko', 'firstname': 'Douglas R', 'initials': 'DR', 'affiliation': None}, {'lastname': 'Clark', 'firstname': 'Christopher M', 'initials': 'CM', 'affiliation': None}, {'lastname': 'Quinn', 'firstname': 'Joseph F', 'initials': 'JF', 'affiliation': None}, {'lastname': ""D'Angelo"", 'firstname': 'Gina', 'initials': 'G', 'affiliation': None}, {'lastname': 'Malone', 'firstname': 'James P', 'initials': 'JP', 'affiliation': None}, {'lastname': 'Townsend', 'firstname': 'R Reid', 'initials': 'RR', 'affiliation': None}, {'lastname': 'Morris', 'firstname': 'John C', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Fagan', 'firstname': 'Anne M', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Holtzman', 'firstname': 'David M', 'initials': 'DM', 'affiliation': None}]",,,"Discovery and validation cohorts, showed higher mean CSF YKL-40 in very mild and mild AD-type dementia (Clinical Dementia Rating [CDR] 0.5 and 1) versus control subjects (CDR 0) and PSP subjects. Importantly, CSF YKL-40/Aβ42 ratio predicted risk of developing cognitive impairment (CDR 0 to CDR > 0 conversion), as well as the best CSF biomarkers identified to date, tau/Aβ42 and p-tau 181/Aβ42. Mean plasma YKL-40 was higher in CDR 0.5 and 1 versus CDR 0, and correlated with CSF levels. YKL-40 immunoreactivity labeled astrocytes near a subset of amyloid plaques, implicating YKL-40 in the neuroinflammatory response to Aβ deposition.",Copyright © 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.,10.1016/j.biopsych.2010.08.025,<Element 'PubmedArticle' at 0x7f05d8b703b0>
336,20965859,"[Effects of estrogen on P-Tau, ChAT and nerve growth factor protein expressions in the brain tissue of rats with Alzheimer's disease].","To examine the effect of estrogen on the expressions of phosphorylated Tau (P-Tau), ChAT and nerve growth factor (NGF) protein in the brain tissue of rat models of Alzheimer disease (AD).
Rat models of AD were established by injecting Aβ1-42 protein fragments in the right lateral ventricle. Two weeks later, 17β-estradiol tablets were implanted subcutaneously at the neck of the rats and maintained for 30 days. The pathological changes in the rats' brain neurons and alterations in the expressions of P-Tau, ChAT and NGF proteins were observed using HE staining and immunohistochemistry, respectively.
In the AD rats, neurofibrillary tangles occurred in the brain tissue, and estrogen treatment significantly reduced the formation of neurofibrillary tangles. Estrogen treatment also resulted in lowered P-Tau expression and increased ChAT and NGF protein expressions in comparison with those in the AD model rats.
Estrogen can up-regulate ChAT and NGF and down-regulate tau protein expression, thus producing obvious therapeutic effect on AD in rats.",[],Nan fang yi ke da xue xue bao = Journal of Southern Medical University,2010-10-23,"[{'lastname': 'Huagn', 'firstname': 'Yue', 'initials': 'Y', 'affiliation': 'Department of Neurology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. hy139378@126.com'}, {'lastname': 'Xu', 'firstname': 'Yu-ming', 'initials': 'YM', 'affiliation': None}, {'lastname': 'Zhang', 'firstname': 'Jie-wen', 'initials': 'JW', 'affiliation': None}, {'lastname': 'Ren', 'firstname': 'Xiu-hua', 'initials': 'XH', 'affiliation': None}, {'lastname': 'Suo', 'firstname': 'Ai-qin', 'initials': 'AQ', 'affiliation': None}]",,"Estrogen can up-regulate ChAT and NGF and down-regulate tau protein expression, thus producing obvious therapeutic effect on AD in rats.","In the AD rats, neurofibrillary tangles occurred in the brain tissue, and estrogen treatment significantly reduced the formation of neurofibrillary tangles. Estrogen treatment also resulted in lowered P-Tau expression and increased ChAT and NGF protein expressions in comparison with those in the AD model rats.",,,<Element 'PubmedArticle' at 0x7f05d8b948b0>
337,"20934413
15807439
16545544
10625733
15135853
10599770
15664693
14687873
1734291
17720235
15939846
16785601
9442354
15653282
9442353
11124043
16688123
11238065
12145327
18045930
18276750
20410196
15723165
8986335
16291949
15246987
17544382
11897260
11748902
15213207
6541508
14624021
11375910
18394690
19204288
16061516
8080389
18486110
11449190
9427614
7972405
8810256
18080736
1678699
3378076
7198030
9799628
12672016
11182481
3324647
9748017
9191758
10513583
12020728
19210439
15761056
16329116
12032347
12515896
18955119
15113628
7624480
20505099
18601700
20646174
9541747
10049607
16844154
16034187
17379422
12974607
14745052
15452574
8918971
7195743
12885581
16176578
12895417
8885820
11113610
10098861
19427328
18304749
12077215
12771113
3717905
17182789
15383512
19428144
11445258
17075721
15611026
11789085
7430918
10943726
11193142
11534968
13979629
8709781
1173305
18635489
2670873
14678749
19359476
7349961
1793176
12128278
15509899
12413371
11796757",Sex differences in β-amyloid accumulation in 3xTg-AD mice: role of neonatal sex steroid hormone exposure.,"The risk of Alzheimer's disease (AD) is higher in women than in men, a sex difference that likely results from the effects of sex steroid hormones. To investigate this relationship, we first compared progression of β-amyloid (Aβ) pathology in male and female triple transgenic (3xTg-AD) mice. We found that female 3xTg-AD mice exhibit significantly greater Aβ burden and larger behavioral deficits than age-matched males. Next, we evaluated how the organizational effects of sex steroid hormones during postnatal development may affect adult vulnerability to Aβ pathology. We observed that male 3xTg-AD mice demasculinized during early development exhibit significantly increased Aβ accumulation in adulthood. In contrast, female mice defeminized during early development exhibit a more male-like pattern of Aβ pathology in adulthood. Taken together, these results demonstrate significant sex differences in pathology in 3xTg-AD mice and suggest that these differences may be mediated by organizational actions of sex steroid hormones during development.",[],Brain research,2010-10-12,"[{'lastname': 'Carroll', 'firstname': 'Jenna C', 'initials': 'JC', 'affiliation': 'Neuroscience Graduate Program, University of Southern California, Los Angeles, CA 90089, USA.'}, {'lastname': 'Rosario', 'firstname': 'Emily R', 'initials': 'ER', 'affiliation': None}, {'lastname': 'Kreimer', 'firstname': 'Sara', 'initials': 'S', 'affiliation': None}, {'lastname': 'Villamagna', 'firstname': 'Angela', 'initials': 'A', 'affiliation': None}, {'lastname': 'Gentzschein', 'firstname': 'Elisabet', 'initials': 'E', 'affiliation': None}, {'lastname': 'Stanczyk', 'firstname': 'Frank Z', 'initials': 'FZ', 'affiliation': None}, {'lastname': 'Pike', 'firstname': 'Christian J', 'initials': 'CJ', 'affiliation': None}]",,,,Copyright © 2010 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2010.10.009,<Element 'PubmedArticle' at 0x7f05d8b9e720>
338,"20807511
12710689
16024764
179788
19633137
16720669
17164307
12782002
10718932
17456772
18045930
18276750
12826696
15985573
9799588
11804699
15598144
2810583
11121509
16310316
15219653
11325319
14624021
11099831
10655508
18067894
19207807
9106355
14763993
16310318
16386941
3324647
15901667
7628354
16192374
12629162
14724248
18338250
16452668
16034187
16122717
16387720
14643377
12895417
17056594
15471969
9192613
11805297
10098861
11689174
18222446
19427328
18395206
14622134
14622899
3717905
17658612
17182789
19428144
15383512
9388012
2324335
8439515
19458604
18821130
18780973
11371645
12370428
1613547
7996203
3702447
18346198
18716201
20053478",Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways.,"Normal, age-related depletion of the androgen testosterone is a risk factor for Alzheimer's disease (AD) in men. Previously, we reported that experimental androgen depletion significantly accelerates development of AD-like neuropathology in the 3xTg-AD triple-transgenic mouse model of AD, an effect prevented by androgen treatment. Because testosterone is metabolized in brain into both the androgen dihydrotestosterone (DHT) and the estrogen 17β-estradiol (E2), testosterone can mediate its effects through androgen and or estrogen pathways. To define the role of androgen and estrogen pathways in regulation of AD-like neuropathology, we compared the effects of testosterone (T) and its metabolites DHT and E2 in male 3xTg-AD mice depleted of endogenous sex steroid hormones by gonadectomy (GDX). Male 3xTg-AD mice were sham GDX or GDX, immediately treated with vehicle, T, DHT, or E2, and 4 months later evaluated for two indices of AD-like neuropathology, β-amyloid (Aβ) accumulation and tau hyperphosphorylation. In comparison to sham GDX mice, we observed a significant increase in Aβ accumulation in GDX mice in subiculum, hippocampus, and amygdala. Treatment of GDX mice with T prevented the increased Aβ accumulation in all three brain regions. DHT treatment yielded similar results, significantly reducing Aβ accumulation across brain regions. Interestingly, E2 prevented Aβ accumulation in hippocampus but exerted only partial effects in subiculum and amygdala. Levels of tau hyperphosphorylation in sham GDX male 3xTg-AD mice were modest and only slightly increased by GDX. Treatment of GDX mice with T or E2 but not DHT reduced tau hyperphosphorylation to levels lower than observed in sham animals. These data suggest that testosterone regulates Aβ pathology through androgen and estrogen pathways and reduces tau pathology largely through estrogen pathways. These findings further define hormone pathways involved in regulation of AD-related pathology, information that is important for understanding disease etiology and developing pathway-specific hormone interventions.",[],Brain research,2010-09-03,"[{'lastname': 'Rosario', 'firstname': 'Emily R', 'initials': 'ER', 'affiliation': 'Neuroscience Graduate Program, Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089, USA.'}, {'lastname': 'Carroll', 'firstname': 'Jenna', 'initials': 'J', 'affiliation': None}, {'lastname': 'Pike', 'firstname': 'Christian J', 'initials': 'CJ', 'affiliation': None}]",,,,Copyright © 2010 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2010.08.068,<Element 'PubmedArticle' at 0x7f05d8b5b2c0>
339,20542922,Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A.,"We have reported recently that inhibition of protein phosphatase (PP)-2A and PP-1 by calyculin A, a specific inhibitor of PP-2A and PP-1, induced Alzheimer-like hyperphosphorylation of tau and spatial memory retention impairment. In this study, we tested the in vivo effects of melatonin on these Alzheimer-like changes. We found that administration of melatonin intraperitoneally for 9 consecutive days before injection of calyculin A could prevent calyculin A-induced synaptophysin loss, memory retention deficits, as well as hyperphosphorylation of tau and neurofilaments. Furthermore, melatonin partially reversed the phosphorylation of the catalytic subunit of PP-2A at Tyrosine 307 (Y307), a crucial site negatively regulating the activity of PP-2A, and reduced the levels of malondialdehyde, a marker of oxidative stress, induced by calyculin A. These results suggest that melatonin could serve as a potential therapeutic agent for preventing Alzheimer-like pathological changes and behavioral abnormality via modulating the activity of PP-2A and oxidative stress.",[],"Journal of psychopharmacology (Oxford, England)",2010-06-15,"[{'lastname': 'Yang', 'firstname': 'Xifei', 'initials': 'X', 'affiliation': 'Department of Pathophysiology, Institute of Neuroscience, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.'}, {'lastname': 'Yang', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Fu', 'firstname': 'Zhengqi', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Li', 'firstname': 'Yin', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Feng', 'firstname': 'Jing', 'initials': 'J', 'affiliation': None}, {'lastname': 'Luo', 'firstname': 'Jinzhuo', 'initials': 'J', 'affiliation': None}, {'lastname': 'Zhang', 'firstname': 'Qiuyue', 'initials': 'Q', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Qun', 'initials': 'Q', 'affiliation': None}, {'lastname': 'Tian', 'firstname': 'Qing', 'initials': 'Q', 'affiliation': None}]",,,,,10.1177/0269881110367723,<Element 'PubmedArticle' at 0x7f05d8b02180>
340,20471965,Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 1. Circadian changes.,"Circadian disturbances, including a fragmented sleep-wake pattern and sundowning, are commonly reported early in the progression of Alzheimer's disease (AD). These changes are distinctly different from those observed in non-pathological aging. Transgenic models of AD are a promising tool in understanding the underlying mechanisms and cause of disease. A novel triple-transgenic model of AD, 3xTg-AD, is the only model to exhibit both Abeta and tau pathology, and mimic human AD. The present study characterized changes pertaining to circadian rhythmicity that occur prior to and post-AD pathology. Both male and female 3xTg-AD mice demonstrated alterations to their circadian pacemaker with decreased nocturnal behavior when compared to controls. Specifically, males showed greater locomotor activity during the day and shorter freerunning periods prior to the onset of AD-pathology, and females had a decrease in activity levels during their typical active phase. Both sexes did not differ in terms of their freerunning periods or photic phase shifting ability. A decrease in vasoactive intestinal polypeptide-containing and vasopressin-containing cells was observed in the suprachiasmatic nucleus of 3xTg-AD mice relative to controls. This study demonstrates that abnormalities in circadian rhythmicity in 3xTg-AD mice precede expected AD pathology. This suggests that human studies may wish to determine if similar circadian dysfunction is predictive of early-onset AD.",[],Brain research,2010-05-18,"[{'lastname': 'Sterniczuk', 'firstname': 'Roxanne', 'initials': 'R', 'affiliation': 'Department of Psychology, University of Calgary, 2500 University Dr. NW, Calgary, AB, Canada T2N 1N4.'}, {'lastname': 'Dyck', 'firstname': 'Richard H', 'initials': 'RH', 'affiliation': None}, {'lastname': 'Laferla', 'firstname': 'Frank M', 'initials': 'FM', 'affiliation': None}, {'lastname': 'Antle', 'firstname': 'Michael C', 'initials': 'MC', 'affiliation': None}]",,,,Copyright 2010 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2010.05.013,<Element 'PubmedArticle' at 0x7f05d8b0f0e0>
341,20164562,"Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients.","Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by severe cognitive deficit, wherein the impairment of episodic memory is the major hallmark. AD patients exhibit augmented accumulation of amyloid-beta (Abeta) and hyperphosphorylated tau protein in specific brain regions. In addition, several neuropeptides/neurotransmitter axes clearly associated with cognitive processes, Abeta turnover, and tau phosphorylation have also been found to be impaired in AD, such as somatostatin (SST)/cortistatin (CST) and dopamine (DA) systems. However, to date there is no precise quantitative data on the expression of these systems in the human brain of AD and normal patients. Here we measured by quantitative real-time PCR the mRNA levels of SST/CST, their receptors (sst1-5 and DA receptors (drd1-5) in addition to neprilysin (a SST-regulated enzyme involved in Abeta degradation) in three regions of the temporal lobe, one of the cortical regions most severely affected by AD. Our results reveal that some components of SST/CST- and DA-axes are divergently altered in the three areas of AD patients. Despite this region-specific regulation, an overall, common reduction of these systems was observed in the temporal lobe of AD patients. Conversely, neprilysin expression was not altered in AD, suggesting that Abeta accumulation observed in AD is due to a lack of neprilysin activation by SST rather than to a reduction of its expression. Collectively, our results define a comprehensive scenario wherein reduction of ssts, drds, and sst ligands SST and CST, could be involved, at least in part, in some of the more important defects observed in AD.",[],Journal of Alzheimer's disease : JAD,2010-02-19,"[{'lastname': 'Gahete', 'firstname': 'Manuel D', 'initials': 'MD', 'affiliation': 'Department of Cell Biology, Physiology and Immunology, University of Córdoba, and Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain.'}, {'lastname': 'Rubio', 'firstname': 'Alicia', 'initials': 'A', 'affiliation': None}, {'lastname': 'Durán-Prado', 'firstname': 'Mario', 'initials': 'M', 'affiliation': None}, {'lastname': 'Avila', 'firstname': 'Jesús', 'initials': 'J', 'affiliation': None}, {'lastname': 'Luque', 'firstname': 'Raúl M', 'initials': 'RM', 'affiliation': None}, {'lastname': 'Castaño', 'firstname': 'Justo P', 'initials': 'JP', 'affiliation': None}]",,,,,10.3233/JAD-2010-1385,<Element 'PubmedArticle' at 0x7f05d8b1b590>
342,"20157255
11089820
14715130
10964604
11296263
9148766
10816423
10588952
17573819
15741649
8261505
10531052
15339642
16865397
8194595
11683988
14687544
12634421
15039230
10786709
16769157
18775495
18845178
19387109
10203350
11979057
15576490
18801339
12020765
8524413
9373175
18088381
16696972
8981437
19096164
8157129
10818523
12920183
17472705
10964604
11930160
8552186
1656157
9920502
14523054
19126211
19158428
15148325
19096162
17851187
18367451
19166821
19429119
7514173
10571182",Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices.,"Accumulation of amyloid-beta (Abeta) peptide and deposition of hyperphosphorylated tau protein are two major pathological hallmarks of Alzheimer's disease (AD). We have shown that cholesterol-enriched diets and its metabolite 27-hydroxycholesterol (27-OHC) increase Abeta and phosphorylated tau levels. However, the mechanisms by which cholesterol and 27-OHC regulate Abeta production and tau phosphorylation remain unclear. Leptin, an adipocytokine involved in cell survival and in learning, has been demonstrated to regulate Abeta production and tau hyperphosphorylation in transgenic mice for AD. However, the involvement of leptin signaling in cholesterol and cholesterol metabolites-induced Abeta accumulation and tau hyperphosphorylation are yet to be examined. In this study, we determined the effect of high cholesterol diet and 27-OHC on leptin expression levels and the extent to which leptin treatment affects 27-OHC-induced AD-like pathology. Our results show that feeding rabbits a 2% cholesterol-enriched diet for 12 weeks reduces the levels of leptin by approximately 80% and incubating organotypic slices from adult rabbit hippocampus with 27-OHC reduced leptin levels by approximately 30%. 27-OHC induces a 1.5-fold increase in Abeta (40) and a 3-fold increase in Abeta (42) and in phosphorylated tau. Treatment with leptin reversed the 27-OHC-induced increase in Abeta and phosphorylated tau by decreasing the levels of BACE-1 and GSK-3beta respectively. Our results suggest that cholesterol-enriched diets and cholesterol metabolites induce AD-like pathology by altering leptin signaling. We propose that leptin administration may prevent the progression of sporadic forms of AD that are related to increased cholesterol and oxidized cholesterol metabolite levels.",[],Journal of Alzheimer's disease : JAD,2010-02-17,"[{'lastname': 'Marwarha', 'firstname': 'Gurdeep', 'initials': 'G', 'affiliation': 'Department of Pharmacology, Physiology and Therapeutics, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, USA.'}, {'lastname': 'Dasari', 'firstname': 'Bhanu', 'initials': 'B', 'affiliation': None}, {'lastname': 'Prasanthi', 'firstname': 'Jaya R P', 'initials': 'JR', 'affiliation': None}, {'lastname': 'Schommer', 'firstname': 'Jared', 'initials': 'J', 'affiliation': None}, {'lastname': 'Ghribi', 'firstname': 'Othman', 'initials': 'O', 'affiliation': None}]",,,,,10.3233/JAD-2010-1298,<Element 'PubmedArticle' at 0x7f05d8aa4d10>
343,"20142765
1759558
12084879
12763021
19299585
12824062
12438432
11932745
12130773
15450169
15734686
16713590
9500964
10448433
10582624
11404397
15172746
17785178
18272675
19057621
10368769
14657605
12543268
18677155
10718932
11560301
8477671
11394198
18439297
14871891
16503402
18413150
18560131
8810256
9291938
11145749
9100663
12536225
11160418
18586353
11917160
15052274
11523060
11165762
17376589
12196135
19251705
9830016
10655101
12832532
18520165
11059815
1414275
7994623
8313943
11958863
8971979
10088996
8423484
10612707
16686651
19204149
17548355",Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease.,"Amyloid-beta peptide (Abeta) plays an essential pathophysiologic role in Alzheimer disease, and elevation of luteinizing hormone (LH) levels during aging has been implicated in its pathogenesis. To assess the effect of LH receptor deficiency on Abeta accumulation, we generated a bigenic mouse model, APPsw(+)/Lhr(-/-), which expresses human amyloid precursor protein (APPsw) in the background of LH receptor (Lhr) knockout. Genetic ablation of Lhr resulted in a significant decrease in the number of Abeta plaques and protein content in the hippocampus and cerebral cortex in both male and female mice. Accordingly, several Abeta deposition-related neuropathologic features and functionally relevant molecules were markedly improved, including decreased astrogliosis, reductions of elevated phosphorylated tau, c-fos, alpha7-nicotinic acetylcholine receptor, and restoration of the altered neuropeptide Y receptors Y1 and Y2. Diminution of Abeta accumulation in the absence of LH receptor supports the contention that dysregulation of LH may impact the pathogenesis of Alzheimer disease. The APPsw(+)/Lhr(-/-) mouse may be a useful tool for advancing understanding of the role of LH-mediated events in Alzheimer disease and a model in which to test therapeutic interventions.",[],Journal of neuropathology and experimental neurology,2010-02-10,"[{'lastname': 'Lin', 'firstname': 'Jing', 'initials': 'J', 'affiliation': ""Department of Obstetrics, Gynecology and Women's Health, University of Louisville School of Medicine, Louisville, Kentucky 40292, USA.""}, {'lastname': 'Li', 'firstname': 'Xian', 'initials': 'X', 'affiliation': None}, {'lastname': 'Yuan', 'firstname': 'Fangping', 'initials': 'F', 'affiliation': None}, {'lastname': 'Lin', 'firstname': 'Ling', 'initials': 'L', 'affiliation': None}, {'lastname': 'Cook', 'firstname': 'Christine L', 'initials': 'CL', 'affiliation': None}, {'lastname': 'Rao', 'firstname': 'Ch V', 'initials': 'ChV', 'affiliation': None}, {'lastname': 'Lei', 'firstname': 'Zhenmin', 'initials': 'Z', 'affiliation': None}]",,,,,10.1097/NEN.0b013e3181d072cf,<Element 'PubmedArticle' at 0x7f05d8ac7810>
344,20136701,"Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3beta, tau and neuroinflammation.","Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by accumulation of extracellular deposits of amyloid-beta (Abeta) peptide in brain regions that are important for memory and cognition. The buildup of Abeta aggregates in the AD is followed by the formation of intracellular neurofibrillary tangles and activation of neuroinflammatory reactions. The present study investigated whether melatonin possesses a neuroprotective effect against Abeta-induced toxicity. For this purpose, organotypic hippocampal slices were cultured and exposed to 25 microm of Abeta(25-35) in the absence or in the presence of melatonin (25, 50, or 100 microm). In addition, the authors have investigated the involvement of GSK-3beta, tau protein, astroglial, and microglial activation, and cytokine levels in the melatonin protection against Abeta-induced neurotoxicity. Melatonin prevented the cell damage in hippocampus induced by the exposure to Abeta(25-35). In addition, melatonin significantly reduced the activation of GSK-3beta, the phosphorylation of tau protein, the glial activation and the Abeta-induced increase of TNF-alpha and IL-6 levels. On the basis of these findings, we speculate that melatonin may provide an effective therapeutic strategy for AD, by attenuating Abeta-induced phosphorylation of tau protein, and preventing GSK-3beta activation and neuroinflammation.",[],Journal of pineal research,2010-02-09,"[{'lastname': 'Hoppe', 'firstname': 'Juliana Bender', 'initials': 'JB', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Frozza', 'firstname': 'Rudimar Luiz', 'initials': 'RL', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Horn', 'firstname': 'Ana Paula', 'initials': 'AP', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Comiran', 'firstname': 'Ricardo Argenta', 'initials': 'RA', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Bernardi', 'firstname': 'Andressa', 'initials': 'A', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Campos', 'firstname': 'Maria Martha', 'initials': 'MM', 'affiliation': 'Faculdade de Odontologia e Instituto de Toxicologia, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Battastini', 'firstname': 'Ana Maria Oliveira', 'initials': 'AMO', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}, {'lastname': 'Salbego', 'firstname': 'Christianne', 'initials': 'C', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.'}]",,,,,10.1111/j.1600-079X.2010.00747.x,<Element 'PubmedArticle' at 0x7f05d8a6fb80>
345,"20045477
19146961
17761438
18234697
16087444
18593276
18688089
19503072
15344473
16237247
16945915
17953663
9113464
9368118
19284597
18322394
17604651
19376059
16950152
17509568
18192287
18648346
11930016
18989116
17187353
18090425
18268196
19376066
19091966
17493040
18771956
17353379
19255408
19786698",Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations.,"Neural network breakdown is a key issue in neurodegenerative disease, but the mechanisms are poorly understood. Here we investigated patterns of brain atrophy produced by defined molecular lesions in the two common forms of genetically mediated frontotemporal lobar degeneration (FTLD). Nine patients with progranulin (GRN) mutations and eleven patients with microtubule-associated protein tau (MAPT) mutations had T1 MR brain imaging. Brain volumetry and grey and white matter voxel-based morphometry (VBM) were used to assess patterns of cross-sectional atrophy in the two groups. In a subset of patients with longitudinal MRI rates of whole-brain atrophy were derived using the brain-boundary-shift integral and a VBM-like analysis of voxel-wise longitudinal volume change was performed. The GRN mutation group showed asymmetrical atrophy whereas the MAPT group showed symmetrical atrophy. Brain volumes were smaller in the GRN group with a faster rate of whole-brain atrophy. VBM delineated a common anterior cingulate-prefrontal-insular pattern of atrophy in both disease groups. Additional disease-specific profiles of grey and white matter loss were identified on both cross-sectional and longitudinal imaging: GRN mutations were associated with asymmetrical inferior frontal, temporal and inferior parietal lobe grey matter atrophy and involvement of long intrahemispheric association white matter tracts, whereas MAPT mutations were associated with symmetrical anteromedial temporal lobe and orbitofrontal grey matter atrophy and fornix involvement. The findings suggest that the effects of GRN and MAPT mutations are expressed in partly overlapping but distinct anatomical networks that link specific molecular dysfunction with clinical phenotype.",[],NeuroImage,2010-01-05,"[{'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, UCL Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.'}, {'lastname': 'Ridgway', 'firstname': 'Gerard R', 'initials': 'GR', 'affiliation': None}, {'lastname': 'Modat', 'firstname': 'Marc', 'initials': 'M', 'affiliation': None}, {'lastname': 'Ourselin', 'firstname': 'Sebastien', 'initials': 'S', 'affiliation': None}, {'lastname': 'Mead', 'firstname': 'Simon', 'initials': 'S', 'affiliation': None}, {'lastname': 'Fox', 'firstname': 'Nick C', 'initials': 'NC', 'affiliation': None}, {'lastname': 'Rossor', 'firstname': 'Martin N', 'initials': 'MN', 'affiliation': None}, {'lastname': 'Warren', 'firstname': 'Jason D', 'initials': 'JD', 'affiliation': None}]",,,,Copyright 2009 Elsevier Inc. All rights reserved.,10.1016/j.neuroimage.2009.12.088,<Element 'PubmedArticle' at 0x7f05d8a88220>
346,19900506,Gender effect on the accumulation of hyperphosphorylated tau in the brain of locus-ceruleus-injured APP-transgenic mouse.,"Locus ceruleus (LC) neurons are preferentially and initially affected in Alzheimer disease (AD); however, the impact of the loss of LC neurons on the pathological sequence of AD, including amyloid beta-protein (Abeta) deposition and neurofibrillary tangle formation, has not been elucidated. In this study, we chemically injured LC neurons of the brains of familial AD-related amyloid precursor protein (APP)-transgenic mice using the LC-noradrenergic neuron-selective neurotoxin, N-(2-chloroethyl)-N-ethyl-bromo-benzylamine (DSP4). The levels of noradrenaline significantly decreased in the cerebral cortices of DSP4-treated mice. The deposition of amyloid fibrils was biochemically observed in the APP-transgenic mouse brains; however, those levels were not significantly altered following DSP4 treatment. In contrast, the levels of accumulated hyperphosphorylated tau markedly increased in the cerebral cortices of DSP4-treated female but not male APP-transgenic mice. Our results suggest that innervation from LC neurons and testosterone secretion are potent and mutually independent suppressors of amyloid-related accumulation of hyperphosphorylated tau in the brain.",[],Neuroscience letters,2009-11-11,"[{'lastname': 'Oikawa', 'firstname': 'Naoto', 'initials': 'N', 'affiliation': ""Department of Alzheimer's Disease Research, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, 36-3, Gengo, Morioka, Obu 474-8522, Japan.""}, {'lastname': 'Ogino', 'firstname': 'Koichi', 'initials': 'K', 'affiliation': None}, {'lastname': 'Masumoto', 'firstname': 'Takumi', 'initials': 'T', 'affiliation': None}, {'lastname': 'Yamaguchi', 'firstname': 'Haruyasu', 'initials': 'H', 'affiliation': None}, {'lastname': 'Yanagisawa', 'firstname': 'Katsuhiko', 'initials': 'K', 'affiliation': None}]",,,,Copyright 2009 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.neulet.2009.11.005,<Element 'PubmedArticle' at 0x7f05d8a9ed60>
347,"19884572
17579875
17805587
14991811
18633132
10436340
12370467
10404983
19350673
19015862
9855500
12833363
8710059
16344531
18234697
19251628
19251627
11971081
11117553
19864668
17569065
18412267
10443890
12876142
15372253
15975068
16862115
16950801
17436289
18192287
18392865
19101631
14755449
18703462
19433740
18362096
18536926
19204154
17278999
19455346",The heritability and genetics of frontotemporal lobar degeneration.,"Frontotemporal lobar degeneration (FTLD) is a genetically and pathologically heterogeneous neurodegenerative disorder.
We collected blood samples from a cohort of 225 patients with a diagnosis within the FTLD spectrum and examined the heritability of FTLD by giving each patient a family history score, from 1 (a clear autosomal dominant history of FTLD) through to 4 (no family history of dementia). We also looked for mutations in each of the 5 disease-causing genes (MAPT, GRN, VCP, CHMP2B, and TARDP) and the FUS gene, known to cause motor neuron disease.
A total of 41.8% of patients had some family history (score of 1, 2, 3, or 3.5), although only 10.2% had a clear autosomal dominant history (score of 1). Heritability varied across the different clinical subtypes of FTLD with the behavioral variant being the most heritable and frontotemporal dementia-motor neuron disease and the language syndromes (particularly semantic dementia) the least heritable. Mutations were found in MAPT (8.9% of the cohort) and GRN (8.4%) but not in any of the other genes. Of the remaining patients without mutations but with a strong family history, 7 had pathologic confirmation, falling into 2 groups: type 3 FTLD-TDP without GRN mutations (6) and FTLD-UPS (1).
These findings show that frontotemporal lobar degeneration (FTLD) is a highly heritable disorder but heritability varies between the different syndromes. Furthermore, while MAPT and GRN mutations account for a substantial proportion of familial cases, there are other genes yet to be discovered, particularly in patients with type 3 FTLD-TDP without a GRN mutation.",[],Neurology,2009-11-04,"[{'lastname': 'Rohrer', 'firstname': 'J D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Institute of Neurology, Queen Square, London WC1N 3BG, UK.'}, {'lastname': 'Guerreiro', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Vandrovcova', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Uphill', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Reiman', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Beck', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Isaacs', 'firstname': 'A M', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Authier', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Ferrari', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Fox', 'firstname': 'N C', 'initials': 'NC', 'affiliation': None}, {'lastname': 'Mackenzie', 'firstname': 'I R A', 'initials': 'IR', 'affiliation': None}, {'lastname': 'Warren', 'firstname': 'J D', 'initials': 'JD', 'affiliation': None}, {'lastname': 'de Silva', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Holton', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Revesz', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Hardy', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Mead', 'firstname': 'S', 'initials': 'S', 'affiliation': None}, {'lastname': 'Rossor', 'firstname': 'M N', 'initials': 'MN', 'affiliation': None}]",,"These findings show that frontotemporal lobar degeneration (FTLD) is a highly heritable disorder but heritability varies between the different syndromes. Furthermore, while MAPT and GRN mutations account for a substantial proportion of familial cases, there are other genes yet to be discovered, particularly in patients with type 3 FTLD-TDP without a GRN mutation.","A total of 41.8% of patients had some family history (score of 1, 2, 3, or 3.5), although only 10.2% had a clear autosomal dominant history (score of 1). Heritability varied across the different clinical subtypes of FTLD with the behavioral variant being the most heritable and frontotemporal dementia-motor neuron disease and the language syndromes (particularly semantic dementia) the least heritable. Mutations were found in MAPT (8.9% of the cohort) and GRN (8.4%) but not in any of the other genes. Of the remaining patients without mutations but with a strong family history, 7 had pathologic confirmation, falling into 2 groups: type 3 FTLD-TDP without GRN mutations (6) and FTLD-UPS (1).",,10.1212/WNL.0b013e3181bf997a,<Element 'PubmedArticle' at 0x7f05d8a2b770>
348,"19847305
17226741
11823324
17579875
17023659
8841663
11912108
12058088
18703462
9633692
16862116
16862115
18543312
18723524
19217189
12876142
17360763
11927198
17701901
16950801
17021754
19016491
19446372",Variation at GRN 3'-UTR rs5848 is not associated with a risk of frontotemporal lobar degeneration in Dutch population.,"A single nucleotide polymorphism (rs5848) located in the 3'- untranslated region of GRN has recently been associated with a risk of frontotemporal lobar degeneration (FTLD) in North American population particularly in pathologically confirmed cases with neural inclusions immunoreactive for ubiquitin and TAR DNA-binding protein 43 (TDP-43), but negative for tau and alpha-synuclein (FTLD-TDP).
In an effort to replicate these results in a different population, rs5848 was genotyped in 256 FTLD cases and 1695 controls from the Netherlands. Single SNP gender-adjusted logistic regression analysis revealed no significant association between variation at rs5848 and FTLD. Fisher's exact test, failed to find any significant association between rs5848 and a subset of 23 pathology confirmed FTLD-TDP cases.
The evidence presented here suggests that variation at rs5848 does not contribute to the etiology of FTLD in the Dutch population.",[],PloS one,2009-10-23,"[{'lastname': 'Simón-Sánchez', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Department of Clinical Genetics, Section of Medical Genomics, VU University Medical Centre, Amsterdam, The Netherlands.'}, {'lastname': 'Seelaar', 'firstname': 'Harro', 'initials': 'H', 'affiliation': None}, {'lastname': 'Bochdanovits', 'firstname': 'Zoltán', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Deeg', 'firstname': 'Dorly J H', 'initials': 'DJ', 'affiliation': None}, {'lastname': 'van Swieten', 'firstname': 'John C', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Heutink', 'firstname': 'Peter', 'initials': 'P', 'affiliation': None}]",,,,,10.1371/journal.pone.0007494,<Element 'PubmedArticle' at 0x7f05d8a4d040>
349,"19815707
15645264
14977212
16630055
15249677
16627930
18407262
12084635
18184791
15750215
15750216
1834965
7747600
9829797
10377336
12668248
1259145
10681533
18473732
17496910
18174027
10542233
7534834
11682063
15583867
17687114
11287063
8930304
15094069
8202552
7585153
8635681
17448147
15977985
16914869
8870824
10499443
17078951
18052981
15853747
11303790
12531514
15449578
15094070
2769254
8179300
9390772
12829252
15238246
14568619
18587388
17047304
18448228
18509201
19183272
18336525
8202528
8673924
8990203
11381127
8835879
11837744
9546672
2697607
6389544
17982898
12472906
16054268","Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease.","Recent studies have suggested a possible role of insulin dysfunction in the pathogenesis of sporadic Alzheimer's disease (AD). In AD, brain glucose metabolism is impaired, and this impairment appears to precede the pathology and clinical symptoms of the disease. However, the exact contribution of impaired insulin signaling to AD is not known. In this study, by using a nontransgenic rat model of sporadic AD generated by intracerebroventricular administration of streptozotocin, we investigated insulin signaling, glucose transporters, protein O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain. We found impaired insulin signaling, overactivation of glycogen synthase kinase-3beta, decreased levels of major brain glucose transporters, down- regulated protein O-GlcNAcylation, increased phosphorylation of tau and neurofilaments, and decreased microtubule-binding activity of tau in the brains of streptozotocin-treated rats. These results suggest that impaired brain insulin signaling may lead to overactivation of glycogen synthase kinase-3beta and down-regulation of O-GlcNAcylation, which, in turn, facilitate abnormal hyperphosphorylation of tau and neurofilaments and, consequently, neurofibrillary degeneration.",[],The American journal of pathology,2009-10-10,"[{'lastname': 'Deng', 'firstname': 'Yanqiu', 'initials': 'Y', 'affiliation': 'Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, NY 10314, USA.'}, {'lastname': 'Li', 'firstname': 'Bin', 'initials': 'B', 'affiliation': None}, {'lastname': 'Liu', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Iqbal', 'firstname': 'Khalid', 'initials': 'K', 'affiliation': None}, {'lastname': 'Grundke-Iqbal', 'firstname': 'Inge', 'initials': 'I', 'affiliation': None}, {'lastname': 'Gong', 'firstname': 'Cheng-Xin', 'initials': 'CX', 'affiliation': None}]",,,,,10.2353/ajpath.2009.090157,<Element 'PubmedArticle' at 0x7f05d8a5dd60>
350,"19706162
11742409
3706356
16089356
9252480
11723053
9217868
15527684
16089356
12566104
15226630
11502050
11304502
12875772
14514581
8214048
10963727
11295530
3252968
15451779
12591762
17400720
11701721
17371246
16950770
9217868
15527684
1486584
13990765
16501301
3850773
14766360
18390897
18469026
11249875
18048761
17592090
3359580
8287395
8353889",Impairment of insulin-stimulated Akt/GLUT4 signaling is associated with cardiac contractile dysfunction and aggravates I/R injury in STZ-diabetic rats.,"In this study, we established systemic in-vivo evidence from molecular to organism level to explain how diabetes can aggravate myocardial ischemia-reperfusion (I/R) injury and revealed the role of insulin signaling (with specific focus on Akt/GLUT4 signaling molecules). The myocardial I/R injury was induced by the left main coronary artery occlusion for 1 hr and then 3 hr reperfusion in control, streptozotocin (STZ)-induced insulinopenic diabetes, and insulin-treated diabetic rats. The diabetic rats showed a significant decrease in heart rate, and a prolonged isovolumic relaxation (tau) which lead to decrease in cardiac output (CO) without changing total peripheral resistance (TPR). The phosphorylated Akt and glucose transporter 4 (GLUT 4) protein levels were dramatically reduced in both I/R and non-I/R diabetic rat hearts. Insulin treatment in diabetes showed improvement of contractile function as well as partially increased Akt phosphorylation and GLUT 4 protein levels. In the animals subjected to I/R, the mortality rates were 25%, 65%, and 33% in the control, diabetic, and insulin-treated diabetic group respectively. The I/R-induced arrhythmias and myocardial infarction did not differ significantly between the control and the diabetic groups. Consistent with its anti-hyperglycemic effects, insulin significantly reduced I/R-induced arrhythmias but had no effect on I/R-induced infarctions. Diabetic rat with I/R exhibited the worse hemodynamic outcome, which included systolic and diastolic dysfunctions. Insulin treatment only partially improved diastolic functions and elevated P-Akt and GLUT 4 protein levels. Our results indicate that cardiac contractile dysfunction caused by a defect in insulin-stimulated Akt/GLUT4 may be a major reason for the high mortality rate in I/R injured diabetic rats.",[],Journal of biomedical science,2009-08-27,"[{'lastname': 'Huang', 'firstname': 'Jiung-Pang', 'initials': 'JP', 'affiliation': 'Department of Life Science, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of China. dddivekimo@yahoo.com.tw'}, {'lastname': 'Huang', 'firstname': 'Shiang-Suo', 'initials': 'SS', 'affiliation': None}, {'lastname': 'Deng', 'firstname': 'Jen-Ying', 'initials': 'JY', 'affiliation': None}, {'lastname': 'Hung', 'firstname': 'Li-Man', 'initials': 'LM', 'affiliation': None}]",,,,,"10.1186/1423-0127-16-77
10.1038/414782a
10.1016/0002-9343(86)90451-1
10.2174/1568008054064869
10.2337/diabetes.50.12.2709
10.1016/S0008-6363(97)00051-5
10.1007/s11906-004-0034-4
10.2174/1568008054064869
10.1016/S0008-6363(02)00718-6
10.1253/circj.68.650
10.1253/jcj.65.731
10.1016/S0735-1097(03)00625-9
10.2337/diacare.26.10.2791
10.1016/S0008-6363(00)00102-4
10.1016/S0891-5849(01)00474-9
10.1093/cvr/22.7.447
10.1161/01.CIR.0000143230.23252.D2
10.1161/01.CIR.0000048192.52098.DD
10.1152/ajpheart.01002.2006
10.1210/jc.86.11.5450
10.1042/BST0350231
10.1074/jbc.M513087200
10.1016/S0008-6363(97)00051-5
10.1007/s11906-004-0034-4
10.1093/cvr/26.10.913
10.1016/S0140-6736(63)91500-9
10.1253/circj.70.327
10.2741/1216
10.1093/cvr/cvn093
10.1093/cvr/cvn116
10.1124/pr.107.06002
10.1161/CIRCULATIONAHA.106.679597
10.1093/cvr/27.11.1908",<Element 'PubmedArticle' at 0x7f05d8a06400>
351,"19679189
17071925
17898010
16873918
17959788
18234697
17296841
19428421
11723259
16513001
11049669
9931268
11113214
10984517
11832223
1202204
9113464
10686172
11468305
17356339
14991811
18633132
11294934
17620554
12901777
16374817
18245784
9343592
7114808
11310619
14561797
17210807
18412267
8232972
9855500
12902311
18090419
19433738
18991338
18848632
17947337
18413474
18648346
19414722
11805245
17130406
11930016
12536133
19376066
17003069
18781435
16837579
17941343
18387548
12709467
18569251
19501654
19124032",Progressive logopenic/phonological aphasia: erosion of the language network.,"The primary progressive aphasias (PPA) are paradigmatic disorders of language network breakdown associated with focal degeneration of the left cerebral hemisphere. Here we addressed brain correlates of PPA in a detailed neuroanatomical analysis of the third canonical syndrome of PPA, logopenic/phonological aphasia (LPA), in relation to the more widely studied clinico-anatomical syndromes of semantic dementia (SD) and progressive nonfluent aphasia (PNFA). 32 PPA patients (9 SD, 14 PNFA, 9 LPA) and 18 cognitively normal controls had volumetric brain MRI with regional volumetry, cortical thickness, grey and white matter voxel-based morphometry analyses. Five of nine patients with LPA had cerebrospinal fluid biomarkers consistent with Alzheimer (AD) pathology (AD-PPA) and 2/9 patients had progranulin (GRN) mutations (GRN-PPA). The LPA group had tissue loss in a widespread left hemisphere network. Compared with PNFA and SD, the LPA group had more extensive involvement of grey matter in posterior temporal and parietal cortices and long association white matter tracts. Overlapping but distinct networks were involved in the AD-PPA and GRN-PPA subgroups, with more anterior temporal lobe involvement in GRN-PPA. The importance of these findings is threefold: firstly, the clinico-anatomical entity of LPA has a profile of brain damage that is complementary to the network-based disorders of SD and PNFA; secondly, the core phonological processing deficit in LPA is likely to arise from temporo-parietal junction damage but disease spread occurs through the dorsal language network (and in GRN-PPA, also the ventral language network); and finally, GRN mutations provide a specific molecular substrate for language network dysfunction.",[],NeuroImage,2009-08-15,"[{'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Institute of Neurology, University College London, Queen Square, London, UK. rohrer@dementia.ion.ucl.ac.uk'}, {'lastname': 'Ridgway', 'firstname': 'Gerard R', 'initials': 'GR', 'affiliation': None}, {'lastname': 'Crutch', 'firstname': 'Sebastian J', 'initials': 'SJ', 'affiliation': None}, {'lastname': 'Hailstone', 'firstname': 'Julia', 'initials': 'J', 'affiliation': None}, {'lastname': 'Goll', 'firstname': 'Johanna C', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Clarkson', 'firstname': 'Matthew J', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Mead', 'firstname': 'Simon', 'initials': 'S', 'affiliation': None}, {'lastname': 'Beck', 'firstname': 'Jonathan', 'initials': 'J', 'affiliation': None}, {'lastname': 'Mummery', 'firstname': 'Cath', 'initials': 'C', 'affiliation': None}, {'lastname': 'Ourselin', 'firstname': 'Sebastien', 'initials': 'S', 'affiliation': None}, {'lastname': 'Warrington', 'firstname': 'Elizabeth K', 'initials': 'EK', 'affiliation': None}, {'lastname': 'Rossor', 'firstname': 'Martin N', 'initials': 'MN', 'affiliation': None}, {'lastname': 'Warren', 'firstname': 'Jason D', 'initials': 'JD', 'affiliation': None}]",,,,,10.1016/j.neuroimage.2009.08.002,<Element 'PubmedArticle' at 0x7f05d89a2770>
352,"19667268
16896004
17634532
15914550
16103753
17483439
16721363
17010609
18628466
15897552
1899446
7906661
14973112
17404087
16293864
15591335
16720680
12569384
16980602
16254100
17453008
18230798
10887484
11902585
15986399
15052538",Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.,"We assessed Tau protein expression in primary breast cancer specimens of patients included in the National Surgical Breast and Bowel Project (NSABP) -B 28 clinical trial. Expression levels were correlated with disease-free survival (DFS) and overall survival (OS). Interaction between this marker and paclitaxel efficacy was also examined.
Tissue microarrays were available for 1,942 patients (63% of all trial participants) who were randomly assigned to receive either four courses of doxorubicin and cyclophosphamide (AC) or AC followed by four courses of adjuvant paclitaxel chemotherapy. All patients who were hormone receptor positive received adjuvant endocrine therapy. Immunohistochemistry was used to measure Tau expression at M. D. Anderson Cancer Center blinded to clinical outcome. Correlation between Tau and OS and DFS was performed by the NSABP Biostatistical Center.
Forty-three percent of patients were Tau positive. Tau positivity correlated with estrogen receptor (ER) -positive status (P < .0001), lower histologic grade (P < .001), and lack of human epidermal growth factor receptor 2 (HER2) expression (P < .0001). In univariate analyses, Tau- and ER-positive status were both associated with better DFS and OS (P < .0001) whereas greater tumor size, high grade, lymph node- and HER2-positive status were each associated with worse DFS and OS (P < .0001). In multivariate analysis, the same variables except HER2 remained significant. There was no significant interaction between Tau expression and benefit from paclitaxel in the total population or among ER-positive or -negative patients.
High Tau protein expression is associated with better prognosis in patients treated with adjuvant anthracycline and paclitaxel chemotherapy and endocrine therapy, but there was no significant interaction between Tau expression and paclitaxel benefit.",[],Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2009-08-12,"[{'lastname': 'Pusztai', 'firstname': 'Lajos', 'initials': 'L', 'affiliation': 'Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, PO Box 301439, Houston, TX 77230-1439, USA. lpusztai@mdanderson.org'}, {'lastname': 'Jeong', 'firstname': 'Jong-Hyeon', 'initials': 'JH', 'affiliation': None}, {'lastname': 'Gong', 'firstname': 'Yun', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Ross', 'firstname': 'Jeffrey S', 'initials': 'JS', 'affiliation': None}, {'lastname': 'Kim', 'firstname': 'Chungyeul', 'initials': 'C', 'affiliation': None}, {'lastname': 'Paik', 'firstname': 'Soonmyung', 'initials': 'S', 'affiliation': None}, {'lastname': 'Rouzier', 'firstname': 'Roman', 'initials': 'R', 'affiliation': None}, {'lastname': 'Andre', 'firstname': 'Fabrice', 'initials': 'F', 'affiliation': None}, {'lastname': 'Hortobagyi', 'firstname': 'Gabriel N', 'initials': 'GN', 'affiliation': None}, {'lastname': 'Wolmark', 'firstname': 'Norman', 'initials': 'N', 'affiliation': None}, {'lastname': 'Symmans', 'firstname': 'W Fraser', 'initials': 'WF', 'affiliation': None}]",,"High Tau protein expression is associated with better prognosis in patients treated with adjuvant anthracycline and paclitaxel chemotherapy and endocrine therapy, but there was no significant interaction between Tau expression and paclitaxel benefit.","Forty-three percent of patients were Tau positive. Tau positivity correlated with estrogen receptor (ER) -positive status (P < .0001), lower histologic grade (P < .001), and lack of human epidermal growth factor receptor 2 (HER2) expression (P < .0001). In univariate analyses, Tau- and ER-positive status were both associated with better DFS and OS (P < .0001) whereas greater tumor size, high grade, lymph node- and HER2-positive status were each associated with worse DFS and OS (P < .0001). In multivariate analysis, the same variables except HER2 remained significant. There was no significant interaction between Tau expression and benefit from paclitaxel in the total population or among ER-positive or -negative patients.",,10.1200/JCO.2008.21.6887,<Element 'PubmedArticle' at 0x7f05d89c8d10>
353,19559700,"Somatostatin, tau, and beta-amyloid within the anterior olfactory nucleus in Alzheimer disease.","Impaired olfaction is an early symptom of Alzheimer disease (AD). This likely to reflect neurodegenerative processes taking place in basal telencephalic structures that mediate olfactory processing, including the anterior olfactory nucleus. Betaeta-amyloid (Abeta) accumulation in AD brain may relate to decline in somatostatin levels: somatostatin induces the expression of the Abeta-degrading enzyme neprilysin and somatostatin deficiency in AD may therefore reduce Abeta clearance. We have investigated the expression of somatostatin in the anterior olfactory nucleus of AD and control brain. We report that somatostatin levels were reduced by approximately 50% in AD brain. Furthermore, triple-immunofluorescence revealed co-localization of somatostatin expression with Abeta (65.43%) with Abeta and tau (19.75%) and with tau (2.47%). These data indicate that somatostatin decreases in AD and its expression may be linked with Abeta deposition.",[],Experimental neurology,2009-06-30,"[{'lastname': 'Saiz-Sanchez', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Laboratorio de Neuroanatomía Humana, Departamento de Ciencias Médicas, Facultad de Medicina, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, 02006 Albacete, Spain.'}, {'lastname': 'Ubeda-Bañon', 'firstname': 'I', 'initials': 'I', 'affiliation': None}, {'lastname': 'de la Rosa-Prieto', 'firstname': 'C', 'initials': 'C', 'affiliation': None}, {'lastname': 'Argandoña-Palacios', 'firstname': 'L', 'initials': 'L', 'affiliation': None}, {'lastname': 'Garcia-Muñozguren', 'firstname': 'S', 'initials': 'S', 'affiliation': None}, {'lastname': 'Insausti', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Martinez-Marcos', 'firstname': 'A', 'initials': 'A', 'affiliation': None}]",,,,Copyright (c) 2009 Elsevier Inc. All rights reserved.,10.1016/j.expneurol.2009.06.010,<Element 'PubmedArticle' at 0x7f05d89654f0>
354,19458322,Familial aggregation of parkinsonism in progressive supranuclear palsy.,"Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disorder characterized by aggregates of the microtubule-associated protein tau (MAPT). A nonsignificant trend for positive family history has been observed in two case-control studies and several pedigrees with familial clustering of parkinsonism have been described. Occasionally, mutations in MAPT are found in patients with a clinical phenotype similar to PSP. In this case-control study, we compared the occurrence of dementia and parkinsonism among first-degree relatives of patients with PSP with an age- and sex-matched control group.
Family history of dementia and parkinsonism was collected from all first-degree relatives of patients with PSP who fulfilled the international National Institute of Neurological Disorders and Stroke criteria for PSP. Age- and sex-matched controls were selected from the Rotterdam Study. Genetic testing and pathologic examination was performed in a subset of familial PSP cases.
Fifty-seven (33%) of the 172 patients with PSP had at least one first-degree relative who had dementia or parkinsonism compared to 131 (25%) of the control subjects (odds ratio [OR] 1.5, 95% confidence interval [CI] 1.01-2.13). In patients with PSP, more first-degree relatives with parkinsonism were observed compared to controls, with an OR 3.9 (95% CI 1.99-7.61). Twelve patients with PSP (7%) fulfilled the criteria for an autosomal dominant mode of transmission. The intrafamilial phenotype within these pedigrees varied among PSP, dementia, tremor, and parkinsonism. Genetic studies revealed one patient with a P301L mutation in MAPT. Pathologic examination of five familial cases confirmed the clinical diagnosis of PSP, with predominant four repeat tau pathology in affected brain areas.
This study demonstrates familial aggregation of parkinsonism in progressive supranuclear palsy.",[],Neurology,2009-05-22,"[{'lastname': 'Donker Kaat', 'firstname': 'L', 'initials': 'L', 'affiliation': ""Erasmus University Medical Center Rotterdam, Department of Neurology, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. l.donkerkaat@erasmusmc.nl""}, {'lastname': 'Boon', 'firstname': 'A J W', 'initials': 'AJ', 'affiliation': None}, {'lastname': 'Azmani', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Kamphorst', 'firstname': 'W', 'initials': 'W', 'affiliation': None}, {'lastname': 'Breteler', 'firstname': 'M M B', 'initials': 'MM', 'affiliation': None}, {'lastname': 'Anar', 'firstname': 'B', 'initials': 'B', 'affiliation': None}, {'lastname': 'Heutink', 'firstname': 'P', 'initials': 'P', 'affiliation': None}, {'lastname': 'van Swieten', 'firstname': 'J C', 'initials': 'JC', 'affiliation': None}]",,This study demonstrates familial aggregation of parkinsonism in progressive supranuclear palsy.,"Fifty-seven (33%) of the 172 patients with PSP had at least one first-degree relative who had dementia or parkinsonism compared to 131 (25%) of the control subjects (odds ratio [OR] 1.5, 95% confidence interval [CI] 1.01-2.13). In patients with PSP, more first-degree relatives with parkinsonism were observed compared to controls, with an OR 3.9 (95% CI 1.99-7.61). Twelve patients with PSP (7%) fulfilled the criteria for an autosomal dominant mode of transmission. The intrafamilial phenotype within these pedigrees varied among PSP, dementia, tremor, and parkinsonism. Genetic studies revealed one patient with a P301L mutation in MAPT. Pathologic examination of five familial cases confirmed the clinical diagnosis of PSP, with predominant four repeat tau pathology in affected brain areas.",,10.1212/WNL.0b013e3181a92bcc,<Element 'PubmedArticle' at 0x7f05d896df90>
355,"19458242
17367877
12826535
10402201
17169337
15094069
10447096
15161126
2888134
6337049
15288712
18230654
18022950
6828535
12600702
11000114
7399423
11853862
14769549
17101229
11812778
10591291
17227324
16740022
17002493
9698307
10758137
14766178
11784813
16763033
16549076
17076598
15504987
18442862
18040829
1100198
3520377
17435648
7818580
7746025
7723470
12818181
2499043
17624453
10078556
17881081
7477295
18752648
3110839
17854350
2403434
18023257
8929536
18277812
16804195
16934246
17298596
2573111
10713291
9010731
2864480
15734146
18023616
17171192
17942819
15750817
19297511
11118610
11032558
18367086
17108956
18283932
15501490
16115657
16246040
12551958
15262337
12122142
18928823
15857517
9575095
18463176
11337002
10798394","Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors.","The role of insulin pathways in olfaction is of significant interest with the widespread pathology of diabetes mellitus and its associated metabolic and neuronal comorbidities. The insulin receptor (IR) kinase is expressed at high levels in the olfactory bulb, in which it suppresses a dominant Shaker ion channel (Kv1.3) via tyrosine phosphorylation of critical N- and C-terminal residues. We optimized a 7 d intranasal insulin delivery (IND) in awake mice to ascertain the biochemical and behavioral effects of insulin to this brain region, given that nasal sprays for insulin have been marketed notwithstanding our knowledge of the role of Kv1.3 in olfaction, metabolism, and axon targeting. IND evoked robust phosphorylation of Kv1.3, as well as increased channel protein-protein interactions with IR and postsynaptic density 95. IND-treated mice had an increased short- and long-term object memory recognition, increased anxiolytic behavior, and an increased odor discrimination using an odor habituation protocol but only moderate change in odor threshold using a two-choice paradigm. Unlike Kv1.3 gene-targeted deletion that alters metabolism, adiposity, and axonal targeting to defined olfactory glomeruli, suppression of Kv1.3 via IND had no effect on body weight nor the size and number of M72 glomeruli or the route of its sensory axon projections. There was no evidence of altered expression of sensory neurons in the epithelium. In mice made prediabetic via diet-induced obesity, IND was no longer effective in increasing long-term object memory recognition nor increasing anxiolytic behavior, suggesting state dependency or a degree of insulin resistance related to these behaviors.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,2009-05-22,"[{'lastname': 'Marks', 'firstname': 'David R', 'initials': 'DR', 'affiliation': 'Department of Biological Science, Program in Neuroscience, The Florida State University, Tallahassee, Florida 32306, USA.'}, {'lastname': 'Tucker', 'firstname': 'Kristal', 'initials': 'K', 'affiliation': None}, {'lastname': 'Cavallin', 'firstname': 'Melissa A', 'initials': 'MA', 'affiliation': None}, {'lastname': 'Mast', 'firstname': 'Thomas G', 'initials': 'TG', 'affiliation': None}, {'lastname': 'Fadool', 'firstname': 'Debra A', 'initials': 'DA', 'affiliation': None}]",,,,,"10.1523/JNEUROSCI.1350-09.2009
10.1152/jn.91169.2008",<Element 'PubmedArticle' at 0x7f05d897c270>
356,19373081,Androgens and Alzheimer's disease.,"To discuss the relationship between androgens, cognition and Alzheimer's disease.
It has been found that low circulating levels of androgens are a risk factor for Alzheimer's disease. Decreased circulating androgens are also associated with declining cognitive performance, particularly in memory-related tasks. Conversely, androgen supplementation to hypogonadal men results in improved memory performance. It has therefore been hypothesized that androgen supplementation may be beneficial in Alzheimer's disease. In recent studies, animal models have been used to elucidate the molecular mechanism behind this relationship between androgens and Alzheimer's disease. These studies have shown that androgen depletion results in increased levels of beta amyloid and hyperphosphorylated tau, changes which are thought to be associated with subsequent neuronal death.
Androgen depletion results in molecular changes associated with Alzheimer's disease. Further human trials are needed to determine whether androgen modulating therapy for Alzheimer's disease has clinical significance.",[],"Current opinion in endocrinology, diabetes, and obesity",2009-04-18,"[{'lastname': 'Drummond', 'firstname': 'Eleanor S', 'initials': 'ES', 'affiliation': 'School of Anatomy and Human Biology, The University of Western Australia, Crawley, Australia.'}, {'lastname': 'Harvey', 'firstname': 'Alan R', 'initials': 'AR', 'affiliation': None}, {'lastname': 'Martins', 'firstname': 'Ralph N', 'initials': 'RN', 'affiliation': None}]",,,,,10.1097/MED.0b013e32832b101f,<Element 'PubmedArticle' at 0x7f05d8929ea0>
357,19346461,Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension.,"We investigated the endogenous production of apelin and the cardiac and pulmonary effects of its chronic administration in monocrotaline (MCT)-induced pulmonary hypertension (PH). Male Wistar rats were injected with MCT (60 mg/kg sc) or vehicle (day 0). One week later, these animals were randomly treated during 17 days with pyroglutamylated apelin-13 (Pyr-AP13; 200 microg*kg(-1)*day(-1) ip) or a similar volume of saline, resulting in four groups: sham (n = 11), sham-AP (n = 11), MCT (n = 16), and MCT-AP (n = 13). On day 25, right ventricular (RV) and left ventricular (LV) hemodynamic and morphometric parameters were assessed. Tissue and plasma samples were collected for histological and molecular analysis. When compared with sham, the MCT group presented a significant increase of RV mass (166 +/- 38%), diameter of cardiomyocyte (40 +/- 10%), myocardial fibrosis (95 +/- 20%), peak systolic pressure (99 +/- 22%), peak rate of ventricular pressure rise (dP/dt(max); 74 +/- 24%), peak rate of ventricular pressure decline (dP/dt(min); 73 +/- 19%), and time constant tau (55 +/- 16%). In these animals, RV expression of apelin (-73 +/- 10%) and its receptor APJ (-61 +/- 20%) was downregulated, whereas mRNA expression of type B natriuretic peptide (9,606 +/- 713%), angiotensinogen (191 +/- 147%), endothelin-1 (RV, 497 +/- 156%; and LV, 799 +/- 309%), plasmatic levels of apelin (104 +/- 48%), and angiotensin 1-7 (161 +/- 151%) were increased. Chronic treatment with Pyr-AP13 significantly attenuated or normalized these changes, preventing apelin-APJ mRNA downregulation and PH-induced neurohumoral activation of several vasoconstrictors, which exacerbates apelin-APJ vasodilator effects. Therefore, apelin delayed the progression of RV hypertrophy and diastolic dysfunction. Together, these observations suggest that the apelin-APJ system may play an important role in the pathophysiology of PH, representing a potential therapeutic target since it significantly attenuates RV overload and PH-induced neurohumoral activation.",[],American journal of physiology. Heart and circulatory physiology,2009-04-07,"[{'lastname': 'Falcão-Pires', 'firstname': 'Inês', 'initials': 'I', 'affiliation': 'Department of Physiology, Cardiovascular R and D Unit, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.'}, {'lastname': 'Gonçalves', 'firstname': 'Nádia', 'initials': 'N', 'affiliation': None}, {'lastname': 'Henriques-Coelho', 'firstname': 'Tiago', 'initials': 'T', 'affiliation': None}, {'lastname': 'Moreira-Gonçalves', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': None}, {'lastname': 'Roncon-Albuquerque', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': None}, {'lastname': 'Leite-Moreira', 'firstname': 'Adelino F', 'initials': 'AF', 'affiliation': None}]",,,,,10.1152/ajpheart.00089.2009,<Element 'PubmedArticle' at 0x7f05d89363b0>
358,"19255408
10404983
9973279
9641683
15365985
16862116
16862115
16950801
18192287
17278999
17071926
11402146
14720172
18234697
18322394
17003069
17353379
17949857
18245784
16157747
10190820
6610841
9855500
7114808
12833363
1202204
3561043
7104545
10860804
15907317
16401855
18413474
11971082
18065436
17196872
17310038
17698705
1416801
17894374
11761471",Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN.,"To compare patterns of gray matter loss in subjects with mutations in the progranulin (PGRN) gene to subjects with mutations in the microtubule-associated protein tau (MAPT) gene.
We identified all subjects seen at the Mayo Clinic, Rochester, MN, who had screened positive for mutations in PGRN or MAPT and had a head MRI. Twelve cases with mutations in the PGRN gene were matched by time from disease onset to scan to 12 subjects with mutations in the MAPT gene. Voxel-based morphometry was used to assess patterns of gray matter loss in the PGRN and MAPT groups compared to a control cohort, and compared to each other. MAPT subjects were younger than the PGRN subjects; therefore, each group was also compared to a specific age-matched control group.
Both PGRN and MAPT groups showed gray matter loss in frontal, temporal, and parietal lobes compared to controls, although loss was predominantly identified in posterior temporal and parietal lobes in PGRN and anteromedial temporal lobes in MAPT. The MAPT group had greater loss compared to healthy subjects of the same age than the PGRN subjects when compared to healthy subjects of the same age. The MAPT subjects showed greater gray matter loss in the medial temporal lobes, insula, and putamen than the PGRN subjects.
These results increase understanding of the biology of these disorders and suggest that patterns of atrophy on MRI may be useful to aid in the differentiation of groups of PGRN and MAPT mutation carriers.",[],Neurology,2009-03-04,"[{'lastname': 'Whitwell', 'firstname': 'J L', 'initials': 'JL', 'affiliation': 'Department of Radiology Research, Mayo Clinic, Rochester, MN 55905, USA.'}, {'lastname': 'Jack', 'firstname': 'C R', 'initials': 'CR', 'affiliation': None}, {'lastname': 'Boeve', 'firstname': 'B F', 'initials': 'BF', 'affiliation': None}, {'lastname': 'Senjem', 'firstname': 'M L', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Baker', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Ivnik', 'firstname': 'R J', 'initials': 'RJ', 'affiliation': None}, {'lastname': 'Knopman', 'firstname': 'D S', 'initials': 'DS', 'affiliation': None}, {'lastname': 'Wszolek', 'firstname': 'Z K', 'initials': 'ZK', 'affiliation': None}, {'lastname': 'Petersen', 'firstname': 'R C', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Josephs', 'firstname': 'K A', 'initials': 'KA', 'affiliation': None}]",,These results increase understanding of the biology of these disorders and suggest that patterns of atrophy on MRI may be useful to aid in the differentiation of groups of PGRN and MAPT mutation carriers.,"Both PGRN and MAPT groups showed gray matter loss in frontal, temporal, and parietal lobes compared to controls, although loss was predominantly identified in posterior temporal and parietal lobes in PGRN and anteromedial temporal lobes in MAPT. The MAPT group had greater loss compared to healthy subjects of the same age than the PGRN subjects when compared to healthy subjects of the same age. The MAPT subjects showed greater gray matter loss in the medial temporal lobes, insula, and putamen than the PGRN subjects.",,10.1212/01.wnl.0000343851.46573.67,<Element 'PubmedArticle' at 0x7f05d8942d10>
359,19221418,Constant illumination induces Alzheimer-like damages with endoplasmic reticulum involvement and the protection of melatonin.,"Most patients with Alzheimer's disease (AD) present decreased levels of melatonin, a day-night rhythm-related hormone. To investigate the role of melatonin deficiency in AD, we used constant illumination to interrupt melatonin metabolism and measured some of the AD-like alterations in rats. Concomitant with decreased serum melatonin, the rats developed spatial memory deficits, tau hyperphosphorylation at multiple sites, activation of glycogen synthase kinase-3 and protein kinase A, as well as suppression of protein phosphatase-1. Prominent oxidative damage and organelle lesions, demonstrated by increased expression of endoplasmic reticulum (ER) stress-related proteins including BiP/GRP78 and CHOP/GADD153, decreased number of rough ER and free ribosome, thinner synapses, and increased superoxide dismutase and monoamine oxidase were also observed in the light exposed rats. Simultaneous supplement of melatonin partially arrested the behavioral and molecular impairments. It is suggested that melatonin deficiency may be an upstream effector responsible for the AD-like behavioral and molecular pathologies with ER stress-involved mechanisms.",[],Journal of Alzheimer's disease : JAD,2009-02-18,"[{'lastname': 'Ling', 'firstname': 'Zhi-Qun', 'initials': 'ZQ', 'affiliation': 'Department of Pathology and Pathophysiology, Key Laboratory of Neurological Disease of National Education Ministry and Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'lastname': 'Tian', 'firstname': 'Qing', 'initials': 'Q', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Li', 'initials': 'L', 'affiliation': None}, {'lastname': 'Fu', 'firstname': 'Zheng-Qi', 'initials': 'ZQ', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Xiao-Chuan', 'initials': 'XC', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Qun', 'initials': 'Q', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Jian-Zhi', 'initials': 'JZ', 'affiliation': None}]",,,,,10.3233/JAD-2009-0949,<Element 'PubmedArticle' at 0x7f05d8960770>
360,19192059,Granular cell tumor of the oral cavity: updated immunohistochemical profile.,"Granular cell tumor (GCT) is a benign lesion that occurs at different body sites with preponderance to the oral cavity. It is generally believed to be of schwann cell/neural cell origin. We used a large panel of both traditional and recently developed antibodies in an attempt to trace the origin of GCTs on the basis of their immunoprofile.
The patients' demographic data and the cytological and architectural features of the lesions were analyzed in a large series of oral GCTs (n = 68). Forty-two lesions were also submitted to a panel of immunohistochemical stains with antibodies against S-100, CD-68 (KP-1 and PG-M1), vimentin, calretinin, NKI/C3, PGP9.5, p75/NGFR and inhibin-alpha.
The tongue was the most common location of oral GCTs (81%). The granular cells demonstrated a wide array of cytological features in terms of cell shape and position of the nucleus. In addition, the lesions showed different architectural patterns, including 'infiltration' with satellite nodules. Interestingly, no recurrences were reported, even in lesions that were not completely excised. Granular cells were usually found to be strongly and diffusely positive for p75, vimentin, calretinin and NKI/C3, inhibin-alpha, PGP9.5, and S-100.
Immunoreactivity of the granular cells to a broad panel of antibodies that characterize different tissues does not confirm any particular cell type for the histogenetic origin of GCTs. Furthermore, GCTs could be regarded as lesions that reflect a local metabolic or reactive change rather than a true neoplasm.",[],Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology,2009-02-05,"[{'lastname': 'Vered', 'firstname': 'Marilena', 'initials': 'M', 'affiliation': 'Department of Oral Pathology and Oral Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel. mvered@post.tau.ac.il'}, {'lastname': 'Carpenter', 'firstname': 'William M', 'initials': 'WM', 'affiliation': None}, {'lastname': 'Buchner', 'firstname': 'Amos', 'initials': 'A', 'affiliation': None}]",,,"The tongue was the most common location of oral GCTs (81%). The granular cells demonstrated a wide array of cytological features in terms of cell shape and position of the nucleus. In addition, the lesions showed different architectural patterns, including 'infiltration' with satellite nodules. Interestingly, no recurrences were reported, even in lesions that were not completely excised. Granular cells were usually found to be strongly and diffusely positive for p75, vimentin, calretinin and NKI/C3, inhibin-alpha, PGP9.5, and S-100.",,10.1111/j.1600-0714.2008.00725.x,<Element 'PubmedArticle' at 0x7f05d88ecbd0>
361,19139911,Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.,"Phosphorylated and proteolytically cleaved TDP-43 is a major component of the ubiquitin-positive inclusions in the most common pathological subtype of frontotemporal lobar degeneration (FTLD-U). Intracellular accumulation of TDP-43 is observed in a subpopulation of patients with other dementia disorders, including Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). However, the pathological significance of TDP-43 pathology in these disorders is unknown, since biochemical features of the TDP-43 accumulated in AD and DLB brains, especially its phosphorylation sites and pattern of fragmentation, are still unclear. To address these issues, we performed immunohistochemical and biochemical analyses of AD and DLB cases, using phosphorylation-dependent anti-TDP-43 antibodies. We found a higher frequency of pathological TDP-43 in AD (36-56%) and in DLB (53-60%) than previously reported. Of the TDP-43-positive cases, about 20-30% showed neocortical TDP-43 pathology resembling the FTLD-U subtype associated with progranulin gene (PGRN) mutations. Immunoblot analyses of the sarkosyl-insoluble fraction from cases with neocortical TDP-43 pathology showed intense staining of several low-molecular-weight bands, corresponding to C-terminal fragments of TDP-43. Interestingly, the band pattern of these C-terminal fragments in AD and DLB also corresponds to that previously observed in the FTLD-U subtype associated with PGRN mutations. These results suggest that the morphological and biochemical features of TDP-43 pathology are common between AD or DLB and a specific subtype of FTLD-U. There may be genetic factors, such as mutations or genetic variants of PGRN underlying the co-occurrence of abnormal deposition of TDP-43, tau and alpha-synuclein.",[],Acta neuropathologica,2009-01-14,"[{'lastname': 'Arai', 'firstname': 'Tetsuaki', 'initials': 'T', 'affiliation': 'Department of Psychogeriatrics, Tokyo Institute of Psychiatry, Tokyo Metropolitan Organization for Medical Research, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo 156-8585, Japan. arai@prit.go.jp'}, {'lastname': 'Mackenzie', 'firstname': 'Ian R A', 'initials': 'IR', 'affiliation': None}, {'lastname': 'Hasegawa', 'firstname': 'Masato', 'initials': 'M', 'affiliation': None}, {'lastname': 'Nonoka', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': None}, {'lastname': 'Niizato', 'firstname': 'Kazhuhiro', 'initials': 'K', 'affiliation': None}, {'lastname': 'Tsuchiya', 'firstname': 'Kuniaki', 'initials': 'K', 'affiliation': None}, {'lastname': 'Iritani', 'firstname': 'Shuji', 'initials': 'S', 'affiliation': None}, {'lastname': 'Onaya', 'firstname': 'Mitsumoto', 'initials': 'M', 'affiliation': None}, {'lastname': 'Akiyama', 'firstname': 'Haruhiko', 'initials': 'H', 'affiliation': None}]",,,,,10.1007/s00401-008-0480-1,<Element 'PubmedArticle' at 0x7f05d88fe9f0>
362,19012747,Behavioral stress accelerates plaque pathogenesis in the brain of Tg2576 mice via generation of metabolic oxidative stress.,"Alzheimer's disease (AD) is a progressive neurodegenerative disease caused by genetic and non-genetic factors. Most AD cases may be triggered and promoted by non-genetic environmental factors. Clinical studies have reported that patients with AD show enhanced baseline levels of stress hormones in the blood, but their physiological significance with respect to the pathophysiology of AD is not clearly understood. Here we report that AD mouse models exposed to restraints for 2 h daily on 16 consecutive days show increased levels of beta-amyloid (Abeta) plaque deposition and commensurable enhancements in Abeta(1-42), tau hyperphosphorylation, and neuritic atrophy of cortical neurons. Repeated restraints in Tg2576 mice markedly increased metabolic oxidative stress and down-regulated the expression of MMP-2, a potent Abeta-degrading enzyme, in the brain. These stress effects were reversed by blocking the activation of the hypothalamus-pituitary-adrenal gland axis with the corticotropin-releasing factor receptor antagonist NBI 27914, further suggesting that over-activation of the hypothalamic-pituitary-adrenal axis is required for stress-enhanced AD-like pathogenesis. Consistent with these findings, corticosteroid treatments to cultured primary cortical neurons increased metabolic oxidative stress and down-regulated MMP-2 expression, and MMP-2 down-regulation was reversed by inhibition of oxidative stress. These results suggest that behavioral stress aggravates AD pathology via generation of metabolic oxidative stress and MMP-2 down-regulation.",[],Journal of neurochemistry,2008-11-18,"[{'lastname': 'Lee', 'firstname': 'Kang-Woo', 'initials': 'KW', 'affiliation': 'Division of Nano Sciences and Brain Disease Research Institute, Ewha Womans University, Seoul, Korea.'}, {'lastname': 'Kim', 'firstname': 'Jung-Bin', 'initials': 'JB', 'affiliation': None}, {'lastname': 'Seo', 'firstname': 'Ji-Seon', 'initials': 'JS', 'affiliation': None}, {'lastname': 'Kim', 'firstname': 'Tae-Kyung', 'initials': 'TK', 'affiliation': None}, {'lastname': 'Im', 'firstname': 'Joo-Young', 'initials': 'JY', 'affiliation': None}, {'lastname': 'Baek', 'firstname': 'In-Sun', 'initials': 'IS', 'affiliation': None}, {'lastname': 'Kim', 'firstname': 'Kyoung-Shim', 'initials': 'KS', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Ja-Kyeong', 'initials': 'JK', 'affiliation': None}, {'lastname': 'Han', 'firstname': 'Pyung-Lim', 'initials': 'PL', 'affiliation': None}]",,,,,10.1111/j.1471-4159.2008.05769.x,<Element 'PubmedArticle' at 0x7f05d890a900>
363,"18974920
17469117
17084815
18433435
15826655
18004574
11470789
11285240
15195661
16157593
17579875
17591968
17219193
17713769
18288693
18546284
17963732
7745706
14502650
18434538
18372902
18607609
16025283
16983685
18183624
17653732
17023659
17360763
18309045
10327401
11118482
15474361
18520774
14966131",Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy.,"TAR DNA-binding protein of 43 kDa (TDP-43) is a major component of the pathological inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy, also called FTLD with ubiquitin-positive, tau-negative inclusions (FTLD-U), and motor neuron disease (MND). TDP-43 is predominantly expressed in the nucleus and regulates gene expression and splicing. In FTLD with TDP-43 proteinopathy, neuronal inclusions present variably as cytoplasmic inclusions (NCIs), dystrophic neurites (DNs), and intranuclear inclusions (NIIs), leading to a fourfold neuropathological classification correlating with genotype. There have been few fine structural studies of these inclusions. Thus, we undertook an immunoelectron microscopic study of FTLD with TDP-43 proteinopathy, including sporadic and familial cases with progranulin (GRN) mutation. TDP-43-immunoreactive inclusions comprised two components: granular and filamentous. Filament widths, expressed as mean (range) were: NCI, 9 nm (4-16 nm); DN, 10 nm (5-16 nm); NII, 18 nm (9-50 nm). Morphologically distinct inclusion components may reflect the process of TDP-43 aggregation and interaction with other proteins: determining these latter may contribute towards understanding the heterogeneous pathogenesis of FTLD with TDP-43 proteinopathy.",[],"Journal of neural transmission (Vienna, Austria : 1996)",2008-11-01,"[{'lastname': 'Thorpe', 'firstname': 'Julian R', 'initials': 'JR', 'affiliation': 'The Sussex Centre for Advanced Microscopy, University of Sussex, Falmer, Brighton, East Sussex, BN1 9QG, UK. j.r.thorpe@sussex.ac.uk'}, {'lastname': 'Tang', 'firstname': 'Helen', 'initials': 'H', 'affiliation': None}, {'lastname': 'Atherton', 'firstname': 'Joe', 'initials': 'J', 'affiliation': None}, {'lastname': 'Cairns', 'firstname': 'Nigel J', 'initials': 'NJ', 'affiliation': None}]",,,,,10.1007/s00702-008-0137-1,<Element 'PubmedArticle' at 0x7f05d8919590>
364,"18806919
17210801
12709467
7826280
11844888
3953862
12603286
16943563
16488378
2375247
11578524
1202204
17586559
17036175
10844576
14706948
17222916
16960575
17151169
17715567
17716786
17639447
17704849
17012293
17615094
11824844
17551018
6610841","Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.","Hypercortisolemia and increased levels of hyperphosphorylated tau proteins in cerebrospinal fluid (CSF) are common features with pathogenic relevance in Alzheimer;s disease (AD). Experimental studies point to an influence of cortisol on Abeta and tau pathology in AD. Association of both parameters have not yet been described in a sample of AD patients. In the present study, serum levels of cortisol were determined in 26 patients with mild AD dementia and 20 age-matched healthy elderly controls by ELISA. In addition, we measured in AD patients CSF levels of cortisol, total tau (T-tau), tau phosphorylated at threonine 181 (P-tau 181), tau protein phosphorylated at threonine 231 (P-tau 231) and beta-Amyloid (Abeta) 1-42 and determined T-tau/Abeta 1-42 ratios in CSF. We found in AD patients significantly increased cortisol serum levels (551.4 +/- 146.1 nmol/l; P = 0.002) as compared to healthy controls (435.3 +/- 83.9 nmol/l). In AD patients, cortisol serum levels were significantly inversely correlated with T-tau (r = -0.496; P = 0.01), P-tau 181 (r = -0.558; P = 0.003) and P-tau 231 (-0.500; P = 0.009) protein levels and T-tau/Abeta 1-42 ratios (r = -0.450; P = 0.021) in CSF. In addition, cortisol serum levels showed a trend of positive correlation with Abeta 1-42 CSF levels (r = 0.386; P = 0.052). However, no significant correlations of cortisol serum with CSF levels as well as cortisol CSF levels with CSF biomarkers could be detected in AD patients. In conclusion, our results show that increased cortisol serum but not CSF levels are associated with minor signs of AD pathology in CSF, indicating a putative neuroprotective effect of moderately elevated cortisol serum levels in patients with mild AD dementia.",[],European archives of psychiatry and clinical neuroscience,2008-09-23,"[{'lastname': 'Laske', 'firstname': 'Christoph', 'initials': 'C', 'affiliation': 'Dept. of Psychiatry and Psychotherapy, University of Tuebingen, Osianderstr. 24, 72076, Tuebingen, Germany. christoph.laske@med.uni-tuebingen.de'}, {'lastname': 'Stransky', 'firstname': 'Elke', 'initials': 'E', 'affiliation': None}, {'lastname': 'Fritsche', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': None}, {'lastname': 'Eschweiler', 'firstname': 'Gerhard W', 'initials': 'GW', 'affiliation': None}, {'lastname': 'Leyhe', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': None}]",,,,,10.1007/s00406-008-0838-3,<Element 'PubmedArticle' at 0x7f05d88b4810>
365,18781435,Progressive anomia revisited: focal degeneration associated with progranulin gene mutation.,"In 2003 we reported a case study of a patient, Newton who presented with a progressive circumscribed anomia in association with focal left hemisphere atrophy. Remarkably, he could spell aloud the names of objects that he could not name, indicating dissociated access to phonology and orthography. We now present follow-up clinical data, post-mortem histopathological findings, and results of molecular genetic analysis. Newton showed tau-negative ubiquitin-positive histology consistent with frontotemporal lobar degeneration (FTLD) and a mutation in the progranulin (PGRN) gene. The case exemplifies the heterogeneity of clinical expression of FTLD and contributes to understanding of primary progressive aphasia.",[],Neurocase,2008-09-11,"[{'lastname': 'Snowden', 'firstname': 'Julie S', 'initials': 'JS', 'affiliation': 'School of Translational Medicine, University of Manchester, Hope Hospital, Salford, UK. julie.snowden@manchester.ac.uk'}, {'lastname': 'Pickering-Brown', 'firstname': 'Stuart M', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Du Plessis', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': None}, {'lastname': 'Mackenzie', 'firstname': 'Ian R A', 'initials': 'IR', 'affiliation': None}, {'lastname': 'Varma', 'firstname': 'Anoop', 'initials': 'A', 'affiliation': None}, {'lastname': 'Mann', 'firstname': 'David M A', 'initials': 'DM', 'affiliation': None}, {'lastname': 'Neary', 'firstname': 'David', 'initials': 'D', 'affiliation': None}]",,,,,10.1080/13554790701851510,<Element 'PubmedArticle' at 0x7f05d88c51d0>
366,18703462,Distinct genetic forms of frontotemporal dementia.,"Frontotemporal dementia (FTD) is the second most common type of presenile dementia and can be distinguished into various clinical variants. The identification of MAPT and GRN defects and the discovery of the TDP-43 protein in FTD have led to the classification of pathologic and genetic subtypes. In addition to these genetic subtypes, there exist familial forms of FTD with unknown genetic defects.
We investigated the frequency, demographic, and clinical data of patients with FTD with a positive family history in our prospective cohort of 364 patients. Genetic analysis of genes associated with FTD was performed on all patients with a positive family history. Immunohistochemical studies were carried out with a panel of antibodies (tau, ubiquitin, TDP-43) in brains collected at autopsy.
In the total cohort of 364 patients, 27% had a positive family history suggestive for an autosomal mode of inheritance, including MAPT (11%) and GRN (6%) mutations. We identified a new Gln300X GRN mutation in a patient with a sporadic FTD. The mean age at onset in GRN patients (61.8 +/- 9.9 years) was higher than MAPT patients (52.4 +/- 5.9 years). In the remaining 10% of patients with suggestive autosomal dominant inheritance, the genetic defect has yet to be identified. Neuropathologically, this group can be distinguished into familial FTLD+MND and familial FTLD-U with hippocampal sclerosis.
Future genetic studies need to identify genetic defects in at least two distinct familial forms of frontotemporal dementia (FTD) with unknown genetic defects: frontotemporal lobe degeneration with ubiquitin-positive inclusions with hippocampal sclerosis and frontotemporal lobe degeneration with motor neuron disease.",[],Neurology,2008-08-16,"[{'lastname': 'Seelaar', 'firstname': 'H', 'initials': 'H', 'affiliation': 'Erasmus University Medical Center Rotterdam, Department of Neurology, Rotterdam, The Netherlands.'}, {'lastname': 'Kamphorst', 'firstname': 'W', 'initials': 'W', 'affiliation': None}, {'lastname': 'Rosso', 'firstname': 'S M', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Azmani', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Masdjedi', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'de Koning', 'firstname': 'I', 'initials': 'I', 'affiliation': None}, {'lastname': 'Maat-Kievit', 'firstname': 'J A', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Anar', 'firstname': 'B', 'initials': 'B', 'affiliation': None}, {'lastname': 'Donker Kaat', 'firstname': 'L', 'initials': 'L', 'affiliation': None}, {'lastname': 'Breedveld', 'firstname': 'G J', 'initials': 'GJ', 'affiliation': None}, {'lastname': 'Dooijes', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Rozemuller', 'firstname': 'J M', 'initials': 'JM', 'affiliation': None}, {'lastname': 'Bronner', 'firstname': 'I F', 'initials': 'IF', 'affiliation': None}, {'lastname': 'Rizzu', 'firstname': 'P', 'initials': 'P', 'affiliation': None}, {'lastname': 'van Swieten', 'firstname': 'J C', 'initials': 'JC', 'affiliation': None}]",,Future genetic studies need to identify genetic defects in at least two distinct familial forms of frontotemporal dementia (FTD) with unknown genetic defects: frontotemporal lobe degeneration with ubiquitin-positive inclusions with hippocampal sclerosis and frontotemporal lobe degeneration with motor neuron disease.,"In the total cohort of 364 patients, 27% had a positive family history suggestive for an autosomal mode of inheritance, including MAPT (11%) and GRN (6%) mutations. We identified a new Gln300X GRN mutation in a patient with a sporadic FTD. The mean age at onset in GRN patients (61.8 +/- 9.9 years) was higher than MAPT patients (52.4 +/- 5.9 years). In the remaining 10% of patients with suggestive autosomal dominant inheritance, the genetic defect has yet to be identified. Neuropathologically, this group can be distinguished into familial FTLD+MND and familial FTLD-U with hippocampal sclerosis.",,10.1212/01.wnl.0000319702.37497.72,<Element 'PubmedArticle' at 0x7f05d88ce3b0>
367,18603054,Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery.,"Although left ventricular restoration is effective for treating ischemic cardiomyopathy caused by left ventricular remodeling and redilation, the initial improvement in left ventricular function is not always sustained. We have reported that the inhibition of the renin-angiotensin-aldosterone system by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers is effective in preventing late remodeling after left ventricular restoration. However, the effects of spironolactone--an aldosterone blocker--after left ventricular restoration have not been elucidated.
Myocardial infarction was induced by ligating the left anterior descending artery. The rats developed left ventricular aneurysms and underwent left ventricular restoration by the plication of the left ventricular aneurysm 4 weeks after the ligation. Thereafter, the rats were randomized into a left ventricular restoration (vehicle) group and left ventricular restoration with spironolactone (100 mg/kg/d, by mouth) group.
Echocardiography revealed that in the left ventricular restoration with spironolactone group, late cardiac redilation was significantly attenuated (left ventricular end-diastolic area: 0.51 +/- 0.03 cm(2) vs 0.63 +/- 0.03 cm(2), P < .05) and late left ventricular function was preserved (fractional area change: 48.8% +/- 3.0% vs 35.8% +/- 2.4%, P < .01). Hemodynamically, rats in the left ventricular restoration with spironolactone group exhibited improved systolic function (maximal end-systolic pressure-volume relationship: 0.38 +/- 0.03 mm Hg/microL vs 0.11 +/- 0.04 mm Hg/microL, P < .01) and diastolic function (tau: 18.5 +/- 1.5 sec vs 23.1 +/- 1.4 sec, P < .05) than those in the LVR group. Histologically, interstitial fibrosis in the remote area was significantly reduced (5.6% +/- 1.3% vs 12% +/- 1.0%, P < .01), and fibrosis around the pledgets (near area) was also attenuated in the left ventricular restoration with spironolactone group. The myocardial messenger ribonucleic acid expressions of transforming growth factor-beta1 and brain natriuretic peptide measured using the real-time polymerase chain reaction were lower in the left ventricular restoration with spironolactone group (transforming growth factor-beta1: 0.13 +/- 0.02 vs 0.28 +/- 0.02, P < .01; brain natriuretic peptide: 0.99 +/- 0.14 vs 1.54 +/- 0.18, P < .05). The systemic blood pressure and heart rate did not differ between the 2 groups.
Spironolactone reduced the gene expression of transforming growth factor-beta1 and brain natriuretic peptide and alleviated not only cardiac redilation but also the deterioration of left ventricular function late after left ventricular restoration without inducing hypotension, a major side effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blocker. Spironolactone is a promising therapeutic option for alleviating remodeling after left ventricular restoration.",[],The Journal of thoracic and cardiovascular surgery,2008-07-08,"[{'lastname': 'Tsukashita', 'firstname': 'Masaki', 'initials': 'M', 'affiliation': 'Department of Cardiovascular Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan. mtsuka@kuhp.kyoto-u.ac.jp'}, {'lastname': 'Marui', 'firstname': 'Akira', 'initials': 'A', 'affiliation': None}, {'lastname': 'Nishina', 'firstname': 'Takeshi', 'initials': 'T', 'affiliation': None}, {'lastname': 'Yoshikawa', 'firstname': 'Eiji', 'initials': 'E', 'affiliation': None}, {'lastname': 'Kanemitsu', 'firstname': 'Hideo', 'initials': 'H', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Jian', 'initials': 'J', 'affiliation': None}, {'lastname': 'Ikeda', 'firstname': 'Tadashi', 'initials': 'T', 'affiliation': None}, {'lastname': 'Komeda', 'firstname': 'Masashi', 'initials': 'M', 'affiliation': None}]",,"Spironolactone reduced the gene expression of transforming growth factor-beta1 and brain natriuretic peptide and alleviated not only cardiac redilation but also the deterioration of left ventricular function late after left ventricular restoration without inducing hypotension, a major side effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blocker. Spironolactone is a promising therapeutic option for alleviating remodeling after left ventricular restoration.","Echocardiography revealed that in the left ventricular restoration with spironolactone group, late cardiac redilation was significantly attenuated (left ventricular end-diastolic area: 0.51 +/- 0.03 cm(2) vs 0.63 +/- 0.03 cm(2), P < .05) and late left ventricular function was preserved (fractional area change: 48.8% +/- 3.0% vs 35.8% +/- 2.4%, P < .01). Hemodynamically, rats in the left ventricular restoration with spironolactone group exhibited improved systolic function (maximal end-systolic pressure-volume relationship: 0.38 +/- 0.03 mm Hg/microL vs 0.11 +/- 0.04 mm Hg/microL, P < .01) and diastolic function (tau: 18.5 +/- 1.5 sec vs 23.1 +/- 1.4 sec, P < .05) than those in the LVR group. Histologically, interstitial fibrosis in the remote area was significantly reduced (5.6% +/- 1.3% vs 12% +/- 1.0%, P < .01), and fibrosis around the pledgets (near area) was also attenuated in the left ventricular restoration with spironolactone group. The myocardial messenger ribonucleic acid expressions of transforming growth factor-beta1 and brain natriuretic peptide measured using the real-time polymerase chain reaction were lower in the left ventricular restoration with spironolactone group (transforming growth factor-beta1: 0.13 +/- 0.02 vs 0.28 +/- 0.02, P < .01; brain natriuretic peptide: 0.99 +/- 0.14 vs 1.54 +/- 0.18, P < .05). The systemic blood pressure and heart rate did not differ between the 2 groups.",,10.1016/j.jtcvs.2007.11.016,<Element 'PubmedArticle' at 0x7f05d88dab30>
368,18586097,Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A.,"The down-regulation of protein phosphatase 2A (PP2A) activity is thought to play an important role in the formation of tau hyperphosphorylation in the Alzheimer's disease (AD) brain. Methylation of the PP2A catalytic subunit at the L309 site can potently activate PP2A for some substrates via the increasing recruitment of its regulatory subunits into the holoenzyme. Abeta is overproduced yet estrogen is deficient in the brains of the menopausal AD patients. Both Abeta and estrogen deficiency can interact with tau kinases such as protein kinase B and glycogen synthase kinase 3. In the current study, levels of demethylated (-m) PP2A (L309) were significantly increased, and methylated (+m) PP2A (L309) were significantly decreased, which corresponded with the increased tau phosphorylation at the Tau-1 and PHF-1 sites in both mouse N2a cells carrying the human APP with Swedish mutation (APPswe) and transgenic APPswe/presenilin (PS) 1 (A246E) mice. These findings were replicated in wild-type N2a cells treated with Abeta25-35, and to a relatively larger extent, in both wild-type N2a cells and APPswe treated by okadaic acid, as well as in the brains of estrogen receptor (ER) alpha-/- and ERbeta-/- mice that mimic the status of estrogen deficiency in menopausal AD patients. Together, these findings suggested that the increased demethylation of PP2A (L309) mediated by Abeta overproduction or estrogen deficiency (ERalpha-/- and ERbeta-/-) may contribute to the reduced PP2A activity observed in the AD brain, resulting in the compromised dephosphorylation of abnormally hyperphosphorylated tau.",[],Neurobiology of disease,2008-07-01,"[{'lastname': 'Zhou', 'firstname': 'Xin-Wen', 'initials': 'XW', 'affiliation': 'Karolinska Institutet, KI-Alzheimer Disease Research Center (KI-ADRC), Novum, Huddinge, Sweden.'}, {'lastname': 'Gustafsson', 'firstname': 'Jan-Ake', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Tanila', 'firstname': 'Heikki', 'initials': 'H', 'affiliation': None}, {'lastname': 'Bjorkdahl', 'firstname': 'Cecilia', 'initials': 'C', 'affiliation': None}, {'lastname': 'Liu', 'firstname': 'Rong', 'initials': 'R', 'affiliation': None}, {'lastname': 'Winblad', 'firstname': 'Bengt', 'initials': 'B', 'affiliation': None}, {'lastname': 'Pei', 'firstname': 'Jin-Jing', 'initials': 'JJ', 'affiliation': None}]",,,,,10.1016/j.nbd.2008.05.013,<Element 'PubmedArticle' at 0x7f05d8868cc0>
369,"18338250
9153165
12214002
16465464
10460255
3088567
11045514
11264469
8226879
11040417
6245082
10817919
16245068
9413580
9024081
15230863
7531159
9462888
15620722
16962721
7488136
7680727
11141318
7566346
206557
12212801
18217188
1899488
1956315
15837120
17078951
12042878
7522386
15033165
9406879
8945754
7822317
16024764
16611827
12530632
8030628
11414282
8780008
11890841
9771888
16079401
15375165
3084478
6278005
17433504
17376439
7821426
1429606
14993042
8261023
14580942",Estradiol attenuates tau hyperphosphorylation induced by upregulation of protein kinase-A.,"Protein kinase A (PKA) plays a crucial role in tau hyperphosphorylation, an early event of Alzheimer disease (AD), and 17beta-estradiol replacement in aging women forestalls the onset of AD. However, the role of estradiol in PKA-induced tau hyperphosphorylation is not known. Here, we investigated the effect of 17beta-estradiol on cAMP/PKA activity and the PKA-induced tau hyperphosphorylation in HEK293 cells stably expressing tau441. We found that 17beta-estradiol effectively attenuated forskolin-induced overactivation of PKA and elevation of cAMP, and thus prevented tau from hyperphosphorylation. These data provide the first evidence that 17beta-estradiol can inhibit PKA overactivation and the PKA-induced tau hyperphosphorylation, implying a preventive role of 17beta-estradiol in AD-like tau pathology.",[],Neurochemical research,2008-03-14,"[{'lastname': 'Liu', 'firstname': 'Xin-An', 'initials': 'XA', 'affiliation': 'Pathophysiology Department, Tongji Medical College, Hua-Zhong University of Science and Technology, Wuhan, 430030, PR China.'}, {'lastname': 'Zhu', 'firstname': 'Ling-Qiang', 'initials': 'LQ', 'affiliation': None}, {'lastname': 'Zhang', 'firstname': 'Qi', 'initials': 'Q', 'affiliation': None}, {'lastname': 'Shi', 'firstname': 'Hai-Rong', 'initials': 'HR', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Shao-Hui', 'initials': 'SH', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Qun', 'initials': 'Q', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Jian-Zhi', 'initials': 'JZ', 'affiliation': None}]",,,,,10.1007/s11064-008-9638-4,<Element 'PubmedArticle' at 0x7f05d88771d0>
370,"18234697
16862116
24487323
17334266
17157414
12833366
12833363
17228326
8163988
17579875
11310620
16862115
17522386
17953663
9113464
16950801
16344531
12939423
15849155
15349867
12913196
9641683
3816245
17278999
17949857
10436340
15786453
17436289
9633693
17439980
8710059
12370467
16401619
17030534
9343592
7420102
16391566
17210807
16983685
9855500
1009768
1182406
17023659
5852918
9629852
12476321
17826340
17947337
18413474
11571213
16170092
17371905
16041373
17003069
17569065
9636220
17917583
9633692
16495329
15034582
17353379","A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series.","Mutations in the progranulin gene (GRN) are a major cause of frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions (FTLD-U) but the distinguishing clinical and anatomical features of this subgroup remain unclear. In a large UK cohort we found five different frameshift and premature termination mutations likely to be causative of FTLD in 25 affected family members. A previously described 4-bp insertion mutation in GRN exon 2 comprised the majority of cases in our cohort (20/25), with four novel mutations being identified in the other five affected members. Additional novel missense changes were discovered, of uncertain pathogenicity, but deletion of the entire gene was not detected. The patient collection was investigated by a single tertiary referral centre and is enriched for familial early onset FTLD with a high proportion of patients undergoing neuropsychological testing, MRI and eventual neuropathological diagnosis. Age at onset was variable, but four mutation carriers presented in their 40s and when analysed as a group, the mean age at onset of disease in GRN mutation carriers was later than tau gene (MAPT) mutation carriers and duration of disease was shorter when compared with both MAPT and FTLD-U without mutation. The most common clinical presentation seen in GRN mutation carriers was behavioural variant FTLD with apathy as the dominant feature. However, many patients had language output impairment that was either a progressive non-fluent aphasia or decreased speech output consistent with a dynamic aphasia. Neurological and neuropsychological examination also suggests that parietal lobe dysfunction is a characteristic feature of GRN mutation and differentiates this group from other patients with FTLD. MR imaging showed evidence of strikingly asymmetrical atrophy with the frontal, temporal and parietal lobes all affected. Both right- and left-sided predominant atrophy was seen even within the same family. As a group, the GRN carriers showed more asymmetry than in other FTLD groups. All pathologically investigated cases showed extensive type 3 TDP-43-positive pathology, including frequent neuronal cytoplasmic inclusions, dystrophic neurites in both grey and white matter and also neuronal intranuclear inclusions. Finally, we confirmed a modifying effect of APOE-E4 genotype on clinical phenotype with a later onset in the GRN carriers suggesting that this gene has distinct phenotypic effects in different neurodegenerative diseases.",[],Brain : a journal of neurology,2008-02-01,"[{'lastname': 'Beck', 'firstname': 'Jonathan', 'initials': 'J', 'affiliation': 'MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': None}, {'lastname': 'Campbell', 'firstname': 'Tracy', 'initials': 'T', 'affiliation': None}, {'lastname': 'Isaacs', 'firstname': 'Adrian', 'initials': 'A', 'affiliation': None}, {'lastname': 'Morrison', 'firstname': 'Karen E', 'initials': 'KE', 'affiliation': None}, {'lastname': 'Goodall', 'firstname': 'Emily F', 'initials': 'EF', 'affiliation': None}, {'lastname': 'Warrington', 'firstname': 'Elizabeth K', 'initials': 'EK', 'affiliation': None}, {'lastname': 'Stevens', 'firstname': 'John', 'initials': 'J', 'affiliation': None}, {'lastname': 'Revesz', 'firstname': 'Tamas', 'initials': 'T', 'affiliation': None}, {'lastname': 'Holton', 'firstname': 'Janice', 'initials': 'J', 'affiliation': None}, {'lastname': 'Al-Sarraj', 'firstname': 'Safa', 'initials': 'S', 'affiliation': None}, {'lastname': 'King', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': None}, {'lastname': 'Scahill', 'firstname': 'Rachael', 'initials': 'R', 'affiliation': None}, {'lastname': 'Warren', 'firstname': 'Jason D', 'initials': 'JD', 'affiliation': None}, {'lastname': 'Fox', 'firstname': 'Nick C', 'initials': 'NC', 'affiliation': None}, {'lastname': 'Rossor', 'firstname': 'Martin N', 'initials': 'MN', 'affiliation': None}, {'lastname': 'Collinge', 'firstname': 'John', 'initials': 'J', 'affiliation': None}, {'lastname': 'Mead', 'firstname': 'Simon', 'initials': 'S', 'affiliation': None}]",,,,,10.1093/brain/awm320,<Element 'PubmedArticle' at 0x7f05d888f090>
371,"18208556
15920161
10441131
11171037
8395566
11259128
15099019
12937126
15992372
11473109
15535135
1325671
7510677
8541516
16513361
11520987
11520988
15294141
8356085
10684871
12196559
14625087
15056716
14711819
16971528
12624792
12937125
15283964
12875979
8938131
15081593
14678749
12515851
17159139
16495456
8294450
10712915
9588762",Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology.,"Down-regulation of protein phosphatase 2A (PP2A) is thought to play a critical role in tau hyperphosphorylation in Alzheimer's disease (AD). In vitro phosphorylation of PP2A catalytic subunit at Y307 efficiently inactivates PP2A. A specific antibody against phosphorylated (p) PP2A (Y307) (PP2Ac-Yp307) was used to investigate possible PP2A down-regulation by known pathophysiological changes associated with AD, such as Abeta accumulation and oestrogen deficiency. Immunohistochemistry and immunofluorescence confocal microscopy showed an aberrant accumulation of PP2Ac-Yp307 in neurons that bear pretangles or tangles in the susceptible brain regions, such as the entorhinal cortical cortex and the hippocampus. Experimentally, increased PP2Ac-Yp307 was observed in mouse N2a neuroblastoma cells that stably express the human amyloid precursor protein with Swedish mutation (APPswe) compared with wild-type, and in the brains of transgenic APPswe/ presenilin (PS1, A246E) mice, which corresponded to the increased tau phosphorylation. Treating N2a cells with Abeta25-35 mimicked the changes of PP2Ac-Yp307 and tau phosphorylation in N2a APPswe cells. Knockout of oestrogen receptor (ER) alpha or ERbeta gave similar changes of PP2Ac-Yp307 level and tau phosphorylation in the mouse brain. Taken together, these findings suggest that increased PP2A phosphorylation (Y307) can be mediated by Abeta deposition or oestrogen deficiency in the AD brain, and consequently compromise dephosphorylation of abnormally hyperphosphorylated tau, and lead to neurofibrillary tangle formation.",[],Journal of cellular and molecular medicine,2008-01-23,"[{'lastname': 'Liu', 'firstname': 'R', 'initials': 'R', 'affiliation': 'Karolinska Institutet, KI-Alzheimer Disease Research Center (KI-ADRC), Novum, Huddinge, Sweden.'}, {'lastname': 'Zhou', 'firstname': 'X-W', 'initials': 'XW', 'affiliation': None}, {'lastname': 'Tanila', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Bjorkdahl', 'firstname': 'C', 'initials': 'C', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'J-Z', 'initials': 'JZ', 'affiliation': None}, {'lastname': 'Guan', 'firstname': 'Z-Z', 'initials': 'ZZ', 'affiliation': None}, {'lastname': 'Cao', 'firstname': 'Y', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Gustafsson', 'firstname': 'J-A', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Winblad', 'firstname': 'B', 'initials': 'B', 'affiliation': None}, {'lastname': 'Pei', 'firstname': 'J-J', 'initials': 'JJ', 'affiliation': None}]",,,,,10.1111/j.1582-4934.2008.00249.x,<Element 'PubmedArticle' at 0x7f05d88354a0>
372,"18077675
8202528
11381127
15190058
12859672
15148141
15044677
9668082
2495152
10482353
16361024
17168643
7522386
12843267
10090668
15583961
17130475
2549856
17049785
9443474
2973668
15308380
10542369
15615645
16567536
0
9000448
3525751
10672251
12084635
6375662
1330687
7519852
7624036
8395566
8137929
7616230
10681533
2116006
17448147
3088567
11976212
8797796
11065271
15033922
9235959
15640274
11113614
12111436
15094078
10513628
11506396
10320789
11171037
8925431
9492899
9334293
9054233
10938436
9930729
16627931
8687413
15249677
17430235
11581097
16116114
10747907
11248668
12087104
7946342
12536218
8736675
17168644
15747152
3091139
12765608
15867159
236308
10599761
499083
11916953
8957742
11441005
15014115
17376970
10581399
16340083
10599878
12191990
16039605
15980612
7926307
12904469
14981233
3304596
1386819
6223804
2571449
9886075
9801171
7036756
10464280
9514514
8275305
7533559
7680727
15920161
12566927
8129030
11259128
17241267
12467491
6479490
6959136
12544832
12566928",Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms.,"Hyperphosphorylated tau is the major component of paired helical filaments in neurofibrillary tangles found in Alzheimer's disease (AD) brains, and tau hyperphosphorylation is thought to be a critical event in the pathogenesis of the disease. The large majority of AD cases is late onset and sporadic in origin, with aging as the most important risk factor. Insulin resistance, impaired glucose tolerance, and diabetes mellitus (DM) are other common syndromes in the elderly also strongly age dependent, and there is evidence supporting a link between insulin dysfunction and AD. To investigate the possibility that insulin dysfunction might promote tau pathology, we induced insulin deficiency and caused DM in mice with streptozotocin (STZ). A mild hyperphosphorylation of tau could be detected 10, 20, and 30 d after STZ injection, and a massive hyperphosphorylation of tau was observed after 40 d. The robust hyperphosphorylation of tau was localized in the axons and neuropil, and prevented tau binding to microtubules. Neither mild nor massive tau phosphorylation induced tau aggregation. Body temperature of the STZ-treated mice did not differ from control animals during 30 d, but dropped significantly thereafter. No change in beta-amyloid (Abeta) precursor protein (APP), APP C-terminal fragments, or Abeta levels were observed in STZ-treated mice; however, cellular protein phosphatase 2A activity was significantly decreased. Together, these data indicate that insulin dysfunction induced abnormal tau hyperphosphorylation through two distinct mechanisms: one was consequent to hypothermia; the other was temperature-independent, inherent to insulin depletion, and probably caused by inhibition of phosphatase activity.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,2007-12-14,"[{'lastname': 'Planel', 'firstname': 'Emmanuel', 'initials': 'E', 'affiliation': ""Laboratory for Alzheimer's Disease, The Institute of Physical and Chemical Research, Saitama 351-0198, Japan. emmanuel@planel.org""}, {'lastname': 'Tatebayashi', 'firstname': 'Yoshitaka', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Miyasaka', 'firstname': 'Tomohiro', 'initials': 'T', 'affiliation': None}, {'lastname': 'Liu', 'firstname': 'Li', 'initials': 'L', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Lili', 'initials': 'L', 'affiliation': None}, {'lastname': 'Herman', 'firstname': 'Mathieu', 'initials': 'M', 'affiliation': None}, {'lastname': 'Yu', 'firstname': 'W Haung', 'initials': 'WH', 'affiliation': None}, {'lastname': 'Luchsinger', 'firstname': 'Jose A', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Wadzinski', 'firstname': 'Brian', 'initials': 'B', 'affiliation': None}, {'lastname': 'Duff', 'firstname': 'Karen E', 'initials': 'KE', 'affiliation': None}, {'lastname': 'Takashima', 'firstname': 'Akihiko', 'initials': 'A', 'affiliation': None}]",,,,,10.1523/JNEUROSCI.3949-07.2007,<Element 'PubmedArticle' at 0x7f05d8851d60>
373,18076866,Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models.,"Increasing beta-amyloid (Abeta) clearance may alter the course of Alzheimer's disease progression and attenuate amyloid plaque pathology. Insulin-like growth factor I (IGF-1) augmentation has been suggested to increase Abeta clearance by facilitating transport of Abeta out of the brain. The availability of safe agents that increase IGF-1 levels therefore makes IGF-1 elevation an attractive target for disease modifying therapy in AD. The present series of studies sought to replicate published paradigms in which peripheral IGF-1 administration lowered brain Abeta acutely, with reduction in plaque pathology after chronic treatment. Thus Abeta levels were measured in several animal models following treatments that elevated IGF-1. Administration of IGF-1 to young or old rats for up to 3 days had no effect on Abeta levels in brain, CSF, or plasma. In adult beagles, 4 days of dosing with the growth hormone secretagogue, CP-424391, doubled baseline plasma IGF-1 levels, yet failed to alter CSF or plasma Abeta. 5-day treatment of young Tg2576 mice with IGF-1 produced robust elevations of IGF-1 levels in plasma, but no effects on Abeta were detected in brain, CSF, or plasma. Finally, 11-month-old Tg2576 mice were implanted with subcutaneous minipumps delivering IGF-1 for 1 month. No significant changes in Abeta (by ELISA or Western blot), plaque pathology, or phospho-tau epitopes were detected. These results do not demonstrate acute or chronic actions of peripherally administered IGF-1 on Abeta levels or the phosphorylation state of tau and therefore do not suggest any disease-modifying benefits of IGF-1 restorative therapy for AD through these mechanisms.",[],Biochemical pharmacology,2007-12-14,"[{'lastname': 'Lanz', 'firstname': 'Thomas A', 'initials': 'TA', 'affiliation': 'CNS Discovery, Pfizer, Inc., Eastern Point Road, Groton, CT 06340, United States. thomas.a.lanz@pfizer.com'}, {'lastname': 'Salatto', 'firstname': 'Christopher T', 'initials': 'CT', 'affiliation': None}, {'lastname': 'Semproni', 'firstname': 'Anthony R', 'initials': 'AR', 'affiliation': None}, {'lastname': 'Marconi', 'firstname': 'Michael', 'initials': 'M', 'affiliation': None}, {'lastname': 'Brown', 'firstname': 'Tracy M', 'initials': 'TM', 'affiliation': None}, {'lastname': 'Richter', 'firstname': 'Karl E G', 'initials': 'KE', 'affiliation': None}, {'lastname': 'Schmidt', 'firstname': 'Kari', 'initials': 'K', 'affiliation': None}, {'lastname': 'Nelson', 'firstname': 'Frederick R', 'initials': 'FR', 'affiliation': None}, {'lastname': 'Schachter', 'firstname': 'Joel B', 'initials': 'JB', 'affiliation': None}]",,,,,10.1016/j.bcp.2007.11.001,<Element 'PubmedArticle' at 0x7f05d880cd60>
374,17950702,"Mutations in progranulin gene: clinical, pathological, and ribonucleic acid expression findings.","There is an increasing interest in the clinico-pathological correlation of mutations in progranulin (PGRN) and frontotemporal lobar degeneration (FTLD) complex diseases. We aim to study the PGRN expression variability in patients with different clinical features for a better understanding of its roles in FTLD disease.
We sequenced the PGRN gene in 72 patients suffering from FTLD (25 familial and 47 sporadic cases) and in 24 asymptomatic at-risk relatives. We also analyzed PGRN expression in blood by quantitative real-time polymerase chain reaction from 37 patients, 8 asymptomatic mutation carriers, and 10 control subjects as well as in brain tissue from 16 patients and 9 control subjects.
Four novel mutations were associated with familial and sporadic FTLD and familial dementia associated with amyotrophic lateral sclerosis. We identified a close association between the IVS6-1G>A mutation in PGRN and corticobasal syndrome. Brain tissue was available for carriers of two of the four mutations (IVS6-1 G>A and P357HfsX3). Immunohistochemical analysis revealed ubiquitin- and TDP-43positive and tau/alpha-synuclein negative immunoreactive neuronal intranuclear inclusions. The relative expression of PGRN in the clinical sample was significantly lower in carriers of the IVS6-1 G>A than in control subjects.
Progranulopathies are a major cause of the main phenotypes included in the FTLD complex. According to our results, the level of expression of PGRN in blood could be a useful marker both for diagnostics of part of the spectrum of FTLD conditions and for monitoring future treatments that might boost the level of PGRN in this disorder.",[],Biological psychiatry,2007-10-24,"[{'lastname': 'López de Munain', 'firstname': 'Adolfo', 'initials': 'A', 'affiliation': 'Servicio de Neurología, Hospital Donostia, San Sebastián, Spain. munain@chdo.osakidetza.net'}, {'lastname': 'Alzualde', 'firstname': 'Ainhoa', 'initials': 'A', 'affiliation': None}, {'lastname': 'Gorostidi', 'firstname': 'Ana', 'initials': 'A', 'affiliation': None}, {'lastname': 'Otaegui', 'firstname': 'David', 'initials': 'D', 'affiliation': None}, {'lastname': 'Ruiz-Martínez', 'firstname': 'Javier', 'initials': 'J', 'affiliation': None}, {'lastname': 'Indakoetxea', 'firstname': 'Begoña', 'initials': 'B', 'affiliation': None}, {'lastname': 'Ferrer', 'firstname': 'Isidro', 'initials': 'I', 'affiliation': None}, {'lastname': 'Pérez-Tur', 'firstname': 'Jordi', 'initials': 'J', 'affiliation': None}, {'lastname': 'Sáenz', 'firstname': 'Amets', 'initials': 'A', 'affiliation': None}, {'lastname': 'Bergareche', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': None}, {'lastname': 'Barandiarán', 'firstname': 'Miriam', 'initials': 'M', 'affiliation': None}, {'lastname': 'Poza', 'firstname': 'Juan José', 'initials': 'JJ', 'affiliation': None}, {'lastname': 'Zabalza', 'firstname': 'Ramón', 'initials': 'R', 'affiliation': None}, {'lastname': 'Ruiz', 'firstname': 'Irune', 'initials': 'I', 'affiliation': None}, {'lastname': 'Urtasun', 'firstname': 'Miguel', 'initials': 'M', 'affiliation': None}, {'lastname': 'Fernández-Manchola', 'firstname': 'Iñaki', 'initials': 'I', 'affiliation': None}, {'lastname': 'Olasagasti', 'firstname': 'Bixen', 'initials': 'B', 'affiliation': None}, {'lastname': 'Espinal', 'firstname': 'Juan Bautista', 'initials': 'JB', 'affiliation': None}, {'lastname': 'Olaskoaga', 'firstname': 'Javier', 'initials': 'J', 'affiliation': None}, {'lastname': 'Ruibal', 'firstname': 'Marta', 'initials': 'M', 'affiliation': None}, {'lastname': 'Moreno', 'firstname': 'Fermin', 'initials': 'F', 'affiliation': None}, {'lastname': 'Carrera', 'firstname': 'Nieves', 'initials': 'N', 'affiliation': None}, {'lastname': 'Martí Massó', 'firstname': 'José Félix', 'initials': 'JF', 'affiliation': None}]",,,Four novel mutations were associated with familial and sporadic FTLD and familial dementia associated with amyotrophic lateral sclerosis. We identified a close association between the IVS6-1G>A mutation in PGRN and corticobasal syndrome. Brain tissue was available for carriers of two of the four mutations (IVS6-1 G>A and P357HfsX3). Immunohistochemical analysis revealed ubiquitin- and TDP-43positive and tau/alpha-synuclein negative immunoreactive neuronal intranuclear inclusions. The relative expression of PGRN in the clinical sample was significantly lower in carriers of the IVS6-1 G>A than in control subjects.,,10.1016/j.biopsych.2007.08.015,<Element 'PubmedArticle' at 0x7f05d8818d10>
375,17826340,Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative.,"The progranulin gene (GRN) is mutated in 5-10% of patients with frontotemporal lobar degeneration (FTLD) and in about 20% of patients with familial FTLD. The most common mutation in GRN is Arg493X. We aimed to establish the contribution of this mutation to FTLD and related disorders.
We measured the frequency of Arg493X in 3405 unrelated patients with various neurodegenerative diseases using Taqman single-nucleotide polymorphism (SNP) genotyping. Clinicopathological characterisation and shared haplotype analysis were done for 30 families with FTLD who carry Arg493X. To investigate the effect of potential modifying loci, we did linear regression analyses with onset age as the covariate for GRN variants, for genotypes of the apolipoprotein E gene (APOE), and for haplotypes of the microtubule-associated protein tau gene (MAPT).
Of 731 patients with FTLD, 16 (2%) carried Arg493X. This mutation was not detected in 2674 patients who did not have FTLD. In 37 patients with Arg493X from 30 families with FTLD, clinical diagnoses included frontotemporal dementia, primary progressive aphasia, corticobasal syndrome, and Alzheimer's disease. Range of onset age was 44-69 years. In all patients who came to autopsy (n=13), the pathological diagnosis was FTLD with neuronal inclusions that contained TAR DNA-binding protein or ubiquitin, but not tau. Neurofibrillary tangle pathology in the form of Braak staging correlated with overall neuropathology in the Arg493X carriers. Haplotype analyses suggested that Arg493X arose twice, with a single founder for 27 families. Linear regression analyses suggested that patients with SNP rs9897528 on their wild-type GRN allele have delayed symptom onset. Onset ages were not associated with the MAPT H1 or H2 haplotypes or APOE genotypes, but early memory deficits were associated with the presence of an APOE epsilon4 allele.
Clinical heterogeneity is associated with GRN haploinsufficiency, and genetic variability on the wild-type GRN allele might have a role in the age-related disease penetrance of GRN mutations.",[],The Lancet. Neurology,2007-09-11,"[{'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA. rademakers.rosa@mayo.edu'}, {'lastname': 'Baker', 'firstname': 'Matt', 'initials': 'M', 'affiliation': None}, {'lastname': 'Gass', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': None}, {'lastname': 'Adamson', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': None}, {'lastname': 'Huey', 'firstname': 'Edward D', 'initials': 'ED', 'affiliation': None}, {'lastname': 'Momeni', 'firstname': 'Parastoo', 'initials': 'P', 'affiliation': None}, {'lastname': 'Spina', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': None}, {'lastname': 'Coppola', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': None}, {'lastname': 'Karydas', 'firstname': 'Anna M', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Stewart', 'firstname': 'Heather', 'initials': 'H', 'affiliation': None}, {'lastname': 'Johnson', 'firstname': 'Nancy', 'initials': 'N', 'affiliation': None}, {'lastname': 'Hsiung', 'firstname': 'Ging-Yuek', 'initials': 'GY', 'affiliation': None}, {'lastname': 'Kelley', 'firstname': 'Brendan', 'initials': 'B', 'affiliation': None}, {'lastname': 'Kuntz', 'firstname': 'Karen', 'initials': 'K', 'affiliation': None}, {'lastname': 'Steinbart', 'firstname': 'Ellen', 'initials': 'E', 'affiliation': None}, {'lastname': 'Wood', 'firstname': 'Elisabeth McCarty', 'initials': 'EM', 'affiliation': None}, {'lastname': 'Yu', 'firstname': 'Chang-En', 'initials': 'CE', 'affiliation': None}, {'lastname': 'Josephs', 'firstname': 'Keith', 'initials': 'K', 'affiliation': None}, {'lastname': 'Sorenson', 'firstname': 'Eric', 'initials': 'E', 'affiliation': None}, {'lastname': 'Womack', 'firstname': 'Kyle B', 'initials': 'KB', 'affiliation': None}, {'lastname': 'Weintraub', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': None}, {'lastname': 'Pickering-Brown', 'firstname': 'Stuart M', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Schofield', 'firstname': 'Peter R', 'initials': 'PR', 'affiliation': None}, {'lastname': 'Brooks', 'firstname': 'William S', 'initials': 'WS', 'affiliation': None}, {'lastname': 'Van Deerlin', 'firstname': 'Vivianna M', 'initials': 'VM', 'affiliation': None}, {'lastname': 'Snowden', 'firstname': 'Julie', 'initials': 'J', 'affiliation': None}, {'lastname': 'Clark', 'firstname': 'Christopher M', 'initials': 'CM', 'affiliation': None}, {'lastname': 'Kertesz', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': None}, {'lastname': 'Boylan', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': None}, {'lastname': 'Ghetti', 'firstname': 'Bernardino', 'initials': 'B', 'affiliation': None}, {'lastname': 'Neary', 'firstname': 'David', 'initials': 'D', 'affiliation': None}, {'lastname': 'Schellenberg', 'firstname': 'Gerard D', 'initials': 'GD', 'affiliation': None}, {'lastname': 'Beach', 'firstname': 'Thomas G', 'initials': 'TG', 'affiliation': None}, {'lastname': 'Mesulam', 'firstname': 'Marsel', 'initials': 'M', 'affiliation': None}, {'lastname': 'Mann', 'firstname': 'David', 'initials': 'D', 'affiliation': None}, {'lastname': 'Grafman', 'firstname': 'Jordan', 'initials': 'J', 'affiliation': None}, {'lastname': 'Mackenzie', 'firstname': 'Ian R', 'initials': 'IR', 'affiliation': None}, {'lastname': 'Feldman', 'firstname': 'Howard', 'initials': 'H', 'affiliation': None}, {'lastname': 'Bird', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': None}, {'lastname': 'Petersen', 'firstname': 'Ron', 'initials': 'R', 'affiliation': None}, {'lastname': 'Knopman', 'firstname': 'David', 'initials': 'D', 'affiliation': None}, {'lastname': 'Boeve', 'firstname': 'Bradley', 'initials': 'B', 'affiliation': None}, {'lastname': 'Geschwind', 'firstname': 'Dan H', 'initials': 'DH', 'affiliation': None}, {'lastname': 'Miller', 'firstname': 'Bruce', 'initials': 'B', 'affiliation': None}, {'lastname': 'Wszolek', 'firstname': 'Zbigniew', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Lippa', 'firstname': 'Carol', 'initials': 'C', 'affiliation': None}, {'lastname': 'Bigio', 'firstname': 'Eileen H', 'initials': 'EH', 'affiliation': None}, {'lastname': 'Dickson', 'firstname': 'Dennis', 'initials': 'D', 'affiliation': None}, {'lastname': 'Graff-Radford', 'firstname': 'Neill', 'initials': 'N', 'affiliation': None}, {'lastname': 'Hutton', 'firstname': 'Mike', 'initials': 'M', 'affiliation': None}]",,,,,10.1016/S1474-4422(07)70221-1,<Element 'PubmedArticle' at 0x7f05d87aa4f0>
376,17698705,"Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations.","Patients with frontotemporal dementia due to mutation of progranulin may have a distinct phenotype.
To identify distinct clinical and pathologic features of patients with frontotemporal dementia who have mutations of progranulin (GRN).
Retrospective clinical-pathologic study.
Academic medical center.
Twenty-eight patients with frontotemporal dementia, including 9 with GRN mutations (4 autopsy cases and 5 with only clinical information) and 19 with the identical pathologic diagnosis--frontotemporal lobar degeneration with ubiquitin-positive and tau-negative inclusions (FTLD-U)--and no GRN mutations.
Demographic, symptom, neuropsychological, and autopsy characteristics.
Patients with and without a GRN mutation have similar demographic features, although family history is significantly more common in patients with frontotemporal dementia and a GRN mutation. Both patient groups have frequent social and personality complaints. Neuropsychological evaluation reveals a significant recognition memory deficit in patients with a GRN mutation but a significant language deficit only in patients without a GRN mutation. At autopsy, the semiquantitative burden of ubiquitin abnormality is relatively modest in both groups of patients.
Patients with a GRN mutation differ clinically from those with the same pathologic diagnosis but no GRN mutation.",[],Archives of neurology,2007-08-19,"[{'lastname': 'Van Deerlin', 'firstname': 'Vivianna M', 'initials': 'VM', 'affiliation': 'Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4283, USA.'}, {'lastname': 'Wood', 'firstname': 'Elisabeth McCarty', 'initials': 'EM', 'affiliation': None}, {'lastname': 'Moore', 'firstname': 'Peachie', 'initials': 'P', 'affiliation': None}, {'lastname': 'Yuan', 'firstname': 'Wuxing', 'initials': 'W', 'affiliation': None}, {'lastname': 'Forman', 'firstname': 'Mark S', 'initials': 'MS', 'affiliation': None}, {'lastname': 'Clark', 'firstname': 'Christopher M', 'initials': 'CM', 'affiliation': None}, {'lastname': 'Neumann', 'firstname': 'Manuela', 'initials': 'M', 'affiliation': None}, {'lastname': 'Kwong', 'firstname': 'Linda K', 'initials': 'LK', 'affiliation': None}, {'lastname': 'Trojanowski', 'firstname': 'John Q', 'initials': 'JQ', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Virginia M-Y', 'initials': 'VM', 'affiliation': None}, {'lastname': 'Grossman', 'firstname': 'Murray', 'initials': 'M', 'affiliation': None}]",,Patients with a GRN mutation differ clinically from those with the same pathologic diagnosis but no GRN mutation.,"Patients with and without a GRN mutation have similar demographic features, although family history is significantly more common in patients with frontotemporal dementia and a GRN mutation. Both patient groups have frequent social and personality complaints. Neuropsychological evaluation reveals a significant recognition memory deficit in patients with a GRN mutation but a significant language deficit only in patients without a GRN mutation. At autopsy, the semiquantitative burden of ubiquitin abnormality is relatively modest in both groups of patients.",,10.1001/archneur.64.8.1148,<Element 'PubmedArticle' at 0x7f05d87c4c20>
377,"17659878
9160703
9116153
1734291
8450993
848276
654888
15939846
12796530
15748844
12391612
12724157
11238065
10373337
3323927
3953862
2233421
9008508
9736007
16943563
7777138
2795152
7838296
16266286
8810256
3324647
8477671
11520987
10932182
7782062
7113661
12895417
16282321
8780856
9238209
17182789
11182466
11274343
15212843",Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice.,"We sought to determine if sex impacts the cognitive and neuropathological phenotype of the 3xTg-AD mice. We find that male and female 3xTg-AD mice show comparable impairments on Morris water maze (MWM) and inhibitory avoidance (IA) at 4 months. Shortly thereafter, however, the cognitive performance varies among the sexes, with females performing worse than males. These behavioral differences are not attributable to differences in Abeta or tau levels. The behavioral effect is transient as from 12 months onward, the disparity is no longer apparent. Because females perform worse than males on stressful tasks, we explored their corticosterone responses and find that young female 3xTg-AD mice show markedly heightened corticosterone response after 5 days of MWM training compared to age-matched male 3xTg-AD mice; this difference is no longer apparent in older mice. Thus, the enhanced corticosterone response of the young female mice likely underlies their poorer performance on stressful tasks.",[],Neurobiology of disease,2007-07-31,"[{'lastname': 'Clinton', 'firstname': 'Lani K', 'initials': 'LK', 'affiliation': 'Department of Neurobiology and Behavior, 1109 Gillespie Neuroscience Research Facility, University of California, Irvine, Irvine, CA 92697-4545, USA.'}, {'lastname': 'Billings', 'firstname': 'Lauren M', 'initials': 'LM', 'affiliation': None}, {'lastname': 'Green', 'firstname': 'Kim N', 'initials': 'KN', 'affiliation': None}, {'lastname': 'Caccamo', 'firstname': 'Antonella', 'initials': 'A', 'affiliation': None}, {'lastname': 'Ngo', 'firstname': 'Jerry', 'initials': 'J', 'affiliation': None}, {'lastname': 'Oddo', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': None}, {'lastname': 'McGaugh', 'firstname': 'James L', 'initials': 'JL', 'affiliation': None}, {'lastname': 'LaFerla', 'firstname': 'Frank M', 'initials': 'FM', 'affiliation': None}]",,,,,10.1016/j.nbd.2007.06.013,<Element 'PubmedArticle' at 0x7f05d87d3680>
378,17596857,Comparative skeletal features between Homo floresiensis and patients with primary growth hormone insensitivity (Laron Syndrome).,"Comparison between the skeletal remains of Homo floresiensis and the auxological and roentgenological findings in a large Israeli cohort of patients with Laron Syndrome (LS, primary or classical GH insensitivity or resistance) revealed striking morphological similarities, including extremely small stature and reduced cranial volume. LS is an autosomal recessive disease caused by a molecular defect of the Growth Hormone (GH) receptor or in the post-receptor cascades. Epidemiological studies have shown that LS occurs more often in consanguineous families and isolates, and it has been described in several countries in South East Asia. It is our conclusion that the findings from the island of Flores, which were attributed to a new species of the genus Homo, may in fact represent a local, highly inbred, Homo sapiens population in whom a mutation for the GH receptor had occurred.",[],American journal of physical anthropology,2007-06-29,"[{'lastname': 'Hershkovitz', 'firstname': 'Israel', 'initials': 'I', 'affiliation': 'Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel. anatom2@post.tau.ac.il'}, {'lastname': 'Kornreich', 'firstname': 'Liora', 'initials': 'L', 'affiliation': None}, {'lastname': 'Laron', 'firstname': 'Zvi', 'initials': 'Z', 'affiliation': None}]",,,,"(c) 2007 Wiley-Liss, Inc.",10.1002/ajpa.20655,<Element 'PubmedArticle' at 0x7f05d8770590>
379,"17522386
12058088
21810890
17569065
9855500
21121521
16718704
17132964
17804958
15592144
9330978
11001602
15133834
16033782
15786453
2011243
10896690
10520939
17579875
20490813
21614463
15349867
16401843
22355793
18668533
17998443
15548495
16908994",Clinicopathologic correlation in PGRN mutations.,"Frontotemporal dementia (FTD) has been linked to the microtubule associated protein tau (MAPT) gene region of chromosome 17. However, many chromosome-17 linked FTLDs do not have MAPT mutations or tau protein deposits, but have ubiquitin positive, tau and alpha-synuclein negative inclusions. Mutations in the progranulin (PGRN) gene, located 1.7 Mb from MAPT at 17q21.31, were recently discovered in some of these individuals. The pathologic phenotype in all cases has thus far included ubiquitinated neuronal intranuclear inclusions (NIIs) and neuronal cytoplasmic inclusions (NCIs).
PGRN mutation analysis was performed in 12 individuals. Informed consent was obtained from next of kin under an IRB-approved protocol. We compared clinical and pathologic findings in those cases with and without PGRN mutations.
PGRN mutations were found in four patients, two with clinical FTD and a positive family history, and two with clinical primary progressive aphasia (PPA), one with and one without a family history. All four cases with, and five of eight cases without, PGRN mutations had ubiquitinated NCIs and NIIs. Brains of individuals with PGRN mutations are associated with more frequent frontal NCIs and dystrophic neurites, less frequent dentate gyrus NCIs, and more frequent striatal NIIs than FTLD-U cases without PGRN mutations.
PGRN mutations at 17q21 may occur in apparently sporadic frontotemporal lobar dementia with ubiquitinated inclusions cases and in cases presenting with either primary progressive aphasia or the behavioral variant of frontotemporal dementia. Some cases without PGRN mutations also have ubiquitinated neuronal intranuclear inclusions. Clinicopathologic differences are observed among individuals with and without PGRN mutations.",[],Neurology,2007-05-25,"[{'lastname': 'Davion', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.'}, {'lastname': 'Johnson', 'firstname': 'N', 'initials': 'N', 'affiliation': None}, {'lastname': 'Weintraub', 'firstname': 'S', 'initials': 'S', 'affiliation': None}, {'lastname': 'Mesulam', 'firstname': 'M-M', 'initials': 'MM', 'affiliation': None}, {'lastname': 'Engberg', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Mishra', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Baker', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Adamson', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Hutton', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Bigio', 'firstname': 'E H', 'initials': 'EH', 'affiliation': None}]",,PGRN mutations at 17q21 may occur in apparently sporadic frontotemporal lobar dementia with ubiquitinated inclusions cases and in cases presenting with either primary progressive aphasia or the behavioral variant of frontotemporal dementia. Some cases without PGRN mutations also have ubiquitinated neuronal intranuclear inclusions. Clinicopathologic differences are observed among individuals with and without PGRN mutations.,"PGRN mutations were found in four patients, two with clinical FTD and a positive family history, and two with clinical primary progressive aphasia (PPA), one with and one without a family history. All four cases with, and five of eight cases without, PGRN mutations had ubiquitinated NCIs and NIIs. Brains of individuals with PGRN mutations are associated with more frequent frontal NCIs and dystrophic neurites, less frequent dentate gyrus NCIs, and more frequent striatal NIIs than FTLD-U cases without PGRN mutations.",,10.1212/01.wnl.0000267701.58488.69,<Element 'PubmedArticle' at 0x7f05d877a540>
380,17439980,"A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology.","Mutations in the progranulin (GRN) gene have recently been reported as a cause of the frontotemporal dementia (FTD) syndrome. We performed a clinical, neuropathological and molecular genetic study of two families with FTD and the same novel mutation in GRN. Age of onset ranged from 35 to 75 years and all individuals progressed to a severe dementia syndrome with a mean disease duration of approximately 6-10 years. Variable clinical presentations included language impairment, behaviour change or parkinsonism. Seven total autopsies in the families (five in Family 1, two in Family 2) showed gross and microscopic evidence of neuronal loss in the neocortex, striatum, hippocampus and substantia nigra. All cases with material available for immunohistochemistry had cytoplasmic and intranuclear ubiquitin positive, tau negative inclusions that stained best with an antibody to the TDP43 protein. In addition, all but one had evidence of distinctive tau pathology. Two cases in Family 1 also had alpha-synuclein (SNCA) pathology, one with diffuse neocortical inclusions and neurites and unusual striatal cytoplasmic inclusions. Affected persons in both families had the same mutation in GRN (c.709-2A>G). A minigene construct showed that this mutation alters splicing of exon 7 and results in reduced mRNA message in brain. A single GRN mutation in these two families was associated with variable clinical presentations consistent with the FTD syndrome. All cases had ubiquitin/TDP43 immuno-positive inclusions and most had additional tau pathology. Two cases had SNCA pathology. These findings suggest a link between mutations in GRN and aggregation of tau, TDP43 and SNCA.",[],Brain : a journal of neurology,2007-04-19,"[{'lastname': 'Leverenz', 'firstname': 'J B', 'initials': 'JB', 'affiliation': 'Mental Illness Research, Education, and Clinical Centers, Veteran Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.'}, {'lastname': 'Yu', 'firstname': 'C E', 'initials': 'CE', 'affiliation': None}, {'lastname': 'Montine', 'firstname': 'T J', 'initials': 'TJ', 'affiliation': None}, {'lastname': 'Steinbart', 'firstname': 'E', 'initials': 'E', 'affiliation': None}, {'lastname': 'Bekris', 'firstname': 'L M', 'initials': 'LM', 'affiliation': None}, {'lastname': 'Zabetian', 'firstname': 'C', 'initials': 'C', 'affiliation': None}, {'lastname': 'Kwong', 'firstname': 'L K', 'initials': 'LK', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'V M-Y', 'initials': 'VM', 'affiliation': None}, {'lastname': 'Schellenberg', 'firstname': 'G D', 'initials': 'GD', 'affiliation': None}, {'lastname': 'Bird', 'firstname': 'T D', 'initials': 'TD', 'affiliation': None}]",,,,,10.1093/brain/awm069,<Element 'PubmedArticle' at 0x7f05d8790f90>
381,17439556,Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8.,"Certain effects of melatonin on senescence were investigated. The experimental model used was 10-month-old senescence-accelerated mouse prone 8 (SAMP8). The mice in the experiment were administered melatonin (10 mg/kg) from the age of 1 month. Results showed that chronic administration of melatonin decreased cell loss in the cerebral cortex and reduced oxidative damage in protein and lipids. There are several studies suggesting that the activation of the cdk5/p35 pathway at its cleavage to cdk5/p25 may play a role in hyperphosphorylation of tau during aging and neurodegenerative diseases. Melatonin not only reduced the cerebral aging disturbances, but also prevented tau hyperphosphorylation present in the experimental model used in this study. Melatonin reduced cdk5 expression, as well as the cleavage of p35 to p25. The other tau kinase studied, GSK3beta, showed a reduction in this activity in comparison with SAMP8 nontreated SAMP8. These data indicate that melatonin possesses neuroprotective properties against cerebral damage gated to senescence. Moreover, these data suggest that the cdk5/GSKbeta signaling cascade has a potential role as a target for neurodegenerative diseases related to aging.",[],Journal of pineal research,2007-04-19,"[{'lastname': 'Gutierrez-Cuesta', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Unitat de Farmacologia i Farmacognòsia, Facultat de Farmàcia and Institut de Biomedicina, Universitat de Barcelona, Nucli Universitari de Pedralbes, Barcelona, Spain.'}, {'lastname': 'Sureda', 'firstname': 'Francesc X', 'initials': 'FX', 'affiliation': None}, {'lastname': 'Romeu', 'firstname': 'Marta', 'initials': 'M', 'affiliation': None}, {'lastname': 'Canudas', 'firstname': 'Anna M', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Caballero', 'firstname': 'Beatriz', 'initials': 'B', 'affiliation': None}, {'lastname': 'Coto-Montes', 'firstname': 'Ana', 'initials': 'A', 'affiliation': None}, {'lastname': 'Camins', 'firstname': 'Antoni', 'initials': 'A', 'affiliation': None}, {'lastname': 'Pallàs', 'firstname': 'Mercè', 'initials': 'M', 'affiliation': None}]",,,,,10.1111/j.1600-079X.2007.00433.x,<Element 'PubmedArticle' at 0x7f05d87a0b30>
382,17436289,Progranulin null mutations in both sporadic and familial frontotemporal dementia.,"Frontotemporal dementia (FTD) is the second most frequent type of neurodegenerative dementias. Mutations in the progranulin gene (GRN, PGRN) were recently identified in FTDU-17, an FTD subtype characterized by ubiquitin-immunoreactive inclusions and linkage to chromosome 17q21. We looked for PGRN mutations in a large series of 210 FTD patients (52 familial, 158 sporadic) to accurately evaluate the frequency of PGRN mutations in both sporadic and familial FTD, and FTD with associated motoneuron disease (FTD-MND), as well as to study the clinical phenotype of patients with a PGRN mutation. We identified nine novel PGRN null mutations in 10 index patients. The relative frequency of PGRN null mutations in FTD was 4.8% (10/210) and 12.8% (5/39) in pure familial forms. Interestingly, 5/158 (3.2%) apparently sporadic FTD patients carried a PGRN mutation, suggesting the possibility of de novo mutations or incomplete penetrance. In contrast, none of the 43 patients with FTD-MND had PGRN mutations, supporting that FTDU-17 and FTD-MND are genetically distinct. The clinical phenotype of PGRN mutation carriers was particular because of the wide range in onset age and the frequent occurrence of early apraxia (50%), visual hallucinations (30%), and parkinsonism (30%) during the course of the disease. This study supports that PGRN null mutations represent a more frequent cause of FTD than MAPT mutations (4.8% vs. 2.9%) but are not responsible for FTD-MND. It also demonstrates that half of the patients with a PGRN mutation in our series had no apparent family history of dementia. Taking this into account, genetic testing should be now considered more systematically, even in patients without obvious familial history of FTD.",[],Human mutation,2007-04-17,"[{'lastname': 'Le Ber', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'INSERM, UMR679, Paris, France.'}, {'lastname': 'van der Zee', 'firstname': 'Julie', 'initials': 'J', 'affiliation': None}, {'lastname': 'Hannequin', 'firstname': 'Didier', 'initials': 'D', 'affiliation': None}, {'lastname': 'Gijselinck', 'firstname': 'Ilse', 'initials': 'I', 'affiliation': None}, {'lastname': 'Campion', 'firstname': 'Dominique', 'initials': 'D', 'affiliation': None}, {'lastname': 'Puel', 'firstname': 'Michèle', 'initials': 'M', 'affiliation': None}, {'lastname': 'Laquerrière', 'firstname': 'Annie', 'initials': 'A', 'affiliation': None}, {'lastname': 'De Pooter', 'firstname': 'Tim', 'initials': 'T', 'affiliation': None}, {'lastname': 'Camuzat', 'firstname': 'Agnès', 'initials': 'A', 'affiliation': None}, {'lastname': 'Van den Broeck', 'firstname': 'Marleen', 'initials': 'M', 'affiliation': None}, {'lastname': 'Dubois', 'firstname': 'Bruno', 'initials': 'B', 'affiliation': None}, {'lastname': 'Sellal', 'firstname': 'François', 'initials': 'F', 'affiliation': None}, {'lastname': 'Lacomblez', 'firstname': 'Lucette', 'initials': 'L', 'affiliation': None}, {'lastname': 'Vercelletto', 'firstname': 'Martine', 'initials': 'M', 'affiliation': None}, {'lastname': 'Thomas-Antérion', 'firstname': 'Catherine', 'initials': 'C', 'affiliation': None}, {'lastname': 'Michel', 'firstname': 'Bernard-François', 'initials': 'BF', 'affiliation': None}, {'lastname': 'Golfier', 'firstname': 'Véronique', 'initials': 'V', 'affiliation': None}, {'lastname': 'Didic', 'firstname': 'Mira', 'initials': 'M', 'affiliation': None}, {'lastname': 'Salachas', 'firstname': 'François', 'initials': 'F', 'affiliation': None}, {'lastname': 'Duyckaerts', 'firstname': 'Charles', 'initials': 'C', 'affiliation': None}, {'lastname': 'Cruts', 'firstname': 'Marc', 'initials': 'M', 'affiliation': None}, {'lastname': 'Verpillat', 'firstname': 'Patrice', 'initials': 'P', 'affiliation': None}, {'lastname': 'Van Broeckhoven', 'firstname': 'Christine', 'initials': 'C', 'affiliation': None}, {'lastname': 'Brice', 'firstname': 'Alexis', 'initials': 'A', 'affiliation': None}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,"(c) 2007 Wiley-Liss, Inc.",10.1002/humu.20520,<Element 'PubmedArticle' at 0x7f05d872dd60>
383,17360763,TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations.,"Frontotemporal dementia is accompanied by motor neuron disease (FTD + MND) in approximately 10% of cases. There is accumulating evidence for a clinicopathological overlap between FTD and MND based on observations of familial aggregation and neuropathological findings of ubiquitin-positive neuronal cytoplasmatic inclusions (NCI) in lower motor neurons, hippocampus and neocortex in both conditions. Several familial forms exist with different genetic loci and defects. We investigated the familial aggregation and clinical presentation of FTD + MND cases in a large cohort of 368 FTD patients in The Netherlands. Immunohistochemistry of available brain tissue of deceased patients was investigated using a panel of antibodies including ubiquitin, p62 and TAR DNA-binding protein of 43 kDa antibodies. A total of eight patients coming from six families had a family history positive for FTD + MND (mean age at onset 53.2 +/- 8.4 years). Five patients presented with behavioural changes and cognitive changes followed by motor neuron disease, whereas symptoms of motor neuron disease were the presenting features in the remaining three patients. Other affected relatives in these families showed dementia/FTD, MND or FTD + MND reflecting the clinical interfamilial variation. No mutations were identified in any of the candidate genes, including Superoxide Dismutase 1, dynactin, angiogenin, Microtubule-Associated Protein Tau, valosin-containing protein and progranulin. Available brain tissue of five patients with familial FTD + MND showed NCI in hippocampus, neocortex and spinal cord in all, and neuronal intranuclear inclusions (NII) in two brains. TDP-43 antibody showed robust staining of neuronal inclusions similar in distribution and morphology to NCI and NII. Additionally, TDP-43 antibody also stained ubiquitin-negative glial inclusions in the basal striatum of one case. In conclusion, there exists considerable clinical variation within families with FTD + MND, which may be determined by other genetic or environmental factors. NII are also found in some cases of familial FTD + MND without Progranulin mutations. The observation of glial TDP-43 positive inclusions in one brain is very interesting, although their pathophysiological significance is yet unknown.",[],Brain : a journal of neurology,2007-03-16,"[{'lastname': 'Seelaar', 'firstname': 'Harro', 'initials': 'H', 'affiliation': 'Department of Neurology, Erasmus University Medical Centre, Rotterdam, The Netherlands.'}, {'lastname': 'Schelhaas', 'firstname': 'H Jurgen', 'initials': 'HJ', 'affiliation': None}, {'lastname': 'Azmani', 'firstname': 'Asma', 'initials': 'A', 'affiliation': None}, {'lastname': 'Küsters', 'firstname': 'Benno', 'initials': 'B', 'affiliation': None}, {'lastname': 'Rosso', 'firstname': 'Sonia', 'initials': 'S', 'affiliation': None}, {'lastname': 'Majoor-Krakauer', 'firstname': 'Danielle', 'initials': 'D', 'affiliation': None}, {'lastname': 'de Rijk', 'firstname': 'Maarten C', 'initials': 'MC', 'affiliation': None}, {'lastname': 'Rizzu', 'firstname': 'Patrizia', 'initials': 'P', 'affiliation': None}, {'lastname': 'ten Brummelhuis', 'firstname': 'Ming', 'initials': 'M', 'affiliation': None}, {'lastname': 'van Doorn', 'firstname': 'Pieter A', 'initials': 'PA', 'affiliation': None}, {'lastname': 'Kamphorst', 'firstname': 'Wouter', 'initials': 'W', 'affiliation': None}, {'lastname': 'Willemsen', 'firstname': 'Rob', 'initials': 'R', 'affiliation': None}, {'lastname': 'van Swieten', 'firstname': 'John C', 'initials': 'JC', 'affiliation': None}]",,,,,10.1093/brain/awm024,<Element 'PubmedArticle' at 0x7f05d873b5e0>
384,17286753,Melatonin is more effective than taurine and 5-hydroxytryptophan against hyperglycemia-induced kidney-cortex tubules injury.,"The antioxidative effects of melatonin (Mel), 5-hydroxytryptophan (5-HTP) and taurine (TAU) on hyperglycemia-induced oxidative stress was investigated in primary cultures of kidney-cortex tubule cells grown in metabolically and hormonally defined medium. In the presence of 30 mm glucose (hyperglycemic conditions), cell viability was decreased by about 35% in comparison with that estimated in the glucose-depleted medium probably as a result of induction of apoptosis, as concluded from: (i) chromatin condensation and DNA fragmentation assays, (ii) a significant enhancement of reactive oxygen species (ROS) production, (iii) 8-hydroxydeoxyguanosine (8-OHdG) generation, (iv) an increased protein peroxidation and (v) a decline of reduced glutathione (GSH) levels leading to a disturbed glutathione redox state. The addition of 100 microm Mel to the hyperglycemic medium resulted in a twofold decrease in both 8-OHdG accumulation and protein peroxidation as well as restoration of the control intracellular ROS levels accompanied by a substantial increase in GSH/oxidized glutathione (GSSG) ratio due to a decline in GSSG content. ROS elimination was also achieved in the presence of 1 mm TAU which diminished protein and DNA injuries by about 25% and 30%, respectively. On the contrary, the action of 100 microm 5-HTP on ROS level, 8-OHdG generation, protein peroxidation and GSH/GSSG ratio was negligible. Thus, in contrast to 5-HTP and TAU, Mel might be considered as beneficial for diabetes therapy, particularly in terms of reduction of hyperglycemia-induced kidney injury.",[],Journal of pineal research,2007-02-09,"[{'lastname': 'Derlacz', 'firstname': 'Rafal A', 'initials': 'RA', 'affiliation': 'Department of Metabolic Regulation, Institute of Biochemistry, Faculty of Biology, Warsaw University, Warsaw, Poland.'}, {'lastname': 'Sliwinska', 'firstname': 'Malgorzata', 'initials': 'M', 'affiliation': None}, {'lastname': 'Piekutowska', 'firstname': 'Anna', 'initials': 'A', 'affiliation': None}, {'lastname': 'Winiarska', 'firstname': 'Katarzyna', 'initials': 'K', 'affiliation': None}, {'lastname': 'Drozak', 'firstname': 'Jakub', 'initials': 'J', 'affiliation': None}, {'lastname': 'Bryla', 'firstname': 'Jadwiga', 'initials': 'J', 'affiliation': None}]",,,,,10.1111/j.1600-079X.2006.00405.x,<Element 'PubmedArticle' at 0x7f05d8746ea0>
385,17278999,Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations.,"Frontotemporal lobar degeneration is heterogeneous; cases with tau- and synuclein-negative, ubiquitin-positive neuronal inclusions are the most common, and some have mutations in the gene for progranulin (PGRN). The purpose of this study was to determine whether there were distinctive clinical and neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with PGRN mutations. A retrospective review of medical records and semiquantitative neuropathologic analysis was performed on 18 PGRN(+) and 24 PGRN(-) cases. Clinically, PGRN(+) cases had more frequent language impairment and parkinsonism. Pathologically, PGRN(+) cases had smaller brains, more marked global atrophy, and more frontal atrophy. There was no difference in the frequency of hippocampal sclerosis. The pathology of PGRN(+) cases was relatively homogeneous, whereas PGRN(-) cases were more heterogenous. PGRN(+) cases had greater density of cortical ubiquitin-immunoreactive lesions, especially dystrophic neurites in layer II. Intranuclear inclusions were present in all PGRN(+) and 42% of PGRN(-) cases. The results suggest that frontotemporal lobar degeneration with ubiquitin-positive inclusions due to PGRN mutations has several characteristic features, including ubiquitin-immunoreactive neuritic pathology in superficial cortical layers and neuronal intranuclear inclusions. On the other hand, there is no histopathologic feature or combination of features that is pathognomonic. Neuronal intranuclear inclusions are virtually always present, but they can be detected in PGRN(-) cases.",[],Journal of neuropathology and experimental neurology,2007-02-07,"[{'lastname': 'Josephs', 'firstname': 'Keith A', 'initials': 'KA', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.'}, {'lastname': 'Ahmed', 'firstname': 'Zeshan', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Katsuse', 'firstname': 'Omi', 'initials': 'O', 'affiliation': None}, {'lastname': 'Parisi', 'firstname': 'Joseph F', 'initials': 'JF', 'affiliation': None}, {'lastname': 'Boeve', 'firstname': 'Bradley F', 'initials': 'BF', 'affiliation': None}, {'lastname': 'Knopman', 'firstname': 'David S', 'initials': 'DS', 'affiliation': None}, {'lastname': 'Petersen', 'firstname': 'Ronald C', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Davies', 'firstname': 'Peter', 'initials': 'P', 'affiliation': None}, {'lastname': 'Duara', 'firstname': 'Ranjan', 'initials': 'R', 'affiliation': None}, {'lastname': 'Graff-Radford', 'firstname': 'Neill R', 'initials': 'NR', 'affiliation': None}, {'lastname': 'Uitti', 'firstname': 'Ryan J', 'initials': 'RJ', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': None}, {'lastname': 'Adamson', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': None}, {'lastname': 'Baker', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': None}, {'lastname': 'Hutton', 'firstname': 'Michael L', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Dickson', 'firstname': 'Dennis W', 'initials': 'DW', 'affiliation': None}]",,,,,10.1097/nen.0b013e31803020cf,<Element 'PubmedArticle' at 0x7f05d874fc70>
386,17210807,Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families.,"Primary progressive aphasia (PPA) is a language-based dementia characterized by fluent or nonfluent language disorder as its principal feature.
To describe progranulin gene mutations in 2 families with PPA.
Report of affected families.
Academic research.
Two families, PPA1 and PPA3, were studied. Genomic DNA was isolated from 3 of 4 siblings in PPA1, from all 3 siblings in PPA3, and from more than 200 control subjects.
All 12 coding exons of the progranulin gene and the 5"" and 3"" untranslated regions were amplified by polymerase chain reaction and were sequenced in both directions using relevant primers.
Both affected members of PPA1 for whom DNA was available and both affected sisters of PPA3 had a progranulin gene mutation not found in the unaffected siblings or in the controls. The mutations likely cause a null allele and a reduction in the level of functional progranulin protein. Both affected members of PPA1 with autopsies had frontotemporal lobar degeneration with tau-negative ubiquinated inclusions.
To our knowledge, these are the only known families in which affected members display phenotypical homogeneity for PPA in the initial stages of the disease. In both families, the disease segregated with progranulin gene mutations. Whether progranulin dysfunction also extends to sporadic PPA and how it affects the initial anatomical specificity of neurodegeneration remain to be determined.",[],Archives of neurology,2007-01-11,"[{'lastname': 'Mesulam', 'firstname': 'Marsel', 'initials': 'M', 'affiliation': ""Cognitive Neurology and Alzheimer's Disease Center and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA. mmesulam@northwestern.edu""}, {'lastname': 'Johnson', 'firstname': 'Nancy', 'initials': 'N', 'affiliation': None}, {'lastname': 'Krefft', 'firstname': 'Thomas A', 'initials': 'TA', 'affiliation': None}, {'lastname': 'Gass', 'firstname': 'Jennifer M', 'initials': 'JM', 'affiliation': None}, {'lastname': 'Cannon', 'firstname': 'Ashley D', 'initials': 'AD', 'affiliation': None}, {'lastname': 'Adamson', 'firstname': 'Jennifer L', 'initials': 'JL', 'affiliation': None}, {'lastname': 'Bigio', 'firstname': 'Eileen H', 'initials': 'EH', 'affiliation': None}, {'lastname': 'Weintraub', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': None}, {'lastname': 'Dickson', 'firstname': 'Dennis W', 'initials': 'DW', 'affiliation': None}, {'lastname': 'Hutton', 'firstname': 'Michael L', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Graff-Radford', 'firstname': 'Neill R', 'initials': 'NR', 'affiliation': None}]",,,Both affected members of PPA1 for whom DNA was available and both affected sisters of PPA3 had a progranulin gene mutation not found in the unaffected siblings or in the controls. The mutations likely cause a null allele and a reduction in the level of functional progranulin protein. Both affected members of PPA1 with autopsies had frontotemporal lobar degeneration with tau-negative ubiquinated inclusions.,,10.1001/archneur.64.1.43,<Element 'PubmedArticle' at 0x7f05d8760e50>
387,"17194713
15134470
14769677
12075055
12398965
12551867
11861032
15321944
12778169
12810616
11489933
14531796
9020076
10436164
11440984
12584367
12860902
14615392
11401930
15191769
14988094
12473544
12451003
14613736
15345590
11839630
12702503
10648408
15046547
14983034",Circulating endothelial progenitor cells in patients with cardiac syndrome X.,"Cardiac syndrome X (CSX) encompasses the constellation of anginal chest pain in the presence of a pathological functional test and a normal coronary angiogram. Endothelial progenitor cells (EPCs) in the peripheral circulation contribute to tissue vascularisation.
To investigate the number and functional properties of circulating EPCs in patients with CSX.
17 patients with CSX and a referent population (n = 20) were matched for age, atherosclerotic risk factors and use of drugs. Numbers of EPCs were studied by FACS, and their functional properties, including their proliferative capacity, adherence to matrix and mature endothelial cells as well as their ability to support in vitro tube formation, were investigated. Levels of soluble markers that associate with peripheral mobilisation and homing were studied in the serum samples of all subjects.
Patients with CSX had significantly increased numbers of circulating EPCs as compared with the referent population (both CD34+/KDR and CD34+/CD133+). The proliferative capacity of EPCs and their ability to support in vitro tube formation were significantly impaired in patients with CSX as compared with the referent population. However, adhesiveness of EPCs from patients with CSX to fibronectin and cultured mature endothelial cells was enhanced as compared with the referent population. Serum vascular endothelial growth factor correlated with peripheral CD34+/KDR cell numbers, whereas serum concentration of erythropoietin correlated with the number of circulating CD34+/CD133+ cells
Patients with CSX have a significantly altered circulating EPC phenotype that could potentially aid in understanding the complex pathogenesis of the syndrome.",[],Heart (British Cardiac Society),2006-12-30,"[{'lastname': 'Shmilovich', 'firstname': 'Haim', 'initials': 'H', 'affiliation': 'Department of Cardiology, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel. jacobg@post.tau.ac.il'}, {'lastname': 'Deutsch', 'firstname': 'Varda', 'initials': 'V', 'affiliation': None}, {'lastname': 'Roth', 'firstname': 'Arie', 'initials': 'A', 'affiliation': None}, {'lastname': 'Miller', 'firstname': 'Hylton', 'initials': 'H', 'affiliation': None}, {'lastname': 'Keren', 'firstname': 'Gad', 'initials': 'G', 'affiliation': None}, {'lastname': 'George', 'firstname': 'Jacob', 'initials': 'J', 'affiliation': None}]",,Patients with CSX have a significantly altered circulating EPC phenotype that could potentially aid in understanding the complex pathogenesis of the syndrome.,"Patients with CSX had significantly increased numbers of circulating EPCs as compared with the referent population (both CD34+/KDR and CD34+/CD133+). The proliferative capacity of EPCs and their ability to support in vitro tube formation were significantly impaired in patients with CSX as compared with the referent population. However, adhesiveness of EPCs from patients with CSX to fibronectin and cultured mature endothelial cells was enhanced as compared with the referent population. Serum vascular endothelial growth factor correlated with peripheral CD34+/KDR cell numbers, whereas serum concentration of erythropoietin correlated with the number of circulating CD34+/CD133+ cells",,10.1136/hrt.2005.077909,<Element 'PubmedArticle' at 0x7f05d86ebf40>
388,17071926,The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene.,"The most common pathology in frontotemporal dementia (FTD) is tau-negative, ubiquitin-immunoreactive (ub-ir) neuronal inclusions (FTLD-U). Recently, we identified mutations in the progranulin (PGRN) gene as the cause of autosomal dominant FTLD-U linked to chromosome 17. Here, we describe the neuropathology in 13 patients from 6 different families, each with FTD caused by a different PGRN mutation. The most consistent feature was the presence of ub-ir lentiform neuronal intranuclear inclusions (NII) in the neocortex and striatum. In addition, the neocortex showed moderate-to-severe superficial laminar spongiosis, chronic degenerative changes, ub-ir neurites and well-defined ub-ir neuronal cytoplasmic inclusions (NCI). In the striatum, there were numerous ub-ir neurites. NCI in the hippocampus usually had a granular appearance. In contrast, familial FTLD-U cases without PGRN mutations had no NII, less severe neocortical and striatal pathology and hippocampal NCI that were more often solid. Eight cases in which genetic analysis was not available also had NII and an overall pathology similar to those with proven mutations. None of our cases of FTLD-U without NII showed the same pattern of pathology as those with mutations. These findings suggest that FTD caused by PGRN mutations has a recognizable pathology with the most characteristic feature being ub-ir NII.",[],Brain : a journal of neurology,2006-10-31,"[{'lastname': 'Mackenzie', 'firstname': 'Ian R A', 'initials': 'IR', 'affiliation': 'Department of Pathology and Laboratory Medicine, University of British Columbia and Vancouver Coastal Health Vancouver, BC, Canada. ian.mackenzie@vch.ca'}, {'lastname': 'Baker', 'firstname': 'Matt', 'initials': 'M', 'affiliation': None}, {'lastname': 'Pickering-Brown', 'firstname': 'Stuart', 'initials': 'S', 'affiliation': None}, {'lastname': 'Hsiung', 'firstname': 'Ging-Yuek R', 'initials': 'GY', 'affiliation': None}, {'lastname': 'Lindholm', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': None}, {'lastname': 'Dwosh', 'firstname': 'Emily', 'initials': 'E', 'affiliation': None}, {'lastname': 'Gass', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': None}, {'lastname': 'Cannon', 'firstname': 'Ashley', 'initials': 'A', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': None}, {'lastname': 'Hutton', 'firstname': 'Mike', 'initials': 'M', 'affiliation': None}, {'lastname': 'Feldman', 'firstname': 'Howard H', 'initials': 'HH', 'affiliation': None}]",,,,,10.1093/brain/awl271,<Element 'PubmedArticle' at 0x7f05d87047c0>
389,17003069,Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia.,"Frontotemporal lobar degeneration (FTLD) refers to a focal, non-Alzheimer form of cerebral degeneration that encompasses the distinct clinical syndromes of frontotemporal dementia (FTD), progressive non-fluent aphasia (PNFA) and semantic dementia. Some patients show tau-based pathological changes and in familial cases mutations have been identified in the microtubule-associated protein tau gene (MAPT) on chromosome 17q21. However, many cases are tau-negative, showing instead ubiquitin-immunoreactive (UBQ-ir) neuronal cytoplasmic inclusions and neurites, and in some familial cases UBQ-ir neuronal intranuclear inclusions of a lentiform appearance. Very recently, mutations have been identified in familial cases in the progranulin (PGRN) gene, also on chromosome 17q21. Clinical, pathological and molecular diversity within FTLD highlights the importance of careful examination of clinical-pathological-genetic relationships. This paper reports, for the first time, a clinico-pathological investigation of two FTLD families with PGRN mutations, and compares the clinical characteristics with those of patients studied in the department with MAPT mutations. The clinical profile associated with PGRN mutations constituted, in some patients, a prototypical picture of FTD and in others one of PNFA, both profiles occurring within the same family. Patients with PGRN mutations exhibited phonological deficits, whereas in patients with MAPT mutations language abnormalities, when present in addition to the prominent behavioural disorder, take the form of semantic disturbance. The findings provide compelling evidence for the link between FTD and PNFA, while raising the possibility of identifiable clinical differences between FTLD patients with MAPT and PGRN mutations.",[],Brain : a journal of neurology,2006-09-28,"[{'lastname': 'Snowden', 'firstname': 'J S', 'initials': 'JS', 'affiliation': 'Clinical Neuroscience Research Group, University of Manchester Salford, Manchester, UK.'}, {'lastname': 'Pickering-Brown', 'firstname': 'S M', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Mackenzie', 'firstname': 'I R', 'initials': 'IR', 'affiliation': None}, {'lastname': 'Richardson', 'firstname': 'A M T', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Varma', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Neary', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Mann', 'firstname': 'D M A', 'initials': 'DM', 'affiliation': None}]",,,,,10.1093/brain/awl267,<Element 'PubmedArticle' at 0x7f05d87109a0>
390,"16943563
10844576
10680787
15748844
9330992
10586975
16242180
3953862
14583441
8515288
15059977
10319819
8780008
3953887
11578779
15917461
16192374
15751228
15659808
15766532
10487842
2560104
10589538
1713799
10735393
7899539
12895417
15294141
11320185
2998738
10737694
11713467
15059975
8083742
9464214
12663692
8346434
11036168
11390503
15668449
8274424
14678756",Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease.,"Various environmental and genetic factors influence the onset and progression of Alzheimer's disease (AD). Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, which controls circulating levels of glucocorticoid hormones, occurs early in AD, resulting in increased cortisol levels. Disturbances of the HPA axis have been associated with memory impairments and may contribute to the cognitive decline that occurs in AD, although it is unknown whether such effects involve modulation of the amyloid beta-peptide (Abeta) and tau. Using in vitro and in vivo experiments, we report that stress-level glucocorticoid administration increases Abeta formation by increasing steady-state levels of amyloid precursor protein (APP) and beta-APP cleaving enzyme. Additionally, glucocorticoids augment tau accumulation, indicating that this hormone also accelerates the development of neurofibrillary tangles. These findings suggest that high levels of glucocorticoids, found in AD, are not merely a consequence of the disease process but rather play a central role in the development and progression of AD.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,2006-09-01,"[{'lastname': 'Green', 'firstname': 'Kim N', 'initials': 'KN', 'affiliation': 'Department of Neurobiology and Behavior, and Center for the Neurobiology of Learning and Memory, University of California, Irvine, Irvine, California 92697-4545, USA.'}, {'lastname': 'Billings', 'firstname': 'Lauren M', 'initials': 'LM', 'affiliation': None}, {'lastname': 'Roozendaal', 'firstname': 'Benno', 'initials': 'B', 'affiliation': None}, {'lastname': 'McGaugh', 'firstname': 'James L', 'initials': 'JL', 'affiliation': None}, {'lastname': 'LaFerla', 'firstname': 'Frank M', 'initials': 'FM', 'affiliation': None}]",,,,,10.1523/JNEUROSCI.2797-06.2006,<Element 'PubmedArticle' at 0x7f05d871d540>
391,16906164,A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism.,"Submicroscopic genomic copy number changes have been identified only recently as an important cause of mental retardation. We describe the detection of three interstitial, overlapping 17q21.31 microdeletions in a cohort of 1,200 mentally retarded individuals associated with a clearly recognizable clinical phenotype of mental retardation, hypotonia and a characteristic face. The deletions encompass the MAPT and CRHR1 genes and are associated with a common inversion polymorphism.",[],Nature genetics,2006-08-15,"[{'lastname': 'Koolen', 'firstname': 'David A', 'initials': 'DA', 'affiliation': 'Department of Human Genetics, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands.'}, {'lastname': 'Vissers', 'firstname': 'Lisenka E L M', 'initials': 'LE', 'affiliation': None}, {'lastname': 'Pfundt', 'firstname': 'Rolph', 'initials': 'R', 'affiliation': None}, {'lastname': 'de Leeuw', 'firstname': 'Nicole', 'initials': 'N', 'affiliation': None}, {'lastname': 'Knight', 'firstname': 'Samantha J L', 'initials': 'SJ', 'affiliation': None}, {'lastname': 'Regan', 'firstname': 'Regina', 'initials': 'R', 'affiliation': None}, {'lastname': 'Kooy', 'firstname': 'R Frank', 'initials': 'RF', 'affiliation': None}, {'lastname': 'Reyniers', 'firstname': 'Edwin', 'initials': 'E', 'affiliation': None}, {'lastname': 'Romano', 'firstname': 'Corrado', 'initials': 'C', 'affiliation': None}, {'lastname': 'Fichera', 'firstname': 'Marco', 'initials': 'M', 'affiliation': None}, {'lastname': 'Schinzel', 'firstname': 'Albert', 'initials': 'A', 'affiliation': None}, {'lastname': 'Baumer', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': None}, {'lastname': 'Anderlid', 'firstname': 'Britt-Marie', 'initials': 'BM', 'affiliation': None}, {'lastname': 'Schoumans', 'firstname': 'Jacqueline', 'initials': 'J', 'affiliation': None}, {'lastname': 'Knoers', 'firstname': 'Nine V', 'initials': 'NV', 'affiliation': None}, {'lastname': 'van Kessel', 'firstname': 'Ad Geurts', 'initials': 'AG', 'affiliation': None}, {'lastname': 'Sistermans', 'firstname': 'Erik A', 'initials': 'EA', 'affiliation': None}, {'lastname': 'Veltman', 'firstname': 'Joris A', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Brunner', 'firstname': 'Han G', 'initials': 'HG', 'affiliation': None}, {'lastname': 'de Vries', 'firstname': 'Bert B A', 'initials': 'BB', 'affiliation': None}]",,,,,10.1038/ng1853,<Element 'PubmedArticle' at 0x7f05d86b87c0>
392,16820652,"Ex vivo activated human macrophages improve healing, remodeling, and function of the infarcted heart.","Activated macrophages have a significant role in wound healing and damaged tissue repair. We sought to explore the ability of ex vivo activated macrophages to promote healing and repair of the infarcted myocardium.
Human activated macrophage suspension (AMS) was prepared from a whole blood unit obtained from young donors in a closed sterile system and was activated by a novel method of hypo-osmotic shock. The AMS (approximately 4 x 10(5) cells) included up to 43% CD14-positive cells and was injected into the ischemic myocardium of rats (n=8) immediately after coronary artery ligation. The control group (n=9) was treated with saline injection. The human cells existed in the infarcted heart 4 to 7 days after injection, as indicated by histology, human growth hormone-specific polymerase chain reaction, and magnetic resonance imaging (MRI) tracking of iron oxide-nanoparticle-labeled cells. After 5 weeks, scar vessel density (+/-SE) (25+/-4 versus 10+/-1 per mm2; P<0.05), myofibroblast accumulation, and recruitment of resident monocytes and macrophages were greater in AMS-treated hearts compared with controls. Serial echocardiography studies, before and 5 weeks after injection, showed that AMS improved scar thickening (0.15+/-0.01 versus 0.11+/-0.01 cm; P<0.05), reduced left ventricular (LV) diastolic dilatation (0.87+/-0.02 versus 0.99+/-0.04 cm; P<0.05), and improved LV fractional shortening (31+/-2 versus 20+/-4%; P<0.05), compared with controls.
Early after myocardial infarction, injection of AMS accelerates vascularization, tissue repair, and improves cardiac remodeling and function. Our work suggests a novel clinically relevant option to promote the repair of ischemic tissue.",[],Circulation,2006-07-06,"[{'lastname': 'Leor', 'firstname': 'Jonathan', 'initials': 'J', 'affiliation': 'Neufeld Cardiac Research Institute, Tel-Aviv University, Israel. Hleorj@post.tau.ac.il'}, {'lastname': 'Rozen', 'firstname': 'Liat', 'initials': 'L', 'affiliation': None}, {'lastname': 'Zuloff-Shani', 'firstname': 'Adi', 'initials': 'A', 'affiliation': None}, {'lastname': 'Feinberg', 'firstname': 'Micha S', 'initials': 'MS', 'affiliation': None}, {'lastname': 'Amsalem', 'firstname': 'Yoram', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Barbash', 'firstname': 'Israel M', 'initials': 'IM', 'affiliation': None}, {'lastname': 'Kachel', 'firstname': 'Erez', 'initials': 'E', 'affiliation': None}, {'lastname': 'Holbova', 'firstname': 'Radka', 'initials': 'R', 'affiliation': None}, {'lastname': 'Mardor', 'firstname': 'Yael', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Daniels', 'firstname': 'Dianne', 'initials': 'D', 'affiliation': None}, {'lastname': 'Ocherashvilli', 'firstname': 'Aharon', 'initials': 'A', 'affiliation': None}, {'lastname': 'Orenstein', 'firstname': 'Arie', 'initials': 'A', 'affiliation': None}, {'lastname': 'Danon', 'firstname': 'David', 'initials': 'D', 'affiliation': None}]",,,,,10.1161/CIRCULATIONAHA.105.000331,<Element 'PubmedArticle' at 0x7f05d86c98b0>
393,16623356,"Ghrelin reverses molecular, structural and hemodynamic alterations of the right ventricle in pulmonary hypertension.","Ghrelin is an endogenous peptide that has a dual effect by activating specific receptors and by stimulating release of growth hormone. There is increasing evidence that ghrelin has a potent vasodilator effect. Recently, we demonstrated that exogenous administration of ghrelin modulates its endogenous levels and attenuates the majority of alterations induced by monocrotaline (MCT). In the present study, we evaluate the effects of chronic administration of ghrelin on hemodynamic and morphometric parameters of the right ventricle, as well as on myocardial levels of SERCA2a and endothelin-1. Adult Wistar rats were injected with MCT (60 mg/kg, sc) or just the vehicle (day 0). One week later, the animals treated with MCT were randomly divided into two groups and treated with ghrelin (100 microg/kg, bid, sc) or with a similar volume of vehicle. Between days 21-25 the animals were instrumented to record right ventricular (RV) pressures and samples were collected for morphological and molecular analysis. Ghrelin treatment attenuated the effects of MCT, namely: RV myocyte fiber diameter, pulmonary vascular remodeling (evaluated by % medial wall thickness of peripheral arteries), RV peak systolic pressure, RV end-diastolic pressure, time constant tau, and SERCA2a and endothelin-1 mRNA levels. Chronic ghrelin administration attenuates MCT-induced pulmonary hypertension, vascular remodeling and RV hypertrophy. These results suggest a potential therapeutic role for the ghrelin-growth hormone axis in pulmonary hypertension.",[],Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology,2006-04-21,"[{'lastname': 'Henriques-Coelho', 'firstname': 'Tiago', 'initials': 'T', 'affiliation': 'Serviço de Fisiologia, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.'}, {'lastname': 'Roncon-Albuquerque Júnior', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': None}, {'lastname': 'Lourenço', 'firstname': 'André P', 'initials': 'AP', 'affiliation': None}, {'lastname': 'Baptista', 'firstname': 'Maria J', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Oliveira', 'firstname': 'Sílvia M', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Brandão-Nogueira', 'firstname': 'Ana', 'initials': 'A', 'affiliation': None}, {'lastname': 'Correia-Pinto', 'firstname': 'Jorge', 'initials': 'J', 'affiliation': None}, {'lastname': 'Leite-Moreira', 'firstname': 'Adelino F', 'initials': 'AF', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05d86d5c20>
394,16432141,"Inclusion-body myositis: clinical, diagnostic, and pathologic aspects.","The diagnostic aspects of sporadic inclusion-body myositis (s-IBM), and a few comments on our own approach to its treatment, are presented to foster the goals of this symposium, which was organized to provoke new ideas concerning the cause and treatment of this currently unsolvable disease. s-IBM is the most common, progressive, debilitating muscle disease beginning in persons over age 50 years, and it is more common in men. Diagnostic parameters reviewed are clinical, muscle-biopsy histochemistry, electrophysiologic and CSF evaluations. Overall, the degenerative phenomena in s-IBM muscle fibers seem to be the major cause of the progressive, unstoppable weakness, rather than the lymphocytic inflammation. Available treatments are of only slight, temporary benefit for only some s-IBM patients, indicating a desperate need for definitive therapies.",[],Neurology,2006-01-25,"[{'lastname': 'Engel', 'firstname': 'W King', 'initials': 'WK', 'affiliation': 'The Neuromuscular Center, Department of Neurology, University of Southern California Keck School of Medicine, Good Samaritan Hospital, Los Angeles, CA, USA. askanas@hsc.usc.edu'}, {'lastname': 'Askanas', 'firstname': 'Valerie', 'initials': 'V', 'affiliation': None}]",,,,,10.1212/01.wnl.0000192260.33106.bb,<Element 'PubmedArticle' at 0x7f05d86e0040>
395,16410221,Effect of systemic insulin and angiotensin II receptor subtype-1 antagonist on endothelin-1 receptor subtype(s) regulation and binding in diabetic rat heart.,"This study reports on the regulation and remodeling role of endothelin-1 (ET-1) and its receptor subtypes, ET(A)-Rs/ET(B)-Rs, at the coronary endothelium (CE) and cardiomyocyte (CM) sites. It is carried out in normal and normotensive rats with streptozotocin-induced diabetes mellitus receiving different treatment modalities. Normal rats were divided into two groups, namely a placebo (N) and a losartan-treated (NL), and diabetic rats into four groups receiving placebo (D), insulin-treated (DI), losartan-treated (DL), and insulin/losartan-treated (DIL) respectively. Binding kinetics of ET-1 to ET(A)-Rs/ET(B)-Rs on CE and CMs were assessed in the above groups to try to explain the effect of therapeutic doses of an angiotensin II receptor subtype-1 blocker on the dynamics of this ligand and its receptor in insulin supplemented diabetic animals. Each group was divided into two subgroups: CHAPS-untreated and CHAPS-treated rat hearts perfused with [125I]ET-1 to respectively estimate ET-1 binding affinity (tau = 1/k-n) to its receptor subtype(s) on CE and CMs using mathematical modeling describing a 1:1 reversible binding stoichiometry. Heart perfusion results revealed that insulin treatment significantly decreased tau on CE but not on CMs in diabetic rats. In diabetics treated with losartan, an increase in tau value on CE but not on CMs was noted. Cotreatment of diabetic rats with insulin and losartan normalized tau on CE but decreased it on CMs. Western blot, using snap-frozen heart tissues, revealed increase in ET(A)-R density in all diabetic groups. However, significant decrease in ET(B)-R density was observed in all groups compared to the normal, and was reconfirmed by immunohistochemical analysis. In conclusion, coadministration of insulin and losartan in nonhypertensive animals suffering from diabetes type 1 may offer new cardiac protection benefits by improving coronary blood flow and cardiomyocyte contractility through modulating ET-1 receptor subtypes density and affinity at CE and CM sites.",[],Endothelium : journal of endothelial cell research,2006-01-18,"[{'lastname': 'Karam', 'firstname': 'Chehade N', 'initials': 'CN', 'affiliation': 'Department of Physiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.'}, {'lastname': 'Nuwayri-Salti', 'firstname': 'Nuha', 'initials': 'N', 'affiliation': None}, {'lastname': 'Usta', 'firstname': 'Julnar A', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Zwainy', 'firstname': 'Darine S', 'initials': 'DS', 'affiliation': None}, {'lastname': 'Abrahamian', 'firstname': 'Roy E', 'initials': 'RE', 'affiliation': None}, {'lastname': 'Al Jaroudi', 'firstname': 'Wael A', 'initials': 'WA', 'affiliation': None}, {'lastname': 'Baasisri', 'firstname': 'Malek J', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Abdallah', 'firstname': 'Samer M', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Bitar', 'firstname': 'Khalil M', 'initials': 'KM', 'affiliation': None}, {'lastname': 'Bikhazi', 'firstname': 'Anwar B', 'initials': 'AB', 'affiliation': None}]",,,,,10.1080/10623320500476450,<Element 'PubmedArticle' at 0x7f05d866b7c0>
396,16340083,Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.,"Reduced glucose utilization and energy metabolism occur early in the course of Alzheimer's disease (AD) and correlate with impaired cognition. Glucose utilization and energy metabolism are regulated by insulin and insulin-like growth factor I (IGF-I), and correspondingly, studies have shown that cognitive impairment may be improved by glucose or insulin administration. Recently, we demonstrated significantly reduced levels of insulin and IGF-I polypeptide genes and their corresponding receptors in advanced AD relative to aged control brains. The abnormalities in gene expression were accompanied by impaired survival signaling downstream through PI3 kinase-Akt. The present work characterizes the abnormalities in insulin and IGF gene expression and receptor binding in brains with different Braak stage severities of AD. Realtime quantitative RT-PCR analysis of frontal lobe tissue demonstrated that increasing AD Braak Stage was associated with progressively reduced levels of mRNA corresponding to insulin, IGF-I, and IGF-II polypeptides and their receptors, tau, which is regulated by insulin and IGF-I, and the Hu D neuronal RNA binding protein. In contrast, progressively increased levels of amyloid beta protein precursor (AbetaPP), glial fibrillary acidic protein, and the IBA1/AIF1 microglial mRNA transcripts were detected with increasing AD Braak Stage. Impairments in growth factor and growth factor receptor expression and function were associated with increasing AD Braak stage dependent reductions in insulin, IGF-I, and IGF-II receptor binding, ATP levels, and choline acetyltransferase (ChAT) expression. Further studies demonstrated that: 1) ChAT expression increases with insulin or IGF-I stimulation; 2) ChAT is expressed in insulin and IGF-I receptor-positive cortical neurons; and 3) ChAT co-localization in insulin or IGF-I receptor-positive neurons is reduced in AD. Together, these data provide further evidence that AD represents a neuro-endocrine disorder that resembles a unique form of diabetes mellitus (? Type 3) and progresses with severity of neurodegeneration.",[],Journal of Alzheimer's disease : JAD,2005-12-13,"[{'lastname': 'Rivera', 'firstname': 'Enrique J', 'initials': 'EJ', 'affiliation': 'Department of Pathology, Rhode Island Hospital and Brown Medical School, Providence, RI 02903, USA.'}, {'lastname': 'Goldin', 'firstname': 'Alison', 'initials': 'A', 'affiliation': None}, {'lastname': 'Fulmer', 'firstname': 'Noah', 'initials': 'N', 'affiliation': None}, {'lastname': 'Tavares', 'firstname': 'Rose', 'initials': 'R', 'affiliation': None}, {'lastname': 'Wands', 'firstname': 'Jack R', 'initials': 'JR', 'affiliation': None}, {'lastname': 'de la Monte', 'firstname': 'Suzanne M', 'initials': 'SM', 'affiliation': None}]",,,,,10.3233/jad-2005-8304,<Element 'PubmedArticle' at 0x7f05d8677270>
397,16300990,Expression of procollagen C-proteinase enhancer-1 in the remodeling rat heart is stimulated by aldosterone.,"Excessive collagen deposition is a common complication of myocardial infarction that causes progressive heart disease. Several pro-fibrotic cytokines and hormones, including aldosterone, control this process. Procollagen processing by procollagen C-proteinase(s) is critical for collagen deposition and is potentiated by procollagen C-proteinase enhancer proteins (PCPEs). We have shown previously that, in addition to stimulation of collagen I expression, aldosterone increases PCPE-1 expression in cultured heart fibroblasts. The present study was designed to examine whether aldosterone acts similarly in vivo. Rats underwent coronary artery ligation to induce myocardial infarction. They were then left either untreated (control) or treated with spironolactone (an aldosterone receptor antagonist) for 5 weeks when they were sacrificed and their hearts removed for analysis. In situ hybridization co-localized PCPE-1 and collagen I mRNAs to fibroblasts surrounding the scar region and adjacent blood vessels. The levels of both transcripts in the remodeling myocardium of untreated rats increased twofold as compared to sham-operated controls, an increase greatly reduced by spironolactone. Correspondingly, a 2-5 fold increase in PCPE-1 and collagen I was observed in the hearts of untreated rats as compared to both the spironolactone-treated and sham-operated controls. The results establish aldosterone as a physiological stimulator of PCPE-1 expression in the remodeling myocardium after infarction. Since PCPE-1 itself is a positive regulator of collagen deposition, this finding suggests PCPE-1 as a new potential target for intervention with cardiac fibrosis.",[],The international journal of biochemistry & cell biology,2005-11-23,"[{'lastname': 'Kessler-Icekson', 'firstname': 'Gania', 'initials': 'G', 'affiliation': 'Basil and Gerald Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel-Aviv University, Petach-Tikva 49100, Israel. icekson@post.tau.ac.il'}, {'lastname': 'Schlesinger', 'firstname': 'Hadassa', 'initials': 'H', 'affiliation': None}, {'lastname': 'Freimann', 'firstname': 'Sarit', 'initials': 'S', 'affiliation': None}, {'lastname': 'Kessler', 'firstname': 'Efrat', 'initials': 'E', 'affiliation': None}]",,,,,10.1016/j.biocel.2005.10.007,<Element 'PubmedArticle' at 0x7f05d8684d60>
398,"15933887
3652064
9339116
436565
1514432
11524292
10069588
10855523
8241360
11935240
3217284
2259406
12006752
4545809
7942186
9488301
8194063
8422323
1994284
8949845
8622798",Short-term dexamethasone treatment for symptomatic slit ventricle syndrome.,"The objective was to report our positive experience of using dexamethasone to treat 13 patients with symptomatic slit ventricle syndrome (SVS).
Thirteen SVS patients who received dexamethasone during acute episodes were studied. The etiology for hydrocephalus was prematurity and intraventricular hemorrhage in 9 patients and neonatal meningitis, chorioamnionitis, Dandy-Walker variant, and congenital in 1 case each. The shunt was inserted at 1.8+/-1.0 months of age and SVS was diagnosed at 4.9+/-3.2 years of age.
All patients reported relief and shorter duration of symptoms with dexamethasone. Surgical intervention was decided upon and carried out within 11+/-8 months of SVS diagnosis in 9 out of 13 patients. The other 4 are being monitored and continue to receive dexamethasone when needed.
Dexamethasone appears to be a useful treatment in acutely increased intracranial pressure caused by SVS. It can provide temporary relief during the decision-making process of whether and when to perform surgery.",[],Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery,2005-06-04,"[{'lastname': 'Fattal-Valevski', 'firstname': 'Aviva', 'initials': 'A', 'affiliation': ""Institute for Child Development and Pediatric Neurology Unit, Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel. afatal@post.tau.ac.il""}, {'lastname': 'Beni-Adani', 'firstname': 'Liana', 'initials': 'L', 'affiliation': None}, {'lastname': 'Constantini', 'firstname': 'Shlomi', 'initials': 'S', 'affiliation': None}]",,,All patients reported relief and shorter duration of symptoms with dexamethasone. Surgical intervention was decided upon and carried out within 11+/-8 months of SVS diagnosis in 9 out of 13 patients. The other 4 are being monitored and continue to receive dexamethasone when needed.,,10.1007/s00381-004-1132-y,<Element 'PubmedArticle' at 0x7f05d8690770>
399,15897816,Spinal cord infarction following cervical transforaminal epidural injection: a case report.,"Case report.
A review of the literature about spinal cord infarction with epidural steroid injections and report of one case.
A 53-year-old man with a history of chronic cervical pain and multilevel degenerative disc disease with multiple posterior disc protrusions on cervical imaging. The patient received a left C6 tranforaminal injection for therapeutic pain relief, with fluoroscopic confirmation of left C6 nerve root sheath spread of injectable contrast. Approximately 10 to 15 minutes post-procedure, he noted weakness in his left arm and bilateral lower limbs. Initial cervical magnetic resonance imaging revealed no cord signal change, but a follow-up study 24 hours later demonstrated patchy increased T2 and short tau inversion recovery signal in the cervical cord from the odontoid to C4-C5 vertebral levels. This was consistent with a diffuse vascular infarct to the cervical cord, resulting in motor-incomplete tetraplegia.
This is one of a few reported cases of spinal cord infarction after cervical epidural injections. No direct cord trauma occurred. Previously reported risk factors of spinal infarction, such as hypotension and large injectate volumes, were noncontributory in this case.
Cervical epidural injections, despite careful localization, carry a risk of vascular infarction to the spinal cord, even in the absence of direct cord trauma. The etiology of these infarctions and identifying those patients at risk remain uncertain.",[],Spine,2005-05-18,"[{'lastname': 'Ludwig', 'firstname': 'Michael A', 'initials': 'MA', 'affiliation': 'Department of Rehabilitation Medicine, University of Washington, Seattle, Washington, USA. drlugnut@hotmail.com'}, {'lastname': 'Burns', 'firstname': 'Stephen P', 'initials': 'SP', 'affiliation': None}]",,,"This is one of a few reported cases of spinal cord infarction after cervical epidural injections. No direct cord trauma occurred. Previously reported risk factors of spinal infarction, such as hypotension and large injectate volumes, were noncontributory in this case.",,10.1097/01.brs.0000162401.47054.00,<Element 'PubmedArticle' at 0x7f05d869e130>
400,15886491,Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease--a follow-up study.,"Malnutrition and inflammation are involved in the pathogenesis of atherosclerosis and increased risk of cardiovascular diseases in end-stage renal disease. The aim of this study was to assess the relationship between concentrations of plasma adiponectin, serum C-reactive protein (CRP), carotid intima-media thickness (IMT) and duration of haemodialysis (HD) treatment in prevalent HD patients.
Plasma adiponectin and serum CRP concentrations were estimated in 80 HD patients and 22 healthy controls. Carotid IMT was measured by ultrasound technique. HD patients were followed up for 23 +/- 16 months. During this period, 24 of them died.
In HD patients, plasma adiponectin concentration was over 3 times higher than in controls (29.0 +/- 2.1 vs. 8.7 +/- 2.6 microg/ml; p < 0.001). HD patients with serum CRP concentrations > or = 5 mg/l were characterized by a lower plasma adiponectin concentration than HD patients with the CRP < 5 mg/l (23.9 +/- 3.5 vs. 33.0 +/- 3.1 microg/ml; p = 0.03). Plasma adiponectin and serum CRP concentrations were inversely related in HD (tau = -0.181; p = 0.02). No relationship between adiponectinaemia and IMT was observed. Survival (Kaplan-Meier analysis) within the lowest plasma adiponectin tertile tended (p = 0.06) to be the worse.
(1) Inflammatory processes are associated with an inadequate low plasma adiponetin concentration in HD patients, and (2) a lower plasma adiponectin concentration seems to be a new predictor of poor outcome in HD patients.",[],Nephron. Clinical practice,2005-05-12,"[{'lastname': 'Ignacy', 'firstname': 'Witold', 'initials': 'W', 'affiliation': 'Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Poland.'}, {'lastname': 'Chudek', 'firstname': 'Jerzy', 'initials': 'J', 'affiliation': None}, {'lastname': 'Adamczak', 'firstname': 'Marcin', 'initials': 'M', 'affiliation': None}, {'lastname': 'Funahashi', 'firstname': 'Tohru', 'initials': 'T', 'affiliation': None}, {'lastname': 'Matsuzawa', 'firstname': 'Yuji', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Kokot', 'firstname': 'Franciszek', 'initials': 'F', 'affiliation': None}, {'lastname': 'Wiecek', 'firstname': 'Andrzej', 'initials': 'A', 'affiliation': None}]",,,"In HD patients, plasma adiponectin concentration was over 3 times higher than in controls (29.0 +/- 2.1 vs. 8.7 +/- 2.6 microg/ml; p < 0.001). HD patients with serum CRP concentrations > or = 5 mg/l were characterized by a lower plasma adiponectin concentration than HD patients with the CRP < 5 mg/l (23.9 +/- 3.5 vs. 33.0 +/- 3.1 microg/ml; p = 0.03). Plasma adiponectin and serum CRP concentrations were inversely related in HD (tau = -0.181; p = 0.02). No relationship between adiponectinaemia and IMT was observed. Survival (Kaplan-Meier analysis) within the lowest plasma adiponectin tertile tended (p = 0.06) to be the worse.",,10.1159/000085707,<Element 'PubmedArticle' at 0x7f05d8625ef0>
401,15690064,Effect of penile size on nocturnal erections: evaluation with NPTR testing with men having micropenis.,"There has been conflicting opinions in the literature regarding sexual function in hypogonadal men with micropenis. In this study we aimed to evaluate erectile function in hypogonadal men with micropenis by nocturnal penile tumescence and rigidity testing (NPTR) and compared the results with young potent normal penile sized men. A total of 15 men (ages 17-30 y) defined having a micropenis with a stretched penile length of less than 9.3 cm were constituted the study group. Mean stretched penile length was 6.8+/-1.6 cm (range 3.6-7.8 cm). Karyotype analysis showed 46XY in all cases. Control group included 22 potent and normal penile sized men (23-29 y). All subjects completed three sessions of consecutive nights using the RigiScan Plus device. Comparison of the results of NPTR of control group with study group revealed that number and duration of erectile episodes (P < 0.001), duration of tip rigidity > 60% (P < 0.01), TAU tip and TAU base (P = 0.001), and RAU base (P = 0.01) were found to be significantly lower in men with micropenis. In conclusion, our study showed that men with micropenis are associated with decreased nocturnal erectile activity.",[],International journal of impotence research,2005-02-04,"[{'lastname': 'Yaman', 'firstname': 'O', 'initials': 'O', 'affiliation': 'Department of Urology, School of Medicine, University of Ankara, Ankara, Turkey. yaman@medicine.ankara.edu.tr'}, {'lastname': 'Soygür', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Akand', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Tokatli', 'firstname': 'Z', 'initials': 'Z', 'affiliation': None}]",,,,,10.1038/sj.ijir.3901292,<Element 'PubmedArticle' at 0x7f05d86310e0>
402,15621207,Genetic epidemiology of skeletal system aging in apparently healthy human population.,"The study of our team was driven by a clinical problem of age-dependent chronic degenerative disease of skeleton that includes osteoporosis (OP) and osteoarthritis (OA)-related phenotypes. The major aims of the study included evaluation of the putative genetic factors determining the rate and pattern of the bone and cartilage loss and identification of the specific genes involved in this process. In addition, we examined genetic effects on circulating molecular factors involved in bone and cartilage metabolism. The skeletal phenotypes were assessed from hand radiographs, in total on about 1200 individuals belonging to ethnically homogeneous nuclear and complex three-generational pedigrees of European origin. The results obtained until now can be divided into three sections: (1) genetic analysis of bone mass/size/geometry characteristics (OP) and traits related to hand OA; (2) pedigree-based investigation of circulating levels of calciotropic hormones, growth factors, cytokines, and biochemical indices of bone and cartilage remodelling; (3) linkage and linkage disequilibrium study of several candidate genes, such as estrogen receptor alpha, collagen type I alpha 1, genes related to extracellular inorganic pyrophosphate transport and OP/OA phenotypes, including biochemical variables. The study provides compelling evidence to suggest strong involvement of the genetic factors in determination of variation of the majority of the examined OP- and OA-related phenotypes.",[],Mechanisms of ageing and development,2004-12-29,"[{'lastname': 'Livshits', 'firstname': 'Gregory', 'initials': 'G', 'affiliation': 'Department of Anatomy and Anthropology, Human Population Biology Research Unit, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, 69978 Tel Aviv, Israel. gregl@post.tau.ac.il'}]",,,,,10.1016/j.mad.2004.08.020,<Element 'PubmedArticle' at 0x7f05d8638a40>
403,15617536,Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia.,"We have previously shown that melatonin reduces infarct volumes and enhances neurobehavioral and electrophysiological recoveries following transient middle cerebral artery (MCA) occlusion in rats. In the study, we examined whether melatonin would display neuroprotection against neuronal, axonal and oligodendrocyte pathology after 24 hr of reperfusion following 1 hr of MCA occlusion in mice. Melatonin (5 mg/kg) or vehicle was given intraperitoneally at the commencement of reperfusion. Neurological deficits were assessed 24 hr after ischemia. Gray matter damage was evaluated by quantitative histopathology. Axonal damage was determined with amyloid precursor protein and microtubule-associated protein tau-1 immunohistochemistry to identify postischemic disrupted axonal flow and oligodendrocyte pathology, respectively. Oxidative damage was assessed by 8-hydroxy-2'-deoxyguanosine (8-OHdG) and 4-hydroxynonenal (4-HNE) immunohistochemistry. Relative to controls, melatonin-treated animals not only had a significantly reduced volume of gray matter infarction by 42% (P<0.001), but also exhibited a decreased score of axonal damage by 42% (P<0.001) and a reduction in the volume of oligodendrocyte pathology by 58% (P<0.005). Melatonin-treated animals also had significantly reduced immunopositive reactions for 8-OHdG and 4-HNE by 53% (P<0.001) and 49% (P<0.001), respectively. In addition, melatonin improved sensory and motor neurobehavioral outcomes by 47 and 30%, respectively (P<0.01). Thus, delayed (1 hr) treatment with melatonin reduced both gray and white matter damage and improved neurobehavioral outcomes following transient focal cerebral ischemia in mice. The finding of reduced oxidative damage observed with melatonin suggests that its major mechanisms of action are mediated through its antioxidant and radical scavenging activity.",[],Journal of pineal research,2004-12-25,"[{'lastname': 'Lee', 'firstname': 'E-Jian', 'initials': 'EJ', 'affiliation': 'Neurophysiology Laboratory, Neurosurgical Service, Department of Surgery and Institute of Biomedical Engineering, National Cheng Kung University Medical Center and Medical School, Tainan, Taiwan. eijan@mail.ncku.edu.tw'}, {'lastname': 'Lee', 'firstname': 'Ming-Yang', 'initials': 'MY', 'affiliation': None}, {'lastname': 'Chen', 'firstname': 'Hung-Yi', 'initials': 'HY', 'affiliation': None}, {'lastname': 'Hsu', 'firstname': 'Yun-Shang', 'initials': 'YS', 'affiliation': None}, {'lastname': 'Wu', 'firstname': 'Tian-Shung', 'initials': 'TS', 'affiliation': None}, {'lastname': 'Chen', 'firstname': 'Shur-Tzu', 'initials': 'ST', 'affiliation': None}, {'lastname': 'Chang', 'firstname': 'Guan-Liang', 'initials': 'GL', 'affiliation': None}]",,,,,10.1111/j.1600-079X.2004.00173.x,<Element 'PubmedArticle' at 0x7f05d8641f40>
404,15364859,Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair.,"Left ventricular aneurysm repair (LVR) reduces LV wall stress and improves LV function. However, as we reported previously, the initial improvement of LVR was short-term because of LV remodeling but could be maintained longer with postoperative use of an angiotensin-converting enzyme (ACE) inhibitor. Atrial natriuretic peptide (ANP) has been used to treat patients with heart failure by natriuretic and vasodilatory actions. Recent reports have suggested that ANP inhibits the rennin-angiotensin system. In this study, the effects of ANP after LVR were evaluated.
Rats that had an LV aneurysm 4 weeks after left anterior descending artery ligation underwent LVR by plicating the LV aneurysm and were randomized into 2 groups: LVR+A group was intravenously administrated with 10 microg/h of carperitide, recombinant alpha-hANP, by osmotic-pump for 4 weeks, and the LVR group was given normal saline. Echocardiography revealed better LV remodeling and function in LVR+A group than in LVR group. Four weeks after LVR, left ventricular end diastolic pressure (LVEDP) and Tau were significantly lower in LVR+A group (LVEDP: 10+/-4 in LVR+A group versus 18+/-6 mm Hg in LVR group, Tau: 13+/-2 versus 17+/-2ms). End-systolic elastance (Ees) was higher in LVR+A group (Ees: 0.34+/-0.2 versus 0.19+/-0.11 mm Hg/microL). The levels of myocardial ACE activity in LVR+A group was significantly lower than in LVR group. The mRNA expressions of brain natriuretic peptide and transforming growth factor beta1 inducing fibrosis significantly decreased in LV myocardium in LVR+A group. Histologically, myocardial fibrosis was significantly reduced in LVR+A group.
Intravenous administration of ANP had beneficial effects on LV remodeling, function, and fibrosis after LVR. ANP could be a useful intravenous infusion drug for postoperative management after LV repair surgery.",[],Circulation,2004-09-15,"[{'lastname': 'Tsuneyoshi', 'firstname': 'Hiroshi', 'initials': 'H', 'affiliation': 'Department of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Japan.'}, {'lastname': 'Nishina', 'firstname': 'Takeshi', 'initials': 'T', 'affiliation': None}, {'lastname': 'Nomoto', 'firstname': 'Takuya', 'initials': 'T', 'affiliation': None}, {'lastname': 'Kanemitsu', 'firstname': 'Hideo', 'initials': 'H', 'affiliation': None}, {'lastname': 'Kawakami', 'firstname': 'Rika', 'initials': 'R', 'affiliation': None}, {'lastname': 'Unimonh', 'firstname': 'Oriyanhan', 'initials': 'O', 'affiliation': None}, {'lastname': 'Nishimura', 'firstname': 'Kazunobu', 'initials': 'K', 'affiliation': None}, {'lastname': 'Komeda', 'firstname': 'Masashi', 'initials': 'M', 'affiliation': None}]",,,,,10.1161/01.CIR.0000138348.77856.ef,<Element 'PubmedArticle' at 0x7f05d864aae0>
405,"15237093
12034159
12093776
10426864
11922896
14684366
11454907
12015474
9776734
11964375
11356638
10423353
2172579
10532945
11293648
11741364
12390293
11259552
1845855
11008069
11158973
9764718
11901052
12456484
7736498
3757183
7962119
11726425
10869261
9716715
11357013
9428974
9506703
8831494
10933369
9622160",Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction.,"The aim of this study was to assess the effects of the Na+-H+ exchange inhibitor cariporide on left ventricular (LV) morphology and function as well as inflammation in rabbits with heart failure. Rabbits with myocardial infarction (MI) and sham controls were randomized to receive either standard chow or chow supplemented with cariporide for 9 weeks. LV morphology was determined by echocardiography. LV systolic and diastolic function was assessed under load-dependent and -independent conditions by analysis of LV pressure-volume loops using piezo-electric crystals. Plasma concentrations of C-reactive protein and aldosterone were measured. Rabbits with MI developed LV dilatation that was reduced by cariporide. Systolic and diastolic LV function was impaired in rabbits with MI when compared to sham, as indicated by a decreased dP/dtmax (MI: 3537 +/- 718 mmHg s(-1), sham: 5839 +/- 247 mmHg s(-1), P < 0.05), the load-independent preload recruitable stroke work (PRSW)(MI: 22 +/-7 mmHg, sham: 81 +/- 23 mmHg, P < 0.05) and a reduction in the time constant of relaxation tau (tau) (MI: 27+/-1 ms, sham: 17+/-1 ms, P < 0.05), and significantly improved by cariporide (dP/dtmax: 4586 +/- 374 mmHg s(-1), PRSW: 67 +/- 18 mmHg, tau: 20 +/- 2 ms; P < 0.05 vs MI/control). Induction of MI was associated with an increase in aldosterone and CRP, indicating activation of the neurohormonal and the inflammatory system that were largely reduced by cariporide. Cariporide improves LV morphology and function post MI and suppresses inflammation and neurohormonal activation in congestive heart failure (CHF). Na+-H+ exchange inhibition may represent a new pharmaceutical approach for the treatment of CHF.",[],British journal of pharmacology,2004-07-09,"[{'lastname': 'Rungwerth', 'firstname': 'Katrin', 'initials': 'K', 'affiliation': 'Aventis Pharma Deutschland GmbH, 65926 Frankfurt, Germany.'}, {'lastname': 'Schindler', 'firstname': 'Ursula', 'initials': 'U', 'affiliation': None}, {'lastname': 'Gerl', 'firstname': 'Martin', 'initials': 'M', 'affiliation': None}, {'lastname': 'Schäfer', 'firstname': 'Stefan', 'initials': 'S', 'affiliation': None}, {'lastname': 'Licher', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': None}, {'lastname': 'Busch', 'firstname': 'Andreas E', 'initials': 'AE', 'affiliation': None}, {'lastname': 'Ruetten', 'firstname': 'Hartmut', 'initials': 'H', 'affiliation': None}]",,,,Copyright 2004 Nature Publishing Group,10.1038/sj.bjp.0705746,<Element 'PubmedArticle' at 0x7f05d865b7c0>
406,15047089,Liminality as biographical disruption: unclassifiability following hormonal therapy for advanced prostate cancer.,"The hormonal treatment of advanced prostate cancer involves life disruptive side-effects, such as impotence, libido loss and bodily feminisation. Conflicting views on the weight of the disruption they cause as against the therapy's survival benefits currently underlie debates over its appropriate mode of administration and its optimal timing in cases that do not necessitate immediate intervention. On the basis of a study of the disruptions caused to various life domains of 15 Israeli patients receiving such treatment, the present paper illustrates an integrated approach to their analysis that sheds new light on their intensity. The study was conducted by means of in-depth interviews and its data were processed according to the constant comparative analysis method. Its findings indicate that the therapy allowed the patients to regain their strength, to retain their need of love, basic masculine self-identification and spousal ties, and to renew their past social contacts. On the other hand they could no longer define themselves as healthy, sexually competent and 'male' in all respects, and their pre-treatment relationships with partners and friends lost the sense of closeness. Further psychosocial costs that were detected include patients' deprivation of their sense of continuity, excitements, hopes and coping capabilities. An integrated analysis of the concurrent normalisation and deviantisation processes undergone by them yielded the conclusion that the therapy subjects them to a liminal state, that is, the inability to classify themselves into culturally available categories. The difficulties entailed in this state highlight the need to take them into consideration when patients' condition allows a choice between alternative forms of hormonal therapy and between its early or deferred commencement. The interpretation of the disruption to their lives in terms of liminality also clarifies former studies' confusing reference to this subject and points to issues that still await investigation.",[],Social science & medicine (1982),2004-03-30,"[{'lastname': 'Navon', 'firstname': 'Liora', 'initials': 'L', 'affiliation': 'Department of Nursing, School of Health Professions, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel. navonl@post.tau.ac.il'}, {'lastname': 'Morag', 'firstname': 'Amira', 'initials': 'A', 'affiliation': None}]",,,,,10.1016/j.socscimed.2003.08.029,<Element 'PubmedArticle' at 0x7f05d85f1a90>
407,15006696,"Protection against inflammatory neurodegeneration and glial cell death by 7beta-hydroxy epiandrosterone, a novel neurosteroid.","It has been demonstrated that neuroprotective effects of dehydroepiandrosterone (DHEA) may be mediated by its 7alpha- and 7beta-hydroxy derivatives. Epiandrosterone is also converted to 7beta-hydroxy epiandrosterone (7beta-OH EPIA) in numerous tissues. The aim of the present study was to establish whether treatment with 7beta-hydroxy epiandrosterone has a neuroprotective effect in animal models of Alzheimer's disease (AD) lesions. Intra-amygdaloid administration of amyloid beta [Abeta(25-35)] increased the number of tau-positive cells in the ipsilateral hippocampus. Intracerebroventricular administration of ethylcholine aziridinium (AF64A) caused cholinergic damage in the septum, and glial lesions in the lateral septal nucleus and in the lateral zones of the hippocampus. These effects were almost completely prevented when animals were treated subcutaneously (b.i.d.) for 10 days with 0.1 mg/kg 7beta-hydroxy epiandrosterone. These findings indicate that 7beta-hydroxy epiandrosterone has powerful cytoprotective effects suggesting that (a) this neurosteroid may have therapeutic potential in various neurodegenerative conditions such as Alzheimer's disease, and (b) 7beta-hydroxy steroids may constitute a novel class of endogenous neuroprotective agents.",[],Neurobiology of disease,2004-03-10,"[{'lastname': 'Dudas', 'firstname': 'Bertalan', 'initials': 'B', 'affiliation': 'Lake Erie College of Osteopathic Medicine, Maywood, IL 16509, USA. bdudas@lecom.edu'}, {'lastname': 'Hanin', 'firstname': 'Israel', 'initials': 'I', 'affiliation': None}, {'lastname': 'Rose', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Wülfert', 'firstname': 'Ernst', 'initials': 'E', 'affiliation': None}]",,,,,10.1016/j.nbd.2003.11.001,<Element 'PubmedArticle' at 0x7f05d85fa4f0>
408,14973531,Cavernosometry: a theoretical analysis.,"Erectile dysfunction may be caused by hormonal, neural, arterial, or venous factors. Cavernosometry is used to test for venous leaks. The outcome of surgical procedures attempting to block off veins that allow blood to leak from the penile tissues is still poor. This procedure commonly follows a diagnostic procedure based on cavernosometry after good arterial inflow has been established. To study the cavernosometry test, a mathematical model of penile hemodynamics was used to analyze the significance of its indications and its sensitivity to both arterial and venous factors. The model elucidates the mechanism of cavernosometry and shows that indeed this test is sensitive to venous factors and insensitive to arterial factors. The model also supports the use of supra-arterial pressure during cavernosometry, and the use of the slope of the flow-to-maintain vs maintained-pressure curve as an indicator of venous leak severity.",[],International journal of impotence research,2004-02-20,"[{'lastname': 'Barnea', 'firstname': 'O', 'initials': 'O', 'affiliation': 'Department of Biomedical Engineering, Tel Aviv University, Ramat Aviv 69978, Israel. barneo@eng.tau.ac.il'}, {'lastname': 'Gillon', 'firstname': 'G', 'initials': 'G', 'affiliation': None}]",,,,,10.1038/sj.ijir.3901182,<Element 'PubmedArticle' at 0x7f05d860c630>
409,14709156,Transgenic overexpression of insulin-like growth factor I prevents streptozotocin-induced cardiac contractile dysfunction and beta-adrenergic response in ventricular myocytes.,"Diabetic cardiomyopathy is characterized by cardiac dysfunction and altered level/function of insulin-like growth factor I (IGF-I). Both endogenous and exogenous IGF-I have been shown to effectively alleviate diabetes-induced cardiac dysfunction and oxidative stress. This study was designed to examine the effect of cardiac overexpression of IGF-I on streptozotocin (STZ)-induced cardiac contractile dysfunction in mouse myocytes. Both IGF-I heterozygous transgenic mice and their wild-type FVB littermates were made diabetic with a single injection of STZ (200 mg/kg, i.p.) and maintained for 2 weeks. The following mechanical indices were evaluated in ventricular myocytes: peak shortening (PS), time-to-PS (TPS), time-to-90% relengthening (TR90) and maximal velocity of shortening/relengthening (+/- dL/dt). Intracellular Ca2+ was evaluated as resting and peak intracellular Ca2+ levels, Ca2+-induced Ca2+ release and intracellular Ca2+ decay rate (tau). STZ led to hyperglycemia in FVB and IGF-I mice. STZ treatment prolonged TPS and TR90, reduced Ca2+-induced Ca2+ release, increased resting intracellular Ca2+ levels and slowed tau associated with normal PS and +/- dL/dt. All of which, except the elevated resting intracellular Ca2+, were prevented by the IGF-I transgene. In addition, myocytes from STZ-treated FVB mice displayed an attenuated contractile response to the beta-adrenergic agonist isoproterenol, which was restored by the IGF-I transgene. Contractile response to the alpha-adrenergic agonist phenylephrine and angiotensin II was not affected by either STZ treatment or IGF-I. These results validate the beneficial role of IGF-I in diabetic cardiomyopathy, possibly due to an improved beta-adrenergic response.",[],The Journal of endocrinology,2004-01-08,"[{'lastname': 'Norby', 'firstname': 'F L', 'initials': 'FL', 'affiliation': 'Division of Pharmaceutical Sciences, University of Wyoming College of Health Sciences, Laramie, Wyoming 82071, USA.'}, {'lastname': 'Aberle', 'firstname': 'N S', 'initials': 'NS', 'affiliation': None}, {'lastname': 'Kajstura', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Anversa', 'firstname': 'P', 'initials': 'P', 'affiliation': None}, {'lastname': 'Ren', 'firstname': 'J', 'initials': 'J', 'affiliation': None}]",,,,,10.1677/joe.0.1800175,<Element 'PubmedArticle' at 0x7f05d8611630>
410,14611864,Steroid hormones and neurosteroids in normal and pathological aging of the nervous system.,"Without medical progress, dementing diseases such as Alzheimer's disease will become one of the main causes of disability. Preventing or delaying them has thus become a real challenge for biomedical research. Steroids offer interesting therapeutical opportunities for promoting successful aging because of their pleiotropic effects in the nervous system: they regulate main neurotransmitter systems, promote the viability of neurons, play an important role in myelination and influence cognitive processes, in particular learning and memory. Preclinical research has provided evidence that the normally aging nervous system maintains some capacity for regeneration and that age-dependent changes in the nervous system and cognitive dysfunctions can be reversed to some extent by the administration of steroids. The aging nervous system also remains sensitive to the neuroprotective effects of steroids. In contrast to the large number of studies documenting beneficial effects of steroids on the nervous system in young and aged animals, the results from hormone replacement studies in the elderly are so far not conclusive. There is also little information concerning changes of steroid levels in the aging human brain. As steroids present in nervous tissues originate from the endocrine glands (steroid hormones) and from local synthesis (neurosteroids), changes in blood levels of steroids with age do not necessarily reflect changes in their brain levels. There is indeed strong evidence that neurosteroids are also synthesized in human brain and peripheral nerves. The development of a very sensitive and precise method for the analysis of steroids by gas chromatography/mass spectrometry (GC/MS) offers new possibilities for the study of neurosteroids. The concentrations of a range of neurosteroids have recently been measured in various brain regions of aged Alzheimer's disease patients and aged non-demented controls by GC/MS, providing reference values. In Alzheimer's patients, there was a general trend toward lower levels of neurosteroids in different brain regions, and neurosteroid levels were negatively correlated with two biochemical markers of Alzheimer's disease, the phosphorylated tau protein and the beta-amyloid peptides. The metabolism of dehydroepiandrosterone has also been analyzed for the first time in the aging brain from Alzheimer patients and non-demented controls. The conversion of dehydroepiandrosterone to Delta5-androstene-3beta,17beta-diol and to 7alpha-OH-dehydroepiandrosterone occurred in frontal cortex, hippocampus, amygdala, cerebellum and striatum of both Alzheimer's patients and controls. The formation of these metabolites within distinct brain regions negatively correlated with the density of beta-amyloid deposits.",[],Progress in neurobiology,2003-11-13,"[{'lastname': 'Schumacher', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Inserm U488, 80 rue du Général Leclerc, Kremlin-Bicêtre 94276, France. schuma@kb.inserm.fr'}, {'lastname': 'Weill-Engerer', 'firstname': 'S', 'initials': 'S', 'affiliation': None}, {'lastname': 'Liere', 'firstname': 'P', 'initials': 'P', 'affiliation': None}, {'lastname': 'Robert', 'firstname': 'F', 'initials': 'F', 'affiliation': None}, {'lastname': 'Franklin', 'firstname': 'R J M', 'initials': 'RJ', 'affiliation': None}, {'lastname': 'Garcia-Segura', 'firstname': 'L M', 'initials': 'LM', 'affiliation': None}, {'lastname': 'Lambert', 'firstname': 'J J', 'initials': 'JJ', 'affiliation': None}, {'lastname': 'Mayo', 'firstname': 'W', 'initials': 'W', 'affiliation': None}, {'lastname': 'Melcangi', 'firstname': 'R C', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Parducz', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Suter', 'firstname': 'U', 'initials': 'U', 'affiliation': None}, {'lastname': 'Carelli', 'firstname': 'C', 'initials': 'C', 'affiliation': None}, {'lastname': 'Baulieu', 'firstname': 'E E', 'initials': 'EE', 'affiliation': None}, {'lastname': 'Akwa', 'firstname': 'Y', 'initials': 'Y', 'affiliation': None}]",,,,,10.1016/j.pneurobio.2003.09.004,<Element 'PubmedArticle' at 0x7f05d861c630>
411,12849558,Advanced prostate cancer patients' relationships with their spouses following hormonal therapy.,"The paper analyses the adverse impact of the hormonal therapy's side-effects on advanced prostate cancer patients' capacity for maintaining their pre-treatment spousal relationships, the pros and cons of their ways of coping with the difficulties involved, and the implications of these issues for oncology nursing interventions. In-depth interviews were conducted with 15 Israeli prostate cancer patients, and the data were processed according to the constant comparative analysis method. The findings show that partners' supportive attitude and patients' attempts to stage resilience led to pre-treatment relationships' maintenance, and that, accordingly, patients' rejection by their partners and resignation to this difficulty resulted in spousal ties' disruption. However, whereas the relationships' maintenance came at the cost of burdensome constant pretence, their disruption was eventually reconstructed by the patients in positive terms. These findings are analysed against the backdrop of the constraints imposed by the hormonal therapy on patients' general coping competence and ability to enjoy non-sexual activities, which impair their capability to solve their marital problems more effectively. They would thus benefit from training oncology nurses who specialize in the unique difficulties facing them and their partners, and from oncology nursing interventions that focus on relevant information provision and counselling.",[],European journal of oncology nursing : the official journal of European Oncology Nursing Society,2003-07-10,"[{'lastname': 'Navon', 'firstname': 'Liora', 'initials': 'L', 'affiliation': 'Department of Nursing, School of Health Professions, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel. navonl@post.tau.ac.il'}, {'lastname': 'Morag', 'firstname': 'Amira', 'initials': 'A', 'affiliation': None}]",,,,,10.1016/s1462-3889(03)00022-x,<Element 'PubmedArticle' at 0x7f05d85a5950>
412,"12764652
7083674
7280236
2925861
438272
9810525
6804147
8372358
7501883
8446753
9651782
9331023
10993540
6484606",MR evaluation of bone cysts treated with intracavital steroid injection.,"The objective of this study was to evaluate the role of MR examination in showing the effects of intralesional steroid injection on bone cysts. Nineteen patients with radiologically suspected (group A, n=15) or already treated (group B, n=4) bone cysts underwent MRI (0.5 T; protocol: T2* gradient recalled echo; short tau inversion recovery or inversion recovery fast spin echo; T1 SE before and after contrast administration, 0.2 mmol/kg). All patients underwent steroid therapy for bone cysts and were followed up for 6-18 months after treatment. Evaluation of bone cyst response to therapy was based mainly on the detection of reparative tissue outlining all cystic portions at first MRI control. In group A, as early as 1 month after the first injection, the presence of a thin reparative tissue lining the cystic wall was observed. Follow-up studies revealed the progressive thickening of this reparative tissue and new bone formation. Similar features were present in the cysts of group B. Residual cystic cavities were depicted in 7 cases, with no evidence of enhancing tissue, requiring further treatment. The formation of a reparative tissue is the first feature of bone cyst recovery after intracavital steroid injection and is appreciable only on MRI. Because of the optimal visualisation of this reparative tissue and of residual cystic cavities, MRI could be proposed as a non-invasive, alternative and effective tool for evaluating the efficacy of steroid injection therapy of bone cysts.",[],European radiology,2003-05-24,"[{'lastname': 'Zampa', 'firstname': 'Virna', 'initials': 'V', 'affiliation': 'Department of Oncology, Transplants and Advanced Technologies in Medicine, Division of Diagnostic and Interventional Radiology, University of Pisa, Via Roma 67, 56126, Pisa, Italy. virna.zampa@hotmail.com'}, {'lastname': 'Bargellini', 'firstname': 'Irene', 'initials': 'I', 'affiliation': None}, {'lastname': 'Michelassi', 'firstname': 'Maria Chiara', 'initials': 'MC', 'affiliation': None}, {'lastname': 'Trippi', 'firstname': 'Donatella', 'initials': 'D', 'affiliation': None}, {'lastname': 'Ortori', 'firstname': 'Simona', 'initials': 'S', 'affiliation': None}, {'lastname': 'Cosottini', 'firstname': 'Mirco', 'initials': 'M', 'affiliation': None}, {'lastname': 'Bartolozzi', 'firstname': 'Carlo', 'initials': 'C', 'affiliation': None}]",,,,,10.1007/s00330-002-1780-9,<Element 'PubmedArticle' at 0x7f05d85ad4f0>
413,12733825,Endothelium and myocyte cellular insulin receptor alterations in a rat model of myocardial infarction.,"Ischemic heart disease is considered to be one of the leading causes of death in adults. While extensive research on mechanisms contributing to the pathogenesis of myocardial infarction (MI) has been underway, it is not known whether insulin receptor characteristics and postreceptor signaling have been fully addressed as yet. Present work attempts to investigate whether the remodeling process effectively induces alteration(s) in insulin-binding characteristics at the coronary endothelium and cardiomyocytes using a rat heart model of MI. MI was induced by ligation of the left anterior descending coronary artery of adult male Sprague-Dawley rats. Two animal groups were used in the study: (i) sham-operated CHAPS-untreated and CHAPS-treated, and (ii) MI CHAPS-untreated and MI CHAPS-treated. A physical model describing 1:1 stoichiometry of reversible insulin binding to its receptors present on the endothelium and at cardiomyocytes after CHAPS treatment was considered for data analysis. Quantitation of the collected effluents after heart perfusion, the inlet at the aortic and outlet at the coronary sinus sites, were curve fitted using a first-order Bessel function, which determines the binding constants (k(n)), the reversible constant (k(-n)), the dissociation constant (k(d) = k(-n)/k(n)), and the residency time constant (tau = 1/k(-n)). In addition, hearts were excised, separated into right and left ventricles, and individually weighed, and areas of infarcted regions were measured. Results of the MI group showed significant increases in relative heart mass, left ventricle mass, and right ventricle mass normalized to total body mass. MI induced severe ischemia and irreversible myocardial injury as assessed by planimetry and histologic studies. The data showed differences in insulin receptor affinities at the endothelial and cardiac myocytes in the sham and in the MI-operated rats. The observed reduction in the binding affinity of insulin at the myocyte postinfarction may explain the pathogenic role of insulin in ischemic heart disease and, hence, resistance. Therefore, insulin administration during and post MI might be cardioprotective.",[],Canadian journal of physiology and pharmacology,2003-05-08,"[{'lastname': 'Jaroudi', 'firstname': 'Wael A', 'initials': 'WA', 'affiliation': 'Department of Physiology, Faculty of Medicine, P.O. Box 11-0236, American University of Beirut, Beirut, Lebanon.'}, {'lastname': 'Jurjus', 'firstname': 'Abdo R', 'initials': 'AR', 'affiliation': None}, {'lastname': 'El-Sabban', 'firstname': 'Marwan E', 'initials': 'ME', 'affiliation': None}, {'lastname': 'Kamal', 'firstname': 'Maud T', 'initials': 'MT', 'affiliation': None}, {'lastname': 'Bitar', 'firstname': 'Khalil M', 'initials': 'KM', 'affiliation': None}, {'lastname': 'Bikhazi', 'firstname': 'Anwar B', 'initials': 'AB', 'affiliation': None}]",,,,,10.1139/y02-157,<Element 'PubmedArticle' at 0x7f05d85b98b0>
414,"12514133
10454556
11057896
10567563
10816416
11042449
18406259
8791419
11641276
11389443
7522959
10998351
9446575
10866661
10847590
9865729
11389051
9438836
10816582
9368054
10482183
7706276
11438457
8816443
8521507
11238375
7711077
10654935
11847121
10441506
7851406
10934038
11150592
11130180
11073973
9482732
2169353
10640683
9626133
9751706
9637778
8880876
9020116
8670870
10848581
8360187",A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer.,"In addition to the classical activation by ligands, nuclear receptor activity is also regulated by ligand-independent signalling. Here, we unravel a novel signal transduction pathway that links the RhoA effector protein kinase C-related kinase PRK1 to the transcriptional activation of the androgen receptor (AR). Stimulation of the PRK signalling cascade results in a ligand-dependent superactivation of AR. We show that AR and PRK1 interact both in vivo and in vitro. The transactivation unit 5 (TAU-5) located in the N-terminus of AR suffices for activation by PRK1. Thus, TAU-5 defines a novel, signal-inducible transactivation domain. Furthermore, PRK1 promotes a functional complex of AR with the co-activator TIF-2. Importantly, PRK signalling also stimulates AR activity in the presence of adrenal androgens, which are still present in prostate tumour patients subjected to testicular androgen ablation therapy. Moreover, PRK1 activates AR even in the presence of the AR antagonist cyproterone acetate that is used in the clinical management of prostate cancer. Since prostate tumours strongly overexpress PRK1, our data support a model in which AR activity is controlled by PRK signalling.",[],The EMBO journal,2003-01-07,"[{'lastname': 'Metzger', 'firstname': 'Eric', 'initials': 'E', 'affiliation': 'Universitäts-Frauenklinik und Zentrum für Klinische Forschung, Klinikum der Universität Freiburg, Breisacherstrasse 66, D-79106 Freiburg, Germany.'}, {'lastname': 'Müller', 'firstname': 'Judith M', 'initials': 'JM', 'affiliation': None}, {'lastname': 'Ferrari', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': None}, {'lastname': 'Buettner', 'firstname': 'Reinhard', 'initials': 'R', 'affiliation': None}, {'lastname': 'Schüle', 'firstname': 'Roland', 'initials': 'R', 'affiliation': None}]",,,,,10.1093/emboj/cdg023,<Element 'PubmedArticle' at 0x7f05d85c2950>
415,12470793,"""Emerging Alzheimer's disease therapies: focusing on the future"".","The Center for Neurodegenerative Disease Research (CNDR) organized a 1 day symposium entitled ""Emerging Alzheimer's disease Therapies: Focusing On The Future"" on November 7th, 2001 at the University of Pennsylvania in Philadelphia, PA. The agenda (Fig. 1) focused on novel therapies for Alzheimer's disease (AD) designed to prevent/eliminate Abeta deposits in the brains of AD patients. While fibrillar Abeta deposits known as senile plaques (SPs) and intraneuronal tau fibrils known as neurofibrillary tangles (NFTs) are diagnostic of AD, >50% of patients with familial or sporadic AD as well as elderly Down's syndrome patients with AD harbor a third type of brain amyloid known as Lewy bodies formed by intraneuronal alpha-synuclein fibrils. Thus, AD is a ""triple brain amyloidosis"" since three different proteins (tau, alpha-synuclein) or peptide fragments (Abeta) of a larger Abeta precursor protein (APP) fibrillize and aggregate into pathological deposits of amyloid within (NFTs, LBs) and outside (SPs) neurons in AD brains. The symposium is summarized here followed by reviews from symposium speakers who describe potential anti-Abeta therapies some of which are in clinical trials.",[],Neurobiology of aging,2002-12-10,"[{'lastname': 'Trojanowski', 'firstname': 'John Q', 'initials': 'JQ', 'affiliation': 'Department of Pathology and Laboratory Medicine, The Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA. trojanow@mail.med.upenn.edu'}]",,,,,10.1016/s0197-4580(02)00123-9,<Element 'PubmedArticle' at 0x7f05d85e02c0>
416,12270512,Sex differences in estrogen receptor alpha and beta expression in vasopressin neurons of the supraoptic nucleus in elderly and Alzheimer's disease patients: no relationship with cytoskeletal alterations.,"In various hypothalamic and adjacent brain regions we have previously found a remarkable increase in nuclear estrogen receptor staining in Alzheimer's disease (AD). In order to see whether this was a general phenomenon or rather specific for those areas that are affected by the AD process we investigated ERalpha and ERbeta expression in the arginine-vasopressin (AVP) neurons of the human dorsolateral suparoptic nucleus (dl-SON), that is the major source of plasma AVP. These neurons remain exceptionally intact in AD. Changes in ER expression were studied in relation to early Alzheimer changes (i.e. hyperphosphorylated tau) and neuronal metabolism in AD as determined by the size of the Golgi apparatus (GA) or cell size. No difference in neuronal metabolism (i.e. GA size or cell size) of AVP neurons was observed between AD and control patients and no early cytoskeletal AD alterations were found confirming the resistance of the dl-SON to AD. While no differences between AD and control patients were present for ERalpha and ERbeta staining except for a lower proportion of nuclear ERbeta AVP-positive neurons in AD subjects, complex sex differences not directly related to AD were observed within each group. The main finding of the present study is that in the dl-SON, that remains active and spared of AD changes, the increase in nuclear ERs seen in adjacent affected areas in AD patients does not occur. This indicates that a rise of nuclear ERs is not a generally occurring phenomenon but rather related to the pathogenetic alterations of the AD process.",[],Brain research,2002-09-25,"[{'lastname': 'Ishunina', 'firstname': 'Tatjana A', 'initials': 'TA', 'affiliation': 'Netherlands Institute for Brain Research, Meibergdreef 33, 1105 AZ Amsterdam, The Netherlands.'}, {'lastname': 'Wouda', 'firstname': 'Jose', 'initials': 'J', 'affiliation': None}, {'lastname': 'Fisser', 'firstname': 'Bart', 'initials': 'B', 'affiliation': None}, {'lastname': 'Swaab', 'firstname': 'Dick F', 'initials': 'DF', 'affiliation': None}]",,,,,10.1016/s0006-8993(02)03269-9,<Element 'PubmedArticle' at 0x7f05d8569590>
417,12200620,Interstitial cells subjacent to the entorhinal region expressing somatostatin-28 immunoreactivity are susceptible to development of Alzheimer's disease-related cytoskeletal changes.,"Interstitial cells are isolated neurons located in the infracortical white matter that are known to express neuropeptides. Twenty-four cases selected for the absence, slight (Braak stages I-II), moderate (Braak stages III-IV), or serious degree (Braak stages V-VI) of cortical neurofibrillary pathology were studied for the presence of Alzheimer's disease-related abnormal tau in interstitial cells of the entorhinal region. AT8-immunoreactive white matter neurons were observed in all Braak stages of cortical neurofibrillary pathology. Both normal-appearing neurons and neurons with degenerative changes in the cellular processes were observed. Normal-appearing cells were predominantly found in stages I and II, whereas degenerative interstitial cells numerically increased from stage I onwards. The normal-appearing cells were medium-sized (10-25 micro m), with ovoid, fusiform, triangular or multipolar cell bodies, and showed an extensive dendritic field, which was oriented perpendicular to the direction of the perforant pathway. Since the morphology of the AT8-immunopositive normal-appearing cells was similar to that reported on somatostatinergic interstitial cells subjacent to the entorhinal region, double-labeling with AT8 and anti-somatostatin-28 (S309) was performed. All AT8-immunoreactive normal-appearing interstitial cells revealed co-staining with somatostatin-28 antiserum, whereas some of the AT8-immunopositive cells with degenerative processes reacted positively and others negatively with S309. In summary, a distinctive interstitial cell type characterized by extensive arborization oriented perpendicular to the course of the perforant pathway and showing somatostatin expression is susceptible to developing the Alzheimer's disease-related cytoskeletal changes. Progression in cytoskeleton change is accompanied by loss of somatostatin.",[],Acta neuropathologica,2002-08-30,"[{'lastname': 'van de Nes', 'firstname': 'J A P', 'initials': 'JA', 'affiliation': 'Institute of Neuropathology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany. johannes.van.de.nes@uni-essen.de'}, {'lastname': 'Sandmann-Keil', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Braak', 'firstname': 'H', 'initials': 'H', 'affiliation': None}]",,,,,10.1007/s00401-002-0551-7,<Element 'PubmedArticle' at 0x7f05d8573810>
418,11812515,Involvement of microtubule integrity in memory impairment caused by colchicine.,"In order to fully evaluate the effects of colchicine treatment on learning ability in rats, colchicine was administered, and both Morris water maze (MWM) and step-through type passive avoidance (PA) learning tests were conducted. In both learning tests, infusion of colchicine into the rat dentate gyrus, at two distinct bilateral rostrocaudal locations, potently impaired memory function in a dose-dependent manner (0.01-2.0 microg/site), whereas systemic injection of colchicine (50-300 microg/kg) did not. In the MWM test, memory impairment was observed even at doses where there was no evidence of any histological changes in the dentate granule cells. This suggests that functional deterioration, that is, learning impairment was induced by the dysfunction of microtubules and/or axons, was caused by colchicine. Moreover, ameliorated learning behavior was observed with chronic treatment of beta-estradiol 3-benzoate, which has been suggested to have an important role as an adjuvant treatment for younger Alzheimer's disease (AD), immediately after colchicine infusion (0.3 microg). These results indicate that the animal model accompanying the colchicine-induced functional defect showing early tau pathology, but not neuronal cell degeneration, may well mimic comparatively early stage of AD.",[],"Pharmacology, biochemistry, and behavior",2002-01-29,"[{'lastname': 'Nakayama', 'firstname': 'Takahiro', 'initials': 'T', 'affiliation': 'BF Research Institute, Inc., c/o National Cardiovascular Center, 7-1, 5-Chome, Fujishiro-dai, Suita, Osaka 565-0873, Japan. Nakayama_Takahiro@takeda.co.jp'}, {'lastname': 'Sawada', 'firstname': 'Tohru', 'initials': 'T', 'affiliation': None}]",,,,,10.1016/s0091-3057(01)00634-7,<Element 'PubmedArticle' at 0x7f05d857d8b0>
419,11777076,Sleep-wake schedule disorder disability: a lifelong untreatable pathology of the circadian time structure.,"Certain sleep-wake schedule disorders (SWSDs) cannot be successfully managed clinically using conventional methods of sleep therapy. We describe two cases of SWSD, the first following head trauma and the second originating during childhood, that had been misdiagnosed by physicians for many years. After conventional treatment for SWSD with light therapy and melatonin failed to bring about substantial improvement, it was determined that they were suffering from an incurable disability. Hence, we propose new medical terminology for such cases--SWSD disability. SWSD disability is an untreatable pathology of the circadian time structure. Patients suffering from SWSD disability should be encouraged to accept the fact that they suffer from a permanent disability, and that their quality of life can only be improved if they are willing to undergo rehabilitation. It is imperative that physicians recognize the medical condition of SWSD disability in their patients and bring it to the notice of the public institutions responsible for vocational and social rehabilitation.",[],Chronobiology international,2002-01-05,"[{'lastname': 'Dagan', 'firstname': 'Y', 'initials': 'Y', 'affiliation': 'Institute for Fatigue and Sleep Medicine, Sheba Medical Center, Tel-Hashomer, Israel. ydagan@post.tau.ac.il'}, {'lastname': 'Abadi', 'firstname': 'J', 'initials': 'J', 'affiliation': None}]",,,,,10.1081/cbi-100107975,<Element 'PubmedArticle' at 0x7f05d8587900>
420,11597356,Vascularity index distribution within the testis: a technique for guiding testicular sperm extraction.,"Azoospermia is defined as the absence of spermatozoa in the ejaculate, although some foci of spermatogenesis may exist in the testes of these men. Currently, there are no clinical, seminal or hormonal parameters for identifying spermatogenesis within the testis sufficient for achieving genetic offspring. As a result, multiple biopsies are performed at several arbitrary sites of both testes in search of spermatozoa. We developed a power Doppler (PD) ultrasound (US) image-based technique that predicts sites with the greatest potential for spermatogenesis. PDUS images of the testes of azoospermic men were acquired at seven cross-sections to reconstruct a 3-D matrix for constructing a spatial map of preferential regions where spermatozoa are most likely to exist. This technique may obviate the need for arbitrary multiple biopsies that inflict some degree of damage upon testicular tissue, and may increase the success rate of identifying viable spermatozoa in testicular biopsies.",[],Ultrasound in medicine & biology,2001-10-13,"[{'lastname': 'Eytan', 'firstname': 'O', 'initials': 'O', 'affiliation': 'Ultrasound Unit, Department of Obstetrics and Gynecology, Lis Maternity Hospital, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. osnate@post.tau.ac.il'}, {'lastname': 'Har-Toov', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Fait', 'firstname': 'G', 'initials': 'G', 'affiliation': None}, {'lastname': 'Yavetz', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Hauser', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Yogev', 'firstname': 'L', 'initials': 'L', 'affiliation': None}, {'lastname': 'Botchan', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Ben-Yosef', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Elad', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Jaffa', 'firstname': 'A J', 'initials': 'AJ', 'affiliation': None}]",,,,,10.1016/s0301-5629(01)00418-5,<Element 'PubmedArticle' at 0x7f05d858dd60>
421,11596111,Effects of the circadian mutation 'tau' on the Harderian glands of Syrian hamsters.,"The Syrian hamster Harderian gland (HG) is an organ continually exposed to oxidative stress caused by high concentrations of porphyric metabolites. According to previous studies, melatonin, which is rhythmically secreted by the pineal gland and tonically produced by the HG, antagonizes the oxidative damage. HGs exhibit a strong gender-dependent correlation between porphyrins, melatonin, and histological appearance. In HGs of both sexes, we have investigated effects of a single gene defect in the circadian clock system (tau mutation) causing a shortened free-running period and an advanced maximum of circulating melatonin. Comparisons were made with wild-type animals, one group of which received daily pharmacological injections of melatonin in late photophase. Changes were observed in histological characteristics, porphyrin content, antioxidant enzyme activities, and damage of proteins and lipids. HGs of tau hamsters showed morphological changes which can be partially interpreted in terms of increased damage. Additionally, tau females exhibited a many-fold augmentation in the percentage of so-called type II cells, which are otherwise typical for the male glands. In tau hamsters of both sexes, major antioxidative enzyme activities (superoxide dismutase, glutathione reductase, and catalase) were markedly enhanced, a presumably compensatory response to increased oxidative stress. Higher oxidative damage in tau HGs was directly demonstrable by a many-fold increase in protein carbonyl. Rises in antioxidative enzymes were also observed upon injections of melatonin; this was, however, not accompanied by changes in protein carbonyl, so that enzyme inductions by the hormone should be understood as protective actions. Our data are not only in accordance with findings on protective effects by melatonin, but also with our earlier observation made in Drosophila that perturbations in the circadian system lead to increased oxidative stress.",[],Journal of cellular biochemistry,2001-10-12,"[{'lastname': 'Coto-Montes', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Departamento de Morfología y Biología Celular, Universidad de Oviedo, E-33006 Oviedo, Asturias, Spain. acoto@correo.uniovi.es'}, {'lastname': 'Tomás-Zapico', 'firstname': 'C', 'initials': 'C', 'affiliation': None}, {'lastname': 'Rodríguez-Colunga', 'firstname': 'M J', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Tolivia-Cadrecha', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Martínez-Fraga', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Hardeland', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Tolivia', 'firstname': 'D', 'initials': 'D', 'affiliation': None}]",,,,"Copyright 2001 Wiley-Liss, Inc.",10.1002/jcb.1240,<Element 'PubmedArticle' at 0x7f05d8595e00>
422,11521696,Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty.,"To analyze incidence and extent of corneal neovascularization (CN) after non-high-risk keratoplasty and to find out whether duration of postoperative topical steroid therapy (6 vs 12 months) affects CN, corneal endothelial cell count, pachymetry, aqueous flare values, and best-corrected visual acuity at 1 year after keratoplasty.
Patients of the prospective Erlangen non-high-risk keratoplasty study with available high-quality corneal photographs taken preoperatively and 1 year later were analyzed (n=136). Corneal photographs were evaluated by two independent observers in a standardized semiquantitative fashion. Slides were projected with 100x magnification and corneal vessels classified into five grades with regard to the limbus, sutures and host-graft junction in each of 12 corneal sectors. Incidence and extent of CN after keratoplasty and relation to short-term (0-6 months) versus long-term (0-12 months) postoperative topical steroid therapy were analyzed. The effect of duration of topical steroid therapy on corneal endothelial cell count, pachymetry, aqueous flare values, and best corrected visual acuity was also analyzed. Of the 136 patients, 69 (51%) were randomly assigned to short-term and 67 to long-term topical prednisolone acetate 1%.
Fifty-eight percent of patients (n=79) developed a CN within 1 year after keratoplasty in at least one corneal sector (mean 3.1 +/- 2.2, range 1-10). At 1 year after keratoplasty, only in 12% of these patients did at least one vessel reach the host-graft junction or grow into the donor cornea, whereas in 51% vessels were seen beyond the outer suture ends of the double running suture without reaching the host-graft junction. In 37%, capillaries were located between limbus and outer suture ends. New vessels usually pointed directly or indirectly to the outer suture ends and usually were located around the 12 o'clock and 6 o'clock positions. There was no significant difference regarding incidence and extent of CN 1 year after keratoplasty between the long-term and the short-term group. Duration of topical steroid therapy had no significant effect on corneal endothelial cell count and thickness, aqueous flare values and best-corrected visual acuity at 6 and 12 months postoperatively (only at 12 months, corneas in the long-term treatment group were slightly thicker; P=0.03). Interobserver correlation of vessel assessment was 0.77 (Kendall's tau B).
CN is a common phenomenon after non-high-risk keratoplasty. New vessels rarely reach the host-graft junction, most commonly develop from the 6 o'clock and 12 o'clock positions and are usually located between epithelium and Bowman's layer (i.e., at the level of the superficial suture). The direction of vessel growth from the limbus towards the outer suture ends suggests release of angiogenic factors in this area. Prolongation of topical steroid therapy after non-high-risk keratoplasty beyond 6 months in this study did not significantly influence incidence and extent of CN, corneal endothelial cell count, aqueous flare values and best-corrected visual acuity observed 1 year after keratoplasty.",[],Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,2001-08-28,"[{'lastname': 'Cursiefen', 'firstname': 'C', 'initials': 'C', 'affiliation': 'Department of Ophthalmology, Friedrich-Alexander University, Erlangen-Nürnberg, Germany. claus.cursiefen@augen.med.uni-erlangen.de'}, {'lastname': 'Wenkel', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Martus', 'firstname': 'P', 'initials': 'P', 'affiliation': None}, {'lastname': 'Langenbucher', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Nguyen', 'firstname': 'N X', 'initials': 'NX', 'affiliation': None}, {'lastname': 'Seitz', 'firstname': 'B', 'initials': 'B', 'affiliation': None}, {'lastname': 'Küchle', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Naumann', 'firstname': 'G O', 'initials': 'GO', 'affiliation': None}]",,,"Fifty-eight percent of patients (n=79) developed a CN within 1 year after keratoplasty in at least one corneal sector (mean 3.1 +/- 2.2, range 1-10). At 1 year after keratoplasty, only in 12% of these patients did at least one vessel reach the host-graft junction or grow into the donor cornea, whereas in 51% vessels were seen beyond the outer suture ends of the double running suture without reaching the host-graft junction. In 37%, capillaries were located between limbus and outer suture ends. New vessels usually pointed directly or indirectly to the outer suture ends and usually were located around the 12 o'clock and 6 o'clock positions. There was no significant difference regarding incidence and extent of CN 1 year after keratoplasty between the long-term and the short-term group. Duration of topical steroid therapy had no significant effect on corneal endothelial cell count and thickness, aqueous flare values and best-corrected visual acuity at 6 and 12 months postoperatively (only at 12 months, corneas in the long-term treatment group were slightly thicker; P=0.03). Interobserver correlation of vessel assessment was 0.77 (Kendall's tau B).",,10.1007/s004170100313,<Element 'PubmedArticle' at 0x7f05d8522360>
423,11389937,Culture and regeneration of human neurons after brain surgery.,"Cortical human brain tissue was obtained from 11 craniotomies for intractable epilepsy or tumor resection. Neuregen transport medium preserved viability at 4 degrees C during transfer to the culture laboratory. Cells were isolated and cultured by methods previously developed for adult rat neurons (Brewer GJ. Isolation and culture of adult rat hippocampal neurons. J. Neurosci. Meth. 1997:71:143-55). In about 40% of the cases, cultures regenerated with a majority of neuron-like cells that stained for neurofilament and not GFAP. After 3 weeks of culture from a 70 year old meningioma case, synapse-like structures were revealed by electron microscopy. Trophic support from basic human recombinant fibroblast growth factor was synergistically improved with the steroid hormone dehydroepiandrosterone 3-sulfate. Another 40% of the cases resulted in cultures that were predominantly GFAP positive astroglia. The remaining 20% of the cases did not regenerate cells with neuron-like or glial processes. Three postmortem cases did not regenerate neurites. These methods may aid development of human culture models of epilepsy as well as human pharmacology, toxicology and development of improved methods for brain grafts.",[],Journal of neuroscience methods,2001-06-08,"[{'lastname': 'Brewer', 'firstname': 'G J', 'initials': 'GJ', 'affiliation': 'Molecular Biology, Microbiology and Biochemistry, Southern Illinois University School of Medicine, Springfield, IL 62794-9626, USA. gbrewer@siumed.edu'}, {'lastname': 'Espinosa', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'McIlhaney', 'firstname': 'M P', 'initials': 'MP', 'affiliation': None}, {'lastname': 'Pencek', 'firstname': 'T P', 'initials': 'TP', 'affiliation': None}, {'lastname': 'Kesslak', 'firstname': 'J P', 'initials': 'JP', 'affiliation': None}, {'lastname': 'Cotman', 'firstname': 'C', 'initials': 'C', 'affiliation': None}, {'lastname': 'Viel', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'McManus', 'firstname': 'D C', 'initials': 'DC', 'affiliation': None}]",,,,,10.1016/s0165-0270(01)00342-9,<Element 'PubmedArticle' at 0x7f05d852cef0>
424,10972978,Hormonal changes affect the bone and bone marrow cells in a rat model.,"In this study, we used a rat model to investigate the effects of gonad hormones and replacement therapy on bone structure and the immune system. In the first phase of the study, 3- and 11-month-old F344 rats underwent ovariectomy (OVX) or were sham operated. Three months later, severe osteopenia was histologically observed in OVX rats of both age groups. The changes in the bone marrow structure of OVX rats included deterioration of cancellous bone that was associated with a remarkable increase of adipocyte cells. Furthermore, differential analyses for the expression of cell surface antigens by lymph-myeloid cells was studied using flow cytometry (FACS). The number of myeloid cells expressing ED-9(+) or CD-44(+) was similar in both age groups, and unaffected by OVX. However, an augmentation of T-lymphoid cells expressing CD4(+), CD5(+), or both, were observed with age, as well as after OVX. In the second phase of the study, 11-month-old rats were divided into five experimental groups: sham-operated, OVX, and OVX treated with sustained-release pellets of 17beta-estradiol (OVX-E), progesterone (OVX-P), or both (OVX-E/P). Hormone replacement therapy maintained low physiological levels, and rats were tested 12 weeks after treatment initiation. Administration of 17beta-E, with or without the addition of progesterone, prevented the rise of T lymphoid cells observed in OVX rats, whereas progesterone alone had no effect. In agreement with findings from the first phase, neither OVX nor replacement therapy affected the myeloid cells expression of ED-9 or CD-44. In summary, the cellular changes in the bone marrow of OVX rats were associated with an increase in adipocytes that was correlated with bone atrophy. An augmentation of T-lymphopoiesis was noted with increase in age or after OVX. This increase was reversed to baseline levels by 17beta-E treatment.",[],Journal of cellular biochemistry,2000-09-06,"[{'lastname': 'Benayahu', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Department of Cell Biology and Histology, Tel Aviv University, Tel Aviv 69978, Israel. dafnab@post.tau.ac.il'}, {'lastname': 'Shur', 'firstname': 'I', 'initials': 'I', 'affiliation': None}, {'lastname': 'Ben-Eliyahu', 'firstname': 'S', 'initials': 'S', 'affiliation': None}]",,,,"Copyright 2000 Wiley-Liss, Inc.",10.1002/1097-4644(20001201)79:3<407::aid-jcb60>3.0.co;2-8,<Element 'PubmedArticle' at 0x7f05d8539e50>
425,10951498,Low-dose staurosporine suppresses proliferation and induces neurites in human prostatic cancer TSU-Pr1 cells.,"Despite the beneficial effects of androgen ablation therapy in patients with prostate carcinoma, advancing prostate cancer usually becomes hormone-refractory. We attempted to establish a new prostate cancer therapy by controlling the malignancy of tumor cells through the induction of differentiation in vitro.
We examined the ability of staurosporine to induce differentiation of human prostate cancer TSU-Pr1 cells into the cells with neuronal characteristics.
At low concentrations, staurosporine remarkably suppressed proliferation of human prostate cancer TSU-Pr1 cells without increasing dead cell number. TSU-Pr1 cells treated with 10(-8) M staurosporine began to extend neurites within 1 day, and approximately 80% of cells were changed to a neuronal morphology at 3 days. The expression of mRNA of tau, a microtubule-associated protein that is one of the essential components of neurite outgrowth, time-dependently increased in the cells treated with 10(-8) M staurosporine. Similarly, the amount of acetylcholinesterase increased. Colony-forming activity of TSU-Pr1 cells treated with 10(-8) M staurosporine for 7 days was 40% that of control cells. The invasive ability of TSU-Pr1 cells treated with staurosporine to penetrate through a reconstituted basement membrane of Matrigel was 20% that of untreated cells.
These results suggest that staurosporine might induce differentiation of human prostate cancer TSU-Pr1 cells to cells with neuronal characteristics.",[],The Prostate,2000-08-22,"[{'lastname': 'Takahashi', 'firstname': 'N', 'initials': 'N', 'affiliation': 'Department of Hygiene-Chemistry, Faculty of Pharmaceutical Sciences, Science University of Tokyo, Japan.'}, {'lastname': 'Shimizu', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Takeda', 'firstname': 'K', 'initials': 'K', 'affiliation': None}]",,,"At low concentrations, staurosporine remarkably suppressed proliferation of human prostate cancer TSU-Pr1 cells without increasing dead cell number. TSU-Pr1 cells treated with 10(-8) M staurosporine began to extend neurites within 1 day, and approximately 80% of cells were changed to a neuronal morphology at 3 days. The expression of mRNA of tau, a microtubule-associated protein that is one of the essential components of neurite outgrowth, time-dependently increased in the cells treated with 10(-8) M staurosporine. Similarly, the amount of acetylcholinesterase increased. Colony-forming activity of TSU-Pr1 cells treated with 10(-8) M staurosporine for 7 days was 40% that of control cells. The invasive ability of TSU-Pr1 cells treated with staurosporine to penetrate through a reconstituted basement membrane of Matrigel was 20% that of untreated cells.","Copyright 2000 Wiley-Liss, Inc.",10.1002/1097-0045(20000901)44:4<328::aid-pros10>3.0.co;2-8,<Element 'PubmedArticle' at 0x7f05d8547d10>
426,10407462,Hyperostosis frontalis interna: an anthropological perspective.,"Hyperostosis frontalis interna (HFI) is manifested by the accretion of bone on the inner table of the frontal bone. Despite the vast literature on HFI, ambiguity exists as to its etiology, osteogenesis, demography, and history. This stimulated the present broad-scale study of HFI which included the evaluation of 1,706 early 20th century skulls (1,007 males and 699 females) from the Hamann-Todd and Terry human osteological collections, as well as 2,019 pre-19th century East-Mediterranean, Amerindian, and Central European skulls. In addition, 72 cadavers were dissected for gross inspection and histology. Special attention was paid to the relationship of the brain and meninges to endocranial lesions. HFI is an independent condition, not a symptom of a more generalized syndrome as suggested in the past. It can appear in a variety of forms but each is the result of the same process and probably of the same etiology. Investigators' previous failure to recognize the mild stages of HFI (types A and B) as an early form of the general HFI process led to erroneous statistics and interpretations of observations. HFI should also be considered a phenomenon separate from HCI, hyperostosis cranialis diffusa (HCD), and other endostoses, even when it appears in association with them. To avoid ambiguity and facilitate the description of cranial hyperostoses, uniform nomenclature (HFI, HCD) has been recommended. HFI is rarely seen in historic populations, regardless of geographical origin. It is most commonly found among females and is believed to be associated with prolonged estrogen stimulation. While its magnitude of manifestation and frequency are much higher in females, HFI is not a purely female phenomenon. Males with hormonal disturbances such as atrophic testis were found to manifest HFI type D. HFI is associated with age insofar as it is much less frequent in females under 40 years of age. Although advanced cases of HFI (types C and D) have been observed in individuals as young as 40 years of age, it is more frequently found after age 60. The frequency of HFI type D will not increase from age 60. Type-predicted analysis by cohort reveals significant ethnic differences. Changes in African American (AA) females appear earlier in life and progress more rapidly than in European American (EA) females. Analysis of radiographs shows a discrepancy between the anatomic prevalence of HFI and its radiological recognition, which is very poor for mild cases. This apparently resulted in the misconceptions that HFI is entirely an old-age phenomenon, and that it is exclusively female. Histological analysis shows that the inner table along with the closely attached dural layer play a major role in the osteogenesis of HFI. Contrary to previous models, no evidence for diploe or ectocranial plate involvement was found. Cadaver study suggests that the predilection for the frontal area may be related to an altered blood supply and/or vascular stretching.",[],American journal of physical anthropology,1999-07-17,"[{'lastname': 'Hershkovitz', 'firstname': 'I', 'initials': 'I', 'affiliation': 'Cleveland Museum of Natural History, Ohio 44106-1767, USA. anatom2@post.tau.ac.il'}, {'lastname': 'Greenwald', 'firstname': 'C', 'initials': 'C', 'affiliation': None}, {'lastname': 'Rothschild', 'firstname': 'B M', 'initials': 'BM', 'affiliation': None}, {'lastname': 'Latimer', 'firstname': 'B', 'initials': 'B', 'affiliation': None}, {'lastname': 'Dutour', 'firstname': 'O', 'initials': 'O', 'affiliation': None}, {'lastname': 'Jellema', 'firstname': 'L M', 'initials': 'LM', 'affiliation': None}, {'lastname': 'Wish-Baratz', 'firstname': 'S', 'initials': 'S', 'affiliation': None}]",,,,,10.1002/(SICI)1096-8644(199907)109:3<303::AID-AJPA3>3.0.CO;2-I,<Element 'PubmedArticle' at 0x7f05d8550cc0>
427,10069680,Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle.,"To evaluate the role of angiotensin II (AII) on diastolic function during post-myocardial infarction (MI) ventricular remodeling, coronary ligation or sham operation was performed in male Sprague-Dawley rats. Experimental animals were maintained on either irbesartan, a selective AT1-receptor antagonist, or no treatment. Measurement of cardiac hypertrophy, diastolic function, and sarcoendoplasmic reticulum adenosine triphosphatase (ATPase; SERCA) and phospholamban (PLB) gene expression was assessed at 6 weeks after MI. Myocardial infarction caused a significant increase in myocardial mass and left ventricular (LV) filling pressure, whereas LV systolic pressure and +dP/dt were reduced. The time constant of isovolumic relaxation (tau) was markedly prolonged after MI. Post-MI hypertrophy was associated with substantial increases in the messenger RNA (mRNA) expression of atrial natriuretic peptide (ANP), but no significant changes in SERCA or PLB levels. Although irbesartan treatment did not significantly alter post-MI LV systolic or filling pressures, it nevertheless effectively decreased ventricular hypertrophy, improved tau, and normalized ANP expression. These results demonstrate that AT1-receptor antagonism has important effects on myocardial hypertrophy and ANP gene expression, which are independent of ventricular loading conditions. In addition, the improvement in diastolic function was not related to changes in SERCA and PLB gene expression, suggesting that enhanced myocardial relaxation was related to the blockade of AII effects on myocyte function or through a reduction of ventricular hypertrophy itself or both.",[],Journal of cardiovascular pharmacology,1999-03-09,"[{'lastname': 'Ambrose', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Division of Cardiovascular Medicine, University of California, San Diego, USA.'}, {'lastname': 'Pribnow', 'firstname': 'D G', 'initials': 'DG', 'affiliation': None}, {'lastname': 'Giraud', 'firstname': 'G D', 'initials': 'GD', 'affiliation': None}, {'lastname': 'Perkins', 'firstname': 'K D', 'initials': 'KD', 'affiliation': None}, {'lastname': 'Muldoon', 'firstname': 'L', 'initials': 'L', 'affiliation': None}, {'lastname': 'Greenberg', 'firstname': 'B H', 'initials': 'BH', 'affiliation': None}]",,,,,10.1097/00005344-199903000-00014,<Element 'PubmedArticle' at 0x7f05d8559450>
428,9710944,Kinetic analysis of prostatic volume and prostate specific antigen (PSA) in patients with advanced prostatic cancer treated by castration.,"The clinical usefulness of the kinetic analysis of prostate specific antigen (PSA) in patients with advanced prostatic cancer treated by castration has not yet been evaluated. The reduction of both prostatic volume and PSA was monitored in 37 patients with Stage C and Stage D prostatic cancer. The change of prostatic volume was measured frequently by transrectal ultrasonography (TRS) after castration, as was the change of PSA. A kinetic analysis of both prostatic volume and PSA was made by comparing the reduction time tau(PSA) (speed of the reduction of PSA) and tau prostatic volume (PV). There was a statistically significant correlation between tau(PSA) and tau(PV) in patients with a tau(PV) of less than 30 days. However, no correlation was observed in patients with a tau(PV) of more than 30 days, because the tau(PSA) in this group fell into a relatively low range similar to the group with a tau(PV) of less than 30 days. It was assumed that the change of PSA after castration reflected mainly the response of the hormone dependent portion of the total cancer volume. However, all data of tau(PV) with a tau(PSA) less than 10 days were within 30 days. In conclusion, tau(PSA) might be promising as a prognostic factor after castration in patient with advanced prostatic cancer, although tau(PSA) was not a direct substitute for tau(PV).",[],The Tohoku journal of experimental medicine,1998-08-26,"[{'lastname': 'Okihara', 'firstname': 'K', 'initials': 'K', 'affiliation': 'Department of Urology, Kyoto Prefectural University of Medicine, Japan.'}, {'lastname': 'Watanabe', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Saitoh', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Kojima', 'firstname': 'M', 'initials': 'M', 'affiliation': None}]",,,,,10.1620/tjem.185.37,<Element 'PubmedArticle' at 0x7f05d84e5950>
429,9492850,Induction of atypical prostatic hyperplasia in rats by sympathomimetic stimulation.,"Prostatic innervation may participate in its homeostasis and growth. alpha-Adrenergic inhibition alleviates clinical symptoms in benign prostatic hyperplasia. However, the prostatic effect of adrenergic agonists has not been investigated. This study deals with the prostatic effect of subchronic sympathomimetic stimulation.
Male rats received daily subcutaneous injections of the alpha-adrenergic agonist phenylephrine, 1, 10, or 20 mg/kg per day, the beta-adrenergic agonist isoproterenol, 1, 2.5 or 5 mg/kg per day, or saline, for 30 days, and the prostates were removed for histopathological examination.
Phenylephrine induced atypical prostatic hyperplasia, characterized by piling-up with papillary and cribriform patterns, and budding-out of epithelial cells. It decreased prostatic secretions and total weight. Similar results were observed in orchidectomized rats receiving exogenous testosterone supplementation. Isoproterenol had no prostatic morphological effect.
These results raise the possibility that sympathetic stimuli play a role in normal and aberrant growth and differentiation of prostatic epithelium, and suggests neurostimulants-treated animals as a model to study the etiology and development of prostatic hyperplasia.",[],The Prostate,1998-03-11,"[{'lastname': 'Golomb', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Department of Pathology, Sackler Medical Faculty, Tel-Aviv University, Israel. egolomb@post.tau.ac.il'}, {'lastname': 'Kruglikova', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Dvir', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Parnes', 'firstname': 'N', 'initials': 'N', 'affiliation': None}, {'lastname': 'Abramovici', 'firstname': 'A', 'initials': 'A', 'affiliation': None}]",,,"Phenylephrine induced atypical prostatic hyperplasia, characterized by piling-up with papillary and cribriform patterns, and budding-out of epithelial cells. It decreased prostatic secretions and total weight. Similar results were observed in orchidectomized rats receiving exogenous testosterone supplementation. Isoproterenol had no prostatic morphological effect.",,10.1002/(sici)1097-0045(19980215)34:3<214::aid-pros9>3.0.co;2-h,<Element 'PubmedArticle' at 0x7f05d84ee310>
430,"9192613
3324647
2329377
8780008
1316615
8774454
7925844
8725909
8030629
8709781
8159272
8774455
8809674
1903545
7777138
3029875
3088567
2116006
8769877
5432063
14907713
4192899
8955115
1382420
7479786
2245817
8597461
1407656
4796896
8013375
8277222
596656
8612562
446345
8637535
7822317
7826642
7595582
8982166
7531159
7759536
8618884
8598911
8943238
7886228
8521507
1347506
8871783
8274436
7761850
8678193
7721258
2494388
1549228",The heat shock-induced hyperphosphorylation of tau is estrogen-independent and prevented by androgens: implications for Alzheimer disease.,"We have shown that heat shock induces rapid dephosphorylation of tau in both female and male rats followed by hyperphosphorylation only in female rats. To investigate the role of gonadal hormones, rats were ovariectomized (OVX), orchiectomized (ORX), or sham-gonadectomized and received replacement therapy with estradiol benzoate (EB), testosterone propionate (TP), or sesame oil (SO) vehicle for 2-3 weeks, respectively. At 0, 3, 6, and 12 hr after heat shock, immunoblot analysis of SDS cerebral extracts was performed using phosphate-dependent and -independent anti-tau antibodies. Seven groups of rats were analyzed: (i) sham-OVX + SO; (ii) OVX + SO; (iii) OVX + EB; (iv) sham-ORX + SO; (v) ORX + SO; (vi) ORX + TP; and (vii) ORX. In all seven groups, there was dephosphorylation of tau at 0 hr after heat shock. In all three groups of female rats, there was hyperphosphorylation of tau at 3 hr after heat shock, and its degree and temporal pattern were identical between the OVX + SO and OVX + EB groups. In male rats, there was hyperphosphorylation of tau at 3 hr after heat shock in both ORX + SO and ORX groups, and its degree was reduced in the ORX + TP group. Thus, dephosphorylation of tau is gonadal hormone-independent, but while its hyperphosphorylation is estrogen-independent it is prevented by androgens. Because tau is abnormally hyperphosphorylated in Alzheimer disease, which is more frequent in women than men, these findings suggest that androgens may exert a neuroprotective effect.",[],Proceedings of the National Academy of Sciences of the United States of America,1997-06-24,"[{'lastname': 'Papasozomenos', 'firstname': 'S C', 'initials': 'SC', 'affiliation': 'Department of Pathology and Laboratory Medicine, The University of Texas-Houston Medical School, Houston, TX 77030, USA.'}]",,,,,10.1073/pnas.94.13.6612,<Element 'PubmedArticle' at 0x7f05d84f74f0>
431,9146609,Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.,"We sought to quantify prostate tissue changes induced by finasteride and to identify a predictor of finasteride response in men with symptomatic benign prostatic hyperplasia (BPH) via a randomized, placebo controlled, double-blind clinical trial.
Men with symptomatic BPH (52 to 78 years old) were randomly assigned to 6 months of treatment with finasteride (26) or placebo (15). Outcome measures were clinical (urinary symptom score and flow rate), chemical (serum prostate specific antigen and dihydrotestosterone levels), volumetric (transrectal ultrasound, and magnetic resonance imaging for whole and zonal prostate volumes) and histological (morphometry of prostate sextant biopsies, separated into inner and outer gland segments, to measure the percent epithelium, stroma and glandular lumen).
In the finasteride group we found a suggestion of decreasing symptom scores and increasing flow rates (not significant) with significant decreases (p < 0.01) in prostate specific antigen (48%), dihydrotestosterone (74%) and prostate volume (21%). Finasteride treatment induced a 55% decrease in inner gland epithelium (p < 0.01) with little effect on stroma or lumina. We also found a linear correlation between pretreatment inner gland epithelial content and prostate volume decrease induced by the drug (tau = 0.58, p = 0.01).
Finasteride treatment results in a major suppression of prostate epithelium, which is most pronounced in the inner gland. Moreover, a finasteride induced prostate volume decrease was predictable by quantification of epithelial tissues of the inner gland. These data lend additional support to the emerging concept of transition zone primacy in symptomatic BPH.",[],The Journal of urology,1997-06-01,"[{'lastname': 'Marks', 'firstname': 'L S', 'initials': 'LS', 'affiliation': 'Department of Surgery/Urology, UCLA School of Medicine, USA.'}, {'lastname': 'Partin', 'firstname': 'A W', 'initials': 'AW', 'affiliation': None}, {'lastname': 'Gormley', 'firstname': 'G J', 'initials': 'GJ', 'affiliation': None}, {'lastname': 'Dorey', 'firstname': 'F J', 'initials': 'FJ', 'affiliation': None}, {'lastname': 'Shery', 'firstname': 'E D', 'initials': 'ED', 'affiliation': None}, {'lastname': 'Garris', 'firstname': 'J B', 'initials': 'JB', 'affiliation': None}, {'lastname': 'Subong', 'firstname': 'E N', 'initials': 'EN', 'affiliation': None}, {'lastname': 'Stoner', 'firstname': 'E', 'initials': 'E', 'affiliation': None}, {'lastname': 'deKernion', 'firstname': 'J B', 'initials': 'JB', 'affiliation': None}]",,,"In the finasteride group we found a suggestion of decreasing symptom scores and increasing flow rates (not significant) with significant decreases (p < 0.01) in prostate specific antigen (48%), dihydrotestosterone (74%) and prostate volume (21%). Finasteride treatment induced a 55% decrease in inner gland epithelium (p < 0.01) with little effect on stroma or lumina. We also found a linear correlation between pretreatment inner gland epithelial content and prostate volume decrease induced by the drug (tau = 0.58, p = 0.01).",,,<Element 'PubmedArticle' at 0x7f05d850f5e0>
432,"8816744
7836768
8527231
6395141
3931290
3942559
3464957
3803578
3568321
3574358
212109
3606719
3121846
3426656
3364352
3042201
2540223
2317166
2244855
2281828
1992816
2292243
1922206
1681744
1750410
1810590
1581106
1630733
1411543
8214145
8274468
8274470
8157673
7909339
8181150
8185424
8040345
8068611
7948005
7527406
7857364
7868986
7788916
7554176
7489365
6310634",Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice.,"We have studied the effects of endogenous and exogenous estrogen on atherosclerotic lesions in apolipoprotein E-deficient mice. Female mice ovariectomized (OVX) at weaning displayed increases (P < 0.01) in fatty streak lesions in the proximal aorta and aortic sinus compared with female mice with intact ovarian function. These differences between the OVX and sham controls were apparent in both chow- and ""Western-type"" diet-fed mice. Moreover, increases in lesion size following OVX occurred without changes in plasma cholesterol. Hormone replacement with subdermal 17-beta-estradiol pellets releasing either 6, 14, or 28 micrograms/day significantly decreased (P < 0.001) atherosclerotic lesion area in both male and OVX female mice. In contrast, neither 17-alpha-estradiol (28 micrograms/day) or tamoxifen (85 micrograms/day) affected lesion progression in OVX female mice. In the Western diet-fed group, exogenous estradiol markedly reduced plasma cholesterol and triglycerides, whereas, in animals fed the chow diet, exogenous estrogen and tamoxifen treatment only decreased plasma and very low density lipoprotein triglycerides. However, lesion area was only weakly correlated with plasma cholesterol and triglycerides, 0.35 and 0.44 tau values, respectively (P < 0.01). In summary, in the apolipoprotein E-deficient mouse 17-beta-estradiol protects against atherosclerotic lesion formation, and this can only be partially explained through effects on plasma lipoprotein levels.",[],Proceedings of the National Academy of Sciences of the United States of America,1996-09-17,"[{'lastname': 'Bourassa', 'firstname': 'P A', 'initials': 'PA', 'affiliation': 'Department of Metabolic Disease, Pfizer Inc., Groton, CT 06340, USA.'}, {'lastname': 'Milos', 'firstname': 'P M', 'initials': 'PM', 'affiliation': None}, {'lastname': 'Gaynor', 'firstname': 'B J', 'initials': 'BJ', 'affiliation': None}, {'lastname': 'Breslow', 'firstname': 'J L', 'initials': 'JL', 'affiliation': None}, {'lastname': 'Aiello', 'firstname': 'R J', 'initials': 'RJ', 'affiliation': None}]",,,,,10.1073/pnas.93.19.10022,<Element 'PubmedArticle' at 0x7f05d8518d10>
433,7788262,Kinetic analysis of prostatic volume in patients with stage D prostatic cancer treated with LHRH analogues in relation to prognosis.,"To evaluate the clinical usefulness of the kinetic analysis of prostatic volume in the prognosis of patients with Stage D prostatic cancer treated using luteinizing hormone-releasing hormone (LHRH) analogues.
The reduction of prostatic volume was monitored in 12 patients with Stage D prostatic cancer using transrectal ultrasonography (TRUS) after treatment with LHRH analogues. Data obtained from the kinetic analysis of prostatic volume were compared with the prognosis.
All the patients having a reduction time, tau (derived from the kinetic analysis of prostatic volume change with time), of less than 41 days had neither clinical progression within 15 months nor death caused by prostatic cancer during the 5-year follow-up, while the disease-specific 5-year survival rate in patients having a tau of greater than 42 days was as low as 17%. The difference in both the progression and disease-specific survival between these groups was statistically significant (P < 0.05) despite the limited number of patients. In contrast, conventional prognostic parameters showed no significant predictability for prognosis with the exception of prostatic acid phosphatase, which correlated strongly with the occurrence of progression within 15 months.
The kinetic analysis of the change of prostatic volume using TRUS shows promise in the prognosis of the patients with Stage D prostatic cancer.",[],British journal of urology,1995-04-01,"[{'lastname': 'Kojima', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Department of Urology, Kyoto Prefectural University of Medicine, Japan.'}, {'lastname': 'Ohe', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Watanabe', 'firstname': 'H', 'initials': 'H', 'affiliation': None}]",,The kinetic analysis of the change of prostatic volume using TRUS shows promise in the prognosis of the patients with Stage D prostatic cancer.,"All the patients having a reduction time, tau (derived from the kinetic analysis of prostatic volume change with time), of less than 41 days had neither clinical progression within 15 months nor death caused by prostatic cancer during the 5-year follow-up, while the disease-specific 5-year survival rate in patients having a tau of greater than 42 days was as low as 17%. The difference in both the progression and disease-specific survival between these groups was statistically significant (P < 0.05) despite the limited number of patients. In contrast, conventional prognostic parameters showed no significant predictability for prognosis with the exception of prostatic acid phosphatase, which correlated strongly with the occurrence of progression within 15 months.",,10.1111/j.1464-410x.1995.tb07271.x,<Element 'PubmedArticle' at 0x7f05d84b0d10>
434,8083742,Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus.,"Glucocorticoids (GCs), the adrenal steroids secreted during stress, endanger the hippocampus, compromising its ability to survive neurological insults. GCs probably do so by disrupting energetics in the hippocampus, thus impairing its ability to contain damaging fluxes of excitatory amino acids and calcium. Superficially, these observations suggest that stress itself should also exacerbate the toxicity of neurological insults. However, most studies have involved unphysiologic GC manipulations, limiting speculations about the endangering effects of stress. In this study, rats were infused with the excitotoxin kainic acid (KA) after either having been adrenalectomized and replaced with a range of physiologic concentrations of GCs, or having been stressed intermittently. We observed that within the CA3 region, increasing CORT concentrations exacerbated the KA-induced neuron loss, the extent of tau immunoreactivity, and of spectrin proteolysis. The transitions from low to high basal GC concentrations and from high basal to stress GC values were both associated with significant exacerbation of neuron loss and tau immunoreactivity; the extent of spectrin proteolysis was less sensitive to increments in GCs. As would be expected from these data, exposure to intermittent stress prior to KA infusion also exacerbated neuron loss, tau immunoreactivity, and spectrin proteolysis in CA3. Thus, physiological elevations of GCs, and stress itself, can exacerbate hippocampal neuron loss and the attendant degenerative markers following an excitotoxic insult. Of significance, seizure and hypoxia-ischemia provoke considerable GC stress responses, which may thus worsen the resultant damage. Furthermore, a number of neuropsychiatric disorders, as well as aging, are associated with elevated basal GC concentrations, which may endanger the hippocampus in the event of neurological insult.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,1994-09-01,"[{'lastname': 'Stein-Behrens', 'firstname': 'B', 'initials': 'B', 'affiliation': 'Department of Biological Sciences, Stanford University, California 94305.'}, {'lastname': 'Mattson', 'firstname': 'M P', 'initials': 'MP', 'affiliation': None}, {'lastname': 'Chang', 'firstname': 'I', 'initials': 'I', 'affiliation': None}, {'lastname': 'Yeh', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Sapolsky', 'firstname': 'R', 'initials': 'R', 'affiliation': None}]",,,,,10.1523/JNEUROSCI.14-09-05373.1994,<Element 'PubmedArticle' at 0x7f05d84b8a40>
435,7812796,"The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas.","The monoclonal antibody Alz-50 is directed against Alzheimer's disease-related modified tau proteins and reveals cytoskeletal changes, i.e. neurofibrillary tangles and dystrophic neurites. The present study shows that, in the hypothalamus of non-demented control subjects, this same antibody gives a distinctive staining pattern of a subpopulation of somatostatin neurons and beaded fibres. Furthermore, Alz-50 occasionally recognizes somatostatin-containing cell bodies and dystrophic neurite-like fibers in the (neuritic) senile plaques of AD patients. These observations have direct consequences for the interpretation of Alz-50 staining in diagnostic usage and for the assessment of Alzheimer's disease-like changes induced by beta-amyloid in experimental animal brains. On dot spotting, Alz-50 was found to bind to a number of fragments from the somatostatin precursor, of which somatostatin 15-28 stained best. Preadsorption of Alz-50 by somatostatin 15-28, as well as other specificity tests, failed, however, to provide any clue to the nature of the unknown compound(s) stained in the control hypothalamus.",[],Brain research,1994-08-29,"[{'lastname': 'van de Nes', 'firstname': 'J A', 'initials': 'JA', 'affiliation': 'Graduate School Neurosciences Amsterdam, Free University Hospital, The Netherlands.'}, {'lastname': 'Sluiter', 'firstname': 'A A', 'initials': 'AA', 'affiliation': None}, {'lastname': 'Pool', 'firstname': 'C W', 'initials': 'CW', 'affiliation': None}, {'lastname': 'Kamphorst', 'firstname': 'W', 'initials': 'W', 'affiliation': None}, {'lastname': 'Ravid', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Swaab', 'firstname': 'D F', 'initials': 'DF', 'affiliation': None}]",,,,,10.1016/0006-8993(94)91602-0,<Element 'PubmedArticle' at 0x7f05d84c1c20>
436,7802968,Neuropeptide Y and somatostatin in the neocortex of young and aging rats: response to nucleus basalis lesions.,"Lesions of the nucleus basalis of Meynert (NBM) have been used to mimic, in part, cholinergic deficits occurring in age-related neurodegenerative disorders, i.e., Alzheimer's disease. In our study, the effect of a persistent cholinergic denervation of the fronto-parietal cortex on neuropeptide Y (NPY) and somatostatin (SOM) was examined in young adult (3 months old) and aging (> 18 months old) rats, 1, 3 and 6 months after bilateral stereotaxic NBM lesions with quisqualic acid. In aging, non-lesioned rats a significant decrease in radioimmunologically and immunohistochemically detectable NPY and SOM was found with no further changes after lesions. Morphological markers for these peptidergic populations (cell size and number, NADPH-diaphorase histochemistry, electron microscopy) demonstrated no signs of alterations in both age groups after lesion. Densitometric analysis of peptide fibre networks displayed a heterogeneous response with a significant rarefication in young rats 1 month after the lesion, followed by restoration and a tendency towards increase 6 months post lesioning in individual animals. These findings were confirmed by radioimmunological measurements. Examination of synaptic and cytoskeletal markers, i.e., synaptophysin, GAP-43, MAP-2, Tau-1 and amyloid precursor protein, did not reveal any signs for neuronal reorganization or sprouting. These data are discussed in the context of plasticity and pathology in age-related neurodegenerative disorders with cholinergic impairment.",[],Journal of chemical neuroanatomy,1994-07-01,"[{'lastname': 'Unger', 'firstname': 'J W', 'initials': 'JW', 'affiliation': 'Department of Anatomy, University of Munich, Germany.'}, {'lastname': 'Schmidt', 'firstname': 'Y', 'initials': 'Y', 'affiliation': None}]",,,,,10.1016/0891-0618(94)90005-1,<Element 'PubmedArticle' at 0x7f05d84c9f90>
437,8409266,Proton magnetic resonance imaging and spectroscopic studies of the pathogenesis and treatment of juvenile dermatomyositis.,"Juvenile dermatomyositis is an inflammatory disorder of muscle, skin, and connective tissue. Immune vasculopathy is central to the pathophysiology. We studied a 13-year-old boy with juvenile dermatomyositis using proton magnetic resonance imaging (MRI) with short tau inversion recovery (STIR), and proton magnetic resonance spectroscopy (MRS) to quantitate lipid and water in affected regions of muscle. Tissue perfusion was assessed by measuring tissue water concentration changes during isometric exercise of the tibialis anterior muscle. During sequential studies over 3 months of steroid treatment, STIR image abnormalities, resting water concentrations, and diminished perfusion returned to normal. Resting lipid concentrations increased during this period. MRI serves to guide muscle biopsy and monitor progress of the disease state. MRS demonstrates the vasculopathy and provides noninvasive assessment of steroid therapy in juvenile dermatomyositis.",[],Journal of child neurology,1993-07-01,"[{'lastname': 'Slopis', 'firstname': 'J M', 'initials': 'JM', 'affiliation': 'Department of Neurology, University of Texas Medical School at Houston 77030.'}, {'lastname': 'Jackson', 'firstname': 'E F', 'initials': 'EF', 'affiliation': None}, {'lastname': 'Narayana', 'firstname': 'P A', 'initials': 'PA', 'affiliation': None}, {'lastname': 'Papasozomenos', 'firstname': 'S C', 'initials': 'SC', 'affiliation': None}, {'lastname': 'Butler', 'firstname': 'I J', 'initials': 'IJ', 'affiliation': None}]",,,,,10.1177/088307389300800307,<Element 'PubmedArticle' at 0x7f05d84d61d0>
438,1519575,Relationship between pancreatic exocrine function and histological changes in chronic pancreatitis.,"To confirm correlation between function and histology of the exocrine pancreas in chronic pancreatitis, we compared exocrine pancreatic function, as estimated by cholecystokinin secretin test (CST), with histological findings in 108 patients. Exocrine pancreatic insufficiency was graded from 0 to 4 according to the number of abnormal CST parameters. Histological findings also were graded from 0 to 4. Results of CST in 108 patients were normal (grade 0) in 52, equivocal (grade 1) in 23, and abnormal (grades 2-4) in 33. Normal histological findings (grade 0) were observed in 54 patients, equivocal (grade 1) in 15, and abnormal (grades 2-4) in 39. We confirmed that there was a significant correlation between histological grading and overall scoring (tau = 0.59, p less than 0.01) or individual parameters (tau = -0.36 for volume, -0.45 for amylase output, and -0.54 for maximal bicarbonate concentration (p less than 0.01) of CST. Sensitivity of CST was 67% in 39 patients with histologically confirmed chronic pancreatitis, specificity was 90% in 69 patients without chronic pancreatitis, based on histological evidence, and efficiency was 81%. In conclusion, we confirmed a highly significant correlation between direct function test (CST) and histology of the exocrine pancreas.",[],The American journal of gastroenterology,1992-09-01,"[{'lastname': 'Hayakawa', 'firstname': 'T', 'initials': 'T', 'affiliation': 'Second Department of Internal Medicine, Nagoya University School of Medicine, Japan.'}, {'lastname': 'Kondo', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Shibata', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Noda', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Suzuki', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Nakano', 'firstname': 'S', 'initials': 'S', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05d84dbe00>
